<SEC-DOCUMENT>0001558370-22-004363.txt : 20220325
<SEC-HEADER>0001558370-22-004363.hdr.sgml : 20220325
<ACCEPTANCE-DATETIME>20220325142431
ACCESSION NUMBER:		0001558370-22-004363
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		126
CONFORMED PERIOD OF REPORT:	20211231
FILED AS OF DATE:		20220325
DATE AS OF CHANGE:		20220325

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Gain Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001819411
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				851726310
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40237
		FILM NUMBER:		22770394

	BUSINESS ADDRESS:	
		STREET 1:		4800 HAMPDEN LANE
		STREET 2:		SUITE 200
		CITY:			BETHESDA
		STATE:			MD
		ZIP:			20814
		BUSINESS PHONE:		(301) 500-1556

	MAIL ADDRESS:	
		STREET 1:		4800 HAMPDEN LANE
		STREET 2:		SUITE 200
		CITY:			BETHESDA
		STATE:			MD
		ZIP:			20814
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>ganx-20211231x10k.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='UTF-8'?>

      <!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 9.6.8042.36810 -->
      <!-- Based on: iXBRL 1.1 -->
      <!-- Created on: 3/25/2022 6:18:15 PM -->
      <!-- iXBRL Library version: 1.0.8042.36816 -->
      <!-- iXBRL Service Job ID: 562bf289-a1f4-42ae-8dff-8de79546dccb -->

  <html xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ganx="http://www.gaintherapeutics.com/20211231" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xbrldi="http://xbrl.org/2006/xbrldi"><head><meta content="text/html" http-equiv="content-type" /><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonFraction unitRef="Unit_Divide_USD_shares_ZUfWDOiJrESFdyfJo2gfWg" sign="-" contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden_ZqfVXUdYkUaQWl9swYAeKg">1.37</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_ZUfWDOiJrESFdyfJo2gfWg" sign="-" contextRef="Duration_1_1_2020_To_12_31_2020_JDEb6LtAmEuXGmEieWNlsw" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden_59XMxIKltEOAN65oF3AfFw">1.33</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw" contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Hidden_lKxvqb-Ic0Ojx_i9R3MPew">10165404</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw" contextRef="Duration_1_1_2020_To_12_31_2020_JDEb6LtAmEuXGmEieWNlsw" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Hidden_B3odu59CiE2QRJMA1CJZhw">2681408</ix:nonFraction><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" name="dei:EntityCentralIndexKey" id="Tc_aTfCrWp3KE2Foa2HC3TAfA_1_1">0001819411</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" name="dei:CurrentFiscalYearEndDate" id="Tc_XU5tUSnECUGTvgWNgHTRxQ_2_1">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" name="dei:DocumentFiscalYearFocus" id="Tc_Mi4Ly1nO7EKGDb2U9zXxKA_3_1">2021</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" name="dei:DocumentFiscalPeriodFocus" id="Tc_uGb-2dEHKUmfaUO8RRyXeg_4_1">FY</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" name="dei:AmendmentFlag" id="Tc_a7VGj4AT-kaOOkHF95BRhQ_5_1">false</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_UOpY8hOKmEaY4smAqVjcoQ" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" id="Hidden_nBFWja__nUKaF0_2r1-5ew">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_SZL-8g69ikyvM5ITtvQ_vA" decimals="INF" name="us-gaap:PreferredStockSharesIssued" id="Hidden_WaxhVkpREkyl-jjvJbdCHQ">2965600</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_UOpY8hOKmEaY4smAqVjcoQ" decimals="INF" name="us-gaap:PreferredStockSharesIssued" id="Hidden_qM3TS5mT-UC-jzM-fri5OQ">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_bnIOh52EIUC-yTsdpcG0NQ" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" id="Hidden_nUKSBhSCh0moQENn0OnE_w">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_HPxGCJIoKkWKHRC95IDwMg" decimals="INF" name="us-gaap:PreferredStockSharesIssued" id="Hidden_OklE6u_bskKwCDxGHn2ymg">1185879</ix:nonFraction><ix:nonNumeric contextRef="As_Of_12_31_2021_srt_RangeAxis_srt_MinimumMember_eU0rUPNa5UKucFJIXpiTPg" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" id="Hidden_ZalXIiQg2kKnz87xVmLaUQ">P3Y</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" decimals="0" name="us-gaap:InterestExpenseDebt" id="Hidden_4WczMy8Ec0ae6MFBpO8JBg">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2020_To_12_31_2020_JDEb6LtAmEuXGmEieWNlsw" decimals="0" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" id="Hidden_4TswneAzZ0yP-xAbG1nbdw">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" decimals="0" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" id="Hidden_os3GPhf0qUifLjdDnxEjsg">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_pure_YPFUW3Xga0mVMPZT28RXUw" contextRef="Duration_3_3_2021_To_3_3_2021_pvtif4URAkie9GX28TaLHA" decimals="7" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" id="Hidden_PPLEqeAgy0iiPmdWllrCSA">1.1353521</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw" contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg" decimals="INF" name="us-gaap:CommonStockSharesIssued" id="Hidden_smJgQqCN6kCASsqGpDK0oA">3543163</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw" contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" id="Hidden_eCHc0lXrwkaLahqSp1jTsw">11883368</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw" contextRef="As_Of_3_16_2021_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredClassAMember_LA-5cb6F00S56dV8R_wEsQ" decimals="INF" name="us-gaap:PreferredStockSharesIssued" id="Hidden_xoy4pURJ0U6SC06b57siOQ">1346390</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw" contextRef="As_Of_3_16_2021_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredClassBMember_HBe32B_mIkuJvMwKt7oZ-g" decimals="INF" name="us-gaap:PreferredStockSharesIssued" id="Hidden_VxK6clrWrk2DfpjK2-sdow">3366999</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_pure_YPFUW3Xga0mVMPZT28RXUw" contextRef="Duration_3_3_2021_To_3_3_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_lfgvFolLLU68lyHCSIQe6A" decimals="INF" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" id="Hidden_VOTL1rq_TUe6F_krbeB0zg">1.1353521</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2020_us-gaap_RelatedPartyTransactionAxis_ganx_LicenseAgreementWithMinoryxTherapeuticsSlMember_VIe1l_ajWEuJhOrR7dlifQ" decimals="-3" name="us-gaap:AccountsPayableRelatedPartiesCurrentAndNoncurrent" id="Hidden_oVxgLsgpXUKvH9ftuFwVIg">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2021_us-gaap_RelatedPartyTransactionAxis_ganx_LicenseAgreementWithMinoryxTherapeuticsSlMember_uoLGxPyxJ0uSfZ7e2uoHkg" decimals="-3" name="us-gaap:AccountsPayableRelatedPartiesCurrentAndNoncurrent" id="Hidden_UBkW5eX88UutloWkqiLS3Q">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_RelatedPartyTransactionAxis_ganx_LicenseAgreementWithMinoryxTherapeuticsSlMember_cr-ykWSWVE6F-fAwmXseZg" decimals="-3" name="us-gaap:RevenueFromRelatedParties" id="Hidden_hWewlVC51Ui9nanprIOh2A">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_RelatedPartyTransactionAxis_ganx_LicenseAgreementWithMinoryxTherapeuticsSlMember_mBz6FxcSTU-e2iDkMK0uyg" decimals="-3" name="us-gaap:RevenueFromRelatedParties" id="Hidden_v0zh4D61U0W62I-2KUdtrQ">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_RelatedPartyTransactionAxis_ganx_LicenseAgreementWithMinoryxTherapeuticsSlMember_cr-ykWSWVE6F-fAwmXseZg" decimals="-3" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" id="Hidden_jR1LzriL-0SBUDw1tY_yqg">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_RelatedPartyTransactionAxis_ganx_LicenseAgreementWithMinoryxTherapeuticsSlMember_mBz6FxcSTU-e2iDkMK0uyg" decimals="-3" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" id="Hidden_OjxvEsGIu0inzt8v3me_aA">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_HPxGCJIoKkWKHRC95IDwMg" decimals="INF" name="us-gaap:PreferredStockSharesIssued" id="Hidden_kdwNLQKYWkiveM0sOQGupw">1185879</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_SZL-8g69ikyvM5ITtvQ_vA" decimals="INF" name="us-gaap:PreferredStockSharesIssued" id="Hidden_iLyIO00eQUWJB3oyw2X5yQ">2965600</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_pure_YPFUW3Xga0mVMPZT28RXUw" contextRef="Duration_3_3_2021_To_3_3_2021_pvtif4URAkie9GX28TaLHA" decimals="INF" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" id="Hidden_R7-eb03Se0uFXfouVE5ALg">1.1353521</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw" contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg" decimals="INF" name="us-gaap:CommonStockSharesIssued" id="Hidden_ofEil3W8JECpBaDUijTFww">3543163</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw" contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" id="Hidden_vhbG_gva8kyxLeHJvfawEw">11883368</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw" contextRef="As_Of_3_16_2021_fYMXRlaU00CBob3C4xDimg" decimals="0" name="us-gaap:CommonStockSharesOutstanding" id="Hidden_ARvqt8O7vki9CqZo9ksCdw">4022736</ix:nonFraction></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="ganx-20211231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="As_Of_12_31_2021_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_ValuationTechniqueAxis_us-gaap_ValuationTechniqueOptionPricingModelMember_imxnCtN6ykq3qhuSJY2jEg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_us-gaap_ValuationTechniqueAxis_us-gaap_ValuationTechniqueOptionPricingModelMember_jbd4-HDMH0K2ZzXOCoSCFA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_us-gaap_ValuationTechniqueAxis_us-gaap_ValuationTechniqueOptionPricingModelMember_9QqzfSmMzkiY1DCoSmnXjg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_ValuationTechniqueAxis_us-gaap_ValuationTechniqueOptionPricingModelMember_pn73ofcvSUeZsLeHLTUKsg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_us-gaap_ValuationTechniqueAxis_us-gaap_ValuationTechniqueOptionPricingModelMember_LWxcsazXDk2P_fSZ_3WyGA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_us-gaap_ValuationTechniqueAxis_us-gaap_ValuationTechniqueOptionPricingModelMember_1wOkdymSaEyzTP505R_Yzw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_uZL4jiBANU-5t9wJ3fQwpA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_17_2021_To_3_17_2021_us-gaap_StatementClassOfStockAxis_ganx_PreferredStockSeriesAndSeriesBMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_r8J2spGPVEeD9l3nZ-VHoQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ganx:PreferredStockSeriesAndSeriesBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-17</xbrli:startDate><xbrli:endDate>2021-03-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_3_2021_To_3_3_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_lfgvFolLLU68lyHCSIQe6A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ganx:OmnibusIncentivePlanTwoThousandTwentyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-03</xbrli:startDate><xbrli:endDate>2021-03-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_3_2021_To_3_3_2021_pvtif4URAkie9GX28TaLHA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-03</xbrli:startDate><xbrli:endDate>2021-03-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_20_2020_To_7_20_2020_CH_oHqEadU-bNi2WtP4JnA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-20</xbrli:startDate><xbrli:endDate>2020-07-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_n0BVNh7nXEOEg7ig4OTueQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_BSZ8PS8MmUKSjqHr7IV3kw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_aTBx7lbU9EmXTzCop7s5VQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_wUcCiJ_aL0uNAaoLQz_kIQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_AmnlCLXS4EW0T11vxuv4dA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_gy5vyeo0XECt7V84YflbPw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_triyROczKkOUjFoGUVGRSg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_5pVNHNLDU0aNGDOeH5tWLQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_gMslWnX56U6NnNQwJeyNJQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_SekcF5i21U2sPnRupyd-qQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredClassBMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_HKF8S1_Sj0ytyt6XZS1DhQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_pyBaEfYw3k-Bre7rOUHY8A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_9f9qYFGKFEi5lUCxbnfGyA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_UWKqqxKGa0GJPrjjqykVHA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_7i8WecRBqEmSQhLalEWwQQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_jyeDTSFma0emcErckg2zrw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_17_2021_us-gaap_SubsidiarySaleOfStockAxis_ganx_IpoExcludingUnderwritersOptionsMember_TfY1dJMilk2kFQZuPi8-sw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ganx:IpoExcludingUnderwritersOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_3_16_2021_To_3_16_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_8OFhhtn3CkCh-eZfG1m3iA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ganx:OmnibusIncentivePlanTwoThousandTwentyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-16</xbrli:startDate><xbrli:endDate>2021-03-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ganx_ExercisePrice7.80Member_azVHc_tr_02k1bZtu5dcVA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ganx:OmnibusIncentivePlanTwoThousandTwentyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ganx:ExercisePrice7.80Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ganx_ExercisePrice5.99Member_IRU-JBn3zUmz8JgkEa1wmQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ganx:OmnibusIncentivePlanTwoThousandTwentyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ganx:ExercisePrice5.99Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ganx_ExercisePrice5.86Member_ldKP04Tc_EiQ1aX3hzo_jQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ganx:OmnibusIncentivePlanTwoThousandTwentyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ganx:ExercisePrice5.86Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ganx_ExercisePrice3.38Member_q48VnEGwiUKrGR7I5_LISQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ganx:OmnibusIncentivePlanTwoThousandTwentyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ganx:ExercisePrice3.38Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ganx_ExercisePrice10.03Member__Arw4xIJUEO-yWegbRND-A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ganx:OmnibusIncentivePlanTwoThousandTwentyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ganx:ExercisePrice10.03Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_liEc-LEvuUmppacbgwHfFg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ganx:OmnibusIncentivePlanTwoThousandTwentyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ganx_ExercisePrice5.99Member__H3l5fnJok-E9OkINM3A4Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ganx:OmnibusIncentivePlanTwoThousandTwentyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ganx:ExercisePrice5.99Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ganx_ExercisePrice5.86Member_gBKLZo1l-0W49gJ_33Ix3Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ganx:OmnibusIncentivePlanTwoThousandTwentyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ganx:ExercisePrice5.86Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ganx_ExercisePrice10.03Member_t43zzwTn0EOG01iusAqyuA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ganx:OmnibusIncentivePlanTwoThousandTwentyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ganx:ExercisePrice10.03Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ganx_ExercisePrice7.80Member_IAhcMx9gQUiYIcwUzGxvUw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ganx:OmnibusIncentivePlanTwoThousandTwentyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ganx:ExercisePrice7.80Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ganx_ExercisePrice3.38Member_vX53-sp5zEGR0K2gPjCseA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ganx:OmnibusIncentivePlanTwoThousandTwentyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ganx:ExercisePrice3.38Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_23_2021_us-gaap_PlanNameAxis_ganx_TwentyTwentyoneInducementEquityIncentivePlanMember_dc6nUQZMq0iDFdVD-aASTQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ganx:TwentyTwentyoneInducementEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_0JEx-N7nxEOplYgSWCGOgw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_24_2020_To_9_24_2020_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_RTjAu4qAPEqUn3L27gh5Ow"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ganx:OmnibusIncentivePlanTwoThousandTwentyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-24</xbrli:startDate><xbrli:endDate>2020-09-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_24_2020_To_9_24_2020_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_7U57Cx256U2tLHUf4s6Y8A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ganx:OmnibusIncentivePlanTwoThousandTwentyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-24</xbrli:startDate><xbrli:endDate>2020-09-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_ganx_ZentalisPharmaceuticalsInc.Member_us-gaap_TypeOfArrangementAxis_ganx_MultiTargetCollaborationAgreementMember_vo15OpWqgkuGY59e7z-yzg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ganx:ZentalisPharmaceuticalsInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ganx:MultiTargetCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ganx_OfficeSpaceViaPietroPeri9DLuganoSwitzerlandMember_DFphXJwj90K3f5xEo5ZU9Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ganx:OfficeSpaceViaPietroPeri9DLuganoSwitzerlandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_RelatedPartyTransactionAxis_ganx_LicenseAgreementWithMinoryxTherapeuticsSlMember_mBz6FxcSTU-e2iDkMK0uyg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ganx:LicenseAgreementWithMinoryxTherapeuticsSlMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_RelatedPartyTransactionAxis_ganx_LicenseAgreementWithMinoryxTherapeuticsSlMember_cr-ykWSWVE6F-fAwmXseZg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ganx:LicenseAgreementWithMinoryxTherapeuticsSlMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_bbRnKwgINUGLy8vnaZzYFA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_-nBpIitRCkCtsIXc9x1o_w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_DEcpOGG1JU2_mxWcWch9wA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ganx_LaboratoryInstrumentsMember_QYgSSMkkV06NDZOYiqbepA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ganx:LaboratoryInstrumentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_eLOEQvd7zk-xTusLDMYb_Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_K3apo3t_cUqHmQGcaov5QQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_6bdG0fwN7EC_-yHkMAKyHQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ganx_LaboratoryInstrumentsMember_5du392y7_Ea3X3SOCPm2GA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ganx:LaboratoryInstrumentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_3_1_2021_To_3_31_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_N45LChwtn0m3vTVdPokCZw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_16_2021_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredClassBMember_HBe32B_mIkuJvMwKt7oZ-g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_16_2021_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredClassAMember_LA-5cb6F00S56dV8R_wEsQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_UOpY8hOKmEaY4smAqVjcoQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_bnIOh52EIUC-yTsdpcG0NQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_SZL-8g69ikyvM5ITtvQ_vA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_HPxGCJIoKkWKHRC95IDwMg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredClassBMember_G4x0CiU2mUOuiMOxwNFS6Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredClassAMember_QpkPvPPAwEiZSl5LOyqQvA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_lVp5EHBSO0a3sKcZW9whJg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_5l4ULFPqR0yL1UAG81fHvA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember_eYHQNzPoa0Kj3sShxdX8jQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_dHaFDA1AQUSlfDaHicQ8uw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember_cfBf_8Ckq0Gp_Dh77YRizw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_MuNTVlrNBkqVSW1-Y7sqjA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_BvTE8F6mxk6Kxv6RzTF0bw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_AYWDjeIOSU-RxGjTZOS7Tw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_1_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ganx_OfficeSpaceInBethesdaMarylandMember_UeSQeDvOw0SJcAM-RLo4Lg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ganx:OfficeSpaceInBethesdaMarylandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_1_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ganx_OfficeSpaceViaSoaveN6LuganoSwitzerlandMember_PifC1TMuyUCNw5rbo-bIqg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ganx:OfficeSpaceViaSoaveN6LuganoSwitzerlandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_srt_RangeAxis_srt_MinimumMember_eU0rUPNa5UKucFJIXpiTPg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_srt_RangeAxis_srt_MaximumMember_Tv-_F37-xki1Z4qnJJZcNg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_11_1_2021_To_11_1_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ganx_OfficeSpaceTorreDBuildingBarcelonaMember_b34IOdjLSEeVrGT01vF1Rg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ganx:OfficeSpaceTorreDBuildingBarcelonaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-01</xbrli:startDate><xbrli:endDate>2021-11-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2021_To_10_1_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ganx_OfficeSpaceInBethesdaMarylandMember_9U2vOl3u9U-cCfj_ThszJA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ganx:OfficeSpaceInBethesdaMarylandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_dei_LegalEntityAxis_ganx_GtGainTherapeuticsSaMember_srt_CounterpartyNameAxis_ganx_Eurostars2Member_YNqIuW1F40W5tgg_Hji_3Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ganx:GtGainTherapeuticsSaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ganx:Eurostars2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_dei_LegalEntityAxis_ganx_GtGainTherapeuticsSaMember_srt_CounterpartyNameAxis_ganx_Eurostars2Member_FaVauHMhk0mEw4Cnb7EatA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ganx:GtGainTherapeuticsSaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ganx:Eurostars2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_31_2019_dei_LegalEntityAxis_ganx_GtGainTherapeuticsSaMember_srt_CounterpartyNameAxis_ganx_Eurostars2Member_bQ8j0nCuy0GId24-qC-Rwg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ganx:GtGainTherapeuticsSaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ganx:Eurostars2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_31_2019_dei_LegalEntityAxis_ganx_ConsortiumWithGtGainTherapeuticsSaInstituteForResearchInBiomedicineAndNeuroSysSasMember_srt_CounterpartyNameAxis_ganx_Eurostars2Member_rZtMNPgqTUK8vf9PccniAQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ganx:ConsortiumWithGtGainTherapeuticsSaInstituteForResearchInBiomedicineAndNeuroSysSasMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ganx:Eurostars2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_28_2019_dei_LegalEntityAxis_ganx_GtGainTherapeuticsSaMember_srt_CounterpartyNameAxis_ganx_MichaelJ.FoxFoundationForParkinsonSResearchMjffMember_pOgW2epL9EG_XiGfjitJLQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ganx:GtGainTherapeuticsSaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ganx:MichaelJ.FoxFoundationForParkinsonSResearchMjffMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_ComputerSoftwareIntangibleAssetMember_IyvNJLfe-0C5bmjgl1g7MQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_RVGfoikIBESMbmCXz6RCfw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ganx:OmnibusIncentivePlanTwoThousandTwentyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_StatementGeographicalAxis_country_ES_No2V5hdzvE6TY_AfyyLEBQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:ES</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_BhPyaAaDOkudfThK5f94MA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_RetirementPlanSponsorLocationAxis_country_CH_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_JNWw1VrK5kqfZgK60b8Pdw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:CH</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_RetirementPlanSponsorLocationAxis_country_CH_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_XR8N6cpyV0WdwjyDiJrSbA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:CH</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_3_1_2020_To_3_31_2020_us-gaap_DebtInstrumentAxis_ganx_March2020ChfLoanMember_S8zeqoa7qEuI5LdFwXbKLw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ganx:March2020ChfLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_1_2020_To_8_31_2020_us-gaap_DebtInstrumentAxis_ganx_August2020ChfLoanMember_QkIhdbW_8Uis0Buu2_viHA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ganx:August2020ChfLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-01</xbrli:startDate><xbrli:endDate>2020-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_31_2020_us-gaap_DebtInstrumentAxis_ganx_August2020ChfLoanMember_os9qx323O06rGZDMfoiU8Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ganx:August2020ChfLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2020_us-gaap_DebtInstrumentAxis_ganx_March2020ChfLoanMember_FV-iSHC9DECOjK6nXfZqag"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ganx:March2020ChfLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_srt_CounterpartyNameAxis_ganx_ZentalisPharmaceuticalsInc.Member_us-gaap_TypeOfArrangementAxis_ganx_MultiTargetCollaborationAgreementMember_VaQZuPvZpUe8IpzXfakMYA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ganx:ZentalisPharmaceuticalsInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ganx:MultiTargetCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_OtherCommitmentsAxis_ganx_CollaborationAgreementsMember_Yr71bAiK8EiGzhgz_kIr8Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">ganx:CollaborationAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_16_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_-yJfbN_d1U6z9SG-fWFZ5A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ganx:OmnibusIncentivePlanTwoThousandTwentyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_16_2021_fYMXRlaU00CBob3C4xDimg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_24_2020_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_yL43kRndvEW68muLtDGB3g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ganx:OmnibusIncentivePlanTwoThousandTwentyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_6_2021_us-gaap_ClassOfWarrantOrRightAxis_ganx_WarrantsToDesigneesOfInvestmentBankIssuedMay2021Member_vInDzK2VLEaPLuCJ2B3g4g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ganx:WarrantsToDesigneesOfInvestmentBankIssuedMay2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_17_2021_us-gaap_ClassOfWarrantOrRightAxis_ganx_WarrantsToDesigneesOfPlacementAgentIssuedJuly2020Member_g-_VaNc3WkybZ1HHEFo_GQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ganx:WarrantsToDesigneesOfPlacementAgentIssuedJuly2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_16_2021_us-gaap_ClassOfWarrantOrRightAxis_ganx_WarrantsToDesigneesOfPlacementAgentIssuedJuly2020Member_YF5W3invl02ldRF6Cq2TAQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ganx:WarrantsToDesigneesOfPlacementAgentIssuedJuly2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_31_2020_us-gaap_ClassOfWarrantOrRightAxis_ganx_WarrantsToDesigneesOfPlacementAgentIssuedJuly2020Member__xz3VXdq4UepWPvW5n-chA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ganx:WarrantsToDesigneesOfPlacementAgentIssuedJuly2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_jVvLJZrhl0W1Aw8CczgC5A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_gnHItaHOm0WTAQXAM2HTwQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CashMember_fDDfSQp6UU-oqPAB4e119Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_YVDinHFXT0-dz2LLkYn02Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CashMember_hSR99mDOLk29CBNFU890Kw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_jwo2h2HgjU-Oaoug1oOjXg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_FairValueByAssetClassAxis_us-gaap_CashAndCashEquivalentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_aPJD3-UwWk2aYpTKhM55uA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_uuaa7xnlyki6ykqgX7Pttw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_yQGxUTb4_kyBt2-oIiFKuQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_FairValueByAssetClassAxis_us-gaap_CashAndCashEquivalentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_zzuqJkU6kk6sqgnOWt5eyA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_c2-Hsc31bki-8GK8iPACMA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_eFtEzOEVSUW8fCSfS0makQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_nWZin8CUEka_hYHuxWQ98g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_BLTwMarrSki4A2b_zuzjjQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_SeriesAPreferredStockMember_gYxd91evBkC5xqONi1hr9g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_PreferredClassBMember_ulJHYyt9xkm7k2JpVT1HlQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PreferredClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_o5CVJWPFxkyUPRNzDIKUWw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_8kdx5frm8UGeszq3O_KyBg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ganx:OmnibusIncentivePlanTwoThousandTwentyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_idnllJAzZk6p-wCg6SCFow"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ganx:OmnibusIncentivePlanTwoThousandTwentyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_W_1SbimhkkmXrYE8c7oscg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ganx:OmnibusIncentivePlanTwoThousandTwentyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_I180bvlxRk2MS8zltC_nhQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ganx:OmnibusIncentivePlanTwoThousandTwentyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_oZ2efAweo0yRRNPJFNieTA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ganx:OmnibusIncentivePlanTwoThousandTwentyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_t7HEGl5NAk-CsgC95XNoeg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_RelatedPartyTransactionAxis_ganx_LicenseAgreementWithMinoryxTherapeuticsSlMember_uoLGxPyxJ0uSfZ7e2uoHkg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ganx:LicenseAgreementWithMinoryxTherapeuticsSlMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_RelatedPartyTransactionAxis_ganx_LicenseAgreementWithMinoryxTherapeuticsSlMember_VIe1l_ajWEuJhOrR7dlifQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ganx:LicenseAgreementWithMinoryxTherapeuticsSlMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_srt_CurrencyAxis_currency_USD_JNFtn3l03kGKX0UlySPmQQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_srt_CurrencyAxis_currency_EUR_FPdG1lChOEK7NjX3VPs_Hw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_srt_CurrencyAxis_currency_CHF_rDufzY5Ouk6hLwlR1vAueQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CHF</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_srt_CurrencyAxis_currency_USD_MG28bHY0C0G-LS6iFm77lQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_srt_CurrencyAxis_currency_EUR_jtopedrPUk-JApA2wqKkRg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_srt_CurrencyAxis_currency_CHF_x9IJv5F-j0en4mIAdI3ZtA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CHF</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_ValuationTechniqueAxis_us-gaap_ValuationTechniqueOptionPricingModelMember_QzEVNtuW9US0oSPFOgMt6A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_ValuationTechniqueAxis_us-gaap_ValuationTechniqueOptionPricingModelMember_2H_dl4e8hE-KkfFPdigrJA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_6_2021_To_5_6_2021_us-gaap_ClassOfWarrantOrRightAxis_ganx_WarrantsToDesigneesOfInvestmentBankIssuedMay2021Member_94Oz4J1U90W8gKhVhzq1zg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ganx:WarrantsToDesigneesOfInvestmentBankIssuedMay2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-06</xbrli:startDate><xbrli:endDate>2021-05-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_ganx_WarrantsToDesigneesOfInvestmentBankIssuedMay2021Member_Xr6HpqPQo0W86a4ZrsARSQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ganx:WarrantsToDesigneesOfInvestmentBankIssuedMay2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_22_2021_To_3_22_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_T4IMo7Q7FkixFavhC2S9FA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-22</xbrli:startDate><xbrli:endDate>2021-03-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_17_2021_To_3_17_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_VPlkneswlU6lplZPmfwMQg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ganx:OmnibusIncentivePlanTwoThousandTwentyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-17</xbrli:startDate><xbrli:endDate>2021-03-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_17_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_NETjxmYYrkyazfL5gwskGw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ganx:OmnibusIncentivePlanTwoThousandTwentyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_12_1_2017_To_12_31_2017_srt_RangeAxis_srt_MaximumMember_us-gaap_RelatedPartyTransactionAxis_ganx_LicenseAgreementWithMinoryxTherapeuticsSlMember_wfhEAoIeSEyyfIL5XTMUAQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ganx:LicenseAgreementWithMinoryxTherapeuticsSlMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-12-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_1_2017_To_12_31_2017_us-gaap_RelatedPartyTransactionAxis_ganx_LicenseAgreementWithMinoryxTherapeuticsSlMember_cbGjmh51ckuCzbppGr1veQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ganx:LicenseAgreementWithMinoryxTherapeuticsSlMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-12-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_ganx_GtGainTherapeuticsSaMember_srt_CounterpartyNameAxis_ganx_MichaelJ.FoxFoundationForParkinsonSResearchMjffMember__G2vs2A3Nk-gHqckeDfJ_w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ganx:GtGainTherapeuticsSaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ganx:MichaelJ.FoxFoundationForParkinsonSResearchMjffMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_ganx_GtGainTherapeuticsSaMember_srt_CounterpartyNameAxis_ganx_Eurostars2Member_QdIjpEm0HEmiFVdv-rxIew"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ganx:GtGainTherapeuticsSaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ganx:Eurostars2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_dei_LegalEntityAxis_ganx_GtGainTherapeuticsSaMember_srt_CounterpartyNameAxis_ganx_MichaelJ.FoxFoundationForParkinsonSResearchMjffMember__vvtnvxiGkihO0mrEzCOXQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ganx:GtGainTherapeuticsSaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ganx:MichaelJ.FoxFoundationForParkinsonSResearchMjffMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_dei_LegalEntityAxis_ganx_GtGainTherapeuticsSaMember_srt_CounterpartyNameAxis_ganx_Eurostars2Member_3HTuGjlZh0OM3ztzJoNVeA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ganx:GtGainTherapeuticsSaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ganx:Eurostars2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_vxw_50xpsk-K6Rt4Xg-w-w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ganx_LaboratoryInstrumentsMember_UGsEilKkZ0-amCM5X6BAdw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ganx:LaboratoryInstrumentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ganx_EquipmentAndFurnitureMember_eYeOQu_NukuBM3xRUGpAow"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ganx:EquipmentAndFurnitureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2019_To_12_31_2019_dei_LegalEntityAxis_ganx_GtGainTherapeuticsSaMember_srt_CounterpartyNameAxis_ganx_Eurostars2Member_kHOQVkb_30--8vvOt4dYkQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ganx:GtGainTherapeuticsSaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ganx:Eurostars2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_18_2021_To_3_18_2021_iMaj3AAJbEqmShHP_jyriA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-18</xbrli:startDate><xbrli:endDate>2021-03-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_17_2021_To_3_17_2021_u6CMktnXaUyF6ar7hHmEcw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-17</xbrli:startDate><xbrli:endDate>2021-03-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_17_2021_To_3_17_2021_us-gaap_SubsidiarySaleOfStockAxis_ganx_IpoExcludingUnderwritersOptionsMember_zUbax__QHU2jXdFcxwazTA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ganx:IpoExcludingUnderwritersOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-17</xbrli:startDate><xbrli:endDate>2021-03-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_1_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ganx_OfficeSpaceTorreIBuildingBarcelonaMember_iI-D9SSrGEKpT_zGFsqoww"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ganx:OfficeSpaceTorreIBuildingBarcelonaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_1_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ganx_OfficeSpaceTorreDBuildingBarcelonaMember_irdsQ60cnEm7ZZpQvK104Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ganx:OfficeSpaceTorreDBuildingBarcelonaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_9J9hcs3P0U-I30H9M7barQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ganx:OmnibusIncentivePlanTwoThousandTwentyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_31_2021_To_8_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ganx_OfficeSpaceViaPietroPeri9DLuganoSwitzerlandMember_KKvzTiG970Ce6TsWGr7BeA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ganx:OfficeSpaceViaPietroPeri9DLuganoSwitzerlandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-31</xbrli:startDate><xbrli:endDate>2021-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_xAFkHxT11EGU0yxL99Adfg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_1HYzj4oHZUevOEIRtTmDzw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredClassBMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember__qh10NtWoEa7l7GjkQhs9A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_ganx_WarrantsToDesigneesOfPlacementAgentIssuedJuly2020Member_YAr_SbLTRk2XAPVCkBuVtg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ganx:WarrantsToDesigneesOfPlacementAgentIssuedJuly2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ubdNM3dDp0mLTH7OlcI_NA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_17_2021_To_3_22_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_SaCdeyGh10qyXh2PUIfaFw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-17</xbrli:startDate><xbrli:endDate>2021-03-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_JDEb6LtAmEuXGmEieWNlsw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_NLtbBeqGQESB9Jjk98teAA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_kMW3hEdOQk-Go8nyyVufvA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_i6PZAoMNcEySLcgBUKmmjw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_HLv731xR10GVgI0Jt-JL5w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_i98h5sWV5U-TOn1S0EBWxQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredClassBMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_W4zZ56C1Q0yKk0LZMBsvMA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_RRjkaPqvD06cYjwCnpc1bQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_20_2021_To_4_20_2021_srt_CounterpartyNameAxis_ganx_ZentalisPharmaceuticalsInc.Member_us-gaap_TypeOfArrangementAxis_ganx_MultiTargetCollaborationAgreementMember_79uwIK2uDU2loW-PUu8mAg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ganx:ZentalisPharmaceuticalsInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ganx:MultiTargetCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-20</xbrli:startDate><xbrli:endDate>2021-04-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_31_2021_srt_CounterpartyNameAxis_ganx_ZentalisPharmaceuticalsInc.Member_us-gaap_TypeOfArrangementAxis_ganx_MultiTargetCollaborationAgreementMember_UAOVQT0JhEyX-WpaUYbKmA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ganx:ZentalisPharmaceuticalsInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ganx:MultiTargetCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_5_1_2021_To_5_31_2021_srt_CounterpartyNameAxis_ganx_ZentalisPharmaceuticalsInc.Member_us-gaap_TypeOfArrangementAxis_ganx_MultiTargetCollaborationAgreementMember_nrRCfgERCkCz3HkVyPGAgA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ganx:ZentalisPharmaceuticalsInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ganx:MultiTargetCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_20_2021_srt_CounterpartyNameAxis_ganx_ZentalisPharmaceuticalsInc.Member_us-gaap_TypeOfArrangementAxis_ganx_MultiTargetCollaborationAgreementMember_MduiqnTW20mQ__WJtWGk9Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ganx:ZentalisPharmaceuticalsInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ganx:MultiTargetCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_5_1_2021_To_5_31_2021_srt_CounterpartyNameAxis_ganx_ZentalisPharmaceuticalsInc.Member_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_ganx_MultiTargetCollaborationAgreementMember_VJHihOl1_0O-yMpbRCHaPA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ganx:ZentalisPharmaceuticalsInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ganx:MultiTargetCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_Coki50uufUmBg7YC34rJmQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_28_2022_K5iAOzWiVE2Y5lP5jccqMA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_item_jlWcaGVl5kGYwaQ1kPo68Q"><xbrli:measure>ganx:item</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_pure_YPFUW3Xga0mVMPZT28RXUw"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_Options_mZpQ0toHqki8W4R9nXDMkA"><xbrli:measure>ganx:Options</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_sqft_u3pgKg_7-0iwjFi0GwLPFg"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_CHF_tZXBcOteZE6rGAnlVuK3Ng"><xbrli:measure>iso4217:CHF</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Divide_USD_shares_ZUfWDOiJrESFdyfJo2gfWg"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="Unit_Standard_EUR_Q6wJYXg2bk-dYmARpDyDyQ"><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unit></ix:resources></ix:header></div><div style="max-width:100%;padding-left:6.05%;padding-right:6.05%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1pt;padding-bottom:1pt;padding-top:1pt;text-align:center;border-bottom:1px solid #000000;border-top:3.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p><a id="_71f3c625_1bdb_455b_a6c6_16278c964b18"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-size:13pt;font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-size:13pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Washington, DC 20549</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:5pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">FORM&#160;</b><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" name="dei:DocumentType" id="Narr_DS9AOj3MPkWPhlTOPO1xJw"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">10-K</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:4pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">(Mark One)</p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" name="dei:DocumentAnnualReport" id="Narr_tUOD0R0-5Eu32QDRzIS1MA"><span style="font-family:'Segoe UI Symbol';">&#9746;</span></ix:nonNumeric></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><b style="font-size:9pt;font-weight:bold;">ANNUAL REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt;"><span style="font-size:4pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;">For the fiscal year ended </span><ix:nonNumeric format="ixt:datemonthdayyearen" contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" name="dei:DocumentPeriodEndDate" id="Narr_ht9GJhwcakOTDDuRZZ7TEg"><span style="font-size:8pt;">December 31, 2021</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:4pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" name="dei:DocumentTransitionReport" id="Narr_j-YZ3RUcDEWGciQPb6tswQ"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><b style="font-size:9pt;font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:4pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt;">For the transition period from <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>&#160; to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:4pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;">Commission file number </span><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" name="dei:EntityFileNumber" id="Narr_fpQtaqzrZE6TFOliZvCbUg"><span style="font-size:8pt;">001-40237</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:3pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:14pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" name="dei:EntityRegistrantName" id="Narr_qs5QnIjEjEemaN9kbDHDsA"><b style="font-weight:bold;">GAIN THERAPEUTICS,&#160;INC</b></ix:nonNumeric><b style="font-weight:bold;">.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;">(Exact name of registrant as specified in its charter)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:4pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-size:2pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_bab4009f_aec9_4dbf_a595_c4293ffca49a"></a><a id="Tc__sNpdRRSOkW5BokZuxAZwg_2_0"></a><a id="Tc_XiZdqvhRIE2JR1c_RB4uqg_2_2"></a><a id="Tc_pwwwAy07c0q_kSTan0kNng_4_0"></a><a id="Tc_i5NVF57L-UmPVvUq9MlIbw_5_0"></a><a id="Tc_qUxztDBbJEidUba3Lw-9aw_5_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:48.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:48.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:stateprovnameen" contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" name="dei:EntityIncorporationStateCountryCode" id="Tc_nfhm164OAkurMzulh5oDcA_1_0"><b style="font-size:8pt;font-weight:bold;">Delaware</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:top;width:48.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" name="dei:EntityTaxIdentificationNumber" id="Tc_Mm64ygh78EWjy5TZ3GwxNg_1_2"><b style="font-size:8pt;font-weight:bold;">85-1726310</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:48.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;">(State or Other Jurisdiction of Incorporation or Organization)</p></td><td style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;">(I.R.S. Employer Identification No.)</p></td></tr><tr><td style="vertical-align:top;width:48.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:48.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" name="dei:EntityAddressAddressLine1" id="Narr_tv2bkqCiHEKxIbf-GTuoNA"><b style="font-size:8pt;font-weight:bold;">4800 Montgomery Lane</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" name="dei:EntityAddressAddressLine2" id="Narr_MkZ3vTakzE2ETEOV3AjwxQ"><b style="font-size:8pt;font-weight:bold;">Suite 220</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;"> </b><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" name="dei:EntityAddressCityOrTown" id="Narr_ZrE0jOxHfU-99yveYXOQrw"><b style="font-size:8pt;font-weight:bold;">Bethesda</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;">, </b><ix:nonNumeric format="ixt-sec:stateprovnameen" contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" name="dei:EntityAddressStateOrProvince" id="Narr_skl_f6xIeEGuU2dGq9_5nQ"><b style="font-size:8pt;font-weight:bold;">Maryland</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" name="dei:EntityAddressPostalZipCode" id="Tc_I12JE9-OXkuHfLBxc6Mu1Q_4_2"><b style="font-size:8pt;font-weight:bold;">20814</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:48.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;">(Address of principal executive offices) </p></td><td style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;">(Zip Code)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:7pt;">Registrant&#8217;s telephone number, including area code: </span><b style="font-size:7pt;font-weight:bold;">(</b><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" name="dei:CityAreaCode" id="Narr__i1hKH7L1Ee_7nbZnn_3mw"><b style="font-size:7pt;font-weight:bold;">301</b></ix:nonNumeric><b style="font-size:7pt;font-weight:bold;">) </b><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" name="dei:LocalPhoneNumber" id="Narr_51rUBkf1JE6oedUjiCo7cg"><b style="font-size:7pt;font-weight:bold;">500-1556</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:4pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:2pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_309c20b8_0ff2_47a1_9f62_3279fd262d48"></a><a id="Tc_pZDeg80vTESU2rHt-N2zgw_1_0"></a><a id="Tc_pOgjmEweukqPg1DWtk-XhQ_1_2"></a><a id="Tc_TDQ_sVMcAEeb6jjJDpL2_A_1_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:37.39%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.9%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:19.81%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:37.04%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:37.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">Title of Each Class</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.9%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:19.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;">Trading Symbol</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:37.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;">Name of Each Exchange on Which Registered</p></td></tr><tr><td style="vertical-align:bottom;width:37.39%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" name="dei:Security12bTitle" id="Tc_MyorGBJrekOdlWXUV3UlBw_2_0"><span style="font-size:8pt;">Common Stock, par value $0.0001 per share</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:19.81%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" name="dei:TradingSymbol" id="Tc_IJOiNQPZbkOAu6QGMcK1yg_2_2"><span style="font-size:8pt;">GANX</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:37.04%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:exchnameen" contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" name="dei:SecurityExchangeName" id="Tc_8d2TkrFDHkiihJMJKo6FLg_2_4"><span style="font-size:8pt;">Nasdaq Global Market</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;">Securities registered pursuant to Section 12(g) of the Act: None</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:4pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-size:8pt;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. &#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span><span style="font-family:'Segoe UI Symbol';">&#160;</span><span style="font-family:'Segoe UI Symbol';">&#160;</span><span style="font-family:'Segoe UI Symbol';">&#160;</span><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" name="dei:EntityWellKnownSeasonedIssuer" id="Narr_xolfJyXbyEy0dDwO8TYQUQ"><span style="font-size:8pt;">No</span></ix:nonNumeric><span style="font-size:8pt;">&#160;&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-size:4pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-size:8pt;white-space:pre-wrap;">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.  Yes &#160;&#160;&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span><span style="font-size:8pt;"> &#160;&#160;&#160;</span><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" name="dei:EntityVoluntaryFilers" id="Narr_xE8rbxefWkOqWcNl5xw42w"><span style="font-size:8pt;">No</span></ix:nonNumeric><span style="font-size:8pt;white-space:pre-wrap;">  </span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-size:4pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.&#160;&#160;</span><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" name="dei:EntityCurrentReportingStatus" id="Narr_Gn9bpUph_U67wolNr4cFaw"><span style="font-size:8pt;">Yes</span></ix:nonNumeric><span style="font-size:8pt;">&#160;&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span><span style="font-size:8pt;">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-family:'Segoe UI Symbol';font-size:4pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;</span><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" name="dei:EntityInteractiveDataCurrent" id="Narr_Q2s2fLKBc02QR-Sw0C1Omw"><span style="font-size:8pt;">Yes</span></ix:nonNumeric><span style="font-size:8pt;">&#160;&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span><span style="font-size:8pt;">&#160;&#160;&#160;No&#160;&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-family:'Segoe UI Symbol';font-size:4pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:18pt;margin:0pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &quot;large accelerated filer,&quot; &quot;accelerated filer,&quot; &quot;smaller reporting company,&quot; and &quot;emerging growth company&quot; in Rule 12b-2 of the Exchange Act:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:4pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-size:2pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_59526d29_b410_4125_ad73_0e92455c18d6"></a><a id="Tc_Eu8oFCyWD0exFKyu7Pry3w_1_0"></a><a id="Tc_hD8slK3X_UuNOIb_YmNztw_1_1"></a><a id="Tc_-dwQ9AiIo06Dp1tjYQOBog_1_2"></a><a id="Tc_yznsdoo8nkSj67-mvguW9w_1_3"></a><a id="Tc_IxZL4lXqT0aI9P54uONBGQ_1_5"></a><a id="Tc_JJRDYm0JxEaygwK-n-zIcg_1_6"></a><a id="Tc_TTku0auuGk2T9t6P8UPM9g_3_6"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:19.75%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:3.25%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:18.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:22.97%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:3.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:25.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.34%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:19.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0pt 18pt;">Large accelerated filer</p></td><td style="vertical-align:bottom;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt;"><span style="font-family:'Segoe UI Symbol';">&#9744;</span>&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:18.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt;">Accelerated filer</p></td><td style="vertical-align:bottom;width:3.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt;"><span style="font-family:'Segoe UI Symbol';">&#9744;</span><span style="font-family:'Segoe UI Symbol';">&#160;</span><span style="font-family:'Segoe UI Symbol';">&#160;</span><span style="font-family:'Segoe UI Symbol';">&#160;</span></p></td><td style="vertical-align:bottom;width:22.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><ix:nonNumeric format="ixt-sec:entityfilercategoryen" contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" name="dei:EntityFilerCategory" id="Tc_hfb7Xn8ObUC88k5V0jPxcw_1_4"><span style="font-size:8pt;">Non-accelerated filer</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:3.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt;"><span style="font-family:'Segoe UI Symbol';">&#9746;</span><span style="font-family:'Segoe UI Symbol';">&#160;</span><span style="font-family:'Segoe UI Symbol';">&#160;</span><span style="font-family:'Segoe UI Symbol';">&#160;</span></p></td><td style="vertical-align:bottom;width:25.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt;">Smaller reporting company</p></td><td style="vertical-align:bottom;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" name="dei:EntitySmallBusiness" id="Tc_jFNwv4d4KUGHoC0YRqTBRQ_1_7"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:19.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:18.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:22.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:25.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:19.75%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:3.25%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:18.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:22.97%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:3.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-family:'Segoe UI Symbol';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:25.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt;">Emerging growth company</p></td><td style="vertical-align:bottom;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" name="dei:EntityEmergingGrowthCompany" id="Tc_LFqtDZ6GuEOH3BL1EOUFHg_3_7"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:3pt;margin:0pt;">&#160;&#160;&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-size:8pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" name="dei:EntityExTransitionPeriod" id="Narr_6Ij0391E902TvOHRd33yMw"><span style="font-family:'MS Mincho';font-size:8pt;">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-size:4pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.&#160;</span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" name="dei:IcfrAuditorAttestationFlag" id="Narr_Qkz8P4JfmUG8g2qvE_FCAw"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-family:'Segoe UI Symbol';font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).&#160;Yes </span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" name="dei:EntityShellCompany" id="Narr_Lg7PfX0TQEm2QMLLcoTMaw"><span style="font-family:'MS Mincho';font-size:8pt;">&#9744;</span></ix:nonNumeric><span style="font-size:8pt;">&#160;&#160;No&#160;&#160;</span><span style="font-family:'MS Mincho';font-size:8pt;">&#9746;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-size:4pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:18pt;margin:0pt;">The aggregate market value of the common equity held by non-affiliates of the Registrant on June 30, 2021 (the last business day of the Registrant&#8217;s second fiscal quarter), based upon the closing price of $10.00 of the Registrant&#8217;s common stock as reported on The Nasdaq Global Market, was approximately $<ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" format="ixt:numdotdecimal" scale="6" contextRef="As_Of_6_30_2021_Coki50uufUmBg7YC34rJmQ" decimals="-5" name="dei:EntityPublicFloat" id="Narr_k423MrtfYkiPWtOs3ileNA">118.7</ix:nonFraction> million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-size:4pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:18pt;margin:0pt;">As of February 28, 2022, <ix:nonFraction unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw" format="ixt:numdotdecimal" scale="0" contextRef="As_Of_2_28_2022_K5iAOzWiVE2Y5lP5jccqMA" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" id="Narr_PSMZBzKflkSRoFkDoaU2gQ">11,883,368</ix:nonFraction> shares of the registrant&#39;s Common Stock were outstanding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:21.6pt;margin:0pt;"><span style="font-size:3pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">DOCUMENTS INCORPORATED BY REFERENCE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:4pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;text-indent:18pt;margin:0pt;">Portions of the definitive Proxy Statement (&#8220;Proxy Statement&#8221;) of Gain Therapeutics, Inc. to be filed pursuant to Regulation 14A of the general rules and regulations under the Securities Exchange Act of 1934, as amended, for the 2022 annual meeting of stockholders to be held within 120 days after the end of the Registrant&#8217;s 2021 fiscal year are incorporated by reference into Part III of this Form 10-K</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:3pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1pt;padding-bottom:1pt;padding-top:1pt;text-align:center;text-indent:0pt;border-bottom:3.0pt solid #000000;border-top:1px solid #000000;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;text-indent:0pt;margin:0pt;"><span style="font-size:0pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:87.91%;border:0;margin:30pt 6.05% 30pt 6.05%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:3pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:3pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_106a9ca5_6ee8_4f6f_adc3_68a6d3c75270"></a><a id="TOC"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">GAIN THERAPEUTICS, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ANNUAL REPORT FORM 10-K</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">TABLE OF CONTENTS</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:10.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:81.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:8.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:10.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:81.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Page</b></p></td></tr><tr><td style="vertical-align:bottom;width:10.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:81.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.2%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:91.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9pt;" href="#CAUTIONARYNOTEREGARDINGFORWARDLOOKINGSTA"><span style="font-style:normal;font-weight:normal;">Cautionary Note Regarding Forward Looking Statements</span></a></p></td><td style="vertical-align:top;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;">3</span></p></td></tr><tr><td style="vertical-align:bottom;width:10.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:81.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3pt;"><a style="font-size:9pt;" href="#PARTI_627814"><b style="font-style:normal;font-weight:bold;">Part I</b></a></p></td><td style="vertical-align:bottom;width:81.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:81.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3pt;"><a style="font-size:9pt;" href="#ITEM1BUSINESS_942174"><span style="font-style:normal;font-weight:normal;">Item 1.</span></a></p></td><td style="vertical-align:bottom;width:81.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9pt;" href="#ITEM1BUSINESS_942174"><span style="font-style:normal;font-weight:normal;">Business</span></a></p></td><td style="vertical-align:top;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;">5</span></p></td></tr><tr><td style="vertical-align:top;width:10.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:81.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3pt;"><a style="font-size:9pt;" href="#ITEM1ARISKFACTORS_98263"><span style="font-style:normal;font-weight:normal;">Item 1A.</span></a></p></td><td style="vertical-align:bottom;width:81.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9pt;" href="#ITEM1ARISKFACTORS_98263"><span style="font-style:normal;font-weight:normal;">Risk Factors</span></a></p></td><td style="vertical-align:top;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;">35</span></p></td></tr><tr><td style="vertical-align:top;width:10.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:81.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3pt;"><a style="font-size:9pt;" href="#ITEM1BUNRESOLVEDSTAFFCOMMENTS_29639"><span style="font-style:normal;font-weight:normal;">Item 1B.</span></a></p></td><td style="vertical-align:bottom;width:81.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9pt;" href="#ITEM1BUNRESOLVEDSTAFFCOMMENTS_29639"><span style="font-style:normal;font-weight:normal;">Unresolved Staff Comments</span></a></p></td><td style="vertical-align:top;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;">64</span></p></td></tr><tr><td style="vertical-align:top;width:10.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:81.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3pt;"><a style="font-size:9pt;" href="#ITEM2PROPERTIES_990758"><span style="font-style:normal;font-weight:normal;">Item 2.</span></a></p></td><td style="vertical-align:bottom;width:81.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9pt;" href="#ITEM2PROPERTIES_990758"><span style="font-style:normal;font-weight:normal;">Properties</span></a></p></td><td style="vertical-align:top;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;">64</span></p></td></tr><tr><td style="vertical-align:top;width:10.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:81.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3pt;"><a style="font-size:9pt;" href="#ITEM3LEGALPROCEEDINGS_174891"><span style="font-style:normal;font-weight:normal;">Item 3.</span></a></p></td><td style="vertical-align:bottom;width:81.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9pt;" href="#ITEM3LEGALPROCEEDINGS_174891"><span style="font-style:normal;font-weight:normal;">Legal Proceedings</span></a></p></td><td style="vertical-align:top;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;">64</span></p></td></tr><tr><td style="vertical-align:top;width:10.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:81.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3pt;"><a style="font-size:9pt;" href="#ITEM4MINESAFETYDISCLOSURES_461102"><span style="font-style:normal;font-weight:normal;">Item 4.</span></a></p></td><td style="vertical-align:bottom;width:81.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9pt;" href="#ITEM4MINESAFETYDISCLOSURES_461102"><span style="font-style:normal;font-weight:normal;">Mine Safety Disclosures</span></a></p></td><td style="vertical-align:top;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;">64</span></p></td></tr><tr><td style="vertical-align:top;width:10.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:81.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3pt;"><a style="font-size:9pt;" href="#PARTII_504996"><b style="font-style:normal;font-weight:bold;">Part II</b></a></p></td><td style="vertical-align:bottom;width:81.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:81.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3pt;"><a style="font-size:9pt;" href="#ITEM5MARKETFORREGISTRANTSCOMMONEQUITYREL"><span style="font-style:normal;font-weight:normal;">Item 5.</span></a></p></td><td style="vertical-align:bottom;width:81.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9pt;" href="#ITEM5MARKETFORREGISTRANTSCOMMONEQUITYREL"><span style="font-style:normal;font-weight:normal;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a></p></td><td style="vertical-align:top;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;">65</span></p></td></tr><tr><td style="vertical-align:top;width:10.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:81.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3pt;"><a style="font-size:9pt;" href="#ITEM6SELECTEDFINANCIALDATA_182437"><span style="font-style:normal;font-weight:normal;">Item 6.</span></a></p></td><td style="vertical-align:bottom;width:81.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9pt;" href="#ITEM6SELECTEDFINANCIALDATA_182437"><span style="font-style:normal;font-weight:normal;">Selected Financial Data</span></a></p></td><td style="vertical-align:top;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;">65</span></p></td></tr><tr><td style="vertical-align:top;width:10.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:81.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3pt;"><a style="font-size:9pt;" href="#ITEM7MANAGEMENTSDISCUSSIONANDANALYSISOFF"><span style="font-style:normal;font-weight:normal;">Item 7.</span></a></p></td><td style="vertical-align:bottom;width:81.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9pt;" href="#ITEM7MANAGEMENTSDISCUSSIONANDANALYSISOFF"><span style="font-style:normal;font-weight:normal;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td><td style="vertical-align:top;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;">65</span></p></td></tr><tr><td style="vertical-align:top;width:10.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:81.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3pt;"><a style="font-size:9pt;" href="#ITEM7AQUANTITATIVEANDQUALITATIVEDISCLOSU"><span style="font-style:normal;font-weight:normal;">Item 7A.</span></a></p></td><td style="vertical-align:bottom;width:81.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9pt;" href="#ITEM7AQUANTITATIVEANDQUALITATIVEDISCLOSU"><span style="font-style:normal;font-weight:normal;">Quantitative and Qualitative Disclosures about Market Risk</span></a></p></td><td style="vertical-align:top;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;">74</span></p></td></tr><tr><td style="vertical-align:top;width:10.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:81.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3pt;"><a style="font-size:9pt;" href="#ITEM8FINANCIALSTATEMENTSANDSUPPLEMENTARY"><span style="font-style:normal;font-weight:normal;">Item 8.</span></a></p></td><td style="vertical-align:bottom;width:81.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9pt;" href="#ITEM8FINANCIALSTATEMENTSANDSUPPLEMENTARY"><span style="font-style:normal;font-weight:normal;">Financial Statements and Supplementary Data</span></a></p></td><td style="vertical-align:top;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;">75</span></p></td></tr><tr><td style="vertical-align:top;width:10.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:81.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3pt;"><a style="font-size:9pt;" href="#ITEM9CHANGESINANDDISAGREEMENTSWITHACCOUN"><span style="font-style:normal;font-weight:normal;">Item 9.</span></a></p></td><td style="vertical-align:bottom;width:81.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9pt;" href="#ITEM9CHANGESINANDDISAGREEMENTSWITHACCOUN"><span style="font-style:normal;font-weight:normal;">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></a></p></td><td style="vertical-align:top;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;">105</span></p></td></tr><tr><td style="vertical-align:top;width:10.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:81.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3pt;"><a style="font-size:9pt;" href="#ITEM9ACONTROLSANDPROCEDURES_641227"><span style="font-style:normal;font-weight:normal;">Item 9A.</span></a></p></td><td style="vertical-align:bottom;width:81.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9pt;" href="#ITEM9ACONTROLSANDPROCEDURES_641227"><span style="font-style:normal;font-weight:normal;">Controls and Procedures</span></a></p></td><td style="vertical-align:top;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;">105</span></p></td></tr><tr><td style="vertical-align:top;width:10.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:81.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3pt;"><a style="font-size:9pt;" href="#ITEM9BOTHERINFORMATION_35024"><span style="font-style:normal;font-weight:normal;">Item 9B.</span></a></p></td><td style="vertical-align:bottom;width:81.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9pt;" href="#ITEM9BOTHERINFORMATION_35024"><span style="font-style:normal;font-weight:normal;">Other information</span></a></p></td><td style="vertical-align:top;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;">106</span></p></td></tr><tr><td style="vertical-align:top;width:10.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:81.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3pt;"><a style="font-size:9pt;" href="#PARTIII_82225"><b style="font-style:normal;font-weight:bold;">Part III</b></a></p></td><td style="vertical-align:bottom;width:81.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:81.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3pt;"><a style="font-size:9pt;" href="#ITEM10DIRECTORSEXECUTIVEOFFICERSANDCORPO"><span style="font-style:normal;font-weight:normal;">Item 10.</span></a></p></td><td style="vertical-align:bottom;width:81.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9pt;" href="#ITEM10DIRECTORSEXECUTIVEOFFICERSANDCORPO"><span style="font-style:normal;font-weight:normal;">Directors, Executive Officers and Corporate Governance</span></a></p></td><td style="vertical-align:top;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;">107</span></p></td></tr><tr><td style="vertical-align:top;width:10.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:81.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3pt;"><a style="font-size:9pt;" href="#_ITEM_11._EXECUTIVE"><span style="font-style:normal;font-weight:normal;">Item 11.</span></a></p></td><td style="vertical-align:bottom;width:81.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9pt;" href="#_ITEM_11._EXECUTIVE"><span style="font-style:normal;font-weight:normal;">Executive Compensation</span></a></p></td><td style="vertical-align:top;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;">107</span></p></td></tr><tr><td style="vertical-align:top;width:10.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:81.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3pt;"><a style="font-size:9pt;" href="#ITEM12SECURITYOWNERSHIPOFCERTAINBENEFICI"><span style="font-style:normal;font-weight:normal;">Item 12.</span></a></p></td><td style="vertical-align:bottom;width:81.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9pt;" href="#ITEM12SECURITYOWNERSHIPOFCERTAINBENEFICI"><span style="font-style:normal;font-weight:normal;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></p></td><td style="vertical-align:top;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;">107</span></p></td></tr><tr><td style="vertical-align:top;width:10.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:81.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3pt;"><a style="font-size:9pt;" href="#_ITEM_13._CERTAIN"><span style="font-style:normal;font-weight:normal;">Item 13.</span></a></p></td><td style="vertical-align:bottom;width:81.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9pt;" href="#_ITEM_13._CERTAIN"><span style="font-style:normal;font-weight:normal;">Certain Relationships and Related Transactions and Director Independence</span></a></p></td><td style="vertical-align:top;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;">107</span></p></td></tr><tr><td style="vertical-align:top;width:10.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:81.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3pt;"><a style="font-size:9pt;" href="#ITEM14PRINCIPALACCOUNTANTFEESANDSERVICES"><span style="font-style:normal;font-weight:normal;">Item 14.</span></a></p></td><td style="vertical-align:bottom;width:81.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9pt;" href="#ITEM14PRINCIPALACCOUNTANTFEESANDSERVICES"><span style="font-style:normal;font-weight:normal;">Principal Accountant Fees and Services</span></a></p></td><td style="vertical-align:top;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;">107</span></p></td></tr><tr><td style="vertical-align:top;width:10.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3pt;"><span style="font-size:9pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:81.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3pt;"><a style="font-size:9pt;" href="#PARTIV_897554"><b style="font-style:normal;font-weight:bold;">Part IV</b></a></p></td><td style="vertical-align:bottom;width:81.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:81.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3pt;"><a style="font-size:9pt;" href="#ITEM15EXHIBITSANDFINANCIALSTATEMENTSCHED"><span style="font-style:normal;font-weight:normal;">Item 15.</span></a></p></td><td style="vertical-align:bottom;width:81.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9pt;" href="#ITEM15EXHIBITSANDFINANCIALSTATEMENTSCHED"><span style="font-style:normal;font-weight:normal;">Exhibits and Financial Statement Schedules</span></a></p></td><td style="vertical-align:top;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;">108</span></p></td></tr><tr><td style="vertical-align:top;width:10.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:81.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3pt;"><a style="font-size:9pt;" href="#_ITEM_16._FORM"><span style="font-style:normal;font-weight:normal;">Item 16.</span></a></p></td><td style="vertical-align:bottom;width:81.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9pt;" href="#_ITEM_16._FORM"><span style="font-style:normal;font-weight:normal;">Form 10-K Summary</span></a></p></td><td style="vertical-align:top;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;">109</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_26284b49_b734_41ee_93eb_77d0062ced6c"></a><a id="CAUTIONARYNOTEREGARDINGFORWARDLOOKINGSTA"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">CAUTIONARY NOTE REGARDING FORWARD LOOKING STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">This Annual Report on Form&#160;10-K contains forward-looking statements which are made pursuant to the safe harbor provisions of Section&#160;27A of the Securities Act of 1933, as amended (the &#8220;Security Act&#8221;), and Section&#160;21E of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). These forward-looking statements can be identified by the fact that they do not relate strictly to historical or current facts and are often characterized by the use of words such as &#8220;aim&#8221;, &#8220;believe,&#8221; &#8220;can,&#8221; &#8220;could,&#8221; &#8220;potential,&#8221; &#8220;plan,&#8221; &#8220;predict,&#8221; &#8220;goals,&#8221; &#8220;seek,&#8221; &#8220;should,&#8221; &#8220;may,&#8221; &#8220;may have,&#8221; &#8220;would,&#8221; &#8220;estimate,&#8221; &#8220;continue,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;expect&#8221; or the negative of these terms, other comparable terminology or by discussions of strategy, plans or intentions. Such forward-looking statements involve known and unknown risks, expectations, uncertainties, assumptions, estimates and projections about our company and other important factors that could cause our actual results, performance or achievements, or industry results, to differ materially from historical results or any future results, performance or achievements expressed, suggested or implied by such forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements. For more information regarding these risks and uncertainties as well as certain additional risks that we face, refer to &#8220;<i style="font-style:italic;">Risk Factors</i>&#8221; as well as the factors more fully described in &#8220;<i style="font-style:italic;">Management&#8217;s Discussion and Analysis of Financial Conditions and Results of Operations</i>&#8221; These include, but are not limited to, statements about:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to develop, obtain regulatory approval for and commercialize our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing of investigational new drug (&#8220;IND&#8221;) submissions, initiation of preclinical studies and clinical trials, and timing of expected clinical results for our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our success in early preclinical studies, which may not be indicative of results obtained in later studies or clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the outbreak of a novel strain of the coronavirus, COVID-19, which could adversely impact our business, including our preclinical studies and any future clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the potential benefits of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to obtain regulatory approval to commercialize our existing or any future product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to identify patients with the diseases treated by our product candidates, and to enroll healthy volunteers and patients in clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the success of our efforts to expand our pipeline of product candidates and develop marketable products through the use of our Site-Directed Enzyme Enhancemenet Therapy (&#8220;SEE-Tx&#174;&#8221;) platform;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our expectations regarding collaborations and other agreements with third parties and their potential benefits;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to obtain, maintain and protect our intellectual property;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our reliance upon intellectual property licensed from third parties, including the license to use our SEE-Tx&#174; platform;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to identify, recruit and retain key personnel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our use of net proceeds from our IPO and the sufficiency of such net proceeds to fund our operations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our financial performance;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">developments or projections relating to our competitors or our industry;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the impact of laws and regulations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our expectations regarding the time during which we will be an emerging growth company under the JOBS Act; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the impact of political instability, natural disaster, events of terrorism, wars, including the recent conflict between Ukraine and Russia, and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">other factors and assumptions described in this Annual Report on Form&#160;10-K.</span></td></tr></table><div style="margin-top:6pt;"></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If one or more of the factors affecting our forward-looking information and statements proves to be incorrect, our actual results, performance or achievements could differ materially from those expressed in, or implied by, forward-looking information and statements. Therefore, we caution not rely on any forward-looking information or statements. The effect of these factors is difficult to predict. Factors other than these also could adversely affect our results, and the reader should not consider these factors to be a complete set of all potential risks or uncertainties. New factors emerge from time to time, and management cannot assess the impact of any such factor on our business or the extent to which any factor, or combination of factors, may cause results to differ materially from those contained in any forward-looking statement. Any forward-looking statements only speak as of the date of this document, and we undertake no obligation to update any forward-looking information or statements, whether written or oral, to reflect any change, except as required by law. All forward-looking statements attributable to us are expressly qualified by these cautionary statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Additional risk factors that could cause actual results to differ materially from our expectations include, but are not limited to, the risks identified by us under the heading &quot;<i style="font-style:italic;">Risk Factors</i>&quot; in Item&#160;1A of this report and the statements made in subsequent filings. Such forward-looking statements speak only as of the date they are made. Except to the extent required by law, we expressly disclaim any obligation to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations with regard thereto or change in events, conditions, or circumstances on which any statement is based.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_47071431_9fc3_4c17_985d_a551c2cd2120"></a><a id="PARTI_627814"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PART&#160;I</p><a id="ITEM1BUSINESS_942174"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">ITEM&#160;1. BUSINESS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Overview</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;margin:0pt;">We are a biotechnology company developing novel small molecule therapeutics to treat diseases across,&#160; several therapeutics areas, including, lysosomal storage disorders (&#8220;LSDs&#8221;), central nervous system disorders (&#8220;CNS&#8221;), metabolic disorders, and oncology. We use our exclusively in-licensed computational target and drug discover platform, Site-Directed Enzyme Enhancement Therapy (&#8220;SEE-Tx&#174;&#8221;), to discover novel allosteric binding sites on proteins implicated in a disease and to identify proprietary small molecules that bind these sites to modulate protein function, and treat the underlying cause of the disease. These binding sites, distinct from the protein&#8217;s active site, are called allosteric sites. We believe that targeting an allosteric binding site instead of the active binding site of a protein provides numerous advantages: the ability to regulate proteins implicated in disease through several different mechanisms of action covering both functional and conformational effects, including stabilization, destabilization, targeted degradation, allosteric inhibition, and allosteric activation of the targeted protein; improved specificity of small molecules because binding to an allosteric binding site is non-competitive with the natural substrate that binds to the active binding site; and the ability to identify small  molecules with more favorable drug-like properties. The SEE-Tx&#174; platform has been used to identify novel allosteric sites and small molecules for all of our internal and partnered programs.&#160; Discovering and targeting novel allosteric sites with our platform not only collapses traditional drug discovery timelines but enables rational drug design and offers the potential for superior small molecule drugs that are highly specific and that can penetrate hard to reach tissues and cross the blood-brain barrier.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">We have filed four patent applications for our novel small molecule drug candidates that are Structurally Targeted Allosteric Regulators (&#8220;STARs&#8221;). In June 2021, the Company announced the publication of two PCT patents. The first was directed at compounds targeting misfolded beta-&#8203;glucocerebrosidase (GBA) addressing CNS diseases such as Parkinson&#8217;s disease, Gaucher disease, Alzheimer&#8217;s disease, and Lewy body dementia. The second was directed at compounds targeting galactosylceramidase (GALC), addressing demyelinating disorders such as Krabbe disease and multiple sclerosis. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">We have identified two different STARs as the lead compounds for our Parkinson&#8217;s disease program and our Gaucher disease program and are currently developing these product candidates through preclinical studies. In September 2021, the Company announced positive topline data of an <i style="font-style:italic;">in vitro</i> study evaluating the two STARs for the treatment of Gaucher and Parkinson&#8217;s disease in neuronal cells derived induced pluripotent stem cells (&#8220;iPSCs&#8221;) of a a patient with Gaucher disease that contained the disease-causing mutation of the GBA1 gene and from iPSCs of a healthy donor with a normal GBA1 gene, so called wild-type cells. The results of the study, conducted at the University of Maryland School of Medicine, demonstrate a significant increase in beta-glucocerebrosidase (&#8220;GCase&#8221;) protein levels, improved trafficking of GCase to the lysosome, and a significant decrease of toxic substrates glucosylceramide and alpha-synuclein p129 levels in both the neuronal cells that contained the mutated GBA1 gene as well as the wild-type cells. Alpha synuclein is consididered to be the hallmark of Parkinson&#8217;s disease. In addition, these data provides further evidence that these product candidates have the potential to treat Gaucher disease and Parkinson&#8217;s disease and slow or stop the progression of GBA Parkinson&#8217;s disease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We expect to complete the preclinical development and submit the regulatory dossier to the Human Research Ethics Committee in Australia to initiate a first-in-human Phase 1 clinical trial in our Parkinson&#8217;s disease program, and to initiate the preclinical toxicology studies for our Gaucher program in the second half of 2022. In addition, we plan to continue to advance research programs and initiate additional programs targeting allosteric binding sites identified with the SEE-Tx&#174; platform.&#160; Through academic partnerships, co-development and licensing arrangements, we intend to develop a broad pipeline of therapeutics, using our novel approach of identifying and targeting previously unknown allosteric sites.&#160;&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Since our inception in 2017, we have devoted substantially all of our resources to identify and develop next-generation brain-penetrant allosteric small molecules for the treatment of devastating diseases with high-unmet medical needs using our in-licensed SEE-Tx&#174; &#160;platform. To date, we do not have any product candidates approved for sale and have not generated any revenue from product sales. We have primarily financed our operations through a combination of sales of our securities and research grants. On March&#160;17, 2021, we completed our IPO and issued and sold approximately 4.1 million shares of our common stock at a public offering price of $11.00 per share, including approximately 0.5 million shares in connection with the full exercise of the underwriters&#8217; option to purchase additional </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:169.51pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">shares, resulting in net proceeds of approximately $40.5 million, after deducting the underwriting discounts and commissions and offering expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our operations have consisted primarily of organizing and expanding the Company&#8217;s operation, securing financing, performing research, conducting preclinical studies and developing licensed technology. We face risks associated with early-stage biotechnology companies whose product candidates are in development. Product candidates currently under development will require significant additional research and development efforts, including extensive preclinical and clinical testing and regulatory approval prior to commercialization. These efforts require significant amounts of additional capital for us to complete our research and development, achieve our research and development objectives, defend our intellectual property rights, and recruit and retain skilled personnel, and key members of management. Even if our product development efforts are successful, it is uncertain when, if ever, we will realize significant revenue from product sales.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our Platform for&#160;Computational Target and Drug Discovery</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Overview</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A majority of disease-causing proteins (up to 90%) cannot be targeted due to the lack of a known binding site. Our exclusively in-licensed platform, SEE-Tx&#174; was designed to address this problem. We use the platform to discover novel binding sites on proteins implicated in a disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. We focus specifically on allosteric binding sites distinct from the protein&#8217;s active, or orthosteric, binding site, where a small molecule can attach and trigger an effect that may lead to a therapeutic benefit. We refer to the small molecules we identify that bind to these allosteric sites as structurally targeted allosteric regulators, or STARs, to reflect their mechanism of action and how they are discovered.&#160; The graphic below provided an overview of SEE-Tx&#174;.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="ganx-20211231x10k001.jpg" alt="Graphic" style="display:inline-block;height:169.06pt;left:0%;padding-bottom:0.45pt;position:relative;top:0pt;width:408.69pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Allosteric Buinding Site Identification</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Using the three-dimensional structure of proteins that have been experimentally derived or generated or that &#160;predictive protein structures from the Alphafold database and our computational technology, our SEE-Tx&#174; platform applies various computational methods and proprietary algorithms to identify and map previously uncharacterized binding sites on the proteins called &#8220;binding hotspots or allosteric binding sites.&#8221; These are key points on the protein surface where a small molecule can potentially bind. The amount, density, nature and quality of these hotspots determine the druggability of the protein, that is, if a drug-like small molecules can effectively bind to the particular site with an appropriate potency.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;padding-bottom:12pt;margin:0pt;">Advantages of Targeting Allosteric Binding Sites&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:19.5pt;background:#ffffff;margin:0pt;">&#160;We focus on allosteric binding site, which offer a number of advantages compared to targeting the active binding site of a protein, including the ability to regulate proteins implicated in disease through several different mechanisms of action covering both functional and conformational effects, improved specificity of small molecules because binding to an allosteric binding site is non-competitive with the natural substrate that binds to the active binding site, </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:172.74pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;">and the ability to identify small molecules with more favorable drug-like properties.&#160; The graphic below provided an overview of the differences and benefits of allosteric binding sites compared to active binding sites.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:19.5pt;background:#ffffff;margin:0pt;"><span style="font-family:'Segoe UI';font-size:9pt;margin-bottom:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="ganx-20211231x10k002.jpg" alt="Graphic" style="display:inline-block;height:172.74pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:401.45pt;" /><br /><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;padding-bottom:12pt;margin:0pt;">Identification of Structurally Targeted Allosteric Regulatotrs (&#8220;STARs&#8221;) &#8211; Our Molecular Hypothesis&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:19.55pt;background:#ffffff;margin:0pt;">After an allosteric site has been identified, characterized and selected for targeting, we then use our proprietary structure-based virtual screening methodology to filter a pool of seven to ten million commercially-available compounds to identify those that may potentially bind to the hotspot and have a functional effect. Using this information, we develop structural templates to guide the development of a narrowed pool of unique and proprietary small molecules that bind to the newly discovered allosteric sites.<span style="font-size:12pt;">&#160;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:19.55pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">We believe our process for identifying STARs is a more efficient and effective drug discovery tool than traditional drug discovery approaches such as random high-throughput screening because we use a validated-target approach. In high-throughput screening, very large libraries of randomly selected molecules are tested for their ability to perform a specific function such as binding to a target protein. This approach typically results in a large number of positive responses that must then be laboriously analyzed to identify compounds with relevant properties and effect. In contrast, every small molecule hit identified by our platform is experimentally tested based on a two-part molecular hypothesis to confirm that (1) the compound has&#8239;a positive effect on the relevant biomarkers implicated in the disease and (2) binding to the allosteric binding site identified with the SEE-Tx&#174; platform has the intended effect on protein function. Compared to high throughput screening, our validated-target approach is significantly less expensive, significantly faster and significantly more effective. We run our SEE-Tx&#174; simulations for target and drug discovery in supercomputer centers where we pay only for time used as and when needed. We can identify a novel allosteric site in one to two weeks, perform virtual screening in three to four weeks, and validate compounds experimentally in two to three weeks. Our average hit rate for validated compounds is 14%, which represents a greater than 1000-fold enrichment compared to traditional high throughput screening methods.<span style="font-size:12pt;">&#160;</span>In addition, traditional screening methods takes months to years to complete.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;padding-bottom:12pt;margin:0pt;">Allosteric Regulators Cover Several Mechanisms of Action &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">Another benefit of targeting allosteric sites, is that it allows for several different mechanisms of action. In our LSD and Parkinson&#8217;s disease programs, we have identified STARs that are designed to&#160;bind to a misfolded protein, stabilize that protein and restore protein function. However, in areas such as oncology, we have identified STARs that are designed to&#160;destabilize normal proteins by binding to a non-native or mutant form of the protein and&#160; render&#160; it inactive. There are several additional potential mechanisms of action including allosteric targeted protein degradation, as well as traditional allosteric inhibition or activation by inducing a conformational change to inhibit or induce binding </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">7</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:175.95pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;">by the natural ligand of the active site of the protein.&#160;&#160;The graphic below provides an overview of the different mechanism of action available through allosteric binding sites.</p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="font-family:'Segoe UI';"><img src="ganx-20211231x10k003.jpg" alt="Graphic" style="display:inline-block;height:172.8pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:372.96pt;" /></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;padding-bottom:12pt;margin:0pt;">Enzyme Misfolding and Disease&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">Proteins are large biomolecules that have a vast array of functions in different cell types in the body. Enzymes are a type of protein that accelerate and facilitate chemical reactions inside of cells by acting on substrates and converting those substrates into different chemical products. To perform their function in the body, enzymes and other proteins must be folded into the correct three-dimensional shape. Misfolded enzymes may not function properly, which can lead to the toxic accumulation of unprocessed substrate which is the cause of many rare genetic diseases, including LSDs and some neurodegenerative diseases such as certain forms of Parkinson&#8217;s disease. Enzyme misfolding may arise from genetic mutations that disrupt the folding pattern as well as from cellular stress due to aging and inflammation. Therapeutic small molecules that facilitate the folding of enzymes into their correct shape can restore function and the proper processing of substrate. As illustrated below, in LSDs, the gene that codes for an enzyme is mutated and results in a misfolded enzyme. The misfolded enzyme cannot traffic through the cell resulting in toxic protein accumulation. We believe that our STARs will have the ability to bind to the allosteric site of the defective enzyme and restore wild type activity and thus serve as potential therapeutic treatments for diseases.&#160;The graphic below provided an overview of the postulated mechanism of action.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt 0pt 6pt 0pt;"><span style="font-size:10pt;margin-bottom:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="ganx-20211231x10k004.jpg" alt="Graphic" style="display:inline-block;height:175.95pt;width:315pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;padding-bottom:12pt;margin:0pt;">Limitations of Current Therapies for the Treatment of LSDs&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">Current therapeutic approaches to address misfolded enzymes have inherent limitations. In standard chaperone therapy, the drug binds to the active site of the enzyme or other target protein which impairs the protein&#8217;s function to some degree by competing with the active substrate, decreasing efficacy and potentially leading to </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">8</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:192.24pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 12pt 0pt;">selectivity issues. Other treatments such as enzyme replacement therapy (&#8220;ERT&#8221;), in which new functional enzymes are infused into the patient, are not optimal for treating neurological conditions because currently available ERTs cannot cross the blood-brain barrier and do not address the root cause of the disease. Gene therapy, which aims to create new, functional enzymes, is not readily accepted for treating neurological conditions because the procedure is invasive in nature and the efficacy of treating neurological conditions remains to be established. Given these limitations on current therapies, we believe patients would benefit from a new therapeutic approach both on its own and, potentially, in combination with existing therapies. We believe our therapeutic approach represents a potentially significant change from current approaches by addressing protein misfolding using our efficient and proprietary ability to identify previously undiscovered allosteric sites and compounds that avoid the active sites of enzymes and cross the blood-brain barrier or penetrate other hard-to-treat tissues such as bone and cartilage. Additionally, our approach enables the less-invasive and more convenience of oral administration.<span style="font-size:12pt;">&#160;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our Pipeline of STARs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are leveraging our SEE-Tx&#174; technology platform to develop a pipeline of novel small molecule drug candidates to address complex diseases. The initial focus of the development pipeline was on several LSDs with high unmet medical need, but has since expanded to include CNS disorders, metabolic diseases, and oncology. The platform is disease agnostic and provides us with the ability to expand our pipeline as we continue to discover new targets. We have entered into a number of collaborations to advance the development of our programs, such as with the Michael J. Fox Foundation for Parkinson&#8217;s Research, The Silverstein Foundation, University of Illinois, Chicago and the University of Maryland; these collaborations are understandings to work together in the research of potential therapies for the treatment of specific diseases. Neither we, nor the institutions we collaborate with, are under contractual obligations to continue the collaboration and all parties retain their respective intellectual property. Additionally, we have a multi-target drug development and commercialization partnership with Zentalis Pharmaceuticals for the development of novel small molecules for the treatment of cancers.&#160;&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We believe that the STARs we have selected for our product pipeline programs have high specificity to their allosteric binding site and do not interact with the active site of the enzyme target, which is designed to enhance both tolerability and response. Our technology allows us to identify STARs that have the ability to bind to both mutant and wild-type enzymes. Because they are small molecules, STARs can be administered orally, have the ability to cross the blood-brain barrier and enter hard-to-treat tissues such as bone and cartilage. We believe the ability to cross the blood-brain barrier is essential to effectively treating diseases with neurological symptoms. In addition, we believe our STARs could be used in combination with ERT or gene therapy approaches to more completely address the patient&#8217;s needs.&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Programs in Preclinical Development</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="ganx-20211231x10k005.jpg" alt="Graphic" style="display:inline-block;height:192.24pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:407.52pt;" /></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">9</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">GCase Enzyme-Related Disorders: GBA1 Parkinson&#8217;s Disease and Neuronopathic Gaucher Disease</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are investigating the restoration of GCase enzymatic function as a treatment for Parkinson&#8217;s Disease (PD) and neuronopathic Gaucher disease (nGD), an LSD. GCase is an enzyme encoded by the GBA1 gene and found in lysosomes that is needed to breakdown the large molecule glucocerebroside (a component of the cell membrane) into sugar and fat. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Homozygous mutations of the GBA1 gene lead to the misfolding of GCase and associated degradation, which in turn&#160;can lead to accumulation of these substrates to toxic levels in the liver, spleen, bone marrow and nervous system and can result in lysosomal storage and neurodegenerative diseases. Unlike other types of Gaucher disease, none of the existing therapeutics are effective in treating nGD.&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The GBA1 gene mutation most commonly associated with nGD is also found in the most pathogenic form of Parkinson&#8217;s disease (PD), where heterozygous mutations of the GBA1 gene also lead to the misfolding of GCase and reduced GCase activity, which similarly leads to accumulation of the toxic substrate alpha-synuclein, a pathological hallmark of Parkinson&#8217;s disease. Decreased GCasse activity is also observed in idiopathic PD (PD that occurs in patients without GBA1 mutuations) and Lewy Body Dementia. Currently, there is no cure for nGD or PD, and there are very limited treatment options. Current treatments such as ERT cannot address central nervous system symptoms because they cannot cross the blood-brain barrier.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;padding-bottom:12pt;margin:0pt;">Overview of GBA1 Parkinson&#8217;s Disease&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:19.5pt;background:#ffffff;margin:0pt;">Parkinson&#8217;s disease is a disorder of the central nervous system that affects movement, often including tremors. Nerve cell damage in the brain causes dopamine levels to drop, leading to the symptoms of Parkinson&#39;s disease. Parkinson&#39;s disease often starts with a tremor in one hand and other symptoms including slow movement, stiffness and loss of balance, and progresses to a severe debilitating disease that eventually require full-time home care or a transfer to a skilled nursing facility.&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:19.5pt;background:#ffffff;margin:0pt;">GBA1 Parkinson&#8217;s disease is caused by mutations in the&#8239;GBA1&#8239;gene, which are among the most pathogenic risk factors for the development of Parkinson&#8217;s disease and related neurodegenerative disorders characterized by the accumulation of alpha-synuclein in cell bodies of neurons. It is widely accepted that GCase deficiency has a biological role as a modifier or facilitator of Parkinson&#8217;s disease pathogenesis in the brain. Brain autopsy studies have shown that even some cases of idiopathic Parkinson&#8217;s disease (without&#8239;<i style="font-style:italic;">GBA1</i>&#8239;mutations) exhibit decreased levels of GCase. Reduced GCase activity may enhance the risk for Parkinson&#8217;s disease by facilitating a pathological hallmark, namely alpha-synuclein accumulation. Alpha-synuclein accumulation and GCase deficiency are thought to act in a debilitating cycle. GCase deficiency can cause the accumulation of glucosylsphingosine substrate, which has been reported to directly affect the accumulation and aggregation of alpha-synuclein. In addition, increased alpha-synuclein levels can lead to less GCase activity, which in turn can lead to more alpha-synuclein accumulation.&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:19.5pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">Parkinson&#8217;s disease is reported to affect about 1 in 780 people worldwide or approximately one million worldwide. Up to 14% of patients with Parkinson&#8217;s disease carry&#8239;GBA1&#8239;mutations, making it the major genetic risk factor for the disease and this rate is higher in certain patient populations. At present, there is no effective cure for Parkinson&#8217;s disease. Treatment options or potential treatments, such as ERT, are limited due to their inability to cross the blood-brain barrier and are therefore unable to prevent neurodegeneration. Current approved therapies for Parkinson&#8217;s disease are limited to symptomatic treatments such as levodopa, dopaminergic receptor agonists and inhibitors of enzymes related to dopamine metabolism such as monoamine oxidase inhibitors and catechol-O-methyltransferase inhibitors. These therapies aim to improve overall dopaminergic function. The benefits of these types of treatments diminish over time as the disease progresses, and these therapies do not impact the non-motor symptoms or the progression of the disease. As the disease progresses, the non-motor symptoms, such as dementia and cognitive impairment, can lead to severe morbidity and mortality. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Preclinical Characterization of Lead Compound GT-02287 for the Treatment of PD&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;padding-bottom:12pt;margin:0pt;">&#160;Biological Activity&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:19.5pt;background:#ffffff;margin:0pt;">We have identified the lead compound GT-02287 targeting GCase for the treatment of GBA1 and idiopathic PD. Biophysical assay results have demonstrated that our STAR compound can bind to GCase protein and increase its thermal stability. We observed a dose-dependent increase in GCase activity in normal and GCase mutant cells when </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">10</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:132.04pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;">treated with our STAR molecule. Additionally, GT-02287 has shown cell type and mutation specific GCase enzyme enhancement in an extended panel of patient derived cells representative of the most frequent and pathogenic GBA1 mutations related to GBA1 Parkinson&#8217;s and neuronopathic Gaucher&#8217;s disease. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:19.5pt;background:#ffffff;margin:0pt;">To assess GCase delivery into the lysosomes upon treatment with GT-02287,&#160;HEK293 were transfected with either GBA WT, GBA L444P and GBA N370S with HaloTag, thirty hours later, compounds and a fluorescent Halo ligand that covalently binds to a pocket in the tag were added for 17 hours. Once the protein reaches the lysosome, the tag is cleaved off GCase but is resistant to lysosomal hydrolases enabling the detection of a 31 kDa fluorescent fragment that corresponds to the protein that reached the lysosome. Full length protein and lysosomal fragment were measured by western blot. Treatment with GT-02287 of transfected cells both with WT and mutated GBA1 (N370S, L444P) leads to enhanced GCase lysosomal delivery.&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:21.3pt;background:#ffffff;margin:0pt;">The efficacy of GT-02287 was assessed in an <i style="font-style:italic;">in vitro</i> model of rat primary mesencephalic neurons where GD was chemically induced by inhibiting GCase using the irreversible inhibitor CBE. Cells were cultured, at day 6, GT-02287 was applied and after 24 hours, CBE (400 &#181;M) was added to the culture medium for 48 hours. On day 8, the culture was fixed and stained with tyrosine hydroxylase (TH), a marker for dopaminergic neurons. Neuronal survival, neurite network was evaluated. GT-02287 was assessed at 100 nM, 500 nM, 1 &#181;M and 12.5 &#181;M and dose-dependently improved neuronal survival, neurite network and decreased CBE-induced a-synuclein accumulation in TH neurons.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:21.3pt;background:#ffffff;margin:0pt;">We used an <i style="font-style:italic;">in vitro</i> model based on patient-derived iPSCs differentiated into cortical neurons to assess the efficacy of GT-02287 in enhancing GCase enzyme activity, protein levels, translocation into the lysosomes, as well as the ability of GT-02287 in reducing toxic substates (GlcCer and a-synuclein). 45-day cortical human neurons were incubated with GT-02287 for 48 hrs. The cell pellets were washed once with 1xPBS and stored at -80&#176;C. Sphingolipids were extracted from pelleted cells and analyzed by LC-MS and data was collected form three independent experiments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:21.3pt;background:#ffffff;margin:0pt;">We reported that GT-02287 increased GCase enzyme levels, co-localization of GCase with lysosomes, reduced both phosphorylated and aggregated a-synuclein as well as reduced GlcCer accumulation in L444P/RecNcil and L444P/L444P patients (see figure below).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:21.3pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;background:#ffffff;margin:0pt;"><img src="ganx-20211231x10k006.jpg" alt="Graphic" style="display:inline-block;height:131.64pt;left:0%;padding-bottom:0.4pt;position:relative;top:0pt;width:338.59pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;padding-bottom:12pt;margin:0pt;">Toxicology and Safety&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">GT-02287 was administered in mice with IV (3 mice per dose group) and oral administration (12 mice per dose group). GT-02287 was safe up to 60 mg/kg IV and was well tolerated up to 120mg/kg PO BID following sub-chronic twelve days treatment. Additional non-clinical studies, which include toxicology, safety and pharmacology studies are currently ongoing for GT-02287.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;padding-bottom:12pt;margin:0pt;">Pharmacokinetics&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">We examined promising STAR molecules in neuro-PK studies to evaluate their brain penetration properties. GT-02287 showed high brain exposure with a brain-to-plasma ratio level greater than one. Additional PK studies will be performed as part of the regulatory non-clinical study package.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">11</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:343.9pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Pharmacology&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">A preclinical rotenone-induced Parkinson&#8217;s disease model in rats demonstrated that oral administration of GT-02287 leads to a dose-dependent depletion of total and phosphorylated alpha-synuclein, increase in tyrosine hydroxylase, reduction of microgliosis as well as improvement in rearing behavior. GT-02287 was administered orally, twice a day for 7 days, to ten rats per group and samples were collected one day after final administration. Rearing behavior and locomotion assessment has been performed at day 8.</span>&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><span style="font-family:'Segoe UI';font-size:9pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:center;margin:0pt;"><span style="font-style:italic;font-weight:bold;"><img src="ganx-20211231x10k007.jpg" alt="Graphic" style="display:inline-block;height:343.9pt;width:417.6pt;" /></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;background:#ffffff;margin:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;margin-bottom:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Overview of GBA Gaucher Disease</span><b style="font-weight:bold;">&#160;</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt;">Gaucher disease is an inherited LSD caused by homozygous mutations of the GBA1 gene that result in<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> </span>the misfolding and subsequent dysfunction of beta-glucocerebrosidase (GCase), an enzyme that breaks down fatty chemicals in the body. Gaucher disease is traditionally classified according to one of three types. Type 1 Gaucher disease is traditionally referred to as a non-neuronopathic form of the disease, for which some treatments are available, but evolving science has shown that patients with type&#8239;1 Gaucher disease may also manifest neurological symptoms later in life. Current ERT and gene therapy treatments are unable to address the onset of type 1 neurological symptoms because these treatments are unable to cross the blood-brain barrier. Unlike Gaucher disease type 1, Gaucher disease types 2 and 3 have early onset brain degeneration that gets progressively worse over time. For this reason, Gaucher disease types 2 and 3 are known as neuronopathic Gaucher disease (nGD). Currently, there is no effective treatment for the severe brain degeneration associated with Gaucher disease types 2 and 3. In type 2 Gaucher disease, there is neurological impairment that presents before birth through the first months of life, progresses rapidly, and is typically fatal within two years. It is a devastating disorder characterized by neurodegeneration and brainstem dysfunction. Additionally, infants with Gaucher disease may have abnormally large organs, deficiency in growth, seizures and compromised swallow and airway problems. Gaucher disease type 3 (also known as chronic neuronopathic Gaucher disease) is thought to be the most common type worldwide. It has a </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">12</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:133.51pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;">later and more gradual onset compared with type 2. People with Gaucher disease type 3 may survive into adulthood with a wide variety of signs and symptoms, including seizures, skeletal irregularities, eye movement disorders, cognitive and coordination problems as well as enlarged liver and spleen, respiratory problems and blood disorders.&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:19.5pt;background:#ffffff;margin:0pt;">Gaucher disease is caused by alterations in the GBA1 gene that encodes GCase, an enzyme which catalyzes a key step in breaking down glucosylceramide and glucosylsphingosine. Partial or complete loss of GCase activity can cause the buildup of glucosylceramide and glucosylsphingosine in the lysosomes of macrophages and the accumulation of these lipid substrates within the CNS can result in neurological symptoms.&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:19.5pt;background:#ffffff;margin:0pt;">The prevalence of Gaucher disease type 1 (non-neuronopathic Gaucher disease) is reported as 1:57,000 to 75,000 people worldwide. Type 1 is the most common form in Western countries (around 95%). The prevalence of type 2 and type 3 Gaucher disease (so called neuronopathic Gaucher disease, or nGD) is approximately 1:100,000 people worldwide, and these forms are the most common in non-Western countries, especially in Asian countries where they make up more than 50% of the Gaucher disease patient population. At present there are no available treatment options for neuronopathic Gaucher disease, but ERT is still used to address organ enlargement, hematological manifestation and bone disease, as well as to improve the quality of life for these patients. ERT does not cross the blood-brain barrier and is not efficient in treating neurological manifestations, therefore creating a significant unmet medical need in this patient population.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Preclinical Characterization of GT-02329 for the Treatment of Gaucher Disease</span><b style="font-weight:bold;">&#160;</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have identified the lead compound GT-02329 targeting GCase for nGD. Biophysical assay results have demonstrated that our STAR compound can bind to GCase protein and increase its thermal stability. We observed a dose-dependent increase in GCase activity in normal and GCase mutant cells when treated with our STAR molecule. The efficacy of GT-02329 in depleting GlcSph (Lyso-Gb1) was assessed in dopaminergic neurons BE(2)-M17 carrying either wild-type or L444P GBA1 mutation after treatment for 10 days with 25 &#956;M of compound. &#160;As shown in the figures below, treatment with GT-02329 of cells bearing wild-type and L444P GCase leads to a decrease of glucosylsphingosine. Media exchange with compound was performed after 3 days, then after 4 days and finally cells were harvested after 3 additional days. &#160;GlcSph (Lyso-Gb1) levels were quantified by LC-MS.&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">STAR compounds decrease glucosylsphingosine levels in the neuronal cell model</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;background:#ffffff;margin:0pt;"><img src="ganx-20211231x10k008.jpg" alt="Graphic" style="display:inline-block;height:132.86pt;left:0%;padding-bottom:0.65pt;position:relative;top:0pt;width:277.94pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">Supported by a grant from the Michael J. Fox Foundation and the Silverstein Foundation, the promising compounds were further evaluated in a neuronal cell model developed by the Vall d&#8217;Hebron Research Institute. These neuronal cell lines express either normal or mutated GCase and display alpha-synuclein accumulation. Since accumulation of alpha-synuclein is the pathological hallmark of Parkinson&#8217;s disease, the use of these cell lines is important to determine the capacity of STAR compounds to decrease accumulation of the most pathogenic form of alpha-synuclein, namely phosphorylated alpha-synuclein (p-synuclein) through enhancement of GCase activity.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;margin:0pt;">In a study with patient-derived iPSCs, 45-day cortical human neurons were incubated with GT-02329 for 48 hrs. The cell pellets were washed once with 1xPBS and stored at -80&#176;C. Sphingolipids were extracted from pelleted cells and analyzed by LC-MS and data was collected form three independent experiments. In this study, GT-02329 was shown to enhance GCase levels and co-localization with lysosomes, and to decrease phosphorylated a-synuclein.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">13</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:105.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;"><i style="font-style:italic;">Pharmacokinetics</i>&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:20pt;background:#ffffff;margin:0pt;">We examined STAR molecules in neuro-PK studies to evaluate their brain penetration properties. GT-02329 showed high brain exposure with a brain-to-plasma ratio level greater than one. Additional PK studies will be performed as part of the regulatory non-clinical study package.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;"><i style="font-style:italic;">Pharmacology</i>&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:19.5pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">A preclinical mouse model demonstrated that oral administration of GT-02329 significantly enhances WT GCase activity both in striatum and plasma and the effect is dose-dependent. GT-02329 was administered orally, twice a day for 12 days, to ten mice per group and samples were collected one hour after the final administration.&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="ganx-20211231x10k009.jpg" alt="Graphic" style="display:inline-block;height:105.5pt;width:278pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="ganx-20211231x10k010.jpg" alt="Graphic" style="display:inline-block;height:30.4pt;width:62pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Pipeline Programs in Research Phase</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:19.5pt;background:#ffffff;margin:0pt;">In addition to our preclinical stage programs for PD and nGD, we have a range of programs in LSDs and a program in a metabolic disease that are in various stages of research.&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">GLB Enzyme-Related Disorders: GM1 Gangliosidosis</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:19.5pt;background:#ffffff;margin:0pt;">GLB is an enzyme found in lysosomes, which are compartments within cells that degrade and recycle different types of molecules, including toxic molecules. GLB is essential for the breakdown of GM1 and keratan sulfate, which serve important functions in the brain and other tissues. Misfolding of GLB allows these substrates to build up to toxic levels and leads to the diseases GM1 Gangliosidosis.&#160;&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:19.5pt;background:#ffffff;margin:0pt;">GM1 gangliosidosis is a rare and often life-threatening LSD in infants (type 1), juveniles (type 2) and adults (type 3). It&#8239;manifests in a continuum of clinical severity by type. In type 1 or the infantile form, the onset is observed earlier and is a more severe and rapidly progressive disease. Type 2 and 3 are less severe manifestations and have slower progression with a juvenile or adult onset. The infantile form of the disease is characterized by onset in the first year of life with symptoms including hypotonia (reduced muscle tone), progressive CNS dysfunction that can lead to deafness, blindness, enlarged liver and spleen rigidity, and progressive skeletal dysplasia that can result in restrictive lung disease and aspiration pneumonia. The disease rapidly progresses, with a life expectancy of two to four years. Juvenile GM1 manifests between 18 months and five years of age with a slower progression compared to infants. The average life expectancy for type 2 GM1 is typically 10&#8239;years. Adult GM1 has an onset age between three and 30. While it is less severe and progresses at a slower rate than infantile or juvenile GM1, adult GM1 causes debilitating symptoms, including muscular atrophy, corneal clouding and dystonia.&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:19.5pt;background:#ffffff;margin:0pt;">The prevalence of GM1 is approximately 1:100,000 to 200,000 live births worldwide. Currently, there is no effective cure for GM1, and symptomatic treatment options, including substrate reduction therapy, ERT, bone marrow transplantation, stem cell transplantation and gene therapy are limited or still under development. Existing approaches are unable to address both the neuronal and systemic symptoms because current treatment options cannot cross the blood-brain barrier or reach other hard-to-treat organs such as bone.&#160;</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">14</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">In Vitro and In Vivo Characterization of STARs for the Treatment of GM1 Gangliosidosis</span>&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:19.5pt;background:#ffffff;margin:0pt;">We have identified novel STAR molecules targeting GLB through our SEE-Tx&#174; platform and conducted our initial studies on these compounds. Binding of two of these compounds to the GLB target has been confirmed using a biophysical assay. Preclinical studies indicate that our STARs help mutated GLB escape premature degradation and travel to the lysosome where it can perform its catalytic activity. These preliminary studies were conducted&#8239;<i style="font-style:italic;">in vitro</i>&#8239;using cells that carried the&#8239;GLB1&#8239;mutation.&#160; In addition, one compound showed clearance of the toxic GM1 ganglioside accumulation in GM1-affected canine cells.&#160;&#160;&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:19.5pt;background:#ffffff;margin:0pt;">We also tested the GLB-targeting compounds in an acute toxicity study in mice after oral administration. No abnormal clinical signs were observed and there were no mortalities at the tested dose levels. As such, we have not yet established a maximum tolerable dose in mice.&#160; Further, we performed preliminary pharmacokinetic (PK) studies with the GLB-targeting compounds in mice confirming that the compounds showed positive brain-penetrating properties. In oral bioavailability studies in mice, we found no central or peripheral clinical abnormalities, and the brain to plasma ratio was greater than one at each dose tested while the bone to plasma ratio increased approximately 3-fold over time from one hour to eight hours. The pharmacokinetic profile was completed with PK studies of one compound after repeated treatments to obtain safety information and exposure in tissues including brain and bone, showing that it was generally well-tolerated after seven days of treatment without showing clinical signs. Comparable plasma exposure was observed at oral doses at two dose levels, and accumulation was not observed after seven days of treatment. Brain concentrations were quantifiable up to eight hours following the last dose showing brain and bone exposure.&#160;&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:19.5pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">After conducting initial pharmacological studies in 2021, we are currently testing additional compounds in in vitro assays to provide the basis for a decision on the lead series selection.&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">IDUA Enzyme-Related Disorders: Mucopolysaccharidosis Type 1 (MPS1)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">IDUA is an enzyme in lysosomes needed to breakdown large sugar molecules called glycosaminoglycans (GAGs), especially heparan sulfate and dermatan sulfate. The misfolding of IDUA can allow substrate to build up to toxic levels in the bone and cartilage and can result in MPS1. There is no cure for MPS1, and treatment options to address symptoms such as enzyme replacement therapy or ERT, laronidase&#174;, and bone marrow transplants are limited.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have identified a STAR targeting IDUA and are applying medicinal chemistry approaches to generate proprietary compounds. Preclinical studies of this compound have shown that in healthy cells, this STAR can stabilize recombinant IDUA and increase its activity. Additionally, when this STAR is co-administrated with laronidase, there is a dose-dependent increase in IDUA activity levels&#160;<i style="font-style:italic;">in vitro</i>&#160;and in mice.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Overview of MPS1</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">MPS1 is a rare LSD that presents as a spectrum of symptoms that can include severe impairment of the CNS. Because there is no clear delineation between the syndromes, patients are best described as having one of two subtypes, severe MPS1 or attenuated MPS1. Patients with severe MPS1 typically have earlier onset of symptoms and experience a decline in intellectual function and a more rapid disease progression.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Symptoms include abnormal formation of the soft tissue of the face, enlarged vocal cords, enlarged liver and spleen, heart valve defects, short stature, joint deformities, corneal clouding, macrocephaly, hydrocephalus, hearing loss, development delays and regression. Children with severe MPS1 usually do not live past the age of 10. Patients with attenuated MPS1 make up approximately 55% of all MPS1 cases and present a variety of symptoms that tend to be less acute than in those seen in severe MPS1. Due to their longer life span, attenuated MPS1 patients also make up a larger fraction of the patient population.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">MPS1 results from mutations in the gene encoding IDUA, an enzyme responsible for the hydrolysis of glycosidic bonds in terminal &#945;-L-iduronic acid residues of complex glycosaminoglycans (GAGs), such as heparan sulfate and dermatan sulfate. Impaired degradation of these molecules can lead to their accumulation within lysosomes and triggers a complex cascade of intracellular events ultimately leading to multisystem morbidity caused by tissue damage and organ dysfunction.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">15</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The prevalence of severe MPS1 is reported as affecting about 1 in 100,000 live births. Attenuated MPS1 is less common and occurs in about 1 in 500,000 live births. At present, there is no effective cure for MPS1 and there are limited treatment options to address symptoms such as enzyme replace therapy or ERT, laronidase, and bone marrow transplants. These approaches, however, do not cross the blood-brain barrier or penetrate the hard to treat tissues like cartilage.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Preclinical Characterization of IDUA Compounds</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Biological Activity</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have identified certain compounds that bind to an allosteric site on IDUA with functional effect. We plan to use this compound as a starting point to generate proprietary compounds. These compounds have been shown to stabilize IDUA and protect the enzyme against denaturation in physiological conditions. Preclinical cell-based studies indicate that stability and cellular uptake of IDUA is enhanced when co-administered with these compounds in MPS-affected fibroblasts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Toxicology and Safety</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The acute toxicity of these preliminary test compounds was investigated after acute intravenous administration to mice to provide information on the maximum tolerated dose to be used in pharmacology studies and determined the maximum tolerable dose for intravenous administration in mice.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Pharmacokinetics</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We performed a neuro-PK study in mice after intravenous administration and determined the compound was not detected in the brain. However, these compounds showed tissue distribution in bone and cartilage, the relevant tissues for MPS1, &#160;after oral administration in mice, which is critical for a potential treatment of MPS1 as current treatments are ineffective at penetrating bone and cartilage. Additionally, at higher doses limited brain penetration was observed and the low brain penetration of this compound was confirmed from a pharmacology study performed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Pharmacology</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Combination therapy of STARs with pharmacological chaperones and ERT can improve tissue uptake and reduce ERT&#8217;s immunogenicity by stabilizing the enzyme in its properly folded and active form&#160;<i style="font-style:italic;">in vivo</i>. In preclinical studies, one of our STAR compounds was co-administered with laronidase (Aldurazyme&#174;), an approved enzyme replacement therapy, intravenously to mice. Data show the combination treatment stabilized the recombinant enzyme, increasing enzymatic activity levels in plasma, liver, bone and cartilage in a dose-dependent manner. Bone and cartilage represent the most critical medical need due to poor ERT uptake in these tissues. The benefit of combination therapy is particularly noticeable at longer times.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">GALC Enzyme-Related Disorders: Krabbe Disease</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are investigating the restoration of GALC function as a treatment for Krabbe disease. GALC is an enzyme in lysosomes needed to breakdown galactolipids, which are fats primarily found in the nervous system and kidneys. Among the galactolipids that GALC breaks down are galactosylceramide, which is an essential component of neuronal myelin, and psychosine, which is formed during myelin production and is toxic to cells. The misfolding of GALC can result in the toxic accumulation of galactosylceramide, inhibiting myelin production, and of psychosine, leading to demyelination of cells and ultimately to Krabbe disease. There is no available cure for Krabbe disease. Current developments in invasive procedures such as bone marrow transplants have not been shown to provide significant neurological improvements, and most developments in gene therapy treatments are still in the preclinical stages.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have identified compounds that bind to allosteric sites on GALC and stabilize the enzyme&#160;<i style="font-style:italic;">in vitro</i>. We are continuing our development of these promising molecules.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Overview of Krabbe Disease</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Krabbe disease is a severe neurological condition that is part of a group of disorders which result from the loss of myelin (demyelination) in the CNS. Myelin is the protective covering around neurons that ensures the rapid </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">16</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">transmission of neural signals. The most common form of Krabbe disease, the infantile form, usually begins before the age of one. Initial symptoms typically include irritability, muscle weakness, feeding difficulties, episodes of fever without any sign of infection, stiff posture and delayed mental and physical development. As the disease progresses, muscles continue to weaken, affecting the infant&#8217;s ability to move, chew, swallow and breathe. Affected infants also experience vision loss and seizures. Because of the severity of the condition, individuals with the infantile form of Krabbe disease rarely survive beyond the age of two. The less common forms, those that have a later onset, begin in childhood, adolescence, or adulthood. Vision problems and walking difficulties are the most common initial symptoms in these late-onset forms of the disorder, however, signs and symptoms vary considerably among affected individuals. Individuals with late-onset Krabbe disease may survive many&#160;years after the condition begins.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:21.3pt;margin:0pt 0pt 12pt 0pt;">Krabbe disease is an inherited LSD caused by mutations in the gene&#160;GALC. In affected individuals, GALC substrate psychosine accumulation can trigger a neuroinflammatory response, a loss of myelin forming cells and a progressive demyelination of the central and peripheral nervous systems.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:21.3pt;margin:0pt 0pt 12pt 0pt;">The prevalence of Krabbe disease is reported as about 1 in 100,000 to 1 in 250,000 live births worldwide. At present, there is no effective cure or disease-modifying treatment for Krabbe Disease. Treatment of a child who is symptomatic before six&#160;months of age is supportive and focused on improving quality of life and avoiding complications. For older individuals, treatment with HSCT is individualized based on disease burden and manifestations, but it serves to delay disease progression and is not an effective cure.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Preclinical Characterization of GALC STAR Lead Compounds</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Biological Activity</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:21.3pt;margin:0pt 0pt 12pt 0pt;">We have identified several compounds that bind to allosteric sites on GALC and are able to stabilize GALC against thermal denaturation. STAR molecules were tested in vitro in transfected HEK293 cells bearing different mutations (WT, G286D, T529M). We examined promising STAR molecules in neuro-PK studies to evaluate their brain penetration properties. Several of the compounds selected showed enhanced enzyme enhancement and high brain exposure with a brain-to-plasma ratio level greater than one.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:21.3pt;margin:0pt;">In collaboration with Ernesto R. Bongarzone, Ph.D., Professor in Neuroscience at the College of Medicine at the University of Illinois, Chicago, initial compounds from this program were tested in mouse glial cultures and cell lines with relevant GALC mutations to measure their effect on GALC enzymatic activity and psychosine levels. We showed that the tested compounds showed significant reduction in psychosine levels in glial cultures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">ARSA Enzyme-related Disorders: Metachromatic Leukodystrophy (MLD)</b>&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:19.5pt;background:#ffffff;margin:0pt;">We are investigating the restoration of ARSA function as a treatment for Metachromatic Leukodystrophy. ARSA is an enzyme in lysosomes needed to breakdown sulfatides and sulfate-containing lipids, which are critical constituents in the nervous system comprising<b style="font-weight:bold;"> </b>approximately 5% of the myelin lipids. The misfolding of ARSA can result in the toxic accumulation of sulfatide in the nervous system, which eventually leads to myelin breakdown (leukodystrophy) and a progressive neurologic disorder.&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:19.5pt;background:#ffffff;margin:0pt;">We have identified two potential allosteric sites and have selected 133 virtual hits obtained from virtual screening with whom to start experimental hit confirmation.&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Overview of MLD</span>&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:14.2pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">Metachromatic leukodystrophy is an autosomal recessive hereditary neurodegenerative disease caused by mutations in the ARSA gene, which encodes the lysosomal enzyme arylsulfatase A. At least 280 ARSA pathogenic variants have been reported, mostly missense mutations. Impaired breakdown of sulfatides and sulfate-containing lipids due to ARSA deficiency in the nervous system eventually leads to myelin breakdown (leukodystrophy) and a progressive neurologic disorder. The exact molecular pathogenic processes of demyelination in MLD are poorly understood.&#160;</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">17</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The clinical presentation of MLD is heterogeneous with respect to the age of onset, the rate of progression, and the initial symptoms. The clinical manifestations and a degree of neurodegeneration depend on the type of mutation and the level of enzyme deficiency. Three clinical subtypes of MLD are primarily distinguished by age of onset:&#160;</p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:54pt;margin-top:0pt;text-align:justify;text-indent:0pt;"><span style="display:inline-block;font-size:10pt;min-width:18pt;white-space:nowrap;">&#9679;</span><span style="font-size:10pt;">Late-infantile MLD, comprising 50%-60% of affected individuals</span></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:54pt;margin-top:0pt;text-align:justify;text-indent:0pt;"><span style="display:inline-block;font-size:10pt;min-width:18pt;white-space:nowrap;">&#9679;</span><span style="font-size:10pt;">Juvenile MLD, approximately 20%-30%</span></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:54pt;margin-top:0pt;text-align:justify;text-indent:0pt;"><span style="display:inline-block;font-size:10pt;min-width:18pt;white-space:nowrap;">&#9679;</span><span style="font-size:10pt;">Adult MLD, approximately 15%-20%</span></div><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:14.2pt;margin:0pt 0pt 12pt 0pt;">Although the presenting symptoms and age of onset vary, all individuals eventually develop complete loss of motor, sensory, and intellectual functions. The disease course may be from several years in the late-infantile-onset form to decades in the juvenile- and adult-onset forms. Death most commonly results from pneumonia or other infection. Life span correlates roughly with the age of onset but can be quite variable, particularly in the later-onset forms.&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Current management is still mostly symptomatic and/or relies on HSCT; however, Libmeldy&#174; (<i style="font-style:italic;">ex vivo</i><span style="font-family:'Calibri','Helvetica','sans-serif';"> </span>gene therapy) has been the first disease-modifying treatment to be approved to date (Dec 2020 in the EU, Ph III in US<span style="font-family:'Calibri','Helvetica','sans-serif';">) </span>and is administered to patients with<span style="font-family:'Calibri','Helvetica','sans-serif';">:</span><span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:54pt;margin-top:0pt;text-align:justify;text-indent:0pt;"><span style="display:inline-block;font-size:10pt;min-width:18pt;white-space:nowrap;">&#9679;</span><span style="font-size:10pt;">late infantile or early juvenile forms of the disease who have not yet developed symptoms;</span><span style="font-size:10pt;">&#160;</span></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:54pt;margin-top:0pt;text-align:justify;text-indent:0pt;"><span style="display:inline-block;font-size:10pt;min-width:18pt;white-space:nowrap;">&#9679;</span><span style="font-size:10pt;">early juvenile forms who have initial symptoms but can still walk independently and have not yet developed mental deterioration.</span><span style="font-size:10pt;">&#160;</span></div><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">There are still limitations and unmet medical needs connected to <i style="font-style:italic;">ex vivo</i> gene therapy. First, it cannot be administered to patients with manifested clinical symptoms therefore it is not ideal for late-onset forms. Moreover, it is very expensive and must be performed in specialized centers since autologous HSCs are transduced <i style="font-style:italic;">ex vivo</i> with ARSA-encoding lentiviral vector and reinfused after the patients had been treated with a myeloablative regimen. Moreover, there is no data yet available on how effective this cross-correction is in the long-term (&gt;15 y).&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:18pt;margin:0pt;">The overall prevalence has been reported at between 1:40,000 and 1:160,000 worldwide. The disorder is pan ethnic; however, most data come from European and North American populations, where prevalence ranges from 1:40,000 to 1:100,000. Incidence is estimated to be 1:40,000 births in the United States of America. Males and females are affected equally and there is no difference in survival.&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;"><i style="font-style:italic;">Primary Screening</i>&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">Hit identification was completed with two orthogonal techniques: hit confirmation was obtained for 8 of 35 compounds (23% hit rate) with consistent K<sub style="font-size:7.5pt;vertical-align:sub;">d</sub>-range in the two-digit &#956;M. Hit analoging was completed with 82 analog compounds tested in dose-response assay. A positive signal was obtained for 22 of 82 compounds (27% hit rate) with consistent K<sub style="font-size:7.5pt;vertical-align:sub;">d</sub>-range in the two-digit &#181;M.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Rare Metabolic Liver/Lung Disorder</b>&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:19.5pt;background:#ffffff;margin:0pt;">We are investigating the stabilization of an undisclosed enzyme to avoid its gain of function in the liver and provide a treatment for a rare lung/liver disease.&#160;We have identified one allosteric site and have selected 146 virtual hits obtained from virtual screening with whom to start experimental hit confirmation.&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;"><i style="font-style:italic;">Primary Screening</i>&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:20pt;background:#ffffff;margin:0pt;">Hit identification completed with Surface Plasmon Resonance (SPR) at one concentration and in dose-response. Binding was confirmed for 23 of 146 compounds (15.6% hit rate). Hit analoging was completed with 85 analog compounds tested in a SPR dose-response assay. Positive signal was observed for 4 of 85 compounds.&#160;</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">18</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Competition</b>&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:19.5pt;background:#ffffff;margin:0pt;">The biotechnology and pharmaceutical industries, including the rare disease field, are characterized by rapidly changing technologies, intense competition and a strong emphasis on intellectual property.&#160;&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:19.5pt;background:#ffffff;margin:0pt;">We are not aware of any other companies that are taking the therapeutic approach to protein folding disorders similar to the one we are pursuing. However, we are aware of companies developing gene therapy approaches for our target indications. For example, Axovant Gene Therapies, Ltd., recently began clinical trial for its gene therapy treatment for juvenile GM1, and Lysogene, S.A. is expected to initiate a clinical trial for its gene therapy treatment for GM1. Additionally, other companies are developing product candidates for the treatment of Krabbe disease such as Chiesi, Ranedis, Passage Bio, MediciNova and Polaryx, which are in the discovery and preclinical stages, and Magenta which is developing a cell-based approach for various inherited metabolic disorders, including Krabbe disease, which is in clinical trials. Companies such as Prevail Therapeutics and Apollo Therapeutics are developing candidates targeting GCase and&#8239;<i style="font-style:italic;">GBA1</i>&#8239;to address type 2 and type 3 Gaucher&#8217;s disease and are in the preclinical and clinical stage for certain candidates. We may also face competition from large pharmaceutical and biotechnology companies, academic research institutions, government agencies and public and private research institutions with genetic medicine and other therapeutic approaches.&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:19.5pt;background:#ffffff;margin:0pt;">Many of our potential competitors, alone or with their strategic partners, may have substantially greater financial, technical and other resources than we do. These may include larger research and development, clinical, marketing and manufacturing organizations and resources. Mergers and acquisitions in the biotechnology and pharmaceutical industries may result in even more resources being concentrated among a smaller number of competitors. Our commercial opportunity could be reduced or eliminated if competitors develop and commercialize products that are safer, more effective, more convenient or less expensive than any product candidates that we may develop. Competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. Additionally, new or advanced technologies developed by our competitors may render our current or future product candidates uneconomical or obsolete, and we may not be successful in marketing our product candidates against competitors. For more information about the risks and challenges we face, see &quot;Risk Factors&quot; under Item&#8239;1A of this Annual Report on Form 10-K.&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Strategic Transactions; Collaboration and Licensing Arrangements</b>&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:21.3pt;background:#ffffff;margin:0pt;">In connection with our business development activities,&#8239;we enter into collaborative and licensing arrangement with third parties, to use our licensed SEE-Tx&#174; computational platform technology to discover novel allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites, potentially restoring protein folding and treating disease. We expect to continue to identify and evaluate collaboration, co-development and licensing opportunities that may be similar to or different from the collaborations and licenses that we have entered into.&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Sumitomo Dainippon Pharma Co.</b>&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">&#160;In September 2020, we entered into a strategic research collaboration agreement with Sumitomo for the research and development of structurally targeted allosteric regulators to restore functional activity of defective lysosomal enzymes in rare genetic and demyelinating diseases. While the goals of the first phase of the research project have been achieved, Sumitomo determined not to continue the research collaboration, and informed the Company on March 22, 2022, that it will send a formal notice letter in due course.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;margin:0pt;"><b style="font-weight:bold;">Zentalis Pharmaceuticals, Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:19.5pt;background:#ffffff;margin:0pt;">On April 20, 2021, the Company entered into a multi-target collaboration agreement with Zentalis Pharmaceuticals, Inc. (&#8220;Zentalis&#8221;) to discover new product candidates for the treatment of cancer. Under the terms of the agreement, the Company will use its licensed SEE-Tx&#174; computational platform technology to identify binding site on target proteins and determine the potential suitability of these sites as drug targets, as well as their prospective therapeutic use in oncology. Pursuant the terms of the agreement, Zentalis agreed to pay the Company, on a program-by-program basis, a non-creditable, non-refundable, program initiation fee and reimburse of expenses incurred by the Company in accordance with the agreed-upon research budget. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">19</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:19.5pt;background:#ffffff;margin:0pt;">With respect to any development program, and subject to the delivery of the data package, the Company granted to Zentalis an option to obtain an exclusive, transferable worldwide license, with the right to sublicense, under relevant intellectual property rights and know-how of the Company arising from the collaboration to develop, manufacture and commercialize any products resulting from the development program. Zentalis may exercise the option, at its reasonable discretion, and shall use commercially reasonable efforts to develop and obtain market approval for products developed from the applicable programs.&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:19.5pt;background:#ffffff;margin:0pt;">Unless terminated earlier, the agreement expires at the expiration of the last valid claim of the licensed patents, subject to certain surviving rights and obligations. Zentalis and the Company can each terminate the agreement in the event of the bankruptcy or insolvency of the other party, or a material breach by the other party and failure to cure such breach within a certain period of time. Zentalis shall have the right, at its sole discretion, exercisable at any time to terminate the agreement on a program-by-program basis, upon ninety (90) days&#8217; prior written notice to the Company or, at any time, if a safety concerns arises with respect to any development program or product.&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:19.5pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">In May 2021, the first target development program was identified, and the estimated development cost were approved and collected in July 2021. The transaction price of this first target development program includes (i)&#8239;$50&#8239;thousand of fixed consideration as program initiation fee, (ii) up to $272 thousand as reimbursement for employee and external research and development cost, (iii) $250 thousand subject to the exercise of a research program option, (iv) up to $41.5&#8239;million of variable consideration in the form of event-based milestone payments, if goals will be met in the future, and (v) other royalty-based payments based on future net sales.&#160; The research project is progressing in accordance with the agreed upon research plans.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Minoryx Therapeutics, S.L.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have entered into a license agreement, dated December&#160;20, 2017 (the &#8220;Minoryx License Agreement&#8221;), with Minoryx Therapeutics, S.L., a company organized under the laws of Spain (&#8220;Minoryx&#8221;), pursuant to which we obtained exclusive worldwide license rights from Minoryx to use and exploit its intellectual property (&#8220;IP&#8221;), including its SEE-Tx&#174; discovery platform for the identification of non-competitive pharmacological chaperones and exclusive worldwide sublicense rights to certain IP licensed by Minoryx from the University of Barcelona and the Instituci&#243; Catalana de Recerca i Estudis Avan&#231;ats. Under the terms of the Minoryx License Agreement, we have an exclusive, worldwide, royalty-bearing, assignable, transferable license, including the right to license through multiple tiers of sublicense, to Minoryx&#8217;s IP to make, have made, use, import, export, offer to sell, have sold, copy, modify, perform, display, create derivative versions of products in the licensed field or otherwise to exploit Minoryx&#8217;s IP in the field. Minoryx&#8217;s IP includes the Site-Directed Enzyme Enhancement Therapy (SEE-Tx&#174;) discovery platform for identification of non-competitive pharmacological chaperones, certain proprietary Minoryx compounds acting as pharmacological chaperones, all patents and pending applications related thereto and Minoryx&#8217;s Know-How and Trademark related to the SEE-Tx&#174; platform. We also have an exclusive, worldwide, royalty-bearing, assignable, transferable sublicense, including the right to sublicense through multiple tiers of sublicense, to the IP of Universitat de Barcelona (UB) and Institucio Catalana de Recerca i Estudis Avancats (ICREA) in EP11380102 and know-how and software related thereto, for the purpose of making, having made, using, importing, offering to sell, selling and having sold, copying, modifying, performing, displaying, and creating derivative versions of products in the field. Under the Minoryx License Agreement, products include any product in the field that would infringe the UB/ICREA IP or the Minoryx IP in the absence of the license provided therein. Also, field encompasses any field of use and commercialization of the UB/ICREA IP or the Minoryx IP. Unless earlier terminated, the Minoryx License Agreement expires upon expiration of the royalty term, which occurs ten&#160;years after the first product covered by the licensed IP is commercialized. Khalid Islam, the Chairman of our board of directors and one of our founders, is currently the Chairman of the board of directors of Minoryx.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As consideration for the license grant from Minoryx, we have agreed to pay Minoryx royalties on a product-by-product basis based on the licensed IP used by us, ranging from a high single digit to low single digit&#160;percentage of net revenues of products during the royalty term commencing on the effective date of the Minoryx License Agreement and continuing until the 10th anniversary of the first product commercialization. Upon the expiration of the royalty term for a product or service in a country, the license with respect to the product or service, as the case may be, shall become royalty-free, fully-paid, irrevocable and perpetual.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition to royalties, we will pay Minoryx certain milestones payments of 1.25% of any consideration received by us in the event of a sale of our company or substantially all of our assets, including by merger, change of control, or reorganization.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">20</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Minoryx License Agreement will terminate upon expiration of the royalty term (which is the 10th anniversary of the commercialization of the first product covered by the licensed IP) or by mutual agreement. In addition, each party has the right to terminate the Minoryx License Agreement upon a material breach by the other party that remains uncured. Minoryx has the right to terminate the Minoryx License Agreement on a country-by-country basis if we abandon the technology or use the technology for purposes in violation of law and we fail to cure such abandonment or unlawful use. We may terminate the Minoryx License Agreement at any time upon 90&#160;days&#8217; written notice.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Intellectual Property</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We strive to protect and enhance the proprietary technologies, inventions and improvements that we believe are important to our business, including seeking, maintaining and defending patent rights, whether developed internally or licensed from third parties. Our policy is to seek to protect our proprietary position by, among other methods, pursuing and obtaining patent protection in the United States and in jurisdictions outside of the United States related to our proprietary technology, inventions, improvements, platforms and our product candidates that are important to the development and implementation of our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of February 2022, our patent portfolio consisted of five pending European patent applications and related national stage applications. In regards to our SEE-Tx&#174; Technology, we in-license a European patent under the Minoryx License Agreement, which is owned by UB/ICREA and has claims directed to a method of binding site and binding energy determination by mixed explicit solvent simulations. This patent is expected to expire in 2032.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In regards to our GLB program, we in-license from Minoryx pursuant to the Minoryx License Agreement, a patent family with a pending European patent application with claims directed to composition of matter and 8 foreign patent applications pending in such jurisdictions such as Canada, Australia, Japan, Europe, and China. These patents applications, if issued, are expected to expire in 2037, not giving effect to any potential patent term extensions and patent term adjustments and assuming payment of all appropriate maintenance, renewal, annuity or other governmental fees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In regards to our GBA program, we in-license from Minoryx pursuant to the Minoryx License Agreement, a patent family with a pending European patent application with claims directed to composition of matter and 8 foreign patent applications pending in such jurisdictions such as Canada, Australia, Japan, Europe, and China. These patent applications, if issued, are expected to expire in 2037, not giving effect to any potential patent term extensions and patent term adjustments and assuming payment of all appropriate maintenance, renewal, annuity or other governmental fees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Individual patents extend for varying periods depending on the date of filing of the patent application or the date of patent issuance and the legal term of patents in the countries in which they are obtained. Generally, patents issued for regularly filed applications in the United States are granted a term of 20&#160;years from the earliest effective non-provisional filing date or the filing date of a PCT application that designates the United States. In addition, in certain instances, a patent term can be extended to recapture a portion of the U.S. Patent and Trademark Office, or USPTO, delay in issuing the patent as well as a portion of the term effectively lost as a result of the FDA regulatory review period. However, as to the FDA component, the restoration period cannot be longer than five&#160;years and the total patent term including the restoration period must not exceed 14&#160;years following FDA approval. The duration of foreign patents varies in accordance with provisions of applicable local law, but typically is also 20&#160;years from the earliest effective filing date, which is typically the filing date of the PCT application. However, the actual protection afforded by a patent varies on a product-by-product basis, from country to country and depends upon many factors, including the type of patent, the scope of its coverage, the availability of regulatory-related extensions, the availability of legal remedies in a particular country and the validity and enforceability of the patent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Furthermore, we rely upon trade secrets and know-how and continuing technological innovation to develop and maintain our competitive position. We seek to protect our proprietary information, in part, using confidentiality agreements with our collaborators, employees and consultants and invention assignment agreements with our employees. We also have confidentiality agreements or invention assignment agreements with our collaborators and selected consultants. These agreements are designed to protect our proprietary information and, in the case of the invention assignment agreements, to grant us ownership of technologies that are developed through a relationship with a third party. These agreements may be breached, and we may not have adequate remedies for any breach. In addition, our trade secrets may otherwise become known or be independently discovered by competitors. To the extent that our </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">21</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">collaborators, employees and consultants use intellectual property owned by others in their work for us, disputes may arise as to the rights in related or resulting know-how and inventions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our success will also depend in part on not infringing upon the proprietary rights of third parties. It is uncertain whether the issuance of any third-party patent would require us to alter our development or commercial strategies, or our drugs or processes, obtain licenses or cease certain activities. Our breach of any license agreements or failure to obtain a license to proprietary rights that we may require to develop or commercialize our future drugs may have an adverse impact on us. If third parties have prepared and filed patent applications prior to March&#160;16, 2013 in the United States that also claim technology to which we have rights, we may have to participate in interference proceedings in the USPTO to determine priority of invention.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Government Regulation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The FDA and other regulatory authorities at federal, state and local levels, as well as in foreign countries, extensively regulate, among other things, the research, development, testing, manufacture, quality control, import, export, safety, effectiveness, labeling, packaging, storage, distribution, record keeping, approval, advertising, promotion, marketing, post-approval monitoring and post-approval reporting of drugs. We, along with our vendors, contract research organizations and contract manufacturers, will be required to navigate the various preclinical, clinical, manufacturing and commercial approval requirements of the governing regulatory agencies of the countries in which we wish to conduct studies or seek approval of our product candidates. The process of obtaining regulatory approvals of drugs and ensuring subsequent compliance with appropriate federal, state, local and foreign statutes and regulations requires the expenditure of substantial time and financial resources.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the U.S., the FDA regulates drug products under the Federal Food, Drug, and Cosmetic Act, or FD&amp;C Act, as amended, its implementing regulations and other laws. If we fail to comply with applicable FDA or other requirements at any time with respect to product development, clinical testing, approval or any other legal requirements relating to product manufacture, processing, handling, storage, quality control, safety, marketing, advertising, promotion, packaging, labeling, export, import, distribution, or sale, we may become subject to administrative or judicial sanctions or other legal consequences. These sanctions or consequences could include, among other things, the FDA&#8217;s refusal to approve pending applications, issuance of clinical holds for ongoing studies, withdrawal of approvals, warning or untitled letters, product withdrawals or recalls, product seizures, relabeling or repackaging, total or partial suspensions of manufacturing or distribution, injunctions, fines, civil penalties or criminal prosecution.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The process required by the FDA before our product candidates are approved as drugs for therapeutic indications and may be marketed in the U.S. generally involves the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">completion of extensive preclinical studies in accordance with applicable regulations, including studies conducted in accordance with good laboratory practice, or GLP, requirements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">submission to the FDA of an IND application, which must become effective before clinical trials may begin;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">approval by an institutional review board, or IRB, or independent ethics committee at each clinical trial site before each trial may be initiated;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">performance of adequate and well-controlled clinical trials in accordance with applicable IND regulations, good clinical practice, or GCP, requirements and other clinical trial-related regulations to establish the safety and efficacy of the investigational product for each proposed indication;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">submission to the FDA of an NDA;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a determination by the FDA within 60&#160;days of its receipt of an NDA, to accept the filing for review;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">satisfactory completion of one or more FDA pre-approval inspections of the manufacturing facility or facilities where the drug will be produced to assess compliance with cGMP requirements to assure that the facilities, methods and controls are adequate to preserve the drug&#8217;s identity, strength, quality and purity;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">22</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">potential FDA audit of the clinical trial sites that generated the data in support of the NDA;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">payment of user fees for FDA review of the NDA; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:17.85pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">FDA review and approval of the NDA, including consideration of the views of any FDA advisory committee, prior to any commercial marketing or sale of the drug in the U.S</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 18pt 53.85pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Preclinical Studies and Clinical Trials for Drugs</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Before testing any drug in humans, the product candidate must undergo rigorous preclinical testing. Preclinical studies include laboratory evaluations of drug chemistry, formulation and stability, as well as in vitro and animal studies to assess safety and in some cases to establish the rationale for therapeutic use. The conduct of preclinical studies is subject to federal and state regulations and requirements, including GLP requirements for safety/toxicology studies. The results of the preclinical studies, together with manufacturing information and analytical data must be submitted to the FDA as part of an IND. An IND is a request for authorization from the FDA to administer an investigational product to humans and must become effective before clinical trials may begin. Some long-term preclinical testing may continue after the IND is submitted. The IND automatically becomes effective 30&#160;days after receipt by the FDA, unless the FDA, within the 30-day time period, raises concerns or questions about the conduct of the clinical trial, including concerns that human research patients will be exposed to unreasonable health risks, and imposes a clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. Submission of an IND may result in the FDA not allowing clinical trials to commence or not allowing clinical trials to commence on the terms originally specified in the IND.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The clinical stage of development involves the administration of the product candidate to healthy volunteers or patients under the supervision of qualified investigators, generally physicians not employed by or under the trial sponsor&#8217;s control, in accordance with GCP requirements, which include the requirement that all research patients provide their informed consent for their participation in any clinical trial. Clinical trials are conducted under protocols detailing, among other things, the objectives of the clinical trial, dosing procedures, subject selection and exclusion criteria and the parameters and criteria to be used in monitoring safety and evaluating effectiveness. Each protocol, and any subsequent amendments to the protocol, must be submitted to the FDA as part of the IND. Furthermore, each clinical trial must be reviewed and approved by an IRB for each institution at which the clinical trial will be conducted to ensure that the risks to individuals participating in the clinical trial are minimized and are reasonable related to the anticipated benefits. The IRB also approves the informed consent form that must be provided to each clinical trial subject or his or her legal representative, and must monitor the clinical trial until completed. The FDA, the IRB or the sponsor may suspend or discontinue a clinical trial at any time on various grounds, including a finding that the patients are being exposed to an unacceptable health risk. There also are requirements governing the reporting of ongoing clinical trials and completed clinical trials to public registries. Information about clinical trials, including clinical trials results, must be submitted within specific timeframes for publication on the www.clinicaltrials.gov website.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A sponsor who wishes to conduct a clinical trial outside of the U.S. may, but need not, obtain FDA authorization to conduct the clinical trial under an IND. If a foreign clinical trial is not conducted under an IND, the sponsor can submit data from the clinical trial to the FDA in support of an NDA. The FDA will accept a well-designed and well-conducted foreign clinical trial not conducted under an IND if the trial was conducted in accordance with GCP requirements, and the FDA is able to validate the data through an onsite inspection if deemed necessary.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Clinical trials to evaluate therapeutic indications to support NDAs for marketing approval are typically conducted in three sequential phases, which may overlap.</p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span><i style="font-style:italic;">Phase I</i>&#8212;Phase I clinical trials involve initial introduction of the investigational product into healthy human volunteers or patients with the target disease or condition. These studies are typically designed to test the safety, dosage tolerance, absorption, metabolism and distribution of the investigational product in humans, excretion the side effects associated with increasing doses, and, if possible, to gain early evidence of effectiveness.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span><i style="font-style:italic;">Phase II</i>&#8212;Phase II clinical trials typically involve administration of the investigational product to a limited patient population with a specified disease or condition to evaluate the preliminary efficacy, optimal dosages and dosing schedule and to identify possible adverse side effects and safety risks.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span><i style="font-style:italic;">Phase III</i>&#8212;Phase III clinical trials typically involve administration of the investigational product to an expanded patient population to further evaluate dosage, to provide statistically significant evidence of clinical </div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">23</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:0pt;">efficacy and to further test for safety, generally at multiple geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall risk/benefit ratio of the investigational product and to provide an adequate basis for product approval and physician labeling.</div><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Post-approval trials, sometimes referred to as Phase IV clinical trials, may be conducted after initial marketing approval. These trials are used to gain additional experience from the treatment of patients in the intended therapeutic indication and are commonly intended to generate additional safety data regarding use of the product in a clinical setting. In certain instances, the FDA may mandate the performance of Phase IV clinical trials as a condition of approval of an NDA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Progress reports detailing the results of the clinical trials, among other information, must be submitted at least annually to the FDA. Written IND safety reports must be submitted to the FDA and the investigators fifteen&#160;days after the trial sponsor determines the information qualifies for reporting for serious and unexpected suspected adverse events, findings from other studies or animal or in vitro testing that suggest a significant risk for human volunteers and any clinically important increase in the severity or rate of a serious suspected adverse reaction over that listed in the investigator brochure. The sponsor must also notify the FDA of any unexpected fatal or life-threatening suspected adverse reaction as soon as possible but in no case later than seven calendar&#160;days after the sponsor&#8217;s initial receipt of the information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Concurrent with clinical trials, companies usually complete additional animal studies and must also develop additional information about the chemistry and physical characteristics of the product candidate and finalize a process for manufacturing the drug product in commercial quantities in accordance with cGMP requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The manufacturing process must be capable of consistently producing quality batches of the product candidate and manufacturers must develop, among other things, methods for testing the identity, strength, quality and purity of the final drug product. Additionally, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">U.S. Marketing Approval for Drugs</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Assuming successful completion of the required clinical testing, the results of the preclinical studies and clinical trials, together with detailed information relating to the product&#8217;s chemistry, manufacture, controls and proposed labeling, among other things, are submitted to the FDA as part of an NDA requesting approval to market the product for one or more indications. An NDA must contain proof of the drug&#8217;s safety and efficacy. The marketing application may include both negative and ambiguous results of preclinical studies and clinical trials, as well as positive findings. Data may come from company-sponsored clinical trials intended to test the safety and efficacy of a product&#8217;s use or from a number of alternative sources, including studies initiated by investigators. To support marketing approval, the data submitted must be sufficient in quality and quantity to establish the safety and efficacy of the investigational product to the satisfaction of the FDA. FDA approval of an NDA must be obtained before a drug may be marketed in the U.S.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The FDA reviews all submitted NDAs before it accepts them for filing and may request additional information rather than accepting the NDA for filing. The FDA must make a decision on accepting an NDA for filing within 60&#160;days of receipt, and such decision could include a refusal to file by the FDA. Once the submission is accepted for filing, the FDA begins an in-depth substantive review of the NDA. The FDA reviews an NDA to determine, among other things, whether the drug is safe and effective and whether the facility in which it is manufactured, processed, packaged or held meets standards designed to assure the product&#8217;s continued safety, quality and purity. Under the goals and polices agreed to by the FDA under the Prescription Drug User Fee Act, or PDUFA, the FDA targets ten&#160;months, from the filing date, in which to complete its initial review of a new molecular entity NDA and respond to the applicant, and six&#160;months from the filing date of a new molecular entity NDA for priority review. The FDA does not always meet its PDUFA goal dates for standard or priority NDAs, and the review process is often extended by FDA requests for additional information or clarification.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Further, under PDUFA, as amended, each NDA must be accompanied by a user fee. The FDA adjusts the PDUFA user fees on an annual basis. Fee waivers or reductions are available in certain circumstances, including a waiver of the application fee for the first application filed by a small business. Additionally, no user fees are assessed on NDAs for products designated as orphan drugs, unless the product also includes a non-orphan indication.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">24</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The FDA also may require submission of a Risk Evaluation and Mitigation Strategy, or REMS, program to ensure that the benefits of the drug outweigh its risks. The REMS program could include medication guides, physician communication plans, assessment plans and/or elements to assure safe use, such as restricted distribution methods, patient registries or other risk-minimization tools.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The FDA may refer an application for a novel drug to an advisory committee. An advisory committee is a panel of independent experts, including clinicians and other scientific experts, which reviews, evaluates and provides a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Before approving an NDA, the FDA typically will inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving an NDA, the FDA may inspect one or more clinical trial sites to assure compliance with GCP and other requirements and the integrity of the clinical data submitted to the FDA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">After evaluating the NDA and all related information, including the advisory committee recommendation, if any, and inspection reports regarding the manufacturing facilities and clinical trial sites, the FDA may issue an approval letter, or, in some cases, a complete response letter. A complete response letter generally contains a statement of specific conditions that must be met in order to secure final approval of the NDA and may require additional clinical or preclinical testing in order for the FDA to reconsider the application. Even with submission of this additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval. If and when those conditions have been met to the FDA&#8217;s satisfaction, the FDA will typically issue an approval letter. An approval letter authorizes commercial marketing of the drug with specific prescribing information for specific indications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Even if the FDA approves a product, depending on the specific risk(s)&#160;to be addressed it may limit the approved indications for use of the product, require that contraindications, warnings or precautions be included in the product labeling, require that post-approval studies, including Phase IV clinical trials, be conducted to further assess a drug&#8217;s safety after approval, require testing and surveillance programs to monitor the product after commercialization or impose other conditions, including distribution and use restrictions or other risk management mechanisms under a REMS, which can materially affect the potential market and profitability of the product. The FDA may prevent or limit further marketing of a product based on the results of post-marketing studies or surveillance programs. After approval, some types of changes to the approved product, such as adding new indications, manufacturing changes and additional labeling claims, are subject to further testing requirements and FDA review and approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Orphan Drug Designation and Exclusivity</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the Orphan Drug Act of 1983, the FDA may grant orphan designation to a drug intended to treat a rare disease or condition, which is a disease or condition that affects fewer than 200,000 individuals in the U.S., or if it affects more than 200,000 individuals in the U.S., there is no reasonable expectation that the cost of developing and making the product available in the U.S. for the disease or condition will be recovered from sales of the product. Orphan designation must be requested before submitting an NDA. Orphan designation does not convey any advantage in or shorten the duration of the regulatory review and approval process, though companies developing orphan products are eligible for certain incentives, including tax credits for qualified clinical testing and waiver of application fees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">If a product that has orphan designation subsequently receives the first FDA approval for the disease or condition for which it has such designation, the product is entitled to a seven-year period of marketing exclusivity during which the FDA may not approve any other applications to market the same therapeutic agent for the same indication, except in limited circumstances, such as a subsequent product&#8217;s showing of clinical superiority over the product with orphan exclusivity or where the original applicant cannot produce sufficient quantities of product. Competitors, however, may receive approval of different therapeutic agents for the indication for which the orphan product has exclusivity or obtain approval for the same therapeutic agent for a different indication than that for which the orphan product has exclusivity. Orphan product exclusivity could block the approval of one of our products for seven&#160;years if a competitor obtains approval for the same therapeutic agent for the same indication before we do, </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">25</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">unless we are able to demonstrate that our product is clinically superior. If an orphan designated product receives marketing approval for an indication broader than what is designated, it may not be entitled to orphan exclusivity. Further, orphan drug exclusive marketing rights in the U.S. may be lost if the FDA later determines that the request for designation was materially defective or the manufacturer of the approved product is unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Expedited Development and Review Programs for Drugs</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The FDA maintains several programs intended to facilitate and expedite development and review of new drugs to address unmet medical needs in the treatment of serious or life-threatening diseases or conditions. These programs include Fast Track designation, Breakthrough Therapy designation, Priority Review and Accelerated Approval, and the purpose of these programs is to either expedite the development or review of important new drugs to get them to patients earlier than under standard FDA development and review procedures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A new drug is eligible for Fast Track designation if it is intended to treat a serious or life-threatening disease or condition and demonstrates the potential to address unmet medical needs for such disease or condition. Fast Track designation provides increased opportunities for sponsor interactions with the FDA during preclinical and clinical development, in addition to the potential for rolling review once a marketing application is filed, meaning that the agency may review portions of the marketing application before the sponsor submits the complete application, as well as Priority Review, discussed below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, a new drug may be eligible for Breakthrough Therapy designation if it is intended to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. Breakthrough Therapy designation provides all the features of Fast Track designation in addition to intensive guidance on an efficient drug development program beginning as early as Phase I, and FDA organizational commitment to expedited development, including involvement of senior managers and experienced review staff in a cross-disciplinary review, where appropriate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Any product submitted to the FDA for approval, including a product with Fast Track or Breakthrough Therapy designation, may also be eligible for additional FDA programs intended to expedite the review and approval process, including Priority Review designation and Accelerated Approval. A product is eligible for Priority Review if it has the potential to provide a significant improvement in safety or effectiveness in the treatment, diagnosis or prevention of a serious disease or condition. Under Priority Review, the FDA must review an application in six&#160;months compared to ten&#160;months for a standard review.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Additionally, products are eligible for Accelerated Approval if they can be shown to have an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or an effect on a clinical endpoint that can be measured earlier than an effect on irreversible morbidity or mortality which is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity or prevalence of the condition and the availability or lack of alternative treatments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Accelerated Approval is usually contingent on a sponsor&#8217;s agreement to conduct additional post-approval studies to verify and describe the product&#8217;s clinical benefit. The FDA may withdraw approval of a drug or indication approved under Accelerated Approval if, for example, the confirmatory trial fails to verify the predicted clinical benefit of the product. In addition, unless otherwise informed by the FDA, the FDA currently requires, as a condition for Accelerated Approval, that all advertising and promotional materials that are intended for dissemination or publication within 120&#160;days following marketing approval be submitted to the agency for review during the pre-approval review period, and that after 120&#160;days following marketing approval, all advertising and promotional materials must be submitted at least 30&#160;days prior to the intended time of initial dissemination or publication.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or the time period for FDA review or approval may not be shortened. Furthermore, Fast Track designation, Breakthrough Therapy designation, Priority Review and Accelerated Approval do not change the scientific or medical standards for approval or the quality of evidence necessary to support approval but may expedite the development or review process.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">26</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">U.S. Post-Approval Requirements for Drugs</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Drugs manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to recordkeeping, periodic reporting, product sampling and distribution, reporting of adverse experiences with the product, complying with promotion and advertising requirements, which include restrictions on promoting products for unapproved uses or patient populations (known as &#8220;off-label use&#8221;) and limitations on industry-sponsored scientific and educational activities. Although physicians may prescribe legally available products for off-label uses, manufacturers may not market or promote such uses. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant liability, including investigation by federal and state authorities. Prescription drug promotional materials must be submitted to the FDA in conjunction with their first use or first publication. Further, if there are any modifications to the drug, including changes in indications, labeling or manufacturing processes or facilities, the applicant may be required to submit and obtain FDA approval of a new NDA or NDA supplement, which may require the development of additional data or preclinical studies and clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The FDA may impose a number of post-approval requirements as a condition of approval of an NDA. For example, the FDA may require post-market testing, including Phase IV clinical trials, and surveillance to further assess and monitor the product&#8217;s safety and effectiveness after commercialization.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, drug manufacturers and their subcontractors involved in the manufacture and distribution of approved drugs are required to register their establishments with the FDA and certain state agencies and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with ongoing regulatory requirements, including cGMP, which impose certain procedural and documentation requirements upon us and our contract manufacturers. Failure to comply with statutory and regulatory requirements can subject a manufacturer to possible legal or regulatory action, such as warning letters, suspension of manufacturing, product seizures, injunctions, civil penalties or criminal prosecution. There is also a continuing, annual prescription drug product program user fee.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information, requirements for post-market studies or clinical trials to assess new safety risks, or imposition of distribution or other restrictions under a REMS.&#160;Other potential consequences include, among other things:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">safety alerts, Dear Healthcare Provider letters, press releases or other communications containing warnings or other safety information about the product;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">fines, warning letters or holds on post-approval clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">refusal of the FDA to approve applications or supplements to approved applications, or withdrawal of product approvals;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product seizure or detention, or refusal to permit the import or export of products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">injunctions or the imposition of civil or criminal penalties; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">consent decrees, corporate integrity agreements, debarment or exclusion from federal healthcare programs; or mandated modification of promotional materials and labeling and issuance of corrective information.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Other Regulatory Matters</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Manufacturing, sales, promotion and other activities of product candidates following product approval, where applicable, or commercialization are also subject to regulation by numerous regulatory authorities in the U.S. in addition to the FDA, which may include the Centers for Medicare&#160;&amp; Medicaid Services, or CMS, other divisions of </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">27</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">the Department of Health and Human Services, the Department of Justice, the Drug Enforcement Administration, the Consumer Product Safety Commission, the Federal Trade Commission, the Occupational Safety&#160;&amp; Health Administration, the Environmental Protection Agency and state and local governments and governmental agencies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Healthcare Reform</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In March&#160;2010, Congress passed the Affordable Care Act, or the ACA, a sweeping law intended to broaden access to health insurance, reduce or constrain the growth of health spending, enhance remedies against fraud and abuse, add new transparency requirements for the healthcare and health insurance industries, impose new taxes and fees on the health industry, and impose additional policy reforms. The ACA, for example, contains provisions that subject products to potential competition by lower-cost products and may reduce the profitability of products through increased rebates for drugs reimbursed by Medicaid programs; address a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected, increase the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program and extends the rebate program to individuals enrolled in Medicaid managed care organizations; establish annual fees and taxes on manufacturers of certain branded prescription drugs; and create a new Medicare Part&#160;D coverage gap discount program, in which manufacturers must agree to offer 50% (increased to 70% pursuant to the Bipartisan Budget Act of 2018, or BBA, effective as of 2019) point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#8217;s outpatient drugs to be covered under Medicare Part&#160;D.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Since its enactment, there have been judicial, administrative, executive and Congressional legislative challenges to certain aspects of the ACA, and we expect there will be additional challenges and amendments to the ACA in the future. For example, various portions of the ACA are currently undergoing constitutional challenges in the U.S. Supreme Court, the Trump Administration has issued various Executive Orders eliminating cost sharing subsidies and various provisions that would impose a fiscal burden on states or a cost, fee, tax, penalty or regulatory burden on individuals, healthcare providers, health insurers, or manufacturers of pharmaceuticals or medical devices, and Congress has introduced several pieces of legislation aimed at significantly revising or repealing the ACA. It is unclear whether the ACA will be overturned, repealed, replaced, or further amended, and we cannot predict what affect further changes to the ACA would have on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Other federal health reform measures have been proposed and adopted in the U.S. since the ACA was enacted:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The Budget Control Act of 2011, among other things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the&#160;years 2013 through 2021, was unable to reach required goals, thereby triggering the legislation&#8217;s automatic reduction to several government programs. These changes included aggregate reductions to Medicare payments to providers of up to 2% per fiscal&#160;year, which went into effect in April&#160;2013 and, due to subsequent legislative amendments to the statute, including the BBA, will remain in effect through 2030, unless additional Congressional action is taken. These Medicare sequester reductions have been suspended from May&#160;1, 2020 through December&#160;31, 2020 due to the COVID-19 pandemic.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The American Taxpayer Relief Act of 2012, among other things, reduced Medicare payments to several providers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five&#160;years.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The Middle Class&#160;Tax Relief and Job Creation Act of 2012 required that CMS reduce the Medicare clinical laboratory fee schedule by 2% in 2013, which served as a base for 2014 and subsequent&#160;years.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">In addition, effective January&#160;1, 2014, CMS also began bundling the Medicare payments for certain laboratory tests ordered while a patient received services in a hospital outpatient setting.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Further, there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which have resulted in several recent Congressional inquiries and proposed and enacted bills designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for products. In addition, the U.S. government, state legislatures, and foreign governments have shown significant interest </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">28</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">in implementing cost containment programs, including price-controls, restrictions on reimbursement and requirements for substitution of generic products for branded prescription drugs to limit the growth of government paid healthcare costs. For example, the U.S. government has passed legislation requiring pharmaceutical manufacturers to provide rebates and discounts to certain entities and governmental payors to participate in federal healthcare programs. Further, Congress and the Trump administration have each indicated that it will continue to seek new legislative and/or administrative measures to control drug costs, and the current administration recently released a &#8220;Blueprint,&#8221; or plan, to reduce the cost of drugs. The Blueprint contains certain measures that the U.S. Department of Health and Human Services is already working to implement. Individual states in the U.S. have also increasingly passed legislation and implemented regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. Congress and the Trump administration have each indicated that it will continue to seek new legislative and/or administrative measures to control drug costs. Additionally, we may face competition in the United States for our development candidates and investigational medicines, if approved, from therapies sourced from foreign countries that have placed price controls on pharmaceutical products. In the United States, the Medicare Modernization Act, or MMA, contains provisions that call for the promulgation of regulations that expand pharmacists&#8217; and wholesalers&#8217; ability to import cheaper versions of an approved drug and competing products from Canada, where there are government price controls. Further, the MMA provides that these changes to U.S. importation laws will not take effect, unless and until the Secretary of the HHS certifies that the changes will pose no additional risk to the public&#8217;s health and safety and will result in a significant reduction in the cost of products to consumers. On September&#160;23, 2020, the Secretary of the HHS made such certification to Congress, and on October&#160;1, 2020, the FDA published a final rule&#160;that allows for the importation of certain prescription drugs from Canada. Under the final rule, States and Indian Tribes, and in certain future circumstances pharmacists and wholesalers, may submit importation program proposals to the FDA for review and authorization. On September&#160;25, 2020, CMS stated drugs imported by States under this rule&#160;will not be eligible for federal rebates under Section&#160;1927 of the Social Security Act and manufacturers would not report these drugs for &#8220;best price&#8221; or Average Manufacturer Price purposes. Since these drugs are not considered covered outpatient drugs, CMS further stated it will not publish a National Average Drug Acquisition Cost for these drugs. Separately, the FDA also issued a final guidance document outlining a pathway for manufacturers to obtain an additional National Drug Code, or NDC, for an FDA-approved drug that was originally intended to be marketed in a foreign country and that was authorized for sale in that foreign country. The market implications of the final rule&#160;and guidance are unknown at this time. Proponents of drug reimportation may attempt to pass legislation that would directly allow reimportation under certain circumstances. Legislation or regulations allowing the reimportation of drugs, if enacted, could decrease the price we receive for any products that we may develop and adversely affect our future revenues and prospects for profitability. Individual states in the U.S. have also been increasingly passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">From time to time, legislation is drafted, introduced, and passed in Congress that could significantly change the statutory provisions governing the sale, marketing, coverage, and reimbursement of products regulated by CMS or other government agencies. In addition to new legislation, CMS regulations and policies are often revised or interpreted by the agency in ways significantly affecting our business and our products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Other Healthcare Laws and Regulations</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If we obtain regulatory approval of our products, we may be subject to various federal and state laws targeting fraud and abuse in the healthcare industry. These laws may impact, among other things, our proposed sales and marketing strategies. In addition, we may be subject to patient privacy regulation by both the federal government and the states in which we conduct our business. These laws include, without limitation, state and federal anti-kickback, fraud and abuse, false claims, privacy and security, and physician sunshine laws and regulations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The federal Anti-Kickback Statute prohibits, among other things, any person from knowingly and willfully offering, soliciting, receiving or paying remuneration (a term interpreted broadly to include anything of value, including, for example, gifts, discounts and credits), directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, order or recommendation of, an item or reimbursable, in whole or in part, under a federal healthcare program, such as the Medicare and Medicaid programs. Violations of the federal Anti-Kickback Statute can result in significant civil monetary and criminal penalties, per kickback plus three times the amount of remuneration and a prison term per violation. Further, violation of the federal </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">29</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Anti-Kickback Statute can also form the basis for False Claims Act liability (discussed below). A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. In addition, many states have adopted laws similar to the federal Anti-Kickback Statute, some of which apply to the referral of patients for healthcare items or services reimbursed by any source, not only government programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Additionally, the civil False Claims Act (the &#8220;FCA&#8221;) prohibits knowingly presenting or causing the presentation of a false, fictitious or fraudulent claim for payment to the U.S. government. Actions under the FCA may be brought by the Attorney General or as a qui tam action by a private individual in the name of the government. Violations of the FCA can result in very significant monetary penalties, for each false claim and treble the amount of the government&#8217;s damages. Manufacturers can be held liable under the FCA even when they do not submit claims directly to government payors if they are deemed to &#8220;cause&#8221; the submission of false or fraudulent claims. The federal government continues to use the FCA, and the accompanying threat of significant liability, in its investigations and prosecutions of pharmaceutical and biotechnology companies throughout the U.S. Such investigations and prosecutions frequently involve, for example, the alleged promotion of products for unapproved uses and other sales and marketing practices. The government has obtained multi-million and multi-billion dollar settlements under the FCA in addition to individual criminal convictions under applicable criminal statutes. Given the significant size of actual and potential settlements, it is expected that the government will continue to devote substantial resources to investigating healthcare providers&#8217; and manufacturers&#8217; compliance with the FCA and other applicable fraud and abuse laws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We may be subject to the federal Civil Monetary Penalties Law, which prohibits, among other things, the offering or transferring of remuneration to a Medicare or Medicaid beneficiary that the person knows or should know is likely to influence the beneficiary&#8217;s selection of a particular supplier of Medicare or Medicaid payable items or services. Federal government price reporting laws require manufacturers to calculate and report complex pricing metrics to government programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The U.S. federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, includes a fraud and abuse provision referred to as the HIPAA All-Payor Fraud Law, which imposes criminal and civil liability for executing a scheme to defraud any healthcare benefit program, or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement in connection with the delivery of or payment for healthcare benefits, items or services. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We may also be subject to data privacy and security regulation by both the federal government and the states in which we conduct our business. HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH, and its implementing regulations, including the final omnibus rule&#160;published on January&#160;25, 2013, imposes certain requirements relating to the privacy, security and transmission of individually identifiable health information. Among other things, HITECH makes HIPAA&#8217;s privacy and security standards directly applicable to &#8220;business associates,&#8221; defined as independent contractors or agents of covered entities that create, receive, maintain or transmit protected health information in connection with providing a service for or on behalf of a covered entity. HITECH also increased the civil and criminal penalties that may be imposed against covered entities, business associates and possibly other persons, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorney&#8217;s fees and costs associated with pursuing federal civil actions. Many states also have laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">California recently enacted the California Consumer Privacy Act, or CCPA, which creates new individual privacy rights for California consumers (as defined in the law) and places increased privacy and security obligations on entities handling personal data of consumers or households. The CCPA will require covered companies to provide certain disclosures to consumers about its data collection, use and sharing practices, and to provide affected California residents with ways to opt-out of certain sales or transfers of personal information. The CCPA went into effect on January&#160;1, 2020, and the California Attorney General commenced enforcement actions against violators beginning July&#160;1, 2020. While there is currently an exception for protected health information that is subject to HIPAA and clinical trial regulations, as currently written, the CCPA may impact our business activities. The California Attorney General has proposed draft regulations, which have not been finalized to date, that may further impact our business activities if they are adopted. The uncertainty surrounding the implementation of CCPA exemplifies the vulnerability of our business to the evolving regulatory environment related to personal data and protected health information.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">30</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We may also be subject to federal transparency laws, including the federal Physician Payment Sunshine Act, which was part of the ACA and requires manufacturers of certain drugs and biologics, among others, to track and disclose payments and other transfers of value they make to U.S. physicians and teaching hospitals, as well as physician ownership and investment interests in the manufacturer. Effective January&#160;1, 2022, these reporting obligations will extend to include transfers of value made to certain non-physician providers such as physician assistants and nurse practitioners. This information is subsequently made publicly available in a searchable format on a CMS website. Failure to disclose required information may result in civil monetary penalties for all payments, transfers of value or ownership or investment interests that are not timely, accurately and completely reported in an annual submission. Certain states also mandate implementation of compliance programs, impose restrictions on drug manufacturer marketing practices and/or require the tracking and reporting of gifts, compensation and other remuneration to physicians and/or other healthcare providers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As noted above, analogous state laws and regulations, such as, state anti-kickback and false claims laws may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers. Some state laws require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government in addition to requiring drug manufacturers to report information related to payments to physicians and other healthcare providers or marketing expenditures. There are also state and local laws that require the registration of pharmaceutical sales representatives.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The scope and enforcement of each of these laws is uncertain and subject to rapid change in the current environment of healthcare reform, especially in light of the lack of applicable precedent and regulations. Federal and state enforcement bodies have recently increased their scrutiny of interactions between healthcare companies and healthcare providers, which has led to a number of investigations, prosecutions, convictions and settlements in the healthcare industry. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, disgorgement, contractual damages, reputational harm, diminished profits and future earnings, imprisonment, exclusion of drugs from government funded healthcare programs, such as Medicare and Medicaid, and the curtailment or restructuring of our operations, as well as additional reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with these laws, any of which could adversely affect our ability to operate our business and our financial results. If any of the physicians or other healthcare providers or entities with whom we expect to do business is found to be not in compliance with applicable laws, they may be subject to significant criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs. Ensuring business arrangements comply with applicable healthcare laws, as well as responding to possible investigations by government authorities, can be time- and resource consuming and can divert a company&#8217;s attention from the business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Government Regulation of Drugs Outside of the United States</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">To market any product outside of the U.S., we would need to comply with numerous and varying regulatory requirements of other countries regarding safety and efficacy and governing, among other things, clinical trials, marketing authorization or identification of an alternate regulatory pathway, manufacturing, commercial sales and distribution of our products. For instance, in the United Kingdom and the European Economic Area, or the EEA (comprised of the 27 EU Member States plus Iceland, Liechtenstein and Norway), medicinal products must be authorized for marketing by using either the centralized authorization procedure or national authorization procedures.</p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-left:36pt;margin-top:0pt;text-align:justify;text-indent:18pt;"><span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span><i style="font-style:italic;">Centralized procedure</i>&#8212;If pursuing marketing authorization of a product candidate for a therapeutic indication under the centralized procedure, following the opinion of the European Medicines Agency&#8217;s Committee for Medicinal Products for Human Use, or, CHMP, the European Commission issues a single marketing authorization valid across the EEA. The centralized procedure is compulsory for human medicines derived from biotechnology processes or advanced therapy medicinal products (such as gene therapy, somatic cell therapy and tissue engineered products), products that contain a new active substance indicated for the treatment of certain diseases, such as HIV/AIDS, cancer, neurodegenerative disorders, diabetes, autoimmune diseases and other immune dysfunctions, viral diseases, and officially designated orphan medicines. For medicines that do not fall within these categories, an applicant has the option of submitting an application for a centralized marketing authorization to the European Medicines Agency, or EMA, as long as the medicine </div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">31</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-left:36pt;margin-top:0pt;text-align:justify;text-indent:0pt;">concerned contains a new active substance not yet authorized in the EEA, is a significant therapeutic, scientific or technical innovation, or if its authorization would be in the interest of public health in the EEA. Under the centralized procedure the maximum timeframe for the evaluation of an MAA by the EMA is 210&#160;days, excluding clock stops, when additional written or oral information is to be provided by the applicant in response to questions asked by the CHMP. Accelerated assessment might be granted by the CHMP in exceptional cases, when a medicinal product is expected to be of a major public health interest, particularly from the point of view of therapeutic innovation. The timeframe for the evaluation of an MAA under the accelerated assessment procedure is 150&#160;days, excluding clock stops.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-left:36pt;margin-top:0pt;text-align:justify;text-indent:18pt;"><span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span><i style="font-style:italic;">National authorization procedures</i>&#8212;There are also two other possible routes to authorize products for therapeutic indications in several countries, which are available for products that fall outside the scope of the centralized procedure:</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-left:36pt;margin-top:0pt;text-align:justify;text-indent:18pt;"><span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span><i style="font-style:italic;">Decentralized procedure</i>&#8212;Using the decentralized procedure, an applicant may apply for simultaneous authorization in more than one EU country of medicinal products that have not yet been authorized in any EU country and that do not fall within the mandatory scope of the centralized procedure.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-left:36pt;margin-top:0pt;text-align:justify;text-indent:18pt;"><span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span><i style="font-style:italic;">Mutual recognition procedure</i>&#8212;In the mutual recognition procedure, a medicine is first authorized in one EU Member State, in accordance with the national procedures of that country.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-top:0pt;text-align:justify;text-indent:18pt;"><span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>Following authorization through either procedure, additional marketing authorizations can be sought from other EU countries in a procedure whereby the countries concerned recognize the validity of the original, national marketing authorization.</div><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the EEA, new products for therapeutic indications that are authorized for marketing (i.e., reference products) qualify for eight&#160;years of data exclusivity and an additional two&#160;years of market exclusivity upon marketing authorization. The data exclusivity period prevents generic or biosimilar applicants from relying on the preclinical and clinical trial data contained in the dossier of the reference product when applying for a generic or biosimilar marketing authorization in the EU during a period of eight&#160;years from the date on which the reference product was first authorized in the EU. The market exclusivity period prevents a successful generic or biosimilar applicant from commercializing its product in the EU until ten&#160;years have elapsed from the initial authorization of the reference product in the EU. The ten-year market exclusivity period can be extended to a maximum of eleven&#160;years if, during the first eight&#160;years of those ten&#160;years, the marketing authorization holder obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to their authorization, are held to bring a significant clinical benefit in comparison with existing therapies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The criteria for designating an &#8220;orphan medicinal product&#8221; in the EEA are similar in principle to those in the U.S. In the EEA a medicinal product may be designated as orphan if (1)&#160;it is intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition; (2)&#160;either (a)&#160;such condition affects no more than five in 10,000 persons in the EU when the application is made, or (b)&#160;the product, without the benefits derived from orphan status, would not generate sufficient return in the EU to justify investment; and (3)&#160;there exists no satisfactory method of diagnosis, prevention or treatment of such condition authorized for marketing in the EU, or if such a method exists, the product will be of significant benefit to those affected by the condition. Orphan medicinal products are eligible for financial incentives such as reduction of fees or fee waivers and are, upon grant of a marketing authorization, entitled to ten&#160;years of market exclusivity for the approved therapeutic indication. During this ten-year orphan market exclusivity period, no marketing authorization application shall be accepted, and no marketing authorization shall be granted for a similar medicinal product for the same indication. An orphan product can also obtain an additional two&#160;years of market exclusivity in the EU for pediatric studies. The ten-year market exclusivity may be reduced to six&#160;years if, at the end of the fifth&#160;year, it is established that the product no longer meets the criteria for orphan designation, for example, if the product is sufficiently profitable not to justify maintenance of market exclusivity. Additionally, marketing authorization may be granted to a similar product for the same indication at any time if (i)&#160;the second applicant can establish that its product, although similar, is safer, more effective or otherwise clinically superior; (ii)&#160;the applicant consents to a second orphan medicinal product application; or (iii)&#160;the applicant cannot supply enough orphan medicinal product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Similar to the United States, the various phases of non-clinical and clinical research in the European Union are subject to significant regulatory controls.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">32</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Clinical Trials Directive 2001/20/EC, the Directive 2005/28/EC on GCP and the related national implementing provisions of the individual EU Member States govern the system for the approval of clinical trials in the European Union. Under this system, an applicant must obtain prior approval from the competent national authority of the EU Member State in which the clinical trial is to be conducted. Furthermore, the applicant may only start a clinical trial at a specific trial site after the competent ethics committee has issued a favorable opinion. The clinical trial application must be accompanied by, among other documents, an investigational medicinal product dossier (the Common Technical Document) with supporting information prescribed by Directive 2001/20/EC, Directive 2005/28/EC, where relevant the implementing national provisions of the individual EU Member States and further detailed in applicable guidance documents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In April&#160;2014, the new Clinical Trials Regulation, (EU) No 536/2014 (Clinical Trials Regulation) was adopted. It is expected that the new Clinical Trials Regulation (EU) No 536/2014 will apply following confirmation of full functionality of the Clinical Trials Information System, or CTIS, the centralized European Union portal and database for clinical trials foreseen by the regulation, through an independent audit. The regulation becomes applicable six&#160;months after the European Commission publishes notice of this confirmation. The Clinical Trials Regulation will be directly applicable in all the EU Member States, repealing the current Clinical Trials Directive 2001/20/EC. Conduct of all clinical trials performed in the European Union will continue to be bound by currently applicable provisions until the new Clinical Trials Regulation becomes applicable. The extent to which ongoing clinical trials will be governed by the Clinical Trials Regulation will depend on when the Clinical Trials Regulation becomes applicable and on the duration of the individual clinical trial. If a clinical trial continues for more than three&#160;years from the day on which the Clinical Trials Regulation becomes applicable the Clinical Trials Regulation will at that time begin to apply to the clinical trial. The new Clinical Trials Regulation aims to simplify and streamline the approval of clinical trials in the European Union. The main characteristics of the regulation include: a streamlined application procedure via a single-entry point, the &#8220;EU portal&#8221;; a single set of documents to be prepared and submitted for the application as well as simplified reporting procedures for clinical trial sponsors; and a harmonized procedure for the assessment of applications for clinical trials, which is divided in two parts. Part&#160;I is assessed by the competent authorities of all EU Member States in which an application for authorization of a clinical trial has been submitted (Member States concerned). Part&#160;II is assessed separately by each Member State concerned. Strict deadlines have been established for the assessment of clinical trial applications. The role of the relevant ethics committees in the assessment procedure will continue to be governed by the national law of the concerned EU Member State. However, overall related timelines will be defined by the Clinical Trials Regulation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The collection and use of personal health data in the European Union, previously governed by the provisions of the Data Protection Directive, is now governed by the General Data Protection Regulation, or the GDPR, which became effective on May&#160;25, 2018. While the Data Protection Directive did not apply to organizations based outside the EU, the GDPR has expanded its reach to include any business, regardless of its location, that provides goods or services to residents in the EU. This expansion would incorporate any clinical trial activities in EU members states. The GDPR imposes strict requirements on controllers and processors of personal data, including special protections for &#8220;sensitive information&#8221; which includes health and genetic information of data patients residing in the EU. GDPR grants individuals the opportunity to object to the processing of their personal information, allows them to request deletion of personal information in certain circumstances, and provides the individual with an express right to seek legal remedies in the event the individual believes his or her rights have been violated. Further, the GDPR imposes strict rules&#160;on the transfer of personal data out of the European Union to the U.S. or other regions that have not been deemed to offer &#8220;adequate&#8221; privacy protections. Failure to comply with the requirements of the GDPR and the related national data protection laws of the European Union Member States, which may deviate slightly from the GDPR, may result in fines of up to 4% of global revenues, or &#8364;20,000,000, whichever is greater. As a result of the implementation of the GDPR, we may be required to put in place additional mechanisms ensuring compliance with the new data protection rules.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">There is significant uncertainty related to the manner in which data protection authorities will seek to enforce compliance with GDPR. For example, it is not clear if the authorities will conduct random audits of companies doing business in the EU, or if the authorities will wait for complaints to be filed by individuals who claim their rights have been violated. Enforcement uncertainty and the costs associated with ensuring GDPR compliance are onerous and may adversely affect our business, financial condition, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Should we utilize third-party distributors, compliance with such foreign governmental regulations would generally be the responsibility of such distributors, who may be independent contractors over whom we have limited control.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">33</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 0pt;"><b style="font-weight:bold;">U.S. Patent Term Restoration and Marketing Exclusivity</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 11pt 0pt;">Depending upon the timing, duration and specifics of FDA approval of our future product candidates, some of our U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, commonly referred to as the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit restoration of the patent term of up to five&#160;years as compensation for patent term lost during the FDA regulatory review process. Patent-term restoration, however, cannot extend the remaining term of a patent beyond a total of 14&#160;years from the product&#8217;s approval date and only those claims covering such approved drug product, a method for using it or a method for manufacturing it may be extended. The patent-term restoration period is generally one-half the time between the effective date of an IND and the submission date of an NDA plus the time between the submission date of an NDA and the approval of that application, except that the review period is reduced by any time during which the applicant failed to exercise due diligence. Only one patent applicable to an approved drug is eligible for the extension and the application for the extension must be submitted prior to the expiration of the patent. The USPTO, in consultation with the FDA, reviews and approves the application for any patent term extension or restoration. In the future, we may apply for restoration of patent term for our currently owned or licensed patents to add patent life beyond its current expiration date, depending on the expected length of the clinical trials and other factors involved in the filing of the relevant NDA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 11pt 0pt;">Marketing exclusivity provisions under the FD&amp;C Act also can delay the submission or the approval of certain applications. The FD&amp;C Act provides a five-year period of non-patent marketing exclusivity within the United States to the first applicant to gain approval of an NDA for a new chemical entity. A drug is a new chemical entity if the FDA has not previously approved any other new drug containing the same active moiety, which is the molecule or ion responsible for the action of the drug substance. During the exclusivity period, the FDA may not accept for review an abbreviated new drug application, or ANDA, or a 505(b)(2)&#160;NDA submitted by another company for another version of such drug where the applicant does not own or have a legal right of reference to all the data required for approval. However, an application may be submitted after four&#160;years if it contains a certification of patent invalidity or non-infringement. The FD&amp;C Act also provides three&#160;years of marketing exclusivity for an NDA, 505(b)(2)&#160;NDA or supplement to an existing NDA if new clinical investigations, other than bioavailability studies, that were conducted or sponsored by the applicant are deemed by the FDA to be essential to the approval of the application, for example, new indications, dosages or strengths of an existing drug. This three-year exclusivity covers only the conditions of use associated with the new clinical investigations and does not prohibit the FDA from approving ANDAs for drugs containing the original active agent. Five-year and three-year exclusivity will not delay the submission or approval of a full NDA. However, an applicant submitting a full NDA would be required to conduct or obtain a right of reference to all of the preclinical studies and adequate and well-controlled clinical trials necessary to demonstrate safety and effectiveness.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 0pt;"><b style="font-weight:bold;">Employees and Human Capital Resources</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 11pt 0pt;">As of December&#160;31, 2021, we had twenty-five full-time employees and four part-time employees. Twelve employees are based in Barcelona, Spain, fourtheen employees are based in Lugano, Switzerland and three employees are based in Bethesda, Maryland. Of these twenty-nine employees, twenty are engaged in research and development activities and nine are engaged in finance, investor relations, business developments and general management. Our employees in Spain are subject to a national collective labor agreement, Convenio General de la Industria Quimica. National agreements are negotiated collectively between the national associations of companies within a given industry and the respective national unions. We consider our relationship with our employees to be good and have not experienced any work stoppages. In addition, we maintain consulting arrangements with a number of scientists at various universities and other research institutions in Europe, Switzerland and the United States, including the five outside members of our Scientific Advisory Board.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 0pt;"><b style="font-weight:bold;">Corporate Governance and Public Information</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:21.6pt;margin:0pt 0pt 11pt 0pt;">The address of Gain Therapeutics&#8217; website is http://www.gaintherapeutics.com/. Stockholders can access a wide variety of information on Gain&#8217;s website, under the &quot;Investor Relations&quot; tab, including corporate governance information, news releases, SEC filings, information Gain is required to post online pursuant to applicable SEC and Nasdaq rules, and online links. Gain makes available via its website all filings it makes under the Securities and Exchange Act of 1934, as amended, including Forms 10-K, 10-Q, and 8-K, as well as any related amendments as soon as reasonably practicable after they are filed with, or furnished to, the SEC. All such filings are available free of charge. Neither the content of Gain&#8217;s website nor any other website referred to in this report are incorporated by reference into this report unless expressly noted.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">34</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_896a2e44_a78e_4d67_bfd6_817911f5cf3c"></a><a id="ITEM1ARISKFACTORS_98263"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">ITEM&#160;1A. RISK FACTORS</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">You should carefully consider the following risks and other information in this Annual Report on Form&#160;10-K in evaluating us and our Common Stock. Any of the following risks could materially and adversely affect our results of operations, our financial condition, and the market price of our Common Stock. Although the risk factors are grouped by general category, many of the risks described in a given category relate to multiple categories.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risk Factor Summary</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are providing the following summary of the risk factors contained in this Annual Report on Form&#160;10-K to enhance the readability and accessibility of our risk factor disclosures. We encourage you to carefully review the full risk factors contained in this annual report on Form&#160;10-K in their entirety for additional information regarding the material factors that make an investment in our securities speculative or risky. These risks and uncertainties include, but are not limited to, the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we have a history of operating losses and expect to incur losses for the foreseeable future. We may never generate revenues or, if we are able to generate revenues, achieve profitability;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we have a limited operating history and we expect a number of factors to cause our operating results to fluctuate on a quarterly and annual basis, which may make it difficult to predict our future performance;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">if preclinical studies or clinical trials for our product candidates cannot be initiated or completed or if they are unsuccessful or delayed, we will be unable to meet our future development and commercialization goals;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the disorders we seek to treat have low prevalence and it may be difficult to identify patients with these disorders, which may lead to delays in enrollment for our trials or slower commercial revenue if approved;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our product candidates are novel and still in development. If we are unable to successfully develop, receive regulatory approval for and commercialize our current or future product candidates, our business will be harmed;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we have not tested any of our product candidates in clinical trials. Success in early preclinical studies or clinical trials may not be indicative of results obtained in later preclinical studies and clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">clinical trials required for our product candidates are expensive and time-consuming, may face enrollment challenges and their outcome is uncertain;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our business and operations may be adversely affected by the evolving and ongoing COVID-19 global pandemic;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we are subject to extensive and costly government regulation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">even if we obtain regulatory approval to market our product candidates, our product candidates may not be accepted by the market; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we rely on a license to use the technology that is material to our business and if the agreements underlying the licenses were to be terminated or if other rights that may be necessary for commercializing our intended products cannot be obtained, it would halt our ability to market our products and technology, as well as have an immediate material adverse effect on our business, operating results and financial condition.</span></td></tr></table><div style="margin-top:10pt;"></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">35</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to Our Business</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We have a history of operating losses and expect to incur losses for the foreseeable future. We may never generate revenues or, if we are able to generate revenues, achieve profitability.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are focused on product development, and we have not generated any significant revenues to date. We have incurred losses in each&#160;year of our operations, and we expect to continue to incur operating losses for the foreseeable future. These operating losses have adversely affected and are likely to continue to adversely affect our working capital, total assets and shareholders&#8217; equity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We and our prospects should be examined in light of the risks and difficulties frequently encountered by new and early-stage companies in new and rapidly evolving markets. These risks include, among other things, the speed at which we can scale up operations, our complete dependence upon development of our product candidates that currently have no market acceptance, our ability to establish and expand our brand name, our ability to expand our operations to meet the commercial demand of our clients, our development of and reliance on strategic and customer relationships and our ability to minimize fraud and other security risks.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The process of developing our product candidates requires significant preclinical, clinical and regulatory development. In addition, commercialization of our product candidates will require that we obtain necessary regulatory approvals and establish sales, marketing and manufacturing capabilities, either through internal hiring or through contractual relationships with others. We expect to incur substantial losses for the foreseeable future as a result of anticipated increases in our research and development costs, including costs associated with conducting preclinical studies and clinical trials and regulatory compliance activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We expect to incur substantial additional operating expenses over the next several&#160;years as our research, development, preclinical studies and clinical trial activities increase. The amount of future losses and when, if ever, we will achieve profitability are uncertain. We have no products that have generated any commercial revenue, do not expect to generate revenues from the commercial sale of products in the near future, and might never generate revenues from the sale of products. Our ability to generate revenue and achieve profitability will depend on, among other things, successful completion of preclinical development and testing and clinical trials of our product candidates; obtaining necessary regulatory approvals from the FDA; establishing manufacturing, sales and marketing arrangements with third parties; successfully commercializing our products; establishing a favorable competitive position; and raising sufficient funds to finance our activities. Many of these factors will depend on circumstances beyond our control. We might not succeed at any of these undertakings. If we are unsuccessful at some or all of these undertakings, our business, prospects and results of operations may be materially adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We have a limited operating history and we expect a number of factors to cause our operating results to fluctuate on a quarterly and annual basis, which may make it difficult to predict our future performance.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are a preclinical stage biopharmaceutical company with a limited operating history. Our operations to date have been primarily limited to organizing and staffing our company, acquiring, developing and securing our in-licensed technology and preclinical development of our product candidates. We have not yet begun or successfully completed any clinical trials, completed Investigational New Drug (&#8220;IND&#8221;) enabling or Good Laboratory Practice (&#8220;GLP&#8221;) compliant studies for any of our product candidates, manufactured our products candidates at clinical or commercial scale or conducted sales and marketing activities that will be necessary to successfully commercialize our product candidates. Consequently, any predictions made about our future success or viability may not be as accurate as they could be if we had a longer operating history or commercialized products. Our financial condition has varied significantly in the past and will continue to fluctuate from quarter-to-quarter or&#160;year-to-year due to a variety of factors, many of which are beyond our control. Factors relating to our business that may contribute to these fluctuations include other factors described elsewhere in this annual report on Form 10-K and also include, among other things:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to obtain additional funding to develop our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to conduct and complete preclinical studies, including GLP-compliant and IND-enabling preclinical studies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delays in the commencement, enrollment and timing of clinical trials;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">36</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the success of our preclinical studies and clinical trials through all phases of development;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any delays in regulatory review and approval of product candidates in clinical development;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to obtain and maintain regulatory approval for our product candidates in the United States and foreign jurisdictions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">potential toxicity and/or side effects of our product candidates that could delay or prevent commercialization, limit the indications for any approved drug, require the establishment of risk evaluation and mitigation strategies (&#8220;REMS&#8221;), or cause an approved drug to be taken off the market;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to establish or maintain collaborations, licensing or other arrangements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">market acceptance of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">competition from existing products, new products or new therapeutic approaches that may emerge;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the ability of patients or healthcare providers to obtain coverage of or sufficient reimbursement for our products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to leverage our in-licensed technology platform to discover and develop additional product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability and our licensors&#8217; abilities to successfully obtain, maintain, defend and enforce intellectual property rights important to our business;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the impact of political instability, natural disasters, events of terrorism, wars, including the recent conflict &#160;between Ukraine and Russia; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">potential product liability claims.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Accordingly, the results of any quarterly or annual periods should not be relied upon as indications of future operating performance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Until such time, if ever, as we can generate substantial revenue, we may finance our cash needs through a combination of equity offerings, government or private party grants, debt financings and license and collaboration agreements. We do not currently have any other committed external sources of funds. To the extent that we raise additional capital through the sale of equity or convertible debt securities, our stockholders&#8217; ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect our stockholders&#8217; rights as a common stockholder. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may be required to relinquish valuable rights to our technologies, future revenue streams or product candidates, grant licenses on terms that may not be favorable to us or commit to future payment streams. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">37</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to Product Development, Regulatory Approval, Manufacturing and Commercialization</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If preclinical studies or clinical trials for our product candidates are unsuccessful or delayed, we will be unable to meet our future development and commercialization goals.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We rely and expect to continue to rely on third parties, including contract research organizations, or CROs, and outside consultants, to conduct, supervise or monitor some or all aspects of preclinical studies and clinical trials involving our product candidates. We have less control over the timing and other aspects of these preclinical studies and clinical trials than if we performed the monitoring and supervision entirely on our own. Third parties may not perform their responsibilities for our preclinical studies and clinical trials on our anticipated schedule or, for clinical trials, consistent with a clinical trial protocol. To date, we have not conducted any IND-enabling studies or GLP compliant preclinical studies. We may not be able to initiate or successfully complete those studies in the future which could delay or restrict the advancement of our programs into the clinic. Delays in preclinical studies and clinical trials could significantly increase our product development costs and delay product commercialization. In addition, many of the factors that may cause, or lead to, a delay in the clinical trials may also ultimately lead to denial of regulatory approval of a product candidate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The commencement of clinical trials can be delayed for a variety of reasons, including delays in:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">demonstrating sufficient safety and efficacy to obtain regulatory approval to commence a clinical trial;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reaching agreement on acceptable terms with prospective CROs and study sites;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">developing a stable formulation of a product candidate;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">manufacturing sufficient quantities of a product candidate; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtaining institutional review board (&#8220;IRB&#8221;) approval to conduct a clinical trial at a prospective site.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Once a clinical trial has begun, it may be delayed, suspended or terminated by us or the FDA or other regulatory authorities due to a number of factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">ongoing discussions with the FDA or other regulatory authorities regarding the scope or design of our clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">failure to conduct clinical trials in accordance with regulatory requirements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">lower than anticipated recruitment or retention rate of patients in clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">inspection of the clinical trial operations or study sites by the FDA or other regulatory authorities resulting in the imposition of a clinical hold;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">lack of adequate funding to continue clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">negative results of clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">investigational drug product out-of-specification; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">nonclinical or clinical safety observations, including adverse events and SAEs.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If clinical trials are unsuccessful, and we are not able to obtain regulatory approvals for our product candidates under development, we will not be able to commercialize these products, and therefore may not be able to generate sufficient revenues to support our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The disorders we seek to treat have low prevalence and it may be difficult to identify patients with these disorders, which may lead to delays in enrollment for our trials or slower commercial revenue if approved.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Genetically defined disorders generally, and especially those for which our current product candidates are targeted, have low incidence and prevalence. For example, the reported incidence of infantile GM1 is approximately </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">38</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">1.4 in 100,000 live births and the incidence of Krabbe disease is approximately 2.6 in 100,000 births. While certain states currently have mandatory newborn genetic screening for Krabbe disease, there is no mandatory screening for GM1. Without mandatory screening, it may be difficult for us to identify a sufficient number of eligible patients to conduct our clinical trials. These could be significant obstacles to the timely recruitment and enrollment of a sufficient number of eligible patients into our trials. Further, we expect to rely in part on relationships with clinical centers of excellence, key opinion leaders and patient advocacy groups to assist in identifying eligible patients, and any deterioration of those relationships could impede our ability to successfully enroll patients. Patient enrollment may be affected by other factors including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the severity of the disease under investigation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">design of the study protocol;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the eligibility criteria for the trial;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the perceived risks, benefits and convenience of administration of the product candidate being studied;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our efforts to facilitate timely enrollment in clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the availability of other clinical trials being conducted for the same indication;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the patient referral practices of physicians; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the proximity and availability of clinical trial sites to prospective patients.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our inability to enroll a sufficient number of patients with these diseases for our future clinical trials would result in significant delays and could require us to not initiate or to abandon clinical trials for one or more indications altogether. Enrollment delays in our clinical trials may result in increased development costs for our product candidates, which would cause the value of our company to decline and limit our ability to obtain additional financing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Additionally, the reported number of people who have GM1, Krabbe disease and other indications we aim to treat, as well as the people with these diseases who have the potential to benefit from treatment with our product candidates, are based on estimates. The total addressable market opportunity for our product candidates will ultimately depend upon, among other things, the final approved product labeling for each of our product candidates, if our product candidates are approved for sale in our target indications, acceptance by the medical community and patient access, drug pricing and reimbursement. The number of patients globally may turn out to be lower than expected, patients may not be otherwise amenable to treatment with our products, or new patients may become increasingly difficult to identify or gain access to, all of which would adversely affect our results of operations and our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our product candidates are novel and still in development. If we are unable to successfully develop, receive regulatory approval for and commercialize our current or future product candidates, our business will be harmed</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Because the SEE-Tx&#174; platform remains untested and our product candidates are in early stages of development, they will require extensive preclinical and clinical testing. None of our product candidates are currently ready for clinical trials. Our drug development methods may not lead to commercially viable drugs for any of several reasons. Also, third parties we rely on for preclinical development such as the providers of supercomputer time needed for our SEE-Tx&#174; platform and collaborators that provide us with materials and resources may fail to fulfill their obligations to us in a timely manner or at all and the development of our product candidates could be significantly delayed as a result. For example, we may fail to identify appropriate targets or compounds, our product candidates may fail to be safe and effective in clinical trials, or we may have inadequate financial or other resources to pursue development efforts for our product candidates. In addition, our product candidates will require significant additional development, preclinical and IND-enabling studies and clinical trials, regulatory clearances and additional investment by us or our collaborators before they can be commercialized. In addition, we are still developing proof of concept for our product candidates in animals and positive data from animal models may not be predictive of positive human results and patients may have side effects that were not observed in animals.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Further, we and our product candidates are subject to extensive regulation by the FDA and comparable regulatory authorities in other countries governing, among other things, research, testing, clinical trials, manufacturing, labeling, promotion, selling, adverse event reporting and recordkeeping. Obtaining FDA approval is a lengthy, </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">39</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">expensive and uncertain process. If required regulatory registrations or approvals are delayed, denied, withdrawn or if the regulatory authorities question the efficacy of our new small molecules as a treatment, such events are likely to have a material adverse effect on our business, results of operations, cash flows, financial condition and/or prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We have not tested any of our product candidates in clinical trials. Success in early preclinical studies or clinical trials may not be indicative of results obtained in later preclinical studies and clinical trials.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our programs largely remain in the early drug discovery stage and few have progressed into initial preclinical studies that will inform future plans to conduct IND-enabling and GLP-compliant preclinical studies. We have not tested any of our product candidates in clinical trials and minimal preclinical work has been conducted to date. Success in early preclinical studies or any clinical trials we may conduct not be indicative of results obtained in later preclinical studies and clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We will be required to demonstrate through adequate and well-controlled clinical trials that our product candidates are safe and effective, with a favorable benefit-risk profile, for use in their target indications before we can seek regulatory approvals for their commercial sale. Trial designs and results from early-phase trials are not necessarily predictive of future clinical trial designs or results, and initial positive results we may observe may not be confirmed in later-phase clinical trials. Our product candidates may also fail to show the desired safety and efficacy in later stages of clinical development even if they successfully advance through initial clinical trials. We may not be able to demonstrate the safety and efficacy of our STAR molecules in our clinical trials. Even if our clinical trials demonstrate acceptable safety and efficacy of STAR molecules for a targeted disease, the labeling we obtain through negotiations with the FDA or foreign regulatory authorities may not include data on secondary endpoints and may not provide us with a competitive advantage over other products approved for the same or similar indications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Many companies in the biotechnology industry have suffered significant setbacks in late-stage clinical trials after achieving positive results in early-stage development and there is a high failure rate for product candidates proceeding through clinical trials. In addition, different methodologies, assumptions and applications we utilize to assess particular safety or efficacy parameters may yield different statistical results. Even if we believe the data collected from clinical trials of our product candidates are promising, these data may not be sufficient to support approval by the FDA or foreign regulatory authorities. Preclinical and clinical data can be interpreted in different ways. Accordingly, the FDA or foreign regulatory authorities could interpret these data in different ways from us or our partners, which could delay, limit or prevent regulatory approval. If our study data do not consistently or sufficiently demonstrate the safety or efficacy of any of our product candidates, then the regulatory approvals for such product candidates could be significantly delayed as we work to meet approval requirements, or, if we are not able to meet these requirements, such approvals could be withheld or withdrawn. Regulatory delays or rejections may be encountered as a result of many factors, including changes in regulatory policy during the period of product development. We may face similar setbacks.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The approach we are taking to discover and develop our product candidates is novel and may never lead to marketable products.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have concentrated our efforts and research and development activities on our novel small molecules for potential treatment of rare and genetic diseases caused by protein misfolding and SEE-Tx&#174;, our target identification platform. Our future success depends on the successful development of such product candidates, including our ability to initiate and successfully complete IND-enabling and GLP-compliant preclinical studies, and the effectiveness of our platform. The scientific discoveries that form the basis for our efforts to discover and develop new drugs are relatively new. The scientific evidence to support the feasibility of developing drugs based on these discoveries is both preliminary and limited. Skepticism as to the feasibility of developing small molecules of this type that can cross the blood-brain barrier generally has been, and may continue to be, expressed in scientific literature. In addition, decisions by other companies with respect to their therapeutic development efforts may increase skepticism in the marketplace regarding the potential for potential therapeutics. There are currently no companies with approved drugs for these indications that have the ability to cross the blood-brain barrier.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">40</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Because we have limited financial and managerial resources, we focus on research programs and product candidates that we identify for specific indications. As a result, we may forego or delay pursuit of opportunities with other product candidates or for other indications that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs and product candidates for specific indications may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Clinical trials required for our product candidates are expensive and time-consuming, and their outcome is uncertain.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">To obtain FDA approval to market a new pharmaceutical product, we must demonstrate proof of safety and effectiveness in humans. To meet these requirements, we must conduct &#8220;adequate and well controlled&#8221; clinical trials. Conducting clinical trials is a lengthy, time-consuming, and expensive process. The length of time may vary substantially according to the type, complexity, novelty, and intended use of the product candidate, and often can be several&#160;years or more per study. Delays in clinical trials for our product candidates may cause us to incur additional operating expenses. The commencement and rate of completion of clinical trials may be delayed by many factors, including, for example: inability to manufacture sufficient quantities of stable and qualified materials under current good manufacturing practices (&#8220;cGMPs&#8221;) for use in clinical trials; slower than expected rates of patient recruitment; failure to recruit a sufficient number of patients, which is a common issue in studies for rare disorders such as the indications we are currently pursuing; modification of clinical trial protocols; changes in regulatory requirements for clinical trials; the lack of effectiveness during clinical trials; the emergence of unforeseen safety issues; delays, suspension, or termination of the clinical trials due to the investigatory authority responsible for overseeing the trial at a particular trial site; and government or regulatory delays or &#8220;clinical holds&#8221; requiring suspension or termination of the studies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our clinical trials may be conducted in patients with neurodegenerative diseases, and in some cases, our product candidates are expected to be used in combination with approved therapies that themselves have significant adverse event profiles. During the course of treatment, these patients could suffer adverse medical events or die for reasons that may or may not be related to our product candidates. Any safety issues that arise with respect to our product candidates may delay or prevent clinical development.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The failure of clinical trials to demonstrate safety and effectiveness for the desired indications could harm the development of that product candidate and other product candidates that use a similar therapeutic approach. This failure could cause us to abandon a product candidate and could delay development of other product candidates. Any delay in, or termination of, our clinical trials would delay our ability to obtain regulatory approvals for and commercialize our product candidates and generate product revenues. Any change in, or termination of, our clinical trials could materially harm our business, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We have limited experience as a company conducting clinical trials and may be unable to complete pivotal clinical trials for any product candidates we may develop.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are not yet a clinical stage company and our success is dependent upon our ability to initiate and successfully complete clinical trials and obtain regulatory approval for and commercialization of our product candidates. We have not demonstrated an ability to perform the functions necessary for the approval or successful commercialization of any product candidate. The successful commercialization of any product candidate may require us to perform a variety of functions, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">continuing to undertake preclinical development;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtaining approval to commence clinical trials;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">41</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">successfully planning and enrolling subjects in clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">participating in regulatory approval processes;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">formulating and manufacturing products; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">conducting sales and marketing activities.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have limited experience designing, conducting and enrolling subjects in clinical trials. While certain members of our management and staff have significant experience in conducting clinical trials, to date, we have not successfully begun or completed any clinical trials as a company. Until recently, our operations have been limited primarily to organizing and staffing our company, acquiring, developing and securing our in-licensed technology and preclinical development of our product candidates. These operations provide a limited basis to assess our ability to develop and commercialize our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Because of this lack of experience, any future clinical trials we may conduct may not be completed on time, if at all. Large-scale trials require significant additional financial and management resources, monitoring and oversight, and reliance on third-party clinical investigators, consultants or contract research organizations (&#8220;CROs&#8221;). Relying on third-party clinical investigators, CROs and manufacturers, which are all also subject to governmental oversight and regulations, may also cause us to encounter delays that are outside of our control.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, we are still in the drug discovery and preclinical development stage for our product candidates and have not yet begun discussions with the FDA as to the design, structure and number of clinical trials that our product candidates would require for approval. Consequently, we may be unable to successfully and efficiently advance any candidates we select for clinical trials or execute and complete necessary GLP-compliant preclinical and IND-enabling studies in a way that leads to IND submission and approval of any product candidate. We may require more time and incur greater costs than our competitors and may not succeed in obtaining regulatory approvals of any product candidates that we develop. Failure to commence or complete, or delays in, future planned clinical trials, could prevent us from or delay us in commercializing our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We are subject to extensive and costly government regulation.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Product candidates employing our technology are subject to extensive and rigorous domestic government regulation including regulation by the FDA, the Centers for Medicare and Medicaid Services, other divisions of the United States Department of Health and Human Services, the United States Department of Justice, state and local governments and their respective foreign equivalents. The FDA regulates the research, development, preclinical studies and clinical trials, manufacture, safety, effectiveness, record-keeping, reporting, labeling, storage, approval, advertising, promotion, sale, distribution, import and export of biopharmaceutical products. If products employing our technologies are marketed abroad, they will also be subject to extensive regulation by foreign governments, whether or not they have obtained the FDA&#8217;s approval for a given product and its uses. Such foreign regulation may be equally or more demanding than corresponding United States regulation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Government regulation substantially increases the cost and risk of researching, developing, manufacturing and selling our products. The regulatory review and approval process, which includes preclinical studies and clinical trials of each product candidate, is lengthy, expensive, and uncertain. We or our collaborators must obtain and maintain regulatory authorization to conduct clinical trials. We or our collaborators must obtain regulatory approval for each product we intend to market, and the manufacturing facilities used for the products must be inspected and meet legal requirements. Securing regulatory approval requires the submission of extensive preclinical and clinical data and other supporting information for each proposed therapeutic indication in order to establish the product&#8217;s safety and efficacy, and in the case of biologics also potency and purity, for each intended use. The development and approval process takes many&#160;years, requires substantial resources, and may never lead to the approval of a product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Even if we are able to obtain regulatory approval for a particular product, the approval may limit the indicated medical uses for the product, may otherwise limit our ability to promote, sell, and distribute the product, may require that we conduct costly post-marketing surveillance, and/or may require that we conduct ongoing post-marketing studies. Material changes to an approved product, such as, for example, manufacturing changes or revised labeling, may require further regulatory review and approval. Once obtained, any approvals may be withdrawn, including, for example, if there is a later discovery of previously unknown problems with the product, such as a previously unknown safety issue.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">42</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If we, our collaborators, or our manufacturers fail to comply with applicable regulatory requirements at any stage during the regulatory process, such noncompliance could result in, among other things delays in the approval of applications or supplements to approved applications; refusal of a regulatory authority, including the FDA, to review pending market approval applications or supplements to approved applications; warning letters; fines; import and/or export restrictions; product recalls or seizures; injunctions; total or partial suspension of production; civil penalties; withdrawals of previously approved marketing applications or licenses; recommendations by the FDA or other regulatory authorities against governmental contracts; and/or criminal prosecutions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we decide to pursue a Fast Track Designation for some of our product candidates, it may not lead to a faster development or regulatory review or approval process.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We may seek Fast Track Designation for one or more of our product candidates. If a drug is intended for the treatment of a serious or life-threatening condition and the drug demonstrates the potential to address unmet medical needs for this condition, the product sponsor may apply for FDA Fast Track Designation. The FDA has broad discretion whether or not to grant this designation, so even if we believe a particular product candidate is eligible for this designation, the FDA may decide not to grant it. Even if we do receive Fast Track Designation, we may not experience a faster development process, review or approval compared to conventional FDA procedures. The FDA may withdraw Fast Track Designation if it believes that the designation is no longer supported by data from our clinical development program.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we decide to seek Orphan Drug Designation for some of our product candidates, we may be unsuccessful or may be unable to maintain the benefits associated with Orphan Drug Designation, including the potential for supplemental market exclusivity.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As part of our business strategy, we may seek Orphan Drug Designation for one or more of our product candidates, and we may be unsuccessful. Regulatory authorities in some jurisdictions, including the United States and Europe, may designate drugs for relatively small patient populations as orphan drugs. Under the Orphan Drug Act, the FDA may designate a drug as an orphan drug if it is a drug intended to treat a rare disease or condition, which is generally defined as a patient population of fewer than 200,000 individuals in the United States, or a patient population greater than 200,000 in the United States where there is no reasonable expectation that the cost of developing the drug will be recovered from sales in the United States. In the United States, Orphan Drug Designation entitles a party to financial incentives such as a 25% tax credit. Opportunities for grant funding toward clinical trial costs may also be available for clinical trials of drugs for rare diseases, regardless of whether the drugs are designated for the orphan use. In addition, if a product that has Orphan Drug Designation subsequently receives the first FDA approval for the disease for which it has such designation, the product is entitled to orphan drug exclusivity, which means that the FDA may not approve any other applications to market the same product for the same indication for seven&#160;years, except in limited circumstances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Even if we obtain Orphan Drug Designation for our product candidates in specific indications, we may not be the first to obtain marketing approval of these product candidates for the orphan-designated indication due to the uncertainties associated with developing pharmaceutical products. If a competitor with a product that is determined by the FDA to be the same as one of our product candidates obtains marketing approval before us for the same indication we are pursuing and obtains orphan drug exclusivity, our product candidate may not be approved until the period of exclusivity ends unless we are able to demonstrate that our product candidate is clinically superior. Even after obtaining approval, we may be limited in our ability to market our product. In addition, exclusive marketing rights in the United States may be limited if we seek approval for an indication broader than the orphan-designated indication or may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition. Further, even if we obtain orphan drug exclusivity for a product, that exclusivity may not effectively protect the product from competition because different drugs with different principal molecular structural features can be approved for the same condition. Orphan Drug Designation neither shortens the development time or regulatory review time of a drug nor gives the drug any advantage in the regulatory review or approval process. While we may seek Orphan Drug Designation for our product candidates, we may never receive such designation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We do not have, and may never obtain, the regulatory approvals we need to market our product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Following completion of clinical trials, the results are evaluated and, depending on the outcome, an NDA is submitted to the FDA to obtain the FDA&#8217;s approval of the product and authorization to commence commercial </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">43</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">marketing. In responding to an NDA, the FDA may require additional testing or information, may require that the product labeling be modified, may impose post-approval study and other commitments or reporting requirements or other restrictions on product distribution, or may deny the application. The FDA has established performance goals for review of NDAs: six&#160;months for priority applications and ten&#160;months for standard applications. However, the FDA is not required to complete its review within these time periods. The timing of final review by the FDA and action varies greatly but can take&#160;years in some cases and may involve the input of an FDA advisory committee of outside experts. Product sales in the United States may commence only when an NDA is approved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">To date, we have not applied for or received the regulatory approvals required for the commercial sale of any of our products in the United States or in any foreign jurisdiction. None of our product candidates have been determined to be safe and effective, and we have not submitted an IND or an NDA to the FDA or an equivalent application to any foreign regulatory authorities for any of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">It is possible that none of our product candidates will be approved for marketing. Failure to obtain regulatory approvals, or delays in obtaining regulatory approvals, may adversely affect the successful commercialization of any drugs or biologics that we or our partners develop, may impose additional costs on us or our collaborators, may diminish any competitive advantages that we or our partners may attain, and/or may adversely affect our receipt of revenues or royalties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our product candidates may cause serious adverse events (&#8220;SAEs&#8221;) or undesirable side effects which may delay or prevent marketing approval, or, if approval is received, require them to be taken off the market, require them to include safety warnings or otherwise limit their sales.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">SAEs or undesirable side effects from our product candidates could arise either during development or, if approved, after the approved product has been marketed. The results of future clinical trials may show that our product candidates cause SAEs or undesirable side effects, which could interrupt, delay or halt clinical trials, resulting in delay of, or failure to obtain, marketing approval from the FDA and other regulatory authorities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If any of our product candidates cause SAEs or undesirable side effects or suffer from quality control issues:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory authorities may impose a clinical hold or REMS, which could result in substantial delays, significantly increase the cost of development, and/or adversely impact our ability to continue development of the product;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory authorities may require the addition of statements, specific warnings, or contraindications to the product label, or restrict the product&#8217;s indication to a smaller potential treatment population;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may be required to change the way the product is administered or conduct additional clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may be required to implement a risk minimization action plan, which could result in substantial cost increases and have a negative impact on our ability to commercialize the product;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may be required to limit the participants who can receive the product;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may be subject to limitations on how we promote the product;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may, voluntarily or involuntarily, initiate field alerts for product recall, which may result in shortages;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">sales of the product may decrease significantly;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory authorities may require us to take our approved product off the market;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may be subject to litigation or product liability claims; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our reputation may suffer.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Any of these events could prevent us from achieving or maintaining market acceptance of the affected product or could substantially increase commercialization costs and expenses, which in turn could delay or prevent us from generating significant revenues from the sale of our products.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">44</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Even if approved, our products will be subject to extensive post-approval regulation.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Once a product is approved, numerous post-approval requirements apply. Among other things, the holder of an approved NDA is subject to periodic and other monitoring and reporting obligations by the FDA, including obligations to monitor and report adverse events and instances of the failure of a product to meet the specifications in the NDA. Application holders must submit new or supplemental applications and obtain the FDA&#8217;s approval for certain changes to the approved product, product labeling, or manufacturing process. Application holders must also submit advertising and other promotional material to the FDA and report on ongoing clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Depending on the circumstances, failure to meet these post-approval requirements can result in criminal prosecution, fines, injunctions, recall or seizure of products, total or partial suspension of production, denial or withdrawal of pre-marketing product approvals or refusal to allow us to enter into supply contracts, including government contracts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, even if we comply with the FDA&#8217;s and others&#8217; requirements, new information regarding the safety or effectiveness of a product could lead the FDA to modify or withdraw product approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Even if we obtain regulatory approval to market our product candidates, our product candidates may not be accepted by the market.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Even if the FDA approves one or more of our product candidates, physicians and patients may not accept it or use it. Even if physicians and patients would like to use our products, our products may not gain market acceptance among healthcare payors such as managed care formularies, insurance companies or government programs such as Medicare or Medicaid. Acceptance and use of our products will depend upon a number of factors including: perceptions by members of the health care community, including physicians, about the safety and effectiveness of our drug or device product; cost-effectiveness of our product relative to competing products; availability of reimbursement for our product from government or other healthcare payors; and effectiveness of marketing and distribution efforts by us and our licensees and distributors, if any.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The degree of market acceptance of any pharmaceutical product that we develop will depend on a number of factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">cost-effectiveness;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the safety and effectiveness of our products, including any significant potential side effects (including drowsiness and dry mouth), as compared to alternative products or treatment methods;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing of market entry as compared to competitive products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the rate of adoption of our products by doctors and nurses;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product labeling or product insert required by the FDA for each of our products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reimbursement policies of government and third-party payors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">effectiveness of our sales, marketing and distribution capabilities and the effectiveness of such capabilities of our collaborative partners, if any; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">unfavorable publicity concerning our products or any similar products.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Because we expect sales of our current product candidates, if approved, to generate substantially all of our product revenues for the foreseeable future, the failure of these products to find market acceptance would harm our business and could require us to seek additional financing, which may not be available.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">45</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may use our financial and human resources to pursue a particular research program or product candidate and fail to capitalize on programs or product candidates that may be more profitable or for which there is a greater likelihood of success.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Because we have limited financial and human resources, we are currently focusing primarily on development of our GLB program (which includes our STARs for Morquio B and GM1) and our GBA program (which includes our STARs for nGD and GBA1+PD). As a result of this focus, we may forego or delay pursuit of opportunities with other product candidates or for other indications that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on existing and future product candidates for specific indications may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through strategic alliance, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate, or we may allocate internal resources to a product candidate in a therapeutic area in which it would have been more advantageous to enter into a partnering arrangement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to Our Financial Condition and Capital Requirements; Competition</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We will need additional capital. If additional capital is not available or is available at unattractive terms, we may be forced to delay, reduce the scope of or eliminate our research and development programs, reduce our commercialization efforts or curtail our operations.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">To develop and bring our product candidates to market, we must commit substantial resources to costly and time-consuming research, preclinical studies and clinical trials and marketing activities. We anticipate that our existing cash and cash equivalents will enable us to maintain our current operations for at least the next 12&#160;months. We anticipate using our cash and cash equivalents to fund further research and development with respect to our product candidates. We will, however, need to raise additional funding sooner if our business or operations change in a manner that consumes available resources more rapidly than we anticipate. Our requirements for additional capital will depend on many factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the time and expense for preclinical studies and clinical trials for our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the time and costs involved in obtaining regulatory approval for our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">costs associated with protecting our intellectual property rights;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">successful commercialization of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">development of marketing and sales capabilities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">payments received under current and future collaborative agreements, if any; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">market acceptance of our products.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">To the extent we raise additional capital through the sale of equity securities, the issuance of those securities could result in dilution to our shareholders. In addition, if we obtain debt financing, a substantial portion of our operating cash flow may be dedicated to the payment of principal and interest on such indebtedness, thus limiting funds available for our business activities. If adequate funds are not available, we may be required to delay, reduce the scope of or eliminate our research and development programs, reduce our commercialization efforts or curtail our operations. In addition, we may be required to obtain funds through arrangements with collaborative partners or others that may require us to relinquish rights to technologies, product candidates or products that we would otherwise seek to develop or commercialize ourselves or license rights to technologies, product candidates or products on terms that are less favorable to us than might otherwise be available.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">We will require substantial additional funds to support our research and development activities, and the anticipated costs of preclinical studies and clinical trials, regulatory approvals and eventual commercialization. Such additional sources of financing may not be available on favorable terms, if at all. If we do not succeed in raising additional funds on acceptable terms, we may be unable to commence or complete clinical trials or obtain approval of any product candidates from the FDA and other regulatory authorities. In addition, we could be forced to discontinue </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">46</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">product development, forego sales and marketing efforts and forego attractive business opportunities. Any additional sources of financing will likely involve the issuance of our equity securities, which will have a dilutive effect on our shareholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We may not be successful in raising the additional funds needed to fund our business plan. If we are not able to raise sufficient capital in the near future, our continued operations will be in jeopardy and we may be forced to cease operations and sell or otherwise transfer all or substantially all of our remaining assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our business and operations may be adversely affected by the evolving and ongoing COVID-19 global pandemic.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our business and operations may be adversely affected by the effects of the recent and evolving COVID-19 virus, which was declared by the World Health Organization as a global pandemic. The COVID-19 pandemic has resulted in travel and other restrictions in order to reduce the spread of the disease, including public health directives and orders in the United States and the European Union that, among other things and for various periods of time, directed individuals to shelter at their places of residence, directed businesses and governmental agencies to cease non-essential operations at physical locations, prohibited certain non-essential gatherings and events and ordered cessation of non-essential travel. Future remote work policies and similar government orders or other restrictions on the conduct of business operations and travel related to the COVID-19 pandemic may negatively impact productivity and may disrupt our ongoing and planned research and development activities, the magnitude of which will depend, in part, on the length and severity of the restrictions and other limitations on our ability to conduct our business, including our continued drug discovery efforts and preclinical studies, in the ordinary course.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The spread of COVID-19, which has caused a broad impact globally, may materially affect us economically. While the potential economic impact brought by, and the duration of, COVID-19 may be difficult to assess or predict, a widespread pandemic could result in significant disruption of global financial markets, reducing our ability to access capital, which could in the future negatively affect our liquidity. In addition, a recession or market correction resulting from the spread of COVID-19 could materially affect our business and the value of our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We face intense competition in the markets targeted by our product candidates. Many of our competitors have substantially greater resources than we do, and we expect that all of our product candidates under development will face intense competition from existing or future drugs.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We expect that all of our product candidates under development, if approved, will face intense competition from existing and future drugs marketed by large companies. These competitors may successfully market products that compete with our products, successfully identify product candidates or develop products earlier than we do, or develop products that are more effective, have fewer side effects or cost less than our products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Additionally, if a competitor receives FDA approval before we do for a drug that is similar to one of our product candidates, FDA approval for our product candidate may be precluded or delayed due to periods of non-patent exclusivity and/or the listing with the FDA by the competitor of patents covering its newly-approved drug product. Periods of non-patent exclusivity for new versions of existing drugs can extend up to three and one-half&#160;years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">These competitive factors could require us to conduct substantial new research and development activities to establish new product targets, which would be costly and time consuming. These activities would adversely affect our ability to commercialize products and achieve revenue and profits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Competition and technological change may make our product candidates and technologies less attractive or obsolete.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">We compete with established pharmaceutical and biotechnology companies that are pursuing other forms of treatment for the same or similar indications we are pursuing and that have greater financial and other resources. Other companies may succeed in developing products earlier than us, obtaining FDA approval for products more rapidly, or developing products that are more effective than our product candidates. Research and development by others may render our technology or product candidates obsolete or noncompetitive, or result in treatments or cures superior to any therapy we develop. For example, other companies may succeed in developing a technology that addresses protein misfolding and proves to be more effective or is more readily accepted than STARs. We face competition from companies that internally develop competing technology or acquire competing technology from universities and other research institutions. As these companies develop their technologies, they may develop competitive positions that may </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">47</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">prevent, make futile, or limit our product commercialization efforts, which would result in a decrease in the revenue we would be able to derive from the sale of any products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We may not be able to obtain marketplace acceptance for any of our product candidates as readily as these or other competing treatments. Furthermore, if our competitors&#8217; products are approved before ours, it could be more difficult for us to obtain approval from the FDA. Even if our products are successfully developed and approved for use by all governing regulatory bodies, physicians and patients may not accept our products as a treatment of choice.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Furthermore, the pharmaceutical research industry is diverse, complex, and rapidly changing. By its nature, the business risks associated therewith are numerous and significant. The effects of competition, intellectual property disputes, market acceptance, and FDA regulations preclude us from forecasting revenues or income with certainty or even confidence.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to Our Intellectual Property Rights and Regulatory Exclusivity</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We rely on a license to use various technologies that are material to our business and if the agreements underlying the licenses were to be terminated or if other rights that may be necessary for commercializing our intended products cannot be obtained, it would halt our ability to market our products and technology, as well as have an immediate material adverse effect on our business, operating results and financial condition.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are significantly dependent upon our license with Minoryx Therapeutics SL (the &#8220;Minoryx License&#8221;), as described in the section &#8220;Business-License Agreement with Minoryx Therapeutics, S.L.&#8221;. The Minoryx License grants us exclusive, worldwide rights to certain patents and related intellectual property. If we breach the terms of the Minoryx License, for example, by failing to comply with any material terms thereof, Minoryx may have the right to terminate the license. If we were to lose our license under this agreement, including because we are unable to maintain the license on acceptable terms, we would not be able to market our products and technology, which would likely require us to cease our current operations which would have an immediate material adverse effect on our business, operating results and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our success depends substantially upon our ability to obtain and maintain intellectual property protection relating to our products and technologies.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are currently seeking patent protection for numerous compounds and methods of treating diseases. There is no assurance that these patents will be issued, and no assurance that, if they do issue, they will prevent other companies from competing with us. Our ability to obtain and enforce patents that may issue from any pending or future patent applications is uncertain and involves complex legal, scientific and factual questions. Thus, we cannot be sure that any patents will issue from any pending or future patent applications owned by or licensed to us. Even if patents do issue, we cannot be sure that the claims of these patents will be held valid or enforceable by a court of law, will provide us with any significant protection against competing products, or will afford us a commercial advantage over competitive products. If, at some point in the future, one or more products resulting from our product candidates is approved for sale by the FDA and we do not have adequate intellectual property protection for those products, competitors could duplicate them for approval and sale in the United States without repeating the extensive testing required of us to obtain FDA approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we fail to protect our intellectual property rights, our ability to pursue the development of our technologies and products would be negatively affected.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our success will depend in part on our ability to obtain, maintain and protect intellectual property rights related to our product candidates. If we do not adequately maintain or protect our intellectual property, competitors may be able to use our technologies to produce and market drugs in direct competition with us and erode our competitive advantage. Furthermore, some foreign countries lack rules&#160;and methods for defending intellectual property rights and do not protect proprietary rights to the same extent as the United States. Many companies have had difficulty protecting their proprietary rights in these foreign countries. For example, the legal systems in India, China and certain other developing countries do not favor the enforcement of patents and other intellectual property rights. We may not be able to prevent misappropriation of our proprietary rights and intellectual property rights in these and other countries.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">48</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, the patent process is subject to numerous risks and uncertainties, and we may not be successful in protecting our products by obtaining and defending patents related to them. These risks and uncertainties include the following: patents that may be issued or licensed may be challenged, invalidated, or circumvented, or otherwise may not provide us any competitive advantage; our competitors, many of which have substantially greater resources than we and many of which have made significant investments in competing technologies, may seek, or may already have obtained, patents that will limit, interfere with, or eliminate our ability to make, use, and sell our potential products either in the United States or in international markets; there may be significant pressure on the United States government and other international governmental bodies to limit the scope of patent protection both inside and outside the United States for treatments that prove successful as a matter of public policy regarding worldwide health concerns; and countries other than the United States may have less robust patent laws than those upheld by United States courts, allowing foreign competitors the ability to exploit these laws to create, develop, and market competing products using our technologies and patents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Moreover, any patents issued to us may not provide us with meaningful protection, or others may challenge, circumvent or narrow our patents. Third parties may also independently develop products similar to our products, duplicate our unpatented products or design around any patents or proprietary technologies on products we develop. Additionally, extensive time is required for development, testing and regulatory review of a potential product. While extensions of patent terms due to regulatory delays may be available, it is possible that, before any of our product candidates can be commercialized, any related patent, even with an extension, may expire or remain in force for only a short period following commercialization, thereby reducing any advantages to us of the patent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, the PTO and patent offices in other jurisdictions have often required that patent applications concerning pharmaceutical and/or biotechnology-related inventions be limited or narrowed substantially to cover only the innovations specifically exemplified in the patent application, thereby limiting the scope of protection against competitive challenges. Thus, even if we or our licensors are able to obtain patents, the patents may be substantially narrower than anticipated, which could deprive us of rights necessary for the successful commercialization of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our success depends on our patents and patent applications that may be licensed exclusively to us and other patents and patent applications to which we may obtain assignment or licenses. We may not be aware, however, of all patents, published applications or published literature that may affect our business either by blocking our ability to commercialize our product candidates, by preventing the patentability of our product candidates by us or our licensors, or by covering the same or similar technologies. These patents, patent applications, and published literature may limit the scope of our future patent claims or adversely affect our ability to market our product candidates. We have not conducted any formal search of patents issued to third parties, and third-party patents containing claims covering our product candidates that predate our patents may exist. Because of the number of patents issued and patent applications filed in our technical areas or fields, our competitors or other third parties may assert that our product candidates are covered by United States or foreign patents held by them.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition to patents, we rely on a combination of trade secrets, confidentiality, nondisclosure and other contractual provisions, and security measures to protect our confidential and proprietary information. These measures may not adequately protect our trade secrets or other proprietary information. If they do not adequately protect our rights, third parties could use our technology, and we could lose any competitive advantage we may have. In addition, others may independently develop similar proprietary information or techniques or otherwise gain access to our trade secrets, which could impair any competitive advantage we may have.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Patent protection and other intellectual property protection is crucial to the success of our business and prospects, and there is a substantial risk that such protections will prove inadequate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may be involved in lawsuits to protect or enforce our patents, which could be expensive and time consuming.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The pharmaceutical industry has been characterized by extensive litigation regarding patents and other intellectual property rights, and companies have employed intellectual property litigation to gain a competitive advantage. We may become subject to infringement claims or litigation arising out of present and future patents and other proceedings of our competitors. The defense and prosecution of intellectual property suits are costly and time-consuming to pursue, divert the attention of our management and scientific personnel, and their outcome is uncertain. Litigation may be necessary to determine the enforceability, scope, and validity of the proprietary rights of others. An adverse determination in litigation to which we may become a party could subject us to significant liabilities, require </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">49</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">us to obtain licenses from third parties, or restrict or prevent us from selling our products in certain markets. Although patent and intellectual property disputes might be settled through licensing or similar arrangements, the costs associated with such arrangements may be substantial and could include our paying large fixed payments and ongoing royalties. Furthermore, the necessary licenses may not be available on satisfactory terms or at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Competitors may infringe our patents, and we may file infringement claims to counter infringement or unauthorized use. Third parties may assert that our patents are invalid and/or unenforceable in these proceedings. Such litigation can be expensive, particularly for a company of our size, and time-consuming. In addition, in an infringement proceeding, a court may decide that a patent of ours is not valid or is unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover its technology. An adverse determination of any litigation or defense proceeding could put one or more of our patents at risk of being invalidated or interpreted narrowly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Third parties may also assert that our patents are invalid in patent office administrative proceedings. These proceedings include oppositions in the European Patent Office and&#160;<i style="font-style:italic;">inter partes</i>&#160;review and post-grant review proceedings in the PTO. The success rate of these administrative challenges to patent validity in the United States is higher than it is for validity challenges in litigation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Interference or derivation proceedings brought before the PTO may be necessary to determine priority of inventions disclosed in our patents or patent applications. Determining whether a product infringes a patent, as well as priority of inventions and other patent-related disputes, involves complex legal and factual issues and the outcome is often uncertain. During these proceedings, it may be determined that we do not have priority of invention for one or more aspects in our patents or patent applications and could result in the invalidation in part or whole of a patent or could put a patent application at risk of not issuing. Even if successful, an interference or derivation proceeding may result in substantial costs and distraction to our management.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation or interference or derivation proceedings, there is a risk that some of our confidential information could be compromised by disclosure. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments. If investors or securities analysts perceive these results to be negative, the price of our common stock could be adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Also, a third party may assert that our patents are invalid or unenforceable. There are not currently any unresolved communications, allegations, complaints or threats of litigation that claim our patents are invalid or unenforceable. Any litigation or claims against us, whether or not merited, may result in substantial costs, place a significant strain on our financial resources, divert the attention of management and harm our reputation. An adverse decision in litigation or administrative proceedings could result in inadequate protection for our product candidates and/or reduce the value of any license agreements we have with third parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we infringe the rights of third parties, we could be prevented from selling products or forced to pay damages and defend against litigation.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If our products, methods, processes and other technologies infringe the proprietary rights of other parties, we could incur substantial costs and we may have to: obtain licenses, which may not be available on commercially reasonable terms or at all; abandon an infringing product candidate; redesign our products or processes to avoid infringement; stop using the subject matter claimed in the patents held by others; pay damages; and/or defend litigation or administrative proceedings which may be costly whether we win or lose, and which could result in a substantial diversion of our financial and management resources.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, because patent applications can take many&#160;years to issue and because publication schedules for pending applications vary by jurisdiction, there may be applications now pending of which we are unaware, and which may result in issued patents that our future products would infringe. Also, because the claims of published patent applications can change between publication and patent grant, there may be published patent applications that may ultimately issue with claims that we infringe.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">We have licensed all of the rights, assets and technology related to the SEE-Tx&#174; platform from Minoryx and we believe that they owned all of such rights prior to our license. Although, to our knowledge, no third party has asserted a claim of infringement or other claim against us, others may hold or claim to hold proprietary or other rights </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">50</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">that could prevent our SEE-Tx&#174; platform from being developed or marketed. Any legal action against us claiming damages and seeking to enjoin commercial activities relating to our SEE-Tx&#174; platform or our processes could subject us to potential liability for damages and require us to obtain a license to continue to manufacture or market any future product candidates based upon the SEE-Tx&#174; platform. We may not prevail in any such actions and any license required under any of these patents may not be made available on commercially acceptable terms, if at all. In addition, we may not be able to redesign any future product candidates or processes to avoid infringement, if necessary. Accordingly, an adverse determination in a judicial or administrative proceeding, or the failure to obtain necessary licenses, could prevent us from developing and commercializing our future product candidates, which could harm our business, financial condition and operating results.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to Third Parties and Collaborators</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We intend to rely on third parties to conduct, supervise and monitor our clinical trials, and if those third parties perform in an unsatisfactory manner, it may harm our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We expect to rely on CROs and clinical trial sites to ensure the proper and timely conduct of our clinical trials. While we will have agreements governing their activities, we will have limited influence over their actual performance. We will control only certain aspects of our CROs&#8217; activities. Nevertheless, we will be responsible for ensuring that our clinical trials are conducted in accordance with the applicable protocol, legal, regulatory and scientific standards and our reliance on the CROs will not relieve us of our regulatory responsibilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We and our CROs are required to comply with the FDA&#8217;s Good Clinical Practices (&#8220;GCPs&#8221;) for conducting, recording and reporting the results of clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity and confidentiality of clinical trial participants are protected. The FDA enforces these GCPs through periodic inspections of study sponsors, principal investigators and clinical trial sites. If we or our CROs fail to comply with applicable GCPs, the clinical data generated in our clinical trials may be deemed unreliable and the FDA may require us to perform additional clinical trials before approving any marketing applications. Upon inspection, the FDA may determine that our clinical trials did not comply with GCPs. In addition, our clinical trials will require enrollment and participation of a sufficiently large number of patients to evaluate the effectiveness and safety of our product candidates. Accordingly, if our CROs fail to comply with these regulations or fail to recruit a sufficient number of participants, our clinical trials may be delayed or we may be required to repeat such clinical trials, which would delay the regulatory approval process.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our CROs are not our employees, and we are not able to control whether or not they devote sufficient time and resources to our clinical trials. These CROs may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical trials, or other drug development activities which could harm our competitive position.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If our CROs do not successfully carry out their contractual duties or obligations, fail to meet expected deadlines, or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols or regulatory requirements, or for any other reasons, our clinical trials may be extended, delayed or terminated, and we may not be able to obtain regulatory approval for, or successfully commercialize our product candidates. As a result, our financial results and the commercial prospects for such product candidates would be harmed, our costs could increase, and our ability to generate revenues could be delayed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We intend to rely on third parties to manufacture the compounds used in our studies, and we intend to rely on them for the manufacture of any approved products for commercial sale. If these third parties do not manufacture our product candidates in sufficient quantities and at an acceptable cost, clinical development and commercialization of our product candidates could be delayed, prevented or impaired.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">We have no manufacturing facilities, and we have no experience in the clinical or commercial-scale manufacture of drugs or in designing drug manufacturing processes. We intend to rely on third party contract manufacturing organizations (&#8220;CMOs&#8221;) to manufacture some or all of our product candidates in future clinical trials and our products that reach commercialization. Initiation and completion of our clinical trials and commercialization of our product candidates requires the manufacture of a sufficient supply of our product candidates. If, for any reason, we become unable to rely on these third parties for the manufacture of our product candidates, either for clinical trials or, at some future date, for commercial quantities, then we would need to identify and contract with additional or replacement third-party manufacturers to manufacture compounds for preclinical, clinical and commercial purposes, </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">51</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">which we may not be able to do on reasonable terms or at all, or we may be forced to manufacture the materials ourselves, for which we may not have the capabilities or resources. In either scenario, our clinical trials supply could be delayed significantly as we establish alternative supply sources. In some cases, the technical skills required to manufacture our products or product candidates may be unique or proprietary to the original CMO and we may have difficulty, or there may be contractual restrictions prohibiting us from, transferring such skills to a back-up or alternate supplier, or we may be unable to transfer such skills at all. In addition, if we are required to change CMOs for any reason, we will be required to verify that the new CMO maintains facilities and procedures that comply with quality standards and with all applicable regulations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We will also need to verify, such as through a manufacturing comparability study, that any new manufacturing process will produce our product candidates according to any specifications previously submitted to the FDA or another regulatory authority. The delays associated with the verification of a new CMO could negatively affect our ability to develop product candidates or commercialize our products in a timely manner or within budget. Furthermore, a CMO may possess technology related to the manufacture of our product candidate that such CMO owns independently. This would increase our reliance on such CMO or require us to obtain a license from such CMO in order to have another CMO manufacture our product candidates. In addition, changes in manufacturers often involve changes in manufacturing procedures and processes, which could require that we conduct bridging studies between our prior clinical supply used in our clinical trials and that of any new manufacturer. We may be unsuccessful in demonstrating the comparability of clinical supplies which could require the conduct of additional clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We believe that there are a variety of manufacturers that we may be able to retain to produce these products. However, once we retain a manufacturing source, if our manufacturers do not perform in a satisfactory manner, we may not be able to develop or commercialize potential products as planned. Certain specialized manufacturers are expected to provide us with modified and unmodified pharmaceutical compounds, including finished products, for use in our preclinical studies and clinical trials. Some of these materials are available from only one supplier or vendor. Any interruption in or termination of service by such sole source suppliers could result in a delay or interruption in manufacturing until we locate an alternative source of supply. Any delay or interruption in our future supply chain and manufacturing operations (or failure to locate a suitable replacement for such suppliers), including on account of the ongoing COVID-19 pandemic or the occurrence of geopolitical conflicts such as the war between Ukraine and Russia, as well as any sanctions or other actions resulting therefrom, impacting one or more of our suppliers may affect their ability to deliver products to us in a timely manner and, could materially adversely affect our business, prospects, or results of operations. If we fail to contract for manufacturing on acceptable terms or if third-party manufacturers do not perform as we expect, our development programs could be materially adversely affected. This may result in delays in filing for and receiving FDA approval for one or more of our products. Any such delays could cause our prospects to suffer significantly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Failure by our third-party manufacturers to comply with the regulatory guidelines set forth by the FDA with respect to our product candidates could delay or prevent the completion of clinical trials, the approval of any product candidates or the commercialization of our products.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Third-party manufacturers must be inspected by the FDA for cGMP compliance before they can produce commercial products. Since March&#160;2020, foreign and domestic inspections by the FDA have largely been on hold due to the COVID-19 pandemic with the FDA announcing plans in July&#160;2020 to resume prioritized domestic inspections. Should the FDA determine that an inspections of manufacturing, establishments or clinical sites are necessary for approval and an inspection cannot be completed during the review cycle due to restrictions on travel, the FDA has stated that it generally intends to issue a complete response letter and several other companies have reported receiving complete response letters. Further, if there is inadequate information to make a determination on the acceptability of a facility, the FDA may defer action on the application until an inspection can be completed. It is unclear how long the COVID-19 pandemic will impact FDA inspection activities and whether foreign regulatory authorities may adopt similar limitations and policies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We may be in competition with other companies for access to these manufacturers&#8217; facilities and may be subject to delays in manufacture if the manufacturers give other clients higher priority than they give to us. If we are unable to secure and maintain third-party manufacturing capacity, the development and sales of our products and our financial performance may be materially affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Manufacturers are obligated to operate in accordance with FDA-mandated requirements. A failure of any of our third-party manufacturers to establish and follow cGMP requirements and to document their adherence to such </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">52</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">practices may lead to significant delays in the availability of material for clinical trials, may delay or prevent filing or approval of marketing applications for our products, and may cause delays or interruptions in the availability of our products for commercial distribution following FDA approval. This could result in higher costs to us or deprive us of potential product revenues.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Drug manufacturers are subject to ongoing periodic unannounced inspections by the FDA, the Drug Enforcement Administration, or DEA, and corresponding state and foreign agencies to ensure strict compliance with cGMP requirements and other requirements under Federal drug laws, other government regulations and corresponding foreign standards. If we or our third-party manufacturers fail to comply with applicable regulations, sanctions could be imposed on us, including fines, injunctions, civil penalties, failure by the government to grant marketing approval of drugs, delays, suspension or withdrawal of approvals, seizures or recalls of product, operating restrictions and criminal prosecutions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Corporate and academic collaborators may take actions to delay, prevent, or undermine the success of our products.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our operating and financial strategy for the development, clinical testing, manufacture, and commercialization of product candidates is heavily dependent on our entering into collaborations with corporations, academic institutions, licensors, licensees, and other parties and we may not be successful in establishing such collaborations. Some of our existing collaborations are, and future collaborations may be, terminable at the sole discretion of the collaborator. Replacement collaborators might not be available on attractive terms, or at all. The activities of any collaborator will not be within our control and may not be within our power to influence. Any collaborators may not perform their obligations to our satisfaction, or at all, we may not derive any revenue or profits from such collaborations, and any collaborators may ultimately compete with us. If any collaboration is not pursued, we may require substantially greater capital to undertake development and marketing of our proposed products and may not be able to develop and market such products effectively, if at all. In addition, a lack of development and marketing collaborations may lead to significant delays in introducing proposed products into certain markets and/or reduced sales of proposed products in such markets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Data provided by collaborators and others upon which we rely that has not been independently verified could turn out to be false, misleading, or incomplete.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We rely on third-party vendors, scientists and collaborators to provide us with significant data and other information related to our projects, clinical trials and our business. If such third parties provide inaccurate, misleading or incomplete data, our business, prospects and results of operations could be materially adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we fail to establish marketing, sales and distribution capabilities, or fail to enter into arrangements with third parties, we will not be able to create a market for our product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our strategy for our product candidates is to control, directly or through contracted third parties, all or most aspects of the product development process, including marketing, sales and distribution. Currently, we do not have any sales, marketing or distribution capabilities. In order to generate sales of any product candidates that receive regulatory approval, we must either acquire or develop an internal marketing and sales force with technical expertise and with supporting distribution capabilities or make arrangements with third parties to perform these services for us. The acquisition or development of a sales and distribution infrastructure would require substantial resources, which may divert the attention of our management and key personnel and defer our product development efforts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">To the extent that we enter into marketing and sales arrangements with other companies, our revenues will depend on the efforts of others. These efforts may not be successful. If we fail to develop sales, marketing and distribution channels, or enter into arrangements with third parties, we will experience delays in product sales and incur increased costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Sales of pharmaceutical products largely depend on the reimbursement of patients&#8217; medical expenses by government health care programs and private health insurers. Without the financial support of the government or third-party payors, the market for our products will be limited. These third-party payors are increasingly challenging the price and examining the cost effectiveness of medical products and services. Recent proposals to change the health care system in the United States have included measures that would limit or eliminate payments for medical products and services or subject the pricing of medical treatment products to government control. Significant uncertainty exists </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">53</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">as to the reimbursement status of newly approved health care products. Third-party payors may not reimburse sales of our products or enable our collaborators to sell them at profitable prices.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our business strategy might involve out-licensing product candidates to or collaborating with larger firms with experience in marketing and selling pharmaceutical products. We may not be able to successfully establish marketing, sales, or distribution relationships and such relationships, if established, may not be successful. Further, we may not be successful in gaining market acceptance for our products. To the extent that we enter into any marketing, sales, or distribution arrangements with third parties, our product revenues will be lower than if we marketed and sold our products directly, and any revenues we receive will depend upon the efforts of such third-parties. If we are unable to establish such third-party sales and marketing relationships, or choose not to do so, we will have to establish and rely on our own in-house capabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We, as a company, have no experience in marketing or selling pharmaceutical products and currently have no sales, marketing, or distribution infrastructure. To market any of our products directly, we would need to develop a marketing, sales, and distribution force that both has technical expertise and the ability to support a distribution capability. The establishment of a marketing, sales, and distribution capability would significantly increase our costs, possibly requiring substantial additional capital. In addition, there is intense competition for proficient sales and marketing personnel, and we may not be able to attract individuals who have the qualifications necessary to market, sell, and distribute our products. We may not be able to establish internal marketing, sales, or distribution capabilities. If we are unable to, or choose not to establish these capabilities, or if the capabilities we establish are not sufficient to meet our needs, we will be required to establish collaborative marketing, sales, or distribution relationships with third parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If any of our existing or future collaborative partners do not satisfy their obligations, we will be unable to develop our partnered product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We may not have day-to-day control over the activities of our existing and future collaborative partners with respect to any of these product candidates. Any collaborative partner may not fulfill its obligations under these agreements. If a collaborative partner fails to fulfill its obligations under an agreement with us, we may be unable to assume the development of the products covered by that agreement or enter into alternative arrangements with a third party. In addition, we may encounter delays in the commercialization of the product candidate that is the subject of the agreement. Accordingly, our ability to receive any revenue from the product candidates covered by these agreements will be dependent on the efforts of our collaborative partner. We could also become involved in disputes with a collaborative partner, which could lead to delays in or termination of our development and commercialization programs and time-consuming and expensive litigation or arbitration. In addition, any such dispute could diminish our collaborators&#8217; commitment to us and reduce the resources they devote to developing and commercializing our products. Conflicts or disputes with our collaborators, and competition from them, could harm our relationships with our other collaborators, restrict our ability to enter future collaboration agreements and delay the research, development or commercialization of our product candidates. If any collaborative partner terminates or breaches its agreement, or otherwise fails to complete its obligations in a timely manner, our chances of successfully developing or commercializing these product candidates would be materially and adversely affected. We may not be able to enter into collaborative agreements with partners on terms favorable to us, or at all. Our inability to enter into collaborative arrangements with collaborative partners, or our failure to maintain such arrangements, would limit the number of product candidates that we could develop and ultimately decrease our sources of any future revenues.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may face risks in connection with existing and future collaborations with respect to the development, manufacture and commercialization of our product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We face a number of risks in connection with our current and future collaborations. Our collaboration agreements are subject to termination under various circumstances. Our collaborators may change the focus of their development and commercialization efforts or may have insufficient resources to effectively assist in the development of our products. Any future collaboration agreements may have the effect of limiting the areas of research and development that we may pursue, either alone or in collaboration with third parties. Further, disagreements with collaborators, including disagreements over proprietary rights, contract interpretation, or the preferred course of development, might cause delays, might result in litigation or arbitration, or might result in termination of the research, development or commercialization of our products. Any such disagreements would divert management attention and resources and be time-consuming and costly.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">54</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">General Company-Related Risks</b></p><a id="_Hlk97733115"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We previously identified material weaknesses in our internal control over financial reporting and may identify additional material weaknesses in the future or otherwise fail to maintain an effective system of internal controls, which may result in material misstatements of our financial statements or cause us to fail to meet our periodic reporting obligations.&#8199;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Prior to our IPO, we were a private company with limited accounting personnel and resources to address our internal controls and procedures. We have identified material weaknesses in our internal control over financial reporting as of December&#160;31, 2020 caused by (i)&#160;lack of sufficient accounting and supervisory personnel who have the appropriate level of technical accounting experience and training, and (ii)&#160;lack of adequate procedures and controls to ensure that accurate financial statements can be prepared and reviewed on a timely basis for reporting purposes. These deficiencies constituted material weaknesses in our internal control over financial reporting in both design and operation. A &#8220;material weakness&#8221; is a deficiency, or combination of deficiencies, in internal controls such that there is a reasonable possibility that a material misstatement in financial statements will not be prevented or detected on a timely basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In 2021, we have initiated a remediation plan, as described in Item 9A, and remediated &#160;the material weakness previously identified relating to our lack of sufficient accounting and supervisory personnel who have the appropriate level of technical accounting experience and training.<i style="font-family:'EYInterstate';font-style:italic;"> </i>With respect to the material weakness related to the lack of adequate procedures and controls to ensure that accurate financial statements can be prepared and reviewed on a timely basis for reporting purposes, until our remediation plan is fully implemented and deemed to be operating effectively, management will continue to devote time and attention to these efforts. Although we are working diligently to improve our control environment, we cannot at this time estimate how long it will take, and our initiatives may not prove to be successful. If we are unable to successfully improve our control environment, or if we discover additional material weaknesses or if we otherwise are unable to report our financial statements accurately or in a timely manner, we would be required to continue disclosing such material weaknesses in future filings with the SEC, which could adversely affect our business, investor confidence in our company and the market price of our common shares and could subject us to litigation or regulatory enforcement actions. As a result, shareholders could lose confidence in our financial and other public reporting, which would harm our business and the market value of our common shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Worldwide economic and social instability could adversely affect our revenue, financial condition, or results of operations.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The global credit and financial markets have recently experienced extreme volatility and disruptions, including severely diminished liquidity and credit availability, declines in economic growth, increases in unemployment rates, supply chain disruptions, persistent inflation, and uncertainty about economic stability. The financial markets and the global economy may also be adversely affected by the current or anticipated impact of military conflict, including the conflict between Russia and Ukraine, terrorism or other geopolitical events. Sanctions imposed by the United States and other countries in response to such conflicts, including the one in Ukraine, may also adversely impact the financial markets and the global economy, and any economic countermeasures by affected countries and others could exacerbate market and economic instability. There can be no assurance that further deterioration in credit and financial markets and confidence in economic conditions will not occur. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our general business strategy, as well as our suppliers&#8217; ability to provide us with raw materials and components, may be adversely affected by any such economic downturn, volatile business environment or continued unpredictable and unstable market conditions, which could directly affect our ability to attain our operating goals on schedule and on budget, including requiring us to delay or abandon certain development plans, and could have a material adverse effect on our growth strategy, financial performance and stock price. In addition, there is a risk that one or more of our current suppliers, may not survive an economic downturn, which could directly affect our ability to attain our operating goals on schedule and on budget.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We will need to expand our operations and increase the size of our company, and we may experience difficulties in managing growth.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">As we advance our product candidates through preclinical studies and clinical trials, and develop new product candidates, we will need to increase our product development, scientific, regulatory and compliance and administrative headcount to manage these programs. In addition, to meet our obligations as a public company, we will need to increase </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">55</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">our general and administrative capabilities. Our management, personnel and systems currently in place may not be adequate to support this future growth. Our need to effectively manage our operations, growth and various projects requires that we:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">successfully attract and recruit new employees with the expertise and experience we will require;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">manage our clinical programs effectively, which we anticipate being conducted at numerous clinical sites;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">develop a marketing, distribution and sales infrastructure in addition to a post-marketing surveillance program if we seek to market our products directly; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">continue to improve our operational, manufacturing, quality assurance, financial and management controls, reporting systems and procedures.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If we are unable to successfully manage this growth and increased complexity of operations, our business may be adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our executive officers and other key personnel are critical to our business, and our future success depends on our ability to retain them.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our success depends to a significant extent upon the continued services of the senior management team. Loss of the services of our key personnel would have a material adverse effect on our growth, revenues and prospective business. The loss of any of our key personnel, or the inability to attract and retain qualified personnel, may significantly delay or prevent the achievement of our research, development or business objectives and could materially adversely affect our business, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Any employment agreement we enter into will not ensure the retention of the employee who is a party to the agreement. In addition, we have only limited ability to prevent former employees from competing with us. Furthermore, our future success will also depend in part on the continued service of our key scientific and management personnel and our ability to identify, hire, and retain additional personnel. We experience intense competition for qualified personnel and may be unable to attract and retain the personnel necessary for the development of our business. Moreover, competition for personnel with the scientific and technical skills that we seek is extremely high and is likely to remain high. Because of this competition, our compensation costs may increase significantly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Under applicable employment laws, we may not be able to enforce covenants not to compete and therefore may be unable to prevent our competitors from benefiting from the expertise of some of our former employees.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our employment agreements generally include covenants not to compete. These agreements prohibit our employees, if they cease working for us, from competing directly with us or working for our competitors for a limited period. We may be unable to enforce these agreements under the laws of the jurisdictions in which our employees work at all or for a sufficient duration of time to prevent members of our management team from competing with us. If we are unable to enforce these covenants not to compete, we may be unable to prevent our competitors from benefiting from the expertise of our former employees or consultants and our competitiveness may be diminished.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we are unable to hire additional qualified personnel, our ability to grow our business may be harmed.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Over time we will need to hire additional qualified personnel with expertise in drug development, product registration, clinical, preclinical and nonclinical research, quality compliance, government regulation, formulation and manufacturing, financial matters and sales and marketing. We compete for qualified individuals with numerous biopharmaceutical companies, universities and other research institutions. Competition for such individuals is intense, and our search for such personnel may not be successful. Attracting and retaining qualified personnel will be critical to our success.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">56</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our relationships with customers, physicians, and third-party payors will be subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, false claims laws, health information privacy and security laws, and other healthcare laws and regulations. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Healthcare providers, physicians and third-party payors in the United States and elsewhere will play a primary role in the recommendation and prescription of any product candidates for which we obtain marketing approval. Our current and future arrangements with healthcare professionals, principal investigators, consultants, customers and third-party payors may subject us to various federal and state fraud and abuse laws and other healthcare laws, including, without limitation, the federal Anti-Kickback Statute, the federal civil and criminal false claims laws and the law commonly referred to as the Physician Payments Sunshine Act and regulations. These laws will impact, among other things, our clinical research, proposed sales, marketing and educational programs. In addition, we may be subject to patient privacy laws by both the federal government and the states in which we conduct or may conduct our business. The laws that will affect our operations include, but are not limited to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the federal Anti-Kickback Statute, which prohibits, among other things, persons or entities from knowingly and willfully soliciting, receiving, offering or paying any remuneration (including any kickback, bribe or rebate), directly or indirectly, overtly or covertly, in cash or in kind, in return for the purchase, recommendation, leasing or furnishing of an item or service reimbursable under a federal healthcare program, such as the Medicare and Medicaid programs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">federal civil and criminal false claims laws, including, without limitation, the False Claims Act, and civil monetary penalty laws which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment or approval from Medicare, Medicaid or other government payors that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which created new federal criminal statutes that prohibit a person from knowingly and willfully executing a scheme or making false or fraudulent statements to defraud any healthcare benefit program, regardless of the payor (e.g., public or private);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH, and its implementing regulations, and as amended again by the final HIPAA omnibus rule, Modifications to the HIPAA Privacy, Security, Enforcement, and Breach Notification Rules&#160;Under HITECH and the Genetic Information Nondiscrimination Act; Other Modifications to HIPAA, published in January&#160;2013, which imposes certain requirements relating to the privacy, security and transmission of individually identifiable health information without appropriate authorization by entities subject to the rule, such as health plans, health care clearinghouses and health care providers, and their respective business associates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">federal transparency laws, including the federal Physician Payments Sunshine Act, which is part of PPACA, that require certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program, with specific exceptions, to report annually to the Centers for Medicare&#160;&amp; Medicaid Services, or CMS, information related to: (i)&#160;payments or other &#8220;transfers of value&#8221; made to physicians and teaching hospitals; and (ii)&#160;ownership and investment interests held by physicians and their immediate family members;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">state and foreign law equivalents of each of the above federal laws, state laws that require manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures, and state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government or to adopt compliance programs as prescribed by state laws and regulations, or that otherwise restrict payments that may be made to healthcare providers; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">state and foreign laws that govern the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</span></td></tr></table><div style="margin-top:10pt;"></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">57</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Because of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available, it is possible that some of our business activities could be subject to challenge under one or more of such laws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, exclusion of drugs from government funded healthcare programs, such as Medicare and Medicaid, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws and the curtailment or restructuring of our operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The risk of our being found in violation of these laws is increased by the fact that many of them have not been fully interpreted by the regulatory authorities or the courts, and their provisions are open to a variety of interpretations. Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management&#8217;s attention from the operation of our business. The shifting compliance environment and the need to build and maintain robust and expandable systems to comply with multiple jurisdictions with different compliance and/or reporting requirements increases the possibility that a healthcare company may run afoul of one or more of the requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Coverage and adequate reimbursement may not be available for our current or any future product candidates, which could make it difficult for us to sell profitably, if approved.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Market acceptance and sales of any product candidates that we commercialize, if approved, will depend in part on the extent to which reimbursement for these drugs and related treatments will be available from third-party payors, including government health administration authorities, managed care organizations and other private health insurers. Third-party payors decide which therapies they will pay for and establish reimbursement levels. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own coverage and reimbursement policies. However, decisions regarding the extent of coverage and amount of reimbursement to be provided for any product candidates that we develop will be made on a payor-by-payor basis. One payor&#8217;s determination to provide coverage for a drug does not determine whether or not another payor will also provide coverage, and adequate reimbursement, for the drug. Additionally, a third-party payor&#8217;s decision to provide coverage for a therapy does not imply that an adequate reimbursement rate will be approved. Each payor determines whether or not it will provide coverage for a therapy, what amount it will pay the manufacturer for the therapy, and on what tier of its formulary it will be placed. The position on a payor&#8217;s list of covered drugs, or formulary, generally determines the co-payment that a patient will need to make to obtain the therapy and can strongly influence the adoption of such therapy by patients and physicians. Patients who are prescribed treatments for their conditions and providers prescribing such services generally rely on third-party payors to reimburse all or part of the associated healthcare costs. Patients are unlikely to use our drugs unless coverage is provided and reimbursement is adequate to cover a significant portion of the cost of our drugs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A primary trend in the U.S. healthcare industry and elsewhere is cost containment. Third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. Coverage and reimbursement may not be available for any drug that we commercialize and, if reimbursement is available, it is uncertain what the level of reimbursement will be. Inadequate coverage and reimbursement may impact the demand for, or the price of, any drug for which we obtain marketing approval. If coverage and adequate reimbursement are not available, or are available only at limited levels, we may not be able to successfully commercialize our current and any future product candidates that we develop.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Healthcare legislative reform measures may have a negative impact on our business and results of operations.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the United States and some foreign jurisdictions, there have been, and continue to be, several legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of product candidates, restrict or regulate post-approval activities, and affect our ability to profitably sell any product candidates for which we obtain marketing approval.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">58</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Among policy makers and payors in the United States and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality and/or expanding access. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by major legislative initiatives. In March&#160;2010, the PPACA was passed, which substantially changed the way healthcare is financed by both the government and private insurers, and significantly impacts the U.S. pharmaceutical industry. The PPACA, among other things: (i)&#160;addresses a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected; (ii)&#160;increases the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program and extends the rebate program to individuals enrolled in Medicaid managed care organizations; (iii)&#160;establishes annual fees and taxes on manufacturers of certain branded prescription drugs; (iv)&#160;expands the availability of lower pricing under the 340B drug pricing program by adding new entities to the program; and (v)&#160;establishes a new Medicare Part&#160;D coverage gap discount program, in which manufacturers must agree to offer 50% point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#8217;s outpatient drugs to be covered under Medicare Part&#160;D. Some of the provisions of the PPACA have yet to be fully implemented, while certain provisions have been subject to judicial and Congressional challenges. In January&#160;2017, Congress voted to adopt a budget resolution for fiscal&#160;year 2017, or the Budget Resolution, that authorizes the implementation of legislation that would repeal portions of the PPACA. The Budget Resolution is not a law; however, it is widely viewed as the first step toward the passage of legislation that would repeal certain aspects of the PPACA. Further, on January&#160;20, 2017, President Trump signed an Executive Order directing federal agencies with authorities and responsibilities under the PPACA to waive, defer, grant exemptions from, or delay the implementation of any provision of the PPACA that would impose a fiscal or regulatory burden on states, individuals, healthcare providers, health insurers, or manufacturers of pharmaceuticals or medical devices. The PPACA remains subject to legislative efforts to repeal, modify or delay the implementation of the law. Recent efforts to repeal, modify or delay implementation of the ACA have resulted in some level of success. If the PPACA is repealed or further modified, or if implementation of certain aspects of the PPACA are delayed, such repeal, modification or delay may materially adversely impact our business, strategies, prospects, operating results or financial condition. Additionally, there has been heightened governmental scrutiny in the United States of pharmaceutical pricing practices in light of the rising cost of prescription drugs and biologics. Such scrutiny has resulted in several recent congressional inquiries and proposed and enacted federal and state legislation designed to bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs and reform government program reimbursement methodologies for products. In addition, changes to the political landscape in the United States (including as a result of the 2020 presidential elections) may impact the market sentiment surrounding the pharmaceutical industry.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We expect that these and other healthcare reform measures that may be adopted in the future may result in more rigorous coverage criteria and in additional downward pressure on the price that we receive for any approved drug. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our drugs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our product candidates or additional pricing pressures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we obtain approval to commercialize any approved products outside of the United States, a variety of risks associated with international operations could materially adversely affect our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If any of our product candidates are approved for commercialization outside of the United States, we intend to enter into agreements with third parties to market them on a worldwide basis or in more limited geographical regions. We expect that we will be subject to additional risks related to entering into international business relationships, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:17.85pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">different regulatory requirements for drug approvals;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:17.85pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reduced protection for intellectual property rights, including trade secret and patent rights;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:17.85pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">unexpected changes in tariffs, trade barriers and regulatory requirements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:17.85pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">economic weakness, including inflation, or political instability in particular foreign economies and markets;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">59</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:17.85pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:17.85pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">foreign taxes, including withholding of payroll taxes;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:17.85pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">foreign currency fluctuations, which could result in increased operating expenses and reduced revenues, and other obligations incident to doing business in another country;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:17.85pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">workforce uncertainty in countries where labor unrest is more common than in the United States;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:17.85pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:17.85pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">business interruptions resulting from geopolitical actions, including war and terrorism, or natural disasters including earthquakes, hurricanes, floods and fires; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:17.85pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">difficulty in importing and exporting clinical trial materials and study samples.</span></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Product liability lawsuits against us could cause us to incur substantial liabilities and could limit commercialization of any product candidates that we may develop. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">We will face an inherent risk of product liability exposure related to the testing of our product candidates in clinical trials and will face an even greater risk if we commercialize any of our product candidates. If we cannot successfully defend ourselves against claims that our product candidates caused injuries, we could incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in: </p><div style="margin-top:6pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">decreased demand for any product candidates that we may develop;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">injury to our reputation and significant negative media attention; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">initiation of investigations by regulators; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">withdrawal of clinical trial participants;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">significant time and expenses to defend the related litigation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">diversion of management and scientific resources from our business operations; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">substantial monetary awards to trial participants or patients; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">loss of revenue; and </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the inability to commercialize any product candidates that we may develop. </span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We currently hold limited product liability insurance coverage. We will need to purchase additional product liability insurance coverage as we expand our clinical trials, and if we commence commercialization of our product candidates. Insurance coverage is increasingly expensive. If we are unable to obtain insurance at an acceptable cost or otherwise protect against potential product liability claims, we will be exposed to significant liabilities, which may materially and adversely affect our business and financial position. If we are sued for any injury allegedly caused by our or our collaborators&#8217; products, our liability could exceed our total assets and our ability to pay the liability. A product liability claim or series of claims brought against us would decrease our cash and could cause our stock price to fall.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to Ownership of Our Common Stock</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The market price for our common stock may be volatile, and your investment in our securities could decline in value.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The stock market in general has experienced extreme price and volume fluctuations. The market prices of the securities of biotechnology and specialty pharmaceutical companies, particularly companies like ours without product revenues and earnings, have been highly volatile and may continue to be highly volatile in the future. This volatility has often been unrelated to the operating performance of particular companies. The following factors, in addition to other risk factors described in this section, may have a significant impact on the market price of our common stock:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:17.85pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">announcements of technological innovations or new products by us or our competitors;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">60</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:17.85pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">announcement of FDA approval or disapproval of our product candidates or other product-related actions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:17.85pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">developments involving our discovery efforts and clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:17.85pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">developments or disputes concerning patents or proprietary rights, including announcements of infringement, interference or other litigation against us or our potential licensees;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:17.85pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">developments involving our efforts to commercialize our products, including developments impacting the timing of commercialization;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:17.85pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">announcements concerning our competitors, or the biotechnology, pharmaceutical or drug delivery industry in general;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:17.85pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">public concerns as to the safety or efficacy of our product candidates or our competitors&#8217; products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in government regulation of the pharmaceutical or medical industry;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in the reimbursement policies of third party insurance companies or government agencies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:17.85pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">actual or anticipated fluctuations in our operating results;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:17.85pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in financial estimates or recommendations by securities analysts;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:17.85pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">developments involving corporate collaborators, if any;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:17.85pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in accounting principles;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:17.85pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the impact of political instability, natural disasters, events of terrorism and or war, such as the war between Ukraine and Russia, and the corresponding tensions created from such conflict between Russia, the United States and countries in Europe as well as other countries such as China; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the loss of any of our key scientific or management personnel.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the past, securities class action litigation has often been brought against companies that experience volatility in the market price of their securities. Whether or not meritorious, litigation brought against us could result in substantial costs and a diversion of management&#8217;s attention and resources, which could adversely affect our business, operating results and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We will incur increased costs as a result of operating as a public company, and our management will be required to devote substantial time to new compliance initiatives and corporate governance practices.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As a public company, and particularly after we no longer qualify as an emerging growth company, we will incur significant legal, accounting and other expenses that we did not incur previously. The&#160;Sarbanes-Oxley Act, the&#160;Dodd-Frank Wall Street Reform and Consumer Protection Act, the listing requirements of Nasdaq, and other applicable securities rules&#160;and regulations impose various requirements on U.S. reporting public companies, including the establishment and maintenance of effective disclosure and financial controls and corporate governance practices. Our management and other personnel will need to devote a substantial amount of time to these compliance initiatives. Moreover, these rules&#160;and regulations will increase our legal and financial compliance costs and will make some activities more time-consuming and costly. These rules&#160;and regulations are often subject to varying interpretations, and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">While we remain an emerging growth company, we will not be required to include an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. To prepare for eventual compliance with Section&#160;404, once we no longer qualify as an emerging growth company, we will be engaged in a process to document and evaluate our internal control over financial reporting, which is both costly and challenging. In this regard, we will need to continue to dedicate internal resources, potentially engage outside consultants and adopt a detailed work plan to assess and document the adequacy of internal control over financial reporting, continue steps to improve control processes as appropriate, validate through testing that controls are functioning as documented and implement a continuous reporting and improvement process for internal control over financial reporting. Despite our efforts, there is a risk that we will not be able to conclude, within the prescribed timeframe or at all, that our internal control over financial reporting is effective as required by Section&#160;404. If we </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">61</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">identify one or more material weaknesses, it could result in an adverse reaction in the financial markets due to a loss of confidence in the reliability of our financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We are an &#8220;emerging growth company,&#8221; and the reduced reporting requirements applicable to emerging growth companies may make our common stock less attractive to investors.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We qualify as an &#8220;emerging growth company,&#8221; as defined in the&#160;JOBS Act. For so long as we remain an emerging growth company, we are permitted and plan to rely on exemptions from certain disclosure requirements that are applicable to public companies that are not emerging growth companies. These provisions include, but are not limited to: being permitted to report only two&#160;years of audited financial statements and only two&#160;years of related selected financial data and management&#8217;s discussion and analysis of financial condition and results of operations disclosure; an exemption from compliance with the auditor attestation requirement in the assessment of our internal control over financial reporting pursuant to Section&#160;404 of the Sarbanes-Oxley Act; reduced disclosure obligations regarding executive compensation arrangements in our periodic reports, registration statements and proxy statements; and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. In addition, the&#160;JOBS Act&#160;permits emerging growth companies to take advantage of an extended transition period to comply with new or revised accounting standards applicable to public companies. As a result, the information we provide might be different from the information that is available for other public companies. We cannot predict whether investors will find our common stock less attractive if we rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock, and the market price of our common stock may be more volatile.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We will remain an emerging growth company until the earliest of (i)&#160;December&#160;31, 2026, (ii)&#160;the first fiscal&#160;year after our annual gross revenue exceeds $1.07 billion, (iii)&#160;the date on which we have, during the immediately preceding three-year period, issued more than $1.00 billion in non-convertible debt securities, or (iv)&#160;the end of any fiscal&#160;year in which the market value of our common stock held by non-affiliates exceeds $700 million as of the end of the second quarter of that fiscal&#160;year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We do not anticipate paying dividends on our common stock and, accordingly, stockholders must rely on stock appreciation for any return on their investment.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have never declared or paid cash dividends on our common stock and do not expect to do so in the foreseeable future. The declaration of dividends is subject to the discretion of our board of directors and limitations under applicable law, and will depend on various factors, including our operating results, financial condition, future prospects and any other factors deemed relevant by our board of directors. You should not rely on an investment in our company if you require dividend income from your investment in our company. The success of your investment will likely depend entirely upon any future appreciation of the market price of our common stock, which is uncertain and unpredictable. There is no guarantee that our common stock will appreciate in value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Sales of a substantial number of shares of our common stock by our existing stockholders in the public market could cause our stock price to fall.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Sales of a substantial number of shares of our common stock in the public market could occur at any time. If our stockholders sell, or the market perceives that our stockholders intend to sell, substantial amounts of our common stock in the public market, the market price of our common stock could decline significantly. We cannot predict what effect, if any, sales of our shares in the public market or the availability of shares for sale will have on the market price of our common stock. However, future sales of substantial amounts of our common stock in the public market, including shares issued upon exercise of outstanding options, or the perception that such sales may occur, could adversely affect the market price of our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We also expect that significant additional capital may be needed in the future to continue our research and development activities and costs associated with operating as a public company. To raise capital, we may sell common stock, convertible securities or other equity securities in one or more transactions at prices and in a manner we determine from time to time. These sales, or the perception in the market that the holders of a large number of shares intend to sell shares, could reduce the market price of our common stock.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">62</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The rights of the holders of our securities may be impaired by the potential issuance of preferred stock.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our articles of incorporation give our board of directors the ability to designate and issue preferred stock in one or more series. As a result, the board of directors may, without stockholder approval, issue preferred stock with voting, dividend, conversion, liquidation or other rights which could adversely affect the relative voting power and equity interest of the holders of common stock. Preferred stock, which could be issued with the right to more than one vote per share, could have the effect of discouraging, delaying or preventing a change of control of us. The possible impact on takeover attempts could adversely affect the price of our securities. Although we have no present intention to designate any series, or issue any shares, of preferred stock, other than pursuant to the IPO, we may do so in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If securities or industry analysts do not publish research or reports about our business, or if they change their recommendations regarding our stock adversely, our stock price and trading volume could decline.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The trading market for our common stock will be influenced by the research and reports that industry or securities analysts publish about us or our business. Our research coverage by industry and financial analysts is currently limited. Even if our analyst coverage increases, if one or more of the analysts who cover us downgrade our stock, our stock price would likely decline. If one or more of these analysts cease coverage of our company or fail to regularly publish reports on us, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Anti-takeover provisions in our organizational documents and Delaware law might discourage or delay attempts to acquire us that you might consider favorable.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our amended and restated certificate of incorporation (the &#8220;Amended Charter&#8221;) and amended and restated bylaws (the &#8220;Amended Bylaws&#8221;) contains provisions that may make the merger or acquisition of us more difficult without the approval of our board of directors. Among other things, these provisions:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">allow us to authorize the issuance of undesignated preferred stock in connection with a stockholder rights plan or otherwise, the terms of which may be established and the shares of which may be issued without stockholder approval, and which may include super voting, special approval, dividend, or other rights or preferences superior to the rights of the holders of common stock;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">provide that our bylaws may be amended or repealed only by a majority vote of our board of directors or by the affirmative vote of the holders of at least 66 2/3% of the votes which all our stockholders would be entitled to cast in any annual election of directors; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establish advance notice requirements for nominations for elections to our board or for proposing matters that can be acted upon by stockholders at stockholder meetings.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Further, as a Delaware corporation, we are also subject to provisions of Delaware law, which may impair a takeover attempt that our stockholders may find beneficial. These anti-takeover provisions and other provisions under Delaware law could discourage, delay, or prevent a transaction involving a change in control of us, including actions that our stockholders may deem advantageous, or could negatively affect the market price of our common stock. These provisions could also discourage proxy contests and make it more difficult for you and other stockholders to elect directors of your choosing and to cause us to take other corporate actions out stockholders desire.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our Amended Charter provides that the Court of Chancery of the State of Delaware will be the sole and exclusive forum for substantially all disputes between us and our stockholders and federal district courts will be the sole and exclusive forum for&#160;Securities Act&#160;claims, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers, or employees.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Our Amended Charter provides that, unless we consent to the selection of an alternative forum, the Court of Chancery of the State of Delaware is the sole and exclusive forum for: (i)&#160;any derivative action or proceeding brought on our behalf; (ii)&#160;any action asserting a claim of breach of fiduciary duty owed by any of our directors, officers, or other employees to us or to our stockholders; (iii)&#160;any action asserting a claim arising pursuant to the Delaware General Corporation Law (the &#8220;DGCL&#8221;), the Amended Charter or the Amended Bylaws or as to which the DGCL confers exclusive jurisdiction on the Court of Chancery of the State of Delaware; or (iv)&#160;any action asserting a claim governed </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">63</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">by the internal affairs doctrine, provided that the exclusive forum provisions will not apply to suits brought to enforce any liability or duty created by the&#160;Securities Exchange Act of 1934, as amended, or the&#160;Exchange Act&#160;or to any claim for which the federal courts have exclusive jurisdiction. Our Amended Charter will further provide that, unless we consent in writing to the selection of an alternative forum, the federal district courts are the sole and exclusive forum for the resolution of any complaint asserting a right under the&#160;Securities Act, subject to a final adjudication in the State of Delaware of the enforceability of such exclusive forum provision. We note that investors cannot waive compliance with the federal securities laws and the rules&#160;and regulations thereunder. The choice of forum provisions may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers, or other employees, which may discourage such lawsuits against us and our directors, officers, and other employees. Alternatively, if a court were to find the choice of forum provisions contained in our Amended Charter to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could harm our business, results of operations, and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Provisions in our organizational documents regarding exculpation and indemnification of our directors and officers may result in substantial expenditures by us and may discourage lawsuits against our directors and officers.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our Amended Charter and Amended Bylaws provide, to the maximum extent permissible under Delaware law, eliminate the personal liability of our directors and officers to us and our stockholders for damages for breach of fiduciary duty. These provisions may discourage us, or our stockholders through derivative litigation, from bringing a lawsuit against any of our current or former directors or officers for any breaches of their fiduciary duties, even if such legal actions, if successful, might benefit us or our stockholders. In addition, our Amended Charter and Amended Bylaws provide that we will, to the fullest extent permitted by Delaware law, indemnify our directors and officers for costs or damages incurred by them in connection with any threatened, pending, or completed action, suit, or proceeding brought against them by reason of their positions as directors and officers. We also intend to enter into indemnification agreements with each of our directors and executive officers. These indemnification obligations could result in our incurring substantial expenditures to cover the cost of settlement or damage awards against our directors or officers.</p><a id="_5ddfbb44_768a_4550_a0d3_3ed1fa26b32b"></a><a id="ITEM1BUNRESOLVEDSTAFFCOMMENTS_29639"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">ITEM 1B. UNRESOLVED STAFF COMMENTS</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-weight:normal;">None.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_e2678a81_d68c_4053_982a_fb3eb9839a18"></a><a id="ITEM2PROPERTIES_990758"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">ITEM 2. PROPERTIES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our principal executive office is located in Bethesda, Maryland, where we lease in a multi-tenant building 1,568 square feet of office space that we use for our administrative, investor relations and business developments and other activities. This lease expires in September 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We lease in a multi-tenant building 2,992 square feet of office space in Via Soave n.6, Lugano Switzerland that we use for our general management team, research and administrative activities. This lease expires in May 2026.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We lease in a multi-tenant building 1,402 square feet on lab space in Cluster II Building in the Parc Cientific de Barcelona, Spain that we use for our biology laboratory. This lease expires in December 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We lease in a multi-tenant building 1,417 square feet of office space in Torre D Building in the Parc Cientific de Barcelona, Spain that we use for our general management and research activities. This lease expires in November 2026.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">We believe our current facilities, including the terms and conditions of the relevant lease agreements, are adequate to operate our businesses as currently conducted. However, as we continue to expand our operations, we may need to lease additional or alternative facilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_c3d93532_4b73_4e7b_9b96_0a0343580807"></a><a id="ITEM3LEGALPROCEEDINGS_174891"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">ITEM 3. LEGAL PROCEEDINGS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_0222f2d8_0d89_4ca3_bbb0_6d40b4bae73d"></a><a id="ITEM4MINESAFETYDISCLOSURES_461102"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">ITEM 4. MINE SAFETY DISCLOSURES</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Not applicable.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">64</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_4ff09716_a920_4d00_8a94_b0e7bfbd37a8"></a><a id="PARTII_504996"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">PART&#160;II</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="ITEM5MARKETFORREGISTRANTSCOMMONEQUITYREL"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">ITEM&#160;5. MARKET FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS, AND ISSUER PURCHASES OF EQUITY SECURITIES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Market Information and Holders</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our Common Stock trades on the Nasdaq Global Market (the &quot;Nasdaq&quot;) under the trading symbol &quot;GANX.&quot; As of February&#160;28, 2022, there were approximately fifty-four holders of record of our Common Stock. Because almost all of our ordinary shares are held by brokers, nominees and other institutions on behalf of shareholders, we are unable to estimate the total number of shareholders represented by these record holders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Dividends</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">We presently have no intention to declare or pay a dividend, and there can be no assurance that we will pay dividends in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_f370ec6f_1b9e_489b_93d2_6e9e4b6f2c7f"></a><a id="ITEM6SELECTEDFINANCIALDATA_182437"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">ITEM&#160;6. SELECTED FINANCIAL DATA</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Reserved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_93ee3f38_7312_4b91_abea_6bcb0cfaa2b7"></a><a id="ITEM7MANAGEMENTSDISCUSSIONANDANALYSISOFF"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">ITEM 7. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">OVERVIEW</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are a biotechnology company developing novel small molecule therapeutics to treat diseases across, &#160;several therapeutic areas, including, lysosomal storage disorders (&#8220;LSDs&#8221;), central nervous system disorders (&#8220;CNS&#8221;), metabolic disorders, and oncology. We use our exclusively in-licensed computational target and drug discovery platform, Site-Directed Enzyme Enhancement Therapy (&#8220;SEE-Tx&#174;&#8221;), to discover novel allosteric binding sites on proteins implicated in a disease and to identify proprietary small molecules that bind these sites to modulate protein function, and treat the underlying cause of the disease. These binding sites, away distinct from the protein&#8217;s active site, are called allosteric sites. We believe that targeting an allosteric binding site instead of the active binding site of a protein provides numerous advantages: the ability to regulate proteins implicated in disease through several different mechanisms of action covering both functional and conformational effects, including stabilization, destabilization, targeted degradation, allosteric inhibition, and allosteric activation of the targeted protein; improved specificity of small molecules because binding to an allosteric binding site is non-competitive with the natural substrate that binds to the active binding site; and the ability to identify small &#160;molecules with more favorable drug-like properties. The SEE-Tx&#174; platform has been used to identify novel allosteric sites and small molecules for all of our internal programs and partnered programs. &#160;Discovering and targeting novel allosteric sites with our platform not only collapses traditional drug discovery timelines but enables rational drug design and offers the potential for superior small molecule drugs that are highly specific and, potent, and that can penetrate hard to reach tissues and cross the blood-brain barrier.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have filed four patent applications for our novel small molecule drug candidates that are Structurally Targeted Allosteric Regulators (&#8220;STARs&#8221;). In June 2021, the Company announced the publication of two PCT patents. The first was directed at compounds targeting misfolded beta-glucocerebrosidase (GBA) addressing CNS diseases such as Parkinson&#8217;s disease, Gaucher disease, Alzheimer&#8217;s disease, and Lewy body dementia. The second was directed at compounds targeting galactosylceramidase (GALC), addressing demyelinating disorders such as Krabbe disease and multiple sclerosis. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">We have identified two different STARs as the lead compounds for our Parkinson&#8217;s disease program and our Gaucher disease program and are currently developing these product candidates through preclinical studies. In September 2021, the Company announced positive topline data of an in vitro study evaluating the two STARs for the treatment of Gaucher and Parkinson&#8217;s disease in neuronal cells derived induced pluripotent stem cells (&#8220;iPSCs&#8221;) of a patient with Gaucher disease that contained the disease-causing mutation of the GBA1 gene and from iPSCs of a healthy donor with a normal GBA1 gene, so called wild-type cells. The results of the study, conducted at the University of Maryland School of Medicine, demonstrate a significant increase in beta-glucocerebrosidase (&#8220;GCase&#8221;) protein </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">65</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">levels, improved trafficking of GCase to the lysosome, and a significant decrease of toxic substrates glucosylceramide and alpha-synuclein p129 levels in both the neuronal cells that contained the mutated GBA1 gene as well as the wild-type cells. Alpha synuclein is considered to be the hallmark of Parkinson&#8217;s disease. &#160;In addition, these data provide further evidence that these product candidates have the potential to treat Gaucher disease and slow or stop the progression of GBA Parkinson&#8217;s disease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We expect to complete the preclinical development and submit the regulatory dossier to the Human Research Ethics Committee in Australia to initiate a first-in-human Phase 1 clinical trial in our Parkinson&#8217;s disease program, and to initiate the preclinical toxicology studies for our Gaucher program in the second half of 2022. In addition, we plan to continue to advance research programs and initiate additional programs targeting allosteric binding sites identified with the SEE-Tx&#174; platform. &#160;Through academic partnerships, co-development and licensing arrangements, we intend to develop a broad pipeline of therapeutics, using our novel approach of identifying and targeting previously unknown allosteric sites. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Since our inception in 2017, we have devoted substantially all of our resources to identify and develop next-generation brain-penetrant allosteric small molecules for the treatment of devastating diseases with high-unmet medical needs using our in-licensed SEE-Tx&#174; platform. To date, we do not have any product candidates approved for sale and have not generated any revenue from product sales. We have primarily financed our operations through a combination of sales of our securities and research grants. On March 17, 2021, we completed our IPO and issued and sold approximately 4.1 million shares of our common stock at a public offering price of $11.00 per share, including approximately 0.5 million shares in connection with the full exercise of the underwriters&#8217; option to purchase additional shares, resulting in net proceeds of approximately $40.5 million, after deducting the underwriting discounts and commissions and offering expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2021, we had cash and cash equivalents of $36,881 thousand. For the year ended December 31, 2021, we had cash outflows from operations of $12,366 thousand. We have incurred recurring losses and negative cash flows from operations since inception and as of December 31, 2021 and December 31, 2020, had an accumulated deficit of $20,925 thousand and $7,035 thousand, respectively. We anticipate incurring additional losses until such time, if ever, that we can generate sales of our product candidates currently in development. We have not generated any product revenues and have not achieved profitable operations. There is no assurance that profitable operations will ever be achieved, and, if achieved, could be sustained on a continuing basis. In addition, we will need significant additional financing to fund our operations and to develop our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our operations have consisted primarily of organizing and expanding the Company&#8217;s operation, securing financing, performing research, conducting preclinical studies and developing licensed technology. We face risks associated with early-stage biotechnology companies whose product candidates are in development. Product candidates currently under development will require significant additional research and development efforts, including extensive preclinical and clinical testing and regulatory approval prior to commercialization. These efforts require significant amounts of additional capital for us to complete our research and development, achieve our research and development objectives, defend our intellectual property rights, and recruit and retain skilled personnel, and key members of management. Even if our product development efforts are successful, it is uncertain when, if ever, we will realize significant revenue from product sales.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We may seek additional funding through public or private equity offerings, debt financings, other collaborations, strategic alliances and licensing arrangements. We may not be able to obtain financing on acceptable terms, or at all, and we may not be able to enter into strategic alliances or other arrangements on favorable terms, or at all. The terms of any financing may adversely affect our holdings or the rights of our stockholders. If we are unable to obtain funding, we could be required to delay, reduce or eliminate research and development programs, product portfolio expansion or future commercialization efforts, which could adversely affect our business prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Strategic Transactions; Collaboration and Licensing Arrangements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In connection with our business development activities,&#160;we enter into collaborative and licensing arrangement with third parties, to use our licensed SEE-Tx&#174; computational platform technology to discover novel allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites, potentially restoring protein folding and treating disease. We expect to continue to identify and evaluate collaboration, co-development and licensing opportunities that may be similar to or different from the collaborations and licenses that we have entered into.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">66</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On April 20, 2021, the Company entered into a multi-target collaboration agreement with Zentalis Pharmaceuticals, Inc. (&#8220;Zentalis&#8221;) to discover new product candidates for the treatment of cancer. Under the terms of the agreement, the Company will use its licensed SEE-Tx&#174; computational platform technology to identify binding site on target proteins and determine the potential suitability of these sites as drug targets, as well as their prospective therapeutic use in oncology. Pursuant the terms of the agreement, Zentalis agreed to pay the Company, on a program-by-program basis, a non-creditable, non-refundable, program initiation fee and reimburse of expenses incurred by the Company in accordance with the agreed-upon research budget.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">With respect to any development program, and subject the delivery of the data package, the Company granted to Zentalis an option to obtain an exclusive, transferable worldwide license, with the right to sublicense, under relevant intellectual property rights and know-how of the Company arising from the collaboration to develop, manufacture and commercialize any products resulting from the development program. Zentalis may exercise the option, at its reasonable discretion, and shall use commercially reasonable efforts to develop and obtain market approval for products developed from the applicable programs. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Unless terminated earlier, the agreement expires at the expiration of the last valid claim of the licensed patents, subject to certain surviving rights and obligations. Zentalis and the Company can each terminate the agreement in the event of the bankruptcy or insolvency of the other party, or a material breach by the other party and failure to cure such breach within a certain period of time. Zentalis shall have the right, at its sole discretion, exercisable at any time to terminate the agreement on a program-by-program basis, upon ninety (90) days&#8217; prior written notice to the Company or, at any time, if a safety concern arises with respect to any development program or product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 6pt 0pt;">In May 2021, the first target development program was identified, and the estimated development cost were approved and collected in July 2021. The transaction price of this first target development program includes (i)&#160;$50&#160;thousand of fixed consideration as program initiation fee, (ii) up to $272 thousand as reimbursement for employee and external research and development cost, (iii) $250 thousand subject to the exercise of a research program option, (iv) up to $41.5&#160;million of variable consideration in the form of event-based milestone payments, if goals will be met in the future, and (v) other royalty-based payments based on future net sales.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2021, the Company recognized $134 thousand of revenues and reported current portion of deferred revenues for $188 thousand.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Components of Our Consolidated Results of Operations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Revenue</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have not generated any revenue from product sales and do not expect to generate any revenue from the sale of products in the foreseeable future. If we fail to complete the development of our product candidates in a timely manner or fail to obtain their regulatory approval, we will not generate revenue in the future. Our current revenues are residual and primarily consist of income from subleases of our office space and collaboration arrangements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Operating Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our expenses since inception have consisted solely of research and development costs and general and administrative costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Research and Development Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Research and development expenses consist primarily of costs incurred for our research activities, including our discovery efforts, and the development of our product candidates, which include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">expenses incurred under collaborations with third parties, including contract research organizations, or CROs, and Universities, that conduct research and preclinical studies, such as in-vitro and in-vivo absorption, distribution, metabolism and excretion (&#8220;ADME&#8221;), cell model studies, in-vivo pharmacology and pharmacokinetic studies, toxicology studies and chemical synthesis, on our behalf;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">employee salaries, benefits and other related costs, including share-based compensation expenses, for employees engaged in research and development functions and overhead allocations consisting of </span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">67</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"></td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">various support and facilities-related expenses, which include rent, utilities and maintenance of our Barcelona labs and Lugano office, depreciation, travel and congress expenses;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">fees paid to consultants who assist with research and development activities and related travel expenses; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the cost of sponsored research, which includes laboratory materials and supplies, manufacturing scale-up expenses and the cost of acquiring and manufacturing preclinical studies.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table provides a breakout of our research and development expenses by major categories of expense:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:63.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:34.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:63.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:34.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Change</b></p></td></tr><tr><td style="vertical-align:top;width:63.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Pre-clinical activities and outside services</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 4,849,576</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1,297,694</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 3,551,882</span></p></td></tr><tr><td style="vertical-align:top;width:63.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Personnel expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 2,223,585</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1,100,722</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1,122,863</span></p></td></tr><tr><td style="vertical-align:top;width:63.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 275,816</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 176,611</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 99,205</span></p></td></tr><tr><td style="vertical-align:top;width:63.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research grants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (184,748)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (315,823)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 131,075</span></p></td></tr><tr><td style="vertical-align:top;width:63.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 7,164,229</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 2,259,204</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 4,905,025</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We recognize research and development costs as incurred. We recognize external development costs based on an evaluation of the progress to completion of specific tasks using information provided to us by our vendors. Payments for these activities are based on the terms of the individual agreements, which may differ from the pattern of costs incurred, and are reflected in our financial statements as prepaid or accrued research and development expenses. We anticipate that our research and development expenses will increase substantially in future periods to support progress in our research and development activities, including the commencement of the clinical trials for product candidates we are developing. These increases will likely also result from increased headcount, expanded infrastructure and increased insurance costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our primary research and development focus since inception has been the application of our in-licensed SEE-Tx&#174; platform to various indications and targets. We are using our platform to design and develop a broad pipeline of STARs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Research and development activities are central to our business model. Product candidates in later stages of clinical development generally incur higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. As a result, we expect that our research and development expenses will continue to increase in the foreseeable future as we (i)&#160;increase personnel costs, including stock-based compensation, (ii)&#160;continue preclinical development of our lead compounds, (iii)&#160;initiate clinical trials for certain product candidates, (iv)&#160;continue to discover and develop additional product candidates, and (v)&#160;pursue later stages of clinical development of product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">General and Administrative Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">General and administrative expenses consist primarily of salaries, bonus and other related costs, including share-based compensation, for personnel in our executive, finance, corporate and business development and administrative functions. General and administrative expenses also include legal fees relating to patent and corporate matters; professional fees for accounting, auditing, tax and consulting services, insurance costs, travel expenses, and facility-related expenses, and other operating costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We anticipate that our general and administrative expenses will increase in the future, in the form of additional compensation, including salaries, benefits, incentive arrangements and share-based compensation awards, as we increase our headcount to support the expected growth, attract and retain additional personnel and the potential commercialization of our product candidates. We also expect to incur increased expenses associated with being a public company, including increased costs of accounting, audit, legal, regulatory and tax-related services associated with maintaining compliance with exchange listing and SEC requirements, director and officer insurance costs and investor and public relations costs.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">68</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Other Financial Income (Expense)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Other financial income (expense) consists of interest income, interest expense and foreign exchange gain or loss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Consolidated Results of Operations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Comparison of the Year Ended December 31, 2021 and 2020</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes our historical results of operations for the periods indicated, together with the changes in those items in dollars.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:59.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:38.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:59.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:38.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Increase</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Decrease)</b></p></td></tr><tr><td style="vertical-align:top;width:59.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Revenues:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:59.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Collaborative Agreements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 133,928</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 133,928</span></p></td></tr><tr><td style="vertical-align:top;width:59.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 31,066</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 28,881</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 2,185</span></p></td></tr><tr><td style="vertical-align:top;width:59.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total revenues</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 164,994</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 28,881</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 136,113</span></p></td></tr><tr><td style="vertical-align:top;width:59.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:59.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:59.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (7,164,229)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (2,259,204)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 4,905,025</span></p></td></tr><tr><td style="vertical-align:top;width:59.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (6,826,938)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (1,249,126)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 5,577,812</span></p></td></tr><tr><td style="vertical-align:top;width:59.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (13,991,167)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (3,508,330)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 10,482,837</span></p></td></tr><tr><td style="vertical-align:top;width:59.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:59.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Loss from operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (13,826,173)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (3,479,449)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 10,346,724</span></p></td></tr><tr><td style="vertical-align:top;width:59.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:59.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Interest income, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 12,495</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 3,637</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 8,858</span></p></td></tr><tr><td style="vertical-align:top;width:59.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Foreign exchange loss, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (72,920)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (96,484)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 23,564</span></p></td></tr><tr><td style="vertical-align:top;width:59.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Loss before income tax</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (13,886,598)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (3,572,296)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 10,314,302</span></p></td></tr><tr><td style="vertical-align:top;width:59.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:59.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Income tax</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (4,008)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (5,386)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (1,378)</span></p></td></tr><tr><td style="vertical-align:top;width:59.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (13,890,606)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (3,577,682)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 10,312,924</span></p></td></tr><tr><td style="vertical-align:top;width:59.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:59.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss per ordinary share:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:59.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Basic and diluted loss per share</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (1.37)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (1.33)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 0.03</span></p></td></tr><tr><td style="vertical-align:top;width:59.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted-average ordinary shares used in per share calculations &#8211; basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 10,165,404</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 2,681,408</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">Comparison of the year ended December 31, 2021 and 2020</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Revenues</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For the year ended December 31, 2021 and 2020 total revenues were $164,994 and $28,881 respectively and consist mainly of income from a collaboration agreement and the sublease of the Lugano office space. Collaboration revenues were $133,928 and nil as of December 31, 2021 and 2020, respectively and refer to a program initiation fee and development services on the first target development program identified under the collaboration agreement with Zentalis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Research and Development Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Research and development expenses increased by $4,905,025 to $7,164,229 for the year ended December 31, 2021, from $2,259,204 for the year ended December 31, 2020. The increase in research and development expenses was primarily attributable to increases in outside services as we continue to expand our research and development activities, including external collaborations for chemical synthesis, toxicology studies, <i style="font-style:italic;">in vitro</i> ADME and model studies, and <i style="font-style:italic;">in vivo</i>, pharmacology and pharmacokinetic studies and increases in personnel-related costs resulting from </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">69</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">an increase in employee headcount and stock-based compensation. As of December, 2021, and 2020, research and development expense are net of research grant of $184,748 and $315,823, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">General and Administrative Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">General and administrative expenses increased by $5,577,812 to $6,826,938 for the year ended December 31, 2021 from $1,249,126 for the year ended December 31, 2020. The increase in general and administrative expenses was primarily attributable to increase in expenses for listing fees, legal fees relating to patent and corporate matters, professional fees for accounting, professional services and investor relations as we continue to expand our business and build management infrastructure and increases in personnel-related costs resulting from an increase in employee headcount, stock-based compensation and warrants issuance costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Liquidity and Capital Resources</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Since our inception, we have not generated any revenue from product sales and have incurred significant operating losses and negative cash flows from our operations. We have not yet commercialized any products or technologies, and we do not expect to generate revenue from sales of any products in the near term, if at all. We have funded our operations to date primarily through a combination of sales of our securities and research grants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We do not currently have any approved products and have never generated any revenue from product sales. To date, we have financed our operations primarily through the sale of equity securities. As of December 31, 2021, &#160;and 2020, we had $36,881 thousand and $7,493 thousand in cash and cash equivalents, respectively, and an accumulated deficit of $20,925 thousand and $7,035, respectively. We had an indebtedness of $694 thousand and $738 thousand as of December 31, 2021 and 2020, respectively. On March 17, 2021, we completed our IPO and issued approximately 4.1 million shares of our common stock including approximately 0.5 million shares in connection with the full exercise of the underwriters&#8217; option to purchase additional shares, at a public offering price of $11.00 per share, resulting in net proceeds of approximately $40.5 million, after deducting the underwriting discounts and commissions and offering expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In August&#160;2020, our wholly-owned subsidiary, GT Gain Therapeutics SA obtained a CHF 638 ($700) thousand nine-year&#160;loan. The loan has zero interest. The loan is due in quarterly installment of CHF 20 ($22) thousand commencing on December&#160;31, 2021 and ending on September&#160;30, 2029. The loan is part of the infrastructure put in place by the Federal Council and Swiss Parliament to assist companies in Switzerland in view of the economic consequences of the coronavirus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Cash Flows</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table provides information regarding our cash flows for the periods presented:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:67.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:30.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:67.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:30.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="5" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:67.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:30.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:67.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash used in operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (12,365,670)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (3,240,237)</span></p></td></tr><tr><td style="vertical-align:top;width:67.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash used in investing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (94,212)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (20,826)</span></p></td></tr><tr><td style="vertical-align:top;width:67.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash provided by financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 41,766,775</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 10,486,961</span></p></td></tr><tr><td style="vertical-align:top;width:67.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net increase in cash, cash equivalents and restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 29,407,671</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 7,190,581</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Cash Used in Operating Activities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the year ended December 31, 2021, we used $12,366 thousand of cash in operating activities, primarily to fund our operations related to the development of our product candidates and related general and administrative support activities. Cash used in operating activities reflected our net loss of $13,891 thousand, which was partially offset by adjustments to reconcile net loss to cash used in operating activities of $1,855 thousand related to stock based compensation, depreciation, internal use-software and issuance of warrants, as well as a $330 thousand decrease in cash flows resulting from changes in our operating assets and liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">During the year ended December 31, 2020, we used $3,240 thousand of cash in operating activities, primarily to fund our operations related to the development of our product candidates and related general and administrative </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">70</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">support activities. Cash used in operating activities reflected our net loss of $3,578 thousand, partially offset by adjustments to reconcile net loss to cash used in operating activities of $91 thousand related to stock based compensation and depreciation, as well as a $246 thousand increase in cash flows resulting from changes in our operating assets and liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Cash Used in Investing Activities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">During the year ended December 31, 2021 and 2020, cash used in investing activities was $94 thousand and $21 thousand, respectively, primarily due to purchases of furniture, computers and lab instruments.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Cash Provided by Financing Activities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the year ended December 31, 2021, cash provided by financing activities was $41,767 thousand of which $42,630 thousand related to proceeds from the issuance of our common stock through the IPO net of underwriter discounts, $12 thousand &#160;proceeds from the exercise of stock options, offset by payment for offering cost of $853 thousand and payment of current portion of long term debts for $22 thousand.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the year ended December 31, 2020, cash provided by financing activities was $10,487 thousand due to (i) net proceeds from the issuance of Series A and Series B Preferred Stock for $10,219 thousand, (ii) proceeds from long term loans for $738 thousand and, (iii) disbursements for offering costs for $471 thousand. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Funding Requirements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our primary use of cash is to fund operating expenses, most significantly research and development expenditures. Cash used to fund operating expenses is impacted by the timing of when we pay these expenses, as reflected in the change in our outstanding accounts payable, accrued expenses and prepaid expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Because of the numerous risks and uncertainties associated with research, development and commercialization of pharmaceutical products, we are unable to estimate the exact amount of our operating capital requirements. Our future funding requirements will depend on many factors, including, but not limited to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the scope, timing, progress and results of discovery, preclinical development, laboratory testing and clinical trials for our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the extent to which we enter into collaborations or other arrangements with additional third parties in order to further develop our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs and fees associated with the discovery, acquisition or in-license of additional product candidates or technologies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to establish additional collaborations on favorable terms, if at all;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs required to scale up our clinical, regulatory and manufacturing capabilities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs of manufacturing our product candidates for clinical trials and in preparation for marketing approval and commercialization;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs of future commercialization activities, if any, including establishing sales, marketing, manufacturing and distribution capabilities, for any of our product candidates for which we receive marketing approval; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">revenue, if any, received from commercial sales of our product candidates, should any of our product candidates receive marketing approval.</span></td></tr></table><div style="margin-top:12pt;"></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">71</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We will need additional funds to meet operational needs and capital requirements for clinical trials, other research and development expenditures, and business development activities. Because of the numerous risks and uncertainties associated with the development of our product candidates, we are unable to estimate the amounts of increased capital outlays and operating expenditures associated with our current and anticipated clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We believe that with our existing cash and cash equivalents, as of December 31, 2021, which include the net proceeds of $40.5 million from our IPO will enable us to fund our operating expenses and capital expenditure requirements up to the second half of 2023. We have based this estimate on assumptions that may prove to be wrong, and we could exhaust our available capital resources sooner than we expect.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Until such time, if ever, as we can generate substantial product revenue, we expect to finance our operations through a combination of equity offerings, debt financings, collaborations, strategic alliances and licensing arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, our stockholders&#8217; ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect our stockholders&#8217; rights as a common stockholder. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making acquisitions or capital expenditures or declaring dividends. If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or drug candidates, or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings or other arrangements when needed, we may be required to delay, limit, reduce or terminate our research, product development or future commercialization efforts, or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Critical Accounting Policies and Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our management&#8217;s discussion and analysis of our financial condition and results of operations are based on our consolidated financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles. The preparation of these consolidated financial statements and related disclosures requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenue, costs and expenses, and the disclosure of contingent assets and liabilities in our financial statements. We base our estimates on historical experience, known trends and events and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. On an ongoing basis, we evaluate our estimates and judgments, including those related to accrued expenses, pension obligations and share-based compensation. Our actual results may differ from these estimates under different assumptions or conditions. During the year ended December 31, 2021, there were no material changes to our critical accounting policies. While our significant accounting policies are described in more detail in Note 2 to our consolidated financial statements included elsewhere in this Form 10-K, we believe the following accounting policies are the most critical to the judgments and estimates used in the preparation of our consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><i style="font-style:italic;">Research grants</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Under the terms of the research and development grants awarded, we are entitled to receive reimbursement of our allowable direct expenses. Contributions from research and development activities under the grants are recorded based on management&#8217;s best estimate of the periods in which the related expenditures are incurred and activities performed and are classified in the statement of operations as a reduction to research and development expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Research and Development Expenses</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Several of our activities and related costs are designated research and development expenses, which primarilyinclude salary and benefits payments to our direct employees, employee stock-based compensation expenses, preclinical activities, outside services, material and supplies and contracted services. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Accrued expenses</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">As part of the process of preparing our financial statements, we are required to estimate our accrued expenses as of each balance sheet date. This process involves reviewing open contracts and purchase orders, communicating with our personnel to identify services that have been performed on our behalf and estimating the level of service performed </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">72</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of the actual cost. We make estimates of our accrued expenses as of each balance sheet date based on facts and circumstances known to us at that time at the date of the preparation of the financial statements. There may be instances in which payments made to our vendors exceed the level of services provided, and result in a prepayment reported under other current assets, which are subsequently expensed in the statement of operations when the related activity has been performed. To date, there have been no material differences between our estimates of accrued expenses reported at each balance sheet date and the amounts actually incurred.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Leases</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Effective January 1, 2018, we adopted Accounting Standards Codification 842, Leases (&#8216;&#8216;ASC 842&#8217;&#8217;) using the additional transition method option provided by ASU 2018-11. Under this transition method, we applied the new accounting guidance as of the date of adoption. Upon adoption, a cumulative effect adjustment was not required. Subsequent to the adoption, we determine if an arrangement contains a lease at inception based on whether or not we have the right to control the asset during the contract period and other facts and circumstances. We are the lessee in a lease contact when it obtains the right to control the asset. Operating lease right of use (&#8216;&#8216;ROU&#8217;&#8217;) assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease, both of which are recognized based on the present value of the future minimum lease payments over the lease term at the commencement date. Leases with a term of 12 months or less at inception are expensed on a straight-line basis over the lease term in the statement of operations. We determine the lease termby assuming the exercise of renewal options that are reasonably certain.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Pension obligations</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 18pt 0pt;">We operate defined benefit pension plans and defined contribution pension plans in accordance with local regulations and practices. These plans are funded by regular contribution made by the employer and the employees to a third-party. For defined benefit pension plans, the liability recognized in the balance sheets is the present value of the defined benefit obligation at the balance sheet date less the fair value of plan assets. The overfunded or underfunded status of the defined benefit plans is calculated as the difference between plan assets and the projected benefit obligations. Estimates are used in determining the assumptions incorporated in the calculation of the pension obligations, which is supported by input from independent actuaries. Actuarial gains and losses arising from experience adjustments and changes in actuarial assumptions are recognized in &#8216;&#8216;Accumulated Other Comprehensive Income (Loss)&#8217;&#8217; in the statements of equity and are charged or credited to income over the employees&#8217; expected average remaining working lives. The measurement date used for our employee benefit plan is December 31.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Equity-based compensation</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We recognize compensation costs related to equity based compensation granted to employees, consultants and directors, based on the estimated fair value of the awards as of &#160;the grant date. We estimate the grant date fair value, and the resulting share-based compensation, using the Black-Scholes option-pricing model. The grant date fair value of the stock based awards is recognized on a straight-line basis over the requisite service period, which is generally the vesting period of the respective awards. We estimate the fair value of stock options using the Black-Scholes option-pricing model, which requires assumptions, including the fair value of our common stock prior to our initial public offering, volatility, the expected term of exercise, the risk free interest rate for a period that approximates the expected term of exercise, and our expected dividend yield. Certain assumptions used in our Black-Scholes option-pricing model represent management&#8217;s best estimates and involve a number of assumptions and the application of management&#8217;s judgment, as they are inherently subjective.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">JOBS Act</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">We qualify as an &#8220;emerging growth company&#8221;, as defined in the JOBS Act. For so long as we remain an emerging growth company, we are permitted and plan to rely on exemptions from certain disclosure requirements that are applicable to public companies that are not emerging growth companies. These provisions include, but are not limited to: being permitted to report only two&#160;years audited financial statements and only two years of related selected financial data and management&#8217;s discussion and analysis of financial conditions and results of operations disclosure; an exemption from compliance with the auditor attestation requirement in the assessment of our internal control over financial reporting pursuant to Section&#160;404 of the Sarbanes-Oxley Act; reduced disclosure obligations regarding executive compensation arrangements in our periodic reports, registration statements and proxy statements; and </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">73</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. In addition, the&#160;JOBS Act&#160;permits emerging growth companies to take advantage of an extended transition period to comply with new or revised accounting standards applicable to public companies. As a result, the information we provide might be different from the information that is available for other public companies. We cannot predict whether investors will find our common stock less attractive if we rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock, and the market price of our common stock may be more volatile.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We will remain an emerging growth company until the earliest of (i)&#160;the last day of our first fiscal&#160;year in which we have total annual gross revenue of $1.07&#160;billion or more, (ii)&#160;December&#160;31, 2026, (iii)&#160;the date on which we have issued more than $1.0&#160;billion of non-convertible debt instruments during the previous three fiscal&#160;years or (iv)&#160;the date on which we are deemed a &#8220;large accelerated filer&#8221; under the rules&#160;of the SEC with at least $700 million of outstanding equity securities held by non-affiliates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Recent Accounting Pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A description of recent accounting pronouncements that may potentially impact our financial position, results of operations or cash flows is disclosed in Note 2 to our audited financial statements included elsewhere in this Annual Report on Form 10-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Off-Balance Sheet Arrangements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined in the rules&#160;and regulations of the SEC.</p><a id="_b8c6350b_0390_499f_8363_90c6036633cf"></a><a id="ITEM7AQUANTITATIVEANDQUALITATIVEDISCLOSU"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISKS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Interest Rates Risk</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are exposed to risk related to changes in interest rates. As of December 31, 2021 and 2020, we had cash and cash equivalents consisting primarily of $33,618 thousand and $6,586 thousand in money market funds. Our primary exposure to market risk is interest rate sensitivity, which is affected by changes in the general level of U.S. interest rates. Due to the short-term nature and the low risk profile of our interest-bearing accounts, an immediate 10% change in interest rates would not have a material effect on the fair market value of our cash and cash equivalents or on our financial position or results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2021, we had financial debt outstanding of CHF 618 thousand ($694 thousand), guaranteed by the Swiss Federal Authority, at a zero&#160;percent interest rate, and we are therefore not exposed to interest rate risk with respect to the cost of servicing and repaying debt. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Foreign Currency</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">We have operations in the U.S., Switzerland and Spain. The functional currency of each foreign reporting entity is the local currency. We are exposed to foreign currency exchange risk as the functional currency financial statements of foreign reporting entities are translated to U.S. dollars. The assets and liabilities of our &#160;foreign operations having a functional currency other than the U.S. dollar are translated into U.S. dollars at the exchange rate prevailing at the balance sheet date, and at the average exchange rate for the reporting period for revenue and expense accounts. The cumulative foreign currency translation adjustment is recorded as a component of accumulated other comprehensive loss in shareholders&#8217; equity. The reported results of our foreign reporting entities will be influenced by their translation into U.S. dollars. Our primary currency translation exposure is related to operation in Switzerland, and a hypothetical 10% strengthening or weakening in the USD-CHF exchange rate would increase or decrease net loss for the&#160;year ended December&#160;31, 2021 by approximately $587 thousand.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:2pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">74</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_d89fb5b0_379c_480e_9f37_9d9fa562d528"></a><a id="ITEM8FINANCIALSTATEMENTSANDSUPPLEMENTARY"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">ITEM&#160;8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</p><a id="INDEXTOFINANCIALSTATEMENTSANDSUPPLEMENTA"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">INDEX TO FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:87.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:10.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Page</b></p></td></tr><tr><td style="vertical-align:bottom;width:87.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ReportofIndependentRegisteredPublicAccou"><span style="font-style:normal;font-weight:normal;">Report of Independent Registered Public Accounting Firm</span></a> (PCAOB ID: <ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" name="dei:AuditorFirmId" id="Narr_khR2Q8QbbkC3ha7aKb570g">1460</ix:nonNumeric>)</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">76</p></td></tr><tr><td style="vertical-align:bottom;width:87.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ConsolidatedBalanceSheets_231072"><span style="font-style:normal;font-weight:normal;">Consolidated Balance Sheets</span></a></p></td><td style="vertical-align:top;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">77</p></td></tr><tr><td style="vertical-align:bottom;width:87.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ConsolidatedStatementofOperations_50812"><span style="font-style:normal;font-weight:normal;">Consolidated Statement of Operations</span></a></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">78</p></td></tr><tr><td style="vertical-align:bottom;width:87.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ConsolidatedStatementofComprehensiveLoss"><span style="font-style:normal;font-weight:normal;">Consolidated Statement of Comprehensive Loss</span></a></p></td><td style="vertical-align:top;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">79</p></td></tr><tr><td style="vertical-align:bottom;width:87.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ConsolidatedStatementofChangesinStockhol"><span style="font-style:normal;font-weight:normal;">Consolidated Statement of Changes in Stockholders&#8217; Equity </span></a></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">80</p></td></tr><tr><td style="vertical-align:bottom;width:87.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ConsolidatedStatementofCashFlows_976628"><span style="font-style:normal;font-weight:normal;">Consolidated Statement of Cash Flows</span></a></p></td><td style="vertical-align:top;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">81</p></td></tr><tr><td style="vertical-align:bottom;width:87.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#NotestotheConsolidatedFinancialStatement"><span style="font-style:normal;font-weight:normal;">Notes to Consolidated Financial Statements</span></a></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">82</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">75</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_15c65c44_5a9d_472a_8adc_3e77789a6adb"></a><a id="ReportofIndependentRegisteredPublicAccou"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Report of Independent Registered Public Accounting Firm</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">To the Stockholders and the Board of Directors of Gain Therapeutics,&#160;Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Opinion on the Financial Statements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have audited the accompanying consolidated balance sheets of Gain Therapeutics,&#160;Inc. (the &#8220;Company&#8221;) as of December&#160;31, 2021 and 2020, the related consolidated statements of operations, comprehensive loss, stockholders&#8217; equity and cash flows for each of the two years in the period ended December 31, 2021, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December&#160;31, 2021 and 2020, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2021, in conformity with U.S. generally accepted accounting principles.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Basis for Opinion</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules&#160;and regulations of the Securities and Exchange Commission and the PCAOB.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ <ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" name="dei:AuditorName" id="Narr_-HlgC2-uiUuI7TnwBFrvcg">Ernst&#160;&amp; Young AG</ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We have served as the Company&#8217;s auditor since 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" name="dei:AuditorLocation" id="Narr_LYpPmSkq-0q-QzTcVGYWXA">Lugano, Switzerland</ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">March&#160;25, 2022</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">76</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_22b6caae_4993_49a1_9298_dcd798d4d53d"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Gain Therapeutics, Inc</b></p><a id="ConsolidatedBalanceSheets_231072"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 6pt 0pt;">Consolidated Balance Sheets</p><a id="_c66b8ad6_bc26_44fb_b16b_2069f8ba2440"></a><a id="Tc_3-WzvKuwC06p43_mJTm1ZQ_1_3"></a><a id="Tc_ZEis1OkxaEy_Xn6wYrxrXA_1_6"></a><a id="Tc_QvbuZJKNHE6mGHvhVzhdTw_2_3"></a><a id="Tc_qGf0sNEQ3kOQRCUqI7iOfg_2_6"></a><a id="Tc_20AX1ZtutEqXjmfii6jE_Q_3_0"></a><a id="Tc_PTkP6SE87EiKH9QBZBkFZw_4_0"></a><a id="Tc_A6ohX1vqI0CDzcS1FsQifA_5_0"></a><a id="Tc_Z1BXsWSlykGT493HUBA3sg_5_3"></a><a id="Tc_9sjMkMdJ2kK0EJ8IkozEYg_5_6"></a><a id="Tc_lnzBpY3fj0iMyC8OWZODgA_6_0"></a><a id="Tc_8SzwSkHpeE-qs5vHgNRsnQ_6_4"></a><a id="Tc_zUA2wBYK30CYxjOFGcV61w_7_0"></a><a id="Tc_CzDEyHsmqkeGJ4yyCRbt4A_7_4"></a><a id="Tc_XwJLbOOuTkyU9pLfFlkbEw_8_0"></a><a id="Tc_QDRREEkNvESJunzWwWwfhA_9_0"></a><a id="Tc_xPo2kuEaUUeAa13JPyZxkw_10_0"></a><a id="Tc_Xp5SPRVKF0mO9e1udmdb3g_10_4"></a><a id="Tc_UZeeaPO7uE6edSrh-128_Q_11_0"></a><a id="Tc_E7og5tn3S0yHYzPosuA4ug_11_3"></a><a id="Tc_RZIiIdu8FESlg0RnfAkHJw_11_6"></a><a id="Tc_0wziZ8dIIUuU9z_hKSXy1g_13_0"></a><a id="Tc_sQCaX-O0f0KaM5ScKz2RMg_14_0"></a><a id="Tc_zLegUElmSUawx8YrpDILXQ_15_0"></a><a id="Tc_Jkn9s4pDckS8fiMJ-q8CDA_15_7"></a><a id="Tc_MKt6jv_FVEGAia7Ki1hHYw_16_0"></a><a id="Tc_Pgtpy8TnPUK9sb7hb8F7cQ_17_0"></a><a id="Tc_QJEGt_TVikWR4IhnHu6EKw_17_7"></a><a id="Tc_oJ9qVUPyS0-p1VOVzLxsWg_18_0"></a><a id="Tc_N71vdVSSJUmuhq5cTI8KQA_19_0"></a><a id="Tc_3I_GgACr0EaqbLTbuoplQQ_20_0"></a><a id="Tc_36eHZB7VukevWIddmvoIzA_20_3"></a><a id="Tc_-Ez6oTB1rEe-XzhmrQQ4Vw_20_6"></a><a id="Tc_CbdLDmRgOki7M4Q4fw2USA_22_0"></a><a id="Tc_P693TQ_xQ0-rWGqlPmrJlA_23_0"></a><a id="Tc_TKXwffgttUyM7zlu4paQsQ_24_0"></a><a id="Tc_sJ4jibS-6kaYusRfsHoHQQ_24_3"></a><a id="Tc_mUFY9gHzfEaokdyeYhm_Qg_24_6"></a><a id="Tc_2N8-yViAX02PvG578WaEgA_25_0"></a><a id="Tc_MsVVaweA4kutAyQbwYeKrQ_26_0"></a><a id="Tc_pRrpo_XMvEuaKfIoNTbSpQ_27_0"></a><a id="Tc_pwneL6tMREWAEOOVeCtY8g_28_0"></a><a id="Tc_7uYTQt_QNUO4oA9Y5oHMPA_29_0"></a><a id="Tc_xBCozSPIeku8FelZZ5WP9A_31_0"></a><a id="Tc_uFTrQLqpLkKDcopgr4IdxQ_32_0"></a><a id="Tc_3uNvO73XgUKUj2QOvwE0YA_33_0"></a><a id="Tc_XwjvIbBTk06OKTewG-D9jg_34_0"></a><a id="Tc_UC9z3evTVUGYTQKRd3SSfw_35_0"></a><a id="Tc_gqAcx4009kG0Jk7Xl0x0DQ_36_0"></a><a id="Tc_-Pfpd64VI0OuPxntUGYtqw_36_3"></a><a id="Tc_isr0393DjkOaNcFWWq3rlw_36_6"></a><a id="Tc_XdoKupo8nEqfCjdAW3HFTA_38_0"></a><a id="Tc_hWGyIeztOEu_jj5qy-88hA_39_0"></a><a id="Tc_VEgT41p0qUGBQodPa7eLYA_39_4"></a><a id="Tc_Y95VXlLgKkCMcUVhLefxvA_40_0"></a><a id="Tc_Tf_vMFXY_kWUpay7OS-nTg_40_4"></a><a id="Tc_ImoE0_vtcEyqTW2JNQh8Dg_41_0"></a><a id="Narr_lkyfLPP7uUS74LVpQx3euQ"></a><a id="Tc_X6qC2n6OOk2ZVsJXPiansA_42_0"></a><a id="Tc_NTpaIgko70-NJFAA89B3xA_43_0"></a><a id="Tc_AY3AYgX30k6XhP_Wv7y4Ug_44_0"></a><a id="Tc_mZASTxdOOUShw3GbqeUCmA_45_0"></a><a id="Tc_vl0x6iksP0SReI6xbVtKPA_46_0"></a><a id="Tc_pzztH-iOd02qIQE7Utw1iA_47_0"></a><a id="Tc_kxspj0jr80WBd98jvwrJvA_47_3"></a><a id="Tc_gkfBb895rEGj3Ji5mpnkag_47_6"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:70.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:top;width:70.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td></tr><tr><td style="vertical-align:top;width:70.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Current assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:70.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" id="Tc_0ZpdnUtAHU6Yx8YoYYLu9Q_5_4">36,880,673</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" id="Tc_U55MsEOjq0e5vvJ-2jQVsw_5_7">7,492,910</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:70.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashCurrent" scale="0" id="Tc_PGMmYhXwZkWnEVxI0P2MFA_6_7">11,371</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:70.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accounts receivable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="0" id="Tc_p_acjEZKmUKCDB5yHcyr_w_7_7">8,548</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:70.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Tax credits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxesAndOtherTaxReceivableCurrent" scale="0" id="Tc_LxVpuMOvYU6pFQhJ7_GUSQ_8_4">113,586</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxesAndOtherTaxReceivableCurrent" scale="0" id="Tc_G1kHuNsc8k2vN3sJO-1FGA_8_7">58,017</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:70.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Prepaid expenses and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" id="Tc_q_0k0mgIYEq6rutJOHZhXQ_9_4">727,785</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" id="Tc_fJmI8cve_E-yboCjAD6usw_9_7">198,994</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:70.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Deferred offering costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredOfferingCosts" scale="0" id="Tc_fcEyWW6EG0-LV8-z-ARTuw_10_7">1,217,988</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:70.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="0" id="Tc_wfVXxW9qs0eFXwpemM7Haw_11_4">37,722,044</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="0" id="Tc_w6P0YdonUEmmXYZJBEALeA_11_7">8,987,828</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:70.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:70.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Non-current assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:70.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" id="Tc_rCkpqKtp_ku9n_SOSArrRg_14_4">105,986</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" id="Tc_o-moV5VtFUGQre6_77x7cQ_14_7">29,633</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:70.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Internal-use software</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A" decimals="0" format="ixt:numdotdecimal" name="ganx:CapitalizedComputerSoftwareForInternalUse" scale="0" id="Tc_1PFb6HXj-0arqqxzuAP5kA_15_4">202,609</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:70.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Operating lease - right of use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" id="Tc_RLOlgQU6Nk6AgICXYvxEZQ_16_4">901,042</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" id="Tc_V9MroYBTk0mMgn_xSKXL5A_16_7">523,080</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:70.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashNoncurrent" scale="0" id="Tc_zWRrk1MftEmVB-QHdAUn2g_17_4">31,279</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:70.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Long-term deposits and other non-current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A" decimals="0" format="ixt:numdotdecimal" name="ganx:DepositsAndOtherAssetsNoncurrent" scale="0" id="Tc_uS_B0T_9B0mCa9bE5BjQgw_18_4">22,111</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg" decimals="0" format="ixt:numdotdecimal" name="ganx:DepositsAndOtherAssetsNoncurrent" scale="0" id="Tc_5ltKBhhR9ES585maTS-n0g_18_7">63,817</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:70.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total non-current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsNoncurrent" scale="0" id="Tc_T6Qey3V5ckau--oSrR5OOA_19_4">1,263,027</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsNoncurrent" scale="0" id="Tc_70s2R3WkzEez5gMgrf7ADw_19_7">616,530</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:70.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="0" id="Tc_CYnQV2wdM0O3d3WS6SHa9A_20_4">38,985,071</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="0" id="Tc_xpA2jkDuNUquUShvxOMYMQ_20_7">9,604,358</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:70.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:70.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Liabilities and stockholder&#39;s equity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:70.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Current liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td></tr><tr><td style="vertical-align:top;width:70.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="0" id="Tc_0QIBAkzZ70ql3NDwYqAeSQ_24_4">560,479</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="0" id="Tc_yyWQ57P3202jixz0O1dm8w_24_7">961,516</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:70.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Operating lease liability - current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" id="Tc__fWP1Gvtvkq8NGS9NPqtfQ_25_4">219,137</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" id="Tc_vtqlyE_EC0GjjnjgzoaEuw_25_7">122,756</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:70.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Other current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesCurrent" scale="0" id="Tc_It1ChEhPA0ynLNfhodbZ0A_26_4">1,402,600</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesCurrent" scale="0" id="Tc_UFTWOZZM9EuT8RsHOLH9rQ_26_7">768,450</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:70.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Deferred income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeCurrent" scale="0" id="Tc_x2fQ4-LuU0CF7TmW8Qc1MQ_27_4">266,504</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeCurrent" scale="0" id="Tc_zvYjFBxKPEKhrQyLFwcA6Q_27_7">239,483</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:70.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Loans - short term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtCurrent" scale="0" id="Tc_COnvdCLqy0-OpNn4_5U2Ww_28_4">103,826</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtCurrent" scale="0" id="Tc_ILhkMc0fxk6kWp5BwBPh1w_28_7">22,626</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:70.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="0" id="Tc_JshuwXNNUUO9lfzV2X_ZgA_29_4">2,552,546</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="0" id="Tc_-2IWhhfyjke6df4TjktvoQ_29_7">2,114,831</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:70.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:70.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Non-current liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:70.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Defined benefit pension plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPensionPlanLiabilitiesNoncurrent" scale="0" id="Tc_3YggIy9t8kG7OtQ8oMT-3A_32_4">329,458</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPensionPlanLiabilitiesNoncurrent" scale="0" id="Tc_OTKTGM8VnEiwmJZhrRsyEg_32_7">171,558</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:70.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Operating lease liability - non-current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" id="Tc_fGCK_6_P8EmvQLsrhC4ejQ_33_4">695,053</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" id="Tc_-wrOMh92lkOoJMWmtMQKeQ_33_7">400,324</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:70.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Loans - long term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="0" id="Tc_KE-8BLhgckGoSe4JyIS5KA_34_4">590,468</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="0" id="Tc_cXdXxhI4R0GgNyWMjZWqDg_34_7">715,656</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:70.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total non-current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesNoncurrent" scale="0" id="Tc_8rOcDf0hTUWGICtFD75Dkw_35_4">1,614,979</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesNoncurrent" scale="0" id="Tc_Ldoua_3lgkCoB1_TGVC7qA_35_7">1,287,538</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:70.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="0" id="Tc_gS4zdO3a4UqT4Kj4xF68DA_36_4">4,167,525</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="0" id="Tc_rsebeWqio0yq7MJNxS8juw_36_7">3,402,369</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:70.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:70.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stockholders&#8217; equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td></tr><tr><td style="vertical-align:top;width:70.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Series A Preferred Stock, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_ZUfWDOiJrESFdyfJo2gfWg" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_HPxGCJIoKkWKHRC95IDwMg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_ybnnqK1brEWVclFm4AOy9g"><ix:nonFraction unitRef="Unit_Divide_USD_shares_ZUfWDOiJrESFdyfJo2gfWg" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_bnIOh52EIUC-yTsdpcG0NQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_ZjLHbPOzgU2TuvA99_1kQg">0.0001</ix:nonFraction></ix:nonFraction> par value: <ix:nonFraction unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_bnIOh52EIUC-yTsdpcG0NQ" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="Narr_lPtU-9NgF0y2MgXhwrDTZA">nil</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_HPxGCJIoKkWKHRC95IDwMg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="Narr_AVK1YEvuTkKLiqCNUunqDg">1,185,879</ix:nonFraction> shares <span style="-sec-ix-hidden:Hidden_OklE6u_bskKwCDxGHn2ymg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">issued</span></span> and <span style="-sec-ix-hidden:Hidden_nUKSBhSCh0moQENn0OnE_w;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">outstanding</span></span> as of December&#160;31,&#160;2021 and December&#160;31,&#160;2020, respectively</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_HPxGCJIoKkWKHRC95IDwMg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PreferredStockValue" scale="0" id="Tc_9X_gmCrPgEK6Rxdfs8pIMA_39_7">118</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:70.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Series B Preferred Stock, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_ZUfWDOiJrESFdyfJo2gfWg" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_SZL-8g69ikyvM5ITtvQ_vA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_XkRDHsX_mUakxnW3NKq3Cg"><ix:nonFraction unitRef="Unit_Divide_USD_shares_ZUfWDOiJrESFdyfJo2gfWg" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_UOpY8hOKmEaY4smAqVjcoQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_CEdZ62UQo0Cg1t_Ngs6N7Q">0.0001</ix:nonFraction></ix:nonFraction> par value: <span style="-sec-ix-hidden:Hidden_qM3TS5mT-UC-jzM-fri5OQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">nil</span></span> and <ix:nonFraction unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_SZL-8g69ikyvM5ITtvQ_vA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="Narr_scHeo2x8Ik-T7BDkCZteKg">2,965,600</ix:nonFraction> shares <span style="-sec-ix-hidden:Hidden_WaxhVkpREkyl-jjvJbdCHQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">issued</span></span> and <span style="-sec-ix-hidden:Hidden_nBFWja__nUKaF0_2r1-5ew;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">outstanding</span></span> as of December&#160;31,&#160;2021 and December&#160;31,&#160;2020, respectively</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_SZL-8g69ikyvM5ITtvQ_vA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PreferredStockValue" scale="0" id="Tc_bjMtcUAgHUaW4dY6kvw-fQ_40_7">297</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:70.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Common Stock, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_ZUfWDOiJrESFdyfJo2gfWg" contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_JeZL91AMv0CzjDVNiYKF8Q"><ix:nonFraction unitRef="Unit_Divide_USD_shares_ZUfWDOiJrESFdyfJo2gfWg" contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_c6wPD9h4bEWNdXHRkA3uEg">0.0001</ix:nonFraction></ix:nonFraction> par value: <ix:nonFraction unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw" contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_IQE_sWkoYESdq3bPtIYXcQ">50,000,000</ix:nonFraction> shares authorized; <ix:nonFraction unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw" contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_Mza9zWRfgUWJtNDk5kvkdw">11,883,368</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw" contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Narr_mMnf3ouxb0C8z99wYEKMgA">3,543,163</ix:nonFraction> <span style="-sec-ix-hidden:Hidden_ofEil3W8JECpBaDUijTFww;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">issued</span></span> and <span style="-sec-ix-hidden:Hidden_vhbG_gva8kyxLeHJvfawEw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">outstanding</span></span> as of December&#160;31,&#160;2021 and December&#160;31,&#160;2020, respectively</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="0" id="Tc_p5uyzQ903UerwwYPn0Xayg_41_4">1,189</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="0" id="Tc_YI8qmcq7WE2Hf7H03Xs-Pg_41_7">354</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:70.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Additional paid-in capital</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="0" id="Tc_ReNv9ZSYAUOFUlUNxSDnow_42_4">55,832,461</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="0" id="Tc_rXV4AwiBgkKqxELVuElzPQ_42_7">13,388,771</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:70.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accumulated other comprehensive loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" sign="-" scale="0" id="Tc_djOg5uyrv02FHVDdKGNDtQ_43_4">90,645</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" sign="-" scale="0" id="Tc_GlYC18d-t0-LllLY4grH9w_43_7">152,698</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:70.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accumulated deficit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="0" id="Tc_kQeOII8YW0SXQxdxgeIU9w_44_4">7,034,853</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="0" id="Tc_A40umysvzkOh6SQQw1K_Eg_44_7">3,457,171</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:70.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Loss of the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A" decimals="0" format="ixt:numdotdecimal" name="ganx:IncomeLossForPeriod" sign="-" scale="0" id="Tc_JUFzgIhjkki2Xk-49aSw6A_45_4">13,890,606</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg" decimals="0" format="ixt:numdotdecimal" name="ganx:IncomeLossForPeriod" sign="-" scale="0" id="Tc_0zmXFVF7kUqeleu733dB8w_45_7">3,577,682</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:70.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total stockholders&#8217; equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_VimogO93a0m4nEO2Q_b9PQ_46_4">34,817,546</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_LGUMcFDECUmDaz7gLNAXlQ_46_7">6,201,989</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:70.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total liabilities and stockholders&#8217; equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" id="Tc_OzS67-4zKUOXaKrjB_i8cw_47_4">38,985,071</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" id="Tc_h4eqZpcuqkWtY1TdQ1yjAQ_47_7">9,604,358</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">77</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_e0081b65_5139_4ef7_9ad8_f904a6fbbe9d"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Gain Therapeutics, Inc</b></p><a id="ConsolidatedStatementofOperations_50812"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">Consolidated Statement of Operations</p><a id="_3106a952_9561_4c56_a9a3_cc05822e81f5"></a><a id="Tc_MYxuh0i02kyJ_KhONmzmww_1_2"></a><a id="Tc_1U-mliZ3vUWc7tYuScGKTQ_2_2"></a><a id="Tc_3IomqEBjmke1L1sBWBqvBg_2_5"></a><a id="Tc_oJ5qpBaINEOg4M8J6mn4MQ_3_0"></a><a id="Tc_1oa_IF6yA0q2q4MeY5ufoA_4_0"></a><a id="Tc_HZYamZYOgkuKyWURBs6nLw_4_2"></a><a id="Tc_aZNnJUANkEGxnhOPomTI0w_4_5"></a><a id="Tc_M5MjFpIpekukBikiLpsqpg_5_0"></a><a id="Tc_ePXsckNlnkGfB04GdTAxkA_6_0"></a><a id="Tc_KHb19jgG9ESotiFumD3smQ_8_0"></a><a id="Tc_9mddwCRqUUmtLMoDFBmaHw_9_0"></a><a id="Tc_4CcLWxDd6UyVr5zTBV2yMg_10_0"></a><a id="Tc_IStktEfBsEiLrTxGr-MD8Q_11_0"></a><a id="Tc_eM2oXJwT4Um-BDogQZjC1Q_13_0"></a><a id="Tc_f8R-pDFQ0EG_q5acU_izlw_15_0"></a><a id="Tc_fHGmDMrlD0idsY7uuMBEDA_16_0"></a><a id="Tc_LMVo5D8x3kCbBjhvcJ_RNA_17_0"></a><a id="Tc_aiG1tC4lKkq13O3_Fn1j9Q_18_0"></a><a id="Tc_Dw7LwQwnbUexl4q_GnuZEw_18_2"></a><a id="Tc_TbE27GJ1eE66Z-IrQ5HRDA_18_5"></a><a id="Tc_le4REq34CU6eUgKXMMPqaQ_20_0"></a><a id="Tc_RLCQ9Gtt6kCKVJaOr9lyyw_22_0"></a><a id="Tc_LCEzWmujvEaepXxaKNxJYg_22_2"></a><a id="Tc_DzvRixaK2UG3FsF8wxLZcA_22_5"></a><a id="Tc__PZ4qVfcX0qI7y3Vl39sng_24_0"></a><a id="Tc_VNbpmwjwWEuA3_UTukQy9A_25_0"></a><a id="Tc_XKc_16-ndU-_7srCPNO-mA_25_2"></a><a id="Tc_yxf4iiP1KEO35Mb2sJ_XfA_25_5"></a><a id="Tc_v-M2viNbS0qoI4EGDEUlbA_26_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:73.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:top;width:73.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Revenues:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:73.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Collaboration revenues</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="Tc_nLaHioOwc0i4m8ZMCJCUIA_4_3">133,928</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:73.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Other income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SubleaseIncome" scale="0" id="Tc_vCYIFLEXPUm6Jpjq3KWt5w_5_3">31,066</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2020_To_12_31_2020_JDEb6LtAmEuXGmEieWNlsw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SubleaseIncome" scale="0" id="Tc_sK232JOYYUq8Lhv9fnLEsQ_5_6">28,881</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total revenues</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="0" id="Tc_pPTRKNjV5UCrVxK259lbEw_6_3">164,994</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2020_To_12_31_2020_JDEb6LtAmEuXGmEieWNlsw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="0" id="Tc_ujo0zWSkl0GsguBhaHx8NQ_6_6">28,881</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:73.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:73.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="Tc_eMaklUKgFUebs-r_ezvPCg_9_3">7,164,229</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2020_To_12_31_2020_JDEb6LtAmEuXGmEieWNlsw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="Tc_9biAt7P_tEGAXqy7286FtQ_9_6">2,259,204</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:73.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" id="Tc_IfjGHYKySUKlndYvq1QmaA_10_3">6,826,938</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2020_To_12_31_2020_JDEb6LtAmEuXGmEieWNlsw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" id="Tc_JheuQjeci06Yy_3Yo1Y00w_10_6">1,249,126</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:73.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="0" id="Tc_ACW0usyWF06ioYprD0j-nw_11_3">13,991,167</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2020_To_12_31_2020_JDEb6LtAmEuXGmEieWNlsw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="0" id="Tc__nxkCRWMDECbkmVW8avqNQ_11_6">3,508,330</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:73.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:73.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Loss from operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="0" id="Tc_x7J573cYFEaMIxFjlGwA7A_13_3">13,826,173</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2020_To_12_31_2020_JDEb6LtAmEuXGmEieWNlsw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="0" id="Tc_JXPjXFNN5Uy_hFtIA9cmQA_13_6">3,479,449</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:73.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:73.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other income (expense):</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:73.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Interest income, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestIncomeExpenseNet" scale="0" id="Tc_hM6Qi3VriUm85aUtqjSqcw_16_3">12,495</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2020_To_12_31_2020_JDEb6LtAmEuXGmEieWNlsw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestIncomeExpenseNet" scale="0" id="Tc_AuHVkT4h6kW58r0jCly6yQ_16_6">3,637</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Foreign exchange loss, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" sign="-" scale="0" id="Tc_suWnCTV-9UCs2FktaN_vFg_17_3">72,920</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2020_To_12_31_2020_JDEb6LtAmEuXGmEieWNlsw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" sign="-" scale="0" id="Tc_dLx2bInU2EyOVFqBUpkNzQ_17_6">96,484</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:73.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Loss before income tax</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="0" id="Tc_1j5jkTzRj0GTGhiKqg0eGw_18_3">13,886,598</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2020_To_12_31_2020_JDEb6LtAmEuXGmEieWNlsw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="0" id="Tc_MMrMUjjJMEaPLb4L80AomQ_18_6">3,572,296</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:73.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:73.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Income tax</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" id="Tc_VXca31RAd0agltwyf_CTMg_20_3">4,008</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2020_To_12_31_2020_JDEb6LtAmEuXGmEieWNlsw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" id="Tc_qe4lCIQlRkuZ4EzbYrzbeg_20_6">5,386</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:73.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:73.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_cn8Hnd4fYUK2L3QQ_sQF3g_22_3">13,890,606</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2020_To_12_31_2020_JDEb6LtAmEuXGmEieWNlsw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_w-YrAdolu0uwtO22EWIL6A_22_6">3,577,682</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:73.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:73.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss per shares:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:73.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss per share attributable to common stockholders - basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_ZUfWDOiJrESFdyfJo2gfWg" contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_FZ649mFMQkuQBIVJqfLTPw_25_3">1.37</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_ZUfWDOiJrESFdyfJo2gfWg" contextRef="Duration_1_1_2020_To_12_31_2020_JDEb6LtAmEuXGmEieWNlsw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_Q2B29faHWE6EjPrt3FNtsA_25_6">1.33</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:73.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average common shares - basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw" contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_LCuuCg5tBECzelefnHAD6g_26_3">10,165,404</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw" contextRef="Duration_1_1_2020_To_12_31_2020_JDEb6LtAmEuXGmEieWNlsw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_VDqfrSVnU0Gdq2D4Xg4eQA_26_6">2,681,408</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">78</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_7ffdac9c_f55b_41a8_9383_42f8dd7c28cb"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Gain Therapeutics, Inc</b></p><a id="ConsolidatedStatementofComprehensiveLoss"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">Consolidated Statement of Comprehensive Loss</p><a id="_cfe992e0_0042_4373_b9d3_716a99008c04"></a><a id="Tc_KZ8l2eSm0Eyu3qoUWdRmMQ_1_2"></a><a id="Tc_q7V89MWruUGJw36mHjql9w_2_2"></a><a id="Tc_Kp-Sz7jJCkKACotuf4hAfQ_2_5"></a><a id="Tc_DjtyvPMdH06O1HfIWm31mQ_3_0"></a><a id="Tc_gEaaXkMrOUavKQ6ojpWomw_3_2"></a><a id="Tc_SFysEIJfHkyDmqQ-0jS-aA_3_5"></a><a id="Tc_xP2VCSQC_k-9KMVck5BlmQ_4_0"></a><a id="Tc_SREJ0-FlhUmx8vJTW3iAlQ_5_0"></a><a id="Tc_xgnhtE_-X0qVJXCP5PtIZQ_6_0"></a><a id="Tc_T0m3hWTFEkuYZPP96TIXKg_6_2"></a><a id="Tc_ZcBtjQJmU0arjBNjDg2ChQ_6_5"></a><a id="Tc_jIyF65waq06mRSjFGpC-Sg_7_0"></a><a id="Tc_Sg7rEToqP0WEvafoFs16qA_7_2"></a><a id="Tc_LSyvL-pDckW3RTZsVaoeIg_7_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:72.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:top;width:72.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_LS8pRaSAGUOX6YNvHZM_og_3_3">13,890,606</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2020_To_12_31_2020_JDEb6LtAmEuXGmEieWNlsw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_8kxYRZoafUWU0q8LswpxDg_3_6">3,577,682</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:72.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Defined benefit pension plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="0" id="Tc_NliVZsXmhEKT60yuGflgbw_4_3">101,780</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2020_To_12_31_2020_JDEb6LtAmEuXGmEieWNlsw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="0" id="Tc_lymsqJ7oDkSfhfbm2JR7HQ_4_6">36,218</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:72.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Foreign currency translation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="0" id="Tc_DCnndCR-qUS4ICgWcYF13A_5_3">163,833</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2020_To_12_31_2020_JDEb6LtAmEuXGmEieWNlsw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" sign="-" scale="0" id="Tc_aH7jZOZxi0SIARMADVkFzA_5_6">35,317</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:72.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other comprehensive gain/(loss):</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="0" id="Tc_t2fe6X_hyk6tvXubjkl8mg_6_3">62,053</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2020_To_12_31_2020_JDEb6LtAmEuXGmEieWNlsw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" sign="-" scale="0" id="Tc_rjdxBC_SGkeYd-DccU-EGw_6_6">71,535</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:72.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Comprehensive loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" sign="-" scale="0" id="Tc_gd5Q1xGqL0KWotaKW-OsZg_7_3">13,828,553</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2020_To_12_31_2020_JDEb6LtAmEuXGmEieWNlsw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" sign="-" scale="0" id="Tc_fzAXjGgKak-rA7uwY21CPA_7_6">3,649,217</ix:nonFraction>)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">79</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_3315c069_0494_42ff_b77a_b4272958a05e"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Gain Therapeutics, Inc</b></p><a id="ConsolidatedStatementofChangesinStockhol"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">Consolidated Statement of Changes in Stockholders&#8217; Equity </p><a id="_ede693a9_52f8_4158_be25_cd6dadc38e41"></a><a id="Tc_y2LPIoxu2Ui5Lkl3T5qb5Q_1_2"></a><a id="Tc_CfOq_NnVbEmhucmK-uR4WA_1_6"></a><a id="Tc_Tx2rkLykl0GQbn3jUg3GDA_1_10"></a><a id="Tc_aT8bOl7730ukTAy0AvloGQ_1_14"></a><a id="Tc_fRjMxxAoa0OCx8ZLb24OlA_1_16"></a><a id="Tc_xBDcw0GM_UmcA4LypVF4iw_1_18"></a><a id="Tc_dxmwzZbF0kmFPkwFx963aw_1_20"></a><a id="Tc_swJw1hsnnESyCJhlIx4CTA_2_2"></a><a id="Tc_kfTJn7GXWkiq8KR3SX8EJg_2_4"></a><a id="Tc_tjImItU3Bk6-QOK58Ac88g_2_6"></a><a id="Tc_A9DzZ2G4c0mQUsJhSqAawg_2_8"></a><a id="Tc_1YrQfiOSEEmJs7kQtyqWXg_2_10"></a><a id="Tc_naEur1LXbE6TGavfYRCBNw_2_12"></a><a id="Tc_UnInAKCltkW8v6MYMCeecA_2_18"></a><a id="Tc_im9BrhZ1N0KnfiGWwtlazQ_3_0"></a><a id="Tc_Dpo7Jdwx8UKVM_TiH1EBGw_4_0"></a><a id="Tc_MaPPCm8wwEWRa78j3yw22Q_4_20"></a><a id="Tc_YpFpSyJmz0OqCAWpjhp1vQ_5_0"></a><a id="Tc_dWVwXWmgnUealftMhlzDQA_5_20"></a><a id="Tc_mVFcSXbcWk-zuauan9rTyg_6_0"></a><a id="Tc_ZAI9zhgdeEqZ1Y2Q2PJHSA_7_0"></a><a id="Tc_Cg9lP7GqvUuB5k4XFF7mhw_7_20"></a><a id="Tc_4w1QGWFEjk2hWNJW2x56gw_8_0"></a><a id="Tc_aIqaGAxmgUW40bq7JYmI8w_9_0"></a><a id="Tc_TW1JoSU55ke4abx2ACGZlA_10_0"></a><a id="Tc_NEjOh5MWD0ezXDMDm-DDSA_11_0"></a><a id="Tc_wb-joad-2U64rPhb6oNb7g_12_0"></a><a id="Tc_0HMuO_quBU-5tZuhjZZjsg_13_0"></a><a id="Tc_QcsKO7xx_ES5g8X9o-I4Pw_14_0"></a><a id="Tc_XfTjKgfA_kaOfAeeumtCvQ_14_2"></a><a id="Tc_uoPokxGEVEC5kahsaR3LbA_14_4"></a><a id="Tc_XewSssPmR0uZGULX-SaEJQ_14_6"></a><a id="Tc_GgDHiaCcCEaTD6alyGjslA_14_8"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:18.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:18.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:15.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Series&#160;A&#160;Preferred&#160;Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:15.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Series&#160;B&#160;Preferred&#160;Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:14.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Common&#160;Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">APIC</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">AOCI</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:top;width:18.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amounts</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amounts</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amounts</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:18.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">Balance as of December&#160;31,&#160;2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_pyBaEfYw3k-Bre7rOUHY8A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_8FqsKSrFi0yNgOv97y_RlQ_3_2">1,185,879</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_pyBaEfYw3k-Bre7rOUHY8A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_yQ5Ch4Ui_0eMpTawXRGQfw_3_4">118</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredClassBMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_HKF8S1_Sj0ytyt6XZS1DhQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_R3wXhbucDUqSMxNpDIqZhA_3_6">2,965,600</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredClassBMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_HKF8S1_Sj0ytyt6XZS1DhQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_tncERw5o0k-RFvEZv3yz-A_3_8">297</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_9f9qYFGKFEi5lUCxbnfGyA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_k2Yt4somwUOcgKLqpW9f5w_3_10">3,543,163</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_9f9qYFGKFEi5lUCxbnfGyA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_HhomVpvA-EGdyCZIlgWmiA_3_12">354</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_AmnlCLXS4EW0T11vxuv4dA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_hx7YlZEXh0-PnJbTnivt5g_3_14">13,388,771</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_gy5vyeo0XECt7V84YflbPw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_X5KVTOnhUEmqz0RFM41wQQ_3_16">152,698</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_wUcCiJ_aL0uNAaoLQz_kIQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_9q94PFE9j028yrfS1fIE1Q_3_18">7,034,853</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_c3jw-7El-Uy--vNd9_F6zQ_3_20">6,201,989</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:18.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">Conversion of Series A Preferred Stock into Common Stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_i98h5sWV5U-TOn1S0EBWxQ" decimals="INF" format="ixt:numdotdecimal" name="ganx:ConversionOfSeriesPreferredStockIntoCommonStockInShares" sign="-" scale="0" id="Tc_dliGMymBsUSfqCR74FH_xA_4_2">1,185,879</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_i98h5sWV5U-TOn1S0EBWxQ" decimals="0" format="ixt:numdotdecimal" name="ganx:ConversionOfSeriesPreferredStockIntoCommonStock" sign="-" scale="0" id="Tc_ldos-bzJhUOZVPu8_7WYCw_4_4">118</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_RRjkaPqvD06cYjwCnpc1bQ" decimals="INF" format="ixt:numdotdecimal" name="ganx:ConversionOfSeriesPreferredStockIntoCommonStockInShares" scale="0" id="Tc_iALT9dyS20GOT4ic7FDByA_4_10">1,185,879</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_RRjkaPqvD06cYjwCnpc1bQ" decimals="0" format="ixt:numdotdecimal" name="ganx:ConversionOfSeriesPreferredStockIntoCommonStock" scale="0" id="Tc_BxgLCSAT9ku7GbDlx07Bmw_4_12">118</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:18.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">Conversion of Series B Preferred Stock into Common Stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredClassBMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_W4zZ56C1Q0yKk0LZMBsvMA" decimals="INF" format="ixt:numdotdecimal" name="ganx:ConversionOfSeriesBPreferredStockIntoCommonStockInShares" sign="-" scale="0" id="Tc_V_vfmBHxXk2mGb_IE1msbw_5_6">2,965,600</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredClassBMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_W4zZ56C1Q0yKk0LZMBsvMA" decimals="0" format="ixt:numdotdecimal" name="ganx:ConversionOfSeriesBPreferredStockIntoCommonStock" sign="-" scale="0" id="Tc_ptZb2UeL30i15UP3dQ__Dw_5_8">297</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_RRjkaPqvD06cYjwCnpc1bQ" decimals="INF" format="ixt:numdotdecimal" name="ganx:ConversionOfSeriesBPreferredStockIntoCommonStockInShares" scale="0" id="Tc_1J5hfA1C90aTP0D3EpKmXQ_5_10">2,965,600</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_RRjkaPqvD06cYjwCnpc1bQ" decimals="0" format="ixt:numdotdecimal" name="ganx:ConversionOfSeriesBPreferredStockIntoCommonStock" scale="0" id="Tc_LBSaquukyEmoT0RAjrFRcg_5_12">297</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:18.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">Issuance of Common Stock in IPO, net of issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_RRjkaPqvD06cYjwCnpc1bQ" decimals="INF" format="ixt:numdotdecimal" name="ganx:IssuanceOfCommonStockInIpoInShares" scale="0" id="Tc_wlLHr7LW-USpnbKVEn4yBA_6_10">4,181,818</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_RRjkaPqvD06cYjwCnpc1bQ" decimals="0" format="ixt:numdotdecimal" name="ganx:IssuanceOfCommonStockInIpoNetOfIssuanceCosts" scale="0" id="Tc_qqV8o-yePkmzdui079tvjw_6_12">419</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ubdNM3dDp0mLTH7OlcI_NA" decimals="0" format="ixt:numdotdecimal" name="ganx:IssuanceOfCommonStockInIpoNetOfIssuanceCosts" scale="0" id="Tc_FTE1u3vM6kGZstVXF6vSdw_6_14">40,558,103</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" decimals="0" format="ixt:numdotdecimal" name="ganx:IssuanceOfCommonStockInIpoNetOfIssuanceCosts" scale="0" id="Tc_-ORAx0npTEGnEcIEDHrQkA_6_20">40,558,522</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:18.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">Issuance of Common Stock due to warrants cashless exercise</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_RRjkaPqvD06cYjwCnpc1bQ" decimals="INF" format="ixt:numdotdecimal" name="ganx:IssuanceOfCommonStockThroughCashlessExerciseOfWarrants" scale="0" id="Tc_njFxm1vGwkyGEdGmgq5G6A_7_10">3,283</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:18.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">Issuance of Common Share due to stock option exercise</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_RRjkaPqvD06cYjwCnpc1bQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_rREIJxiCEUGec_MJTKHurA_8_10">3,625</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_RRjkaPqvD06cYjwCnpc1bQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" id="Tc_jACajxFjLUuFrrvNgcsDyw_8_12">1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ubdNM3dDp0mLTH7OlcI_NA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" id="Tc_3ig-oISOjkKZ7XIG857hEg_8_14">12,216</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" id="Tc_m8h17-RQt0W5aTooWiQANw_8_20">12,217</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:18.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">Stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ubdNM3dDp0mLTH7OlcI_NA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="Tc_G6MKpJv2eUKjDllXwWaE0A_9_14">839,371</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="Tc_KU331pXmQkSsewFPRWTiJQ_9_20">839,371</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:18.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">Issuance of warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ubdNM3dDp0mLTH7OlcI_NA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="0" id="Tc_DxQ7mGq2bEqiVaGfLUzRxA_10_14">1,034,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="0" id="Tc_ZU-52nFA9kG6AkofmqqbDw_10_20">1,034,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:18.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">Defined benefit pension plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_lVp5EHBSO0a3sKcZW9whJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="0" id="Tc_FKD6ljmAbkSNVXDwxGfzVA_11_16">101,780</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="0" id="Tc_B_H6d2zjN0GEMYPk7aE0mA_11_20">101,780</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:18.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">Foreign currency translation </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_lVp5EHBSO0a3sKcZW9whJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="0" id="Tc_hRMihA0VckObE8wnpYc-ug_12_16">163,833</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="0" id="Tc_jM0kBl_KAE69vRqnSyX8-Q_12_20">163,833</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:18.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_BvTE8F6mxk6Kxv6RzTF0bw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_52gJALzJVkKz7Dk-dYra1A_13_18">13,890,606</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_ERY_v9OSf0-FLxuEQoYLaw_13_20">13,890,606</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:18.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><b style="font-weight:bold;">Balance as of December&#160;31,&#160;2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_SekcF5i21U2sPnRupyd-qQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_dH4f6pJLX0uROKNuJ2La9w_14_10">11,883,368</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_SekcF5i21U2sPnRupyd-qQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_9lugp4Hmd0WrKQv8uGB8Cg_14_12">1,189</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_BSZ8PS8MmUKSjqHr7IV3kw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_dtFuy8a5q0SoMBADWatZRw_14_14">55,832,461</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_aTBx7lbU9EmXTzCop7s5VQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_HXzFkkCuV0iSQhPFpqZxDg_14_16">90,645</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_n0BVNh7nXEOEg7ig4OTueQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_dV39iBjfSUC9oWiZbaRW_g_14_18">20,925,459</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_YBSsQ5_0a0eDSTFOauX25w_14_20">34,817,546</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_7f90fc8d_8673_4706_85e8_f7976da52776"></a><a id="Tc_UgFzu1UYuUyyO-aCfXDcPw_1_2"></a><a id="Tc_5aTK4JEocUK_dWz74rnCZQ_1_6"></a><a id="Tc_dn226N2Ci0Su601TTIb3-w_1_10"></a><a id="Tc_jyriQNZkCkyRRe-fB6W6Uw_1_14"></a><a id="Tc_JxxwfUrAn0eglypKX7kyOQ_1_16"></a><a id="Tc_GbDRLV0kX0Cf5_TGXdCkTw_1_18"></a><a id="Tc_1nEA2sVUV06BpFdftzHcDw_1_20"></a><a id="Tc_nor1-2TWL0q-K1a5UV1snQ_2_2"></a><a id="Tc_vUkelElvz0m_xr6eQWzIzA_2_4"></a><a id="Tc_KOQt_Y2Xv0SkbTGY2YxK_g_2_6"></a><a id="Tc_ACBlg_B3tki4K865E-yCvw_2_8"></a><a id="Tc_EC0DtUnIxkWv12-EiGBQKQ_2_10"></a><a id="Tc_ZAZ8iKDoNkuo12H_4DAcww_2_12"></a><a id="Tc_G9iTABR3WkmidsuAsZi7Nw_2_18"></a><a id="Tc_8NCZerMNwUW3lPdTB3RQyQ_3_0"></a><a id="Tc_SySm00j59kSNrH1X2GZjkw_4_0"></a><a id="Tc_vKYIj-umME640Cyw0KPXSQ_4_10"></a><a id="Tc_5rH6KB0ODUK2uOrPkeigpQ_4_12"></a><a id="Tc_2Dlia-ACTkeKvKjG7pmxHw_4_16"></a><a id="Tc_JUL7fuNjxka_XCWwmPA2aA_4_18"></a><a id="Tc_KDSLOcHUF0WCsWLrRiJjIw_5_0"></a><a id="Tc_nXCbTIu-mUK_iSBu9Psw4w_6_0"></a><a id="Tc_dgj0bNhx_UmkcY3OE0DR6g_7_0"></a><a id="Tc_4fhbcqHltUK8mhqu1Ezlew_8_0"></a><a id="Tc_2S6htqTM6UmAXQuzWOsIOw_9_0"></a><a id="Tc_xMug5Nsl5EC6sYWL1GKnmA_10_0"></a><a id="Tc_sUiyFlZnOE-d625rMAPfAw_11_0"></a><a id="Tc_3KHVrkASfEiFlxpLh2h9LA_12_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:19.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:19.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:15.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Series&#160;A&#160;Preferred&#160;Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:15.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Series&#160;B&#160;Preferred&#160;Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:13.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Common&#160;Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">APIC</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">AOCI</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:top;width:19.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amounts</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amounts</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amounts</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:19.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">Balance as of December&#160;31,&#160;2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw" contextRef="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_UWKqqxKGa0GJPrjjqykVHA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_JjUqUktaUEGO_u9qqI4PPQ_3_2">875,006</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_UWKqqxKGa0GJPrjjqykVHA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_NfM_SVF6pEKqiH9spRFg8Q_3_4">87</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw" contextRef="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_7i8WecRBqEmSQhLalEWwQQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_8z9diGjF6UmVFIv4rcNmfg_3_10">1,981,765</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_7i8WecRBqEmSQhLalEWwQQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_bEtwYsncI0-cB3f4A01ioQ_3_12">198</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_5pVNHNLDU0aNGDOeH5tWLQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_hMrDCKv94E6-rcv4Xun1Tg_3_14">3,088,193</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_gMslWnX56U6NnNQwJeyNJQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_ejUMfeNbRE6-qNczPdZ2-Q_3_16">81,163</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_triyROczKkOUjFoGUVGRSg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_pvjDd_fHnUCm8Oixq8skvw_3_18">3,457,171</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2019_jVvLJZrhl0W1Aw8CczgC5A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_sCx4C0CY7kCchGhlV_Hjqg_3_20">449,856</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:19.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">Issuance of Series A Preferred Stock, net of issuance cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_xAFkHxT11EGU0yxL99Adfg" decimals="INF" format="ixt:numdotdecimal" name="ganx:IssuanceOfSeriesPreferredStockInShares" scale="0" id="Tc_Ve08TRNp80ejF3xD9G9rIA_4_2">310,873</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_xAFkHxT11EGU0yxL99Adfg" decimals="0" format="ixt:numdotdecimal" name="ganx:IssuanceOfSeriesPreferredStockNetOfIssuanceCost" scale="0" id="Tc_nmIQ86Y7b0Su3PdAJO19_w_4_4">31</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_1HYzj4oHZUevOEIRtTmDzw" decimals="0" format="ixt:numdotdecimal" name="ganx:IssuanceOfSeriesPreferredStockNetOfIssuanceCost" scale="0" id="Tc_Rb_NN4C1YkmFD_tr-zXAJA_4_14">1,091,314</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2020_To_12_31_2020_JDEb6LtAmEuXGmEieWNlsw" decimals="0" format="ixt:numdotdecimal" name="ganx:IssuanceOfSeriesPreferredStockNetOfIssuanceCost" scale="0" id="Tc_Jw28ZVlqAkC99iGdkMj7Uw_4_20">1,091,345</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:19.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">Issuance of Series B Preferred Stock, net of issuance cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredClassBMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember__qh10NtWoEa7l7GjkQhs9A" decimals="INF" format="ixt:numdotdecimal" name="ganx:IssuanceOfSeriesBPreferredStockInShares" scale="0" id="Tc_CHb29esOe0KzGskcDAeKhA_5_6">2,965,600</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredClassBMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember__qh10NtWoEa7l7GjkQhs9A" decimals="0" format="ixt:numdotdecimal" name="ganx:IssuanceOfSeriesBPreferredStockNetOfIssuanceCost" scale="0" id="Tc_YJqvZIlvC0mfkqm3l2_8Kg_5_8">297</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_1HYzj4oHZUevOEIRtTmDzw" decimals="0" format="ixt:numdotdecimal" name="ganx:IssuanceOfSeriesBPreferredStockNetOfIssuanceCost" scale="0" id="Tc_EoKtrVpIZEiULSfTM2Medg_5_14">8,713,716</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2020_To_12_31_2020_JDEb6LtAmEuXGmEieWNlsw" decimals="0" format="ixt:numdotdecimal" name="ganx:IssuanceOfSeriesBPreferredStockNetOfIssuanceCost" scale="0" id="Tc_IFy2ttos1kSuX_lab-e5uA_5_20">8,714,013</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:19.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">Issuance of Common Stock, net of issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_uZL4jiBANU-5t9wJ3fQwpA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc_SQl7kc4IF0CVqu3ZVpIu_Q_6_10">1,561,398</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_uZL4jiBANU-5t9wJ3fQwpA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="Tc_PHzTYT0d0EGjV9DgmhF6BQ_6_12">156</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_1HYzj4oHZUevOEIRtTmDzw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="Tc_P-07XOdeLkuI7HTbpj0Wtg_6_14">21</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2020_To_12_31_2020_JDEb6LtAmEuXGmEieWNlsw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="Tc_DRwJd0nax0Ky008RU6QY_A_6_20">177</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:19.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">Issuance of warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_1HYzj4oHZUevOEIRtTmDzw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="0" id="Tc_QdnMn1cwxEWJcWcNpfmMhA_7_14">413,887</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2020_To_12_31_2020_JDEb6LtAmEuXGmEieWNlsw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="0" id="Tc_Mfx41tphj0K2-EDYvCxIaA_7_20">413,887</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:19.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">Stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_1HYzj4oHZUevOEIRtTmDzw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="Tc_4Xmr6I44PE-jzZCYqXb6Iw_8_14">81,640</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2020_To_12_31_2020_JDEb6LtAmEuXGmEieWNlsw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="Tc_A1mxN9WHsUqhO8uiLISoCA_8_20">81,640</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:19.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">Defined benefit pension plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_5l4ULFPqR0yL1UAG81fHvA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="0" id="Tc_vQEMp08ApkGnfQG7k3YFqA_9_16">36,218</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2020_To_12_31_2020_JDEb6LtAmEuXGmEieWNlsw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="0" id="Tc_PHgzQa9sDEONLXmApe6n0w_9_20">36,218</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:19.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">Foreign currency translation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_5l4ULFPqR0yL1UAG81fHvA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" sign="-" scale="0" id="Tc_WdNAIJ-o50yB_eZSYRD2SQ_10_16">35,317</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2020_To_12_31_2020_JDEb6LtAmEuXGmEieWNlsw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" sign="-" scale="0" id="Tc_S6JVRAiX3ESTNW6wHEBhNA_10_20">35,317</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:19.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_AYWDjeIOSU-RxGjTZOS7Tw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc__wvsLmzen0SfLec4KPheaw_11_18">3,577,682</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2020_To_12_31_2020_JDEb6LtAmEuXGmEieWNlsw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_xEwcbzHOTEO6tpjHPfDEQw_11_20">3,577,682</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:19.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><b style="font-weight:bold;">Balance as of December&#160;31,&#160;2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_pyBaEfYw3k-Bre7rOUHY8A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_S8omJMXcR0qmfMUAzfTFQQ_12_2">1,185,879</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_pyBaEfYw3k-Bre7rOUHY8A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_D4y4fGnH40-wYeNCjHcpkg_12_4">118</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredClassBMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_HKF8S1_Sj0ytyt6XZS1DhQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_NmlTlKxDUEyfnlKHOuTQ0A_12_6">2,965,600</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredClassBMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_HKF8S1_Sj0ytyt6XZS1DhQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_k3hoDoWD4Ei9PDnNRcx9_w_12_8">297</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_9f9qYFGKFEi5lUCxbnfGyA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_gpIv6BLvu067Et8Dds675Q_12_10">3,543,163</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_9f9qYFGKFEi5lUCxbnfGyA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_roxIYG14yU63XbjIuDbldA_12_12">354</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_AmnlCLXS4EW0T11vxuv4dA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_ntmZJBNe9UaksgjX0DXlfQ_12_14">13,388,771</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_gy5vyeo0XECt7V84YflbPw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_OGKZSmvWS0K7UjdRt6tnhA_12_16">152,698</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_wUcCiJ_aL0uNAaoLQz_kIQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_WZJolZ0JIUest4H32rjwsw_12_18">7,034,853</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_VT-ovVQ3m0aLMIXAPVrI5w_12_20">6,201,989</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">80</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_4bd7ca1e_2950_476a_b17e_fe6c7d84d043"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Gain Therapeutics, Inc</b></p><a id="ConsolidatedStatementofCashFlows_976628"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">Consolidated Statement of Cash Flows</p><a id="_c7e2ef90_b3af_42d8_90bf_d67b389f72e7"></a><a id="Tc_UMiLpT2rAkygxWkrDnyZxQ_1_2"></a><a id="Tc_qJlyHTVgLkqkr00jAjD6cQ_2_2"></a><a id="Tc_TWFXAvp8Lk633NYA7JbmMg_2_5"></a><a id="Tc_BpBOXv3IVEyVQIAnNZiKmA_4_0"></a><a id="Tc_8iy7ahqw2kmeDtiMjkDPJw_5_0"></a><a id="Tc_FV8HugNp2Em05GXwclZzqA_5_2"></a><a id="Tc_rIlWUNYWz0S9SDyNpU14Tg_5_5"></a><a id="Tc_G4gFnpnfakqNTgec5GJgmw_7_0"></a><a id="Tc_D4i5TNYHckyD9B43mBpg7w_8_0"></a><a id="Tc_cviX1edvT0KLaiWuHRINsg_9_0"></a><a id="Tc_z2HiqKrQn0eTU1P_-K4o2Q_10_0"></a><a id="Tc_CDWksJHroU6frqSPEkY7Rg_10_6"></a><a id="Tc_Oy2XPIrFR0qUl6Ki4BoZig_11_0"></a><a id="Tc_ME6SiYjdVUC0Rl_e5qiFWA_11_6"></a><a id="Tc_fBwfI1dDgEul8_HZVScqcw_12_0"></a><a id="Tc_LHW04xRnmU2-qylSgBm8eg_13_0"></a><a id="Tc_cP-RLHI-XUStgYpbLIzJDg_14_0"></a><a id="Tc_1F2kRvLMJkOMgieR03laFQ_15_0"></a><a id="Tc_ZkBFTeZb-06LZlwH_ZL7VA_16_0"></a><a id="Tc_HW_Dizz2uU6Yib7LRbBtbw_17_0"></a><a id="Tc_dLG7WYVatUKHVUos4KmwqQ_18_0"></a><a id="Tc_Nq66rGjAREm8oR6JAuNiow_19_0"></a><a id="Tc_AL1ht69LwE2JU4JAgf8GGA_20_0"></a><a id="Tc_BArXZCw5rk2qM4ba_xnUow_21_0"></a><a id="Tc_6iGQGOHHdkiKOMTV93C6JA_22_0"></a><a id="Tc_27dmNOIG_U-0Qj2QnsUgZw_24_0"></a><a id="Tc__ZLmucB2M0GFkzgcFsAGaQ_25_0"></a><a id="Tc_9wUo1sc9oU-kBp_6Wju3Nw_26_0"></a><a id="Tc_LzgG5Vh_vE2wTHnj5qkGjQ_28_0"></a><a id="Tc_hDfhTWZAhkW0_b1F1ylGQw_29_0"></a><a id="Tc_lVOIsip7GUOXbpPAXhfkpg_29_3"></a><a id="Tc_OACmxgyWfkuWiWvWJJ9YGg_30_0"></a><a id="Tc_5y2vI0V3REezAAvnaD9KYw_30_3"></a><a id="Tc_cnjd95uK-ke-gtjozstmAQ_31_0"></a><a id="Tc_8QYkDZFewkWhEws0kLLdPw_31_3"></a><a id="Tc_jq62H6AQIEeVyIdFSBw-jw_32_0"></a><a id="Tc_RhQkxanyTUu0jMEXUivLcw_33_0"></a><a id="Tc_DdUe7m0aaU6MN8056CYhPw_34_0"></a><a id="Tc_iRbosRMWZEOKLIc5Q6t44A_34_6"></a><a id="Tc_UcCE5OqXYESg38sV11scNA_35_0"></a><a id="Tc_sm8w6eRPT0O0t-2g7Vd3fA_35_6"></a><a id="Tc_1gpX52mzg0iGNeZ3M_hFlQ_36_0"></a><a id="Tc_x5zxKaVhHE-ZFxEHj8_lGg_36_2"></a><a id="Tc_8HlaEt72VUCxTKwueMZHwg_36_5"></a><a id="Tc_o2C_ollBg0uQMGUaN-J0GA_37_0"></a><a id="Tc_eB708AJrvUamLOfyJu44_Q_38_0"></a><a id="Tc_BVuuBuMIREKO8zvCBwswHw_38_2"></a><a id="Tc_KFQi0cmlIUqwEQm-pkFliQ_38_5"></a><a id="Tc_fkVgcYY6N0mbaTzv5jROOA_39_0"></a><a id="Tc_iYxZNfLxHUSQPD0mZExVgA_40_0"></a><a id="Tc_ZTisdIY5w0CFqgAxrlo_-Q_40_2"></a><a id="Tc_22FEVvjE4kSO4QL65PsivQ_40_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:71.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:71.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Operating activities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td></tr><tr><td style="vertical-align:top;width:71.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="0" id="Tc_6SwF3o6Tl0-4jGfJmQX5AA_5_3">13,890,606</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2020_To_12_31_2020_JDEb6LtAmEuXGmEieWNlsw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="0" id="Tc_pq_0OEfdrEOT4GPW0gVRbg_5_6">3,577,682</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:71.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:71.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Adjustments to reconcile net loss to net cash used in operating activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#ff0000;">&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:71.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="0" id="Tc_BqkiCG7KnEGsmlqsosp2xA_8_3">15,484</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2020_To_12_31_2020_JDEb6LtAmEuXGmEieWNlsw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="0" id="Tc_D068D4Ed2E2_g5IUHLmLow_8_6">9,592</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:71.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Stock based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="0" id="Tc_jxec6FMEmUie_42mUzoAmw_9_3">839,371</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2020_To_12_31_2020_JDEb6LtAmEuXGmEieWNlsw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="0" id="Tc_GEkXTZiRX0WvfqxQzHpUkQ_9_6">81,640</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:71.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Issuance of warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" scale="0" id="Tc_bp0A9KfHlkGgqaosL98Qow_10_3">1,034,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:71.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Internal-use software</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" decimals="0" format="ixt:numdotdecimal" name="ganx:CapitalizedComputerSoftwareAdjustment" scale="0" id="Tc_ZIWY7Bvr9k2mSO4r_BV9fQ_11_3">34,135</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:71.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Changes in operating assets and liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:71.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Account receivables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" sign="-" scale="0" id="Tc_ou20pOwoWEmyBTDSzm3Wpw_13_3">8,264</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2020_To_12_31_2020_JDEb6LtAmEuXGmEieWNlsw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="0" id="Tc_AGZZdb1T8EyW-6MmUJH-Mw_13_6">196</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:71.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Prepaid expenses and other currents assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="0" id="Tc_zdVoCCfD5ESvtEb6fTsIFw_14_3">534,502</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2020_To_12_31_2020_JDEb6LtAmEuXGmEieWNlsw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="0" id="Tc_OvawNs37cEeq1D_OlNt28Q_14_6">117,704</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:71.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">VAT credits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" decimals="0" format="ixt:numdotdecimal" name="ganx:IncreaseDecreaseInValueAddedTaxCredits" scale="0" id="Tc_Tv6F12Q7s0uFyL2dkGjBAw_15_3">71,618</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2020_To_12_31_2020_JDEb6LtAmEuXGmEieWNlsw" decimals="0" format="ixt:numdotdecimal" name="ganx:IncreaseDecreaseInValueAddedTaxCredits" scale="0" id="Tc_ehV78JuIQES9-wcXVfAMYw_15_6">21,454</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:71.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Long term deposit and other non current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" sign="-" scale="0" id="Tc_oucjFT9IcESBgMapgHWIqg_16_3">33,979</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2020_To_12_31_2020_JDEb6LtAmEuXGmEieWNlsw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="0" id="Tc_lJQtHY_TsE6qnBQDo40kEw_16_6">63,095</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:71.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" sign="-" scale="0" id="Tc_ir4Igy41cEiQfj2rDqt_kA_17_3">521,394</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2020_To_12_31_2020_JDEb6LtAmEuXGmEieWNlsw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="0" id="Tc_FqCjzmxv4Ue5kNTZtVQGTQ_17_6">395,543</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:71.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Other current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" scale="0" id="Tc_BaFy9Iq23kCRx5m3-oWxbA_18_3">665,460</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2020_To_12_31_2020_JDEb6LtAmEuXGmEieWNlsw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" scale="0" id="Tc_1kTyr7jcNUOn7qtjdd5Fcw_18_6">173,725</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:71.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Defined benefit pension plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PensionExpenseReversalOfExpenseNoncash" scale="0" id="Tc_-dBDpSMxeEGmEJeCbqoEOw_19_3">55,326</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2020_To_12_31_2020_JDEb6LtAmEuXGmEieWNlsw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PensionExpenseReversalOfExpenseNoncash" scale="0" id="Tc_KUhGpYaGRkCJSx-AJ3xvug_19_6">8,709</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:71.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Deferred income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInDeferredLiabilities" scale="0" id="Tc_5Wr73B-az0KIv_Z6Z8FlIg_20_3">34,701</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2020_To_12_31_2020_JDEb6LtAmEuXGmEieWNlsw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInDeferredLiabilities" sign="-" scale="0" id="Tc_ESDcbdob6E2MAusM40n78A_20_6">129,315</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:71.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total changes in operating assets and liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" decimals="0" format="ixt:numdotdecimal" name="ganx:IncreaseDecreaseInOperatingAssetsAndLiabilities" scale="0" id="Tc_ddGvM8Wa7k6i8SzFQptZvw_21_3">329,784</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2020_To_12_31_2020_JDEb6LtAmEuXGmEieWNlsw" decimals="0" format="ixt:numdotdecimal" name="ganx:IncreaseDecreaseInOperatingAssetsAndLiabilities" sign="-" scale="0" id="Tc_XJS0CbIgbkSv5wtSYdrKvw_21_6">246,213</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:71.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">          Net cash used in operating activities</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="0" id="Tc_YCsE-3bse0GrAi9yDqqG1g_22_3">12,365,670</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2020_To_12_31_2020_JDEb6LtAmEuXGmEieWNlsw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="0" id="Tc_3V6pFJp31Eyl1UXpINaHfA_22_6">3,240,237</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:71.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#ff0000;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:71.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Cash flows from investing activities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td></tr><tr><td style="vertical-align:top;width:71.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Purchase of property and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="0" id="Tc_6eWn5A1BsU6ou95CeR2Oug_25_3">94,212</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2020_To_12_31_2020_JDEb6LtAmEuXGmEieWNlsw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="0" id="Tc_x7vZ9rHdgkKnlmPa20CHfg_25_6">20,826</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:71.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">        Net cash used in investing activities</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="0" id="Tc_LjAvwNU0pkOXZdHX5S5KUQ_26_3">94,212</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2020_To_12_31_2020_JDEb6LtAmEuXGmEieWNlsw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="0" id="Tc_XE2-4-QfnEG0YnNM7VWyPg_26_6">20,826</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:71.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:71.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Cash flow from financing activities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td></tr><tr><td style="vertical-align:top;width:71.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Proceeds from long-term debts</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2020_To_12_31_2020_JDEb6LtAmEuXGmEieWNlsw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="0" id="Tc_KgbMTZUw9EmAtUX5UWwwsg_29_6">738,282</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:71.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Proceeds from issuance of Series A Preferred Stock, net of issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2020_To_12_31_2020_JDEb6LtAmEuXGmEieWNlsw" decimals="0" format="ixt:numdotdecimal" name="ganx:ProceedsFromIssuanceOfSeriesA.PreferredStockNetOfIssuanceCosts" scale="0" id="Tc_ufhMMeaqI0yEfa3d5nr2Gg_30_6">1,091,345</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:71.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Proceeds from issuance of Series B Preferred Stock, net of issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2020_To_12_31_2020_JDEb6LtAmEuXGmEieWNlsw" decimals="0" format="ixt:numdotdecimal" name="ganx:ProceedsFromIssuanceOfSeriesBPreferredStockNetOfIssuanceCosts" scale="0" id="Tc_rMN5hExyuEiwYiChlxMxJg_31_6">9,127,902</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:71.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Proceeds from issuance of common shares upon completion of initial public offering, net of underwriter discounts</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" scale="0" id="Tc__wp1QORiWEamaXjLWjOV5Q_32_3">42,629,998</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2020_To_12_31_2020_JDEb6LtAmEuXGmEieWNlsw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" scale="0" id="Tc__54r2Nba2ESgr7d3QvBeVA_32_6">177</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:71.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Payments of deferred offering costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="0" id="Tc_kHRXKWFt-0e2P96-aa97lQ_33_3">853,488</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2020_To_12_31_2020_JDEb6LtAmEuXGmEieWNlsw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="0" id="Tc_X7OCNIpp5kWOyjKaMG3s3g_33_6">470,745</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:71.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Payments of current portion of long-term debt</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfShortTermDebt" scale="0" id="Tc__eNK2_WMy0CKRTySf8z4OQ_34_3">21,951</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:71.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Proceeds from stock option exercise</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="0" id="Tc_fwKSG4-qMUqtbkglIaQ_VQ_35_3">12,216</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:71.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">      Net cash provided by financing activities</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" id="Tc_eHgCVNNHRk2ir3pCuDXNyw_36_3">41,766,775</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2020_To_12_31_2020_JDEb6LtAmEuXGmEieWNlsw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" id="Tc_eTPYDNC19UqL_6LQ6spZ_g_36_6">10,486,961</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:71.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Effect of exchange rate changes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents" scale="0" id="Tc_6Jim5DHKVEOOAPzS3m_EfA_37_3">100,778</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2020_To_12_31_2020_JDEb6LtAmEuXGmEieWNlsw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents" sign="-" scale="0" id="Tc_jJDAQSj8jkWnVSGjuEjkCg_37_6">35,317</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:71.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net increase in cash, cash equivalents and restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="0" id="Tc_Ci-rY-ToDkibkoxzGTXAfQ_38_3">29,407,671</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2020_To_12_31_2020_JDEb6LtAmEuXGmEieWNlsw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="0" id="Tc_KnhCSfaP20qMEc-RzU_BxQ_38_6">7,190,581</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:71.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash, cash equivalents and restricted cash at beginning of period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="Tc_E4PpsUh_Yky-w3uL5fBy3A_39_3">7,504,281</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2019_jVvLJZrhl0W1Aw8CczgC5A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="Tc_Ae_fwZaLDEKAE7yjCldiAA_39_6">313,700</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:71.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash, cash equivalents and restricted cash at end of period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="Tc_yFmbLLTFL0me04tVf6_pdg_40_3">36,911,952</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="Tc_QLarmY90w06HreMli-23og_40_6">7,504,281</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">81</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_0ba3d58f_420c_4b97_9fc1_7bc8960a3559"></a><a id="NotestotheConsolidatedFinancialStatement"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">Notes&#160;to the Consolidated Financial Statements</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="Tb_2jGxi3CD40y15DwXRYi54Q" continuedAt="Tb_2jGxi3CD40y15DwXRYi54Q_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">1.&#160;&#160;&#160;&#160;Nature of the business and basis of presentation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Operations and business</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Gain Therapeutics,&#160;Inc. (and together with its subsidiary, the &#8220;Company&#8221;), was incorporated under the laws of the state of Delaware (U.S.) on June&#160;26, 2020. On July&#160;20, 2020, the Company consummated a corporate reorganization, pursuant to which all of the issued and outstanding common and preferred stock of GT Gain Therapeutics SA, a Swiss company formed in 2017, were exchanged for common stock or preferred stock, as applicable, of Gain Therapeutics,&#160;Inc., reflecting a <ix:nonFraction unitRef="Unit_Standard_pure_YPFUW3Xga0mVMPZT28RXUw" contextRef="Duration_7_20_2020_To_7_20_2020_CH_oHqEadU-bNi2WtP4JnA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" scale="0" id="Narr_axeh2Ldxnk2XsyTvIStvyg">10</ix:nonFraction>:1 stock split. The corporate reorganization was accounted for as a recapitalization for accounting purposes, with GT Gain Therapeutics SA resulting in the predecessor entity of the Company. As a result of the corporate reorganization, GT Gain Therapeutics SA became a wholly-owned subsidiary of Gain Therapeutics,&#160;Inc. For periods and at dates prior to the corporate reorganization, the consolidated financial statements presented were prepared based on the historical financial statements of GT Gain Therapeutics SA, adjusted to give retroactive effect to the share exchange transactions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On March 17, 2021, the Company&#8217;s registration statement on Form S-1 related to its Initial Public Offering (&#8220;IPO&#8221;) was declared effective by the Securities and Exchange Commission (&#8220;SEC&#8221;). The IPO closed on March 17, 2021 at the Nasdaq. In conjunction with the IPO the Company completed a reverse stock split of the Company&#8217;s outstanding equity instruments. The reverse stock split was approved by the stockholders on March 4, 2021 and became effective on March 17, 2021. Upon closing of the IPO, the Series A and the Series B Preferred Stock, as resulting form the reverse stock split, were converted to common stock at a ratio of <ix:nonFraction unitRef="Unit_Standard_pure_YPFUW3Xga0mVMPZT28RXUw" contextRef="Duration_3_17_2021_To_3_17_2021_us-gaap_StatementClassOfStockAxis_ganx_PreferredStockSeriesAndSeriesBMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_r8J2spGPVEeD9l3nZ-VHoQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" scale="0" id="Narr_UxkYgociAU2UY1wpoIhsZw">1</ix:nonFraction>-for-1. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company is a biotechnology company developing novel therapies to treat diseases caused by protein misfolding, with an initial focus on rare genetic diseases and neurological disorders. We use our licensed platform, SEE-Tx&#174;, to discover novel allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites, potentially restoring protein folding and treating disease. These small molecule binding sites, away from the protein&#8217;s active areas, are called allosteric sites. Targeting the allosteric binding site instead of the active binding site provides superior regulation of misfolded enzymes implicated by disease, is non-competitive with the natural substrate, provides superior drug-like properties and ultimately enhances both safety and efficacy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Risks and uncertainties</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, risks associated with completion and success of preclinical studies and clinical testing, dependence on key personnel, protection of proprietary technology, compliance with applicable governmental regulations, development by competitors of new technological innovations, protection of proprietary technology and the ability to secure additional capital to fund operations. Drug candidates currently under development will require significant additional research and development efforts, including preclinical and clinical testing and prior to regulatory approval and commercialization. These efforts require significant amounts of additional capital, adequate personnel, and infrastructure and extensive compliance-reporting capabilities. Even if the Company&#8217;s drug development efforts are successful, it is uncertain when, if ever, the Company will realize revenue from product sales.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Going concern</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has incurred recurring losses and negative cash flows from operations since its inception and has primarily funded these losses through proceeds from capital contributions. The Company anticipates incurring additional losses until such time, if ever, that it can generate significant sales of its product candidates currently in development. Substantial additional capital will be needed by the Company to fund its operations and to develop its product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In March 2021, the Company closed its initial public offering, or IPO, in which the Company issued and sold <ix:nonFraction unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw" contextRef="Duration_3_1_2021_To_3_31_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_N45LChwtn0m3vTVdPokCZw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_3GGSDe8bl0K-b9w1saIURw">4,181,818</ix:nonFraction> shares of its common stock, which included shares sold pursuant to an option granted to the underwriters to purchase additional shares, at a public offering price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_ZUfWDOiJrESFdyfJo2gfWg" contextRef="As_Of_3_31_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_jyeDTSFma0emcErckg2zrw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharePrice" scale="0" id="Narr_LROCJnS1ZE--nA-3NU65lA">11.00</ix:nonFraction> per share for net proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_3_1_2021_To_3_31_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_N45LChwtn0m3vTVdPokCZw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="Narr_934PgupmUEW6fPQRKMWuVQ">40.5</ix:nonFraction> million after deducting underwriting discounts, commissions and other offering expenses.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">82</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_2jGxi3CD40y15DwXRYi54Q_cont1" continuedAt="Tb_2jGxi3CD40y15DwXRYi54Q_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s operations have consisted primarily of organizing the Company, securing financing, developing licensed technology, performing research and conducting preclinical studies. The Company faces risks associated with early-stage biotechnology companies whose product candidates are in development. Product candidates currently under development will require significant additional research and development efforts, including extensive preclinical and clinical testing, establishing manufacturing capacity and regulatory approval prior to commercialization. These efforts require significant amounts of additional capital for the Company to complete its research and development, achieve its research and development objectives, defend its intellectual property rights, and recruit and retain skilled personnel, and key members of management. Even if the Company&#8217;s product development efforts are successful, it is uncertain when, if ever, the Company will realize revenue from product sales. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company plans to seek additional funding through public or private equity offerings, debt financings, other collaborations,strategic alliances and licensing arrangements. The Company may not be able to obtain financing on acceptable terms, or at all,and the Company may not be able to enter into strategic alliances or other arrangements on favorable terms, or at all. The terms of any financing may adversely affect the holdings or the rights of the Company&#8217;s stockholders. If the Company is unable to obtain funding, the Company could be required to delay, reduce or eliminate research and development programs, product portfolio expansion or future commercialization efforts, which could adversely affect its business prospects. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In accordance with Accounting Standards Update, or &#8220;ASU&#8221;, No. 2014-15, Disclosure of Uncertainties about an Entity&#8217;s Ability to Continue as a Going Concern, the Company has evaluated whether there are certain conditions and events, considered in the aggregate, that raise substantial doubt about the Company&#8217;s ability to continue as a going concern within one year after the date that the financial statements are issued. As of the issuance date of these financial statements, the Company expects that its cash and cash equivalents will be sufficient to fund its forecasted operating expenses and capital expenditure requirements for at least the next twelve months from the issuance date of these financialstatements. Accordingly, the consolidated financial statements have been prepared assuming that the Company will continue as a going concern.</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="Tb_lkYCjsbcQkCo4OdRE9mP4g" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Basis of presentation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The consolidated financial statements reflect the accounts of the Gain Therapeutics, Inc., GT Gain Therapeutics SA and its wholly owned branch, Gain Therapeutics Sucursal en Espa&#241;a. All intercompany transactions and balances have been eliminated in the preparation of the consolidated financial statements. The consolidated financial statements as of December 31, 2021, represented by the Consolidated Balance Sheet, the Consolidated Statement of Operations, the Consolidated Statements of Changes in Shareholders&#8217; Equity, the Consolidated Statement of Comprehensive Loss, the Consolidated Statements of Cash Flows and the accompanying Notes, have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;US GAAP&#8221;). Any reference in these notes to applicable guidance is meant to refer to the authoritative United States generally accepted accounting principles as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Update (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The &#160;financial statements as of December 31, 2021 reflect, for all periods presented, the retroactive application of the reverse stock split that occurred on March 17, 2021. All amounts in the consolidated financial statements are expressed in United States Dollars (USD/$) and disclosed within these explanatory notes in United States Dollars (USD/$) or Swiss Franc (CHF), which are the functional currencies of the Company and its operating subsidiary, GT Gain Therapeutics SA, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The consolidated financial statements have been prepared on the same basis as the audited annual consolidated financial statements as of and for the year ended December 31, 2020, and, in the opinion of management, reflect all adjustments, consisting of normal recurring adjustments, necessary for the fair presentation of the Company&#8217;s financial position as of December 31, 2021, and the results of its operations for the years ended December 31, 2021 and 2020, its statements of stockholders&#8217; equity and its statements of cash flows for the years then ended. </p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" name="ganx:ReverseStockSplitPolicyPolicyTextBlock" id="Tb_NDdjNs5pY0W_JC9kG458Zw" continuedAt="Tb_NDdjNs5pY0W_JC9kG458Zw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Reverse Stock Split </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">On March 3, 2021, the Board approved a 1-for-<span style="-sec-ix-hidden:Hidden_PPLEqeAgy0iiPmdWllrCSA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">0.880784</span></span> reverse stock split of the Company&#8217;s outstanding equity instruments. The reverse stock split was approved by the stockholders on March 4, 2021 and became effective in conjunction with the IPO on March 17, 2021. Stockholders were no entitled to fractional shares as a result of the reverse stock split. All share and per share data shown in the accompanying consolidated financial statements and </p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">83</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_2jGxi3CD40y15DwXRYi54Q_cont2"><ix:continuation id="Tb_NDdjNs5pY0W_JC9kG458Zw_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">related notes have been retroactively revised to reflect the reverse stock split. Shares of common stock underlying outstanding stock options and other equity instruments were proportionately reduced and the respective exercise prices, if applicable, were proportionately increased in accordance with the terms of the agreements governing such securities.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" name="ganx:InitialPublicOfferingPolicyTextBlock" id="Tb_4NGgRDPRQki34GLBDg0WHQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Initial Public Offering </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On March 17, 2021, the Company&#8217;s registration statement on Form S-1 relating to its IPO was declared effective by the Securities and Exchange Commission (&#8220;SEC&#8221;). The IPO closed on March 17, 2021 and the Company issued and sold <ix:nonFraction unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw" contextRef="Duration_3_17_2021_To_3_17_2021_us-gaap_SubsidiarySaleOfStockAxis_ganx_IpoExcludingUnderwritersOptionsMember_zUbax__QHU2jXdFcxwazTA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_Q_jtdXi8T0GSoLkz_4xgaQ">3,636,364</ix:nonFraction> common shares at a public offering price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_ZUfWDOiJrESFdyfJo2gfWg" contextRef="As_Of_3_17_2021_us-gaap_SubsidiarySaleOfStockAxis_ganx_IpoExcludingUnderwritersOptionsMember_TfY1dJMilk2kFQZuPi8-sw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharePrice" scale="0" id="Narr_21M-wBf8F0OZ2PN7x9fZ_Q">11.00</ix:nonFraction> per share for net proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_3_17_2021_To_3_17_2021_us-gaap_SubsidiarySaleOfStockAxis_ganx_IpoExcludingUnderwritersOptionsMember_zUbax__QHU2jXdFcxwazTA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="Narr_lbnzInjiDkq2SCBHzbYsMg">34,978</ix:nonFraction> thousand after deducting underwriting discounts and commissions of $<ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_3_17_2021_To_3_17_2021_us-gaap_SubsidiarySaleOfStockAxis_ganx_IpoExcludingUnderwritersOptionsMember_zUbax__QHU2jXdFcxwazTA" decimals="-3" format="ixt:numdotdecimal" name="ganx:UnderwritingDiscountsAndCommissions" scale="3" id="Narr_wzHHfo5y5UmVQAwpw1zapA">2,950</ix:nonFraction> thousand and other offering expenses of $<ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_3_17_2021_To_3_17_2021_us-gaap_SubsidiarySaleOfStockAxis_ganx_IpoExcludingUnderwritersOptionsMember_zUbax__QHU2jXdFcxwazTA" decimals="-3" format="ixt:numdotdecimal" name="ganx:OtherOfferingExpenses" scale="3" id="Narr_8O_UzCg0C0OgkbtwQ2RVag">2,071</ix:nonFraction> thousand. On March 22, 2021, the Company issued and sold <ix:nonFraction unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw" contextRef="Duration_3_22_2021_To_3_22_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_T4IMo7Q7FkixFavhC2S9FA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_9YseH0c01UevRyg-TXOH7A">545,454</ix:nonFraction> additional common shares, pursuant to the full exercise of the underwriters&#8217; option to purchase additional shares, for net proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_3_22_2021_To_3_22_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_T4IMo7Q7FkixFavhC2S9FA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="Narr_kVjM69SlFUiz91HRBmBtpQ">5,580</ix:nonFraction> thousand after deducting underwriting discounts and commissions of $<ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_3_22_2021_To_3_22_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_T4IMo7Q7FkixFavhC2S9FA" decimals="-3" format="ixt:numdotdecimal" name="ganx:UnderwritingDiscountsAndCommissions" scale="3" id="Narr_iOhVUaKauU2ps_WHCYlJmQ">420</ix:nonFraction> thousand. Thus, the aggregate net proceeds to the Company from the IPO, after deducting underwriting discounts commissions, were $<ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_3_17_2021_To_3_22_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_SaCdeyGh10qyXh2PUIfaFw" decimals="-3" format="ixt:numdotdecimal" name="ganx:GrossProceedsFromIssuanceOfCommonStock" scale="3" id="Narr_0MGIXdV4OEeqqz4NsW-pgw">42,630</ix:nonFraction> thousand. After deducting other IPO offering expenses amounting to $<ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_3_17_2021_To_3_22_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_SaCdeyGh10qyXh2PUIfaFw" decimals="-3" format="ixt:numdotdecimal" name="ganx:UnderwritingDiscountsAndCommissions" scale="3" id="Narr_jW-_jHb7RE2VKY7L9P-wbA">2,071</ix:nonFraction> thousand, the net cash proceeds resulting from the IPO were $<ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_3_17_2021_To_3_22_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_SaCdeyGh10qyXh2PUIfaFw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="Narr_IqNNLEht3kq3MlsRxjWsag">40,558</ix:nonFraction> thousand, which are reflected in the statement of stockholders&#8217; equity as Issuance of Common Stock in IPO, net of issuance costs. Upon the closing of the IPO, series A convertible preferred stock (the &#8220;Series A Preferred Stock&#8221;) and series B convertible preferred stock (the &#8220;Series B Preferred Stock&#8221;, and together with the Series A Preferred Stock, are collectively referred to as the &#8220;Preferred Stock&#8221;) were converted into shares of common stock at ratio of <ix:nonFraction unitRef="Unit_Standard_pure_YPFUW3Xga0mVMPZT28RXUw" contextRef="Duration_3_18_2021_To_3_18_2021_iMaj3AAJbEqmShHP_jyriA" decimals="INF" format="ixt:numdotdecimal" name="ganx:PreferredStockToCommonStockConversionRatio" scale="0" id="Narr_0jkP8FuVV0eyZ5Z1xvPz8w">1</ix:nonFraction>-for-1.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="Tb_14rFpqpGj0yujN958-wx-A" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Segment information</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Operating segments are defined as components of an enterprise for which separate discrete information is available for evaluation by the chief operating decision-maker in deciding how to allocate resources and assess performance. The Company&#8217;s chief operating decision-maker, the Chief Executive Officer, oversees the Company&#8217;s operations and manages the business as a single operating segment, which is research and development in the pharmaceutical sector with a focus on developing novel therapeutics to treat diseases caused by protein misfolding, such as rare genetic diseases and neurological disorders. Geographically, the research and development activities are mainly performed in Switzerland and Spain. The Company does not consider these geographies to be separate segments.</p></ix:nonNumeric></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="Tb_Ztqo9jWWIUua8VOE7WvLOQ" continuedAt="Tb_Ztqo9jWWIUua8VOE7WvLOQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">2. &#160;&#160;&#160;&#160;Summary of significant accounting policies</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="Tb_xO4bdTHsW0i-mkcE23rZLA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Foreign currency translation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company is incorporated in the United States of America and has operations in Switzerland and Spain. The Company&#8217;s functional currency is USD. The functional currencies of the Company&#8217;s foreign operations are the local currencies (Swiss Franc in Switzerland and Euro in Spain). Assets and liabilities reported in the consolidated balance sheets are translated into U.S. dollars (the currency in which these financial statements are presented) at the exchange rates applicable at the balance sheet dates and for the consolidated statement of operations at the average exchange rates for the periods presented. Items representing the share capital and additional paid-in capital are presented at the historical exchange rates. Adjustments resulting from the translation of the financial statements of the Company&#8217;s foreign operations into U.S. dollars are excluded from the determination of net income and are recorded in accumulated other comprehensive income/(loss), a separate component of shareholders&#8217; equity. The Company has not utilized any foreign currency hedging strategies to mitigate the effect of its foreign currency exposure. As of December 31, 2021 and 2020, accumulated currency translation adjustment recorded in the accumulated other comprehensive loss amounted to $<ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" scale="0" id="Narr_0ZWOwuRKhEmH36WNXQnkHw">165,156</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" scale="0" id="Narr_5afVZmbuNUm7XHv3XLGcCA">1,323</ix:nonFraction>, respectively.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" name="us-gaap:UseOfEstimates" id="Tb_7F0-OpU300qL4yNXbzGSdA" continuedAt="Tb_7F0-OpU300qL4yNXbzGSdA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The preparation of our consolidated financial statements in conformity with US GAAP requires management to make estimates, judgments and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting periods. On an ongoing basis, we evaluate our estimates judgments and, assumptions including those related to recognition of grant funds, accrued expenses, defined benefit pension liability, warrants and stock-based compensation. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the </p></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">84</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_pUfO4pDsVECsa1Dd_B2tsQ_1_0"></a><a id="Tc_lJC-A30AS0G7W6iRkZcKeA_1_3"></a><a id="Tc_m3KxTseS6UuxIC0SWu_xVw_2_0"></a><a id="Tc_qT5h8miDj0ewjoayh6f18A_2_3"></a><a id="Tc_c0zzx7-_fkuC0TGVxr29VQ_3_0"></a><a id="Tc_2iqmTwdIyU6srOyigXsw_g_3_2"></a><a id="Tc_cTS1lbyC-EKFhvq_HJ8qXA_4_0"></a><a id="Tc_TIrbdDNBwkW3IEQeJ1ROUg_4_3"></a><ix:continuation id="Tb_Ztqo9jWWIUua8VOE7WvLOQ_cont1" continuedAt="Tb_Ztqo9jWWIUua8VOE7WvLOQ_cont2"><ix:continuation id="Tb_7F0-OpU300qL4yNXbzGSdA_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. Changes in estimates are recorded in the period in which they become known. To the extent that material differences arise between the estimates and actual results, the Company&#8217;s future results of operations will be affected. The COVID-19 pandemic did not have a significant impact on the Company&#8217;s estimates.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="Tb_EdfHnc4E1Uyb_ngvBx-Hfw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Cash and cash equivalents</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company reports cash on hand and held at banks, and all highly liquid investments in money market, certificates of deposit, time deposit, and other short-term liquid securities with original maturities of less than 90 day, as cash and cash equivalents.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" name="us-gaap:ConcentrationRiskCreditRisk" id="Tb_acrftdZ-I0enGoLVcjHaFQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Concentrations of credit risk</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has no significant off-balance sheet risk, such as foreign exchange contracts, option contracts, or other foreign hedging arrangements. Financial instruments that may expose the Company to concentrations of credit risk consist primarily of cash, cash equivalents which are deposited in accredited financial institutions in excess of federally insured limits. The Company deposits its cash and cash equivalents in financial institutions that it believes have high credit quality and has not experienced any losses on such accounts and does not believe it is exposed to any unusual credit risk beyond the normal credit risk associated with commercial banking relationships.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" name="us-gaap:DeferredChargesPolicyTextBlock" id="Tb_1uIwOBFW7UWFCRPJU9SsrA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Deferred Issuance Costs</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company capitalizes certain legal, professional accounting and other third-party fees that are directly associated with in-process equity financings as deferred issuance costs until such financings are consummated. After consummation of the equity financing, these costs are recorded as a reduction of the proceeds generated as a result of the offering. Should the planned equity financing be abandoned, the deferred issuance costs will be expensed immediately as a charge to operating expenses in the consolidated statements of operations. There were <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:DeferredFinanceCostsNet" scale="0" id="Narr_JVIf-g3GJE-xf95rNN3fcQ">nil</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredFinanceCostsNet" scale="0" id="Narr_2dkiYhv7WEG2NM8OWpwyTA">1,217,988</ix:nonFraction> deferred issuance costs as of December 31, 2021 and 2020, respectively.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="Tb_9e4T_glEWkWMZLrZsp0hOA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Property and equipment</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Property and equipment are stated at cost, including any accessory and direct costs that are necessary to make the assets fit for use, and adjusted by the corresponding accumulated depreciation. The depreciation rates recorded in the consolidated financial statements of operations have been calculated by taking into consideration the use, purpose and financial-technical duration of the assets, on the basis of their estimated useful economic lives. The Company believes the above criteria to be represented by the following depreciation rates:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" name="ganx:DepreciationRatesOnPropertyPlantAndEquipmentTableTextBlock" id="Tb_1X9VTprqS0G7id067aqOmA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:61.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:33.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:61.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">-&#8195; Equipment &amp; Furniture</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:33.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_YPFUW3Xga0mVMPZT28RXUw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ganx_EquipmentAndFurnitureMember_eYeOQu_NukuBM3xRUGpAow" decimals="3" format="ixt:numdotdecimal" name="ganx:PropertyPlantAndEquipmentDepreciationRates" scale="-2" id="Tc_y2mjfDjNLEGppZ2T2isqTQ_1_2">12.5</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:top;width:61.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">-&#8195; Electronic office equipment:</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:33.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_YPFUW3Xga0mVMPZT28RXUw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_vxw_50xpsk-K6Rt4Xg-w-w" decimals="2" format="ixt:numdotdecimal" name="ganx:PropertyPlantAndEquipmentDepreciationRates" scale="-2" id="Tc_A_aeLC_UwUiYARvXi72sYQ_2_2">20</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:top;width:61.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">-&#8195; Leasehold Improvements</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:33.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">based on the terms of the lease</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:61.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">-&#8195; Laboratory equipment:</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:33.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_YPFUW3Xga0mVMPZT28RXUw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ganx_LaboratoryInstrumentsMember_UGsEilKkZ0-amCM5X6BAdw" decimals="2" format="ixt:numdotdecimal" name="ganx:PropertyPlantAndEquipmentDepreciationRates" scale="-2" id="Tc_RRYppYCRL0uaxJ1tnjpA9g_4_2">15</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Ordinary maintenance costs are entirely attributed to the consolidated statements of operations in the&#160;year in which they are incurred. Extraordinary maintenance costs, the purpose of which is to extend the useful economic life of the asset, to technologically upgrade it and/or to increase its productivity or safety for the purposes of the economic productivity of the Company, are attributed to the asset to which they refer and depreciated on the basis of its estimated useful economic lives. Amortization of leasehold improvements is computed using the straight-line method based upon the terms of the applicable lease or estimated useful life of the improvements, whichever is lower.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" name="us-gaap:ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" id="Tb_y3B0SED6sU2shy5BcgVpRg" continuedAt="Tb_y3B0SED6sU2shy5BcgVpRg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Capitalized Software Development Costs</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company capitalizes the costs of software obtained for internal use in accordance with ASC 350-40, Internal-Use Software. Capitalized software development costs consist of costs incurred during the development stage and include purchased software licenses, implementation costs, consulting costs, and payroll-related costs for projects that qualify for capitalization. All other costs, primarily related to maintenance and minor software fixes, are expensed as incurred. As of December 31, 2021 and 2020, internal-use software amount to $<ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CapitalizedComputerSoftwareNet" scale="0" id="Narr_qg3VxC1i40-dqXCqc2aVYA">202,609</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:CapitalizedComputerSoftwareNet" scale="0" id="Narr_Ib8BTfftjka67PRL3F5dLQ">nil</ix:nonFraction>, and refer to the </p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">85</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_Ztqo9jWWIUua8VOE7WvLOQ_cont2" continuedAt="Tb_Ztqo9jWWIUua8VOE7WvLOQ_cont3"><ix:continuation id="Tb_y3B0SED6sU2shy5BcgVpRg_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">external and internal labor costs incurred in the development of the Company ERP, amounting respectively to $<ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CapitalizedComputerSoftwareAdditions" scale="0" id="Narr_3NmZX6p4G0apoU9cBKAOfQ">168,474</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2020_To_12_31_2020_JDEb6LtAmEuXGmEieWNlsw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CapitalizedComputerSoftwareAdditions" scale="0" id="Narr_N8Oa_w0Xm0WtHm2WQ5gHTg">34,135</ix:nonFraction>. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company amortizes the capitalized software development costs on a straight-line basis over the estimated useful life of the software, which is generally <ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_ComputerSoftwareIntangibleAssetMember_IyvNJLfe-0C5bmjgl1g7MQ" format="ixt-sec:durwordsen" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="Narr_ofCd-LZU2kyke-sqLvt45g">six years</ix:nonNumeric>, beginning when the asset is substantially ready for use. The amortization of capitalized software development costs is reflected in general and administrative expenses. </p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="Tb_pncA-bYEDUmuL9LH5iRRJw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Impairment of long-lived assets</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">In accordance with ASC Topic 360-10-20, &#8220;Property, Plant and Equipment,&#8221; the Company performs an impairment test whenever events or circumstances indicate that the carrying value of long-lived assets with finite lives may be impaired. Impairment is measured by comparing the carrying value of the long-lived assets to the estimated undiscounted pre-tax cash flows expected to result from the use of such assets and their ultimate disposition. In circumstances where impairment is determined to exist, the Company will write down the asset to its fair value based on the present value of estimated cash flows. </span><span style="font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2020_To_12_31_2020_JDEb6LtAmEuXGmEieWNlsw" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:AssetImpairmentCharges" scale="0" id="Narr_PElOgxtOEkaXPMRIlZkOTg"><ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:AssetImpairmentCharges" scale="0" id="Narr_JdecyAtmDEmZMwIyX614Lw">No</ix:nonFraction></ix:nonFraction></span><span style="font-weight:normal;"> impairments have been identified by management as of and for any periods presented.</span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" name="us-gaap:IntangibleAssetsFiniteLivedPolicy" id="Tb_jLYdija_C0qeP1tzXlghPg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Patents</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">Patent-related costs, refer to legal fees incurred in connection with filing and prosecuting patent applications and are expensed as incurred due to uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses.</span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" name="us-gaap:LesseeLeasesPolicyTextBlock" id="Tb_gmVkyXb4REm3YcGVR3TT1A" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Leases</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Effective January&#160;1, 2018, the Company adopted ASC 842, using the additional transition method option provided by ASU 2018-11. Under this transition method, we applied the new accounting guidance as of the date of adoption. Upon adoption, a cumulative effect adjustment was not required.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Subsequent to the adoption, the Company determines if an arrangement contains a lease at inception based on whether or not the Company has the right to control the asset during the contract period and other facts and circumstances. The Company is the lessee in a lease contract when it obtains the right to control the asset. Operating lease right of use (&#8220;ROU&#8221;) assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease, both of which are recognized based on the present value of the future minimum lease payments over the lease term at the commencement date. Leases with a term of 12 months or less at inception are expensed on a straight-line basis over the lease term in the statement of operations. The Company determines the lease term by assuming the exercise of renewal options that are reasonably certain. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, the Company subleases portions of its office premises in Lugano. The Company recognizes sublease income on a straight-line basis over the sublease terms, reported within other income. </p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" name="ganx:AccountsPayablePolicyTextBlock" id="Tb_gF9xDbSxQkqbt30yF3DiJQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Accounts Payable</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Accounts payable are reported at their nominal amounts due to their short-term maturities. Trade accounts payable are recorded net of trade discounts; cash discounts are recorded at the time of payment.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" name="ganx:PayablesForSocialSecuritiesPolicyTextBlock" id="Tb_3ect8K-3IEu3ixrtxeyp8w" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Payables for Social Securities</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Social Security charges are reported in compliance with rules and laws applicable in the countries where our employees work. Charges are accrued in accordance with the policies stipulated and in connection with salaries due for the period.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" name="ganx:AccruedExpensesPolicyPolicyTextBlock" id="Tb_Au_9HCw5oEyjU-x1fDJILA" continuedAt="Tb_Au_9HCw5oEyjU-x1fDJILA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Accrued expenses</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">As part of the process of preparing our consolidated financial statements, we are required to estimate our accrued expenses as of each balance sheet date. This process involves reviewing open contracts and purchase orders, communicating with our personnel to identify services that have been performed on our behalf and estimating the level </p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">86</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_Hlk94201402"></a><ix:continuation id="Tb_Ztqo9jWWIUua8VOE7WvLOQ_cont3" continuedAt="Tb_Ztqo9jWWIUua8VOE7WvLOQ_cont4"><ix:continuation id="Tb_Au_9HCw5oEyjU-x1fDJILA_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of the actual cost. We make estimates of our accrued expenses as of each balance sheet date based on facts and circumstances known to us at that time at the date of the preparation of the consolidated financial statements. There may be instances in which payments made to our vendors exceed the level of services provided, and result in prepayment reported under other current assets, which are subsequently expenses in the consolidated statement of operations when the related activity has been performed rather than when the payment is made. To date, there have been no material differences between our estimates of accrued expenses reported at each balance sheet date and the amounts actually incurred.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" name="us-gaap:PensionAndOtherPostretirementPlansPolicy" id="Tb__f3pX9Xl5UOH7cWY02gTbA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Pension obligations</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We operate defined benefit pension plan and defined contribution pension plans in accordance with local regulations and practices in the countries in which the Company operates. These plans are funded by regular contribution made by the employer and the employees. For defined benefit pension plan, the liability recognized in the consolidated balance sheets is the present value of the defined benefit obligation at the balance sheet date less the fair value of plan assets. The overfunded or underfunded status of the defined benefit plan is calculated as the difference between plan assets and the projected benefit obligations. Estimates are used in determining the assumptions incorporated in the calculation of the pension obligations, which is supported by input from independent actuaries. Actuarial gains and losses arising from experience adjustments and changes in actuarial assumptions are recognized in &#8220;Accumulated other comprehensive income (loss)&#8221; in the consolidated statements of equity and are charged or credited to income over the employees&#8217; expected average remaining working lives. The measurement date used for our employee benefit plan is December 31.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For defined contribution pension plans, the Company pays contributions to publicly or privately administered pension insurance plans on a mandatory, contractual or volutanry basis. The Company has no further payment obligations once the contributions have been paid. The contributions are recognized as employee benefit expense when they are due. </p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" name="us-gaap:CompensationRelatedCostsPolicyTextBlock" id="Tb_xVoYgGjVaEOyhReCE-2dLw" continuedAt="Tb_xVoYgGjVaEOyhReCE-2dLw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Equity-based Compensation and Warrants</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company applies the fair value method of measuring equity-based compensation and warrants, which requires an entity to measure the cost of services received in exchange for an award of equity instruments based on the grant-date fair value of the award. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company issues equity-based compensation with only service-based vesting conditions and record the expense for these awards using the straight-line method. The Company has not issued any stock-based awards with performance- or market-based vesting conditions.The Company recognizes the related costs in the consolidated statement of operations and as additional paid-in capital in the consolidated statement of shareholders&#8217; equity, in accordance with the vesting period during which the award recipients are required to provide services in exchange for the award. The Company accounts for forfeitures as they occur.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Before being a public company, given the absence of an active market for the Company&#8217;s common stock, the Company and the Board of Directors estimated the fair value of the Company&#8217;s common stock at the grant date determining the estimated fair value of the Company&#8217;s equity instruments based on a number of factors, including prices paid for the Company&#8217;s convertible preferred stock sold to outside investors in arm&#8217;s-length transactions; the Company&#8217;s stage of development; the fact that the grants of stock-based awards involved illiquid securities in a private company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The fair value of each stock option award is estimated on the date of grant using the Black-Scholes option pricing model. Given the absence of an active public market for the Company&#8217;s common stock prior to March 19, 2021, which was the first day of trading, the Company determined the volatility and the expected term for awards granted based on an analysis of reported data for a peer group of similar biopharmaceuticals companies that issued options with substantially similar terms. After the IPO, we continued to do so, and we expect not to change our methodology until such time as we will have reliable historical data regarding the volatility of our traded stock price and expected term of exercise patterns. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. The Company has not paid, and does not anticipate paying, cash dividends on our common stock; therefore, the expected dividend yield is assumed to be <ix:nonFraction unitRef="Unit_Standard_pure_YPFUW3Xga0mVMPZT28RXUw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_0JEx-N7nxEOplYgSWCGOgw" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Narr_qmM9_ZMSi0yEP93FxXaqFQ">zero</ix:nonFraction>.</p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">87</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_Ztqo9jWWIUua8VOE7WvLOQ_cont4" continuedAt="Tb_Ztqo9jWWIUua8VOE7WvLOQ_cont5"><ix:continuation id="Tb_xVoYgGjVaEOyhReCE-2dLw_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Black-Scholes option pricing model is also used for warrants issued, using consistent inputs and methodology to quantify such inputs, as described above in relation &#160;to equity-based compensation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The assumptions used in calculating the fair value of share-based awards and warrants represent management&#8217;s best estimates and involve inherent uncertainties and the application of management&#8217;s judgment. </p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="Tb_-ik0vbZwak-2fy-tYrvQMA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Revenue Recognition</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company derives revenues from collaboration and licensing agreements. The Company recognize revenue related to these agreements in accordance with&#160;ASC&#160;606, <i style="font-style:italic;">Revenues from contracts with customers</i> and ASC 808, <i style="font-style:italic;">Collaborative arrangements</i>. The terms of these arrangements typically include payment from third parties customers of one or more of the following: non-refundable initiation fee, reimbursement of development costs, development and regulatory milestone payments and royalties on net sales of the licensed product. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In determining the appropriate amount of revenue to be recognized as we fulfill our obligations, the Company applies the five steps model of ASC606: (i)&#160;identify the contract(s) with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when (or as) we satisfy a performance obligation. The Company only apply the five-step model to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods and services it transfers to the customer. If a contract is determined to be within the scope of ASC 606 at inception, the Company assesses the goods or services promised within such contract, determines which of those goods and services are performance obligations, and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Costs and revenues associated with collaborative arrangements are reported in the consolidated statements of operations on a gross basis when the counterpart is identified as being a customer, when the performance obligations incurred and rendered to fulfil the agreements are deemed to be in the ordinary course of the Company&#8217;s business, or when there is an expectation that the collaborative arrangement will result in a future constant flow of revenues in the form of sale of products, royalties or licenses.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" name="ganx:ResearchGrantsPolicyPolicyTextBlock" id="Tb_G0sFCQA0i0KDK8vMZN4uYA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Research grants</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the terms of the research and development grants awarded (such as those awarded by the The Michael J. Fox Foundation for Parkinson&#8217;s Research (MJFF) and The Silverstein Foundation for Parkinson&#8217;s Disease and from Innosuisse &#8211; Swiss Innovation Agency), we are entitled to receive reimbursement of our allowable direct expenses and payroll costs. Contributions from research and development activities under the grants are recorded based on management&#8217;s best estimate of the periods in which the related expenditures are incurred and activities performed and are classified in the statement of operations as a reduction to research and development expenses, measuring according to the time periods during which the research and development activities are carried out and related costs sustained.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="Tb_wUgzge6CDEi8YlgV4DCXTQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Research and development expenses</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company expenses all costs incurred in performing research and development activities. Research and development expenses include salaries and other related costs, materials and supplies, preclinical expenses, manufacturing expenses, contract services and other third-party expenses. </p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" name="us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock" id="Tb_UUuzElvrvESFLh2kBf3b8A" continuedAt="Tb_UUuzElvrvESFLh2kBf3b8A_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">General and administrative expenses</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">General and administrative expenses consist primarily of salaries, benefits and other related costs, for personnel and consultants in the Company&#8217;s executive and finance functions. General and administrative expenses also include professional fees for legal, finance, accounting, intellectual property, auditing, tax and consulting services, travel expenses and facility-related expenses, which include allocated expenses for rent and maintenance of facilities and other operating costs not otherwise included in research and development expenses.</p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">88</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_Ztqo9jWWIUua8VOE7WvLOQ_cont5" continuedAt="Tb_Ztqo9jWWIUua8VOE7WvLOQ_cont6"><ix:continuation id="Tb_UUuzElvrvESFLh2kBf3b8A_cont1"></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" name="us-gaap:IncomeTaxPolicyTextBlock" id="Tb_VFWPov0mYE-aVUog9uVA-Q" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Income taxes</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for income taxes under the liability method. Under this method deferred income tax liabilities and assets are determined based on the difference between the financial statement carrying amounts of assets and liabilities and the related tax basis using enacted tax rates in effect in the&#160;years in which the associated deferred taxes are expected to reverse. A valuation allowance is recorded if it is &#8220;more likely than not&#8221; that a portion or all of a deferred tax asset will not be realized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of each reporting date, the Company considers existing evidence, both positive and negative, that could impact its view with regards to future realization of deferred tax assets. In consideration of the start-up status of the Company, a full valuation allowance has been established to offset the deferred tax assets, as the related realization is currently uncertain. In the future, should management conclude that it is more likely than not that the deferred tax assets are partially or fully realizable, the valuation allowance will be reduced to the extent of such expected realization, and the corresponding amount will be recognized as income tax benefit in the Company&#8217;s consolidated statement of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company recognizes tax liabilities from an uncertain tax position if it is more likely than not that the tax position will not be sustained upon examination by the taxing authorities, based on the technical merits of the tax position. There are <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A" decimals="0" format="ixt-sec:numwordsen" name="ganx:UncertainTaxPositionsRecognized" scale="0" id="Narr_BytsCEf0Xkm3GMWsqZM9sQ">no</ix:nonFraction> uncertain tax positions that have been recognized in the accompanying consolidated financial statements.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="Tb_DW_lwz8FdEi18gKvjqC4OQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Fair value measurements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Company applies the following fair value hierarchy, which prioritizes the inputs used to measure fair value into three levels based on their observability in the market and degree of judgment involved:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:21.3pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:14.15pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 1&#160;&#8211; Quoted prices in active markets for identical assets or liabilities.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:21.3pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:14.15pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 2&#160;&#8211; Observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:21.3pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:14.15pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 3&#160;&#8211; Inputs that are generally unobservable and typically reflect management&#8217;s estimates of assumptions that market participants would use in pricing the asset or liability.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In determining fair value, we utilize valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and consider counterparty credit risk in their assessment of fair value.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="Tb_drMhfaBOf0Wm-1R_MUfKTg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Comprehensive income/(loss)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">Comprehensive income/(loss) is composed of net income(loss) and certain changes in stockholder&#8217;s equity that are excluded from the net income(loss), primarily foreign currency translation adjustments and defined benefit obligation adjustments.</span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" name="us-gaap:EarningsPerSharePolicyTextBlock" id="Tb_uQ3blQu5M0SWTR8jBD9BIw" continuedAt="Tb_uQ3blQu5M0SWTR8jBD9BIw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Net loss per share</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Basic net loss per share is computed by dividing the reported net loss by the weighted average number of shares of common stock outstanding during the period. The Company gives consideration to all potentially dilutive impacts, except where the effect of including such securities would be antidilutive. As of December 31, 2021, common stock equivalents consisted of stock options and warrants, while as of &#160;December 31, 2020, common stock equivalents consisted of the Series&#160;A preferred stock, Series B preferred stock, stock options and warrants. Because the Company has reported net losses since inception, these potential impacts would be anti-dilutive, and therefore common stock equivalents have been excluded from the computation, resulting in basic and diluted net loss per share being the same for all periods presented.</p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">89</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_Ztqo9jWWIUua8VOE7WvLOQ_cont6"><ix:continuation id="Tb_uQ3blQu5M0SWTR8jBD9BIw_cont1"></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="Tb_wx9nhncQRkCsFCZkhY1Hqg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Recently issued accounting pronouncements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that we adopt as of the specified effective date. We do not believe that the adoption of any recently issued standards have or may have a material impact on our consolidated financial statements or disclosures.</p></ix:nonNumeric></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" name="ganx:ResearchGrantsDisclosureTextBlock" id="Tb_1e-aTl6cHUaqdARUMtayag" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">3.&#160;&#160;&#160;&#160;Research Grants </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In December 2018 and in February 2019, our wholly owned subsidiary, GT Gain Therapeutics SA, obtained a research grants for a total amount of USD <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_2_28_2019_dei_LegalEntityAxis_ganx_GtGainTherapeuticsSaMember_srt_CounterpartyNameAxis_ganx_MichaelJ.FoxFoundationForParkinsonSResearchMjffMember_pOgW2epL9EG_XiGfjitJLQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GrantsReceivable" scale="0" id="Narr_5I7SQVuzbkOMpNPZ0T-jzA">186,956</ix:nonFraction> from The Michael J. Fox Foundation for Parkinson&#39;s Research (MJFF) and The Silverstein Foundation for Parkinson&#39;s disease with GBA to advance its proprietary non-competitive molecular chaperones for Parkinson&#39;s disease and research project &quot;therapeutic target of GCase enzyme in Parkinson&#39;s disease with novel pharmacological chaperones&quot;. Under the terms of the research and development grants awarded, we are entitled to receive reimbursement of our allowable direct expenses. As of December 31, 2021 and 2020, we recorded as reductions to research and development expenses of <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_ganx_GtGainTherapeuticsSaMember_srt_CounterpartyNameAxis_ganx_MichaelJ.FoxFoundationForParkinsonSResearchMjffMember__G2vs2A3Nk-gHqckeDfJ_w" decimals="0" format="ixt-sec:numwordsen" name="ganx:ReductionOfResearchAndDevelopmentExpensesThroughExpensesReimbursed" scale="0" id="Narr_2Ikunp3SekGTPAlO6rzZDA">nil</ix:nonFraction>, since the grant term terminated in 2020, &#160;and USD <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2020_To_12_31_2020_dei_LegalEntityAxis_ganx_GtGainTherapeuticsSaMember_srt_CounterpartyNameAxis_ganx_MichaelJ.FoxFoundationForParkinsonSResearchMjffMember__vvtnvxiGkihO0mrEzCOXQ" decimals="0" format="ixt:numdotdecimal" name="ganx:ReductionOfResearchAndDevelopmentExpensesThroughExpensesReimbursed" scale="0" id="Narr_uFpIc9VnLEySIQw9r5R5ig">98,318</ix:nonFraction>, respectively. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In July 2019, our wholly owned subsidiary, GT Gain Therapeutics SA, announced that, in a consortium with the Institute for Research in Biomedicine, Bellinzone (Switzerland) and Neuro-Sys SAS in Gardanne (France), it obtained a research grant of approximately USD <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_7_31_2019_dei_LegalEntityAxis_ganx_ConsortiumWithGtGainTherapeuticsSaInstituteForResearchInBiomedicineAndNeuroSysSasMember_srt_CounterpartyNameAxis_ganx_Eurostars2Member_rZtMNPgqTUK8vf9PccniAQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GrantsReceivable" scale="0" id="Narr_wFfZ1KChdEiw1l-A0Rv2pg">1,500,000</ix:nonFraction> from Eurostars-2 joint programme, with co-funding from the European Union Horizon 2020 research and Innosuisse &#8211; Swiss Innovation Agency. The contribution attributed to our subsidiary was CHF <ix:nonFraction unitRef="Unit_Standard_CHF_tZXBcOteZE6rGAnlVuK3Ng" contextRef="As_Of_7_31_2019_dei_LegalEntityAxis_ganx_GtGainTherapeuticsSaMember_srt_CounterpartyNameAxis_ganx_Eurostars2Member_bQ8j0nCuy0GId24-qC-Rwg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GrantsReceivable" scale="0" id="Narr_SBKmZZTrhkC4XTLqHzN_Pg">386,218</ix:nonFraction>, of which CHF <ix:nonFraction unitRef="Unit_Standard_CHF_tZXBcOteZE6rGAnlVuK3Ng" contextRef="Duration_7_1_2019_To_12_31_2019_dei_LegalEntityAxis_ganx_GtGainTherapeuticsSaMember_srt_CounterpartyNameAxis_ganx_Eurostars2Member_kHOQVkb_30--8vvOt4dYkQ" decimals="0" format="ixt:numdotdecimal" name="ganx:ProceedsFromGrants" scale="0" id="Narr_OyoObZgg_UuLFRLTkRCpaw">286,787</ix:nonFraction> was already received as of December 31, 2019. The funding will support the development of the drugs portfolio for the treatment of Gaucher Disease, GM1 Gangliosidosis, Mucopolysaccharidosis type 1 and Krabbe. Under the terms of the research and development grants awarded, we are entitled to receive reimbursement of our allowable direct expenses. As of December 31, 2021 and 2020, we recorded as reductions to research and development expenses USD <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_ganx_GtGainTherapeuticsSaMember_srt_CounterpartyNameAxis_ganx_Eurostars2Member_QdIjpEm0HEmiFVdv-rxIew" decimals="0" format="ixt:numdotdecimal" name="ganx:ReductionOfResearchAndDevelopmentExpensesThroughExpensesReimbursed" scale="0" id="Narr_QwTlZ31IE0mWQCcJFjiHNA">136,177</ix:nonFraction> and USD <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2020_To_12_31_2020_dei_LegalEntityAxis_ganx_GtGainTherapeuticsSaMember_srt_CounterpartyNameAxis_ganx_Eurostars2Member_3HTuGjlZh0OM3ztzJoNVeA" decimals="0" format="ixt:numdotdecimal" name="ganx:ReductionOfResearchAndDevelopmentExpensesThroughExpensesReimbursed" scale="0" id="Narr_ZEU05VbKG0eOIBGeqrPOHQ">151,230</ix:nonFraction>, respectively and receivables of USD <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_ganx_GtGainTherapeuticsSaMember_srt_CounterpartyNameAxis_ganx_Eurostars2Member_YNqIuW1F40W5tgg_Hji_3Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GrantsReceivable" scale="0" id="Narr_FNOvdvtG9kO34Uc3vTdhjQ">81,862</ix:nonFraction> and USD <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2020_dei_LegalEntityAxis_ganx_GtGainTherapeuticsSaMember_srt_CounterpartyNameAxis_ganx_Eurostars2Member_FaVauHMhk0mEw4Cnb7EatA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GrantsReceivable" scale="0" id="Narr_958npUTQPEijr6lKvDye5Q">51,665</ix:nonFraction>, respectively. The unrecognized portions of the grants are reported as deferred income on the consolidated balance sheet.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="Tc_hH676h6NtUqz3aTetUSk-A_1_2"></a><a id="Tc_7mJQNkcv-UmqiV2bdR2QEA_1_5"></a><a id="Tc_NGx6WEdOuEya72fBrK0WUw_2_2"></a><a id="Tc_moxjMZdd_US8Fq_cVmEhrg_2_5"></a><a id="Tc_izvRCQ8Kz0OSiQE41VJLyA_3_0"></a><a id="Tc_EYRdpKL95Ei94zj4CWAoAg_4_0"></a><a id="Tc_mr0jf5orNkio_4LUPOMJeA_5_0"></a><a id="Tc_MFQvwJoCdE2Ifp9CQIJEYw_5_2"></a><a id="Tc_xveF475wOEOUxz_Gr6ALeg_5_5"></a><a id="Tc_EOWqcwtw9kmFTKMKIgXpDQ_6_0"></a><a id="Tc_9YcvTee4l06kNvTb5B-sLw_6_2"></a><a id="Tc_hxi2KZ9ft0eYYut28PbjRA_6_5"></a><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" name="us-gaap:CashAndCashEquivalentsDisclosureTextBlock" id="Tb_6LvLYCBvske3ieJAyI159g" continuedAt="Tb_6LvLYCBvske3ieJAyI159g_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">4.&#160;&#160;&#160;&#160; Cash, cash equivalents and restricted cash</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company considers all short-term, highly liquid investments, with an original maturity of three&#160;months or less, to be cash equivalents. The Company&#8217;s cash and cash equivalents include short-term highly liquid investments which are readily convertible into cash. These investments relate to money market securities with maturities of three&#160;months or less when acquired. The Company&#8217;s institutional money market accounts permit daily redemption and the fair values of these investments are based upon the quoted prices in active markets provided by the holding financial institutions, which are considered Level 1 inputs in the fair value hierarchy (see note 12). Given their short-term maturities and the underlying being represented by cash equivalents, their face value amount approximate the related fair market value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has not experienced any losses in these accounts and does not believe it is exposed to any significant credit risk on cash and cash equivalents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Cash, cash equivalents and restricted cash are broken down as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" name="us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" id="Tb_qKbGTWsC6kyzHlH1bvGYXQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:67.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:67.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:top;width:67.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2021_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CashMember_fDDfSQp6UU-oqPAB4e119Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" id="Tc_F0905GiNWE2uHxaX09DGpA_3_3">3,262,977</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2020_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CashMember_hSR99mDOLk29CBNFU890Kw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" id="Tc_zTLCxCH3dUKghD2gmnvsBw_3_6">907,255</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:67.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Money Market</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2021_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_gnHItaHOm0WTAQXAM2HTwQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" id="Tc_OrtDDce51UOM6uIG2UxxBQ_4_3">33,617,696</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2020_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_YVDinHFXT0-dz2LLkYn02Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" id="Tc__Pd6I53eH0KogE7ji_w_xA_4_6">6,585,655</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:67.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" id="Tc_xlI_6gq9YkaWb-_RFeoPZA_5_3">36,880,673</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" id="Tc_TDEI3Pg_6kG6R29d3x7img_5_6">7,492,910</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:67.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RestrictedCash" scale="0" id="Tc_lfelnBciz0CrB5XAdNdydg_6_3">31,279</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RestrictedCash" scale="0" id="Tc_WhS1rUTbO0q-zaDPacSUsA_6_6">11,371</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Restricted cash refers to an amount required under our Lugano new office lease agreement and deposited into a restricted bank account as a guarantee for expenses to be incurred in case of damage to the premises noted at the termination of the lease. </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">90</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_evQ2xN2Zx024vkkbhC3rtA_1_2"></a><a id="Tc_A02rPfPO-UmVKFT-S1jx-w_1_4"></a><a id="Tc_9igJCpkGUEmwolTW_yzfcw_2_2"></a><a id="Tc_tGBclWqF9E6yFQgB0w6KVg_2_4"></a><a id="Tc_m1bHoZZLTkiN5aofF5QK8g_3_0"></a><a id="Tc_hosNkNWLvUySRkWLt7UeFA_4_0"></a><a id="Tc_F0FyyPxQtk-NOZYnWvbMyg_5_0"></a><ix:continuation id="Tb_6LvLYCBvske3ieJAyI159g_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Details of the cash and cash equivalents balances as of December 31, 2021 and 2020, broken down by currency in which the funds are denominated, are reported in the following table:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" name="ganx:ScheduleOfCashAndCashEquivalentsBalancesTableTextBlock" id="Tb__K6pXaL6Nk2ZAY7mxyGfcg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:69.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:top;width:69.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash in CHF</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2021_srt_CurrencyAxis_currency_CHF_rDufzY5Ouk6hLwlR1vAueQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="Tc_4YGpMDZ6CkKXnw1p21U6rA_3_2">157,310</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2020_srt_CurrencyAxis_currency_CHF_x9IJv5F-j0en4mIAdI3ZtA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="Tc_WKg3c9EMSki7g6-sTG6dCg_3_4">128,074</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:69.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash in EUR</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2021_srt_CurrencyAxis_currency_EUR_FPdG1lChOEK7NjX3VPs_Hw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="Tc_VvOuE2AhzEeCbwkmlwImGA_4_2">338,766</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2020_srt_CurrencyAxis_currency_EUR_jtopedrPUk-JApA2wqKkRg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="Tc_EDKFyyKQTkmtrL3d6H8fTQ_4_4">145,726</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:69.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash in USD</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2021_srt_CurrencyAxis_currency_USD_JNFtn3l03kGKX0UlySPmQQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="Tc_wZudlV1H-kqF-ye_38pWgA_5_2">36,322,777</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2020_srt_CurrencyAxis_currency_USD_MG28bHY0C0G-LS6iFm77lQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="Tc_EoK_F6oKeUmlUXrBvkpvVw_5_4">7,149,386</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:continuation><a id="Tc_sJgKR-5igEuc8IZsJAKCSQ_1_2"></a><a id="Tc_Zo7pdMO-lUuyD5eeOFCr7Q_1_5"></a><a id="Tc_jhFTkjgS6kyct7pY4h7Uow_2_2"></a><a id="Tc_Qeljod967k2ZcFNXQViGNw_2_5"></a><a id="Tc_7wR4oHCzqkmwr1a5k19r7w_3_0"></a><a id="Tc_Ko2uf5lmY0i_zRmbaLg9IQ_5_0"></a><a id="Tc_-TuwIMdTEU26dJPTHee4UA_6_0"></a><a id="Tc_26UvQll5iU6ozSVmpSnMhQ_7_0"></a><a id="Tc_l7sBZV5om0-uCjQuvKFpcQ_7_6"></a><a id="Tc_PFRhz9wbOE26GGGOLS3sqA_8_0"></a><a id="Tc_QYR1i9fRSUW4CzVtypQv0Q_8_2"></a><a id="Tc_XHgFNM-zAECsW5pKTR9-_w_8_5"></a><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" name="ganx:PrepaidExpensesAndOtherCurrentAssetsTextBlock" id="Tb_i_XnfVOSWUaYel-X7TiqmA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="font-style:italic;">5.&#160;&#160;&#160;&#160;Other Current Assets</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Other current assets consist of the following:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" name="ganx:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" id="Tb_ncTP1f4c4U6BA8X85MtN7w" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:73.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:top;width:73.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Tax Credits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxesAndOtherTaxReceivableCurrent" scale="0" id="Tc_IGbFUJlmkUaTSNpvFt7JiA_3_3">113,586</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxesAndOtherTaxReceivableCurrent" scale="0" id="Tc_xD5c11DBQ0-_PaHMswiLSQ_3_6">58,017</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:73.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepaid and deferred expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherPrepaidExpenseCurrent" scale="0" id="Tc_JHReo3_lJESt_iMuPLuYBw_5_3">498,252</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherPrepaidExpenseCurrent" scale="0" id="Tc_7e4higlzR0yUA-_CWJyXEg_5_6">198,994</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other receivable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherReceivablesNetCurrent" scale="0" id="Tc_oI-5iybrCkWq_K2wyFwwug_6_3">81,862</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:73.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepaid D&amp;O Insurance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PrepaidInsurance" scale="0" id="Tc_M5rdGESkA0awceJbPmIfsw_7_3">147,671</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total Prepaid expenses and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" id="Tc_zm7LmC1TskmuCYhbACqPVQ_8_3">727,785</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" id="Tc_BLXs1tcmg0uatBl5kleX-w_8_6">198,994</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Tax credit consist of a value added tax credit (&#8220;VAT&#8221;). It is an indirect tax receivables from Switzerland and Spain tax authorities on purchases of goods and services executed on those countries. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Prepaid expenses refers to pre-payments made to vendors for future services. Deferred expenses mainly refer to research agreements entered into with third parties for research projects that will be recognized as expenses throughout the research period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Prepaid D&amp;O insurance costs relate to insurance premium which will be recognized in the statement of operations on a monthly basis through the twelve months insurance period.</p></ix:nonNumeric><a id="Tc_j8aEhGVdzEaB6v3hCyVnnA_1_2"></a><a id="Tc_rmCohqbPZUyCA6XrMYgOaA_1_5"></a><a id="Tc_OVCnF28CfUe_jJsYQttT-Q_2_2"></a><a id="Tc_jovspDMBfEO_tKooR3vJZw_2_5"></a><a id="Tc_qIwVN31QdEeo6dCad-q-Pg_3_0"></a><a id="Tc_3NXNgKwTiEqJeG2xTdjekw_3_2"></a><a id="Tc_QfQnawEKRUGiT3v8S-25tA_3_5"></a><a id="Tc_hVAxmjXGk0ipDuEHogqAVw_4_0"></a><a id="Tc_r4fKR8TB5ESbvLXXhgb5mw_5_0"></a><a id="Tc_qcoQJVuH3ESkZL0h01pmFQ_6_0"></a><a id="Tc_ZqF2U-Qn60GxEzWCfoyCdA_7_0"></a><a id="Tc_eNYaCzo6-UmRkCkpjKO1TA_7_2"></a><a id="Tc_h3medC22pEqEMdTmhpDyvQ_7_5"></a><a id="Tc_q182UfWW9U2-ca-35jClWQ_8_0"></a><a id="Tc_ggqMyPYVb0exgF7cY1_E0w_9_0"></a><a id="Tc_8WM3MINsdUadhYeXGEHjlg_9_2"></a><a id="Tc_wQ5cEwRxN0CRGLEfDKQBJA_9_5"></a><a id="_777ffad5_c4dd_4395_83f5_44f98bface7d"></a><a id="_777ffad5_c4dd_4395_83f5_44f98bface7d_2"></a><a id="_777ffad5_c4dd_4395_83f5_44f98bface7d_3"></a><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="Tb_mZsstONLU0i55Pho_obTcQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">6.&#160;&#160;&#160;&#160;Property and Equipment, net</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Property and equipment, net, consists of the following<span style="font-size:11pt;">:</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="Tb_SFdxhCBKLk6z6iHuAHnChg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:69.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:69.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:top;width:69.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Computer</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_DEcpOGG1JU2_mxWcWch9wA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="Tc_bj3ZnH3GykuYwnqPUXzs1A_3_3">55,141</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_6bdG0fwN7EC_-yHkMAKyHQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="Tc_--r2l2xNBkenIhcYc_3_Iw_3_6">25,436</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:69.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Furniture and fixtures</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_-nBpIitRCkCtsIXc9x1o_w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="Tc_qllOGe5oG0KFY7cQKzbYGQ_4_3">42,148</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_K3apo3t_cUqHmQGcaov5QQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="Tc_Mv45sLdNXEqXEYJkyE3rDw_4_6">4,865</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:69.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_bbRnKwgINUGLy8vnaZzYFA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="Tc_KntTfNNtKE-v1nfBDyHRBQ_5_3">17,327</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_eLOEQvd7zk-xTusLDMYb_Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="Tc_ELgOyOXPHEGBB4qyh2C73w_5_6">8,889</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:69.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Laboratory instruments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ganx_LaboratoryInstrumentsMember_QYgSSMkkV06NDZOYiqbepA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="Tc__hcu3_ojHUel4OwUpaHlAQ_6_3">19,759</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ganx_LaboratoryInstrumentsMember_5du392y7_Ea3X3SOCPm2GA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="Tc_yqtQUu5YL06fP15WB7M0NQ_6_6">3,348</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:69.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total property and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="Tc_bEpFbj0Sqk2vT3O0frFoNg_7_3">134,375</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="Tc_SqbwdlcF3UinLTAmlQx6YQ_7_6">42,538</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:69.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: accumulated depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="0" id="Tc_p5U8Gxsk5kGn6jHTJ8q8Ww_8_3">28,389</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="0" id="Tc_2t7-it3RQEqtVkLNIq8WwQ_8_6">12,905</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:69.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" id="Tc_qytVinA5a0un60TseU-CBg_9_3">105,986</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" id="Tc_moe2kl1w7kOw9wy-OJadLw_9_6">29,633</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Property and equipment mainly consist of computers and set-up of a conference room in our Spanish and Lugano offices. <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2020_To_12_31_2020_JDEb6LtAmEuXGmEieWNlsw" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:PropertyPlantAndEquipmentDisposals" scale="0" id="Narr_GMKwXE_nREuir94cRA2NZg"><ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:PropertyPlantAndEquipmentDisposals" scale="0" id="Narr__wq9a95Ya0yOtuy_XpCCXA">No</ix:nonFraction></ix:nonFraction> disposals, nor impairments occurred during the periods. Depreciation has been calculated by taking into consideration the use, purpose and financial-technical duration of the assets, based on their estimated economic lives.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Depreciation expense for the year ended December 31, 2021, and 2020 was USD <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="0" id="Narr_BbbhvEV5s0eM1tlixu2GcQ">15,484</ix:nonFraction> and USD <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2020_To_12_31_2020_JDEb6LtAmEuXGmEieWNlsw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="0" id="Narr_QZQ4wFy_X0yy1lNS12oB2g">9,592</ix:nonFraction>, respectively.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" name="us-gaap:LesseeOperatingLeasesTextBlock" id="Tb_so6A4nWfL02HCwH3RyQa6w" continuedAt="Tb_so6A4nWfL02HCwH3RyQa6w_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">7.&#160;&#160;&#160;&#160;Operating lease. Right of use (&#8220;ROU&#8221;) assets</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Our leased assets include offices in Bethesda, Lugano and Barcelona and a lab in Barcelona. Our current lease portfolio consists of leases with remaining terms ranging from <span style="-sec-ix-hidden:Hidden_ZalXIiQg2kKnz87xVmLaUQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">three</span></span> to <ix:nonNumeric contextRef="As_Of_12_31_2021_srt_RangeAxis_srt_MaximumMember_Tv-_F37-xki1Z4qnJJZcNg" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" id="Narr_yIQu0ZocnUqFO_ZK4eoB-Q">five years</ix:nonNumeric>. Renewal options are excluded </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">91</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_swFQ-HBtRUSNhDLql7b2EA_1_2"></a><a id="Tc_-icTjOLruEam7JwfUs_eKg_1_5"></a><a id="Tc_JzESqUgNwEidx-fOV-99UA_2_2"></a><a id="Tc_s-C5qYB9SEmfE-Cor-2oHw_2_5"></a><a id="Tc_YQHYCfyXjUetvZ8XK5MLiw_3_0"></a><a id="Tc_RfmDBjstlka3bpSr0C8sAg_4_0"></a><a id="Tc_mGA4k2ect02Y_3QwJe0Rtw_4_2"></a><a id="Tc_XB-XJtkUsUOTSLXh4BYVJg_4_5"></a><a id="Tc_76_vq8ouxUiYSo2upgBDPg_6_0"></a><a id="Tc_UU6IuThpm0eAW-qc-2L0eQ_6_2"></a><a id="Tc_IziTU3E7uUeW47g2M1fadQ_6_5"></a><a id="Tc_QyzDHJeinEiBu8FhBbMV-g_7_0"></a><a id="Tc_xlbWwbRMlUKmfx2M0HA-4A_7_2"></a><a id="Tc_pH5NJQdHqUKyVF_ZSIS5ug_7_5"></a><a id="Tc_FgUxiMFHA0mcZeuNL8fNJA_8_0"></a><a id="Tc_Pltwzd2OukSB8tP4XEiAWw_9_0"></a><a id="Tc_uhLnTZqkJES_uq3k1IXFKw_1_2"></a><a id="Tc_PudrNdXkF0aXFXX-e2IdVQ_1_4"></a><a id="Tc_neUpn62oTkCuXmlmNgub_A_2_2"></a><a id="Tc_jpSjAdOJDU-oDGH3Manxlw_2_4"></a><a id="Tc_P21mQFeMU0WYolfOYeYW3w_3_0"></a><a id="Tc_U7nKwIP_LU2iS0U-xZvegQ_3_1"></a><a id="Tc_vcuuL0Jh80WHEe3iZjoVfw_3_3"></a><ix:continuation id="Tb_so6A4nWfL02HCwH3RyQa6w_cont1" continuedAt="Tb_so6A4nWfL02HCwH3RyQa6w_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">from our calculation of lease liabilities unless we are reasonably certain that we will exercise the renewal option. Our lease agreements do not contain residual value guarantees or material restrictive covenants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On June 1, 2021, the Company entered into a <ix:nonNumeric contextRef="As_Of_6_1_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ganx_OfficeSpaceViaSoaveN6LuganoSwitzerlandMember_PifC1TMuyUCNw5rbo-bIqg" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="Narr_fE-Nja0KCUWqPhFUr02FAA">five year</ix:nonNumeric> operating lease agreement to lease office space in Via Soave, n.6 in Lugano, Switzerland. The lease agreement is renewable for additional <ix:nonNumeric contextRef="As_Of_6_1_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ganx_OfficeSpaceViaSoaveN6LuganoSwitzerlandMember_PifC1TMuyUCNw5rbo-bIqg" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="Narr__8xl1VjBCUm_HRSAsRjnAg">five years</ix:nonNumeric>. The Company is required to pay for operating costs, including heating and water, which are adjusted and billed yearly based on usage. These additional charges are considered variable lease costs and are recognized in the period in which the costs are incurred. In connection with the lease, as guarantee for any damages claimed by the lessor, the Company deposited into a restricted bank account CHF <ix:nonFraction unitRef="Unit_Standard_CHF_tZXBcOteZE6rGAnlVuK3Ng" contextRef="As_Of_6_1_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ganx_OfficeSpaceViaSoaveN6LuganoSwitzerlandMember_PifC1TMuyUCNw5rbo-bIqg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RestrictedCash" scale="0" id="Narr_Ck7Ih-dWOEetK5-rTq9Hyg">28,500</ix:nonFraction> or USD <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_6_1_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ganx_OfficeSpaceViaSoaveN6LuganoSwitzerlandMember_PifC1TMuyUCNw5rbo-bIqg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RestrictedCash" scale="0" id="Narr_OpSFyVbR80q0b6SYWEG9Nw">31,279</ix:nonFraction> classified as restricted cash. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On August 31, 2021, the <ix:nonNumeric contextRef="Duration_8_31_2021_To_8_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ganx_OfficeSpaceViaPietroPeri9DLuganoSwitzerlandMember_KKvzTiG970Ce6TsWGr7BeA" format="ixt-sec:durwordsen" name="ganx:LesseeOperatingLeaseTermOfCancelledContract" id="Narr_1BiVECrBX0axW_QNefK85g">three year</ix:nonNumeric> operating lease agreement to lease office space in Via Pietro Peri, 9D Lugano, Switzerland terminated and CHF <ix:nonFraction unitRef="Unit_Standard_CHF_tZXBcOteZE6rGAnlVuK3Ng" contextRef="As_Of_8_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ganx_OfficeSpaceViaPietroPeri9DLuganoSwitzerlandMember_DFphXJwj90K3f5xEo5ZU9Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RestrictedCash" scale="0" id="Narr_X3aLH-8Q9kK2cSIJV-McUQ">10,500</ix:nonFraction> or USD <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_8_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ganx_OfficeSpaceViaPietroPeri9DLuganoSwitzerlandMember_DFphXJwj90K3f5xEo5ZU9Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RestrictedCash" scale="0" id="Narr_OUbprBISfE6PICLND56ZMA">11,371</ix:nonFraction> deposited into a restricted bank account were remitted to the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On October 1, 2021, the Company entered into a <ix:nonNumeric contextRef="As_Of_10_1_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ganx_OfficeSpaceInBethesdaMarylandMember_UeSQeDvOw0SJcAM-RLo4Lg" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="Narr_lgK2cRZwlkGhU5xWXOE_jg">three year</ix:nonNumeric> operating lease agreement to lease office space in Bethesda, Maryland. In connection with the lease, the Company paid a security deposit of USD <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_10_1_2021_To_10_1_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ganx_OfficeSpaceInBethesdaMarylandMember_9U2vOl3u9U-cCfj_ThszJA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInSecurityDeposits" scale="0" id="Narr_F8CZ2Q47T0S46iEEvN3nDg">5,227</ix:nonFraction>, classified as deposit in non-current assets, for the performance of all obligations, covenants and conditions and agreements under the lease. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On November 1, 2021, the Company entered into a <ix:nonNumeric contextRef="As_Of_11_1_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ganx_OfficeSpaceTorreDBuildingBarcelonaMember_irdsQ60cnEm7ZZpQvK104Q" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="Narr_71q7uSgs_ESEDurvkQVc_Q">five-years</ix:nonNumeric> new operating lease agreement in Torre D Building with Parc Cientific de Barcelona for larger office space of <ix:nonFraction unitRef="Unit_Standard_sqft_u3pgKg_7-0iwjFi0GwLPFg" contextRef="As_Of_11_1_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ganx_OfficeSpaceTorreDBuildingBarcelonaMember_irdsQ60cnEm7ZZpQvK104Q" decimals="0" format="ixt:numdotdecimal" name="ganx:OfficeSpace" scale="0" id="Narr_Va_baf6gHE2vOfyZTZJUoQ">1,417</ix:nonFraction> square feet to accommodate the Company&#8217;s continued continuos growth and contemporaneosly terminated a lease, entered in October 2020, in Torre I Building for <ix:nonFraction unitRef="Unit_Standard_sqft_u3pgKg_7-0iwjFi0GwLPFg" contextRef="As_Of_11_1_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ganx_OfficeSpaceTorreIBuildingBarcelonaMember_iI-D9SSrGEKpT_zGFsqoww" decimals="0" format="ixt:numdotdecimal" name="ganx:OfficeSpace" scale="0" id="Narr_ZA6zUiibQk2Q6qtkJQ41nw">830</ix:nonFraction> square feet. In connection with the Torre D Building lease, the Company paid a security deposit of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_Q6wJYXg2bk-dYmARpDyDyQ" contextRef="Duration_11_1_2021_To_11_1_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ganx_OfficeSpaceTorreDBuildingBarcelonaMember_b34IOdjLSEeVrGT01vF1Rg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInSecurityDeposits" scale="0" id="Narr_eIyuX1zRQEyVzfBlvwwblQ">4,325</ix:nonFraction> or USD <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_11_1_2021_To_11_1_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ganx_OfficeSpaceTorreDBuildingBarcelonaMember_b34IOdjLSEeVrGT01vF1Rg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInSecurityDeposits" scale="0" id="Narr_kAM2IACHrEyPnBavKjG7gg">4,918</ix:nonFraction> classified as deposit in non-current assets. The Company is required to pay for operating costs, including general services, scientific services, utilities, waste management services and taxes, which are billed monthly based on the Company&#39;s share of the total rentable square footage. These additional charges are considered variable lease costs and are recognized in the period in which the costs are incurred. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Operating leases are reflected on our balance sheet as operating lease ROU assets and the related current and non-current operating lease liabilities. ROU assets represent the right to use an underlying asset for the lease term, and lease liabilities represent the obligation to make lease payments arising from the lease agreement. Operating lease ROU assets and liabilities are recognized at the commencement date, or the date on which the lessor makes the underlying asset available for use, based upon the present value of the lease payments over the respective lease term. Lease expense is recognized on a straight-line basis over the lease term. Variable lease costs such as common area maintenance, property taxes and insurance are expensed as incurred.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The breakdown of the significant components of ROU assets and lease liabilities as of December 31, 2021 and 2020 is reported in the table below, together with the discount rate used in order to calculate the net present value of the lease liabilities as of those periods.</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" name="us-gaap:OperatingLeaseLeaseIncomeTableTextBlock" id="Tb_wottwxrP3EmMgz-nEVBEJg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:69.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:top;width:69.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating Lease</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:69.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease- right of use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" id="Tc_eeMa8kwcxUy79nNOy0CXbA_4_3">901,042</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" id="Tc_f9YkC3lD9kag_VwjeB97rw_4_6">523,080</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:69.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:69.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease liability - current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" id="Tc_DWYudpPjJkWe6x4w9MxoLQ_6_3">219,137</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" id="Tc_feZ7Fq3IHkWuTisWh40Jdw_6_6">122,756</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:69.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease liability - non current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" id="Tc_djbiVFT9W0GxbrLx4feS4w_7_3">695,053</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" id="Tc_SHkwERY0A0SW8HlqF-htog_7_6">400,324</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:69.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average remaining lease term - years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><ix:nonNumeric contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="Tc_Q09evtjwxUKGLwfJd7sOKw_8_3"> 4</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><ix:nonNumeric contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="Tc_86ZmHtrSAkyDZvVd-s_Wuw_8_6"> 5</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:69.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average discount rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_YPFUW3Xga0mVMPZT28RXUw" contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A" decimals="4" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="Tc__gpY5vxm5kSSZQ45uBMTgg_9_3">1.86</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_YPFUW3Xga0mVMPZT28RXUw" contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg" decimals="4" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="Tc_LENh6kth6UKEBj2Eic_YCg_9_6">3.61</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The components of the lease costs which are included in the consolidated statements of operations and comprehensive loss were as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" name="us-gaap:LeaseCostTableTextBlock" id="Tb_um6JfueeGE2rOElK0vhe7w" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:69.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:top;width:69.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseExpense" scale="0" id="Tc_Vn8t0l5klUKUB5wx8zOpOw_3_2">191,329</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2020_To_12_31_2020_JDEb6LtAmEuXGmEieWNlsw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseExpense" scale="0" id="Tc_8siX9EmKGU6N2Jss0QNNwQ_3_4">121,800</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">92</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_0wLL4w8SWUqcmW7zsq9CMQ_1_0"></a><a id="Tc_BntvLqswn02I0aSpjS1hQA_1_2"></a><a id="Tc_WUlyKO8AhE6I_beEJ2-iwg_2_0"></a><a id="Tc_nE_WBCVbsE-QiiHAERZYFg_2_1"></a><a id="Tc_-v5nN763LkCqIoyq3ALA8Q_3_0"></a><a id="Tc_XQZ9SULpfkimUZDVxrFivw_4_0"></a><a id="Tc_ANV-5_2fckCLnLH4KVsghw_5_0"></a><a id="Tc_kASKsH-z5ECUq4SDLq0w7g_6_0"></a><a id="Tc_BBjUGbaCsEazhZXkWjQb7A_7_0"></a><a id="Tc_gPZN0LGE60asOXhmAVVIZg_7_2"></a><a id="Tc_tr4ZrqZXyUO_MzgLDCI5Mw_8_0"></a><a id="Tc_yZWcnA4t_0yPe_cxvzxHzw_9_0"></a><a id="Tc_O4mq4Rxq7Uu0TUKm9s-Zkw_10_0"></a><a id="Tc_CgPCRRQohEyy7uYbtfXzMA_10_1"></a><ix:continuation id="Tb_so6A4nWfL02HCwH3RyQa6w_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The future minimum lease payments for the Company&#8217;s operating leases as of December 31, 2021, were as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="Tb_0liG3joA0kawcNrSDsvGDQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:68.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:27.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Fiscal Year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Operating Leases</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent" scale="0" id="Tc_wpKxb19O90GlLN1CJw3IfQ_2_2">237,926</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears" scale="0" id="Tc_TsmY8iide0Kr_OwyTVd3fw_3_2">245,685</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears" scale="0" id="Tc_ciOI_D75s0ymeY6Ul8JkpQ_4_2">227,115</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears" scale="0" id="Tc_US42PjNLR0qbcMGJV9QoXQ_5_2">167,526</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears" scale="0" id="Tc_KStTtO8OXUSUEwVJiHqfCA_6_2">58,738</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total future minimum lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDue" scale="0" id="Tc_DtDiRSzxIkSbJCyo5mpLBA_8_2">936,990</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less amount representing interest or imputed interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A" decimals="0" format="ixt:numdotdecimal" name="ganx:AdjustmentToReconcileOperatingLeaseLiabilitiesAmountsRepresentingInterestOrImputedInterest" scale="0" id="Tc_bGXzbcshzEi3kCO1uhJ8pA_9_2">22,800</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Present value of lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.99%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="0" id="Tc_-AbFyk8hZEWUdnVnBMQN6Q_10_2">914,190</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="Tc_4OzbfLX3JEytOhMiote3FQ_1_2"></a><a id="Tc_p27t8r1rhk2wJ71HOdow3w_1_4"></a><a id="Tc_oBdQeOELRECZtID4n7BABg_2_2"></a><a id="Tc_ISRZgoo3BUqLTMICnxa9bw_2_4"></a><a id="Tc_CDgQG_rxKE2amwkBv3rBZA_3_0"></a><a id="Tc_hICjUpI6X02C1eXskm1Ymw_4_0"></a><a id="Tc_zodzFbfBa0e-AEGXdHQBMg_5_0"></a><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" id="Tb_iIYti8xjLEuOdu3NkwcYuQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">8.&#160;&#160;&#160;&#160;Accounts Payable</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Accounts payable are reported at their nominal value. Accounts payable refer to amounts due to third parties on outstanding invoices received before year-end for services already provided. As of December 31, 2021 and 2020, accounts payable amounted to USD <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="0" id="Narr_9HQlerwGfkKFH-yDbLj0wg">560,479</ix:nonFraction> and USD <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="0" id="Narr_veyM_szFp0Kgple76P93wg">961,516</ix:nonFraction>, respectively. All accounts payable are due in less than 12&#160;months. Details of the vendor outstanding payables as of December&#160;31, 2021 and 2020, broken down by currencies in which they are denominated, are reported in the following table:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" id="Tb_Z1LO0i-DsUCQbB5Wu16hcg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:69.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:top;width:69.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Vendors Payables in CHF</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2021_srt_CurrencyAxis_currency_CHF_rDufzY5Ouk6hLwlR1vAueQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="0" id="Tc_b99HSFjJWkyLSuwUYWvb9w_3_2">13,166</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2020_srt_CurrencyAxis_currency_CHF_x9IJv5F-j0en4mIAdI3ZtA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="0" id="Tc_XvD3ptXY4EK3AIsVdMn_Hw_3_4">29,423</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:69.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Vendors Payables in EUR</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2021_srt_CurrencyAxis_currency_EUR_FPdG1lChOEK7NjX3VPs_Hw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="0" id="Tc_Z5aIJ26C20qlrJ4twHGRCQ_4_2">309,378</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2020_srt_CurrencyAxis_currency_EUR_jtopedrPUk-JApA2wqKkRg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="0" id="Tc_FkINQAN_yUSAlaOYpjruhw_4_4">202,223</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:69.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Vendors Payables in USD</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2021_srt_CurrencyAxis_currency_USD_JNFtn3l03kGKX0UlySPmQQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="0" id="Tc_G1bafZFjWE663P6BfAIg1Q_5_2">197,045</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2020_srt_CurrencyAxis_currency_USD_MG28bHY0C0G-LS6iFm77lQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="0" id="Tc_D2h8S7ZMFE6poP7jWnJpJw_5_4">673,600</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><a id="Tc_gelpR9P5H0mebhWCV9-UZQ_1_2"></a><a id="Tc_A42GTiXI-0KTcHUxtSxlMQ_1_5"></a><a id="Tc_7bmIXn3_akqVlk3QMyuafg_2_2"></a><a id="Tc_JeDK3O2QmUaF3bXOm-ivtg_2_5"></a><a id="Tc_G1BZur_Gh0Wo6UGX6RCqIg_3_0"></a><a id="Tc_ownrS52Sskij_O_wSKSYyw_3_2"></a><a id="Tc_8TqJkil3P0GGnVEPdDbMvA_3_5"></a><a id="Tc_I2bIrGhwdki3rNDK9H6Ipw_4_0"></a><a id="Tc_UU4_rIiIFU6ljd6aBh9sgw_5_0"></a><a id="Tc_YKqRHi28hEKGsrcTLtJTKA_6_0"></a><a id="Tc_L87TuTtEXEi4LFV4YKiF4g_7_0"></a><a id="Tc_JuayY0ht00mxsq8ozfmSKg_7_3"></a><a id="Tc_EPRmSQJZOkqPAl9bfGoJzw_8_0"></a><a id="Tc_LVSA6sCZSE2mji5wcT7fSg_8_2"></a><a id="Tc_WXs8eXP98U-bcVghMGyZ5g_8_5"></a><a id="Tc_JW9HsY6_6UKRoy5Fg4obRw_9_0"></a><a id="Tc_Mn4CWQvvQkeVIf6FSUmuJQ_10_0"></a><a id="Tc_lbJ15spxcECpBXmxz4PgHw_10_2"></a><a id="Tc_BfQrBA4sHkSmH5DYV5kWAQ_10_5"></a><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" name="ganx:OtherCurrentLiabilitiesAndDeferredIncomeTextBlock" id="Tb_GdVxgpmlqkOIwJ1D0HoiBQ" continuedAt="Tb_GdVxgpmlqkOIwJ1D0HoiBQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">9.&#160;&#160;&#160;&#160;Other current liabilities and deferred income</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Other current liabilities and deferred income consist of the following as of December&#160;31, 2021 and 2020:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" name="ganx:OtherCurrentLiabilitiesAndDeferredIncomeTableTextBlock" id="Tb_zxdPKAoiRE64wSeK_4xkDQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:68.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:top;width:68.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Payable for social securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A" decimals="0" format="ixt:numdotdecimal" name="ganx:PayableForSocialSecuritiesCurrent" scale="0" id="Tc_UlgCY1u_HE2LdqVC0LlgHg_3_3">255,068</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg" decimals="0" format="ixt:numdotdecimal" name="ganx:PayableForSocialSecuritiesCurrent" scale="0" id="Tc_71QMOSOmAkeXWT7bPfGv7Q_3_6">88,334</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:68.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued payroll</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A" decimals="0" format="ixt:numdotdecimal" name="ganx:AccruedPayrollCurrent" scale="0" id="Tc_23CUyiuC70ezm_Ql4i9JgA_4_3">465,382</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg" decimals="0" format="ixt:numdotdecimal" name="ganx:AccruedPayrollCurrent" scale="0" id="Tc_d7hTBiQPi02wgfKfRhWfMA_4_6">294,469</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:68.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="0" id="Tc_CBxpdbO_UkuTqiAdySzF-w_5_3">681,770</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="0" id="Tc_--QVmTV5f0-LeyossGcetQ_5_6">379,270</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:68.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Tax provision</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TaxesPayableCurrent" scale="0" id="Tc_4ZNbKdMr00aLbFElUDDWkQ_6_3">380</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TaxesPayableCurrent" scale="0" id="Tc_moemJHcFv0mkfyx2k6bEsQ_6_6">1,070</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:68.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deposit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg" decimals="0" format="ixt:numdotdecimal" name="ganx:DepositsCurrent" scale="0" id="Tc_IARNZ_JJhEehmTFry7-HYg_7_6">5,307</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:68.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">  Total Other Current Liabilities</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesCurrent" scale="0" id="Tc_8PCoD2ykEEWI0B2pOclPGA_8_3">1,402,600</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesCurrent" scale="0" id="Tc_vqWCFcmTgEegUaH5kKWlkQ_8_6">768,450</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:68.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeCurrent" scale="0" id="Tc_TasHfvyq30qlXp01rwYHXA_9_3">266,504</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeCurrent" scale="0" id="Tc_Rt9e3katTkalqsTzmd-u3w_9_6">239,483</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:68.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">  Total Other Current Liabilities and Deferred Income</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredCreditsAndOtherLiabilitiesCurrent" scale="0" id="Tc_FioXV412bEiq5k7QvY74mA_10_3">1,669,104</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredCreditsAndOtherLiabilitiesCurrent" scale="0" id="Tc_gr90dxSVMkKJTfXo7vjisw_10_6">1,007,933</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Payables for social securities refer to amounts due to social securities and employees withholding tax. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Accrued payroll refers to accruals for year-end bonuses, accrued vacations and extra-hours including social security charges, to be paid to employees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Accrued expenses refer to invoices to be received from vendors for services performed and not yet billed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Deferred income mainly refers to research grants received and, as of December 31, 2021, to a collaboration agreement entered into with Zentalis. Deferred income will be recognized in the consolidated statement of operations in accordance with the costs sustained.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">93</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_GdVxgpmlqkOIwJ1D0HoiBQ_cont1"></ix:continuation><a id="_e85096ac_7045_4815_8549_43f7d9e13ade"></a><a id="Tc_FDPCrf5Es0yQMohvLcuzsw_1_2"></a><a id="Tc_01gPD1l5i0-GxE3owuODxw_1_5"></a><a id="Tc_hEkYOPArhkGufc-Nsefj1A_2_2"></a><a id="Tc_O9NFvZ5S9U2F0NcAgABPVQ_2_5"></a><a id="Tc_G9xd0UePPE6MY7xcMiSPuw_3_0"></a><a id="Tc_pDL5qwSuBEWS3qx75XlyGQ_4_0"></a><a id="Tc_QBOAlOiFx0qtNnCmNaLb8Q_4_2"></a><a id="Tc_hL0GDpS61EOyrAzZFSuukQ_4_5"></a><a id="Tc_81bbaDgvIkWFtLq9SsazCw_5_0"></a><a id="Tc_t89ItaKcIEWJjS_Oxk8eTA_6_0"></a><a id="Tc_BW190Q1wmEWDl-8D7Vmu1g_6_2"></a><a id="Tc_tHhQf7w1QEuFWGDrr7jgUA_6_5"></a><a id="Tc_vQj__AdK3U2sikavntxFGw_8_0"></a><a id="Tc_J97NA1PMGE-2OZ99FzAMQw_10_0"></a><a id="Tc_sOGLfjGeoEq1RBXmkdAJVQ_11_0"></a><a id="Tc_pX2og4e_W0SMhXUXXAzuag_11_2"></a><a id="Tc_g_hYyrblQkOxkbHweVkE2w_11_5"></a><a id="Tc__Ha_nZYB_Ei0VK-TZT5aFw_12_0"></a><a id="Tc_HxubOk1pFEOdTxNMZIH2iw_13_0"></a><a id="Tc_dMf5uwq5pE-Sy208H-Y_xA_14_0"></a><a id="Tc_e6MwXmiuL0-Lum0yqi5NAg_15_0"></a><a id="Tc_h2PjEEBeOEeabFBgXKFKzg_16_0"></a><a id="Tc_Uji4ihvv7kCwz5yxGdaxkQ_16_2"></a><a id="Tc_D5W5nOGx_UamvE-l6Zqcbg_16_5"></a><a id="Tc_EerAY_Wy7EifB2V-YgDAaQ_18_0"></a><a id="Tc_Lckp9IuaZUSJ1Z8OMglI2w_19_0"></a><a id="Tc_Eo4alegQMUKLg9JE93CxBw_19_2"></a><a id="Tc_SVyZW147p0GLlwbqsjeFSg_19_5"></a><a id="Tc_kobhe3Ybsk-5l7jRGHlqsw_20_0"></a><a id="Tc_tlZgmLttoU6MW-Jous0JAg_21_0"></a><a id="Tc_mjEsvmfNqE6b0fiFbsquOw_22_0"></a><a id="Tc_dHAAS-IWX0GiHN2-zTasQA_23_0"></a><a id="Tc_h28zwbTpl0aWsZ4WOCG7gA_23_6"></a><a id="Tc_RdpFPwj6O0W7uXkUVykKDg_24_0"></a><a id="Tc__uSO5jKHk0qc3rQj-TDGTA_24_2"></a><a id="Tc_noQU16sdkkC0I4W5LBMWVA_24_5"></a><a id="Tc_r_tksG1gRkW1tbHNQLI3tg_26_0"></a><a id="Tc_X5b1c38WtEC3VlVOfaSmCg_28_0"></a><a id="Tc_4I1BgFJeI0erFhKEWbDW0A_29_0"></a><a id="Tc_Bi-kxlNWRUy7OnBxscl-xA_29_2"></a><a id="Tc_uRDA9GfBlUq9LpJ16gUlFQ_29_5"></a><a id="Tc_R7-4uGfmDEyqjPUCNnJ0_A_30_0"></a><a id="Tc_FbcDl4Qft0Oa2eFAd5fvPA_31_0"></a><a id="Tc_mjNtkcjCPkqmqWDANMuoZQ_32_0"></a><a id="Tc_9mNjmrsugUe8eq9gtxyM3Q_33_0"></a><a id="Tc__lOHoZlfHUaA36eyte6A9A_34_0"></a><a id="Tc_YhR0aRRItES_iqx9SzvdOQ_35_0"></a><a id="Tc_Y4A6dXLQW0Gue8dg9wFBDw_35_6"></a><a id="Tc_HPP9rosiRUqy6bT4I1mJhA_36_0"></a><a id="Tc_N5BngpS6qUmHUaqjtVbXIw_37_0"></a><a id="Tc_4WeC5konPk-Bhy65MxriKw_37_6"></a><a id="Tc_93xqMAMupUqxxIiRl0oigg_38_2"></a><a id="Tc_WdE99BcvUUOWkxwne6Fa4g_38_5"></a><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="Tb_cUf1gTgbbUWJ1_DNWqkIAg" continuedAt="Tb_cUf1gTgbbUWJ1_DNWqkIAg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">10.&#160;&#160;&#160;&#160;Pension obligations</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" name="us-gaap:ScheduleOfDefinedBenefitPlansDisclosuresTextBlock" id="Tb_SYsvhMeC_0C9in7Y10fbkw" continuedAt="Tb_SYsvhMeC_0C9in7Y10fbkw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Net pension obligations related to the Company&#8217;s defined pension plan refer only to Swiss employees and as of December&#160;31, 2021 and 2020, can be summarized as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">End of year funed status:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Fair value of plan assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2021_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_i6PZAoMNcEySLcgBUKmmjw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="0" id="Tc_Q27ZdDWE0kq53DyMQHFXgg_4_3">943,025</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2020_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_HLv731xR10GVgI0Jt-JL5w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="0" id="Tc_edSNlr6Yn0ScXmoEopVshg_4_6">477,288</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">(Projected benefit obligation)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2021_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_i6PZAoMNcEySLcgBUKmmjw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanBenefitObligation" scale="0" id="Tc_JLi6GcGp4kyOwi6K3vREmg_5_3">1,272,483</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2020_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_HLv731xR10GVgI0Jt-JL5w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanBenefitObligation" scale="0" id="Tc_oPHfv3JRIUyZKWMwcg0EPQ_5_6">648,846</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Funded status</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2021_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_i6PZAoMNcEySLcgBUKmmjw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFundedStatusOfPlan" sign="-" scale="0" id="Tc_FzjJ3rggdk23d421YxMTiA_6_3">329,458</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2020_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_HLv731xR10GVgI0Jt-JL5w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFundedStatusOfPlan" sign="-" scale="0" id="Tc_avwiyMdFGU2PuFpZsApe7w_6_6">171,558</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accumululated benefit obligation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2021_us-gaap_RetirementPlanSponsorLocationAxis_country_CH_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_JNWw1VrK5kqfZgK60b8Pdw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation" scale="0" id="Tc_xFRQcVo8BEKX1D8PRWk8-Q_8_3">1,233,053</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2020_us-gaap_RetirementPlanSponsorLocationAxis_country_CH_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_XR8N6cpyV0WdwjyDiJrSbA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation" scale="0" id="Tc_nbRwcoA0cUG3xRVArH4HYg_8_6">652,445</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Reconciliation of funded status:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Funded status beginning of year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2020_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_HLv731xR10GVgI0Jt-JL5w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFundedStatusOfPlan" sign="-" scale="0" id="Tc_WbzBZubPZU6n-3kSaBhWtw_11_3">171,558</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2019_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_t7HEGl5NAk-CsgC95XNoeg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFundedStatusOfPlan" sign="-" scale="0" id="Tc_kdmpSoAEE0OaTkqAC2dUlg_11_6">126,629</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_kMW3hEdOQk-Go8nyyVufvA" decimals="0" format="ixt:numdotdecimal" name="ganx:IncreaseDecreaseThroughTotalExpensesToReconcileFundedStatusOfDefinedBenefitPlan" scale="0" id="Tc_l89hIsdCX0CDZKL2WthIJQ_12_3">144,146</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_NLtbBeqGQESB9Jjk98teAA" decimals="0" format="ixt:numdotdecimal" name="ganx:IncreaseDecreaseThroughTotalExpensesToReconcileFundedStatusOfDefinedBenefitPlan" scale="0" id="Tc_-cGqCHkoD06oTiuvmkXj6A_12_6">44,474</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Employer contribution</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_kMW3hEdOQk-Go8nyyVufvA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" scale="0" id="Tc_H98mdQEYTkunfdoAdqNCWQ_13_3">88,819</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_NLtbBeqGQESB9Jjk98teAA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" scale="0" id="Tc_8BIlCqxFckqJtxWvCByaBw_13_6">36,264</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Translation differences</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_kMW3hEdOQk-Go8nyyVufvA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" scale="0" id="Tc_biu970vIU0uoAXh9PLDVwQ_14_3">1,437</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_NLtbBeqGQESB9Jjk98teAA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" scale="0" id="Tc_jKZm6CerR0mjAtmbHHgh8w_14_6">501</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Change in AOCI over the year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_kMW3hEdOQk-Go8nyyVufvA" decimals="0" format="ixt:numdotdecimal" name="ganx:IncreaseDecreaseInAccumulatedOtherComprehensiveIncomeToReconcileFundedStatusOfDefinedBenefitPlan" scale="0" id="Tc_OxZ6MgT3SESpuxghwuwt5g_15_3">101,136</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_NLtbBeqGQESB9Jjk98teAA" decimals="0" format="ixt:numdotdecimal" name="ganx:IncreaseDecreaseInAccumulatedOtherComprehensiveIncomeToReconcileFundedStatusOfDefinedBenefitPlan" scale="0" id="Tc_wxP239XwikSdrfxVZu-Qwg_15_6">36,218</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Funded status at end of year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2021_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_i6PZAoMNcEySLcgBUKmmjw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFundedStatusOfPlan" sign="-" scale="0" id="Tc_F8Et3vUy_k-EJGHgeOB6ig_16_3">329,458</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2020_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_HLv731xR10GVgI0Jt-JL5w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFundedStatusOfPlan" sign="-" scale="0" id="Tc_MuhG19vO60igGDbaEO2s8Q_16_6">171,558</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Component of net periodic pension costs:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Service cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_kMW3hEdOQk-Go8nyyVufvA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanServiceCost" scale="0" id="Tc_Q2KToW-kk0yaGVREX2TvyA_19_3">132,809</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_NLtbBeqGQESB9Jjk98teAA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanServiceCost" scale="0" id="Tc_P-tuIj0hlEC5S6W40OtcRw_19_6">36,597</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Interest cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_kMW3hEdOQk-Go8nyyVufvA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanInterestCost" scale="0" id="Tc_pqS1fb4QekS8tx10IyXYHw_20_3">1,318</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_NLtbBeqGQESB9Jjk98teAA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanInterestCost" scale="0" id="Tc_ml2wl2GYGk-3m0twJtdx_A_20_6">947</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Expected return on plan assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_kMW3hEdOQk-Go8nyyVufvA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="0" id="Tc_ZlkW842UJUuzu0Fb5CgJGg_21_3">5,558</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_NLtbBeqGQESB9Jjk98teAA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="0" id="Tc_4k3uYO1FcEuZmekLPyNXsw_21_6">3,564</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Amortization of (gain)/losses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_kMW3hEdOQk-Go8nyyVufvA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" sign="-" scale="0" id="Tc_QsbaJNvfJ0qrPmcas9cUgw_22_3">16,212</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_NLtbBeqGQESB9Jjk98teAA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" sign="-" scale="0" id="Tc_RB815e35JU6kdWLnezqVTw_22_6">10,494</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Amortization of prior service cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_kMW3hEdOQk-Go8nyyVufvA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" sign="-" scale="0" id="Tc_o24YiHME8UyhuUJIkYTmCw_23_3">635</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_kMW3hEdOQk-Go8nyyVufvA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="0" id="Tc_XSpZ4ldgH06u26D9kK600A_24_3">144,146</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_NLtbBeqGQESB9Jjk98teAA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="0" id="Tc_sGPfURTQ1k6tflgF1flEsA_24_6">44,474</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="7" style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Service cost is reported in research and development and general and administrative expenses. All other components of net period costs are reported in interest income, net in the consolidated statement of operations</p></td></tr><tr><td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Reconciliation of projected benefit obligation:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Projected benefit obligation at January 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2020_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_HLv731xR10GVgI0Jt-JL5w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanBenefitObligation" scale="0" id="Tc_k6OGlJcHHUSG8bnlATdMUg_29_3">648,846</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2019_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_t7HEGl5NAk-CsgC95XNoeg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanBenefitObligation" scale="0" id="Tc_endUBZjkYECjJub7BTRUmQ_29_6">496,819</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Services cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_kMW3hEdOQk-Go8nyyVufvA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanServiceCost" scale="0" id="Tc_eVoyLG9a90mBgJILROJaAA_30_3">132,809</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_NLtbBeqGQESB9Jjk98teAA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanServiceCost" scale="0" id="Tc_YK9NZsYGgUmzxGAde_llCg_30_6">36,597</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Employee contribution</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_kMW3hEdOQk-Go8nyyVufvA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant" scale="0" id="Tc_kRqyBjnIDEGIf2UNLPMN3g_31_3">59,208</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_NLtbBeqGQESB9Jjk98teAA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant" scale="0" id="Tc_lDWCwa8o_Ea_PCJ29ZASNg_31_6">25,770</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Interest Cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_kMW3hEdOQk-Go8nyyVufvA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanInterestCost" scale="0" id="Tc_eBHfeObnbEKz1nzpXmAGIg_32_3">1,318</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_NLtbBeqGQESB9Jjk98teAA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanInterestCost" scale="0" id="Tc_8PkUNfLX_UC_EQiYtO1ZRg_32_6">947</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Benefit payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_kMW3hEdOQk-Go8nyyVufvA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid" scale="0" id="Tc__vpIz_tfN0a-BsGLyyRIsw_33_3">315,300</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_NLtbBeqGQESB9Jjk98teAA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid" scale="0" id="Tc_aa-kej0dh0KuT3JSj6MnRA_33_6">48,602</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"> (Gain)/loss on financial assumption</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_kMW3hEdOQk-Go8nyyVufvA" decimals="0" format="ixt:numdotdecimal" name="ganx:DefinedBenefitPlanBenefitObligationGainsLossesOnFinancialAssumptions" scale="0" id="Tc_119fa-jbB06gA5BBKTKqsA_34_3">27,799</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_NLtbBeqGQESB9Jjk98teAA" decimals="0" format="ixt:numdotdecimal" name="ganx:DefinedBenefitPlanBenefitObligationGainsLossesOnFinancialAssumptions" sign="-" scale="0" id="Tc_RQbOIsCRNkmipdbhohHfyw_34_6">4,379</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"> (Gain)/loss on demographic assumption</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_kMW3hEdOQk-Go8nyyVufvA" decimals="0" format="ixt:numdotdecimal" name="ganx:DefinedBenefitPlanBenefitObligationGainsLossesOnDemographicAssumptions" scale="0" id="Tc_TVuyNCX2mkiPrO123XsOfg_35_3">43,123</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"> (Gain)/loss on experience</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_kMW3hEdOQk-Go8nyyVufvA" decimals="0" format="ixt:numdotdecimal" name="ganx:DefinedBenefitPlanBenefitObligationGainsLossesOnExperience" sign="-" scale="0" id="Tc_RrArjlZMFUSn30wwMp3TYQ_36_3">193,984</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_NLtbBeqGQESB9Jjk98teAA" decimals="0" format="ixt:numdotdecimal" name="ganx:DefinedBenefitPlanBenefitObligationGainsLossesOnExperience" sign="-" scale="0" id="Tc_nncm7njGoUivy9uPwz9RKQ_36_6">35,732</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">    Plan Amendement</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_kMW3hEdOQk-Go8nyyVufvA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanPlanAmendments" sign="-" scale="0" id="Tc_XQej1CiMnUaBj4gk5dM9XA_37_3">8,060</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2021_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_i6PZAoMNcEySLcgBUKmmjw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanBenefitObligation" scale="0" id="Tc_FMucpMDwCUuKgd_htq0b2Q_38_3">1,272,483</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2020_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_HLv731xR10GVgI0Jt-JL5w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanBenefitObligation" scale="0" id="Tc_DSxj91DiwkGDPYDS6Uh9Eg_38_6">648,846</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">94</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_2f3b5465_da1e_4f79_b4a6_a31e3a083cf1"></a><a id="Tc_XfliPEHFUk-PQcAmAH3ZYA_1_2"></a><a id="Tc_Wxl1394ESUKtyXKgEc1gwg_1_5"></a><a id="Tc_NsY_-NTN60-f9x0Goe33CA_2_2"></a><a id="Tc_V3f1P79qmkm9Y0-PJN5kJg_2_5"></a><a id="Tc_IJGc6SkK40avhCH3Ahz8Dw_3_0"></a><a id="Tc_kh8E_9x56UCcsUVZnibjWA_4_0"></a><a id="Tc_9uwbsuPk_0uuM4EpG-dafA_4_2"></a><a id="Tc_vi_QqfQQc0WxJxUUTytsaA_4_5"></a><a id="Tc_j__snWtKTkObyqn3K2qBCQ_5_0"></a><a id="Tc_KUmxTMqKK0SE86Oiy1e4EA_6_0"></a><a id="Tc_ii0tkmQsIkicJX96wxxuqw_7_0"></a><a id="Tc_pBMo6lRfZUullVcGULndWQ_8_0"></a><a id="Tc_R2DO0TNUTUaNCpulW8p3kg_9_0"></a><a id="Tc_3dGFvw38pEOejvP_DpLwzA_10_0"></a><a id="Tc_Z7SoJvNo4kqzFA9TUOMOpw_10_3"></a><a id="Tc_bhHNOASlekq16jf-1WWB3A_11_0"></a><a id="Tc_YWwoirlLIEuCmQPNls00xg_11_2"></a><a id="Tc_Z4YqC2-UrUGfwIIV5AdKhw_11_5"></a><a id="_60bf1897_1176_40bd_acbf_817bd04524a8"></a><a id="Tc_1aUalRk44UqOmxmjelVNAQ_1_2"></a><a id="Tc_ohViV8wKN0iEm0a0kj-_ZQ_1_5"></a><a id="Tc_b7MEKR_dvkuFMAYDCO-fZQ_2_2"></a><a id="Tc_MINlZT6vFkOcxGJei6UYIw_2_5"></a><a id="Tc_0cg4svbwvECKcdBhzohQkw_3_0"></a><a id="Tc_6cxoNrYT0UC7Pz8zWlxkCw_4_0"></a><a id="Tc_zy3BktsjZUu6QAxjjybPQQ_4_2"></a><a id="Tc_vMTpr7Cc60yaL9n_et_cHQ_4_5"></a><a id="Tc_n1DFYJ1cwUK6PyHDA3bdHw_5_0"></a><a id="Tc_OtuNUUE52EKmhWc_uEyHnQ_6_0"></a><a id="Tc_Uror_NHz8k--BBj8o9r1Gw_7_0"></a><a id="Tc_HYgw-V3K2kmm1NqI3CL2zw_8_0"></a><a id="Tc_hyJLz6RTX0Cq6bkYs4t4vg_8_2"></a><a id="Tc_ic4FZlM1TkekS7Z_Wp3X_Q_8_5"></a><a id="_dce27a11_644d_4b69_8de6_9b1d6fb614b9"></a><a id="Tc_KFYlCH8rXUy7evCTouUKIg_1_2"></a><a id="Tc_2Jv30-Heok-VyIbJSoe_Gg_1_5"></a><a id="Tc_MG8YBhmDoUi1r1EUSz3Ghg_2_2"></a><a id="Tc_B3-BNcEkfEqftqgENeuuVw_2_5"></a><a id="Tc_FVXUZ4mzyEWz94keslQBvw_3_0"></a><a id="Tc_X1DOUEaQh0eic5TJpmTfxw_4_0"></a><a id="Tc_e97EQEgYukeV1LeYnGZYmg_4_2"></a><a id="Tc_bY72VQCoX0eGYAZQnIkkBQ_4_5"></a><a id="Tc_-TdIIkjZJ0SDLl0O4uYPkw_5_0"></a><a id="Tc_UOMR5Yz_TEy8Cc0nb2OE6w_6_0"></a><a id="Tc_dIqYXAcMQUuaua3GqrtUqw_7_0"></a><a id="Tc_aLTjHn5MYUGVwWIazKSE3Q_8_0"></a><a id="Tc_a3WOqFzBrU-u8vXjQuPgWA_8_6"></a><a id="Tc_GNrLf_kVpkSlvxn8Kc7K9g_9_0"></a><a id="Tc_AeEgcQp8_0W-L0bDMakihw_9_6"></a><a id="Tc_TeWjmRLKBUaInlmWu2NAwA_10_0"></a><a id="Tc_OAB_M3EBXU-DmNTsPgn0-A_10_2"></a><a id="Tc_X0ovdFh3Lk6HAK5cS38Muw_10_5"></a><a id="_ed5d2156_f8a7_434b_9e40_d3ed6c7fc93d"></a><a id="Tc_xtzQsCL_g0eme2JaX3z11A_1_2"></a><a id="Tc_RczoScM6vEu5eY-Vw4Ct6g_1_5"></a><a id="Tc_qaJ-nyOJ7kCfGVVlhptu-w_2_2"></a><a id="Tc_1LunQn3wT0iC2m_X8fVATg_2_5"></a><a id="Tc_9WyDf0mN3UOMAyiwEqXmZQ_3_0"></a><a id="Tc_y5HAAwLg406CLwGx5WifvQ_4_0"></a><a id="Tc_gzrxl36dcUyFIR6AsbzqXg_5_0"></a><a id="Tc_burNy-Ae2keJX2vVbYvMRA_6_0"></a><a id="Tc_cjlnNCV-TUCkTq5SkJu32g_7_0"></a><a id="Tc_7_0cStytuk-iNAcf4Bv0XA_8_0"></a><a id="Tc_wDSG3QjAqkquB9cRiqj5Rw_9_0"></a><a id="Tc_4wMll1uTr0ajmB8b58uJ8Q_10_0"></a><a id="Narr_aAOFcW6vr0CCBPj11lS0pQ"></a><a id="Tc_5ZsCscqJeECNIfp-0tux5Q_10_3"></a><a id="Narr_E2bOwtW2zEyYvBvpUBpQug"></a><a id="Tc_jcSN_nP9GEWg1qc0vnlgMA_10_6"></a><a id="Tc_HiH3cXkvdkKYN5sseoLIDA_11_0"></a><a id="Tc_hMtfK_EGIEC3Qkd1r1Rnvw_11_3"></a><a id="Tc_lDmQW9LOhEmdoYfcgEAyjw_12_0"></a><a id="Tc_aB1leP1Gc0C_b8FCaJe4tQ_12_3"></a><a id="Tc_vqIL4kC6J0ib_9esJZILNw_12_6"></a><a id="Tc_Rwe-w_neiUGHcDTWLt6YCQ_13_0"></a><a id="Tc_hE7T1Y1rukmyn3lJAD2gQQ_13_3"></a><a id="Tc_ceFsPGUNsUSCJ0Altw133g_13_6"></a><a id="Tc_Fl5cmv70vUyhAKVZh7dw4A_14_0"></a><a id="Tc_Iq9xPPxZK0aly-h_6w0clg_14_3"></a><a id="Tc_1nvyUWryJ0yMboBe_OKsfQ_14_6"></a><a id="Tc_TD_BoXYH206emrciCS7HKA_15_0"></a><a id="Tc_g7SYHxjk30eC3j8O7eHD7g_15_3"></a><a id="Tc_otYLDxxO3UuAJobVJSjOpw_15_6"></a><a id="Tc_ke13DwP-d0qSB6p5YCwEWw_16_0"></a><a id="Tc_v97wQvYoBkCPfhGllSEJxQ_16_3"></a><a id="Tc_e9HoT6Zp5kC3nazot2uLvA_16_6"></a><ix:continuation id="Tb_cUf1gTgbbUWJ1_DNWqkIAg_cont1" continuedAt="Tb_cUf1gTgbbUWJ1_DNWqkIAg_cont2"><ix:continuation id="Tb_SYsvhMeC_0C9in7Y10fbkw_cont1"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Reconciliation of fair value of plan assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Fair value at January 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2020_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_HLv731xR10GVgI0Jt-JL5w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="0" id="Tc_lKTtwSEZ0kaSeAOv8tVyIQ_4_3">477,288</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2019_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_t7HEGl5NAk-CsgC95XNoeg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="0" id="Tc_jy-rfbr7cU-bjuFQ6UoLPw_4_6">370,190</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Expected return on plan assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_kMW3hEdOQk-Go8nyyVufvA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="0" id="Tc_xsHG3l4tGk2vIJ-9yj8DRA_5_3">5,558</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_NLtbBeqGQESB9Jjk98teAA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="0" id="Tc_DaR2VpVeUU2fwssheLDq-Q_5_6">3,564</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Gain/(loss) on plan assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_kMW3hEdOQk-Go8nyyVufvA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets" sign="-" scale="0" id="Tc_LnDXr4gVakac_H3nbbZ_xw_6_3">3,148</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_NLtbBeqGQESB9Jjk98teAA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets" sign="-" scale="0" id="Tc_thRv21BGg02dhQoe8Q_tog_6_6">9,454</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Employer contributions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_kMW3hEdOQk-Go8nyyVufvA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" scale="0" id="Tc_tiCBSbzAok-KvGf-BUIfdA_7_3">88,819</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_NLtbBeqGQESB9Jjk98teAA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" scale="0" id="Tc_p8S1t2FIzkGJHGtJGyZR3A_7_6">36,264</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Employee contributions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_kMW3hEdOQk-Go8nyyVufvA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant" scale="0" id="Tc_9mrzLOPri0WQCcobXqq_Ew_8_3">59,208</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_NLtbBeqGQESB9Jjk98teAA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant" scale="0" id="Tc_u_PHpAtmEUaSnYgIjPaD5w_8_6">25,770</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Benefit payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_kMW3hEdOQk-Go8nyyVufvA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid" scale="0" id="Tc_3aoNo-mOLES2NyINiZADYA_9_3">315,300</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_NLtbBeqGQESB9Jjk98teAA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid" scale="0" id="Tc_f7d8DBBhDUuQEbdU-e0r1w_9_6">48,602</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Others</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_NLtbBeqGQESB9Jjk98teAA" decimals="0" format="ixt:numdotdecimal" name="ganx:DefinedBenefitPlanPlanAssetsOtherIncreasesDecreases" scale="0" id="Tc_N_wF6a5oiUe0GOymxvkhkg_10_6">2,352</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Fair value at December 31</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2021_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_i6PZAoMNcEySLcgBUKmmjw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="0" id="Tc_5PblzWlbD0SZ5jwmFvJl-w_11_3">943,025</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2020_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_HLv731xR10GVgI0Jt-JL5w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="0" id="Tc_D67DQMgZZEiIwMKRWIxA_Q_11_6">477,288</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change in net (gain)/loss:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">(Gain)/loss at beginning of year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2020_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_HLv731xR10GVgI0Jt-JL5w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax" scale="0" id="Tc_eBcy3cwKY0mXoTxmKhPCHw_4_3">154,665</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2019_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_t7HEGl5NAk-CsgC95XNoeg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax" scale="0" id="Tc_yGDXDMKK-U-FuHdJnsizQw_4_6">117,803</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">(Gain)/loss on PBO during year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_kMW3hEdOQk-Go8nyyVufvA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanBenefitObligationPeriodIncreaseDecrease" scale="0" id="Tc_RRIAmsKskEKxBWTzHUEQmw_5_3">122,895</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_NLtbBeqGQESB9Jjk98teAA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanBenefitObligationPeriodIncreaseDecrease" scale="0" id="Tc_8AykUM7MiEmXHyDYocUfCA_5_6">37,902</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">(Gain)/loss on assets during year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_kMW3hEdOQk-Go8nyyVufvA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssetsPeriodIncreaseDecrease" scale="0" id="Tc_MSiNe4eHk06sTMF2F8AlCQ_6_3">3,148</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_NLtbBeqGQESB9Jjk98teAA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssetsPeriodIncreaseDecrease" scale="0" id="Tc_Zy8VpYcPcUu7c6sn68-8Dw_6_6">9,454</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Amortization of gain/(loss)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_kMW3hEdOQk-Go8nyyVufvA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" sign="-" scale="0" id="Tc_linhj_S0UkqEdMbLx5AJNg_7_3">16,212</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_NLtbBeqGQESB9Jjk98teAA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" sign="-" scale="0" id="Tc_ipwaBlI32keSOuMnDWorCg_7_6">10,494</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">(Gain)/loss at end of year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2021_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_i6PZAoMNcEySLcgBUKmmjw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax" scale="0" id="Tc_b4a2Kd07_kyCGFJmQDyh4A_8_3">264,496</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2020_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_HLv731xR10GVgI0Jt-JL5w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax" scale="0" id="Tc_SSXxdcMQMEmdgbzXj6P67g_8_6">154,665</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Change in accumulated other comprehensive income (AOCI):</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">AOCI at beginning of year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2020_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_HLv731xR10GVgI0Jt-JL5w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax" scale="0" id="Tc_DeTjN0Ij3kqn3sBGHREJTQ_4_3">154,665</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2019_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_t7HEGl5NAk-CsgC95XNoeg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax" scale="0" id="Tc_9Zr93sF5TkSjrv8tUprw2Q_4_6">117,803</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Net gain/(loss) amortized</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_kMW3hEdOQk-Go8nyyVufvA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" sign="-" scale="0" id="Tc_iMmG1vCnOU2WRJWzisXQXw_5_3">16,212</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_NLtbBeqGQESB9Jjk98teAA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" sign="-" scale="0" id="Tc_cZKgW90G90mgFJqlqSw2Mw_5_6">10,494</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">(Gain)/loss on PBO during the year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_kMW3hEdOQk-Go8nyyVufvA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanBenefitObligationPeriodIncreaseDecrease" scale="0" id="Tc_rJJX5XaPKEqQASUr_pRqcg_6_3">122,895</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_NLtbBeqGQESB9Jjk98teAA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanBenefitObligationPeriodIncreaseDecrease" scale="0" id="Tc_5wnK_CQQ-UOUv_W1gaca1w_6_6">37,902</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">(Gain)/loss on assets during the year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_kMW3hEdOQk-Go8nyyVufvA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssetsPeriodIncreaseDecrease" scale="0" id="Tc_IhwFSN3XZU2p4zrfRHx88g_7_3">3,148</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_NLtbBeqGQESB9Jjk98teAA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssetsPeriodIncreaseDecrease" scale="0" id="Tc_j_QeWjGgq0u1HniS6Oxouw_7_6">9,454</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Prior Service Cost/(credit) occurring over the year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_kMW3hEdOQk-Go8nyyVufvA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" sign="-" scale="0" id="Tc_KCKG5lloBkufYWJklrDf7g_8_3">8,060</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Net prior service (cost)/credit amortized</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_kMW3hEdOQk-Go8nyyVufvA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" sign="-" scale="0" id="Tc_JdW0RTUfJUiuTZXol8-ImA_9_3">635</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total AOCI at end of year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2021_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_i6PZAoMNcEySLcgBUKmmjw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax" scale="0" id="Tc_jmjlGNk2dECxnbsSCQPXoQ_10_3">255,801</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2020_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_HLv731xR10GVgI0Jt-JL5w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax" scale="0" id="Tc_wDLH0rLmBky8pIPBYDZQgg_10_6">154,665</ix:nonFraction></p></td></tr></table></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" name="us-gaap:ScheduleOfAssumptionsUsedTableTextBlock" id="Tb_DEk84f5zB0WCftFOI40W-A" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The assumptions used in the determination of the benefit obligation and the plan assets for the pension plans and the pension obligation were as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:60.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:top;width:60.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Actuarial Assumptions (%pa):</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:60.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Discount rate </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_YPFUW3Xga0mVMPZT28RXUw" contextRef="As_Of_12_31_2021_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_i6PZAoMNcEySLcgBUKmmjw" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" scale="-2" id="Tc_VH1CRsihlkiNeJvEBkPYgg_4_3">0.30</ix:nonFraction>%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_YPFUW3Xga0mVMPZT28RXUw" contextRef="As_Of_12_31_2020_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_HLv731xR10GVgI0Jt-JL5w" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" scale="-2" id="Tc_Y1h4Oe9jxkeeeIuatt105g_4_6">0.15</ix:nonFraction>%</p></td></tr><tr><td style="vertical-align:top;width:60.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Interest credit rate / ERoA </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_YPFUW3Xga0mVMPZT28RXUw" contextRef="As_Of_12_31_2021_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_i6PZAoMNcEySLcgBUKmmjw" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate" scale="-2" id="Tc_wv3ZtiwWU0isps8SqY_Bbw_5_3">1.00</ix:nonFraction>%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_YPFUW3Xga0mVMPZT28RXUw" contextRef="As_Of_12_31_2020_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_HLv731xR10GVgI0Jt-JL5w" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate" scale="-2" id="Tc_ISFz4rSNT0qwsK2gHfR6pg_5_6">1.00</ix:nonFraction>%</p></td></tr><tr><td style="vertical-align:top;width:60.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Salary increases </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_YPFUW3Xga0mVMPZT28RXUw" contextRef="As_Of_12_31_2021_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_i6PZAoMNcEySLcgBUKmmjw" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" scale="-2" id="Tc_r2wJyP8frk-uRBhRy0lnhw_6_3">1.00</ix:nonFraction>%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_YPFUW3Xga0mVMPZT28RXUw" contextRef="As_Of_12_31_2020_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_HLv731xR10GVgI0Jt-JL5w" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" scale="-2" id="Tc__b4Y0oSY9kanVjg0T1PErQ_6_6">1.00</ix:nonFraction>%</p></td></tr><tr><td style="vertical-align:top;width:60.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Pension increases </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_YPFUW3Xga0mVMPZT28RXUw" contextRef="As_Of_12_31_2021_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_i6PZAoMNcEySLcgBUKmmjw" decimals="4" format="ixt:numdotdecimal" name="ganx:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfPensionIncreases" scale="-2" id="Tc_4msnr7ebPUq3H4EL-fAPDw_7_3">0.00</ix:nonFraction>%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_YPFUW3Xga0mVMPZT28RXUw" contextRef="As_Of_12_31_2020_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_HLv731xR10GVgI0Jt-JL5w" decimals="4" format="ixt:numdotdecimal" name="ganx:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfPensionIncreases" scale="-2" id="Tc_nCVA5kXG-UKsyoB4qtGG7A_7_6">0.00</ix:nonFraction>%</p></td></tr><tr><td style="vertical-align:top;width:60.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Demographic Assumptions:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:60.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Lump-sum option </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_YPFUW3Xga0mVMPZT28RXUw" contextRef="As_Of_12_31_2021_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_i6PZAoMNcEySLcgBUKmmjw" decimals="2" format="ixt:numdotdecimal" name="ganx:DefinedBenefitPlanDemographicAssumptionLumpSumOption" scale="-2" id="Tc_bBpzcjIs1E6KZz5d7Aoj6g_9_3">25</ix:nonFraction>%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_YPFUW3Xga0mVMPZT28RXUw" contextRef="As_Of_12_31_2020_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_HLv731xR10GVgI0Jt-JL5w" decimals="2" format="ixt:numdotdecimal" name="ganx:DefinedBenefitPlanDemographicAssumptionLumpSumOption" scale="-2" id="Tc_wHC97_YHEE65oocgyGJflg_9_6">25</ix:nonFraction>%</p></td></tr><tr><td style="vertical-align:top;width:60.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Retirement age </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">65/64</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">65/64</p></td></tr><tr><td style="vertical-align:top;width:60.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Proportion married </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">.BVG 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_YPFUW3Xga0mVMPZT28RXUw" contextRef="As_Of_12_31_2020_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_HLv731xR10GVgI0Jt-JL5w" decimals="4" name="ganx:DefinedBenefitPlanDemographicAssumptionProportionMarried" scale="-2" id="Tc_CNmBlHjYFkyWxyOo8nin9Q_11_6">.80</ix:nonFraction>%</p></td></tr><tr><td style="vertical-align:top;width:60.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Allowance for child pensions </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:17.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_YPFUW3Xga0mVMPZT28RXUw" contextRef="As_Of_12_31_2021_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_i6PZAoMNcEySLcgBUKmmjw" decimals="2" format="ixt:numdotdecimal" name="ganx:DefinedBenefitPlanDemographicAssumptionAllowanceForChildPensions" scale="-2" id="Narr_GjSdlzjjWkeI0hw2ivpIew">5</ix:nonFraction>% loading on risk benefits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:17.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_YPFUW3Xga0mVMPZT28RXUw" contextRef="As_Of_12_31_2020_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_HLv731xR10GVgI0Jt-JL5w" decimals="2" format="ixt:numdotdecimal" name="ganx:DefinedBenefitPlanDemographicAssumptionAllowanceForChildPensions" scale="-2" id="Narr_QClPknMHMUqNxbmI05bKNQ">5</ix:nonFraction>% loading on risk benefits</p></td></tr><tr><td style="vertical-align:top;width:60.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Mortality base table </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">.BVG 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">.BVG 2015</p></td></tr><tr><td style="vertical-align:top;width:60.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Longevity improvement </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">CMI 2018 (<ix:nonFraction unitRef="Unit_Standard_pure_YPFUW3Xga0mVMPZT28RXUw" contextRef="As_Of_12_31_2021_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_i6PZAoMNcEySLcgBUKmmjw" decimals="4" format="ixt:numdotdecimal" name="ganx:DefinedBenefitPlanMortalityImprovementPercentage" scale="-2" id="Narr_DPdsoM8yL0-jVrrGV-Rlbg">1.25</ix:nonFraction>%)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">CMI 2016 (<ix:nonFraction unitRef="Unit_Standard_pure_YPFUW3Xga0mVMPZT28RXUw" contextRef="As_Of_12_31_2020_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_HLv731xR10GVgI0Jt-JL5w" decimals="4" format="ixt:numdotdecimal" name="ganx:DefinedBenefitPlanMortalityImprovementPercentage" scale="-2" id="Narr_e1_wR1H6nk2O41DkvzTmbw">1.25</ix:nonFraction>%)</p></td></tr><tr><td style="vertical-align:top;width:60.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Turnover </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">.BVG 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">.BVG 2015</p></td></tr><tr><td style="vertical-align:top;width:60.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Disability </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_YPFUW3Xga0mVMPZT28RXUw" contextRef="As_Of_12_31_2021_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_i6PZAoMNcEySLcgBUKmmjw" decimals="4" format="ixt:numdotdecimal" name="ganx:DefinedBenefitPlanDisabilityPercentage" scale="-2" id="Narr_2V4W0DYv40WtPGFbbM3PXw">80</ix:nonFraction>%.BVG 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_YPFUW3Xga0mVMPZT28RXUw" contextRef="As_Of_12_31_2020_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_HLv731xR10GVgI0Jt-JL5w" decimals="4" format="ixt:numdotdecimal" name="ganx:DefinedBenefitPlanDisabilityPercentage" scale="-2" id="Narr_Ap-OhTCxmkmurgybqH-ahQ">80</ix:nonFraction>% BVG 2015</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" name="us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock" id="Tb_aEhD-AMUIUiMnH4ux2xpSw" continuedAt="Tb_aEhD-AMUIUiMnH4ux2xpSw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">95</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_phe3gldHS0KKsMJOsBzkig_1_3"></a><a id="Tc_uJBKd3pRnU2hJALJr1rOoQ_1_6"></a><a id="Tc_DHif4b9LqkSCvpdPbKOqDw_2_3"></a><a id="Tc_MVj-2PPDdECDFWFY2UZu4g_2_6"></a><a id="Tc_c3ymN22czk22oJu5GQHGjw_3_0"></a><a id="Tc_d-FXmsM9e0COh0ZIMLr9Yw_4_0"></a><a id="Tc_ZSoJdy9E9U2eDWPAgg36aQ_4_2"></a><a id="Tc_4gOe6aULaUyc6CGPs8q3Sw_4_5"></a><a id="Tc_z1KxF4IbCkKDpWYLgg8u2Q_5_0"></a><a id="Tc_8VJ-tQRtokK3IPBAqfClvQ_6_0"></a><a id="Tc__H8snp77B0i_S6em_bYoEw_7_0"></a><a id="Tc_3tEyKPbSm0aRoOEzOp0cjw_8_0"></a><a id="Tc_QLVzMBCbtUaSNRcjzOQ0Zw_9_0"></a><a id="Tc_Ab3DbjcU60eCw35egeH8bA_9_2"></a><a id="Tc_-IUQzr1ACUGnZyZCoT1fNA_9_5"></a><a id="Tc_IZncKwtux0WX3USK2luigw_11_0"></a><a id="Tc_BlfoK8LGdUiV_ZPdtNJp6w_12_0"></a><a id="Tc_t4spaZVM7kO5_omj6VDSlg_12_2"></a><a id="Tc_08W8GxZOfkquIFnIZ8QEsg_12_5"></a><ix:continuation id="Tb_cUf1gTgbbUWJ1_DNWqkIAg_cont2"><ix:continuation id="Tb_aEhD-AMUIUiMnH4ux2xpSw_cont1"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:68.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected benefit payments:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Year 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2021_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_i6PZAoMNcEySLcgBUKmmjw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" scale="0" id="Tc_6Rzfr0T5hkWZfeDbZ8XV_w_4_3">162,208</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2020_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_HLv731xR10GVgI0Jt-JL5w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" scale="0" id="Tc_G2-MYeTLOkyouRUu50OSvg_4_6">11,363</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Year 2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2021_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_i6PZAoMNcEySLcgBUKmmjw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" scale="0" id="Tc_jjdWDL3os02qpifEIOzbmQ_5_3">54,723</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2020_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_HLv731xR10GVgI0Jt-JL5w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" scale="0" id="Tc_rHWxAjCXDUOXGJFnwMb0bQ_5_6">141,225</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Year 3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2021_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_i6PZAoMNcEySLcgBUKmmjw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" scale="0" id="Tc_BzbXPWaSL0ek4I9urHoPJQ_6_3">58,224</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2020_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_HLv731xR10GVgI0Jt-JL5w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" scale="0" id="Tc_KNX_ldSO_kuqVNC0V8eA7A_6_6">29,330</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Year 4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2021_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_i6PZAoMNcEySLcgBUKmmjw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" scale="0" id="Tc_V-D8VrCbJkurOJnEo6uSFg_7_3">60,869</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2020_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_HLv731xR10GVgI0Jt-JL5w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" scale="0" id="Tc_SILJb_4L0EO7CJGS_eue8A_7_6">30,793</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Year 5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2021_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_i6PZAoMNcEySLcgBUKmmjw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" scale="0" id="Tc_ATfV4E3xFUWg-Atq86GTug_8_3">63,281</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2020_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_HLv731xR10GVgI0Jt-JL5w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" scale="0" id="Tc_Av_M45SHhkm8I3jurQ3zdQ_8_6">31,963</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Next 5 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2021_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_i6PZAoMNcEySLcgBUKmmjw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" scale="0" id="Tc_eU7YnyQkUkmYS_H5dgdWwQ_9_3">428,371</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2020_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_HLv731xR10GVgI0Jt-JL5w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" scale="0" id="Tc_1glGETqKYE62Ml65ZVSogA_9_6">169,658</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other disclosure items:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Next year&#39;s expected employer contribution</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2021_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_i6PZAoMNcEySLcgBUKmmjw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" scale="0" id="Tc_NqlT9I95JUybfq3xVkIy9Q_12_3">112,396</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2020_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_HLv731xR10GVgI0Jt-JL5w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" scale="0" id="Tc_3qDgVfalk0qcBfzAA5wklA_12_6">38,873</ix:nonFraction></p></td></tr></table></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s investment strategy for its pension plans is to optimize the long-term investment return on plan assets in relation to the liability structure to maintain an acceptable level of risk while minimizing the cost of providing pension benefits and maintaining adequate funding levels in accordance with applicable rules in each jurisdiction.&#160;The Company does not manage any assets internally. The plan assest relates to mandatory and discretionary contributions made in accordance with Swiss Law to a leading pension provider. The capital is fully insured and provides for a fixed rate of return. The fair value is based on the value of the assets held by the provider and as such has been classified within Level 3 of the fair value hierarchy. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We maintain a 401(k) saving Plan, which is available to all U.S. employees. Participants may make voluntary contributions. We make matching contributions according to the 401(k) Saving Plan&#8217;s matching formula. All matching contributions and participant contribution vest immediately. &#160;The expense related to our 401(k) Savings Pan consist of our matching contributions. Expenses related to our 401(k) Savings Plan totaled USD <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" scale="0" id="Narr_p-dfRP3-FE-52NK3UFuWSQ">3,243</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2020_To_12_31_2020_JDEb6LtAmEuXGmEieWNlsw" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" scale="0" id="Narr_xVhpZNbJkUeqDH2odMh4NA">nil</ix:nonFraction> for the years ended December 31, 2021 and 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:continuation><a id="Tc_iXmKJ9TmlkK6HoYsoGy_WA_1_2"></a><a id="Tc_sVDGkHHUJE2nFVyB17iYNA_1_4"></a><a id="Tc_6ZkmY4HiBEGzp-KNMdYD5A_1_6"></a><a id="Tc_NJZChjASz0miSygD-mDYGw_1_8"></a><a id="Tc_ofTqT-xA10qXscmbU6Lq2A_1_10"></a><a id="Tc_tM_qdlhfqUm8Q3tBMuWFcg_1_12"></a><a id="Tc_I2oVu8ipAECIwAD0w8XgdQ_1_14"></a><a id="Tc_p1Eg8OjYX0elwK-diMO9nw_2_0"></a><a id="Tc_2jU1-yztxEqzYyz3rxuKBQ_2_1"></a><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" name="us-gaap:DebtDisclosureTextBlock" id="Tb_I5-8FQl_j0KrnPvlp4CoZw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">11</span><span style="font-style:italic;">.&#160;&#160;&#160;&#160;Loans</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In March&#160;2020, the Company obtained a CHF <ix:nonFraction unitRef="Unit_Standard_CHF_tZXBcOteZE6rGAnlVuK3Ng" contextRef="As_Of_3_31_2020_us-gaap_DebtInstrumentAxis_ganx_March2020ChfLoanMember_FV-iSHC9DECOjK6nXfZqag" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" id="Narr_L0QEw_e7YkS-0sNcRwuxBg">14,600</ix:nonFraction> (USD <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_3_31_2020_us-gaap_DebtInstrumentAxis_ganx_March2020ChfLoanMember_FV-iSHC9DECOjK6nXfZqag" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" id="Narr_qibc7i-ds0KVutTHQjDK0Q">16,024</ix:nonFraction>) <ix:nonNumeric contextRef="Duration_3_1_2020_To_3_31_2020_us-gaap_DebtInstrumentAxis_ganx_March2020ChfLoanMember_S8zeqoa7qEuI5LdFwXbKLw" format="ixt-sec:durwordsen" name="us-gaap:DebtInstrumentTerm" id="Narr_RP4dPBjUGEapiiFhhi6wPg">five-year</ix:nonNumeric> loan. The loan had <ix:nonFraction unitRef="Unit_Standard_pure_YPFUW3Xga0mVMPZT28RXUw" contextRef="As_Of_3_31_2020_us-gaap_DebtInstrumentAxis_ganx_March2020ChfLoanMember_FV-iSHC9DECOjK6nXfZqag" decimals="2" format="ixt-sec:numwordsen" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_Ie3qXWMAZkKPhn_BzntvKg">zero</ix:nonFraction> interest and original maturity on March 31, 2025. The loan was guaranteed through joint and several sureties by the Swiss government. The loan is part of the infrastructure put in place by the Federal Council and Swiss Parliament in view of the economic consequences of the coronavirus. As of December 31, 2021, the outstanding balance has been reclassified as current as the Company decided to estinguish the loan. <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A" decimals="0" format="ixt-sec:numwordsen" name="ganx:ExpensesOrChargesDueForEarlyExtinguishmentOfDebt" scale="0" id="Narr_sloEmN99uUu3lDnnJxcRRw">No</ix:nonFraction> expenses or charges were due for the early extinguishment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In August&#160;2020, the Company obtained a CHF <ix:nonFraction unitRef="Unit_Standard_CHF_tZXBcOteZE6rGAnlVuK3Ng" contextRef="As_Of_8_31_2020_us-gaap_DebtInstrumentAxis_ganx_August2020ChfLoanMember_os9qx323O06rGZDMfoiU8Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" id="Narr_rCXr9TBqL0CHhixjld6YFg">638,000</ix:nonFraction> (USD <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_8_31_2020_us-gaap_DebtInstrumentAxis_ganx_August2020ChfLoanMember_os9qx323O06rGZDMfoiU8Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" id="Narr_1ufqka3vGE-YdRQV14uqBw">700,221</ix:nonFraction> at the historical forex exchange rate) <ix:nonNumeric contextRef="Duration_8_1_2020_To_8_31_2020_us-gaap_DebtInstrumentAxis_ganx_August2020ChfLoanMember_QkIhdbW_8Uis0Buu2_viHA" format="ixt-sec:durwordsen" name="us-gaap:DebtInstrumentTerm" id="Narr_RyXcSF3JFEOFX3_JxOnt7A">nine-year</ix:nonNumeric> loan. The loan has <ix:nonFraction unitRef="Unit_Standard_pure_YPFUW3Xga0mVMPZT28RXUw" contextRef="As_Of_8_31_2020_us-gaap_DebtInstrumentAxis_ganx_August2020ChfLoanMember_os9qx323O06rGZDMfoiU8Q" decimals="2" format="ixt-sec:numwordsen" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_NZ3Q5qeXB0u4o_dVf3iV9A">zero</ix:nonFraction> interest. The loan is due in quarterly installments of CHF <ix:nonFraction unitRef="Unit_Standard_CHF_tZXBcOteZE6rGAnlVuK3Ng" contextRef="Duration_8_1_2020_To_8_31_2020_us-gaap_DebtInstrumentAxis_ganx_August2020ChfLoanMember_QkIhdbW_8Uis0Buu2_viHA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentPeriodicPayment" scale="0" id="Narr_-0bBPDdrPEqeiqoi3t4T8w">20,000</ix:nonFraction>, with payments commencing on December&#160;31, 2021 and ending on September&#160;30, 2029. The loan is part of the infrastructure put in place by the Federal Council and Swiss Parliament in view of the economic consequences of the coronavirus. Loans granted do <span style="-sec-ix-hidden:Hidden_4WczMy8Ec0ae6MFBpO8JBg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">not</span></span> bear interest and <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:DeferredFinanceCostsNet" scale="0" id="Narr_nMrgpYQz6kqZ7Q5yABCIkw">no</ix:nonFraction> issuance costs have been borne. As such they have been accounted for at face value, which is deemed to approximate the related fair value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The future loan payments are reported in the table below:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="Tb_Y5s9rlkYZUCiYLMSu720-A" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2026</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Thereafter</b></p></td></tr><tr><td style="vertical-align:top;width:11.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Loan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="0" id="Tc_3pHTFK67OkmTIERZ-wNa6Q_2_2">694,294</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" scale="0" id="Tc_1usnZGfwt0-47d3-0_yW0A_2_4">103,826</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" scale="0" id="Tc_OjyMRjDSxkmAb7B-p5chow_2_6">87,806</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" scale="0" id="Tc_FFTaVVquUk22JqFk1YUInA_2_8">87,806</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" scale="0" id="Tc_6ndpm3UxxEe0GiTSUwaEwg_2_10">87,806</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" scale="0" id="Tc_fc8Ut2Iqx0OElMSHjp4Y1A_2_12">87,806</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" scale="0" id="Tc_PFfBKCfr1EeLWwvL1iyjHw_2_14">239,244</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" name="us-gaap:FairValueDisclosuresTextBlock" id="Tb_-ldaStEofUe_xsvJQkpiEg" continuedAt="Tb_-ldaStEofUe_xsvJQkpiEg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">12.&#160;&#160;&#160;&#160;Fair value measurement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:28.8pt;margin:0pt 0pt 12pt 0pt;">Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The Company&#8217;s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability. </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">96</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_XybEiLUIPECGWvAEKAdroQ_1_2"></a><a id="Tc_KpfA4QpSqEmx1zIgPdyfnQ_2_2"></a><a id="Tc_DD07ZXYGPkG19o4MHEJDfA_2_5"></a><a id="Tc_wwNfqn0g6EWwBe0t52U4kQ_2_7"></a><a id="Tc_GJNYizJTgUCHSNK4jJDwpg_3_2"></a><a id="Tc_3kndiY_LkEWdN5scYlj2iw_3_5"></a><a id="Tc_umNmpU0wgkeMClUAXs8-ng_3_7"></a><a id="Tc_jPoARJ98kUS9CanmBt5RTQ_4_0"></a><a id="Tc_BSy0e3EgxkiSAV7x-cgOcw_5_0"></a><a id="Tc_yRRWJ3ZUXU-EBMO4cDS3oQ_6_0"></a><a id="Tc_IC3OQHIACUa6SgzLQA6VEw_7_0"></a><a id="Tc_FiM68u-zfUKxsMF3yCFBwA_7_5"></a><a id="Tc_MHhQrt_kn0SbrEq63R5U1A_7_7"></a><a id="Tc_Z02JZw2ZHEykfD8Ba4etYg_8_0"></a><a id="Tc_WjvTW2v7-ki35faTmk4haQ_8_2"></a><a id="Tc_h1rx9ihPz0OMBikwvJDs5g_8_5"></a><a id="Tc_-FaKJFY42EmvG2DgCPpo6A_8_7"></a><a id="Tc_LlUDC1aWgUS0vhF9nTXvCg_10_0"></a><a id="Tc_4YdJF84vSUehtOuJe62aig_10_5"></a><a id="Tc_3HjKXFnqSEmuB6GYDNb2Tg_10_7"></a><a id="Tc_LGlUwVDudUurriG8d5hz9Q_12_0"></a><a id="Tc_7AXtc5v98EGa3CjHhRwqdw_13_0"></a><a id="Tc_3qZj5mOM4kSCiODEEb_uew_14_0"></a><a id="Tc_74QkHrvC80yVg8MZS43UHg_15_0"></a><a id="Tc_Uw-OM-dFI0eNBMrAX4pE1g_15_5"></a><a id="Tc_88xqwDe860yOWsF2r8hJXQ_15_7"></a><a id="Tc_L9sZQuAXZUuOMeEdjSv5Cg_16_0"></a><a id="Tc_gdrllvPMEUalsv4DMLYpxA_16_2"></a><a id="Tc_NXWMkOlasUWteYtJd7eJDA_16_5"></a><a id="Tc_l09p0duOFkayJkmOt7d-Aw_16_7"></a><a id="Tc_9S5CReVLqkeLmbjy1yEiGQ_18_0"></a><a id="Tc_VS-adLRroUGKlodlA59ybA_18_5"></a><a id="Tc_g9uYo0YhQU-UBde37_8R1w_18_7"></a><ix:continuation id="Tb_-ldaStEofUe_xsvJQkpiEg_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:28.8pt;margin:0pt 0pt 12pt 0pt;">The carrying amounts of the Company&#8217;s cash and cash equivalents, including money market funds, restricted cash and financial liabilities are considered to be representative of their respective fair values because of the short-term nature and the contractual terms of those instruments. The fair values of money market funds are based upon the quoted prices in active markets provided by the holding financial institution, which are considered Level 1 inputs in the fair value hierarchy according to ASC820.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:28.8pt;margin:0pt 0pt 12pt 0pt;">There have been no changes to the valuation methods utilized by the Company, nor were there transfers between levels of the fair value hierarchy.</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" name="us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" id="Tb_UnpUOBBGJEWDXscNHyvWxg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100.48%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:56.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:56.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="6" style="vertical-align:bottom;white-space:nowrap;width:41.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair value measurement at reporting date using</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Quoted prices in active market for identical assets</b></p></td><td style="vertical-align:bottom;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant other observable inputs</b></p></td><td style="vertical-align:bottom;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant unobservable inputs</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:13.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(level 1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:11.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(level 2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:11.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(level 3)</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">December 31, 2021:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Cash and cash equivalents:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2021_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_jwo2h2HgjU-Oaoug1oOjXg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="0" id="Tc_PuPRf844M0uP5PYx6mUSDw_7_3">33,617,696</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:56.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2021_us-gaap_FairValueByAssetClassAxis_us-gaap_CashAndCashEquivalentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_aPJD3-UwWk2aYpTKhM55uA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="0" id="Tc_4-Q5IpFcqkSwh3bKfLhznA_8_3">33,617,696</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:56.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total financial assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_uuaa7xnlyki6ykqgX7Pttw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="0" id="Tc_nT_-PMp2PUqQdX-p5G6aVA_10_3">33,617,696</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:56.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">December 31, 2020:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Cash and cash equivalents:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2020_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_yQGxUTb4_kyBt2-oIiFKuQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="0" id="Tc_C1Rmh5e9w0yxC4syO0W5ug_15_3">6,585,655</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:56.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2020_us-gaap_FairValueByAssetClassAxis_us-gaap_CashAndCashEquivalentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_zzuqJkU6kk6sqgnOWt5eyA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="0" id="Tc_cfN5ADn6MkGf4_Ow0L2QWg_16_3">6,585,655</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:56.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total financial assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_c2-Hsc31bki-8GK8iPACMA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="0" id="Tc_khtTbQ5eHEGzciGho2OeJw_18_3">6,585,655</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:28.8pt;margin:0pt 0pt 12pt 0pt;">The carrying amounts of prepaid expenses and other current assets, accounts payable and accrued expenses approximate their &#160;fair value due to their short-term maturities.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="Tb_iaYH-axrxEqBfgXM3XHw_w" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">13.&#160;&#160;&#160;&#160;Common and Preferred Stock</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2021 and 2020, the authorized capital stock of the Company included <ix:nonFraction unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw" contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr__Ap69RDEwE2ctZYPGGsF3Q"><ix:nonFraction unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw" contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_D1I7IiTgtUiWnpxAdmQD4Q">50,000,000</ix:nonFraction></ix:nonFraction> shares of common stock, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_ZUfWDOiJrESFdyfJo2gfWg" contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_XeAyo2mKCEOqTIpqjG_hlA"><ix:nonFraction unitRef="Unit_Divide_USD_shares_ZUfWDOiJrESFdyfJo2gfWg" contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_90PjsW7RZkejuXpPKc5L4Q">0.0001</ix:nonFraction></ix:nonFraction> par value and <ix:nonFraction unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw" contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_qnPUIHi9b0GALYVtRZ8ipA"><ix:nonFraction unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw" contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_fnbeLl7qrU6WAyjeHXY9ug">10,000,000</ix:nonFraction></ix:nonFraction> shares of preferred stock, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_ZUfWDOiJrESFdyfJo2gfWg" contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg" decimals="4" format="ixt:numdotdecimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_7LojEldETUadtKRbSwGvqg"><ix:nonFraction unitRef="Unit_Divide_USD_shares_ZUfWDOiJrESFdyfJo2gfWg" contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A" decimals="4" format="ixt:numdotdecimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_FbtDjrnUUkWjgRFJn2eSyA">0.0001</ix:nonFraction></ix:nonFraction> par value. As of December 31, 2021 and 2020, <ix:nonFraction unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw" contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_rNqLbYh7WkiwpOzHjsOS4w">11,883,368</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw" contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Narr_J4iGouVOiE2fLxLeu8KY2Q">3,543,163</ix:nonFraction> (<ix:nonFraction unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw" contextRef="As_Of_3_16_2021_fYMXRlaU00CBob3C4xDimg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_bzbjkEhUc06iL_cqGGOJXA">4,022,736</ix:nonFraction> <span style="-sec-ix-hidden:Hidden_ARvqt8O7vki9CqZo9ksCdw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">before</span></span> the reverse stock split) shares of common stock, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_ZUfWDOiJrESFdyfJo2gfWg" contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_6aqH3f4AsUGtlADISb4edA"><ix:nonFraction unitRef="Unit_Divide_USD_shares_ZUfWDOiJrESFdyfJo2gfWg" contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_cRd2EY0AgkueKPKZGNykLA">0.0001</ix:nonFraction></ix:nonFraction> par value, were <span style="-sec-ix-hidden:Hidden_smJgQqCN6kCASsqGpDK0oA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">issued</span></span> and <span style="-sec-ix-hidden:Hidden_eCHc0lXrwkaLahqSp1jTsw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">outstanding</span></span>. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw" contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="Narr_e-9V1uvqPUStUPnKVjLhFQ">No</ix:nonFraction> preferred stocks were outstanding as of December 31, 2021. There were <ix:nonFraction unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredClassAMember_QpkPvPPAwEiZSl5LOyqQvA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="Narr_Po7C2nxNFUu5j-K-8FlPwg">1,185,879</ix:nonFraction> &#160;(<ix:nonFraction unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw" contextRef="As_Of_3_16_2021_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredClassAMember_LA-5cb6F00S56dV8R_wEsQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="Narr_7c25fXz-X0OEfED1pHUO-Q">1,346,390</ix:nonFraction> before the reverse stock split) <span style="-sec-ix-hidden:Hidden_xoy4pURJ0U6SC06b57siOQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">shares</span></span> of Series&#160;A <span style="-sec-ix-hidden:Hidden_kdwNLQKYWkiveM0sOQGupw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Preferred</span></span> Stock, par value $<ix:nonFraction unitRef="Unit_Divide_USD_shares_ZUfWDOiJrESFdyfJo2gfWg" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredClassAMember_QpkPvPPAwEiZSl5LOyqQvA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_6GeduYpAFE-hTC2h49Xpzw">0.0001</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredClassBMember_G4x0CiU2mUOuiMOxwNFS6Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="Narr_MMV68o1LeU6NIhc0aezLNA">2,965,600</ix:nonFraction> (<ix:nonFraction unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw" contextRef="As_Of_3_16_2021_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredClassBMember_HBe32B_mIkuJvMwKt7oZ-g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="Narr_7XLFKAT_e0mYRvTxnJ2Xrw">3,366,999</ix:nonFraction> before the reverse stock split) <span style="-sec-ix-hidden:Hidden_VxK6clrWrk2DfpjK2-sdow;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">shares</span></span> of Series&#160;B <span style="-sec-ix-hidden:Hidden_iLyIO00eQUWJB3oyw2X5yQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Preferred</span></span> Stock, par value $<ix:nonFraction unitRef="Unit_Divide_USD_shares_ZUfWDOiJrESFdyfJo2gfWg" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredClassBMember_G4x0CiU2mUOuiMOxwNFS6Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_b6U59OrBeU2RooQ2K_x4uw">0.0001</ix:nonFraction>, issued and outstanding as of December&#160;31, 2020. The reverse stock split did not result in any change of the original par value of the Company common and preferred stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Upon closing of the IPO, the Preferred Stock, as resulting from the reverse stock split, were converted to common stock at a ratio of <ix:nonFraction unitRef="Unit_Standard_pure_YPFUW3Xga0mVMPZT28RXUw" contextRef="Duration_3_17_2021_To_3_17_2021_u6CMktnXaUyF6ar7hHmEcw" decimals="INF" format="ixt:numdotdecimal" name="ganx:PreferredStockToCommonStockConversionRatio" scale="0" id="Narr_nS5p6-Uvik695CDBMNPyJQ">1</ix:nonFraction>-for-<ix:nonFraction unitRef="Unit_Standard_pure_YPFUW3Xga0mVMPZT28RXUw" contextRef="Duration_3_17_2021_To_3_17_2021_u6CMktnXaUyF6ar7hHmEcw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" scale="0" id="Narr_6ZfMIgh0MkiebE-L6gzkYA">1</ix:nonFraction>.The holders of the Company&#8217;s Preferred Stock had certain voting, dividend, and redemption rights, as well as liquidation preferences and conversion privileges. All rights, preferences, and privileges associated with the preferred stock were terminated at the time of the Company&#8217;s IPO in conjunction with the conversion of all outstanding shares of Preferred Stock into shares of common stock.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" name="ganx:WarrantsAndRightsNoteDisclosureTextBlock" id="Tb_5qSLNxljFEWk1_HAGOMZ-g" continuedAt="Tb_5qSLNxljFEWk1_HAGOMZ-g_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">14.&#160;&#160;&#160;&#160;Warrants</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:35.45pt;margin:0pt;">In July, 2020, in connection with the issuance of the Series B Preferred Stock through a private placement, the Company issued equity-classified warrants to designees of the placement agent to purchase an aggregate of <ix:nonFraction unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw" contextRef="As_Of_7_31_2020_us-gaap_ClassOfWarrantOrRightAxis_ganx_WarrantsToDesigneesOfPlacementAgentIssuedJuly2020Member__xz3VXdq4UepWPvW5n-chA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_KV_A3lZH2kyW4uWKxvBXbQ">269,360</ix:nonFraction> shares of our common stock at an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_ZUfWDOiJrESFdyfJo2gfWg" contextRef="As_Of_7_31_2020_us-gaap_ClassOfWarrantOrRightAxis_ganx_WarrantsToDesigneesOfPlacementAgentIssuedJuly2020Member__xz3VXdq4UepWPvW5n-chA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_5k662-voo0qGOiCauR_uow">4.46</ix:nonFraction> per share, valued in the aggregate at USD <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_7_31_2020_us-gaap_ClassOfWarrantOrRightAxis_ganx_WarrantsToDesigneesOfPlacementAgentIssuedJuly2020Member__xz3VXdq4UepWPvW5n-chA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:WarrantsAndRightsOutstanding" scale="0" id="Narr_rajswGZl106-SM9Oz_7JiA">413,887</ix:nonFraction> and included in the issuance costs of the Series B Preferred Stock. The warrants vested immediately upon issuance, </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">97</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_GM1MXiR5qkC5MQ8si6S6IQ_1_2"></a><a id="Tc_GfRAeBGR_kGRzxcymGpisA_2_2"></a><a id="Tc_e4pEorbmh0Cc6mj3xk6krg_2_4"></a><a id="Tc_CVsRWkFQU0GC4u5atbJW1w_3_0"></a><a id="Tc_-vs3wb_tREassBonmCilEw_3_1"></a><a id="Tc_HWDs9WVB1EWmU18R7vPe0w_3_3"></a><a id="Tc_mmRKaoBMJEG-OvjYAv-Qzw_4_0"></a><a id="Tc_SGwuNW8WnUqamIr1kzqbbg_4_3"></a><a id="Tc_HN8jQIootEuwncJGq_IYzQ_4_5"></a><a id="Tc_63nFqprvX0O1bQ1bsJexGw_5_0"></a><a id="Tc_vsWxw73jFkShpDsZ2w3P3w_6_0"></a><a id="Tc_QQc9_Dj3_USKTx_IxtF_7g_7_0"></a><a id="Tc_W0d_NSB5006pYuejEX-rcw_7_2"></a><a id="Tc_gdJsbWN0eEm9ck3JrxiZOQ_7_4"></a><ix:continuation id="Tb_5qSLNxljFEWk1_HAGOMZ-g_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">provide for a cashless exercise right and are exercisable for a period of <ix:nonNumeric contextRef="As_Of_7_31_2020_us-gaap_ClassOfWarrantOrRightAxis_ganx_WarrantsToDesigneesOfPlacementAgentIssuedJuly2020Member__xz3VXdq4UepWPvW5n-chA" format="ixt-sec:durwordsen" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="Narr_yW890Pexw0W4cyqATHmXjw">five years</ix:nonNumeric> from July&#160;20, 2020. &#160;On March&#160;3, 2021, the Board approved a 1-for-<span style="-sec-ix-hidden:Hidden_R7-eb03Se0uFXfouVE5ALg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">0.880784</span></span> reverse stock split of the Company&#8217;s outstanding equity instruments. The reverse stock split was approved by the stockholders on March&#160;4, 2021 and became effective on March&#160;17, 2021. Shares of common stock underlying outstanding warrants were proportionately reduced from <ix:nonFraction unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw" contextRef="As_Of_3_16_2021_us-gaap_ClassOfWarrantOrRightAxis_ganx_WarrantsToDesigneesOfPlacementAgentIssuedJuly2020Member_YF5W3invl02ldRF6Cq2TAQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Narr_bZ7RQFMY-0u4S9YvJk2Dyw">269,360</ix:nonFraction> to <ix:nonFraction unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw" contextRef="As_Of_3_17_2021_us-gaap_ClassOfWarrantOrRightAxis_ganx_WarrantsToDesigneesOfPlacementAgentIssuedJuly2020Member_g-_VaNc3WkybZ1HHEFo_GQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Narr_yEGyJ9vc40y3e5ORLEvHeg">237,249</ix:nonFraction> and the respective exercise prices, were proportionately increased from $<ix:nonFraction unitRef="Unit_Divide_USD_shares_ZUfWDOiJrESFdyfJo2gfWg" contextRef="As_Of_3_16_2021_us-gaap_ClassOfWarrantOrRightAxis_ganx_WarrantsToDesigneesOfPlacementAgentIssuedJuly2020Member_YF5W3invl02ldRF6Cq2TAQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_ZJVdgvkj0kyS1QjRrwHCfA">4.46</ix:nonFraction> to $<ix:nonFraction unitRef="Unit_Divide_USD_shares_ZUfWDOiJrESFdyfJo2gfWg" contextRef="As_Of_3_17_2021_us-gaap_ClassOfWarrantOrRightAxis_ganx_WarrantsToDesigneesOfPlacementAgentIssuedJuly2020Member_g-_VaNc3WkybZ1HHEFo_GQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_IdHF2ua9BUqrC5ElhfCWag">5.07</ix:nonFraction> in accordance with the terms of the agreements governing such securities. As of December 31, 2021, <ix:nonFraction unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_ganx_WarrantsToDesigneesOfPlacementAgentIssuedJuly2020Member_YAr_SbLTRk2XAPVCkBuVtg" decimals="INF" format="ixt:numdotdecimal" name="ganx:WarrantsAndRightsExercisedOrExchangedNumber" scale="0" id="Narr_rVEar5eMzk6sYXeX7eNg9g">11,862</ix:nonFraction> warrants were exercised resulting in <ix:nonFraction unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_ganx_WarrantsToDesigneesOfPlacementAgentIssuedJuly2020Member_YAr_SbLTRk2XAPVCkBuVtg" decimals="INF" format="ixt:numdotdecimal" name="ganx:IssuanceOfCommonStockThroughCashlessExerciseOfWarrants" scale="0" id="Narr_3ASeayB2w0Cv0RBZ8e_abA">3,283</ix:nonFraction> shares having been issued following the cashless mechanism as per the terms of the agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On May 6, 2021, the Company entered into <ix:nonNumeric contextRef="Duration_5_6_2021_To_5_6_2021_us-gaap_ClassOfWarrantOrRightAxis_ganx_WarrantsToDesigneesOfInvestmentBankIssuedMay2021Member_94Oz4J1U90W8gKhVhzq1zg" format="ixt-sec:durwordsen" name="ganx:WarrantsAndRightsServicePeriod" id="Narr_O0jJ587PWEqliR6RRwsGzg">nine months</ix:nonNumeric> investing banking services and financial advisory agreement and issued equity-classified warrants to designees of the investment bank to purchase an aggregate of <ix:nonFraction unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw" contextRef="As_Of_5_6_2021_us-gaap_ClassOfWarrantOrRightAxis_ganx_WarrantsToDesigneesOfInvestmentBankIssuedMay2021Member_vInDzK2VLEaPLuCJ2B3g4g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_zWVL-4osjUKS0cLepA7HNA">200,000</ix:nonFraction> shares of the Company common stock at an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_ZUfWDOiJrESFdyfJo2gfWg" contextRef="As_Of_5_6_2021_us-gaap_ClassOfWarrantOrRightAxis_ganx_WarrantsToDesigneesOfInvestmentBankIssuedMay2021Member_vInDzK2VLEaPLuCJ2B3g4g" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_WhhmTtwHPEOjzFRqs1ytRQ">13.75</ix:nonFraction> per share, valued in the aggregate at USD <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_5_6_2021_us-gaap_ClassOfWarrantOrRightAxis_ganx_WarrantsToDesigneesOfInvestmentBankIssuedMay2021Member_vInDzK2VLEaPLuCJ2B3g4g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WarrantsAndRightsOutstanding" scale="3" id="Narr_9PHCDMdeC06iu85z500YJQ">1,034</ix:nonFraction> thousand. The warrants vested immediately upon issuance, do not provide cashless exercise right and are exercisable for a period of <ix:nonNumeric contextRef="As_Of_5_6_2021_us-gaap_ClassOfWarrantOrRightAxis_ganx_WarrantsToDesigneesOfInvestmentBankIssuedMay2021Member_vInDzK2VLEaPLuCJ2B3g4g" format="ixt-sec:durwordsen" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="Narr_uyvHWc3Ia0-VKFusnOPMqA">four years</ix:nonNumeric> from May 6, 2021. The fair value of the warrants is recognized on a straight-line basis over the <ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_ganx_WarrantsToDesigneesOfInvestmentBankIssuedMay2021Member_Xr6HpqPQo0W86a4ZrsARSQ" format="ixt-sec:durwordsen" name="ganx:WarrantsAndRightsServicePeriod" id="Narr_x7Fx48L1HkyLNtOlYjVzXA">nine months</ix:nonNumeric> service period as general and administrative expense. As of December 30, 2021, <ix:nonFraction unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_ganx_WarrantsToDesigneesOfInvestmentBankIssuedMay2021Member_Xr6HpqPQo0W86a4ZrsARSQ" decimals="INF" format="ixt-sec:numwordsen" name="ganx:WarrantsAndRightsExercisedOrExchangedNumber" scale="0" id="Narr_sWqevyQCOEulWGNOLfdWJg">no</ix:nonFraction> warrants were exercised or exchanged.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The fair value of the warrants issued in 2020 and 2021 is estimated using the Black-Scholes option pricing model with the following assumptions:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" id="Tb_gyaHAdmg60-3sCUi8gt6Hg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:70.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:70.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Grant date fair value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_ZUfWDOiJrESFdyfJo2gfWg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_ValuationTechniqueAxis_us-gaap_ValuationTechniqueOptionPricingModelMember_QzEVNtuW9US0oSPFOgMt6A" decimals="2" format="ixt:numdotdecimal" name="ganx:WarrantsGrantDateFairValue" scale="0" id="Tc_srXvw9lLm0afsDE0GynMGg_3_2">5.17</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_ZUfWDOiJrESFdyfJo2gfWg" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_ValuationTechniqueAxis_us-gaap_ValuationTechniqueOptionPricingModelMember_2H_dl4e8hE-KkfFPdigrJA" decimals="2" format="ixt:numdotdecimal" name="ganx:WarrantsGrantDateFairValue" scale="0" id="Tc_nkmaasfY0Uq9jaMhweby6A_3_4">1.54</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:70.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_YPFUW3Xga0mVMPZT28RXUw" contextRef="As_Of_12_31_2021_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_us-gaap_ValuationTechniqueAxis_us-gaap_ValuationTechniqueOptionPricingModelMember_jbd4-HDMH0K2ZzXOCoSCFA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="Tc_FbSeZm-E6EifPEUiv8Y9MA_4_2">70</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_YPFUW3Xga0mVMPZT28RXUw" contextRef="As_Of_12_31_2020_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_us-gaap_ValuationTechniqueAxis_us-gaap_ValuationTechniqueOptionPricingModelMember_LWxcsazXDk2P_fSZ_3WyGA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="Tc_L9nzN32sz0CxNacAC2jndA_4_4">75</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;">%</span></p></td></tr><tr><td style="vertical-align:top;width:70.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected term (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_YPFUW3Xga0mVMPZT28RXUw" contextRef="As_Of_12_31_2021_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_us-gaap_ValuationTechniqueAxis_us-gaap_ValuationTechniqueOptionPricingModelMember_9QqzfSmMzkiY1DCoSmnXjg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" id="Tc_1zWHueB0xUyyxpzwsUfjZA_5_2">4.00</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_YPFUW3Xga0mVMPZT28RXUw" contextRef="As_Of_12_31_2020_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_us-gaap_ValuationTechniqueAxis_us-gaap_ValuationTechniqueOptionPricingModelMember_1wOkdymSaEyzTP505R_Yzw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" id="Tc_ujJKJvqRjUOb2sxKJNqcIg_5_4">5.00</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:70.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2021_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_ValuationTechniqueAxis_us-gaap_ValuationTechniqueOptionPricingModelMember_imxnCtN6ykq3qhuSJY2jEg" decimals="4" format="ixt:numdotdecimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="Tc_Rd8FM-EvJUmIIP4J5WeiTg_6_2">0.81</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2020_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_ValuationTechniqueAxis_us-gaap_ValuationTechniqueOptionPricingModelMember_pn73ofcvSUeZsLeHLTUKsg" decimals="4" format="ixt:numdotdecimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="Tc_LlJCz9jAtUyUh-5nMS8VOg_6_4">0.28</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:70.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected dividend yield -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" name="us-gaap:CompensationRelatedCostsGeneralTextBlock" id="Tb_IL4-MsoXiEm_eUc1pxjSwg" continuedAt="Tb_IL4-MsoXiEm_eUc1pxjSwg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">15.&#160;&#160;&#160;&#160;Equity Incentive Plan</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On September 24, 2020, the Board of Directors adopted the 2020 Omnibus Incentive Plan (the &#8220;2020 Omnibus Plan&#8221;). The 2020 Omnibus Plan provides for the granting of equity-based awards to our named executive officers, other employees, consultants and non-employee directors at a price to be determined by the Board of Directors. The 2020 Omnibus Plan is intended to encourage ownership of stock by employees and consultants of the Company and to provide additional incentives for them to promote the success of the Company&#8217;s business. The maximum number of shares to be issued under the 2020 Omnibus Plan is <ix:nonFraction unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw" contextRef="As_Of_9_24_2020_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_yL43kRndvEW68muLtDGB3g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Narr_wIHOdtLBsE-kNMu5RTPRMg">1,310,000</ix:nonFraction>. The 2020 Omnibus Plan expires after <ix:nonNumeric contextRef="Duration_9_24_2020_To_9_24_2020_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_7U57Cx256U2tLHUf4s6Y8A" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="Narr_kxeAFdVr30uDY3an9XkiSg">ten years</ix:nonNumeric>, unless terminated prior to that date by the Board of Directors. The Board of Directors is responsible for determining the individuals to be granted options, the number of options each individual will receive, the option price per share, and the exercise period of each option. <ix:nonFraction unitRef="Unit_Standard_Options_mZpQ0toHqki8W4R9nXDMkA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_9J9hcs3P0U-I30H9M7barQ" decimals="INF" format="ixt-sec:numwordsen" name="ganx:NumberOfOptionsSubjectToTermThreshold" scale="0" id="Narr_9mWOso2_DkWBX5Mo4ZdTdA">No</ix:nonFraction> option will have a term in excess of <ix:nonNumeric contextRef="Duration_9_24_2020_To_9_24_2020_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_RTjAu4qAPEqUn3L27gh5Ow" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="Narr__xmQbn4ANECGlRzB3H9guQ">10 years</ix:nonNumeric>. The exercise price for a stock option awarded under the 2020 Omnibus Plan shall not be less than the fair market value of the Company&#8217;s common stock on the date of the grant. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On December 23, 2021, the Board of Directors, has determined that it is advisable and in the best interests of the Company to adopt an Inducement Equity Incentive Plan (the &#8220;2021 Inducement Equity Incentive Plan&#8221;) intended to induce new employees to join the Company for the benefit of individuals who satisfy the standards for inducement grants under Rule 5635(c)(4) of the NASDAQ Listing Rules and the related guidance issued thereunder with respect to the Company and its affiliates. The maximum number of shares reserved for issuance pursuant to awards to be granted under the 2021 Inducement Equity Incentive Plan is to <ix:nonFraction unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw" contextRef="As_Of_12_23_2021_us-gaap_PlanNameAxis_ganx_TwentyTwentyoneInducementEquityIncentivePlanMember_dc6nUQZMq0iDFdVD-aASTQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="Narr_Ep6BwY3J90mMufh-swOe7w">1,000,000</ix:nonFraction>.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">98</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_1b13046c_0a8e_4665_b5a0_c78d5ca3bd9b"></a><a id="Tc_n0boN0nTVkmw1uehBHCGQw_2_8"></a><a id="Tc_hW35qWjizU2Gx9MZr4wHng_2_10"></a><a id="Tc_X1XNNff-zUuZKOxyApoU6w_3_4"></a><a id="Tc_Lwj24fLhJE6ymmonATDtFg_3_6"></a><a id="Tc_s3a28eE0gU6kZCRu_CQQ0g_3_8"></a><a id="Tc_gnxrZGmgf0ewu0ffFoweyA_3_10"></a><a id="Tc_HrQOKnPxh0i-XpwktDSTQQ_4_2"></a><a id="Tc_GeybozMp-k-ilcG5JT2frw_4_4"></a><a id="Tc_bJJRKCii3EuEsCHr0rIz5g_4_6"></a><a id="Tc_OVgnPbbQckG9tUcSng-wxQ_4_8"></a><a id="Tc_4kkionFDVU6o6Gl4lhIK6g_4_10"></a><a id="Tc_WgeEkwXsF06dvDZamIPfww_5_0"></a><a id="Tc_x9-O1D1qPUCuPPETRBf1jA_5_10"></a><a id="Tc_ARyACoJRv0m4MICuP1l9iw_6_0"></a><a id="Tc_rhf6ECVml0Cq2XbnM-Uy4A_6_10"></a><a id="Tc_IJIwn5txt02EBKSsGT4-Xg_7_0"></a><a id="Tc_rMjEnkkHgEqn86a-sq73_w_7_10"></a><a id="Tc_DGsDKSvGa0i6iAuB2GUPQw_8_0"></a><a id="Tc_cDE_N6N_x0GrnipQOo-omA_8_8"></a><a id="Tc_wMtAke0sE0KijR6XVz-How_8_10"></a><a id="Tc_Horrt78ml0mqaWial0PrWA_9_0"></a><a id="Tc_LnZKxtnMo0q3bFx4s9HE9Q_9_8"></a><a id="Tc_c_cAgTsAzkikrlUE7nij7g_9_10"></a><a id="Tc_ws6dhdEk_EqJMiNBqq1GLg_10_0"></a><a id="_dfce6d1e_735d_4158_a733_6f55c491c260"></a><a id="Tc_13fupElQZ0ufjAIdCbWdVw_1_0"></a><a id="Tc_CyQMHc96SkaM5WpdbnvtKQ_1_12"></a><a id="Tc__99H9w7GOE2aeRzDlRmDUw_2_6"></a><a id="Tc_xT7iSJKuW0ak1jCEbAk4Gg_2_9"></a><a id="Tc_BAAPDOnc1kKm6kgvMPM5JA_2_14"></a><a id="Tc_OwXqfJlNq0eFHaZqYzKDXg_3_4"></a><a id="Tc_S5LNJhlvdEqkwT-WqTMoIw_3_6"></a><a id="Tc_MXxWo3q2rEeqeNndEzzqyQ_3_9"></a><a id="Tc_LQUUz9nwqEaeJjsrQB2fUA_3_14"></a><a id="Tc_E6LIyi2gKUS4lsYrGuszIQ_4_0"></a><a id="Tc_NbUwjfc-K0SDeVQQsjiK9Q_4_2"></a><a id="Tc_CbIa5-8XCkqDzNnEBqJE0g_4_4"></a><a id="Tc_4gZu5xWW_USHiqt4zVTS5w_4_6"></a><a id="Tc_UUgbbKPRqkCLjKWtGY2bBA_4_9"></a><a id="Tc_LoSj_zE-oU6sKZgQwWQYLQ_4_12"></a><a id="Tc_XZUGzRFbOE-YjWeBKygBNA_4_14"></a><a id="Tc_l8tmzS3-eUWPm3b_fYoSlA_5_0"></a><a id="Tc_zZ0tN9mNqkOYETrBmH_cDQ_5_2"></a><a id="Tc_iKf_bWBVe0uixaRVBxkQyQ_5_4"></a><a id="Tc_VxBRHTylaUi8Xd_o1ocyXQ_5_6"></a><a id="Tc_FqJ5cqE6IkKJAqfLCh5Rhg_5_12"></a><a id="Tc_jnBU-znZAEWfrV6SwX1k4w_5_14"></a><a id="Tc_VzDfqbzSOUG_MxtzMy7NmQ_6_6"></a><a id="Tc_Fi_H37mwUU-f8mJoQzeimg_6_9"></a><a id="Tc_qWf5xY12xEmfgLuauCcbTg_6_14"></a><a id="Tc_LiZYVYQUiEmmTwKd7Nkiww_7_6"></a><a id="Tc_noeZY_-F8UygE0jwt04O2g_7_9"></a><a id="Tc_RrxuKDwBN0C5GfVk_Y6pZQ_7_12"></a><a id="Tc_pngDMBToJEeXfWl13anDzg_7_15"></a><a id="Tc_OsSljQMUF0S4syv8ttIUsg_8_6"></a><a id="Tc_eCCBnM3D8EC6nGlfpSckxA_8_9"></a><a id="Tc_hgspAzgva0ikMi5bBbjmnA_8_12"></a><a id="Tc_Nwhv0hC-FEyGCMPhan0khw_8_15"></a><a id="Tc_5cKfeFiJI0i5zK2eJKFbDA_9_6"></a><a id="Tc_tiLMw9rrhkiA-d5xOAXbLw_9_9"></a><a id="Tc_HOBrLb6sMk-0L-N_Udprdg_10_6"></a><a id="Tc_W55ukKaKlk6N92qF1uPsmg_10_9"></a><a id="Tc_Z5HgBMvtv0SV68Us8c-IrA_10_12"></a><a id="Tc_j0cQp-k2iEW_h5pA_sOStQ_10_15"></a><ix:continuation id="Tb_IL4-MsoXiEm_eUc1pxjSwg_cont1" continuedAt="Tb_IL4-MsoXiEm_eUc1pxjSwg_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Stock Option Grants</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The following tables summarize stock option activity for the year ended December 31, 2021 :</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="Tb_Iy0WKfWebk2iQQvlN0lB1g" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:29.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:29.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:29.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;width:29.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted&#160;Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted&#160;Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Remaining Contractual </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td></tr><tr><td style="vertical-align:bottom;width:29.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Grant Date Fair Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise&#160;Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Terms (Years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="vertical-align:top;width:29.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Outstanding as of December&#160;31,&#160;2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw" contextRef="As_Of_12_31_2020_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_liEc-LEvuUmppacbgwHfFg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_YcQkDiGH50icp5iZHu7HyA_5_2">488,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_ZUfWDOiJrESFdyfJo2gfWg" contextRef="As_Of_12_31_2020_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_liEc-LEvuUmppacbgwHfFg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_UIY1MBh-t0OwCgmoymMRaQ_5_6">2.97</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_oZ2efAweo0yRRNPJFNieTA" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_oZ53J1M4V0iAkODIfhldgQ_5_8"> 9.70</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:29.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Options outstanding after stock splits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw" contextRef="As_Of_3_17_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_NETjxmYYrkyazfL5gwskGw" decimals="INF" format="ixt:numdotdecimal" name="ganx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAfterStockSplitsNumber" scale="0" id="Tc_WVZE4q0EKUSJnHNNUUnqeA_6_2">429,822</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_ZUfWDOiJrESFdyfJo2gfWg" contextRef="As_Of_3_17_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_NETjxmYYrkyazfL5gwskGw" decimals="2" format="ixt:numdotdecimal" name="ganx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionNonvestedWeightedAverageExercisePriceAfterStockSplit" scale="0" id="Tc_9XIukwRAqUuzFPIqHq_pnQ_6_4">2.42</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw" contextRef="As_Of_3_17_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_NETjxmYYrkyazfL5gwskGw" decimals="2" format="ixt:numdotdecimal" name="ganx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAfterStockSplitsWeightedAverageExercisePrice" scale="0" id="Tc_TtMgllWvBEyXRsgvdCH6GQ_6_6">3.38</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_3_17_2021_To_3_17_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_VPlkneswlU6lplZPmfwMQg" format="ixt-sec:duryear" name="ganx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAfterStockSplitWeightedAverageRemainingContractualTerm" id="Tc_BMpOTU1R3EGDBfbALnZqqw_6_8"> 9.01</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:29.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Options granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_9J9hcs3P0U-I30H9M7barQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Tc_lO3K_dHVZkO7zoi-GGwu3Q_7_2">535,780</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_ZUfWDOiJrESFdyfJo2gfWg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_9J9hcs3P0U-I30H9M7barQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Tc_qBDumGguuUu00qpRSyK-0g_7_4">4.27</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_ZUfWDOiJrESFdyfJo2gfWg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_9J9hcs3P0U-I30H9M7barQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_r1ZdiodvPkOWtYALkcaHOA_7_6">6.53</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_9J9hcs3P0U-I30H9M7barQ" format="ixt-sec:duryear" name="ganx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" id="Tc_1cjAoHvfrk-I5-kELQgnzw_7_8"> 5.66</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:29.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Options exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_9J9hcs3P0U-I30H9M7barQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_zj-P_WRtJE2xfROEiK_Scw_8_2">3,625</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_ZUfWDOiJrESFdyfJo2gfWg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_9J9hcs3P0U-I30H9M7barQ" decimals="2" format="ixt:numdotdecimal" name="ganx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedDuringPeriodWeightedAverageGrantDateFairValue" scale="0" id="Tc_RRsoCViPL06-pGuGd5DDVQ_8_4">2.42</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_ZUfWDOiJrESFdyfJo2gfWg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_9J9hcs3P0U-I30H9M7barQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_n3NrAPqzQkOL2zG2r8PjoA_8_6">3.38</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:29.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Options cancelled/forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_9J9hcs3P0U-I30H9M7barQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" scale="0" id="Tc_EhIl1DFdtE6lmDwKr0X0Aw_9_2">1,761</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_ZUfWDOiJrESFdyfJo2gfWg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_9J9hcs3P0U-I30H9M7barQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" scale="0" id="Tc_PimsX3S-q0Kc4gdr1Qm73A_9_4">2.42</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_ZUfWDOiJrESFdyfJo2gfWg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_9J9hcs3P0U-I30H9M7barQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_fop0zfHHYEuFxIXGhqGcMA_9_6">3.38</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:29.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Options outstanding as of December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw" contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_RVGfoikIBESMbmCXz6RCfw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_NXTmjEHySUCcevpBI2tM1Q_10_2">960,216</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_ZUfWDOiJrESFdyfJo2gfWg" contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_RVGfoikIBESMbmCXz6RCfw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="Tc_hFoR8lFpX0qxPRaV0WBr8A_10_4">3.46</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_ZUfWDOiJrESFdyfJo2gfWg" contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_RVGfoikIBESMbmCXz6RCfw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_jR5L1BxMTEqEKEduUxAEtw_10_6">5.13</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_9J9hcs3P0U-I30H9M7barQ" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_ketCbWfDs0if_J7kbreGVQ_10_8"> 6.25</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_RVGfoikIBESMbmCXz6RCfw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="0" id="Tc_RjydcVSzUkmbt7r1R3zbSw_10_10">163,237</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:27.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:19.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td colspan="8" style="vertical-align:bottom;width:68.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Options&#160;Outstanding</b></p></td><td style="vertical-align:bottom;width:0.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:17.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Options&#160;Exercisable</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:27.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:27.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted-&#160;Average&#160;Years</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Grant Date</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:27.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Remaining&#160;on&#160;Contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise</b></p></td></tr><tr><td style="vertical-align:bottom;width:27.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Life</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercisable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Price</b></p></td></tr><tr><td style="vertical-align:bottom;width:27.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_ZUfWDOiJrESFdyfJo2gfWg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ganx_ExercisePrice3.38Member_q48VnEGwiUKrGR7I5_LISQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="Tc_TNr-z7QybUCQH76gKgSkDQ_6_0">3.38</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw" contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ganx_ExercisePrice3.38Member_vX53-sp5zEGR0K2gPjCseA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_8_o27WsU40CbqHwl0ibtHA_6_2">512,516</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ganx_ExercisePrice3.38Member_q48VnEGwiUKrGR7I5_LISQ" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_bTZx_bpxdkqe4mTPxW2TmQ_6_4"> 8.91</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_ZUfWDOiJrESFdyfJo2gfWg" contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ganx_ExercisePrice3.38Member_vX53-sp5zEGR0K2gPjCseA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_HRkkaVsyjEOGA5Aey7rl9g_6_7">3.38</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_ZUfWDOiJrESFdyfJo2gfWg" contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ganx_ExercisePrice3.38Member_vX53-sp5zEGR0K2gPjCseA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="Tc_Pr6W5kSCKUm260aoiXKOIA_6_10">2.42</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw" contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ganx_ExercisePrice3.38Member_vX53-sp5zEGR0K2gPjCseA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="Tc_BVjGO8rmJU-Q_t-8fBs3FA_6_12">174,621</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_ZUfWDOiJrESFdyfJo2gfWg" contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ganx_ExercisePrice3.38Member_vX53-sp5zEGR0K2gPjCseA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="Tc_T9CVgF9toUOrrajOtCgq5g_6_15">3.38</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:27.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_ZUfWDOiJrESFdyfJo2gfWg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ganx_ExercisePrice5.86Member_ldKP04Tc_EiQ1aX3hzo_jQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="Tc_g5h2bb3dLECGUrRIPfvCdA_7_0">5.86</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw" contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ganx_ExercisePrice5.86Member_gBKLZo1l-0W49gJ_33Ix3Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_WRm1kNe0U0eChIjmTzQf_g_7_2">210,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ganx_ExercisePrice5.86Member_ldKP04Tc_EiQ1aX3hzo_jQ" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_Tcvd2hz2C0SBCSfjiMiC6Q_7_4"> 9.98</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_ZUfWDOiJrESFdyfJo2gfWg" contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ganx_ExercisePrice5.86Member_gBKLZo1l-0W49gJ_33Ix3Q" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_f2EyR5nvMU6ifNCLMwORMw_7_7">5.86</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_ZUfWDOiJrESFdyfJo2gfWg" contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ganx_ExercisePrice5.86Member_gBKLZo1l-0W49gJ_33Ix3Q" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="Tc_chaO6l44BEWgB-xIXVFKeQ_7_10">4.00</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:27.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_ZUfWDOiJrESFdyfJo2gfWg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ganx_ExercisePrice5.99Member_IRU-JBn3zUmz8JgkEa1wmQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="Tc_v4_4ZdPfWU6cZA4brpgSog_8_0">5.99</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw" contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ganx_ExercisePrice5.99Member__H3l5fnJok-E9OkINM3A4Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_D11WfjLmDEaq9LoQ0fBplw_8_2">45,500</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ganx_ExercisePrice5.99Member_IRU-JBn3zUmz8JgkEa1wmQ" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_Tm5xfNZuVUGV02N7MjPB3g_8_4"> 9.94</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_ZUfWDOiJrESFdyfJo2gfWg" contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ganx_ExercisePrice5.99Member__H3l5fnJok-E9OkINM3A4Q" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_fyFBkT7dVE6uIat-oNyj8g_8_7">5.99</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_ZUfWDOiJrESFdyfJo2gfWg" contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ganx_ExercisePrice5.99Member__H3l5fnJok-E9OkINM3A4Q" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="Tc_H3z0uy1DVUig8cKFc2YlGQ_8_10">4.34</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:27.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_ZUfWDOiJrESFdyfJo2gfWg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ganx_ExercisePrice7.80Member_azVHc_tr_02k1bZtu5dcVA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="Tc_oV4uTsHUC0G_ctTMnxrqVQ_9_0">7.80</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw" contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ganx_ExercisePrice7.80Member_IAhcMx9gQUiYIcwUzGxvUw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_gR_L-IzIxUKhCuEwG1nOZw_9_2">104,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ganx_ExercisePrice7.80Member_azVHc_tr_02k1bZtu5dcVA" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_w-fGu0WwHkCEOCO4F16UHg_9_4"> 9.61</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_ZUfWDOiJrESFdyfJo2gfWg" contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ganx_ExercisePrice7.80Member_IAhcMx9gQUiYIcwUzGxvUw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_s8wjgtmos0WIBOlDuuXbxw_9_7">780</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_ZUfWDOiJrESFdyfJo2gfWg" contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ganx_ExercisePrice7.80Member_IAhcMx9gQUiYIcwUzGxvUw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="Tc_TwMFcBkEcEeU1G7zDrC2HQ_9_10">5.63</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw" contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ganx_ExercisePrice7.80Member_IAhcMx9gQUiYIcwUzGxvUw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="Tc_KqUKQhALpkie0qeQsbatnA_9_12">2,664</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_ZUfWDOiJrESFdyfJo2gfWg" contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ganx_ExercisePrice7.80Member_IAhcMx9gQUiYIcwUzGxvUw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="Tc_8Vj-0oe64UqL1_XnrY7CWQ_9_15">780</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:27.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_ZUfWDOiJrESFdyfJo2gfWg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ganx_ExercisePrice10.03Member__Arw4xIJUEO-yWegbRND-A" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="Tc_VwCzY2KnrEOvhS6S87UNkA_10_0">10.03</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw" contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ganx_ExercisePrice10.03Member_t43zzwTn0EOG01iusAqyuA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_gRpYCRvXak2ob7v57Kkj_Q_10_2">88,200</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ganx_ExercisePrice10.03Member__Arw4xIJUEO-yWegbRND-A" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_Z4zKnt4i6kKbdmWKnoxFgQ_10_4"> 9.36</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_ZUfWDOiJrESFdyfJo2gfWg" contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ganx_ExercisePrice10.03Member_t43zzwTn0EOG01iusAqyuA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_hmlOc-v6hkScYntOm7l2DA_10_7">10.03</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_ZUfWDOiJrESFdyfJo2gfWg" contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ganx_ExercisePrice10.03Member_t43zzwTn0EOG01iusAqyuA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="Tc_oQakhTae602vBtWEdWdU9g_10_10">5.15</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On March&#160;3, 2021, the Board approved a 1-for-<span style="-sec-ix-hidden:Hidden_VOTL1rq_TUe6F_krbeB0zg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">0.880784</span></span> reverse stock split of the Company&#8217;s outstanding equity instruments. The reverse stock split was approved by the stockholders on March&#160;4, 2021 and became effective on March&#160;17, 2021. Shares of common stock underlying outstanding stock options were proportionately reduced from <ix:nonFraction unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw" contextRef="As_Of_3_16_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_-yJfbN_d1U6z9SG-fWFZ5A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Narr__i5V4SNPeEeBpgX21aOJZQ">588,000</ix:nonFraction> to <ix:nonFraction unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw" contextRef="As_Of_3_17_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_NETjxmYYrkyazfL5gwskGw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Narr_-VzToYB0eEaaUnIR9U50uw">517,902</ix:nonFraction> and the respective exercise prices, were proportionately increased from $<ix:nonFraction unitRef="Unit_Divide_USD_shares_ZUfWDOiJrESFdyfJo2gfWg" contextRef="Duration_3_16_2021_To_3_16_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_8OFhhtn3CkCh-eZfG1m3iA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="Narr_xH8J4V3YWEGTdgOYcfdJkA">2.97</ix:nonFraction> to $<ix:nonFraction unitRef="Unit_Divide_USD_shares_ZUfWDOiJrESFdyfJo2gfWg" contextRef="Duration_3_17_2021_To_3_17_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_VPlkneswlU6lplZPmfwMQg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="Narr_pjIfQsd-CEm0pCXk0L6GwA">3.38</ix:nonFraction> in accordance with the terms of the agreements governing such securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The reverse stock split did not impact the fair value of the stock option previously recorded and no modification accounting is required because all the three following conditions were met: &#160;(i)&#160;the fair value of the modified award is the same as the fair value of the original award immediately before the original award is modified; (ii)&#160;the vesting conditions of the modified award are the same as the vesting conditions of the original award immediately before the original award is modified and (iii)&#160;the classification of the modified award as an equity instrument is the same as the classification of the original award immediately before modification.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The aggregate intrinsic value of stock options is calculated as the difference between the weighted average exercise price of the underlying stock options and the market price of the Company&#8217;s common stock on December 31, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2021, the total unrecognized compensation cost related to non-vested stock options granted was USD <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_RVGfoikIBESMbmCXz6RCfw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="3" id="Narr_bfWEUsch40y9srJBmZGA-w">2,403</ix:nonFraction> thousand and is expected to be recognized over <ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_9J9hcs3P0U-I30H9M7barQ" format="ixt-sec:durwordsen" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="Narr_IdRRFMqMnkaq-r6sqf-yUw">4 years</ix:nonNumeric>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company uses the Black-Scholes option pricing model to estimate the fair value of stock options on the date of grant. The Black-Scholes option pricing model takes into account variables such as volatility, dividend yield rate, and risk-free interest rate. The computation of expected volatility and expected term of exercise is based on a representative group of companies with similar characteristics, including stage of product development and life science industry focus, since we do not have a reliable history. The risk-free interest rate is based on US treasury bonds whose term is consistent with the expected term of exercise of the stock options. The expected dividend yield is assumed to be <ix:nonFraction unitRef="Unit_Standard_pure_YPFUW3Xga0mVMPZT28RXUw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_9J9hcs3P0U-I30H9M7barQ" decimals="2" format="ixt-sec:numwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Narr_YAE_pIa09UWgD_r6kOnr5Q">zero</ix:nonFraction> as we have never paid dividends and have no current plans to pay any dividends on our common stock. The Company&#8217;s policy is to account for forfeitures when they occur.</p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">99</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_r0WkMGyIvUS_KoAjq4SNtA_1_2"></a><a id="Tc_XcLAnIptHkeAL9OTWzoHNg_2_2"></a><a id="Tc_tm5eVW3EQ0C8zgqU3rhbtw_2_4"></a><a id="Tc_l0OznwcZeEOXqu9m1hr5Xg_3_0"></a><a id="Tc_zLe2VuwpcEqJtVUVb-Je-g_3_1"></a><a id="Tc_pk18tQboR0ucX17mhCDbZw_3_3"></a><a id="Tc_BVfHdZPNFUyz6LKAHd-6SQ_4_0"></a><a id="Tc_MGW9V99sOU2CYQsHIbwcLg_4_3"></a><a id="Tc_8gwE_03DoUy9nVzYkzPhNQ_4_5"></a><a id="Tc_9QW0lxsVaEuFSvxMfvFmqg_5_0"></a><a id="Tc_u86EPmF0zUWnFmjoZyIjYQ_6_0"></a><a id="Tc_1tmec95uukCrT7_m5OSR-w_7_0"></a><a id="Tc_GeeXy3V3J0Ke0g_Kbzy_BA_7_2"></a><a id="Tc_wMmoaxabrUSyjd_al3V7hg_7_4"></a><a id="Tc_Bx1mlmB8LUOHeanyzLSTMw_1_2"></a><a id="Tc_sSIn2OZKWkGXt4D7xv617Q_2_2"></a><a id="Tc_DotYTB6ZiU20ImZ1hG1LTg_2_4"></a><a id="Tc_sU8cr9X-Wk-jvPGwG9JtNw_3_0"></a><a id="Tc_XvPH8FMuZUmMB2xUCJ2E3w_4_0"></a><a id="Tc_sVM1J_TxmUyeACMI_LZlPQ_5_0"></a><a id="Tc_XUx4WsJn10aL89jNP0QCoA_5_1"></a><a id="Tc_h_BGSyyOOUunO2My_VR-Mw_5_3"></a><ix:continuation id="Tb_IL4-MsoXiEm_eUc1pxjSwg_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The assumptions that the Company used to determine the grant-date fair value of stock options granted were as follows, presented on a weighted-average basis:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="Tb_c5r-Nc2qcky6_StOXdIJRw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:70.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:70.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Grant date fair value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_ZUfWDOiJrESFdyfJo2gfWg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_9J9hcs3P0U-I30H9M7barQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Tc_SgNa9vUWj0qkxVZIy0qWuQ_3_2">4.27</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_ZUfWDOiJrESFdyfJo2gfWg" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_oZ2efAweo0yRRNPJFNieTA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Tc_qFEkOw4jSU2SOc0prvNg1g_3_4">2.13</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:70.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_YPFUW3Xga0mVMPZT28RXUw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_9J9hcs3P0U-I30H9M7barQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Tc_c-iq8USlQkqzJ2H247VCxg_4_2">80</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_YPFUW3Xga0mVMPZT28RXUw" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_oZ2efAweo0yRRNPJFNieTA" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Tc_JQP-DBg7lkegb2uoCHFeWg_4_4">80</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:top;width:70.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected term (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_9J9hcs3P0U-I30H9M7barQ" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Tc_8fETv3pQhUWuozLlYqbKkg_5_2"> 5.66</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_oZ2efAweo0yRRNPJFNieTA" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Tc_gPDcO99pcUKQruAC2A7ASg_5_4"> 7.00</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:70.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_YPFUW3Xga0mVMPZT28RXUw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_9J9hcs3P0U-I30H9M7barQ" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Tc_VHcH4ImNHEmMqq1S7VJj3g_6_2">0.98</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_YPFUW3Xga0mVMPZT28RXUw" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_oZ2efAweo0yRRNPJFNieTA" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Tc_UirheTLX-EKyAN0fu4SzYA_6_4">0.67</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:70.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected dividend yield </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Each of these inputs is subjective and generally requires significant judgment to determine. The weighted average grant-date fair value of the Company&#8217;s stock options granted as of December 31, 2021 and 2020 was $<ix:nonFraction unitRef="Unit_Divide_USD_shares_ZUfWDOiJrESFdyfJo2gfWg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_9J9hcs3P0U-I30H9M7barQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_ea43AOs_L0iARzBFqaZ-wA">4.27</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Divide_USD_shares_ZUfWDOiJrESFdyfJo2gfWg" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_oZ2efAweo0yRRNPJFNieTA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_yqebQB9RoES6EA5I4CtuoA">2.13</ix:nonFraction>, respectively. Total stock-based compensation expense is recognized for stock options granted to employees and non-employees and has been reported in the Company&#8217;s condensed consolidated statements of operations and comprehensive loss as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Total stock-based compensation expense is recognized for stock options granted to employees and non-employees and has been reported in the Company&#8217;s consolidated statements of operations as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" id="Tb_PsEFNagtVE2s7QaF0bRXFg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;width:24.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td></tr><tr><td style="vertical-align:top;width:73.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_8kdx5frm8UGeszq3O_KyBg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Tc_qpdsHsNioUGf9fz6exgMiA_3_2">344,304</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_W_1SbimhkkmXrYE8c7oscg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Tc_5c_jCXNkPU6AKakDwBoNqg_3_4">57,049</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:73.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_idnllJAzZk6p-wCg6SCFow" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Tc_BGmwQyPLD068EaGsmt0hzQ_4_2">495,067</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_I180bvlxRk2MS8zltC_nhQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Tc_C4WDaa8KT0in2QDqlAbDJw_4_4">24,591</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:73.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_9J9hcs3P0U-I30H9M7barQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Tc_tvGeWI8N3Um6hV_TuHSMjw_5_2">839,371</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_oZ2efAweo0yRRNPJFNieTA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Tc_nnR4faCyikmWoM7uxiVdvw_5_4">81,640</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="Tb_NkbJOo_RrUS-bUfg0QObMQ" continuedAt="Tb_NkbJOo_RrUS-bUfg0QObMQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">16.&#160;&#160;&#160;&#160;Collaboration Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On April 20, 2021, the Company entered into a multi-target collaboration agreement with Zentalis Pharmaceuticals, Inc. (&#8220;Zentalis&#8221;) to discover new product candidates for the treatment of cancer. Under the terms of the agreement, the Company will use its in-licensed SEE-Tx&#174; computational platform technology to identify binding sites on target proteins and determine the potential suitability of these sites as drug targets, as well as their prospective therapeutic use in oncology. Pursuant the terms of the agreement, Zentalis agreed to pay the Company, on a program-by-program basis, a non-creditable, non-refundable, program initiation fee and reimbursement of expenses incurred by the Company in accordance with the agreed-upon research budget for each target in a multi-target agreement with a maximum of <ix:nonFraction unitRef="Unit_Standard_item_jlWcaGVl5kGYwaQ1kPo68Q" contextRef="As_Of_4_20_2021_srt_CounterpartyNameAxis_ganx_ZentalisPharmaceuticalsInc.Member_us-gaap_TypeOfArrangementAxis_ganx_MultiTargetCollaborationAgreementMember_MduiqnTW20mQ__WJtWGk9Q" decimals="INF" format="ixt-sec:numwordsen" name="ganx:CollaborativeArrangementMinimumNumberOfTargets" scale="0" id="Narr_y2tVMDkbhUSVieBkoEQGDA">five</ix:nonFraction> mutually agreed to targets at the option of Zentalis. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">With respect to any development program, and subject the delivery of the data package, the Company granted to Zentalis an option to obtain an exclusive, transferable worldwide license, with the right to sublicense, under relevant intellectual property rights and know-how of the Company arising from the collaboration to develop, manufacture and commercialize any products resulting from the development program. Zentalis may exercise the option, at its reasonable discretion, and shall use commercially reasonable efforts to develop and obtain market approval for products developed from the applicable programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Unless terminated earlier, the agreement expires at the expiration of the last valid claim of the licensed patents, subject to certain surviving rights and obligations. Zentalis and the Company can each terminate the agreement in the event of the bankruptcy or insolvency of the other party, or a material breach by the other party and failure to cure such breach within a certain period of time. Zentalis shall have the right, at its sole discretion, exercisable at any time to terminate the agreement on a program-by-program basis, upon ninety (<ix:nonNumeric contextRef="Duration_4_20_2021_To_4_20_2021_srt_CounterpartyNameAxis_ganx_ZentalisPharmaceuticalsInc.Member_us-gaap_TypeOfArrangementAxis_ganx_MultiTargetCollaborationAgreementMember_79uwIK2uDU2loW-PUu8mAg" format="ixt-sec:durday" name="ganx:CollaborativeArrangementTerminationNoticePeriodDays" id="Narr_Of1GX6YPSE6WQfAoZqfbCw">90</ix:nonNumeric>) days&#8217; prior written notice to the Company or, at any time, if a safety concerns arises with respect to any development program or product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In May 2021, the first target development program was identified, and the estimated development cost were approved and collected in July 2021. The transaction price of this first target development program includes (i) $<ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_5_31_2021_srt_CounterpartyNameAxis_ganx_ZentalisPharmaceuticalsInc.Member_us-gaap_TypeOfArrangementAxis_ganx_MultiTargetCollaborationAgreementMember_UAOVQT0JhEyX-WpaUYbKmA" decimals="-3" format="ixt:numdotdecimal" name="ganx:CollaborativeArrangementProgramInitiationFee" scale="3" id="Narr_fwjB0yYi9UWXcPslZkpXVQ">50</ix:nonFraction>&#160;thousand of fixed consideration as program initiation fee, (ii) up to $<ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_5_1_2021_To_5_31_2021_srt_CounterpartyNameAxis_ganx_ZentalisPharmaceuticalsInc.Member_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_ganx_MultiTargetCollaborationAgreementMember_VJHihOl1_0O-yMpbRCHaPA" decimals="-3" format="ixt:numdotdecimal" name="ganx:CollaborativeArrangementEmployeeAndExternalResearchAndDevelopmentCosts" scale="3" id="Narr__5VKm9j8M0O4Gx_3qmLyqg">272</ix:nonFraction> thousand as reimbursement for employee and external research and development cost, (iii) $<ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_5_1_2021_To_5_31_2021_srt_CounterpartyNameAxis_ganx_ZentalisPharmaceuticalsInc.Member_us-gaap_TypeOfArrangementAxis_ganx_MultiTargetCollaborationAgreementMember_nrRCfgERCkCz3HkVyPGAgA" decimals="-3" format="ixt:numdotdecimal" name="ganx:CollaborativeArrangementOptionExerciseFee" scale="3" id="Narr_84H8rhzPLUSH8dM3uCwnFg">250</ix:nonFraction> thousand subject to the exercise of a research program option, (iv) up to $<ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_5_1_2021_To_5_31_2021_srt_CounterpartyNameAxis_ganx_ZentalisPharmaceuticalsInc.Member_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_ganx_MultiTargetCollaborationAgreementMember_VJHihOl1_0O-yMpbRCHaPA" decimals="-5" format="ixt:numdotdecimal" name="ganx:CollaborativeArrangementEventBasedMilestonePayments" scale="6" id="Narr_MnDyBKJOfUSj2KIVmN0IqA">41.5</ix:nonFraction>&#160;million of variable consideration in the form of event-based milestone payments, if goals will be met in the future, and (v) other royalty-based payments based on future net sales.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">100</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_NkbJOo_RrUS-bUfg0QObMQ_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company analyzed the Zentalis Collaboration Agreement and concluded that it represents a contract with a customer within the scope of ASC 606 and ASC 808. Based on that evaluation, (i) the program initiation fee was recognized as revenue in full as of June 30, 2021 at a point in time, at program inception as there is <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2021_srt_CounterpartyNameAxis_ganx_ZentalisPharmaceuticalsInc.Member_us-gaap_TypeOfArrangementAxis_ganx_MultiTargetCollaborationAgreementMember_VaQZuPvZpUe8IpzXfakMYA" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:RevenueRemainingPerformanceObligation" scale="0" id="Narr__n4eTwyg-kmID8nh5x50Sw">no</ix:nonFraction> unsatisfied performance obligation; (ii) the performance obligation to provide development services, is satisfied over a period of time as services are performed and Zentalis receives the benefit for the services. The Company will recognize revenue associated with the performance obligation as the research and development services are provided using an input method, according to the costs incurred.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">As of December 31, 2021, the Company recognized $<ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_ganx_ZentalisPharmaceuticalsInc.Member_us-gaap_TypeOfArrangementAxis_ganx_MultiTargetCollaborationAgreementMember_vo15OpWqgkuGY59e7z-yzg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Narr_dTG6QnZZnUGo-g_K-9ZPQw">167</ix:nonFraction> thousand of revenues and reported current portion of deferred revenues for $<ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2021_srt_CounterpartyNameAxis_ganx_ZentalisPharmaceuticalsInc.Member_us-gaap_TypeOfArrangementAxis_ganx_MultiTargetCollaborationAgreementMember_VaQZuPvZpUe8IpzXfakMYA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="3" id="Narr_DtfD3VyQzku_j9nZ62uTTg">155</ix:nonFraction> thousand.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="Tc_xm5IMYIJgU-HzAvRK7rPAg_1_2"></a><a id="Tc_bGPgwNrjAUejosgQSSjc1A_2_2"></a><a id="Tc_606htsy48UymU1ESpmw51Q_3_2"></a><a id="Tc_eudn1d32H0aVMQ5nUBlmpA_3_5"></a><a id="Tc_x6_M7FUvZ0SKttA12lKcDQ_4_0"></a><a id="Tc_purWhDUQg06MJnQmDMWquw_4_2"></a><a id="Tc_HUUK7kO7KUWuj6Mja4UFZA_4_5"></a><a id="Tc_-GBXKyTigUqwODcllFalKA_5_0"></a><a id="Tc_QtXSi7qXhkq9NuKM8VsKcA_6_0"></a><a id="Tc_1wtHqRcIlU2EnD7u8E2g6w_6_2"></a><a id="Tc_GMsk5Tt1R0u_NN0lH9ahaQ_6_5"></a><a id="Tc_lca5-rfwxUGIQi4uAtUQOQ_1_2"></a><a id="Tc_1YcmZCV0qEKY2r1bR6khIw_2_2"></a><a id="Tc_Z_CpUBZDi02TZKU_WRQJVg_3_2"></a><a id="Tc_yY6TiENzXE-0v0goHxdReA_3_5"></a><a id="Tc_wAHdEmQwJkmk1biv2UWsPQ_4_0"></a><a id="Tc_w5E8yZxeAkG-0T62qYcwQQ_5_0"></a><a id="Tc_VhUxiG1ARUuArB-sERKFqQ_5_3"></a><a id="Tc_BKH1VzycOEWRWgAnHqwynA_5_6"></a><a id="Tc_mIyuMcxxQE-nwDn3tdEMcw_6_0"></a><a id="Tc_DyLiM3BPWUi7kLK5f2G2Ug_6_3"></a><a id="Tc_UM5YZD8upkyXVKBEUTBSkA_6_6"></a><a id="Tc_XtcvDLJq2UealIWPIWgOTQ_7_0"></a><a id="Tc_8oX3JMmAc0uAABOdXY65jg_8_0"></a><a id="Tc_Rj-gO9MoQ0GPtoaBNzpe3w_8_2"></a><a id="Tc_fXq5irKTaU2NWKtHd21Vbw_8_5"></a><a id="Tc_8oF3rFjgOUGiKWl1kSDDoQ_9_0"></a><a id="Tc_AWpXij7ZuEaL0gd72kzUmg_10_0"></a><a id="Tc_Vg8H2IsjQ0qPHkq8uv_XxA_10_3"></a><a id="Tc_B4kNZVpwRkiwW8ZVjxDhDg_10_6"></a><a id="Tc_zrgmLEsvBkSFbvU1J3Hp7Q_11_0"></a><a id="Tc__Vk-LDJI60iRWzXJ_gHNbQ_11_3"></a><a id="Tc_bG3kBG-ka0WoXt0V7jK_FA_11_6"></a><a id="Tc_gMHOvWp_Wkub0sgtPhJKww_12_0"></a><a id="Tc_Hlcu7XNp50WQbDcMoNu83Q_12_3"></a><a id="Tc_Lu7puFOUZkqgEGKhYUYq-A_12_6"></a><a id="Tc_LY4a-s-uYUOypakcgMcWmg_13_0"></a><a id="Tc_H-kx9z_4Bkye1rH2-_LDdw_13_3"></a><a id="Tc_PBOH5Z609UmMcWYr8XqE6w_13_6"></a><a id="Tc_Wg5SHeojGEShptSqbNZZQA_14_0"></a><a id="Tc_vb2kHxzH1UaU3sjUzqhStA_14_2"></a><a id="Tc_NAQx_i0vh06JG2v5DHQ_fw_14_5"></a><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" name="us-gaap:IncomeTaxDisclosureTextBlock" id="Tb_oFE0HtXL60euR2qH_3Jn0A" continuedAt="Tb_oFE0HtXL60euR2qH_3Jn0A_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">17.&#160;&#160;&#160;&#160;Income taxes</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company is subject to taxation in the U.S., Switzerland and in Spain. Taxes are recorded on an accrual basis and represent the allowances for taxes paid or to be paid for the&#160;year, calculated according to the current enacted rates and applicable laws. The Company has accumulated net tax losses since inception in Switzerland and in the U.S. The Company report a provision for income taxes due to the Spanish tax authorities pertaining to our branch Gain Therapeutics Sucursal en Espa&#241;a. Spanish corporate income taxes have been computed based on an effective tax rate of <ix:nonFraction unitRef="Unit_Standard_pure_YPFUW3Xga0mVMPZT28RXUw" contextRef="Duration_1_1_2021_To_12_31_2021_srt_StatementGeographicalAxis_country_ES_No2V5hdzvE6TY_AfyyLEBQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="Narr_uTvY43SVUEijduFQcfOdNA">25</ix:nonFraction>%, which represents the statutory tax rate, as no discrete items were noted in the computation of income taxes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">For financial reporting purposes, loss before income taxes provision includes the following components:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" id="Tb_gVCm6AbL20ikfyQ74mxfmg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:65.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:65.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:top;width:65.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Domestic</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" sign="-" scale="0" id="Tc_QEAoJq9h2kCCrZhdbv7rqA_4_3">7,601,640</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2020_To_12_31_2020_JDEb6LtAmEuXGmEieWNlsw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" sign="-" scale="0" id="Tc_BWlW_Hkaz0S-NEYngtBrKQ_4_6">623,667</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:65.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Foreign</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" sign="-" scale="0" id="Tc_ASrafMdIakG4ijkoN8blLw_5_3">6,284,958</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2020_To_12_31_2020_JDEb6LtAmEuXGmEieWNlsw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" sign="-" scale="0" id="Tc_T1lUE0E-dk6s5nSLXMGLvQ_5_6">2,948,629</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:65.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  Total </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="0" id="Tc_KrKHCwRSCEuN8gGIHB-KVg_6_3">13,886,598</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2020_To_12_31_2020_JDEb6LtAmEuXGmEieWNlsw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="0" id="Tc_dkUxnlfn30OorHLo0uNciQ_6_6">3,572,296</ix:nonFraction>)</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Following is the breakdown of the components of income tax expense provision for the&#160;years ended December&#160;31, 2021 and 2020:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="Tb_drHJ5l7DHUKz8vJU1tWGyg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:73.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:middle;width:73.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:middle;width:73.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;border-bottom:1.5pt solid #ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;width:2.33%;border-bottom:1.5pt solid #ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:top;width:73.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Current:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:73.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Federal</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:73.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">State</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:73.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Foreign</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="0" id="Tc_-4pdYSKWGEuRxESwz2jMrQ_7_3">4,008</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2020_To_12_31_2020_JDEb6LtAmEuXGmEieWNlsw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="0" id="Tc_hxbuuXG4RkC5syHlbaHfJg_7_6">5,386</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">        Total</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="0" id="Tc_rg15yn9EYkqHWcLmoP9opw_8_3">4,008</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2020_To_12_31_2020_JDEb6LtAmEuXGmEieWNlsw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="0" id="Tc_rpZj4DayXkSk2ZAmOQ2gMw_8_6">5,386</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:73.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">   Federal</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:73.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">State</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:73.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Foreign</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:73.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">       Total</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:73.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total income tax expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" id="Tc_ZDhV6JbNHE-FSoMBBXJe9A_14_3">4,008</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2020_To_12_31_2020_JDEb6LtAmEuXGmEieWNlsw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" id="Tc_vExJYCR48Em8W_nJdYNsTA_14_6">5,386</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">101</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_o6cwKLajs0aumR4QoSYE5Q_1_2"></a><a id="Tc_yCas_u144EuEujwVLoChAQ_2_2"></a><a id="Tc_SvXD_5i8Z06gs5Me0t3fRw_3_2"></a><a id="Tc_SBn4wabCKkat2GTGtMuMAw_3_5"></a><a id="Tc_zVVBgWUnv0yI-CpQnuCqPg_4_0"></a><a id="Tc_SiAcJwjC1ki1f9FtXTQukQ_4_2"></a><a id="Tc_fOxcyHkr5UCo800eDMPMwA_4_5"></a><a id="Tc_yuma0uJ2u0-hpkBuRzahzw_5_0"></a><a id="Tc_ABK96yq6HUitHY00A3cWZg_6_0"></a><a id="Tc_QOy2fmtc606Myn6gr9B8XA_6_2"></a><a id="Tc_G2mzd2jsI0mm8VNFo_mobg_6_5"></a><a id="Tc_uPvHjOLdPkSro56x2hG4Fg_9_0"></a><a id="Tc_l1RrcH6k3kWI2E8xwPYRIg_10_0"></a><a id="Tc_4MZKaVhWPEO6GB-yVrFM7A_11_0"></a><a id="Tc_nfvGCMGILk2Tvdx8USfNYA_12_0"></a><a id="Tc_QzKhJidSMkis69HOfcfHVA_13_0"></a><a id="Tc_RuGE5Hj8EE-u5Y4z7Ytapg_13_6"></a><a id="Tc_lxSOzhyMYUuz8ChHIEV8VQ_14_0"></a><a id="Tc_AAsH7oEBfUOc4bGmX4cHYQ_14_6"></a><a id="Tc_aGH6w8NM20Wwz-bbk4kQ0w_15_0"></a><a id="Tc_ngcHp20t_Ei7NZduD5cwmQ_15_2"></a><a id="Tc_AoLhwWmicUW7hZ22tdwd7Q_15_5"></a><a id="Tc_Va-hA36FtEezlhKsH7w72w_16_0"></a><a id="Tc_FOg4c8d1_0SWcYu2DPJeHg_17_0"></a><a id="Tc_NjNHteXrJEmmcor_kamj6Q_18_0"></a><a id="Tc_wCuzZww4jE-1wm7oDxgBxw_18_2"></a><a id="Tc_iGdax1fd2kCq1nLeeJyIaQ_18_5"></a><a id="Tc_QWdA0hBRjUSA3a1xWRJbZg_20_0"></a><a id="Tc__Giye9lXC0moLEAo8HInYg_21_0"></a><a id="Tc_06gB6Fhc0E-LIQSrTpirLQ_21_3"></a><a id="Tc_ivwKT3dio0qFE_--JTTKog_21_6"></a><ix:continuation id="Tb_oFE0HtXL60euR2qH_3Jn0A_cont1" continuedAt="Tb_oFE0HtXL60euR2qH_3Jn0A_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">The breakdown of domestic and foreign NOLs and related DTAs are reported in the following table:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="Tb_MWuFn9dl1ESUxjcaVQ4LEg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:65.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:65.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:65.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:65.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;width:2.13%;border-bottom:1.5pt solid #ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:top;width:65.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">NOLs (foreign) </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember_eYHQNzPoa0Kj3sShxdX8jQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="0" id="Tc_vSk-afSa6k6YCFfb-vrSZw_4_3">12,021,483</ix:nonFraction>)</p></td><td style="vertical-align:bottom;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2020_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember_cfBf_8Ckq0Gp_Dh77YRizw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="0" id="Tc_73PpJ8hLyUKwcB_BdPlcNw_4_6">6,076,187</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:65.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">NOLs (domestic)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_dHaFDA1AQUSlfDaHicQ8uw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="0" id="Tc_W_NgyEO3QE-TYDSd-sDqSA_5_3">6,218,309</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2020_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_MuNTVlrNBkqVSW1-Y7sqjA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="0" id="Tc_IrsGpdi4FEmq7XhDrONusg_5_6">532,209</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:65.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">   Total NOLs</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="0" id="Tc_VcmfUU_OZ0OLncy5fhexXA_6_3">18,239,792</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="0" id="Tc_NOHgLD-iIUSA0zUdiup7jA_6_6">6,608,396</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:65.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:65.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:65.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Deferred tax assets related to:</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:65.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  Net operating loss (foreign)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign" scale="0" id="Tc_e32TC2DG2Ue3r3vUfjxRGQ_10_3">2,243,668</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign" scale="0" id="Tc_10xpFZdSVEafqnyzjjbKNA_10_6">1,111,942</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:65.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  Net operating loss (domestic)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic" scale="0" id="Tc_ypOjss2_Jk-er09ZS9uBew_11_3">1,677,610</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic" scale="0" id="Tc__TYk3ZF0hkKSxHFpHcvgSw_11_6">146,451</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:65.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  Stock based compensation</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="0" id="Tc_4WxjMjPl9ECUCTcJfTOznQ_12_3">253,439</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="0" id="Tc_1UZQWx9j2ke2Lhv4jILShg_12_6">22,465</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:65.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  Warrant expense</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A" decimals="0" format="ixt:numdotdecimal" name="ganx:DeferredTaxAssetsFmwWarrant" scale="0" id="Tc_bOL-kz1s2E-8vh5pFURCEg_13_3">284,531</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:65.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  Other temporary differences</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOther" scale="0" id="Tc_EN6lGmxrqkGPdxnifQt3Eg_14_3">4,010</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:65.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">            Total deferred tax assets</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="0" id="Tc_umAkbou2IECt31Yl0M8NyQ_15_3">4,463,258</ix:nonFraction></p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="0" id="Tc_XM86NcnVXEeqONrER0PoCQ_15_6">1,280,858</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:65.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Deferred tax liabilities</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:65.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  Depreciation and other</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="0" id="Tc_BAccOHUKEEWHWzeNP60tQg_17_3">1,137</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="0" id="Tc_5pv9E4RDFUOZrVrRyypsMA_17_6">2,682</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:65.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">            Total deferred tax liabilities</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilities" scale="0" id="Tc_DeNgQORlxEiW5iZvcTAbZw_18_3">1,137</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilities" scale="0" id="Tc_285BUrx1Bk2JUKT3ub5sdQ_18_6">2,682</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:65.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:65.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  Valuation allowance</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="0" id="Tc_Fj8e-_YqO0W4dC0nPPpZkg_20_3">4,462,121</ix:nonFraction></p></td><td style="vertical-align:bottom;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="0" id="Tc_OHNFMHvsuESZpyk2PxPX7w_20_6">1,278,176</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:65.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">According to Swiss tax law, the NOLs can be carried forward for seven&#160;years and will begin to expire commencing from 2025 for the NOLs generated in 2017.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">According to the U.S. Tax Cuts and Jobs Act (&#8220;TCJA&#8221;) that was signed into law on December 22, 2017, federal net operating losses (&#8220;NOLs&#8221;) incurred after December 31, 2017 can be carried forward indefinitely and are limited to 80% of taxable income in any tax period. The NOLs and tax credit carryforwards are subject to review and possible adjustment by the Internal Revenue Service and state tax authorities. NOLs and tax credit carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant stockholders over a three-year period in excess of 50 percent, as defined under Sections 382 and 383 of the Internal Revenue Code, as well as similar state provisions. This could limit the amount of tax attributes that can be utilized annually to offset future taxable income or tax liabilities. The amount of the annual limitation is determined based on the value of the Company immediately prior to the ownership change. Subsequent ownership changes may further affect the limitation in future years. The Company has not done an analysis to determine whether or not ownership changes have occurred since inception.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Deferred tax assets require an assessment of both positive and negative evidence when determining whether it is more likely than not that they can be recovered. Such assessment is made on a jurisdiction-by-jurisdiction basis. The Company&#8217;s assessment includes an evaluation of cumulative losses, future sources of taxable income, exclusive of reversing temporary differences, and risks and uncertainties related to our business. As of December&#160;31, 2021 and 2020, the Company has determined that there is not sufficient evidence that the Company will be able to realize the benefits of the domestic and foreign deferred tax assets. Accordingly, due to uncertainty regarding the realization of our deferred tax assets, the Company continues to maintain a full valuation allowance on the Company&#8217;s domestic and foreign deferred tax assets as of December&#160;31, 2021 and 2020 and until sufficient positive evidence will exist to support the reversal of the valuation allowance.</p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">102</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_vlSOxwuaVkiG6CdoZkvNkg_1_3"></a><a id="Tc_knBMh_MGNku65tfY9AsUEQ_2_3"></a><a id="Tc_Y4Hdw6HmjkyxPqHnxPLVTw_3_3"></a><a id="Tc_a1C0Uya4pU6HF1spNTHU9Q_3_6"></a><a id="Tc_hD7CcY4QC0WRuMqs-ZSofg_4_0"></a><a id="Tc_ArPY-azi-0ufLPgW-gG6EQ_5_0"></a><a id="Tc_Dyn-482wXkWS1T9JPoqF4w_6_0"></a><a id="Tc_of1lQ2UrhUOuGEt_CJDSng_7_0"></a><a id="Tc_qU7-D9ybnkeEY3zT8PSeEQ_8_0"></a><a id="Tc_SO3yFePkq0Ki-yt7KIBFhQ_9_0"></a><a id="Tc_4dkoWFEEREKMDpHYP3ffKw_10_0"></a><ix:continuation id="Tb_oFE0HtXL60euR2qH_3Jn0A_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A reconciliation of income tax expense (benefit) computed at the statuory federal income tax rate to the Compan&#8217;s effective tax rate as reflected in the consolidated financial statements is as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="Tb_H970w4VlGkC8hi-kuU7gBg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:71.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;width:1.44%;border-bottom:1.5pt solid #ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Federal income tax at US statutory rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_YPFUW3Xga0mVMPZT28RXUw" contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" decimals="4" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Tc_F1Ry8MUkUkqE3ItNfpzcgA_4_3">21.00</ix:nonFraction>%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_YPFUW3Xga0mVMPZT28RXUw" contextRef="Duration_1_1_2020_To_12_31_2020_JDEb6LtAmEuXGmEieWNlsw" decimals="4" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Tc_nAfsyQFgrEOZ0e2MaJJxig_4_6">21.00</ix:nonFraction>%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">State income taxes, net of federal benefit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_YPFUW3Xga0mVMPZT28RXUw" contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" decimals="4" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="Tc_XTZp2duPI0WFvIn37oZbmw_5_3">6.52</ix:nonFraction>%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_YPFUW3Xga0mVMPZT28RXUw" contextRef="Duration_1_1_2020_To_12_31_2020_JDEb6LtAmEuXGmEieWNlsw" decimals="4" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="Tc_zTPWPjamCkKX4DU3XejMYg_5_6">6.52</ix:nonFraction>%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Permanent differences</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(<ix:nonFraction unitRef="Unit_Standard_pure_YPFUW3Xga0mVMPZT28RXUw" contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" decimals="4" format="ixt:numdotdecimal" name="ganx:EffectiveIncomeTaxRateReconciliationPermanentDifferences" sign="-" scale="-2" id="Tc_lw-d5khB10Oxq4eUGR0Lnw_6_3">0.10</ix:nonFraction>)%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_YPFUW3Xga0mVMPZT28RXUw" contextRef="Duration_1_1_2020_To_12_31_2020_JDEb6LtAmEuXGmEieWNlsw" decimals="4" format="ixt:numdotdecimal" name="ganx:EffectiveIncomeTaxRateReconciliationPermanentDifferences" scale="-2" id="Tc_S5vBRuBlr0SULEd7l-PPew_6_6">0.00</ix:nonFraction>%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Provision to return</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_YPFUW3Xga0mVMPZT28RXUw" contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" decimals="4" format="ixt:numdotdecimal" name="ganx:EffectiveIncomeTaxRateReconciliationProvisionToReturn" scale="-2" id="Tc_9XoRK8OI6UCaZ6ig_9RZeQ_7_3">0.13</ix:nonFraction>%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_YPFUW3Xga0mVMPZT28RXUw" contextRef="Duration_1_1_2020_To_12_31_2020_JDEb6LtAmEuXGmEieWNlsw" decimals="4" format="ixt:numdotdecimal" name="ganx:EffectiveIncomeTaxRateReconciliationProvisionToReturn" scale="-2" id="Tc_uFGRnRPnjEG35bk1qNyl4Q_7_6">0.00</ix:nonFraction>%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Foreign tax</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(<ix:nonFraction unitRef="Unit_Standard_pure_YPFUW3Xga0mVMPZT28RXUw" contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" decimals="4" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" sign="-" scale="-2" id="Tc_w0Ai9oibmUOy3UChiffjGQ_8_3">0.03</ix:nonFraction>)%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(<ix:nonFraction unitRef="Unit_Standard_pure_YPFUW3Xga0mVMPZT28RXUw" contextRef="Duration_1_1_2020_To_12_31_2020_JDEb6LtAmEuXGmEieWNlsw" decimals="4" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" sign="-" scale="-2" id="Tc_39Gp-9oWd0qczz135EQdcQ_8_6">0.15</ix:nonFraction>)%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(<ix:nonFraction unitRef="Unit_Standard_pure_YPFUW3Xga0mVMPZT28RXUw" contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" decimals="4" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" sign="-" scale="-2" id="Tc_lMjlkLYK6UqDTRdDyCwjcA_9_3">27.52</ix:nonFraction>)%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(<ix:nonFraction unitRef="Unit_Standard_pure_YPFUW3Xga0mVMPZT28RXUw" contextRef="Duration_1_1_2020_To_12_31_2020_JDEb6LtAmEuXGmEieWNlsw" decimals="4" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" sign="-" scale="-2" id="Tc_ezjt3V6G4UWLr93ZWsjDew_9_6">27.37</ix:nonFraction>)%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Effective income tax rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_YPFUW3Xga0mVMPZT28RXUw" contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" decimals="4" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="Tc_UO01vQR0YkiS2ATYjFznIg_10_3">0.00</ix:nonFraction>%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_YPFUW3Xga0mVMPZT28RXUw" contextRef="Duration_1_1_2020_To_12_31_2020_JDEb6LtAmEuXGmEieWNlsw" decimals="4" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="Tc_ArVXID8A5EGfCPHmEfO7DQ_10_6">0.00</ix:nonFraction>%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2021 and 2020, the Company had <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" scale="0" id="Narr_QW3XK8KIi0GV7dg_XmnQbA"><ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" scale="0" id="Narr_Jo3oaeIBv0eJwCB7ytyn-g">no</ix:nonFraction></ix:nonFraction> accrued interest or penalties related to uncertain tax positions and <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2020_To_12_31_2020_JDEb6LtAmEuXGmEieWNlsw" decimals="0" format="ixt-sec:numwordsen" name="ganx:ExpenseForInterestAndPenaltiesRelatedToUncertainTaxPositionRecognizedInStatementOfOperations" scale="0" id="Narr_oHyKKKuzc0GXHuS4MOUnkA"><ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" decimals="0" format="ixt-sec:numwordsen" name="ganx:ExpenseForInterestAndPenaltiesRelatedToUncertainTaxPositionRecognizedInStatementOfOperations" scale="0" id="Narr_tFipniISB0m65tqpHO53Fw">no</ix:nonFraction></ix:nonFraction> amounts have been recognized in the Company&#8217;s statement of operations.There are no changes expected to occur in the next 12&#160;months with respect to the status of the Company&#8217;s uncertain tax positions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company files income tax returns in Switzerland, Spain and in the United States. Tax years from 2018 and after remain subject to examination by the taxing jurisdictions. The NOL and tax carryforwards remain subject to review until utilized. The Company is currently not under examination by any tax authorities.</p></ix:continuation><a id="Tc_6k7C-v4Y4USOO49V9ug8mg_1_2"></a><a id="Tc_sdEJMsa9jkearwjArySpWw_2_2"></a><a id="Tc_DZCezPnBJkWq-z8vzWVqTA_2_4"></a><a id="Tc_pPf_6J70bU65VWJYOs1J4w_3_0"></a><a id="Tc_wFsipX7yQUeAYqaf1Vfbeg_3_2"></a><a id="Tc_uiZQVSPwGEGYIJM-jkOinQ_4_0"></a><a id="Tc_ZfGDcsiRC0W3ClBLige-uw_4_2"></a><a id="Tc_-JLf42wHnECROdz0g0yb6A_5_0"></a><a id="Tc_Aah_GqTQYUqhcBX4scaDuw_6_0"></a><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" name="us-gaap:EarningsPerShareTextBlock" id="Tb_2jLidE0Kg06shwlAy7pgRQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">18.&#160;&#160;&#160;&#160;Net loss per common share</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Basic net loss per common share is computed by dividing the net loss available to common stockholders by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per common share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock and potentially dilutive securities outstanding during the period determined using the treasury-stock and if-converted methods. For purposes of the diluted net loss per share calculation, preferred stock, warrants and stock options are considered to be potentially dilutive securities, but are excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive and therefore basic and diluted net loss per share are the same for all periods presented.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table sets forth the outstanding potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to do so would have resulted in anti-dilutive impacts:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="Tb_Wh77tnIY20SL3BVV5sH3MA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series A Preferred Stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_SeriesAPreferredStockMember_gYxd91evBkC5xqONi1hr9g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_gbIT6hAmAUGelU7hd74UJg_3_4">1,185,879</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:74.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series B Preferred Stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_PreferredClassBMember_ulJHYyt9xkm7k2JpVT1HlQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_QuEs6viYOk2RQF3tKA5LRw_4_4">2,695,600</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:74.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Options to purchase common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_nWZin8CUEka_hYHuxWQ98g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_R9Sgam6QPEORc8I_JOG_1w_5_2">960,216</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_o5CVJWPFxkyUPRNzDIKUWw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_pp8yXbCr0UGUIidnnzL64g_5_4">429,822</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:74.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrants to purchase common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_eFtEzOEVSUW8fCSfS0makQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_WnwkJyCC1E2uGF0zW_WRPA_6_2">425,387</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_BLTwMarrSki4A2b_zuzjjQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_LzwB71SvuUymNPPSvsuyzg_6_4">237,249</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The net loss per share for the comparative period ending December 31, 2020 of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_ZUfWDOiJrESFdyfJo2gfWg" contextRef="Duration_1_1_2020_To_12_31_2020_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_BhPyaAaDOkudfThK5f94MA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Narr_NLgvbe9UyUubD_mP5ymM_A">1.17</ix:nonFraction> has been recomputed to take into account the reverse stock split, resulting in $<ix:nonFraction unitRef="Unit_Divide_USD_shares_ZUfWDOiJrESFdyfJo2gfWg" contextRef="Duration_1_1_2020_To_12_31_2020_JDEb6LtAmEuXGmEieWNlsw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Narr_lnv6wpAYYEy5KsUOe9Wrqg">1.33</ix:nonFraction> net loss per share.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="Tb_R7PwWZNc2Eag0vSJfhgAUg" continuedAt="Tb_R7PwWZNc2Eag0vSJfhgAUg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">19.&#160;&#160;&#160;&#160;Related Parties</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Dr.&#160;Khalid Islam, the Chairman of our Board of Directors, shareholders and founder of the Company, is currently the Chairman of the board of directors of Minoryx, and therefore Minoryx is considered a related party. In December&#160;2017, the Company entered into an exclusive worldwide, royalty-bearing, assignable, transferable license agreement with Minoryx Therapeutics SL to use and exploit Minoryx&#8217;s IP and into an exclusive worldwide, royalty-bearing, assignable, transferable sublicense agreement with Universitat de Barcelona and Institucio Catalana Recerca Estudis Avancats in order to be able to develop its business, directly or indirectly, through sub-licensing to third parties </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">103</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_a3a4da12_669c_4636_b63e_4a0984123f2f"></a><a id="_a3a4da12_669c_4636_b63e_4a0984123f2f_2"></a><a id="_a3a4da12_669c_4636_b63e_4a0984123f2f_3"></a><a id="_313cfb62_d1fc_4807_8e93_f697b16000af"></a><a id="_313cfb62_d1fc_4807_8e93_f697b16000af_2"></a><a id="_313cfb62_d1fc_4807_8e93_f697b16000af_3"></a><a id="_47192d0e_df68_46fd_aadc_d014d1884c98"></a><a id="_47192d0e_df68_46fd_aadc_d014d1884c98_2"></a><a id="_47192d0e_df68_46fd_aadc_d014d1884c98_3"></a><ix:continuation id="Tb_R7PwWZNc2Eag0vSJfhgAUg_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">or any other way of operation. According to the Minoryx License Agreement, &#160;the Company shall pay to Minoryx as royalties:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">an amount equal to </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_pure_YPFUW3Xga0mVMPZT28RXUw" contextRef="Duration_12_1_2017_To_12_31_2017_srt_RangeAxis_srt_MaximumMember_us-gaap_RelatedPartyTransactionAxis_ganx_LicenseAgreementWithMinoryxTherapeuticsSlMember_wfhEAoIeSEyyfIL5XTMUAQ" decimals="INF" format="ixt:numdotdecimal" name="ganx:RelatedPartyTransactionPercentageOfNetRevenuesBasedOnOneCompositionOfMatterClaim" scale="-2" id="Narr_3GCgSf9STk2NH1R3xdrs2Q">8</ix:nonFraction>%</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> of (i)&#160;net revenues with regard to products that would infringe (a)&#160;at least one composition of matter claim or (b)&#160;Minoryx molecules and (ii)&#160;sublicensing revenues;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">an amount equal to </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_pure_YPFUW3Xga0mVMPZT28RXUw" contextRef="Duration_12_1_2017_To_12_31_2017_srt_RangeAxis_srt_MaximumMember_us-gaap_RelatedPartyTransactionAxis_ganx_LicenseAgreementWithMinoryxTherapeuticsSlMember_wfhEAoIeSEyyfIL5XTMUAQ" decimals="INF" format="ixt:numdotdecimal" name="ganx:RelatedPartyTransactionPercentageOfNetRevenuesBasedOnOneMethodOfClaim" scale="-2" id="Narr_9RrLxq3GUEWdtKGvUYuU5g">3</ix:nonFraction>%</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> of net revenues with regard to products that would infringe at least (a)&#160;one method of claim or (b)&#160;Minoryx know-how.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In addition to royalties, the Company shall pay Minoryx certain milestones payments of <ix:nonFraction unitRef="Unit_Standard_pure_YPFUW3Xga0mVMPZT28RXUw" contextRef="Duration_12_1_2017_To_12_31_2017_us-gaap_RelatedPartyTransactionAxis_ganx_LicenseAgreementWithMinoryxTherapeuticsSlMember_cbGjmh51ckuCzbppGr1veQ" decimals="4" format="ixt:numdotdecimal" name="ganx:RelatedPartyTransactionPercentageOfConsiderationReceived" scale="-2" id="Narr_T_vq8OXMSECzjDX3-oXlEA">1.25</ix:nonFraction>% of any consideration received in the event of a sale of the Company or substantially all of the assets, including by merger, change of control, or reorganization.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">As of December 31, 2021 and 2020, there were <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2020_us-gaap_RelatedPartyTransactionAxis_ganx_LicenseAgreementWithMinoryxTherapeuticsSlMember_VIe1l_ajWEuJhOrR7dlifQ" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:AccountsReceivableRelatedParties" scale="0" id="Narr_2a-czAJVJEeqLR6yOMwBYA"><ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2021_us-gaap_RelatedPartyTransactionAxis_ganx_LicenseAgreementWithMinoryxTherapeuticsSlMember_uoLGxPyxJ0uSfZ7e2uoHkg" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:AccountsReceivableRelatedParties" scale="0" id="Narr_Jh1rPwTkvEGpIGxvGSEPxg">no</ix:nonFraction></ix:nonFraction> receivables and payables, revenues or expenses with Minoryx.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" name="ganx:OtherInformationDisclosureTextBlock" id="Tb_mIk3_1imsESQghW-XYmV6Q" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">20.&#160;&#160;&#160;&#160;Other Information</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Own Shares</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company does not hold, either directly or indirectly, its own shares and in these periods &#160;has not purchased or alienated its own shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Commitments</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31,2021, the Company had research commitments with contractual maturity date in 2022 for $ <ix:nonFraction unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA" contextRef="As_Of_12_31_2021_us-gaap_OtherCommitmentsAxis_ganx_CollaborationAgreementsMember_Yr71bAiK8EiGzhgz_kIr8Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ContractualObligationDueInNextTwelveMonths" scale="0" id="Narr_yxiEHRpycUKGhbZeCkoyvw">453,305</ix:nonFraction>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA" name="us-gaap:SubsequentEventsTextBlock" id="Tb__3krA90G70GT5FRy3WR0NQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">21.&#160;&#160;&#160;&#160;Significant events after the balance sheet date</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:14.2pt;margin:0pt 0pt 12pt 0pt;">None.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">104</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_75cfc751_6ca0_4378_8348_b1d60791aadb"></a><a id="ITEM9CHANGESINANDDISAGREEMENTSWITHACCOUN"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">ITEM&#160;9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL</span><span style="font-weight:normal;"> DISCLOSURE</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">None.</p><a id="_0b26ade3_dd9a_462a_9401_29cba7f35b61"></a><a id="ITEM9ACONTROLSANDPROCEDURES_641227"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">ITEM&#160;9A. CONTROLS AND PROCEDURES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Evaluation of Disclosure Controls and Procedures</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act), as of the end of the period covered by this Annual Report. Based upon that evaluation, as a result of the material weakness in internal control over financial reporting described below, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were not effective as of December 31, 2021. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Management&#8217;s Report on Internal Control Over Financial Reporting</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">This Annual Report on Form&#160;10-K does not include a report of management&#8217;s assessment regarding internal control over financial reporting as permitted in this transition period under the rules&#160;of the SEC for newly public companies.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Attestation Report of Independent Registered Public Accounting Firm</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">This Annual Report on Form 10-K does not include an attestation report of our independent registered public accounting firm regarding internal controls over financial reporting. We are not required to engage our independent audit firm to perform an audit of the effectiveness of our internal controls over financial reporting for as long as we are an &#8220;emerging growth company&#8221; pursuant to the provisions of the JOBS Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Previously Reported Material Weakness</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim consolidated financial statements will not be prevented or detected on a timely basis. As previously reported, in connection with the preparation of our consolidated financial statements as of and for the year ended December 31, 2020, we identified material weaknesses in our internal control over financial reporting. The material weaknesses we identified were as follows: (i)&#160;lack of sufficient accounting and supervisory personnel who have the appropriate level of technical accounting experience and training, and (ii)&#160;lack of adequate procedures and controls to ensure that accurate financial statements can be prepared and reviewed on a timely basis for reporting purposes. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 6pt 0pt;">We have initiated a remediation plan designed to improve our internal control over financial reporting. This includes: </p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:17.85pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">hiring additional resources with appropriate technical knowledge and expertise for financial reporting purposes, and provided training;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:17.85pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">implementing </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a more</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> streamlined process for the preparation and review of financial information;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:17.85pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">initiating</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> a process aimed at strengthening, formalizing, documenting accounting processes, policies and internal controls procedures with the assistance of a professional accounting service firm;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:17.85pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">engaging</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> of consultants to provide additional US GAAP technical accounting expertise;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:17.85pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">commencing the implementation of</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> a new ERP system to automate certain processes, including a purchase requisition system, expense reporting system, consolidation, budgeting and reporting.</span></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">As result of &#160;these actions we believe that as of December 31, 2021, there is no longer a material weakness related to lack of sufficient accounting and supervisory personnel who have the appropriate level of technical accounting experience and training; however, the material weakness related to lack of adequate procedures and controls to ensure that accurate financial statements can be prepared and reviewed on a timely basis for reporting purposes is unremediated.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">105</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We believe progress was made in 2021 to enhance and strengthen our internal control over financial reporting. Management remains committed to improving the Company&#8217;s control environment, although <span style="background:#ffffff;">the Company will require additional time to demonstrate the effectiveness of its remediation efforts.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Changes in Internal Control Over Financial Reporting</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Other than as noted above there have been no changes in internal control over financial reporting during 2021.</span></p><a id="_58b80530_ec49_49a8_839f_221933a6f9c0"></a><a id="ITEM9BOTHERINFORMATION_35024"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">ITEM&#160;9B. OTHER INFORMATION</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">Not</span> <span style="font-weight:normal;">applicable.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">106</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_63ee52d1_405d_4d55_bed5_678969b9e6b0"></a><a id="PARTIII_82225"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">PART&#160;III</p><a id="ITEM10DIRECTORSEXECUTIVEOFFICERSANDCORPO"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">ITEM&#160;10. DIRECTORS, EXECUTIVE OFFICERS, AND CORPORATE GOVERNANCE</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The information required by this item is incorporated by reference to our Proxy Statement relating to our 2022 Meeting of Stockholders. The Proxy statement will be filed with the Securities and Exchange Commission within 120&#160;days of the end of the fiscal&#160;year ended December&#160;31, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Code of Ethics</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have a code of ethics that applies to all of our employees, including our principal executive officer, principal financial officer and principal accounting officer. This code of ethics is posted on our Internet website.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Internet address for our website is www.gaintherapeutics.com, and the code of ethics may be found on the &#8220;Corporate Governance&#8221; section of our &#8220;Investors&#160;&amp; Media&#8221; webpage.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">We intend to satisfy the disclosure requirement under Item&#160;5.05 of Form&#160;8-K regarding an amendment to, or waiver from, a provision of this code of ethics by posting such information on our website, at the address and location specified above, or as otherwise required by the Nasdaq Global Market.</span></p><a id="_3a5490a7_f453_4603_9478_51b6269a1159"></a><a id="_ITEM_11._EXECUTIVE"></a><a id="ITEM11EXECUTIVECOMPENSATION_126511"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">ITEM&#160;11. EXECUTIVE COMPENSATION</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The information required by this item is incorporated by reference to our Proxy Statement relating to our 2022 Meeting of Stockholders. The Proxy statement will be filed with the Securities and Exchange Commission within 120&#160;days of the end of the fiscal&#160;year ended December&#160;31, 2021.</p><a id="_9658c1d1_d72e_486f_83fd_067b583fd01b"></a><a id="ITEM12SECURITYOWNERSHIPOFCERTAINBENEFICI"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">ITEM&#160;12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND</span><span style="font-weight:normal;"> RELATED STOCKHOLDER MATTERS</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">The information required by this item is incorporated by reference to our Proxy Statement relating to our 2022 Meeting of Stockholders. The Proxy statement will be filed with the Securities and Exchange Commission within 120&#160;days of the end of the fiscal&#160;year ended December&#160;31, 2021.</span></p><a id="_20386955_81fd_47e7_a334_2b1e4e3cd808"></a><a id="_ITEM_13._CERTAIN"></a><a id="ITEM13CERTAINRELATIONSHIPSANDRELATEDTRAN"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">ITEM&#160;13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS AND DIRECTOR INDEPENDENCE</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The information required by this item is incorporated by reference to our Proxy Statement relating to our 2022 Meeting of Stockholders. The Proxy statement will be filed with the Securities and Exchange Commission within 120&#160;days of the end of the fiscal&#160;year ended December&#160;31, 2021.</p><a id="_d9eb7a3e_bb51_4807_bf5a_c3a93834ccba"></a><a id="ITEM14PRINCIPALACCOUNTANTFEESANDSERVICES"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">ITEM&#160;14. PRINCIPAL ACCOUNTANT FEES AND SERVICES</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">The information required by this item is incorporated by reference to our Proxy Statement relating to our 2022 Meeting of Stockholders. The Proxy statement will be filed with the Securities and Exchange Commission within 120&#160;days of the end of the fiscal&#160;year ended December&#160;31, 2021.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">107</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:9.2pt;"><a id="_31710a15_b210_45a2_903e_07ddfd9d3597"></a><a id="PARTIV_897554"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 6pt 0pt;">PART&#160;IV</p><a id="ITEM15EXHIBITSANDFINANCIALSTATEMENTSCHED"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">ITEM&#160;15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(a)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Financial Statements, Financial Statement Schedules and Exhibits.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Financial Statements.</span></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 6pt 36pt;">The financial statements required by Item 15(a) are filed as part of this Annual Report on Form 10-K under Item 8 &#8220;Financial Statements and Supplementary Data.&#8221;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Financial Statement Schedules.</span></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 6pt 36pt;">All schedules are omitted as the required information is not applicable or the information is presented in the Consolidated financial statements or related notes.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(3)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Exhibits.</span></td></tr></table><div style="margin-top:6pt;"></div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:8.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0pt 3pt;"><span style="font-size:9pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:52.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="4" style="vertical-align:bottom;width:35.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Incorported by Reference</b></p></td></tr><tr><td style="vertical-align:bottom;width:8.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:top;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:52.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Exhibit</b></p></td><td style="vertical-align:top;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.72%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Form</p></td><td style="vertical-align:bottom;width:9.67%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">File No.</p></td><td style="vertical-align:bottom;width:8.15%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Exhibit</p></td><td style="vertical-align:bottom;width:9.83%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Filing Date</p></td></tr><tr><td style="vertical-align:top;width:8.16%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">3.1</p></td><td style="vertical-align:top;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:52.6%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="https://www.sec.gov/Archives/edgar/data/1819411/000114036121009490/nt10015006x18_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;background:#ffffff;">Amended and Restated Certificate of Incorporation of Gain Therapeutics,&#160;Inc.</span></a></p></td><td style="vertical-align:top;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.72%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">8-K</p></td><td style="vertical-align:top;width:9.67%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">001-40237</p></td><td style="vertical-align:top;width:8.15%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">3.1</p></td><td style="vertical-align:top;width:9.83%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">3/17.2021</p></td></tr><tr><td style="vertical-align:top;width:8.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">3.2</p></td><td style="vertical-align:top;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:52.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="https://www.sec.gov/Archives/edgar/data/1819411/000114036121009490/nt10015006x18_ex3-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;background:#ffffff;">Amended and Restated Bylaws of Gain Therapeutics,&#160;Inc.</span></a></p></td><td style="vertical-align:top;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">8-K</p></td><td style="vertical-align:top;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">001-40237</p></td><td style="vertical-align:top;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">3.2</p></td><td style="vertical-align:top;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">3/17/2021</p></td></tr><tr><td style="vertical-align:top;width:8.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">4.1*</p></td><td style="vertical-align:top;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:52.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="ganx-20211231xex4d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Description of Securities</span></a> </p></td><td style="vertical-align:top;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">4.2</p></td><td style="vertical-align:top;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:52.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="https://www.sec.gov/Archives/edgar/data/1819411/000114036121005495/nt10015006x7_ex4-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Investors&#8217; Rights Agreement, dated as of July&#160;20, 2020, by and among Gain Therapeutics, Inc. and certain holders of its capital stock</span><sup style="font-family:'Times New Roman','Times','serif';font-size:6.75pt;font-style:normal;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;">(a)</sup></a></p></td><td style="vertical-align:top;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">S-1</p></td><td style="vertical-align:top;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">333-253303</p></td><td style="vertical-align:top;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">4.2</p></td><td style="vertical-align:top;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">2/19/2021</p></td></tr><tr><td style="vertical-align:top;width:8.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">10.1</p></td><td style="vertical-align:top;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:52.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="https://www.sec.gov/Archives/edgar/data/1819411/000114036121007922/nt10015006x9_ex10-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Indemnification Agreement for Officers and Directors(a)</span></a></p></td><td style="vertical-align:top;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">S-1/A</p></td><td style="vertical-align:top;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">333-253303</p></td><td style="vertical-align:top;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">10.3</p></td><td style="vertical-align:top;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">3/10/2021</p></td></tr><tr><td style="vertical-align:top;width:8.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">10.2</p></td><td style="vertical-align:top;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:52.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="https://www.sec.gov/Archives/edgar/data/1819411/000114036121007922/nt10015006x9_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">2020 Omnibus Incentive Plan(a)</span></a></p></td><td style="vertical-align:top;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">S-1/A</p></td><td style="vertical-align:top;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">333-253303</p></td><td style="vertical-align:top;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">10.2</p></td><td style="vertical-align:top;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">3/10/2021</p></td></tr><tr><td style="vertical-align:top;width:8.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:52.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1819411/000155837021017044/ganx-20211223xex10d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Gain Therapeutics, Inc. 2021 Inducement Equity Incentive Plan</span></a> </p></td><td style="vertical-align:top;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">8-K</p></td><td style="vertical-align:top;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">001-40237</p></td><td style="vertical-align:top;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">10.1</p></td><td style="vertical-align:top;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">12/28/2021</p></td></tr><tr><td style="vertical-align:top;width:8.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:52.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="https://www.sec.gov/Archives/edgar/data/1819411/000155837021017044/ganx-20211223xex10d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Stock Option Agreement under the 2021 Inducement Plan</span></a></p></td><td style="vertical-align:top;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">8-K</p></td><td style="vertical-align:top;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">001-40237</p></td><td style="vertical-align:top;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">10.2</p></td><td style="vertical-align:top;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">12/28/2021</p></td></tr><tr><td style="vertical-align:top;width:8.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">10.3</p></td><td style="vertical-align:top;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:52.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="https://www.sec.gov/Archives/edgar/data/1819411/000114036121005495/nt10015006x7_ex10-3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Minoryx Agreement between Minoryx Therapeutics, S.L. and GT Gain Therapeutics SA</span></a></p></td><td style="vertical-align:top;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">S-1</p></td><td style="vertical-align:top;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">333-253303</p></td><td style="vertical-align:top;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">10.3</p></td><td style="vertical-align:top;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">2/19/2021</p></td></tr><tr><td style="vertical-align:top;width:8.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">10.4</p></td><td style="vertical-align:top;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:52.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="https://www.sec.gov/Archives/edgar/data/1819411/000114036121005495/nt10015006x7_ex10-4.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;background:#ffffff;">Executive Employment Agreement, effective as of July&#160;20, 2020, between Gain Therapeutics, Inc. and Eric I. Richman(a)</span></a></p></td><td style="vertical-align:top;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">S-1</p></td><td style="vertical-align:top;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">333-253303</p></td><td style="vertical-align:top;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">10.4</p></td><td style="vertical-align:top;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">2/19/2021</p></td></tr><tr><td style="vertical-align:top;width:8.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">10.5</p></td><td style="vertical-align:top;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:52.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="https://www.sec.gov/Archives/edgar/data/1819411/000114036121005495/nt10015006x7_ex10-5.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Executive Employment Agreement, effective as of August&#160;13, 2020, between Gain Therapeutics, Inc. and Manolo Bellotto (a)</span></a></p></td><td style="vertical-align:top;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">S-1</p></td><td style="vertical-align:top;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">333-253303</p></td><td style="vertical-align:top;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">10.5</p></td><td style="vertical-align:top;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">2/19/2021</p></td></tr><tr><td style="vertical-align:top;width:8.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">10.6</p></td><td style="vertical-align:top;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:52.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="https://www.sec.gov/Archives/edgar/data/1819411/000114036121005495/nt10015006x7_ex10-6.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Consulting Agreement effective as of September 1, 2019, between GT Gain Therapeutics S.A. and Sal Calabrese</span></a></p></td><td style="vertical-align:top;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">S-1</p></td><td style="vertical-align:top;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">333-253303</p></td><td style="vertical-align:top;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">10.6</p></td><td style="vertical-align:top;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">2/19/2021</p></td></tr><tr><td style="vertical-align:top;width:8.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">10.7</p></td><td style="vertical-align:top;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:52.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="https://www.sec.gov/Archives/edgar/data/1819411/000114036121005495/nt10015006x7_ex10-8.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;background:#ffffff;">Executive Employment Agreement, effective as of November 2, 2020, between Gain Therapeutics, Inc. and Salvatore Calabrese(a)</span></a></p></td><td style="vertical-align:top;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">S-1</p></td><td style="vertical-align:top;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">333-253303</p></td><td style="vertical-align:top;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">10.8</p></td><td style="vertical-align:top;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">2/19/2021</p></td></tr><tr><td style="vertical-align:top;width:8.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">10.8*</p></td><td style="vertical-align:top;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:52.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="ganx-20211231xex10d8.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;background:#ffffff;">Executive Employment Agreement, effective as of October 15, 2021, between Gain Therapeutics, Inc. and Matthias Alder</span></a></p></td><td style="vertical-align:top;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">10.9</p></td><td style="vertical-align:top;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:52.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="https://www.sec.gov/Archives/edgar/data/1819411/000114036121005495/nt10015006x7_ex10-10.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;background:#ffffff;">Form of Exchange Agreement</span></a></p></td><td style="vertical-align:top;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">S-1</p></td><td style="vertical-align:top;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">333-253303</p></td><td style="vertical-align:top;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">10.10</p></td><td style="vertical-align:top;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">2/19/2021</p></td></tr><tr><td style="vertical-align:top;width:8.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">10.10</p></td><td style="vertical-align:top;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:52.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="https://www.sec.gov/Archives/edgar/data/1819411/000114036121005495/nt10015006x7_ex10-11.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;background:#ffffff;">Form of Placement Agent Warrant</span></a></p></td><td style="vertical-align:top;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">S-1</p></td><td style="vertical-align:top;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">333-253303</p></td><td style="vertical-align:top;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">10.11</p></td><td style="vertical-align:top;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">2/19/2021</p></td></tr><tr><td style="vertical-align:top;width:8.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">21.1*</p></td><td style="vertical-align:top;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:52.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1819411/000114036121005495/nt10015006x7_ex21-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Subsidiaries of Registrant</span></a> </p></td><td style="vertical-align:top;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">23.1*</p></td><td style="vertical-align:top;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:52.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="ganx-20211231xex23d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Consent of Independent Registered Public Accounting Firm.</span></a></p></td><td style="vertical-align:top;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">24.1*</p></td><td style="vertical-align:top;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:52.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9pt;" href="#POWEROFATTORNEY_564449"><span style="font-style:normal;font-weight:normal;background:#ffffff;">Power of Attorney (included in the signature pages attached to this Annual Report on Form 10-K).</span></a></p></td><td style="vertical-align:top;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">31.1*</p></td><td style="vertical-align:top;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:52.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="ganx-20211231xex31d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;background:#ffffff;">Section 302 Certification of Chief Executive Officer.</span></a></p></td><td style="vertical-align:top;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">31.2*</p></td><td style="vertical-align:top;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:52.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="ganx-20211231xex31d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;background:#ffffff;">Section 302 Certification of Chief Financial Officer.</span></a></p></td><td style="vertical-align:top;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">32.1#</p></td><td style="vertical-align:top;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:52.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="ganx-20211231xex32d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Section 906 Certification of Chief Executive Officer and Chief Financial Officer.</span></a></p></td><td style="vertical-align:top;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="background:#ffffff;">101.INS*</span></p></td><td style="vertical-align:top;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:52.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Inline XBRL Instance Document &#8211; the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document</p></td><td style="vertical-align:top;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="background:#ffffff;">101.SCH*</span></p></td><td style="vertical-align:top;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:52.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="background:#ffffff;">Inline XBRL Taxonomy Extension Schema Document.</span></p></td><td style="vertical-align:top;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="background:#ffffff;">101.CAL*</span></p></td><td style="vertical-align:top;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:52.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Inline XBRL Taxonomy Extension Calculation Linkbase Document.</p></td><td style="vertical-align:top;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="background:#ffffff;">101.DEF*</span></p></td><td style="vertical-align:top;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:52.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="background:#ffffff;">Inline XBRL Taxonomy Extension Definition Linkbase Document.</span></p></td><td style="vertical-align:top;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="background:#ffffff;">101.LAB*</span></p></td><td style="vertical-align:top;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:52.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="background:#ffffff;">Inline XBRL Taxonomy Extension Label Linkbase Document.</span></p></td><td style="vertical-align:top;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="background:#ffffff;">101.PRE*</span></p></td><td style="vertical-align:top;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:52.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Inline XBRL Taxonomy Extension Presentation Linkbase Document.</p></td><td style="vertical-align:top;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">104</p></td><td style="vertical-align:top;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:52.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).</p></td><td style="vertical-align:top;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Filed herewith.</p></td><td style="vertical-align:top;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:8.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">(a)&#160;Management contract or compensatory plan or arrangement.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">108</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">*&#160;Filed herewith</p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 12pt 0pt;">#&#160;<span style="background:#ffffff;">The certifications furnished in Exhibit 32.1 hereto are deemed to accompany this Annual Report on Form 10-K are not deemed filed with the SEC and are not to be incorporated by reference into any filing of the Registrant under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date of this Annual Report on Form 10-K.</span></p><a id="_3a2f6ef2_e29e_4cca_b578_7a6e2bcc2f23"></a><a id="_ITEM_16._FORM"></a><a id="ITEM16FORM10KSUMMARY_232137"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">ITEM&#160;16. FORM&#160;10-K SUMMARY</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:21.6pt;margin:0pt 0pt 12pt 0pt;">None.</p><a id="_fa6d5081_7231_47a7_8b84_aafc2255f34c"></a><a id="SIGNATURES_996224"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">SIGNATURES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the requirements of Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">GAIN THERAPEUTICS, INC.</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Registrant)</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">March 25, 2022</p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:44.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Eric I Richman</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date</p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.99%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Eric I. Richman</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Executive Officer </p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(<i style="font-style:italic;">Principal Executive Officer</i>)</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">March 25, 2022</p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:44.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Salvatore Calabrese</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date</p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.99%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Salvatore Calabrese</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Financial Officer</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(<i style="font-style:italic;">Principal Financial and Accounting Officer</i>)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">109</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="POWEROFATTORNEY_564449"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;background:#ffffff;">POWER OF ATTORNEY</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">We, the undersigned directors and officers of Gain Therapeutics, Inc., hereby severally constitute and appoint Eric Richman, Salvatore Calabrese and Matthias Alder, and each of them singly, our true and lawful attorneys, with full power to them, and to each of them singly, to sign for us and in our names in the capacities indicated below, all amendments to this Annual Report on Form 10-K, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as each of us might or could do in person, and hereby ratifying and confirming all that said attorneys, and each of them, or their substitute or substitutes, shall do or cause to be done by virtue of this Power of Attorney.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant in the capacities and on the dates indicated.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:48.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:48.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:48.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dated: March 25, 2022</p></td><td style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:48.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Eric Richman</p></td></tr><tr><td style="vertical-align:bottom;width:48.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:48.96%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Eric Richman</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Executive Officer and Director </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Principal Executive Officer)</p></td></tr><tr><td style="vertical-align:bottom;width:48.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:48.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dated: March 25, 2022</p></td><td style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:48.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Salvatore Calabrese</p></td></tr><tr><td style="vertical-align:bottom;width:48.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:48.96%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Salvatore Calabrese </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Financial Officer</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Principal Financial and Accounting Officer)</p></td></tr><tr><td style="vertical-align:bottom;width:48.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:48.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:48.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Khalid Islam</p></td></tr><tr><td style="vertical-align:bottom;width:48.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dated: March 25, 2022</p></td><td style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:48.96%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Khalid Islam</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chairman of the Board of Director</p></td></tr><tr><td style="vertical-align:bottom;width:48.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:48.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:48.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Dov Goldstein</p></td></tr><tr><td style="vertical-align:bottom;width:48.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dated: March 25, 2023</p></td><td style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:48.96%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dov Goldstein</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td></tr><tr><td style="vertical-align:bottom;width:48.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:48.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:48.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:48.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Han Peter Hasler</p></td></tr><tr><td style="vertical-align:bottom;width:48.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dated: March 25, 2022</p></td><td style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:48.96%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Hans Peter Hasler</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td></tr><tr><td style="vertical-align:bottom;width:48.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:48.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:48.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:48.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Gwen Melincoff</p></td></tr><tr><td style="vertical-align:bottom;width:48.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dated: March 25, 2022</p></td><td style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:48.96%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Gwen Melincoff </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td></tr><tr><td style="vertical-align:bottom;width:48.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:48.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:48.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Claude Nicaise</p></td></tr><tr><td style="vertical-align:bottom;width:48.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dated: March 25, 2022</p></td><td style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:48.96%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Claude Nicaise</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td></tr><tr><td style="vertical-align:bottom;width:48.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:48.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:48.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Jeff Riley</p></td></tr><tr><td style="vertical-align:bottom;width:48.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dated: March 25, 2022</p></td><td style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:48.96%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Jeff Riley</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td></tr><tr><td style="vertical-align:bottom;width:48.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:48.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">110</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:10.64%;margin-right:10.64%;margin-top:30pt;page-break-after:avoid;width:78.72%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>2
<FILENAME>ganx-20211231xex4d1.htm
<DESCRIPTION>EX-4.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 3/25/2022 06:19:01 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">EXHIBIT 4.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">DESCRIPTION OF THE REGISTRANT&#8217;S SECURITIES<br>REGISTERED PURSUANT TO SECTION 12 OF THE<br>SECURITIES ACT OF 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">The following is a description of the common stock, par value $0.0001 per share (the &#8220;Common Stock&#8221;) of Gain Therapeutics, Inc. (the &#8220;Company&#8221;) which is the only security of the Company registered pursuant to Section 12 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">General</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><font style="font-size:12pt;">The Company is authorized to issue 50,000,000 shares of Common Stock, par value $0.0001 per share, of which 11,883,368 shares were issued and outstanding as of February 28, 2022, and 10,000,000 shares of preferred stock, par value $0.0001 per share no shares of which are outstanding as of December 31, 2021. Unless our board of directors determines otherwise, we will issue all shares of our capital stock in uncertificated form.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><font style="font-size:12pt;">The following description summarizes selected information regarding the Common Stock, as well as relevant provisions of: (i) the Company&#8217;s Restated Certificate of Incorporation, as amended, as currently in effect, (ii) the Company&#8217;s Amended and Restated bylaws, as currently in effect and (iii) the Delaware General Corporation Law (the &#8220;DGCL&#8221;). The following summary description of the Common Stock is qualified in its entirety by, and should be read in conjunction with, the Articles and the bylaws, copies of which have been filed as exhibits to the Company&#8217;s periodic reports under the Exchange Act, and the applicable provisions of the DGCL.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Common Stock</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20pt;margin:0pt;"><font style="font-size:12pt;">The following description of certain rights of our common stock does not purport to be complete and is qualified in its entirety by reference to our amended and restated certificate of incorporation and our amended and restated bylaws.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20pt;margin:0pt;"><i style="font-size:12pt;font-style:italic;">Voting Rights</i><font style="font-size:12pt;">. Holders of shares of our common stock are entitled to one vote for each share held of record on all matters on which stockholders are entitled to vote generally, including the election or removal of directors elected by our stockholders generally. The holders of our common stock do not have cumulative voting rights in the election of directors.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20pt;margin:0pt;"><i style="font-size:12pt;font-style:italic;">Dividends and Liquidation Rights</i><font style="font-size:12pt;">. Holders of shares of our common stock are entitled to receive dividends when, as and if declared by our board of directors out of funds legally available therefor, subject to any statutory or contractual restrictions on the payment of dividends and to any restrictions on the payment of dividends imposed by the terms of any outstanding preferred stock. Upon our liquidation, dissolution or winding up and after payment in full of all amounts required to be paid to creditors and to the holders of preferred stock having liquidation preferences, if any, the holders of shares of our common stock will be entitled to receive our remaining assets available for distribution on a pro rata basis.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20pt;margin:0pt;"><i style="font-size:12pt;font-style:italic;">Miscellaneous</i><font style="font-size:12pt;">. All shares of our common stock that will be outstanding are fully paid and non-assessable. The common stock will not be subject to further calls or assessments by us. Holders of shares of our common stock do not have preemptive, subscription, redemption or conversion rights. There will be no redemption or sinking fund provisions applicable to the common stock. The rights powers, preferences and privileges of our common stock will be subject to those of the holders of any shares of our preferred stock or any other series or class of stock we may authorize and issue in the future.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20pt;margin:0pt;"><i style="font-size:12pt;font-style:italic;">Listing</i><font style="font-size:12pt;">. Our Common Stock is listed on the Nasdaq Global Market under the symbol &#8220;GANX.&#8221;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20pt;margin:0pt;"><i style="font-size:12pt;font-style:italic;">Transfer Agent and Registrar</i><font style="font-size:12pt;">. The transfer agent and registrar for our Common Stock is Philadelphia Stock Transfer, Inc.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Preferred Stock</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20pt;margin:0pt;"><i style="font-size:12pt;font-style:italic;">Voting Rights</i><font style="font-size:12pt;">. No shares of preferred stock are issued or outstanding as of December 31, 2021. Our Amended Charter authorizes our board of directors to establish one or more series of preferred stock (including convertible preferred stock). Unless required by law or any stock exchange, the authorized shares of preferred stock will be available for issuance without further action by the holders of our common stock. Our board of directors is able to determine, with respect to any series of preferred stock, the powers (including voting powers), preferences and relative, participating, optional or other special rights, and the qualifications, limitations or restrictions thereof, including, without limitation:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:20pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">the designation of the series;</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:20pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">the number of shares of the series, which our board of directors may, except where otherwise provided in the preferred stock designation, increase (but not above the total number of authorized shares of the class) or decrease (but not below the number of shares then outstanding);</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:20pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">whether dividends, if any, will be cumulative or non-cumulative and the dividend rate of the series;</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:20pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">the dates at which dividends, if any, will be payable;</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:20pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">the redemption or repurchase rights and price or prices, if any, for shares of the series;</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:20pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">the terms and amounts of any sinking fund provided for the purchase or redemption of shares of the series;</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:20pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">the amounts payable on shares of the series in the event of any voluntary or involuntary liquidation, dissolution or winding-up of our affairs;</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:20pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">whether the shares of the series will be convertible into shares of any other class or series, or any other security, of us or any other entity, and, if so, the specification of the other class or series or other security, the conversion price or prices or rate or rates, any rate adjustments, the date or dates as of which the shares will be convertible and all other terms and conditions upon which the conversion may be made;</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:20pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">restrictions on the issuance of shares of the same series or of any other class or series; and</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:20pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">the voting rights, if any, of the holders of the series.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">2</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20pt;margin:0pt;"><font style="font-size:12pt;">We could issue a series of preferred stock that could, depending on the terms of the series, impede or discourage an acquisition attempt or other transaction that some, or a majority, of the holders of our common stock might believe to be in their best interests or in which the holders of our common stock might receive a premium over the market price of the shares of our common stock. Additionally, the issuance of preferred stock may adversely affect the rights of holders of our common stock by restricting dividends on the common stock, diluting the voting power of the common stock or subordinating the liquidation rights of the common stock. As a result of these or other factors, the issuance of preferred stock could have an adverse impact on the market price of our common stock.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Anti-Takeover Effects of Our Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws and Certain Provisions of Delaware Law</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20pt;margin:0pt;"><font style="font-size:12pt;">Our Amended Charter, Amended Bylaws and the DGCL contains provisions that are intended to enhance the likelihood of continuity and stability in the composition of our board of directors. These provisions are intended to avoid costly takeover battles, reduce our vulnerability to a hostile or abusive change of control and enhance the ability of our board of directors to maximize stockholder value in connection with any unsolicited offer to acquire us. However, these provisions may have an anti-takeover effect and may delay, deter or prevent a merger or acquisition of our company by means of a tender offer, a proxy contest or other takeover attempt that a stockholder might consider in its best interest, including those attempts that might result in a premium over the prevailing market price for the shares of common stock held by stockholders.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Authorized but Unissued Capital Stock</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20pt;margin:0pt;"><font style="font-size:12pt;">The authorized but unissued shares of common stock and preferred stock are available for future issuance without stockholder approval, subject to any limitations imposed by the listing standards of the Nasdaq Global Market. These additional shares may be used for a variety of corporate finance transactions, acquisitions and employee benefit plans. The existence of authorized but unissued and unreserved common stock and preferred stock could make more difficult or discourage an attempt to obtain control of us by means of a proxy contest, tender offer, merger or otherwise.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Business Combinations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20pt;margin:0pt;"><font style="font-size:12pt;">We are subject to Section 203 of the DGCL, which prohibits persons deemed to be &#8220;interested stockholders&#8221; from engaging in a &#8220;business combination&#8221; with a publicly held Delaware corporation for three years following the date these persons become interested stockholders unless the business combination is, or the transaction in which the person became an interested stockholder was, approved in a prescribed manner or another prescribed exception applies. Generally, an &#8220;interested stockholder&#8221; is a person who, together with affiliates and associates, owns, or within three years prior to the determination of interested stockholder status did own, 15% or more of a corporation&#8217;s voting stock. Generally, a &#8220;business combination&#8221; includes a merger, asset or stock sale, or other transaction resulting in a financial benefit to the interested stockholder. The existence of this provision may have an anti-takeover effect with respect to transactions not approved in advance by the board of directors.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">3</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">No Cumulative Voting</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20pt;margin:0pt;"><font style="font-size:12pt;">Under Delaware law, the right to vote cumulatively does not exist unless the certificate of incorporation specifically authorizes cumulative voting. Our Amended Charter does not authorize cumulative voting. Therefore, stockholders holding a majority of the shares of our stock entitled to vote generally in the election of directors will be able to elect all our directors.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Special Stockholder Meetings</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20pt;margin:0pt;"><font style="font-size:12pt;">Our Amended Charter provides that special meetings of our stockholders may be called at any time only by or at the direction of the board of directors or the chairman of the board of directors. Our Amended Bylaws prohibit the conduct of any business at a special meeting other than as specified in the notice for such meeting. These provisions may have the effect of deferring, delaying, or discouraging hostile takeovers, or changes in control or management of our company.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Director Nominations and Stockholder Proposals</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20pt;margin:0pt;"><font style="font-size:12pt;">Our amended and restated bylaws establish advance notice procedures with respect to stockholder proposals and the nomination of candidates for election as directors, other than nominations made by or at the direction of the board of directors or a committee of the board of directors. In order for any matter to be &#8220;properly brought&#8221; before a meeting, a stockholder will have to comply with advance notice requirements and provide us with certain information. Generally, to be timely, a stockholder&#8217;s notice must be received at our principal executive offices not less than 90 days nor more than 120 days prior to the first anniversary date of the immediately preceding annual meeting of stockholders. Our Amended Bylaws also specify requirements as to the form and content of a stockholder&#8217;s notice. Our Amended Bylaws allow the chairman of the meeting at a meeting of the stockholders to adopt rules and regulations for the conduct of meetings that may have the effect of precluding the conduct of certain business at a meeting if the rules and regulations are not followed. These provisions may also defer, delay, or discourage a potential acquirer from conducting a solicitation of proxies to elect the acquirer&#8217;s own slate of directors or otherwise attempting to influence or obtain control of the company.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Stockholder Action by Written Consent</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20pt;margin:0pt;"><font style="font-size:12pt;">Pursuant to Section 228 of the DGCL, any action required to be taken at any annual or special meeting of the stockholders may be taken without a meeting, without prior notice, and without a vote if a consent or consents in writing, setting forth the action so taken, is or are signed by the holders of outstanding stock having not less than the minimum number of votes that would be necessary to authorize or take such action at a meeting at which all shares of our stock entitled to vote thereon were present and voted, unless our amended and restated certificate of incorporation will provide otherwise. Our Amended Charter will preclude stockholder action by written consent at any time.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">4</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Amendment of Amended and Restated Certificate of Incorporation or Bylaws</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20pt;margin:0pt;"><font style="font-size:12pt;">The DGCL provides generally that the affirmative vote of a majority of the shares entitled to vote on any matter is required to amend a corporation&#8217;s certificate of incorporation or bylaws, unless a corporation&#8217;s certificate of incorporation or bylaws, as the case may be, requires a greater percentage. Our bylaws may be amended or repealed by a majority vote of our board of directors or by the affirmative vote of the holders of at least 66 2/3% of the votes which all our stockholders would be entitled to cast in any annual election of directors. In addition, the affirmative vote of the holders of at least 66 2/3% of the votes which all our stockholders would be entitled to cast in any election of directors will be required to amend or repeal or to adopt any provisions inconsistent with any of the provisions of our certificate described above.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20pt;margin:0pt;"><font style="font-size:12pt;">The foregoing provisions of our Amended Charter and Amended Bylaws could discourage potential acquisition proposals and could delay or prevent a change in control. These provisions are intended to enhance the likelihood of continuity and stability in the composition of our board of directors and in the policies formulated by our board of directors and to discourage certain types of transactions that may involve an actual or threatened change of control. These provisions are designed to reduce our vulnerability to an unsolicited acquisition proposal. The provisions also are intended to discourage certain tactics that may be used in proxy fights. However, such provisions could have the effect of discouraging others from making tender offers for our shares and, as a consequence, they also may inhibit fluctuations in the market price of our shares of common stock that could result from actual or rumored takeover attempts. Such provisions also may have the effect of preventing changes in our management or delaying or preventing a transaction that might benefit you or other minority stockholders.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Dissenters&#8217; Rights of Appraisal and Payment</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20pt;margin:0pt;"><font style="font-size:12pt;">Under the DGCL, with certain exceptions, our stockholders will have appraisal rights in connection with a merger or consolidation of us. Pursuant to the DGCL, stockholders who properly request and perfect appraisal rights in connection with such merger or consolidation will have the right to receive payment of the fair value of their shares as determined by the Delaware Court of Chancery.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Stockholders&#8217; Derivative Actions</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20pt;margin:0pt;"><font style="font-size:12pt;">Under the DGCL, any of our stockholders may bring an action in our name to procure a judgment in our favor, also known as a derivative action, provided that the stockholder bringing the action is a holder of our shares at the time of the transaction to which the action relates or such stockholder&#8217;s stock thereafter devolved by operation of law.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Exclusive Forum</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20pt;margin:0pt;"><font style="font-size:12pt;">Our Amended Charter will provide that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware will, to the fullest extent permitted by applicable law, be the sole and exclusive forum for: (1) any derivative action or proceeding brought on our behalf; (2) any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers or other employees or stockholders to us or our stockholders; (3) any action asserting a claim against us, any director or our officers and employees arising </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">5</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">pursuant to any provision of the DGCL, our Amended Charter or our amended and restated bylaws, or as to which the DGCL confers exclusive jurisdiction on the Court of Chancery; or (4) any action asserting a claim against us, any director or our officers or employees that is governed by the internal affairs doctrine; provided that the exclusive forum provisions will not apply to suits brought to enforce any liability or duty created by the Exchange Act, or to any claim for which the federal courts have exclusive jurisdiction. Our Amended Charter further provides that, unless we consent in writing to the selections of an alternative forum, the federal district courts are the sole and exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act, subject to a final adjudication in the State of Delaware of the enforceability of such exclusive forum provision. We note that investors cannot waive compliance with the federal securities laws and the rules and regulations thereunder. Although we believe the provision benefits us by providing increased consistency in the application of Delaware law in the types of lawsuits to which it applies, the provision may have the effect of discouraging lawsuits against our directors and officers.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Officers and Directors</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20pt;margin:0pt;"><font style="font-size:12pt;">The DGCL authorizes corporations to limit or eliminate the personal liability of directors to corporations and their stockholders for monetary damages for breaches of directors&#8217; fiduciary duties, subject to certain exceptions. Our Amended Charter includes a provision that eliminates the personal liability of directors for monetary damages to the corporation or its stockholders for any breach of fiduciary duty as a director, except to the extent such exemption from liability or limitation thereof is not permitted under the DGCL. The effect of these provisions is to eliminate the rights of us and our stockholders, through stockholders&#8217; derivative suits on our behalf, to recover monetary damages from a director for breach of fiduciary duty as a director, including breaches resulting from grossly negligent behavior. However, exculpation does not apply to any breaches of the director&#8217;s duty of loyalty, any acts or omissions not in good faith or that involve intentional misconduct or knowing violation of law, any authorization of dividends or stock redemptions or repurchases paid or made in violation of the DGCL, or for any transaction from which the director derived an improper personal benefit.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20pt;margin:0pt;"><font style="font-size:12pt;">Our Amended Bylaws generally provide that we must indemnify and advance expenses to our directors and officers to the fullest extent authorized by the DGCL. We also are expressly authorized to carry directors&#8217; and officers&#8217; liability insurance providing indemnification for our directors, officers and certain employees for some liabilities. We believe that these indemnification and advancement provisions and insurance are useful to attract and retain qualified directors and executive officers.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20pt;margin:0pt;"><font style="font-size:12pt;">The limitation of liability, indemnification and advancement provisions in our Amended Charter and Amended Bylaws may discourage stockholders from bringing a lawsuit against directors for breach of their fiduciary duty. These provisions also may have the effect of reducing the likelihood of derivative litigation against directors and officers, even though such an action, if successful, might otherwise benefit us and our stockholders. In addition, your investment may be adversely affected to the extent we pay the costs of settlement and damage awards against directors and officers pursuant to these indemnification provisions.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">6</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20pt;margin:0pt;"><font style="font-size:12pt;">There is currently no pending material litigation or proceeding involving any of our directors, officers or employees for which indemnification is sought.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Indemnification Agreements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20pt;margin:0pt;"><font style="font-size:12pt;">We entered into an indemnification agreement with each of our directors and executive officers. Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors or executive officers, we have been informed that in the opinion of the SEC such indemnification is against public policy and is therefore unenforceable.</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">7</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.8
<SEQUENCE>3
<FILENAME>ganx-20211231xex10d8.htm
<DESCRIPTION>EX-10.8
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 3/25/2022 06:19:06 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:10.78%;padding-right:5.56%;position:relative;"><div style="margin-top:9.4pt;min-height:57.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 10.8</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><img src="ganx-20211231xex10d8001.jpg" alt="Logo&#10;&#10;Description automatically generated" style="display:inline-block;height:42pt;width:87.5pt;"></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-weight:bold;text-align:center;text-indent:0pt;margin:4.05pt 0pt 0pt 0pt;">EMPLOYMENT<b style="font-weight:bold;letter-spacing:-0.2pt;"> </b>AGREEMENT</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0.2pt 0pt 0pt 0pt;"><font style="font-size:14.5pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;text-indent:36pt;margin:0pt 31.3pt 0pt 6pt;">This<font style="letter-spacing:2.3pt;"> </font>Employment<font style="letter-spacing:2.35pt;"> </font>Agreement<font style="letter-spacing:2.2pt;"> </font>(&#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Agreement</u>&#8221;)<font style="letter-spacing:2.2pt;"> </font>is<font style="letter-spacing:2.2pt;"> </font>effective<font style="letter-spacing:2.3pt;"> </font>as<font style="letter-spacing:2.3pt;"> </font>of<font style="letter-spacing:2.35pt;"> </font>October<font style="letter-spacing:2.35pt;"> </font>15,<font style="letter-spacing:2.3pt;"> </font>2021<font style="letter-spacing:2.3pt;"> </font>(&#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Effective</u><font style="letter-spacing:-2.6pt;"> </font><u style="text-decoration:underline;text-decoration-color:#000000;">Date</u>&#8221;),<font style="letter-spacing:-0.05pt;"> </font>by<font style="letter-spacing:-0.2pt;"> </font>and between<font style="letter-spacing:-0.05pt;"> </font>Gain<font style="letter-spacing:-0.05pt;"> </font>Therapeutics, Inc.<font style="letter-spacing:-0.2pt;"> </font>(&#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Company</u>&#8221;) and<font style="letter-spacing:-0.15pt;"> </font>Matthias<font style="letter-spacing:-0.05pt;"> </font>Alder<font style="letter-spacing:-0.1pt;"> </font>(&#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Executive</u>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;text-indent:36pt;margin:7.94pt 31.3pt 0pt 5.95pt;"><b style="font-weight:bold;">WHEREAS</b>,<font style="letter-spacing:0.3pt;"> </font>the<font style="letter-spacing:0.4pt;"> </font>Company<font style="letter-spacing:0.25pt;"> </font>desires<font style="letter-spacing:0.25pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>retain<font style="letter-spacing:0.25pt;"> </font>the<font style="letter-spacing:0.4pt;"> </font>services<font style="letter-spacing:0.4pt;"> </font>of<font style="letter-spacing:0.35pt;"> </font>Executive<font style="letter-spacing:0.2pt;"> </font>as<font style="letter-spacing:0.4pt;"> </font>Chief<font style="letter-spacing:0.35pt;"> </font>Operating<font style="letter-spacing:0.35pt;"> </font>Officer<font style="letter-spacing:-2.6pt;"> </font>as<font style="letter-spacing:-0.05pt;"> </font>further<font style="letter-spacing:-0.1pt;"> </font>set<font style="letter-spacing:0.05pt;"> </font>forth<font style="letter-spacing:-0.15pt;"> </font>in<font style="letter-spacing:-0.15pt;"> </font>this Agreement;<font style="letter-spacing:-0.1pt;"> </font>and</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;text-indent:36pt;margin:7.94pt 0pt 0pt 5.95pt;"><b style="font-weight:bold;">WHEREAS</b>,<font style="letter-spacing:0.65pt;"> </font>Executive<font style="letter-spacing:0.7pt;"> </font>desires<font style="letter-spacing:0.7pt;"> </font>to<font style="letter-spacing:0.65pt;"> </font>serve<font style="letter-spacing:0.75pt;"> </font>the<font style="letter-spacing:0.7pt;"> </font>Company<font style="letter-spacing:0.55pt;"> </font>in<font style="letter-spacing:0.65pt;"> </font>such<font style="letter-spacing:0.6pt;"> </font>capacity,<font style="letter-spacing:0.65pt;"> </font>subject<font style="letter-spacing:0.6pt;"> </font>to<font style="letter-spacing:0.65pt;"> </font>the<font style="letter-spacing:0.7pt;"> </font>terms<font style="letter-spacing:0.7pt;"> </font>and<font style="letter-spacing:-2.6pt;"> </font>conditions<font style="letter-spacing:-0.05pt;"> </font>of<font style="letter-spacing:0.05pt;"> </font>this Agreement;</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;text-indent:36pt;margin:8pt 0pt 0pt 5.95pt;"><b style="font-weight:bold;">NOW,</b><b style="font-weight:bold;letter-spacing:-0.45pt;"> </b><b style="font-weight:bold;">THEREFORE</b>,<font style="letter-spacing:-0.55pt;"> </font>for<font style="letter-spacing:-0.45pt;"> </font>and<font style="letter-spacing:-0.45pt;"> </font>in<font style="letter-spacing:-0.4pt;"> </font>consideration<font style="letter-spacing:-0.45pt;"> </font>of<font style="letter-spacing:-0.4pt;"> </font>the<font style="letter-spacing:-0.5pt;"> </font>mutual<font style="letter-spacing:-0.4pt;"> </font>promises,<font style="letter-spacing:-0.45pt;"> </font>covenants<font style="letter-spacing:-0.5pt;"> </font>and<font style="letter-spacing:-0.45pt;"> </font>obligations<font style="letter-spacing:-2.6pt;"> </font>contained<font style="letter-spacing:-0.05pt;"> </font>herein, the Company and Executive<font style="letter-spacing:-0.05pt;"> </font>agree as<font style="letter-spacing:-0.1pt;"> </font>follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0.34pt 0pt 0pt 0pt;"><font style="font-size:13.5pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-weight:bold;margin-bottom:0pt;margin-left:5.95pt;margin-top:0pt;padding-left:36.05pt;text-indent:-36.05pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">1.</font>EMPLOYMENT<b style="font-weight:bold;letter-spacing:-0.1pt;"> </b>BY<b style="font-weight:bold;letter-spacing:-0.1pt;"> </b>THE<b style="font-weight:bold;letter-spacing:-0.1pt;"> </b>COMPANY</div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0.2pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;text-align:justify;text-indent:35.95pt;margin:0pt 37.6pt 0pt 5.95pt;"><font style="display:inline-block;font-family:'Times New Roman';font-weight:bold;min-width:36.1pt;text-indent:0pt;white-space:nowrap;">1.1.</font><b style="font-weight:bold;">Position.</b><b style="font-weight:bold;letter-spacing:0.05pt;"> </b>Subject to terms set forth herein, the Company agrees to employ Executive in<font style="letter-spacing:0.05pt;"> </font>the position of Chief Operating Officer, and Executive hereby accepts such employment.<font style="letter-spacing:0.05pt;"> </font>During his<font style="letter-spacing:0.05pt;"> </font>employment with the Company, Executive will devote his best efforts and substantially all of his time and<font style="letter-spacing:-2.6pt;"> </font>attention to the business of the Company, except as provided in Section <a href="#_bookmark4"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">4 </font></a>below and for vacation periods<font style="letter-spacing:0.05pt;"> </font>and<font style="letter-spacing:0.05pt;"> </font>reasonable<font style="letter-spacing:0.05pt;"> </font>periods<font style="letter-spacing:0.05pt;"> </font>of<font style="letter-spacing:0.05pt;"> </font>illness<font style="letter-spacing:0.05pt;"> </font>or<font style="letter-spacing:0.05pt;"> </font>other<font style="letter-spacing:0.05pt;"> </font>incapacities<font style="letter-spacing:0.05pt;"> </font>in<font style="letter-spacing:0.05pt;"> </font>accordance<font style="letter-spacing:0.05pt;"> </font>with<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>Company&#8217;s<font style="letter-spacing:0.05pt;"> </font>general<font style="letter-spacing:0.05pt;"> </font>employment policies.</div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0.44pt 0pt 0pt 0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;text-align:justify;text-indent:36pt;margin:0pt 37.7pt 0pt 5.95pt;"><font style="display:inline-block;font-family:'Times New Roman';font-weight:bold;min-width:36.1pt;text-indent:0pt;white-space:nowrap;">1.2.</font><b style="font-weight:bold;">Duties.</b><b style="font-weight:bold;letter-spacing:0.05pt;"> </b>Executive will serve in an executive capacity performing such duties as are<font style="letter-spacing:0.05pt;"> </font>normally<font style="letter-spacing:-0.45pt;"> </font>associated<font style="letter-spacing:-0.3pt;"> </font>with<font style="letter-spacing:-0.3pt;"> </font>his<font style="letter-spacing:-0.3pt;"> </font>then<font style="letter-spacing:-0.3pt;"> </font>current<font style="letter-spacing:-0.4pt;"> </font>position<font style="letter-spacing:-0.4pt;"> </font>and<font style="letter-spacing:-0.3pt;"> </font>such<font style="letter-spacing:-0.3pt;"> </font>duties<font style="letter-spacing:-0.3pt;"> </font>as<font style="letter-spacing:-0.3pt;"> </font>are<font style="letter-spacing:-0.4pt;"> </font>assigned<font style="letter-spacing:-0.35pt;"> </font>to<font style="letter-spacing:-0.25pt;"> </font>him<font style="letter-spacing:-0.25pt;"> </font>from<font style="letter-spacing:-0.35pt;"> </font>time<font style="letter-spacing:-0.4pt;"> </font>to<font style="letter-spacing:-0.45pt;"> </font>time,<font style="letter-spacing:-2.6pt;"> </font>subject<font style="letter-spacing:-0.4pt;"> </font>to<font style="letter-spacing:-0.4pt;"> </font>the<font style="letter-spacing:-0.4pt;"> </font>oversight<font style="letter-spacing:-0.35pt;"> </font>and<font style="letter-spacing:-0.55pt;"> </font>direction<font style="letter-spacing:-0.4pt;"> </font>of<font style="letter-spacing:-0.5pt;"> </font>the<font style="letter-spacing:-0.35pt;"> </font>Chief<font style="letter-spacing:-0.4pt;"> </font>Executive<font style="letter-spacing:-0.35pt;"> </font>Officer<font style="letter-spacing:-0.4pt;"> </font>and<font style="letter-spacing:-0.4pt;"> </font>the<font style="letter-spacing:-0.35pt;"> </font>Company&#8217;s<font style="letter-spacing:-0.4pt;"> </font>Board<font style="letter-spacing:-0.4pt;"> </font>of<font style="letter-spacing:-0.4pt;"> </font>Directors<font style="letter-spacing:-2.6pt;"> </font>(&#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Board</u>&#8221;) or<font style="letter-spacing:-0.1pt;"> </font>a committee thereof.</div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0.3pt 0pt 0pt 0pt;"><font style="font-size:7.5pt;visibility:hidden;">&#8203;</font></p><div style="margin-top:4.59pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;text-align:justify;text-indent:36pt;margin:0pt 37.7pt 0pt 5.95pt;"><font style="display:inline-block;font-family:'Times New Roman';font-weight:bold;min-width:36.1pt;text-indent:0pt;white-space:nowrap;">1.3.</font><b style="font-weight:bold;">Location.</b><b style="font-weight:bold;letter-spacing:0.05pt;"> </b>Executive&#8217;s primary office location will be at the Company&#8217;s corporate offices<font style="letter-spacing:-2.65pt;"> </font>in Bethesda, Maryland.<font style="letter-spacing:0.05pt;"> </font>The Company reserves the right to reasonably require Executive to perform his<font style="letter-spacing:0.05pt;"> </font>duties at places other than at his primary office location from time to time, and to require reasonable<font style="letter-spacing:0.05pt;"> </font>business<font style="letter-spacing:-0.1pt;"> </font>travel.</div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0.4pt 0pt 0pt 0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;text-align:justify;text-indent:36pt;margin:0pt 37.8pt 0pt 5.95pt;"><font style="display:inline-block;font-family:'Times New Roman';font-weight:bold;min-width:36.1pt;text-indent:0pt;white-space:nowrap;">1.4.</font><b style="font-weight:bold;">Term.</b><b style="font-weight:bold;letter-spacing:-0.45pt;"> </b>The<font style="letter-spacing:-0.4pt;"> </font>term<font style="letter-spacing:-0.35pt;"> </font>of<font style="letter-spacing:-0.4pt;"> </font>this<font style="letter-spacing:-0.35pt;"> </font>Agreement<font style="letter-spacing:-0.4pt;"> </font>will<font style="letter-spacing:-0.3pt;"> </font>commence<font style="letter-spacing:-0.4pt;"> </font>on<font style="letter-spacing:-0.35pt;"> </font>the<font style="letter-spacing:-0.3pt;"> </font>Effective<font style="letter-spacing:-0.25pt;"> </font>Date<font style="letter-spacing:-0.4pt;"> </font>and<font style="letter-spacing:-0.4pt;"> </font>will<font style="letter-spacing:-0.35pt;"> </font>continue<font style="letter-spacing:-2.6pt;"> </font>until<font style="letter-spacing:-0.15pt;"> </font>terminated<font style="letter-spacing:-0.15pt;"> </font>in accordance with Section <a href="#_bookmark7"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">6.</font></a></div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;text-align:justify;text-indent:36pt;margin:0pt 37.8pt 0pt 5.95pt;"><font style="display:inline-block;font-family:'Times New Roman';font-weight:bold;min-width:36.1pt;text-indent:0pt;white-space:nowrap;">1.5.</font><b style="font-weight:bold;letter-spacing:-0.05pt;">Policies</b><b style="font-weight:bold;letter-spacing:-0.7pt;"> </b><b style="font-weight:bold;letter-spacing:-0.05pt;">and</b><b style="font-weight:bold;letter-spacing:-0.75pt;"> </b><b style="font-weight:bold;">Procedures.</b><b style="font-weight:bold;letter-spacing:1.3pt;"> </b>The<font style="letter-spacing:-0.7pt;"> </font>employment<font style="letter-spacing:-0.7pt;"> </font>relationship<font style="letter-spacing:-0.75pt;"> </font>between<font style="letter-spacing:-0.85pt;"> </font>the<font style="letter-spacing:-0.7pt;"> </font>parties<font style="letter-spacing:-0.7pt;"> </font>will<font style="letter-spacing:-0.7pt;"> </font>be<font style="letter-spacing:-0.85pt;"> </font>subject<font style="letter-spacing:-2.65pt;"> </font>to<font style="letter-spacing:-0.5pt;"> </font>the<font style="letter-spacing:-0.4pt;"> </font>Company&#8217;s<font style="letter-spacing:-0.4pt;"> </font>personnel<font style="letter-spacing:-0.5pt;"> </font>policies<font style="letter-spacing:-0.4pt;"> </font>and<font style="letter-spacing:-0.45pt;"> </font>procedures<font style="letter-spacing:-0.4pt;"> </font>as<font style="letter-spacing:-0.4pt;"> </font>they<font style="letter-spacing:-0.45pt;"> </font>may<font style="letter-spacing:-0.45pt;"> </font>be<font style="letter-spacing:-0.55pt;"> </font>interpreted,<font style="letter-spacing:-0.45pt;"> </font>adopted,<font style="letter-spacing:-0.55pt;"> </font>revised<font style="letter-spacing:-0.55pt;"> </font>or<font style="letter-spacing:-0.4pt;"> </font>deleted<font style="letter-spacing:-2.65pt;"> </font>from<font style="letter-spacing:-0.5pt;"> </font>time<font style="letter-spacing:-0.55pt;"> </font>to<font style="letter-spacing:-0.55pt;"> </font>time<font style="letter-spacing:-0.55pt;"> </font>in<font style="letter-spacing:-0.55pt;"> </font>the<font style="letter-spacing:-0.4pt;"> </font>Company&#8217;s<font style="letter-spacing:-0.5pt;"> </font>sole<font style="letter-spacing:-0.55pt;"> </font>discretion;<font style="letter-spacing:-0.45pt;"> </font>provided<font style="letter-spacing:-0.55pt;"> </font>that<font style="letter-spacing:-0.5pt;"> </font>if<font style="letter-spacing:-0.5pt;"> </font>the<font style="letter-spacing:-0.5pt;"> </font>terms<font style="letter-spacing:-0.55pt;"> </font>of<font style="letter-spacing:-0.5pt;"> </font>this<font style="letter-spacing:-0.4pt;"> </font>Agreement<font style="letter-spacing:-0.5pt;"> </font>differ<font style="letter-spacing:-0.5pt;"> </font>from<font style="letter-spacing:-2.6pt;"> </font>or<font style="letter-spacing:-0.05pt;"> </font>are<font style="letter-spacing:-0.05pt;"> </font>in<font style="letter-spacing:-0.05pt;"> </font>conflict with<font style="letter-spacing:-0.1pt;"> </font>the<font style="letter-spacing:-0.05pt;"> </font>Company&#8217;s<font style="letter-spacing:-0.15pt;"> </font>personnel policies<font style="letter-spacing:-0.05pt;"> </font>or<font style="letter-spacing:-0.05pt;"> </font>procedures,<font style="letter-spacing:-0.2pt;"> </font>this<font style="letter-spacing:-0.05pt;"> </font>Agreement will<font style="letter-spacing:-0.15pt;"> </font>control.</div><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;text-align:justify;margin:0pt;"><font style="font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:46.8pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:12pt 0.55pt 0pt 0.55pt;"><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">Gain</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.2pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">Therapeutics,</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.15pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">Inc.</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.15pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">-</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.05pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">4800</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.15pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">Hampden</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.15pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">Ln,</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.15pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">St</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.05pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">200, Bethesda,</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.1pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">MD</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:2.65pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">20814</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0.5pt 0.3pt 0pt 0.55pt;"><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">P:</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.25pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">+1</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.2pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">301-500-1556</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:1.8pt;"> </font><u style="color:#0562c1;font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-decoration:underline;text-decoration-color:#0562c1;">www.gaintherapeutics.com</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:right;margin:0pt 0.3pt 0pt 0.55pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;">1</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.78%;margin-right:5.56%;margin-top:30pt;page-break-after:always;width:83.66%;border-width:0;"><div style="max-width:100%;padding-left:10.78%;padding-right:5.56%;position:relative;"><div style="margin-top:9.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><img src="ganx-20211231xex10d8001.jpg" alt="Logo&#10;&#10;Description automatically generated" style="display:inline-block;height:42pt;width:87.5pt;"></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-weight:bold;margin-left:5.95pt;margin-top:4.05pt;padding-left:36.05pt;text-indent:-36.05pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">2.</font>COMPENSATION</div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0.34pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;text-align:justify;text-indent:36pt;margin:0pt 37.7pt 0pt 5.95pt;"><font style="display:inline-block;font-family:'Times New Roman';font-weight:bold;min-width:36.1pt;text-indent:0pt;white-space:nowrap;">2.1.</font><b style="font-weight:bold;">Base Salary.</b><b style="font-weight:bold;letter-spacing:0.05pt;"> </b>For services rendered by Executive pursuant to this Agreement, Executive<font style="letter-spacing:0.05pt;"> </font>will receive an annualized base salary of four hundred thousand US dollars (US$400,000) as may be<font style="letter-spacing:0.05pt;"> </font>adjusted from time to time by the compensation committee of the Board at its discretion (&#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Base Salary</u>&#8221;),<font style="letter-spacing:0.05pt;"> </font>payable in accordance with the Company&#8217;s regular payroll schedule, less any payroll withholding and<font style="letter-spacing:0.05pt;"> </font>deductions<font style="letter-spacing:-0.05pt;"> </font>in accordance with<font style="letter-spacing:-0.15pt;"> </font>applicable law.</div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0.3pt 0pt 0pt 0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;text-align:justify;text-indent:36pt;margin:0pt 37.7pt 0pt 5.95pt;"><font style="display:inline-block;font-family:'Times New Roman';font-weight:bold;min-width:36.1pt;text-indent:0pt;white-space:nowrap;">2.2.</font><b style="font-weight:bold;letter-spacing:-0.05pt;">Annual</b><b style="font-weight:bold;letter-spacing:-0.55pt;"> </b><b style="font-weight:bold;letter-spacing:-0.05pt;">Incentive.</b><b style="font-weight:bold;letter-spacing:1.55pt;"> </b><font style="letter-spacing:-0.05pt;">During</font><font style="letter-spacing:-0.75pt;"> </font>Executive&#8217;s<font style="letter-spacing:-0.6pt;"> </font>employment<font style="letter-spacing:-0.5pt;"> </font>with<font style="letter-spacing:-0.6pt;"> </font>the<font style="letter-spacing:-0.6pt;"> </font>Company,<font style="letter-spacing:-0.6pt;"> </font>and<font style="letter-spacing:-0.6pt;"> </font>as<font style="letter-spacing:-0.6pt;"> </font>determined<font style="letter-spacing:-2.6pt;"> </font>by the Board in its sole discretion, Executive will be eligible for an annual incentive cash bonus (&#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Annual</u><font style="letter-spacing:0.05pt;"> </font><u style="text-decoration:underline;text-decoration-color:#000000;">Incentive</u>&#8221;) with a target of thirty-five percent (35%) of the Base Salary (&#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Target Annual Incentive</u>&#8221;).<font style="letter-spacing:0.05pt;"> </font>The<font style="letter-spacing:-2.6pt;"> </font>actual Annual Incentive earned in any particular year may be more or less, including zero, than the Target<font style="letter-spacing:-2.6pt;"> </font>Annual<font style="letter-spacing:-0.15pt;"> </font>Incentive<font style="letter-spacing:-0.15pt;"> </font>based<font style="letter-spacing:-0.3pt;"> </font>on<font style="letter-spacing:-0.3pt;"> </font>the<font style="letter-spacing:-0.15pt;"> </font>achievement<font style="letter-spacing:-0.15pt;"> </font>of<font style="letter-spacing:-0.15pt;"> </font>Company<font style="letter-spacing:-0.2pt;"> </font>and<font style="letter-spacing:-0.2pt;"> </font>personal<font style="letter-spacing:-0.25pt;"> </font>objectives<font style="letter-spacing:-0.3pt;"> </font>established<font style="letter-spacing:-0.15pt;"> </font>and<font style="letter-spacing:-0.3pt;"> </font>approved<font style="letter-spacing:-2.65pt;"> </font>by the Board, and the achievement of which is determined at the discretion of the Board. The Annual<font style="letter-spacing:0.05pt;"> </font>Incentive will be paid to Executive as soon as practicable, but in no event later than the date that is two-<font style="letter-spacing:0.05pt;"> </font>and-one-half months following the<font style="letter-spacing:-0.05pt;"> </font>end of<font style="letter-spacing:-0.1pt;"> </font>the<font style="letter-spacing:-0.1pt;"> </font>fiscal year<font style="letter-spacing:0.05pt;"> </font>in which<font style="letter-spacing:-0.15pt;"> </font>such<font style="letter-spacing:-0.2pt;"> </font>incentive<font style="letter-spacing:-0.1pt;"> </font>is<font style="letter-spacing:-0.1pt;"> </font>earned.</div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0.34pt 0pt 0pt 0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-weight:bold;margin-bottom:0pt;margin-left:41.95pt;margin-top:0pt;padding-left:36.05pt;text-indent:-36.05pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">2.3.</font>Long-Term<b style="font-weight:bold;letter-spacing:-0.05pt;"> </b>Equity<b style="font-weight:bold;letter-spacing:-0.1pt;"> </b>Incentives.</div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0.25pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;text-align:justify;text-indent:108pt;margin:0pt 37.65pt 0pt 5.95pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36.1pt;text-indent:0pt;white-space:nowrap;">(i)</font><u style="text-decoration:underline;text-decoration-color:#000000;">Initial Equity Incentive Grants.</u><font style="letter-spacing:0.05pt;"> </font>On the Effective Date, Executive will<font style="letter-spacing:0.05pt;"> </font>receive the following equity incentive grants (&#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Initial Grants</u>&#8221;) pursuant to the terms and conditions of the<font style="letter-spacing:0.05pt;"> </font>Company&#8217;s<font style="letter-spacing:-0.3pt;"> </font>2020<font style="letter-spacing:-0.3pt;"> </font>Omnibus<font style="letter-spacing:-0.35pt;"> </font>Incentive<font style="letter-spacing:-0.3pt;"> </font>Plan,<font style="letter-spacing:-0.4pt;"> </font>the<font style="letter-spacing:-0.3pt;"> </font>Executive<font style="letter-spacing:-0.25pt;"> </font>shall<font style="letter-spacing:-0.4pt;"> </font>receive<font style="letter-spacing:-0.2pt;"> </font>200,000<font style="letter-spacing:-0.3pt;"> </font>stock<font style="letter-spacing:-0.3pt;"> </font>options<font style="letter-spacing:-0.35pt;"> </font>in<font style="letter-spacing:-0.45pt;"> </font>the<font style="letter-spacing:-0.35pt;"> </font>form<font style="letter-spacing:-0.25pt;"> </font>of<font style="letter-spacing:-2.6pt;"> </font>incentive stock options (ISOs) to the extent permitted by applicable law,<a href="#_bookmark17"><sup style="font-family:'Times New Roman','Times','serif';font-size:8.25pt;font-style:normal;font-weight:normal;text-align:justify;vertical-align:top;">i</sup><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;"> </font></a>and the balance in the form of<font style="letter-spacing:0.05pt;"> </font>non-qualified stock options (NQs), vesting over a four (4) year period from the Effective Date, with 25%<font style="letter-spacing:0.05pt;"> </font>vesting<font style="letter-spacing:-0.45pt;"> </font>on<font style="letter-spacing:-0.4pt;"> </font>the<font style="letter-spacing:-0.4pt;"> </font>first<font style="letter-spacing:-0.35pt;"> </font>anniversary<font style="letter-spacing:-0.35pt;"> </font>of<font style="letter-spacing:-0.4pt;"> </font>the<font style="letter-spacing:-0.4pt;"> </font>Effective<font style="letter-spacing:-0.4pt;"> </font>Date,<font style="letter-spacing:-0.25pt;"> </font>and<font style="letter-spacing:-0.3pt;"> </font>the<font style="letter-spacing:-0.3pt;"> </font>balance<font style="letter-spacing:-0.4pt;"> </font>vesting<font style="letter-spacing:-0.35pt;"> </font>in<font style="letter-spacing:-0.45pt;"> </font>equal<font style="letter-spacing:-0.35pt;"> </font>monthly<font style="letter-spacing:-0.4pt;"> </font>installments<font style="letter-spacing:-2.6pt;"> </font>over<font style="letter-spacing:-0.1pt;"> </font>the<font style="letter-spacing:-0.15pt;"> </font>remainder<font style="letter-spacing:0.05pt;"> </font>of<font style="letter-spacing:-0.1pt;"> </font>the vesting period;<font style="letter-spacing:-0.1pt;"> </font>and</div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0.34pt 0pt 0pt 0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;text-align:justify;text-indent:108pt;margin:0pt 37.75pt 0pt 6pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(ii)</font><u style="text-decoration:underline;text-decoration-color:#000000;">Performance-Based Equity Incentive Grants.</u><font style="letter-spacing:0.05pt;"> </font>Subject to the Executive<font style="letter-spacing:0.05pt;"> </font>meeting the specified criteria below, the Executive shall be entitled to a grant of up to 200,000 restricted<font style="letter-spacing:0.05pt;"> </font>stock<font style="letter-spacing:-0.5pt;"> </font>units<font style="letter-spacing:-0.4pt;"> </font>(&#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">RSUs</u>&#8221;)<font style="letter-spacing:-0.4pt;"> </font>as<font style="letter-spacing:-0.4pt;"> </font>follows:<font style="letter-spacing:-0.25pt;"> </font>(i)<font style="letter-spacing:-0.4pt;"> </font>100,000<font style="letter-spacing:-0.3pt;"> </font>RSUs<font style="letter-spacing:-0.3pt;"> </font>vesting<font style="letter-spacing:-0.3pt;"> </font>upon<font style="letter-spacing:-0.3pt;"> </font>(a)<font style="letter-spacing:-0.4pt;"> </font>the<font style="letter-spacing:-0.4pt;"> </font>closing<font style="letter-spacing:-0.3pt;"> </font>of<font style="letter-spacing:-0.25pt;"> </font>an<font style="letter-spacing:-0.35pt;"> </font>exclusive<font style="letter-spacing:-0.4pt;"> </font>license<font style="letter-spacing:-0.3pt;"> </font>deal<font style="letter-spacing:-2.6pt;"> </font>for one or more Company pipeline programs and/or research, development and commercialization of a<font style="letter-spacing:0.05pt;"> </font>collaboration deal with a Validating Industry Partner (defined herein as a Top 25 pharma company by<font style="letter-spacing:0.05pt;"> </font>revenue, a top 15 pharma or biotech company by CNS product revenue, a biotech company with a market<font style="letter-spacing:0.05pt;"> </font>cap<font style="letter-spacing:-0.4pt;"> </font>in<font style="letter-spacing:-0.4pt;"> </font>excess<font style="letter-spacing:-0.35pt;"> </font>of<font style="letter-spacing:-0.4pt;"> </font>$20<font style="letter-spacing:-0.45pt;"> </font>billion,<font style="letter-spacing:-0.4pt;"> </font>or<font style="letter-spacing:-0.4pt;"> </font>a<font style="letter-spacing:-0.4pt;"> </font>company<font style="letter-spacing:-0.4pt;"> </font>that<font style="letter-spacing:-0.4pt;"> </font>does<font style="letter-spacing:-0.3pt;"> </font>not<font style="letter-spacing:-0.45pt;"> </font>meet<font style="letter-spacing:-0.35pt;"> </font>the<font style="letter-spacing:-0.35pt;"> </font>specified<font style="letter-spacing:-0.4pt;"> </font>criteria<font style="letter-spacing:-0.3pt;"> </font>but<font style="letter-spacing:-0.25pt;"> </font>provides<font style="letter-spacing:-0.35pt;"> </font>comparable<font style="letter-spacing:-2.65pt;"> </font>validation of the partnered programs or drug discovery platform as determined in the discretion of the<font style="letter-spacing:0.05pt;"> </font>Board), <b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">and</b><b style="font-weight:bold;"> </b>(b) a resulting extension of the Company&#8217;s cash runway by one (1) year or more with one or<font style="letter-spacing:0.05pt;"> </font>more<font style="letter-spacing:-0.3pt;"> </font>transactions;<font style="letter-spacing:-0.25pt;"> </font>and/or<font style="letter-spacing:-0.25pt;"> </font>(ii)<font style="letter-spacing:-0.25pt;"> </font>100,000<font style="letter-spacing:-0.3pt;"> </font>RSUs<font style="letter-spacing:-0.3pt;"> </font>upon<font style="letter-spacing:-0.3pt;"> </font>the<font style="letter-spacing:-0.4pt;"> </font>Company&#8217;s<font style="letter-spacing:-0.4pt;"> </font>initiation<font style="letter-spacing:-0.3pt;"> </font>(patient<font style="letter-spacing:-0.25pt;"> </font>first<font style="letter-spacing:-0.25pt;"> </font>dosing)<font style="letter-spacing:-0.25pt;"> </font>in<font style="letter-spacing:-0.3pt;"> </font>a<font style="letter-spacing:-0.3pt;"> </font>phase<font style="letter-spacing:-2.6pt;"> </font>1B<font style="letter-spacing:-0.35pt;"> </font>clinical<font style="letter-spacing:-0.2pt;"> </font>study<font style="letter-spacing:-0.25pt;"> </font>conducted<font style="letter-spacing:-0.4pt;"> </font>in<font style="letter-spacing:-0.25pt;"> </font>the<font style="letter-spacing:-0.25pt;"> </font>United<font style="letter-spacing:-0.25pt;"> </font>States<font style="letter-spacing:-0.25pt;"> </font>or<font style="letter-spacing:-0.35pt;"> </font>any<font style="letter-spacing:-0.35pt;"> </font>clinical<font style="letter-spacing:-0.2pt;"> </font>efficacy<font style="letter-spacing:-0.25pt;"> </font>study<font style="letter-spacing:-0.25pt;"> </font>dosing<font style="letter-spacing:-0.25pt;"> </font>under<font style="letter-spacing:-0.2pt;"> </font>a<font style="letter-spacing:-0.25pt;"> </font>United<font style="letter-spacing:-0.3pt;"> </font>States<font style="letter-spacing:-2.6pt;"> </font>Food<font style="letter-spacing:0.05pt;"> </font>&amp;<font style="letter-spacing:0.05pt;"> </font>Drug<font style="letter-spacing:0.05pt;"> </font>Administration<font style="letter-spacing:0.05pt;"> </font>Investigational<font style="letter-spacing:0.05pt;"> </font>New<font style="letter-spacing:0.05pt;"> </font>Drug<font style="letter-spacing:0.05pt;"> </font>Application<font style="letter-spacing:0.05pt;"> </font>(Commercial<font style="letter-spacing:0.05pt;"> </font>IND).<font style="letter-spacing:0.05pt;"> </font>The<font style="letter-spacing:0.05pt;"> </font>Compensation Committee of the Board shall be responsible for verification and confirmation of the<font style="letter-spacing:0.05pt;"> </font>achievement of<font style="letter-spacing:0.05pt;"> </font>the specified criteria in<font style="letter-spacing:-0.15pt;"> </font>(i) and (ii).</div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0.34pt 0pt 0pt 0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;text-align:justify;text-indent:36pt;margin:0pt 37.55pt 0pt 5.95pt;"><font style="display:inline-block;font-family:'Times New Roman';font-weight:bold;min-width:36.1pt;text-indent:0pt;white-space:nowrap;">2.4.</font><a name="_bookmark0"></a><b style="font-weight:bold;">Business and Entertainment Expenses. </b>Subject to the Company&#8217;s standard policies and<font style="letter-spacing:-2.6pt;"> </font>procedures for expense reimbursement as applied to its executive employees generally, the Company will<font style="letter-spacing:0.05pt;"> </font>reimburse<font style="letter-spacing:0.15pt;"> </font>Executive<font style="letter-spacing:0.2pt;"> </font>for,<font style="letter-spacing:0.2pt;"> </font>or<font style="letter-spacing:0.05pt;"> </font>pay<font style="letter-spacing:0.2pt;"> </font>on<font style="letter-spacing:0.2pt;"> </font>behalf<font style="letter-spacing:0.15pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>Executive,<font style="letter-spacing:0.2pt;"> </font>reasonable<font style="letter-spacing:0.15pt;"> </font>out-of-pocket<font style="letter-spacing:0.1pt;"> </font>expenses<font style="letter-spacing:0.2pt;"> </font>for<font style="letter-spacing:0.2pt;"> </font>Company-</div><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;text-align:justify;margin:0pt;"><font style="font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:46.8pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:12pt 0.55pt 0pt 0.55pt;"><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">Gain</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.2pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">Therapeutics,</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.15pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">Inc.</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.15pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">-</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.05pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">4800</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.15pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">Hampden</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.15pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">Ln,</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.15pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">St</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.05pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">200, Bethesda,</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.1pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">MD</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:2.65pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">20814</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0.5pt 0.3pt 0pt 0.55pt;"><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">P:</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.25pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">+1</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.2pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">301-500-1556</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:1.8pt;"> </font><u style="color:#0562c1;font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-decoration:underline;text-decoration-color:#0562c1;">www.gaintherapeutics.com</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:right;margin:0pt 0.3pt 0pt 0.55pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;">2</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.78%;margin-right:5.56%;margin-top:30pt;page-break-after:always;width:83.66%;border-width:0;"><div style="max-width:100%;padding-left:10.78%;padding-right:5.56%;position:relative;"><div style="margin-top:9.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><img src="ganx-20211231xex10d8001.jpg" alt="Logo&#10;&#10;Description automatically generated" style="display:inline-block;height:42pt;width:87.5pt;"></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;margin:4.05pt 0pt 0pt 5.95pt;">related<font style="letter-spacing:0.35pt;"> </font>travel,<font style="letter-spacing:0.3pt;"> </font>entertainment,<font style="letter-spacing:0.4pt;"> </font>professional<font style="letter-spacing:0.3pt;"> </font>licensing,<font style="letter-spacing:0.3pt;"> </font>continuing<font style="letter-spacing:0.3pt;"> </font>education<font style="letter-spacing:0.3pt;"> </font>and<font style="letter-spacing:0.25pt;"> </font>other<font style="letter-spacing:0.45pt;"> </font>expenses<font style="letter-spacing:0.25pt;"> </font>incurred<font style="letter-spacing:0.3pt;"> </font>by<font style="letter-spacing:-2.6pt;"> </font>Executive<font style="letter-spacing:-0.15pt;"> </font>on behalf<font style="letter-spacing:0.05pt;"> </font>of<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:-0.1pt;"> </font>Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0.34pt 0pt 0pt 0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;text-align:justify;text-indent:36pt;margin:0pt 37.8pt 0pt 5.95pt;"><font style="display:inline-block;font-family:'Times New Roman';font-weight:bold;min-width:36.05pt;text-indent:0pt;white-space:nowrap;">2.5.</font><b style="font-weight:bold;letter-spacing:-0.05pt;">Other</b><b style="font-weight:bold;letter-spacing:-0.55pt;"> </b><b style="font-weight:bold;">Company</b><b style="font-weight:bold;letter-spacing:-0.6pt;"> </b><b style="font-weight:bold;">Benefits.</b><b style="font-weight:bold;letter-spacing:1.45pt;"> </b>Executive<font style="letter-spacing:-0.55pt;"> </font>will<font style="letter-spacing:-0.55pt;"> </font>be<font style="letter-spacing:-0.7pt;"> </font>entitled<font style="letter-spacing:-0.7pt;"> </font>to<font style="letter-spacing:-0.55pt;"> </font>participate<font style="letter-spacing:-0.6pt;"> </font>in<font style="letter-spacing:-0.6pt;"> </font>all<font style="letter-spacing:-0.65pt;"> </font>employee<font style="letter-spacing:-0.5pt;"> </font>benefit<font style="letter-spacing:-2.65pt;"> </font>plans, practices and programs maintained by the Company and made available to its similarly situated<font style="letter-spacing:0.05pt;"> </font>executives.<font style="letter-spacing:0.05pt;"> </font>Executive will also be entitled to annual vacation in accordance with the Company&#8217;s standard<font style="letter-spacing:-2.6pt;"> </font>policies and as otherwise provided for senior executive officers, but in no event less than twenty (20)<font style="letter-spacing:0.05pt;"> </font>working days.<font style="letter-spacing:0.05pt;"> </font>Working days are all calendar days with the exception of Saturdays, Sundays and the<font style="letter-spacing:0.05pt;"> </font>designated<font style="letter-spacing:-0.05pt;"> </font>Company holidays.</div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0.44pt 0pt 0pt 0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:5.9pt;"></td><td style="font-family:'Times New Roman';font-size:11pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;">3.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;text-align:left;">INSURANCE</b><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;letter-spacing:-0.2pt;text-align:left;"> </b><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;text-align:left;">AND</b><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;letter-spacing:-0.2pt;text-align:left;"> </b><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;text-align:left;">INDEMNIFICATION</b></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0.2pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;text-align:justify;text-indent:36pt;margin:0pt 37.8pt 0pt 5.95pt;"><font style="display:inline-block;font-family:'Times New Roman';font-weight:bold;min-width:36.05pt;text-indent:0pt;white-space:nowrap;">3.1.</font><a name="_bookmark1"></a><b style="font-weight:bold;">Life,</b><b style="font-weight:bold;letter-spacing:-0.45pt;"> </b><b style="font-weight:bold;">Disability</b><b style="font-weight:bold;letter-spacing:-0.4pt;"> </b><b style="font-weight:bold;">and</b><b style="font-weight:bold;letter-spacing:-0.4pt;"> </b><b style="font-weight:bold;">Key</b><b style="font-weight:bold;letter-spacing:-0.5pt;"> </b><b style="font-weight:bold;">Man</b><b style="font-weight:bold;letter-spacing:-0.4pt;"> </b><b style="font-weight:bold;">Insurance.</b><b style="font-weight:bold;letter-spacing:1.95pt;"> </b>In<font style="letter-spacing:-0.4pt;"> </font>the<font style="letter-spacing:-0.35pt;"> </font>event<font style="letter-spacing:-0.35pt;"> </font>the<font style="letter-spacing:-0.35pt;"> </font>Company<font style="letter-spacing:-0.45pt;"> </font>establishes<font style="letter-spacing:-0.35pt;"> </font>plans<font style="letter-spacing:-0.5pt;"> </font>for<font style="letter-spacing:-2.65pt;"> </font>life, disability and key man insurance, Executive will be entitled to participation in those plans pursuant to<font style="letter-spacing:-2.6pt;"> </font>the<font style="letter-spacing:-0.15pt;"> </font>terms<font style="letter-spacing:-0.1pt;"> </font>and<font style="letter-spacing:-0.15pt;"> </font>conditions<font style="letter-spacing:-0.1pt;"> </font>of<font style="letter-spacing:-0.15pt;"> </font>those<font style="letter-spacing:-0.1pt;"> </font>plans and there applicability<font style="letter-spacing:-0.05pt;"> </font>to employees such as<font style="letter-spacing:-0.05pt;"> </font>Executive.</div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0.4pt 0pt 0pt 0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;text-align:justify;text-indent:36pt;margin:0pt 37.75pt 0pt 5.95pt;"><font style="display:inline-block;font-family:'Times New Roman';font-weight:bold;min-width:36.05pt;text-indent:0pt;white-space:nowrap;">3.2.</font><a name="_bookmark2"></a><b style="font-weight:bold;">D&amp;O Insurance.</b><b style="font-weight:bold;letter-spacing:0.05pt;"> </b>The Company will obtain and maintain at the Company&#8217;s expense<font style="letter-spacing:0.05pt;"> </font>during the term of this Agreement and for six (6) years thereafter liability insurance for the directors and<font style="letter-spacing:0.05pt;"> </font>officers<font style="letter-spacing:-0.5pt;"> </font>of<font style="letter-spacing:-0.6pt;"> </font>the<font style="letter-spacing:-0.45pt;"> </font>Company<font style="letter-spacing:-0.55pt;"> </font>(D&amp;O<font style="letter-spacing:-0.6pt;"> </font>insurance)<font style="letter-spacing:-0.55pt;"> </font>in<font style="letter-spacing:-0.55pt;"> </font>the<font style="letter-spacing:-0.5pt;"> </font>amount<font style="letter-spacing:-0.45pt;"> </font>of<font style="letter-spacing:-0.5pt;"> </font>at<font style="letter-spacing:-0.5pt;"> </font>least<font style="letter-spacing:-0.45pt;"> </font>US$10<font style="letter-spacing:-0.55pt;"> </font>million<font style="letter-spacing:-0.6pt;"> </font>for<font style="letter-spacing:-0.5pt;"> </font>any<font style="letter-spacing:-0.55pt;"> </font>acts<font style="letter-spacing:-0.45pt;"> </font>or<font style="letter-spacing:-0.5pt;"> </font>omissions<font style="letter-spacing:-2.65pt;"> </font>of Executive<font style="letter-spacing:-0.1pt;"> </font>covered by the applicable insurance policy.</div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0.4pt 0pt 0pt 0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;text-align:justify;text-indent:36pt;margin:0pt 37.75pt 0pt 5.95pt;"><font style="display:inline-block;font-family:'Times New Roman';font-weight:bold;min-width:36.05pt;text-indent:0pt;white-space:nowrap;">3.3.</font><a name="_bookmark3"></a><b style="font-weight:bold;">Indemnification.</b><b style="font-weight:bold;letter-spacing:2.75pt;"> </b>The Company and Executive acknowledge that they have entered into<font style="letter-spacing:0.05pt;"> </font>a separate indemnification agreement, and the Company will indemnify Executive in accordance with the<font style="letter-spacing:0.05pt;"> </font>terms<font style="letter-spacing:-0.15pt;"> </font>of<font style="letter-spacing:0.05pt;"> </font>such agreement.</div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0.4pt 0pt 0pt 0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:5.9pt;"></td><td style="font-family:'Times New Roman';font-size:11pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;">4.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;text-align:left;"><a name="_bookmark4"></a></b><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;text-align:left;">OUTSIDE</b><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;letter-spacing:-0.25pt;text-align:left;"> </b><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;text-align:left;">ACTIVITIES</b><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;letter-spacing:-0.3pt;text-align:left;"> </b><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;text-align:left;">DURING</b><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;letter-spacing:-0.15pt;text-align:left;"> </b><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;text-align:left;">EMPLOYMENT</b></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0.2pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;text-align:justify;text-indent:35.95pt;margin:0pt 37.7pt 0pt 5.95pt;"><font style="display:inline-block;font-family:'Times New Roman';font-weight:bold;min-width:36.1pt;text-indent:0pt;white-space:nowrap;">4.1.</font><b style="font-weight:bold;">Exclusive Employment.</b><b style="font-weight:bold;letter-spacing:0.05pt;"> </b>Executive will not engage in any business activity which, in the<font style="letter-spacing:-2.65pt;"> </font>reasonable judgment of the Chief Executive Officer or the Board, is likely to interfere with Executive&#8217;s<font style="letter-spacing:0.05pt;"> </font>ability<font style="letter-spacing:-0.35pt;"> </font>to<font style="letter-spacing:-0.3pt;"> </font>discharge<font style="letter-spacing:-0.3pt;"> </font>his<font style="letter-spacing:-0.3pt;"> </font>duties<font style="letter-spacing:-0.3pt;"> </font>and<font style="letter-spacing:-0.5pt;"> </font>responsibilities<font style="letter-spacing:-0.3pt;"> </font>to<font style="letter-spacing:-0.45pt;"> </font>the<font style="letter-spacing:-0.3pt;"> </font>Company.<font style="letter-spacing:2.1pt;"> </font>Executive<font style="letter-spacing:-0.4pt;"> </font>may<font style="letter-spacing:-0.3pt;"> </font>engage<font style="letter-spacing:-0.3pt;"> </font>in<font style="letter-spacing:-0.3pt;"> </font>civic<font style="letter-spacing:-0.3pt;"> </font>and<font style="letter-spacing:-0.5pt;"> </font>not-<font style="letter-spacing:-2.6pt;"> </font>for-profit<font style="letter-spacing:-0.3pt;"> </font>activities<font style="letter-spacing:-0.3pt;"> </font>and<font style="letter-spacing:-0.3pt;"> </font>participate<font style="letter-spacing:-0.3pt;"> </font>in<font style="letter-spacing:-0.3pt;"> </font>industry<font style="letter-spacing:-0.3pt;"> </font>associations,<font style="letter-spacing:-0.3pt;"> </font>including<font style="letter-spacing:-0.3pt;"> </font>by<font style="letter-spacing:-0.35pt;"> </font>joining<font style="letter-spacing:-0.3pt;"> </font>civic<font style="letter-spacing:-0.3pt;"> </font>boards<font style="letter-spacing:-0.3pt;"> </font>and<font style="letter-spacing:-0.3pt;"> </font>boards<font style="letter-spacing:-0.3pt;"> </font>of<font style="letter-spacing:-2.65pt;"> </font>industry<font style="letter-spacing:-0.6pt;"> </font>associations<font style="letter-spacing:-0.65pt;"> </font>so<font style="letter-spacing:-0.55pt;"> </font>long<font style="letter-spacing:-0.55pt;"> </font>as<font style="letter-spacing:-0.55pt;"> </font>such<font style="letter-spacing:-0.55pt;"> </font>activities<font style="letter-spacing:-0.5pt;"> </font>do<font style="letter-spacing:-0.55pt;"> </font>not<font style="letter-spacing:-0.6pt;"> </font>materially<font style="letter-spacing:-0.6pt;"> </font>interfere<font style="letter-spacing:-0.5pt;"> </font>with<font style="letter-spacing:-0.55pt;"> </font>the<font style="letter-spacing:-0.5pt;"> </font>performance<font style="letter-spacing:-0.55pt;"> </font>of<font style="letter-spacing:-0.5pt;"> </font>his<font style="letter-spacing:-0.5pt;"> </font>duties<font style="letter-spacing:-2.65pt;"> </font>hereunder.<font style="letter-spacing:2.2pt;"> </font>Executive<font style="letter-spacing:-0.35pt;"> </font>may<font style="letter-spacing:-0.4pt;"> </font>join<font style="letter-spacing:-0.4pt;"> </font>the<font style="letter-spacing:-0.2pt;"> </font>board<font style="letter-spacing:-0.25pt;"> </font>of<font style="letter-spacing:-0.2pt;"> </font>directors<font style="letter-spacing:-0.25pt;"> </font>of<font style="letter-spacing:-0.2pt;"> </font>for<font style="letter-spacing:-0.2pt;"> </font>profit<font style="letter-spacing:-0.2pt;"> </font>companies<font style="letter-spacing:-0.25pt;"> </font>with<font style="letter-spacing:-0.35pt;"> </font>the<font style="letter-spacing:-0.3pt;"> </font>prior<font style="letter-spacing:-0.2pt;"> </font>approval<font style="letter-spacing:-0.2pt;"> </font>of<font style="letter-spacing:-0.2pt;"> </font>the<font style="letter-spacing:-2.6pt;"> </font>Board.</div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0.34pt 0pt 0pt 0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;text-align:justify;text-indent:36pt;margin:0pt 37.75pt 0pt 5.95pt;"><font style="display:inline-block;font-family:'Times New Roman';font-weight:bold;min-width:36.05pt;text-indent:0pt;white-space:nowrap;">4.2.</font><b style="font-weight:bold;">No Adverse Interests.</b><b style="font-weight:bold;letter-spacing:0.05pt;"> </b>Except as permitted by Section <a href="#_bookmark5"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">4.3,</font></a> Executive agrees not to<font style="letter-spacing:0.05pt;"> </font>acquire, assume or participate in, directly or indirectly, any position, investment or interest known by him<font style="letter-spacing:0.05pt;"> </font>to be adverse or antagonistic to the Company, its business or prospects, financial or otherwise, or engage<font style="letter-spacing:0.05pt;"> </font>in<font style="letter-spacing:-0.05pt;"> </font>any<font style="letter-spacing:-0.15pt;"> </font>business that<font style="letter-spacing:-0.1pt;"> </font>creates<font style="letter-spacing:-0.1pt;"> </font>a conflict<font style="letter-spacing:-0.1pt;"> </font>of<font style="letter-spacing:-0.1pt;"> </font>interest<font style="letter-spacing:0.05pt;"> </font>with<font style="letter-spacing:-0.15pt;"> </font>his duties<font style="letter-spacing:-0.1pt;"> </font>of<font style="letter-spacing:-0.1pt;"> </font>loyalty to<font style="letter-spacing:-0.15pt;"> </font>the<font style="letter-spacing:-0.1pt;"> </font>Company.</div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0.4pt 0pt 0pt 0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;text-align:justify;text-indent:35.95pt;margin:0pt 37.65pt 0pt 5.95pt;"><font style="display:inline-block;font-family:'Times New Roman';font-weight:bold;min-width:36.1pt;text-indent:0pt;white-space:nowrap;">4.3.</font><a name="_bookmark5"></a><b style="font-weight:bold;">Non-Competition during Term of Agreement.</b><b style="font-weight:bold;letter-spacing:0.05pt;"> </b>During the term of this Agreement,<font style="letter-spacing:0.05pt;"> </font>except on behalf of the Company or as expressly authorized by the Board, Executive will not directly or<font style="letter-spacing:0.05pt;"> </font>indirectly,<font style="letter-spacing:0.05pt;"> </font>whether<font style="letter-spacing:0.05pt;"> </font>as<font style="letter-spacing:0.05pt;"> </font>an<font style="letter-spacing:0.05pt;"> </font>officer,<font style="letter-spacing:0.05pt;"> </font>director,<font style="letter-spacing:0.05pt;"> </font>stockholder,<font style="letter-spacing:0.05pt;"> </font>partner,<font style="letter-spacing:0.05pt;"> </font>proprietor,<font style="letter-spacing:0.05pt;"> </font>associate,<font style="letter-spacing:0.05pt;"> </font>representative,<font style="letter-spacing:0.05pt;"> </font>consultant, or in any capacity whatsoever engage in, become financially interested in, be employed by or<font style="letter-spacing:0.05pt;"> </font>have<font style="letter-spacing:0.1pt;"> </font>any<font style="letter-spacing:0.05pt;"> </font>business<font style="letter-spacing:0.2pt;"> </font>connection<font style="letter-spacing:0.05pt;"> </font>with<font style="letter-spacing:0.05pt;"> </font>any<font style="letter-spacing:0.2pt;"> </font>other<font style="letter-spacing:0.25pt;"> </font>person,<font style="letter-spacing:0.2pt;"> </font>corporation,<font style="letter-spacing:0.05pt;"> </font>firm,<font style="letter-spacing:0.2pt;"> </font>partnership<font style="letter-spacing:0.05pt;"> </font>or<font style="letter-spacing:0.1pt;"> </font>other<font style="letter-spacing:0.1pt;"> </font>entity</div><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;text-align:justify;margin:0pt;"><font style="font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:46.8pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:12pt 0.55pt 0pt 0.55pt;"><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">Gain</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.2pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">Therapeutics,</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.15pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">Inc.</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.15pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">-</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.05pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">4800</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.15pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">Hampden</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.15pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">Ln,</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.15pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">St</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.05pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">200, Bethesda,</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.1pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">MD</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:2.65pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">20814</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0.5pt 0.3pt 0pt 0.55pt;"><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">P:</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.25pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">+1</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.2pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">301-500-1556</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:1.8pt;"> </font><u style="color:#0562c1;font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-decoration:underline;text-decoration-color:#0562c1;">www.gaintherapeutics.com</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:right;margin:0pt 0.3pt 0pt 0.55pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;">3</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.78%;margin-right:5.56%;margin-top:30pt;page-break-after:always;width:83.66%;border-width:0;"><div style="max-width:100%;padding-left:10.78%;padding-right:5.56%;position:relative;"><div style="margin-top:9.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><img src="ganx-20211231xex10d8001.jpg" alt="Logo&#10;&#10;Description automatically generated" style="display:inline-block;height:42pt;width:87.5pt;"></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;text-align:justify;margin:4.05pt 37.7pt 0pt 6pt;">whatsoever<font style="letter-spacing:-0.4pt;"> </font>which<font style="letter-spacing:-0.4pt;"> </font>were<font style="letter-spacing:-0.4pt;"> </font>known<font style="letter-spacing:-0.4pt;"> </font>by<font style="letter-spacing:-0.45pt;"> </font>him<font style="letter-spacing:-0.35pt;"> </font>to<font style="letter-spacing:-0.4pt;"> </font>compete<font style="letter-spacing:-0.4pt;"> </font>directly<font style="letter-spacing:-0.4pt;"> </font>with<font style="letter-spacing:-0.45pt;"> </font>the<font style="letter-spacing:-0.35pt;"> </font>Company,<font style="letter-spacing:-0.4pt;"> </font>throughout<font style="letter-spacing:-0.5pt;"> </font>the<font style="letter-spacing:-0.35pt;"> </font>world,<font style="letter-spacing:-0.45pt;"> </font>in<font style="letter-spacing:-0.4pt;"> </font>any<font style="letter-spacing:-2.65pt;"> </font><font style="letter-spacing:-0.05pt;">line</font><font style="letter-spacing:-0.6pt;"> </font><font style="letter-spacing:-0.05pt;">of</font><font style="letter-spacing:-0.55pt;"> </font><font style="letter-spacing:-0.05pt;">business</font><font style="letter-spacing:-0.55pt;"> </font>engaged<font style="letter-spacing:-0.75pt;"> </font>in<font style="letter-spacing:-0.55pt;"> </font>(or<font style="letter-spacing:-0.55pt;"> </font>planned<font style="letter-spacing:-0.75pt;"> </font>to<font style="letter-spacing:-0.55pt;"> </font>be<font style="letter-spacing:-0.6pt;"> </font>engaged<font style="letter-spacing:-0.7pt;"> </font>in)<font style="letter-spacing:-0.7pt;"> </font>by<font style="letter-spacing:-0.55pt;"> </font>the<font style="letter-spacing:-0.6pt;"> </font>Company;<font style="letter-spacing:-0.7pt;"> </font>provided,<font style="letter-spacing:-0.7pt;"> </font>however,<font style="letter-spacing:-0.75pt;"> </font>that<font style="letter-spacing:-0.5pt;"> </font>anything<font style="letter-spacing:-2.65pt;"> </font><font style="letter-spacing:-0.05pt;">above</font><font style="letter-spacing:-0.6pt;"> </font><font style="letter-spacing:-0.05pt;">to</font><font style="letter-spacing:-0.75pt;"> </font><font style="letter-spacing:-0.05pt;">the</font><font style="letter-spacing:-0.6pt;"> </font><font style="letter-spacing:-0.05pt;">contrary</font><font style="letter-spacing:-0.55pt;"> </font>notwithstanding,<font style="letter-spacing:-0.6pt;"> </font>he<font style="letter-spacing:-0.6pt;"> </font>or<font style="letter-spacing:-0.5pt;"> </font>his<font style="letter-spacing:-0.6pt;"> </font>immediate<font style="letter-spacing:-0.6pt;"> </font>family<font style="letter-spacing:-0.55pt;"> </font>may<font style="letter-spacing:-0.6pt;"> </font>own,<font style="letter-spacing:-0.6pt;"> </font>as<font style="letter-spacing:-0.55pt;"> </font>a<font style="letter-spacing:-0.6pt;"> </font>passive<font style="letter-spacing:-0.6pt;"> </font>investor,<font style="letter-spacing:-0.55pt;"> </font>securities<font style="letter-spacing:-2.65pt;"> </font>of any competitor corporation, so long as his direct holdings in any one such corporation will not in the<font style="letter-spacing:0.05pt;"> </font>aggregate<font style="letter-spacing:-0.05pt;"> </font>constitute<font style="letter-spacing:-0.1pt;"> </font>more<font style="letter-spacing:-0.1pt;"> </font>than one<font style="letter-spacing:-0.1pt;"> </font>percent<font style="letter-spacing:0.05pt;"> </font>(1%)<font style="letter-spacing:0.05pt;"> </font>of<font style="letter-spacing:-0.1pt;"> </font>the<font style="letter-spacing:-0.1pt;"> </font>voting stock<font style="letter-spacing:-0.2pt;"> </font>of<font style="letter-spacing:0.05pt;"> </font>such<font style="letter-spacing:-0.15pt;"> </font>corporation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0.4pt 0pt 0pt 0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-top:0.05pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:5.95pt;"></td><td style="font-family:'Times New Roman';font-size:11pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;">5.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;text-align:justify;"><a name="_bookmark6"></a></b><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;text-align:justify;">CONFIDENTIAL</b><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;letter-spacing:-0.4pt;text-align:justify;"> </b><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;text-align:justify;">INFORMATION,</b><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;letter-spacing:-0.6pt;text-align:justify;"> </b><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;text-align:justify;">NON-COMPETITION</b><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;letter-spacing:-0.4pt;text-align:justify;"> </b><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;text-align:justify;">AND</b><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;letter-spacing:-0.35pt;text-align:justify;"> </b><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;text-align:justify;">NON-SOLICITATION</b></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0.2pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;text-align:justify;text-indent:36pt;margin:0pt 37.7pt 0pt 5.95pt;">As<font style="letter-spacing:0.05pt;"> </font>a<font style="letter-spacing:0.05pt;"> </font>condition<font style="letter-spacing:0.05pt;"> </font>of<font style="letter-spacing:0.05pt;"> </font>employment,<font style="letter-spacing:0.05pt;"> </font>Executive<font style="letter-spacing:0.05pt;"> </font>agrees<font style="letter-spacing:0.05pt;"> </font>to<font style="letter-spacing:0.05pt;"> </font>execute<font style="letter-spacing:0.05pt;"> </font>and<font style="letter-spacing:0.05pt;"> </font>abide<font style="letter-spacing:0.05pt;"> </font>by<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>Employee<font style="letter-spacing:0.05pt;"> </font>Confidential Information and Inventions Assignment Agreement, Non-competition and Non-solicitation<font style="letter-spacing:0.05pt;"> </font>attached<font style="letter-spacing:-0.2pt;"> </font>hereto<font style="letter-spacing:-0.15pt;"> </font>as<font style="letter-spacing:-0.15pt;"> </font><u style="text-decoration:underline;text-decoration-color:#000000;">Exhibit</u><u style="letter-spacing:-0.2pt;text-decoration:underline;text-decoration-color:#000000;"> </u><u style="text-decoration:underline;text-decoration-color:#000000;">A</u><font style="letter-spacing:-0.25pt;"> </font>(&#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">CIIAA</u>&#8221;),<font style="letter-spacing:-0.15pt;"> </font>which<font style="letter-spacing:-0.2pt;"> </font>is<font style="letter-spacing:-0.1pt;"> </font>incorporated<font style="letter-spacing:-0.2pt;"> </font>herein<font style="letter-spacing:-0.15pt;"> </font>by<font style="letter-spacing:-0.2pt;"> </font>reference,<font style="letter-spacing:-0.15pt;"> </font>as<font style="letter-spacing:-0.15pt;"> </font>may<font style="letter-spacing:-0.15pt;"> </font>be<font style="letter-spacing:-0.15pt;"> </font>amended<font style="letter-spacing:-0.15pt;"> </font>by<font style="letter-spacing:-2.65pt;"> </font>the parties from time to time, and which contains provisions that are intended by the parties to survive and<font style="letter-spacing:-2.6pt;"> </font>that do survive termination or expiration of this Agreement, including certain non-solicitation and non-<font style="letter-spacing:0.05pt;"> </font>competition<font style="letter-spacing:-0.05pt;"> </font>covenants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0.3pt 0pt 0pt 0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-top:0.05pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:5.95pt;"></td><td style="font-family:'Times New Roman';font-size:11pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;">6.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;text-align:justify;"><a name="_bookmark7"></a></b><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;text-align:justify;">TERMINATION</b><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;letter-spacing:-0.3pt;text-align:justify;"> </b><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;text-align:justify;">OF</b><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;letter-spacing:-0.25pt;text-align:justify;"> </b><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;text-align:justify;">EMPLOYMENT</b></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0.3pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;text-indent:36pt;margin:0pt 37.75pt 0pt 5.95pt;"><font style="display:inline-block;font-family:'Times New Roman';font-weight:bold;min-width:36pt;text-indent:0pt;white-space:nowrap;">6.1.</font><b style="font-weight:bold;">Definitions.</b><b style="font-weight:bold;letter-spacing:1.45pt;"> </b>For<font style="letter-spacing:2pt;"> </font>purposes<font style="letter-spacing:2.15pt;"> </font>of<font style="letter-spacing:2pt;"> </font>this<font style="letter-spacing:2.15pt;"> </font>Section<font style="letter-spacing:1.95pt;"> </font><a href="#_bookmark7"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:left;">6,</font></a><font style="letter-spacing:2.15pt;"> </font>the<font style="letter-spacing:2pt;"> </font>following<font style="letter-spacing:2.05pt;"> </font>terms<font style="letter-spacing:2.05pt;"> </font>have<font style="letter-spacing:2.1pt;"> </font>the<font style="letter-spacing:2.05pt;"> </font>following<font style="letter-spacing:-2.6pt;"> </font>meanings:</div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0.4pt 0pt 0pt 0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;text-align:justify;text-indent:72pt;margin:0pt 37.75pt 0pt 5.95pt;">&#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Accrued Obligations</u>&#8221; means (i) Executive&#8217;s earned but unpaid Base Salary through the<font style="letter-spacing:0.05pt;"> </font>Termination Date; (ii) the amount of any Annual Incentive and any other annual, long-term, or other<font style="letter-spacing:0.05pt;"> </font>incentive<font style="letter-spacing:-0.3pt;"> </font>award,<font style="letter-spacing:-0.45pt;"> </font>in<font style="letter-spacing:-0.3pt;"> </font>each<font style="letter-spacing:-0.45pt;"> </font>case<font style="letter-spacing:-0.3pt;"> </font>which<font style="letter-spacing:-0.45pt;"> </font>relates<font style="letter-spacing:-0.4pt;"> </font>to<font style="letter-spacing:-0.3pt;"> </font>a<font style="letter-spacing:-0.35pt;"> </font>completed<font style="letter-spacing:-0.35pt;"> </font>fiscal<font style="letter-spacing:-0.25pt;"> </font>year<font style="letter-spacing:-0.4pt;"> </font>or<font style="letter-spacing:-0.25pt;"> </font>performance<font style="letter-spacing:-0.3pt;"> </font>period,<font style="letter-spacing:-0.3pt;"> </font>as<font style="letter-spacing:-0.4pt;"> </font>applicable,<font style="letter-spacing:-2.6pt;"> </font>not yet paid on or before the Termination Date; (iii) a lump-sum payment in respect of accrued but unused<font style="letter-spacing:-2.6pt;"> </font>vacation<font style="letter-spacing:0.5pt;"> </font>days<font style="letter-spacing:0.55pt;"> </font>at<font style="letter-spacing:0.55pt;"> </font>Executive&#8217;s<font style="letter-spacing:0.55pt;"> </font>per-business-day<font style="letter-spacing:0.5pt;"> </font>Base<font style="letter-spacing:0.55pt;"> </font>Salary<font style="letter-spacing:0.5pt;"> </font>rate<font style="letter-spacing:0.45pt;"> </font>in<font style="letter-spacing:0.5pt;"> </font>effect<font style="letter-spacing:0.6pt;"> </font>as<font style="letter-spacing:0.55pt;"> </font>of<font style="letter-spacing:0.55pt;"> </font>the<font style="letter-spacing:0.55pt;"> </font>Termination<font style="letter-spacing:0.5pt;"> </font>Date;<font style="letter-spacing:0.55pt;"> </font>and</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:12.6pt;text-align:justify;margin:0pt 0pt 0pt 5.95pt;">(iv) any<font style="letter-spacing:-0.2pt;"> </font>unpaid<font style="letter-spacing:-0.05pt;"> </font>expense<font style="letter-spacing:-0.05pt;"> </font>or<font style="letter-spacing:-0.25pt;"> </font>other reimbursements due<font style="letter-spacing:-0.05pt;"> </font>pursuant<font style="letter-spacing:-0.15pt;"> </font>to<font style="letter-spacing:-0.05pt;"> </font>Section<font style="letter-spacing:-0.05pt;"> </font><a href="#_bookmark0"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:12.6pt;text-align:justify;">2.4</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;line-height:12.6pt;text-align:justify;"> </font></a>hereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0.2pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;text-align:justify;text-indent:72pt;margin:0pt 37.75pt 0pt 6pt;">&#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Beneficiary</u>&#8221;<font style="letter-spacing:2.6pt;"> </font>means<font style="letter-spacing:2.6pt;"> </font>the<font style="letter-spacing:2.6pt;"> </font>designee(s)<font style="letter-spacing:2.6pt;"> </font>listed<font style="letter-spacing:2.6pt;"> </font>in &#160;<u style="text-decoration:underline;text-decoration-color:#000000;">Exhibit</u><u style="letter-spacing:2.65pt;text-decoration:underline;text-decoration-color:#000000;"> </u><u style="text-decoration:underline;text-decoration-color:#000000;">B</u><font style="letter-spacing:2.6pt;"> </font>who<font style="letter-spacing:2.6pt;"> </font>are<font style="letter-spacing:2.6pt;"> </font>entitled<font style="letter-spacing:2.65pt;"> </font>to<font style="letter-spacing:2.55pt;"> </font>receive<font style="letter-spacing:-2.65pt;"> </font>payments<font style="letter-spacing:-0.05pt;"> </font>under<font style="letter-spacing:0.05pt;"> </font>Section <a href="#_bookmark8"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">6.3</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;line-height:1.28;text-align:justify;"> </font></a>upon the death<font style="letter-spacing:-0.15pt;"> </font>of<font style="letter-spacing:0.05pt;"> </font>Executive.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;text-align:justify;text-indent:72pt;margin:0pt 37.7pt 0pt 6pt;">&#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Cause</u>&#8221; means (i) Executive&#8217;s conviction of, or plea of guilty or nolo contendere to, any<font style="letter-spacing:0.05pt;"> </font>felony<font style="letter-spacing:-0.45pt;"> </font>or<font style="letter-spacing:-0.4pt;"> </font>any<font style="letter-spacing:-0.4pt;"> </font>crime<font style="letter-spacing:-0.4pt;"> </font>involving<font style="letter-spacing:-0.45pt;"> </font>theft,<font style="letter-spacing:-0.4pt;"> </font>embezzlement,<font style="letter-spacing:-0.45pt;"> </font>dishonesty<font style="letter-spacing:-0.4pt;"> </font>or<font style="letter-spacing:-0.4pt;"> </font>moral<font style="letter-spacing:-0.4pt;"> </font>turpitude;<font style="letter-spacing:-0.45pt;"> </font>(ii)<font style="letter-spacing:-0.4pt;"> </font>any<font style="letter-spacing:-0.4pt;"> </font>act<font style="letter-spacing:-0.4pt;"> </font>by<font style="letter-spacing:-0.45pt;"> </font>Executive<font style="letter-spacing:-2.6pt;"> </font>constituting willful misconduct, deliberate malfeasance, dishonesty, unethical conduct or gross negligence<font style="letter-spacing:-2.6pt;"> </font>in<font style="letter-spacing:-0.2pt;"> </font>the<font style="letter-spacing:-0.15pt;"> </font>performance<font style="letter-spacing:-0.15pt;"> </font>of<font style="letter-spacing:-0.15pt;"> </font>his<font style="letter-spacing:-0.1pt;"> </font>duties;<font style="letter-spacing:-0.25pt;"> </font>(iii)<font style="letter-spacing:-0.15pt;"> </font>Executive&#8217;s<font style="letter-spacing:-0.3pt;"> </font>willful<font style="letter-spacing:-0.1pt;"> </font>and<font style="letter-spacing:-0.3pt;"> </font>continued<font style="letter-spacing:-0.3pt;"> </font>failure<font style="letter-spacing:-0.25pt;"> </font>to<font style="letter-spacing:-0.3pt;"> </font>perform<font style="letter-spacing:-0.15pt;"> </font>any<font style="letter-spacing:-0.3pt;"> </font>of<font style="letter-spacing:-0.2pt;"> </font>the<font style="letter-spacing:-0.3pt;"> </font>duties<font style="letter-spacing:-2.65pt;"> </font>of<font style="letter-spacing:-0.05pt;"> </font>his<font style="letter-spacing:-0.15pt;"> </font>position<font style="letter-spacing:-0.2pt;"> </font>(which<font style="letter-spacing:-0.05pt;"> </font>has<font style="letter-spacing:-0.1pt;"> </font>not been<font style="letter-spacing:-0.2pt;"> </font>cured<font style="letter-spacing:-0.05pt;"> </font>within<font style="letter-spacing:-0.2pt;"> </font>thirty<font style="letter-spacing:-0.25pt;"> </font>(30)<font style="letter-spacing:-0.15pt;"> </font>days<font style="letter-spacing:-0.05pt;"> </font>following<font style="letter-spacing:-0.2pt;"> </font>the<font style="letter-spacing:-0.15pt;"> </font>first<font style="letter-spacing:-0.05pt;"> </font>written<font style="letter-spacing:-0.2pt;"> </font>notice<font style="letter-spacing:-0.05pt;"> </font>from<font style="letter-spacing:-0.15pt;"> </font>the<font style="letter-spacing:-2.65pt;"> </font>Company<font style="letter-spacing:-0.6pt;"> </font>describing<font style="letter-spacing:-0.55pt;"> </font>such<font style="letter-spacing:-0.65pt;"> </font>failure<font style="letter-spacing:-0.65pt;"> </font>in<font style="letter-spacing:-0.65pt;"> </font>reasonable<font style="letter-spacing:-0.65pt;"> </font>detail);<font style="letter-spacing:-0.6pt;"> </font>or<font style="letter-spacing:-0.55pt;"> </font>(v)<font style="letter-spacing:-0.5pt;"> </font>any<font style="letter-spacing:-0.65pt;"> </font>material<font style="letter-spacing:-0.5pt;"> </font>breach<font style="letter-spacing:-0.55pt;"> </font>(which<font style="letter-spacing:-0.6pt;"> </font>has<font style="letter-spacing:-0.5pt;"> </font>not<font style="letter-spacing:-0.5pt;"> </font>been<font style="letter-spacing:-0.65pt;"> </font>cured<font style="letter-spacing:-2.65pt;"> </font>within thirty (30) days following the first written notice from the Company describing such breach in<font style="letter-spacing:0.05pt;"> </font>reasonable detail) by Executive of this Agreement or any other agreement between Executive and the<font style="letter-spacing:0.05pt;"> </font>Company<font style="letter-spacing:-0.05pt;"> </font>or<font style="letter-spacing:-0.1pt;"> </font>any of<font style="letter-spacing:0.05pt;"> </font>its<font style="letter-spacing:-0.1pt;"> </font>affiliates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0.25pt 0pt 0pt 0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;text-align:justify;text-indent:72pt;margin:0.05pt 37.75pt 0pt 5.95pt;">&#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Change of Control</u>&#8221; means the occurrence of any of the following: (i) any third party or<font style="letter-spacing:0.05pt;"> </font>group of third parties becomes the beneficial owner, directly or indirectly, of securities of the Company<font style="letter-spacing:0.05pt;"> </font>representing<font style="letter-spacing:0.05pt;"> </font>more<font style="letter-spacing:0.05pt;"> </font>than<font style="letter-spacing:0.05pt;"> </font>fifty<font style="letter-spacing:0.05pt;"> </font>percent<font style="letter-spacing:0.05pt;"> </font>(50%)<font style="letter-spacing:0.05pt;"> </font>of<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>combined<font style="letter-spacing:0.05pt;"> </font>voting<font style="letter-spacing:0.05pt;"> </font>power<font style="letter-spacing:0.05pt;"> </font>of<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>Company&#8217;s<font style="letter-spacing:0.05pt;"> </font>then<font style="letter-spacing:0.05pt;"> </font>outstanding securities; provided that if the third party or group of third parties is already deemed to own<font style="letter-spacing:0.05pt;"> </font>more<font style="letter-spacing:-0.05pt;"> </font>than<font style="letter-spacing:-0.05pt;"> </font>50%<font style="letter-spacing:0.05pt;"> </font>of<font style="letter-spacing:-0.15pt;"> </font>the total fair<font style="letter-spacing:0.05pt;"> </font>market value or<font style="letter-spacing:-0.15pt;"> </font>total<font style="letter-spacing:0.05pt;"> </font>voting<font style="letter-spacing:-0.05pt;"> </font>power, then<font style="letter-spacing:-0.05pt;"> </font>the acquisition<font style="letter-spacing:-0.05pt;"> </font>of<font style="letter-spacing:0.05pt;"> </font>additional stock</p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;text-align:justify;margin:0pt;"><font style="font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:46.8pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:12pt 0.55pt 0pt 0.55pt;"><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">Gain</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.2pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">Therapeutics,</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.15pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">Inc.</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.15pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">-</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.05pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">4800</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.15pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">Hampden</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.15pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">Ln,</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.15pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">St</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.05pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">200, Bethesda,</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.1pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">MD</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:2.65pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">20814</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0.5pt 0.3pt 0pt 0.55pt;"><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">P:</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.25pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">+1</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.2pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">301-500-1556</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:1.8pt;"> </font><u style="color:#0562c1;font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-decoration:underline;text-decoration-color:#0562c1;">www.gaintherapeutics.com</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:right;margin:0pt 0.3pt 0pt 0.55pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;">4</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.78%;margin-right:5.56%;margin-top:30pt;page-break-after:always;width:83.66%;border-width:0;"><div style="max-width:100%;padding-left:10.78%;padding-right:5.56%;position:relative;"><div style="margin-top:9.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><img src="ganx-20211231xex10d8001.jpg" alt="Logo&#10;&#10;Description automatically generated" style="display:inline-block;height:42pt;width:87.5pt;"></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;text-align:justify;margin:4.05pt 37.75pt 0pt 5.95pt;">by such third party or group of third parties will not constitute an additional Change in Control; (ii) the<font style="letter-spacing:0.05pt;"> </font>stockholders of the Company approve a plan of complete liquidation of the Company; (iii) the sale or<font style="letter-spacing:0.05pt;"> </font>disposition<font style="letter-spacing:0.05pt;"> </font>of<font style="letter-spacing:0.05pt;"> </font>all<font style="letter-spacing:0.05pt;"> </font>or<font style="letter-spacing:0.05pt;"> </font>substantially<font style="letter-spacing:0.05pt;"> </font>all<font style="letter-spacing:0.05pt;"> </font>of<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>Company&#8217;s<font style="letter-spacing:0.05pt;"> </font>assets;<font style="letter-spacing:0.05pt;"> </font>or<font style="letter-spacing:0.05pt;"> </font>(iv)<font style="letter-spacing:0.05pt;"> </font>a<font style="letter-spacing:0.05pt;"> </font>merger,<font style="letter-spacing:0.05pt;"> </font>consolidation<font style="letter-spacing:0.05pt;"> </font>or<font style="letter-spacing:0.05pt;"> </font>reorganization of the Company with or involving any other entity, other than a merger, consolidation or<font style="letter-spacing:0.05pt;"> </font>reorganization that would result in the voting securities of the Company outstanding immediately prior<font style="letter-spacing:0.05pt;"> </font>thereto<font style="letter-spacing:-0.65pt;"> </font>continuing<font style="letter-spacing:-0.65pt;"> </font>to<font style="letter-spacing:-0.6pt;"> </font>represent<font style="letter-spacing:-0.6pt;"> </font>(either<font style="letter-spacing:-0.55pt;"> </font>by<font style="letter-spacing:-0.65pt;"> </font>remaining<font style="letter-spacing:-0.5pt;"> </font>outstanding<font style="letter-spacing:-0.65pt;"> </font>or<font style="letter-spacing:-0.6pt;"> </font>by<font style="letter-spacing:-0.6pt;"> </font>being<font style="letter-spacing:-0.65pt;"> </font>converted<font style="letter-spacing:-0.6pt;"> </font>into<font style="letter-spacing:-0.55pt;"> </font>voting<font style="letter-spacing:-0.6pt;"> </font>securities<font style="letter-spacing:-2.65pt;"> </font>of the surviving entity) at least a 50% of the combined voting power of the Company (or such surviving<font style="letter-spacing:0.05pt;"> </font>entity)<font style="letter-spacing:-0.55pt;"> </font>outstanding<font style="letter-spacing:-0.55pt;"> </font>immediately<font style="letter-spacing:-0.55pt;"> </font>after<font style="letter-spacing:-0.55pt;"> </font>such<font style="letter-spacing:-0.65pt;"> </font>merger,<font style="letter-spacing:-0.55pt;"> </font>consolidation<font style="letter-spacing:-0.55pt;"> </font>or<font style="letter-spacing:-0.55pt;"> </font>reorganization<font style="letter-spacing:-0.65pt;"> </font>owned<font style="letter-spacing:-0.55pt;"> </font>in<font style="letter-spacing:-0.55pt;"> </font>approximately<font style="letter-spacing:-2.65pt;"> </font>the<font style="letter-spacing:-0.05pt;"> </font>same<font style="letter-spacing:-0.05pt;"> </font>proportion of such<font style="letter-spacing:-0.2pt;"> </font>ownership by<font style="letter-spacing:-0.05pt;"> </font>each of<font style="letter-spacing:-0.15pt;"> </font>the<font style="letter-spacing:-0.05pt;"> </font>prior<font style="letter-spacing:0.05pt;"> </font>shareholders<font style="letter-spacing:-0.15pt;"> </font>as<font style="letter-spacing:-0.05pt;"> </font>prior<font style="letter-spacing:-0.1pt;"> </font>to<font style="letter-spacing:-0.2pt;"> </font>the<font style="letter-spacing:-0.1pt;"> </font>transaction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0.4pt 0pt 0pt 0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:justify;text-indent:72pt;margin:0pt 37.75pt 0pt 6pt;">&#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Change of Control Period</u>&#8221; means the period starting three (3) months prior to a Change<font style="letter-spacing:0.05pt;"> </font>of Control<font style="letter-spacing:0.05pt;"> </font>and<font style="letter-spacing:-0.15pt;"> </font>ending twenty-four<font style="letter-spacing:-0.1pt;"> </font>(24)<font style="letter-spacing:-0.15pt;"> </font>months after<font style="letter-spacing:0.05pt;"> </font>a<font style="letter-spacing:-0.25pt;"> </font>Change of<font style="letter-spacing:0.05pt;"> </font>Control.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0.05pt 0pt 0pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;text-align:justify;text-indent:72pt;margin:0pt 37.85pt 0pt 6pt;">&#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Change of Control Termination</u>&#8221; means a termination of this Agreement during the<font style="letter-spacing:0.05pt;"> </font>Change of Control Period by the Company without Cause, by Executive for Good Reason, or due to<font style="letter-spacing:0.05pt;"> </font>Executive&#8217;s<font style="letter-spacing:-0.15pt;"> </font>death or<font style="letter-spacing:0.05pt;"> </font>Disability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0.4pt 0pt 0pt 0pt;"><font style="font-size:7.5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:4.59pt 0pt 0pt 78pt;">&#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">COBRA</u>&#8221;<font style="letter-spacing:2.55pt;"> </font>means<font style="letter-spacing:2.5pt;"> </font>the<font style="letter-spacing:2.45pt;"> </font>Consolidated<font style="letter-spacing:2.4pt;"> </font>Omnibus<font style="letter-spacing:2.5pt;"> </font>Budget<font style="letter-spacing:2.65pt;"> </font>Reconciliation<font style="letter-spacing:2.5pt;"> </font>Act<font style="letter-spacing:2.65pt;"> </font>of<font style="letter-spacing:2.5pt;"> </font>1985,<font style="letter-spacing:2.5pt;"> </font>as</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:1pt 0pt 0pt 6pt;">amended.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0.25pt 0pt 0pt 0pt;"><font style="font-size:8.5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;text-align:justify;text-indent:72pt;margin:4.59pt 37.7pt 0pt 5.95pt;"><font style="letter-spacing:-0.05pt;">&#8220;</font><u style="letter-spacing:-0.05pt;text-decoration:underline;text-decoration-color:#000000;">Disability</u><font style="letter-spacing:-0.05pt;">&#8221;</font><font style="letter-spacing:-0.6pt;"> </font>means<font style="letter-spacing:-0.6pt;"> </font>Executive&#8217;s<font style="letter-spacing:-0.6pt;"> </font>becoming<font style="letter-spacing:-0.75pt;"> </font>incapacitated<font style="letter-spacing:-0.55pt;"> </font>for<font style="letter-spacing:-0.55pt;"> </font>a<font style="letter-spacing:-0.6pt;"> </font>period<font style="letter-spacing:-0.6pt;"> </font>of<font style="letter-spacing:-0.5pt;"> </font>at<font style="letter-spacing:-0.55pt;"> </font>least<font style="letter-spacing:-0.55pt;"> </font>one<font style="letter-spacing:-0.7pt;"> </font>hundred<font style="letter-spacing:-2.6pt;"> </font>eighty<font style="letter-spacing:-0.5pt;"> </font>(180)<font style="letter-spacing:-0.4pt;"> </font>days<font style="letter-spacing:-0.4pt;"> </font>by<font style="letter-spacing:-0.45pt;"> </font>accident,<font style="letter-spacing:-0.5pt;"> </font>sickness<font style="letter-spacing:-0.4pt;"> </font>or<font style="letter-spacing:-0.4pt;"> </font>other<font style="letter-spacing:-0.4pt;"> </font>circumstance<font style="letter-spacing:-0.45pt;"> </font>that<font style="letter-spacing:-0.5pt;"> </font>renders<font style="letter-spacing:-0.4pt;"> </font>Executive<font style="letter-spacing:-0.4pt;"> </font>mentally<font style="letter-spacing:-0.5pt;"> </font>or<font style="letter-spacing:-0.4pt;"> </font>physically<font style="letter-spacing:-2.6pt;"> </font>incapable of performing the material duties and services required of Executive hereunder on a full-time<font style="letter-spacing:0.05pt;"> </font>basis during<font style="letter-spacing:-0.15pt;"> </font>such<font style="letter-spacing:-0.15pt;"> </font>period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0.4pt 0pt 0pt 0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;text-align:justify;text-indent:72pt;margin:0pt 37.7pt 0pt 5.95pt;">&#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Good Reason</u>&#8221; means: (i) any material diminution of Executive&#8217;s authority, duties or<font style="letter-spacing:0.05pt;"> </font><font style="letter-spacing:-0.05pt;">responsibilities</font><font style="letter-spacing:-0.6pt;"> </font><font style="letter-spacing:-0.05pt;">or</font><font style="letter-spacing:-0.5pt;"> </font><font style="letter-spacing:-0.05pt;">the</font><font style="letter-spacing:-0.6pt;"> </font><font style="letter-spacing:-0.05pt;">assignment</font><font style="letter-spacing:-0.5pt;"> </font><font style="letter-spacing:-0.05pt;">to</font><font style="letter-spacing:-0.6pt;"> </font><font style="letter-spacing:-0.05pt;">Executive</font><font style="letter-spacing:-0.55pt;"> </font>of<font style="letter-spacing:-0.55pt;"> </font>duties<font style="letter-spacing:-0.55pt;"> </font>or<font style="letter-spacing:-0.55pt;"> </font>responsibilities<font style="letter-spacing:-0.55pt;"> </font>which<font style="letter-spacing:-0.6pt;"> </font>are<font style="letter-spacing:-0.55pt;"> </font>materially<font style="letter-spacing:-0.75pt;"> </font>inconsistent<font style="letter-spacing:-2.65pt;"> </font>with Executive&#8217;s position; (ii) any reduction by the Company in Executive&#8217;s Base Salary other than a<font style="letter-spacing:0.05pt;"> </font>reduction that is also applicable in a substantially similar manner and proportion to the other senior<font style="letter-spacing:0.05pt;"> </font>executives<font style="letter-spacing:-0.3pt;"> </font>of<font style="letter-spacing:-0.3pt;"> </font>the<font style="letter-spacing:-0.15pt;"> </font>Company;<font style="letter-spacing:-0.25pt;"> </font>(iii)<font style="letter-spacing:-0.25pt;"> </font>a<font style="letter-spacing:-0.3pt;"> </font>relocation<font style="letter-spacing:-0.2pt;"> </font>of<font style="letter-spacing:-0.15pt;"> </font>Executive&#8217;s<font style="letter-spacing:-0.3pt;"> </font>place<font style="letter-spacing:-0.3pt;"> </font>of<font style="letter-spacing:-0.25pt;"> </font>employment<font style="letter-spacing:-0.25pt;"> </font>to<font style="letter-spacing:-0.2pt;"> </font>a<font style="letter-spacing:-0.3pt;"> </font>location<font style="letter-spacing:-0.3pt;"> </font>in<font style="letter-spacing:-0.3pt;"> </font>excess<font style="letter-spacing:-0.3pt;"> </font>of<font style="letter-spacing:-2.6pt;"> </font>50 miles from the Company&#8217;s current offices in Bethesda, Maryland; (iv) any material breach of this<font style="letter-spacing:0.05pt;"> </font>Agreement<font style="letter-spacing:-0.4pt;"> </font>by<font style="letter-spacing:-0.4pt;"> </font>the<font style="letter-spacing:-0.4pt;"> </font>Company;<font style="letter-spacing:-0.35pt;"> </font>or<font style="letter-spacing:-0.35pt;"> </font>(v)<font style="letter-spacing:-0.35pt;"> </font>any<font style="letter-spacing:-0.45pt;"> </font>failure<font style="letter-spacing:-0.35pt;"> </font>by<font style="letter-spacing:-0.45pt;"> </font>the<font style="letter-spacing:-0.5pt;"> </font>Company<font style="letter-spacing:-0.4pt;"> </font>to<font style="letter-spacing:-0.45pt;"> </font>obtain<font style="letter-spacing:-0.4pt;"> </font>the<font style="letter-spacing:-0.4pt;"> </font>assumption<font style="letter-spacing:-0.4pt;"> </font>of<font style="letter-spacing:-0.4pt;"> </font>this<font style="letter-spacing:-0.35pt;"> </font>Agreement<font style="letter-spacing:-2.65pt;"> </font>by<font style="letter-spacing:-0.2pt;"> </font>any<font style="letter-spacing:-0.15pt;"> </font>successor<font style="letter-spacing:-0.1pt;"> </font>or<font style="letter-spacing:-0.1pt;"> </font>assign<font style="letter-spacing:-0.15pt;"> </font>of<font style="letter-spacing:-0.1pt;"> </font>the<font style="letter-spacing:-0.1pt;"> </font>Company<font style="letter-spacing:-0.15pt;"> </font>which,<font style="letter-spacing:-0.15pt;"> </font>for<font style="letter-spacing:-0.2pt;"> </font>purposes<font style="letter-spacing:-0.1pt;"> </font>of<font style="letter-spacing:-0.2pt;"> </font>this<font style="letter-spacing:-0.1pt;"> </font>provision,<font style="letter-spacing:-0.3pt;"> </font>will<font style="letter-spacing:-0.1pt;"> </font>be<font style="letter-spacing:-0.1pt;"> </font>a<font style="letter-spacing:-0.1pt;"> </font>material<font style="letter-spacing:-0.1pt;"> </font>breach<font style="letter-spacing:-2.6pt;"> </font>of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0.25pt 0pt 0pt 0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;text-align:justify;text-indent:72pt;margin:0pt 37.7pt 0pt 5.95pt;">&#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Pro-Rata Annual Incentive</u>&#8221; means an amount equal to (i) the Annual Incentive that<font style="letter-spacing:0.05pt;"> </font>Executive would have been entitled to receive for the calendar year that includes the Termination Date if<font style="letter-spacing:0.05pt;"> </font>his employment hereunder had continued (as determined by the Board based upon the actual achievement<font style="letter-spacing:0.05pt;"> </font>of<font style="letter-spacing:-0.15pt;"> </font>the<font style="letter-spacing:-0.25pt;"> </font>applicable<font style="letter-spacing:-0.15pt;"> </font>performance<font style="letter-spacing:-0.1pt;"> </font>goals),<font style="letter-spacing:-0.25pt;"> </font>multiplied<font style="letter-spacing:-0.2pt;"> </font>by<font style="letter-spacing:-0.15pt;"> </font>(ii)<font style="letter-spacing:-0.2pt;"> </font>a<font style="letter-spacing:-0.15pt;"> </font>fraction,<font style="letter-spacing:-0.15pt;"> </font>the<font style="letter-spacing:-0.1pt;"> </font>numerator<font style="letter-spacing:-0.15pt;"> </font>of<font style="letter-spacing:-0.2pt;"> </font>which<font style="letter-spacing:-0.15pt;"> </font>is<font style="letter-spacing:-0.3pt;"> </font>the<font style="letter-spacing:-0.1pt;"> </font>number<font style="letter-spacing:-0.1pt;"> </font>of<font style="letter-spacing:-2.65pt;"> </font>days he was employed hereunder during such year and the denominator of which is the number of days in<font style="letter-spacing:0.05pt;"> </font>such year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0.44pt 0pt 0pt 0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt 11.75pt 0pt 32.75pt;">&#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Release</u>&#8221;<font style="letter-spacing:-0.1pt;"> </font>means<font style="letter-spacing:-0.15pt;"> </font>the<font style="letter-spacing:-0.05pt;"> </font>release<font style="letter-spacing:-0.05pt;"> </font>of claims<font style="letter-spacing:-0.05pt;"> </font>substantially<font style="letter-spacing:-0.2pt;"> </font>in<font style="letter-spacing:-0.2pt;"> </font>the<font style="letter-spacing:-0.2pt;"> </font>form attached<font style="letter-spacing:-0.05pt;"> </font>as<font style="letter-spacing:-0.05pt;"> </font><u style="text-decoration:underline;text-decoration-color:#000000;">Exhibit C</u>.</p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;text-align:center;margin:0pt;"><font style="font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:46.8pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:12pt 0.55pt 0pt 0.55pt;"><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">Gain</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.2pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">Therapeutics,</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.15pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">Inc.</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.15pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">-</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.05pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">4800</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.15pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">Hampden</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.15pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">Ln,</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.15pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">St</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.05pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">200, Bethesda,</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.1pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">MD</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:2.65pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">20814</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0.5pt 0.3pt 0pt 0.55pt;"><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">P:</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.25pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">+1</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.2pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">301-500-1556</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:1.8pt;"> </font><u style="color:#0562c1;font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-decoration:underline;text-decoration-color:#0562c1;">www.gaintherapeutics.com</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:right;margin:0pt 0.3pt 0pt 0.55pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;">5</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.78%;margin-right:5.56%;margin-top:30pt;page-break-after:always;width:83.66%;border-width:0;"><div style="max-width:100%;padding-left:10.78%;padding-right:5.56%;position:relative;"><div style="margin-top:9.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><img src="ganx-20211231xex10d8001.jpg" alt="Logo&#10;&#10;Description automatically generated" style="display:inline-block;height:42pt;width:87.5pt;"></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:4.05pt 0pt 0pt 78pt;">&#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Severance</u><u style="letter-spacing:0.1pt;text-decoration:underline;text-decoration-color:#000000;"> </u><u style="text-decoration:underline;text-decoration-color:#000000;">Period</u>&#8221;<font style="letter-spacing:-0.05pt;"> </font>means the<font style="letter-spacing:0.1pt;"> </font>period<font style="letter-spacing:0.1pt;"> </font>starting<font style="letter-spacing:0.05pt;"> </font>on<font style="letter-spacing:-0.05pt;"> </font>the<font style="letter-spacing:0.15pt;"> </font>Termination<font style="letter-spacing:0.05pt;"> </font>Date<font style="letter-spacing:0.15pt;"> </font>and<font style="letter-spacing:0.05pt;"> </font>ending<font style="letter-spacing:0.1pt;"> </font>twelve</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;margin:1.04pt 21.9pt 0pt 6pt;">(12)<font style="letter-spacing:0.35pt;"> </font>months<font style="letter-spacing:0.3pt;"> </font>after<font style="letter-spacing:0.45pt;"> </font>the<font style="letter-spacing:0.45pt;"> </font>Termination<font style="letter-spacing:0.3pt;"> </font>Date,<font style="letter-spacing:0.4pt;"> </font>or<font style="letter-spacing:0.35pt;"> </font>in<font style="letter-spacing:0.3pt;"> </font>connection<font style="letter-spacing:0.4pt;"> </font>with<font style="letter-spacing:0.4pt;"> </font>a<font style="letter-spacing:0.45pt;"> </font>Change<font style="letter-spacing:0.45pt;"> </font>of<font style="letter-spacing:0.45pt;"> </font>Control<font style="letter-spacing:0.45pt;"> </font>Termination,<font style="letter-spacing:0.3pt;"> </font>twenty-<font style="letter-spacing:-2.6pt;"> </font>four<font style="letter-spacing:-0.15pt;"> </font>(24)<font style="letter-spacing:0.05pt;"> </font>months after<font style="letter-spacing:-0.1pt;"> </font>the<font style="letter-spacing:-0.1pt;"> </font>Termination Date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0.34pt 0pt 0pt 0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;text-align:justify;text-indent:72pt;margin:0pt 37.7pt 0pt 6pt;">&#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Stock Awards</u>&#8221; means the Initial Grants and any future stock options, RSUs, restricted<font style="letter-spacing:0.05pt;"> </font>stock and such other awards granted pursuant to the Company&#8217;s stock option and equity incentive award<font style="letter-spacing:0.05pt;"> </font>plans<font style="letter-spacing:-0.15pt;"> </font>or<font style="letter-spacing:-0.1pt;"> </font>agreements and any shares of<font style="letter-spacing:0.05pt;"> </font>stock<font style="letter-spacing:-0.2pt;"> </font>issued<font style="letter-spacing:-0.15pt;"> </font>upon exercise<font style="letter-spacing:-0.1pt;"> </font>thereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0.4pt 0pt 0pt 0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;text-align:justify;text-indent:72pt;margin:0pt 37.8pt 0pt 6pt;">&#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Termination</u><u style="letter-spacing:-0.6pt;text-decoration:underline;text-decoration-color:#000000;"> </u><u style="text-decoration:underline;text-decoration-color:#000000;">Date</u>&#8221;<font style="letter-spacing:-0.5pt;"> </font>means<font style="letter-spacing:-0.65pt;"> </font>the<font style="letter-spacing:-0.6pt;"> </font>date<font style="letter-spacing:-0.4pt;"> </font>on<font style="letter-spacing:-0.45pt;"> </font>which<font style="letter-spacing:-0.55pt;"> </font>this<font style="letter-spacing:-0.45pt;"> </font>Agreement<font style="letter-spacing:-0.5pt;"> </font>and<font style="letter-spacing:-0.55pt;"> </font>Executive&#8217;s<font style="letter-spacing:-0.6pt;"> </font>employment<font style="letter-spacing:-2.6pt;"> </font>hereunder terminates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0.34pt 0pt 0pt 0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;text-align:justify;text-indent:36pt;margin:0pt 37.65pt 0pt 5.95pt;"><font style="display:inline-block;font-family:'Times New Roman';font-weight:bold;min-width:36.05pt;text-indent:0pt;white-space:nowrap;">6.2.</font><b style="font-weight:bold;">Termination of Agreement.</b><b style="font-weight:bold;letter-spacing:0.05pt;"> </b>This Agreement and Executive&#8217;s employment with the<font style="letter-spacing:0.05pt;"> </font>Company<font style="letter-spacing:-0.55pt;"> </font>is<font style="letter-spacing:-0.65pt;"> </font>terminable<font style="letter-spacing:-0.45pt;"> </font>at<font style="letter-spacing:-0.6pt;"> </font>will<font style="letter-spacing:-0.5pt;"> </font>by<font style="letter-spacing:-0.6pt;"> </font>the<font style="letter-spacing:-0.55pt;"> </font>Company<font style="letter-spacing:-0.5pt;"> </font>or<font style="letter-spacing:-0.6pt;"> </font>by<font style="letter-spacing:-0.55pt;"> </font>Executive<font style="letter-spacing:-0.6pt;"> </font>for<font style="letter-spacing:-0.5pt;"> </font>any<font style="letter-spacing:-0.6pt;"> </font>reason<font style="letter-spacing:-0.55pt;"> </font>or<font style="letter-spacing:-0.5pt;"> </font>no<font style="letter-spacing:-0.6pt;"> </font>reason,<font style="letter-spacing:-0.55pt;"> </font>each<font style="letter-spacing:-0.5pt;"> </font>by<font style="letter-spacing:-0.55pt;"> </font>written<font style="letter-spacing:-2.65pt;"> </font>notice<font style="letter-spacing:-0.3pt;"> </font>to<font style="letter-spacing:-0.3pt;"> </font>the<font style="letter-spacing:-0.3pt;"> </font>other<font style="letter-spacing:-0.25pt;"> </font>party<font style="letter-spacing:-0.3pt;"> </font>effective<font style="letter-spacing:-0.3pt;"> </font>upon<font style="letter-spacing:-0.25pt;"> </font>receipt<font style="letter-spacing:-0.25pt;"> </font>or<font style="letter-spacing:-0.25pt;"> </font>on<font style="letter-spacing:-0.3pt;"> </font>a<font style="letter-spacing:-0.4pt;"> </font>later<font style="letter-spacing:-0.25pt;"> </font>termination<font style="letter-spacing:-0.3pt;"> </font>date<font style="letter-spacing:-0.35pt;"> </font>agreed<font style="letter-spacing:-0.45pt;"> </font>with<font style="letter-spacing:-0.3pt;"> </font>the<font style="letter-spacing:-0.3pt;"> </font>other<font style="letter-spacing:-0.25pt;"> </font>party.<font style="letter-spacing:2.3pt;"> </font>In<font style="letter-spacing:-2.65pt;"> </font>addition,<font style="letter-spacing:-0.05pt;"> </font>this Agreement<font style="letter-spacing:-0.1pt;"> </font>terminates<font style="letter-spacing:-0.1pt;"> </font>upon death or Disability of<font style="letter-spacing:-0.1pt;"> </font>Executive.</div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0.4pt 0pt 0pt 0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-top:0.05pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:41.95pt;"></td><td style="font-family:'Times New Roman';font-size:11pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;">6.3.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;text-align:left;"><a name="_bookmark8"></a></b><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;text-align:left;">Terminations</b><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;letter-spacing:-0.25pt;text-align:left;"> </b><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;text-align:left;">with</b><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;letter-spacing:-0.2pt;text-align:left;"> </b><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;text-align:left;">Severance.</b></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0.3pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><div style="margin-top:0.05pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;text-align:justify;text-indent:72pt;margin:0pt 37.8pt 0pt 5.95pt;"><font style="display:inline-block;font-family:'Times New Roman';font-weight:bold;min-width:36.1pt;text-indent:0pt;white-space:nowrap;">(a)</font><a name="_bookmark9"></a>If the Company terminates this Agreement without Cause, Executive terminates<font style="letter-spacing:0.05pt;"> </font>this Agreement for Good Reason, or this Agreement terminates upon death or Disability of Executive, the<font style="letter-spacing:-2.6pt;"> </font>Company<font style="letter-spacing:-0.3pt;"> </font>will<font style="letter-spacing:-0.25pt;"> </font>pay<font style="letter-spacing:-0.4pt;"> </font>or<font style="letter-spacing:-0.2pt;"> </font>award<font style="letter-spacing:-0.45pt;"> </font>to<font style="letter-spacing:-0.3pt;"> </font>Executive<font style="letter-spacing:-0.35pt;"> </font>(or<font style="letter-spacing:-0.25pt;"> </font>his<font style="letter-spacing:-0.3pt;"> </font>Beneficiaries<font style="letter-spacing:-0.3pt;"> </font>upon<font style="letter-spacing:-0.35pt;"> </font>termination<font style="letter-spacing:-0.3pt;"> </font>for<font style="letter-spacing:-0.4pt;"> </font>the<font style="letter-spacing:-0.25pt;"> </font>death<font style="letter-spacing:-0.45pt;"> </font>of<font style="letter-spacing:-0.25pt;"> </font>Executive)<font style="letter-spacing:-2.6pt;"> </font>the Accrued Obligations on the Termination Date, and subject to execution and non-revocation of the<font style="letter-spacing:0.05pt;"> </font>Release,<font style="letter-spacing:-0.55pt;"> </font>on<font style="letter-spacing:-0.6pt;"> </font>the<font style="letter-spacing:-0.5pt;"> </font>date<font style="letter-spacing:-0.5pt;"> </font>on<font style="letter-spacing:-0.65pt;"> </font>which<font style="letter-spacing:-0.5pt;"> </font>the<font style="letter-spacing:-0.5pt;"> </font>Release<font style="letter-spacing:-0.5pt;"> </font>may<font style="letter-spacing:-0.5pt;"> </font>no<font style="letter-spacing:-0.65pt;"> </font>longer<font style="letter-spacing:-0.45pt;"> </font>be<font style="letter-spacing:-0.65pt;"> </font>revoked,<font style="letter-spacing:-0.6pt;"> </font>the<font style="letter-spacing:-0.65pt;"> </font>following<font style="letter-spacing:-0.6pt;"> </font>payments<font style="letter-spacing:-0.45pt;"> </font>and<font style="letter-spacing:-0.65pt;"> </font>severance<font style="letter-spacing:-2.65pt;"> </font>benefits<font style="letter-spacing:-0.05pt;"> </font>(&#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Severance Benefits</u>&#8221;):</div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0.34pt 0pt 0pt 0pt;"><font style="font-size:7.5pt;visibility:hidden;">&#8203;</font></p><div style="margin-top:4.55pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;text-align:justify;text-indent:108pt;margin:0pt 37.8pt 0pt 5.95pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36.1pt;text-indent:0pt;white-space:nowrap;">(i)</font><a name="_bookmark10"></a>an<font style="letter-spacing:-0.25pt;"> </font>amount<font style="letter-spacing:-0.25pt;"> </font>equal<font style="letter-spacing:-0.25pt;"> </font>to<font style="letter-spacing:-0.3pt;"> </font>Executive&#8217;s<font style="letter-spacing:-0.25pt;"> </font>Base<font style="letter-spacing:-0.15pt;"> </font>Salary<font style="letter-spacing:-0.3pt;"> </font>in<font style="letter-spacing:-0.3pt;"> </font>effect<font style="letter-spacing:-0.25pt;"> </font>immediately<font style="letter-spacing:-0.3pt;"> </font>prior<font style="letter-spacing:-0.25pt;"> </font>to<font style="letter-spacing:-2.65pt;"> </font>the<font style="letter-spacing:-0.4pt;"> </font>Termination<font style="letter-spacing:-0.45pt;"> </font>Date<font style="letter-spacing:-0.4pt;"> </font>that<font style="letter-spacing:-0.4pt;"> </font>would<font style="letter-spacing:-0.45pt;"> </font>be<font style="letter-spacing:-0.5pt;"> </font>payable<font style="letter-spacing:-0.5pt;"> </font>to<font style="letter-spacing:-0.45pt;"> </font>Executive<font style="letter-spacing:-0.4pt;"> </font>if<font style="letter-spacing:-0.45pt;"> </font>this<font style="letter-spacing:-0.4pt;"> </font>Agreement<font style="letter-spacing:-0.5pt;"> </font>continued<font style="letter-spacing:-0.45pt;"> </font>during<font style="letter-spacing:-0.55pt;"> </font>the<font style="letter-spacing:-0.35pt;"> </font>applicable<font style="letter-spacing:-2.65pt;"> </font>Severance<font style="letter-spacing:-0.05pt;"> </font>Period;</div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0.4pt 0pt 0pt 0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;text-align:justify;text-indent:108pt;margin:0pt 37.75pt 0pt 5.95pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36.05pt;text-indent:0pt;white-space:nowrap;">(ii)</font>the<font style="letter-spacing:-0.3pt;"> </font>Pro-Rata<font style="letter-spacing:-0.3pt;"> </font>Annual<font style="letter-spacing:-0.25pt;"> </font>Incentive;<font style="letter-spacing:-0.25pt;"> </font>or<font style="letter-spacing:-0.25pt;"> </font>upon<font style="letter-spacing:-0.3pt;"> </font>a<font style="letter-spacing:-0.3pt;"> </font>Change<font style="letter-spacing:-0.3pt;"> </font>of<font style="letter-spacing:-0.25pt;"> </font>Control<font style="letter-spacing:-0.25pt;"> </font>Termination,<font style="letter-spacing:-2.65pt;"> </font>the<font style="letter-spacing:-0.35pt;"> </font>Pro-Rata<font style="letter-spacing:-0.3pt;"> </font>Annual<font style="letter-spacing:-0.25pt;"> </font>Incentive<font style="letter-spacing:-0.3pt;"> </font>and<font style="letter-spacing:-0.3pt;"> </font>the<font style="letter-spacing:-0.25pt;"> </font>amount<font style="letter-spacing:-0.25pt;"> </font>of<font style="letter-spacing:-0.4pt;"> </font>the<font style="letter-spacing:-0.3pt;"> </font>Target<font style="letter-spacing:-0.25pt;"> </font>Annual<font style="letter-spacing:-0.25pt;"> </font>Incentive<font style="letter-spacing:-0.3pt;"> </font>that<font style="letter-spacing:-0.35pt;"> </font>would<font style="letter-spacing:-0.3pt;"> </font>accrue<font style="letter-spacing:-0.35pt;"> </font>during<font style="letter-spacing:-0.4pt;"> </font>the<font style="letter-spacing:-2.6pt;"> </font>applicable<font style="letter-spacing:-0.05pt;"> </font>Severance Period;</div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0.34pt 0pt 0pt 0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p><div style="margin-top:0.05pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;text-align:justify;text-indent:108pt;margin:0pt 37.75pt 0pt 5.95pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36.05pt;text-indent:0pt;white-space:nowrap;">(iii)</font>for the applicable Severance Period, the cost of continuation coverage<font style="letter-spacing:0.05pt;"> </font>pursuant<font style="letter-spacing:0.05pt;"> </font>to<font style="letter-spacing:0.05pt;"> </font>COBRA<font style="letter-spacing:0.05pt;"> </font>or<font style="letter-spacing:0.05pt;"> </font>applicable<font style="letter-spacing:0.05pt;"> </font>state<font style="letter-spacing:0.05pt;"> </font>continuation<font style="letter-spacing:0.05pt;"> </font>coverage<font style="letter-spacing:0.05pt;"> </font>laws,<font style="letter-spacing:0.05pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>Executive<font style="letter-spacing:0.05pt;"> </font>and<font style="letter-spacing:0.05pt;"> </font>his<font style="letter-spacing:0.05pt;"> </font>eligible<font style="letter-spacing:-2.6pt;"> </font>dependents<font style="letter-spacing:-0.45pt;"> </font>who<font style="letter-spacing:-0.45pt;"> </font>were<font style="letter-spacing:-0.5pt;"> </font>covered<font style="letter-spacing:-0.45pt;"> </font>under<font style="letter-spacing:-0.4pt;"> </font>the<font style="letter-spacing:-0.45pt;"> </font>Company&#8217;s<font style="letter-spacing:-0.4pt;"> </font>health<font style="letter-spacing:-0.45pt;"> </font>insurance<font style="letter-spacing:-0.4pt;"> </font>plans<font style="letter-spacing:-0.4pt;"> </font>as<font style="letter-spacing:-0.4pt;"> </font>of<font style="letter-spacing:-0.45pt;"> </font>the<font style="letter-spacing:-0.4pt;"> </font>date<font style="letter-spacing:-0.4pt;"> </font>of<font style="letter-spacing:-0.5pt;"> </font>the<font style="letter-spacing:-0.4pt;"> </font>termination<font style="letter-spacing:-2.65pt;"> </font>of this Agreement (provided that Executive will be solely responsible for all matters relating to his<font style="letter-spacing:0.05pt;"> </font>continuation<font style="letter-spacing:-0.6pt;"> </font>of<font style="letter-spacing:-0.6pt;"> </font>coverage<font style="letter-spacing:-0.55pt;"> </font>pursuant<font style="letter-spacing:-0.6pt;"> </font>to<font style="letter-spacing:-0.55pt;"> </font>COBRA<font style="letter-spacing:-0.65pt;"> </font>or<font style="letter-spacing:-0.5pt;"> </font>any<font style="letter-spacing:-0.6pt;"> </font>corresponding<font style="letter-spacing:-0.55pt;"> </font>state<font style="letter-spacing:-0.65pt;"> </font>law,<font style="letter-spacing:-0.6pt;"> </font>including,<font style="letter-spacing:-0.55pt;"> </font>without<font style="letter-spacing:-0.6pt;"> </font>limitation,<font style="letter-spacing:-2.65pt;"> </font>his<font style="letter-spacing:-0.05pt;"> </font>election of<font style="letter-spacing:0.05pt;"> </font>such coverage and his<font style="letter-spacing:-0.1pt;"> </font>timely<font style="letter-spacing:-0.05pt;"> </font>payment<font style="letter-spacing:-0.1pt;"> </font>of<font style="letter-spacing:-0.1pt;"> </font>premiums);</div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0.3pt 0pt 0pt 0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;text-align:justify;text-indent:108pt;margin:0pt 37.85pt 0pt 5.95pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36.05pt;text-indent:0pt;white-space:nowrap;">(iv)</font><a name="_bookmark11"></a>for the applicable Severance Period, the amount of any life insurance and<font style="letter-spacing:-2.6pt;"> </font>long-term<font style="letter-spacing:0.05pt;"> </font>disability<font style="letter-spacing:0.05pt;"> </font>insurance<font style="letter-spacing:0.05pt;"> </font>premiums<font style="letter-spacing:0.05pt;"> </font>it<font style="letter-spacing:0.05pt;"> </font>was<font style="letter-spacing:0.05pt;"> </font>paying<font style="letter-spacing:0.05pt;"> </font>prior<font style="letter-spacing:0.05pt;"> </font>to<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>date<font style="letter-spacing:0.05pt;"> </font>of<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>termination<font style="letter-spacing:0.05pt;"> </font>of<font style="letter-spacing:0.05pt;"> </font>this<font style="letter-spacing:-2.6pt;"> </font>Agreement;</div><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;text-align:justify;margin:0pt;"><font style="font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:46.8pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:12pt 0.55pt 0pt 0.55pt;"><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">Gain</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.2pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">Therapeutics,</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.15pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">Inc.</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.15pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">-</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.05pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">4800</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.15pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">Hampden</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.15pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">Ln,</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.15pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">St</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.05pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">200, Bethesda,</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.1pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">MD</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:2.65pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">20814</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0.5pt 0.3pt 0pt 0.55pt;"><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">P:</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.25pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">+1</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.2pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">301-500-1556</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:1.8pt;"> </font><u style="color:#0562c1;font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-decoration:underline;text-decoration-color:#0562c1;">www.gaintherapeutics.com</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:right;margin:0pt 0.3pt 0pt 0.55pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;">6</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.78%;margin-right:5.56%;margin-top:30pt;page-break-after:always;width:83.66%;border-width:0;"><div style="max-width:100%;padding-left:10.78%;padding-right:5.56%;position:relative;"><div style="margin-top:9.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><img src="ganx-20211231xex10d8001.jpg" alt="Logo&#10;&#10;Description automatically generated" style="display:inline-block;height:42pt;width:87.5pt;"></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="margin-top:4.05pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;text-align:justify;text-indent:108pt;margin:0pt 37.65pt 0pt 5.95pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36.1pt;text-indent:0pt;white-space:nowrap;">(v)</font>acceleration of vesting of (A) Executive&#8217;s outstanding unvested Stock<font style="letter-spacing:0.05pt;"> </font>Awards that would have vested over the twelve (12) month period following the date of termination had<font style="letter-spacing:0.05pt;"> </font>Executive remained continuously employed by the Company during such period, or (B) all of Executive&#8217;s<font style="letter-spacing:-2.6pt;"> </font>outstanding unvested Stock Awards if this Agreement is terminated pursuant to a Change of Control<font style="letter-spacing:0.05pt;"> </font>Termination,<font style="letter-spacing:-0.2pt;"> </font>provided<font style="letter-spacing:-0.2pt;"> </font>that<font style="letter-spacing:-0.2pt;"> </font>if<font style="letter-spacing:-0.15pt;"> </font>any<font style="letter-spacing:-0.15pt;"> </font>unvested<font style="letter-spacing:-0.2pt;"> </font>Stock<font style="letter-spacing:-0.15pt;"> </font>Awards<font style="letter-spacing:-0.15pt;"> </font>have<font style="letter-spacing:-0.15pt;"> </font>lapsed<font style="letter-spacing:-0.15pt;"> </font>or<font style="letter-spacing:-0.15pt;"> </font>been<font style="letter-spacing:-0.15pt;"> </font>forfeited<font style="letter-spacing:-0.2pt;"> </font>upon<font style="letter-spacing:-0.15pt;"> </font>a<font style="letter-spacing:-0.3pt;"> </font>termination<font style="letter-spacing:-2.65pt;"> </font>during the Change of Control Period but prior to a Change of Control, the Company will make a cash<font style="letter-spacing:0.05pt;"> </font>payment<font style="letter-spacing:-0.6pt;"> </font>to<font style="letter-spacing:-0.5pt;"> </font>the<font style="letter-spacing:-0.55pt;"> </font>Executive,<font style="letter-spacing:-0.5pt;"> </font>no<font style="letter-spacing:-0.5pt;"> </font>later<font style="letter-spacing:-0.5pt;"> </font>than<font style="letter-spacing:-0.5pt;"> </font>ten<font style="letter-spacing:-0.6pt;"> </font>(10)<font style="letter-spacing:-0.5pt;"> </font>days<font style="letter-spacing:-0.45pt;"> </font>after<font style="letter-spacing:-0.45pt;"> </font>the<font style="letter-spacing:-0.55pt;"> </font>effective<font style="letter-spacing:-0.45pt;"> </font>date<font style="letter-spacing:-0.55pt;"> </font>of<font style="letter-spacing:-0.45pt;"> </font>the<font style="letter-spacing:-0.45pt;"> </font>Change<font style="letter-spacing:-0.55pt;"> </font>of<font style="letter-spacing:-0.45pt;"> </font>Control,<font style="letter-spacing:-0.5pt;"> </font>equal<font style="letter-spacing:-2.65pt;"> </font>to the economic value of the terminated Stock Award to Executive at the time of the Change of Control<font style="letter-spacing:0.05pt;"> </font>(calculated for stock options as the difference between the exercise price of the option and the fair market<font style="letter-spacing:0.05pt;"> </font>value of the shares underlying the option at the time of the Change of Control, and for stock awards as the<font style="letter-spacing:-2.6pt;"> </font>fair market value of the shares at the time of the Change of Control).<font style="letter-spacing:0.05pt;"> </font>The provisions concerning vesting<font style="letter-spacing:0.05pt;"> </font>pursuant to clauses (A) and (B) below will be cumulative and are hereby deemed to be a part of all equity<font style="letter-spacing:0.05pt;"> </font>incentive grants, including the Initial Grants and any future stock options, RSUs, restricted stock and such<font style="letter-spacing:-2.6pt;"> </font>other<font style="letter-spacing:0.05pt;"> </font>awards<font style="letter-spacing:0.05pt;"> </font>granted<font style="letter-spacing:0.05pt;"> </font>pursuant<font style="letter-spacing:0.05pt;"> </font>to<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>Company&#8217;s<font style="letter-spacing:0.05pt;"> </font>stock<font style="letter-spacing:0.05pt;"> </font>option<font style="letter-spacing:0.05pt;"> </font>and equity incentive<font style="letter-spacing:0.05pt;"> </font>award<font style="letter-spacing:0.05pt;"> </font>plans<font style="letter-spacing:0.05pt;"> </font>or<font style="letter-spacing:0.05pt;"> </font>agreements<font style="letter-spacing:-0.15pt;"> </font>and<font style="letter-spacing:-0.25pt;"> </font>any<font style="letter-spacing:-0.3pt;"> </font>shares<font style="letter-spacing:-0.25pt;"> </font>of<font style="letter-spacing:-0.15pt;"> </font>stock<font style="letter-spacing:-0.25pt;"> </font>issued<font style="letter-spacing:-0.3pt;"> </font>upon<font style="letter-spacing:-0.25pt;"> </font>exercise<font style="letter-spacing:-0.15pt;"> </font>thereof,<font style="letter-spacing:-0.25pt;"> </font>(each<font style="letter-spacing:-0.2pt;"> </font>a<font style="letter-spacing:-0.25pt;"> </font>&#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Stock</u><u style="letter-spacing:-0.2pt;text-decoration:underline;text-decoration-color:#000000;"> </u><u style="text-decoration:underline;text-decoration-color:#000000;">Award</u>&#8221;)<font style="letter-spacing:-0.1pt;"> </font>and<font style="letter-spacing:-0.3pt;"> </font>to<font style="letter-spacing:-0.25pt;"> </font>supersede<font style="letter-spacing:-2.65pt;"> </font>any<font style="letter-spacing:-0.05pt;"> </font>less<font style="letter-spacing:-0.1pt;"> </font>favorable<font style="letter-spacing:-0.05pt;"> </font>provision in<font style="letter-spacing:-0.05pt;"> </font>any agreement or<font style="letter-spacing:0.05pt;"> </font>plan<font style="letter-spacing:-0.2pt;"> </font>regarding such<font style="letter-spacing:-0.05pt;"> </font>Stock Award.</div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0.3pt 0pt 0pt 0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;text-align:justify;text-indent:72pt;margin:0pt 37.7pt 0pt 5.95pt;"><font style="display:inline-block;font-family:'Times New Roman';font-weight:bold;min-width:36.05pt;text-indent:0pt;white-space:nowrap;">(b)</font>Notwithstanding anything herein, if this Agreement is terminated pursuant to<font style="letter-spacing:0.05pt;"> </font>Executive&#8217;s death or Disability and if the Company has paid for or provided the Executive with life<font style="letter-spacing:0.05pt;"> </font>insurance or long term disability insurance coverage as set forth in Section <a href="#_bookmark1"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">2.6</font></a>, then the payment pursuant<font style="letter-spacing:-2.6pt;"> </font>to such insurance will replace the Company&#8217;s obligation to pay the Severance Benefits set forth in Section<font style="letter-spacing:-2.6pt;"> </font><a href="#_bookmark8"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">6.3</font></a><a href="#_bookmark9"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">(a)</font></a><a href="#_bookmark10"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">(i)</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;line-height:1.28;text-align:justify;"> </font></a>and <a href="#_bookmark11"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">(iv).</font></a></div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0.3pt 0pt 0pt 0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;text-align:justify;text-indent:72pt;margin:0pt 37.75pt 0pt 5.95pt;"><font style="display:inline-block;font-family:'Times New Roman';font-weight:bold;min-width:36.05pt;text-indent:0pt;white-space:nowrap;">(c)</font>As a condition precedent to receipt of any Severance Benefits, Executive will<font style="letter-spacing:0.05pt;"> </font>provide<font style="letter-spacing:-0.3pt;"> </font>the<font style="letter-spacing:-0.3pt;"> </font>Company<font style="letter-spacing:-0.3pt;"> </font>with<font style="letter-spacing:-0.35pt;"> </font>the<font style="letter-spacing:-0.3pt;"> </font>executed<font style="letter-spacing:-0.3pt;"> </font>and<font style="letter-spacing:-0.25pt;"> </font>effective<font style="letter-spacing:-0.3pt;"> </font>Release,<font style="letter-spacing:-0.3pt;"> </font>or<font style="letter-spacing:-0.25pt;"> </font>a<font style="letter-spacing:-0.25pt;"> </font>release<font style="letter-spacing:-0.4pt;"> </font>in<font style="letter-spacing:-0.3pt;"> </font>such<font style="letter-spacing:-0.35pt;"> </font>other<font style="letter-spacing:-0.25pt;"> </font>form<font style="letter-spacing:-0.35pt;"> </font>as<font style="letter-spacing:-0.3pt;"> </font>the<font style="letter-spacing:-0.25pt;"> </font>parties<font style="letter-spacing:-2.65pt;"> </font>may<font style="letter-spacing:-0.25pt;"> </font>agree<font style="letter-spacing:-0.25pt;"> </font>upon<font style="letter-spacing:-0.35pt;"> </font>at<font style="letter-spacing:-0.3pt;"> </font>the<font style="letter-spacing:-0.35pt;"> </font>time.<font style="letter-spacing:2.15pt;"> </font>Such<font style="letter-spacing:-0.25pt;"> </font>Release<font style="letter-spacing:-0.25pt;"> </font>must<font style="letter-spacing:-0.2pt;"> </font>be<font style="letter-spacing:-0.25pt;"> </font>executed<font style="letter-spacing:-0.35pt;"> </font>and<font style="letter-spacing:-0.25pt;"> </font>delivered<font style="letter-spacing:-0.4pt;"> </font>to<font style="letter-spacing:-0.25pt;"> </font>the<font style="letter-spacing:-0.25pt;"> </font>Company<font style="letter-spacing:-0.25pt;"> </font>by<font style="letter-spacing:-0.25pt;"> </font>no<font style="letter-spacing:-0.4pt;"> </font>later<font style="letter-spacing:-0.35pt;"> </font>than<font style="letter-spacing:-2.65pt;"> </font>twenty-one (21) days after the date of Executive&#8217;s termination from employment and must not be revoked<font style="letter-spacing:-2.6pt;"> </font>during the seven (7) days following such delivery. If such Release is not executed in a timely manner or is<font style="letter-spacing:-2.6pt;"> </font>revoked, all Severance Benefits will immediately cease and Executive shall be required to repay to the<font style="letter-spacing:0.05pt;"> </font>Company<font style="letter-spacing:-0.05pt;"> </font>any<font style="letter-spacing:-0.15pt;"> </font>such<font style="letter-spacing:-0.15pt;"> </font>payments that<font style="letter-spacing:-0.1pt;"> </font>have<font style="letter-spacing:-0.1pt;"> </font>already been paid to<font style="letter-spacing:-0.15pt;"> </font>Executive.</div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0.3pt 0pt 0pt 0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;text-align:justify;text-indent:35.95pt;margin:0pt 37.8pt 0pt 5.95pt;"><font style="display:inline-block;font-family:'Times New Roman';font-weight:bold;min-width:36.1pt;text-indent:0pt;white-space:nowrap;">6.4.</font><b style="font-weight:bold;">Terminations without Severance.</b><b style="font-weight:bold;letter-spacing:0.05pt;"> </b>If this Agreement is terminated by Executive without<font style="letter-spacing:-2.6pt;"> </font>Good Reason or by the Company for Cause, Executive will be entitled to the Accrued Obligations, but no<font style="letter-spacing:0.05pt;"> </font>other payments<font style="letter-spacing:-0.1pt;"> </font>or<font style="letter-spacing:-0.1pt;"> </font>severance benefits.</div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0.4pt 0pt 0pt 0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:41.9pt;"></td><td style="font-family:'Times New Roman';font-size:11pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;">6.5.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;text-align:left;"><a name="_bookmark12"></a></b><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;text-align:left;">Cooperation</b><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;letter-spacing:-0.25pt;text-align:left;"> </b><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;text-align:left;">Obligations.</b></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0.34pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><div style="margin-top:0.05pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;text-align:justify;text-indent:72pt;margin:0pt 37.65pt 0pt 6pt;"><font style="display:inline-block;font-family:'Times New Roman';font-weight:bold;min-width:36.05pt;text-indent:0pt;white-space:nowrap;">(a)</font><u style="text-decoration:underline;text-decoration-color:#000000;">Resignation from Positions</u>.<font style="letter-spacing:0.05pt;"> </font>Upon the termination of Executive&#39;s employment for<font style="letter-spacing:-2.65pt;"> </font>any reason, Executive will immediately resign from each position held with the Company and its affiliates<font style="letter-spacing:-2.6pt;"> </font>as of the Termination Date, if requested to do so by the Company, subject to any applicable legal<font style="letter-spacing:0.05pt;"> </font>requirements<font style="letter-spacing:-0.15pt;"> </font>regarding<font style="letter-spacing:-0.15pt;"> </font>such resignation.</div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0.4pt 0pt 0pt 0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;text-align:justify;text-indent:72pt;margin:0pt 37.8pt 0pt 6pt;"><font style="display:inline-block;font-family:'Times New Roman';font-weight:bold;min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font><u style="text-decoration:underline;text-decoration-color:#000000;">Transition Activities</u>.<font style="letter-spacing:0.05pt;"> </font>After delivery or receipt by Executive of any notice of<font style="letter-spacing:0.05pt;"> </font>termination,<font style="letter-spacing:-0.65pt;"> </font>and<font style="letter-spacing:-0.65pt;"> </font>for<font style="letter-spacing:-0.55pt;"> </font>a<font style="letter-spacing:-0.65pt;"> </font>reasonable<font style="letter-spacing:-0.6pt;"> </font>period<font style="letter-spacing:-0.65pt;"> </font>following<font style="letter-spacing:-0.65pt;"> </font>any<font style="letter-spacing:-0.6pt;"> </font>termination<font style="letter-spacing:-0.55pt;"> </font>of<font style="letter-spacing:-0.45pt;"> </font>this<font style="letter-spacing:-0.5pt;"> </font>Agreement<font style="letter-spacing:-0.5pt;"> </font>(to<font style="letter-spacing:-0.6pt;"> </font>include<font style="letter-spacing:-0.65pt;"> </font>any<font style="letter-spacing:-0.5pt;"> </font>period<font style="letter-spacing:-2.65pt;"> </font>for<font style="letter-spacing:-0.05pt;"> </font>which<font style="letter-spacing:-0.1pt;"> </font>Executive<font style="letter-spacing:-0.1pt;"> </font>has<font style="letter-spacing:-0.15pt;"> </font>been<font style="letter-spacing:-0.1pt;"> </font>provided<font style="letter-spacing:-0.05pt;"> </font>Base<font style="letter-spacing:-0.2pt;"> </font>Salary<font style="letter-spacing:-0.25pt;"> </font>as<font style="letter-spacing:-0.15pt;"> </font>a<font style="letter-spacing:-0.1pt;"> </font>severance<font style="letter-spacing:-0.1pt;"> </font>benefit),<font style="letter-spacing:-0.05pt;"> </font>Executive<font style="letter-spacing:-0.1pt;"> </font>will<font style="letter-spacing:-0.15pt;"> </font>fully<font style="letter-spacing:-0.05pt;"> </font>cooperate</div><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;text-align:justify;margin:0pt;"><font style="font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:46.8pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:12pt 0.55pt 0pt 0.55pt;"><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">Gain</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.2pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">Therapeutics,</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.15pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">Inc.</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.15pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">-</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.05pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">4800</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.15pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">Hampden</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.15pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">Ln,</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.15pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">St</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.05pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">200, Bethesda,</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.1pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">MD</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:2.65pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">20814</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0.5pt 0.3pt 0pt 0.55pt;"><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">P:</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.25pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">+1</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.2pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">301-500-1556</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:1.8pt;"> </font><u style="color:#0562c1;font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-decoration:underline;text-decoration-color:#0562c1;">www.gaintherapeutics.com</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:right;margin:0pt 0.3pt 0pt 0.55pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;">7</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.78%;margin-right:5.56%;margin-top:30pt;page-break-after:always;width:83.66%;border-width:0;"><div style="max-width:100%;padding-left:10.78%;padding-right:5.56%;position:relative;"><div style="margin-top:9.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><img src="ganx-20211231xex10d8001.jpg" alt="Logo&#10;&#10;Description automatically generated" style="display:inline-block;height:42pt;width:87.5pt;"></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;margin:4.05pt 31.3pt 0pt 6pt;">with<font style="letter-spacing:0.55pt;"> </font>the<font style="letter-spacing:0.55pt;"> </font>Company<font style="letter-spacing:0.45pt;"> </font>in<font style="letter-spacing:0.55pt;"> </font>all<font style="letter-spacing:0.65pt;"> </font>matters<font style="letter-spacing:0.45pt;"> </font>relating<font style="letter-spacing:0.4pt;"> </font>to<font style="letter-spacing:0.6pt;"> </font>the<font style="letter-spacing:0.55pt;"> </font>winding<font style="letter-spacing:0.6pt;"> </font>up<font style="letter-spacing:0.55pt;"> </font>of<font style="letter-spacing:0.65pt;"> </font>Executive&#8217;s<font style="letter-spacing:0.55pt;"> </font>pending<font style="letter-spacing:0.55pt;"> </font>work<font style="letter-spacing:0.6pt;"> </font>and<font style="letter-spacing:0.4pt;"> </font>the<font style="letter-spacing:0.6pt;"> </font>orderly<font style="letter-spacing:-2.6pt;"> </font>transfer of<font style="letter-spacing:0.05pt;"> </font>any<font style="letter-spacing:-0.2pt;"> </font>such pending<font style="letter-spacing:-0.05pt;"> </font>work to<font style="letter-spacing:-0.05pt;"> </font>such other<font style="letter-spacing:-0.15pt;"> </font>employees<font style="letter-spacing:-0.1pt;"> </font>as<font style="letter-spacing:-0.15pt;"> </font>may be<font style="letter-spacing:-0.05pt;"> </font>designated<font style="letter-spacing:-0.15pt;"> </font>by<font style="letter-spacing:-0.05pt;"> </font>the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0.34pt 0pt 0pt 0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p><div style="margin-top:0.05pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;text-align:justify;text-indent:72pt;margin:0pt 37.6pt 0pt 6pt;"><font style="display:inline-block;font-family:'Times New Roman';font-weight:bold;min-width:36.05pt;text-indent:0pt;white-space:nowrap;">(c)</font><u style="text-decoration:underline;text-decoration-color:#000000;">Return of the Company&#8217;s Property</u>.<font style="letter-spacing:0.05pt;"> </font>If the Company has delivered or received a<font style="letter-spacing:0.05pt;"> </font>notice<font style="letter-spacing:-0.4pt;"> </font>of<font style="letter-spacing:-0.4pt;"> </font>termination<font style="letter-spacing:-0.4pt;"> </font>of<font style="letter-spacing:-0.4pt;"> </font>this<font style="letter-spacing:-0.55pt;"> </font>Agreement,<font style="letter-spacing:-0.5pt;"> </font>the<font style="letter-spacing:-0.4pt;"> </font>Company<font style="letter-spacing:-0.5pt;"> </font>will<font style="letter-spacing:-0.5pt;"> </font>have<font style="letter-spacing:-0.55pt;"> </font>the<font style="letter-spacing:-0.5pt;"> </font>right,<font style="letter-spacing:-0.55pt;"> </font>at<font style="letter-spacing:-0.45pt;"> </font>its<font style="letter-spacing:-0.4pt;"> </font>option,<font style="letter-spacing:-0.55pt;"> </font>to<font style="letter-spacing:-0.4pt;"> </font>require<font style="letter-spacing:-0.4pt;"> </font>Executive<font style="letter-spacing:-2.6pt;"> </font>to vacate his offices and to cease all activities on the Company&#8217;s behalf prior to the effective date of<font style="letter-spacing:0.05pt;"> </font>termination.<font style="letter-spacing:0.05pt;"> </font>Upon the termination of this Agreement, as a condition to Executive&#8217;s receipt of any post-<font style="letter-spacing:0.05pt;"> </font>termination benefits described in this Agreement, Executive will immediately surrender to the Company<font style="letter-spacing:0.05pt;"> </font>all lists, books and records of, or in connection with, the Company&#8217;s business, and all other tangible and<font style="letter-spacing:0.05pt;"> </font>intangible property belonging to the Company, it being distinctly understood that all such lists, books and<font style="letter-spacing:0.05pt;"> </font>records, and other property, are the property of the Company.<font style="letter-spacing:0.05pt;"> </font>Executive will deliver to the Company a<font style="letter-spacing:0.05pt;"> </font>signed statement certifying compliance with this Section <a href="#_bookmark12"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">6.5 </font></a>prior to the receipt of any post-termination<font style="letter-spacing:0.05pt;"> </font>benefits<font style="letter-spacing:-0.05pt;"> </font>described in<font style="letter-spacing:-0.15pt;"> </font>this Agreement.</div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0.4pt 0pt 0pt 0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;text-align:justify;text-indent:72pt;margin:0pt 37.7pt 0pt 6pt;"><font style="display:inline-block;font-family:'Times New Roman';font-weight:bold;min-width:36pt;text-indent:0pt;white-space:nowrap;">(d)</font><u style="text-decoration:underline;text-decoration-color:#000000;">Litigation</u>.<font style="letter-spacing:1.85pt;"> </font>After<font style="letter-spacing:-0.5pt;"> </font>the<font style="letter-spacing:-0.5pt;"> </font>termination<font style="letter-spacing:-0.45pt;"> </font>of<font style="letter-spacing:-0.5pt;"> </font>this<font style="letter-spacing:-0.45pt;"> </font>Agreement,<font style="letter-spacing:-0.45pt;"> </font>Executive<font style="letter-spacing:-0.4pt;"> </font>will<font style="letter-spacing:-0.4pt;"> </font>cooperate<font style="letter-spacing:-0.4pt;"> </font>with<font style="letter-spacing:-2.65pt;"> </font>the Company in responding to the reasonable requests of the Company&#8217;s Chairman of the Board, CEO or<font style="letter-spacing:0.05pt;"> </font>General Counsel, in connection with any and all existing or future litigation, arbitrations, mediations or<font style="letter-spacing:0.05pt;"> </font>investigations brought by or against the Company, or its or their respective affiliates, agents, officers,<font style="letter-spacing:0.05pt;"> </font>directors<font style="letter-spacing:0.05pt;"> </font>or<font style="letter-spacing:0.05pt;"> </font>employees,<font style="letter-spacing:0.05pt;"> </font>whether<font style="letter-spacing:0.05pt;"> </font>administrative,<font style="letter-spacing:0.05pt;"> </font>civil<font style="letter-spacing:0.05pt;"> </font>or<font style="letter-spacing:0.05pt;"> </font>criminal<font style="letter-spacing:0.05pt;"> </font>in<font style="letter-spacing:0.05pt;"> </font>nature,<font style="letter-spacing:0.05pt;"> </font>in<font style="letter-spacing:0.05pt;"> </font>which<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>Company<font style="letter-spacing:-2.6pt;"> </font>reasonably deems Executive&#8217;s cooperation necessary or desirable.<font style="letter-spacing:0.05pt;"> </font>In such matters, Executive agrees to<font style="letter-spacing:0.05pt;"> </font>provide<font style="letter-spacing:-0.7pt;"> </font>the<font style="letter-spacing:-0.65pt;"> </font>Company<font style="letter-spacing:-0.7pt;"> </font>with<font style="letter-spacing:-0.65pt;"> </font>reasonable<font style="letter-spacing:-0.65pt;"> </font>advice,<font style="letter-spacing:-0.7pt;"> </font>assistance<font style="letter-spacing:-0.65pt;"> </font>and<font style="letter-spacing:-0.7pt;"> </font>information,<font style="letter-spacing:-0.65pt;"> </font>including<font style="letter-spacing:-0.65pt;"> </font>offering<font style="letter-spacing:-0.7pt;"> </font>and<font style="letter-spacing:-0.65pt;"> </font>explaining<font style="letter-spacing:-2.65pt;"> </font>evidence, providing sworn statements, and participating in discovery and trial preparation and testimony.<font style="letter-spacing:0.05pt;"> </font>Executive also agrees to promptly send the Company copies of all correspondence (for example, but not<font style="letter-spacing:0.05pt;"> </font>limited to, subpoenas) received by Executive in connection with any such legal proceedings, unless<font style="letter-spacing:0.05pt;"> </font>Executive<font style="letter-spacing:-0.15pt;"> </font>is<font style="letter-spacing:-0.1pt;"> </font>expressly<font style="letter-spacing:-0.15pt;"> </font>prohibited by law<font style="letter-spacing:-0.05pt;"> </font>from<font style="letter-spacing:-0.1pt;"> </font>so doing.</div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0.3pt 0pt 0pt 0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;text-align:justify;text-indent:72pt;margin:0pt 37.6pt 0pt 5.95pt;"><font style="display:inline-block;font-family:'Times New Roman';font-weight:bold;min-width:36.1pt;text-indent:0pt;white-space:nowrap;">(e)</font><u style="text-decoration:underline;text-decoration-color:#000000;">Expenses and Fees</u>.<font style="letter-spacing:0.05pt;"> </font>The Company will reimburse Executive for reasonable out-<font style="letter-spacing:0.05pt;"> </font>of-pocket expenses incurred by Executive as a result of his cooperation with the obligations described in<font style="letter-spacing:0.05pt;"> </font>this<font style="letter-spacing:-0.6pt;"> </font>Section<font style="letter-spacing:-0.55pt;"> </font><a href="#_bookmark12"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">6.5</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;line-height:1.28;text-align:justify;"> </font></a>(b)<font style="letter-spacing:-0.65pt;"> </font>and<font style="letter-spacing:-0.65pt;"> </font>(d),<font style="letter-spacing:-0.65pt;"> </font>within<font style="letter-spacing:-0.65pt;"> </font>thirty<font style="letter-spacing:-0.7pt;"> </font>(30)<font style="letter-spacing:-0.6pt;"> </font>days<font style="letter-spacing:-0.65pt;"> </font>of<font style="letter-spacing:-0.6pt;"> </font>the<font style="letter-spacing:-0.55pt;"> </font>presentation<font style="letter-spacing:-0.55pt;"> </font>of<font style="letter-spacing:-0.5pt;"> </font>appropriate<font style="letter-spacing:-0.55pt;"> </font>documentation<font style="letter-spacing:-0.65pt;"> </font>thereof,<font style="letter-spacing:-2.6pt;"> </font>in<font style="letter-spacing:-0.35pt;"> </font>accordance<font style="letter-spacing:-0.35pt;"> </font>with<font style="letter-spacing:-0.45pt;"> </font>the<font style="letter-spacing:-0.35pt;"> </font>Company&#8217;s<font style="letter-spacing:-0.35pt;"> </font>standard<font style="letter-spacing:-0.45pt;"> </font>reimbursement<font style="letter-spacing:-0.3pt;"> </font>policies<font style="letter-spacing:-0.45pt;"> </font>and<font style="letter-spacing:-0.45pt;"> </font>procedures.<font style="letter-spacing:1.95pt;"> </font>Except<font style="letter-spacing:-0.4pt;"> </font>as<font style="letter-spacing:-0.45pt;"> </font>provided<font style="letter-spacing:-0.45pt;"> </font>in<font style="letter-spacing:-2.65pt;"> </font><font style="letter-spacing:-0.05pt;">the</font><font style="letter-spacing:-0.6pt;"> </font><font style="letter-spacing:-0.05pt;">preceding</font><font style="letter-spacing:-0.6pt;"> </font><font style="letter-spacing:-0.05pt;">sentence,</font><font style="letter-spacing:-0.6pt;"> </font>Executive<font style="letter-spacing:-0.55pt;"> </font>will<font style="letter-spacing:-0.55pt;"> </font>not<font style="letter-spacing:-0.55pt;"> </font>be<font style="letter-spacing:-0.6pt;"> </font>entitled<font style="letter-spacing:-0.55pt;"> </font>to<font style="letter-spacing:-0.75pt;"> </font>any<font style="letter-spacing:-0.6pt;"> </font>compensation<font style="letter-spacing:-0.75pt;"> </font>for<font style="letter-spacing:-0.65pt;"> </font>activities<font style="letter-spacing:-0.6pt;"> </font>performed<font style="letter-spacing:-0.75pt;"> </font>pursuant<font style="letter-spacing:-2.6pt;"> </font>to this Section <a href="#_bookmark12"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">6.5 </font></a>during the applicable Severance Period.<font style="letter-spacing:0.05pt;"> </font>In the event the Company requests extensive<font style="letter-spacing:0.05pt;"> </font>time<font style="letter-spacing:-0.4pt;"> </font>from<font style="letter-spacing:-0.35pt;"> </font>the<font style="letter-spacing:-0.4pt;"> </font>Executive<font style="letter-spacing:-0.45pt;"> </font>in<font style="letter-spacing:-0.55pt;"> </font>connection<font style="letter-spacing:-0.45pt;"> </font>with<font style="letter-spacing:-0.4pt;"> </font>this<font style="letter-spacing:-0.4pt;"> </font>Section<font style="letter-spacing:-0.45pt;"> </font>6.5<font style="letter-spacing:-0.4pt;"> </font>(b)<font style="letter-spacing:-0.4pt;"> </font>and/or<font style="letter-spacing:-0.5pt;"> </font>(d),<font style="letter-spacing:-0.5pt;"> </font>the<font style="letter-spacing:-0.4pt;"> </font>Company<font style="letter-spacing:-0.45pt;"> </font>will<font style="letter-spacing:-0.35pt;"> </font>pay<font style="letter-spacing:-0.45pt;"> </font>Executive<font style="letter-spacing:-2.6pt;"> </font>a compensation for activities performed based on an hourly rate of 160th of Executive&#8217;s monthly Base<font style="letter-spacing:0.05pt;"> </font><font style="letter-spacing:-0.05pt;">Salary</font><font style="letter-spacing:-0.75pt;"> </font><font style="letter-spacing:-0.05pt;">immediately</font><font style="letter-spacing:-0.75pt;"> </font><font style="letter-spacing:-0.05pt;">preceding</font><font style="letter-spacing:-0.55pt;"> </font>the<font style="letter-spacing:-0.7pt;"> </font>termination<font style="letter-spacing:-0.7pt;"> </font>of<font style="letter-spacing:-0.7pt;"> </font>employment<font style="letter-spacing:-0.65pt;"> </font>(the<font style="letter-spacing:-0.7pt;"> </font>&#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Fees</u>&#8221;).<font style="letter-spacing:1.5pt;"> </font>In<font style="letter-spacing:-0.6pt;"> </font>performing<font style="letter-spacing:-0.7pt;"> </font>obligations<font style="letter-spacing:-0.7pt;"> </font>under<font style="letter-spacing:-2.6pt;"> </font>this Section <a href="#_bookmark12"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">6.5</font></a>(b) and (d) following termination of this Agreement, Executive agrees and acknowledges<font style="letter-spacing:0.05pt;"> </font>that he will be serving as an independent contractor, not as a Company employee, and he will be entirely<font style="letter-spacing:0.05pt;"> </font><font style="letter-spacing:-0.05pt;">responsible</font><font style="letter-spacing:-0.7pt;"> </font>for<font style="letter-spacing:-0.7pt;"> </font>the<font style="letter-spacing:-0.6pt;"> </font>payment<font style="letter-spacing:-0.7pt;"> </font>of<font style="letter-spacing:-0.55pt;"> </font>all<font style="letter-spacing:-0.55pt;"> </font>income<font style="letter-spacing:-0.6pt;"> </font>taxes<font style="letter-spacing:-0.7pt;"> </font>and<font style="letter-spacing:-0.6pt;"> </font>any<font style="letter-spacing:-0.6pt;"> </font>other<font style="letter-spacing:-0.5pt;"> </font>taxes<font style="letter-spacing:-0.6pt;"> </font>due<font style="letter-spacing:-0.6pt;"> </font>and<font style="letter-spacing:-0.6pt;"> </font>owing<font style="letter-spacing:-0.6pt;"> </font>as<font style="letter-spacing:-0.6pt;"> </font>a<font style="letter-spacing:-0.6pt;"> </font>result<font style="letter-spacing:-0.55pt;"> </font>of<font style="letter-spacing:-0.7pt;"> </font>the<font style="letter-spacing:-0.6pt;"> </font>payment<font style="letter-spacing:-2.6pt;"> </font>of<font style="letter-spacing:-0.05pt;"> </font>Fees,<font style="letter-spacing:-0.05pt;"> </font>will not be<font style="letter-spacing:-0.05pt;"> </font>eligible<font style="letter-spacing:-0.15pt;"> </font>to<font style="letter-spacing:-0.05pt;"> </font>participate<font style="letter-spacing:-0.15pt;"> </font>in<font style="letter-spacing:-0.05pt;"> </font>any<font style="letter-spacing:-0.05pt;"> </font>Company<font style="letter-spacing:-0.05pt;"> </font>benefit plans<font style="letter-spacing:-0.05pt;"> </font>while<font style="letter-spacing:-0.05pt;"> </font>performing<font style="letter-spacing:-0.2pt;"> </font>such<font style="letter-spacing:-0.2pt;"> </font>services.</div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0.2pt 0pt 0pt 0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:41.9pt;"></td><td style="font-family:'Times New Roman';font-size:11pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;">6.6.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;text-align:left;">Modification</b><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;letter-spacing:-0.2pt;text-align:left;"> </b><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;text-align:left;">of</b><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;letter-spacing:-0.1pt;text-align:left;"> </b><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;text-align:left;">Payments.</b></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0.34pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;text-align:justify;text-indent:71.95pt;margin:0pt 37.75pt 0pt 5.95pt;"><font style="display:inline-block;font-family:'Times New Roman';font-weight:bold;min-width:36.1pt;text-indent:0pt;white-space:nowrap;">(a)</font><font style="letter-spacing:-0.05pt;">In</font><font style="letter-spacing:-0.6pt;"> </font><font style="letter-spacing:-0.05pt;">the</font><font style="letter-spacing:-0.7pt;"> </font><font style="letter-spacing:-0.05pt;">event</font><font style="letter-spacing:-0.55pt;"> </font>it<font style="letter-spacing:-0.7pt;"> </font>is<font style="letter-spacing:-0.65pt;"> </font>determined<font style="letter-spacing:-0.75pt;"> </font>that<font style="letter-spacing:-0.55pt;"> </font>any<font style="letter-spacing:-0.75pt;"> </font>payment,<font style="letter-spacing:-0.75pt;"> </font>right<font style="letter-spacing:-0.65pt;"> </font>or<font style="letter-spacing:-0.7pt;"> </font>distribution<font style="letter-spacing:-0.6pt;"> </font>by<font style="letter-spacing:-0.75pt;"> </font>the<font style="letter-spacing:-0.7pt;"> </font>Company<font style="letter-spacing:-2.6pt;"> </font>or any other person or entity to or for the benefit of Executive pursuant to the terms of this Agreement or<font style="letter-spacing:0.05pt;"> </font><font style="letter-spacing:-0.05pt;">otherwise,</font><font style="letter-spacing:-0.75pt;"> </font><font style="letter-spacing:-0.05pt;">in</font><font style="letter-spacing:-0.75pt;"> </font><font style="letter-spacing:-0.05pt;">connection</font><font style="letter-spacing:-0.75pt;"> </font>with,<font style="letter-spacing:-0.7pt;"> </font>or<font style="letter-spacing:-0.7pt;"> </font>arising<font style="letter-spacing:-0.75pt;"> </font>out<font style="letter-spacing:-0.65pt;"> </font>of,<font style="letter-spacing:-0.75pt;"> </font>his<font style="letter-spacing:-0.7pt;"> </font>employment<font style="letter-spacing:-0.65pt;"> </font>with<font style="letter-spacing:-0.75pt;"> </font>the<font style="letter-spacing:-0.7pt;"> </font>Company<font style="letter-spacing:-0.7pt;"> </font>or<font style="letter-spacing:-0.7pt;"> </font>a<font style="letter-spacing:-0.7pt;"> </font>change<font style="letter-spacing:-0.7pt;"> </font>in<font style="letter-spacing:-0.7pt;"> </font>ownership</div><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;text-align:justify;margin:0pt;"><font style="font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:46.8pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:12pt 0.55pt 0pt 0.55pt;"><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">Gain</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.2pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">Therapeutics,</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.15pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">Inc.</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.15pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">-</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.05pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">4800</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.15pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">Hampden</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.15pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">Ln,</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.15pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">St</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.05pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">200, Bethesda,</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.1pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">MD</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:2.65pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">20814</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0.5pt 0.3pt 0pt 0.55pt;"><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">P:</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.25pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">+1</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.2pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">301-500-1556</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:1.8pt;"> </font><u style="color:#0562c1;font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-decoration:underline;text-decoration-color:#0562c1;">www.gaintherapeutics.com</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:right;margin:0pt 0.3pt 0pt 0.55pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;">8</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.78%;margin-right:5.56%;margin-top:30pt;page-break-after:always;width:83.66%;border-width:0;"><div style="max-width:100%;padding-left:10.78%;padding-right:5.56%;position:relative;"><div style="margin-top:9.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><img src="ganx-20211231xex10d8001.jpg" alt="Logo&#10;&#10;Description automatically generated" style="display:inline-block;height:42pt;width:87.5pt;"></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;text-align:justify;margin:4.05pt 37.7pt 0pt 6pt;">or effective control of the Company or a substantial portion of its assets (a &#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Payment</u>&#8221;) is a &#8220;parachute<font style="letter-spacing:0.05pt;"> </font>payment&#8221; within the meaning of Section 280G of the Internal Revenue Code of 1986, as amended (the<font style="letter-spacing:0.05pt;"> </font>&#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Code</u>&#8221;)<font style="letter-spacing:-0.15pt;"> </font>on<font style="letter-spacing:-0.15pt;"> </font>account<font style="letter-spacing:-0.15pt;"> </font>of<font style="letter-spacing:-0.2pt;"> </font>the<font style="letter-spacing:-0.15pt;"> </font>aggregate<font style="letter-spacing:-0.1pt;"> </font>value<font style="letter-spacing:-0.15pt;"> </font>of<font style="letter-spacing:-0.2pt;"> </font>the<font style="letter-spacing:-0.15pt;"> </font>Payments<font style="letter-spacing:-0.1pt;"> </font>due<font style="letter-spacing:-0.15pt;"> </font>to<font style="letter-spacing:-0.15pt;"> </font>Executive<font style="letter-spacing:-0.1pt;"> </font>being<font style="letter-spacing:-0.3pt;"> </font>equal<font style="letter-spacing:-0.2pt;"> </font>to<font style="letter-spacing:-0.2pt;"> </font>or<font style="letter-spacing:-0.2pt;"> </font>greater<font style="letter-spacing:-0.15pt;"> </font>than<font style="letter-spacing:-2.6pt;"> </font>three times the &#8220;base amount,&#8221; as defined in Section 280G(b)(3) of the Code, (the &#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Parachute Threshold</u>&#8221;)<font style="letter-spacing:-2.6pt;"> </font>so that Executive would be subject to the excise tax imposed by Section 4999 of the Code (the &#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Excise</u><font style="letter-spacing:0.05pt;"> </font><u style="text-decoration:underline;text-decoration-color:#000000;">Tax</u>&#8221;)<font style="letter-spacing:-0.25pt;"> </font>and<font style="letter-spacing:-0.25pt;"> </font>the<font style="letter-spacing:-0.3pt;"> </font>net<font style="letter-spacing:-0.2pt;"> </font>after-tax<font style="letter-spacing:-0.4pt;"> </font>benefit<font style="letter-spacing:-0.35pt;"> </font>that<font style="letter-spacing:-0.2pt;"> </font>Executive<font style="letter-spacing:-0.25pt;"> </font>would<font style="letter-spacing:-0.3pt;"> </font>receive<font style="letter-spacing:-0.25pt;"> </font>by<font style="letter-spacing:-0.25pt;"> </font>reducing<font style="letter-spacing:-0.3pt;"> </font>the<font style="letter-spacing:-0.25pt;"> </font>Payments<font style="letter-spacing:-0.35pt;"> </font>to<font style="letter-spacing:-0.3pt;"> </font>the<font style="letter-spacing:-0.25pt;"> </font>Parachute<font style="letter-spacing:-2.65pt;"> </font>Threshold is greater than the net after-tax benefit Executive would receive if the full amount of the<font style="letter-spacing:0.05pt;"> </font>Payments were paid to Executive, then the Payments payable to Executive will be reduced (but not below<font style="letter-spacing:0.05pt;"> </font>zero)<font style="letter-spacing:-0.45pt;"> </font>so<font style="letter-spacing:-0.55pt;"> </font>that<font style="letter-spacing:-0.4pt;"> </font>the<font style="letter-spacing:-0.4pt;"> </font>Payments<font style="letter-spacing:-0.55pt;"> </font>due<font style="letter-spacing:-0.4pt;"> </font>to<font style="letter-spacing:-0.5pt;"> </font>Executive<font style="letter-spacing:-0.4pt;"> </font>do<font style="letter-spacing:-0.45pt;"> </font>not<font style="letter-spacing:-0.4pt;"> </font>exceed<font style="letter-spacing:-0.45pt;"> </font>the<font style="letter-spacing:-0.45pt;"> </font>amount<font style="letter-spacing:-0.4pt;"> </font>of<font style="letter-spacing:-0.5pt;"> </font>the<font style="letter-spacing:-0.4pt;"> </font>Parachute<font style="letter-spacing:-0.4pt;"> </font>Threshold,<font style="letter-spacing:-0.55pt;"> </font>reducing<font style="letter-spacing:-2.65pt;"> </font>first<font style="letter-spacing:-0.15pt;"> </font>any Payments under<font style="letter-spacing:0.05pt;"> </font>Section <a href="#_bookmark8"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">6.3</font></a><a href="#_bookmark9"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">(a)</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;line-height:1.28;text-align:justify;"> </font></a>hereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0.3pt 0pt 0pt 0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;text-align:justify;text-indent:72pt;margin:0pt 37.55pt 0pt 5.95pt;"><font style="display:inline-block;font-family:'Times New Roman';font-weight:bold;min-width:36.1pt;text-indent:0pt;white-space:nowrap;">(b)</font>The<font style="letter-spacing:0.05pt;"> </font>Company<font style="letter-spacing:0.05pt;"> </font>hereby<font style="letter-spacing:0.05pt;"> </font>agrees<font style="letter-spacing:0.05pt;"> </font>that,<font style="letter-spacing:0.05pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>purposes<font style="letter-spacing:0.05pt;"> </font>of<font style="letter-spacing:0.05pt;"> </font>determining<font style="letter-spacing:0.05pt;"> </font>whether<font style="letter-spacing:0.05pt;"> </font>any<font style="letter-spacing:0.05pt;"> </font>payment<font style="letter-spacing:-0.6pt;"> </font>and<font style="letter-spacing:-0.55pt;"> </font>benefits<font style="letter-spacing:-0.45pt;"> </font>set<font style="letter-spacing:-0.6pt;"> </font>forth<font style="letter-spacing:-0.55pt;"> </font>in<font style="letter-spacing:-0.5pt;"> </font>Section<font style="letter-spacing:-0.65pt;"> </font><a href="#_bookmark8"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">6.3</font></a><a href="#_bookmark9"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">(a)</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;line-height:1.28;text-align:justify;"> </font></a>above<font style="letter-spacing:-0.45pt;"> </font>would<font style="letter-spacing:-0.55pt;"> </font>be<font style="letter-spacing:-0.45pt;"> </font>subject<font style="letter-spacing:-0.5pt;"> </font>to<font style="letter-spacing:-0.55pt;"> </font>the<font style="letter-spacing:-0.45pt;"> </font>Excise<font style="letter-spacing:-0.5pt;"> </font>Tax,<font style="letter-spacing:-0.55pt;"> </font>the<font style="letter-spacing:-0.5pt;"> </font>non-<font style="letter-spacing:-0.6pt;"> </font>compete<font style="letter-spacing:-2.65pt;"> </font>set forth in the CIIAA above will be treated as an agreement for the performance of personal services. The<font style="letter-spacing:-2.6pt;"> </font>Company hereby agrees to indemnify, defend, and hold harmless Executive from and against any adverse<font style="letter-spacing:0.05pt;"> </font>impact, tax, penalty, or excise tax resulting from the Company or accountant&#8217;s attribution of a value to the<font style="letter-spacing:-2.6pt;"> </font>non-compete<font style="letter-spacing:-0.4pt;"> </font>set<font style="letter-spacing:-0.25pt;"> </font>forth<font style="letter-spacing:-0.45pt;"> </font>in<font style="letter-spacing:-0.45pt;"> </font>the<font style="letter-spacing:-0.3pt;"> </font>CIIAA<font style="letter-spacing:-0.3pt;"> </font>that<font style="letter-spacing:-0.25pt;"> </font>is<font style="letter-spacing:-0.4pt;"> </font>less<font style="letter-spacing:-0.3pt;"> </font>than<font style="letter-spacing:-0.3pt;"> </font>the<font style="letter-spacing:-0.3pt;"> </font>total<font style="letter-spacing:-0.35pt;"> </font>compensation<font style="letter-spacing:-0.4pt;"> </font>amount<font style="letter-spacing:-0.25pt;"> </font>that<font style="letter-spacing:-0.25pt;"> </font>would<font style="letter-spacing:-0.3pt;"> </font>be<font style="letter-spacing:-0.3pt;"> </font>disclosed<font style="letter-spacing:-2.6pt;"> </font>under<font style="letter-spacing:-0.55pt;"> </font>Item<font style="letter-spacing:-0.5pt;"> </font>402(c)<font style="letter-spacing:-0.5pt;"> </font>of<font style="letter-spacing:-0.5pt;"> </font>Securities<font style="letter-spacing:-0.5pt;"> </font>and<font style="letter-spacing:-0.55pt;"> </font>Exchange<font style="letter-spacing:-0.55pt;"> </font>Commission<font style="letter-spacing:-0.55pt;"> </font>Regulation<font style="letter-spacing:-0.6pt;"> </font>S-K<font style="letter-spacing:-0.6pt;"> </font>if<font style="letter-spacing:-0.5pt;"> </font>Executive<font style="letter-spacing:-0.5pt;"> </font>had<font style="letter-spacing:-0.55pt;"> </font>been<font style="letter-spacing:-0.65pt;"> </font>a<font style="letter-spacing:-0.5pt;"> </font>&#8220;named<font style="letter-spacing:-2.65pt;"> </font>executive officer&#8221; of the Company in the year prior to year of the event that triggers the Excise Tax, to the<font style="letter-spacing:-2.6pt;"> </font>extent<font style="letter-spacing:-0.15pt;"> </font>the<font style="letter-spacing:-0.1pt;"> </font>use<font style="letter-spacing:-0.15pt;"> </font>of<font style="letter-spacing:-0.1pt;"> </font>such<font style="letter-spacing:-0.15pt;"> </font>lesser<font style="letter-spacing:-0.25pt;"> </font>amount<font style="letter-spacing:-0.1pt;"> </font>results<font style="letter-spacing:-0.15pt;"> </font>in<font style="letter-spacing:-0.15pt;"> </font>a<font style="letter-spacing:-0.1pt;"> </font>larger<font style="letter-spacing:-0.25pt;"> </font>Excise<font style="letter-spacing:-0.1pt;"> </font>Tax<font style="letter-spacing:-0.2pt;"> </font>than<font style="letter-spacing:-0.15pt;"> </font>Executive<font style="letter-spacing:-0.1pt;"> </font>would<font style="letter-spacing:-0.2pt;"> </font>have<font style="letter-spacing:-0.1pt;"> </font>been<font style="letter-spacing:-0.2pt;"> </font>subject<font style="letter-spacing:-2.6pt;"> </font>to had the Company or accountant attributed a value to the non-compete set forth in the CIIAA that is at<font style="letter-spacing:0.05pt;"> </font>least equal to the total compensation amount disclosed under Item 402(c) of Securities and Exchange<font style="letter-spacing:0.05pt;"> </font>Commission<font style="letter-spacing:-0.2pt;"> </font>Regulation S-K<font style="letter-spacing:-0.05pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>such year.</div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0.3pt 0pt 0pt 0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-weight:bold;margin-bottom:0pt;margin-left:41.9pt;margin-top:0pt;padding-left:36.1pt;text-indent:-36.1pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36.05pt;text-indent:0pt;white-space:nowrap;">6.7.</font>Section<b style="font-weight:bold;letter-spacing:-0.05pt;"> </b>409A.</div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0.34pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;text-align:justify;text-indent:72pt;margin:0pt 37.8pt 0pt 5.95pt;"><font style="display:inline-block;font-family:'Times New Roman';font-weight:bold;min-width:36.1pt;text-indent:0pt;white-space:nowrap;">(a)</font>Notwithstanding anything herein to the contrary, this Agreement is intended to be<font style="letter-spacing:-2.6pt;"> </font>interpreted<font style="letter-spacing:-0.4pt;"> </font>and<font style="letter-spacing:-0.4pt;"> </font>applied<font style="letter-spacing:-0.45pt;"> </font>so<font style="letter-spacing:-0.45pt;"> </font>that<font style="letter-spacing:-0.35pt;"> </font>the<font style="letter-spacing:-0.4pt;"> </font>payment<font style="letter-spacing:-0.25pt;"> </font>of<font style="letter-spacing:-0.4pt;"> </font>the<font style="letter-spacing:-0.4pt;"> </font>benefits<font style="letter-spacing:-0.3pt;"> </font>set<font style="letter-spacing:-0.3pt;"> </font>forth<font style="letter-spacing:-0.45pt;"> </font>herein<font style="letter-spacing:-0.3pt;"> </font>either<font style="letter-spacing:-0.4pt;"> </font>will<font style="letter-spacing:-0.2pt;"> </font>either<font style="letter-spacing:-0.4pt;"> </font>be<font style="letter-spacing:-0.4pt;"> </font>exempt<font style="letter-spacing:-0.25pt;"> </font>from<font style="letter-spacing:-2.65pt;"> </font>the requirements of Section 409A of the Code (&#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Section 409A</u>&#8221;) or will comply with the requirements of<font style="letter-spacing:0.05pt;"> </font>such<font style="letter-spacing:-0.05pt;"> </font>provision.</div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0.3pt 0pt 0pt 0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;text-align:justify;text-indent:72pt;margin:0pt 37.75pt 0pt 5.95pt;"><font style="display:inline-block;font-family:'Times New Roman';font-weight:bold;min-width:36.05pt;text-indent:0pt;white-space:nowrap;">(b)</font>Notwithstanding<font style="letter-spacing:-0.35pt;"> </font>any<font style="letter-spacing:-0.3pt;"> </font>provision<font style="letter-spacing:-0.2pt;"> </font>of<font style="letter-spacing:-0.3pt;"> </font>this<font style="letter-spacing:-0.15pt;"> </font>Agreement<font style="letter-spacing:-0.25pt;"> </font>to<font style="letter-spacing:-0.3pt;"> </font>the<font style="letter-spacing:-0.2pt;"> </font>contrary,<font style="letter-spacing:-0.3pt;"> </font>if<font style="letter-spacing:-0.15pt;"> </font>Executive<font style="letter-spacing:-0.35pt;"> </font>is<font style="letter-spacing:-0.3pt;"> </font>a<font style="letter-spacing:-2.6pt;"> </font>&#8220;specified employee&#8221; within the meaning of Section 409A, any payments or arrangements due upon a<font style="letter-spacing:0.05pt;"> </font>termination of Executive&#8217;s employment under any arrangement that constitutes a &#8220;nonqualified deferral of<font style="letter-spacing:-2.6pt;"> </font>compensation&#8221;<font style="letter-spacing:0.05pt;"> </font>within the meaning of<font style="letter-spacing:0.05pt;"> </font>Section 409A and which do not<font style="letter-spacing:0.05pt;"> </font>otherwise<font style="letter-spacing:0.05pt;"> </font>qualify under<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>exemptions under Treas. Regs. Section 1.409A-1 (including without limitation, the short-term deferral<font style="letter-spacing:0.05pt;"> </font>exemption or the permitted payments under Treas. Regs. Section 1.409A-1(b)(9)(iii)(A)), will be delayed<font style="letter-spacing:0.05pt;"> </font>and<font style="letter-spacing:-0.5pt;"> </font>paid<font style="letter-spacing:-0.45pt;"> </font>or<font style="letter-spacing:-0.4pt;"> </font>provided,<font style="letter-spacing:-0.45pt;"> </font>without<font style="letter-spacing:-0.4pt;"> </font>interest,<font style="letter-spacing:-0.45pt;"> </font>on<font style="letter-spacing:-0.45pt;"> </font>the<font style="letter-spacing:-0.4pt;"> </font>earlier<font style="letter-spacing:-0.4pt;"> </font>of<font style="letter-spacing:-0.5pt;"> </font>(i)<font style="letter-spacing:-0.5pt;"> </font>the<font style="letter-spacing:-0.4pt;"> </font>date<font style="letter-spacing:-0.4pt;"> </font>which<font style="letter-spacing:-0.6pt;"> </font>is<font style="letter-spacing:-0.5pt;"> </font>six<font style="letter-spacing:-0.55pt;"> </font>(6)<font style="letter-spacing:-0.5pt;"> </font>months<font style="letter-spacing:-0.4pt;"> </font>after<font style="letter-spacing:-0.4pt;"> </font>Executive&#8217;s<font style="letter-spacing:-2.6pt;"> </font>&#8220;separation<font style="letter-spacing:-0.2pt;"> </font>from<font style="letter-spacing:-0.15pt;"> </font>service&#8221;<font style="letter-spacing:-0.3pt;"> </font>(as<font style="letter-spacing:-0.15pt;"> </font>such<font style="letter-spacing:-0.25pt;"> </font>term<font style="letter-spacing:-0.25pt;"> </font>is<font style="letter-spacing:-0.3pt;"> </font>defined<font style="letter-spacing:-0.3pt;"> </font>in<font style="letter-spacing:-0.2pt;"> </font>Section<font style="letter-spacing:-0.25pt;"> </font>409A<font style="letter-spacing:-0.25pt;"> </font>and<font style="letter-spacing:-0.25pt;"> </font>the<font style="letter-spacing:-0.3pt;"> </font>regulations<font style="letter-spacing:-0.25pt;"> </font>and<font style="letter-spacing:-0.3pt;"> </font>other<font style="letter-spacing:-0.25pt;"> </font>published<font style="letter-spacing:-2.6pt;"> </font>guidance<font style="letter-spacing:-0.15pt;"> </font>thereunder) for<font style="letter-spacing:0.05pt;"> </font>any<font style="letter-spacing:-0.05pt;"> </font>reason other than death,<font style="letter-spacing:-0.05pt;"> </font>and<font style="letter-spacing:-0.05pt;"> </font>(ii)<font style="letter-spacing:-0.1pt;"> </font>the<font style="letter-spacing:-0.15pt;"> </font>date of Executive&#8217;s death.</div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0.34pt 0pt 0pt 0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;text-align:justify;text-indent:71.95pt;margin:0pt 37.75pt 0pt 5.95pt;"><font style="display:inline-block;font-family:'Times New Roman';font-weight:bold;min-width:36.1pt;text-indent:0pt;white-space:nowrap;">(c)</font>After any Termination Date, Executive will have no duties or responsibilities that<font style="letter-spacing:-2.6pt;"> </font>are inconsistent<font style="letter-spacing:0.05pt;"> </font>with having<font style="letter-spacing:0.05pt;"> </font>a<font style="letter-spacing:0.05pt;"> </font>&#8220;separation from service&#8221;<font style="letter-spacing:0.05pt;"> </font>within the meaning of<font style="letter-spacing:0.05pt;"> </font>Section<font style="letter-spacing:0.05pt;"> </font>409A and,<font style="letter-spacing:0.05pt;"> </font>notwithstanding anything in the Agreement to the contrary, distributions upon termination of employment<font style="letter-spacing:-2.6pt;"> </font>of<font style="letter-spacing:0.05pt;"> </font>nonqualified deferred compensation<font style="letter-spacing:-0.1pt;"> </font>may only<font style="letter-spacing:-0.1pt;"> </font>be<font style="letter-spacing:-0.1pt;"> </font>made<font style="letter-spacing:0.05pt;"> </font>upon a<font style="letter-spacing:-0.1pt;"> </font>&#8220;separation<font style="letter-spacing:-0.05pt;"> </font>from<font style="letter-spacing:0.05pt;"> </font>service&#8221;<font style="letter-spacing:0.05pt;"> </font>as<font style="letter-spacing:0.05pt;"> </font>determined</div><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;text-align:justify;margin:0pt;"><font style="font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:46.8pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:12pt 0.55pt 0pt 0.55pt;"><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">Gain</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.2pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">Therapeutics,</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.15pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">Inc.</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.15pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">-</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.05pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">4800</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.15pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">Hampden</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.15pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">Ln,</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.15pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">St</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.05pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">200, Bethesda,</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.1pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">MD</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:2.65pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">20814</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0.5pt 0.3pt 0pt 0.55pt;"><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">P:</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.25pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">+1</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.2pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">301-500-1556</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:1.8pt;"> </font><u style="color:#0562c1;font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-decoration:underline;text-decoration-color:#0562c1;">www.gaintherapeutics.com</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:right;margin:0pt 0.3pt 0pt 0.55pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;">9</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.78%;margin-right:5.56%;margin-top:30pt;page-break-after:always;width:83.66%;border-width:0;"><div style="max-width:100%;padding-left:10.78%;padding-right:5.56%;position:relative;"><div style="margin-top:9.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><img src="ganx-20211231xex10d8001.jpg" alt="Logo&#10;&#10;Description automatically generated" style="display:inline-block;height:42pt;width:87.5pt;"></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;text-align:justify;margin:4.05pt 37.7pt 0pt 5.95pt;">under Section 409A and such date will be the Termination Date for purposes of this Agreement.<font style="letter-spacing:0.05pt;"> </font>Each<font style="letter-spacing:0.05pt;"> </font>payment under this Agreement or otherwise will be treated as a separate payment for purposes of Section<font style="letter-spacing:0.05pt;"> </font>409A.<font style="letter-spacing:0.05pt;"> </font>In no event may Executive, directly or indirectly, designate the calendar year of any payment to be<font style="letter-spacing:-2.6pt;"> </font>made under this Agreement<font style="letter-spacing:0.05pt;"> </font>which constitutes a &#8220;nonqualified deferral of compensation&#8221;<font style="letter-spacing:0.05pt;"> </font>within the<font style="letter-spacing:0.05pt;"> </font>meaning of Section 409A and to the extent an amount is payable within a time period, the time during<font style="letter-spacing:0.05pt;"> </font>which such amount<font style="letter-spacing:-0.1pt;"> </font>is paid<font style="letter-spacing:-0.15pt;"> </font>will<font style="letter-spacing:-0.1pt;"> </font>be<font style="letter-spacing:-0.1pt;"> </font>in the discretion<font style="letter-spacing:-0.15pt;"> </font>of<font style="letter-spacing:-0.1pt;"> </font>the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0.3pt 0pt 0pt 0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:5.9pt;"></td><td style="font-family:'Times New Roman';font-size:11pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;">7.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;text-align:left;"><a name="_bookmark13"></a></b><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;text-align:left;">GENERAL</b><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;letter-spacing:-0.35pt;text-align:left;"> </b><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;text-align:left;">PROVISIONS</b></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0.34pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;text-align:justify;text-indent:36.8pt;margin:0pt 37.8pt 0pt 5.95pt;"><font style="display:inline-block;font-family:'Times New Roman';font-weight:bold;min-width:35.25pt;text-indent:0pt;white-space:nowrap;">7.1.</font><b style="font-weight:bold;">Notices. </b>Any notices provided hereunder must be in writing and will be deemed effective<font style="letter-spacing:-2.6pt;"> </font>upon the earlier of personal delivery or receipt if delivered by mail or courier service, to the Company at<font style="letter-spacing:0.05pt;"> </font>its primary office location and to Executive at his address as listed on the Company payroll or Executive&#8217;s<font style="letter-spacing:-2.6pt;"> </font>then<font style="letter-spacing:-0.15pt;"> </font>current<font style="letter-spacing:0.05pt;"> </font>place<font style="letter-spacing:-0.1pt;"> </font>of<font style="letter-spacing:0.05pt;"> </font>abode.</div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0.4pt 0pt 0pt 0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;text-align:justify;text-indent:36.8pt;margin:0pt 37.7pt 0pt 5.95pt;"><font style="display:inline-block;font-family:'Times New Roman';font-weight:bold;min-width:35.25pt;text-indent:0pt;white-space:nowrap;">7.2.</font><b style="font-weight:bold;">Confidentiality.</b><b style="font-weight:bold;letter-spacing:0.05pt;"> </b>Unless publicly disclosed by the Company, Executive will hold the<font style="letter-spacing:0.05pt;"> </font>provisions of this Agreement in strictest confidence and will not publicize or disclose this Agreement in<font style="letter-spacing:0.05pt;"> </font><font style="letter-spacing:-0.05pt;">any</font><font style="letter-spacing:-0.6pt;"> </font><font style="letter-spacing:-0.05pt;">manner</font><font style="letter-spacing:-0.55pt;"> </font><font style="letter-spacing:-0.05pt;">whatsoever;</font><font style="letter-spacing:-0.5pt;"> </font><font style="letter-spacing:-0.05pt;">provided,</font><font style="letter-spacing:-0.6pt;"> </font>however,<font style="letter-spacing:-0.6pt;"> </font>that<font style="letter-spacing:-0.5pt;"> </font>Executive<font style="letter-spacing:-0.6pt;"> </font>may<font style="letter-spacing:-0.6pt;"> </font>disclose<font style="letter-spacing:-0.65pt;"> </font>this<font style="letter-spacing:-0.6pt;"> </font>Agreement:<font style="letter-spacing:-0.5pt;"> </font>(a)<font style="letter-spacing:-0.7pt;"> </font>to<font style="letter-spacing:-0.6pt;"> </font>Executive&#8217;s<font style="letter-spacing:-2.6pt;"> </font>immediate family; (b) in confidence to his attorneys, accountants, auditors, tax preparers, and financial<font style="letter-spacing:0.05pt;"> </font>advisors; (c) insofar as such disclosure may be necessary to enforce its terms or as otherwise permitted or<font style="letter-spacing:0.05pt;"> </font>required by law.<font style="letter-spacing:0.05pt;"> </font>In particular, and without limitation, Executive agrees not to disclose the terms of this<font style="letter-spacing:0.05pt;"> </font>Agreement to any<font style="letter-spacing:-0.15pt;"> </font>current<font style="letter-spacing:0.05pt;"> </font>or former<font style="letter-spacing:-0.1pt;"> </font>employee of<font style="letter-spacing:0.05pt;"> </font>the Company.</div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0.34pt 0pt 0pt 0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;text-align:justify;text-indent:36.85pt;margin:0pt 37.6pt 0pt 5.95pt;"><font style="display:inline-block;font-family:'Times New Roman';font-weight:bold;min-width:35.2pt;text-indent:0pt;white-space:nowrap;">7.3.</font><b style="font-weight:bold;">Reasonableness of Restrictions. </b>Executive acknowledges and agrees that (a) he has read<font style="letter-spacing:-2.6pt;"> </font>this Agreement in its entirety and understands it, (b) the limitations imposed in this Agreement and the<font style="letter-spacing:0.05pt;"> </font>CIIAA do not prevent him from earning a living or pursuing his career following the termination of this<font style="letter-spacing:0.05pt;"> </font>Agreement,<font style="letter-spacing:-0.5pt;"> </font>and<font style="letter-spacing:-0.45pt;"> </font>(c)<font style="letter-spacing:-0.25pt;"> </font>the<font style="letter-spacing:-0.4pt;"> </font>restrictions<font style="letter-spacing:-0.3pt;"> </font>contained<font style="letter-spacing:-0.3pt;"> </font>herein<font style="letter-spacing:-0.45pt;"> </font>and<font style="letter-spacing:-0.3pt;"> </font>therein<font style="letter-spacing:-0.5pt;"> </font>are<font style="letter-spacing:-0.3pt;"> </font>reasonable,<font style="letter-spacing:-0.4pt;"> </font>proper,<font style="letter-spacing:-0.45pt;"> </font>and<font style="letter-spacing:-0.45pt;"> </font>necessitated<font style="letter-spacing:-0.3pt;"> </font>by<font style="letter-spacing:-2.65pt;"> </font>the Company&#8217;s legitimate business interests.<font style="letter-spacing:0.05pt;"> </font>Executive represents and agrees that he is entering into this<font style="letter-spacing:0.05pt;"> </font>Agreement and the CIIAA freely and with knowledge of its contents with the intent to be bound by the<font style="letter-spacing:0.05pt;"> </font>Agreement and<font style="letter-spacing:-0.15pt;"> </font>the restrictions contained<font style="letter-spacing:-0.15pt;"> </font>in<font style="letter-spacing:-0.15pt;"> </font>it.</div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0.3pt 0pt 0pt 0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p><div style="margin-top:0.05pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;text-align:justify;text-indent:36.8pt;margin:0pt 37.6pt 0pt 5.95pt;"><font style="display:inline-block;font-family:'Times New Roman';font-weight:bold;min-width:35.25pt;text-indent:0pt;white-space:nowrap;">7.4.</font><b style="font-weight:bold;">Arbitration</b><b style="font-weight:bold;letter-spacing:-0.15pt;"> </b><b style="font-weight:bold;">and</b><b style="font-weight:bold;letter-spacing:-0.2pt;"> </b><b style="font-weight:bold;">Remedies.</b><b style="font-weight:bold;letter-spacing:2.7pt;"> </b>The<font style="letter-spacing:-0.15pt;"> </font>parties<font style="letter-spacing:-0.15pt;"> </font>recognize<font style="letter-spacing:-0.1pt;"> </font>that<font style="letter-spacing:-0.15pt;"> </font>litigation<font style="letter-spacing:-0.2pt;"> </font>in<font style="letter-spacing:-0.2pt;"> </font>federal<font style="letter-spacing:-0.15pt;"> </font>or<font style="letter-spacing:-0.15pt;"> </font>state<font style="letter-spacing:-0.15pt;"> </font>courts<font style="letter-spacing:-2.65pt;"> </font>or before federal or state administrative agencies of disputes arising out of Executive&#8217;s employment with<font style="letter-spacing:0.05pt;"> </font>the Company or out of this Agreement, or Executive&#8217;s termination of employment or termination of this<font style="letter-spacing:0.05pt;"> </font>Agreement, may not be in the best interests of either Executive or the Company, and may result in<font style="letter-spacing:0.05pt;"> </font>unnecessary costs, delays, complexities, and uncertainty.<font style="letter-spacing:0.05pt;"> </font>The parties agree that any dispute between the<font style="letter-spacing:0.05pt;"> </font>parties<font style="letter-spacing:-0.55pt;"> </font>arising<font style="letter-spacing:-0.7pt;"> </font>out<font style="letter-spacing:-0.5pt;"> </font>of<font style="letter-spacing:-0.55pt;"> </font>or<font style="letter-spacing:-0.65pt;"> </font>relating<font style="letter-spacing:-0.65pt;"> </font>to<font style="letter-spacing:-0.7pt;"> </font>the<font style="letter-spacing:-0.65pt;"> </font>negotiation,<font style="letter-spacing:-0.7pt;"> </font>execution,<font style="letter-spacing:-0.55pt;"> </font>performance<font style="letter-spacing:-0.6pt;"> </font>or<font style="letter-spacing:-0.65pt;"> </font>termination<font style="letter-spacing:-0.55pt;"> </font>of<font style="letter-spacing:-0.65pt;"> </font>this<font style="letter-spacing:-0.5pt;"> </font>Agreement<font style="letter-spacing:-2.65pt;"> </font>or Executive&#8217;s employment, including, but not limited to, any claim arising out of this Agreement, claims<font style="letter-spacing:0.05pt;"> </font>under Title VII of the Civil Rights Act of 1964, as amended, the Civil Rights Act of 1991, the Age<font style="letter-spacing:0.05pt;"> </font>Discrimination in Employment Act of 1967, the Americans with Disabilities Act of 1990, Section 1981 of<font style="letter-spacing:-2.6pt;"> </font>the Civil Rights Act of 1966, as amended, the Family Medical Leave Act, Executive Retirement Income<font style="letter-spacing:0.05pt;"> </font>Security Act, and any similar federal, state or local law, statute, regulation, or any common law doctrine,<font style="letter-spacing:0.05pt;"> </font>whether<font style="letter-spacing:-0.3pt;"> </font>that<font style="letter-spacing:-0.2pt;"> </font>dispute<font style="letter-spacing:-0.35pt;"> </font>arises<font style="letter-spacing:-0.3pt;"> </font>during<font style="letter-spacing:-0.25pt;"> </font>or<font style="letter-spacing:-0.2pt;"> </font>after<font style="letter-spacing:-0.25pt;"> </font>employment,<font style="letter-spacing:-0.25pt;"> </font>will<font style="letter-spacing:-0.2pt;"> </font>be<font style="letter-spacing:-0.3pt;"> </font>settled<font style="letter-spacing:-0.25pt;"> </font>by<font style="letter-spacing:-0.25pt;"> </font>binding<font style="letter-spacing:-0.35pt;"> </font>arbitration<font style="letter-spacing:-0.3pt;"> </font>in<font style="letter-spacing:-0.35pt;"> </font>accordance<font style="letter-spacing:-2.6pt;"> </font>with<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>National<font style="letter-spacing:0.05pt;"> </font>Rules<font style="letter-spacing:0.05pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>Resolution<font style="letter-spacing:0.05pt;"> </font>of<font style="letter-spacing:0.05pt;"> </font>Employment<font style="letter-spacing:0.05pt;"> </font>Disputes<font style="letter-spacing:0.05pt;"> </font>of<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>American<font style="letter-spacing:0.05pt;"> </font>Arbitration<font style="letter-spacing:0.05pt;"> </font>Association by a single arbitrator selected in accordance with said rules; provided however, that as it may<font style="letter-spacing:0.05pt;"> </font>be<font style="letter-spacing:0.1pt;"> </font>impossible<font style="letter-spacing:-0.05pt;"> </font>to<font style="letter-spacing:-0.05pt;"> </font>assess<font style="letter-spacing:0.1pt;"> </font>the<font style="letter-spacing:-0.05pt;"> </font>damages<font style="letter-spacing:-0.05pt;"> </font>caused<font style="letter-spacing:-0.05pt;"> </font>by<font style="letter-spacing:0.05pt;"> </font>violation<font style="letter-spacing:0.05pt;"> </font>of this<font style="letter-spacing:0.15pt;"> </font>Agreement<font style="letter-spacing:0.1pt;"> </font>or<font style="letter-spacing:0.1pt;"> </font>any<font style="letter-spacing:-0.05pt;"> </font>of<font style="letter-spacing:0.1pt;"> </font>its<font style="letter-spacing:-0.05pt;"> </font>terms,<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.1pt;"> </font>parties</div><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;text-align:justify;margin:0pt;"><font style="font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:46.8pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:12pt 0.55pt 0pt 0.55pt;"><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">Gain</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.2pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">Therapeutics,</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.15pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">Inc.</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.15pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">-</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.05pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">4800</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.15pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">Hampden</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.15pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">Ln,</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.15pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">St</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.05pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">200, Bethesda,</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.1pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">MD</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:2.65pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">20814</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0.5pt 0.3pt 0pt 0.55pt;"><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">P:</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.25pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">+1</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.2pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">301-500-1556</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:1.8pt;"> </font><u style="color:#0562c1;font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-decoration:underline;text-decoration-color:#0562c1;">www.gaintherapeutics.com</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:right;margin:0pt 0.3pt 0pt 0.55pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;">10</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.78%;margin-right:5.56%;margin-top:30pt;page-break-after:always;width:83.66%;border-width:0;"><div style="max-width:100%;padding-left:10.78%;padding-right:5.56%;position:relative;"><div style="margin-top:9.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><img src="ganx-20211231xex10d8001.jpg" alt="Logo&#10;&#10;Description automatically generated" style="display:inline-block;height:42pt;width:87.5pt;"></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;text-align:justify;margin:4.05pt 37.65pt 0pt 6pt;">agree<font style="letter-spacing:-0.1pt;"> </font>upon<font style="letter-spacing:-0.05pt;"> </font>the<font style="letter-spacing:-0.15pt;"> </font>threatened<font style="letter-spacing:-0.1pt;"> </font>or actual violation<font style="letter-spacing:-0.2pt;"> </font>of<font style="letter-spacing:-0.2pt;"> </font>this<font style="letter-spacing:-0.15pt;"> </font>Agreement or any<font style="letter-spacing:-0.1pt;"> </font>of<font style="letter-spacing:-0.15pt;"> </font>its<font style="letter-spacing:-0.15pt;"> </font>terms<font style="letter-spacing:-0.15pt;"> </font>the<font style="letter-spacing:-0.2pt;"> </font>aggrieved<font style="letter-spacing:-0.05pt;"> </font>party<font style="letter-spacing:-0.05pt;"> </font>will<font style="letter-spacing:-2.65pt;"> </font>have<font style="letter-spacing:-0.65pt;"> </font>the<font style="letter-spacing:-0.6pt;"> </font>right<font style="letter-spacing:-0.55pt;"> </font>to<font style="letter-spacing:-0.65pt;"> </font>obtain<font style="letter-spacing:-0.6pt;"> </font>injunctive<font style="letter-spacing:-0.6pt;"> </font>relief<font style="letter-spacing:-0.55pt;"> </font>from<font style="letter-spacing:-0.6pt;"> </font>a<font style="letter-spacing:-0.6pt;"> </font>court,<font style="letter-spacing:-0.6pt;"> </font>without<font style="letter-spacing:-0.55pt;"> </font>bond<font style="letter-spacing:-0.65pt;"> </font>and<font style="letter-spacing:-0.6pt;"> </font>without<font style="letter-spacing:-0.45pt;"> </font>prejudice<font style="letter-spacing:-0.6pt;"> </font>to<font style="letter-spacing:-0.65pt;"> </font>any<font style="letter-spacing:-0.6pt;"> </font>other<font style="letter-spacing:-0.55pt;"> </font>rights<font style="letter-spacing:-2.65pt;"> </font>and remedies for a breach or threatened breach of this Agreement. The location for the arbitration will be<font style="letter-spacing:0.05pt;"> </font>the Washington, D.C. metropolitan area.<font style="letter-spacing:0.05pt;"> </font>Any award made by such panel will be final, binding and<font style="letter-spacing:0.05pt;"> </font>conclusive<font style="letter-spacing:-0.2pt;"> </font>on<font style="letter-spacing:-0.2pt;"> </font>the<font style="letter-spacing:-0.15pt;"> </font>parties<font style="letter-spacing:-0.15pt;"> </font>for<font style="letter-spacing:-0.15pt;"> </font>all<font style="letter-spacing:-0.25pt;"> </font>purposes,<font style="letter-spacing:-0.25pt;"> </font>and<font style="letter-spacing:-0.3pt;"> </font>judgment<font style="letter-spacing:-0.15pt;"> </font>upon<font style="letter-spacing:-0.3pt;"> </font>the<font style="letter-spacing:-0.15pt;"> </font>award<font style="letter-spacing:-0.3pt;"> </font>rendered<font style="letter-spacing:-0.2pt;"> </font>by<font style="letter-spacing:-0.25pt;"> </font>the<font style="letter-spacing:-0.3pt;"> </font>arbitrators<font style="letter-spacing:-0.3pt;"> </font>may<font style="letter-spacing:-0.3pt;"> </font>be<font style="letter-spacing:-2.6pt;"> </font>entered in any court having jurisdiction thereof. The arbitrators&#8217; fees and expenses and all administrative<font style="letter-spacing:0.05pt;"> </font>fees and expenses associated with the filing of the arbitration will be borne by the Company; provided<font style="letter-spacing:0.05pt;"> </font>however, that at Executive&#8217;s option, Executive may voluntarily pay up to one-half the costs and fees. The<font style="letter-spacing:0.05pt;"> </font>parties acknowledge and agree that their obligations to arbitrate under this Section survive the termination<font style="letter-spacing:-2.6pt;"> </font>of this Agreement and continue after the termination of the employment relationship between Executive<font style="letter-spacing:0.05pt;"> </font>and the Company. The parties each further agree that the arbitration provisions of this Agreement will<font style="letter-spacing:0.05pt;"> </font>provide each party with its exclusive remedy, and each party expressly waives any right it might have to<font style="letter-spacing:0.05pt;"> </font>seek redress in any other forum, except as otherwise expressly provided in this Agreement.<font style="letter-spacing:0.05pt;"> </font>By election<font style="letter-spacing:0.05pt;"> </font>arbitration as the means for final settlement of all claims (other than the Excluded Claims), the parties<font style="letter-spacing:0.05pt;"> </font>hereby waive their respective rights to, and agree not to, sue each other in any action in a Federal, State or<font style="letter-spacing:-2.6pt;"> </font>local court with respect to such claims, but may seek to enforce in court an arbitration award rendered<font style="letter-spacing:0.05pt;"> </font>pursuant<font style="letter-spacing:-0.35pt;"> </font>to<font style="letter-spacing:-0.25pt;"> </font>this<font style="letter-spacing:-0.3pt;"> </font>Agreement.<font style="letter-spacing:2.1pt;"> </font>The<font style="letter-spacing:-0.25pt;"> </font>parties<font style="letter-spacing:-0.3pt;"> </font>specifically<font style="letter-spacing:-0.25pt;"> </font>agree<font style="letter-spacing:-0.25pt;"> </font>to<font style="letter-spacing:-0.3pt;"> </font>waive<font style="letter-spacing:-0.35pt;"> </font>their<font style="letter-spacing:-0.25pt;"> </font>respective<font style="letter-spacing:-0.25pt;"> </font>rights<font style="letter-spacing:-0.4pt;"> </font>to<font style="letter-spacing:-0.25pt;"> </font>a<font style="letter-spacing:-0.3pt;"> </font>trial<font style="letter-spacing:-0.2pt;"> </font>by<font style="letter-spacing:-0.25pt;"> </font>jury,<font style="letter-spacing:-2.65pt;"> </font>and<font style="letter-spacing:-0.05pt;"> </font>further<font style="letter-spacing:-0.1pt;"> </font>agree<font style="letter-spacing:-0.1pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>no demand,<font style="letter-spacing:-0.15pt;"> </font>request or<font style="letter-spacing:-0.1pt;"> </font>motion will<font style="letter-spacing:0.05pt;"> </font>be made<font style="letter-spacing:-0.1pt;"> </font>for<font style="letter-spacing:-0.15pt;"> </font>trial<font style="letter-spacing:0.05pt;"> </font>by<font style="letter-spacing:-0.15pt;"> </font>jury.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0.15pt 0pt 0pt 0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;text-align:justify;text-indent:36.8pt;margin:0pt 37.7pt 0pt 6pt;"><font style="display:inline-block;font-family:'Times New Roman';font-weight:bold;min-width:35.25pt;text-indent:0pt;white-space:nowrap;">7.5.</font><b style="font-weight:bold;">Surviving Clauses.</b><b style="font-weight:bold;letter-spacing:0.05pt;"> </b>Sections <a href="#_bookmark2"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">3.2, </font></a><a href="#_bookmark3"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">3.3, </font></a><a href="#_bookmark6"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">5, </font></a><a href="#_bookmark7"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">6, </font></a><a href="#_bookmark13"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">7 </font></a>and Exhibit A (the CIIAA), attached hereto<font style="letter-spacing:0.05pt;"> </font><font style="letter-spacing:-0.05pt;">(including</font><font style="letter-spacing:-0.75pt;"> </font><font style="letter-spacing:-0.05pt;">the</font><font style="letter-spacing:-0.6pt;"> </font><font style="letter-spacing:-0.05pt;">definitions</font><font style="letter-spacing:-0.7pt;"> </font><font style="letter-spacing:-0.05pt;">of</font><font style="letter-spacing:-0.7pt;"> </font>any<font style="letter-spacing:-0.75pt;"> </font>defined<font style="letter-spacing:-0.75pt;"> </font>terms<font style="letter-spacing:-0.7pt;"> </font>referenced<font style="letter-spacing:-0.6pt;"> </font>therein)<font style="letter-spacing:-0.55pt;"> </font>will<font style="letter-spacing:-0.55pt;"> </font>survive<font style="letter-spacing:-0.7pt;"> </font>any<font style="letter-spacing:-0.75pt;"> </font>termination<font style="letter-spacing:-0.75pt;"> </font>or<font style="letter-spacing:-0.7pt;"> </font>expiration<font style="letter-spacing:-2.6pt;"> </font>of this Agreement.</div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0.4pt 0pt 0pt 0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;text-align:justify;text-indent:36.8pt;margin:0pt 37.6pt 0pt 6pt;"><font style="display:inline-block;font-family:'Times New Roman';font-weight:bold;min-width:35.25pt;text-indent:0pt;white-space:nowrap;">7.6.</font><a name="_bookmark14"></a><b style="font-weight:bold;">Severability.</b><b style="font-weight:bold;letter-spacing:2.75pt;"> </b>In the event that a court finds this Agreement, or any of its restrictions, to<font style="letter-spacing:0.05pt;"> </font>be<font style="letter-spacing:-0.45pt;"> </font>ambiguous,<font style="letter-spacing:-0.45pt;"> </font>unenforceable,<font style="letter-spacing:-0.5pt;"> </font>or<font style="letter-spacing:-0.4pt;"> </font>invalid,<font style="letter-spacing:-0.55pt;"> </font>the<font style="letter-spacing:-0.4pt;"> </font>parties<font style="letter-spacing:-0.45pt;"> </font>agree<font style="letter-spacing:-0.4pt;"> </font>that<font style="letter-spacing:-0.5pt;"> </font>the<font style="letter-spacing:-0.55pt;"> </font>court<font style="letter-spacing:-0.4pt;"> </font>will<font style="letter-spacing:-0.5pt;"> </font>read<font style="letter-spacing:-0.5pt;"> </font>the<font style="letter-spacing:-0.4pt;"> </font>Agreement<font style="letter-spacing:-0.4pt;"> </font>as<font style="letter-spacing:-0.45pt;"> </font>a<font style="letter-spacing:-0.4pt;"> </font>whole<font style="letter-spacing:-2.65pt;"> </font>and interpret the restriction(s) at issue to be enforceable and valid to the maximum extent allowed by law.<font style="letter-spacing:0.05pt;"> </font>If the court declines to enforce this Agreement in the manner provided in this Section <a href="#_bookmark14"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">7.6, </font></a>Executive and<font style="letter-spacing:0.05pt;"> </font>the Company agree that this Agreement will be automatically modified to provide the Company with the<font style="letter-spacing:0.05pt;"> </font>maximum protection of its business interests allowed by law and Executive agrees to be bound by this<font style="letter-spacing:0.05pt;"> </font>Agreement as modified.<font style="letter-spacing:0.05pt;"> </font>In case any one or more of the provisions, subsections, or sentences contained in<font style="letter-spacing:-2.6pt;"> </font>this Agreement will, for any reason, be held to be invalid, illegal or unenforceable in any respect, such<font style="letter-spacing:0.05pt;"> </font>invalidity, illegality or unenforceability will not affect the other provisions of this Agreement, and this<font style="letter-spacing:0.05pt;"> </font>Agreement<font style="letter-spacing:-0.5pt;"> </font>will<font style="letter-spacing:-0.45pt;"> </font>be<font style="letter-spacing:-0.5pt;"> </font>construed<font style="letter-spacing:-0.5pt;"> </font>as<font style="letter-spacing:-0.55pt;"> </font>if<font style="letter-spacing:-0.5pt;"> </font>such<font style="letter-spacing:-0.6pt;"> </font>invalid,<font style="letter-spacing:-0.6pt;"> </font>illegal<font style="letter-spacing:-0.6pt;"> </font>or<font style="letter-spacing:-0.45pt;"> </font>unenforceable<font style="letter-spacing:-0.45pt;"> </font>provision<font style="letter-spacing:-0.55pt;"> </font>had<font style="letter-spacing:-0.5pt;"> </font>never<font style="letter-spacing:-0.55pt;"> </font>been<font style="letter-spacing:-0.55pt;"> </font>contained<font style="letter-spacing:-2.6pt;"> </font>herein.</div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0.3pt 0pt 0pt 0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;text-align:justify;text-indent:36.8pt;margin:0pt 37.7pt 0pt 6pt;"><font style="display:inline-block;font-family:'Times New Roman';font-weight:bold;min-width:35.25pt;text-indent:0pt;white-space:nowrap;">7.7.</font><b style="font-weight:bold;">Waiver.</b><b style="font-weight:bold;letter-spacing:0.05pt;"> </b>If either party should waive any breach of any provisions of this Agreement or<font style="letter-spacing:0.05pt;"> </font>fail to enforce performance by the other party, he or it will not thereby be deemed to have waived any<font style="letter-spacing:0.05pt;"> </font>preceding<font style="letter-spacing:-0.3pt;"> </font>or<font style="letter-spacing:-0.4pt;"> </font>succeeding<font style="letter-spacing:-0.4pt;"> </font>breach<font style="letter-spacing:-0.3pt;"> </font>or<font style="letter-spacing:-0.25pt;"> </font>performance<font style="letter-spacing:-0.3pt;"> </font>of<font style="letter-spacing:-0.25pt;"> </font>the<font style="letter-spacing:-0.4pt;"> </font>same<font style="letter-spacing:-0.3pt;"> </font>or<font style="letter-spacing:-0.4pt;"> </font>any<font style="letter-spacing:-0.35pt;"> </font>other<font style="letter-spacing:-0.25pt;"> </font>provision<font style="letter-spacing:-0.45pt;"> </font>of<font style="letter-spacing:-0.25pt;"> </font>this<font style="letter-spacing:-0.4pt;"> </font>Agreement.<font style="letter-spacing:2.05pt;"> </font>Any<font style="letter-spacing:-2.6pt;"> </font>such waiver will be effective only if made in writing and signed by the Party waiving such breach or<font style="letter-spacing:0.05pt;"> </font>performance.</div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0.4pt 0pt 0pt 0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;text-align:justify;text-indent:36.8pt;margin:0pt 37.7pt 0pt 6.05pt;"><font style="display:inline-block;font-family:'Times New Roman';font-weight:bold;min-width:35.25pt;text-indent:0pt;white-space:nowrap;">7.8.</font><b style="font-weight:bold;">Complete Agreement; Amendment.</b><b style="font-weight:bold;letter-spacing:0.05pt;"> </b>This Agreement and its Exhibits, constitute the<font style="letter-spacing:0.05pt;"> </font>entire<font style="letter-spacing:0.05pt;"> </font>agreement<font style="letter-spacing:0.05pt;"> </font>between<font style="letter-spacing:0.05pt;"> </font>Executive<font style="letter-spacing:0.05pt;"> </font>and<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>Company<font style="letter-spacing:0.05pt;"> </font>and<font style="letter-spacing:0.05pt;"> </font>it<font style="letter-spacing:0.05pt;"> </font>is<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>complete,<font style="letter-spacing:0.05pt;"> </font>final,<font style="letter-spacing:0.05pt;"> </font>and<font style="letter-spacing:0.05pt;"> </font>exclusive<font style="letter-spacing:-2.6pt;"> </font>embodiment of their agreement with regard to this subject matter.<font style="letter-spacing:0.05pt;"> </font>This Agreement replaces all previous<font style="letter-spacing:0.05pt;"> </font>agreements<font style="letter-spacing:0.8pt;"> </font>regarding<font style="letter-spacing:0.65pt;"> </font>the<font style="letter-spacing:0.65pt;"> </font>service<font style="letter-spacing:0.65pt;"> </font>relationship<font style="letter-spacing:0.75pt;"> </font>of<font style="letter-spacing:0.8pt;"> </font>Executive<font style="letter-spacing:0.8pt;"> </font>with<font style="letter-spacing:0.75pt;"> </font>the<font style="letter-spacing:0.8pt;"> </font>Company.<font style="letter-spacing:0.75pt;"> </font>It<font style="letter-spacing:0.7pt;"> </font>is<font style="letter-spacing:0.8pt;"> </font>entered<font style="letter-spacing:0.65pt;"> </font>into<font style="letter-spacing:0.75pt;"> </font>without</div><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;text-align:justify;margin:0pt;"><font style="font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:46.8pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:12pt 0.55pt 0pt 0.55pt;"><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">Gain</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.2pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">Therapeutics,</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.15pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">Inc.</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.15pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">-</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.05pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">4800</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.15pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">Hampden</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.15pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">Ln,</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.15pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">St</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.05pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">200, Bethesda,</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.1pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">MD</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:2.65pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">20814</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0.5pt 0.3pt 0pt 0.55pt;"><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">P:</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.25pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">+1</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.2pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">301-500-1556</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:1.8pt;"> </font><u style="color:#0562c1;font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-decoration:underline;text-decoration-color:#0562c1;">www.gaintherapeutics.com</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:right;margin:0pt 0.3pt 0pt 0.55pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;">11</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.78%;margin-right:5.56%;margin-top:30pt;page-break-after:always;width:83.66%;border-width:0;"><div style="max-width:100%;padding-left:10.78%;padding-right:5.56%;position:relative;"><div style="margin-top:9.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><img src="ganx-20211231xex10d8001.jpg" alt="Logo&#10;&#10;Description automatically generated" style="display:inline-block;height:42pt;width:87.5pt;"></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;text-align:justify;margin:4.05pt 37.8pt 0pt 6pt;">reliance on any promise or representation other than those expressly contained herein.<font style="letter-spacing:0.05pt;"> </font>This Agreement<font style="letter-spacing:0.05pt;"> </font>cannot<font style="letter-spacing:-0.15pt;"> </font>be<font style="letter-spacing:-0.3pt;"> </font>modified<font style="letter-spacing:-0.2pt;"> </font>or<font style="letter-spacing:-0.1pt;"> </font>amended<font style="letter-spacing:-0.2pt;"> </font>except<font style="letter-spacing:-0.15pt;"> </font>in<font style="letter-spacing:-0.3pt;"> </font>a<font style="letter-spacing:-0.1pt;"> </font>writing<font style="letter-spacing:-0.2pt;"> </font>signed<font style="letter-spacing:-0.2pt;"> </font>by<font style="letter-spacing:-0.15pt;"> </font>an<font style="letter-spacing:-0.3pt;"> </font>authorized<font style="letter-spacing:-0.2pt;"> </font>representative<font style="letter-spacing:-0.15pt;"> </font>of<font style="letter-spacing:-0.2pt;"> </font>the<font style="letter-spacing:-0.15pt;"> </font>Company<font style="letter-spacing:-2.65pt;"> </font>and Executive.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0.4pt 0pt 0pt 0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;text-align:justify;text-indent:36.8pt;margin:0pt 37.7pt 0pt 6pt;"><font style="display:inline-block;font-family:'Times New Roman';font-weight:bold;min-width:35.25pt;text-indent:0pt;white-space:nowrap;">7.9.</font><b style="font-weight:bold;">Counterparts.</b><b style="font-weight:bold;letter-spacing:0.05pt;"> </b>This Agreement may be executed in separate counterparts, any one of<font style="letter-spacing:0.05pt;"> </font>which need not contain signatures of more than one party, but all of which taken together will constitute<font style="letter-spacing:0.05pt;"> </font>one and<font style="letter-spacing:-0.15pt;"> </font>the<font style="letter-spacing:-0.1pt;"> </font>same Agreement.</div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0.34pt 0pt 0pt 0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-top:0.05pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:42.8pt;"></td><td style="font-family:'Times New Roman';font-size:11pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:35.2pt;padding:0pt;">7.10.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;text-align:left;"><a name="_bookmark15"></a></b><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;text-align:left;">Assignment;</b><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;letter-spacing:-0.15pt;text-align:left;"> </b><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;text-align:left;">Assumption</b><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;letter-spacing:-0.45pt;text-align:left;"> </b><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;text-align:left;">by</b><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;letter-spacing:-0.15pt;text-align:left;"> </b><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;text-align:left;">Successor;</b><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;letter-spacing:-0.15pt;text-align:left;"> </b><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;text-align:left;">Non-transferability</b><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;letter-spacing:-0.2pt;text-align:left;"> </b><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;text-align:left;">of</b><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;letter-spacing:-0.1pt;text-align:left;"> </b><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;text-align:left;">Interest.</b></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0.3pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;text-align:justify;text-indent:72pt;margin:0pt 37.7pt 0pt 6pt;"><font style="display:inline-block;font-family:'Times New Roman';font-weight:bold;min-width:36.05pt;text-indent:0pt;white-space:nowrap;">(a)</font>The Company may assign this Agreement, without the consent of Executive, to<font style="letter-spacing:0.05pt;"> </font>any business entity which at any time, whether by purchase, merger or otherwise, directly or indirectly,<font style="letter-spacing:0.05pt;"> </font>acquires all or substantially all of the assets or business of the Company.<font style="letter-spacing:0.05pt;"> </font>The Company will require any<font style="letter-spacing:0.05pt;"> </font>successor (whether direct or indirect, by purchase, merger or otherwise) to all or substantially all of the<font style="letter-spacing:0.05pt;"> </font>business<font style="letter-spacing:-0.3pt;"> </font>or<font style="letter-spacing:-0.2pt;"> </font>assets<font style="letter-spacing:-0.3pt;"> </font>of<font style="letter-spacing:-0.2pt;"> </font>the<font style="letter-spacing:-0.15pt;"> </font>Company<font style="letter-spacing:-0.25pt;"> </font>expressly<font style="letter-spacing:-0.3pt;"> </font>to<font style="letter-spacing:-0.25pt;"> </font>assume<font style="letter-spacing:-0.3pt;"> </font>and<font style="letter-spacing:-0.25pt;"> </font>to<font style="letter-spacing:-0.3pt;"> </font>agree<font style="letter-spacing:-0.25pt;"> </font>to<font style="letter-spacing:-0.3pt;"> </font>perform<font style="letter-spacing:-0.2pt;"> </font>this<font style="letter-spacing:-0.3pt;"> </font>Agreement<font style="letter-spacing:-0.2pt;"> </font>in<font style="letter-spacing:-0.3pt;"> </font>the<font style="letter-spacing:-0.25pt;"> </font>same<font style="letter-spacing:-2.65pt;"> </font>manner<font style="letter-spacing:-0.25pt;"> </font>and<font style="letter-spacing:-0.25pt;"> </font>to<font style="letter-spacing:-0.25pt;"> </font>the<font style="letter-spacing:-0.25pt;"> </font>same<font style="letter-spacing:-0.3pt;"> </font>extent<font style="letter-spacing:-0.2pt;"> </font>that<font style="letter-spacing:-0.2pt;"> </font>the<font style="letter-spacing:-0.1pt;"> </font>Company<font style="letter-spacing:-0.2pt;"> </font>would<font style="letter-spacing:-0.15pt;"> </font>be<font style="letter-spacing:-0.25pt;"> </font>required<font style="letter-spacing:-0.25pt;"> </font>to<font style="letter-spacing:-0.15pt;"> </font>perform<font style="letter-spacing:-0.25pt;"> </font>it<font style="letter-spacing:-0.2pt;"> </font>if<font style="letter-spacing:-0.1pt;"> </font>no<font style="letter-spacing:-0.25pt;"> </font>such<font style="letter-spacing:-0.3pt;"> </font>succession<font style="letter-spacing:-0.15pt;"> </font>had<font style="letter-spacing:-2.6pt;"> </font>taken place; provided, however, that no such assumption will relieve the Company of its obligations<font style="letter-spacing:0.05pt;"> </font>hereunder.<font style="letter-spacing:0.05pt;"> </font>As used in this Agreement, the &#8220;Company&#8221; will mean the Company as herein defined and any<font style="letter-spacing:-2.6pt;"> </font>successor to its business and/or assets as aforesaid which assumes and agrees to perform this Agreement<font style="letter-spacing:0.05pt;"> </font>by<font style="letter-spacing:-0.05pt;"> </font>operation of<font style="letter-spacing:-0.1pt;"> </font>law<font style="letter-spacing:-0.05pt;"> </font>or<font style="letter-spacing:-0.1pt;"> </font>otherwise.</div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0.25pt 0pt 0pt 0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p><div style="margin-top:0.05pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;text-align:justify;text-indent:72pt;margin:0pt 37.75pt 0pt 5.95pt;"><font style="display:inline-block;font-family:'Times New Roman';font-weight:bold;min-width:36.05pt;text-indent:0pt;white-space:nowrap;">(b)</font><a name="_bookmark16"></a>None of the rights of Executive to receive any form of compensation payable<font style="letter-spacing:0.05pt;"> </font>pursuant to this Agreement will be assignable or transferable except through a testamentary disposition or<font style="letter-spacing:0.05pt;"> </font>by the laws of descent and distribution upon the death of Executive.<font style="letter-spacing:0.05pt;"> </font>Any attempted assignment, transfer,<font style="letter-spacing:0.05pt;"> </font><font style="letter-spacing:-0.05pt;">conveyance,</font><font style="letter-spacing:-0.6pt;"> </font><font style="letter-spacing:-0.05pt;">or</font><font style="letter-spacing:-0.55pt;"> </font><font style="letter-spacing:-0.05pt;">other</font><font style="letter-spacing:-0.55pt;"> </font>disposition<font style="letter-spacing:-0.6pt;"> </font>(other<font style="letter-spacing:-0.55pt;"> </font>than<font style="letter-spacing:-0.6pt;"> </font>as<font style="letter-spacing:-0.7pt;"> </font>aforesaid)<font style="letter-spacing:-0.55pt;"> </font>of<font style="letter-spacing:-0.55pt;"> </font>any<font style="letter-spacing:-0.6pt;"> </font>interest<font style="letter-spacing:-0.55pt;"> </font>in<font style="letter-spacing:-0.75pt;"> </font>the<font style="letter-spacing:-0.6pt;"> </font>rights<font style="letter-spacing:-0.6pt;"> </font>of<font style="letter-spacing:-0.55pt;"> </font>Executive<font style="letter-spacing:-0.7pt;"> </font>to<font style="letter-spacing:-0.6pt;"> </font>receive<font style="letter-spacing:-2.65pt;"> </font>any<font style="letter-spacing:-0.05pt;"> </font>form<font style="letter-spacing:0.05pt;"> </font>of<font style="letter-spacing:-0.1pt;"> </font>compensation<font style="letter-spacing:-0.15pt;"> </font>to be made<font style="letter-spacing:-0.15pt;"> </font>by the Company<font style="letter-spacing:-0.15pt;"> </font>pursuant<font style="letter-spacing:-0.1pt;"> </font>to<font style="letter-spacing:-0.15pt;"> </font>this<font style="letter-spacing:-0.05pt;"> </font>Agreement<font style="letter-spacing:-0.1pt;"> </font>will<font style="letter-spacing:-0.1pt;"> </font>be void.</div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0.25pt 0pt 0pt 0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p><div style="margin-top:0.05pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;text-align:justify;text-indent:72pt;margin:0pt 37.7pt 0pt 6pt;"><font style="display:inline-block;font-family:'Times New Roman';font-weight:bold;min-width:36.05pt;text-indent:0pt;white-space:nowrap;">(c)</font>Notwithstanding the foregoing Section <a href="#_bookmark15"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">7.10</font></a><a href="#_bookmark16"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">(b)</font></a>, this Agreement and all rights of<font style="letter-spacing:0.05pt;"> </font>Executive hereunder shall inure to the benefit of, and be enforceable by, the Beneficiaries or Executive&#8217;s<font style="letter-spacing:0.05pt;"> </font>personal or legal representatives, executors, administrators, successors, heirs, distributees, devisees and<font style="letter-spacing:0.05pt;"> </font>legatees.<font style="letter-spacing:0.05pt;"> </font>If Executive should die while any amounts would still be payable to him hereunder if he had<font style="letter-spacing:0.05pt;"> </font>continued to live, all such amounts, unless otherwise provided herein, shall be paid in accordance with the<font style="letter-spacing:-2.6pt;"> </font>terms of this Agreement to the Beneficiaries or Executive&#8217;s devisee, legatee or other designee or, should<font style="letter-spacing:0.05pt;"> </font>there<font style="letter-spacing:-0.05pt;"> </font>be<font style="letter-spacing:-0.1pt;"> </font>no such designee,<font style="letter-spacing:-0.15pt;"> </font>to Executive&#8217;s estate.</div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0.3pt 0pt 0pt 0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;text-align:justify;text-indent:36.8pt;margin:0pt 37.8pt 0pt 5.95pt;"><font style="display:inline-block;font-family:'Times New Roman';font-weight:bold;min-width:35.3pt;text-indent:0pt;white-space:nowrap;">7.11.</font><b style="font-weight:bold;">Headings. </b>The headings of the sections hereof are inserted for convenience only and will<font style="letter-spacing:0.05pt;"> </font>not be<font style="letter-spacing:-0.1pt;"> </font>deemed<font style="letter-spacing:-0.15pt;"> </font>to<font style="letter-spacing:-0.15pt;"> </font>constitute<font style="letter-spacing:-0.1pt;"> </font>a part<font style="letter-spacing:0.05pt;"> </font>hereof<font style="letter-spacing:0.05pt;"> </font>nor<font style="letter-spacing:0.05pt;"> </font>to<font style="letter-spacing:-0.05pt;"> </font>affect<font style="letter-spacing:-0.1pt;"> </font>the meaning<font style="letter-spacing:-0.15pt;"> </font>thereof.</div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;text-align:justify;text-indent:36.8pt;margin:0pt 37.6pt 0pt 5.95pt;"><font style="display:inline-block;font-family:'Times New Roman';font-weight:bold;min-width:35.3pt;text-indent:0pt;white-space:nowrap;">7.12.</font><b style="font-weight:bold;">Construction.</b><b style="font-weight:bold;letter-spacing:0.05pt;"> </b>The language in all parts of this Agreement will in all cases be construed<font style="letter-spacing:0.05pt;"> </font>simply, according to its fair meaning, and not strictly for or against any of the parties hereto.<font style="letter-spacing:0.05pt;"> </font>Without<font style="letter-spacing:0.05pt;"> </font>limitation,<font style="letter-spacing:-0.35pt;"> </font>there<font style="letter-spacing:-0.3pt;"> </font>will<font style="letter-spacing:-0.25pt;"> </font>be<font style="letter-spacing:-0.3pt;"> </font>no<font style="letter-spacing:-0.4pt;"> </font>presumption<font style="letter-spacing:-0.3pt;"> </font>against<font style="letter-spacing:-0.35pt;"> </font>any<font style="letter-spacing:-0.3pt;"> </font>party<font style="letter-spacing:-0.4pt;"> </font>on<font style="letter-spacing:-0.3pt;"> </font>the<font style="letter-spacing:-0.3pt;"> </font>ground<font style="letter-spacing:-0.45pt;"> </font>that<font style="letter-spacing:-0.35pt;"> </font>such<font style="letter-spacing:-0.4pt;"> </font>party<font style="letter-spacing:-0.3pt;"> </font>was<font style="letter-spacing:-0.4pt;"> </font>responsible<font style="letter-spacing:-0.4pt;"> </font>for<font style="letter-spacing:-2.6pt;"> </font>drafting<font style="letter-spacing:-0.05pt;"> </font>this<font style="letter-spacing:-0.1pt;"> </font>Agreement<font style="letter-spacing:-0.1pt;"> </font>or<font style="letter-spacing:-0.1pt;"> </font>any part<font style="letter-spacing:-0.1pt;"> </font>thereof.</div><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;text-align:justify;margin:0pt;"><font style="font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:46.8pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:12pt 0.55pt 0pt 0.55pt;"><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">Gain</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.2pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">Therapeutics,</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.15pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">Inc.</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.15pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">-</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.05pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">4800</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.15pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">Hampden</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.15pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">Ln,</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.15pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">St</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.05pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">200, Bethesda,</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.1pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">MD</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:2.65pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">20814</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0.5pt 0.3pt 0pt 0.55pt;"><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">P:</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.25pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">+1</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.2pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">301-500-1556</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:1.8pt;"> </font><u style="color:#0562c1;font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-decoration:underline;text-decoration-color:#0562c1;">www.gaintherapeutics.com</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:right;margin:0pt 0.3pt 0pt 0.55pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;">12</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.78%;margin-right:5.56%;margin-top:30pt;page-break-after:always;width:83.66%;border-width:0;"><div style="max-width:100%;padding-left:10.78%;padding-right:5.56%;position:relative;"><div style="margin-top:9.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><img src="ganx-20211231xex10d8001.jpg" alt="Logo&#10;&#10;Description automatically generated" style="display:inline-block;height:42pt;width:87.5pt;"></p></div><div style="clear:both;max-width:100%;position:relative;min-height:35.95pt;"><div style="margin-top:4.05pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;text-align:justify;text-indent:36.8pt;margin:0pt 37.65pt 0pt 5.95pt;"><font style="display:inline-block;font-family:'Times New Roman';font-weight:bold;min-width:35.3pt;text-indent:0pt;white-space:nowrap;">7.13.</font><b style="font-weight:bold;">Choice of Law.</b><b style="font-weight:bold;letter-spacing:0.05pt;"> </b>All questions concerning the construction, validity, interpretation of this<font style="letter-spacing:-2.6pt;"> </font>Agreement<font style="letter-spacing:-0.55pt;"> </font>will<font style="letter-spacing:-0.55pt;"> </font>be<font style="letter-spacing:-0.5pt;"> </font>governed<font style="letter-spacing:-0.6pt;"> </font>by<font style="letter-spacing:-0.65pt;"> </font>the<font style="letter-spacing:-0.65pt;"> </font>laws<font style="letter-spacing:-0.7pt;"> </font>of<font style="letter-spacing:-0.6pt;"> </font>Maryland<font style="letter-spacing:-0.7pt;"> </font>as<font style="letter-spacing:-0.55pt;"> </font>applicable<font style="letter-spacing:-0.7pt;"> </font>to<font style="letter-spacing:-0.65pt;"> </font>contracts<font style="letter-spacing:-0.65pt;"> </font>made<font style="letter-spacing:-0.55pt;"> </font>and<font style="letter-spacing:-0.55pt;"> </font>wholly<font style="letter-spacing:-0.7pt;"> </font>performed<font style="letter-spacing:-2.6pt;"> </font>within<font style="letter-spacing:-0.05pt;"> </font>Maryland<font style="letter-spacing:-0.15pt;"> </font>by residents of<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:-0.05pt;"> </font>state.</div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:7.84pt 21.9pt 0pt 5.95pt;"><b style="font-weight:bold;">IN</b><b style="font-weight:bold;letter-spacing:1.05pt;"> </b><b style="font-weight:bold;">WITNESS</b><b style="font-weight:bold;letter-spacing:1.1pt;"> </b><b style="font-weight:bold;">WHEREOF,</b><b style="font-weight:bold;letter-spacing:1.15pt;"> </b>the<font style="letter-spacing:1.05pt;"> </font>parties<font style="letter-spacing:1.05pt;"> </font>have<font style="letter-spacing:1.05pt;"> </font>executed<font style="letter-spacing:1.15pt;"> </font>this<font style="letter-spacing:1.15pt;"> </font>Agreement<font style="letter-spacing:1.15pt;"> </font>on<font style="letter-spacing:1.15pt;"> </font>the<font style="letter-spacing:1.15pt;"> </font>day<font style="letter-spacing:1.15pt;"> </font>and<font style="letter-spacing:1pt;"> </font>year<font style="letter-spacing:1.05pt;"> </font>first<font style="letter-spacing:1.05pt;"> </font>above<font style="letter-spacing:-2.6pt;"> </font>written.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:13.5pt;visibility:hidden;">&#8203;</font></p><div style="height:0pt;position:relative;width:100%;"><div style="height:35.94pt;left:10.35%;max-width:89.65%;position:absolute;top:24.03pt;width:73.26pt;z-index:251660288;"><div style="height:35.94pt;left:0pt;padding-bottom:0pt;position:relative;top:0pt;width:73.26pt;"><img src="ganx-20211231xex10d8003.jpg" alt="Graphic" style="height:35.94pt;width:73.26pt;"></div></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-weight:bold;text-indent:0pt;margin:0pt 0pt 0pt 5.95pt;">GAIN<b style="font-weight:bold;letter-spacing:-0.2pt;"> </b>THERAPEUTICS,<b style="font-weight:bold;letter-spacing:-0.1pt;"> </b>INC.:</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0.1pt 0pt 0pt 0pt;"><font style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 129.2pt;"><font style="font-family:'Lucida Console';">10/8/2021</font><font style="font-family:'Lucida Console';letter-spacing:0.2pt;"> </font><font style="font-family:'Lucida Console';">|</font><font style="font-family:'Lucida Console';letter-spacing:0.25pt;"> </font><font style="font-family:'Lucida Console';">23:03:50</font><font style="font-family:'Lucida Console';letter-spacing:0.2pt;"> </font><font style="font-family:'Lucida Console';">CEST</font></p><div style="height:0.1pt;left:1.17%;max-width:98.83%;position:relative;top:0pt;width:209.05pt;z-index:-9223372036603107328;"><div style="height:0.1pt;left:0pt;padding-bottom:0pt;position:relative;top:0pt;width:209.05pt;"><img src="ganx-20211231xex10d8004.jpg" alt="Graphic" style="height:0.1pt;width:209.05pt;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="font-family:'Lucida Console';font-size:7.5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0.05pt 0pt 0pt 0pt;"><font style="font-family:'Lucida Console';font-size:9pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt 0pt 0pt 5.95pt;">Name:<font style="letter-spacing:1.15pt;"> </font>Eric<font style="letter-spacing:-0.05pt;"> </font>I.<font style="letter-spacing:-0.05pt;"> </font>Richman</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:8.94pt 0pt 0pt 5.95pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">Title:</font></font>Chief<font style="letter-spacing:-0.05pt;"> </font>Executive<font style="letter-spacing:-0.1pt;"> </font>Officer</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0.2pt 0pt 0pt 0pt;"><font style="font-size:14.5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-weight:bold;text-indent:0pt;margin:0pt 0pt 0pt 5.95pt;">EXECUTIVE:</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><font style="font-size:0pt;visibility:hidden;">&#8203;</font></p><div style="position:relative;white-space:nowrap;"><div style="display:inline-block;padding-right:0.38%;vertical-align:top;white-space:normal;width:21.16%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="font-size:14pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><div style="height:0pt;position:relative;width:100%;"><div style="height:35.95pt;left:1.17%;max-width:94.46%;position:absolute;top:-41.7pt;width:181.6pt;z-index:-9223372036603109376;"><div style="height:35.95pt;left:0pt;padding-bottom:0pt;position:relative;top:0pt;width:181.6pt;"><div style="height:0.09pt;left:-0.05pt;position:absolute;top:32.55pt;width:181.6pt;"><img src="ganx-20211231xex10d8005.jpg" alt="Graphic" style="height:0.09pt;width:181.6pt;"></div><div style="height:35.95pt;left:46pt;position:absolute;top:0pt;width:91.55pt;"><img src="ganx-20211231xex10d8006.jpg" alt="Graphic" style="height:35.95pt;width:91.55pt;"></div></div></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0.05pt 0pt 0pt 5.95pt;">Name:<font style="letter-spacing:3.3pt;"> </font>Matthias<font style="letter-spacing:-0.25pt;"> </font>Alder</p></div><div style="display:inline-block;padding-left:0.38%;vertical-align:top;white-space:normal;width:78.09%;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:5.09pt 0pt 0pt 5.95pt;"><font style="font-family:'Lucida Console';">10/8/2021</font><font style="font-family:'Lucida Console';letter-spacing:0.25pt;"> </font><font style="font-family:'Lucida Console';">|</font><font style="font-family:'Lucida Console';letter-spacing:0.25pt;"> </font><font style="font-family:'Lucida Console';">16:06:34</font><font style="font-family:'Lucida Console';letter-spacing:0.25pt;"> </font><font style="font-family:'Lucida Console';">CEST</font></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><font style="font-family:'Lucida Console';font-size:0pt;visibility:hidden;">&#8203;</font></p></div></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:46.8pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:12pt 0.55pt 0pt 0.55pt;"><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">Gain</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.2pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">Therapeutics,</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.15pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">Inc.</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.15pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">-</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.05pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">4800</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.15pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">Hampden</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.15pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">Ln,</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.15pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">St</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.05pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">200, Bethesda,</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.1pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">MD</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:2.65pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">20814</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0.5pt 0.3pt 0pt 0.55pt;"><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">P:</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.25pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">+1</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.2pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">301-500-1556</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:1.8pt;"> </font><u style="color:#0562c1;font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-decoration:underline;text-decoration-color:#0562c1;">www.gaintherapeutics.com</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:right;margin:0pt 0.3pt 0pt 0.55pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;">13</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.78%;margin-right:5.56%;margin-top:30pt;page-break-after:always;width:83.66%;border-width:0;"><div style="max-width:100%;padding-left:10.78%;padding-right:5.56%;position:relative;"><div style="margin-top:9.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><img src="ganx-20211231xex10d8001.jpg" alt="Logo&#10;&#10;Description automatically generated" style="display:inline-block;height:42pt;width:87.5pt;"></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:4.05pt 56.55pt 0pt 24.7pt;"><b style="font-weight:bold;">Exhibit A</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0.2pt 0pt 0pt 0pt;"><font style="font-size:14.5pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-weight:bold;line-height:1.28;text-align:center;text-indent:0pt;margin:0pt 56.55pt 0pt 24.65pt;">EMPLOYEE CONFIDENTIAL INFORMATION AND INVENTIONS ASSIGNMENT,<b style="font-weight:bold;letter-spacing:-2.6pt;"> </b>NONCOMPETITON<b style="font-weight:bold;letter-spacing:-0.1pt;"> </b>AND<b style="font-weight:bold;letter-spacing:-0.05pt;"> </b>NONSOLICITATION<b style="font-weight:bold;letter-spacing:-0.15pt;"> </b>AGREEMENT</p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;text-align:center;margin:0pt;"><font style="font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:46.8pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:12pt 0.55pt 0pt 0.55pt;"><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">Gain</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.2pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">Therapeutics,</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.15pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">Inc.</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.15pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">-</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.05pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">4800</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.15pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">Hampden</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.15pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">Ln,</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.15pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">St</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.05pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">200, Bethesda,</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.1pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">MD</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:2.65pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">20814</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0.5pt 0.3pt 0pt 0.55pt;"><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">P:</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.25pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">+1</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.2pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">301-500-1556</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:1.8pt;"> </font><u style="color:#0562c1;font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-decoration:underline;text-decoration-color:#0562c1;">www.gaintherapeutics.com</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:right;margin:0pt 0.3pt 0pt 0.55pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;">14</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.78%;margin-right:5.56%;margin-top:30pt;page-break-after:always;width:83.66%;border-width:0;"><div style="max-width:100%;padding-left:10.78%;padding-right:5.56%;position:relative;"><div style="margin-top:9.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><img src="ganx-20211231xex10d8001.jpg" alt="Logo&#10;&#10;Description automatically generated" style="display:inline-block;height:42pt;width:87.5pt;"></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-weight:bold;line-height:2.03;text-align:center;text-indent:0.25pt;margin:4.05pt 228.55pt 0pt 196.55pt;">Exhibit B<b style="font-weight:bold;letter-spacing:0.05pt;"> </b><b style="font-weight:bold;letter-spacing:-0.05pt;">BENEFICIARIES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0.3pt 0pt 0pt 0pt;"><font style="font-size:13.5pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:4.55pt 0pt 0pt 6pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">Primary</u><u style="letter-spacing:-0.2pt;text-decoration:underline;text-decoration-color:#000000;"> </u><u style="text-decoration:underline;text-decoration-color:#000000;">Beneficiary</u>:</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:8.94pt 0pt 0pt 6pt;">Janice<font style="letter-spacing:-0.1pt;"> </font>Alder</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0.2pt 0pt 0pt 0pt;"><font style="font-size:14.5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:2.03;margin:0pt 225.55pt 0pt 6pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">Secondary Beneficiaries</u> (if Primary Beneficiary pre-deceased):<font style="letter-spacing:-2.6pt;"> </font>Marcus<font style="letter-spacing:-0.05pt;"> </font>Alder<font style="letter-spacing:-0.1pt;"> </font>(50%)</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0.05pt 0pt 0pt 5.95pt;">Leonie<font style="letter-spacing:-0.15pt;"> </font>Alder (50%)</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div style="height:11.85pt;left:83.52%;max-width:16.48%;position:relative;top:0pt;width:15.75pt;z-index:251658240;"><div style="height:11.85pt;left:0pt;padding-bottom:0pt;position:relative;top:0pt;width:15.75pt;"><img src="ganx-20211231xex10d8007.jpg" alt="Graphic" style="height:11.85pt;width:15.75pt;"></div></div><div style="height:18.9pt;left:94.1%;max-width:5.9%;position:relative;top:0pt;width:23.7pt;z-index:251659264;"><div style="height:18.9pt;left:0pt;padding-bottom:0pt;position:relative;top:0pt;width:23.7pt;"><img src="ganx-20211231xex10d8008.jpg" alt="Graphic" style="height:18.89pt;width:23.69pt;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0.2pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><font style="font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:46.8pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:12pt 0.55pt 0pt 0.55pt;"><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">Gain</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.2pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">Therapeutics,</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.15pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">Inc.</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.15pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">-</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.05pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">4800</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.15pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">Hampden</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.15pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">Ln,</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.15pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">St</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.05pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">200, Bethesda,</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.1pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">MD</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:2.65pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">20814</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0.5pt 0.3pt 0pt 0.55pt;"><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">P:</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.25pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">+1</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.2pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">301-500-1556</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:1.8pt;"> </font><u style="color:#0562c1;font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-decoration:underline;text-decoration-color:#0562c1;">www.gaintherapeutics.com</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:right;margin:0pt 0.3pt 0pt 0.55pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;">15</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.78%;margin-right:5.56%;margin-top:30pt;page-break-after:always;width:83.66%;border-width:0;"><div style="max-width:100%;padding-left:10.78%;padding-right:5.56%;position:relative;"><div style="margin-top:9.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><img src="ganx-20211231xex10d8001.jpg" alt="Logo&#10;&#10;Description automatically generated" style="display:inline-block;height:42pt;width:87.5pt;"></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-weight:bold;line-height:2.03;text-align:center;text-indent:0pt;margin:0pt;">Exhibit C<b style="font-weight:bold;letter-spacing:0.05pt;"><br></b><b style="font-weight:bold;letter-spacing:-0.05pt;">GENERAL</b><b style="font-weight:bold;letter-spacing:-0.5pt;"> </b>RELEASE</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><div style="margin-top:7.84pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:5.95pt;"></td><td style="font-family:'Times New Roman';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">1.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">I, Matthias Alder (&#8220;Executive&#8221;), for and in consideration of the commitments of Gain Therapeutics,</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">Inc.</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">(the &#8220;Company&#8221;) as set forth in Section </font><a href="#_bookmark7"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">6 </font></a><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">of the Employment Agreement dated as of October 1,</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">2021</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">(the</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">&#8220;Employment</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">Agreement&#8221;),</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">and</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">intending</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">to</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">be</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">legally</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">bound,</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">do</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">hereby</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">REMISE,</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">RELEASE</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">AND</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">FOREVER</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">DISCHARGE</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">the</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">Company</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">and</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">its</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">present</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">and</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">former</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">divisions,</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-2.6pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">subsidiaries, parents, predecessor and successor corporations, officers, directors, and their respective</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">successors,</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">predecessors,</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.3pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">assigns,</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">heirs,</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.3pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">executors,</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.3pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">and</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">administrators</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.3pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">(collectively,</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.3pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">&#8220;Releasees&#8221;)</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">from</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-2.65pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">all causes of action, suits, debts, claims and demands whatsoever in law or in equity, which Executive</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-2.6pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">ever had, now has, or hereafter may have, whether known or unknown, or which Executive&#8217;s heirs,</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">executors, or administrators may have, by reason of any matter, cause or thing whatsoever, up to the</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">date of Executive&#8217;s execution of this General Release, particularly, but without limitation of the</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">foregoing general terms, any claims arising from or relating in any way to Executive&#8217;s employment</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">relationship with the Company and Releasees, the terms and conditions of that relationship, and the</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">termination of that relationship, including, but not limited to, any claims arising under any applicable</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">Company employee benefit plan(s), the Age Discrimination in Employment Act, the Older Workers&#8217;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;line-height:1.28;text-align:justify;">Benefit</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">Protection</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.6pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">Act,</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.6pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">Title</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.6pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">VII</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">of</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">The</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.6pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">Civil</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">Rights</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.6pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">Act</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">of</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">1964,</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.75pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">the</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.6pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">Civil</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">Rights</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">Act</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">of</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">1991,</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.6pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">Sections</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-2.6pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">1981 through 1988 of Title 42 of the United States Code, the Americans with Disabilities Act, the</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">Employee Retirement Income Security Act of 1974, the Family and Medical Leave Act, the Worker</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">Adjustment and Retraining Notification Act, Pennsylvania employment laws, and any other federal,</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">state and local employment laws, as amended, and any other claims under any federal, state or local</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">common law, statutory, or regulatory provision, now or hereafter recognized, and any claims for</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">attorneys&#8217; fees and costs.</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">This General Release is effective without regard to the legal nature of the</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">claims raised and without regard to whether any such claims are based upon tort, equity, implied or</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">express</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">contract</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">or</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">discrimination of</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">any</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">sort.</font></td><td style="width:37.7pt;"></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0.15pt 0pt 0pt 0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:6pt;"></td><td style="font-family:'Times New Roman';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">2.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">To the fullest extent permitted by law, and subject to the provisions of Paragraph 3 below, Executive</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">represents and affirms that (i) Executive has not filed or caused to be filed on Executive&#8217;s behalf any</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">claim for relief against the Company or any Releasee and, to the best of Executive&#8217;s knowledge and</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">belief,</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.6pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">no</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">outstanding</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">claims</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.45pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">for</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">relief</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">have</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.45pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">been</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">filed</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.45pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">or</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.45pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">asserted</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">against</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">the</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">Company</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">or</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">any</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">Releasee</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-2.65pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">on Executive&#8217;s behalf; and (ii) Executive has no knowledge of any improper, unethical or illegal</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">conduct or activities that Executive has not already reported to any supervisor, manager, department</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">head,</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">human</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">resources</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.3pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">representative,</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">agent</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">or</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">other</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">representative</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">of</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">the</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.3pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">Company,</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">to</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.3pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">any</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">member</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">of</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-2.65pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">the Company&#8217;s legal or compliance departments, or to the ethics hotline; and (iii) Executive will not</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">file, commence, prosecute or participate in any judicial or arbitral action or proceeding against the</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">Company or any Releasee based upon or arising out of any act, omission, transaction, occurrence,</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">contract,</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">claim</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">or</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">event</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.45pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">existing</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">or</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">occurring</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">on</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">or</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">before</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">the</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">date</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.45pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">of</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">execution</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">of</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">this</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.45pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">General</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">Release.</font></td><td style="width:37.6pt;"></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0.3pt 0pt 0pt 0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:6pt;"></td><td style="font-family:'Times New Roman';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">3.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">The release of claims described in Paragraph 1 of this General Release does not preclude Executive</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">from filing a charge with the U.S. Equal Employment Opportunity Commission.</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">However, Executive</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-2.6pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">agrees</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.3pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">and</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.3pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">hereby</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">waives</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.3pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">any</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">and</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">all</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">rights</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.3pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">to</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">any</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.3pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">monetary</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.3pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">relief</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">or</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">other</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">personal</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">recovery</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.3pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">from</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">any</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-2.65pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">such</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">charge, including costs and attorneys&#8217;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">fees.</font></td><td style="width:37.75pt;"></td></tr></table><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;text-align:justify;margin:0pt;"><font style="font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:46.8pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:12pt 0.55pt 0pt 0.55pt;"><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">Gain</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.2pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">Therapeutics,</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.15pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">Inc.</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.15pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">-</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.05pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">4800</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.15pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">Hampden</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.15pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">Ln,</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.15pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">St</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.05pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">200, Bethesda,</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.1pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">MD</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:2.65pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">20814</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0.5pt 0.3pt 0pt 0.55pt;"><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">P:</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.25pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">+1</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.2pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">301-500-1556</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:1.8pt;"> </font><u style="color:#0562c1;font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-decoration:underline;text-decoration-color:#0562c1;">www.gaintherapeutics.com</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:right;margin:0pt 0.3pt 0pt 0.55pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;">16</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.78%;margin-right:5.56%;margin-top:30pt;page-break-after:always;width:83.66%;border-width:0;"><div style="max-width:100%;padding-left:10.78%;padding-right:5.56%;position:relative;"><div style="margin-top:9.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><img src="ganx-20211231xex10d8001.jpg" alt="Logo&#10;&#10;Description automatically generated" style="display:inline-block;height:42pt;width:87.5pt;"></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="margin-top:4.05pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:5.95pt;"></td><td style="font-family:'Times New Roman';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">4.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">Subject to the provisions of Paragraph 3 of this General Release, in further consideration of the</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">commitments of the Company as described in the Employment Agreement, Executive agrees that</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;line-height:1.28;text-align:justify;">Executive</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.6pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">will</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">not</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">file,</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.6pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">claim,</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.6pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">sue</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.6pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">or</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">cause</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.6pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">or</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">permit</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">to</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.75pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">be</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.6pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">filed,</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.6pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">any</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.6pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">civil</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">action,</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.6pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">suit</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">or</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">legal</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">proceeding</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-2.6pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">seeking equitable or monetary relief (including damages, injunctive, declaratory, monetary or other</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">relief) for himself involving any matter released in Paragraph 1. In the event that suit is filed in breach</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-2.6pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">of</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.45pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">this</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">release</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">of</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">claims,</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">it</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">is</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">expressly</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">understood</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">and</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">agreed</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">that</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">this</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">release</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">of</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">claims</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">shall</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">constitute</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-2.6pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">a complete defense to any such suit.</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">In the event any Releasee is required to institute litigation to</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">enforce the terms of this paragraph, Releasees shall be entitled to recover reasonable costs and</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">attorneys&#8217; fees incurred in such enforcement.</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">Executive further agrees and covenants that should any</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">person, organization, or other entity file, claim, sue, or cause or permit to be filed any civil action, suit</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-2.6pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">or legal proceeding involving any matter occurring at any time in the past, Executive will not seek or</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">accept personal equitable or monetary relief in such civil action, suit or legal proceeding.</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">Nothing in</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">this General Release shall prohibit or restrict Executive from: making any disclosure of information</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">required by law; (ii) providing information to, or testifying or otherwise assisting in any investigation</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">or proceeding brought by any federal regulatory or law enforcement agency or legislative body, any</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">self-regulatory organization, or the Company&#8217;s designated legal, compliance or human resources</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">officers; or (iii) filing, testifying, participating in or otherwise assisting in a proceeding relating to an</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">alleged</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.45pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">violation</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">of</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">any</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">federal,</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">state</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">or</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">municipal</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">law</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.45pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">relating</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">to</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">fraud,</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">or</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">any</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">rule</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">or</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">regulation</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">of</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">the</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-2.65pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">Securities</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">and Exchange Commission or</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">any self-regulatory organization.</font></td><td style="width:37.65pt;"></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0.2pt 0pt 0pt 0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:5.95pt;"></td><td style="font-family:'Times New Roman';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">5.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">Executive</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">understands</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">and</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">agrees</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">that</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">the</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">payments,</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">benefits</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">and</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">agreements</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">provided</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">in</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">the</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">Employment Agreement are being provided to Executive in consideration for Executive&#8217;s acceptance</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">and</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.3pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">execution</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.3pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">of,</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.3pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">and</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">in</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.3pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">reliance</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.3pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">upon</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">Executive&#8217;s</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.3pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">representations</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.3pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">in,</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.3pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">the</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">Employment</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">Agreement</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">and</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-2.6pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">this General Release, and that they are greater than the payments, benefits and agreements, if any, to</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">which Executive would have received if Executive had not executed the Employment Agreement and</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">this General Release. In addition, Executive acknowledges and agrees that Executive has been paid all</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-2.65pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">amounts</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">owed to</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">Executive</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">as</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">of</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">the</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">date of Executive&#8217;s signing</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">of</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">this General Release.</font></td><td style="width:37.7pt;"></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0.3pt 0pt 0pt 0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:5.95pt;"></td><td style="font-family:'Times New Roman';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">6.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">Executive and the Company agree and acknowledge that the agreement by the Company described in</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">the Employment Agreement, and the settlement and termination of any asserted or unasserted claims</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">against the Releasees, are not and shall not be construed to be an admission of any violation of any</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">federal,</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">state</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">or</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">local</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">statute</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">or</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">regulation,</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">or of</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">any</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">duty</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">owed</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">by</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">any</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">of</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">the</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">Releasees</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">to</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">Executive.</font></td><td style="width:37.65pt;"></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0.4pt 0pt 0pt 0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p><div style="margin-top:0.05pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:5.95pt;"></td><td style="font-family:'Times New Roman';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">7.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">This General Release and the obligations of the parties hereunder shall be construed, interpreted and</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">enforced</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">in</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">accordance</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">with</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">and</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.45pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">be</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">governed</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.45pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">by</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">the</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">laws</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">of</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">Maryland</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">without</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">reference</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">to</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">its</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">conflicts</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-2.65pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">of laws principles.</font></td><td style="width:37.75pt;"></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0.34pt 0pt 0pt 0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:5.9pt;"></td><td style="font-family:'Times New Roman';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18.05pt;padding:0pt;">8.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">Executive</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;text-align:left;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">certifies</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;text-align:left;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">and</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;text-align:left;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">acknowledges</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;text-align:left;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">as</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;text-align:left;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">follows:</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0.15pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23.95pt;"></td><td style="font-family:'Calibri';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">a.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">that</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;line-height:1.27;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">Executive</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;line-height:1.27;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">has</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;line-height:1.27;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">read</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.3pt;line-height:1.27;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">the</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.3pt;line-height:1.27;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">terms</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.3pt;line-height:1.27;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">of</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;line-height:1.27;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">this</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;line-height:1.27;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">General</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;line-height:1.27;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">Release,</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;line-height:1.27;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">and</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.3pt;line-height:1.27;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">that</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;line-height:1.27;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">Executive</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;line-height:1.27;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">understands</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.3pt;line-height:1.27;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">its</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;line-height:1.27;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">terms</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-2.65pt;line-height:1.27;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">and</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;line-height:1.27;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">effects,</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;line-height:1.27;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">including</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;line-height:1.27;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">the</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;line-height:1.27;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">fact</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;line-height:1.27;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">that</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;line-height:1.27;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">Executive</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;line-height:1.27;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">has</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;line-height:1.27;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">agreed</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;line-height:1.27;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">to</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;line-height:1.27;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">RELEASE</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;line-height:1.27;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">AND</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;line-height:1.27;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">FOREVER</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;line-height:1.27;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">DISCHARGE the Company and each and every one of its affiliated entities from any legal action</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;line-height:1.27;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">arising</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;line-height:1.27;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">out</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;line-height:1.27;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">of Executive&#8217;s</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;line-height:1.27;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">relationship</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;line-height:1.27;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">with</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;line-height:1.27;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">the</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;line-height:1.27;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">Company</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;line-height:1.27;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">and</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;line-height:1.27;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">the</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;line-height:1.27;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">termination</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;line-height:1.27;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">of</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;line-height:1.27;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">that relationship;</font></td><td style="width:37.8pt;"></td></tr></table><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;text-align:justify;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:46.8pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:12pt 0.55pt 0pt 0.55pt;"><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">Gain</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.2pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">Therapeutics,</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.15pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">Inc.</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.15pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">-</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.05pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">4800</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.15pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">Hampden</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.15pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">Ln,</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.15pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">St</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.05pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">200, Bethesda,</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.1pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">MD</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:2.65pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">20814</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0.5pt 0.3pt 0pt 0.55pt;"><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">P:</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.25pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">+1</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.2pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">301-500-1556</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:1.8pt;"> </font><u style="color:#0562c1;font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-decoration:underline;text-decoration-color:#0562c1;">www.gaintherapeutics.com</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:right;margin:0pt 0.3pt 0pt 0.55pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;">17</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.78%;margin-right:5.56%;margin-top:30pt;page-break-after:always;width:83.66%;border-width:0;"><div style="max-width:100%;padding-left:10.78%;padding-right:5.56%;position:relative;"><div style="margin-top:9.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><img src="ganx-20211231xex10d8001.jpg" alt="Logo&#10;&#10;Description automatically generated" style="display:inline-block;height:42pt;width:87.5pt;"></p></div><div style="clear:both;max-width:100%;position:relative;min-height:35.94pt;"><div style="margin-top:4.05pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23.95pt;"></td><td style="font-family:'Times New Roman';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">b.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;"><a name="_bookmark17"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">that</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">Executive</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">has</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">signed</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">this</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">Release</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">voluntarily</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">and</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">knowingly</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.45pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">in</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">exchange</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">for</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">the</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">consideration</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-2.65pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">described herein and in the Employment Agreement, which Executive acknowledges is adequate</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">and satisfactory to Executive and to which Executive acknowledges that Executive would not</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">otherwise</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">be</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">entitled;</font></td><td style="width:37.7pt;"></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0.4pt 0pt 0pt 0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23.95pt;"></td><td style="font-family:'Times New Roman';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">c.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">that</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">Executive</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">has</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">been</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">and</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">is</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">hereby</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">advised</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">in</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">writing</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.45pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">to</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">consult</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.45pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">with</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">an</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">attorney</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.45pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">prior</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.45pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">to</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">signing</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-2.6pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">this</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">General</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">Release;</font></td><td style="width:37.75pt;"></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0.34pt 0pt 0pt 0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p><div style="margin-top:0.05pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23.95pt;"></td><td style="font-family:'Times New Roman';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">d.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">that Executive does not waive rights or claims that may arise after the date this General Release is</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-2.6pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">executed;</font></td><td style="width:37.85pt;"></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0.34pt 0pt 0pt 0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23.95pt;"></td><td style="font-family:'Times New Roman';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18.05pt;padding:0pt;">e.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">that the Company has provided Executive with at least 21 (twenty-one) days within which to</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">consider this General Release, that any modifications, material or otherwise, made to this General</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-2.6pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">Release</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">have</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">not</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">restarted</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">or</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">affected</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">in</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">any</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">manner</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.6pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">the</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">original</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">21</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">(twenty-one)</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">day</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">consideration</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-2.6pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">period,</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.6pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">and</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">that</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">Executive</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">has</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.45pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">signed</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.45pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">on</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">the</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">date</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">indicated</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.45pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">below</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.6pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">after</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">concluding</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">that</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">this</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.45pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">General</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-2.6pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">Release</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">is satisfactory</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">to Executive;</font></td><td style="width:37.75pt;"></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0.4pt 0pt 0pt 0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23.95pt;"></td><td style="font-family:'Times New Roman';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18.05pt;padding:0pt;">f.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">that</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">Executive</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">acknowledges</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">that</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">this</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">General</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">Release</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.3pt;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">may</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">be</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">revoked</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">by</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">Executive</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">within</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">seven</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;text-align:justify;margin:1.04pt 37.7pt 0pt 42pt;">(7) days after Executive&#8217;s execution, and it shall not become effective until the expiration of such<font style="letter-spacing:0.05pt;"> </font>seven-day<font style="letter-spacing:-0.55pt;"> </font>revocation<font style="letter-spacing:-0.45pt;"> </font>period.<font style="letter-spacing:1.9pt;"> </font>If<font style="letter-spacing:-0.4pt;"> </font>the<font style="letter-spacing:-0.55pt;"> </font>last<font style="letter-spacing:-0.4pt;"> </font>day<font style="letter-spacing:-0.45pt;"> </font>of<font style="letter-spacing:-0.5pt;"> </font>the<font style="letter-spacing:-0.55pt;"> </font>revocation<font style="letter-spacing:-0.45pt;"> </font>period<font style="letter-spacing:-0.45pt;"> </font>is<font style="letter-spacing:-0.35pt;"> </font>a<font style="letter-spacing:-0.4pt;"> </font>Saturday,<font style="letter-spacing:-0.55pt;"> </font>Sunday,<font style="letter-spacing:-0.45pt;"> </font>or<font style="letter-spacing:-0.4pt;"> </font>legal<font style="letter-spacing:-2.65pt;"> </font>holiday<font style="letter-spacing:-0.3pt;"> </font>in<font style="letter-spacing:-0.3pt;"> </font>the<font style="letter-spacing:-0.15pt;"> </font>state<font style="letter-spacing:-0.3pt;"> </font>in<font style="letter-spacing:-0.3pt;"> </font>which<font style="letter-spacing:-0.2pt;"> </font>Executive<font style="letter-spacing:-0.3pt;"> </font>resides,<font style="letter-spacing:-0.3pt;"> </font>then<font style="letter-spacing:-0.3pt;"> </font>the<font style="letter-spacing:-0.15pt;"> </font>revocation<font style="letter-spacing:-0.3pt;"> </font>period<font style="letter-spacing:-0.3pt;"> </font>shall<font style="letter-spacing:-0.15pt;"> </font>not<font style="letter-spacing:-0.15pt;"> </font>expire<font style="letter-spacing:-0.3pt;"> </font>until<font style="letter-spacing:-0.25pt;"> </font>the<font style="letter-spacing:-2.65pt;"> </font>next following day which is not a Saturday, Sunday, or legal holiday.<font style="letter-spacing:0.05pt;"> </font>In the event of a timely<font style="letter-spacing:0.05pt;"> </font><font style="letter-spacing:-0.05pt;">revocation</font><font style="letter-spacing:-0.6pt;"> </font><font style="letter-spacing:-0.05pt;">by</font><font style="letter-spacing:-0.5pt;"> </font><font style="letter-spacing:-0.05pt;">Executive,</font><font style="letter-spacing:-0.6pt;"> </font>this<font style="letter-spacing:-0.4pt;"> </font>General<font style="letter-spacing:-0.45pt;"> </font>Release<font style="letter-spacing:-0.45pt;"> </font>and<font style="letter-spacing:-0.55pt;"> </font>the<font style="letter-spacing:-0.5pt;"> </font>Employment<font style="letter-spacing:-0.55pt;"> </font>Agreement<font style="letter-spacing:-0.5pt;"> </font>will<font style="letter-spacing:-0.7pt;"> </font>be<font style="letter-spacing:-0.45pt;"> </font>deemed<font style="letter-spacing:-0.45pt;"> </font>null<font style="letter-spacing:-2.65pt;"> </font>and void<font style="letter-spacing:-0.05pt;"> </font>and<font style="letter-spacing:-0.15pt;"> </font>the Company<font style="letter-spacing:-0.15pt;"> </font>will<font style="letter-spacing:-0.1pt;"> </font>have<font style="letter-spacing:-0.1pt;"> </font>no obligations<font style="letter-spacing:-0.1pt;"> </font>hereunder;<font style="letter-spacing:-0.1pt;"> </font>and</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0.3pt 0pt 0pt 0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24pt;"></td><td style="font-family:'Times New Roman';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">g.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">that this General Release may not be signed prior to the third calendar day before the last day of</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">the Term of the Employment Agreement.</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">If this General Release is signed prior to the last day of</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-2.6pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">the Term of the Employment Agreement, the Company reserves the right to have Executive ratify</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-2.6pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">the</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">General</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">Release on</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">or</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">after</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">the last day</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">of</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;line-height:1.28;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">the Term.</font></td><td style="width:37.65pt;"></td></tr></table><div style="height:0pt;position:relative;width:100%;"><div style="height:35.94pt;left:10.91%;max-width:89.09%;position:absolute;top:43.84pt;width:91.54pt;z-index:251665408;"><div style="height:35.94pt;left:0pt;padding-bottom:0pt;position:relative;top:0pt;width:91.54pt;"><img src="ganx-20211231xex10d8009.jpg" alt="Graphic" style="height:35.94pt;width:91.54pt;"></div></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:8pt 0pt 0pt 6pt;">Intending<font style="letter-spacing:1.85pt;"> </font>to<font style="letter-spacing:1.85pt;"> </font>be<font style="letter-spacing:1.9pt;"> </font>legally<font style="letter-spacing:1.9pt;"> </font>bound<font style="letter-spacing:1.85pt;"> </font>hereby,<font style="letter-spacing:1.85pt;"> </font>Executive<font style="letter-spacing:1.8pt;"> </font>executed<font style="letter-spacing:1.75pt;"> </font>the<font style="letter-spacing:1.75pt;"> </font>foregoing<font style="letter-spacing:1.9pt;"> </font>General<font style="letter-spacing:1.9pt;"> </font>Release<font style="letter-spacing:1.9pt;"> </font>on<font style="letter-spacing:1.9pt;"> </font>the<font style="letter-spacing:1.9pt;"> </font>date<font style="letter-spacing:-2.6pt;"> </font>indicated below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><font style="font-size:0pt;visibility:hidden;">&#8203;</font></p><div style="position:relative;white-space:nowrap;"><div style="display:inline-block;padding-right:10.01%;vertical-align:top;white-space:normal;width:29.19%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0.34pt 0pt 0pt 0pt;"><font style="font-size:10.5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt 0pt 0pt 6pt;">Matthias<font style="letter-spacing:-0.1pt;"> </font>Alder</p></div><div style="display:inline-block;padding-left:0.52%;padding-right:0.52%;vertical-align:top;white-space:normal;width:6.25%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:15.5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt 0pt 0pt 6pt;">Date:</p></div><div style="display:inline-block;padding-left:0.52%;vertical-align:top;white-space:normal;width:43.5%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0.55pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="height:0pt;position:relative;width:100%;"><div style="left:1.17%;max-width:97.31%;position:absolute;top:17.55pt;width:209.05pt;z-index:251661312;"><div style="left:0pt;padding-bottom:0pt;position:relative;top:0pt;width:209.05pt;"><img src="ganx-20211231xex10d8004.jpg" alt="Graphic" style="width:209.05pt;"></div></div></div><div style="height:0pt;position:relative;width:100%;"><div style="left:55.6%;max-width:0%;position:absolute;top:17.55pt;width:121.05pt;z-index:251663360;"><div style="left:0pt;padding-bottom:0pt;position:relative;top:0pt;width:121.05pt;"><img src="ganx-20211231xex10d8011.jpg" alt="Graphic" style="width:121.05pt;"></div></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;"><font style="font-family:'Lucida Console';">10/8/2021</font><font style="font-family:'Lucida Console';letter-spacing:0.2pt;"> </font><font style="font-family:'Lucida Console';">|</font><font style="font-family:'Lucida Console';letter-spacing:0.25pt;"> </font><font style="font-family:'Lucida Console';">16:06:34</font><font style="font-family:'Lucida Console';letter-spacing:0.2pt;"> </font><font style="font-family:'Lucida Console';">CEST</font></p></div></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:46.8pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:12pt 0.55pt 0pt 0.55pt;"><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">Gain</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.2pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">Therapeutics,</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.15pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">Inc.</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.15pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">-</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.05pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">4800</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.15pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">Hampden</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.15pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">Ln,</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.15pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">St</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.05pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">200, Bethesda,</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.1pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">MD</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:2.65pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">20814</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0.5pt 0.3pt 0pt 0.55pt;"><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">P:</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.25pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">+1</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.2pt;"> </font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';">301-500-1556</font><font style="color:#285362;font-family:'Arial','Helvetica','sans-serif';letter-spacing:1.8pt;"> </font><u style="color:#0562c1;font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-decoration:underline;text-decoration-color:#0562c1;">www.gaintherapeutics.com</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:right;margin:0pt 0.3pt 0pt 0.55pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;">18</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.78%;margin-right:5.56%;margin-top:30pt;page-break-after:avoid;width:83.66%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>ganx-20211231xex23d1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 3/25/2022 06:19:09 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td rowspan="2" style="vertical-align:bottom;width:19.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><font style="color:#808080;font-size:7.5pt;"><img src="ganx-20211231xex23d1001.jpg" alt="Graphic" style="display:inline-block;height:77.75pt;left:0%;padding-bottom:0.25pt;position:relative;top:0pt;width:67.7pt;"></font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="color:#808080;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:25.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="color:#808080;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:54.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">EXHIBIT 23.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="color:#808080;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="display:none;vertical-align:bottom;width:19.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="color:#808080;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:25.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><font style="color:#808080;">Ernst &amp; Young AG</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><font style="color:#808080;">Corso Elvezia 9,</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><font style="color:#808080;">Lugano, 6901, Switzerland</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="color:#808080;font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:54.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><font style="color:#808080;">Phone: +41 58 286 24 24</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><font style="color:#808080;white-space:pre-wrap;">Fax:     +41 58 286 24 00</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><font style="color:#808080;">www.ey.com/ch</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 18pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 18pt 0pt;"><b style="font-weight:bold;">Consent of Independent Registered Public Accounting Firm</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 0pt;">We consent to the incorporation by reference in the Registration Statement (Form S-8 No. 333-255061) pertaining to the 2020 Omnibus Incentive Plan of Gain Therapeutics, Inc. of our report dated March 25, 2022, with respect to the consolidated financial statements of Gain Therapeutics, Inc., included in this Annual Report (Form 10-K) for the year ended December 31, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 18pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">/s/ Ernst &amp; Young AG</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">Lugano, Switzerland</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">March 25, 2022</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>ganx-20211231xex31d1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 3/25/2022 06:19:12 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 31.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="text-decoration:underline;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Management Certification Pursuant to</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Section 302 of the Sarbanes-Oxley Act of 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">I, Eric I Richman, certify that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">1. I have reviewed this Annual Report on Form 10-K, for the fiscal year ended December 31, 2021 of Gain Therapeutics, Inc.;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">4. The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;">(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;">(b) Paragraph omitted in accordance with Exchange Act Rule 13a-14(a);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;">(c) Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;">(d) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">5. The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;">(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;">(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;">March 25, 2022</p></td><td style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Eric I Richman</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;">Date</p></td><td style="vertical-align:bottom;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Eric I. Richman</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Executive Officer</p></td></tr><tr style="height:12pt;"><td style="vertical-align:middle;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">(Principal Executive Officer)</i></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>ganx-20211231xex31d2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 3/25/2022 06:19:15 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 31.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="text-decoration:underline;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Management Certification Pursuant to</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Section 302 of the Sarbanes-Oxley Act of 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">I, Salvatore Calabrese, certify that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">1. I have reviewed this Annual Report on Form 10-K, for the fiscal year ended December 31, 2021 of Gain Therapeutics, Inc.;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">4. The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;">(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;">(b) Paragraph omitted in accordance with Exchange Act Rule 13a-14(a);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;">(c) Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;">(d) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">5. The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;">(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;">(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">0</p></div></div></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;">March 25, 2022</p></td><td style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Salvatore Calabrese</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;">Date</p></td><td style="vertical-align:bottom;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Salvatore Calabrese</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Financial Officer</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">(Principal Financial Officer)</i></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>ganx-20211231xex32d1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 3/25/2022 06:19:19 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.64pt 0pt;"><b style="font-weight:bold;">Exhibit 32.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.64pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.64pt 0pt;"><b style="font-weight:bold;">Certification of CEO and CFO Pursuant to</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.64pt 0pt;"><b style="font-weight:bold;">18 U.S.C. Section 1350,</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.64pt 0pt;"><b style="font-weight:bold;">as Adopted Pursuant to</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Section 906 of the Sarbanes-Oxley Act of 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In connection with the Annual Report on Form 10-K of Gain Therapeutics, Inc. (the &quot;Company&quot;) for the year ended December 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the &quot;Report&quot;), Eric I. Richman, as Chief Executive Officer of the Company, and Salvatore Calabrese as Chief Financial Officer of the Company, each hereby certifies, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">(1)</font></font>The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">(2)</font></font>The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date:&#160;March 25, 2022</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ </p></div></div></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Eric I Richman</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Eric I. Richman</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Executive Officer</p></td></tr><tr style="height:12pt;"><td style="vertical-align:middle;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">(Principal Executive Officer)</i></p></td></tr><tr style="height:12pt;"><td style="vertical-align:middle;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:12pt;"><td style="vertical-align:middle;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Salvatore Calabrese</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Salvatore Calabrese</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Financial Officer</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">(Principal Financial Officer)</i></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>ganx-20211231x10k001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ganx-20211231x10k001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %3 S,# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MLN+W_.M#/U_*C/U_*@+(S_[+B]_SH_LN+W_.M#/U_*C/U_*@+(S_ .RXO?\
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MD?Z0W0D?P&O)\G^\_P#WV?\ &O6/BY_R#--_Z^&_] ->3UK#8B6X9/\ ??\
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MX@UOMK&H#Z7+_P"--_X2'6_^@SJ/_@2_^-4#FFGFHLC1,T#XAUO_ *#.H_\
M@2_^-:NB:WKRWL<O]LZ@&_A_TE_SZU@VML96W,/D'ZUNZ42FH(5XX/\ *KA3
M3>I:.L'B?Q.?^8[J?_@2W^-*/$OB@]-=U/\ \"6_QJNMY.G ;]!4J:G=)]U_
M_'1_A75]7IEDH\1>*CTUO4__  (?_&E_X2#Q9_T&M4_\"'_QIR:[>H!MD_\
M'1_A4@\3:D!@3#'^Z*?U>F!!_P )#XJ'76]4_P# AO\ &FGQ+XH'_,=U/_P)
M;_&IG\0Z@Y^:0?\ ?(J%M5NG!W2?^.C_  H^KTPL-/B?Q,.NO:G_ .!+?XU2
MG\8^*2^(_$&I*H[_ &EN?UJ:3479]AE '=L#_"H#('0%ISNW<C Z?E42PT'H
MB6R,^,/%@_YF34__  );_&D_X3'Q9_T,>J?^!+?XU8"6YDDW77RA<J>.3^5*
MD-F1;[KPC<?WG3Y?TJ/J2)YO(K?\)AXL_P"ACU3_ ,"6I1XO\6G_ )F/5/\
MP):I&LXI[QHEEW0Y^23'/Z59FT*:UCS)&5'TZT+!7V'=%,>+_%I./^$AU7_P
M):G?\)9XL/3Q'JO_ ($M566/:<!0/KUI@0D<@G\:CZM%%%W_ (2[Q9W\2:G_
M .!+4G_"7>*_^AEU/_P):J9C'M^ I1$#1]70%S_A+?%?_0R:G_X$M2'Q;XM[
M>(]3_P# EO\ &JGD^V?PIACYQC%'U9 7!XN\6-Q_PD>J9][EJ0^+_%H_YF/5
M/_ EJ9:6AD?: &)-:3Z%(D32NNV-?O9'Z#WJU@^97%H9_P#PF/BS//B/5!_V
M\M7N7P=U+4-4\*W$VHWT]W*+EE#SR%R!@<9->%O!(' B1E4\ ;>!^->]_":T
M-GX6E1FW.9RS?7 K"OA^2#D--7L=V_W35'3Q_I-Q]15Y_NFJ-A_Q\W'U%<(W
MN:%%%% PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HI"0
MH))  Y)-8]QJ;7(Q;NT=N>DH'SR?[@/;_:/X>M &C<7L%LP1V+2G[L:#<Q_
M54DO[ION110>GG,6;_OE>GYU#;6K\JB^4K<MSEF_WF/)-:*6BQ@!1B@#/,EV
M_P!ZZF^D<:)_/)INRX[7%]G_ *Z)_P#$UKK"H'3-&Q<_=H Q_/O$/%U*,?\
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MNR1H<J$) 7_97U/J:V]4O&EU"2"-&6VMU.V<]/1G]SV%9$Y2*TCN9HHPN?\
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M)<7ES,DCRF""%.7;^(\]AC&3Z5B0^(+32/#7]NL'U5+XIF'RP"4)YSDG&.<
MU<$MV<N(J2C91-S3_$7A?19X=-AU-9II0%>8$LF0.-S=!Z "N<NKO49O'5WH
M]EJ?VC3KU3=%D966'CIOY"C<#V[UQ&E7JZSXBECMK>VM-/FN0SPS$JL4(/\
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ML"A50;5 Q@$5%=+ C*(MS<?,2>]9ION=:2V$:_G\M?F&(SD=.?P[U0!MSO\
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MP_K4^EC$ ]J 'W;,/NMM?M52SU59I7@EVK)G"G.0W_UZT+F,2PLO?L?2N;:
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M##'%)&L>[YVP!UY -:(A_M.U$LJQQ3%B(Y(EZ''>J+0RS?N1;QK<Q)@%6QN
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M%=%(F.67'<]<'TK=G06,8MD.40<-US6/;3X7(VCGIZUJ7.K0R:8T1A^?/7'
MK.-)4JB<(Z,GH9US<%=K;=R@\BK5Y?W&@20W#V,)DDCRBR888]?K61+=;U(4
MJA4=N]6KV]O=?M+2TCMDWPC8CYRS?X5ABXQ]HIMG53Q,XTG2MH07'BFXU>R%
MI+&J+&V\G.<_3T%/T*[L(=31KP@(?E5F'R@GN:SKO0+S18?-NWB.]MI6-L[?
MJ:EM[JR2$B3!8]JYIXEQA[."T.>QO>>-7O-3$6U8M@$7LJGBNVT DZ3:YZ[!
M7 >'PHBOIAPH3 KT#0EVZ7:C_8%7BFG1C;R_(SD=!!6A#VK/@K0A[5Y@T78Z
MF:-98RCC*L,&H8ZDEGCM;=YYFVQH,L:1:,.UL7TV_CMG+/"<F.5NY)R0?>N@
MF$C0LL3A)"N%8C(!^E<EIM[<>(M6COB7BLESY,1X[XR?>NND0R1E [(2,;EZ
MCZ4#,>YGBTB 6T,@-W+RTLG))[L?7Z5R7COQM!X*TM(-/*W&K7@W"5_FP/[[
M?T%:L_AZ;4==O-NLWL<UO'&L9D*NN#DDE< 'I7@OQ#LKC3/&MY:7-U-<E I2
M27J01V X SVK*/M.=\UN7H1>7-Y$NF:9<^*+B?6M<NYW@#[6D+9DF?\ N+G@
M#U/05U=EHDVL(=)T:TCM4."WE?+@>KO]X_G^%9FEQI-X-TN:&>?RXWDCF57&
M$D)STQQD5VO@"XLX[BXLKC4+JWEF(,;"8*&]LXZUA4ESU/9MV1]+@Z,:&">*
MA#FG]]OD6M*^$4-L!-?:S<W$H4X1/N@_5LUCVNE^&(H(K.?5KFUO YB/F1AD
MW;B!R*](OM,U"$&2UOW>%8SF*7 ;/]X-@Y^A%>;>&/A%;ZA<VFO7=].OF2-/
M)&I4EVW'H0HVC\ZU]A&UDCR:F98QR4HSM\D2:WHNI^'P(KLQW-C(<*6&^-O8
MJW0URFH>!;K4+!M7\/:?<#RV_>6\>2,_WHSUX].W:O3/'D]C:Z6VGC4+N:ZD
M(_=FX+; .Y]*X;3=6UO3+:^%OJLEOI<$#2R,1N*MC@ GN3649>SJ\L7H>M5I
M2Q>!=>I!*2Z[71K?#7X@7%]<KX8\1,9BX*02S?>R/X'SU]CUKU&(FVNO[-NC
MYMO,I\AGY) ZH?7':OE;0WNKSQ)8,KN;J6Y4[E.&+$\G-?3>MZ6L5O:R"ZO6
ME%S&%S<L>2<'%=A\XC?M[=;:!(49RB]-[%CCZFN4OC]G^(%NP_Y:VO/X-76P
MPB"%4#R.%[R,6)_$UQ^LMN\?6*C^"V)/XM0,[0=**1?NBB@#+\1J?[%EF RU
MNR3C'^PP8_H#4VG842(#P&X^G:KDT23P20R#*2*58>H(P:Q-$=XX4AE/[R#-
MO)_O)P#^(P?QH UW0&-\@?C6!J,(E6-<?-U<@=A[UT;X*XQQ69/ Y),?$B\#
M/?V- CFS%%+BT4!DE!7:3G=GJ#7F/B.WU;P=?ZBMC9//;SR!TNF9W,+=PP'4
MG.!]*]DACM-+EE:Y3]\"65@O4'ICL/2J0UN1'G>*T0^8^_+C)Y[''M33L3*"
MDK,PHY[BQ\+RWZH5\RV2:1&3[LA7G(ZCGKWS7DT>V"^%_</;W4<,ZQM&\Q>;
M=]_)![>]>]>)-+M9]#E9PZ>>FPJI^Z6[C-<!IWPKBU"]DN%UF:-,HS!;<9)'
M'<XZ5;G<Y(8>4;W.2U[4+K7=12\LEF>0.,C?NP">, =<CCGIFO1_"_@NR9UU
M*;3?[/@<KY%@LY8<<Y;L>><=!5W2O!&E^'+F)H@+F6)6$3R$DKN[GMG^5=5;
MA)W82/B51PAX+<?R^E2Y7-H4K;F5>V=O%?B*)I @7<%SD*<],FMW3%9K7<5&
MW.0*S+FW99EF 4>8<;0.,@\ YK8L6V1E,8'4#TJ3=%M1@FJ^IW2V6EW=TQPL
M,+N3] 35KI7->,YO,TZWTI3\]_,$8#J(U^9S^0Q^- SGO#.FZG!I4&+:-B4!
M)+D<GD]O>NBC&J1C_CQC/_;4_P"%;6G0^3:(,8)&:MGI0*R,Z*4" 2RX0!=S
M9/"\9/-9-LKZ_J0NG!%G"<0J>_\ M'W-0:K)/>W-OID(*P/\TS_WL?P_3UKI
M[2W2UMTB08 % (\E^.^IWFA6/AW4--G:WNK>]9HW4 X/EGUZCVK.\._&[P]K
M5G#!XQLA!=PD$3I$9(G/3.!RI]N14W[1W_(OZ+_U]O\ ^@&OG7ITK6,4T)NS
M/K6]^(_PUOK-4N]9L)H5P50Q/D?0!<BN(\3?'32-+L&L/!=B&E88^U2Q;(T]
MPIY8_7'XUX 313]F@YBU>:E=ZA>37EW,9[F9B\DK@%F)[FH/-;T7_OD4SM16
MA-D;.B^)+S1Y<*0]LQR\1 P?<>AKUGX?^(8&\5Z;=03*8I9/)DR,$;AC!].<
M5X;5K3M1N=+O$N;64QR(P;CH<'-#VL8SHQ<N=;GW;4%[,;>QGF6)I3'&S!%Z
MM@=!63X/\01>*?"FGZO%P9XAO7.=KCAA^8K1U2&YGTRYALY?*N7B98Y/[K8X
M-<IU'A2W0G22%I-_!>&,IGYCG@_2K5VCK%;7"+Y4@"HZCG<>F">U1ZE97>EW
MTUMJ&(+C*2X#!SSQG(_$T\N2\BVESY]S(5.XG' Z@]JUB['-6I<Z+"7=S+?K
M \ 2-3N= P"CWS5*:2:?5$G6!FC)V+@_>'H:DN+B:]C2%EBC5WP/FR0P]O2I
M%E=;ME>.*1PH "G S[4Y.Y%*BJ7D/#)#.A*R0,-S$OR"?2I&81VHD8E&D&YB
M#]\^GM44LJM&S- 5?RN'!SWZF@(8V6$.KQR8 (Y*^HI%LD#>;^XN)P\:+N(Z
M$_C4>%E(DB#NH7$B[N2O:B=8HF8"V C1@&..<=\5)##$'$L,+^6P.T+D=._O
M3)225D:6@QZFMXC6T<DB+A0PQA >S5Z":YCPKJR7"+:+$JG!8L/O9]6KIB3F
MH8Q#7E?Q<ORLVG6*$=&E8$9]A_6O5'(522< =37SSXRU;^V?%-Y<*^Z%&\J(
M]MH_Q.35PW)9GQW;0I;N)8 RECY<D096Z=:2,R/N)N8\YSPO!Z]?\]Z?:WSV
M2Q.LD(R'!22/<&!QD?C3UO/,=F,D(&[.T(<#D_Y_&O5H_"CR,1=-V_K\"2%W
MP!)+" #NW"/YON@8SZ5K6T,^IW+_ &>)6D";BL28PHZGZ]ZIK?LUF+9/*"D[
MBWE<L<# )]JDL[JX@F+6]R8W((9TXX/6NI+L<,]=QZHZPM</(L>050NIQD?P
M\=ZV](U:ZT?1[[2WCB;[1U<\E<_A6'+//#?0(EQ;I%%P)(B"Q##GKUXXJP;B
M'(".F%&-VY<M[GGK5:2T>QG*\5>)=MY/LP41[N!PH /'KS5W3S#%?6SXNY(H
M^7>27 4'@C&<XSCFE\/VFE7]Q>1ZI<*%BB#H=X(8]NGIZ54TF5[B[DD:*U,1
MF($S1X)4\8 ':G*5[I&'LW!<S9D7MRGVV?RBS1>8VT^8>1FJGVH>8"49@.WF
M&EN8FM+J:WDVYC<H?E)Z5"8]P^7:QQDX4\5K=V.A02"]N'EN6:W$D<9Z+FJX
MNKR.)XUD)5Q@[N?R-*K1*X):(?[RFH+J1)IV<2!5)R 5)Q6,C>$%M8DAO;VT
MGWJ#. .49CM/ZU9MM->V/VBX55FE&Y5'1 :DTS2+=[5[V23S&4_(N-H_(]:L
MRN6 !8D+P,]JY:D[Z'?AZ:3YD0N6 X8#\:@<O_?'YU*VW!^8#BJY3()WH/J<
M5D=B0VX\R(*3+G<,C:<U6EF:1%61F.T';\O-3/"1R2@R,C+8S3/*#1M^\B!4
M9^_U]J5F:*Q096/8U%+&T1&]""1D9]*M/O*X#*./[PIOV>6:!Y7G!\M> #N_
M_54V-5*VYG-UR?U%7=&=X]15XR4(!PR\'IZU29B0?F/YU;TF5C>A"V5P3@_2
MKIOWT:6.A+<\DD^M&[;@CK3<BM+2M0T^Q7-UID=W() P9VXV^F*[YS<5HKE#
M9=,>+2(=1:>,+*Y41$$-]1ZBJ(/&:M7I^VPF[BE1560J+,,285/(QGJ/I3]*
M>*ROO-U"WW(L9=8Y4R'.../3WK&&(M%N6_;] L43( <4J_.0!WIKXGN"0H0,
MWW5&=N3T%7[NWM=/*&&Y>:X5AF)HL!1WR2>OMBKG5<4^XN:*FHLJNC0R%6X9
M3SS6G875K:V%S/-+&TSCRHX7CR,GN#ZBLZ:TN/M)509B!OS"-XQUSQ5F>>-8
M(;>&4O&5#L=NW+'K]<>M9SFZB4(O5EVCJQ[6-]8QQ7+#:CMM1TE!YQ['-=%_
MPCEJFC0W+)+]HDW1RB4_<?&1@"N/W' !)P#P.U=WX=U%]7LI[*2(KE%$<G\)
MD7I]#P.*NK*<8IWVW(*5Y9--X9MO,VO+$OEEU';J/Z_E7'8P<>E=[#<1Q1SP
MW)V1.I)&,E?7CV-<GK%C]FN$FART,X!4^]*E*UTP,_EF"KU_E3R_E#94D:!%
MY')ZGUJ.11(,=#V-:2[HM(DBN%VD,20.<#K6WHND)JJO)-,0I.U0#S7*2QRQ
MG(4D#N*DL=<O=,+&!@03RK@GFN:I5DE9:!H=?/9^'M"1SJAFE<Y,<>,Y_+^M
M<M9:DLUV(()#")9,1[S]WGC)%4KZ[O\ 5[HS3%G<C'(PB_A4MA;_ &*03;]\
MRG(8C@?05SJE.KN%S>UC2+VS1C<S_:H-P'F!B1DU9\#RV%EKA%U%&ZRKM5I5
M!VGVJKJ'B&XO]/2S:-$B!R<=2:BT-T35899(RT:')XK=TKT6IK5"ZG7:CI<=
MK]H2Q1C#<2ACA<!!W_"NCT&WO+S3!-;Q1LJN4 +$'';M4^FZC:26[EXP4 Y)
M["MWPE (=,E<-D2REU3^XIZ#\N:\Z=9SIVET!Q5RFL&J1C/V*,_]M#_A4EI=
M:C+*R'3T 0C)\T_X5TS_ '36?9?ZZZ_"N0+)$@940NY"JHR2>PK&_>>(;P8#
M+81'@?\ /0^I_I1<K/J]V+.,%;13EV_OG_"NAMK>.VA6.-0 !0-&!HL2VC/;
M@8\F=X\>Q.1_.ND!Z5@W,9M?$#'I'=1A@?\ ;7K^8K88-<6C+'*8G9<*Z@$J
M?6@9FZANT[5$U0 FW=/*N<<[1GA_P[^U<;\4?A\_BRTCU32MIU*!,!<\3IUQ
MGU]*[BUOV#BQU)5CN3P&Q\DP]5]_5>M(MC<:>2=/*O;YS]ED. /]QNWT/'TH
M ^5M*UC4?"M_<6TUN2C'9=65PI ;'J.H([$5UEOJV@ZDH-OJ(LI3_P N]_\
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M>K?H/:MZQTN&RC4*HX&!@8 H J:)HD6G6Z@+SU.3DDGJ2>Y/K6U110 4444
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MZ6RAASZXJH5^:2BEN58\ ^UV0ZI,?^!+3DN]*'WX+D_1U_PKIOL=K_S[0_\
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MV'_?A:/^$8T'_H"V'_?A:7]H?W0YCP1F%1LV.!BOH#_A%] _Z FG_P#@.O\
MA1_PBWA__H":?_X#K_A4O'+L+F/GII,>M,,N*^B/^$5\/'KH>G'_ +=U_P *
M7_A%/#W_ $ ]._\  =?\*EXSR"Y\YF4'O49D]Q^=?2'_  B?AT]="T[_ ,!E
M_P *7_A$_#I'.A:;C_KV7_"E];\@N?-GV@)SNI&OSP=^".F*^E/^$2\.'_F
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M!). .37(QZY?N(K/S<W=L\INCM&61.1QVSQ3=,NM:NEMKHI>O#.C-/YQB\H
M@X*!3N&* .LM[B&Z@6:"19(F^ZR]#4M<9I4UU<V^E:7%=R6D;P22N\0&]L,1
M@$@XI4U+4Y5M;,:@4?[<]LUP$7<Z@9],9H [*BN-EU'4[>.YLH[]V>&]CA2X
M=%+;6Z@\8)%$[ZK#_:R#6+@K8!9(B43<Y(SACCD>PQ0!V5%<=<:GJM_>RQ6R
MWH,-O&Z"U\H NPSEMYR1["IGFU>\O9;>6^DLC%9+,Z0JI/F?4@\>U '59&<9
M&?2EKC+7[3J6M:-=R7LR226C,PC"XR#SU'>NSH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH HW?\ Q^P?[IJZO052N_\ C]@_W35U>@H$
MCF_&O_(*A_Z[#^1KA:[KQK_R"H?^NP_D:X6NBG\)X^-_BL****T.0*W- TK[
M0XNYU_=(?D4_Q'_ 52TK3FU&ZV\B)>7;V]/K7;1QI%&J(H55& !V%93E;1';
MA*',^>6PM+169XCO;K3M!NKJS3=.BC'RYVC/)Q[5B>HW97-2BN4L]0G_ + O
MK^WU[[>4MBP#1*K0R8]NWL:;H.IS7MN)V\1K=3BW:22S$2 H<=R.>#BJ<6KF
M:JIV7?T.NI:XSPOJMQJC6KW'B17N&)+V/DH"0.V<9Z<UTFL6^H2VH:QOS9-'
MEF/E!]XQTYZ4.-G9CA4YH\R1H4N*XG1]9U*#18]>U2_ENK1B4>".!04YP&)X
MX%;,U_\ V_#>6FE.X,)4-/G".3SM!]<4.+0HU4U<WL4M4M*MKBTT^.&YD\R4
M9YSG ],U>J6:)W0E+12T#"BEHH *6BEH&>=>/O\ D,V__7#_ -F-<I75^/O^
M0U;_ /7#_P!F-<I7T.%_@Q/E\;_O$O4****Z#E'1QO-*L<:EG8X51U)KTO0-
M%32+/# -<R#,C>GL/:LWPIH/V2(7]TG[]Q^[4_P#U^IKJ:\;&XGG?LX['NX#
M"<B]I/=[!2@$]J*X[Q3))!K-M)J OO[&\LAC:.5VOZMCFN!*[L>C.7*KG8@'
ML*7!]#7":S=0>9H,<-]J$]A(KY:WD8RR#\.212ZU)';:1I?V:;54MY;OYQ([
MB<C'(]?H*KD,W6W\CN\$=12A3Z&L+1Y]-LK)I1<W<,<DF!_:<A5L@=M_:L7Q
M18^7=65U;:G?!;VY5&$=R=@4C^'%)1N[%.I:/,=OBD,B*ZHSJ&;HI8 GZ"N5
MN-9'A.9M.GBGGA,9DMII)2[ROG[AXXJ^^B2ZE<VVH7,GD2E%,D*Y;:?0&CEZ
M]!\]]%N;U+1UI:DT"BEHH *6BEH *P/&O_(I7_\ NC^=;]8/C7_D4K__ '1_
M.M*/\2/JAGBU36MW<V,XGM9Y()5Z/&Q4U#17T=KFA:O=2OM2D$E[=S7#*, R
M.3CZ55HK7\/:%-KNHB%<K GS2R?W1Z?4U#<:<;O1(1J>#O#1U2Y%[=)_H<3<
M _\ +1O3Z5Z@!@8 P*CMK:&SMH[>! D4:[54=A4M>%B*[K3N]C-NX4N#CH:C
MG\S[/)Y./,VG9GU[5Q7AR>W744AU*XU&#6@S;DFE;RYO8#IBL4KF<I\K2[G=
M;3Z&EP?0UY_H#PWE](+N;6GG^ULJ-$[F$#/ 8C@402PW/B#4H[V;66*W.V(6
MC.44>^.!5<A'MM+V/0 /2EVGT-9]R;'48I--74 LI&TB"<"48_6N3T?3IY-2
MU;9?7\SV$H\B-[I@K\9PWK22N7*;35E<[VD1TD!,;JX!P2K US6F^(V\0RK8
MPVIC)B;[6Q8_N#TP..36IHVC#25E'G&0O[8 H<;;CC/F^'8U**6BI+"EHI:
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M **** "BBB@ HHHH **** *-W_Q^P?[IJZO052N_^/V#_=-75Z"@2.;\:_\
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M[6!02?-U$I:*6D4%%+10,*6BEH 2L'QK_P BC?\ ^Z/YUT&*Y_QM_P BC?\
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M&DZ?#/%!*9FG=9+R9DC4!CUQU/H*[+[/#L5/)CV*<JNP8!]AVIS0QR !XT8
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MY_J1_O52IWTL1R)2<NK"BEI<4#$I<4M+0,3%4-;O)=/T:YNH AEC4%=XR,Y
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MK35KF86DL]I''!=,40K*68'G!(QC!Q6Q5&/2TCM[.$2L1:OO4X'S=>OYU?H
M*7%%+2 ,4N**6@88J1.E,IZ=* !_NFJ.G_\ 'S<?45>?[IJCI_\ Q\W'U% G
MN:%%%% PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH HW?_'[!_NFKJ]!5*[_X_8/]TU=7
MH*!(AN_]2/K5+%7;K_5#ZU4IB8F*7%+10 4M%+0 E+12T %&*6B@88I:*6@
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M^Z:HZ?\ \?-Q]15Y_NFJ.G_\?-Q]10)[FA1110,**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** *-W_ ,?L'^Z:NKT%4;O_ (_8/]TU>7H*!(1D#C##(IOD1_W?UI[MM1FP
M3@9P.]4$U3S(8V%M(LC[L(Y"X ZDD]!0,N>1'_=_6CR8_3]:@-^BRP1LC9E&
M2000OIDCUJ'^UX=V#'(,QLX/&#@D8^O!H N^2GI^M+Y*>GZU#-?0P/&LC!!(
MA8%B .,<?K3%U&-I+=0C_OD#@]ER,@'W//Y4 6?*3T_6CRD]/UJM#J"RV<MS
MY9"("<;@2<=CZ'VJ/^UHQ"7:)PP<*R@@XXSG([ <T 7?*3TH\M/2JLNH-%-*
MC6[;8XS(7#CE?\BFKJL9: .A FSAE8,!C'4CUSB@"[Y:^E'EKZ5174RS#%L^
MPQ>;NW#[OTH34S)'$T=N7,F2 LBG@#/7UYZ4 7MB^E&Q?2JLFI0I';2;6*3M
M@''W?K4<NK1QO*HC8^6ZIN+!02?<^F* +^T>E&T>E47U%D<JULVT1^:6#J1B
ME.J0LVV$>:Y"[0C#DMGC/;I0!=VBC JC_:1+"-;:0RY8,FX<8 /7OU%']JHR
M&6.%WA7&]^!MS[=\=Z +V!1@55:^7RP4C9G:0QJF0,D9SSZ<5'_:8/RK"WFK
MG>K,%"8]3T[B@"_BBJB7Z/<BW\MA*><<<+C.[Z=J1=0#:@UKL^[U;=TXXR/0
M]* ++1HYRPR:3R(_[OZU'-=I#<10LK$R?Q#HOIGZGBHVU!?*1DC9G=F55R!T
MSDD]AQ0!8\F/^[^M'DQ^GZU5.H' "6[.P3>X5UPH^O?I3!J\32E1&Q4#(8$<
M_+NZ=1Q0!=\E/3]:7R4]/UJDVIE"Y:W8(D8D+;QT-$FKV\9.W,BAU4LA! SW
M_#% %WRD]/UH\I/3]:ACO8Y+N:!5;,2@ENQ]J@;5HTA,CQ./E# #G()Q0!=\
MI/2CRT]*IRZI'$7Q&S;<X((P<8_QH74_-^6*W=Y!G<NX<8]^] %WRU]*/+7T
MJE+JB*B/'&75DWGG!&3@#\_Y4L6I>>P6&W=W&=XW ;><=>] %S8OI1L7TJO!
M=O,\RM;LGE'!)8')ZU%_:T))&Q_]5YG_ -;ZT 7MHHVBJ::AND7,+B)G\L29
M'WNG3TSQ2W%^+:;;)"VTJ2K @YQ[4 6]HHP*I#41PKP2*_F"-AD$+GH<T\7R
M_:I(63;L4MNW \>^.E %K HP*SEU8 !I(&5.A8$'!(R!CZ8IPU3,$DHMV/EX
M+ .O"D9!_P#K4 :&*1E#C!'%4DU)9)S&D3'.0IW 9(&<8[4AU(B S&W;:KE'
M^8<'V]: +?D1_P!W]:/(C_N_K4=S=I;-&&5CO../X1ZGVJ.6^:&5XV@;*H74
M[A\P'\J +'DQ^GZT>3'Z?K3T8.BLO1AD4M $?DIZ?K2^4GI^M/HH 9Y2>GZT
M>4GI^M/HH 9Y:>E+Y:^E.HH ;Y:^E&Q?2G44 -V+Z4;!Z4ZB@!-HHVBEHH 3
M:*,"EHH 3 I<"BB@ HHHH :_W35&P_X^;CZBKS_=-4=/_P"/FX^HH$]S0HHH
MH&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% %"[_X_8/]TU>7H*S[Z18[R L<<&K NX@!
M\PH$6:KW-H+AE<.R.H(#  Y!Z@@]12_:X_[PH^U1_P!X4#*RZ/;*@&7+*%"O
MGE=O(QVZTKZ3;R0O$S289<9!&1R3D>_-3_:XO[PH^UQ?WA0(5[6.22-VSE$*
M >QQ_A5<:3;@ Y?>NW:^>5V],?Y[FI_M<7]X4OVN/^\* T(UL%VW >1G:<;7
M; ''/H.O/6D?3+60(K1C8BE0@X'/4\=ZE^UQ?WA1]KB_O"@9']@C\ME+R'="
M(221G'K]:0Z=&\>R61Y/D*= .#CT'7BI?M<7]X4?:XO[PH$,2PB1%4.YVP^3
MDD=/7ZU&-.PL0%S*#$"%8*H.",8Z5/\ :XO[PH^UQ?WA0 Q]/@>&.([@D8(
M!ZY&/ZU'_940156212NW#<$Y7)R<CODYJ?[7%_>%'VN+^\*!C7LDDW%W<EHC
M$3P.#W^M,?3HF8.KNC@+M9<<;<X[>]2_:XO[PH^UQ?WA0!!_9HRKBXE63+%G
M&,MD 'MQT%']EQ*"B22+"V-\8QAL>_7ZU/\ :XO[PH^UQ?WA0(A_LX DK<2
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M_GBOZU9HH"Q6_L^U_P">*_K1_9]K_P \5_6K-% 6*W]GVO\ SQ7]:/[/M?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
#'__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>ganx-20211231x10k002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ganx-20211231x10k002.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %; R4# 2(  A$! Q$!_\0
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M#.I1SB$K#O-L+K_6@?(?KW]JS5-"P])[#Y8GJ@^*5F?^89<_]_%IX^)UF?\
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M8DTEM=2L@ )Q6E!*BJ?,3=D=^U<)YAC([V[U8>_9^"35AX5E?.*IW,*Q-D4
M6+9&D;..*O/(L:X-5M/OUMU.54Y&.:BGE\]_EH M-<1[.U5X)(GN '.%SUJ$
MVSA,TVWC!DP30!IR7*6SDP-T[U6%VT\G)R33Y[?$>1TK,^>&3<,\4 :EQ9G8
M"PQFJ\442GG%/%Y-=*%9LX&!6SX=\-6NLW9BNK^6!QR(E0?./8T-V!'9^ ;B
M272)8VR8HY,1D_RKK:JZ?I]MI=E':6D>R)!P.I/N:M5F:!7,_$+_ )$+6/\
MKA_45TU<S\0O^1"UC_KA_44UN*6S/EP=*[7X;:?'-XADU*Y=(K738C.\L@^5
M6Z+G\:XH=*L17-Q#%)#%/+'%+@2(CD*_U Z_C6QQ+<]7U2TBUCPUIE]!JMOJ
MESIM^JRS0!ON.X(!W#/%7-85'_X359#B,R6X8^@XS7D$%Y=VT;QP7,\228WK
M'(5#8Z9 /-2MJ%]*)A)>7+B;'F[I6/F8Z;N>?QJ>7^ON*]IU_KJ>RM'=)XB?
M1?[.B7PNM@6S]G7R\;<[]^.N?>LJP$UYX(:TT])=->VMFED$UDK0W:YR&$A'
M!KS;^VM5:P%@=1NS9CCR#,VS\LTX:OJ?]G_8/[0NOL?_ #P\UMGY9Q3Y0]HC
MUNXENM8N?",5_"DFESPH\S^0NPR@'"[L<?2J?B"Z@G@%K=VE_-/%J$8AFFTU
M8$A7=@H&'4&O,/[3U V4=F;VY^RQMN2'S3M4^H':I[G7-6OHXX[O4[R=(R"B
MR3,P4CH1SUHY=1.II8]/>^:Y^*,6CM;6JV-N79(U@498IR3QS5&%-4L?"%A)
MX;L5GDN9Y1>%;=92<' 5LC@8KSD7UX+LW?VNX^TG_EMYK;_^^LYJ:UU;4K**
M6*UO[J".7_6+'*RAOKBCET%[74Z3X=!O^$YMPR?-MERH_P!WI72:A;I)X+D4
MZ5-HJ0ZBC""1BPN26'/S#->96]Q/:S":WFEAE'22-RK#\1S4]QJ%]>LK7=Y<
MW#+]TRRLY'TR:;5W<A3M%H]6O#%I]_XLNHK2V9[>"W>(20AE5L=<4RV2'5->
MT#4+BV@>]GTQY@HC 624?=XZ5Y<U_>R>:7O+AO. $NZ5CO Z;N>?QI4O;M7A
M<74X:#B(^8?W?^[Z?A0HC=77;^KGJ%U+JEWX7TY]9LU@N'U>,%?)$>]><$K2
M7DXTJ'Q7>6UM;&:"]3RC)"&"' Y KS>;5=1NGW3W]U*VX/EYF/S#H>O6FM>W
M<BRK)=3NLIW2!I&(<^K<\GZT<O\ 7W?Y ZJ_KY_YGJBVBWGB5;R.&*.[FT=9
MA(L0;9*>-P3N?I7+>.KR:2XL;25)"UO!^\F>V\GSG/5@, XK-T/Q++ICW N8
MY;M)X!!GSRDD:@]$;G'TI-=\0'68;.W2!XK>T4K'YLQED;/4LQZT<NO]>8G4
M3@^__#'6Z+9R>(-.M-*US1)TCBMR;74D! 1,9&X]"*DTDBP@\(M"(MTES-$\
MFP?.N['6N"35=12R-FM_="U/'DB5MN/I40N;C9$GGR[(CF-=YPA]0.WX4^74
MCVB2VU/4+59Y=9\0W=[%)'>VX"VK1VBNZQ;C\RH>&/O7*>,+B"YO+26.WN(Y
MC !-)/;B$RD'[VT5B?VOJ37BW9O[HW*KM$OFG<!Z9]*9<WEU?3>==W$L\F,;
MY7+''XT1C:P3JJ2:(A3Q3!3Q6ASCA3Q3!3Q0(<*<*:*>*!#A3A313Q0(>M2"
MHUJ04 2+4BU&M2+0,D%/%,%/% R5:D%1K4@H&/6I5J):E6D,D%2+48J1:!G5
M>#_O77T7^M=37+>#_O77T7^M=37/4^(]/#_PT%%%%0;A1110!SGB/P?H/B2Z
M@GU?3TNI(4*(S.RX!.<<$5CCX6^"_P#H!Q?]_9/_ (JNTG^^OTJ(5:DTM&,Y
M$?"_P:.FAQ?]_9/_ (JG?\*R\'#_ )@D?_?V3_XJNMK,UC7]-T*))-0N!&7^
MXB@LS?0"G%S;LKC2;=D8X^&G@\=-%C_[^R?_ !5.'PV\(_\ 0&C_ ._K_P#Q
M5:.A^*='\0ETTZ[#RQC+Q.I1P/7![5IW-S%9VLMS.VV*)2S'&< 4.4XNS;!W
M3LSG!\./"0_Y@T?_ ']?_P"*IP^'7A,=-'C_ ._K_P"-:T6K&6VDG.G7L810
MRK(B@N#Z<X_ U9AO[6>[FM8Y5,T.-Z9Y&1G\:.>?<5S"'P\\*C_F$1_]_'_Q
MIP^'WA8?\PE/^_C_ .-=%'-%,6$4L;E3AMC X/OCI3MZ -EE^7KST^M+VD^X
M79SG_" ^%Q_S"D_[^/\ XTX> _#(_P"84G_?Q_\ &M?4=0CTZSDN74R; #L5
M@"<D#^M64ECE#>7(C[3AMK X/H:?M)]V%V8(\"^&O^@6G_?Q_P#&G#P/X;'_
M ##$_P"_C_XUN1W$,JLT<T;JIPQ5P0#[TANK=8V=KB((IVLQ<  ^A/K1[2?=
MA=F*/!/AW_H&)_W\?_&G?\(7X>'_ ##4_P"_C?XUN@@C<""",@@\4U9XGD\M
M)8V<#)4,"<>N*/:S[L+LQO\ A#?#_P#T#D_[[;_&G#PAH(Z:>O\ WVW^-:HN
MK<^8!/$3&,N X)7Z^E,LM0M;^V2XMIE>-^ <X/Y4>UJ?S,.9F</"6ACI8+_W
MVW^-/'A71!_RXK_WVW^-:ID09)=1@X.2.*9]LMOD_P!)A_>?<_>#YOISS2]K
M/^9AS/N9X\,:,.EDO_?;?XTH\-Z0.EFO_?;?XU:@OUGU"ZLQ&P:W"$L3P=V?
M\*B35E>:XC6WE8P3+"=N#G(!SUZ4>TGW878T>'M+'2T'_?3?XU(NBZ<IXM@/
M^!'_ !JU]I@$IB,\0D'\&\9_*G)/$\C(DL;.OWE# D?44N>7<+LKC2[->D(_
M[Z-/&GVHZ1?J:F$L;/L$B%L9VAAG%0SWL<#HG#LSA"%897/K2YGW"YSWB!8X
M[J&&-< +N/-58%Z5-K;;M8<>B@4VW'2NM? C5;&A;KTK4@3I5"W'2M*,-Y3;
M/OXX^M839#*NM>'M.\06J0:A"75&W*RMM93[&N.\8?#R6]LK0:'.ELML"&BD
MR0P/4_6NCMM9;3KN1-9F6U0CY#,XP3[&MJ>\MH[,W#7,20E<K*SC;[<UER_:
ML+GDX\M]"EH-I''X<M;.1Q<*D0C<N,AO7(KE1XJLO#?BT^'H;$16SL,;!M"D
M]P,=*SO#.C>*H=?N]06XCDLFWLD@ER)L] !VJK8ZQXHLCJ5UJ>C-<W*G9$LR
M R $\E<#D8]*"36MM"\(>+=<OI)K2"66)_F 4Q$^YP1FCQ#X:\/W^GOH5E:6
MUFD:>8MW$@Q$P_O-Z>N:N^%_#VG-I-PPTN;3KBY4M+(68,"?3T^E>?>)=/D\
M(:*5ANVU"*]=HI!*F%7N#QWJX.3:29I!R<DDS@;B%K"[EM_.AG\MMOF0MN1O
M<&K=J#(A=B,#WJIM#1>]+#')G SBO8C='JQNCI]#N5\YX&Y4#</:M=SN;Y>E
M<QIG[EF!SYA[^U=/IUQ $;S@2<<5YU?^(]+'EXM?O7H3IM5.>M4+D>8]+<W0
M\S"GBK5DJ3N YP/6L3F*(MB$R*@20Q2\UORQQQDJ#D>M8=XH,GRT 7C<B2+
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M0.\JX.WZ^E)9WMO?VL=S;2!XG4,#[>_I1=AR1[&?_P (KH/_ $"+/_OW2_\
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MF9"!NQW'/2I!<0>1Y_G1^3C/F;QMQ]>E%V/DCV*?]@Z5_P ^$'_?-*-"TO\
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M" '"^QK9T6!DT5IK@,)KK=/+M^\-W.!]!6C>6L5[:O;S@F)\;@#C/.:E "@
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MSQCO]37616T$5J+:.)5@5-@C X"^E5K71K&T2!(HWVP.7BWR,VPD8XR>F.U
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M04(0,@@]>U;2:39)Y1\IF:)616>1F.&Z\D\YI\>FV<2VH2$ 6O\ J>3\G&*
M+=+WI*7O0 4444 9>O6QGTXNHRT1W#Z=ZYJ!^E=PRAU*L,@C!%<7?6K:??/%
MSL/*'VKHHRNN4T@^A?@DZ5?MQ&K[PBACU8#FL6&3WK1AE]Z<XC:-H$2Q-&>C
M#%>+RVT'@[QFMUJMZ)XHI6DB%NA>5\]FSP/SKU>6\6WM)96D5 B%MS' '%?/
MMWJ,%[,9B&DF:1F<GD'GK64(-S4;-IFV&PRJW;=K?B>UZ?XW\,^*(Y+&8^6)
M%PT-X@4,/KG%<QK6A^$M06&RT;Q%9:<5E^>)&!1@>,?6O+KB5?3 ]*B65%0X
MQ7=+!1OHS9X.%]&=[K'@SQ'H,S6F@F:\TR:/=YC., ]Q[5T'@O4M8T?PS,^I
M6\UO#&_RF<$X'<C/:O)X[Z\OA%;2WD[PQ<1QM(=J_05T/A[7[G1K](&E::RF
M81SVSG<C \=#6?U-J#=S)X-VNF=3XK^(QAM$ETNZ#S2YC4@8V?[6.AKS/RY+
MR1[J=B[N=S.1U-=A\1=%LX+"&YLEM[<0R%?(CQD@]#ZUPD%Q.(_+!.WTK3")
M)7L:85)1V.NT:2.>%X7"AHQQ@=12W>(V^6LO1)"DLBG.]AQ]*U9(BYY-<U>*
M4VD<>)BHU'9%59_F&16S#J2I:^4 N/6LP6/>E-LW05D<^Y::Z+' -.,+2)D"
MJ7E/&V2#6C!.5CP10!GF-XW.*<)F+8:K^Y'/O51XX_.^<D+ZB@!945DR!S4E
MH^TX(HMS&SE0<KVS5Q(Q'('3&?>@"*>)9^@YJJMJ4;K5J5BC%CU/I40+R<C-
M #FB(7@U4WM#,&89P>E78V*N >:?<6W(WKC/- "#4%?HH4'L*V[#Q!J\,2B.
M\D,*# 1@"N/2N6G@*8V9)[ 5+:7-Z3]ECAG9B?\ 5A#G- 'KVBZJ-5LO-*A9
M%.UP.F:TQ7/^%-+N--TLF[&V>9MY3/W?:N@%2 E HH%(!:44E9?B'4'TS1Y)
MX^&+! WIGO0E<3?*FV:F1G&>?2EKS?6+FWCT]+FUFDCNE&XRAN<_6NQ\+ZI+
MK/ANQOYU EECRV.A/3-7*'*8T,0JU[*QJO+'%CS)$3/3<P'\Z<K*ZAE8,IZ$
M'(-<UKL$ESXBTV..SMKMO(E/EW)^7J.>AJ>X:^34;73;66*P0VK2,L48;:P/
M1<CI^%0=%C?/2BN5L=4U,II=W<72R)=LZ/"L04# )!!ZYXI=)U/5[Z6TN1'<
MO#,Y\U6A41(G."K9SD<=>M 6.II&=$QN95R<#)QD^E<FFIZD-&COYK[F><0A
M4A!\M=Q&0.I; J1+F],5M)<N9XWU%4A:> *WEX/S8QP?>@+'545RRZCJ?E_;
MC> QK?\ V?R!$,%-VWD]<TB:EJ-YJGEV]U*,7C1O$D ,:Q+GYMY'7\:%J%CJ
MZ!6#XBBN)+G2!#=O!FZV_*@/.UN>?Y55OM6NK>_!MKJYFC2Y2"1?LZB$9.""
MW7/TH&=2*.]<O/J.I)#J]X+L!+69H881$".H&3W)&>!4+ZKJ5K9WMRMQ<7$(
M:**W>6W"G<Q 8@8&<9^E 6.N%)O3?LWKO(SMSSCUQ7'ZC)JLNBZ@DSW<<*^6
MT<L\2([$L R\<8Z'-6[^YN=/O)!YB2S1:7)*)GB4,6#<=.WM2"QTXH-<Q_:6
MI6$RF>[2X$VGR7(5HPBQNH' QVY[U)H5UJ%Y?!Y+JXFM!;JS^;;B,"4]5' .
M *8'1TM<QXAU6XM)+EK*YN3);1B1XHK=6C7O\['GD>G2G75WJ5Q>:DMO?K;1
MVENDRJ(@Q+%2>2?X>*5QV.EI37+0ZAJ6JW 6&]6S3^SXKH@1!CO;/KVXHT_5
M-1U>YTY5N!;1RV(N9=D8)9M^,#/0&F(ZBEKDH=4U-M.L]:-V#'<72QFS\L;0
MC/M !Z[AUJ3^V+G^V;4P7-Q/:37AMVW6ZK#T;A6ZD@KUZ'FD,ZAF5%+,0%49
M)/841NDL:R1L&1@&5E.00>]<U9SWVIZ+/J<M[B&6.<"U$:[54;E W=<\9-1Z
M)/?V9T&"6[$UO>6A_=^6%$>U%(P>O0X.: .JI169)>3+XEMK(,/(DM9)2,<[
M@R@<_0FL:TU34]072(DNUA:[^T^;(L8)PC?+CL#B@#J7FBCDC1Y%5Y"0BD\L
M<9XJ2N.BO;BYNM%>Z82S07MS$SA<;]BL <=B0*EMM3U/[#IFK27BO'>SK&UJ
M(P%56) VGKD?XT#.J9E12S$!0,DGL*(Y$EC62-@Z, 593D$>M<W9S7VI:1<:
ME+>XAD68"U$:[54;E SUSQFLRPUV]A\.-+&1&;6&"".W* OE@H$A]0<\#IQS
M0!W5,$T9F,(D4R* Q3/(![XKEI-4UBTM+HL+@*3$D,]W"BLK,VT\*<$#.:M:
M5#<0>*[Z.XN_M+"UBPY0*V-S<''% '14444 +1110 4444 %%%% $$_WU^E1
M"I9_OK]*B%,8M!HKSSQIXPO+37%T33[E;,I&'FN" 6YZ 9Z<5I2IRJ2Y8E0@
MYRY4>B"@5Y-X+\?ZE+XIAT/5+D7D-R2L,Y4!U8#(SCJ#BO5)_M'D-]E\KSOX
M?-SM_''-%2FZ<N603@X2Y6345SUIKEVL<]UJ1LH+2"=H':/>6W X!'MDU=EU
M^QAB6607*H5W$FW?Y!TRW' K,@U:*RM2UZSL$=3*6F$)E&R-G"C'!8CH#[U3
M7Q"\.GI=3^4[?8%NFB16W%C^@6@9T7>BLFWUE+IK!T9(TN%9F25&#<+GCC&!
MZFI+;7].N[A(8IGW29\MFC95DQUVL1@T"-,4"LNV\0:;=W$<,,[,9251C&P5
MF'4!B,9]JDCUFSDNQ:AI5E8D(7B95<CJ Q&#0!H]Z*SM'OGO=)2[N"BL6<,0
M,  ,1_(52'B2"YU6QMK-RT4Q?>SQ,NY0I.5)ZC/>D!O]J*RX/$&FW$1DBF<Q
M!@GF>6P4L3C ..3FK$^JV5L;@2S;3;A3(-I)&[I]<T 7.]+64GB+3F25MTRF
M)@C(T#AMQZ #&2:N&[#Z>]S$&&$9@)$*D$>H/- %GM2U@Z/XDMM0M;97DVW<
ML6_F-E1F Y"D\''M4L?B&TCM+9[F=6FG5F1;>-VWX.#@8S0!LTO>LM]>TY+6
M"Y$S.DYQ&L<;,S$=?E SQWI-%U0ZE8S73$%%F=5*J1E1TX]: -6BL:Q\26=U
M9S7,H>%8Y"F&1N><#'')/I5^SU"WO@_DLVY#AT="K+]0: +54=4T]=0MRO E
M7E&]ZO4=Z:;3N@3L<)\\$K12J5=3@@T7VL1:79-<S9..%4=6/I75ZII,=^FY
M<).HX;U]C7F_C+3KL6"JZ%7A?=@]&'M73SJ4;K<UYKHP?%_B75=1\.RQB-(K
M=V&\(#G;]:X?3KB!&_>C(KI&GE>W\E^8SU4]*KP>%K6YS(IFC7J0IXJJ%;DW
M+P^(4%:1F>2FHW)BCRJX)R.U/'AN[[W$6SUP<_E736>GVMDGEPIC/5B<DU-<
M;0FU:)XB4I70JF+DY7CL<5+H][!*?LX,R=BIP?RJ"Y2[M'1+E#&S#(!/-=<M
MO)DL,UF:OI[WH4CB5/ND]_:G#$23L]BJ6*=[2,Z&(/%YC#(/>H)'6)\ ?E3D
MT_45^0QX7U+#%;VFQI9PD-AW/+$BNB>)C&/N[G54Q,(K35E/28IS+Y[HRJ!A
M<C!-;.Y@P)'%$<Z-*,]*T9A;R(/*&..<UPSFYRNSS*M5U)<S*37:A0M7M/:W
M()E!/'%47L2^2*A!> XS4&9HW3Q XQQ4#2QJG%5^9B.:E-JRIS0 ZW96?DU/
M<0JR<8JA$C^9A<U?C##[] &6 \<F!TK2B+>7N)J*ZV=5ZU6-PZC:<T 7(SY]
MP$9@H)ZU=>..W4A6#8[UGVB!VW9J2]D*+@&@"LUR#/U[UI"82Q@ELD5S^"Q+
M9JS:3@3*LC87O1<+':^#]&LK[4TN+J\0R1'=';8()/J2>OX5Z=(H",0 #ZUX
MD;];2=);9R&0AE-;:^,M<U2XQ%.ENG]U$'ZDU+3N4GH>D4HKE=#\17$UVMG?
M%79N$D QSZ&NJ%! E HH%(8M0WEG#?VDEK<)NBD&&%34HH XB7X=13/Y3ZK<
M?8R<F+:,D>FZNQM;6&RM8K:WC$<,2A$4= !4U%-MO<F,(Q^%%*^TFRU*2-[J
M$N\8(1ED9" >O*D5)#IMI;O&\<1#1QF-&9V8A2<XR3S5'4-9&G:Q;6\N?)EA
M9\)&7<L#V JW:ZM8WCQ)!.&:6,R(,$94'!Z^A[4BQZ:99Q1VZ) H6W8M$,GY
M2:A@T2PMKK[1#$Z-N+!1*VP$]2%SBIX[^UFLC>)*/LX!)D/ P.IJJFOZ>UO)
M.9)4C3',D++NSTV@CG/M0!%J>AI<:;#9VB0K%',)#%+NV/UX)'(Y.:32]"%L
MC_:A&1YPFBAC9BD) QP2<_TJ==>TYK::=IFC2 @2B6-E9,],@C-1'Q/I2A]T
MTH*??4P/N4?WB,<+[T 7AIMGY)A\A?+,OG%<G[^<Y_.L%/#-RM]YN^V5C<&8
MW2%Q*1G.W'W?:M>ZU[3K.0QRS,7""0K'&SG8?XN!TJ>+4;2:58XI@[&(3#'0
MH>] "WVGVVHP+%<H656#J58J5([@CD57.@:8]P9VMR7+B3!D;;O'\6,XS[U7
ME\2VB7=A%&LDL=XK,LBHQP!TXQ_^JK0UNR^UBV+3*[$JI:%@K$=0#C!- QFH
MZ.EUIEW:VVR)KE_,<L"0YR"<_7&.*IZ=X=$1NENX[=;:>-4-K"SLG!^]\W?Z
M>E.M?$D=[9-/$H@9;@0GSD?:06V\''4_IWJW/K^G6]TT$DSAD8([B-BB,>@9
ML8!H ?'HEA':SVQCDDBG&V02S.Y([<D\?A3ET:P$>PPEQY)@R\C,2A.2"2:B
MN/$&FVMP\$L[;XV"R;8V(CSTW$# '/6I+K6;.SG\J=I5Y +B)BBYZ9;&!0 7
M^DPW=JZQ@13BW:"*7&=BL.1COT%9^CZ!-I]^EP1;V\:1&,Q6S.1(>/F;=Z8X
M^M:-C>RW&I:C;OMV6\B*F!S@J#S5:U\1VUS/?1M',@M'*D^4QW 8YZ=<GI0!
M/=Z'IU_.\US;EV=0K@.P#@=-P!P<55F\,VEYJMU=7D8DCE2-$5793A1@AL'D
M'CBK*Z]I_P!FGN'E>)+<@2B6-D9,],@C/--D\1:?%$KNTXW*S[?(?<$'5B,9
M"^] R"Y\-VM[JTMS<H#";=(45'9&7!.1P1\I!'%:D=C:PS)-%"J2)$(5*\80
M'(4"J<GB#3HXXW,DK!X_.^2%F*I_>8 ?*/K34U^WDUS^S51VS"LBRJC%3N/K
MC&,=Z!$D>@:9%>B[2VQ(',BKO;8KGJP7. ??%+'H&F170N5MOWBR&5/G;:CG
MJ57.!G/-27VJVFG21)<._F2Y*I'&78@=3@#H/6LW2]=DO+33III;=1=/.#\K
M LJ$X*]AP,G-(9>30-,CNI+A;;#R;B5\QMF6&&(7. 3Z@5973[1#:E80#:(4
M@Y/R C!'Y =:K1Z[826<MWYDB6\:AC))$RAE/0KD?-GVH.O6"VAN':9!O$81
MX6#LQY "XR?PH EO])LM3:)KJ$NT6=C*Y4@'J,@C(/I2V^DV-K]G\BV6/[,'
M$."?D#?>Q]:BM]<T^Y:)(YB'ED:)4="K!P,E2#T..>:676["(LOFL[B4PA(X
MV9F<#)  '.!UH E32K&-XW2W4-'*\R')X=L[C^.34-OX?TRVO!=16VV16+H-
M[%$8]2JDX!^@I)/$.F1V\$YN"5N"RQ*L;%F9>J[<9S[5,-8L?LLUP9L1P/Y<
MF5(*MQQCKW% $2:!IL=W)<+;D.Y8D>8VW+##$+G )]:>^AZ;(JHUHA40?9\9
M/^K_ +IYYZ?A5^EH&9T>@Z>EK-;&*26*8!7$LSOD#H 2>/PJ2PT>QTV1Y+6$
MK)( KR,[,S =,DDYJ]10 4444 +1110 4444 %%%% $$_P!]?I40J6?[Z_2H
MA3&+7GWCSX?W'B"^75-+FCCO-@22.0X60#H<]C7H-%7"<H/FB.,G%W1YAX(^
M&M[I>OQZWK4D D@!$%O"V[#$8W,?IVKU 4"@43FYOF82DY.[.>?1[MM-N8-J
M;Y-0^T*-XQLW@_G@=*;K^GZI?W,\<2RRVTD&R()=>4J/SDN!RW;UKI*0L%&2
M0![FH$<T=/U6T>X6VM(IQ=VD<+,TP41.JE3GU'/:B/0KWR/+81C.DBTSO_Y:
M9_E[UT@FB:9H1(AE4!F0'D ]"13Z'J(YPZ;?WT6F^? +8P0R0R@RAB,Q[01C
MKS3;6PU29=+M+JTC@BT\@F99@WFE5*C:!R,YR<UTO>AW5$+NP55&22> * .?
MMM'O(M-TF!E026MR99/GX RW3UZBJUOI.KR:I:3W:R,T$[M)*]WN1E((&R/H
M."/>NHBFBE56CD1U==RE6SD>H]J>* ,C3],FB\.OI\Q5)7$HRIR!N8D?SK/M
M+#5I)M*6YLX88K!&C9Q,&+_)M! '0?7FNG[TM(#G?[(O4\*6]FB1F[@<2>7O
MP&(?=C/N*SM7BOQ;W]Y=PQVK74D"Q+YP.TAOXFZ+]>17:=J1D612CJK*>H89
M!H X^T4WMM?VS637UR)4DDECO%^8]BK@  C'3BMZPM[\:$8+U]]RRN!N<,0#
MG:"W<X[UH111PKLBC2-?[J* /TJ2@#E++3-6D32[6ZM(H([!23*LP;S#M(
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M\)D!"&,  ,PXR1G/UJ*;P[=P0:7,B27$T E^TI#<F%V:3EF5@1T/;N*ZVE%
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MRQ^2%YQM4?,"#C]<UT3:78/);NUI%NMAB$@8V#T'M38]%TV.Z:Y2RA69B26
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M)Y=P4>W'7W-)#9>I:2EIB"E[4E+VI#$I124HH *7M24O:@ [T4=Z*!BT444
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M*N64[O>NJ\7> +N\U*34M'9&>7F2!VV\^H/2LK3? /B"ZD"7@CLXAU9G#G\
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M(<'[K=21BMRZL+>\DADF5M\)RC*Y4C\NU5X]#T^.Y6=8#O5S(@,C%48]2!G
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MOZUI06\<"X1<>I/4T-I%1IREOH0VED(/G?!D/Z5;HHK-NYTQBHJR FFTIIM
MQ:***! >E%!Z44#%HHHH 7M24O:DH 6E%)2B@ %'>@4=Z "EI*6@8"@T"@T
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M_A+O#O\ T%K3_ONBS#VD.Z-?M161_P )=X=_Z"UI_P!]T?\ "7>'?^@M:?\
M?=%F'M(=T:_>EK'_ .$N\/?]!>T_[[H_X2[P]_T%[3_ONBS#VD.Z-CM2UC?\
M)=X>_P"@O:?]]T?\)?X>_P"@O:?]]T68>TAW1LTO>L7_ (2_P]_T%[3_ +[H
M_P"$O\/?]!>T_P"^Z+,/:0[HVJ*Q?^$O\/?]!>T_[[H_X2_P]_T%[3_ONBS#
MVD.Z-JCO6+_PE_A[_H+VG_?='_"7^'O^@O:?]]T68>TAW1MFBL3_ (2_P]_T
M%[7_ +[H_P"$O\/?]!>U_P"^Z+,/:0[HVZ*Q/^$O\/?]!>U_[[H_X2_P]_T%
M[7_ONBS#VD.Z-NBL3_A+_#W_ $%[7_ONC_A+_#W_ $%[7_ONBS#VD.Z-NBL3
M_A+_  ]_T%[7_ONC_A+_  ]_T%[7_ONBS#VD.Z-NBL3_ (2_P]_T%[7_ +[H
M_P"$O\/?]!>U_P"^Z+,/:0[HVZ*Q/^$O\/?]!>U_[[H_X2_P]_T%[7_ONBS#
MVD.Z-NBL3_A+_#W_ $%[7_ONC_A+_#W_ $%[7_ONBS#VD.Z-NBL3_A+_  ]_
MT%[7_ONC_A+_  ]_T%[7_ONBS#VD.Z-JEK$_X2_P]_T%[7_ONC_A+_#W_07M
M?^^Z+,/:0[HVZ*Q/^$O\/?\ 07M?^^Z/^$O\/?\ 07M?^^Z+,/:0[HVZ*Q/^
M$O\ #W_07M?^^Z/^$O\ #W_07M?^^Z+,/:0[HVSR,&J\EC;2G+0KGU'%9G_"
M7^'O^@O:_P#?='_"7^'O^@O:_P#?=%F)SIO=HN-I%L>AD7Z-33I%N 3OD/XB
MJO\ PE_A[_H+VO\ WW1_PE_A[_H+VO\ WW3]XBU'R+*V%LO\!;_>.:G2-(QA
M%"_05G?\);X=_P"@M:?]]T?\);X=_P"@M:?]]T:C3IK9HTS169_PEOAW_H+6
MG_?='_"6^'?^@M:?]]4K,?/#NC3)I,UF_P#"6^'?^@M:?]]4?\);X<_Z"MI_
MWU3LPYX?S(T:*SO^$L\._P#05M/^^J/^$L\.?]!6T_[[HLPYX=T:-+6;_P )
M;X<_Z"UI_P!]T?\ "6^'?^@M:?\ ?=%F'/#^9&D>E%9O_"6^'?\ H+6G_?='
M_"6^'/\ H+6G_?=%F'/#NC3HK,_X2WP[_P!!:T_[[H_X2WP[_P!!:T_[[HLP
MYX=T:G:DK,_X2WP[_P!!:T_[[H_X2WP[_P!!:T_[[HLPYX=T:E**RO\ A+?#
MO_06M/\ ONC_ (2WP[_T%K3_ +[I68<\.Z-44=ZRO^$M\._]!:T_[[H_X2WP
M[_T%K3_ONG9ASP[HU:6LG_A+?#O_ $%K3_ONC_A+?#O_ $%K3_ONE9CYX=T:
MPH-9/_"7>'?^@M:?]]TO_"7>'?\ H+6G_?=%F'/#NC5I:R/^$N\._P#06M/^
M^Z7_ (2[P[_T%K3_ +[HLPYX=T:U*:R/^$N\._\ 06M/^^Z/^$N\._\ 06M/
M^^Z+,.>'=&M2UD?\)=X=_P"@M:?]]T?\)=X=_P"@M:?]]T68>TAW1KTO:L?_
M (2[P[_T%[3_ +[H_P"$N\/?]!>T_P"^Z+,/:0[HUZ45C_\ "7>'O^@O:?\
M?='_  EWA[_H+VG_ 'W19C]I#NC8I>U8W_"7>'O^@O:?]]T?\)?X>_Z"]I_W
MW19A[2'=&SWHK&_X2[P]_P!!>T_[[H_X2_P]_P!!>T_[[HLP]I#NC:HK%_X2
M_P /?]!>T_[[H_X2_P /?]!>T_[[HLP]I#NC:HK%_P"$O\/?]!>T_P"^Z/\
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MT_ 9;:R;<::HM<K9L6(W_?)[^U+)K$:I>I:V9B%S(KDM)N(P<X_&G?V#J/\
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M1O=CYJUE%*WR"UUBWCL[6*YT\SRVA)A82[5_X$,<T^R\27%K]L>2W6:6X?S
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M6U\E@5>.+RI1YOWAC'R^E5X]5M[;5(;VWLYR8@W^ON2[$D<')'&*=_8.H_\
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M*3^Z*?10%AGE)_=%'E)_=%/HH"PSRD_NBCRD_NBGT4!89Y2?W11Y2?W13Z*
ML,\I/[HH\I/[HI]% 6&>4G]T4>4G]T4^B@+#/*3^Z*/*3^Z*?10%AGE)_=%'
ME)_=%/HH"PSRD_NBCRD_NBGT4!89Y2?W11Y2?W13Z* L,\I/[HH\I/[HI]%
06&B- <A13J** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>ganx-20211231x10k003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ganx-20211231x10k003.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %: NH# 2(  A$! Q$!_\0
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MQAV0&V/B!XM_Z#=Q^2_X4X>/O%O_ $&[C\E_PK%$-/$-'LJ?\J VAX]\6?\
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MLKE;W2Y6*1J5\IHV)R,]<X/%61\)_$O_ #SM/^_XIP^%/B3_ )YVO_?\4_\
M9_YOQ#0=)XVLQJUE=1W6KSV\5R9Y+>:.%57@@!=O)//4UD:9XBAT^UUM1!(T
MM_-'+%TPNU]WS?\ UJUQ\*O$G_/.U_[_ (IP^%?B/_GG:_\ ?\4TZ"5KH-#%
M\3W^AZU<R:C9V]_'J%PX:42LOEIQ@[<<G/O6EI'BNST^+P^DEO<,=-6=9-N/
MFW@XV\U;'PM\1#_EG:_]_P ?X4X?"[Q%_P \[7_O^/\ "GS4''E<OQ J:%XI
ML]+MM(BDMYV-E>37#[,?,'4@ <]>:71O%%IIUI90R6\[&WU-KUBH&"I4C YZ
M\U<'PP\0_P#/.V_[_C_"G#X8^(/^>=M_W_'^%)N@[^]^/]=PT&6GB70VMK%+
M^TOS)97DMW$82F"6<L%.?PY]J:WC"*5[&=[63SH-5>_=01M*M_"#ZU./AGX@
M_P">=M_W_'^%.'PTU_\ YYVW_?X4O]G_ )OQ#0JKXATZQ355TZ"Z;[7=0W4?
MGA>&1]S X[>E37GB/2=NK3V%K>"[U8KYXG*[(@#EMN.3GWJ8?#;7_P#GG;?]
M_A3A\-]>_P">=M_W^%.]"]^;\?Z[!H5-0\1VMY?>(;A()E74X$BC!QE2,?>Y
M]JY<0UVH^'.N_P#/.V_[_"G#X=Z[_P \[;_O\*N%2C%64D!Q:0\U;LEACO8'
MN59H%<&14ZE<\@5U7_"O=<49\NW_ ._PI1X!UO\ YYV__?X5R8BI"4[IGFXJ
M$W4O%7'MXS%U=WR7=C#]BNHVC_=1 2XQ\N6SSBHSXDMC%(H@FRVF+9@G'W@>
MO7I3QX"UK^Y;_P#?X4X> ]9_YYV__?X5S>X9?O\ L$OB+3FFFU&.VNAJ4UM]
MG96*^4O&-P/7\*1_$%H+"SA"75U+;RQNLERJ!HU7JJL.2#[T\>!=9_N0?]_1
M2CP-K']R#_OZ*?N=P_?]OP)(_$EA'/J"PB^AAO)!-YBJC.C]Q@\$52NM:BN-
M/U*V)NIFNFC*23;<X7UQQ^56QX'U?^Y!_P!_13AX)U?^Y!_W]%'N=P:K/2PV
M#Q#9^7';S6\YMVL_LTI3&X<YRM95NVG6VLPSQQ7#6<;!MKD;VQ^E;(\%:M_<
M@_[^BG#P7JW]R'_OZ*+Q[B<*KM>/X"'Q3]J2^BN[2$17 RIAC"MN!X+'/-0W
M>I:;<WL.I+!<B]4H74E=GR]<=ZL#P9JO]R'_ +^BG#P;JG]R'_OX*7NC:K/=
M%>XU2R)U/[-'<#[8 1YFWY6SD].U6KKQ#;7,-HAM&.'5[H-C$NT8% \'ZI_<
MA_[^4X>$-3_N0_\ ?P4>[W':MV_ 6ZU^UD2%88YV$=P)@'1% ']T!:C;5K.(
MWAM8IR;B591YF."#DCBI1X1U+^[#_P!_*</">I?W8O\ OY1[O<;59]!LNL6(
M^US6T%Q]HO,>8)"-J\Y./6F2ZM!)-J+B*0"ZB6-<XX(]:G'A74?[D7_?RE'A
M;4?[L7_?RCW0M5?0YT0^U.\JNB'A?4/[L7_?RG_\(MJ']V+_ +^4^==S/V,^
MQV9ZT4'J:QM!U6_U-KH7M@;3RF CR&&\<\\_2N>QZ3DD[&S2UR-QJUXUQ>7+
MWES!;VUU]G$5M CA<8^:3=S@D]JL7?B1_.N[540!89FCE@D)(*#W7&?IG%5R
MLCVL3IJ7M7-)XCG2:.(V8>!&@BDF:7YLR*"#C'/7FM2^U&:WFECA@600P^=*
M6?;\N2,#CKP:35C2,E+8T1163837,TNH7#$$ XA7S#@#:".,8'7K5>PU*:#3
M2TZF25;?[0Q,A;.3TY'%(HZ"@UC'6I(Y29+51;B4Q!Q)EB0N[.,=.W6E>_U(
MQV<BV]N@GD48,A/RD9].M(#7IU8::M/L<0P"5HP\DAEDQ\H;&!@4^+6Y)9D8
M6H%LTB1[S)\V6 (XQ[^M S9I:2EH 2DI:2@8M%%%  ?NFFTX_=-5KV66"QGE
M@C\V5$)1/[Q]*:5] )Z*R="O[_4-*-QJ-G]DN,L/+P1QV/-9EGKUVND6'"7-
M[=S/&IE?:HP3U(%:>RE=KL!U5%<E%XON9'C!TY4#*P!+DB209^5"!C/'?%:-
MEKKW6D_:C%$9S*(O*5F&UCV;< 011*E."NQFY16 MY>7>M0VKJD8A9_-$<K8
M8C&"/7KT-/L[RXCOKCSP'WR2!<2-A0G08/ K(1N4M8:ZY.P\TVT8MU*!CO.[
MYESP,8XH.HZE(^GND5LD5S)TW,3MVDXZ=>.U &Y1VKGK?7)S9F=8 \,.P3&2
M7YSN(Z<8.,CKUJYI^JSW4\236\<:3QM)&4<D@*0#GCW% &M16 WB"42O''##
M*24$;*S!3N?;U(Y_#-*=;O?.E@6U@,L"2/*3*0IVD?=X[@]^E &]2U@0Z[=7
M,JI#:Q 2S&&$O(>R[B6P...U-'B-A)$&AC_UHAF1"S,C9(SG&,<<9.30!T%)
M6$U]J4ZZ=,D4""XDW(OFG!4HQ^;CZ'BM2QNC>6,5P4V%UY7.<'.#_*@"SWI&
MZTO>D;K0 E%9VN:LNB:5+?M"\PC*C8AP3DXJ/^UVF\+OJ\,6QC;-,J/S@@'@
M_E5J$FK]-@-:CM6#/XD6UM;,M:37-Q-;"YD2  ;$P,MR??I5?_A-;$QW$L=O
M.\4*J=V5!.[&."<@<]3Q5*C-[(#IJ*S_ .U0;.VF2VD>6Y_U<*NI/3)^;.,8
M'7-5;;4[B]U%C%'(EM'#NVG9RV2"#W&".U9M6T VZ*PM-UEWLGEO%D\P(9B,
M+@+G  Q_6I3XAA7>\EM<)$"RK(0I#LO4 9S2 V**Q9M9NHY3&VGRPCRFD+.R
M,5QCL#SUI_\ ;T:*':WF,/W1,-N&8#.,9S0!KTM4+34Q=)(3;2Q.B!]CE<E2
M,CH<543Q%'*?+BM)I)]Y3RXW1NV<[@<4 ;5**Q5\1PL-ZVMP85V^9+A0$)[$
M9SV[4+X@WJ633[I@%+GE,[ <;NOZ=: -FD-9#>(K9)=C1OM*;T(926_X"#D?
MC4<VLW4-Z@>PG$?DEWCRA*X/7.?3M0!M]J*:CB2-77[K $?0TZ@!M%':L.'Q
M"9?$\FC?8I $4GS\_*?PQ5Q@Y7MT W*6L>;5GM]>EMI"HM8K3SV.WYLYYK/D
M\:0PQ[IM.N8BR+)$&9<.A.-Q.?E'UJE1F]D!U%%8UCXACOM5-BMLR,$#%FE3
MN,\#.6'N.*CN]>D6SDDM[5P&5O(E9EPQ'7CMZC-1*+CHP-VE-8%[?WMF+ 'S
M63RWEG8,F]MH''3'?M5N?61'<K;Q6LLTSE0H# #E2W4_2I U**R(M;-VA:TL
MI9 J;G)=5V'&<<]??%10:Y*XB\VV;SYD0QP(PP2<G.[TP* -RBL8^(5RP%E-
M^[7=/\R_N_F*D=>>1V[59OM5CL;B&.1 5D91N\Q01DX&%ZGF@#1HK%/B)5B\
MU[&<(ZL8OF4F3:P4C&>.H(S3FUXI)Y3V4HF5F\U=ZX15 8MGN,,* -FDK(&N
MX4^9:-$[1B6,2RJH9"<9)[$9''O3!KIN[9WL[:1ML/F2/N7$1(./][[N>.U
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MQ]* ,T:!: *=]P73:(W,F6C"] OM2IH5I$ (WN$79L<+*?W@R3\WK]XUJ4E
M%:&RA@E$D8(80K",G^%<X_G5BBB@!K_=_&HR,C!Z5(_W?QIE B"WM+:T#"VM
MXH0QRPC0+D^^*S]1T,7MTUS#=O;2O'Y4F(U=77W![CUK7K-O]66QNXH6C1E<
MJ"1)\PR<9VXZ?B*=V2XIJS,QO!\#26S"\EVP+&JAD4GY#G@]L]\587PU"BLH
MN9/FBEC^Z.DC9)_"GG772)YI+%EB_>^6PE!+E,Y&,<9P<4]M8G3]VVGD7!>-
M5C\X8(?.#NQQC'-/F9*IP[$[Z:1;VB0W#1R6JA4DV!LC&#D4ZRTU+)]ZR,YV
M;3N Y);<3^9J!=7?S%+VFV%G,2R>:/O@<Y&.!D$9J.'76N!LBM5><R!%59OD
M.03G=CT![4BR>32]WS17+1R"8S*^P-@D8(Q]*CBT1([>2(W$C;XA&6*C/WB<
M_K48U.[BU"X6:V)@4Q!OW@_=EL]!CFMJD,R_[)813P+=N+>7)\O8/E)[Y_I0
MVD,TGGB[87 *L)!&, J"/N^AS6I13 RX]'1/,)G=GDC9'8J.23DG_P"M6C&G
MEQH@.0J@9^E/HI )12T4 )12T4 )4@Z4RGCI0 P]:*#U-9^F:U9:N9Q9R,_D
M$*^Y"N#_ )%.Q#:3L7);>*>.1'0$2*58@8)!&.M->S@=(D:,;8W#J!QR/7UJ
MC_;.U[YF@_<V>[?M?,F0,_<QT/8YJPNJVK&%2TB&;;MWQ,!D] 21@$T#+@4#
M& !@8&!T%)Y:;678N&ZC:,'ZUEV^O6\]DTNY5F5&<HVY5.TX.&(YQWQG%31:
MF'ED1T "-(/ERS$+CH .>M S0V(<91>#D<#BC ]!^59W]N604RF4+ $+%V#
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ML)QD'!Q],5%=ZY#&B?9E>5G\L[A&2BACQD]C0! NC7$<\*H+;R([A)MQ+%P
M -HX]NN:+_3[F\U&Z2.. 12PHAED!RO)^[QS^E6KO6X;43@V]RTD2E@GEXW@
M'!(_.GMJT<9<.DF[Y L2H3(2P)QC\* *QT>:-8GB\AI8[AIMKY"OGCDXZU&N
MAW 0KOA'F12)(5R-A8Y^7CD?E5MM>LP$(6=MREFVQ$[ #@[O3!K3!!&1R"*
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MQSBK= RE!I=M!*LH\QY 7)>1]Q8M@$G\ *8FBVB1NF9F1HS$H>0G8I[+Z?\
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MXM@4412>4I+'<[XR0!CICW[&I9-5L(B@>\A4ORH+=1G&?IGB@HQVTJ<&X?\
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M:V[K%]N\Q;MV:+;)B4$D@!ATZYST]:Z=Y$C&7=5_WF H,J*VTR*& S@L,XH
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M'&4!]LCK[U>L9[BX1K6;]]Y*?NHG^;!/7Z@>OI3:,U4T/1W=8T+NP5%&2S'
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M:9W_ (<D464MI'()H+24PQ3 Y#+U SWQG%;5>>:3K^H26J63,L*@;M\4:H4
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M<&FB))M7;-SP[HZ30&\O[6W:4OF(H>B^A ..O:LO6M.M-&NYI#<7LRW+&5H
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MS4]$M=4DBFD!6>+[D@ ) ],'@UIT=J :N>:3VTT6MRR785([>3(^T/N) Z$
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M@D,4\S0QABPD4XPV.,UHPM;A6,+1;<[F*$8SZFJ.I3W%S:O%IDT?FE3B0$$
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M*<YE? S]!7="M2='EJ;C.AU;S/[)N_*SO\IL8Z]*\HM].:WAC<ZC'Y!4':^
M<_7->LWU[%86DDS#<8T+",'YCBO)KIM1O]3N-]K:QR;O,C 540 ]\@98UPB-
M30?$%E:ZL)[V*YG>,>7]JFN"XB!_N+C@'UZUM77CJXLGC>2QBDCE;Y(TD(?'
MKSQ7*1Z'<>8$2(27,_R_ZS_6'T.< >U6/$MC+H\&G7=]"8V=C'P=PC&.Y&?T
MH ZJ[UK6-9N3!X?:&W6&W$\DD\6\L3T0#^M9R>)[C5(T&K7#Z#:P)_I#EQ%)
M-)Z)GD+[UA0ZE?W.H&:P2Y@T\(D<J1GRY9E7N,\]/I7>:3H_ANZ@6]L]-@9F
M/+SQ;I ?1MV3F@!WA&^NM0T,3W#22+YC+#+(,-)&#\K&MZD  4   #H!2T -
MK/U"]D@&R$J&QDL1G%:%86M[H)/-QE6%7!)RU P]7U_6_L;P6TD,3MQ]H5#O
M ]ATS[US>C>(=4T?68!/>W$]M+(J2QSR%P<G&X9Z'/I6CJFJ6T<;;G"D=C7+
MZ#%/XJ\6V]O;1L;2VE6:YEQP IR!^)KTXTZ4:4FT![J*BN+B&U@::XFCAB49
M9Y&"J/J33I94MXFDD.U%&3P3^@JE>V$.LV_D7D,4MA+'\\$T62Q/KGIC\Z\D
M#@?B%X"N-=N%U_0&62Z*#S(E8+YH X93TSCL>M<!#I7C5Y/LJ:/?F3I\]OC'
M_ CQ7T5%$D,211C"(H51Z 5(>E=5+%U*<>5#N<#X!\!3:!*^K:O*LVJ2KM55
M.Y85/4 ]R>YKOJY7Q_?W>G: DUG<202&8*6C.#C!XJ+X>ZC>:EHMQ+>W,EQ(
MLY4-(<D# XJ94YS@ZTF!UXH- H-<XB&YMX;N!X)T#Q/PRGOWJJVB::Q4M:H2
MK%AR>"7#GO\ W@#5_O2TU)K9@8]SHVAQ1YN88HE9N&:0K\V6;@YZY9C^-2IH
M>DE0([6,>4Z$;&(VL@PO0]@?UJ+7-.NM0,:0G"".12WF;<,P R>#D8SQ3/[+
MO#(KF;#(P*8D(5?G)/'?Y0HQ[FGSR[@3V^B:1:W0\BUC2=2)5 8DKC(&!G@?
M,>.G-74_X_)O]Q/ZU@QZ1J #2,!YSF($F<L&VY+%O8DG@8Z"MY/^/R;_ '%_
MK0Y-[L"?M4%S<K;1[B"S'HH[U/VK*U9BC(Q^[@BE%7=B9.RN4[GQ0MHCF6QF
M=@/E\I@0?KG&*Y)_'FO0W?G26]F8,_\ 'L$(.WV?/7\,5MSM"48DKGWKBO$F
MJ6\$94$$CD =SZ"O4P^&I2OS(\?$XRM%I19Z_87L.I:?;WMNV89T#KGK@]C[
MU8KG_",8TWPUI>G74J+>B#>T1/S#<2V,>V<5J3;]0M;B!!+ #\GF.A&1W*\@
M_C7EO?0]E:K4X?XM6]P-+T_48@2EK/\ O/\ 9## )]LUR.CZO9F,AW".>N>H
M]J];TSPY8Z;H3:/^\NK5M^_[2QD:0,<G<3UK@]4^#RO<L^DZH(82>(;F(OL^
MC @D?4?C7H8/%PIQY)GE8_ SK2YZ9A:KKUM';LBN#D?B:[KP/X4LX=!@O=2T
MZ%[ZX)F/G)N* _=&#P.*K>'/A9I^DW*7>I7!U"X0[D3R]D2GUVY)8_4_A7<R
MS;'Q48O$JM:,-D7@<&\/><]V3H H    & !VIU,0Y4'VI]<)Z95U&UDO;":V
MBE\II%V[\9P.]8,7A)K:="EU'/"CEA'<Q;P,C!/&!GTKJ**:;1$J<9.[.8_X
M1-OLQB%Q$A56$;)%C:2V0QYZBF/X09Y(LW49C2,J08N22.3[\\\UO:K<-:Z7
M<3(VUU7Y3Z&N<M-4U,;41O-;<=KR$NF#WR -PZT^9D^QAV)CX2D=DS<0* BK
ME82&4@8PISP#W%:]M8IIUC9VL84"-@"57 )QUK%GUV^EDA@W0POD%P592PP3
MG/\ "O3KFM>RNI;VQM9YMN]I.=JX'X<G/UHYFQ^SC'5&E3NU-IW:I-"$]:6+
MCS/K_2D/6EBZO]?Z4R%N<EI_C<O!<3WMLH1/+""$,"6=F 7#=?NYW#BK_P#P
MF5C@_P"CW8/EHZJR!6<L0 H!//)QGI6DVA:6T8C-E%M"!!@$84-N 'T/-55T
M_P /W=U-:B.VGG1/+DC+EF5>.V>.U:7@^ABE62MS(;-XHL[4/]IAN(C&^QPR
M@E3Y?F=CZ#\Z=!XEM9]'?41!<*BR"/RV0;F8XP!S@YR.<TX:3H7VQ_\ 1+<W
M$,0W@@DJA! S^&14EG;:/=Z<]G:I%-:$ L@)8<C(Z\],8I>[V*7M+[HHV7B*
M34=<CM8;9XK=87>8R*-RNK;=O!['ZU>EO[>1IG:0""V/S[N-S>GT%6+?2K*T
M*FWM4B*H8P5R#M)R1GZ\UCZKX=CN;H3AY%A8_OHXQEF]P>OX5+:;T+@I)>\]
M2EHKO<W?FE?^/J9B^1CY!R/Y4^9)[*^N)T)6-I2T;J.-PQE35BY6VM&1+2U:
M)BI'G2,RX4#KMSD]N3BKVBW<:Z>BR7"8W'RRQ"EE]?SS4EF8;&>XE-R]^+9Y
M6W>7/" 0.P#&MG38XK3S8V7$N SR%MP<>N?Z5R6LW<OSRVVJVMQ(;@1R1.!(
M8,G'0&N+N/$M_H>K:G9W5U+<6LH\MU90-H(!5E   Y/:J46S.=6,79G;^([F
MV\4Q1QV5]<O:1[O^/8$!I <88^G6N>B\&I:ZPMRM[/:P J9BI>02KW!'3KWS
M6CIUL%UF(643_O8O.,42X![<GH!G'6NFCAEMM2M1?VZ[&.T$'<FX].?7ZUXU
M>MC8XM1@ER;7L[:]]=UY=S>E"E4I<\MW^AT-M-'<6Z2PAA&1\NY2IQ]#4E+2
M5ZY(M%%%  ?NFH;C_CWD_P!TU,?NFH;C_CWD_P!TTT!FZIJ5W9&TBLXX'>5&
M8^<2  HSVJG:^+8Y)(Q+ X$K(J[1@(2,_,Q./I6Q<Z99:C#"+RW2;8,KN[9%
M5[BQT9+J&.:"%9I"#&F"-Q7IP/2M8NG:S6HRNGBFU968VURB@$@LJ_, VW(Y
M]:K2^,H0N(+"Y=]P"AMH#C=M)!SV/K5Y+'0;^00)%:SO;$_(IR4.<\X]ZAM=
M$T.UCO(BD<K EKAI/O ?>Y]/6J7LNJ8#(_%,2/(DT$S,DA5S&@ C7=M!;)YY
M]*M:=XAMM1GDB6&>+:F\-*H 9<D9&#ZBE@TW1+PK+!;P2F)MP9<G!///KZU;
MCTNRAR8K=(R4*94=LYQ^=3)T[:)W$/MKN&[B,L+[E#%3D8((/((-8.K^)Y-/
MV/!'%(KOM1&SEP.ISVJEK>G>()3.+!/+C?YI1'<#;-CV*[@2.H!YK&N(KFZM
M'N[YH8G3'E1@988[8YQFLTC.I)K8Z'4O%$L=M%<6\<;6\A"'.=W(YP1TYXK!
MGN+9474K:)A-GR'0H&[9!/7\ZTO#L$5Y:1)=K%';Q90J[C]ZQZX]N:GU'3=/
M\.6WGQI=332OB/Y_N8'TQC'J#3T6A#4I*[*6B/J.KW<!>."2W1\R,8@HVX((
MQG)_*MOQ98:>/#LDLYF@CM3YJ"TPK%N@4<8R20*X.3X@6ME?6[RVK2A9OFGM
MTV[0/O#D_-QV%6=9\5WM_P"(9HXIEDT@)L$,9(\P8#!]P[D$_3 J:ETFTKFM
M&#:U..U+[3Y?GP:)<^4\A\V*YN5E8M]XGE1@\YQ7KWP]N+N[\(6MQ=/*PD9C
M")LEQ'GY02>3W_#%9L<%F+%0(SD#S]C/EQD=3FNKTRQEM$+374DS,  A;*(/
M1?\ &O-P&9?7.9*+5GOIMTZ[G77AR)*Y?I*6DKT3F#O2-UI>](W6@""?_76W
M_77_ -E-8<_B2>.V+K!%N\^XB&2?^6:L0?QVUN3?ZZU_ZZ_^RFH)-(TI)Y+J
M2UA62;*N[<;MW!]LGI[UI!Q7Q(#'7QA&!$9X)8BL;-/&R9;(0,-N#CG-6U\5
M6I24R6US$\08NCJN1@J".#ZL*F;2-"M!';/;6L?FEDC1CRY(P0,]>!56QT;P
M\[M;Q)%<.DCRJK$DIR 0/;*]^]:_NFKV8RJWBR8+,/LP_=Q/)YVWY>)-N-N<
MU<'BRTVS$VUPHC!(+;5$F&VG&3Z^M7I=&TD(7EM(5558$MP,,<G/X\TY]$TR
M6/:UE&5P<<'N=W\^:ERI/H!C'Q>)1(\-JZ0*D3B609X=L8(!]JDF\7P>5^YM
M+DR,5\I64?.I) 8<]..]:$>D:/(S+':0L80(V !^7!W '\>:@>S\/6DKP-':
M1RG]ZR9^88YSCMWIWI/118%NUU:"ZTZ&Z0X:5>$/4'TQ7/>*'=;$.I(=)%?<
M#@Y'-;D.EVK1H+:8^7'PH7!"]\>O>N?\3VKSV#Q0>83YJJ2K $#/).>*P>^@
MCE[XW-U)!J85S.X:65@?F5<=OH*J?:I[IH[:%%FEBR2X"Y*D<8SQ74^&KVRL
M-82RN2K3R+Y<+F3=M_V2,#&?6IO&E]#I4<%G:Z; 1)F0NL>"AZ9&",$^M(3=
ME=F5X3TF-M7MI;ATM)(FW1P_,6D/^]]W^9KN/$-P5TJ>*"5%N2N5&06 [L![
M5Y?%=ZS#+#)&X)C<./-=2>/PJ34KBZU"]:[:T03.V6/G]O0''&*ODEV,/K5'
M^8E.GZG>WL40FEEFQ^YE^TX#^WS'K[5Z/X?TZ;3-(CAN65KEB7E*]-QKS+3+
MB^LKF(S0^=;QR>8$\_YLCMDCI77_ /">.#F32&"#J5N 3CZ8HY)=@^M4?YCL
M^U%16UQ'=VL5Q$28Y%#+GT-2U!T#:9-#'<1&*5 Z-U!I]%,#F+OP)I%Z^97N
M@AZHL@ _/&:VM+TC3]%M!:Z=:QV\(.2$'+'U)ZD^YJ[2TW)O1L"*&WA@9VBC
M5&<Y8CJ3[U+112 *4TE*:0'&?$S_ )%F/_KX7^1J+X7_ /( N?\ KX/\A4GQ
M,_Y%J/\ Z[C^1J+X7#_B07/_ %\'^0KO7^Y_,?0[G'O1CWI,#TI"J^@K@$+@
M_P!X?E2;6_OC\JJO>V27OV-G7S]NXKM) 'N<8'0]:);JRAGBAD:,/+G;TQP
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MW# G:^,\],TR2Q7*W/AN\>'4#'<Y:YO!-Y!E*QO'\N5) R"<=:Z+][_SU_\
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M#4WANROX-<OIKVVG!?(65W^7KTQW/O759/K^E+DT.O)Q:8KB5DZ[I#:G8-'
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M(WFM^]XP,KC@@]P:Z/YO[WZ4<^OZ5/MI7N(XM_"-^L;1Q21*IG\UMD[*9!M
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M_P )KJ3-A;"T&>WF.?Z5?))F$L323LV=S2FN/B\9W49'VS2&V=WMY=Q'_ 6
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M_H.*DAO(F;"L3SM#!3MSZ9Z9KS/KD>?]W=H=C6V2,.+AQ^"_X4+ PE$CS.Y
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M]GJ&E:I'IMI!.6:8?VD@EN8_X0J]0!R>2,DUT?POUV'37AT&T\N:RFD;RV0
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M:?9A&%B P%7C;]*GHK*E0ITE:"L.Y3AL?*<%YWD Z @#\\=:N445I&,8JT4
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MR/:_#?A_3=5\)P/J9CU59U5R9(MH&T$ 8SG/7)SS5G1_$^DQ6LR1V2V-M!C
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M+Q9./F /(^GY5[S:^!M!>TL3?6<-]<6\>%GD4C=GGH#C'/?->!>'-2EL?$<
M3PZMU 3MD6\BZD^G7+5]06S,]M$SQ>2Q0$QDYV\=*),*C'10QP1+%#&D<:#"
MHB@ #V IEU_JX_\ KHO\ZFJ&Z_U<?_71?YU*,RLVM6D0NVG<Q):RB)F;G<Q
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MO(5#'UP.,^]30V4B95(I69CN9FR68^I)Y)KE)XM8U"6,W%WY<*<^7!F,,?\
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M^C_A6WMG;5(9R)MM<F^SR3C4C(IE29-T>PDKQ@#JF?6D5/$T49CA6Y1DMR$
MV>4!Y8V@=]^_/M78#SNZQ?F:4"7N$_,T_;OL@,[1$U"**YCU"264K,?*DEQN
M9-H/;WS6I3</Z+^=+AO]FL)/F=Q"T=J.?:DY]J0"]Z1NM+WI&ZT )2TE+3 S
M]9T73_$&F2:=J=N)[60@LA8KR#D$$<@U0M?!'A:SACB@\/Z<HCQM8VZEAC_:
M//ZUOT=J #'&*HZ9H]AHZSII\ @CFD,KHK';N/4@$X7/H*O44@%HHHH @N?O
MP?\ 745RATW4UU6>:TLY8K@3O)]I9P$=-O"XSSS[<5UEQ&\@0QE=R,&^;.#^
M5(#=_P!R#_OIO\*TA-PV X6?4M>M'LX+NYO(O,8E_P!VN\=..^X9S6C<)XDC
MA@:%KR69Y69LLFU!G@$8Z8KJO]([K!^9_P *<//[K%^9K1UUI[J&<.+?Q&MQ
M=736]\UPT?E[PR#'S9^3'\.,=>:LBSUUG9Y$N9)G6%P)"IC5AG/'8]*[#$OI
M'^9I0)/1/S-#KOL@N<=''XIE7:9+V)2WS,WE[@<'.W_9SC%=5IYN#I]N;L$7
M&P>9GUJ?#^B_F:7YO]FLYU.;HD(6E%-Y]J49K,!&ZTE!.:*8!2TE+2 1E#*5
M89!&#7SGJMO>>"_$EQ8W,;/;^89(6Q]]">"/ZU]&UGZOHFF:[:_9M4LHKF('
M*AQRI]01R#]*Z,/7=&7,AGA4GBZT\DE ^[']WI75_#SPNVN2S:[K-GFT9?+M
M(I,C<,Y+X]*ZVR^&GA.QN1.FEB5U.5$\K2*#_NDXKK0 J@*  . !VK;$8SVD
M>2*LA%>TL+/3X_+L[6&W0]1$@7/Y59HHKA **** %HHHH 6DI:2@!**** %%
M+2"EH **** "BBB@ KS/XM6T\2:7JL2;HX)&CD..@8<9]N,?C7IE5[VRMM1L
MI;2[A6:WE4JZ,."*TI3]G-3[&=:G[2FX=SQ72=5L6@.757ZG/6H=7UJ)T%O;
M_O)7.U%')9CP.*Z74/@VCW!;3=8,,)/^KN(?,*CV8$9_&NA\+_#G2_#EPMY)
M(][?+]V610JI_NJ.A]SDUZL\PI\MX[GAPRNJY^_L7/#O@_3--TNS^T6$,EZL
M8,CRC>0W4XSD#\*Z8  8%%%>,W<]]*RL%%%% PHHHH **** "BBB@" ]:*#U
MHID!2TE+0 4O:DI>U  **!10,=0:*#0 E.IM.I#"EI*6@!*2EI*!BT444 !^
MZ:;3C]TTV@ HHHI@+1110 =J*.U%( I:2EH *.U%':@!:*** "EI*6@!*2EI
M* #O2-UI>](W6@!*6DI:8!1VHH[4 %%%%(!:*** "BBB@ I:2EH *44E** $
MI#2TAH .U%':B@!M%%%, I:2EI %%%%, I324II %%%% !1110 M%%% "TE+
M24 )1110 HIU-6G4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4E+24 0'K14I ST%)@>@ID$=+4F!Z"C ]!0!'2]J?@>@HP/04#&"BGX'I1@>
ME "4&G8'I1@>E(!E.I<#TI<4#&T4[%&!0"&TE/ 'I1@>E QM%/P/2C% ##]V
MFU+1@>@H BHJ7 ]*,#/2@".BI,#TI<#TH BHJ7 ]*,#TH BI:?@48H 91VJ3
M HQ0 RBGXHH 92TZB@!E)4E% $?>D;K4N*9CF@!E+3L#THP/2F VCM3L#THP
M/2D VBG8I<4 -HIV!1@4 -HIV*,4 -I:7%% "4HI<44 -I#3L48'I0 WM13L
M#TI: (J*?@>E&!Z4P&4M.P*,#/2D VBG8HP* &TII<"EP* &T4[ HQ0 VBG8
MHH 2BEHH *2G4F.: &T4_ ]*,"@!JTZBB@ HHHH **** "BBB@ HHHH ****
4 "BBB@ HHHH **** "DI:6@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>ganx-20211231x10k004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ganx-20211231x10k004.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %C GP# 2(  A$! Q$!_\0
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M5TGAC5WRK#Y'/\C75>)](DNHX]2L5S?6H)"_\]4_B0_T]Z\\N5CM)%OK?/\
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M\T&%X+Y7U+1&&UG(W2P+Z,/XU]^HI(=$AL($U'PDT2QL-S6H?,-P/;^ZWO\
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M7HD7Z*Q+7Q=H-]J4>GVNIPS7,@)5$R0<>_2MNAJP)I[!1110,**** "BBB@
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MY]#/V37]PB7B+454F.0?[>/N-]>#33>Z%**DK2.!-H\$)N-++W=DIP]N?]=
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M^H2BYU*48>3'RQC^X@[#^=:Y.!D\"GML3ON<]J5O"_BG14AAC$T9>1F50"$
MQC\ZZ:N<\/L-3U/4-8#!HBWV:WQ_=7[Q_$_RKHZ3*CW"BBBD4%%%% !1110
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MEI]W<9_B\O8G_?38J62QN8B#J6HVFG(>D<9\R4_3/] :UUT[4-;<KI]Y=W<
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M /3'_6PG_@#=/P(IGV[Q%8DB\TF*]C'_ "UL)<-^,;X_0FIE\9: QP=11/\
MKHCI_,"K]MK.F7F/LVH6LQ/9)E)_+-/7J*T>C,Q/%VD[]EU)-82?W;V%HOU(
MQ^M:UO=6]VF^VGBF7UC<-_*BXAL=7LYK:817-N_R2)D,/H<5ECP7H$<:K!IZ
M6Y085X&:-A^(.31H%I&U16'_ &%JEH<Z=KTY4=(KV,3+^?##\Z;_ &IK=@3_
M &EHOGQ#_EOITGF?FC8;\LT6"_<WJ*SM/US3=4)6UNE,H^]"X*2+]5/-:-(
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MDL0 .236!-XG2XD:#1+634YU."T9VPH?]J0\?EFHQH5WJ9\S7[WSTZBRM\I
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M98]1U],BNOJ/R(O[@J9*ZL:T9^SES,XT0:[$C&%W"* J0?(#C;UR<\[O<TR
M^()G-O\ :77RPI>9HT#$DC<O3:<#)R/6NU\B+^X*/(B_N"H]GYG3];7\J^XX
MF:'Q2D"B&Y21R07+*@(Z],#']TG-6=0C\0$.UG,@(2,!<+R>=Y&>_3VZUUOV
M>+^X*/L\?_/.CV?F'UM7^%?<<48O$L0&R0R.TP9F9DV[>,@#&<=:<;?Q%'"Q
M@FC#8*K&P7:..N<9SG-=+%%'_:]T"ORB-, G@=:FEGT^#_6W%O'_ +\H']:/
M9^8?6U_*ON.3A@\027=B;N0F..4/)L**NW#9W=R<D=.*LQ0:S'=JWF@0"89B
MPN&0EMQSUS]VM2;Q#X>@.&U&U9O[D;[V/T"Y-0KKGVD_Z#H&I7"GH[QB%3^+
MD?RI^R9+QD7T7W&'+I>JR27(53E[D.K/*54Q[LX)5L],< "M[1X;F#3[>*[8
MF=1\_P V[OT![CZ\TAFU]_\ 5>'K5!_TVON?_'5-)N\2@Y_L;3#]+U__ (BA
M4["GB^96:_ Z&BL1=0\0I_K?#T;C_IC?*?\ T("FGQ'-!_Q]Z#JL0'5DB64?
M^.DUI8X[F[16+%XLT20A7OEMW/\ !<HT1_\ '@*UH9X;E-\$L<J?WHV##]*5
MF--,DHHHH 9+-'!&9)I$C0=6=@ /Q-4TU#2(F9H[NQ1F^\5D0$_6H/$:AM*5
M6 (-S "",@_O%J\]C:X;;:6V[G&8EQG\J=E:Y#;O9%+4+K2]0T^XM'U*V59D
M*;EG4$9[]:-/N=+T[3K>S34[=UAC";FG4EL#KUKGM%U:1-=?2=?M=.CN)>+;
MR(D(8C[P."<>P.#76&UL!(L9MK8.P)"F-<G'X4[JUA6=[C?[6TW_ *"%I_W^
M7_&I8+VTN6*P7,,K 9(CD#$?E2?8;/\ Y]+?_OTO^%4!!##XEA\J*./-J^=B
M@9^9?2BR8[R6Y?OY(X=/N))H_,B6-BR?WACI6*+W22JRR62K(!O&Q<A<CC+#
M@9QC\*Z"2-)8VCD4,C##*>A%0RV%I-(LDEO&[J-H)'0>E":02BWL8"7NBKL:
M/3P$926<H0IZ C/\76I8KS0H?+EBM'1U^<8A.Y0<?,?;I6L-)T]6)%G""1@_
M+45WHEE>&/>C*$QQ&<9 Z \=*?,B.22[$ZZ=9B8SBVC$A.[=CG/K5EW5$+NP
M55&22< "LB\\1V-M,;6WWWUYT%O:C>P_WCT7\367!IVO:[J[_P!OVT5MI$:A
MH[6&;=YK?]-".N/3I]:FW<UTV189I/%D_DP[DT6-OWLO0W1'\*_['J>]=.B+
M'&J(H5%& H& !0B)$BHBA448"J, "J][J5CIL7F7MW# O8R.!GZ>M)ZE)6U9
M:HKGQXG^U'&F:5?7@_YZ%/*C_P"^GQ_*D-]XH<Y32].C7^[)>,3^BXHY6'.C
MH::X)0@=:R=.UJ6>]-AJ%F;.\V;U <.DB]RK?T(K8HM8:=RGY+YSMYH\F3^[
M5RBD,IF%SU3-'DR?W:N44 4_)D_NT>3)_=/YU<HH I^3)_=H\F3^[5RB@"GY
M,G]V@0,HPJ ?3 JY10!4\F3^Z?SI/)D_NU<HH I^3)_=IRQ.!RM6J* "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "LSQ!IAU;1KBU4XD(
MW1GT8<BM.B@&KGF]E<_:(RLBE+B([)HSU1A5P5OZYX9AU207=M(;34%&%G49
M#C^ZX_B'ZURTT]SI<P@UBW^S,3A9UYA?Z-V^AJM]B;VW+RT\5&I! (((/0BI
M!2&/%/%,%/% A);>&YC,<\4<J'JKJ&'ZU470[>#FPFNM/;UM)BJ_]\G*G\JT
M%IZT[B:3*R7/B.T3:EY::@G3;=1>6Y_X$G'Z52E.D&0S:KX5EM9#]ZXL?F'U
MS&0WZ5LBGBBXFBA8V&AZB<:9XBU%&_YY)J#;A_P%\FM ^%YQ]SQ)K:_69#_-
M*K7>E6&H8^UV<,I'1F7YA]".14,>F7]DV=,UFZB0=(+G]_'_ ./?,/P-.XK>
M1>_X1BZ_Z&?6O^_D?_Q%*/"\O\7B+7&_[>%'\EJ*/6M<M3B\TF*Z0?\ +6QE
MY_[X?'\ZLP^+]'=_+N)WLI?[EY&8OU/'ZTM1^Z,_X11#]_6=:?V-Z1_(4H\(
M:;_RUFU&7_?OY?Z-6W#<0W"!X)4E0]&1@P_2I*5V5RQ.8C\*Z+)J,T$ED)8T
M16422.^">O4U?B\*>'X3E-&L<^IA4_SJS#_R&;K_ *YI_6K]%V/E78@@LK6U
M&+>VAB'I'&%_E4]%%(84444 %%%% $<L,4Z%)HTD0]5=01^M9$WA'1)',D=B
MMM*?^6EJ[0M_XZ16W13NT)I/<Y"]TCQ3IUW:_P!AZM]JMF;$Z:GA_+'J& #'
MOWJZ-0\06>?MNBQW*#_EI83Y/_?#X/ZFNBHI\Q/)V./U/Q#8WUM':;;FWNC<
M0D0W,#1L<2+G&1@_G5KQ=XC3P_IK%6VW4RL(69-R CN:O^)/^06O_7S!_P"C
M%JOXBTN;6X5T]K>![21E,DKR$,F#S@8YR..HZT]+(SL^9_+]3SA/#UQ<:#+X
MH>_2.1PTL<<?RECDY(.1@]\"I])\8ZSJE]86]I#!+>0QX0O)\TR\;MV?8=>M
M1:YX&FTFZ@FGO#-II?;D';Y7/"X)^Z1P<5A7'V>PU"3^S[B6!HUWQB$#)+'G
MYA@@#'0YZUB\3'VZH6=[7OT*]A)4O:WLMO,][4L4!8 -CD YP:RYY$C\1P,[
MJJ_97Y8X'WEK"\.^-UU)+6UG@/VIW\LE'!R!@;L=>O6M>_TZSU+7[>&^MHKB
M,6[L$E7<,[ASBMEN)NZ5BS<>(=&M?]?JEFA]/.4G\A53_A++&5MME;7]\W_3
MO:L5_P"^C@5<3PSH<=W!=QZ5:1SP?ZMTB"[?RK3DEBA7=+(B+ZLP I71=F8!
MO/$=X0+72;>S0_\ +2]GW-_WPG^-*/#5Q>MNUG5[F[0];>']Q#^(7YC^)JQ<
M^*M$MF*'4(I9/^>=OF5OR7-5VUW4KQ?^)9HDV#TFOF$*CWV\L?RHU%[O5W-B
MRT^STV 06=M%;Q#^&-0HJA>^)=/M)_LT1>\N^GV>U7S&'UQPOXFJ;:+?ZD<Z
MQJLCQ'K:V8,,1]BWWF_,5J6=A::= (+.VB@B'\,:X_/UHLNH[OH9;)XAU7/F
MS1Z1;G^"#$LY'NQ^5?P!JQ9>'M,LI?/6W\ZY[W%PQED/_ FZ?ABM2BBXK=PH
MHJIJ6H1:98R74V2%'RJ.K-V ]S0!0E(NO&-G%'S]D@>20CMNX KHJQ_#VG36
MEK)=7G-]>-YLQ_N^B_0"MBDRHK0****104444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %,
MFABN(FBFC62-AAE<9!'TI]% '*77@W[.QET.[-IW-M)EX3]!U7\/RK(FN[K3
M"%UBRDM1G'GI^\A/_ AT_$"O0J1E#*58 @]0>]._<GE['&0RQS1B2)U=#T93
MD'\:F%7+SP=I\LK7%@TNFW+<E[8X5C_M(?E/Y5ES6>NZ8?W]HFH0#_EM:?*X
M^L9_H:?H*[6Y;6GK5&RU.SO69(9AYJ_>B<%77ZJ>:O+2'>X\5(.E1BI!TH <
MO6I!3%IXH$2"G,B2ILD174]F&1^M-%2"@#*?POH[RF6.T^S2GGS+1VA;_P =
M(IPTG5+<YLO$5X%[)=1I./SP&_6M9:>*=V39&#'-XA@OYMB:=>3!%W\M"".V
M/O<U;76]8CXN/#DY]3;W$<@_7!JS!_R&+G_KFG]:OT#U[F2WBF*+_7Z5JT7U
MM"P_\=S31XST4?ZR:XB_ZZ6LJ_\ LM;%&3ZFC0+R,H>,_#Q_YB<0_P!Y6'\Q
M3O\ A,/#W_06MO\ OJM(JIZJ#^%)Y:?W%_[Y%%D.\C-/C'P\/^8K ?ID_P A
M3#XTT'^"\=S_ +%O(W\EK5"(.BK^5.''3BBR%>1CCQ?I[?ZNVU*3W2QD_P *
M=_PE,1^[I6KG_MS8?SK6R?4T4:!=F5_PDP[:-K'_ ("__7I?^$C8]-$U?_P'
M'_Q5:E%&@7?<YO6M;:XL4232[^V3[1"6FN$544"13R=U;AU;3<G_ (F%K_W^
M7_&IV577:RAAZ$9%1_9H/^>$7_? IZ6L3:5[E6YN]%O%1;FYL9E1PZAY%(##
MH>M4M4M/#6KQ2+=3V6^0!3+'*JR8';<.:U)H(5AD801 A21^['I]*HZ 5O-
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MZ/$$D<CW<\+9(9@RI&,# ((P?J#72U#5C2$N97"BBBD6%%%% !1110 4444
M%%%% '/W'BZSM;RY@DM+XQ6SB.:Y6(-&A/J<YQ[XJ>/Q-IF<7%S# 6E,<8:4
M$OCN,52N?"MS<75_MU4Q6=]('FA6 ;C[!R>!^%59_ BM,KV^HM;E92X>./$B
MJ<?*&##CCN#6=YG8HX9K5_G_ %N;P\0Z07N$&I6Q:W&90)!\@]Z9_P )+HOD
MPS?VG;%)VVQD/]XU@P> $MO/\G4I%+*RPR;#OCW')YW<Y]@*CC^'YBCC$>JE
M)5E:4S)$1(,G)"MNSCZYHO/L'L\-_._Z^1TRZ]I+7$T U&V\V!2TJ^8,J!U)
MJ/2O$.GZU=74-A,LZV^W=*A!4DC/%8"?#VV$EQNO7>*0.8]R9>-F().<X/3I
MBMG1-"FTNZN[FXOA=37.P'; (PH48' --.=]43.-!1?+*[_K^O\ ,VZK7FG6
M6HQ>5>6L-PG]V5 W\ZLT59RG.GPC;VY+:7?WU@>R1R[X_P#OA\C\L5']D\2V
M9.'L-00>H:!_ZBNFHIW9/*NAS=IJ\CWRV-]I\]C<NI:,2%623'7:P/;TK8%8
MLY-[XQD4\+86P$??#R=3^0%8VJ:CKV@3QRS7L%XDK!5B$.W\<CH>1ZU5KD7L
M=L*6O/+OQ9J$&KQK);RVI&#-$O._\".!TYKH(_&FF/'"6WH[L%=2/N$^_>CE
M87.CHK#NM4OKK5(K'1_L9S;_ &AIK@L592<  +_.GF\\0VX_?Z-!< =[2Z )
M_!P/YTK#N;-%88\30Q<7NG:G9^IEM691_P "3(J>W\3:'=-MBU:S+_W6E"G\
MCBBS%=&K12(RR*&C8.I[J<C]*7I0,**** "BBB@ JEJNKV6BV?VO4)O)@WJF
M_:3@GITJ[5#5M'M=;M5M[L2F-7WCRW*GH1C([8)% '!Z]\0[IT\G3K::S60J
MT-S*O,JG^ZI'>N8\2Z%J>B.NH7S0%[B;S% Y);.YB1C]/:N[\8>#HKJS2YTV
MV N(42(1^9M01K['T'Z"N)OM8U3Q1#!IET8HH[=MT=SRJ],#<W0<=ZM;:&,M
M]?D3/I#ZK<6TFGS10F]E#B*,,(@6Z$<\<#TYKV.&)8(4B0 !0!P*PM,\)Z-I
M5A;%[>,RV^V0W#R$D, .=Q/W?;I4G]LWFK,T>@6Z21 X-]/D0C_='5_PX]ZY
M</3J0BU4GS.^YU590E*\(V-WH">PZFLFX\3:/;S&'[<DTX_Y8VX,K_DN:8OA
M6*Z82:S>W&HO_P \W;9"/I&O'YYK:M;&TL8O*M+:&"/^[$@4?I6]T19LPUU7
M5[TD:?HDL:]IK]Q$/^^1EOY51O[2X\R&'7+^]NC-DK::;&8T('7)!W$?C78U
MEZEHD&J7MK-<_-' &^3)&21Z@BFFKZDSB[:;BZ?_ &5I]HL5I'!:1@A3$ $(
M8] P]?K4\6JZ?.TBQ7ULYC&7"R@[1[^E9%SX9FDOB\-XD=JTL<S1&/+948P&
MSTJ-_!\;VL$(G5#''(K,L8RQ9LY/K]*+1[D\U1;1-0^(=)\R*-+^WD>4$QA)
M =V.HSTJ2#5[*58 ]Q%%-,NY(7D7<1],\UFGP_=/)!.]S:B>/<&V6P52K#'3
M/7WJJG@YHU6,7B&(A/,S#E\ITVMG@4[0[BYJM]C?CU?3I3(([^V8Q#+XE!VC
MU/I48UFRDEMDAF687#%4>(AER!DY-90\*%+>%(;M8I(TD4R+$,G><YHTOPM)
M87,4[W@D9)C*0%/.5QU)-%H=Q\U6Z5CI:***S-PHHHH **** "BBB@ HHHH
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MJ,]ZU/[)M5T^>UM(8[6.=2&,,8&<]3Z'K6E/!%<PO#/$DL3C#(ZY!'N*Q?\
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M:A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6+JUU/
M-=KIML_E!H]\THZJI. %]SSS6U6!=?)XE8?\]+56_)C30F20PQV\*0Q+M1!@
M"I*** "J$UN]B9+S3W,,@R[Q?\LY?7(['W%7ZJ:I-Y&F7#@9.S:/J>!_.A"9
MNVTXN;6*=1@2*&Q]:2YM;>\A,-S!'-$>J2(&!_ TEG$(+*&(=$0#]*GI%&&/
M!WAT/N&C6>?0Q@C\NE;$,,5O$L4,:1QKP$10 /P%244[L226P4444AA1110
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M$K.I)6%OF7/.3_#]#71TFK%QFI;!1112*"BBB@ HHHH **** "BBB@ HHHH
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MK\RSOR\A]2?Z=!56T4W'B34KASGR%2WC'ID;F_F/RK59@BECT R:K8C=BTA
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M57P[$\6@VOF+M=U,A'IN);^M4IY?^$@NA96Q+6$3YN9U^ZY'_+-3W]S70
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
J**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>ganx-20211231x10k005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ganx-20211231x10k005.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %+ K\# 2(  A$! Q$!_\0
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ME;8TC[G9>.6Y(!SGH<>PK4H =YC4>8U-HH =YC4Y&)=?K_2HZ?']]?K_ $H
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MM8EC,OD(LK%E*$;027YW<] <\],59N[2PN[VYMB+:V6YNV6W*38B3,>4D/)
M!/!^O:N4"CKBE"CT%'*+G\CH[NST4:/-/:0NY^<+('&8V5]JYR_0J,XVG[W!
MXKG M."C.<<TX+5)6)<KC+CAH_\ KFM/N[&[L-GVRVE@W_=\Q<9IMV/G0?\
M3-:Z0:]9S:U<-N6UM!(\T3*K'S9&*@E\AB/E!X 'IQFI9229S$,4EQ)Y<2EW
MVLVT>@!)/Y FFE66)92,1N2%;L2.O\ZZ:/6].@OX0D:MIZR7;R0K'L,@?<(U
MR!G&"![9J*35K2".Y>UE1KDI+Y,GV95VEFB*#&, A58>V..M*['RKN<YD>HH
MW+C.1CZUU:ZIHWFR&0H+?[9YR11P'+ D9W@C!4<D $>F,&HFUF""/*W$4]]L
MB22Z6V $F)2S8!7LF!G STHN'*NYSLD,D,<,DB%5F4M&3_$ 2"1^(-3)IU[)
M9M>):3/;+G,JIE1CK^5:<=]9F#5HFF"12LWV8!"7VC=L09! 3D9&01U%+I]]
M9VT&F7,ER5FLO.W6ZQL6DW'@9Z8/0Y/3/%%PLC$D1HGV2*5; .#Z$9'Z4S<N
M,Y&/K731ZCI0MV27:80T#&*.(AY2JQAU;(P5^5NX.?7-6DUC2SK"SRSPJB+@
M-'$V)%,F2KY3/"] !CL31<.5=SC\CGD<4O6NIM]3TF,6OF.G[HRB-$B(5,AM
MKO\ +G<"5Z$\<XR*P]5N([K4I9HA$%8+S$"%8@ $\@')/)X'-.XFK+<I4444
M"/7?A7_R+-U_U]M_Z"M=Q7#_  K_ .19NO\ K[;_ -!6NXKGG\3.VG\**D^J
MZ?;7L5E/?6\5U+CRX7D =LG X]ST]:;!K&F7*7#P:A:RK; F<I*"(@,Y+>@X
M//L:Q)]*UJ#6[F6QV>3=W\-T]P)E4A%"*\<B,I+#"';M(Y;M6):>$-=2.2W9
MHHH9XUMIGEF$P\H3F4[% &%()4J3SN]N8+.[_M"RW6J_:X-UV,VP\P9F&,Y3
M^]QSQ5BN/M]#U:R71;?[';72Z;?2.MRLBQG[.0X50IR1CS/NYZ)784P,;Q;_
M ,B?J_\ UZM7@=>^>+?^1/U?_KU:O ZVI;'+7W04445H8A1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %!&1BBB@#VOX:>,O[8LQHVH2YU"V3]T[
M'F:,?^S#]1SZUZ#7C'PN\)27^HIK]UO2TM7_ -' .#+(._\ NC]3QZU[/7/-
M)/0[J3;CJ)_'^%+2?Q_A2U!H%%%% !1110 4444 )_$?I2TG\1^E+0 4444
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M^YSIUC7U(!T4$E4)VEB!DC/U(R>./ND]"*;:ZMK[-'"VCJG[M6DE*LB[L$L
M.>X _&NDVM_=;\J-K?W6_*B_D%GW*]C//<:?!-<PM!,Z!I(C_ ?2K&3ZFC:W
M]UORHVM_=;\J0PR?4TF32[6_NM^5&UO[K?E0 9/J:,GU-&UO[K?E1M;^ZWY4
M &3ZFK%E_K#]*K[6_NM^56;-2)#D$?44#1\\J*>!5BUA22SOI&7+11*R<]"7
M4?R)K2CT2+=&9+HA)\&WPH!E&T'C)P#EMO/<&NRYXBBWL9(%. K5&CQ*NV6X
M>*5$CEEWQ?*B.P'7.<C(S^/I4HT5!(B-+*IF9E@^16!PH;+$'&#D8QGCFBZ#
MDD9(%/ K7CT>U<HGVN82,T2$>4,;I$W#G/0=#3[/24\N">0DEN'B?'\2,RD8
M.<?+WQFES(.21D 5(!5VRAAGT^51&K70#/\ /N&4 R=A'&1R2#UJ[)I%L;UX
MHIIE1IS!%E <,%!RW/3D>_7TIW$H-JZ,@"G@5IV^E13311>=+EDC9VVJ%0OC
M:,D\]?QJ:/1%:.W#3E)9B-N5&TCYB<<YX"^G<4<R#V<F9(%2 5+<P10RJ(9A
M*C*&R"./8XX_*F 4S-Z&=?\ _'U_P!?Y56JU? F\"@9)50!4USIJP!E261W2
M7RG<Q[8MW<!R>Q]<5-S1)M&?15MM,NED5-BDLZ(I# ABXRN#Z'!J6WTF:615
MD:./?&SJ#(N[A2P)&> <=:+H?*S/HJ\FD7KLZK&IVXP0XPY*[@%]<CGBFC3I
M1>6MO*R(UP4QA@Q4-C!('3@YQ1=!RLIT5H'35DA,UK*\L8WJ04"LK+@X(SC!
M!ZC\J:NCWCSR0HD;/&P1L2#&XYPO^]P>*+H.5E&BKD>F74R1O&J,')7AQ\I
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MC_\ 0.L?^_*_X4?V/H__ $#K'_ORO^%'M5V#ZA+^8\+R/449'J*]T_L?1_\
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M]?[R_G1O7^\OYT '\9^@I:9O7>?F'0=Z=O7^\OYT +12;U_O+^=&]?[R_G0
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MEC,GE!#N4!BO(_#]:+CLRED^IHR?4U8CLKAPK&)T1BP#LIVY )(Z>QJ.6":
M(98GCWKN7>N,CU% K,CR?4T9/J:**8'I'P^YT&?_ *^3_P"@BNLKD_A]_P @
M&?\ Z^3_ .@BNLKGE\3/2H_ @HK,NM:BM]0:QBM+R[FC57F^SH"(E;.W<21R
M<$X&3@9ID_B&T@LQ<K#<2@WK6*HBKN:52P/4@8^4\DU)J:U%95KXALKVXTZ&
M!+D_VA;M<02-$53:!D@D_P 6#T&:U:  W$5FK7,Y*Q1 NY S@#VJI_PG'A__
M )^I/^_#?X4S6?\ D!W_ /UP?^5>5U<(*6YR8C$3I-*)ZO\ \)QX?_Y^I/\
MOPW^%'_"<>'_ /GZD_[\-_A7E%%7[-'/]>J>1ZO_ ,)QX?\ ^?J3_OPW^%'_
M  G'A_\ Y^I/^_#?X5Y111[-!]>J>1ZO_P )QX?_ .?J3_OPW^%'_"<>'_\
MGZD_[\-_A7E%%'LT'UZIY'JQ\;^'^/\ 2I.O_/%O\*7_ (3CP_\ \_4G_?AO
M\*\HHH]F@^O5/(]7_P"$X\/_ //U)_WX;_"C_A./#_\ S]2?]^&_PKRBBCV:
M#Z]4\CV72_$&EZQ,\5E/OD1=Q5D*G'J,]:U,#TKPVRO9]/O8KNV?9-$V5/\
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M/J=4\UHKTD_#K2QC_2[S\U_PI?\ A76E_P#/W>?FO^%'M(A]3J]CS6BO2O\
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M]?)_]!6NOKD/AS_R+]Q_U\G_ -!6NOKFG\3/7H?PT<I<:#J\/B%M7L#92O\
M;)9UCGD9!M>WCBY(4\@H3CT/6J$'@K4K*Q?2X+BTEL[N.V6YF<LCQF)MS;$
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M_D8]=_Z^K/\ ] 6KFJ:RNERI&T)DW6T]QD-CB)02/QS5.'_D8]=_Z^K/_P!
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M>,]/%MO=7MA:V-O/*UU,$+2(4"QE682#U!"G'T-4[CQMY,\J"R^6-G4LTO\
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M]O\ 2O'?^$Q\0_\ 03D_[X7_  H_X3'Q#_T$Y/\ OA?\*/9,/KU/LSV+R?\
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M3G&.U9NIP1VMZUK&5;R (W=>CN/O'\^/PH3)DG:]RG1113)"BBB@#T[X<_\
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MDDHW/Z5RM%'U> ?4J7F=3_;&G_\ /<_]^V_PH_MC3_\ GN?^_;?X5RU%'U>
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M.*RZUM<UO^VI%D:V$<@=G+LP9CNQ\N0H^4=LY/)YK)IQO;WMQA1115 %%%%
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M 'R:/*D_YYO_ -\FL_<W]X_G1N;^\?SHYF'LT:'E2?\ /-_^^31Y4G_/-_\
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M1110 4444 )_'^%+2?Q_A2T %%%% !1110 4444 )_$?I2TG\1^E+0 4444
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A\J L96QO[I_*K-FI$AR"*N>6G]Q?RI0JCHH'T%(+'__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>ganx-20211231x10k006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ganx-20211231x10k006.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $) JD# 2(  A$! Q$!_\0
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHY]* "BCGTHY]* "BCGTHY]* "BCGTHY]* "BCGTI.?2@!:*.?2CGT
MH **.?2CGTH **.?2CGTH **.?2CGTH **.?2B@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MU6/4/M5Q),D\LYW[?F9XTC.<#T0'ZDT ;U%%% !1110 4444 %%%% !1110
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MX9!&1Z4 ;-%8-EXOTB_<+#)*,R(BEXF4,'SL<9ZHQ4@-TS6]0 4444 %%%%
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M0%QR<,"/QJU<Z%XIOO"J>'GALK>&UM5A\Y)LFZ*%=H Q^[!53G.>N.E>@T4
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "N,^*__ "3#7/\ KDG_ *,6NSKC/BO_ ,DPUS_KDG_HQ: .OM_^/>+_
M '!_*I*CM_\ CWB_W!_*I* "BBB@ HHHH **** "BBB@ HHHH **CG61[>18
M7V2E2$;&=IQP:HZ#;:E9Z-;P:O>+>7R B2=%VAN>./IB@#2HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH 1ON'Z5Q?PF_Y)MIG^_/_ .CGKM&^X?I7%_";
M_DFVF?[\_P#Z.>@#M:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MDNV'!![_ .LKL6'RGZ5S?P^'_%!:-_U[#^9H Z6BBB@ HHHH **** "BBB@
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MI)&\Q*LI/((KZTKXI^&W_)2?#O\ U_1_SK[6H ***;)(D4;22.J(HR68X H
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M<B'(858H **** "BBB@ HHHH ***R=&FUN6?41J]M;PQ+<$69A8DO%V+>AH
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M:G)J5TK,6N'4*3DY P/2M6B@ HHHH **** "BBB@ HHIKND4;22,%102S,<
M =S0!E^(--O]4L(X=.U673IEF20RQJ&+*#DKSZUK5B?\)AX9_P"A@TO_ ,"T
M_P :L67B+1=1N1;V.KV-S.02(X;A78@=3@&@#3HHHH **** "D.<'')I:0D
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M5YGJ7B+QG=^--<TO1)](AM-.,('VN%V9M\8;J#ZYKTRO--._Y*5XT_ZZ6?\
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M+\P(/4\#T]: .OTQ[:WT&S=&CCM8[9""'RJH%'\1ZC'<U-'J-E-8&^CNX7M
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M+M8%VHI.2!G/7O5ZN?TWQ0^HW\=J?#^MV@?/[ZYM@D:X&>3N-=!0 5Y]K/\
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M\"?]?ES_ .B#7;]J /D_X^_\E0G_ .O6'^1KS"O3_C[_ ,E0G_Z]8?Y&O,*
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M-'&8E91R%+;B,^YY-:%% $%W9VU_;-;7<*30L061QD'!!'Z@51_X1G1!<27
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A_GM6I:6-K8)(EI!'"LCF1@@P"QP,_H*L44 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>ganx-20211231x10k007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ganx-20211231x10k007.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (P J@# 2(  A$! Q$!_\0
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MXYSC&<<9ZCFO(?#'AZ;^U/#>G+X5U&SUZPO))-:U6>,^5<0D.'!E)_>>9N7
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M1<[T+ YB.2&W>F:?XQT/6[Z7QR+.QNV\R/27*)&93.D>\R*N<"4CC(SST[T
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M'MW;@<C'7->+3^"[R]LP;S0GGF@\ QV<'FP[MEV WR+GI(#CW%>G>%[>[M?
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MR@*^,[6VMSC/;C.!6Y<:)>76M^%[G2]"DTBV@N-1=U)4>3YD#*DC!20NYCG
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M!D8^8!CQU[UM:5'-'9_".)U=+]&E7;("'6,0,'&#T&,#\J /8J*** "BBB@
MHHHH **** "BBB@ HHHH **** ,>^\6>&],O)+._\0:5:74>-\,]['&ZY (R
MI.1D$'\:K_\ "=^#_P#H:]#_ /!C#_\ %4>#?^0'<_\ 85U+_P!+9JZ"@#G_
M /A._!__ $->A_\ @QA_^*H_X3OP?_T->A_^#&'_ .*KH** ./&O_#P:B;_^
MW?#GVD@ O]OAZABV<;L;MQ)W8S[T7.O_  \O+U+NXUWPY).H8;FOX?F#  [A
MNPW  YSC'%=A10!S_P#PG?@__H:]#_\ !C#_ /%4?\)WX/\ ^AKT/_P8P_\
MQ5=!10!S_P#PG?@__H:]#_\ !C#_ /%4?\)WX/\ ^AKT/_P8P_\ Q5=!7/\
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M!Z+1110 4444 %<_X[_Y)YXE_P"P5=?^BFKH*Y_QW_R3SQ+_ -@JZ_\ 134
M=!1110 4444 %%%% !1110 4444 %!( R3@"BLOQ!87>IZ/)9V<L4;2LJR>;
MG:\>?G3CD;AE<^A- %NPU"TU6QBO;"XCN+64$QRQG*L <<'ZBK-<AX5\-:MI
MW@;3]&N=0?3+NV=R7TX1-\I9B%_>HPQ\PZ#/ YZYM^%!=Q7GB.UN]2N]0-OJ
M:I'-=%-P4VMN^ $55 RQX"CJ3R220#I***,C.,T %%&1G&:,C.,\T <_XA_Y
M#GA/_L*R?^D5U7049&<9YHH ***,C.,\T %%&1G&:* "BBB@ HHHH Y_P]_R
M'/%G_85C_P#2*UKH*Y_P]_R'/%G_ &%8_P#TBM:Z"@ HHHH **** "BBB@!&
MSM.T@-CC/3->.2?#KQ*+KQ3 9;6Y;5-'\MKW84^TW!=VYRYP>0.F -H& *]D
MHH Y#0M)U.XN?$FH3?:]%;5;J&2 *87FB6.&-"2"'3DHPZ'CT/2WHAU"U\5:
MKI=WJ]WJ,$5E:7$374<*LC2/<*P'E1H",1)U![UTE<_9_P#)0]9_[!5A_P"C
M;N@#H***R_$&JS:-I/VNWMH[F=KBWMXXI)3$I:69(@2P5B "^>AZ4 <#H?P]
MU[3_ (A/K$^H(VGJJ,MN))C&/F?Y4S*3E<Y^<%?G; &*-5^'NO7GQ$AUF'4$
MCT_,DC0"281_>0[6Q*#N;&3M&S*#(.:[+[9XP_Z 6A_^#F;_ .1:/MGC#_H!
M:'_X.9O_ )%H Y+QSX"UWQ#XILM0T[4!;6PF7S4224 @1L-SXE7_ '/DP<.<
MDUZ1;1F&TAB;;N1%4[<XX';//YUB?;/&'_0"T/\ \',W_P BU<\/ZK-K.D_:
M[BVCMIUN+BWDBCE,JAHIGB)#%5)!*9Z#K0!J4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 445R7Q&EU.#PNLVESZC Z747G2Z=")IDBSAR
M$/WASVZ=>U '6T5XWX/U;Q-+XVLUAU+Q#J.B3/Y;/J=@(5*B)V<@X!&UQ$ >
M,[R.W/LE !1110!S_C+_ ) =M_V%=-_]+8:Z"N?\9?\ (#MO^PKIO_I;#704
M 5[^^M],TZYO[R3R[6UB>:9]I.U%!+' Y. #TK'_ .$AU3_H3-<_[_67_P D
M4>._^2>>)?\ L%77_HIJZ"@#G_\ A(=4_P"A,US_ +_67_R14<OBNYM3 U[X
M7UFT@EN(;?SY)+1E1I9%C4D).S8W..@-=)6/XEL;C4-*@AM8_,D74+*8C<!A
M([J*1SSZ*K'WQQS0!)JNM#3;BWM(;"[U"\N$>1+:U,8;RT*AW)D=%P"Z#&<_
M,, @$BG_ ,)#JG_0F:Y_W^LO_DBI+J"9O'6DW"Q2&!-,O4>0*=JLTMJ5!/0$
MA6('?:?2MR@#G_\ A(=4_P"A,US_ +_67_R11_PD.J?]"9KG_?ZR_P#DBN@H
MH Y__A(=4_Z$S7/^_P!9?_)%'_"0ZI_T)FN?]_K+_P"2*Z"B@#GXO$\W]IV%
ME>^'=5L/MTK0PS3O;,F\1O)@^7,S#Y8V[5T%8>NP33:QX8>**1TAU-WE95)"
M+]DN%RWH-S*,GN0.];E !7/^._\ DGGB7_L%77_HIJZ"N?\ '?\ R3SQ+_V"
MKK_T4U '04444 %%%% !1110 4444 %%>3?%"VNQXC@N6'B$VDMAY$']D:BL
M $X=CF16(XPR_-^?05TWPSM]9M?#$D6LM=,XN3Y'VJ?SG\O8F</_ !+YGF%3
M_=*T =G1110 5S_A[_D.>+/^PK'_ .D5K705S_A[_D.>+/\ L*Q_^D5K0!T%
M>=>%/"/B?2O&=_J.IZJ9]/D8%8?.<Y^3 ^;<2^W[O[P>XZ5Z+7/WNLZQ_P )
M#/I.DZ78W/V>TAN9);N_>#_6/*H4!87SCRB<DCJ* .:\*>$?$^E>-+_4M2U4
MSV$C K#YKG/R87YMQ,FW[O[P>XH'A'Q./B8^L_VJ?[(.#]G\Y_N[R=F[=N_V
MMN-G.WI72_;/&'_0"T/_ ,',W_R+1]L\8?\ 0"T/_P ',W_R+0!S0\(^)Q\3
M'UG^U3_9!P?L_G/]W>3LW;MW^UMQLYV]*]%K'T'5KS4VU."_LH+2ZL+L6SK!
M<F=&S%'*&#%$/24#&.U9>DZ]XJUG1K'5+?0-&6"]MX[B-9-8E#!74, <6Q&<
M'U- '65YT/"/B<?$Q]9_M4_V0<'[/YS_ '=Y.S=NW?[6W&SG;TKI?MGC#_H!
M:'_X.9O_ )%H^V>,/^@%H?\ X.9O_D6@#FO%'A'Q/JGCBRU/3=5,&GQJ=T/F
MN/X5!&X,&CW8Q\@_AR>M>BUS_P!L\8?] +0__!S-_P#(M'VSQA_T M#_ /!S
M-_\ (M '045S_P!L\8?] +0__!S-_P#(M:&A:G_;?A[3-6\GR?MUI%<^5NW;
M-Z!MN<#.,XS@4 :%%%% '/\ A[_D.>+/^PK'_P"D5K705S_A[_D.>+/^PK'_
M .D5K704 %%%% !1110 4444 %%%% !7/V?_ "4/6?\ L%6'_HV[KH*Y^S_Y
M*'K/_8*L/_1MW0!T%9>OZ;-JNG16\#1JZ7MI<$N2!MBN(Y6' /.U"![XZ=:U
M*Y;6-0F;Q!)I\FNG1+>&T2YCE AS<,6<."958;4"KD#!^<<@8R =316=H%]<
M:GH%C>W<0BGGA5W4 @9/< \@'K@\C-:- !7/^#?^0'<_]A74O_2V:N@KG_!O
M_(#N?^PKJ7_I;-0!T%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %<9\3$NY_#$<%G%?3L;N%IH+&X$,LD0.6&\]!Q_(>]=G7 _%#0$O]'B
MU"#0(-7NXIHEFAFE$8>W#%F!8L O^]S@]C0 SX;6T5O/J)CT?6]/RL>3J=\+
M@/RWW?F.,=_J*]!KSWX8VNGQ"_N-.\'IH,4@0><E\ERMQ@MQE6.-N?UKT*@
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MB@M+(4 ?JN&'(/!KHZXSXGM:IX162YOQ9M'>0O 3:?:A)*&^5#%_%G].O:@
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M]A6[_P#1[USXEVBGYGL9)'GKRC_=_5'.1)BYW1V[1@OG.T#C'^/:OI?X(?\
M).8_^OVX_P#0S7SO7T1\$/\ DG,?_7[<?^AFL\/+FD=N;T52HI)[M_H+\0=$
MO[^XO91I,NJ+)9+'8^6JO]EF!8L<,<J6RGSKR-O; SQ-[9VT][JUI9^"=0CN
M'M(7M8_[.53"^6!;@_*Q(_U@Y^7K\HSZUJWBLZ;K3Z7;Z+J&H31V\=Q(ULT"
MJBNSJH/F2*2<QMT![5S<7BR]'CB[G_X175R3IL*>5YUKN&))3N_UV,'..N>#
MQTSZ"YK:(^7?+?5FAX1TJ2UUJ6ZM-&DT;3C;&.6W=$C\Z;<NUMJ$CY5# MWW
M#KBNEU^VO;SP]J%MILWDWLMNZ02;MNUR#CGM]>W6J>A^)AK.H7=A)I5[I]S:
MQ13,ETT3;DD+A2#&[#K&W7':MVIE>^I2M;0^>KGP-K;F[^S^$YXS(J);\0CR
MY1G<?O\ !/R_O/;KP*[[X>:!J6EZS=7!TR32M.: QR6[A%\Z;<NUPJDCY5##
M=WW#KCCJ+[QEI&G7?V:Y35%E,ODKMTB[=7?!.$98R&X!/!/ K6L+Z'4;1;F!
M+A(V) %Q;R0/P<<I(JL/Q%;3Q,IQ<6EKY&4*$8M--EFO%_C9X.\5>)=5TZ;2
M+>2]L(X0GV=) /+EW$ER"1]Y2HSVVG.*]HHJ*%:5&:G%)O7?7=6-6KJQY1\%
M/"WB/PW:ZG_;$+VEI,R>1:.X)WC.Y\ D+D8'OCV%>KT44\17E7JRJR23?;1
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MA0,$8[>E24R(J84*L67:,,3R1ZT^@ KG[/\ Y*'K/_8*L/\ T;=UT%<_9_\
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MYH7S1@2;MV_&.N><=,]JM:)I45IXT\/8GN)4GU+=)'*X97<0R,&/'4%%([#
MP!5ZG:?_ ,CEX7_["+?^D\U>_B:<52DTCQZ$Y.HDV>F>-9/)\!^(9?+23R],
MN7V2#*MB)C@CTKXRD@Q&Y\U^F2..?TK[*\=_\D\\2_\ 8*NO_135\=O&C_>&
M:WX7PZKPKJUW[MM6M^;L>O7=FB!X2D)<2OE5)&<>GTK[@TI431[)8T2-!;QA
M41<*HVC@ =!7Q%)&J02[1CY#_*OMW2_^039?]<$_]!%1Q105*5-)6T[M_GZ#
MH.]RW1117R9N%%%% !1110!X'\3]6\':MXTU"VU/5(K:\L+*"*%KFRFF03++
M(SIM '!1ERV<'<I!^4Y]B\'*R>"- 5T:-ETVW!1DV%3Y:\%>WT[5R'CW3?&=
MSXD63PW%(EK-8".:YMI8HI0T;/)LW,,Y;Y%4\@;W)')KO-'2^CT2P35'1]06
MVC%TZ?=:7:-Y'MNS0!=HHJKJ6I6>D:?-?W]PD%K",O(YX&3@#W))  ')) %
M%JN?\/?\ASQ9_P!A6/\ ](K6M/2-4M];T>SU2TW_ &>[A6:/>,-M89&1ZUF>
M'O\ D.>+/^PK'_Z16M '05S]G_R4/6?^P58?^C;NK6K>)=*T6YM[6\GE-S<9
M,4%O;27$C  G.R-6;'!YQV-84GQ'\'6KS7LDUU$^P)+.VDW2DHCLH!;RN@=F
M'H"2.N: .SKROX]?\B=I7_853_T1-7H6EZ]I^L-(EH\XDC 9H[BVD@?:>C!9
M%4E3@\@8XKSWX]?\B=I7_853_P!$35%3X'Z'3@_]YI_XE^9X)77?"W_DJ7A_
M_KI/_P"DTM<C77?"W_DJ7A__ *Z3_P#I-+7G4?XB/L<R_P!TGZ'O_C[_ ))W
MXE_[!=S_ .BFIM.\??\ )._$O_8+N?\ T4U9.J^(M,T:6.*]FD$LF-L<,$DS
M<G R$4D9/ SU/ KW*.S/S^KT(?%'_(+MO^PGI_\ Z5PUWU>;ZSJ-KJ>B6\MJ
M[$+JM@CK)&T;HWVN$X9& 93@@X('!%>D5-;=#I;'SSI%J]UX7T<)=W%OMLXN
M82HS\@ZY!JWINE#352..]NI8D38L<I4J!^"@UFZ7K-CIWAK3!<R2#980NYCA
M>0(-@Y8J#M_&K\/B#3IKB. 23))( 4\VVEC!!.!RR@<G@>M?2P=.T;O6W<\*
M:G=V6GH>L_#S_DG'AO\ [!L'_H KYP^+:(?BGX@9HPY\R+L"?]1'7T?\//\
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M,;99MV\1^5W#<CYMV >0,?2OH73/^059_P#7!/\ T$5X9XB_Y%C5O^O.;_T
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M<S2D,Q(+D-@MSSCO7I^CVDFGZ'864JP));VT<3+;J5B!50"$!Y"\<9[5=HH
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M_$O_ &"[G_T4U-IWC[_DG?B7_L%W/_HIJ;7N4.I^?U>AB^*/^07;?]A/3_\
MTKAKOJX'Q1_R"[;_ +">G_\ I7#7?5-?=#I;'@7AW_D6-)_Z\X?_ $ 5I5F^
M'?\ D6-)_P"O.'_T 5I5]53^!>A\]/XF>C?#S_DG'AO_ +!L'_H KYS^*_\
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MO?\ T;:U[%#H? 8OXY''ZA(KW][K[?81?Z=<&"&S>VC:60 @*-Y&\,X.5P0
M&'!YSU<'_)1=(_[!E]_Z,M:LO8VDEXEX]K UT@VI,8P74>@;J.IJM!_R472/
M^P9??^C+6NJ:M%G'%^\C0^(?_)./$G_8-G_] -><UZ-\0_\ DG'B3_L&S_\
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MMI(9<=>ASS@=G7.1>#+"'Q"-66XNBJW3WJ6A9?*6X>/RVD'&[[N>,XRQ.,]
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MFG15-W3-L;F4\5%1E&UCS.Y\7^&6\=:C<#Q%I!@?3+-%D%['M9EEN2P!W8R
MRDCMN'K5W_A,_"W_ $,NC_\ @=%_\57?T5UQJN*L>3*FF[GFNB>,/#$7C;5K
MB3Q'I"0R:=9HDC7T85F62Y) .[!(#+D=LCUJM\1?%OAJ^M=#%IXATFX,>I[Y
M!%>QOL7[/.,G#<#+ 9]2/6O4Z*4:CC44^SN.4+P<.YX%_P )%H?_ $&=/_\
M I/\:6Q\1Z&GBSPY,VLZ<L45^7D<W2!47R)1DG/ R0/Q%>^45WU<SG4@XN.Y
MQT\!&$E*YP?C3QIX5NO OB&WM_$NC33RZ9<I'''?Q,SL8F   ;))/&*^5?/B
M_P">J?\ ?0K[FHK;*<YGEO/R14N:V_E?_,ZZE-3/A:::(P2 2(25/&X>E?8&
MG>.?"*:9:(_BG1%984!!U"($':/]JNIHJ<US>>8RC*<4K=@ITU KV-_9ZG9Q
MWEA=P7=K)G9-!()$;!(.&'!P01^%6***\@T"BBB@ HHHH **** "N?\ &EA<
MZCX>$5M;FYV7EK-+;J1F6))T=UYX.54\=^E=!10!R?AW3-;L_"P@M'MM-G>^
MN9TBN[8SB.!YI'1-J2)@X9>YQR,>A9:#XJL;K4;B+7]&+W]P+B4-H\N PBCB
MPO\ I/3;&IYSR3]!UE% ')QZ#XJBUFYU1=?T;S[BWAMW4Z/+M"QM(RD?Z3G.
M96SSV'3O<^Q^,/\ H.Z'_P"":;_Y*KH** .3CT'Q5%K-SJBZ_HWGW%O#;NIT
M>7:%C:1E(_TG.<RMGGL.G?,\7>!?$'C/3;>PU'Q%ID44%P+A3;Z1(K%@C+@[
MK@\8<_I7?T4FKJS*C)QDI1W1XE_PH"Y_Z&N+_P %A_\ CU:.@?!G4O#NOV>L
M6?BBU>XM&=D6;2F*'<C(<@3@]&/?KBO7**A4H)W2.F>.Q-2+C*;:9R>KZ!XI
MUK1;[2[G7]&2"\MWMY&CT>4,%=2I(S<D9P?0TG_"/^*?^@_H_P#X)Y?_ ))K
MK:*U4FMCC:3W.(O_  CXDU&WCAF\0Z4JI/#."FD2 [HI%D4<W/3*#/MGI6O]
MC\8?]!W0_P#P33?_ "57044.3>X));'F%E\+=8L;"WLXO$MB8X(EB4MI+Y(4
M8&?](Z\5/_PKC7/^ADT__P %+_\ R17I%%="QE=*RDS%X:B]>4Y'1O#_ (IT
M/1+'2K;7]'>"S@2"-I='E+%5& 21<@9X]*XOQ#\$;_Q+K]YK-YXIMH[F[96=
M8=+8(-J*HP#.3T4=Z]BHJ</B:V'G[2C*S[FSBFK,\*_X9UE_Z&Q/_!8?_CU=
MIX.\!:_X)TJ?3M-\1Z9+#-<&X9KG2)&8,55<#;<#C"#]:]!HK;$YCBL5#DK3
M<EOKW$H1CJD9^F0ZQ%YO]K7UC=9QY?V2S>WV]<YW2OGMTQC!ZYXT***XB@HH
MHH **** "N=\=:;=:OX)U2QLH?/N)(P5BR!YF&#%>>.0".>.:Z*B@#C_  [9
M:J1XEOK95T]]1U$3VGVVV9\((HD+-$&0\E&QR#T/L9(]!\51:S<ZHNOZ-Y]Q
M;PV[J='EVA8VD92/])SG,K9Y[#IWZRB@#D[W0?%5]=:=<2Z_HP>PN#<1!='E
MP6,4D6&_TGIMD8\8Y ^AN?8_&'_0=T/_ ,$TW_R57044 <GJ>@^*M5M4MY]?
MT942X@N 4T>4'=%*LJCFY/&Y #[9Z=:N?8_&'_0=T/\ \$TW_P E5JZI?_V7
MI=Q??9+J[\A"_D6D?F2R>RKQD^U<AH'Q0L_$.M'3(/#?B6V=',<\UU8A(K9@
MI;$K!SLX]1W% '$Q_L^7$421KXKBPJA1G3#V_P"VU/\ ^% 7/_0UQ?\ @L/_
M ,>KU8^*M .F7FHQZU836=D";B6&X201>QVDX/MU-5K3QOX:NM#L]8;6K&VL
MKL?NGN;E(\GNIR?O#N.HK/V,.QVK,,4E939C>%O!WB/PEHB:38>(=*D@21Y
MT^D2%LLQ8\BY ZGTJ>\\,^)[W5[74Y/$&D":V@EMT5='DVE9&C8D_P"DYSF)
M<<]S^&PGB>QD\7+X;19FNVTX:DLRA3$8C)Y> <YSGGIC'>L;7?B-::'XAET1
M- \0:I=Q0I-)_9EF)U56SC/S CIZ5HM-CCDW)WD3?\(_XI_Z#^C_ /@GE_\
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M@#'_ #]5IIK^C2:4VJIJU@VG*2#=K<H8A@X/SYQU]Z0>(=%-I/=#6-/^S6Y
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M0<;0PP5?YL<'OCO530]2^'_A!CX=TG4-,L)?M)C:U\_]X9N!\Q8EB>@R3[4
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MDK1^7U4?>!(Y'?I4\5KHUYX?\8)I&IW^G^"UN+1K>26"YFB:0 F9"H_>",G
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M7NIC/.4&/,D/!8^_ H \.U>PU'4/$OQ#TFQ\+#69[TVUNMZSQK]F?R1ACNY
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M2&PN]0O+A'D2VM3&&\M"H=R9'1< N@QG/S# (!( -2BN?_X2'5/^A,US_O\
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MO/MJ2PI]IC678C'@]!@'^).0<#FK'@3X>MX.O+ZXEU)[TSLZIYP#,J;@1AL
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M:GJW]KZ'-]AM);GRO[(F7?L0MMS]I.,XQG!KL*Y_QW_R3SQ+_P!@JZ_]%-0
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M"J<>FPQ:S<ZHK2>?<6\-NZDC:%C:1E(XSG,K9Y[#IW +E%%% !1110 4444
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MI?\ ;?\ ]-L% 'H%%%% !1110 4444 <_P"#?^0'<_\ 85U+_P!+9JZ"N?\
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M(KVGPWIMCJ?AZ>*_LK:[C75]294GB60 _;)^0".M;%EX?T73IQ/8Z186LP!
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MYS-7,/PGIESI6C-#<HD)DGDFCMD;*VZ,<A 1QQU..,D@<<UN444AA7/^#?\
MD!W/_85U+_TMFKH*Y_P;_P @.Y_["NI?^ELU '04444 <_>?\E#T;_L%7_\
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M5_\ ^C;2N@KG[S_DH>C?]@J__P#1MI2&=!1110 4444 %%%% !1110 4444
M>:>-;OQ9;ZW>PZ;8O,)HK<:5=(T 2UEW$MO\SGYB,'U7ISFO2DW;%WXW8YQT
MS7FWC'X5R^+?$-W?2:JD=I<0HOD/"7*R*K(&ZXPJN[ =F;->CY2W@S))A(U^
M9W;L.Y- #Z*R--\5>'M8NFM=,US3KR=1DQV]RCMCUP#R*QOB+?SZ?X=DFL]9
M.GWR1326T8ECC^T.L9(!9QC"_?QQG;CI0!V%<_X$_P"2>>&O^P5:_P#HI:D;
M7+R.VLY+?0=3U))K=)3/;&WC7)'0K+*C ]\8QSUZU'X$_P"2>>&O^P5:_P#H
MI: #P;_R [G_ +"NI?\ I;-705Q=AJ,VD^!M2O;=4,D>JWXW2 E(PU_*ID8#
M&54$L>1PIY%:7A_4[FXU2^T^348=4A@BBE6\A15PSEP8VVG;D!0W'.&&>Q(
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M76;;5&:3S[>WFMT4$;2LC1LQ/&<YB7'/<]>TE%RBBB@ HHHH **** "BBB@
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M9)=F>N-P.,X'Y4 5'U+5=-M[2WDT/4-5G%NAGN+-[94,F,,,22H>HSP,<CW
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MQ4T!!B10\F$10",P2@]/3K7,_9;?_GA%_P!\"NP^%4,4?Q3T I&BDR3_ '5
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MVM/(DMU9HPI898D_>.T>W(^M4'^(?BQ==33_ .V[387V>8;1.NW=MZ_>X_\
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M8U1H6,@9P@,;)*-N/0BO=]2U"/2["2[EBGE5,#RX(C([$D  */<CV'4X )H
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M5-.HY.S-\;@Z=&FIP;=WW7;\RK=ZD=*U7Q7<);M<S-JT$44"L%,CM:VH !/
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MZU+J"VOQ!^T[3")DO+?_ %>[=M''3/->[PY\B/=NSM&=W7IWH ?7.^-O#O\
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M]&S5Z[\+?^1-;_L(WO\ Z4/7D7Q]_P"2AVG_ &"HO_1LU<>0_P#(WI_]O?\
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M)NWR,_W?LQQC=CKVK/#TY0;YD=F;XVAB(15*5[/L_P!2>R_Y&7Q5_P!A*/\
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MUF08Z=O4YYXHZ-H?C#3+&2W_ +;T,;[NYN/^05,_^MF>3K]H7^_TQQTRV-Q
M-#P]_P ASQ9_V%8__2*UKH*Y.RT'Q58W6HW$6OZ,7O[@7$H;1Y<!A%'%A?\
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MFY(S@^AI/^$?\4_]!_1__!/+_P#)->E2FHWN?)U(N6QF^,_^1&\0?]@VY_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MR07;)A)9@SCLF?2* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M RE2#&I!#!OO$C!QC<HH KV-K]BLX[<W$]PRY+33ON=V)))/89)/  4=
M+%%% !16?J>M66D>4+IIVDER4AMK:2XD8#&6V1JS;1E06Q@%E!.2,T[WQ=H^
MGZ7'J<\EV;-TD=I8;&>41!/O^9L0F(J<@A]I!5@>5. #<HJGINIP:K;M/;QW
M:(KE"+JTEMVS@'A9%4D<]<8Z^AK/A\7Z',Y'VN2*+8SK<W%O+#;R*JEB4F=1
M&XVAFRK'*J6&0": -RBL./Q=H[I,SR7=N8TW^7=V,]N\@W!?W:2(&D.YD7"
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MZ,AD0LA8D"23"NS(-V N H&I86-OIFG6UA9Q^7:VL20PIN)VHH 49/)P .M
M%BBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MR #^[')XP 7+^_U*YUF32-(EM+:>WMX[J>XNX&F7;(TBHBHKH2<Q.2Q88PH
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M>_%_QKJ?@OPS:S:.(Q>WES]G66:%G2)=C$L#]T.#MP&SGGY3@XJ,7.2C%7;
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M$TK%GD6"=X5=R>KE8P6/<DG Z4 ;E%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 5C^)_#&E^+M#FTC5X/-MY.59>'B<='0]F&3^9!!!(.Q10!SG@WP/HO@;3
M)++2(Y"TS[Y[F<AIICSC<P & #@   <GJ23T=%%#=]6!3&E6.-05K:-TU%]]
MVDGSK,?+6,Y4Y&-B*,=./<UGGPCH[6%Q9O'=RI.\3R2RWT[SYC</'B9G,BA6
M&X , "21U.=RB@#+A\/:9;ZH=1C@D$^]I%0SR&*-VSN=(BVQ'.YLLJ@G>^3\
MS9(_#FD16]I;BQC:"TLFT^&.0EU%NP0-&0Q(8$1H/FR>/<YU** ,>#POI,$#
MQ>3/-OEAF:2YNY9Y"T3B2,>8[%MJN-P7.W);CYCF2Y\/:9=BY\R"17N;@73R
MQ3R1R"41K$'1U8,AV*%.TC(R#]XYU** *]C8V^G6<=K:Q^7"F2 6+$DDEF9C
MDLQ))+$DDDDDDU(((5N'N%BC$[HJ/(%&YE4DJ">I +,0.VX^M244 9^IZ+9:
MOY1NEG62+(2:VN9+>10<97?&RMM.%)7."54D9 P'1-.;0YM%-OFPFB>&6,NV
M9%?.\LV=Q9MS$L3N))).3FM"B@ K#A\(Z/;N6BCNU 1DBC^W3E+<,I7]RF_;
M"0I*@QA2H) P#BMRB@#FX_ NA1:7-IBKJ1L);?[*UNVK73((N/D4&3"C"@<8
MXR.A(-@>$M*%N\+-J4@9U=7EU2YDDB8 C,;M(6C)#,"4(R"0<CBMRB@#+MO#
MVF6@MO+@D9[:X-TDLL\DDAE,;1%W=F+.=C%1N)P, ?=&+E_8V^IZ=<V%Y'YE
MK=1/#,FXC<C AAD<C()Z58HH Y]/#,6H6=J=?'VJ_BB$%Q-!,\27BJ3CS8T*
MJZMDL8V#*OF.HR"2UB^\+Z3J-Y)<W$,Y:7'GQ1W<L<,^ !^]B5@DF5 4[U.5
M 4Y  K8HH KW%C;W<]I-/'ODM)3- =Q&QRC1D\=?E=ASZ^N*KQZ)IT7V;9;X
M^S7<M[%\[?+-+YF]NO.?.DX/ W< 8&-"B@#A]+\#!=:BO-1L;&*.UB\J+[+<
MS/YQ$T,L9"OCR(T: %859T'F,!P#NZAM$TYIY)S;_OI+M+UI [!A,J+&&!!^
M7Y$"D# *E@00S9T** .+?PK>CQ/'JL5EIH-G<3W=M*+J4>:SQR)Y?E%66 ,9
M0SNA;>T88IEL+TFB:9_8^CP633>?,NZ2>?;M\Z9V+R2;<G;N=F;:.!G X K0
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
4@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>ganx-20211231x10k008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ganx-20211231x10k008.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #_ A0# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M1>*=&\*VT-QK-Z+6*9]B,5+9;&<< USW_"X? O\ T'4_[]/_ (4 =U17"_\
M"X? G_0=3_OT_P#A5[2/B7X2UW5(=-TW5EGNY\^7&(W&[ )/)'H#0!UE%%%
M!1110 4444 4-;BDN-"U"&)"\DEO(JJ.I)4X%?-B^ /%@4#^P;O\A_C7U%16
MD*CAL85:$:K5SY>_X0#Q9_T ;O\ (?XU[Q\/+"[TSP3I]I?0/!<1AM\;]1\Q
MKJ:,4YU7-68J6'C2=T<IX]TV^OM(L[G3H/M-SIU[%>BVS@S!#RH]\'BN:N]9
MU37O$-A+H)\20.;B,W5M<6XBMHHA]_)89S]#7J%%9'0<G+:W!^*MO="&0VXT
MET,NWY0WF XSZUE>*M$\2OI;W,]^NJ1VMW#=16D%J$?:CY(!S\QV]J]!HH \
MQEURZ@U;7O&%EH]]/";2&RM(7MV5YI,DD[>H49'/UH\/:J]E9ZEK!T_5M3UN
M78]ZTEJT.(\XVP@]0H.<=37IU% 'D5EJ=UX;;7]4T'1M3N=.NO*$"7,+F1[D
MYW-S\VP+^O IT-M:7_A?5IYK76[W6'DBN;JZ^RF"0,K?*80W!"=E[BO6Z* /
M/? MG>7/BG5-=GGU"XA>VBM8Y[Z$0M*023M3LHX^I)KT*BB@ HHHH **** "
MBBB@#S?QKK%M;Z^UIJ7C"^TNT$2N+6QM3O/J6E /'L*YA+WP(&26T\;^)HIY
M"%2;SI6#,>G!7!KUOQ%I1UOP]J&FK-Y#W4#1"8#[A(ZUYO-;^*-=\/+X;-OX
M;@L[<Q0S7]O>;_*VD8*ICY6XXYH ]$\/6&J:?8M#J>KG5#NS%,\(C<)CHV."
M?>GZ_8ZIJ&GFWTO48K&1B0\DD'FY4C! &1CZUI1(8XD0L6*J!N/4^]/H X*P
M^'=PO@F?PKJNL"ZL=@6V>*W$;P$-N#9R<G-6K#P5?2ZO:ZAXCUK^U6LH7AM8
MEMQ$B[AM9FY.6(XS79T4 >=P_#6[6Q@T.?Q#)+X;@G$J67D 2%0VX1M)GE0?
M:MSXA@+\.-? & +*0 #Z5U%<Q\1?^2=:_P#]>4G\J -C0_\ D7]-_P"O6+_T
M 5XW^T=_Q[>'O^NDW\EKV30_^1?TW_KUB_\ 0!7C?[1W_'MX>_ZZ3?R6@#P6
MBBBD(]V_9P_YF;_MU_\ :U>[UX1^SA_S,W_;K_[6KW>F,**** "BBB@ HHHH
M **** "BBB@ HHHH **** "N#\9:W<6FKQV)\7Z;H-JT0<[HM]PW/.-WR@5W
ME9/B#1(=8TJ\@$-N+N6W>**>2(,4)! .2/6@#S4W^F!M\7QANO.[;_+9,_[N
M*]%\-Q:Y%9NNM7]G?Y(-O<6\1C+H1_$.F?I7FLNCZU<^$U\*Q> [*&[CC6$Z
M@MQ$8XV'_+7/WL\9Q7K]G%)!900RR>9)'&JL^,;B!@F@"IK2:M)8%-&>S6Y)
MP3=ABFWO]WG-<7I/@'5AX$O/"6LWEB]G)&P@FM5?>KE]^6W<$ XKT6B@#A+3
MPCKVH:KI-SXFU"QN+?20Q@BM(V4RR%=N]R>G'85G#X>:\NAR>%!J]F/#;SEL
M^4WVD1%]QC_N]>]>F44 8'BV)8/ FL11C:B6$BJ/0!"!3_!O_(DZ'_UXP_\
MH H\9?\ (E:W_P!>4O\ Z":/!O\ R).A_P#7C#_Z * /-?VBO^1;T;_K\;_T
M U\\5]#_ +17_(MZ-_U^-_Z :^>*0!7;_"#_ )*GHO\ O2_^BVKB*[?X0?\
M)4]%_P!Z7_T6U CZVHHHIC"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHKEM8^(7AW0M7DTN^NIEO(T5VCCMW?"GH<@&@#J:*X&
MX^*FC2W>G6FEB:XGN[R.W99K>2,*K'ELD 9'I7?4 9'BFSN-0\+:I9VDZP7$
MUNZ)(S;0"1W/;TS7C\&FZJMGK6BV?@RYTZ/4X[6+S79%@@9/OR%\\\\@]37I
MGQ T;4-:\+75O9:PFFJ(G,QD0%)%QT9C]T>XKSF74=)U+3(])U+XI^=9LL<<
ML$5FJ[@,?*' SCCK0![; ABMXHV;<50*6]<#K4E1P*B6\:QDE H"Y],<5)0
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M%R>^!4E !1110 5S'Q%_Y)UK_P#UY2?RKIZYCXB_\DZU_P#Z\I/Y4 ;&A_\
M(OZ;_P!>L7_H KQO]H[_ (]O#W_72;^2U[)H?_(OZ;_UZQ?^@"O&_P!H[_CV
M\/?]=)OY+0!X+1112$>[?LX?\S-_VZ_^UJ]WKPC]G#_F9O\ MU_]K5[O3&CR
MWXX_\BWIO_7W_P"RFO#:]S^./_(MZ=_U]_\ LIKPRNVA\!Y.,_B!75_#3_DH
M>D?[[_\ H!KE*ZOX:?\ )0](_P!]_P#T UI/X68T?XB/IBEI*6O./<"BBB@
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M_P"@&OGBOH?]HK_D6]&_Z_&_] -?/%(05V_P@_Y*GHOUE_\ 1;5Q%=O\(/\
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MI:RNIDGA:1Y(P"#E 0/FXZT >C1<PI\Q;Y1R>II],B3RXD0L6VJ!N/4^]/H
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M&G_)0](_WW_] -<I75_#3_DH>D?[[_\ H!K2?PLQH_Q$?3%+24M><>X%%%%
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MZOX:?\E#TC_??_T UI/X68T?XB/IBEI.]+7G'N!1110 4444 %%%% !1110
M55O;6RU&&2RO(HITD0AHG .5/!X_K5JN'\=C3?MEAM74QK^US9RZ6FZ9$&-V
MX="F2,@]: -*YUGP?H%W#I=Q<Z=:7$:JJ1,HR@Z+DXX_&NE4A@"""#R"*\+A
M=]2ENY]=U.YTVPU=A#<WD5JIAF=/D*ON!:!^,'MZ&O;[2**&R@B@.84C58SG
M.5 P.>_% $U%%% !1110!A^,O^1*UO\ Z\I?_031X-_Y$G0_^O&'_P! %'C+
M_D2M;_Z\I?\ T$T>#?\ D2=#_P"O&'_T 4 >:_M%?\BWHW_7XW_H!KYXKZ'_
M &BO^1;T;_K\;_T U\\4A!7;_"#_ )*GHOUE_P#1;5Q%=O\ "#_DJ>B_67_T
M6U)[ ?6U?-_Q7_Y*/J/^Y#_Z+6OI"OF_XK_\E'U'_<A_]%K73A_C.7&_P_F<
M71117:>4>V? S_D$ZQ_U\)_Z#7K%>3_ S_D$ZQ_U\)_Z#7K%>?5^-GLX;^$@
MHHHK,W"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** //O'%C
M>7.JQSS>&;K4+.),17>F7IBN4S]Y2N1N7/O56T\46T&C1Z)9?#[7Y;8*4^S3
M6H"'//S,QP<GO7I=% &-X=N=7NK$R:OID.FMNQ#;QS>853'&XCC/TK9HHH *
M*** "N8^(O\ R3K7_P#KRD_E73US'Q%_Y)UK_P#UY2?RH V-#_Y%_3?^O6+_
M - %>-_M'?\ 'MX>_P"NDW\EKV30_P#D7]-_Z]8O_0!7C?[1W_'MX>_ZZ3?R
M6@#P6BBBD(]V_9P_YF;_ +=?_:U>[UX1^SA_S,W_ &Z_^UJ]WIC1Y;\<?^1;
MT[_K[_\ 937AM>Y?''_D7--_Z^__ &4UX;7;0^ \G&?Q KJ_AI_R4/2/]]__
M $ URE=7\-/^2AZ1_OO_ .@&M)_"S&C_ !$?3%+24M><>X%%%% !1110 444
M4 %%%% !7!>.K*]NK^WD?PW/J5E"GR7.G7AANHB?O#&1E3@<9KO:* /,M/\
M$]K8:,NC67@'Q#) 00T$UJ"&)Y)9F.#D]2:['PS<ZO<V3'5-'ATJ-<+;6R3"
M1E0#^+' ^@K<HH **** "BBB@##\9?\ (E:W_P!>4O\ Z":/!O\ R).A_P#7
MC#_Z */&7_(E:W_UY2_^@FCP;_R).A_]>,/_ * * /-?VBO^1;T;_K\;_P!
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M\Q,M9.0-PR>* -S0_P#D7]-_Z]8O_0!7C?[1W_'MX>_ZZ3?R6O7]$N8!H&G
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M\B3H?_7C#_Z *C\7SQ2>!M8=74J]A(R\]04.*=X.EC'@K0P77/V&'O\ [ H
M\W_:*_Y%O1O^OQO_ $ U\\5]"_M$.K>&]'VL#_IC=#_L&OGJD(*[?X0_\E3T
M7ZR_^BVKB*[;X0D#XI:,20!F7K_US:D]@/K>OF_XK_\ )1]1_P!R'_T6M?2%
M?-WQ8(_X6/J7/\$/_HM:Z</\9RXS^'\SC**3-&179<\NS/;?@9_R"=8_Z^$_
M]!KUBO)?@:ZKI.K[F4?Z0G4_[->K^='_ ,]%_P"^A7!5^-GL8?\ A(?12 @C
M(YI:S-PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "JFIVS7NE7EJA >>!XU)[%E(_K5NB@#Q#[7/??"ZT\ IIM\NO!DLY8F
MMV"1A9,F0OC;MP,]:]+U'P)X;UJ5;C5-,CNKCRUC:1G89"C X!Q7244 <B/A
MAX- P-#AQ_UTD_\ BJ1_A;X*DQO\/V[XZ;G<_P#LU=?10!QW_"J? W_0N6GY
MM_C1_P *I\"_]"W:?FW^-=C7$^*_$NI^'O&OAF#?%_8VI2-;3@I\RR_PG=VZ
MC\J 'M\)_ Q*G_A'H%VG/R22+GZX;G\:R;OX5Z*?%>FM;:':#11!+]K0L<F3
MC9C)SZ]#4/Q%^(E]X4\6:+868C:T;$NHY3<5C9PHY[=ZV?'/B74=+N_#VFZ(
M\7VW5;U8\NF\"$#+''T[TK(=VB<_"WP45P?#]N1Z%WQ_Z%3?^%5^!_\ H7;7
M\W_QKEO%^J_$/PM]BE;7=*FCO;U;6-5LL%-QX)YYQ7=^'+3Q-:_:/^$BU2RO
MMQ'D_9K<Q;/7/KVIB>NYF_\ "J_ _P#T+MK^;?XTH^%G@E3E?#UL#ZAG']:[
M"BBXK(Y+_A6/@W_H!Q?]_)/_ (JMC1/#6D>'4F32;)+59B#(%9CN(Z=2:U:*
M!A1110 4444 %%%% !1110 4444 %%%% !1110!'<1F:VEB!P70KGZBO$X[N
MXC^%DW@ Z;?'7BS68B^SML(,F?,WXV[<<]:]PHH Y:]\ ^']8CMVU:Q%S<16
MZ0%_,=<A1CH#BJZ_"SP<BA1I   P/W\G_P 578T4 <:_PJ\%R@"314<#H&E<
M_P S3/\ A4G@;_H 0?\ ?;?XUVM<MX-\4S^)I-;6>VC@_LZ_>T38Q.]5[G/>
M@"G_ ,*D\#?] "#_ +[;_&E3X3^"(W#KH,(8=")'!_0UM>*?$5MX7T&XU.X&
MXIA(8A]Z60\*@]R:R?AYXNOO&&C7=UJ%A'97-M=-;O%&Q8 KC/7O0!B?\*JT
M4^,BW]BPC0_L?"^8<^?NZ]=WW??%;+?"KP2YRVA1%O[QED)/_CU9&I_%"6#Q
M_9Z!IUA'<V+W2V=Q>LQ 68C)5<<$@=:['Q/X@M?#&@7.J77S"(8CC'660\*@
M]R:$K; ]=S#_ .%3^"/^@%#_ -_'_P :/^%3>"/^@%#_ -_'_P :3P!XSO\
MQ;HNHW>H:?'97-E<-"T*,3R!GG/>N:L?B7XPN_#;^)5\+V,VCQ,_F>3=GS0J
MG!(4BB[%9'4+\*_!D>0FBHH/7;,X_P#9J=_PJ[P?_P! C_R/)_\ %5T&B:O;
M:]HMGJMF6^SW40D3<,$ ]C6A0,@L[2&PM(K6V39#"@1%R3@#H.:GHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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6BBB@ HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>ganx-20211231x10k009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ganx-20211231x10k009.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #7 C<# 2(  A$! Q$!_\0
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M:\Q][WD]NM 'OM%8O@_[0/!NBB[$@N!91"02@A@VT9SGG-;5 !1110 4444
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MX&!%KK6?^@S=?^A"NJH **** "BBB@ HHHH ,4444 &*,444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110!2U:XN+32;J>T2)[B.,M&LI(0GMDC
MG%>9Z)H.NZAXG@U>X&FSC[8)YI+?6)Y-BY^Z(S\N!TP:]8->6*OB*X^("336
M6HI:)J&%D2PB6+R@>"9 =Y&.YH ]4H(R*** .0TSP'#I%TT]EJEZK(/+M@P1
MA;PF3S'C7CD,>YYQ4-GX"GM%U #Q+J9-XYF9T6-'67<"&W 9.,8VGC'&*[6B
M@#BM9\/6NB?#G7X0SW4SVES/+<S@%Y)&4EFZ8'T'I72:#_R+VF?]>D7_ * *
MI>-O^1&U[_L'S_\ H!J]H/\ R+VF_P#7K%_Z * -"BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ K*O-#AO==T_57D</91RQK& -KB0 '/Y5JT4)M; <QH
M7@NST*^:YCNKF?9$UO;),1BWB9MQ5<#GGN?05/8>&8[#1K/24O)GLH5E26-E
M7]^KYX;TQD]*WSTKFK;1=9C\:7&J2ZHS:8Z;4M<]#VSQTR6]^G)JU)N]V!2M
M_AY:V]O*G]JZBTPBC@MKC>JO;QQMN11@8.#USG-78/!MO#I"Z<;N>1)+IKNZ
MD?&Z>1@>3C@<X/ _A%=-12YY=P,7POX>3PSHZZ>EPTX$C.790O)] .G3^=;5
M%%)MMW8!1112 **** "BBB@ HHHH *\\\>:AH=Q<P6VH7NO6DUE-\KZ7#(&8
MNF>&"G(QUQ7H=<9X\^VS+I\6E7]O'?13><MK+=F 3!<'EAV'H>#GVH TO!!M
M&\*VIL;B_N+<M)MEU $3M\YSOSSG/K70UA^$OM9\.V[7]W;W-RS2-(]NQ9%)
M=OD!/)V_=R?2MR@ HHHH Y7P,3]EUK/_ $&;K_T(5U5<KX'.;76O;6;H?^/"
MNJH **** "BBB@ HHHH ***,T %%)FC- "T4F:,T +1110 4F12UY=XEO+C2
M?&EIJ5IJUS/"]R\,\:W 9(W\H[8/*'3) ;<>:J$.=V ]0R*,BO+?A[J-R-8M
MA/JD]U'?:*E_<>?+N"3F4KQG[HQQCVJMJEW?:;XWN=4O[R8V#WQMX/LU_N$!
M$61OA'!'!)!YJ_9/F:N*YZWD49KP[PW'X@UFSNM/CO[K[1<V5M>QQS7C$7";
MSN8..8]W V]JZ7PMXD6WUFW@U6[N9YFBCL+>106B;:Q5I6/^W("H/HOO3E1:
MZC/3:*!THK$ HHHH **** (+RV%Y9S6YEEB$J%"\3[77/<'L:\RM)-'A\<K:
MR:MK+7R7RI%;-J)D\SKDM%CY4&._8@UZDX+(0K%21P1V]Z\VTN6[3QM%97GC
M*TN+J*5O,A33 DD@Y/EF7IT(X'I0!Z71110 45E:;XDTC6+VZL]/OX;B>U.)
M40_=YQ^(R,9'>JB^./#3F^"ZO;'["-T_)^49VY'KSQQGGB@!WC;_ )$;7O\
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MMXUA;S+Y8#[F"OP<G'7![UZ+H/\ R+VF_P#7K%_Z *H^-?\ D1M>_P"P?/\
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M]8O_ $ 51\:D'P+KQ!_YA\__ * :O:#_ ,B]IO\ UZQ?^@"@#0HHHH ****
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M3C^]_P"/FC//WO\ Q\TN]?[W_D2E#KG[W_D2BX'UEX _Y$'0_P#KT2NDKF_
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M$G^Z?Y5\D7Y?^U69E NU<_98L_+*/5OUKJPVS)97(??;[L>=C_B7D=%'^W0
M/](V]?\ F(Y_B_W*0;=DX5B8F/\ IK$\P'T3_P"M2Y/[C/&W_CQY_P!?_O\
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M")]W9@X/UKZ%KFQ'Q+T*0V3_ %;?0U\7SK_I$G7[Y]/6OM!_]6WT-?%MP/\
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M7[1+ROWSV/K6F%Z@R/C^X/\ OV:./[@_[]FC"_[/Y&C"_P"S^1KJ)#C^X/\
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M!KL&+>3]_.<GZ;<UZ*3BN)M+_P 2+J=U,([==+1Y5CCFF$DUPP)QY8&-H..
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M<^E.^?SC_HZ_:,<V7\(7^_\ 6CY]Q/V91/CFQ_A5?^>GUIN$V8^TGR<_\?\
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M7%_&4_\ $TL#GI"3UQCD\Y[?7M6-?X3GQ7\,\O\ K[YSQ]>G3\.G;G-'^?\
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MZ_W5]Z0;_,N=N/.Q_P 3#T*_['ZTP^3]GM]P;[%N_P!" ^\'_P!KVS0!]0^
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MK+P!_P B#H?_ %Z)725S?@#_ )$'0_\ KT2NDKS9_$RPHHHJ0"BBB@ HHHH
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MX=U/_/2EYW$?:1N_Y_\ L1_SSKO)#G/_ !]C=C_D(?\ M.D_A_X]OE_Z!_\
M?_Z:497;G[*=G_0/[Y_YZ4O.['VH;\<7_9!_SSI =]\(,_\ "=1YE^T'R7_?
M>G'W/P_K7T-7SS\'L?\ "<1XC\@>3)^Y/4G'W_Q_I7T-7)B/B7H4ALG^K;Z&
MOBVX_P"/F7YE^^>K'UK[2D_U;?0U\6W!_P!)E^;'SG^+'>M,-U!D>?\ :7_O
MHT<_WE_[Z-&[_:_\?HW#^_\ ^/UTDAS_ 'E_[Z-'?[R_]]&C</[_ /X_1N&?
MO_\ C],#ZT\ ?\B#H?\ UZ)725S?@#_D0=#_ .O1*Z2O,G\3+"BBBI ****
M"BBB@ HHHH *Y#Q[<:O:V=E-I,AW1S>9) DR1-,%P<9;C;P<@<\UU]>=_%A+
M*33-/2[M+JZS,W[N"98PR8&Y6+=CQP.>M '4^$[B^N_#EK<ZBT37$N]_W4@D
M55+$JNX<' P,^U;=<O\ #V2*;P99300+!&[2D1*RL$_>-P"O'Y5U% !1110!
MRO@<8M=:]]9NC_X]7"?&;_D*6&?^>)SGZG]/IS7=^!\_9=:S_P!!FZ_]"%<)
M\9O^0I8<](2>N,<G\OKVK&O\)SXK^&>88]3]<_KG'ZX_#G-!^I_S_P#6_3IS
M1C'7C'X8Q_+'7VZ]Z"/\X_'_ .O[=>M<QYV@@'O_ )__ %?I[T8]#Z=/\_E^
MO-+C_/Z__7_\>ZTF,^^?QZ_SS^O6@6AZ5\&\?V_>=/\ CW/\Q^GZ^M>UBO%/
M@W_R,%YSUMR>N>XY]_KWKVNNFA\)Z.$_A_,CG_U$G^Z?Y5\D7ZM_:4J%PTKN
M3%<=K8>A_P ]Z^MY_P#42?[I_E7R-?>7]HOBJD6@D/VN,CYI&]5_2O0PW4W9
M ,;9"$PL?^OCQ_Q]GU%+C_5YY\S_ % _Y\_K00V^W#$&5O\ CQ;'$0_VJ!C_
M $C;@%?^/_\ Z:_[M=(@"MN<!\.G^OD_Y^QZ"DRH1',):%SB&WQS;'^\:#L\
MNW+#,+'_ $%1UB/JU/ E\^<*ZB["_P"F2$?+(GHOOBD!]/> \_\ "#Z3D[CY
M/)]>3S71US?@''_""Z1M&%\G@'TR:Z2N"I\;+/)?CS_R+NE_]?9[X_@->"9^
MO_?8KWOX]?\ (NZ7_P!?9[9_@->"8/H?^^*[L/\ PT0]PS]?^^A1GZ_]]"C!
M]#_WS1@^A_[YK;409^O_ 'V*ZGX;G/Q$T3K_ ,?'KG^$URV#Z'_OFNI^&^?^
M%B:)D'_CX_NX_A-3/X6-'U8.E% Z45Y*+"BBBF 4444 5-2NFLM.N+E0I:-"
MRAC@$]LGM7//X=M+:]T_49II8[@7GFLL4@V%W&-O3)7)S^)KH-5>W32KIKJ+
MS;<1-YD8&=ZXY'XUP>FZ3I>@^+]-BGDUZX>:/S+2.ZD,D%H3D;3Z-V&: /2*
M**1L[3CK0 9%&1ZUY1X$UB4:W%)<ZE+(US9ROJ*3RY6*Y\_;&H!^X2,@#OBL
M :O?A<_VK>9NU']M?O3_ *+_ *6$./\ GG\F1QVYH ]9\:G/@77O^P?/_P"@
M&KN@_P#(NZ;_ ->L7_H KSVS?Q'JW@O4=*TJTCO["=[NTM[RYN\-Y6XJAY&6
M '?OBM^QN_&EEIUM:?\ ".6+^1$D>[^T ,[0!G[OM0!Y/XO_ .1MU,;<_OV_
MG_GZ]ZQ,Y/W<_KG_ #^O0\5V^K^ O&>JZK<WW]GV49G=GV?:@0,_A^?K5(_#
M/QGSBTLN_6Y![?3_ /6.*X?8S['E/#5+['+?\!S_ )_R/?ITH[_=_P ]/_K?
MITKJO^%9^,^?]#LN_6Y'I]/\CBC_ (5GXS_Y]+/_ ,"1Z8_S[<4>QGV#ZM4[
M'*9_V?\ /3_ZWZ=*]_\ AX,>"[$8Q][C&.YKRO\ X5GXS_Y]+/\ \"AZ8]/\
MCBN\\/)XTT'18-._L"QF\K/S_;@N<G/3'%:4:<HRNT;X:C.$[M'H%>8_&S;_
M ,(U9[H#,/M!^0=^.OX=:Z+^U?&O_0M6/_@P'_Q-<SXUT?QOXNTR&TCTBRLV
MCDW^8+T-GC!&,5VTVHR39VL\-PV2/M(\W'-]V8?\\_K2?+@G[,?*S_QX=P?^
M>GTKNO\ A3WBW<8_L5C]DQE8/M7 ?^]G%-_X5%XWV^9Y5E]KS@S_ &@9*?W<
M8KJ]M#N*QQ.'W8^U#S<?\?\ _#C_ )Y_6D^7;G[,?*[V'=S_ 'Z[G_A3WBS=
MY?V&Q^QXS]G^U<;_ .]G%)_PJ+QOL,GEV7VP<+<?:!E4_NXQ2]K$+$WP@R/'
M4>^3SV\E_P!\.@&/N?A_6OH:O$O"/@3QAX3UU=0ATNQEC",##]L RQ&"V<5Z
M#_:OC7_H6K'_ ,& _P#B:PK24G=#1U4G^K;Z&OB^?_CXEY/WS_$/6OJ5M4\:
MLI'_  C5CR,?\A ?_$UXQ)\%O&4DK/Y5D-Q)QYX_PJZ$XPO<&>??B?\ OH4?
MB?\ OH5W_P#PI3QE_P \[+_O^O\ A1_PI3QG_P \[+_O^O\ A6_MX=Q69P'X
MG_OH4?B?^^A7?_\ "E/&?_/.R_[_ *_X4?\ "E/&?_/.R_[_ *_X4>WAW"Q[
MEX _Y$'0_P#KT2NDK@M _P"$TT/0;'2QX?L91:PB+S/MX&['?&VNLT>XU2YM
M7;5K&*SG#X"1S"0%?7.*X9.\FRC1HHHI %%%% !1110 4444 %<@^J:5_P )
M+JEOK6HVX%LT;06ET$"Q@H#YBDC)))89[8KKZX/Q3I$/B)]4DG\.V6I2::%2
MS\QB'ED(5BIQT7YO6@#?\(3V]QX=A:S6(6BR2I T2!$= [ , /6MVL;PO=/=
M:#;^;8QV$L):![6-@RQ%"5V@C@CBMF@!"0 23@#O5'3=9T[6%E;3KV"Z6)]C
MF)PVT^AI^K02W6CWMO <2RV\B(<XPQ4@?K7FO@30M7\N^,,4^A,--LK'?) ,
MM/%N\QPIX(YQGOF@#K/ Y)M=:S_T&;K_ -"%<+\9?^0II_.,19Z^Y_SFNLL?
M!>OZ<DZVOB^5!/,\\F;)#EV.2>M9^M?#'4?$$T4NI>*I96C&%Q9H./3KS6=2
M+DK(RK0<XV1XGMQC'&.F.,>GT_'IU/%&!_G_ #Z_KSTKU<? Y1C_ (J.<XQU
MMUYQ^/Y^M+_PH]/^ACN/_ =?7/K^'TXK+V,CD^JS[GD^/\_K_/GZ\]*3&1_C
MS_G^O4<5ZS_PH]/^ABG_ / =?7/K^'TXH_X4>F/^1BG[]+=?\?R]*/8R#ZK,
MH?!S_D/WG7F GK[C_.>E>U"O.-%^&%[X?N))]-\3RQ22 JQ-HIX].OM6[_PC
MWB;/_(WR?^ 2?XUK2BXJS.JA3<(V9T\_^HD_W3_*ODC4-_\ :Y+!1>!C]D7^
M%ES_ !?K7T>?#GB5@0?%\F#QC[$G^-<:_P "XI#,6\17!:5MQ;R%R/H<\5U4
M:BA>YJT>,@)Y=R%/[IC_ *>>Z'_8I3_R[;L87_CPQ_'_ +]>R'X$PDQG_A(9
MQLZ?Z.N&^O//XTG_  HB$>9_Q45Q^\Z_Z.OR_P"[SQ^%;>WB*QXZ-_F7)7;Y
MS#_3P3PB_P"Q3"(?(MP['[&&_P!#;^)G]&]LU[(?@1$1&/\ A(KC]WT/V=<M
M]>>?QI1\"8A([_\ "13_ #C&/LRX'T&>*7MXA8[WP'N_X0C2MV WD\X]<FNC
MKB-/\&>(-+L(;*U\7RI!"NU%-DAP/KFK0\.>)_\ H<I/_ %/\:Y9.\FRCDOC
MU_R+FE_]?9_] ->!\>WZU])>(/AMJ?B>UBMM5\532QQ/O3;:*N#C'8USW_"@
M;7_H8KK_ +\+_C732KQA&S):/#^/;]:./;]:]P_X4#:_]##=?]^5_P :7_A0
M-K_T,-U_WX7_ !K3ZS +'AO'M^M=5\-\?\+$T3I_Q\>_]TUZ1_PH&U_Z&&Z_
M[\K_ (U;TSX)C1]2@U"S\27"7,#;HV:W4@'Z9I2Q$6F@L>LCI17*?\([XFW
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M HQ110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
3%%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>ganx-20211231x10k010.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ganx-20211231x10k010.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  _ ( # 2(  A$! Q$!_\0
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M +]%8EAXLT>^TP:@UW':6YN)+93=NL6YT<H0,GGE3BMH$$ @@@]"* %HHHH
M*\AF^&WB.?4-1N$;35CN+^YGC$EPX;8\SNN0$('##O7KU<ZWCSPJCLC:]8AD
M8JP,G((."#[YK.KAX5URS5T88C#TL1'DJJZ.7\*^!M<T7Q3::A>FQ:WC216\
MB9F8%EP.&1:Z?QEH%_KNEP?V3=Q6FJ6LWFV\\H)5<J48''/*L?QQ5O3O%>@:
MM>"TT_5K6YN&!81QR98@=3BIM6UJ'23;1&&:YNKIV2WMH-N^4A2QQN(4  $Y
M) _.G3HQHQY(JR*HT:=&')35D<E=?#A3<V(M9E^R0VUM;-')-*H00OO#@(1N
M8GU(P<'GH<#5?A+J]]X;MM,AO[%)8XKQ'8E]K&:Y693PO95P?>N\UWQ=#X?\
M/QZU<:7J4MJQ02+&D:R0EF5%#*[J>68#C/Y<U=U'78=*TF&^O+:XC>9XXH[7
MY#*TKD*L?#;=Q)Q]['OBK-3DM5\"ZI>:!K>BV\^G>1>FX>&XG5VF#2N&VD@8
M11@CC=N^7[N.;VD>!Y-,\72ZNUP)8C//<(6FD+JTH4% N0@48ZD'/R\#&:NR
M^.M.BTR/4C:7[6@+BXE$2[;4J^QA(=V,AN,+N/< CFIHO%UM+>7MFNG:E]HM
M8_-$?D@M,N[;E0&R,GH&VDCGIS0!'I?A^^T75-3-C-;&PU*_:_F,H8R(6159
M% .#DKD,3QG&T]:Y>Y^&%]+H6JV*:A#YL^EKIMN6+;6 F:7S)./O?-CC/0\\
MUO2_$?1H;9I##>&:(SBYME5#);B#'G,WS;2%!!^4MG/&:WKG7+"UCLY))ALO
M 6B8="H0N6Y[!1F@#B+SX<ZA/XSEUV*\M1$;B=T@.X826T$'7'!#+G'<'J*<
M?AO=R:1I=B]_&GDZ=:65RZ;OE\B59-T?NQ4CG'8]L5O)XZTV33%OTM;TI-+%
M#:IL0-=-(,H$RV 2.<,5([@58TWQOX<U6W66WU6W!+*C1R.%='()",.S<'CV
MH YF3X>ZA_PCD-C'<6GVR*[O)DGWR*8Q.[,,$=< C<K*0V,9'6O0+.%[>R@@
MDD$CQQJC.%"[B!@G Z9]*H7'B;1+6S6\GU6TCMV5G$C2@#"G!/X$@56U#Q=I
MVF:_8Z1=+,DMX9MDV%\I?*C$C;B6R.#Z=: -ZBLU/$&D274-K'J%N]S/D10J
MXW.0F\@#UV\_2K&GW\&IV$5Y;,3%(,C/4$'!!]P010!:KQ/4?AGXIFUG4KB"
M.Q:&XO;B>-FN<':\S.!C8<9! /Z5[96,?%WAI20?$.D@C@@WL?\ \56]#$5*
M$N:F[/832>YP?@CP'X@T3Q7;ZCJ,-DEO%"Z$Q3[FR0<#&T<#-=OX@\/G5;W3
M=1@,/VS3S*(UG4F-TD0HZMCL>#^%7;+Q!HNI7 M['5["ZF()\N"Y1VP.IP#F
MGZEJUMI8A$_F/+.Y2&&)=SR$ L0![ $U-:M.M/GF]022V.4D\!3_ /"KX_"*
MZB))ED1_M4BG!Q<"8C&<]!M'X5K^(?#4VM;)!J4Q:"Z@O+:WE5/)CDB8,/NJ
M'(.#G+'J<#I4VK>*]/T71(M7NX[L6;[066W;*%F"KN4\C)8"KEYK-KI^F)?W
M2RQ)(R(D13]XSN0%0+_>)(&*R&<H/!%_#:V=HLME<6B7,M]<6\Q=4DN'D+@\
M9RJD\ ]^3TJ_/X=UF74K[5$O[6*_DM#9P-$C*FTN&WN,G+ # //?UQ5R7QGH
M\-E'>.\XMF#&27R&V0[6VMYAZ+AN,5(OBO3FGN8-EV)H(S+Y9MGW2(&V[D&,
MD;N/_K4 85QX$>Y\/0Z4(=.M@B3P^9&9&8+*N&;)(WDDDE6!#<9J[K/@Z&^E
MT*.(-]EL;>>Q==_(AEA\LGW(VK^M3R>/-!BMC,UR^4:59HA&3)#Y6/,+KU 7
M()^HK7NM7L+**"6>X1(Y\F-B>" I8GZ!03F@#B+;X:36]M:L;^-[JP>R>U&&
M$1:V4J'<?WG#,#^'I6?I7PAETEB(M1A:-M8LM3(,9S^YR9%_X$Q./2NRA\<:
M)/8FZCEF*DQ"./RCOE\W_5E%[ANHJ]I_B31M3@26UU.U<,!\AE4.I(S@J3D'
M'.#0!YEK7PSU==/N[.R_TJ:^MY[9I=P$42R77G@D,P(('!(!S^%=3XF^'P\2
M:KI=U+<QQQVDEW)(H!R[2H%0C_=VJ3GKBNMEU;38+5;J;4+2.W8%EE>90A Z
MD$G%5+KQ+IMEK=GI%Q*R75X91%E3M/EH'?+=!A30!Q&D>#M:LO&5A=SQ[X+:
M^NK^>X++B1Y;?RMJ?-NQGG! P..<5V?A/1WT+P]#92_ZTR2S.,YPTCLY'X;J
MOKJNG/+%$E];/+*,QQK,I:3Y=WRC//'/';FI;.\@O[2.ZMGWQ2#*F@">OGC6
MO@AXKUGQ%J^IQ3Z5!#=ZA<S1I/<.'V-*Q4G:C 9!!Z]^<'(KZ'HKHPV+JX6;
MG1=G:W]7%**EHSQ;X<_"GQ%X.\:6^J:A+I\UMY,D;&UF9F4D<9#(O'TS7I'B
M+0;C4M1TK5+)HS=Z<9@L4LSQ)(LL91AN4$J1P00#C!]:Z&BIQ&(J8B?M*KNP
M225D<)>>#=:N_A8OAFXU5;W5/,C=[RZD<AMMRLN"QW,<*-H^@Z5K^)O#M[K2
M1/%>H3:WEO>VUO(NQ-\3AL,X!.&P1G!QGH<5TE%8C//?^$-UJ'3+?30EA<V+
MW4U]>P->20^9*\ID"9$3;HQGVSZ5I/H.OIJVI:O:MIL%[-:?9HDC=U29M^5E
MD.PD,J_*/O?EP.PHH \[G\ W5QH*626MC;731W4$MS]LDF=UG7YW9C&I<EN2
MN!T&&'2M?4O"^Z]\,K$IGLM/AFLY8GY5D>$(&8=_N@?1C76T4 >9P_#2[C2U
MO!);"_L9K.2V@\]S#MMPX5"Y7< 5D8#@D8'+=:RM(^$&I:4SK]IL)8WUJQU%
MMS-DI%DRK]WJ68[1T(ZXKV&B@#Q+7O &MQ:7=V*K]KN;RWN+>%41WA3S;OSE
M(;;\C!<!MP Z8)P177>*_ %WXDUC2KH74445M)>//^\;<?-15C"C'(^4;AD#
M&>M=_10!Y3H_AG6+?QSIMS<VY<V]_=WUU-Y;!5$EL(@B.1M9=P^4 Y"]0I&*
?[CP=I<^C^&X+6Y+>:9)9F#')7?(SA?P#8K>HH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>ganx-20211231xex10d8007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ganx-20211231xex10d8007.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !/ &D# 2(  A$! Q$!_\0
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M5/!?A"&ZT<QQW=U<K;B9U#>4-K,2 >"?EQSQS7HE>(?M*7(3PWHEID9DNWD
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M\&Z3K&X,]S;JTI'3S!\KC\&#"N9^+?P[;QWX?C>QV+J]B6>W+\"53]Z,GMG
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# /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>ganx-20211231xex10d8009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ganx-20211231xex10d8009.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #J E0# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?/'9E'Z/0!ZO\.ACX;^&^ /^)=#T_P!P5TU><_!#7!K7PSLHB29M/=K.3/\
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M:7,8D@GC:*1"2-RL,$<>QH ^<?V<=<%KXEU/19) $O8!+&I'62,]!_P%F/\
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MRQMZJP!!_(U/5'1-,31="T_2XWWK9VT< ?:!NVJ%S@<<XS5Z@ HHHH ****
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>ganx-20211231xex10d8003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ganx-20211231xex10d8003.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #J =T# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MU'U6V4X_-_?M^=;?PZ^%>E>![=;J4)>ZU(H\V[9<^6<<K'GH,YYZGOZ5Z!0
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M2UR4EIM0N.6!(P0G<#\R<]>P[>@"MI^G6>E6,5E86T5M;1#:D4:X515FBB@
MKQ;Q=XFU/XD>)Y? GA.8Q:?$<:KJ2\J5!P54C^'\06(QT!SI?$GQCJ&IZD/
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M!M >\FVRWLOR6EJ#\TK_ $_NCJ3_ %(KFOAKX%OTO9?&GB\&;Q%>DO%'(/\
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M WRM_>8]S4?@_P ):?X,T"'2[!<L/FGG8?//(>K,?Y>@P*WZ "BBB@ HHHH
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MD44<$211(L<:*%1$& H'  '84^@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .8\<>.=+\":,+_ %#=
M)+*2MO;(0'E8#WZ <9/;-?,5_P"/;_Q;XG&J:OI[:K.A"V6EC)MHSTY09+\X
MXXR>IQQ7U1XE\'Z!XPMX(->T];R.!R\69'0J2,'!4@X/IG' ]*30/!OAWPN@
M71M(MK4C_EH 6D/_  -LL?SH \-M_AI\0OB3=1ZAXLU!].M"=R0SJ<QJ1T2$
M8"]AS@^N2*]3\*?"'PGX4*S1V0OKT?\ +S> 2%?]U?NK]0,^]=Y10   # &
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MJ   !P .U+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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DH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>ganx-20211231xex10d8004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ganx-20211231xex10d8004.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  ! :,# 2(  A$! Q$!_\0
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/ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>ganx-20211231xex10d8001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ganx-20211231xex10d8001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #8 < # 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MKF/%?C?3_#$9B;_2+YAE+=#C'H6/8?K32;T1,I**NSI)IHK>%IIY4BB099W8
M*JCW)KA=;^*VC:>6BT^-]0F'\2G9&/\ @1Y/X#\:\LU[Q/JWB.<O?W+&('*0
M)Q&GT']3S6+MK>-%=3BJ8MO2!V6I?%'Q)?$B":&RC/:",$X^K9/Y8KF[G7M8
MO&+7.J7LN>S3L1^6:H[:-M:J*6QRRJ2ENQK%G.78L?4G-20W-Q;G,-Q+&?\
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MD$4M<IZ85P7Q%\17WAJ^T.\LVR"TPEB8_+*OR<'^A[5WM>6_&49AT;_>F_\
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M''49\M/R'/ZUUFGZ-INE(%L;&"#'\2(-Q^IZFM7570Y(82;^)V*WAG4+K4]
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MNN5GOQ^%!7"_$@9CTWZR?^RUW5</\11F/3OK)_[+54_B,<5_!?\ 74\^VU)
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MU=17,^.AG0H_^OA?_06IP^)$8C^%(\VVT;:DVT;:Z3PSV'3/^039_P#7!/\
MT$5:JKIO_(*L_P#K@G_H(JU7(SZ"/PH*XGXAC,>G_63_ -EKMJXOX@#*:?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MDD<N'G*4I7?4P?%VLW.A:,MW:+&TAE5,2 D8(/H1Z5P__"R=;_YXV7_?MO\
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E6M:NFH:C'*EN)!+)),,-*<YP >H/K115S]U:&%"]:?ON]C__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>ganx-20211231xex10d8005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ganx-20211231xex10d8005.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  ! 6P# 2(  A$! Q$!_\0
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L@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>ganx-20211231xex10d8011.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ganx-20211231xex10d8011.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  ! /,# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#Y_HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
0H **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>ganx-20211231xex10d8008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ganx-20211231xex10d8008.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !^ )X# 2(  A$! Q$!_\0
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M0W+?*[MQN<#/R*,\ 'J1G.,UZ)X+\*6W@WPQ;:/;OYK)EYYR,&:4_><C)_\
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M7:D:# '_ ->@#+\)>#=&\%:2+#2+?9G!FG?F29L=6/\ 0<#L*Z"BB@ HHHH
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9D;N[>Y/)K5HHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>ganx-20211231xex10d8006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ganx-20211231xex10d8006.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !N 1@# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BJ5EK&FZC=WMI97T%Q<63B.YCC<,8F(X#>G0_B"
M.QJ[0 4444 %%>1:A>/JO[2^E64=Q,8=)TYVDB+$*)'1R2![B2//KC':O7:
M"LB\\3Z/8>(K#0+B\"ZG?JSV\ 4DLJ@DDD# 'RG&>N#7G7AJ\?6?VBO$\ZW,
MTMKI]@+:-3(=J-F,,H'IN$GX\TW3X)M6_:;U6>XRT6CZ:@MR1]S>B<?^19*
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/ 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>ganx-20211231xex23d1001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ganx-20211231xex23d1001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "B (T# 2(  A$! Q$!_\0
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M%%%;$A1110!&\(DX9WQZ X_E34M+=/NPIGU(S4U%8O#TI2YY13?=J[*YGM<
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MZ[MH8;2RG$[2K*&+8)(&/7DTB>%KB"_F@?2[:\M99S(+A[AD*H3G!4'D^^*
M+EMXAO6\4ZC;O9WDD$2 1Q*@^3 )R?\ >QQ]12:!XFE?3[^YU-+@1PR.YF9
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M_P *-?>)9[QF3['- 0RYY\S84!Q[ YSZU!!X3O$\-"V::(:BMT+I7))4LHP
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GQI#&L<2*B*,*JC  ]A110 ZBBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>28
<FILENAME>ganx-20211231.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.8042.36810 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/25/2022 6:18:32 PM-->
<!--Modified on: 3/25/2022 6:18:32 PM-->
<xsd:schema targetNamespace="http://www.gaintherapeutics.com/20211231" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:us-roles="http://fasb.org/us-roles/2021-01-31" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:naics="http://xbrl.sec.gov/naics/2021" xmlns:srt-roles="http://fasb.org/srt-roles/2021-01-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns:exch="http://xbrl.sec.gov/exch/2021" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:sic="http://xbrl.sec.gov/sic/2021" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:attributeFormDefault="unqualified" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:ganx="http://www.gaintherapeutics.com/20211231" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:dei="http://xbrl.sec.gov/dei/2021q4">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.gaintherapeutics.com/role/DisclosureStandardAndCustomAxisDomainDefaults" id="DisclosureStandardAndCustomAxisDomainDefaults">
        <link:definition>99900 - Disclosure - Standard And Custom Axis Domain Defaults</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gaintherapeutics.com/role/StatementConsolidatedBalanceSheets" id="StatementConsolidatedBalanceSheets">
        <link:definition>00100 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfOperations" id="StatementConsolidatedStatementOfOperations">
        <link:definition>00200 - Statement - Consolidated Statement of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfComprehensiveLoss" id="StatementConsolidatedStatementOfComprehensiveLoss">
        <link:definition>00300 - Statement - Consolidated Statement of Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfCashFlows" id="StatementConsolidatedStatementOfCashFlows">
        <link:definition>00500 - Statement - Consolidated Statement of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gaintherapeutics.com/role/DisclosureOtherCurrentAssetsDetails" id="DisclosureOtherCurrentAssetsDetails">
        <link:definition>40501 - Disclosure - Other current assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gaintherapeutics.com/role/DisclosurePropertyAndEquipmentNetDetails" id="DisclosurePropertyAndEquipmentNetDetails">
        <link:definition>40601 - Disclosure - Property and Equipment, net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gaintherapeutics.com/role/DisclosureOperatingLeaseRightOfUseRouAssetsFutureMinimumLeasePaymentsDetails" id="DisclosureOperatingLeaseRightOfUseRouAssetsFutureMinimumLeasePaymentsDetails">
        <link:definition>40704 - Disclosure - Operating lease. Right of use (ROU) assets - Future minimum lease payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gaintherapeutics.com/role/DisclosureOtherCurrentLiabilitiesAndDeferredIncomeDetails" id="DisclosureOtherCurrentLiabilitiesAndDeferredIncomeDetails">
        <link:definition>40901 - Disclosure - Other current liabilities and deferred income (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gaintherapeutics.com/role/DisclosurePensionObligationsEndOfYearFundedStatusDetails" id="DisclosurePensionObligationsEndOfYearFundedStatusDetails">
        <link:definition>41001 - Disclosure - Pension obligations - End of year funded status (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gaintherapeutics.com/role/DisclosurePensionObligationsComponentOfNetPeriodicPensionCostsDetails" id="DisclosurePensionObligationsComponentOfNetPeriodicPensionCostsDetails">
        <link:definition>41003 - Disclosure - Pension obligations - Component of net periodic pension costs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gaintherapeutics.com/role/DisclosureLoansFutureLoanPaymentsDetails" id="DisclosureLoansFutureLoanPaymentsDetails">
        <link:definition>41102 - Disclosure - Loans - Future loan payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gaintherapeutics.com/role/DisclosureIncomeTaxesDomesticAndForeignNetOperatingLossesDetails" id="DisclosureIncomeTaxesDomesticAndForeignNetOperatingLossesDetails">
        <link:definition>41701 - Disclosure - Income taxes - Domestic and foreign net operating losses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gaintherapeutics.com/role/DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseDetails" id="DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseDetails">
        <link:definition>41702 - Disclosure - Income taxes - Components of income tax expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gaintherapeutics.com/role/DisclosureIncomeTaxesDomesticAndForeignNetOperatingLossesAndRelatedDeferredTaxAssetsDetails" id="DisclosureIncomeTaxesDomesticAndForeignNetOperatingLossesAndRelatedDeferredTaxAssetsDetails">
        <link:definition>41703 - Disclosure - Income taxes - Domestic and foreign net operating losses and related deferred tax assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gaintherapeutics.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails" id="DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails">
        <link:definition>41705 - Disclosure - Income taxes - Effective income tax rate reconciliation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gaintherapeutics.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gaintherapeutics.com/role/StatementConsolidatedBalanceSheetsParenthetical" id="StatementConsolidatedBalanceSheetsParenthetical">
        <link:definition>00105 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfChangesInStockholdersEquityDeficit" id="StatementConsolidatedStatementOfChangesInStockholdersEquityDeficit">
        <link:definition>00400 - Statement - Consolidated Statement of Changes in Stockholders' Equity (Deficit)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gaintherapeutics.com/role/DisclosureNatureOfBusinessAndBasisOfPresentationDetails" id="DisclosureNatureOfBusinessAndBasisOfPresentationDetails">
        <link:definition>40101 - Disclosure - Nature of the Business and Basis of Presentation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gaintherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesDetails">
        <link:definition>40201 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gaintherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalDisclosuresDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesAdditionalDisclosuresDetails">
        <link:definition>40202 - Disclosure - Summary of Significant Accounting Policies - Additional disclosures (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gaintherapeutics.com/role/DisclosureResearchGrantsDetails" id="DisclosureResearchGrantsDetails">
        <link:definition>40301 - Disclosure - Research Grants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gaintherapeutics.com/role/DisclosureCashCashEquivalentsAndRestrictedCashDetails" id="DisclosureCashCashEquivalentsAndRestrictedCashDetails">
        <link:definition>40401 - Disclosure - Cash, cash equivalents and restricted cash (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gaintherapeutics.com/role/DisclosureCashCashEquivalentsAndRestrictedCashScheduleOfCashAndCashEquivalentsBalancesDetails" id="DisclosureCashCashEquivalentsAndRestrictedCashScheduleOfCashAndCashEquivalentsBalancesDetails">
        <link:definition>40402 - Disclosure - Cash, cash equivalents and restricted cash - Schedule of Cash and cash equivalents balances (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gaintherapeutics.com/role/DisclosureOperatingLeaseRightOfUseRouAssetsAdditionalInformationDetails" id="DisclosureOperatingLeaseRightOfUseRouAssetsAdditionalInformationDetails">
        <link:definition>40701 - Disclosure - Operating lease. Right of use (ROU) assets - Additional information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gaintherapeutics.com/role/DisclosureAccountsPayableDetails" id="DisclosureAccountsPayableDetails">
        <link:definition>40801 - Disclosure - Accounts Payable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gaintherapeutics.com/role/DisclosurePensionObligationsReconciliationOfFundedStatusDetails" id="DisclosurePensionObligationsReconciliationOfFundedStatusDetails">
        <link:definition>41002 - Disclosure - Pension obligations - Reconciliation of funded status (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gaintherapeutics.com/role/DisclosurePensionObligationsReconciliationOfProjectedBenefitObligationDetails" id="DisclosurePensionObligationsReconciliationOfProjectedBenefitObligationDetails">
        <link:definition>41004 - Disclosure - Pension obligations - Reconciliation of projected benefit obligation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gaintherapeutics.com/role/DisclosurePensionObligationsReconciliationOfFairValueOfPlanAssetsDetails" id="DisclosurePensionObligationsReconciliationOfFairValueOfPlanAssetsDetails">
        <link:definition>41005 - Disclosure - Pension obligations - Reconciliation of fair value of plan assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gaintherapeutics.com/role/DisclosurePensionObligationsChangeInNetGainLossDetails" id="DisclosurePensionObligationsChangeInNetGainLossDetails">
        <link:definition>41006 - Disclosure - Pension obligations - Change in net (gain) loss (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gaintherapeutics.com/role/DisclosurePensionObligationsChangeInAccumulatedOtherComprehensiveIncomeAociDetails" id="DisclosurePensionObligationsChangeInAccumulatedOtherComprehensiveIncomeAociDetails">
        <link:definition>41007 - Disclosure - Pension obligations - Change in accumulated other comprehensive income (AOCI) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gaintherapeutics.com/role/DisclosurePensionObligationsAssumptionsDetails" id="DisclosurePensionObligationsAssumptionsDetails">
        <link:definition>41008 - Disclosure - Pension obligations - Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gaintherapeutics.com/role/DisclosurePensionObligationsExpectedBenefitPaymentsDetails" id="DisclosurePensionObligationsExpectedBenefitPaymentsDetails">
        <link:definition>41009 - Disclosure - Pension obligations - Expected benefit payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gaintherapeutics.com/role/DisclosureLoansDetails" id="DisclosureLoansDetails">
        <link:definition>41101 - Disclosure - Loans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gaintherapeutics.com/role/DisclosureFairValueMeasurementDetails" id="DisclosureFairValueMeasurementDetails">
        <link:definition>41201 - Disclosure - Fair value measurement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gaintherapeutics.com/role/DisclosureCommonAndPreferredStockDetails" id="DisclosureCommonAndPreferredStockDetails">
        <link:definition>41301 - Disclosure - Common and Preferred Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gaintherapeutics.com/role/DisclosureWarrantsDetails" id="DisclosureWarrantsDetails">
        <link:definition>41401 - Disclosure - Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gaintherapeutics.com/role/DisclosureWarrantsAssumptionsUnderBlackScholesPricingModelDetails" id="DisclosureWarrantsAssumptionsUnderBlackScholesPricingModelDetails">
        <link:definition>41402 - Disclosure - Warrants - Assumptions under black-scholes pricing model (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gaintherapeutics.com/role/DisclosureEquityIncentivePlanDetails" id="DisclosureEquityIncentivePlanDetails">
        <link:definition>41501 - Disclosure - Equity Incentive Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gaintherapeutics.com/role/DisclosureEquityIncentivePlanStockOptionActivityDetails" id="DisclosureEquityIncentivePlanStockOptionActivityDetails">
        <link:definition>41502 - Disclosure - Equity Incentive Plan - Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gaintherapeutics.com/role/DisclosureEquityIncentivePlanOptionsOutstandingAndExercisableDetails" id="DisclosureEquityIncentivePlanOptionsOutstandingAndExercisableDetails">
        <link:definition>41503 - Disclosure - Equity Incentive Plan - Options Outstanding and Exercisable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gaintherapeutics.com/role/DisclosureEquityIncentivePlanAssumptionsDetails" id="DisclosureEquityIncentivePlanAssumptionsDetails">
        <link:definition>41504 - Disclosure - Equity Incentive Plan - Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gaintherapeutics.com/role/DisclosureEquityIncentivePlanStockBasedCompensationDetails" id="DisclosureEquityIncentivePlanStockBasedCompensationDetails">
        <link:definition>41505 - Disclosure - Equity Incentive Plan - Stock-based compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gaintherapeutics.com/role/DisclosureCollaborationAgreementDetails" id="DisclosureCollaborationAgreementDetails">
        <link:definition>41601 - Disclosure - Collaboration Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gaintherapeutics.com/role/DisclosureIncomeTaxesAdditionalDisclosuresDetails" id="DisclosureIncomeTaxesAdditionalDisclosuresDetails">
        <link:definition>41704 - Disclosure - Income taxes - Additional disclosures (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gaintherapeutics.com/role/DisclosureNetLossPerCommonShareComputationOfDilutedNetLossPerShareDetails" id="DisclosureNetLossPerCommonShareComputationOfDilutedNetLossPerShareDetails">
        <link:definition>41801 - Disclosure - Net loss per common share - Computation of diluted net loss per share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gaintherapeutics.com/role/DisclosureRelatedPartiesDetails" id="DisclosureRelatedPartiesDetails">
        <link:definition>41901 - Disclosure - Related Parties (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gaintherapeutics.com/role/DisclosureOtherInformationDetails" id="DisclosureOtherInformationDetails">
        <link:definition>42001 - Disclosure - Other Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gaintherapeutics.com/role/DisclosureNatureOfBusinessAndBasisOfPresentation" id="DisclosureNatureOfBusinessAndBasisOfPresentation">
        <link:definition>10101 - Disclosure - Nature of the Business and Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gaintherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPolicies" id="DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>10201 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gaintherapeutics.com/role/DisclosureResearchGrants" id="DisclosureResearchGrants">
        <link:definition>10301 - Disclosure - Research Grants</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gaintherapeutics.com/role/DisclosureCashCashEquivalentsAndRestrictedCash" id="DisclosureCashCashEquivalentsAndRestrictedCash">
        <link:definition>10401 - Disclosure - Cash, cash equivalents and restricted cash</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gaintherapeutics.com/role/DisclosureOtherCurrentAssets" id="DisclosureOtherCurrentAssets">
        <link:definition>10501 - Disclosure - Other Current Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gaintherapeutics.com/role/DisclosurePropertyAndEquipmentNet" id="DisclosurePropertyAndEquipmentNet">
        <link:definition>10601 - Disclosure - Property and Equipment, net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gaintherapeutics.com/role/DisclosureOperatingLeaseRightOfUserouAssets" id="DisclosureOperatingLeaseRightOfUserouAssets">
        <link:definition>10701 - Disclosure - Operating lease. Right of use ("ROU") assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gaintherapeutics.com/role/DisclosureAccountsPayable" id="DisclosureAccountsPayable">
        <link:definition>10801 - Disclosure - Accounts Payable</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gaintherapeutics.com/role/DisclosureOtherCurrentLiabilitiesAndDeferredIncome" id="DisclosureOtherCurrentLiabilitiesAndDeferredIncome">
        <link:definition>10901 - Disclosure - Other current liabilities and deferred income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gaintherapeutics.com/role/DisclosurePensionObligations" id="DisclosurePensionObligations">
        <link:definition>11001 - Disclosure - Pension obligations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gaintherapeutics.com/role/DisclosureLoans" id="DisclosureLoans">
        <link:definition>11101 - Disclosure - Loans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gaintherapeutics.com/role/DisclosureFairValueMeasurement" id="DisclosureFairValueMeasurement">
        <link:definition>11201 - Disclosure - Fair value measurement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gaintherapeutics.com/role/DisclosureCommonAndPreferredStock" id="DisclosureCommonAndPreferredStock">
        <link:definition>11301 - Disclosure - Common and Preferred Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gaintherapeutics.com/role/DisclosureWarrants" id="DisclosureWarrants">
        <link:definition>11401 - Disclosure - Warrants</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gaintherapeutics.com/role/DisclosureEquityIncentivePlan" id="DisclosureEquityIncentivePlan">
        <link:definition>11501 - Disclosure - Equity Incentive Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gaintherapeutics.com/role/DisclosureCollaborationAgreement" id="DisclosureCollaborationAgreement">
        <link:definition>11601 - Disclosure - Collaboration Agreement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gaintherapeutics.com/role/DisclosureIncomeTaxes" id="DisclosureIncomeTaxes">
        <link:definition>11701 - Disclosure - Income taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gaintherapeutics.com/role/DisclosureNetLossPerCommonShare" id="DisclosureNetLossPerCommonShare">
        <link:definition>11801 - Disclosure - Net loss per common share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gaintherapeutics.com/role/DisclosureRelatedParties" id="DisclosureRelatedParties">
        <link:definition>11901 - Disclosure - Related Parties</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gaintherapeutics.com/role/DisclosureOtherInformation" id="DisclosureOtherInformation">
        <link:definition>12001 - Disclosure - Other Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gaintherapeutics.com/role/DisclosureSignificantEventsAfterBalanceSheetDate" id="DisclosureSignificantEventsAfterBalanceSheetDate">
        <link:definition>12101 - Disclosure - Significant events after the balance sheet date</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gaintherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>20202 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gaintherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" id="DisclosureSummaryOfSignificantAccountingPoliciesTables">
        <link:definition>30203 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gaintherapeutics.com/role/DisclosureCashCashEquivalentsAndRestrictedCashTables" id="DisclosureCashCashEquivalentsAndRestrictedCashTables">
        <link:definition>30403 - Disclosure - Cash, cash equivalents and restricted cash (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gaintherapeutics.com/role/DisclosureOtherCurrentAssetsTables" id="DisclosureOtherCurrentAssetsTables">
        <link:definition>30503 - Disclosure - Other Current Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gaintherapeutics.com/role/DisclosurePropertyAndEquipmentNetTables" id="DisclosurePropertyAndEquipmentNetTables">
        <link:definition>30603 - Disclosure - Property and Equipment, net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gaintherapeutics.com/role/DisclosureOperatingLeaseRightOfUserouAssetsTables" id="DisclosureOperatingLeaseRightOfUserouAssetsTables">
        <link:definition>30703 - Disclosure - Operating lease. Right of use ("ROU") assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gaintherapeutics.com/role/DisclosureAccountsPayableTables" id="DisclosureAccountsPayableTables">
        <link:definition>30803 - Disclosure - Accounts Payable (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gaintherapeutics.com/role/DisclosureOtherCurrentLiabilitiesAndDeferredIncomeTables" id="DisclosureOtherCurrentLiabilitiesAndDeferredIncomeTables">
        <link:definition>30903 - Disclosure - Other current liabilities and deferred income (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gaintherapeutics.com/role/DisclosurePensionObligationsTables" id="DisclosurePensionObligationsTables">
        <link:definition>31003 - Disclosure - Pension obligations (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gaintherapeutics.com/role/DisclosureLoansTables" id="DisclosureLoansTables">
        <link:definition>31103 - Disclosure - Loans (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gaintherapeutics.com/role/DisclosureFairValueMeasurementTables" id="DisclosureFairValueMeasurementTables">
        <link:definition>31203 - Disclosure - Fair value measurement (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gaintherapeutics.com/role/DisclosureWarrantsTables" id="DisclosureWarrantsTables">
        <link:definition>31403 - Disclosure - Warrants (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gaintherapeutics.com/role/DisclosureEquityIncentivePlanTables" id="DisclosureEquityIncentivePlanTables">
        <link:definition>31503 - Disclosure - Equity Incentive Plan (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gaintherapeutics.com/role/DisclosureIncomeTaxesTables" id="DisclosureIncomeTaxesTables">
        <link:definition>31703 - Disclosure - Income taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gaintherapeutics.com/role/DisclosureNetLossPerCommonShareTables" id="DisclosureNetLossPerCommonShareTables">
        <link:definition>31803 - Disclosure - Net loss per common share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gaintherapeutics.com/role/DisclosureOperatingLeaseRightOfUseRouAssetsSummaryOfComponentsOfLeaseAccountingDetails" id="DisclosureOperatingLeaseRightOfUseRouAssetsSummaryOfComponentsOfLeaseAccountingDetails">
        <link:definition>40702 - Disclosure - Operating lease. Right of use (ROU) assets - Summary of components of lease accounting (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gaintherapeutics.com/role/DisclosureOperatingLeaseRightOfUseRouAssetsSummaryOfComponentsOfLeaseExpenseDetails" id="DisclosureOperatingLeaseRightOfUseRouAssetsSummaryOfComponentsOfLeaseExpenseDetails">
        <link:definition>40703 - Disclosure - Operating lease. Right of use (ROU) assets - Summary of components of lease expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gaintherapeutics.com/role/DisclosurePensionObligationsAdditionalInformationDetails" id="DisclosurePensionObligationsAdditionalInformationDetails">
        <link:definition>41010 - Disclosure - Pension obligations - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="ganx-20211231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="ganx-20211231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="ganx-20211231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="ganx-20211231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links, all" />
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/currency/2021" schemaLocation="https://xbrl.sec.gov/currency/2021/currency-2021.xsd" />
  <xsd:element id="ganx_PrepaidExpensesAndOtherCurrentAssetsTextBlock" name="PrepaidExpensesAndOtherCurrentAssetsTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="ganx_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" name="ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="ganx_LaboratoryInstrumentsMember" name="LaboratoryInstrumentsMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ganx_AccountsPayableCurrentTable" name="AccountsPayableCurrentTable" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ganx_AccountsPayableCurrentLineItems" name="AccountsPayableCurrentLineItems" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ganx_PayableForSocialSecuritiesCurrent" name="PayableForSocialSecuritiesCurrent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="ganx_AccruedPayrollCurrent" name="AccruedPayrollCurrent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="ganx_OtherCurrentLiabilitiesAndDeferredIncomeTextBlock" name="OtherCurrentLiabilitiesAndDeferredIncomeTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="ganx_OtherCurrentLiabilitiesAndDeferredIncomeTableTextBlock" name="OtherCurrentLiabilitiesAndDeferredIncomeTableTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="ganx_LicenseAgreementWithMinoryxTherapeuticsSlMember" name="LicenseAgreementWithMinoryxTherapeuticsSlMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ganx_RelatedPartyTransactionPercentageOfNetRevenuesBasedOnOneCompositionOfMatterClaim" name="RelatedPartyTransactionPercentageOfNetRevenuesBasedOnOneCompositionOfMatterClaim" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="ganx_RelatedPartyTransactionPercentageOfNetRevenuesBasedOnOneMethodOfClaim" name="RelatedPartyTransactionPercentageOfNetRevenuesBasedOnOneMethodOfClaim" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="ganx_RelatedPartyTransactionPercentageOfConsiderationReceived" name="RelatedPartyTransactionPercentageOfConsiderationReceived" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="ganx_OmnibusIncentivePlanTwoThousandTwentyMember" name="OmnibusIncentivePlanTwoThousandTwentyMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ganx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAfterStockSplitsNumber" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAfterStockSplitsNumber" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <xsd:element id="ganx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAfterStockSplitsWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAfterStockSplitsWeightedAverageExercisePrice" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <xsd:element id="ganx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAfterStockSplitWeightedAverageRemainingContractualTerm" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAfterStockSplitWeightedAverageRemainingContractualTerm" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="ganx_ReverseStockSplitPolicyPolicyTextBlock" name="ReverseStockSplitPolicyPolicyTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="ganx_InitialPublicOfferingPolicyTextBlock" name="InitialPublicOfferingPolicyTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="ganx_AccruedExpensesPolicyPolicyTextBlock" name="AccruedExpensesPolicyPolicyTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="ganx_ResearchGrantsPolicyPolicyTextBlock" name="ResearchGrantsPolicyPolicyTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="ganx_UnderwritingDiscountsAndCommissions" name="UnderwritingDiscountsAndCommissions" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="ganx_OtherOfferingExpenses" name="OtherOfferingExpenses" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="ganx_PropertyPlantAndEquipmentDepreciationRates" name="PropertyPlantAndEquipmentDepreciationRates" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="ganx_EquipmentAndFurnitureMember" name="EquipmentAndFurnitureMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ganx_ScheduleOfCashAndCashEquivalentsBalancesTableTextBlock" name="ScheduleOfCashAndCashEquivalentsBalancesTableTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="ganx_DepreciationRatesOnPropertyPlantAndEquipmentTableTextBlock" name="DepreciationRatesOnPropertyPlantAndEquipmentTableTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="ganx_CollaborationAgreementsMember" name="CollaborationAgreementsMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ganx_IncreaseDecreaseInOperatingAssetsAndLiabilities" name="IncreaseDecreaseInOperatingAssetsAndLiabilities" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="ganx_DepositsCurrent" name="DepositsCurrent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="ganx_IncomeLossForPeriod" name="IncomeLossForPeriod" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="ganx_NumberOfOptionsSubjectToTermThreshold" name="NumberOfOptionsSubjectToTermThreshold" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="ganx_DepositsAndOtherAssetsNoncurrent" name="DepositsAndOtherAssetsNoncurrent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="ganx_WarrantsAndRightsNoteDisclosureTextBlock" name="WarrantsAndRightsNoteDisclosureTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="ganx_WarrantsAndRightsServicePeriod" name="WarrantsAndRightsServicePeriod" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="ganx_WarrantsAndRightsExercisedOrExchangedNumber" name="WarrantsAndRightsExercisedOrExchangedNumber" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="ganx_CollaborationAgreementAbstract" name="CollaborationAgreementAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ganx_MultiTargetCollaborationAgreementMember" name="MultiTargetCollaborationAgreementMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ganx_ZentalisPharmaceuticalsInc.Member" name="ZentalisPharmaceuticalsInc.Member" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ganx_CollaborativeArrangementMinimumNumberOfTargets" name="CollaborativeArrangementMinimumNumberOfTargets" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <xsd:element id="ganx_CollaborativeArrangementTerminationNoticePeriodDays" name="CollaborativeArrangementTerminationNoticePeriodDays" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="ganx_CollaborativeArrangementProgramInitiationFee" name="CollaborativeArrangementProgramInitiationFee" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="ganx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="ganx_ExercisePrice3.38Member" name="ExercisePrice3.38Member" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ganx_ExercisePrice10.03Member" name="ExercisePrice10.03Member" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ganx_CapitalizedComputerSoftwareAdjustment" name="CapitalizedComputerSoftwareAdjustment" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="ganx_CollaborativeArrangementEmployeeAndExternalResearchAndDevelopmentCosts" name="CollaborativeArrangementEmployeeAndExternalResearchAndDevelopmentCosts" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="ganx_CollaborativeArrangementOptionExerciseFee" name="CollaborativeArrangementOptionExerciseFee" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="ganx_CollaborativeArrangementEventBasedMilestonePayments" name="CollaborativeArrangementEventBasedMilestonePayments" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="ganx_CapitalizedComputerSoftwareForInternalUse" name="CapitalizedComputerSoftwareForInternalUse" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="ganx_IssuanceOfCommonStockThroughCashlessExerciseOfWarrants" name="IssuanceOfCommonStockThroughCashlessExerciseOfWarrants" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="ganx_ProceedsFromIssuanceOfSeriesBPreferredStockNetOfIssuanceCosts" name="ProceedsFromIssuanceOfSeriesBPreferredStockNetOfIssuanceCosts" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="ganx_ProceedsFromIssuanceOfSeriesA.PreferredStockNetOfIssuanceCosts" name="ProceedsFromIssuanceOfSeriesA.PreferredStockNetOfIssuanceCosts" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="ganx_ExercisePrice7.80Member" name="ExercisePrice7.80Member" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ganx_March2020ChfLoanMember" name="March2020ChfLoanMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ganx_August2020ChfLoanMember" name="August2020ChfLoanMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ganx_WarrantsToDesigneesOfPlacementAgentIssuedJuly2020Member" name="WarrantsToDesigneesOfPlacementAgentIssuedJuly2020Member" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ganx_WarrantsToDesigneesOfInvestmentBankIssuedMay2021Member" name="WarrantsToDesigneesOfInvestmentBankIssuedMay2021Member" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ganx_ConversionOfSeriesPreferredStockIntoCommonStock" name="ConversionOfSeriesPreferredStockIntoCommonStock" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="ganx_ConversionOfSeriesBPreferredStockIntoCommonStock" name="ConversionOfSeriesBPreferredStockIntoCommonStock" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="ganx_ConversionOfSeriesBPreferredStockIntoCommonStockInShares" name="ConversionOfSeriesBPreferredStockIntoCommonStockInShares" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="ganx_ConversionOfSeriesPreferredStockIntoCommonStockInShares" name="ConversionOfSeriesPreferredStockIntoCommonStockInShares" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="ganx_IssuanceOfCommonStockInIpoNetOfIssuanceCosts" name="IssuanceOfCommonStockInIpoNetOfIssuanceCosts" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="ganx_IssuanceOfCommonStockInIpoInShares" name="IssuanceOfCommonStockInIpoInShares" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="ganx_IssuanceOfSeriesBPreferredStockNetOfIssuanceCost" name="IssuanceOfSeriesBPreferredStockNetOfIssuanceCost" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="ganx_IssuanceOfSeriesPreferredStockNetOfIssuanceCost" name="IssuanceOfSeriesPreferredStockNetOfIssuanceCost" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="ganx_IssuanceOfSeriesPreferredStockInShares" name="IssuanceOfSeriesPreferredStockInShares" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="ganx_IssuanceOfSeriesBPreferredStockInShares" name="IssuanceOfSeriesBPreferredStockInShares" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="ganx_PreferredStockToCommonStockConversionRatio" name="PreferredStockToCommonStockConversionRatio" nillable="true" type="xbrli:pureItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element name="IpoExcludingUnderwritersOptionsMember" id="ganx_IpoExcludingUnderwritersOptionsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="GrossProceedsFromIssuanceOfCommonStock" id="ganx_GrossProceedsFromIssuanceOfCommonStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="UncertainTaxPositionsRecognized" id="ganx_UncertainTaxPositionsRecognized" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="ResearchGrantsAbstract" id="ganx_ResearchGrantsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="GtGainTherapeuticsSaMember" id="ganx_GtGainTherapeuticsSaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="MichaelJ.FoxFoundationForParkinsonSResearchMjffMember" id="ganx_MichaelJ.FoxFoundationForParkinsonSResearchMjffMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ReductionOfResearchAndDevelopmentExpensesThroughExpensesReimbursed" id="ganx_ReductionOfResearchAndDevelopmentExpensesThroughExpensesReimbursed" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="ConsortiumWithGtGainTherapeuticsSaInstituteForResearchInBiomedicineAndNeuroSysSasMember" id="ganx_ConsortiumWithGtGainTherapeuticsSaInstituteForResearchInBiomedicineAndNeuroSysSasMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="Eurostars2Member" id="ganx_Eurostars2Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ProceedsFromGrants" id="ganx_ProceedsFromGrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="OfficeSpaceViaSoaveN6LuganoSwitzerlandMember" id="ganx_OfficeSpaceViaSoaveN6LuganoSwitzerlandMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="LesseeOperatingLeaseTermOfCancelledContract" id="ganx_LesseeOperatingLeaseTermOfCancelledContract" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="OfficeSpaceInBethesdaMarylandMember" id="ganx_OfficeSpaceInBethesdaMarylandMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="OfficeSpaceTorreDBuildingBarcelonaMember" id="ganx_OfficeSpaceTorreDBuildingBarcelonaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="OfficeSpaceTorreIBuildingBarcelonaMember" id="ganx_OfficeSpaceTorreIBuildingBarcelonaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="OfficeSpace" id="ganx_OfficeSpace" type="dtr-types:areaItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="DefinedBenefitPlanBenefitObligationGainsLossesOnFinancialAssumptions" id="ganx_DefinedBenefitPlanBenefitObligationGainsLossesOnFinancialAssumptions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="DefinedBenefitPlanBenefitObligationGainsLossesOnDemographicAssumptions" id="ganx_DefinedBenefitPlanBenefitObligationGainsLossesOnDemographicAssumptions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="DefinedBenefitPlanBenefitObligationGainsLossesOnExperience" id="ganx_DefinedBenefitPlanBenefitObligationGainsLossesOnExperience" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="ExercisePrice5.86Member" id="ganx_ExercisePrice5.86Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ExercisePrice5.99Member" id="ganx_ExercisePrice5.99Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="OfficeSpaceViaPietroPeri9DLuganoSwitzerlandMember" id="ganx_OfficeSpaceViaPietroPeri9DLuganoSwitzerlandMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="IncreaseDecreaseInValueAddedTaxCredits" id="ganx_IncreaseDecreaseInValueAddedTaxCredits" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="ExpensesOrChargesDueForEarlyExtinguishmentOfDebt" id="ganx_ExpensesOrChargesDueForEarlyExtinguishmentOfDebt" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionNonvestedWeightedAverageExercisePriceAfterStockSplit" id="ganx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionNonvestedWeightedAverageExercisePriceAfterStockSplit" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedDuringPeriodWeightedAverageGrantDateFairValue" id="ganx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedDuringPeriodWeightedAverageGrantDateFairValue" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="WarrantsGrantDateFairValue" id="ganx_WarrantsGrantDateFairValue" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="TwentyTwentyoneInducementEquityIncentivePlanMember" id="ganx_TwentyTwentyoneInducementEquityIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="AccountsPayablePolicyTextBlock" id="ganx_AccountsPayablePolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="PayablesForSocialSecuritiesPolicyTextBlock" id="ganx_PayablesForSocialSecuritiesPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ResearchGrantsDisclosureTextBlock" id="ganx_ResearchGrantsDisclosureTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="DeferredTaxAssetsFmwWarrant" id="ganx_DeferredTaxAssetsFmwWarrant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="OtherInformationAbstract" id="ganx_OtherInformationAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="OtherInformationDisclosureTextBlock" id="ganx_OtherInformationDisclosureTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="EffectiveIncomeTaxRateReconciliationPermanentDifferences" id="ganx_EffectiveIncomeTaxRateReconciliationPermanentDifferences" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="EffectiveIncomeTaxRateReconciliationProvisionToReturn" id="ganx_EffectiveIncomeTaxRateReconciliationProvisionToReturn" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfPensionIncreases" id="ganx_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfPensionIncreases" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="DefinedBenefitPlanDemographicAssumptionLumpSumOption" id="ganx_DefinedBenefitPlanDemographicAssumptionLumpSumOption" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="DefinedBenefitPlanDemographicAssumptionProportionMarried" id="ganx_DefinedBenefitPlanDemographicAssumptionProportionMarried" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="DefinedBenefitPlanDemographicAssumptionAllowanceForChildPensions" id="ganx_DefinedBenefitPlanDemographicAssumptionAllowanceForChildPensions" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="DefinedBenefitPlanMortalityImprovementPercentage" id="ganx_DefinedBenefitPlanMortalityImprovementPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="DefinedBenefitPlanDisabilityPercentage" id="ganx_DefinedBenefitPlanDisabilityPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="ExpenseForInterestAndPenaltiesRelatedToUncertainTaxPositionRecognizedInStatementOfOperations" id="ganx_ExpenseForInterestAndPenaltiesRelatedToUncertainTaxPositionRecognizedInStatementOfOperations" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="IncreaseDecreaseThroughTotalExpensesToReconcileFundedStatusOfDefinedBenefitPlan" id="ganx_IncreaseDecreaseThroughTotalExpensesToReconcileFundedStatusOfDefinedBenefitPlan" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="IncreaseDecreaseInAccumulatedOtherComprehensiveIncomeToReconcileFundedStatusOfDefinedBenefitPlan" id="ganx_IncreaseDecreaseInAccumulatedOtherComprehensiveIncomeToReconcileFundedStatusOfDefinedBenefitPlan" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="PreferredStockSeriesAndSeriesBMember" id="ganx_PreferredStockSeriesAndSeriesBMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="AdjustmentToReconcileOperatingLeaseLiabilitiesAmountsRepresentingInterestOrImputedInterest" id="ganx_AdjustmentToReconcileOperatingLeaseLiabilitiesAmountsRepresentingInterestOrImputedInterest" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="DefinedBenefitPlanPlanAssetsOtherIncreasesDecreases" id="ganx_DefinedBenefitPlanPlanAssetsOtherIncreasesDecreases" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>29
<FILENAME>ganx-20211231_cal.xml
<DESCRIPTION>EX-101.CAL
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.8042.36810 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/25/2022 6:18:32 PM-->
<!--Modified on: 3/25/2022 6:18:32 PM-->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <roleRef xlink:type="simple" xlink:href="ganx-20211231.xsd#StatementConsolidatedBalanceSheets" roleURI="http://www.gaintherapeutics.com/role/StatementConsolidatedBalanceSheets" />
  <roleRef xlink:type="simple" xlink:href="ganx-20211231.xsd#StatementConsolidatedStatementOfOperations" roleURI="http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfOperations" />
  <roleRef xlink:type="simple" xlink:href="ganx-20211231.xsd#StatementConsolidatedStatementOfComprehensiveLoss" roleURI="http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfComprehensiveLoss" />
  <roleRef xlink:type="simple" xlink:href="ganx-20211231.xsd#StatementConsolidatedStatementOfCashFlows" roleURI="http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfCashFlows" />
  <roleRef xlink:type="simple" xlink:href="ganx-20211231.xsd#DisclosureOtherCurrentAssetsDetails" roleURI="http://www.gaintherapeutics.com/role/DisclosureOtherCurrentAssetsDetails" />
  <roleRef xlink:type="simple" xlink:href="ganx-20211231.xsd#DisclosurePropertyAndEquipmentNetDetails" roleURI="http://www.gaintherapeutics.com/role/DisclosurePropertyAndEquipmentNetDetails" />
  <roleRef xlink:type="simple" xlink:href="ganx-20211231.xsd#DisclosureOperatingLeaseRightOfUseRouAssetsFutureMinimumLeasePaymentsDetails" roleURI="http://www.gaintherapeutics.com/role/DisclosureOperatingLeaseRightOfUseRouAssetsFutureMinimumLeasePaymentsDetails" />
  <roleRef xlink:type="simple" xlink:href="ganx-20211231.xsd#DisclosureOtherCurrentLiabilitiesAndDeferredIncomeDetails" roleURI="http://www.gaintherapeutics.com/role/DisclosureOtherCurrentLiabilitiesAndDeferredIncomeDetails" />
  <roleRef xlink:type="simple" xlink:href="ganx-20211231.xsd#DisclosurePensionObligationsEndOfYearFundedStatusDetails" roleURI="http://www.gaintherapeutics.com/role/DisclosurePensionObligationsEndOfYearFundedStatusDetails" />
  <roleRef xlink:type="simple" xlink:href="ganx-20211231.xsd#DisclosurePensionObligationsComponentOfNetPeriodicPensionCostsDetails" roleURI="http://www.gaintherapeutics.com/role/DisclosurePensionObligationsComponentOfNetPeriodicPensionCostsDetails" />
  <roleRef xlink:type="simple" xlink:href="ganx-20211231.xsd#DisclosureLoansFutureLoanPaymentsDetails" roleURI="http://www.gaintherapeutics.com/role/DisclosureLoansFutureLoanPaymentsDetails" />
  <roleRef xlink:type="simple" xlink:href="ganx-20211231.xsd#DisclosureIncomeTaxesDomesticAndForeignNetOperatingLossesDetails" roleURI="http://www.gaintherapeutics.com/role/DisclosureIncomeTaxesDomesticAndForeignNetOperatingLossesDetails" />
  <roleRef xlink:type="simple" xlink:href="ganx-20211231.xsd#DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseDetails" roleURI="http://www.gaintherapeutics.com/role/DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseDetails" />
  <roleRef xlink:type="simple" xlink:href="ganx-20211231.xsd#DisclosureIncomeTaxesDomesticAndForeignNetOperatingLossesAndRelatedDeferredTaxAssetsDetails" roleURI="http://www.gaintherapeutics.com/role/DisclosureIncomeTaxesDomesticAndForeignNetOperatingLossesAndRelatedDeferredTaxAssetsDetails" />
  <roleRef xlink:type="simple" xlink:href="ganx-20211231.xsd#DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails" roleURI="http://www.gaintherapeutics.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails" />
  <calculationLink xlink:role="http://www.gaintherapeutics.com/role/StatementConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - Consolidated Balance Sheets">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_637560093955817064" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_637838291101392354" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets_637560093955817064" xlink:to="us-gaap_AssetsCurrent_637838291101392354" order="1" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_637838291101392354" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637838291101392354" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_637838291101392354" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent_637838291101392354" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637838291101392354" xlink:to="us-gaap_RestrictedCashCurrent_637838291101392354" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent_637838291101402367" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637838291101392354" xlink:to="us-gaap_AccountsReceivableNetCurrent_637838291101402367" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_637838291101402367" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637838291101392354" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_637838291101402367" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredOfferingCosts" xlink:label="us-gaap_DeferredOfferingCosts_637838291101402367" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637838291101392354" xlink:to="us-gaap_DeferredOfferingCosts_637838291101402367" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxesAndOtherTaxReceivableCurrent" xlink:label="us-gaap_DeferredIncomeTaxesAndOtherTaxReceivableCurrent_637838291101402367" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637838291101392354" xlink:to="us-gaap_DeferredIncomeTaxesAndOtherTaxReceivableCurrent_637838291101402367" order="6" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent_637838291101402367" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets_637560093955817064" xlink:to="us-gaap_AssetsNoncurrent_637838291101402367" order="2" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_637838291101402367" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent_637838291101402367" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_637838291101402367" order="1" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_637838291101402367" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent_637838291101402367" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_637838291101402367" order="2" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent_637838291101402367" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent_637838291101402367" xlink:to="us-gaap_RestrictedCashNoncurrent_637838291101402367" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_DepositsAndOtherAssetsNoncurrent" xlink:label="ganx_DepositsAndOtherAssetsNoncurrent_637838291101402367" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent_637838291101402367" xlink:to="ganx_DepositsAndOtherAssetsNoncurrent_637838291101402367" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_CapitalizedComputerSoftwareForInternalUse" xlink:label="ganx_CapitalizedComputerSoftwareForInternalUse_637838291101402367" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent_637838291101402367" xlink:to="ganx_CapitalizedComputerSoftwareForInternalUse_637838291101402367" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_637560093955846979" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_637838291101412343" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity_637560093955846979" xlink:to="us-gaap_Liabilities_637838291101412343" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_637838291101412343" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_637838291101412343" xlink:to="us-gaap_LiabilitiesCurrent_637838291101412343" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_637838291101412343" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637838291101412343" xlink:to="us-gaap_AccountsPayableCurrent_637838291101412343" order="1" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_637838291101412343" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637838291101412343" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_637838291101412343" order="2" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent_637838291101412343" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637838291101412343" xlink:to="us-gaap_OtherLiabilitiesCurrent_637838291101412343" order="3" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeCurrent" xlink:label="us-gaap_DeferredIncomeCurrent_637838291101412343" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637838291101412343" xlink:to="us-gaap_DeferredIncomeCurrent_637838291101412343" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent_637838291101412343" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637838291101412343" xlink:to="us-gaap_LongTermDebtCurrent_637838291101412343" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent_637838291101422343" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_637838291101412343" xlink:to="us-gaap_LiabilitiesNoncurrent_637838291101422343" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent" xlink:label="us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent_637838291101422343" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent_637838291101422343" xlink:to="us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent_637838291101422343" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_637838291101422343" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent_637838291101422343" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_637838291101422343" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent_637838291101422343" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent_637838291101422343" xlink:to="us-gaap_LongTermDebtNoncurrent_637838291101422343" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637838291101422343" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity_637560093955846979" xlink:to="us-gaap_StockholdersEquity_637838291101422343" order="2" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_637838291101422343" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637838291101422343" xlink:to="us-gaap_PreferredStockValue_637838291101422343" order="1" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_637838291101422343" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637838291101422343" xlink:to="us-gaap_CommonStockValue_637838291101422343" order="2" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_637838291101422343" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637838291101422343" xlink:to="us-gaap_AdditionalPaidInCapital_637838291101422343" order="3" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_637838291101432341" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637838291101422343" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_637838291101432341" order="4" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_IncomeLossForPeriod" xlink:label="ganx_IncomeLossForPeriod_637838291101432341" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637838291101422343" xlink:to="ganx_IncomeLossForPeriod_637838291101432341" order="5" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_637838291101432341" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637838291101422343" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_637838291101432341" order="6" use="optional" weight="1" priority="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfOperations" xlink:type="extended" xlink:title="00200 - Statement - Consolidated Statement of Operations">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637560093955886871" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_637838291101432341" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_637560093955886871" xlink:to="us-gaap_IncomeTaxExpenseBenefit_637838291101432341" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_637838291101432341" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_637560093955886871" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_637838291101432341" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_637838291101432341" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_637838291101432341" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_637838291101432341" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="us-gaap_InterestIncomeExpenseNet_637838291101442345" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_637838291101432341" xlink:to="us-gaap_InterestIncomeExpenseNet_637838291101442345" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_637838291101442345" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_637838291101432341" xlink:to="us-gaap_OperatingIncomeLoss_637838291101442345" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_637838291101442345" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_637838291101442345" xlink:to="us-gaap_OperatingExpenses_637838291101442345" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_637838291101442345" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_637838291101442345" xlink:to="us-gaap_GeneralAndAdministrativeExpense_637838291101442345" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_637838291101442345" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_637838291101442345" xlink:to="us-gaap_ResearchAndDevelopmentExpense_637838291101442345" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues_637838291101442345" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_637838291101442345" xlink:to="us-gaap_Revenues_637838291101442345" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_637838291101442345" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Revenues_637838291101442345" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_637838291101442345" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubleaseIncome" xlink:label="us-gaap_SubleaseIncome_637838291101442345" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Revenues_637838291101442345" xlink:to="us-gaap_SubleaseIncome_637838291101442345" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfComprehensiveLoss" xlink:type="extended" xlink:title="00300 - Statement - Consolidated Statement of Comprehensive Loss">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_637560093955897191" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_637838291101442345" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax_637560093955897191" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_637838291101442345" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_637838291101452345" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_637838291101442345" xlink:to="us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_637838291101452345" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_637838291101452345" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_637838291101442345" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_637838291101452345" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637838291101452345" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax_637560093955897191" xlink:to="us-gaap_NetIncomeLoss_637838291101452345" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfCashFlows" xlink:type="extended" xlink:title="00500 - Statement - Consolidated Statement of Cash Flows">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_637838291101452345" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_637838291101452345" order="1" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_637838291101452345" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637838291101452345" xlink:to="us-gaap_ProfitLoss_637838291101452345" order="1" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_637838291101452345" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637838291101452345" xlink:to="us-gaap_Depreciation_637838291101452345" order="2" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_637838291101452345" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637838291101452345" xlink:to="us-gaap_ShareBasedCompensation_637838291101452345" order="3" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_637838291101452345" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637838291101452345" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_637838291101452345" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_CapitalizedComputerSoftwareAdjustment" xlink:label="ganx_CapitalizedComputerSoftwareAdjustment_637838291101452345" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637838291101452345" xlink:to="ganx_CapitalizedComputerSoftwareAdjustment_637838291101452345" order="5" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_IncreaseDecreaseInOperatingAssetsAndLiabilities" xlink:label="ganx_IncreaseDecreaseInOperatingAssetsAndLiabilities_637838291101462347" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637838291101452345" xlink:to="ganx_IncreaseDecreaseInOperatingAssetsAndLiabilities_637838291101462347" order="6" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_637838291101462347" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ganx_IncreaseDecreaseInOperatingAssetsAndLiabilities_637838291101462347" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_637838291101462347" order="1" use="optional" weight="1" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_637838291101462347" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ganx_IncreaseDecreaseInOperatingAssetsAndLiabilities_637838291101462347" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_637838291101462347" order="2" use="optional" weight="1" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_637838291101462347" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ganx_IncreaseDecreaseInOperatingAssetsAndLiabilities_637838291101462347" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_637838291101462347" order="3" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionExpenseReversalOfExpenseNoncash" xlink:label="us-gaap_PensionExpenseReversalOfExpenseNoncash_637838291101462347" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ganx_IncreaseDecreaseInOperatingAssetsAndLiabilities_637838291101462347" xlink:to="us-gaap_PensionExpenseReversalOfExpenseNoncash_637838291101462347" order="4" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredLiabilities" xlink:label="us-gaap_IncreaseDecreaseInDeferredLiabilities_637838291101462347" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ganx_IncreaseDecreaseInOperatingAssetsAndLiabilities_637838291101462347" xlink:to="us-gaap_IncreaseDecreaseInDeferredLiabilities_637838291101462347" order="5" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_IncreaseDecreaseInValueAddedTaxCredits" xlink:label="ganx_IncreaseDecreaseInValueAddedTaxCredits_637838291101462347" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ganx_IncreaseDecreaseInOperatingAssetsAndLiabilities_637838291101462347" xlink:to="ganx_IncreaseDecreaseInValueAddedTaxCredits_637838291101462347" order="6" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_637838291101462347" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ganx_IncreaseDecreaseInOperatingAssetsAndLiabilities_637838291101462347" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_637838291101462347" order="7" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_637838291101462347" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ganx_IncreaseDecreaseInOperatingAssetsAndLiabilities_637838291101462347" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_637838291101462347" order="8" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_637838291101472343" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_637838291101472343" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637838291101472343" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_637838291101472343" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637838291101472343" order="1" use="optional" weight="-1" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_637838291101472343" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_637838291101472343" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt_637838291101472343" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637838291101472343" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt_637838291101472343" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfShortTermDebt" xlink:label="us-gaap_RepaymentsOfShortTermDebt_637838291101472343" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637838291101472343" xlink:to="us-gaap_RepaymentsOfShortTermDebt_637838291101472343" order="2" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_ProceedsFromIssuanceOfSeriesA.PreferredStockNetOfIssuanceCosts" xlink:label="ganx_ProceedsFromIssuanceOfSeriesA.PreferredStockNetOfIssuanceCosts_637838291101472343" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637838291101472343" xlink:to="ganx_ProceedsFromIssuanceOfSeriesA.PreferredStockNetOfIssuanceCosts_637838291101472343" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_ProceedsFromIssuanceOfSeriesBPreferredStockNetOfIssuanceCosts" xlink:label="ganx_ProceedsFromIssuanceOfSeriesBPreferredStockNetOfIssuanceCosts_637838291101472343" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637838291101472343" xlink:to="ganx_ProceedsFromIssuanceOfSeriesBPreferredStockNetOfIssuanceCosts_637838291101472343" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_637838291101472343" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637838291101472343" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_637838291101472343" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_637838291101482342" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637838291101472343" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_637838291101482342" order="6" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_637838291101482342" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637838291101472343" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_637838291101482342" order="7" use="optional" weight="-1" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_637838291101482342" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_637838291101482342" order="4" use="optional" weight="1" priority="3" />
  </calculationLink>
  <calculationLink xlink:role="http://www.gaintherapeutics.com/role/DisclosureOtherCurrentAssetsDetails" xlink:type="extended" xlink:title="40501 - Disclosure - Other current assets (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance_637838291101482342" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidInsurance_637838291101482342" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="us-gaap_OtherReceivablesNetCurrent_637838291101482342" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_OtherReceivablesNetCurrent_637838291101482342" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_637838291101482342" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_637838291101482342" order="3" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.gaintherapeutics.com/role/DisclosurePropertyAndEquipmentNetDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Property and Equipment, net (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_637838291101492347" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_637838291101492347" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_637838291101492347" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_637838291101492347" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.gaintherapeutics.com/role/DisclosureOperatingLeaseRightOfUseRouAssetsFutureMinimumLeasePaymentsDetails" xlink:type="extended" xlink:title="40704 - Disclosure - Operating lease. Right of use (ROU) assets - Future minimum lease payments (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_637838291101492347" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_637838291101492347" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_637838291101492347" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_637838291101492347" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_637838291101492347" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_637838291101492347" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_637838291101492347" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_637838291101492347" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_637838291101492347" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_637838291101492347" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_637838291101492347" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_637838291101492347" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_637838291101492347" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_637838291101492347" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_637838291101492347" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_637838291101492347" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_637838291101492347" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_AdjustmentToReconcileOperatingLeaseLiabilitiesAmountsRepresentingInterestOrImputedInterest" xlink:label="ganx_AdjustmentToReconcileOperatingLeaseLiabilitiesAmountsRepresentingInterestOrImputedInterest_637838291101492347" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="ganx_AdjustmentToReconcileOperatingLeaseLiabilitiesAmountsRepresentingInterestOrImputedInterest_637838291101492347" order="2" use="optional" weight="-1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.gaintherapeutics.com/role/DisclosureOtherCurrentLiabilitiesAndDeferredIncomeDetails" xlink:type="extended" xlink:title="40901 - Disclosure - Other current liabilities and deferred income (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent" xlink:label="us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeCurrent" xlink:label="us-gaap_DeferredIncomeCurrent_637838291101502345" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent" xlink:to="us-gaap_DeferredIncomeCurrent_637838291101502345" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent_637838291101502345" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_637838291101502345" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_637838291101502345" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherLiabilitiesCurrent_637838291101502345" xlink:to="us-gaap_AccruedLiabilitiesCurrent_637838291101502345" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_AccruedPayrollCurrent" xlink:label="ganx_AccruedPayrollCurrent_637838291101502345" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherLiabilitiesCurrent_637838291101502345" xlink:to="ganx_AccruedPayrollCurrent_637838291101502345" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_DepositsCurrent" xlink:label="ganx_DepositsCurrent_637838291101502345" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherLiabilitiesCurrent_637838291101502345" xlink:to="ganx_DepositsCurrent_637838291101502345" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_PayableForSocialSecuritiesCurrent" xlink:label="ganx_PayableForSocialSecuritiesCurrent_637838291101502345" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherLiabilitiesCurrent_637838291101502345" xlink:to="ganx_PayableForSocialSecuritiesCurrent_637838291101502345" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxesPayableCurrent" xlink:label="us-gaap_TaxesPayableCurrent_637838291101502345" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherLiabilitiesCurrent_637838291101502345" xlink:to="us-gaap_TaxesPayableCurrent_637838291101502345" order="5" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.gaintherapeutics.com/role/DisclosurePensionObligationsEndOfYearFundedStatusDetails" xlink:type="extended" xlink:title="41001 - Disclosure - Pension obligations - End of year funded status (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanFundedStatusOfPlan" xlink:label="us-gaap_DefinedBenefitPlanFundedStatusOfPlan" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:label="us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_637838291101502345" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DefinedBenefitPlanFundedStatusOfPlan" xlink:to="us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_637838291101502345" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligation" xlink:label="us-gaap_DefinedBenefitPlanBenefitObligation_637838291101512345" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DefinedBenefitPlanFundedStatusOfPlan" xlink:to="us-gaap_DefinedBenefitPlanBenefitObligation_637838291101512345" order="2" use="optional" weight="-1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.gaintherapeutics.com/role/DisclosurePensionObligationsComponentOfNetPeriodicPensionCostsDetails" xlink:type="extended" xlink:title="41003 - Disclosure - Pension obligations - Component of net periodic pension costs (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:label="us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanServiceCost" xlink:label="us-gaap_DefinedBenefitPlanServiceCost_637838291101512345" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:to="us-gaap_DefinedBenefitPlanServiceCost_637838291101512345" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanInterestCost" xlink:label="us-gaap_DefinedBenefitPlanInterestCost_637838291101512345" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:to="us-gaap_DefinedBenefitPlanInterestCost_637838291101512345" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:label="us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_637838291101512345" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:to="us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_637838291101512345" order="3" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:label="us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_637838291101512345" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:to="us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_637838291101512345" order="4" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:label="us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_637838291101512345" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:to="us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_637838291101512345" order="5" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.gaintherapeutics.com/role/DisclosureLoansFutureLoanPaymentsDetails" xlink:type="extended" xlink:title="41102 - Disclosure - Loans - Future loan payments (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_637838291101512345" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_637838291101512345" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_637838291101512345" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_637838291101512345" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_637838291101512345" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_637838291101512345" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_637838291101522347" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_637838291101522347" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_637838291101522347" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_637838291101522347" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_637838291101522347" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_637838291101522347" order="6" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.gaintherapeutics.com/role/DisclosureIncomeTaxesDomesticAndForeignNetOperatingLossesDetails" xlink:type="extended" xlink:title="41701 - Disclosure - Income taxes - Domestic and foreign net operating losses (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_637838291101522347" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_637838291101522347" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_637838291101522347" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_637838291101522347" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.gaintherapeutics.com/role/DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseDetails" xlink:type="extended" xlink:title="41702 - Disclosure - Income taxes - Components of income tax expense (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_637838291101522347" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_637838291101522347" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit_637838291101522347" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit_637838291101522347" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit_637838291101522347" order="1" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.gaintherapeutics.com/role/DisclosureIncomeTaxesDomesticAndForeignNetOperatingLossesAndRelatedDeferredTaxAssetsDetails" xlink:type="extended" xlink:title="41703 - Disclosure - Income taxes - Domestic and foreign net operating losses and related deferred tax assets (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_637838291101532346" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_637838291101532346" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross_637838291101532346" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsGross_637838291101532346" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_637838291101532346" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_637838291101532346" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_637838291101532346" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther_637838291101532346" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_637838291101532346" xlink:to="us-gaap_DeferredTaxAssetsOther_637838291101532346" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_637838291101532346" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_637838291101532346" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_637838291101532346" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_DeferredTaxAssetsFmwWarrant" xlink:label="ganx_DeferredTaxAssetsFmwWarrant_637838291101532346" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_637838291101532346" xlink:to="ganx_DeferredTaxAssetsFmwWarrant_637838291101532346" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_637838291101532346" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_637838291101532346" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_637838291101532346" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_637838291101532346" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_637838291101532346" order="3" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_637838291101532346" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities_637838291101532346" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_637838291101532346" order="1" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.gaintherapeutics.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails" xlink:type="extended" xlink:title="41705 - Disclosure - Income taxes - Effective income tax rate reconciliation (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_637838291101542345" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_637838291101542345" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_637838291101542345" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_637838291101542345" order="2" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_EffectiveIncomeTaxRateReconciliationPermanentDifferences" xlink:label="ganx_EffectiveIncomeTaxRateReconciliationPermanentDifferences_637838291101542345" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="ganx_EffectiveIncomeTaxRateReconciliationPermanentDifferences_637838291101542345" order="3" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_637838291101542345" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_637838291101542345" order="4" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_EffectiveIncomeTaxRateReconciliationProvisionToReturn" xlink:label="ganx_EffectiveIncomeTaxRateReconciliationProvisionToReturn_637838291101542345" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="ganx_EffectiveIncomeTaxRateReconciliationProvisionToReturn_637838291101542345" order="5" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_637838291101542345" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_637838291101542345" order="6" use="optional" weight="-1" />
  </calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>30
<FILENAME>ganx-20211231_def.xml
<DESCRIPTION>EX-101.DEF
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.8042.36810 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/25/2022 6:18:32 PM-->
<!--Modified on: 3/25/2022 6:18:32 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="ganx-20211231.xsd#StatementConsolidatedBalanceSheets" roleURI="http://www.gaintherapeutics.com/role/StatementConsolidatedBalanceSheets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ganx-20211231.xsd#StatementConsolidatedBalanceSheetsParenthetical" roleURI="http://www.gaintherapeutics.com/role/StatementConsolidatedBalanceSheetsParenthetical" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ganx-20211231.xsd#StatementConsolidatedStatementOfChangesInStockholdersEquityDeficit" roleURI="http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfChangesInStockholdersEquityDeficit" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ganx-20211231.xsd#DisclosureNatureOfBusinessAndBasisOfPresentationDetails" roleURI="http://www.gaintherapeutics.com/role/DisclosureNatureOfBusinessAndBasisOfPresentationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ganx-20211231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesAdditionalDisclosuresDetails" roleURI="http://www.gaintherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalDisclosuresDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ganx-20211231.xsd#DisclosureResearchGrantsDetails" roleURI="http://www.gaintherapeutics.com/role/DisclosureResearchGrantsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ganx-20211231.xsd#DisclosureCashCashEquivalentsAndRestrictedCashDetails" roleURI="http://www.gaintherapeutics.com/role/DisclosureCashCashEquivalentsAndRestrictedCashDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ganx-20211231.xsd#DisclosureCashCashEquivalentsAndRestrictedCashScheduleOfCashAndCashEquivalentsBalancesDetails" roleURI="http://www.gaintherapeutics.com/role/DisclosureCashCashEquivalentsAndRestrictedCashScheduleOfCashAndCashEquivalentsBalancesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ganx-20211231.xsd#DisclosurePropertyAndEquipmentNetDetails" roleURI="http://www.gaintherapeutics.com/role/DisclosurePropertyAndEquipmentNetDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ganx-20211231.xsd#DisclosureOperatingLeaseRightOfUseRouAssetsAdditionalInformationDetails" roleURI="http://www.gaintherapeutics.com/role/DisclosureOperatingLeaseRightOfUseRouAssetsAdditionalInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ganx-20211231.xsd#DisclosureAccountsPayableDetails" roleURI="http://www.gaintherapeutics.com/role/DisclosureAccountsPayableDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ganx-20211231.xsd#DisclosurePensionObligationsEndOfYearFundedStatusDetails" roleURI="http://www.gaintherapeutics.com/role/DisclosurePensionObligationsEndOfYearFundedStatusDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ganx-20211231.xsd#DisclosurePensionObligationsReconciliationOfFundedStatusDetails" roleURI="http://www.gaintherapeutics.com/role/DisclosurePensionObligationsReconciliationOfFundedStatusDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ganx-20211231.xsd#DisclosurePensionObligationsComponentOfNetPeriodicPensionCostsDetails" roleURI="http://www.gaintherapeutics.com/role/DisclosurePensionObligationsComponentOfNetPeriodicPensionCostsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ganx-20211231.xsd#DisclosurePensionObligationsReconciliationOfProjectedBenefitObligationDetails" roleURI="http://www.gaintherapeutics.com/role/DisclosurePensionObligationsReconciliationOfProjectedBenefitObligationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ganx-20211231.xsd#DisclosurePensionObligationsReconciliationOfFairValueOfPlanAssetsDetails" roleURI="http://www.gaintherapeutics.com/role/DisclosurePensionObligationsReconciliationOfFairValueOfPlanAssetsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ganx-20211231.xsd#DisclosurePensionObligationsChangeInNetGainLossDetails" roleURI="http://www.gaintherapeutics.com/role/DisclosurePensionObligationsChangeInNetGainLossDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ganx-20211231.xsd#DisclosurePensionObligationsChangeInAccumulatedOtherComprehensiveIncomeAociDetails" roleURI="http://www.gaintherapeutics.com/role/DisclosurePensionObligationsChangeInAccumulatedOtherComprehensiveIncomeAociDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ganx-20211231.xsd#DisclosurePensionObligationsAssumptionsDetails" roleURI="http://www.gaintherapeutics.com/role/DisclosurePensionObligationsAssumptionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ganx-20211231.xsd#DisclosurePensionObligationsExpectedBenefitPaymentsDetails" roleURI="http://www.gaintherapeutics.com/role/DisclosurePensionObligationsExpectedBenefitPaymentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ganx-20211231.xsd#DisclosureLoansDetails" roleURI="http://www.gaintherapeutics.com/role/DisclosureLoansDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ganx-20211231.xsd#DisclosureFairValueMeasurementDetails" roleURI="http://www.gaintherapeutics.com/role/DisclosureFairValueMeasurementDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ganx-20211231.xsd#DisclosureCommonAndPreferredStockDetails" roleURI="http://www.gaintherapeutics.com/role/DisclosureCommonAndPreferredStockDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ganx-20211231.xsd#DisclosureWarrantsDetails" roleURI="http://www.gaintherapeutics.com/role/DisclosureWarrantsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ganx-20211231.xsd#DisclosureWarrantsAssumptionsUnderBlackScholesPricingModelDetails" roleURI="http://www.gaintherapeutics.com/role/DisclosureWarrantsAssumptionsUnderBlackScholesPricingModelDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ganx-20211231.xsd#DisclosureEquityIncentivePlanDetails" roleURI="http://www.gaintherapeutics.com/role/DisclosureEquityIncentivePlanDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ganx-20211231.xsd#DisclosureEquityIncentivePlanStockOptionActivityDetails" roleURI="http://www.gaintherapeutics.com/role/DisclosureEquityIncentivePlanStockOptionActivityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ganx-20211231.xsd#DisclosureEquityIncentivePlanOptionsOutstandingAndExercisableDetails" roleURI="http://www.gaintherapeutics.com/role/DisclosureEquityIncentivePlanOptionsOutstandingAndExercisableDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ganx-20211231.xsd#DisclosureEquityIncentivePlanAssumptionsDetails" roleURI="http://www.gaintherapeutics.com/role/DisclosureEquityIncentivePlanAssumptionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ganx-20211231.xsd#DisclosureEquityIncentivePlanStockBasedCompensationDetails" roleURI="http://www.gaintherapeutics.com/role/DisclosureEquityIncentivePlanStockBasedCompensationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ganx-20211231.xsd#DisclosureCollaborationAgreementDetails" roleURI="http://www.gaintherapeutics.com/role/DisclosureCollaborationAgreementDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ganx-20211231.xsd#DisclosureIncomeTaxesDomesticAndForeignNetOperatingLossesAndRelatedDeferredTaxAssetsDetails" roleURI="http://www.gaintherapeutics.com/role/DisclosureIncomeTaxesDomesticAndForeignNetOperatingLossesAndRelatedDeferredTaxAssetsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ganx-20211231.xsd#DisclosureIncomeTaxesAdditionalDisclosuresDetails" roleURI="http://www.gaintherapeutics.com/role/DisclosureIncomeTaxesAdditionalDisclosuresDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ganx-20211231.xsd#DisclosureNetLossPerCommonShareComputationOfDilutedNetLossPerShareDetails" roleURI="http://www.gaintherapeutics.com/role/DisclosureNetLossPerCommonShareComputationOfDilutedNetLossPerShareDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ganx-20211231.xsd#DisclosureRelatedPartiesDetails" roleURI="http://www.gaintherapeutics.com/role/DisclosureRelatedPartiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ganx-20211231.xsd#DisclosureOtherInformationDetails" roleURI="http://www.gaintherapeutics.com/role/DisclosureOtherInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" />
  <link:roleRef roleURI="http://www.gaintherapeutics.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:href="ganx-20211231.xsd#DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="simple" />
  <roleRef xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd#eedm" roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended" xlink:title="Extensible Enumeration Domain Members" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:definitionLink xlink:role="http://www.gaintherapeutics.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="extended" xlink:title="99900 - Disclosure - Standard And Custom Axis Domain Defaults">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="dei_EntityAddressesAddressTypeAxis_1" xlink:title="dei_EntityAddressesAddressTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AddressTypeDomain" xlink:label="dei_AddressTypeDomain_1" xlink:title="dei_AddressTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="dei_EntityAddressesAddressTypeAxis_1" xlink:to="dei_AddressTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:dei_EntityAddressesAddressTypeAxis_1 To dei_AddressTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_1" xlink:title="us-gaap_StatementClassOfStockAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_1" xlink:title="us-gaap_ClassOfStockDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementClassOfStockAxis_1" xlink:to="us-gaap_ClassOfStockDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementClassOfStockAxis_1 To us-gaap_ClassOfStockDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_1" xlink:title="us-gaap_StatementEquityComponentsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_1" xlink:title="us-gaap_EquityComponentDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementEquityComponentsAxis_1" xlink:to="us-gaap_EquityComponentDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementEquityComponentsAxis_1 To us-gaap_EquityComponentDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_1" xlink:title="us-gaap_SubsidiarySaleOfStockAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_1" xlink:title="us-gaap_SaleOfStockNameOfTransactionDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_1" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_SubsidiarySaleOfStockAxis_1 To us-gaap_SaleOfStockNameOfTransactionDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:title="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:title="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_PropertyPlantAndEquipmentByTypeAxis_1 To us-gaap_PropertyPlantAndEquipmentTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis_1" xlink:title="us-gaap_CashAndCashEquivalentsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1" xlink:title="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_CashAndCashEquivalentsAxis_1" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_CashAndCashEquivalentsAxis_1 To us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CurrencyAxis" xlink:label="srt_CurrencyAxis_1" xlink:title="srt_CurrencyAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_AllCurrenciesDomain" xlink:label="currency_AllCurrenciesDomain_1" xlink:title="currency_AllCurrenciesDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_CurrencyAxis_1" xlink:to="currency_AllCurrenciesDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_CurrencyAxis_1 To currency_AllCurrenciesDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_1" xlink:title="srt_RangeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_1" xlink:title="srt_RangeMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_RangeAxis_1" xlink:to="srt_RangeMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_RangeAxis_1 To srt_RangeMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis" xlink:label="us-gaap_RetirementPlanTypeAxis_1" xlink:title="us-gaap_RetirementPlanTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="us-gaap_RetirementPlanTypeDomain_1" xlink:title="us-gaap_RetirementPlanTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_RetirementPlanTypeAxis_1" xlink:to="us-gaap_RetirementPlanTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_RetirementPlanTypeAxis_1 To us-gaap_RetirementPlanTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_1" xlink:title="us-gaap_DebtInstrumentAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_1" xlink:title="us-gaap_DebtInstrumentNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_DebtInstrumentAxis_1" xlink:to="us-gaap_DebtInstrumentNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_DebtInstrumentAxis_1 To us-gaap_DebtInstrumentNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_1" xlink:title="us-gaap_PlanNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_1" xlink:title="us-gaap_PlanNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_PlanNameAxis_1" xlink:to="us-gaap_PlanNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_PlanNameAxis_1 To us-gaap_PlanNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1 To us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_1" xlink:title="us-gaap_IncomeStatementLocationAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_1" xlink:title="us-gaap_IncomeStatementLocationDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeStatementLocationAxis_1" xlink:to="us-gaap_IncomeStatementLocationDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_IncomeStatementLocationAxis_1 To us-gaap_IncomeStatementLocationDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_1" xlink:title="us-gaap_ClassOfWarrantOrRightAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_1" xlink:title="us-gaap_ClassOfWarrantOrRightDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_1" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ClassOfWarrantOrRightAxis_1 To us-gaap_ClassOfWarrantOrRightDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis_1" xlink:title="us-gaap_MeasurementInputTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_1" xlink:title="us-gaap_MeasurementInputTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_MeasurementInputTypeAxis_1" xlink:to="us-gaap_MeasurementInputTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_MeasurementInputTypeAxis_1 To us-gaap_MeasurementInputTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationTechniqueAxis" xlink:label="us-gaap_ValuationTechniqueAxis_1" xlink:title="us-gaap_ValuationTechniqueAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="us-gaap_ValuationTechniqueDomain_1" xlink:title="us-gaap_ValuationTechniqueDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ValuationTechniqueAxis_1" xlink:to="us-gaap_ValuationTechniqueDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ValuationTechniqueAxis_1 To us-gaap_ValuationTechniqueDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_1" xlink:title="us-gaap_TypeOfArrangementAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:title="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_TypeOfArrangementAxis_1" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_TypeOfArrangementAxis_1 To us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_1" xlink:title="srt_CounterpartyNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_1" xlink:title="srt_RepurchaseAgreementCounterpartyNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_CounterpartyNameAxis_1" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_CounterpartyNameAxis_1 To srt_RepurchaseAgreementCounterpartyNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" xlink:title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_1" xlink:title="us-gaap_AntidilutiveSecuritiesNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1 To us-gaap_AntidilutiveSecuritiesNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis_1" xlink:title="us-gaap_RelatedPartyTransactionAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain_1" xlink:title="us-gaap_RelatedPartyTransactionDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_RelatedPartyTransactionAxis_1" xlink:to="us-gaap_RelatedPartyTransactionDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_RelatedPartyTransactionAxis_1 To us-gaap_RelatedPartyTransactionDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="us-gaap_OtherCommitmentsAxis_1" xlink:title="us-gaap_OtherCommitmentsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain_1" xlink:title="us-gaap_OtherCommitmentsDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_OtherCommitmentsAxis_1" xlink:to="us-gaap_OtherCommitmentsDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_OtherCommitmentsAxis_1 To us-gaap_OtherCommitmentsDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1" xlink:title="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1" xlink:title="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1 To us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_1" xlink:title="dei_LegalEntityAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_1" xlink:title="dei_EntityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="dei_LegalEntityAxis_1" xlink:to="dei_EntityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:dei_LegalEntityAxis_1 To dei_EntityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="us-gaap_FairValueByMeasurementBasisAxis_1" xlink:title="us-gaap_FairValueByMeasurementBasisAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember_1" xlink:title="us-gaap_PortionAtFairValueFairValueDisclosureMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FairValueByMeasurementBasisAxis_1" xlink:to="us-gaap_PortionAtFairValueFairValueDisclosureMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FairValueByMeasurementBasisAxis_1 To us-gaap_PortionAtFairValueFairValueDisclosureMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" xlink:title="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" xlink:title="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FairValueByFairValueHierarchyLevelAxis_1 To us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis_1" xlink:title="us-gaap_FairValueByAssetClassAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1" xlink:title="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FairValueByAssetClassAxis_1" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FairValueByAssetClassAxis_1 To us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis_1" xlink:title="us-gaap_IncomeTaxAuthorityAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_1" xlink:title="us-gaap_IncomeTaxAuthorityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeTaxAuthorityAxis_1" xlink:to="us-gaap_IncomeTaxAuthorityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_IncomeTaxAuthorityAxis_1 To us-gaap_IncomeTaxAuthorityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis_1" xlink:title="srt_StatementGeographicalAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_1" xlink:title="srt_SegmentGeographicalDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_StatementGeographicalAxis_1" xlink:to="srt_SegmentGeographicalDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_StatementGeographicalAxis_1 To srt_SegmentGeographicalDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_1" xlink:title="srt_StatementScenarioAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_1" xlink:title="srt_ScenarioUnspecifiedDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_StatementScenarioAxis_1" xlink:to="srt_ScenarioUnspecifiedDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_StatementScenarioAxis_1 To srt_ScenarioUnspecifiedDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis" xlink:label="us-gaap_RetirementPlanSponsorLocationAxis_1" xlink:title="us-gaap_RetirementPlanSponsorLocationAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain" xlink:label="us-gaap_RetirementPlanSponsorLocationDomain_1" xlink:title="us-gaap_RetirementPlanSponsorLocationDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_RetirementPlanSponsorLocationAxis_1" xlink:to="us-gaap_RetirementPlanSponsorLocationDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_RetirementPlanSponsorLocationAxis_1 To us-gaap_RetirementPlanSponsorLocationDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis_1" xlink:title="srt_RestatementAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain_1" xlink:title="srt_RestatementDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_RestatementAxis_1" xlink:to="srt_RestatementDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_RestatementAxis_1 To srt_RestatementDomain_1" order="1" />
  </link:definitionLink>
  <definitionLink xlink:role="http://www.gaintherapeutics.com/role/StatementConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - Consolidated Balance Sheets" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_RestrictedCashCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxesAndOtherTaxReceivableCurrent" xlink:label="us-gaap_DeferredIncomeTaxesAndOtherTaxReceivableCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_DeferredIncomeTaxesAndOtherTaxReceivableCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredOfferingCosts" xlink:label="us-gaap_DeferredOfferingCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_DeferredOfferingCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="us-gaap_AssetsNoncurrentAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_CapitalizedComputerSoftwareForInternalUse" xlink:label="ganx_CapitalizedComputerSoftwareForInternalUse" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="ganx_CapitalizedComputerSoftwareForInternalUse" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_RestrictedCashNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_DepositsAndOtherAssetsNoncurrent" xlink:label="ganx_DepositsAndOtherAssetsNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="ganx_DepositsAndOtherAssetsNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAbstract" xlink:label="us-gaap_LiabilitiesAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxesPayableCurrent" xlink:label="us-gaap_TaxesPayableCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_TaxesPayableCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeCurrent" xlink:label="us-gaap_DeferredIncomeCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DeferredIncomeCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LongTermDebtCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent" xlink:label="us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LongTermDebtNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_Liabilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_IncomeLossForPeriod" xlink:label="ganx_IncomeLossForPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="ganx_IncomeLossForPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.gaintherapeutics.com/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:type="extended" xlink:title="00105 - Statement - Consolidated Balance Sheets (Parenthetical)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfChangesInStockholdersEquityDeficit" xlink:type="extended" xlink:title="00400 - Statement - Consolidated Statement of Changes in Stockholders' Equity (Deficit)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredClassAMember" xlink:label="us-gaap_PreferredClassAMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_PreferredClassAMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredClassBMember" xlink:label="us-gaap_PreferredClassBMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_PreferredClassBMember" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_ConversionOfSeriesPreferredStockIntoCommonStock" xlink:label="ganx_ConversionOfSeriesPreferredStockIntoCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="ganx_ConversionOfSeriesPreferredStockIntoCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_ConversionOfSeriesPreferredStockIntoCommonStockInShares" xlink:label="ganx_ConversionOfSeriesPreferredStockIntoCommonStockInShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="ganx_ConversionOfSeriesPreferredStockIntoCommonStockInShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_IssuanceOfSeriesPreferredStockNetOfIssuanceCost" xlink:label="ganx_IssuanceOfSeriesPreferredStockNetOfIssuanceCost" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="ganx_IssuanceOfSeriesPreferredStockNetOfIssuanceCost" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_IssuanceOfSeriesPreferredStockInShares" xlink:label="ganx_IssuanceOfSeriesPreferredStockInShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="ganx_IssuanceOfSeriesPreferredStockInShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_ConversionOfSeriesBPreferredStockIntoCommonStock" xlink:label="ganx_ConversionOfSeriesBPreferredStockIntoCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="ganx_ConversionOfSeriesBPreferredStockIntoCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_ConversionOfSeriesBPreferredStockIntoCommonStockInShares" xlink:label="ganx_ConversionOfSeriesBPreferredStockIntoCommonStockInShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="ganx_ConversionOfSeriesBPreferredStockIntoCommonStockInShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_IssuanceOfSeriesBPreferredStockNetOfIssuanceCost" xlink:label="ganx_IssuanceOfSeriesBPreferredStockNetOfIssuanceCost" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="ganx_IssuanceOfSeriesBPreferredStockNetOfIssuanceCost" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_IssuanceOfSeriesBPreferredStockInShares" xlink:label="ganx_IssuanceOfSeriesBPreferredStockInShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_StatementLineItems" xlink:to="ganx_IssuanceOfSeriesBPreferredStockInShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_IssuanceOfCommonStockInIpoNetOfIssuanceCosts" xlink:label="ganx_IssuanceOfCommonStockInIpoNetOfIssuanceCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_StatementLineItems" xlink:to="ganx_IssuanceOfCommonStockInIpoNetOfIssuanceCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_IssuanceOfCommonStockInIpoInShares" xlink:label="ganx_IssuanceOfCommonStockInIpoInShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_StatementLineItems" xlink:to="ganx_IssuanceOfCommonStockInIpoInShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_IssuanceOfCommonStockThroughCashlessExerciseOfWarrants" xlink:label="ganx_IssuanceOfCommonStockThroughCashlessExerciseOfWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_StatementLineItems" xlink:to="ganx_IssuanceOfCommonStockThroughCashlessExerciseOfWarrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="21" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="22" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="23" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.gaintherapeutics.com/role/DisclosureNatureOfBusinessAndBasisOfPresentationDetails" xlink:type="extended" xlink:title="40101 - Disclosure - Nature of the Business and Basis of Presentation (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_OverAllotmentOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_IpoExcludingUnderwritersOptionsMember" xlink:label="ganx_IpoExcludingUnderwritersOptionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IPOMember" xlink:to="ganx_IpoExcludingUnderwritersOptionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_PreferredStockSeriesAndSeriesBMember" xlink:label="ganx_PreferredStockSeriesAndSeriesBMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="ganx_PreferredStockSeriesAndSeriesBMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SharePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_UnderwritingDiscountsAndCommissions" xlink:label="ganx_UnderwritingDiscountsAndCommissions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="ganx_UnderwritingDiscountsAndCommissions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_OtherOfferingExpenses" xlink:label="ganx_OtherOfferingExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="ganx_OtherOfferingExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_GrossProceedsFromIssuanceOfCommonStock" xlink:label="ganx_GrossProceedsFromIssuanceOfCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="ganx_GrossProceedsFromIssuanceOfCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_PreferredStockToCommonStockConversionRatio" xlink:label="ganx_PreferredStockToCommonStockConversionRatio" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="ganx_PreferredStockToCommonStockConversionRatio" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.gaintherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalDisclosuresDetails" xlink:type="extended" xlink:title="40202 - Disclosure - Summary of Significant Accounting Policies - Additional disclosures (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_EquipmentAndFurnitureMember" xlink:label="ganx_EquipmentAndFurnitureMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="ganx_EquipmentAndFurnitureMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_OfficeEquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_LaboratoryInstrumentsMember" xlink:label="ganx_LaboratoryInstrumentsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="ganx_LaboratoryInstrumentsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:label="us-gaap_ComputerSoftwareIntangibleAssetMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_ComputerSoftwareIntangibleAssetMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_PropertyPlantAndEquipmentDepreciationRates" xlink:label="ganx_PropertyPlantAndEquipmentDepreciationRates" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="ganx_PropertyPlantAndEquipmentDepreciationRates" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedComputerSoftwareNet" xlink:label="us-gaap_CapitalizedComputerSoftwareNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_CapitalizedComputerSoftwareNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedComputerSoftwareAdditions" xlink:label="us-gaap_CapitalizedComputerSoftwareAdditions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_CapitalizedComputerSoftwareAdditions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AssetImpairmentCharges" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_UncertainTaxPositionsRecognized" xlink:label="ganx_UncertainTaxPositionsRecognized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="ganx_UncertainTaxPositionsRecognized" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.gaintherapeutics.com/role/DisclosureResearchGrantsDetails" xlink:type="extended" xlink:title="40301 - Disclosure - Research Grants (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="dei_LegalEntityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_GtGainTherapeuticsSaMember" xlink:label="ganx_GtGainTherapeuticsSaMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="dei_EntityDomain" xlink:to="ganx_GtGainTherapeuticsSaMember" use="optional" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_ConsortiumWithGtGainTherapeuticsSaInstituteForResearchInBiomedicineAndNeuroSysSasMember" xlink:label="ganx_ConsortiumWithGtGainTherapeuticsSaInstituteForResearchInBiomedicineAndNeuroSysSasMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="dei_EntityDomain" xlink:to="ganx_ConsortiumWithGtGainTherapeuticsSaInstituteForResearchInBiomedicineAndNeuroSysSasMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_MichaelJ.FoxFoundationForParkinsonSResearchMjffMember" xlink:label="ganx_MichaelJ.FoxFoundationForParkinsonSResearchMjffMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="ganx_MichaelJ.FoxFoundationForParkinsonSResearchMjffMember" use="optional" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_Eurostars2Member" xlink:label="ganx_Eurostars2Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="ganx_Eurostars2Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrantsReceivable" xlink:label="us-gaap_GrantsReceivable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_GrantsReceivable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_ReductionOfResearchAndDevelopmentExpensesThroughExpensesReimbursed" xlink:label="ganx_ReductionOfResearchAndDevelopmentExpensesThroughExpensesReimbursed" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="ganx_ReductionOfResearchAndDevelopmentExpensesThroughExpensesReimbursed" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_ProceedsFromGrants" xlink:label="ganx_ProceedsFromGrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="ganx_ProceedsFromGrants" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.gaintherapeutics.com/role/DisclosureCashCashEquivalentsAndRestrictedCashDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Cash, cash equivalents and restricted cash (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashMember" xlink:label="us-gaap_CashMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_CashMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems" xlink:label="us-gaap_CashAndCashEquivalentsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_RestrictedCash" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.gaintherapeutics.com/role/DisclosureCashCashEquivalentsAndRestrictedCashScheduleOfCashAndCashEquivalentsBalancesDetails" xlink:type="extended" xlink:title="40402 - Disclosure - Cash, cash equivalents and restricted cash - Schedule of Cash and cash equivalents balances (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CurrencyAxis" xlink:label="srt_CurrencyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:to="srt_CurrencyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_AllCurrenciesDomain" xlink:label="currency_AllCurrenciesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CurrencyAxis" xlink:to="currency_AllCurrenciesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_CHF" xlink:label="currency_CHF" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="currency_AllCurrenciesDomain" xlink:to="currency_CHF" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_EUR" xlink:label="currency_EUR" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="currency_AllCurrenciesDomain" xlink:to="currency_EUR" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_USD" xlink:label="currency_USD" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="currency_AllCurrenciesDomain" xlink:to="currency_USD" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems" xlink:label="us-gaap_CashAndCashEquivalentsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.gaintherapeutics.com/role/DisclosurePropertyAndEquipmentNetDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Property and Equipment, net (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_LaboratoryInstrumentsMember" xlink:label="ganx_LaboratoryInstrumentsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="ganx_LaboratoryInstrumentsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisposals" xlink:label="us-gaap_PropertyPlantAndEquipmentDisposals" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentDisposals" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_DepreciationDepletionAndAmortization" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.gaintherapeutics.com/role/DisclosureOperatingLeaseRightOfUseRouAssetsAdditionalInformationDetails" xlink:type="extended" xlink:title="40701 - Disclosure - Operating lease. Right of use (ROU) assets - Additional information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_OfficeSpaceViaSoaveN6LuganoSwitzerlandMember" xlink:label="ganx_OfficeSpaceViaSoaveN6LuganoSwitzerlandMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="ganx_OfficeSpaceViaSoaveN6LuganoSwitzerlandMember" use="optional" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_OfficeSpaceViaPietroPeri9DLuganoSwitzerlandMember" xlink:label="ganx_OfficeSpaceViaPietroPeri9DLuganoSwitzerlandMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="ganx_OfficeSpaceViaPietroPeri9DLuganoSwitzerlandMember" use="optional" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_OfficeSpaceInBethesdaMarylandMember" xlink:label="ganx_OfficeSpaceInBethesdaMarylandMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="ganx_OfficeSpaceInBethesdaMarylandMember" use="optional" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_OfficeSpaceTorreDBuildingBarcelonaMember" xlink:label="ganx_OfficeSpaceTorreDBuildingBarcelonaMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="ganx_OfficeSpaceTorreDBuildingBarcelonaMember" use="optional" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_OfficeSpaceTorreIBuildingBarcelonaMember" xlink:label="ganx_OfficeSpaceTorreIBuildingBarcelonaMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="ganx_OfficeSpaceTorreIBuildingBarcelonaMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_RestrictedCash" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInSecurityDeposits" xlink:label="us-gaap_IncreaseDecreaseInSecurityDeposits" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_IncreaseDecreaseInSecurityDeposits" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_LesseeOperatingLeaseTermOfCancelledContract" xlink:label="ganx_LesseeOperatingLeaseTermOfCancelledContract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="ganx_LesseeOperatingLeaseTermOfCancelledContract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_OfficeSpace" xlink:label="ganx_OfficeSpace" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="ganx_OfficeSpace" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.gaintherapeutics.com/role/DisclosureAccountsPayableDetails" xlink:type="extended" xlink:title="40801 - Disclosure - Accounts Payable (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_AccountsPayableCurrentTable" xlink:label="ganx_AccountsPayableCurrentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CurrencyAxis" xlink:label="srt_CurrencyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ganx_AccountsPayableCurrentTable" xlink:to="srt_CurrencyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_AllCurrenciesDomain" xlink:label="currency_AllCurrenciesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CurrencyAxis" xlink:to="currency_AllCurrenciesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_CHF" xlink:label="currency_CHF" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="currency_AllCurrenciesDomain" xlink:to="currency_CHF" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_EUR" xlink:label="currency_EUR" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="currency_AllCurrenciesDomain" xlink:to="currency_EUR" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_USD" xlink:label="currency_USD" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="currency_AllCurrenciesDomain" xlink:to="currency_USD" use="optional" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_AccountsPayableCurrentLineItems" xlink:label="ganx_AccountsPayableCurrentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ganx_AccountsPayableCurrentLineItems" xlink:to="ganx_AccountsPayableCurrentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ganx_AccountsPayableCurrentLineItems" xlink:to="us-gaap_AccountsPayableCurrent" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.gaintherapeutics.com/role/DisclosurePensionObligationsEndOfYearFundedStatusDetails" xlink:type="extended" xlink:title="41001 - Disclosure - Pension obligations - End of year funded status (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis" xlink:label="us-gaap_RetirementPlanSponsorLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="us-gaap_RetirementPlanSponsorLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain" xlink:label="us-gaap_RetirementPlanSponsorLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RetirementPlanSponsorLocationAxis" xlink:to="us-gaap_RetirementPlanSponsorLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticPlanMember" xlink:label="us-gaap_DomesticPlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RetirementPlanSponsorLocationDomain" xlink:to="us-gaap_DomesticPlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_CH" xlink:label="country_CH" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DomesticPlanMember" xlink:to="country_CH" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis" xlink:label="us-gaap_RetirementPlanTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="us-gaap_RetirementPlanTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="us-gaap_RetirementPlanTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RetirementPlanTypeAxis" xlink:to="us-gaap_RetirementPlanTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember" xlink:label="us-gaap_PensionPlansDefinedBenefitMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RetirementPlanTypeDomain" xlink:to="us-gaap_PensionPlansDefinedBenefitMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:label="us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligation" xlink:label="us-gaap_DefinedBenefitPlanBenefitObligation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedBenefitPlanBenefitObligation" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanFundedStatusOfPlan" xlink:label="us-gaap_DefinedBenefitPlanFundedStatusOfPlan" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedBenefitPlanFundedStatusOfPlan" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation" xlink:label="us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.gaintherapeutics.com/role/DisclosurePensionObligationsReconciliationOfFundedStatusDetails" xlink:type="extended" xlink:title="41002 - Disclosure - Pension obligations - Reconciliation of funded status (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis" xlink:label="us-gaap_RetirementPlanTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="us-gaap_RetirementPlanTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="us-gaap_RetirementPlanTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RetirementPlanTypeAxis" xlink:to="us-gaap_RetirementPlanTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember" xlink:label="us-gaap_PensionPlansDefinedBenefitMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RetirementPlanTypeDomain" xlink:to="us-gaap_PensionPlansDefinedBenefitMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanFundedStatusOfPlan" xlink:label="us-gaap_DefinedBenefitPlanFundedStatusOfPlan" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedBenefitPlanFundedStatusOfPlan" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_IncreaseDecreaseThroughTotalExpensesToReconcileFundedStatusOfDefinedBenefitPlan" xlink:label="ganx_IncreaseDecreaseThroughTotalExpensesToReconcileFundedStatusOfDefinedBenefitPlan" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="ganx_IncreaseDecreaseThroughTotalExpensesToReconcileFundedStatusOfDefinedBenefitPlan" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:label="us-gaap_DefinedBenefitPlanContributionsByEmployer" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedBenefitPlanContributionsByEmployer" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" xlink:label="us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_IncreaseDecreaseInAccumulatedOtherComprehensiveIncomeToReconcileFundedStatusOfDefinedBenefitPlan" xlink:label="ganx_IncreaseDecreaseInAccumulatedOtherComprehensiveIncomeToReconcileFundedStatusOfDefinedBenefitPlan" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="ganx_IncreaseDecreaseInAccumulatedOtherComprehensiveIncomeToReconcileFundedStatusOfDefinedBenefitPlan" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.gaintherapeutics.com/role/DisclosurePensionObligationsComponentOfNetPeriodicPensionCostsDetails" xlink:type="extended" xlink:title="41003 - Disclosure - Pension obligations - Component of net periodic pension costs (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis" xlink:label="us-gaap_RetirementPlanTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="us-gaap_RetirementPlanTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="us-gaap_RetirementPlanTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RetirementPlanTypeAxis" xlink:to="us-gaap_RetirementPlanTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember" xlink:label="us-gaap_PensionPlansDefinedBenefitMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RetirementPlanTypeDomain" xlink:to="us-gaap_PensionPlansDefinedBenefitMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanServiceCost" xlink:label="us-gaap_DefinedBenefitPlanServiceCost" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedBenefitPlanServiceCost" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanInterestCost" xlink:label="us-gaap_DefinedBenefitPlanInterestCost" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedBenefitPlanInterestCost" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:label="us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:label="us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:label="us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:label="us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.gaintherapeutics.com/role/DisclosurePensionObligationsReconciliationOfProjectedBenefitObligationDetails" xlink:type="extended" xlink:title="41004 - Disclosure - Pension obligations - Reconciliation of projected benefit obligation (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis" xlink:label="us-gaap_RetirementPlanTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="us-gaap_RetirementPlanTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="us-gaap_RetirementPlanTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RetirementPlanTypeAxis" xlink:to="us-gaap_RetirementPlanTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember" xlink:label="us-gaap_PensionPlansDefinedBenefitMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RetirementPlanTypeDomain" xlink:to="us-gaap_PensionPlansDefinedBenefitMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligation" xlink:label="us-gaap_DefinedBenefitPlanBenefitObligation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedBenefitPlanBenefitObligation" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanServiceCost" xlink:label="us-gaap_DefinedBenefitPlanServiceCost" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedBenefitPlanServiceCost" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant" xlink:label="us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanInterestCost" xlink:label="us-gaap_DefinedBenefitPlanInterestCost" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedBenefitPlanInterestCost" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid" xlink:label="us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_DefinedBenefitPlanBenefitObligationGainsLossesOnFinancialAssumptions" xlink:label="ganx_DefinedBenefitPlanBenefitObligationGainsLossesOnFinancialAssumptions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="ganx_DefinedBenefitPlanBenefitObligationGainsLossesOnFinancialAssumptions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_DefinedBenefitPlanBenefitObligationGainsLossesOnDemographicAssumptions" xlink:label="ganx_DefinedBenefitPlanBenefitObligationGainsLossesOnDemographicAssumptions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="ganx_DefinedBenefitPlanBenefitObligationGainsLossesOnDemographicAssumptions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_DefinedBenefitPlanBenefitObligationGainsLossesOnExperience" xlink:label="ganx_DefinedBenefitPlanBenefitObligationGainsLossesOnExperience" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="ganx_DefinedBenefitPlanBenefitObligationGainsLossesOnExperience" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPlanAmendments" xlink:label="us-gaap_DefinedBenefitPlanPlanAmendments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedBenefitPlanPlanAmendments" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.gaintherapeutics.com/role/DisclosurePensionObligationsReconciliationOfFairValueOfPlanAssetsDetails" xlink:type="extended" xlink:title="41005 - Disclosure - Pension obligations - Reconciliation of fair value of plan assets (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis" xlink:label="us-gaap_RetirementPlanTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="us-gaap_RetirementPlanTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="us-gaap_RetirementPlanTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RetirementPlanTypeAxis" xlink:to="us-gaap_RetirementPlanTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember" xlink:label="us-gaap_PensionPlansDefinedBenefitMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RetirementPlanTypeDomain" xlink:to="us-gaap_PensionPlansDefinedBenefitMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:label="us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:label="us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets" xlink:label="us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:label="us-gaap_DefinedBenefitPlanContributionsByEmployer" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedBenefitPlanContributionsByEmployer" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant" xlink:label="us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid" xlink:label="us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_DefinedBenefitPlanPlanAssetsOtherIncreasesDecreases" xlink:label="ganx_DefinedBenefitPlanPlanAssetsOtherIncreasesDecreases" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="ganx_DefinedBenefitPlanPlanAssetsOtherIncreasesDecreases" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.gaintherapeutics.com/role/DisclosurePensionObligationsChangeInNetGainLossDetails" xlink:type="extended" xlink:title="41006 - Disclosure - Pension obligations - Change in net (gain) loss (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis" xlink:label="us-gaap_RetirementPlanTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="us-gaap_RetirementPlanTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="us-gaap_RetirementPlanTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RetirementPlanTypeAxis" xlink:to="us-gaap_RetirementPlanTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember" xlink:label="us-gaap_PensionPlansDefinedBenefitMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RetirementPlanTypeDomain" xlink:to="us-gaap_PensionPlansDefinedBenefitMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax" xlink:label="us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligationPeriodIncreaseDecrease" xlink:label="us-gaap_DefinedBenefitPlanBenefitObligationPeriodIncreaseDecrease" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedBenefitPlanBenefitObligationPeriodIncreaseDecrease" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssetsPeriodIncreaseDecrease" xlink:label="us-gaap_DefinedBenefitPlanFairValueOfPlanAssetsPeriodIncreaseDecrease" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedBenefitPlanFairValueOfPlanAssetsPeriodIncreaseDecrease" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:label="us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.gaintherapeutics.com/role/DisclosurePensionObligationsChangeInAccumulatedOtherComprehensiveIncomeAociDetails" xlink:type="extended" xlink:title="41007 - Disclosure - Pension obligations - Change in accumulated other comprehensive income (AOCI) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis" xlink:label="us-gaap_RetirementPlanTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="us-gaap_RetirementPlanTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="us-gaap_RetirementPlanTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RetirementPlanTypeAxis" xlink:to="us-gaap_RetirementPlanTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember" xlink:label="us-gaap_PensionPlansDefinedBenefitMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RetirementPlanTypeDomain" xlink:to="us-gaap_PensionPlansDefinedBenefitMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:label="us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligationPeriodIncreaseDecrease" xlink:label="us-gaap_DefinedBenefitPlanBenefitObligationPeriodIncreaseDecrease" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedBenefitPlanBenefitObligationPeriodIncreaseDecrease" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssetsPeriodIncreaseDecrease" xlink:label="us-gaap_DefinedBenefitPlanFairValueOfPlanAssetsPeriodIncreaseDecrease" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedBenefitPlanFairValueOfPlanAssetsPeriodIncreaseDecrease" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" xlink:label="us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:label="us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.gaintherapeutics.com/role/DisclosurePensionObligationsAssumptionsDetails" xlink:type="extended" xlink:title="41008 - Disclosure - Pension obligations - Assumptions (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis" xlink:label="us-gaap_RetirementPlanTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="us-gaap_RetirementPlanTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="us-gaap_RetirementPlanTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RetirementPlanTypeAxis" xlink:to="us-gaap_RetirementPlanTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember" xlink:label="us-gaap_PensionPlansDefinedBenefitMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RetirementPlanTypeDomain" xlink:to="us-gaap_PensionPlansDefinedBenefitMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedInCalculationsAbstract" xlink:label="us-gaap_DefinedBenefitPlanAssumptionsUsedInCalculationsAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedBenefitPlanAssumptionsUsedInCalculationsAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" xlink:label="us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DefinedBenefitPlanAssumptionsUsedInCalculationsAbstract" xlink:to="us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate" xlink:label="us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DefinedBenefitPlanAssumptionsUsedInCalculationsAbstract" xlink:to="us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" xlink:label="us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DefinedBenefitPlanAssumptionsUsedInCalculationsAbstract" xlink:to="us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfPensionIncreases" xlink:label="ganx_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfPensionIncreases" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_DefinedBenefitPlanAssumptionsUsedInCalculationsAbstract" xlink:to="ganx_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfPensionIncreases" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_DefinedBenefitPlanDemographicAssumptionLumpSumOption" xlink:label="ganx_DefinedBenefitPlanDemographicAssumptionLumpSumOption" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_DefinedBenefitPlanAssumptionsUsedInCalculationsAbstract" xlink:to="ganx_DefinedBenefitPlanDemographicAssumptionLumpSumOption" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_DefinedBenefitPlanDemographicAssumptionProportionMarried" xlink:label="ganx_DefinedBenefitPlanDemographicAssumptionProportionMarried" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_DefinedBenefitPlanAssumptionsUsedInCalculationsAbstract" xlink:to="ganx_DefinedBenefitPlanDemographicAssumptionProportionMarried" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_DefinedBenefitPlanDemographicAssumptionAllowanceForChildPensions" xlink:label="ganx_DefinedBenefitPlanDemographicAssumptionAllowanceForChildPensions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_DefinedBenefitPlanAssumptionsUsedInCalculationsAbstract" xlink:to="ganx_DefinedBenefitPlanDemographicAssumptionAllowanceForChildPensions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_DefinedBenefitPlanMortalityImprovementPercentage" xlink:label="ganx_DefinedBenefitPlanMortalityImprovementPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_DefinedBenefitPlanAssumptionsUsedInCalculationsAbstract" xlink:to="ganx_DefinedBenefitPlanMortalityImprovementPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_DefinedBenefitPlanDisabilityPercentage" xlink:label="ganx_DefinedBenefitPlanDisabilityPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_DefinedBenefitPlanAssumptionsUsedInCalculationsAbstract" xlink:to="ganx_DefinedBenefitPlanDisabilityPercentage" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.gaintherapeutics.com/role/DisclosurePensionObligationsExpectedBenefitPaymentsDetails" xlink:type="extended" xlink:title="41009 - Disclosure - Pension obligations - Expected benefit payments (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis" xlink:label="us-gaap_RetirementPlanTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="us-gaap_RetirementPlanTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="us-gaap_RetirementPlanTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RetirementPlanTypeAxis" xlink:to="us-gaap_RetirementPlanTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember" xlink:label="us-gaap_PensionPlansDefinedBenefitMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RetirementPlanTypeDomain" xlink:to="us-gaap_PensionPlansDefinedBenefitMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" xlink:label="us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" xlink:label="us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" xlink:label="us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" xlink:label="us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" xlink:label="us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" xlink:label="us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" xlink:label="us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.gaintherapeutics.com/role/DisclosureLoansDetails" xlink:type="extended" xlink:title="41101 - Disclosure - Loans (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_March2020ChfLoanMember" xlink:label="ganx_March2020ChfLoanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="ganx_March2020ChfLoanMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_August2020ChfLoanMember" xlink:label="ganx_August2020ChfLoanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="ganx_August2020ChfLoanMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_ExpensesOrChargesDueForEarlyExtinguishmentOfDebt" xlink:label="ganx_ExpensesOrChargesDueForEarlyExtinguishmentOfDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="ganx_ExpensesOrChargesDueForEarlyExtinguishmentOfDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="us-gaap_DebtInstrumentPeriodicPayment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentPeriodicPayment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestExpenseDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="us-gaap_DeferredFinanceCostsNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DeferredFinanceCostsNet" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.gaintherapeutics.com/role/DisclosureFairValueMeasurementDetails" xlink:type="extended" xlink:title="41201 - Disclosure - Fair value measurement (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByAssetClassAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsMember" xlink:label="us-gaap_CashAndCashEquivalentsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CashAndCashEquivalentsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_CashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.gaintherapeutics.com/role/DisclosureCommonAndPreferredStockDetails" xlink:type="extended" xlink:title="41301 - Disclosure - Common and Preferred Stock (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredClassAMember" xlink:label="us-gaap_PreferredClassAMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_PreferredClassAMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredClassBMember" xlink:label="us-gaap_PreferredClassBMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_PreferredClassBMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_PreferredStockToCommonStockConversionRatio" xlink:label="ganx_PreferredStockToCommonStockConversionRatio" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="ganx_PreferredStockToCommonStockConversionRatio" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.gaintherapeutics.com/role/DisclosureWarrantsDetails" xlink:type="extended" xlink:title="41401 - Disclosure - Warrants (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_WarrantsToDesigneesOfPlacementAgentIssuedJuly2020Member" xlink:label="ganx_WarrantsToDesigneesOfPlacementAgentIssuedJuly2020Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="ganx_WarrantsToDesigneesOfPlacementAgentIssuedJuly2020Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_WarrantsToDesigneesOfInvestmentBankIssuedMay2021Member" xlink:label="ganx_WarrantsToDesigneesOfInvestmentBankIssuedMay2021Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="ganx_WarrantsToDesigneesOfInvestmentBankIssuedMay2021Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_WarrantsAndRightsExercisedOrExchangedNumber" xlink:label="ganx_WarrantsAndRightsExercisedOrExchangedNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="ganx_WarrantsAndRightsExercisedOrExchangedNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_IssuanceOfCommonStockThroughCashlessExerciseOfWarrants" xlink:label="ganx_IssuanceOfCommonStockThroughCashlessExerciseOfWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="ganx_IssuanceOfCommonStockThroughCashlessExerciseOfWarrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_WarrantsAndRightsServicePeriod" xlink:label="ganx_WarrantsAndRightsServicePeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="ganx_WarrantsAndRightsServicePeriod" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.gaintherapeutics.com/role/DisclosureWarrantsAssumptionsUnderBlackScholesPricingModelDetails" xlink:type="extended" xlink:title="41402 - Disclosure - Warrants - Assumptions under black-scholes pricing model (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_MeasurementInputTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedTermMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationTechniqueAxis" xlink:label="us-gaap_ValuationTechniqueAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ValuationTechniqueAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="us-gaap_ValuationTechniqueDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ValuationTechniqueAxis" xlink:to="us-gaap_ValuationTechniqueDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationTechniqueOptionPricingModelMember" xlink:label="us-gaap_ValuationTechniqueOptionPricingModelMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ValuationTechniqueDomain" xlink:to="us-gaap_ValuationTechniqueOptionPricingModelMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_WarrantsGrantDateFairValue" xlink:label="ganx_WarrantsGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="ganx_WarrantsGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.gaintherapeutics.com/role/DisclosureEquityIncentivePlanDetails" xlink:type="extended" xlink:title="41501 - Disclosure - Equity Incentive Plan (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_OmnibusIncentivePlanTwoThousandTwentyMember" xlink:label="ganx_OmnibusIncentivePlanTwoThousandTwentyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="ganx_OmnibusIncentivePlanTwoThousandTwentyMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_TwentyTwentyoneInducementEquityIncentivePlanMember" xlink:label="ganx_TwentyTwentyoneInducementEquityIncentivePlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PlanNameDomain" xlink:to="ganx_TwentyTwentyoneInducementEquityIncentivePlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_NumberOfOptionsSubjectToTermThreshold" xlink:label="ganx_NumberOfOptionsSubjectToTermThreshold" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ganx_NumberOfOptionsSubjectToTermThreshold" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.gaintherapeutics.com/role/DisclosureEquityIncentivePlanStockOptionActivityDetails" xlink:type="extended" xlink:title="41502 - Disclosure - Equity Incentive Plan - Stock Option Activity (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_OmnibusIncentivePlanTwoThousandTwentyMember" xlink:label="ganx_OmnibusIncentivePlanTwoThousandTwentyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="ganx_OmnibusIncentivePlanTwoThousandTwentyMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAfterStockSplitsNumber" xlink:label="ganx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAfterStockSplitsNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="ganx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAfterStockSplitsNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionNonvestedWeightedAverageExercisePriceAfterStockSplit" xlink:label="ganx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionNonvestedWeightedAverageExercisePriceAfterStockSplit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:to="ganx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionNonvestedWeightedAverageExercisePriceAfterStockSplit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedDuringPeriodWeightedAverageGrantDateFairValue" xlink:label="ganx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedDuringPeriodWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:to="ganx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedDuringPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAfterStockSplitsWeightedAverageExercisePrice" xlink:label="ganx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAfterStockSplitsWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="ganx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAfterStockSplitsWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAfterStockSplitWeightedAverageRemainingContractualTerm" xlink:label="ganx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAfterStockSplitWeightedAverageRemainingContractualTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="ganx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAfterStockSplitWeightedAverageRemainingContractualTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" xlink:label="ganx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="ganx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.gaintherapeutics.com/role/DisclosureEquityIncentivePlanOptionsOutstandingAndExercisableDetails" xlink:type="extended" xlink:title="41503 - Disclosure - Equity Incentive Plan - Options Outstanding and Exercisable (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_OmnibusIncentivePlanTwoThousandTwentyMember" xlink:label="ganx_OmnibusIncentivePlanTwoThousandTwentyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="ganx_OmnibusIncentivePlanTwoThousandTwentyMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_ExercisePrice3.38Member" xlink:label="ganx_ExercisePrice3.38Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="ganx_ExercisePrice3.38Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_ExercisePrice7.80Member" xlink:label="ganx_ExercisePrice7.80Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="ganx_ExercisePrice7.80Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_ExercisePrice10.03Member" xlink:label="ganx_ExercisePrice10.03Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="ganx_ExercisePrice10.03Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_ExercisePrice5.86Member" xlink:label="ganx_ExercisePrice5.86Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="ganx_ExercisePrice5.86Member" use="optional" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_ExercisePrice5.99Member" xlink:label="ganx_ExercisePrice5.99Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="ganx_ExercisePrice5.99Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharePrice" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.gaintherapeutics.com/role/DisclosureEquityIncentivePlanAssumptionsDetails" xlink:type="extended" xlink:title="41504 - Disclosure - Equity Incentive Plan - Assumptions (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_OmnibusIncentivePlanTwoThousandTwentyMember" xlink:label="ganx_OmnibusIncentivePlanTwoThousandTwentyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="ganx_OmnibusIncentivePlanTwoThousandTwentyMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.gaintherapeutics.com/role/DisclosureEquityIncentivePlanStockBasedCompensationDetails" xlink:type="extended" xlink:title="41505 - Disclosure - Equity Incentive Plan - Stock-based compensation (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_OmnibusIncentivePlanTwoThousandTwentyMember" xlink:label="ganx_OmnibusIncentivePlanTwoThousandTwentyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="ganx_OmnibusIncentivePlanTwoThousandTwentyMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.gaintherapeutics.com/role/DisclosureCollaborationAgreementDetails" xlink:type="extended" xlink:title="41601 - Disclosure - Collaboration Agreement (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_MultiTargetCollaborationAgreementMember" xlink:label="ganx_MultiTargetCollaborationAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ganx_MultiTargetCollaborationAgreementMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_ZentalisPharmaceuticalsInc.Member" xlink:label="ganx_ZentalisPharmaceuticalsInc.Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="ganx_ZentalisPharmaceuticalsInc.Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_CollaborativeArrangementMinimumNumberOfTargets" xlink:label="ganx_CollaborativeArrangementMinimumNumberOfTargets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ganx_CollaborativeArrangementMinimumNumberOfTargets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_CollaborativeArrangementTerminationNoticePeriodDays" xlink:label="ganx_CollaborativeArrangementTerminationNoticePeriodDays" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ganx_CollaborativeArrangementTerminationNoticePeriodDays" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_CollaborativeArrangementProgramInitiationFee" xlink:label="ganx_CollaborativeArrangementProgramInitiationFee" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ganx_CollaborativeArrangementProgramInitiationFee" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_CollaborativeArrangementEmployeeAndExternalResearchAndDevelopmentCosts" xlink:label="ganx_CollaborativeArrangementEmployeeAndExternalResearchAndDevelopmentCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ganx_CollaborativeArrangementEmployeeAndExternalResearchAndDevelopmentCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_CollaborativeArrangementOptionExerciseFee" xlink:label="ganx_CollaborativeArrangementOptionExerciseFee" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ganx_CollaborativeArrangementOptionExerciseFee" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_CollaborativeArrangementEventBasedMilestonePayments" xlink:label="ganx_CollaborativeArrangementEventBasedMilestonePayments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ganx_CollaborativeArrangementEventBasedMilestonePayments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="us-gaap_RevenueRemainingPerformanceObligation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligation" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_AccountsReceivableNetCurrent" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.gaintherapeutics.com/role/DisclosureIncomeTaxesDomesticAndForeignNetOperatingLossesAndRelatedDeferredTaxAssetsDetails" xlink:type="extended" xlink:title="41703 - Disclosure - Income taxes - Domestic and foreign net operating losses and related deferred tax assets (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_ForeignCountryMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_DeferredTaxAssetsFmwWarrant" xlink:label="ganx_DeferredTaxAssetsFmwWarrant" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="ganx_DeferredTaxAssetsFmwWarrant" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsOther" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.gaintherapeutics.com/role/DisclosureIncomeTaxesAdditionalDisclosuresDetails" xlink:type="extended" xlink:title="41704 - Disclosure - Income taxes - Additional disclosures (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="srt_StatementGeographicalAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_ES" xlink:label="country_ES" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_ES" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_ExpenseForInterestAndPenaltiesRelatedToUncertainTaxPositionRecognizedInStatementOfOperations" xlink:label="ganx_ExpenseForInterestAndPenaltiesRelatedToUncertainTaxPositionRecognizedInStatementOfOperations" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="ganx_ExpenseForInterestAndPenaltiesRelatedToUncertainTaxPositionRecognizedInStatementOfOperations" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.gaintherapeutics.com/role/DisclosureNetLossPerCommonShareComputationOfDilutedNetLossPerShareDetails" xlink:type="extended" xlink:title="41801 - Disclosure - Net loss per common share - Computation of diluted net loss per share (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredClassBMember" xlink:label="us-gaap_PreferredClassBMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_PreferredClassBMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="srt_RestatementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="srt_ScenarioPreviouslyReportedMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RestatementDomain" xlink:to="srt_ScenarioPreviouslyReportedMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_EarningsPerShareBasic" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.gaintherapeutics.com/role/DisclosureRelatedPartiesDetails" xlink:type="extended" xlink:title="41901 - Disclosure - Related Parties (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_LicenseAgreementWithMinoryxTherapeuticsSlMember" xlink:label="ganx_LicenseAgreementWithMinoryxTherapeuticsSlMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="ganx_LicenseAgreementWithMinoryxTherapeuticsSlMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_RelatedPartyTransactionPercentageOfNetRevenuesBasedOnOneCompositionOfMatterClaim" xlink:label="ganx_RelatedPartyTransactionPercentageOfNetRevenuesBasedOnOneCompositionOfMatterClaim" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="ganx_RelatedPartyTransactionPercentageOfNetRevenuesBasedOnOneCompositionOfMatterClaim" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_RelatedPartyTransactionPercentageOfNetRevenuesBasedOnOneMethodOfClaim" xlink:label="ganx_RelatedPartyTransactionPercentageOfNetRevenuesBasedOnOneMethodOfClaim" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="ganx_RelatedPartyTransactionPercentageOfNetRevenuesBasedOnOneMethodOfClaim" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_RelatedPartyTransactionPercentageOfConsiderationReceived" xlink:label="ganx_RelatedPartyTransactionPercentageOfConsiderationReceived" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="ganx_RelatedPartyTransactionPercentageOfConsiderationReceived" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableRelatedParties" xlink:label="us-gaap_AccountsReceivableRelatedParties" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_AccountsReceivableRelatedParties" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent" xlink:label="us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromRelatedParties" xlink:label="us-gaap_RevenueFromRelatedParties" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RevenueFromRelatedParties" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.gaintherapeutics.com/role/DisclosureOtherInformationDetails" xlink:type="extended" xlink:title="42001 - Disclosure - Other Information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentsTable" xlink:label="us-gaap_OtherCommitmentsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="us-gaap_OtherCommitmentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_OtherCommitmentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_CollaborationAgreementsMember" xlink:label="ganx_CollaborationAgreementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_OtherCommitmentsDomain" xlink:to="ganx_CollaborationAgreementsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="us-gaap_OtherCommitmentsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OtherCommitmentsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:label="us-gaap_ContractualObligationDueInNextTwelveMonths" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_ContractualObligationDueInNextTwelveMonths" priority="1" use="optional" />
  </definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>31
<FILENAME>ganx-20211231_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.8042.36810 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/25/2022 6:18:32 PM-->
<!--Modified on: 3/25/2022 6:18:32 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document and Entity Information [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressesTable" xlink:label="dei_EntityAddressesTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressesTable" xlink:to="dei_EntityAddressesTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressesTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Addresses [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressesLineItems" xlink:label="dei_EntityAddressesLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressesLineItems" xlink:to="dei_EntityAddressesLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Addresses [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Annual Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Transition Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Adress Line Two</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address State Or Province</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Well-known Seasoned Issuer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Voluntary Filers</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Current Reporting Status</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Interactive Data Current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Filer Category</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Small Business</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ICFR Auditor Attestation Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Ex Transition Period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Shell Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Public Float</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Common Stock, Shares Outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current Fiscal Year End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Year Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Period Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName" xlink:label="dei_AuditorName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Auditor Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Auditor Firm ID</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Auditor Location</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consolidated Balance Sheets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Stock [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series A Preferred Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesBPreferredStockMember" xlink:to="us-gaap_SeriesBPreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series B Preferred Stock.</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current assets:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, at Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashCurrent" xlink:to="us-gaap_RestrictedCashCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted Cash, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedCashCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Receivable, after Allowance for Credit Loss, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Recorded receivables</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxesAndOtherTaxReceivableCurrent" xlink:label="us-gaap_DeferredIncomeTaxesAndOtherTaxReceivableCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxesAndOtherTaxReceivableCurrent" xlink:to="us-gaap_DeferredIncomeTaxesAndOtherTaxReceivableCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxesAndOtherTaxReceivableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Income Taxes and Other Tax Receivable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredIncomeTaxesAndOtherTaxReceivableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax credits</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid Expense and Other Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses and other current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total Prepaid expenses and other current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredOfferingCosts" xlink:label="us-gaap_DeferredOfferingCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredOfferingCosts" xlink:to="us-gaap_DeferredOfferingCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredOfferingCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Offering Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredOfferingCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred offering costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="us-gaap_AssetsNoncurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Noncurrent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-current assets:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment, net</label>
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_CapitalizedComputerSoftwareForInternalUse" xlink:label="ganx_CapitalizedComputerSoftwareForInternalUse" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ganx_CapitalizedComputerSoftwareForInternalUse" xlink:to="ganx_CapitalizedComputerSoftwareForInternalUse_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ganx_CapitalizedComputerSoftwareForInternalUse_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Carrying amount of capitalized internally use software as on date.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ganx_CapitalizedComputerSoftwareForInternalUse_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capitalized Computer Software For Internal Use</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ganx_CapitalizedComputerSoftwareForInternalUse_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Internal-use software</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Right-of-Use Asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease - right of use assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease- right of use assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashNoncurrent" xlink:to="us-gaap_RestrictedCashNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted Cash, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted cash</label>
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_DepositsAndOtherAssetsNoncurrent" xlink:label="ganx_DepositsAndOtherAssetsNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ganx_DepositsAndOtherAssetsNoncurrent" xlink:to="ganx_DepositsAndOtherAssetsNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ganx_DepositsAndOtherAssetsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer and noncurrent assets classified as other.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ganx_DepositsAndOtherAssetsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deposits And Other Assets, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ganx_DepositsAndOtherAssetsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term deposits and other non-current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total non-current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Equity:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAbstract" xlink:label="us-gaap_LiabilitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_LiabilitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current liabilities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease liability - current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease liability - current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Current Liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxesPayableCurrent" xlink:label="us-gaap_TaxesPayableCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxesPayableCurrent" xlink:to="us-gaap_TaxesPayableCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxesPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Taxes Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TaxesPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax provision</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeCurrent" xlink:label="us-gaap_DeferredIncomeCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeCurrent" xlink:to="us-gaap_DeferredIncomeCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Income, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredIncomeCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtCurrent" xlink:to="us-gaap_LongTermDebtCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term Debt, Current Maturities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loans - short term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Noncurrent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-current liabilities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent" xlink:label="us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent" xlink:to="us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liability, Defined Benefit Pension Plan, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined benefit pension plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Liability, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease liability - non-current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease liability - non current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtNoncurrent" xlink:to="us-gaap_LongTermDebtNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term Debt, Excluding Current Maturities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loans - long term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total non-current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Attributable to Parent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, $0.0001 par value: 11,883,368 and 3,543,163 issued and outstanding as of December 31, 2021 and December 31, 2020, respectively</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid in Capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional paid-in capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Other Comprehensive Income (Loss), Net of Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated other comprehensive loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retained Earnings (Accumulated Deficit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated deficit</label>
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_IncomeLossForPeriod" xlink:label="ganx_IncomeLossForPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ganx_IncomeLossForPeriod" xlink:to="ganx_IncomeLossForPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ganx_IncomeLossForPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The current period income or loss.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ganx_IncomeLossForPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Loss For The Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ganx_IncomeLossForPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss of the period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities and stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, par value (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, shares authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Authorized capital, Preferred stock (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, shares issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, shares outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, par value (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock par value (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Authorized capital, Common stock (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares, issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock issued (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares, outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock outstanding (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consolidated Statement of Operations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenuesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenuesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenues [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenuesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenues:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue from Contract with Customer, Excluding Assessed Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration revenues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenues</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubleaseIncome" xlink:label="us-gaap_SubleaseIncome" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubleaseIncome" xlink:to="us-gaap_SubleaseIncome_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubleaseIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sublease Income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubleaseIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total revenues</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Expenses [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating expenses:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and administrative</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total operating expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Income (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss from operations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nonoperating Income (Expense) [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other income (expense):</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="us-gaap_InterestIncomeExpenseNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNet" xlink:to="us-gaap_InterestIncomeExpenseNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeExpenseNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest Income (Expense), Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestIncomeExpenseNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest income, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign Currency Transaction Gain (Loss), before Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign exchange loss, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss before income tax</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total income tax expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income (Loss) Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDilutedAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Basic and Diluted [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss per shares:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss per share attributable to common stockholders - Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss per share attributable to common stockholders - Diluted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number of Shares Outstanding, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average common shares - Basic</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number of Shares Outstanding, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average common shares - Diluted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consolidated Statement of Comprehensive Loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Comprehensive Income (Loss), Net of Tax [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other comprehensive gain/(loss):</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined benefit pension plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign currency translation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other comprehensive gain/(loss):</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consolidated Statement of Changes in Stockholders' Equity (Deficit)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Components [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Component [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">APIC</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">AOCI</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredClassAMember" xlink:label="us-gaap_PreferredClassAMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredClassAMember" xlink:to="us-gaap_PreferredClassAMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredClassAMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series A Preferred Stock.</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredClassBMember" xlink:label="us-gaap_PreferredClassBMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredClassBMember" xlink:to="us-gaap_PreferredClassBMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredClassBMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series B Preferred Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IPOMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IPO</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance (in shares)</label>
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_ConversionOfSeriesPreferredStockIntoCommonStock" xlink:label="ganx_ConversionOfSeriesPreferredStockIntoCommonStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ganx_ConversionOfSeriesPreferredStockIntoCommonStock" xlink:to="ganx_ConversionOfSeriesPreferredStockIntoCommonStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ganx_ConversionOfSeriesPreferredStockIntoCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The increase (decrease) in equity from conversion of Series A Preferred Stock into Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ganx_ConversionOfSeriesPreferredStockIntoCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of Series A Preferred Stock into Common Stock</label>
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_ConversionOfSeriesPreferredStockIntoCommonStockInShares" xlink:label="ganx_ConversionOfSeriesPreferredStockIntoCommonStockInShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ganx_ConversionOfSeriesPreferredStockIntoCommonStockInShares" xlink:to="ganx_ConversionOfSeriesPreferredStockIntoCommonStockInShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ganx_ConversionOfSeriesPreferredStockIntoCommonStockInShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The increase (decrease) in number of shares resulting from the conversion of Series B Preferred Stock into Common Stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ganx_ConversionOfSeriesPreferredStockIntoCommonStockInShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of Series A Preferred Stock into Common Stock (in shares)</label>
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_IssuanceOfSeriesPreferredStockNetOfIssuanceCost" xlink:label="ganx_IssuanceOfSeriesPreferredStockNetOfIssuanceCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ganx_IssuanceOfSeriesPreferredStockNetOfIssuanceCost" xlink:to="ganx_IssuanceOfSeriesPreferredStockNetOfIssuanceCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ganx_IssuanceOfSeriesPreferredStockNetOfIssuanceCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The increase (decrease) in equity resulting from the issuance of Series A Preferred Stock, net of issuance cost.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ganx_IssuanceOfSeriesPreferredStockNetOfIssuanceCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of Series A Preferred Stock, net of issuance cost</label>
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_IssuanceOfSeriesPreferredStockInShares" xlink:label="ganx_IssuanceOfSeriesPreferredStockInShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ganx_IssuanceOfSeriesPreferredStockInShares" xlink:to="ganx_IssuanceOfSeriesPreferredStockInShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ganx_IssuanceOfSeriesPreferredStockInShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The increase in number of shares resulting from issuance of Series A Preferred Stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ganx_IssuanceOfSeriesPreferredStockInShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of Series A Preferred Stock (in shares)</label>
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_ConversionOfSeriesBPreferredStockIntoCommonStock" xlink:label="ganx_ConversionOfSeriesBPreferredStockIntoCommonStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ganx_ConversionOfSeriesBPreferredStockIntoCommonStock" xlink:to="ganx_ConversionOfSeriesBPreferredStockIntoCommonStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ganx_ConversionOfSeriesBPreferredStockIntoCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The increase (decrease) in equity from conversion of Series B Preferred Stock into Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ganx_ConversionOfSeriesBPreferredStockIntoCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of Series B Preferred Stock into Common Stock</label>
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_ConversionOfSeriesBPreferredStockIntoCommonStockInShares" xlink:label="ganx_ConversionOfSeriesBPreferredStockIntoCommonStockInShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ganx_ConversionOfSeriesBPreferredStockIntoCommonStockInShares" xlink:to="ganx_ConversionOfSeriesBPreferredStockIntoCommonStockInShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ganx_ConversionOfSeriesBPreferredStockIntoCommonStockInShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The increase (decrease) in number of shares resulting from the conversion of Series B Preferred Stock into Common Stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ganx_ConversionOfSeriesBPreferredStockIntoCommonStockInShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of Series B Preferred Stock into Common Stock (in shares)</label>
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_IssuanceOfSeriesBPreferredStockNetOfIssuanceCost" xlink:label="ganx_IssuanceOfSeriesBPreferredStockNetOfIssuanceCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ganx_IssuanceOfSeriesBPreferredStockNetOfIssuanceCost" xlink:to="ganx_IssuanceOfSeriesBPreferredStockNetOfIssuanceCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ganx_IssuanceOfSeriesBPreferredStockNetOfIssuanceCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The increase (decrease) in equity resulting from the issuance of Series B Preferred Stock, net of issuance cost.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ganx_IssuanceOfSeriesBPreferredStockNetOfIssuanceCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of Series B Preferred Stock, net of issuance cost</label>
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_IssuanceOfSeriesBPreferredStockInShares" xlink:label="ganx_IssuanceOfSeriesBPreferredStockInShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ganx_IssuanceOfSeriesBPreferredStockInShares" xlink:to="ganx_IssuanceOfSeriesBPreferredStockInShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ganx_IssuanceOfSeriesBPreferredStockInShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The increase in number of shares resulting from issuance of Series B Preferred Stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ganx_IssuanceOfSeriesBPreferredStockInShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of Series B Preferred Stock (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of stock, net of issuance costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of stock, net of issuance costs (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares issued</label>
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_IssuanceOfCommonStockInIpoNetOfIssuanceCosts" xlink:label="ganx_IssuanceOfCommonStockInIpoNetOfIssuanceCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ganx_IssuanceOfCommonStockInIpoNetOfIssuanceCosts" xlink:to="ganx_IssuanceOfCommonStockInIpoNetOfIssuanceCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ganx_IssuanceOfCommonStockInIpoNetOfIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The increase (decrease) in equity from the issuance of common stock in initial public offering, net of issuance costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ganx_IssuanceOfCommonStockInIpoNetOfIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of Common Stock in IPO, net of issuance costs</label>
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_IssuanceOfCommonStockInIpoInShares" xlink:label="ganx_IssuanceOfCommonStockInIpoInShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ganx_IssuanceOfCommonStockInIpoInShares" xlink:to="ganx_IssuanceOfCommonStockInIpoInShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ganx_IssuanceOfCommonStockInIpoInShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The increase in shares issued resulting from the company's initial public offering.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ganx_IssuanceOfCommonStockInIpoInShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of Common Stock in IPO (In shares)</label>
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_IssuanceOfCommonStockThroughCashlessExerciseOfWarrants" xlink:label="ganx_IssuanceOfCommonStockThroughCashlessExerciseOfWarrants" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ganx_IssuanceOfCommonStockThroughCashlessExerciseOfWarrants" xlink:to="ganx_IssuanceOfCommonStockThroughCashlessExerciseOfWarrants_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ganx_IssuanceOfCommonStockThroughCashlessExerciseOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock through cashless exercise of warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ganx_IssuanceOfCommonStockThroughCashlessExerciseOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock through cashless exercise of warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ganx_IssuanceOfCommonStockThroughCashlessExerciseOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of Common Stock due to warrants cashless exercise</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of Common Share due to stock option exercise</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options exercised (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of Common Share due to stock option exercise (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock based compensation expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to Additional Paid in Capital, Warrant Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consolidated Statement of Cash Flows</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to reconcile net loss to net cash used in operating activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Noncash Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock based compensation expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of Stock and Warrants for Services or Claims</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of warrants</label>
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_CapitalizedComputerSoftwareAdjustment" xlink:label="ganx_CapitalizedComputerSoftwareAdjustment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ganx_CapitalizedComputerSoftwareAdjustment" xlink:to="ganx_CapitalizedComputerSoftwareAdjustment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ganx_CapitalizedComputerSoftwareAdjustment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of adjustment for capitalized computer software.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ganx_CapitalizedComputerSoftwareAdjustment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capitalized Computer Software, Adjustment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ganx_CapitalizedComputerSoftwareAdjustment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Internal-use software</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Operating Capital [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Changes in operating assets and liabilities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Accounts Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Account receivables</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Prepaid Expense and Other Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses and other current assets</label>
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_IncreaseDecreaseInValueAddedTaxCredits" xlink:label="ganx_IncreaseDecreaseInValueAddedTaxCredits" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ganx_IncreaseDecreaseInValueAddedTaxCredits" xlink:to="ganx_IncreaseDecreaseInValueAddedTaxCredits_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ganx_IncreaseDecreaseInValueAddedTaxCredits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of increase (decrease) in value-added tax credits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ganx_IncreaseDecreaseInValueAddedTaxCredits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in value-added tax credits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ganx_IncreaseDecreaseInValueAddedTaxCredits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">VAT credits</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Other Noncurrent Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long term deposit and other non current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Accounts Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Other Current Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionExpenseReversalOfExpenseNoncash" xlink:label="us-gaap_PensionExpenseReversalOfExpenseNoncash" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionExpenseReversalOfExpenseNoncash" xlink:to="us-gaap_PensionExpenseReversalOfExpenseNoncash_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PensionExpenseReversalOfExpenseNoncash_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pension Expense (Reversal of Expense), Noncash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PensionExpenseReversalOfExpenseNoncash_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined benefit pension plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredLiabilities" xlink:label="us-gaap_IncreaseDecreaseInDeferredLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredLiabilities" xlink:to="us-gaap_IncreaseDecreaseInDeferredLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDeferredLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Deferred Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInDeferredLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred income</label>
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_IncreaseDecreaseInOperatingAssetsAndLiabilities" xlink:label="ganx_IncreaseDecreaseInOperatingAssetsAndLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ganx_IncreaseDecreaseInOperatingAssetsAndLiabilities" xlink:to="ganx_IncreaseDecreaseInOperatingAssetsAndLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ganx_IncreaseDecreaseInOperatingAssetsAndLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Operating Assets and Liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ganx_IncreaseDecreaseInOperatingAssetsAndLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Operating Assets and Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="ganx_IncreaseDecreaseInOperatingAssetsAndLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total changes in operating assets and liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash used in operating activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from investing activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments to Acquire Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase of property and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash used in investing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flow from financing activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance of Long-term Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from long-term debts</label>
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_ProceedsFromIssuanceOfSeriesA.PreferredStockNetOfIssuanceCosts" xlink:label="ganx_ProceedsFromIssuanceOfSeriesA.PreferredStockNetOfIssuanceCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ganx_ProceedsFromIssuanceOfSeriesA.PreferredStockNetOfIssuanceCosts" xlink:to="ganx_ProceedsFromIssuanceOfSeriesA.PreferredStockNetOfIssuanceCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ganx_ProceedsFromIssuanceOfSeriesA.PreferredStockNetOfIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from issuance of Series A Preferred Stock, net of issuance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ganx_ProceedsFromIssuanceOfSeriesA.PreferredStockNetOfIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from issuance of Series A. Preferred Stock, net of issuance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ganx_ProceedsFromIssuanceOfSeriesA.PreferredStockNetOfIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from issuance of Series A Preferred Stock, net of issuance costs</label>
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_ProceedsFromIssuanceOfSeriesBPreferredStockNetOfIssuanceCosts" xlink:label="ganx_ProceedsFromIssuanceOfSeriesBPreferredStockNetOfIssuanceCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ganx_ProceedsFromIssuanceOfSeriesBPreferredStockNetOfIssuanceCosts" xlink:to="ganx_ProceedsFromIssuanceOfSeriesBPreferredStockNetOfIssuanceCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ganx_ProceedsFromIssuanceOfSeriesBPreferredStockNetOfIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from issuance of Series B Preferred Stock, net of issuance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ganx_ProceedsFromIssuanceOfSeriesBPreferredStockNetOfIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from issuance of Series B Preferred Stock, net of issuance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ganx_ProceedsFromIssuanceOfSeriesBPreferredStockNetOfIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from issuance of Series B Preferred Stock, net of issuance costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance Initial Public Offering</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from issuance of common shares upon completion of initial public offering, net of underwriter discounts</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments of Stock Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments of deferred offering costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfShortTermDebt" xlink:label="us-gaap_RepaymentsOfShortTermDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfShortTermDebt" xlink:to="us-gaap_RepaymentsOfShortTermDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfShortTermDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repayments of Short-term Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfShortTermDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments of current portion of long-term debt</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from stock option exercise</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash provided by financing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effect of Exchange Rate on Cash and Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effect of exchange rate changes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net increase in cash, cash equivalents and restricted cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, cash equivalents and restricted cash at end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, cash equivalents and restricted cash at beginning of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents balances</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nature of the Business and Basis of Presentation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nature of the Business and Basis of Presentation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of Significant Accounting Policies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Significant Accounting Policies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of Significant Accounting Policies</label>
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_ResearchGrantsAbstract" xlink:label="ganx_ResearchGrantsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ganx_ResearchGrantsAbstract" xlink:to="ganx_ResearchGrantsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ganx_ResearchGrantsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Information pertaining to research grants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ganx_ResearchGrantsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research Grants</label>
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_ResearchGrantsDisclosureTextBlock" xlink:label="ganx_ResearchGrantsDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ganx_ResearchGrantsDisclosureTextBlock" xlink:to="ganx_ResearchGrantsDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ganx_ResearchGrantsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The entire disclosure of information pertaining to research grants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ganx_ResearchGrantsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research Grants Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ganx_ResearchGrantsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research Grants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, cash equivalents and restricted cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, cash equivalents and restricted cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Current Assets</label>
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_PrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:label="ganx_PrepaidExpensesAndOtherCurrentAssetsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ganx_PrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:to="ganx_PrepaidExpensesAndOtherCurrentAssetsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ganx_PrepaidExpensesAndOtherCurrentAssetsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The entire disclosure for Prepaid expenses and other current assets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ganx_PrepaidExpensesAndOtherCurrentAssetsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid Expenses and Other Current Assets [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ganx_PrepaidExpensesAndOtherCurrentAssetsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Current Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentNetAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNetAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNetAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and Equipment, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and Equipment, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease. Right of use ("ROU") assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Leases [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease. Right of use ("ROU") assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrentAbstract" xlink:label="us-gaap_AccountsPayableCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCreditsAndOtherLiabilitiesAbstract" xlink:label="us-gaap_DeferredCreditsAndOtherLiabilitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCreditsAndOtherLiabilitiesAbstract" xlink:to="us-gaap_DeferredCreditsAndOtherLiabilitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCreditsAndOtherLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other current liabilities and deferred income</label>
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_OtherCurrentLiabilitiesAndDeferredIncomeTextBlock" xlink:label="ganx_OtherCurrentLiabilitiesAndDeferredIncomeTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ganx_OtherCurrentLiabilitiesAndDeferredIncomeTextBlock" xlink:to="ganx_OtherCurrentLiabilitiesAndDeferredIncomeTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ganx_OtherCurrentLiabilitiesAndDeferredIncomeTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The entire disclosure for other current liabilities and deferred income.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ganx_OtherCurrentLiabilitiesAndDeferredIncomeTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Current Liabilities and Deferred Income [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ganx_OtherCurrentLiabilitiesAndDeferredIncomeTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other current liabilities and deferred income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pension obligations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retirement Benefits [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pension obligations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loans</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loans</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value measurement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Disclosures [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value measurement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common and Preferred Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Note Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common and Preferred Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="us-gaap_WarrantsAndRightsNoteDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants</label>
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_WarrantsAndRightsNoteDisclosureTextBlock" xlink:label="ganx_WarrantsAndRightsNoteDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ganx_WarrantsAndRightsNoteDisclosureTextBlock" xlink:to="ganx_WarrantsAndRightsNoteDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ganx_WarrantsAndRightsNoteDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entire disclosure of warrant and rights.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ganx_WarrantsAndRightsNoteDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants and Rights Note Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ganx_WarrantsAndRightsNoteDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationRelatedCostsAbstract" xlink:label="us-gaap_CompensationRelatedCostsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsAbstract" xlink:to="us-gaap_CompensationRelatedCostsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationRelatedCostsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Incentive Plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationRelatedCostsGeneralTextBlock" xlink:label="us-gaap_CompensationRelatedCostsGeneralTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsGeneralTextBlock" xlink:to="us-gaap_CompensationRelatedCostsGeneralTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationRelatedCostsGeneralTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Compensation Related Costs, General [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CompensationRelatedCostsGeneralTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Incentive Plan</label>
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_CollaborationAgreementAbstract" xlink:label="ganx_CollaborationAgreementAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ganx_CollaborationAgreementAbstract" xlink:to="ganx_CollaborationAgreementAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ganx_CollaborationAgreementAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Information pertaining to Collaboration Agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ganx_CollaborationAgreementAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration Agreement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration Agreement [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration Agreement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss per common share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss per common share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Parties</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transactions Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Parties</label>
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_OtherInformationAbstract" xlink:label="ganx_OtherInformationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ganx_OtherInformationAbstract" xlink:to="ganx_OtherInformationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ganx_OtherInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ganx_OtherInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Information</label>
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_OtherInformationDisclosureTextBlock" xlink:label="ganx_OtherInformationDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ganx_OtherInformationDisclosureTextBlock" xlink:to="ganx_OtherInformationDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ganx_OtherInformationDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The entire disclosure of information pertaining to other information.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ganx_OtherInformationDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Information Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ganx_OtherInformationDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Significant events after the balance sheet date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Events [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Significant events after the balance sheet date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of Accounting, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of presentation</label>
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_ReverseStockSplitPolicyPolicyTextBlock" xlink:label="ganx_ReverseStockSplitPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ganx_ReverseStockSplitPolicyPolicyTextBlock" xlink:to="ganx_ReverseStockSplitPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ganx_ReverseStockSplitPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of accounting policy for reverse stock split.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ganx_ReverseStockSplitPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reverse Stock Split Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ganx_ReverseStockSplitPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reverse Stock Split</label>
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_InitialPublicOfferingPolicyTextBlock" xlink:label="ganx_InitialPublicOfferingPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ganx_InitialPublicOfferingPolicyTextBlock" xlink:to="ganx_InitialPublicOfferingPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ganx_InitialPublicOfferingPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of accounting policy for initial public offering.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ganx_InitialPublicOfferingPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Initial Public Offering [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ganx_InitialPublicOfferingPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Initial Public Offering</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment Reporting, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign Currency Transactions and Translations Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign currency translation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Use of Estimates, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Use of Estimates</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentrations of Credit Risk</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredChargesPolicyTextBlock" xlink:label="us-gaap_DeferredChargesPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredChargesPolicyTextBlock" xlink:to="us-gaap_DeferredChargesPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredChargesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Charges, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredChargesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Issuance Costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" xlink:label="us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" xlink:to="us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research, Development, and Computer Software, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capitalized Software Development Costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment of long-lived assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intangible Assets, Finite-Lived, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Patents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Leases [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leases</label>
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_AccountsPayablePolicyTextBlock" xlink:label="ganx_AccountsPayablePolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ganx_AccountsPayablePolicyTextBlock" xlink:to="ganx_AccountsPayablePolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ganx_AccountsPayablePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of accounting policy for accounts payable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ganx_AccountsPayablePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ganx_AccountsPayablePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable</label>
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_PayablesForSocialSecuritiesPolicyTextBlock" xlink:label="ganx_PayablesForSocialSecuritiesPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ganx_PayablesForSocialSecuritiesPolicyTextBlock" xlink:to="ganx_PayablesForSocialSecuritiesPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ganx_PayablesForSocialSecuritiesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of accounting policy for payables for social securities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ganx_PayablesForSocialSecuritiesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payables for Social Securities Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ganx_PayablesForSocialSecuritiesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payables for Social Securities</label>
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_AccruedExpensesPolicyPolicyTextBlock" xlink:label="ganx_AccruedExpensesPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ganx_AccruedExpensesPolicyPolicyTextBlock" xlink:to="ganx_AccruedExpensesPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ganx_AccruedExpensesPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of accounting policy for accrued expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ganx_AccruedExpensesPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Expenses Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ganx_AccruedExpensesPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementPlansPolicy" xlink:label="us-gaap_PensionAndOtherPostretirementPlansPolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementPlansPolicy" xlink:to="us-gaap_PensionAndOtherPostretirementPlansPolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PensionAndOtherPostretirementPlansPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pension and Other Postretirement Plans, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PensionAndOtherPostretirementPlansPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pension obligations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Compensation Related Costs, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity-based Compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue from Contract with Customer [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue Recognition</label>
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_ResearchGrantsPolicyPolicyTextBlock" xlink:label="ganx_ResearchGrantsPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ganx_ResearchGrantsPolicyPolicyTextBlock" xlink:to="ganx_ResearchGrantsPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ganx_ResearchGrantsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of accounting policy research grants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ganx_ResearchGrantsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research Grants Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ganx_ResearchGrantsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research grants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Selling, General and Administrative Expenses, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and administrative expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurement, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value measurements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive Income, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive income/(loss)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Recently issued accounting pronouncements</label>
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_DepreciationRatesOnPropertyPlantAndEquipmentTableTextBlock" xlink:label="ganx_DepreciationRatesOnPropertyPlantAndEquipmentTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ganx_DepreciationRatesOnPropertyPlantAndEquipmentTableTextBlock" xlink:to="ganx_DepreciationRatesOnPropertyPlantAndEquipmentTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ganx_DepreciationRatesOnPropertyPlantAndEquipmentTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular disclosure for depreciation rates on property plant and equipment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ganx_DepreciationRatesOnPropertyPlantAndEquipmentTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation Rates On Property Plant And Equipment [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ganx_DepreciationRatesOnPropertyPlantAndEquipmentTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of depreciation rates</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:label="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:to="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restrictions on Cash and Cash Equivalents [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of cash, cash equivalents and restricted cash</label>
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_ScheduleOfCashAndCashEquivalentsBalancesTableTextBlock" xlink:label="ganx_ScheduleOfCashAndCashEquivalentsBalancesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ganx_ScheduleOfCashAndCashEquivalentsBalancesTableTextBlock" xlink:to="ganx_ScheduleOfCashAndCashEquivalentsBalancesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ganx_ScheduleOfCashAndCashEquivalentsBalancesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular disclosure of cash and cash equivalents balances.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ganx_ScheduleOfCashAndCashEquivalentsBalancesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Cash And cash Equivalents Balances [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ganx_ScheduleOfCashAndCashEquivalentsBalancesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of cash and cash equivalents balances broken down by currency</label>
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:label="ganx_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ganx_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:to="ganx_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ganx_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular disclosure for Prepaid expenses and other current assets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ganx_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Prepaid Expenses and Other Current Assets [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ganx_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Other Current Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Property and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLeaseIncomeTableTextBlock" xlink:label="us-gaap_OperatingLeaseLeaseIncomeTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLeaseIncomeTableTextBlock" xlink:to="us-gaap_OperatingLeaseLeaseIncomeTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLeaseIncomeTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Lease Income [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLeaseIncomeTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of components of lease accounting</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease, Cost [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of components of lease expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of future minimum lease payments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of vendor outstanding payables</label>
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_OtherCurrentLiabilitiesAndDeferredIncomeTableTextBlock" xlink:label="ganx_OtherCurrentLiabilitiesAndDeferredIncomeTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ganx_OtherCurrentLiabilitiesAndDeferredIncomeTableTextBlock" xlink:to="ganx_OtherCurrentLiabilitiesAndDeferredIncomeTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ganx_OtherCurrentLiabilitiesAndDeferredIncomeTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular disclosure for other current liabilities and deferred income.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ganx_OtherCurrentLiabilitiesAndDeferredIncomeTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Current Liabilities and Deferred Income [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ganx_OtherCurrentLiabilitiesAndDeferredIncomeTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Other current liabilities and deferred income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock" xlink:to="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Defined Benefit Plans Disclosures [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Pension obligations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:label="us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:to="us-gaap_ScheduleOfAssumptionsUsedTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAssumptionsUsedTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Benefit Plan, Assumptions [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAssumptionsUsedTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of assumptions used</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock" xlink:label="us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock" xlink:to="us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Expected Benefit Payments [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of expected benefit payments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Maturities of Long-term Debt [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of future loan payments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Assets Measured on Recurring and Nonrecurring Basis [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of assets measured at fair value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of fair value of the warrants is estimated using the Black-Scholes option pricing model</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Option, Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of the Company's stock option activity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of grant-date fair value of stock options granted to employees and directors</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Cost by Plan [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of stock-based compensation expense is recognized for stock options granted to employees and non-employees</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of components of loss before income taxes provision</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of components of income tax expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of net operating losses and related deferred tax assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of effective income tax rate reconciliation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of potentially dilutive common stock excluded from the computation of diluted net loss per share attributable to common stockholders</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OverAllotmentOptionMember" xlink:to="us-gaap_OverAllotmentOptionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Underwriters' option</label>
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_IpoExcludingUnderwritersOptionsMember" xlink:label="ganx_IpoExcludingUnderwritersOptionsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ganx_IpoExcludingUnderwritersOptionsMember" xlink:to="ganx_IpoExcludingUnderwritersOptionsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ganx_IpoExcludingUnderwritersOptionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">First sale of stock by a private company to the public excluding underwriters' options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ganx_IpoExcludingUnderwritersOptionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IPO excluding underwriters' options [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ganx_IpoExcludingUnderwritersOptionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IPO excluding underwriters' options</label>
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_PreferredStockSeriesAndSeriesBMember" xlink:label="ganx_PreferredStockSeriesAndSeriesBMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ganx_PreferredStockSeriesAndSeriesBMember" xlink:to="ganx_PreferredStockSeriesAndSeriesBMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ganx_PreferredStockSeriesAndSeriesBMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to Preferred stock Series A and Series B</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ganx_PreferredStockSeriesAndSeriesBMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock Series A and Series B [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ganx_PreferredStockSeriesAndSeriesBMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock Series A and Series B</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsidiary, Sale of Stock [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Note, Stock Split, Conversion Ratio</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock split ratio</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reverse stock split ratio</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Public offering price</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds</label>
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_UnderwritingDiscountsAndCommissions" xlink:label="ganx_UnderwritingDiscountsAndCommissions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ganx_UnderwritingDiscountsAndCommissions" xlink:to="ganx_UnderwritingDiscountsAndCommissions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ganx_UnderwritingDiscountsAndCommissions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of underwriting discount and commission incurred during the reporting period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ganx_UnderwritingDiscountsAndCommissions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Underwriting Discounts and Commissions</label>
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_OtherOfferingExpenses" xlink:label="ganx_OtherOfferingExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ganx_OtherOfferingExpenses" xlink:to="ganx_OtherOfferingExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ganx_OtherOfferingExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of other offering expense incurred during the reporting period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ganx_OtherOfferingExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Offering Expenses</label>
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_GrossProceedsFromIssuanceOfCommonStock" xlink:label="ganx_GrossProceedsFromIssuanceOfCommonStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ganx_GrossProceedsFromIssuanceOfCommonStock" xlink:to="ganx_GrossProceedsFromIssuanceOfCommonStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ganx_GrossProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The cash inflow from the additional capital contribution to the entity, before deduction of offering expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ganx_GrossProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross proceeds from Issuance of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ganx_GrossProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds before deduction of offering expenses</label>
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_PreferredStockToCommonStockConversionRatio" xlink:label="ganx_PreferredStockToCommonStockConversionRatio" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ganx_PreferredStockToCommonStockConversionRatio" xlink:to="ganx_PreferredStockToCommonStockConversionRatio_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ganx_PreferredStockToCommonStockConversionRatio_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The conversion ratio for conversion of preferred stock to common stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ganx_PreferredStockToCommonStockConversionRatio_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock to common stock conversion ratio</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Stock by Class [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Stock [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common and Preferred Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated currency translation adjustments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="us-gaap_DeferredFinanceCostsNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFinanceCostsNet" xlink:to="us-gaap_DeferredFinanceCostsNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFinanceCostsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Issuance Costs, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredFinanceCostsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred issuance costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Lived Tangible Asset [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Lived Tangible Asset [Domain]</label>
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_EquipmentAndFurnitureMember" xlink:label="ganx_EquipmentAndFurnitureMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ganx_EquipmentAndFurnitureMember" xlink:to="ganx_EquipmentAndFurnitureMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ganx_EquipmentAndFurnitureMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to Equipment &amp; Furniture.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ganx_EquipmentAndFurnitureMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equipment and Furniture</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficeEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OfficeEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Electronic office equipment</label>
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_LaboratoryInstrumentsMember" xlink:label="ganx_LaboratoryInstrumentsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ganx_LaboratoryInstrumentsMember" xlink:to="ganx_LaboratoryInstrumentsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ganx_LaboratoryInstrumentsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to Laboratory instruments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ganx_LaboratoryInstrumentsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Laboratory instruments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Assets by Major Class [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Assets, Major Class Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:label="us-gaap_ComputerSoftwareIntangibleAssetMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:to="us-gaap_ComputerSoftwareIntangibleAssetMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComputerSoftwareIntangibleAssetMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Computer Software, Intangible Asset [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComputerSoftwareIntangibleAssetMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capitalized Software</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and Equipment, net</label>
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_PropertyPlantAndEquipmentDepreciationRates" xlink:label="ganx_PropertyPlantAndEquipmentDepreciationRates" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ganx_PropertyPlantAndEquipmentDepreciationRates" xlink:to="ganx_PropertyPlantAndEquipmentDepreciationRates_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ganx_PropertyPlantAndEquipmentDepreciationRates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of depreciation on property plant and equipment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ganx_PropertyPlantAndEquipmentDepreciationRates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property Plant and Equipment, Depreciation Rates</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ganx_PropertyPlantAndEquipmentDepreciationRates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation rates (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedComputerSoftwareNet" xlink:label="us-gaap_CapitalizedComputerSoftwareNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalizedComputerSoftwareNet" xlink:to="us-gaap_CapitalizedComputerSoftwareNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalizedComputerSoftwareNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capitalized Computer Software, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CapitalizedComputerSoftwareNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Internal-use software</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedComputerSoftwareAdditions" xlink:label="us-gaap_CapitalizedComputerSoftwareAdditions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalizedComputerSoftwareAdditions" xlink:to="us-gaap_CapitalizedComputerSoftwareAdditions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalizedComputerSoftwareAdditions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capitalized Computer Software, Additions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CapitalizedComputerSoftwareAdditions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">External and internal labor costs incurred in the development stage of the Company ERP</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Asset, Useful Life</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetImpairmentCharges" xlink:to="us-gaap_AssetImpairmentCharges_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetImpairmentCharges_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Asset Impairment Charges</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetImpairmentCharges_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairments of long-lived assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dividend yield</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected dividend yield</label>
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_UncertainTaxPositionsRecognized" xlink:label="ganx_UncertainTaxPositionsRecognized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ganx_UncertainTaxPositionsRecognized" xlink:to="ganx_UncertainTaxPositionsRecognized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ganx_UncertainTaxPositionsRecognized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Carrying value of uncertain tax positions that the entity has recognized.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ganx_UncertainTaxPositionsRecognized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Uncertain tax positions recognized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DisaggregationOfRevenueTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisaggregationOfRevenueTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disaggregation of Revenue [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Legal Entity [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity [Domain]</label>
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_GtGainTherapeuticsSaMember" xlink:label="ganx_GtGainTherapeuticsSaMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ganx_GtGainTherapeuticsSaMember" xlink:to="ganx_GtGainTherapeuticsSaMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ganx_GtGainTherapeuticsSaMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to GT Gain Therapeutics SA</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ganx_GtGainTherapeuticsSaMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">GT Gain Therapeutics SA [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ganx_GtGainTherapeuticsSaMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">GT Gain Therapeutics SA</label>
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_ConsortiumWithGtGainTherapeuticsSaInstituteForResearchInBiomedicineAndNeuroSysSasMember" xlink:label="ganx_ConsortiumWithGtGainTherapeuticsSaInstituteForResearchInBiomedicineAndNeuroSysSasMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ganx_ConsortiumWithGtGainTherapeuticsSaInstituteForResearchInBiomedicineAndNeuroSysSasMember" xlink:to="ganx_ConsortiumWithGtGainTherapeuticsSaInstituteForResearchInBiomedicineAndNeuroSysSasMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ganx_ConsortiumWithGtGainTherapeuticsSaInstituteForResearchInBiomedicineAndNeuroSysSasMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to a consortium with GT Gain Therapeutics SA, Institute for Research in Biomedicine and Neuro-Sys SAS</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ganx_ConsortiumWithGtGainTherapeuticsSaInstituteForResearchInBiomedicineAndNeuroSysSasMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consortium with GT Gain Therapeutics SA, Institute for Research in Biomedicine and Neuro-Sys SAS [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ganx_ConsortiumWithGtGainTherapeuticsSaInstituteForResearchInBiomedicineAndNeuroSysSasMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consortium with GT Gain Therapeutics SA, Institute for Research in Biomedicine and Neuro-Sys SAS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CounterpartyNameAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Counterparty Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Counterparty Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_MichaelJ.FoxFoundationForParkinsonSResearchMjffMember" xlink:label="ganx_MichaelJ.FoxFoundationForParkinsonSResearchMjffMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ganx_MichaelJ.FoxFoundationForParkinsonSResearchMjffMember" xlink:to="ganx_MichaelJ.FoxFoundationForParkinsonSResearchMjffMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ganx_MichaelJ.FoxFoundationForParkinsonSResearchMjffMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to The Michael J. Fox Foundation for Parkinson's Research (MJFF)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ganx_MichaelJ.FoxFoundationForParkinsonSResearchMjffMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The Michael J. Fox Foundation for Parkinson's Research (MJFF) [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ganx_MichaelJ.FoxFoundationForParkinsonSResearchMjffMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The Michael J. Fox Foundation for Parkinson's Research (MJFF)</label>
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_Eurostars2Member" xlink:label="ganx_Eurostars2Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ganx_Eurostars2Member" xlink:to="ganx_Eurostars2Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ganx_Eurostars2Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to Eurostars-2</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ganx_Eurostars2Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Eurostars 2 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ganx_Eurostars2Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Eurostars-2</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisaggregationOfRevenueLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disaggregation of Revenue [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrantsReceivable" xlink:label="us-gaap_GrantsReceivable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrantsReceivable" xlink:to="us-gaap_GrantsReceivable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrantsReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grants Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GrantsReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research grants</label>
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_ReductionOfResearchAndDevelopmentExpensesThroughExpensesReimbursed" xlink:label="ganx_ReductionOfResearchAndDevelopmentExpensesThroughExpensesReimbursed" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ganx_ReductionOfResearchAndDevelopmentExpensesThroughExpensesReimbursed" xlink:to="ganx_ReductionOfResearchAndDevelopmentExpensesThroughExpensesReimbursed_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ganx_ReductionOfResearchAndDevelopmentExpensesThroughExpensesReimbursed_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The reduction of research and development expenses through expenses reimbursed</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ganx_ReductionOfResearchAndDevelopmentExpensesThroughExpensesReimbursed_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reduction of research and development expenses through expenses reimbursed</label>
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_ProceedsFromGrants" xlink:label="ganx_ProceedsFromGrants" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ganx_ProceedsFromGrants" xlink:to="ganx_ProceedsFromGrants_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ganx_ProceedsFromGrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from grants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ganx_ProceedsFromGrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from grants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Cash and Cash Equivalents [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_CashAndCashEquivalentsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashMember" xlink:label="us-gaap_CashMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashMember" xlink:to="us-gaap_CashMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Money Market</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems" xlink:label="us-gaap_CashAndCashEquivalentsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_CashAndCashEquivalentsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, cash equivalents and restricted cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCash" xlink:to="us-gaap_RestrictedCash_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCash_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedCash_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CurrencyAxis" xlink:label="srt_CurrencyAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CurrencyAxis" xlink:to="srt_CurrencyAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CurrencyAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Currency [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_AllCurrenciesDomain" xlink:label="currency_AllCurrenciesDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_AllCurrenciesDomain" xlink:to="currency_AllCurrenciesDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="currency_AllCurrenciesDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">All Currencies [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_CHF" xlink:label="currency_CHF" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_CHF" xlink:to="currency_CHF_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="currency_CHF_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CHF</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_EUR" xlink:label="currency_EUR" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_EUR" xlink:to="currency_EUR_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="currency_EUR_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">EUR</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_USD" xlink:label="currency_USD" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_USD" xlink:to="currency_USD_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="currency_USD_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">USD</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPrepaidExpenseCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Prepaid Expense, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid and deferred expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="us-gaap_OtherReceivablesNetCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivablesNetCurrent" xlink:to="us-gaap_OtherReceivablesNetCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherReceivablesNetCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Receivables, Net, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherReceivablesNetCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other receivable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidInsurance" xlink:to="us-gaap_PrepaidInsurance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidInsurance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid Insurance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PrepaidInsurance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid D&amp;O Insurance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Computer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Furniture and fixtures</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leasehold improvements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total property and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less: accumulated depreciation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisposals" xlink:label="us-gaap_PropertyPlantAndEquipmentDisposals" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisposals" xlink:to="us-gaap_PropertyPlantAndEquipmentDisposals_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisposals_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Disposals</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentDisposals_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disposals</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation, Depletion and Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment of Long-Lived Assets Held-for-use</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Lease, Description [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statistical Measurement [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statistical Measurement [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum</label>
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_OfficeSpaceViaSoaveN6LuganoSwitzerlandMember" xlink:label="ganx_OfficeSpaceViaSoaveN6LuganoSwitzerlandMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ganx_OfficeSpaceViaSoaveN6LuganoSwitzerlandMember" xlink:to="ganx_OfficeSpaceViaSoaveN6LuganoSwitzerlandMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ganx_OfficeSpaceViaSoaveN6LuganoSwitzerlandMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Office space, Via Soave n6 (Lugano, Switzerland)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ganx_OfficeSpaceViaSoaveN6LuganoSwitzerlandMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Office space, Via Soave n6 (Lugano, Switzerland) [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ganx_OfficeSpaceViaSoaveN6LuganoSwitzerlandMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Office space, Via Soave n6 (Lugano, Switzerland)</label>
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_OfficeSpaceViaPietroPeri9DLuganoSwitzerlandMember" xlink:label="ganx_OfficeSpaceViaPietroPeri9DLuganoSwitzerlandMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ganx_OfficeSpaceViaPietroPeri9DLuganoSwitzerlandMember" xlink:to="ganx_OfficeSpaceViaPietroPeri9DLuganoSwitzerlandMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ganx_OfficeSpaceViaPietroPeri9DLuganoSwitzerlandMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Office space, Via Pietro Peri, 9D (Lugano, Switzerland)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ganx_OfficeSpaceViaPietroPeri9DLuganoSwitzerlandMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Office Space Via Pietro Peri 9 D Lugano Switzerland [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ganx_OfficeSpaceViaPietroPeri9DLuganoSwitzerlandMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Office Space Via Pietro Peri 9 D (Lugano Switzerland)</label>
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_OfficeSpaceInBethesdaMarylandMember" xlink:label="ganx_OfficeSpaceInBethesdaMarylandMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ganx_OfficeSpaceInBethesdaMarylandMember" xlink:to="ganx_OfficeSpaceInBethesdaMarylandMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ganx_OfficeSpaceInBethesdaMarylandMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Office space in Bethesda, Maryland</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ganx_OfficeSpaceInBethesdaMarylandMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Office space in Bethesda, Maryland [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ganx_OfficeSpaceInBethesdaMarylandMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Office space in Bethesda, Maryland</label>
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_OfficeSpaceTorreDBuildingBarcelonaMember" xlink:label="ganx_OfficeSpaceTorreDBuildingBarcelonaMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ganx_OfficeSpaceTorreDBuildingBarcelonaMember" xlink:to="ganx_OfficeSpaceTorreDBuildingBarcelonaMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ganx_OfficeSpaceTorreDBuildingBarcelonaMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Office space, Torre D building (Barcelona)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ganx_OfficeSpaceTorreDBuildingBarcelonaMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Office space, Torre D building (Barcelona) [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ganx_OfficeSpaceTorreDBuildingBarcelonaMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Office space, Torre D building (Barcelona)</label>
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_OfficeSpaceTorreIBuildingBarcelonaMember" xlink:label="ganx_OfficeSpaceTorreIBuildingBarcelonaMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ganx_OfficeSpaceTorreIBuildingBarcelonaMember" xlink:to="ganx_OfficeSpaceTorreIBuildingBarcelonaMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ganx_OfficeSpaceTorreIBuildingBarcelonaMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Office space, Torre I building (Barcelona)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ganx_OfficeSpaceTorreIBuildingBarcelonaMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Office space, Torre I building (Barcelona) [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ganx_OfficeSpaceTorreIBuildingBarcelonaMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Office space, Torre I building (Barcelona)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Lease, Description [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:to="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Remaining Lease Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease remaining term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Term of Contract</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Renewal Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease renewal term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInSecurityDeposits" xlink:label="us-gaap_IncreaseDecreaseInSecurityDeposits" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInSecurityDeposits" xlink:to="us-gaap_IncreaseDecreaseInSecurityDeposits_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInSecurityDeposits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Security Deposits</label>
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_LesseeOperatingLeaseTermOfCancelledContract" xlink:label="ganx_LesseeOperatingLeaseTermOfCancelledContract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ganx_LesseeOperatingLeaseTermOfCancelledContract" xlink:to="ganx_LesseeOperatingLeaseTermOfCancelledContract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ganx_LesseeOperatingLeaseTermOfCancelledContract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term of lessee's cancelled operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ganx_LesseeOperatingLeaseTermOfCancelledContract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, term of cancelled contract</label>
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_OfficeSpace" xlink:label="ganx_OfficeSpace" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ganx_OfficeSpace" xlink:to="ganx_OfficeSpace_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ganx_OfficeSpace_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Office space, measured as an area</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ganx_OfficeSpace_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Office space</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Weighted Average Remaining Lease Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average remaining lease term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Weighted Average Discount Rate, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average discount rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Leases, Future Minimum Payments Due, Next Twelve Months</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2022</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Leases, Future Minimum Payments, Due in Two Years</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2023</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Leases, Future Minimum Payments, Due in Three Years</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2024</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Leases, Future Minimum Payments, Due in Four Years</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2025</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Leases, Future Minimum Payments, Due in Five Years</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2026</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Leases, Future Minimum Payments Due</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total future minimum lease payments</label>
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_AdjustmentToReconcileOperatingLeaseLiabilitiesAmountsRepresentingInterestOrImputedInterest" xlink:label="ganx_AdjustmentToReconcileOperatingLeaseLiabilitiesAmountsRepresentingInterestOrImputedInterest" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ganx_AdjustmentToReconcileOperatingLeaseLiabilitiesAmountsRepresentingInterestOrImputedInterest" xlink:to="ganx_AdjustmentToReconcileOperatingLeaseLiabilitiesAmountsRepresentingInterestOrImputedInterest_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ganx_AdjustmentToReconcileOperatingLeaseLiabilitiesAmountsRepresentingInterestOrImputedInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustment to reconcile operating lease liabilities, amounts representing interest or imputed interest not recognized in balance sheet.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ganx_AdjustmentToReconcileOperatingLeaseLiabilitiesAmountsRepresentingInterestOrImputedInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustment to reconcile operating lease liabilities, amounts representing interest or imputed interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ganx_AdjustmentToReconcileOperatingLeaseLiabilitiesAmountsRepresentingInterestOrImputedInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less amount representing interest or imputed interest</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Present value of lease liabilities</label>
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_AccountsPayableCurrentTable" xlink:label="ganx_AccountsPayableCurrentTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ganx_AccountsPayableCurrentTable" xlink:to="ganx_AccountsPayableCurrentTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ganx_AccountsPayableCurrentTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule that describes accounts payable current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ganx_AccountsPayableCurrentTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable Current [Table]</label>
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_AccountsPayableCurrentLineItems" xlink:label="ganx_AccountsPayableCurrentLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ganx_AccountsPayableCurrentLineItems" xlink:to="ganx_AccountsPayableCurrentLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ganx_AccountsPayableCurrentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ganx_AccountsPayableCurrentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable Current [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ganx_AccountsPayableCurrentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable</label>
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_PayableForSocialSecuritiesCurrent" xlink:label="ganx_PayableForSocialSecuritiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ganx_PayableForSocialSecuritiesCurrent" xlink:to="ganx_PayableForSocialSecuritiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ganx_PayableForSocialSecuritiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Carrying value as of the balance sheet date of obligations incurred and payable for current portion of payable for social securities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ganx_PayableForSocialSecuritiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payable for Social Securities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ganx_PayableForSocialSecuritiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payable for social securities</label>
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_AccruedPayrollCurrent" xlink:label="ganx_AccruedPayrollCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ganx_AccruedPayrollCurrent" xlink:to="ganx_AccruedPayrollCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ganx_AccruedPayrollCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Carrying value as of the balance sheet date of obligations incurred and payable for current portion of payroll.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ganx_AccruedPayrollCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Payroll Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ganx_AccruedPayrollCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued payroll</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued expenses</label>
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_DepositsCurrent" xlink:label="ganx_DepositsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ganx_DepositsCurrent" xlink:to="ganx_DepositsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ganx_DepositsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of current deposits.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ganx_DepositsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deposits, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ganx_DepositsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deposit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent" xlink:label="us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent" xlink:to="us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Credits and Other Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total Other Current Liabilities and Deferred Income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Defined Benefit Plans Disclosures [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis" xlink:label="us-gaap_RetirementPlanTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetirementPlanTypeAxis" xlink:to="us-gaap_RetirementPlanTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetirementPlanTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retirement Plan Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="us-gaap_RetirementPlanTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetirementPlanTypeDomain" xlink:to="us-gaap_RetirementPlanTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetirementPlanTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retirement Plan Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember" xlink:label="us-gaap_PensionPlansDefinedBenefitMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionPlansDefinedBenefitMember" xlink:to="us-gaap_PensionPlansDefinedBenefitMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PensionPlansDefinedBenefitMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pension Plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis" xlink:label="us-gaap_RetirementPlanSponsorLocationAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetirementPlanSponsorLocationAxis" xlink:to="us-gaap_RetirementPlanSponsorLocationAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetirementPlanSponsorLocationAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retirement Plan Sponsor Location [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain" xlink:label="us-gaap_RetirementPlanSponsorLocationDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetirementPlanSponsorLocationDomain" xlink:to="us-gaap_RetirementPlanSponsorLocationDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetirementPlanSponsorLocationDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retirement Plan Sponsor Location [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticPlanMember" xlink:label="us-gaap_DomesticPlanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticPlanMember" xlink:to="us-gaap_DomesticPlanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DomesticPlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Domestic Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DomesticPlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Domestic Plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_CH" xlink:label="country_CH" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_CH" xlink:to="country_CH_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_CH_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SWITZERLAND</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Benefit Plan Disclosure [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reconciliation of funded status</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:label="us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:to="us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Benefit Plan, Plan Assets, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value at December 31</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value at January 1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value of plan assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligation" xlink:label="us-gaap_DefinedBenefitPlanBenefitObligation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanBenefitObligation" xlink:to="us-gaap_DefinedBenefitPlanBenefitObligation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanBenefitObligation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Benefit Plan, Benefit Obligation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DefinedBenefitPlanBenefitObligation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">(Projected benefit obligation)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_DefinedBenefitPlanBenefitObligation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Projected benefit obligation at December 31</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_DefinedBenefitPlanBenefitObligation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Projected benefit obligation at January 1</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanFundedStatusOfPlan" xlink:label="us-gaap_DefinedBenefitPlanFundedStatusOfPlan" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanFundedStatusOfPlan" xlink:to="us-gaap_DefinedBenefitPlanFundedStatusOfPlan_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanFundedStatusOfPlan_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Benefit Plan, Funded (Unfunded) Status of Plan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_DefinedBenefitPlanFundedStatusOfPlan_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Funded status at end of year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_DefinedBenefitPlanFundedStatusOfPlan_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Funded status beginning of the year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DefinedBenefitPlanFundedStatusOfPlan_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Funded status</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation" xlink:label="us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation" xlink:to="us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Benefit Plan, Accumulated Benefit Obligation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumululated benefit obligation</label>
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_IncreaseDecreaseThroughTotalExpensesToReconcileFundedStatusOfDefinedBenefitPlan" xlink:label="ganx_IncreaseDecreaseThroughTotalExpensesToReconcileFundedStatusOfDefinedBenefitPlan" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ganx_IncreaseDecreaseThroughTotalExpensesToReconcileFundedStatusOfDefinedBenefitPlan" xlink:to="ganx_IncreaseDecreaseThroughTotalExpensesToReconcileFundedStatusOfDefinedBenefitPlan_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ganx_IncreaseDecreaseThroughTotalExpensesToReconcileFundedStatusOfDefinedBenefitPlan_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (decrease) through total expenses to reconcile funded status of defined benefit plan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ganx_IncreaseDecreaseThroughTotalExpensesToReconcileFundedStatusOfDefinedBenefitPlan_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (decrease) through total expenses to reconcile funded status of defined benefit plan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ganx_IncreaseDecreaseThroughTotalExpensesToReconcileFundedStatusOfDefinedBenefitPlan_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:label="us-gaap_DefinedBenefitPlanContributionsByEmployer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:to="us-gaap_DefinedBenefitPlanContributionsByEmployer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanContributionsByEmployer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Benefit Plan, Plan Assets, Contributions by Employer</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedBenefitPlanContributionsByEmployer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employer contributions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" xlink:label="us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" xlink:to="us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Benefit Plan, Plan Assets, Foreign Currency Translation Gain (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Translation difference</label>
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_IncreaseDecreaseInAccumulatedOtherComprehensiveIncomeToReconcileFundedStatusOfDefinedBenefitPlan" xlink:label="ganx_IncreaseDecreaseInAccumulatedOtherComprehensiveIncomeToReconcileFundedStatusOfDefinedBenefitPlan" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ganx_IncreaseDecreaseInAccumulatedOtherComprehensiveIncomeToReconcileFundedStatusOfDefinedBenefitPlan" xlink:to="ganx_IncreaseDecreaseInAccumulatedOtherComprehensiveIncomeToReconcileFundedStatusOfDefinedBenefitPlan_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ganx_IncreaseDecreaseInAccumulatedOtherComprehensiveIncomeToReconcileFundedStatusOfDefinedBenefitPlan_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (decrease) in accumulated other comprehensive income to reconcile funded status of defined benefit plan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ganx_IncreaseDecreaseInAccumulatedOtherComprehensiveIncomeToReconcileFundedStatusOfDefinedBenefitPlan_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (decrease) in accumulated other comprehensive income to reconcile funded status of defined benefit plan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ganx_IncreaseDecreaseInAccumulatedOtherComprehensiveIncomeToReconcileFundedStatusOfDefinedBenefitPlan_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in AOCI over the year</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanServiceCost" xlink:label="us-gaap_DefinedBenefitPlanServiceCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanServiceCost" xlink:to="us-gaap_DefinedBenefitPlanServiceCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanServiceCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Benefit Plan, Service Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedBenefitPlanServiceCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Services cost</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanInterestCost" xlink:label="us-gaap_DefinedBenefitPlanInterestCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanInterestCost" xlink:to="us-gaap_DefinedBenefitPlanInterestCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanInterestCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Benefit Plan, Interest Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedBenefitPlanInterestCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest cost</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:label="us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:to="us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Benefit Plan, Expected Return (Loss) on Plan Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected return on plan asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected return on plan assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:label="us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:to="us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Benefit Plan, Amortization of Gain (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization of (gain)/losses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization of (gain)/losses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net gain/(loss) amortized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:label="us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:to="us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Benefit Plan, Amortization of Prior Service Cost (Credit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization of prior year service cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net prior service (cost)/credit amortized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:label="us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:to="us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Benefit Plan, Net Periodic Benefit Cost (Credit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant" xlink:label="us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant" xlink:to="us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Benefit Plan, Benefit Obligation, Contributions by Plan Participant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee contribution</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid" xlink:label="us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid" xlink:to="us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Benefit Plan, Benefit Obligation, Benefits Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Benefit payments</label>
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_DefinedBenefitPlanBenefitObligationGainsLossesOnFinancialAssumptions" xlink:label="ganx_DefinedBenefitPlanBenefitObligationGainsLossesOnFinancialAssumptions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ganx_DefinedBenefitPlanBenefitObligationGainsLossesOnFinancialAssumptions" xlink:to="ganx_DefinedBenefitPlanBenefitObligationGainsLossesOnFinancialAssumptions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ganx_DefinedBenefitPlanBenefitObligationGainsLossesOnFinancialAssumptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of gains (losses) on financial assumptions by defined benefit plan which decreases (increases) benefit obligation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ganx_DefinedBenefitPlanBenefitObligationGainsLossesOnFinancialAssumptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Benefit Plan, Benefit Obligation, Gains (Losses) on financial assumptions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ganx_DefinedBenefitPlanBenefitObligationGainsLossesOnFinancialAssumptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">(Gain)/loss on financial assumption</label>
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_DefinedBenefitPlanBenefitObligationGainsLossesOnDemographicAssumptions" xlink:label="ganx_DefinedBenefitPlanBenefitObligationGainsLossesOnDemographicAssumptions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ganx_DefinedBenefitPlanBenefitObligationGainsLossesOnDemographicAssumptions" xlink:to="ganx_DefinedBenefitPlanBenefitObligationGainsLossesOnDemographicAssumptions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ganx_DefinedBenefitPlanBenefitObligationGainsLossesOnDemographicAssumptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of gains (losses) on demographic assumptions by defined benefit plan which decreases (increases) benefit obligation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ganx_DefinedBenefitPlanBenefitObligationGainsLossesOnDemographicAssumptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Benefit Plan, Benefit Obligation, Gains (Losses) on demographic assumptions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ganx_DefinedBenefitPlanBenefitObligationGainsLossesOnDemographicAssumptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">(Gain)/loss on demographic assumption</label>
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_DefinedBenefitPlanBenefitObligationGainsLossesOnExperience" xlink:label="ganx_DefinedBenefitPlanBenefitObligationGainsLossesOnExperience" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ganx_DefinedBenefitPlanBenefitObligationGainsLossesOnExperience" xlink:to="ganx_DefinedBenefitPlanBenefitObligationGainsLossesOnExperience_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ganx_DefinedBenefitPlanBenefitObligationGainsLossesOnExperience_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of gains (losses) on experience by defined benefit plan which decreases (increases) benefit obligation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ganx_DefinedBenefitPlanBenefitObligationGainsLossesOnExperience_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Benefit Plan, Benefit Obligation, Gains (Losses) on experience</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ganx_DefinedBenefitPlanBenefitObligationGainsLossesOnExperience_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">(Gain)/loss on experience</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPlanAmendments" xlink:label="us-gaap_DefinedBenefitPlanPlanAmendments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanPlanAmendments" xlink:to="us-gaap_DefinedBenefitPlanPlanAmendments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanPlanAmendments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Benefit Plan, Benefit Obligation, Increase (Decrease) for Plan Amendment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedBenefitPlanPlanAmendments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Plan Amendment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets" xlink:label="us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets" xlink:to="us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gain/(loss) on plan assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant" xlink:label="us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant" xlink:to="us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Benefit Plan, Plan Assets, Contributions by Plan Participant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee contributions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid" xlink:label="us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid" xlink:to="us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Benefit Plan, Plan Assets, Benefits Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Benefit payments</label>
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_DefinedBenefitPlanPlanAssetsOtherIncreasesDecreases" xlink:label="ganx_DefinedBenefitPlanPlanAssetsOtherIncreasesDecreases" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ganx_DefinedBenefitPlanPlanAssetsOtherIncreasesDecreases" xlink:to="ganx_DefinedBenefitPlanPlanAssetsOtherIncreasesDecreases_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ganx_DefinedBenefitPlanPlanAssetsOtherIncreasesDecreases_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of other changes to the plan assets in a defined benefit plan which increases (decreases) plan assets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ganx_DefinedBenefitPlanPlanAssetsOtherIncreasesDecreases_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Benefit Plan, Plan Assets, other increases (decreases)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ganx_DefinedBenefitPlanPlanAssetsOtherIncreasesDecreases_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Others</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax" xlink:label="us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax" xlink:to="us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), after Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">(Gain)/loss at end of year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">(Gain)/loss at beginning of year</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligationPeriodIncreaseDecrease" xlink:label="us-gaap_DefinedBenefitPlanBenefitObligationPeriodIncreaseDecrease" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanBenefitObligationPeriodIncreaseDecrease" xlink:to="us-gaap_DefinedBenefitPlanBenefitObligationPeriodIncreaseDecrease_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanBenefitObligationPeriodIncreaseDecrease_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Benefit Plan, Benefit Obligation, Period Increase (Decrease)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedBenefitPlanBenefitObligationPeriodIncreaseDecrease_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">(Gain)/loss on PBO during year</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssetsPeriodIncreaseDecrease" xlink:label="us-gaap_DefinedBenefitPlanFairValueOfPlanAssetsPeriodIncreaseDecrease" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanFairValueOfPlanAssetsPeriodIncreaseDecrease" xlink:to="us-gaap_DefinedBenefitPlanFairValueOfPlanAssetsPeriodIncreaseDecrease_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanFairValueOfPlanAssetsPeriodIncreaseDecrease_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Benefit Plan, Plan Assets, Period Increase (Decrease)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedBenefitPlanFairValueOfPlanAssetsPeriodIncreaseDecrease_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">(Gain)/loss on assets during year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DefinedBenefitPlanFairValueOfPlanAssetsPeriodIncreaseDecrease_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">(Gain)/loss on assets during the year</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total AOCI at end of year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">AOCI at beginning of year</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" xlink:label="us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" xlink:to="us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), after Reclassification Adjustment, before Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prior Service Cost/(credit) occurring over the year</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedInCalculationsAbstract" xlink:label="us-gaap_DefinedBenefitPlanAssumptionsUsedInCalculationsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanAssumptionsUsedInCalculationsAbstract" xlink:to="us-gaap_DefinedBenefitPlanAssumptionsUsedInCalculationsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanAssumptionsUsedInCalculationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Benefit Plan, Assumptions Used in Calculations [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedBenefitPlanAssumptionsUsedInCalculationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial and Demographic Assumptions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" xlink:label="us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" xlink:to="us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Discount rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate" xlink:label="us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate" xlink:to="us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Weighted-Average Interest Crediting Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest credit rate / ERoA</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" xlink:label="us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" xlink:to="us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Rate of Compensation Increase</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Salary increases</label>
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfPensionIncreases" xlink:label="ganx_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfPensionIncreases" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ganx_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfPensionIncreases" xlink:to="ganx_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfPensionIncreases_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ganx_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfPensionIncreases_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average rate increase of pension, used to determine benefit obligation of defined benefit plan. Plan includes, but is not limited to, pension-related defined benefit plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ganx_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfPensionIncreases_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Rate of Pension Increases</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ganx_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfPensionIncreases_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pension increases</label>
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_DefinedBenefitPlanDemographicAssumptionLumpSumOption" xlink:label="ganx_DefinedBenefitPlanDemographicAssumptionLumpSumOption" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ganx_DefinedBenefitPlanDemographicAssumptionLumpSumOption" xlink:to="ganx_DefinedBenefitPlanDemographicAssumptionLumpSumOption_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ganx_DefinedBenefitPlanDemographicAssumptionLumpSumOption_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Demographic assumption of lumpsum option under the defined benefit plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ganx_DefinedBenefitPlanDemographicAssumptionLumpSumOption_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Benefit Plan, Demographic Assumption Lump Sum Option</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ganx_DefinedBenefitPlanDemographicAssumptionLumpSumOption_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lump-sum option</label>
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_DefinedBenefitPlanDemographicAssumptionProportionMarried" xlink:label="ganx_DefinedBenefitPlanDemographicAssumptionProportionMarried" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ganx_DefinedBenefitPlanDemographicAssumptionProportionMarried" xlink:to="ganx_DefinedBenefitPlanDemographicAssumptionProportionMarried_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ganx_DefinedBenefitPlanDemographicAssumptionProportionMarried_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Demographic assumption of proportion of married persons under the defined benefit pension plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ganx_DefinedBenefitPlanDemographicAssumptionProportionMarried_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Benefit Plan, Demographic Assumption, Proportion Married</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ganx_DefinedBenefitPlanDemographicAssumptionProportionMarried_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proportion married</label>
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_DefinedBenefitPlanDemographicAssumptionAllowanceForChildPensions" xlink:label="ganx_DefinedBenefitPlanDemographicAssumptionAllowanceForChildPensions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ganx_DefinedBenefitPlanDemographicAssumptionAllowanceForChildPensions" xlink:to="ganx_DefinedBenefitPlanDemographicAssumptionAllowanceForChildPensions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ganx_DefinedBenefitPlanDemographicAssumptionAllowanceForChildPensions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Demographic assumption of allowance for child pensions  under the defined benefit pension plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ganx_DefinedBenefitPlanDemographicAssumptionAllowanceForChildPensions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Benefit Plan, Demographic Assumption, Allowance for Child Pensions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ganx_DefinedBenefitPlanDemographicAssumptionAllowanceForChildPensions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Allowance for child pensions</label>
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_DefinedBenefitPlanMortalityImprovementPercentage" xlink:label="ganx_DefinedBenefitPlanMortalityImprovementPercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ganx_DefinedBenefitPlanMortalityImprovementPercentage" xlink:to="ganx_DefinedBenefitPlanMortalityImprovementPercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ganx_DefinedBenefitPlanMortalityImprovementPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Mortality improvement percentage in a defined benefit plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ganx_DefinedBenefitPlanMortalityImprovementPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Benefit Plan, Mortality Improvement Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ganx_DefinedBenefitPlanMortalityImprovementPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Longevity improvement</label>
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_DefinedBenefitPlanDisabilityPercentage" xlink:label="ganx_DefinedBenefitPlanDisabilityPercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ganx_DefinedBenefitPlanDisabilityPercentage" xlink:to="ganx_DefinedBenefitPlanDisabilityPercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ganx_DefinedBenefitPlanDisabilityPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disability percentage in a defined benefit plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ganx_DefinedBenefitPlanDisabilityPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Benefit Plan, Disability Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ganx_DefinedBenefitPlanDisabilityPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disability</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" xlink:label="us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" xlink:to="us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Benefit Plan, Expected Future Benefit Payment, Year One</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Year 1</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" xlink:label="us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" xlink:to="us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Benefit Plan, Expected Future Benefit Payment, Year Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Year 2</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" xlink:label="us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" xlink:to="us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Benefit Plan, Expected Future Benefit Payment, Year Three</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Year 3</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" xlink:label="us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" xlink:to="us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Benefit Plan, Expected Future Benefit Payment, Year Four</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Year 4</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" xlink:label="us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" xlink:to="us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Benefit Plan, Expected Future Benefit Payment, Year Five</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Year 5</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" xlink:label="us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" xlink:to="us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Benefit Plan, Expected Future Benefit Payment, after Year Five for Next Five Years</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Next 5 years</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" xlink:label="us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" xlink:to="us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Benefit Plan, Expected Future Employer Contributions, Next Fiscal Year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Next year's expected employer contribution</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Contribution Plan, Employer Discretionary Contribution Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expenses related to savings plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Long-term Debt Instruments [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_March2020ChfLoanMember" xlink:label="ganx_March2020ChfLoanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ganx_March2020ChfLoanMember" xlink:to="ganx_March2020ChfLoanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ganx_March2020ChfLoanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">March 2020 CHF loan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ganx_March2020ChfLoanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">March 2020 CHF loan</label>
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_August2020ChfLoanMember" xlink:label="ganx_August2020ChfLoanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ganx_August2020ChfLoanMember" xlink:to="ganx_August2020ChfLoanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ganx_August2020ChfLoanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">August 2020 CHF loan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ganx_August2020ChfLoanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">August 2020 CHF loan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Face Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loan amount</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTerm" xlink:to="us-gaap_DebtInstrumentTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term of loan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Interest Rate, Stated Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest rate (as a percent)</label>
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_ExpensesOrChargesDueForEarlyExtinguishmentOfDebt" xlink:label="ganx_ExpensesOrChargesDueForEarlyExtinguishmentOfDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ganx_ExpensesOrChargesDueForEarlyExtinguishmentOfDebt" xlink:to="ganx_ExpensesOrChargesDueForEarlyExtinguishmentOfDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ganx_ExpensesOrChargesDueForEarlyExtinguishmentOfDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of expenses or charges due for early extinguishment of debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ganx_ExpensesOrChargesDueForEarlyExtinguishmentOfDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expenses or charges due for early extinguishment of debt</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="us-gaap_DebtInstrumentPeriodicPayment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentPeriodicPayment" xlink:to="us-gaap_DebtInstrumentPeriodicPayment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentPeriodicPayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Periodic Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentPeriodicPayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loan is due in quarterly installments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest Expense, Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InterestExpenseDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LongTermDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Term Debt, Maturity, Year One</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2022</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Term Debt, Maturity, Year Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2023</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Term Debt, Maturity, Year Three</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2024</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Term Debt, Maturity, Year Four</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2025</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Term Debt, Maturity, Year Five</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2026</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Term Debt, Maturity, after Year Five</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Thereafter</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Hierarchy and NAV [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Hierarchy and NAV [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Inputs, Level 1 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Level 1</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueByAssetClassAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Asset Class [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Asset Class [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsMember" xlink:label="us-gaap_CashAndCashEquivalentsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsMember" xlink:to="us-gaap_CashAndCashEquivalentsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Fair Value Disclosure</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right [Domain]</label>
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_WarrantsToDesigneesOfPlacementAgentIssuedJuly2020Member" xlink:label="ganx_WarrantsToDesigneesOfPlacementAgentIssuedJuly2020Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ganx_WarrantsToDesigneesOfPlacementAgentIssuedJuly2020Member" xlink:to="ganx_WarrantsToDesigneesOfPlacementAgentIssuedJuly2020Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ganx_WarrantsToDesigneesOfPlacementAgentIssuedJuly2020Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants to designees of the placement agent, issued July 2020</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ganx_WarrantsToDesigneesOfPlacementAgentIssuedJuly2020Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants to designees of the placement agent, issued July 2020</label>
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_WarrantsToDesigneesOfInvestmentBankIssuedMay2021Member" xlink:label="ganx_WarrantsToDesigneesOfInvestmentBankIssuedMay2021Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ganx_WarrantsToDesigneesOfInvestmentBankIssuedMay2021Member" xlink:to="ganx_WarrantsToDesigneesOfInvestmentBankIssuedMay2021Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ganx_WarrantsToDesigneesOfInvestmentBankIssuedMay2021Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants to designees of investment bank, issued May 2021</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ganx_WarrantsToDesigneesOfInvestmentBankIssuedMay2021Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants to designees of investment bank, issued May 2021</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants to purchase common stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants exercise price</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstanding" xlink:to="us-gaap_WarrantsAndRightsOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants and Rights Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants and Rights Outstanding, Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Outstanding</label>
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_WarrantsAndRightsExercisedOrExchangedNumber" xlink:label="ganx_WarrantsAndRightsExercisedOrExchangedNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ganx_WarrantsAndRightsExercisedOrExchangedNumber" xlink:to="ganx_WarrantsAndRightsExercisedOrExchangedNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ganx_WarrantsAndRightsExercisedOrExchangedNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of warrants or rights exercised or exchanged.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ganx_WarrantsAndRightsExercisedOrExchangedNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants and Rights, Exercised or Exchanged, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ganx_WarrantsAndRightsExercisedOrExchangedNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants exercised or exchanged</label>
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_WarrantsAndRightsServicePeriod" xlink:label="ganx_WarrantsAndRightsServicePeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ganx_WarrantsAndRightsServicePeriod" xlink:to="ganx_WarrantsAndRightsServicePeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ganx_WarrantsAndRightsServicePeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Service period for fair value of the warrants to be recognized.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ganx_WarrantsAndRightsServicePeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants and Rights, Service Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ganx_WarrantsAndRightsServicePeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants, Service period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Input Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Input Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Volatility</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedTermMember" xlink:to="us-gaap_MeasurementInputExpectedTermMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExpectedTermMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Risk-free interest rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationTechniqueAxis" xlink:label="us-gaap_ValuationTechniqueAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationTechniqueAxis" xlink:to="us-gaap_ValuationTechniqueAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationTechniqueAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valuation Approach and Technique [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="us-gaap_ValuationTechniqueDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationTechniqueDomain" xlink:to="us-gaap_ValuationTechniqueDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationTechniqueDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valuation Approach and Technique [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationTechniqueOptionPricingModelMember" xlink:label="us-gaap_ValuationTechniqueOptionPricingModelMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationTechniqueOptionPricingModelMember" xlink:to="us-gaap_ValuationTechniqueOptionPricingModelMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationTechniqueOptionPricingModelMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valuation Technique, Option Pricing Model [Member]</label>
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_WarrantsGrantDateFairValue" xlink:label="ganx_WarrantsGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ganx_WarrantsGrantDateFairValue" xlink:to="ganx_WarrantsGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ganx_WarrantsGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The grant date fair value of warrants granted during period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ganx_WarrantsGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants, grant date fair value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ganx_WarrantsGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grant date fair value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants and Rights Outstanding, Measurement Input</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Plan Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Plan Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_OmnibusIncentivePlanTwoThousandTwentyMember" xlink:label="ganx_OmnibusIncentivePlanTwoThousandTwentyMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ganx_OmnibusIncentivePlanTwoThousandTwentyMember" xlink:to="ganx_OmnibusIncentivePlanTwoThousandTwentyMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ganx_OmnibusIncentivePlanTwoThousandTwentyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to Omnibus Incentive Plan 2020.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ganx_OmnibusIncentivePlanTwoThousandTwentyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2020 Omnibus Plan</label>
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_TwentyTwentyoneInducementEquityIncentivePlanMember" xlink:label="ganx_TwentyTwentyoneInducementEquityIncentivePlanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ganx_TwentyTwentyoneInducementEquityIncentivePlanMember" xlink:to="ganx_TwentyTwentyoneInducementEquityIncentivePlanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ganx_TwentyTwentyoneInducementEquityIncentivePlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to the 2021 Inducement Equity Incentive Plan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ganx_TwentyTwentyoneInducementEquityIncentivePlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Twenty-twentyone Inducement Equity Incentive Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ganx_TwentyTwentyoneInducementEquityIncentivePlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2021 Inducement Equity Incentive Plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Incentive Plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Capital Shares Reserved for Future Issuance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum number of shares available to be issued</label>
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_NumberOfOptionsSubjectToTermThreshold" xlink:label="ganx_NumberOfOptionsSubjectToTermThreshold" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ganx_NumberOfOptionsSubjectToTermThreshold" xlink:to="ganx_NumberOfOptionsSubjectToTermThreshold_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ganx_NumberOfOptionsSubjectToTermThreshold_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number of options subject to the term threshold.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ganx_NumberOfOptionsSubjectToTermThreshold_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Options Subject To Term Threshold</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ganx_NumberOfOptionsSubjectToTermThreshold_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of options subject to term threshold</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Award Expiry term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum number of shares reserved for issuance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise prices upper limit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise price</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options outstanding as at end of period (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding as at beginning of period (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number outstanding</label>
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAfterStockSplitsNumber" xlink:label="ganx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAfterStockSplitsNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ganx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAfterStockSplitsNumber" xlink:to="ganx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAfterStockSplitsNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ganx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAfterStockSplitsNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of options outstanding after stock split, including both vested and non-vested options.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ganx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAfterStockSplitsNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, After Stock Splits Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ganx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAfterStockSplitsNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options outstanding after stock splits (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options granted (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options cancelled/forfeited (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Grant Date Fair Value</label>
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionNonvestedWeightedAverageExercisePriceAfterStockSplit" xlink:label="ganx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionNonvestedWeightedAverageExercisePriceAfterStockSplit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ganx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionNonvestedWeightedAverageExercisePriceAfterStockSplit" xlink:to="ganx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionNonvestedWeightedAverageExercisePriceAfterStockSplit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ganx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionNonvestedWeightedAverageExercisePriceAfterStockSplit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average grant-date fair value of non-vested options outstanding after stock split.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ganx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionNonvestedWeightedAverageExercisePriceAfterStockSplit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price, after stock split</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ganx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionNonvestedWeightedAverageExercisePriceAfterStockSplit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Grant Date Fair Value, options outstanding after stock split</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Grant Date Fair Value, options granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grant date fair value</label>
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedDuringPeriodWeightedAverageGrantDateFairValue" xlink:label="ganx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedDuringPeriodWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ganx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedDuringPeriodWeightedAverageGrantDateFairValue" xlink:to="ganx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedDuringPeriodWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ganx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedDuringPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The weighted average grant-date fair value of options exercised during the reporting period as calculated by applying the disclosed option pricing methodology.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ganx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedDuringPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, exercised during the period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ganx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedDuringPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Grant Date Fair Value, options exercised</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Grant Date Fair Value, options cancelled/forfeited</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Grant Date Fair Value, options outstanding as of December 31</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Grant Date Fair Value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Exercise Price</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options outstanding as at end of period (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding as at beginning of period (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Exercise Price</label>
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAfterStockSplitsWeightedAverageExercisePrice" xlink:label="ganx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAfterStockSplitsWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ganx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAfterStockSplitsWeightedAverageExercisePrice" xlink:to="ganx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAfterStockSplitsWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ganx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAfterStockSplitsWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average price at which grantees can acquire the shares reserved for issuance after stock split under the stock option plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ganx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAfterStockSplitsWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, After Stock Splits Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ganx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAfterStockSplitsWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options outstanding after stock splits (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options granted (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options exercised (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options cancelled/forfeited (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional disclosures</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted- Average Years Remaining on Contractual Life</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Remaining Contractual Years Outstanding</label>
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAfterStockSplitWeightedAverageRemainingContractualTerm" xlink:label="ganx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAfterStockSplitWeightedAverageRemainingContractualTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ganx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAfterStockSplitWeightedAverageRemainingContractualTerm" xlink:to="ganx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAfterStockSplitWeightedAverageRemainingContractualTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ganx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAfterStockSplitWeightedAverageRemainingContractualTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average remaining contractual term for option awards outstanding after stock splits, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ganx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAfterStockSplitWeightedAverageRemainingContractualTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, After Stock Split Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ganx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAfterStockSplitWeightedAverageRemainingContractualTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Remaining Contractual Years Outstanding Options outstanding after stock splits</label>
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" xlink:label="ganx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ganx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" xlink:to="ganx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ganx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average remaining contractual term for option awards granted, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ganx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement By Share Based Payment Award Options Granted, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ganx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Remaining Contractual Years Options granted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate Intrinsic Value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price Range [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price Range [Domain]</label>
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_ExercisePrice3.38Member" xlink:label="ganx_ExercisePrice3.38Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ganx_ExercisePrice3.38Member" xlink:to="ganx_ExercisePrice3.38Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ganx_ExercisePrice3.38Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to exercise price 3.38.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ganx_ExercisePrice3.38Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">$3.38</label>
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_ExercisePrice5.86Member" xlink:label="ganx_ExercisePrice5.86Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ganx_ExercisePrice5.86Member" xlink:to="ganx_ExercisePrice5.86Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ganx_ExercisePrice5.86Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to exercise price 5.86.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ganx_ExercisePrice5.86Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">$5.86</label>
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_ExercisePrice5.99Member" xlink:label="ganx_ExercisePrice5.99Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ganx_ExercisePrice5.99Member" xlink:to="ganx_ExercisePrice5.99Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ganx_ExercisePrice5.99Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to exercise price 5.99.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ganx_ExercisePrice5.99Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">$5.99</label>
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_ExercisePrice7.80Member" xlink:label="ganx_ExercisePrice7.80Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ganx_ExercisePrice7.80Member" xlink:to="ganx_ExercisePrice7.80Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ganx_ExercisePrice7.80Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price 7.80</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ganx_ExercisePrice7.80Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">$7.80</label>
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_ExercisePrice10.03Member" xlink:label="ganx_ExercisePrice10.03Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ganx_ExercisePrice10.03Member" xlink:to="ganx_ExercisePrice10.03Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ganx_ExercisePrice10.03Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to exercise price 10.03.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ganx_ExercisePrice10.03Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">$10.03</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number exercisable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Exercise Price</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total unrecognized compensation cost related to non-vested stock options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized compensation recognition period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Volatility</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected term (years)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Risk-free interest rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Statement Location [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Statement Location [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and administrative</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total stock-based compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</label>
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_MultiTargetCollaborationAgreementMember" xlink:label="ganx_MultiTargetCollaborationAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ganx_MultiTargetCollaborationAgreementMember" xlink:to="ganx_MultiTargetCollaborationAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ganx_MultiTargetCollaborationAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information relating to Multi-target collaboration agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ganx_MultiTargetCollaborationAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Multi-target collaboration agreement</label>
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_ZentalisPharmaceuticalsInc.Member" xlink:label="ganx_ZentalisPharmaceuticalsInc.Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ganx_ZentalisPharmaceuticalsInc.Member" xlink:to="ganx_ZentalisPharmaceuticalsInc.Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ganx_ZentalisPharmaceuticalsInc.Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information relating to Zentalis Pharmaceuticals, Inc.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ganx_ZentalisPharmaceuticalsInc.Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Zentalis Pharmaceuticals, Inc.</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration Agreement</label>
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_CollaborativeArrangementMinimumNumberOfTargets" xlink:label="ganx_CollaborativeArrangementMinimumNumberOfTargets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ganx_CollaborativeArrangementMinimumNumberOfTargets" xlink:to="ganx_CollaborativeArrangementMinimumNumberOfTargets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ganx_CollaborativeArrangementMinimumNumberOfTargets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum number of targets mutually agreed per agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ganx_CollaborativeArrangementMinimumNumberOfTargets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement, Minimum Number of targets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ganx_CollaborativeArrangementMinimumNumberOfTargets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of targets</label>
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_CollaborativeArrangementTerminationNoticePeriodDays" xlink:label="ganx_CollaborativeArrangementTerminationNoticePeriodDays" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ganx_CollaborativeArrangementTerminationNoticePeriodDays" xlink:to="ganx_CollaborativeArrangementTerminationNoticePeriodDays_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ganx_CollaborativeArrangementTerminationNoticePeriodDays_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Notice period days for agreement termination.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ganx_CollaborativeArrangementTerminationNoticePeriodDays_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement, Termination , Notice Period Days</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ganx_CollaborativeArrangementTerminationNoticePeriodDays_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Agreement termination notice period days</label>
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_CollaborativeArrangementProgramInitiationFee" xlink:label="ganx_CollaborativeArrangementProgramInitiationFee" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ganx_CollaborativeArrangementProgramInitiationFee" xlink:to="ganx_CollaborativeArrangementProgramInitiationFee_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ganx_CollaborativeArrangementProgramInitiationFee_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of first target development program initiation fees receivable per terms of agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ganx_CollaborativeArrangementProgramInitiationFee_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement, Program Initiation Fee</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ganx_CollaborativeArrangementProgramInitiationFee_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">First target development program initiation fees</label>
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_CollaborativeArrangementEmployeeAndExternalResearchAndDevelopmentCosts" xlink:label="ganx_CollaborativeArrangementEmployeeAndExternalResearchAndDevelopmentCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ganx_CollaborativeArrangementEmployeeAndExternalResearchAndDevelopmentCosts" xlink:to="ganx_CollaborativeArrangementEmployeeAndExternalResearchAndDevelopmentCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ganx_CollaborativeArrangementEmployeeAndExternalResearchAndDevelopmentCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of first target development program reimbursement for employee and external research and development costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ganx_CollaborativeArrangementEmployeeAndExternalResearchAndDevelopmentCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement, Employee and External Research and Development Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ganx_CollaborativeArrangementEmployeeAndExternalResearchAndDevelopmentCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee and external research and development cost</label>
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_CollaborativeArrangementOptionExerciseFee" xlink:label="ganx_CollaborativeArrangementOptionExerciseFee" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ganx_CollaborativeArrangementOptionExerciseFee" xlink:to="ganx_CollaborativeArrangementOptionExerciseFee_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ganx_CollaborativeArrangementOptionExerciseFee_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of first target development program option exercise fee.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ganx_CollaborativeArrangementOptionExerciseFee_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement, Option Exercise Fee</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ganx_CollaborativeArrangementOptionExerciseFee_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Option exercise fees</label>
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_CollaborativeArrangementEventBasedMilestonePayments" xlink:label="ganx_CollaborativeArrangementEventBasedMilestonePayments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ganx_CollaborativeArrangementEventBasedMilestonePayments" xlink:to="ganx_CollaborativeArrangementEventBasedMilestonePayments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ganx_CollaborativeArrangementEventBasedMilestonePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of first target development program event-based milestone payments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ganx_CollaborativeArrangementEventBasedMilestonePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement, Event Based Milestone Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ganx_CollaborativeArrangementEventBasedMilestonePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Event-based milestone payments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="us-gaap_RevenueRemainingPerformanceObligation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRemainingPerformanceObligation" xlink:to="us-gaap_RevenueRemainingPerformanceObligation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRemainingPerformanceObligation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue, Remaining Performance Obligation, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueRemainingPerformanceObligation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unsatisfied performance obligation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiability" xlink:to="us-gaap_ContractWithCustomerLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract with Customer, Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred revenue</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Components of income (loss) before income taxes provision</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income (Loss) from Continuing Operations before Income Taxes, Domestic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Domestic</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income (Loss) from Continuing Operations before Income Taxes, Foreign</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Components of Income Tax Expense (Benefit), Continuing Operations [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Components of income tax expense (benefit)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current Foreign Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Authority [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Authority [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCountryMember" xlink:to="us-gaap_ForeignCountryMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCountryMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DomesticCountryMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Domestic</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total NOLs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Components of Deferred Tax Assets and Liabilities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Components of deferred tax assets and liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Components of Deferred Tax Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax assets related to:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Operating Loss Carryforwards, Foreign</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net operating loss (foreign)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Operating Loss Carryforwards, Domestic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net operating loss (domestic)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock based compensation</label>
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_DeferredTaxAssetsFmwWarrant" xlink:label="ganx_DeferredTaxAssetsFmwWarrant" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ganx_DeferredTaxAssetsFmwWarrant" xlink:to="ganx_DeferredTaxAssetsFmwWarrant_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ganx_DeferredTaxAssetsFmwWarrant_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from fmw warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ganx_DeferredTaxAssetsFmwWarrant_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Fmw Warrant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ganx_DeferredTaxAssetsFmwWarrant_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other temporary differences</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total deferred tax assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Components of Deferred Tax Liabilities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Liabilities, Property, Plant and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation and other</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Liabilities, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total deferred tax liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valuation allowance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net deferred tax assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementGeographicalAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Geographical [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_SegmentGeographicalDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Geographical [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_ES" xlink:label="country_ES" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_ES" xlink:to="country_ES_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_ES_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Spain</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective tax rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective income tax rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued interest or penalties</label>
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_ExpenseForInterestAndPenaltiesRelatedToUncertainTaxPositionRecognizedInStatementOfOperations" xlink:label="ganx_ExpenseForInterestAndPenaltiesRelatedToUncertainTaxPositionRecognizedInStatementOfOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ganx_ExpenseForInterestAndPenaltiesRelatedToUncertainTaxPositionRecognizedInStatementOfOperations" xlink:to="ganx_ExpenseForInterestAndPenaltiesRelatedToUncertainTaxPositionRecognizedInStatementOfOperations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ganx_ExpenseForInterestAndPenaltiesRelatedToUncertainTaxPositionRecognizedInStatementOfOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expense for interest and penalties related to uncertain tax position, recognized in statement of operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ganx_ExpenseForInterestAndPenaltiesRelatedToUncertainTaxPositionRecognizedInStatementOfOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expense for interest and penalties related to uncertain tax position, recognized in statement of operations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Percent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income tax rate reconciliation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Federal income tax at US statutory rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State income taxes, net of federal benefit</label>
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_EffectiveIncomeTaxRateReconciliationPermanentDifferences" xlink:label="ganx_EffectiveIncomeTaxRateReconciliationPermanentDifferences" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ganx_EffectiveIncomeTaxRateReconciliationPermanentDifferences" xlink:to="ganx_EffectiveIncomeTaxRateReconciliationPermanentDifferences_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ganx_EffectiveIncomeTaxRateReconciliationPermanentDifferences_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations attributable to permanent differences.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ganx_EffectiveIncomeTaxRateReconciliationPermanentDifferences_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Permanent Differences</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ganx_EffectiveIncomeTaxRateReconciliationPermanentDifferences_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Permanent differences</label>
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_EffectiveIncomeTaxRateReconciliationProvisionToReturn" xlink:label="ganx_EffectiveIncomeTaxRateReconciliationProvisionToReturn" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ganx_EffectiveIncomeTaxRateReconciliationProvisionToReturn" xlink:to="ganx_EffectiveIncomeTaxRateReconciliationProvisionToReturn_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ganx_EffectiveIncomeTaxRateReconciliationProvisionToReturn_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations attributable to provision to return.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ganx_EffectiveIncomeTaxRateReconciliationProvisionToReturn_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Provision to Return</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ganx_EffectiveIncomeTaxRateReconciliationProvisionToReturn_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Provision to return</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign tax</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valuation allowance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options to purchase common stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants to purchase common stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RestatementAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revision of Prior Period [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RestatementDomain" xlink:to="srt_RestatementDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RestatementDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revision of Prior Period [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="srt_ScenarioPreviouslyReportedMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioPreviouslyReportedMember" xlink:to="srt_ScenarioPreviouslyReportedMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScenarioPreviouslyReportedMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Previously Reported [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="srt_ScenarioPreviouslyReportedMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Previously reported</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss per common share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive securities excluded from computation of diluted net loss per share attributable to common stockholders (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Related Party Transactions, by Related Party [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transaction [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_RelatedPartyTransactionDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transaction [Domain]</label>
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_LicenseAgreementWithMinoryxTherapeuticsSlMember" xlink:label="ganx_LicenseAgreementWithMinoryxTherapeuticsSlMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ganx_LicenseAgreementWithMinoryxTherapeuticsSlMember" xlink:to="ganx_LicenseAgreementWithMinoryxTherapeuticsSlMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ganx_LicenseAgreementWithMinoryxTherapeuticsSlMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to license agreement with Minoryx Therapeutics SL.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ganx_LicenseAgreementWithMinoryxTherapeuticsSlMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License agreement Minoryx Therapeutics SL</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transaction [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Parties</label>
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_RelatedPartyTransactionPercentageOfNetRevenuesBasedOnOneCompositionOfMatterClaim" xlink:label="ganx_RelatedPartyTransactionPercentageOfNetRevenuesBasedOnOneCompositionOfMatterClaim" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ganx_RelatedPartyTransactionPercentageOfNetRevenuesBasedOnOneCompositionOfMatterClaim" xlink:to="ganx_RelatedPartyTransactionPercentageOfNetRevenuesBasedOnOneCompositionOfMatterClaim_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ganx_RelatedPartyTransactionPercentageOfNetRevenuesBasedOnOneCompositionOfMatterClaim_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of revenues that would infringe at least one composition of matter claim.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ganx_RelatedPartyTransactionPercentageOfNetRevenuesBasedOnOneCompositionOfMatterClaim_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transaction, Percentage of Net Revenues, Based on One Composition of Matter Claim</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ganx_RelatedPartyTransactionPercentageOfNetRevenuesBasedOnOneCompositionOfMatterClaim_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of net revenue based on one composition matter</label>
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_RelatedPartyTransactionPercentageOfNetRevenuesBasedOnOneMethodOfClaim" xlink:label="ganx_RelatedPartyTransactionPercentageOfNetRevenuesBasedOnOneMethodOfClaim" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ganx_RelatedPartyTransactionPercentageOfNetRevenuesBasedOnOneMethodOfClaim" xlink:to="ganx_RelatedPartyTransactionPercentageOfNetRevenuesBasedOnOneMethodOfClaim_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ganx_RelatedPartyTransactionPercentageOfNetRevenuesBasedOnOneMethodOfClaim_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of revenues that would infringe at least one method of matter claim.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ganx_RelatedPartyTransactionPercentageOfNetRevenuesBasedOnOneMethodOfClaim_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transaction, Percentage of Net Revenues, Based on One Method of Claim</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ganx_RelatedPartyTransactionPercentageOfNetRevenuesBasedOnOneMethodOfClaim_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of net revenue based on one method of claim</label>
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_RelatedPartyTransactionPercentageOfConsiderationReceived" xlink:label="ganx_RelatedPartyTransactionPercentageOfConsiderationReceived" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ganx_RelatedPartyTransactionPercentageOfConsiderationReceived" xlink:to="ganx_RelatedPartyTransactionPercentageOfConsiderationReceived_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ganx_RelatedPartyTransactionPercentageOfConsiderationReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of consideration received in the event of a sale of the Company or substantially all of the assets, including by merger, change of control, or reorganization.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ganx_RelatedPartyTransactionPercentageOfConsiderationReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transaction, Percentage of Consideration Received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ganx_RelatedPartyTransactionPercentageOfConsiderationReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of consideration received</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableRelatedParties" xlink:label="us-gaap_AccountsReceivableRelatedParties" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableRelatedParties" xlink:to="us-gaap_AccountsReceivableRelatedParties_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableRelatedParties_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Receivable, Related Parties</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccountsReceivableRelatedParties_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Receivables</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent" xlink:label="us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent" xlink:to="us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable, Related Parties</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payables</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromRelatedParties" xlink:label="us-gaap_RevenueFromRelatedParties" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromRelatedParties" xlink:to="us-gaap_RevenueFromRelatedParties_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromRelatedParties_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue from Related Parties</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RevenueFromRelatedParties_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenues</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transaction, Expenses from Transactions with Related Party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentsTable" xlink:label="us-gaap_OtherCommitmentsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_OtherCommitmentsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCommitmentsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Commitments [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="us-gaap_OtherCommitmentsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCommitmentsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Commitments [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsDomain" xlink:to="us-gaap_OtherCommitmentsDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCommitmentsDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Commitments [Domain]</label>
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_CollaborationAgreementsMember" xlink:label="ganx_CollaborationAgreementsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ganx_CollaborationAgreementsMember" xlink:to="ganx_CollaborationAgreementsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ganx_CollaborationAgreementsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to Collaboration agreements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ganx_CollaborationAgreementsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration Agreements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ganx_CollaborationAgreementsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research agreements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="us-gaap_OtherCommitmentsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OtherCommitmentsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCommitmentsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Commitments [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherCommitmentsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:label="us-gaap_ContractualObligationDueInNextTwelveMonths" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:to="us-gaap_ContractualObligationDueInNextTwelveMonths_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractualObligationDueInNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contractual Obligation, to be Paid, Year One</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ContractualObligationDueInNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitment with contractual maturity date in 2022</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>32
<FILENAME>ganx-20211231_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.8042.36810 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/25/2022 6:18:32 PM-->
<!--Modified on: 3/25/2022 6:18:32 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="ganx-20211231.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.gaintherapeutics.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ganx-20211231.xsd#StatementConsolidatedBalanceSheets" roleURI="http://www.gaintherapeutics.com/role/StatementConsolidatedBalanceSheets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ganx-20211231.xsd#StatementConsolidatedBalanceSheetsParenthetical" roleURI="http://www.gaintherapeutics.com/role/StatementConsolidatedBalanceSheetsParenthetical" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ganx-20211231.xsd#StatementConsolidatedStatementOfOperations" roleURI="http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ganx-20211231.xsd#StatementConsolidatedStatementOfComprehensiveLoss" roleURI="http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfComprehensiveLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ganx-20211231.xsd#StatementConsolidatedStatementOfChangesInStockholdersEquityDeficit" roleURI="http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfChangesInStockholdersEquityDeficit" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ganx-20211231.xsd#StatementConsolidatedStatementOfCashFlows" roleURI="http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ganx-20211231.xsd#DisclosureNatureOfBusinessAndBasisOfPresentation" roleURI="http://www.gaintherapeutics.com/role/DisclosureNatureOfBusinessAndBasisOfPresentation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ganx-20211231.xsd#DisclosureSummaryOfSignificantAccountingPolicies" roleURI="http://www.gaintherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ganx-20211231.xsd#DisclosureResearchGrants" roleURI="http://www.gaintherapeutics.com/role/DisclosureResearchGrants" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ganx-20211231.xsd#DisclosureCashCashEquivalentsAndRestrictedCash" roleURI="http://www.gaintherapeutics.com/role/DisclosureCashCashEquivalentsAndRestrictedCash" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ganx-20211231.xsd#DisclosureOtherCurrentAssets" roleURI="http://www.gaintherapeutics.com/role/DisclosureOtherCurrentAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ganx-20211231.xsd#DisclosurePropertyAndEquipmentNet" roleURI="http://www.gaintherapeutics.com/role/DisclosurePropertyAndEquipmentNet" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ganx-20211231.xsd#DisclosureOperatingLeaseRightOfUserouAssets" roleURI="http://www.gaintherapeutics.com/role/DisclosureOperatingLeaseRightOfUserouAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ganx-20211231.xsd#DisclosureAccountsPayable" roleURI="http://www.gaintherapeutics.com/role/DisclosureAccountsPayable" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ganx-20211231.xsd#DisclosureOtherCurrentLiabilitiesAndDeferredIncome" roleURI="http://www.gaintherapeutics.com/role/DisclosureOtherCurrentLiabilitiesAndDeferredIncome" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ganx-20211231.xsd#DisclosurePensionObligations" roleURI="http://www.gaintherapeutics.com/role/DisclosurePensionObligations" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ganx-20211231.xsd#DisclosureLoans" roleURI="http://www.gaintherapeutics.com/role/DisclosureLoans" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ganx-20211231.xsd#DisclosureFairValueMeasurement" roleURI="http://www.gaintherapeutics.com/role/DisclosureFairValueMeasurement" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ganx-20211231.xsd#DisclosureCommonAndPreferredStock" roleURI="http://www.gaintherapeutics.com/role/DisclosureCommonAndPreferredStock" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ganx-20211231.xsd#DisclosureWarrants" roleURI="http://www.gaintherapeutics.com/role/DisclosureWarrants" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ganx-20211231.xsd#DisclosureEquityIncentivePlan" roleURI="http://www.gaintherapeutics.com/role/DisclosureEquityIncentivePlan" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ganx-20211231.xsd#DisclosureCollaborationAgreement" roleURI="http://www.gaintherapeutics.com/role/DisclosureCollaborationAgreement" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ganx-20211231.xsd#DisclosureIncomeTaxes" roleURI="http://www.gaintherapeutics.com/role/DisclosureIncomeTaxes" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ganx-20211231.xsd#DisclosureNetLossPerCommonShare" roleURI="http://www.gaintherapeutics.com/role/DisclosureNetLossPerCommonShare" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ganx-20211231.xsd#DisclosureRelatedParties" roleURI="http://www.gaintherapeutics.com/role/DisclosureRelatedParties" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ganx-20211231.xsd#DisclosureOtherInformation" roleURI="http://www.gaintherapeutics.com/role/DisclosureOtherInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ganx-20211231.xsd#DisclosureSignificantEventsAfterBalanceSheetDate" roleURI="http://www.gaintherapeutics.com/role/DisclosureSignificantEventsAfterBalanceSheetDate" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ganx-20211231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.gaintherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ganx-20211231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesTables" roleURI="http://www.gaintherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ganx-20211231.xsd#DisclosureCashCashEquivalentsAndRestrictedCashTables" roleURI="http://www.gaintherapeutics.com/role/DisclosureCashCashEquivalentsAndRestrictedCashTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ganx-20211231.xsd#DisclosureOtherCurrentAssetsTables" roleURI="http://www.gaintherapeutics.com/role/DisclosureOtherCurrentAssetsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ganx-20211231.xsd#DisclosurePropertyAndEquipmentNetTables" roleURI="http://www.gaintherapeutics.com/role/DisclosurePropertyAndEquipmentNetTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ganx-20211231.xsd#DisclosureOperatingLeaseRightOfUserouAssetsTables" roleURI="http://www.gaintherapeutics.com/role/DisclosureOperatingLeaseRightOfUserouAssetsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ganx-20211231.xsd#DisclosureAccountsPayableTables" roleURI="http://www.gaintherapeutics.com/role/DisclosureAccountsPayableTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ganx-20211231.xsd#DisclosureOtherCurrentLiabilitiesAndDeferredIncomeTables" roleURI="http://www.gaintherapeutics.com/role/DisclosureOtherCurrentLiabilitiesAndDeferredIncomeTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ganx-20211231.xsd#DisclosurePensionObligationsTables" roleURI="http://www.gaintherapeutics.com/role/DisclosurePensionObligationsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ganx-20211231.xsd#DisclosureLoansTables" roleURI="http://www.gaintherapeutics.com/role/DisclosureLoansTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ganx-20211231.xsd#DisclosureFairValueMeasurementTables" roleURI="http://www.gaintherapeutics.com/role/DisclosureFairValueMeasurementTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ganx-20211231.xsd#DisclosureWarrantsTables" roleURI="http://www.gaintherapeutics.com/role/DisclosureWarrantsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ganx-20211231.xsd#DisclosureEquityIncentivePlanTables" roleURI="http://www.gaintherapeutics.com/role/DisclosureEquityIncentivePlanTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ganx-20211231.xsd#DisclosureIncomeTaxesTables" roleURI="http://www.gaintherapeutics.com/role/DisclosureIncomeTaxesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ganx-20211231.xsd#DisclosureNetLossPerCommonShareTables" roleURI="http://www.gaintherapeutics.com/role/DisclosureNetLossPerCommonShareTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ganx-20211231.xsd#DisclosureNatureOfBusinessAndBasisOfPresentationDetails" roleURI="http://www.gaintherapeutics.com/role/DisclosureNatureOfBusinessAndBasisOfPresentationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ganx-20211231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesDetails" roleURI="http://www.gaintherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ganx-20211231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesAdditionalDisclosuresDetails" roleURI="http://www.gaintherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalDisclosuresDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ganx-20211231.xsd#DisclosureResearchGrantsDetails" roleURI="http://www.gaintherapeutics.com/role/DisclosureResearchGrantsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ganx-20211231.xsd#DisclosureCashCashEquivalentsAndRestrictedCashDetails" roleURI="http://www.gaintherapeutics.com/role/DisclosureCashCashEquivalentsAndRestrictedCashDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ganx-20211231.xsd#DisclosureCashCashEquivalentsAndRestrictedCashScheduleOfCashAndCashEquivalentsBalancesDetails" roleURI="http://www.gaintherapeutics.com/role/DisclosureCashCashEquivalentsAndRestrictedCashScheduleOfCashAndCashEquivalentsBalancesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ganx-20211231.xsd#DisclosureOtherCurrentAssetsDetails" roleURI="http://www.gaintherapeutics.com/role/DisclosureOtherCurrentAssetsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ganx-20211231.xsd#DisclosurePropertyAndEquipmentNetDetails" roleURI="http://www.gaintherapeutics.com/role/DisclosurePropertyAndEquipmentNetDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ganx-20211231.xsd#DisclosureOperatingLeaseRightOfUseRouAssetsAdditionalInformationDetails" roleURI="http://www.gaintherapeutics.com/role/DisclosureOperatingLeaseRightOfUseRouAssetsAdditionalInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ganx-20211231.xsd#DisclosureOperatingLeaseRightOfUseRouAssetsSummaryOfComponentsOfLeaseAccountingDetails" roleURI="http://www.gaintherapeutics.com/role/DisclosureOperatingLeaseRightOfUseRouAssetsSummaryOfComponentsOfLeaseAccountingDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ganx-20211231.xsd#DisclosureOperatingLeaseRightOfUseRouAssetsSummaryOfComponentsOfLeaseExpenseDetails" roleURI="http://www.gaintherapeutics.com/role/DisclosureOperatingLeaseRightOfUseRouAssetsSummaryOfComponentsOfLeaseExpenseDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ganx-20211231.xsd#DisclosureOperatingLeaseRightOfUseRouAssetsFutureMinimumLeasePaymentsDetails" roleURI="http://www.gaintherapeutics.com/role/DisclosureOperatingLeaseRightOfUseRouAssetsFutureMinimumLeasePaymentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ganx-20211231.xsd#DisclosureAccountsPayableDetails" roleURI="http://www.gaintherapeutics.com/role/DisclosureAccountsPayableDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ganx-20211231.xsd#DisclosureOtherCurrentLiabilitiesAndDeferredIncomeDetails" roleURI="http://www.gaintherapeutics.com/role/DisclosureOtherCurrentLiabilitiesAndDeferredIncomeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ganx-20211231.xsd#DisclosurePensionObligationsEndOfYearFundedStatusDetails" roleURI="http://www.gaintherapeutics.com/role/DisclosurePensionObligationsEndOfYearFundedStatusDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ganx-20211231.xsd#DisclosurePensionObligationsReconciliationOfFundedStatusDetails" roleURI="http://www.gaintherapeutics.com/role/DisclosurePensionObligationsReconciliationOfFundedStatusDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ganx-20211231.xsd#DisclosurePensionObligationsComponentOfNetPeriodicPensionCostsDetails" roleURI="http://www.gaintherapeutics.com/role/DisclosurePensionObligationsComponentOfNetPeriodicPensionCostsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ganx-20211231.xsd#DisclosurePensionObligationsReconciliationOfProjectedBenefitObligationDetails" roleURI="http://www.gaintherapeutics.com/role/DisclosurePensionObligationsReconciliationOfProjectedBenefitObligationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ganx-20211231.xsd#DisclosurePensionObligationsReconciliationOfFairValueOfPlanAssetsDetails" roleURI="http://www.gaintherapeutics.com/role/DisclosurePensionObligationsReconciliationOfFairValueOfPlanAssetsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ganx-20211231.xsd#DisclosurePensionObligationsChangeInNetGainLossDetails" roleURI="http://www.gaintherapeutics.com/role/DisclosurePensionObligationsChangeInNetGainLossDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ganx-20211231.xsd#DisclosurePensionObligationsChangeInAccumulatedOtherComprehensiveIncomeAociDetails" roleURI="http://www.gaintherapeutics.com/role/DisclosurePensionObligationsChangeInAccumulatedOtherComprehensiveIncomeAociDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ganx-20211231.xsd#DisclosurePensionObligationsAssumptionsDetails" roleURI="http://www.gaintherapeutics.com/role/DisclosurePensionObligationsAssumptionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ganx-20211231.xsd#DisclosurePensionObligationsExpectedBenefitPaymentsDetails" roleURI="http://www.gaintherapeutics.com/role/DisclosurePensionObligationsExpectedBenefitPaymentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ganx-20211231.xsd#DisclosurePensionObligationsAdditionalInformationDetails" roleURI="http://www.gaintherapeutics.com/role/DisclosurePensionObligationsAdditionalInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ganx-20211231.xsd#DisclosureLoansDetails" roleURI="http://www.gaintherapeutics.com/role/DisclosureLoansDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ganx-20211231.xsd#DisclosureLoansFutureLoanPaymentsDetails" roleURI="http://www.gaintherapeutics.com/role/DisclosureLoansFutureLoanPaymentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ganx-20211231.xsd#DisclosureFairValueMeasurementDetails" roleURI="http://www.gaintherapeutics.com/role/DisclosureFairValueMeasurementDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ganx-20211231.xsd#DisclosureCommonAndPreferredStockDetails" roleURI="http://www.gaintherapeutics.com/role/DisclosureCommonAndPreferredStockDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ganx-20211231.xsd#DisclosureWarrantsDetails" roleURI="http://www.gaintherapeutics.com/role/DisclosureWarrantsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ganx-20211231.xsd#DisclosureWarrantsAssumptionsUnderBlackScholesPricingModelDetails" roleURI="http://www.gaintherapeutics.com/role/DisclosureWarrantsAssumptionsUnderBlackScholesPricingModelDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ganx-20211231.xsd#DisclosureEquityIncentivePlanDetails" roleURI="http://www.gaintherapeutics.com/role/DisclosureEquityIncentivePlanDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ganx-20211231.xsd#DisclosureEquityIncentivePlanStockOptionActivityDetails" roleURI="http://www.gaintherapeutics.com/role/DisclosureEquityIncentivePlanStockOptionActivityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ganx-20211231.xsd#DisclosureEquityIncentivePlanOptionsOutstandingAndExercisableDetails" roleURI="http://www.gaintherapeutics.com/role/DisclosureEquityIncentivePlanOptionsOutstandingAndExercisableDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ganx-20211231.xsd#DisclosureEquityIncentivePlanAssumptionsDetails" roleURI="http://www.gaintherapeutics.com/role/DisclosureEquityIncentivePlanAssumptionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ganx-20211231.xsd#DisclosureEquityIncentivePlanStockBasedCompensationDetails" roleURI="http://www.gaintherapeutics.com/role/DisclosureEquityIncentivePlanStockBasedCompensationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ganx-20211231.xsd#DisclosureCollaborationAgreementDetails" roleURI="http://www.gaintherapeutics.com/role/DisclosureCollaborationAgreementDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ganx-20211231.xsd#DisclosureIncomeTaxesDomesticAndForeignNetOperatingLossesDetails" roleURI="http://www.gaintherapeutics.com/role/DisclosureIncomeTaxesDomesticAndForeignNetOperatingLossesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ganx-20211231.xsd#DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseDetails" roleURI="http://www.gaintherapeutics.com/role/DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ganx-20211231.xsd#DisclosureIncomeTaxesDomesticAndForeignNetOperatingLossesAndRelatedDeferredTaxAssetsDetails" roleURI="http://www.gaintherapeutics.com/role/DisclosureIncomeTaxesDomesticAndForeignNetOperatingLossesAndRelatedDeferredTaxAssetsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ganx-20211231.xsd#DisclosureIncomeTaxesAdditionalDisclosuresDetails" roleURI="http://www.gaintherapeutics.com/role/DisclosureIncomeTaxesAdditionalDisclosuresDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ganx-20211231.xsd#DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails" roleURI="http://www.gaintherapeutics.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ganx-20211231.xsd#DisclosureNetLossPerCommonShareComputationOfDilutedNetLossPerShareDetails" roleURI="http://www.gaintherapeutics.com/role/DisclosureNetLossPerCommonShareComputationOfDilutedNetLossPerShareDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ganx-20211231.xsd#DisclosureRelatedPartiesDetails" roleURI="http://www.gaintherapeutics.com/role/DisclosureRelatedPartiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ganx-20211231.xsd#DisclosureOtherInformationDetails" roleURI="http://www.gaintherapeutics.com/role/DisclosureOtherInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <presentationLink xlink:role="http://www.gaintherapeutics.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType_637838291102482378" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentType_637838291102482378" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport_637838291102482378" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentAnnualReport_637838291102482378" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport_637838291102482378" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentTransitionReport_637838291102482378" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_637838291102482378" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentPeriodEndDate_637838291102482378" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_637838291102482378" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityFileNumber_637838291102482378" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_637838291102482378" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityRegistrantName_637838291102482378" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_637838291102482378" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_637838291102482378" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_637838291102482378" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber_637838291102482378" order="8" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_637838291102482378" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressAddressLine1_637838291102482378" order="9" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2_637838291102482378" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressAddressLine2_637838291102482378" order="10" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_637838291102482378" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressCityOrTown_637838291102482378" order="11" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_637838291102482378" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince_637838291102482378" order="12" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_637838291102482378" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode_637838291102482378" order="13" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_637838291102482378" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_CityAreaCode_637838291102482378" order="14" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_637838291102492361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_LocalPhoneNumber_637838291102492361" order="15" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_637838291102492361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_Security12bTitle_637838291102492361" order="16" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_637838291102492361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_TradingSymbol_637838291102492361" order="17" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_637838291102492361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_SecurityExchangeName_637838291102492361" order="18" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer_637838291102492361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer_637838291102492361" order="19" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers_637838291102492361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityVoluntaryFilers_637838291102492361" order="20" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus_637838291102492361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus_637838291102492361" order="21" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent_637838291102492361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent_637838291102492361" order="22" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory_637838291102492361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityFilerCategory_637838291102492361" order="23" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness_637838291102492361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntitySmallBusiness_637838291102492361" order="24" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_637838291102502355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany_637838291102502355" order="25" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag_637838291102502355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag_637838291102502355" order="26" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod_637838291102502355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityExTransitionPeriod_637838291102502355" order="27" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany_637838291102502355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityShellCompany_637838291102502355" order="28" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat_637838291102502355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityPublicFloat_637838291102502355" order="29" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding_637838291102502355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding_637838291102502355" order="30" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_637838291102502355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityCentralIndexKey_637838291102502355" order="31" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate_637838291102502355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate_637838291102502355" order="32" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus_637838291102512356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus_637838291102512356" order="33" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus_637838291102512356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus_637838291102512356" order="34" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_637838291102512356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_AmendmentFlag_637838291102512356" order="35" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName" xlink:label="dei_AuditorName_637838291102512356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_AuditorName_637838291102512356" order="36" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId_637838291102512356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_AuditorFirmId_637838291102512356" order="37" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation_637838291102512356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_AuditorLocation_637838291102512356" order="38" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gaintherapeutics.com/role/StatementConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - Consolidated Balance Sheets" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_637560093955088995" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637838291102522356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_637560093955088995" xlink:to="us-gaap_StatementTable_637838291102522356" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_637838291102522356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637838291102522356" xlink:to="us-gaap_StatementClassOfStockAxis_637838291102522356" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_637838291102522356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_637838291102522356" xlink:to="us-gaap_ClassOfStockDomain_637838291102522356" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember_637838291102522356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637838291102522356" xlink:to="us-gaap_SeriesAPreferredStockMember_637838291102522356" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember_637838291102522356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637838291102522356" xlink:to="us-gaap_SeriesBPreferredStockMember_637838291102522356" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637838291102522356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637838291102522356" xlink:to="us-gaap_StatementLineItems_637838291102522356" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract_637838291102522356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637838291102522356" xlink:to="us-gaap_AssetsAbstract_637838291102522356" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract_637838291102522356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637838291102522356" xlink:to="us-gaap_AssetsCurrentAbstract_637838291102522356" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_637838291102522356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637838291102522356" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_637838291102522356" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent_637838291102522356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637838291102522356" xlink:to="us-gaap_RestrictedCashCurrent_637838291102522356" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent_637838291102522356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637838291102522356" xlink:to="us-gaap_AccountsReceivableNetCurrent_637838291102522356" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxesAndOtherTaxReceivableCurrent" xlink:label="us-gaap_DeferredIncomeTaxesAndOtherTaxReceivableCurrent_637838291102522356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637838291102522356" xlink:to="us-gaap_DeferredIncomeTaxesAndOtherTaxReceivableCurrent_637838291102522356" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_637838291102522356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637838291102522356" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_637838291102522356" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredOfferingCosts" xlink:label="us-gaap_DeferredOfferingCosts_637838291102532355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637838291102522356" xlink:to="us-gaap_DeferredOfferingCosts_637838291102532355" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_637838291102532355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637838291102522356" xlink:to="us-gaap_AssetsCurrent_637838291102532355" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="us-gaap_AssetsNoncurrentAbstract_637838291102532355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637838291102522356" xlink:to="us-gaap_AssetsNoncurrentAbstract_637838291102532355" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_637838291102532355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract_637838291102532355" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_637838291102532355" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_CapitalizedComputerSoftwareForInternalUse" xlink:label="ganx_CapitalizedComputerSoftwareForInternalUse_637838291102532355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract_637838291102532355" xlink:to="ganx_CapitalizedComputerSoftwareForInternalUse_637838291102532355" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_637838291102532355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract_637838291102532355" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_637838291102532355" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent_637838291102532355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract_637838291102532355" xlink:to="us-gaap_RestrictedCashNoncurrent_637838291102532355" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_DepositsAndOtherAssetsNoncurrent" xlink:label="ganx_DepositsAndOtherAssetsNoncurrent_637838291102532355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract_637838291102532355" xlink:to="ganx_DepositsAndOtherAssetsNoncurrent_637838291102532355" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent_637838291102532355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract_637838291102532355" xlink:to="us-gaap_AssetsNoncurrent_637838291102532355" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_637838291102532355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637838291102522356" xlink:to="us-gaap_Assets_637838291102532355" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637838291102532355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637838291102522356" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637838291102532355" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAbstract" xlink:label="us-gaap_LiabilitiesAbstract_637838291102542358" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637838291102532355" xlink:to="us-gaap_LiabilitiesAbstract_637838291102542358" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_637838291102542358" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAbstract_637838291102542358" xlink:to="us-gaap_LiabilitiesCurrentAbstract_637838291102542358" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_637838291102542358" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637838291102542358" xlink:to="us-gaap_AccountsPayableCurrent_637838291102542358" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_637838291102542358" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637838291102542358" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_637838291102542358" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent_637838291102542358" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637838291102542358" xlink:to="us-gaap_OtherLiabilitiesCurrent_637838291102542358" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxesPayableCurrent" xlink:label="us-gaap_TaxesPayableCurrent_637838291102542358" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637838291102542358" xlink:to="us-gaap_TaxesPayableCurrent_637838291102542358" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeCurrent" xlink:label="us-gaap_DeferredIncomeCurrent_637838291102542358" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637838291102542358" xlink:to="us-gaap_DeferredIncomeCurrent_637838291102542358" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent_637838291102542358" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637838291102542358" xlink:to="us-gaap_LongTermDebtCurrent_637838291102542358" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_637838291102542358" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637838291102542358" xlink:to="us-gaap_LiabilitiesCurrent_637838291102542358" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_637838291102552355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAbstract_637838291102542358" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_637838291102552355" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent" xlink:label="us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent_637838291102552355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract_637838291102552355" xlink:to="us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent_637838291102552355" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_637838291102552355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract_637838291102552355" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_637838291102552355" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent_637838291102552355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract_637838291102552355" xlink:to="us-gaap_LongTermDebtNoncurrent_637838291102552355" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent_637838291102552355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract_637838291102552355" xlink:to="us-gaap_LiabilitiesNoncurrent_637838291102552355" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_637838291102552355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAbstract_637838291102542358" xlink:to="us-gaap_Liabilities_637838291102552355" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract_637838291102552355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637838291102532355" xlink:to="us-gaap_StockholdersEquityAbstract_637838291102552355" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_637838291102552355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637838291102552355" xlink:to="us-gaap_PreferredStockValue_637838291102552355" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_637838291102562355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637838291102552355" xlink:to="us-gaap_CommonStockValue_637838291102562355" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_637838291102562355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637838291102552355" xlink:to="us-gaap_AdditionalPaidInCapital_637838291102562355" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_637838291102562355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637838291102552355" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_637838291102562355" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_637838291102562355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637838291102552355" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_637838291102562355" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_IncomeLossForPeriod" xlink:label="ganx_IncomeLossForPeriod_637838291102562355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637838291102552355" xlink:to="ganx_IncomeLossForPeriod_637838291102562355" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637838291102562355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637838291102552355" xlink:to="us-gaap_StockholdersEquity_637838291102562355" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_637838291102572355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637838291102532355" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_637838291102572355" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gaintherapeutics.com/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:type="extended" xlink:title="00105 - Statement - Consolidated Balance Sheets (Parenthetical)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637838291102572355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable_637838291102572355" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_637838291102572355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637838291102572355" xlink:to="us-gaap_StatementClassOfStockAxis_637838291102572355" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_637838291102572355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_637838291102572355" xlink:to="us-gaap_ClassOfStockDomain_637838291102572355" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember_637838291102572355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637838291102572355" xlink:to="us-gaap_SeriesAPreferredStockMember_637838291102572355" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember_637838291102572355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637838291102572355" xlink:to="us-gaap_SeriesBPreferredStockMember_637838291102572355" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637838291102572355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637838291102572355" xlink:to="us-gaap_StatementLineItems_637838291102572355" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_637838291102572355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637838291102572355" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_637838291102572355" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized_637838291102572355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637838291102572355" xlink:to="us-gaap_PreferredStockSharesAuthorized_637838291102572355" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued_637838291102572355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637838291102572355" xlink:to="us-gaap_PreferredStockSharesIssued_637838291102572355" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding_637838291102582360" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637838291102572355" xlink:to="us-gaap_PreferredStockSharesOutstanding_637838291102582360" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_637838291102582360" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637838291102572355" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_637838291102582360" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_637838291102582360" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637838291102572355" xlink:to="us-gaap_CommonStockSharesAuthorized_637838291102582360" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_637838291102582360" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637838291102572355" xlink:to="us-gaap_CommonStockSharesIssued_637838291102582360" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_637838291102582360" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637838291102572355" xlink:to="us-gaap_CommonStockSharesOutstanding_637838291102582360" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfOperations" xlink:type="extended" xlink:title="00200 - Statement - Consolidated Statement of Operations" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract_637560093955876898" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract_637838291102582360" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_637560093955876898" xlink:to="us-gaap_RevenuesAbstract_637838291102582360" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_637838291102582360" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract_637838291102582360" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_637838291102582360" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubleaseIncome" xlink:label="us-gaap_SubleaseIncome_637838291102582360" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract_637838291102582360" xlink:to="us-gaap_SubleaseIncome_637838291102582360" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues_637838291102582360" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract_637838291102582360" xlink:to="us-gaap_Revenues_637838291102582360" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract_637838291102582360" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_637560093955876898" xlink:to="us-gaap_OperatingExpensesAbstract_637838291102582360" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_637838291102582360" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_637838291102582360" xlink:to="us-gaap_ResearchAndDevelopmentExpense_637838291102582360" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_637838291102582360" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_637838291102582360" xlink:to="us-gaap_GeneralAndAdministrativeExpense_637838291102582360" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_637838291102592359" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_637838291102582360" xlink:to="us-gaap_OperatingExpenses_637838291102592359" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_637838291102592359" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_637560093955876898" xlink:to="us-gaap_OperatingIncomeLoss_637838291102592359" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_637838291102592359" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_637560093955876898" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_637838291102592359" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="us-gaap_InterestIncomeExpenseNet_637838291102592359" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_637838291102592359" xlink:to="us-gaap_InterestIncomeExpenseNet_637838291102592359" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_637838291102592359" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_637838291102592359" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_637838291102592359" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_637838291102592359" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_637838291102592359" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_637838291102592359" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_637838291102592359" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_637560093955876898" xlink:to="us-gaap_IncomeTaxExpenseBenefit_637838291102592359" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637838291102592359" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_637560093955876898" xlink:to="us-gaap_NetIncomeLoss_637838291102592359" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract_637838291102592359" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_637560093955876898" xlink:to="us-gaap_EarningsPerShareBasicAndDilutedAbstract_637838291102592359" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_637838291102592359" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract_637838291102592359" xlink:to="us-gaap_EarningsPerShareBasic_637838291102592359" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_637838291102592359" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract_637838291102592359" xlink:to="us-gaap_EarningsPerShareDiluted_637838291102592359" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_637838291102592359" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract_637838291102592359" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_637838291102592359" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_637838291102602356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract_637838291102592359" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_637838291102602356" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfComprehensiveLoss" xlink:type="extended" xlink:title="00300 - Statement - Consolidated Statement of Comprehensive Loss" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_637560093955897191" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637838291102602356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_637560093955897191" xlink:to="us-gaap_NetIncomeLoss_637838291102602356" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_637838291102602356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_637560093955897191" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_637838291102602356" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_637838291102602356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_637838291102602356" xlink:to="us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_637838291102602356" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_637838291102602356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_637838291102602356" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_637838291102602356" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_637838291102602356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_637838291102602356" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_637838291102602356" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_637838291102602356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_637838291102602356" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_637838291102602356" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfChangesInStockholdersEquityDeficit" xlink:type="extended" xlink:title="00400 - Statement - Consolidated Statement of Changes in Stockholders' Equity (Deficit)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637838291102602356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable_637838291102602356" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_637838291102602356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637838291102602356" xlink:to="us-gaap_StatementEquityComponentsAxis_637838291102602356" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember_637838291102602356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637838291102602356" xlink:to="us-gaap_PreferredStockMember_637838291102602356" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_637838291102602356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637838291102602356" xlink:to="us-gaap_CommonStockMember_637838291102602356" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember_637838291102612360" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637838291102602356" xlink:to="us-gaap_AdditionalPaidInCapitalMember_637838291102612360" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_637838291102612360" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637838291102602356" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_637838291102612360" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember_637838291102612360" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637838291102602356" xlink:to="us-gaap_RetainedEarningsMember_637838291102612360" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_637838291102612360" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637838291102602356" xlink:to="us-gaap_EquityComponentDomain_637838291102612360" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_637838291102612360" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637838291102602356" xlink:to="us-gaap_StatementClassOfStockAxis_637838291102612360" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredClassAMember" xlink:label="us-gaap_PreferredClassAMember_637838291102612360" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_637838291102612360" xlink:to="us-gaap_PreferredClassAMember_637838291102612360" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredClassBMember" xlink:label="us-gaap_PreferredClassBMember_637838291102612360" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_637838291102612360" xlink:to="us-gaap_PreferredClassBMember_637838291102612360" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_637838291102612360" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_637838291102612360" xlink:to="us-gaap_CommonStockMember_637838291102612360" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_637838291102612360" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_637838291102612360" xlink:to="us-gaap_ClassOfStockDomain_637838291102612360" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_637838291102612360" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637838291102602356" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_637838291102612360" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember_637838291102612360" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_637838291102612360" xlink:to="us-gaap_IPOMember_637838291102612360" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_637838291102612360" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_637838291102612360" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_637838291102612360" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637838291102612360" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637838291102602356" xlink:to="us-gaap_StatementLineItems_637838291102612360" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637838291102622357" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637838291102612360" xlink:to="us-gaap_StockholdersEquity_637838291102622357" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_637838291102622357" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637838291102612360" xlink:to="us-gaap_SharesOutstanding_637838291102622357" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_ConversionOfSeriesPreferredStockIntoCommonStock" xlink:label="ganx_ConversionOfSeriesPreferredStockIntoCommonStock_637838291102622357" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637838291102612360" xlink:to="ganx_ConversionOfSeriesPreferredStockIntoCommonStock_637838291102622357" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_ConversionOfSeriesPreferredStockIntoCommonStockInShares" xlink:label="ganx_ConversionOfSeriesPreferredStockIntoCommonStockInShares_637838291102622357" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637838291102612360" xlink:to="ganx_ConversionOfSeriesPreferredStockIntoCommonStockInShares_637838291102622357" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_IssuanceOfSeriesPreferredStockNetOfIssuanceCost" xlink:label="ganx_IssuanceOfSeriesPreferredStockNetOfIssuanceCost_637838291102622357" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637838291102612360" xlink:to="ganx_IssuanceOfSeriesPreferredStockNetOfIssuanceCost_637838291102622357" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_IssuanceOfSeriesPreferredStockInShares" xlink:label="ganx_IssuanceOfSeriesPreferredStockInShares_637838291102622357" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637838291102612360" xlink:to="ganx_IssuanceOfSeriesPreferredStockInShares_637838291102622357" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_ConversionOfSeriesBPreferredStockIntoCommonStock" xlink:label="ganx_ConversionOfSeriesBPreferredStockIntoCommonStock_637838291102622357" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637838291102612360" xlink:to="ganx_ConversionOfSeriesBPreferredStockIntoCommonStock_637838291102622357" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_ConversionOfSeriesBPreferredStockIntoCommonStockInShares" xlink:label="ganx_ConversionOfSeriesBPreferredStockIntoCommonStockInShares_637838291102622357" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637838291102612360" xlink:to="ganx_ConversionOfSeriesBPreferredStockIntoCommonStockInShares_637838291102622357" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_IssuanceOfSeriesBPreferredStockNetOfIssuanceCost" xlink:label="ganx_IssuanceOfSeriesBPreferredStockNetOfIssuanceCost_637838291102622357" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637838291102612360" xlink:to="ganx_IssuanceOfSeriesBPreferredStockNetOfIssuanceCost_637838291102622357" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_IssuanceOfSeriesBPreferredStockInShares" xlink:label="ganx_IssuanceOfSeriesBPreferredStockInShares_637838291102622357" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637838291102612360" xlink:to="ganx_IssuanceOfSeriesBPreferredStockInShares_637838291102622357" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_637838291102632355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637838291102612360" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_637838291102632355" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637838291102632355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637838291102612360" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637838291102632355" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_IssuanceOfCommonStockInIpoNetOfIssuanceCosts" xlink:label="ganx_IssuanceOfCommonStockInIpoNetOfIssuanceCosts_637838291102632355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637838291102612360" xlink:to="ganx_IssuanceOfCommonStockInIpoNetOfIssuanceCosts_637838291102632355" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_IssuanceOfCommonStockInIpoInShares" xlink:label="ganx_IssuanceOfCommonStockInIpoInShares_637838291102632355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637838291102612360" xlink:to="ganx_IssuanceOfCommonStockInIpoInShares_637838291102632355" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_IssuanceOfCommonStockThroughCashlessExerciseOfWarrants" xlink:label="ganx_IssuanceOfCommonStockThroughCashlessExerciseOfWarrants_637838291102632355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637838291102612360" xlink:to="ganx_IssuanceOfCommonStockThroughCashlessExerciseOfWarrants_637838291102632355" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_637838291102632355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637838291102612360" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_637838291102632355" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_637838291102632355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637838291102612360" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_637838291102632355" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_637838291102632355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637838291102612360" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_637838291102632355" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_637838291102642357" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637838291102612360" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_637838291102642357" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_637838291102642357" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637838291102612360" xlink:to="us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_637838291102642357" order="20" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_637838291102642357" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637838291102612360" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_637838291102642357" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637838291102642357" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637838291102612360" xlink:to="us-gaap_NetIncomeLoss_637838291102642357" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637838291102642357" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637838291102612360" xlink:to="us-gaap_StockholdersEquity_637838291102642357" order="23" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_637838291102642357" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637838291102612360" xlink:to="us-gaap_SharesOutstanding_637838291102642357" order="24" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfCashFlows" xlink:type="extended" xlink:title="00500 - Statement - Consolidated Statement of Cash Flows" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637838291102652356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637838291102652356" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_637838291102652356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637838291102652356" xlink:to="us-gaap_ProfitLoss_637838291102652356" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637838291102652356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637838291102652356" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637838291102652356" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_637838291102652356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637838291102652356" xlink:to="us-gaap_Depreciation_637838291102652356" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_637838291102652356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637838291102652356" xlink:to="us-gaap_ShareBasedCompensation_637838291102652356" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_637838291102652356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637838291102652356" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_637838291102652356" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_CapitalizedComputerSoftwareAdjustment" xlink:label="ganx_CapitalizedComputerSoftwareAdjustment_637838291102652356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637838291102652356" xlink:to="ganx_CapitalizedComputerSoftwareAdjustment_637838291102652356" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637838291102652356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637838291102652356" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637838291102652356" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_637838291102652356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637838291102652356" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_637838291102652356" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_637838291102652356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637838291102652356" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_637838291102652356" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_IncreaseDecreaseInValueAddedTaxCredits" xlink:label="ganx_IncreaseDecreaseInValueAddedTaxCredits_637838291102652356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637838291102652356" xlink:to="ganx_IncreaseDecreaseInValueAddedTaxCredits_637838291102652356" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_637838291102652356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637838291102652356" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_637838291102652356" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_637838291102662358" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637838291102652356" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_637838291102662358" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_637838291102662358" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637838291102652356" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_637838291102662358" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionExpenseReversalOfExpenseNoncash" xlink:label="us-gaap_PensionExpenseReversalOfExpenseNoncash_637838291102662358" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637838291102652356" xlink:to="us-gaap_PensionExpenseReversalOfExpenseNoncash_637838291102662358" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredLiabilities" xlink:label="us-gaap_IncreaseDecreaseInDeferredLiabilities_637838291102662358" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637838291102652356" xlink:to="us-gaap_IncreaseDecreaseInDeferredLiabilities_637838291102662358" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_IncreaseDecreaseInOperatingAssetsAndLiabilities" xlink:label="ganx_IncreaseDecreaseInOperatingAssetsAndLiabilities_637838291102662358" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637838291102652356" xlink:to="ganx_IncreaseDecreaseInOperatingAssetsAndLiabilities_637838291102662358" order="9" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_637838291102662358" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637838291102652356" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_637838291102662358" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637838291102662358" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637838291102662358" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637838291102662358" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637838291102662358" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637838291102662358" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_637838291102662358" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637838291102662358" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_637838291102662358" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637838291102662358" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637838291102662358" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt_637838291102662358" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637838291102662358" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt_637838291102662358" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_ProceedsFromIssuanceOfSeriesA.PreferredStockNetOfIssuanceCosts" xlink:label="ganx_ProceedsFromIssuanceOfSeriesA.PreferredStockNetOfIssuanceCosts_637838291102722371" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637838291102662358" xlink:to="ganx_ProceedsFromIssuanceOfSeriesA.PreferredStockNetOfIssuanceCosts_637838291102722371" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_ProceedsFromIssuanceOfSeriesBPreferredStockNetOfIssuanceCosts" xlink:label="ganx_ProceedsFromIssuanceOfSeriesBPreferredStockNetOfIssuanceCosts_637838291102732384" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637838291102662358" xlink:to="ganx_ProceedsFromIssuanceOfSeriesBPreferredStockNetOfIssuanceCosts_637838291102732384" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_637838291102732384" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637838291102662358" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_637838291102732384" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_637838291102732384" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637838291102662358" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_637838291102732384" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfShortTermDebt" xlink:label="us-gaap_RepaymentsOfShortTermDebt_637838291102732384" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637838291102662358" xlink:to="us-gaap_RepaymentsOfShortTermDebt_637838291102732384" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_637838291102732384" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637838291102662358" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_637838291102732384" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_637838291102732384" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637838291102662358" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_637838291102732384" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_637838291102732384" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_637838291102732384" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_637838291102732384" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_637838291102732384" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_637838291102742363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_637838291102742363" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6378382911027423631" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6378382911027423631" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="6" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gaintherapeutics.com/role/DisclosureNatureOfBusinessAndBasisOfPresentation" xlink:type="extended" xlink:title="10101 - Disclosure - Nature of the Business and Basis of Presentation" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_637838291102742363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_637838291102742363" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gaintherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="extended" xlink:title="10201 - Disclosure - Summary of Significant Accounting Policies" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_637838291102742363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_637838291102742363" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gaintherapeutics.com/role/DisclosureResearchGrants" xlink:type="extended" xlink:title="10301 - Disclosure - Research Grants" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_ResearchGrantsAbstract" xlink:label="ganx_ResearchGrantsAbstract_1" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_ResearchGrantsDisclosureTextBlock" xlink:label="ganx_ResearchGrantsDisclosureTextBlock_637838291102752366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ganx_ResearchGrantsAbstract_1" xlink:to="ganx_ResearchGrantsDisclosureTextBlock_637838291102752366" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gaintherapeutics.com/role/DisclosureCashCashEquivalentsAndRestrictedCash" xlink:type="extended" xlink:title="10401 - Disclosure - Cash, cash equivalents and restricted cash" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsDisclosureTextBlock_637838291102752366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsDisclosureTextBlock_637838291102752366" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gaintherapeutics.com/role/DisclosureOtherCurrentAssets" xlink:type="extended" xlink:title="10501 - Disclosure - Other Current Assets" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_PrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:label="ganx_PrepaidExpensesAndOtherCurrentAssetsTextBlock_637838291102752366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="ganx_PrepaidExpensesAndOtherCurrentAssetsTextBlock_637838291102752366" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gaintherapeutics.com/role/DisclosurePropertyAndEquipmentNet" xlink:type="extended" xlink:title="10601 - Disclosure - Property and Equipment, net" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentNetAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_637838291102752366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_637838291102752366" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gaintherapeutics.com/role/DisclosureOperatingLeaseRightOfUserouAssets" xlink:type="extended" xlink:title="10701 - Disclosure - Operating lease. Right of use (&quot;ROU&quot;) assets" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_637838291102762362" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_637838291102762362" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gaintherapeutics.com/role/DisclosureAccountsPayable" xlink:type="extended" xlink:title="10801 - Disclosure - Accounts Payable" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrentAbstract" xlink:label="us-gaap_AccountsPayableCurrentAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_637838291102762362" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableCurrentAbstract" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_637838291102762362" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gaintherapeutics.com/role/DisclosureOtherCurrentLiabilitiesAndDeferredIncome" xlink:type="extended" xlink:title="10901 - Disclosure - Other current liabilities and deferred income" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCreditsAndOtherLiabilitiesAbstract" xlink:label="us-gaap_DeferredCreditsAndOtherLiabilitiesAbstract" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_OtherCurrentLiabilitiesAndDeferredIncomeTextBlock" xlink:label="ganx_OtherCurrentLiabilitiesAndDeferredIncomeTextBlock_637838291102762362" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCreditsAndOtherLiabilitiesAbstract" xlink:to="ganx_OtherCurrentLiabilitiesAndDeferredIncomeTextBlock_637838291102762362" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gaintherapeutics.com/role/DisclosurePensionObligations" xlink:type="extended" xlink:title="11001 - Disclosure - Pension obligations" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_637560093955897191" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_637838291102762362" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract_637560093955897191" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_637838291102762362" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gaintherapeutics.com/role/DisclosureLoans" xlink:type="extended" xlink:title="11101 - Disclosure - Loans" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock_637838291102772362" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock_637838291102772362" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gaintherapeutics.com/role/DisclosureFairValueMeasurement" xlink:type="extended" xlink:title="11201 - Disclosure - Fair value measurement" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock_637838291102772362" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock_637838291102772362" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gaintherapeutics.com/role/DisclosureCommonAndPreferredStock" xlink:type="extended" xlink:title="11301 - Disclosure - Common and Preferred Stock" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_637838291102772362" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_637838291102772362" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gaintherapeutics.com/role/DisclosureWarrants" xlink:type="extended" xlink:title="11401 - Disclosure - Warrants" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_WarrantsAndRightsNoteDisclosureTextBlock" xlink:label="ganx_WarrantsAndRightsNoteDisclosureTextBlock_637838291102772362" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="ganx_WarrantsAndRightsNoteDisclosureTextBlock_637838291102772362" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gaintherapeutics.com/role/DisclosureEquityIncentivePlan" xlink:type="extended" xlink:title="11501 - Disclosure - Equity Incentive Plan" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationRelatedCostsAbstract" xlink:label="us-gaap_CompensationRelatedCostsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationRelatedCostsGeneralTextBlock" xlink:label="us-gaap_CompensationRelatedCostsGeneralTextBlock_637838291102782361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationRelatedCostsAbstract" xlink:to="us-gaap_CompensationRelatedCostsGeneralTextBlock_637838291102782361" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gaintherapeutics.com/role/DisclosureCollaborationAgreement" xlink:type="extended" xlink:title="11601 - Disclosure - Collaboration Agreement" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_CollaborationAgreementAbstract" xlink:label="ganx_CollaborationAgreementAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_637838291102782361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ganx_CollaborationAgreementAbstract" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_637838291102782361" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gaintherapeutics.com/role/DisclosureIncomeTaxes" xlink:type="extended" xlink:title="11701 - Disclosure - Income taxes" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_637838291102782361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_637838291102782361" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gaintherapeutics.com/role/DisclosureNetLossPerCommonShare" xlink:type="extended" xlink:title="11801 - Disclosure - Net loss per common share" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock_637838291102782361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock_637838291102782361" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gaintherapeutics.com/role/DisclosureRelatedParties" xlink:type="extended" xlink:title="11901 - Disclosure - Related Parties" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_637838291102792363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_637838291102792363" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gaintherapeutics.com/role/DisclosureOtherInformation" xlink:type="extended" xlink:title="12001 - Disclosure - Other Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_OtherInformationAbstract" xlink:label="ganx_OtherInformationAbstract" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_OtherInformationDisclosureTextBlock" xlink:label="ganx_OtherInformationDisclosureTextBlock_637838291102792363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ganx_OtherInformationAbstract" xlink:to="ganx_OtherInformationDisclosureTextBlock_637838291102792363" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gaintherapeutics.com/role/DisclosureSignificantEventsAfterBalanceSheetDate" xlink:type="extended" xlink:title="12101 - Disclosure - Significant events after the balance sheet date" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock_637838291102792363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock_637838291102792363" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gaintherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" xlink:title="20202 - Disclosure - Summary of Significant Accounting Policies (Policies)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_637838291102802362" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_637838291102802362" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_ReverseStockSplitPolicyPolicyTextBlock" xlink:label="ganx_ReverseStockSplitPolicyPolicyTextBlock_637838291102802362" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ganx_ReverseStockSplitPolicyPolicyTextBlock_637838291102802362" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_InitialPublicOfferingPolicyTextBlock" xlink:label="ganx_InitialPublicOfferingPolicyTextBlock_637838291102802362" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ganx_InitialPublicOfferingPolicyTextBlock_637838291102802362" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_637838291102802362" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_637838291102802362" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_637838291102802362" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_637838291102802362" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates_637838291102802362" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates_637838291102802362" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_637838291102802362" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_637838291102802362" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk_637838291102802362" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk_637838291102802362" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredChargesPolicyTextBlock" xlink:label="us-gaap_DeferredChargesPolicyTextBlock_637838291102802362" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DeferredChargesPolicyTextBlock_637838291102802362" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_637838291102802362" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_637838291102802362" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" xlink:label="us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_637838291102802362" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_637838291102802362" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_637838291102802362" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_637838291102802362" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy_637838291102802362" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy_637838291102802362" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_637838291102802362" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_637838291102802362" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_AccountsPayablePolicyTextBlock" xlink:label="ganx_AccountsPayablePolicyTextBlock_637838291102812361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ganx_AccountsPayablePolicyTextBlock_637838291102812361" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_PayablesForSocialSecuritiesPolicyTextBlock" xlink:label="ganx_PayablesForSocialSecuritiesPolicyTextBlock_637838291102812361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ganx_PayablesForSocialSecuritiesPolicyTextBlock_637838291102812361" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_AccruedExpensesPolicyPolicyTextBlock" xlink:label="ganx_AccruedExpensesPolicyPolicyTextBlock_637838291102812361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ganx_AccruedExpensesPolicyPolicyTextBlock_637838291102812361" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementPlansPolicy" xlink:label="us-gaap_PensionAndOtherPostretirementPlansPolicy_637838291102812361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PensionAndOtherPostretirementPlansPolicy_637838291102812361" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_637838291102812361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_637838291102812361" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_637838291102812361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_637838291102812361" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_ResearchGrantsPolicyPolicyTextBlock" xlink:label="ganx_ResearchGrantsPolicyPolicyTextBlock_637838291102812361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ganx_ResearchGrantsPolicyPolicyTextBlock_637838291102812361" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_637838291102812361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_637838291102812361" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_637838291102812361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_637838291102812361" order="23" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_637838291102812361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_637838291102812361" order="24" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_637838291102822358" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_637838291102822358" order="25" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_637838291102822358" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_637838291102822358" order="26" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_637838291102822358" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_637838291102822358" order="27" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_637838291102822358" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_637838291102822358" order="28" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gaintherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:type="extended" xlink:title="30203 - Disclosure - Summary of Significant Accounting Policies (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_637560842869561730" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_DepreciationRatesOnPropertyPlantAndEquipmentTableTextBlock" xlink:label="ganx_DepreciationRatesOnPropertyPlantAndEquipmentTableTextBlock_637838291102822358" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_637560842869561730" xlink:to="ganx_DepreciationRatesOnPropertyPlantAndEquipmentTableTextBlock_637838291102822358" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gaintherapeutics.com/role/DisclosureCashCashEquivalentsAndRestrictedCashTables" xlink:type="extended" xlink:title="30403 - Disclosure - Cash, cash equivalents and restricted cash (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:label="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_637838291102832362" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_637838291102832362" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_ScheduleOfCashAndCashEquivalentsBalancesTableTextBlock" xlink:label="ganx_ScheduleOfCashAndCashEquivalentsBalancesTableTextBlock_637838291102832362" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="ganx_ScheduleOfCashAndCashEquivalentsBalancesTableTextBlock_637838291102832362" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gaintherapeutics.com/role/DisclosureOtherCurrentAssetsTables" xlink:type="extended" xlink:title="30503 - Disclosure - Other Current Assets (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:label="ganx_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_637838291102832362" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="ganx_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_637838291102832362" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gaintherapeutics.com/role/DisclosurePropertyAndEquipmentNetTables" xlink:type="extended" xlink:title="30603 - Disclosure - Property and Equipment, net (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentNetAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_637838291102832362" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_637838291102832362" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gaintherapeutics.com/role/DisclosureOperatingLeaseRightOfUserouAssetsTables" xlink:type="extended" xlink:title="30703 - Disclosure - Operating lease. Right of use (&quot;ROU&quot;) assets (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLeaseIncomeTableTextBlock" xlink:label="us-gaap_OperatingLeaseLeaseIncomeTableTextBlock_637838291102842363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLeaseIncomeTableTextBlock_637838291102842363" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock_637838291102842363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock_637838291102842363" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_637838291102842363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_637838291102842363" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gaintherapeutics.com/role/DisclosureAccountsPayableTables" xlink:type="extended" xlink:title="30803 - Disclosure - Accounts Payable (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrentAbstract" xlink:label="us-gaap_AccountsPayableCurrentAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_637838291102842363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableCurrentAbstract" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_637838291102842363" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gaintherapeutics.com/role/DisclosureOtherCurrentLiabilitiesAndDeferredIncomeTables" xlink:type="extended" xlink:title="30903 - Disclosure - Other current liabilities and deferred income (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCreditsAndOtherLiabilitiesAbstract" xlink:label="us-gaap_DeferredCreditsAndOtherLiabilitiesAbstract" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_OtherCurrentLiabilitiesAndDeferredIncomeTableTextBlock" xlink:label="ganx_OtherCurrentLiabilitiesAndDeferredIncomeTableTextBlock_637838291102842363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCreditsAndOtherLiabilitiesAbstract" xlink:to="ganx_OtherCurrentLiabilitiesAndDeferredIncomeTableTextBlock_637838291102842363" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gaintherapeutics.com/role/DisclosurePensionObligationsTables" xlink:type="extended" xlink:title="31003 - Disclosure - Pension obligations (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_637560093955907162" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock_637838291102852361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract_637560093955907162" xlink:to="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock_637838291102852361" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:label="us-gaap_ScheduleOfAssumptionsUsedTableTextBlock_637838291102852361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract_637560093955907162" xlink:to="us-gaap_ScheduleOfAssumptionsUsedTableTextBlock_637838291102852361" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock" xlink:label="us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock_637838291102852361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract_637560093955907162" xlink:to="us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock_637838291102852361" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gaintherapeutics.com/role/DisclosureLoansTables" xlink:type="extended" xlink:title="31103 - Disclosure - Loans (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_637838291102852361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract_2" xlink:to="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_637838291102852361" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gaintherapeutics.com/role/DisclosureFairValueMeasurementTables" xlink:type="extended" xlink:title="31203 - Disclosure - Fair value measurement (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_637838291102852361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract_2" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_637838291102852361" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gaintherapeutics.com/role/DisclosureWarrantsTables" xlink:type="extended" xlink:title="31403 - Disclosure - Warrants (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_637838291102862362" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_637838291102862362" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gaintherapeutics.com/role/DisclosureEquityIncentivePlanTables" xlink:type="extended" xlink:title="31503 - Disclosure - Equity Incentive Plan (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationRelatedCostsAbstract" xlink:label="us-gaap_CompensationRelatedCostsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_637838291102862362" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationRelatedCostsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_637838291102862362" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_637838291102862362" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationRelatedCostsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_637838291102862362" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_637838291102862362" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationRelatedCostsAbstract" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_637838291102862362" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gaintherapeutics.com/role/DisclosureIncomeTaxesTables" xlink:type="extended" xlink:title="31703 - Disclosure - Income taxes (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_637838291102862362" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_1" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_637838291102862362" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_637838291102872363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_1" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_637838291102872363" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_637838291102872363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_1" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_637838291102872363" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_637838291102872363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_1" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_637838291102872363" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gaintherapeutics.com/role/DisclosureNetLossPerCommonShareTables" xlink:type="extended" xlink:title="31803 - Disclosure - Net loss per common share (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_637838291102872363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_637838291102872363" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gaintherapeutics.com/role/DisclosureNatureOfBusinessAndBasisOfPresentationDetails" xlink:type="extended" xlink:title="40101 - Disclosure - Nature of the Business and Basis of Presentation (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_637838291102872363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_637838291102872363" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_637838291102872363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_637838291102872363" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_637838291102872363" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_637838291102872363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_637838291102872363" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_637838291102872363" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember_637838291102872363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_637838291102872363" xlink:to="us-gaap_IPOMember_637838291102872363" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember_637838291102872363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IPOMember_637838291102872363" xlink:to="us-gaap_OverAllotmentOptionMember_637838291102872363" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_IpoExcludingUnderwritersOptionsMember" xlink:label="ganx_IpoExcludingUnderwritersOptionsMember_637838291102882363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IPOMember_637838291102872363" xlink:to="ganx_IpoExcludingUnderwritersOptionsMember_637838291102882363" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_637838291102882363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_637838291102872363" xlink:to="us-gaap_StatementClassOfStockAxis_637838291102882363" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_637838291102882363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_637838291102882363" xlink:to="us-gaap_ClassOfStockDomain_637838291102882363" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_PreferredStockSeriesAndSeriesBMember" xlink:label="ganx_PreferredStockSeriesAndSeriesBMember_637838291102882363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637838291102882363" xlink:to="ganx_PreferredStockSeriesAndSeriesBMember_637838291102882363" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_637838291102882363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_637838291102872363" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_637838291102882363" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_637838291102882363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_637838291102882363" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_637838291102882363" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637838291102882363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_637838291102882363" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637838291102882363" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice_637838291102882363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_637838291102882363" xlink:to="us-gaap_SharePrice_637838291102882363" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_637838291102882363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_637838291102882363" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_637838291102882363" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_UnderwritingDiscountsAndCommissions" xlink:label="ganx_UnderwritingDiscountsAndCommissions_637838291102882363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_637838291102882363" xlink:to="ganx_UnderwritingDiscountsAndCommissions_637838291102882363" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_OtherOfferingExpenses" xlink:label="ganx_OtherOfferingExpenses_637838291102882363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_637838291102882363" xlink:to="ganx_OtherOfferingExpenses_637838291102882363" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_GrossProceedsFromIssuanceOfCommonStock" xlink:label="ganx_GrossProceedsFromIssuanceOfCommonStock_637838291102882363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_637838291102882363" xlink:to="ganx_GrossProceedsFromIssuanceOfCommonStock_637838291102882363" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_PreferredStockToCommonStockConversionRatio" xlink:label="ganx_PreferredStockToCommonStockConversionRatio_637838291102882363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_637838291102882363" xlink:to="ganx_PreferredStockToCommonStockConversionRatio_637838291102882363" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gaintherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" xlink:type="extended" xlink:title="40201 - Disclosure - Summary of Significant Accounting Policies (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_637838291102892364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_637838291102892364" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="us-gaap_DeferredFinanceCostsNet_637838291102892364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DeferredFinanceCostsNet_637838291102892364" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gaintherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalDisclosuresDetails" xlink:type="extended" xlink:title="40202 - Disclosure - Summary of Significant Accounting Policies - Additional disclosures (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637838291102892364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637838291102892364" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_637838291102892364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637838291102892364" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_637838291102892364" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_637838291102892364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_637838291102892364" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_637838291102892364" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_EquipmentAndFurnitureMember" xlink:label="ganx_EquipmentAndFurnitureMember_637838291102892364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637838291102892364" xlink:to="ganx_EquipmentAndFurnitureMember_637838291102892364" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember_637838291102892364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637838291102892364" xlink:to="us-gaap_OfficeEquipmentMember_637838291102892364" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_LaboratoryInstrumentsMember" xlink:label="ganx_LaboratoryInstrumentsMember_637838291102892364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637838291102892364" xlink:to="ganx_LaboratoryInstrumentsMember_637838291102892364" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_637838291102892364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637838291102892364" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_637838291102892364" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_637838291102892364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_637838291102892364" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_637838291102892364" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:label="us-gaap_ComputerSoftwareIntangibleAssetMember_637838291102902362" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_637838291102892364" xlink:to="us-gaap_ComputerSoftwareIntangibleAssetMember_637838291102902362" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_637838291102902362" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637838291102892364" xlink:to="us-gaap_StatementClassOfStockAxis_637838291102902362" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_637838291102902362" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_637838291102902362" xlink:to="us-gaap_ClassOfStockDomain_637838291102902362" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_637838291102902362" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637838291102902362" xlink:to="us-gaap_CommonStockMember_637838291102902362" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_637838291102902362" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637838291102892364" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_637838291102902362" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_PropertyPlantAndEquipmentDepreciationRates" xlink:label="ganx_PropertyPlantAndEquipmentDepreciationRates_637838291102902362" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_637838291102902362" xlink:to="ganx_PropertyPlantAndEquipmentDepreciationRates_637838291102902362" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedComputerSoftwareNet" xlink:label="us-gaap_CapitalizedComputerSoftwareNet_637838291102902362" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_637838291102902362" xlink:to="us-gaap_CapitalizedComputerSoftwareNet_637838291102902362" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedComputerSoftwareAdditions" xlink:label="us-gaap_CapitalizedComputerSoftwareAdditions_637838291102902362" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_637838291102902362" xlink:to="us-gaap_CapitalizedComputerSoftwareAdditions_637838291102902362" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_637838291102902362" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_637838291102902362" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_637838291102902362" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges_637838291102902362" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_637838291102902362" xlink:to="us-gaap_AssetImpairmentCharges_637838291102902362" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_637838291102902362" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_637838291102902362" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_637838291102902362" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_UncertainTaxPositionsRecognized" xlink:label="ganx_UncertainTaxPositionsRecognized_637838291102902362" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_637838291102902362" xlink:to="ganx_UncertainTaxPositionsRecognized_637838291102902362" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gaintherapeutics.com/role/DisclosureResearchGrantsDetails" xlink:type="extended" xlink:title="40301 - Disclosure - Research Grants (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_ResearchGrantsAbstract" xlink:label="ganx_ResearchGrantsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable_637838291102912360" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ganx_ResearchGrantsAbstract" xlink:to="us-gaap_DisaggregationOfRevenueTable_637838291102912360" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_637838291102912360" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable_637838291102912360" xlink:to="dei_LegalEntityAxis_637838291102912360" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_637838291102912360" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis_637838291102912360" xlink:to="dei_EntityDomain_637838291102912360" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_GtGainTherapeuticsSaMember" xlink:label="ganx_GtGainTherapeuticsSaMember_637838291102912360" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain_637838291102912360" xlink:to="ganx_GtGainTherapeuticsSaMember_637838291102912360" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_ConsortiumWithGtGainTherapeuticsSaInstituteForResearchInBiomedicineAndNeuroSysSasMember" xlink:label="ganx_ConsortiumWithGtGainTherapeuticsSaInstituteForResearchInBiomedicineAndNeuroSysSasMember_637838291102912360" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain_637838291102912360" xlink:to="ganx_ConsortiumWithGtGainTherapeuticsSaInstituteForResearchInBiomedicineAndNeuroSysSasMember_637838291102912360" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_637838291102912360" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable_637838291102912360" xlink:to="srt_CounterpartyNameAxis_637838291102912360" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_637838291102912360" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_637838291102912360" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_637838291102912360" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_MichaelJ.FoxFoundationForParkinsonSResearchMjffMember" xlink:label="ganx_MichaelJ.FoxFoundationForParkinsonSResearchMjffMember_637838291102912360" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_637838291102912360" xlink:to="ganx_MichaelJ.FoxFoundationForParkinsonSResearchMjffMember_637838291102912360" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_Eurostars2Member" xlink:label="ganx_Eurostars2Member_637838291102912360" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_637838291102912360" xlink:to="ganx_Eurostars2Member_637838291102912360" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems_637838291102912360" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable_637838291102912360" xlink:to="us-gaap_DisaggregationOfRevenueLineItems_637838291102912360" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrantsReceivable" xlink:label="us-gaap_GrantsReceivable_637838291102912360" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems_637838291102912360" xlink:to="us-gaap_GrantsReceivable_637838291102912360" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_ReductionOfResearchAndDevelopmentExpensesThroughExpensesReimbursed" xlink:label="ganx_ReductionOfResearchAndDevelopmentExpensesThroughExpensesReimbursed_637838291102912360" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems_637838291102912360" xlink:to="ganx_ReductionOfResearchAndDevelopmentExpensesThroughExpensesReimbursed_637838291102912360" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_ProceedsFromGrants" xlink:label="ganx_ProceedsFromGrants_637838291102922363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems_637838291102912360" xlink:to="ganx_ProceedsFromGrants_637838291102922363" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gaintherapeutics.com/role/DisclosureCashCashEquivalentsAndRestrictedCashDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Cash, cash equivalents and restricted cash (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTable_637838291102922363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTable_637838291102922363" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis_637838291102922363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCashAndCashEquivalentsTable_637838291102922363" xlink:to="us-gaap_CashAndCashEquivalentsAxis_637838291102922363" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_637838291102922363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis_637838291102922363" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_637838291102922363" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashMember" xlink:label="us-gaap_CashMember_637838291102922363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_637838291102922363" xlink:to="us-gaap_CashMember_637838291102922363" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember_637838291102922363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_637838291102922363" xlink:to="us-gaap_MoneyMarketFundsMember_637838291102922363" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems" xlink:label="us-gaap_CashAndCashEquivalentsLineItems_637838291102922363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCashAndCashEquivalentsTable_637838291102922363" xlink:to="us-gaap_CashAndCashEquivalentsLineItems_637838291102922363" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_637838291102922363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsLineItems_637838291102922363" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_637838291102922363" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash_637838291102922363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsLineItems_637838291102922363" xlink:to="us-gaap_RestrictedCash_637838291102922363" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gaintherapeutics.com/role/DisclosureCashCashEquivalentsAndRestrictedCashScheduleOfCashAndCashEquivalentsBalancesDetails" xlink:type="extended" xlink:title="40402 - Disclosure - Cash, cash equivalents and restricted cash - Schedule of Cash and cash equivalents balances (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTable_637838291102922363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTable_637838291102922363" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CurrencyAxis" xlink:label="srt_CurrencyAxis_637838291102932363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCashAndCashEquivalentsTable_637838291102922363" xlink:to="srt_CurrencyAxis_637838291102932363" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_AllCurrenciesDomain" xlink:label="currency_AllCurrenciesDomain_637838291102932363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CurrencyAxis_637838291102932363" xlink:to="currency_AllCurrenciesDomain_637838291102932363" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_CHF" xlink:label="currency_CHF_637838291102932363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="currency_AllCurrenciesDomain_637838291102932363" xlink:to="currency_CHF_637838291102932363" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_EUR" xlink:label="currency_EUR_637838291102932363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="currency_AllCurrenciesDomain_637838291102932363" xlink:to="currency_EUR_637838291102932363" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_USD" xlink:label="currency_USD_637838291102932363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="currency_AllCurrenciesDomain_637838291102932363" xlink:to="currency_USD_637838291102932363" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems" xlink:label="us-gaap_CashAndCashEquivalentsLineItems_637838291102932363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCashAndCashEquivalentsTable_637838291102922363" xlink:to="us-gaap_CashAndCashEquivalentsLineItems_637838291102932363" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_637838291102932363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsLineItems_637838291102932363" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_637838291102932363" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gaintherapeutics.com/role/DisclosureOtherCurrentAssetsDetails" xlink:type="extended" xlink:title="40501 - Disclosure - Other current assets (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxesAndOtherTaxReceivableCurrent" xlink:label="us-gaap_DeferredIncomeTaxesAndOtherTaxReceivableCurrent_637838291102932363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_DeferredIncomeTaxesAndOtherTaxReceivableCurrent_637838291102932363" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_637838291102932363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_637838291102932363" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="us-gaap_OtherReceivablesNetCurrent_637838291102932363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_OtherReceivablesNetCurrent_637838291102932363" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance_637838291102932363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidInsurance_637838291102932363" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_637838291102932363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_637838291102932363" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gaintherapeutics.com/role/DisclosurePropertyAndEquipmentNetDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Property and Equipment, net (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentNetAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637838291102942364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637838291102942364" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_637838291102942364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637838291102942364" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_637838291102942364" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_637838291102942364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_637838291102942364" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_637838291102942364" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember_637838291102942364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637838291102942364" xlink:to="us-gaap_ComputerEquipmentMember_637838291102942364" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember_637838291102942364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637838291102942364" xlink:to="us-gaap_FurnitureAndFixturesMember_637838291102942364" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember_637838291102942364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637838291102942364" xlink:to="us-gaap_LeaseholdImprovementsMember_637838291102942364" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_LaboratoryInstrumentsMember" xlink:label="ganx_LaboratoryInstrumentsMember_637838291102942364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637838291102942364" xlink:to="ganx_LaboratoryInstrumentsMember_637838291102942364" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_637838291102942364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637838291102942364" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_637838291102942364" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_637838291102942364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_637838291102942364" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_637838291102942364" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_637838291102942364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_637838291102942364" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_637838291102942364" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_637838291102942364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_637838291102942364" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_637838291102942364" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisposals" xlink:label="us-gaap_PropertyPlantAndEquipmentDisposals_637838291102942364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_637838291102942364" xlink:to="us-gaap_PropertyPlantAndEquipmentDisposals_637838291102942364" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization_637838291102942364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_637838291102942364" xlink:to="us-gaap_DepreciationDepletionAndAmortization_637838291102942364" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_637838291102942364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_637838291102942364" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_637838291102942364" order="6" use="optional" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gaintherapeutics.com/role/DisclosureOperatingLeaseRightOfUseRouAssetsAdditionalInformationDetails" xlink:type="extended" xlink:title="40701 - Disclosure - Operating lease. Right of use (ROU) assets - Additional information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable_637838291102952364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeLeaseDescriptionTable_637838291102952364" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_637838291102952364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable_637838291102952364" xlink:to="srt_RangeAxis_637838291102952364" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637838291102952364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_637838291102952364" xlink:to="srt_RangeMember_637838291102952364" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_637838291102952364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637838291102952364" xlink:to="srt_MinimumMember_637838291102952364" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_637838291102952364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637838291102952364" xlink:to="srt_MaximumMember_637838291102952364" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_637838291102952364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable_637838291102952364" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_637838291102952364" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_637838291102952364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_637838291102952364" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_637838291102952364" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_OfficeSpaceViaSoaveN6LuganoSwitzerlandMember" xlink:label="ganx_OfficeSpaceViaSoaveN6LuganoSwitzerlandMember_637838291102952364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637838291102952364" xlink:to="ganx_OfficeSpaceViaSoaveN6LuganoSwitzerlandMember_637838291102952364" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_OfficeSpaceViaPietroPeri9DLuganoSwitzerlandMember" xlink:label="ganx_OfficeSpaceViaPietroPeri9DLuganoSwitzerlandMember_637838291102952364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637838291102952364" xlink:to="ganx_OfficeSpaceViaPietroPeri9DLuganoSwitzerlandMember_637838291102952364" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_OfficeSpaceInBethesdaMarylandMember" xlink:label="ganx_OfficeSpaceInBethesdaMarylandMember_637838291102952364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637838291102952364" xlink:to="ganx_OfficeSpaceInBethesdaMarylandMember_637838291102952364" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_OfficeSpaceTorreDBuildingBarcelonaMember" xlink:label="ganx_OfficeSpaceTorreDBuildingBarcelonaMember_637838291102952364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637838291102952364" xlink:to="ganx_OfficeSpaceTorreDBuildingBarcelonaMember_637838291102952364" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_OfficeSpaceTorreIBuildingBarcelonaMember" xlink:label="ganx_OfficeSpaceTorreIBuildingBarcelonaMember_637838291102952364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637838291102952364" xlink:to="ganx_OfficeSpaceTorreIBuildingBarcelonaMember_637838291102952364" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_637838291102962364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable_637838291102952364" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_637838291102962364" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_637838291102962364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_637838291102962364" xlink:to="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_637838291102962364" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_637838291102962364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_637838291102962364" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_637838291102962364" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_637838291102962364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_637838291102962364" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_637838291102962364" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash_637838291102962364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_637838291102962364" xlink:to="us-gaap_RestrictedCash_637838291102962364" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInSecurityDeposits" xlink:label="us-gaap_IncreaseDecreaseInSecurityDeposits_637838291102962364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_637838291102962364" xlink:to="us-gaap_IncreaseDecreaseInSecurityDeposits_637838291102962364" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_LesseeOperatingLeaseTermOfCancelledContract" xlink:label="ganx_LesseeOperatingLeaseTermOfCancelledContract_637838291102962364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_637838291102962364" xlink:to="ganx_LesseeOperatingLeaseTermOfCancelledContract_637838291102962364" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_OfficeSpace" xlink:label="ganx_OfficeSpace_637838291102962364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_637838291102962364" xlink:to="ganx_OfficeSpace_637838291102962364" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gaintherapeutics.com/role/DisclosureOperatingLeaseRightOfUseRouAssetsSummaryOfComponentsOfLeaseAccountingDetails" xlink:type="extended" xlink:title="40702 - Disclosure - Operating lease. Right of use (ROU) assets - Summary of components of lease accounting (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_637838291102972365" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_637838291102972365" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_637838291102972365" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_637838291102972365" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_637838291102972365" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_637838291102972365" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_637838291102972365" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_637838291102972365" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_637838291102972365" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_637838291102972365" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gaintherapeutics.com/role/DisclosureOperatingLeaseRightOfUseRouAssetsSummaryOfComponentsOfLeaseExpenseDetails" xlink:type="extended" xlink:title="40703 - Disclosure - Operating lease. Right of use (ROU) assets - Summary of components of lease expense (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense_637838291102972365" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseExpense_637838291102972365" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gaintherapeutics.com/role/DisclosureOperatingLeaseRightOfUseRouAssetsFutureMinimumLeasePaymentsDetails" xlink:type="extended" xlink:title="40704 - Disclosure - Operating lease. Right of use (ROU) assets - Future minimum lease payments (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_637838291102972365" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract_1" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_637838291102972365" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_637838291102972365" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract_1" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_637838291102972365" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_637838291102982365" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract_1" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_637838291102982365" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_637838291102982365" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract_1" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_637838291102982365" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_637838291102982365" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract_1" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_637838291102982365" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_637838291102982365" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract_1" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_637838291102982365" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_AdjustmentToReconcileOperatingLeaseLiabilitiesAmountsRepresentingInterestOrImputedInterest" xlink:label="ganx_AdjustmentToReconcileOperatingLeaseLiabilitiesAmountsRepresentingInterestOrImputedInterest_637838291102982365" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract_1" xlink:to="ganx_AdjustmentToReconcileOperatingLeaseLiabilitiesAmountsRepresentingInterestOrImputedInterest_637838291102982365" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_637838291102982365" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract_1" xlink:to="us-gaap_OperatingLeaseLiability_637838291102982365" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gaintherapeutics.com/role/DisclosureAccountsPayableDetails" xlink:type="extended" xlink:title="40801 - Disclosure - Accounts Payable (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrentAbstract" xlink:label="us-gaap_AccountsPayableCurrentAbstract" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_AccountsPayableCurrentTable" xlink:label="ganx_AccountsPayableCurrentTable_637838291102982365" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableCurrentAbstract" xlink:to="ganx_AccountsPayableCurrentTable_637838291102982365" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CurrencyAxis" xlink:label="srt_CurrencyAxis_637838291102982365" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ganx_AccountsPayableCurrentTable_637838291102982365" xlink:to="srt_CurrencyAxis_637838291102982365" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_AllCurrenciesDomain" xlink:label="currency_AllCurrenciesDomain_637838291102982365" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CurrencyAxis_637838291102982365" xlink:to="currency_AllCurrenciesDomain_637838291102982365" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_CHF" xlink:label="currency_CHF_637838291102982365" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="currency_AllCurrenciesDomain_637838291102982365" xlink:to="currency_CHF_637838291102982365" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_EUR" xlink:label="currency_EUR_637838291102982365" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="currency_AllCurrenciesDomain_637838291102982365" xlink:to="currency_EUR_637838291102982365" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_USD" xlink:label="currency_USD_637838291102982365" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="currency_AllCurrenciesDomain_637838291102982365" xlink:to="currency_USD_637838291102982365" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_AccountsPayableCurrentLineItems" xlink:label="ganx_AccountsPayableCurrentLineItems_637838291102982365" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ganx_AccountsPayableCurrentTable_637838291102982365" xlink:to="ganx_AccountsPayableCurrentLineItems_637838291102982365" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_637838291102992367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ganx_AccountsPayableCurrentLineItems_637838291102982365" xlink:to="us-gaap_AccountsPayableCurrent_637838291102992367" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gaintherapeutics.com/role/DisclosureOtherCurrentLiabilitiesAndDeferredIncomeDetails" xlink:type="extended" xlink:title="40901 - Disclosure - Other current liabilities and deferred income (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCreditsAndOtherLiabilitiesAbstract" xlink:label="us-gaap_DeferredCreditsAndOtherLiabilitiesAbstract" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_PayableForSocialSecuritiesCurrent" xlink:label="ganx_PayableForSocialSecuritiesCurrent_637838291102992367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCreditsAndOtherLiabilitiesAbstract" xlink:to="ganx_PayableForSocialSecuritiesCurrent_637838291102992367" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_AccruedPayrollCurrent" xlink:label="ganx_AccruedPayrollCurrent_637838291102992367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCreditsAndOtherLiabilitiesAbstract" xlink:to="ganx_AccruedPayrollCurrent_637838291102992367" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_637838291102992367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCreditsAndOtherLiabilitiesAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent_637838291102992367" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxesPayableCurrent" xlink:label="us-gaap_TaxesPayableCurrent_637838291102992367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCreditsAndOtherLiabilitiesAbstract" xlink:to="us-gaap_TaxesPayableCurrent_637838291102992367" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_DepositsCurrent" xlink:label="ganx_DepositsCurrent_637838291102992367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCreditsAndOtherLiabilitiesAbstract" xlink:to="ganx_DepositsCurrent_637838291102992367" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent_637838291102992367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCreditsAndOtherLiabilitiesAbstract" xlink:to="us-gaap_OtherLiabilitiesCurrent_637838291102992367" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeCurrent" xlink:label="us-gaap_DeferredIncomeCurrent_637838291102992367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCreditsAndOtherLiabilitiesAbstract" xlink:to="us-gaap_DeferredIncomeCurrent_637838291102992367" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent" xlink:label="us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent_637838291102992367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCreditsAndOtherLiabilitiesAbstract" xlink:to="us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent_637838291102992367" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="6" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gaintherapeutics.com/role/DisclosurePensionObligationsEndOfYearFundedStatusDetails" xlink:type="extended" xlink:title="41001 - Disclosure - Pension obligations - End of year funded status (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_637838291102992367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_637838291102992367" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis" xlink:label="us-gaap_RetirementPlanTypeAxis_637838291102992367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_637838291102992367" xlink:to="us-gaap_RetirementPlanTypeAxis_637838291102992367" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="us-gaap_RetirementPlanTypeDomain_637838291103002365" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RetirementPlanTypeAxis_637838291102992367" xlink:to="us-gaap_RetirementPlanTypeDomain_637838291103002365" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember" xlink:label="us-gaap_PensionPlansDefinedBenefitMember_637838291103002365" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RetirementPlanTypeDomain_637838291103002365" xlink:to="us-gaap_PensionPlansDefinedBenefitMember_637838291103002365" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis" xlink:label="us-gaap_RetirementPlanSponsorLocationAxis_637838291103002365" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_637838291102992367" xlink:to="us-gaap_RetirementPlanSponsorLocationAxis_637838291103002365" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain" xlink:label="us-gaap_RetirementPlanSponsorLocationDomain_637838291103002365" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RetirementPlanSponsorLocationAxis_637838291103002365" xlink:to="us-gaap_RetirementPlanSponsorLocationDomain_637838291103002365" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticPlanMember" xlink:label="us-gaap_DomesticPlanMember_637838291103002365" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RetirementPlanSponsorLocationDomain_637838291103002365" xlink:to="us-gaap_DomesticPlanMember_637838291103002365" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_CH" xlink:label="country_CH_637838291103002365" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DomesticPlanMember_637838291103002365" xlink:to="country_CH_637838291103002365" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems_637838291103002365" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_637838291102992367" xlink:to="us-gaap_DefinedBenefitPlanDisclosureLineItems_637838291103002365" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:label="us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_637838291103002365" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems_637838291103002365" xlink:to="us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_637838291103002365" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligation" xlink:label="us-gaap_DefinedBenefitPlanBenefitObligation_637838291103002365" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems_637838291103002365" xlink:to="us-gaap_DefinedBenefitPlanBenefitObligation_637838291103002365" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanFundedStatusOfPlan" xlink:label="us-gaap_DefinedBenefitPlanFundedStatusOfPlan_637838291103002365" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems_637838291103002365" xlink:to="us-gaap_DefinedBenefitPlanFundedStatusOfPlan_637838291103002365" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation" xlink:label="us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation_637838291103002365" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems_637838291103002365" xlink:to="us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation_637838291103002365" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gaintherapeutics.com/role/DisclosurePensionObligationsReconciliationOfFundedStatusDetails" xlink:type="extended" xlink:title="41002 - Disclosure - Pension obligations - Reconciliation of funded status (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_637560093955907162" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_637838291103012364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract_637560093955907162" xlink:to="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_637838291103012364" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis" xlink:label="us-gaap_RetirementPlanTypeAxis_637838291103012364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_637838291103012364" xlink:to="us-gaap_RetirementPlanTypeAxis_637838291103012364" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="us-gaap_RetirementPlanTypeDomain_637838291103012364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RetirementPlanTypeAxis_637838291103012364" xlink:to="us-gaap_RetirementPlanTypeDomain_637838291103012364" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember" xlink:label="us-gaap_PensionPlansDefinedBenefitMember_637838291103012364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RetirementPlanTypeDomain_637838291103012364" xlink:to="us-gaap_PensionPlansDefinedBenefitMember_637838291103012364" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems_637838291103012364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_637838291103012364" xlink:to="us-gaap_DefinedBenefitPlanDisclosureLineItems_637838291103012364" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanFundedStatusOfPlan" xlink:label="us-gaap_DefinedBenefitPlanFundedStatusOfPlan_637838291103012364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems_637838291103012364" xlink:to="us-gaap_DefinedBenefitPlanFundedStatusOfPlan_637838291103012364" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_IncreaseDecreaseThroughTotalExpensesToReconcileFundedStatusOfDefinedBenefitPlan" xlink:label="ganx_IncreaseDecreaseThroughTotalExpensesToReconcileFundedStatusOfDefinedBenefitPlan_637838291103012364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems_637838291103012364" xlink:to="ganx_IncreaseDecreaseThroughTotalExpensesToReconcileFundedStatusOfDefinedBenefitPlan_637838291103012364" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:label="us-gaap_DefinedBenefitPlanContributionsByEmployer_637838291103012364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems_637838291103012364" xlink:to="us-gaap_DefinedBenefitPlanContributionsByEmployer_637838291103012364" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" xlink:label="us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss_637838291103012364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems_637838291103012364" xlink:to="us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss_637838291103012364" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_IncreaseDecreaseInAccumulatedOtherComprehensiveIncomeToReconcileFundedStatusOfDefinedBenefitPlan" xlink:label="ganx_IncreaseDecreaseInAccumulatedOtherComprehensiveIncomeToReconcileFundedStatusOfDefinedBenefitPlan_637838291103012364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems_637838291103012364" xlink:to="ganx_IncreaseDecreaseInAccumulatedOtherComprehensiveIncomeToReconcileFundedStatusOfDefinedBenefitPlan_637838291103012364" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanFundedStatusOfPlan" xlink:label="us-gaap_DefinedBenefitPlanFundedStatusOfPlan_6378382911030123641" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems_637838291103012364" xlink:to="us-gaap_DefinedBenefitPlanFundedStatusOfPlan_6378382911030123641" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gaintherapeutics.com/role/DisclosurePensionObligationsComponentOfNetPeriodicPensionCostsDetails" xlink:type="extended" xlink:title="41003 - Disclosure - Pension obligations - Component of net periodic pension costs (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_637838291103012364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract_2" xlink:to="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_637838291103012364" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis" xlink:label="us-gaap_RetirementPlanTypeAxis_637838291103022363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_637838291103012364" xlink:to="us-gaap_RetirementPlanTypeAxis_637838291103022363" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="us-gaap_RetirementPlanTypeDomain_637838291103022363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RetirementPlanTypeAxis_637838291103022363" xlink:to="us-gaap_RetirementPlanTypeDomain_637838291103022363" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember" xlink:label="us-gaap_PensionPlansDefinedBenefitMember_637838291103022363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RetirementPlanTypeDomain_637838291103022363" xlink:to="us-gaap_PensionPlansDefinedBenefitMember_637838291103022363" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems_637838291103022363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_637838291103012364" xlink:to="us-gaap_DefinedBenefitPlanDisclosureLineItems_637838291103022363" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanServiceCost" xlink:label="us-gaap_DefinedBenefitPlanServiceCost_637838291103022363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems_637838291103022363" xlink:to="us-gaap_DefinedBenefitPlanServiceCost_637838291103022363" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanInterestCost" xlink:label="us-gaap_DefinedBenefitPlanInterestCost_637838291103022363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems_637838291103022363" xlink:to="us-gaap_DefinedBenefitPlanInterestCost_637838291103022363" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:label="us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_637838291103022363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems_637838291103022363" xlink:to="us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_637838291103022363" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:label="us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_637838291103022363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems_637838291103022363" xlink:to="us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_637838291103022363" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:label="us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_637838291103022363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems_637838291103022363" xlink:to="us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_637838291103022363" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:label="us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_637838291103022363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems_637838291103022363" xlink:to="us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_637838291103022363" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gaintherapeutics.com/role/DisclosurePensionObligationsReconciliationOfProjectedBenefitObligationDetails" xlink:type="extended" xlink:title="41004 - Disclosure - Pension obligations - Reconciliation of projected benefit obligation (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_637838291103022363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract_1" xlink:to="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_637838291103022363" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis" xlink:label="us-gaap_RetirementPlanTypeAxis_637838291103022363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_637838291103022363" xlink:to="us-gaap_RetirementPlanTypeAxis_637838291103022363" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="us-gaap_RetirementPlanTypeDomain_637838291103022363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RetirementPlanTypeAxis_637838291103022363" xlink:to="us-gaap_RetirementPlanTypeDomain_637838291103022363" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember" xlink:label="us-gaap_PensionPlansDefinedBenefitMember_637838291103032364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RetirementPlanTypeDomain_637838291103022363" xlink:to="us-gaap_PensionPlansDefinedBenefitMember_637838291103032364" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems_637838291103032364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_637838291103022363" xlink:to="us-gaap_DefinedBenefitPlanDisclosureLineItems_637838291103032364" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligation" xlink:label="us-gaap_DefinedBenefitPlanBenefitObligation_637838291103032364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems_637838291103032364" xlink:to="us-gaap_DefinedBenefitPlanBenefitObligation_637838291103032364" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanServiceCost" xlink:label="us-gaap_DefinedBenefitPlanServiceCost_637838291103032364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems_637838291103032364" xlink:to="us-gaap_DefinedBenefitPlanServiceCost_637838291103032364" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant" xlink:label="us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant_637838291103032364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems_637838291103032364" xlink:to="us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant_637838291103032364" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanInterestCost" xlink:label="us-gaap_DefinedBenefitPlanInterestCost_637838291103032364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems_637838291103032364" xlink:to="us-gaap_DefinedBenefitPlanInterestCost_637838291103032364" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid" xlink:label="us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_637838291103032364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems_637838291103032364" xlink:to="us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_637838291103032364" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_DefinedBenefitPlanBenefitObligationGainsLossesOnFinancialAssumptions" xlink:label="ganx_DefinedBenefitPlanBenefitObligationGainsLossesOnFinancialAssumptions_637838291103032364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems_637838291103032364" xlink:to="ganx_DefinedBenefitPlanBenefitObligationGainsLossesOnFinancialAssumptions_637838291103032364" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_DefinedBenefitPlanBenefitObligationGainsLossesOnDemographicAssumptions" xlink:label="ganx_DefinedBenefitPlanBenefitObligationGainsLossesOnDemographicAssumptions_637838291103032364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems_637838291103032364" xlink:to="ganx_DefinedBenefitPlanBenefitObligationGainsLossesOnDemographicAssumptions_637838291103032364" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_DefinedBenefitPlanBenefitObligationGainsLossesOnExperience" xlink:label="ganx_DefinedBenefitPlanBenefitObligationGainsLossesOnExperience_637838291103032364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems_637838291103032364" xlink:to="ganx_DefinedBenefitPlanBenefitObligationGainsLossesOnExperience_637838291103032364" order="8" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPlanAmendments" xlink:label="us-gaap_DefinedBenefitPlanPlanAmendments_637838291103032364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems_637838291103032364" xlink:to="us-gaap_DefinedBenefitPlanPlanAmendments_637838291103032364" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligation" xlink:label="us-gaap_DefinedBenefitPlanBenefitObligation_6378382911030323641" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems_637838291103032364" xlink:to="us-gaap_DefinedBenefitPlanBenefitObligation_6378382911030323641" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gaintherapeutics.com/role/DisclosurePensionObligationsReconciliationOfFairValueOfPlanAssetsDetails" xlink:type="extended" xlink:title="41005 - Disclosure - Pension obligations - Reconciliation of fair value of plan assets (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_637838291103042366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract_4" xlink:to="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_637838291103042366" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis" xlink:label="us-gaap_RetirementPlanTypeAxis_637838291103042366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_637838291103042366" xlink:to="us-gaap_RetirementPlanTypeAxis_637838291103042366" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="us-gaap_RetirementPlanTypeDomain_637838291103042366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RetirementPlanTypeAxis_637838291103042366" xlink:to="us-gaap_RetirementPlanTypeDomain_637838291103042366" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember" xlink:label="us-gaap_PensionPlansDefinedBenefitMember_637838291103042366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RetirementPlanTypeDomain_637838291103042366" xlink:to="us-gaap_PensionPlansDefinedBenefitMember_637838291103042366" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems_637838291103042366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_637838291103042366" xlink:to="us-gaap_DefinedBenefitPlanDisclosureLineItems_637838291103042366" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:label="us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_637838291103042366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems_637838291103042366" xlink:to="us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_637838291103042366" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:label="us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_637838291103042366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems_637838291103042366" xlink:to="us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_637838291103042366" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets" xlink:label="us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_637838291103042366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems_637838291103042366" xlink:to="us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_637838291103042366" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:label="us-gaap_DefinedBenefitPlanContributionsByEmployer_637838291103042366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems_637838291103042366" xlink:to="us-gaap_DefinedBenefitPlanContributionsByEmployer_637838291103042366" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant" xlink:label="us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant_637838291103042366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems_637838291103042366" xlink:to="us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant_637838291103042366" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid" xlink:label="us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_637838291103042366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems_637838291103042366" xlink:to="us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_637838291103042366" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_DefinedBenefitPlanPlanAssetsOtherIncreasesDecreases" xlink:label="ganx_DefinedBenefitPlanPlanAssetsOtherIncreasesDecreases_637838291103042366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems_637838291103042366" xlink:to="ganx_DefinedBenefitPlanPlanAssetsOtherIncreasesDecreases_637838291103042366" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:label="us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_6378382911030423661" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems_637838291103042366" xlink:to="us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_6378382911030423661" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gaintherapeutics.com/role/DisclosurePensionObligationsChangeInNetGainLossDetails" xlink:type="extended" xlink:title="41006 - Disclosure - Pension obligations - Change in net (gain) loss (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_637838291103052364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract_5" xlink:to="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_637838291103052364" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis" xlink:label="us-gaap_RetirementPlanTypeAxis_637838291103052364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_637838291103052364" xlink:to="us-gaap_RetirementPlanTypeAxis_637838291103052364" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="us-gaap_RetirementPlanTypeDomain_637838291103052364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RetirementPlanTypeAxis_637838291103052364" xlink:to="us-gaap_RetirementPlanTypeDomain_637838291103052364" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember" xlink:label="us-gaap_PensionPlansDefinedBenefitMember_637838291103052364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RetirementPlanTypeDomain_637838291103052364" xlink:to="us-gaap_PensionPlansDefinedBenefitMember_637838291103052364" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems_637838291103052364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_637838291103052364" xlink:to="us-gaap_DefinedBenefitPlanDisclosureLineItems_637838291103052364" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax" xlink:label="us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax_637838291103052364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems_637838291103052364" xlink:to="us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax_637838291103052364" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligationPeriodIncreaseDecrease" xlink:label="us-gaap_DefinedBenefitPlanBenefitObligationPeriodIncreaseDecrease_637838291103052364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems_637838291103052364" xlink:to="us-gaap_DefinedBenefitPlanBenefitObligationPeriodIncreaseDecrease_637838291103052364" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssetsPeriodIncreaseDecrease" xlink:label="us-gaap_DefinedBenefitPlanFairValueOfPlanAssetsPeriodIncreaseDecrease_637838291103052364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems_637838291103052364" xlink:to="us-gaap_DefinedBenefitPlanFairValueOfPlanAssetsPeriodIncreaseDecrease_637838291103052364" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:label="us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_637838291103052364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems_637838291103052364" xlink:to="us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_637838291103052364" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax" xlink:label="us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax_6378382911030523641" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems_637838291103052364" xlink:to="us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax_6378382911030523641" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gaintherapeutics.com/role/DisclosurePensionObligationsChangeInAccumulatedOtherComprehensiveIncomeAociDetails" xlink:type="extended" xlink:title="41007 - Disclosure - Pension obligations - Change in accumulated other comprehensive income (AOCI) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_8" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_637838291103062366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract_8" xlink:to="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_637838291103062366" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis" xlink:label="us-gaap_RetirementPlanTypeAxis_637838291103062366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_637838291103062366" xlink:to="us-gaap_RetirementPlanTypeAxis_637838291103062366" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="us-gaap_RetirementPlanTypeDomain_637838291103062366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RetirementPlanTypeAxis_637838291103062366" xlink:to="us-gaap_RetirementPlanTypeDomain_637838291103062366" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember" xlink:label="us-gaap_PensionPlansDefinedBenefitMember_637838291103062366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RetirementPlanTypeDomain_637838291103062366" xlink:to="us-gaap_PensionPlansDefinedBenefitMember_637838291103062366" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems_637838291103062366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_637838291103062366" xlink:to="us-gaap_DefinedBenefitPlanDisclosureLineItems_637838291103062366" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax_637838291103062366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems_637838291103062366" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax_637838291103062366" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:label="us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_637838291103062366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems_637838291103062366" xlink:to="us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_637838291103062366" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligationPeriodIncreaseDecrease" xlink:label="us-gaap_DefinedBenefitPlanBenefitObligationPeriodIncreaseDecrease_637838291103062366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems_637838291103062366" xlink:to="us-gaap_DefinedBenefitPlanBenefitObligationPeriodIncreaseDecrease_637838291103062366" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssetsPeriodIncreaseDecrease" xlink:label="us-gaap_DefinedBenefitPlanFairValueOfPlanAssetsPeriodIncreaseDecrease_637838291103062366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems_637838291103062366" xlink:to="us-gaap_DefinedBenefitPlanFairValueOfPlanAssetsPeriodIncreaseDecrease_637838291103062366" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" xlink:label="us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_637838291103062366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems_637838291103062366" xlink:to="us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_637838291103062366" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:label="us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_637838291103062366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems_637838291103062366" xlink:to="us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_637838291103062366" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax_6378382911030623661" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems_637838291103062366" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax_6378382911030623661" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gaintherapeutics.com/role/DisclosurePensionObligationsAssumptionsDetails" xlink:type="extended" xlink:title="41008 - Disclosure - Pension obligations - Assumptions (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_637838291103072369" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract_7" xlink:to="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_637838291103072369" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis" xlink:label="us-gaap_RetirementPlanTypeAxis_637838291103072369" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_637838291103072369" xlink:to="us-gaap_RetirementPlanTypeAxis_637838291103072369" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="us-gaap_RetirementPlanTypeDomain_637838291103072369" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RetirementPlanTypeAxis_637838291103072369" xlink:to="us-gaap_RetirementPlanTypeDomain_637838291103072369" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember" xlink:label="us-gaap_PensionPlansDefinedBenefitMember_637838291103072369" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RetirementPlanTypeDomain_637838291103072369" xlink:to="us-gaap_PensionPlansDefinedBenefitMember_637838291103072369" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems_637838291103072369" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_637838291103072369" xlink:to="us-gaap_DefinedBenefitPlanDisclosureLineItems_637838291103072369" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedInCalculationsAbstract" xlink:label="us-gaap_DefinedBenefitPlanAssumptionsUsedInCalculationsAbstract_637838291103072369" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems_637838291103072369" xlink:to="us-gaap_DefinedBenefitPlanAssumptionsUsedInCalculationsAbstract_637838291103072369" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" xlink:label="us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate_637838291103072369" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlanAssumptionsUsedInCalculationsAbstract_637838291103072369" xlink:to="us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate_637838291103072369" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate" xlink:label="us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate_637838291103072369" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlanAssumptionsUsedInCalculationsAbstract_637838291103072369" xlink:to="us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate_637838291103072369" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" xlink:label="us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease_637838291103072369" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlanAssumptionsUsedInCalculationsAbstract_637838291103072369" xlink:to="us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease_637838291103072369" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfPensionIncreases" xlink:label="ganx_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfPensionIncreases_637838291103072369" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlanAssumptionsUsedInCalculationsAbstract_637838291103072369" xlink:to="ganx_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfPensionIncreases_637838291103072369" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_DefinedBenefitPlanDemographicAssumptionLumpSumOption" xlink:label="ganx_DefinedBenefitPlanDemographicAssumptionLumpSumOption_637838291103072369" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlanAssumptionsUsedInCalculationsAbstract_637838291103072369" xlink:to="ganx_DefinedBenefitPlanDemographicAssumptionLumpSumOption_637838291103072369" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_DefinedBenefitPlanDemographicAssumptionProportionMarried" xlink:label="ganx_DefinedBenefitPlanDemographicAssumptionProportionMarried_637838291103072369" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlanAssumptionsUsedInCalculationsAbstract_637838291103072369" xlink:to="ganx_DefinedBenefitPlanDemographicAssumptionProportionMarried_637838291103072369" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_DefinedBenefitPlanDemographicAssumptionAllowanceForChildPensions" xlink:label="ganx_DefinedBenefitPlanDemographicAssumptionAllowanceForChildPensions_637838291103072369" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlanAssumptionsUsedInCalculationsAbstract_637838291103072369" xlink:to="ganx_DefinedBenefitPlanDemographicAssumptionAllowanceForChildPensions_637838291103072369" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_DefinedBenefitPlanMortalityImprovementPercentage" xlink:label="ganx_DefinedBenefitPlanMortalityImprovementPercentage_637838291103082367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlanAssumptionsUsedInCalculationsAbstract_637838291103072369" xlink:to="ganx_DefinedBenefitPlanMortalityImprovementPercentage_637838291103082367" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_DefinedBenefitPlanDisabilityPercentage" xlink:label="ganx_DefinedBenefitPlanDisabilityPercentage_637838291103082367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlanAssumptionsUsedInCalculationsAbstract_637838291103072369" xlink:to="ganx_DefinedBenefitPlanDisabilityPercentage_637838291103082367" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gaintherapeutics.com/role/DisclosurePensionObligationsExpectedBenefitPaymentsDetails" xlink:type="extended" xlink:title="41009 - Disclosure - Pension obligations - Expected benefit payments (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_9" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_637838291103082367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract_9" xlink:to="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_637838291103082367" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis" xlink:label="us-gaap_RetirementPlanTypeAxis_637838291103082367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_637838291103082367" xlink:to="us-gaap_RetirementPlanTypeAxis_637838291103082367" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="us-gaap_RetirementPlanTypeDomain_637838291103082367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RetirementPlanTypeAxis_637838291103082367" xlink:to="us-gaap_RetirementPlanTypeDomain_637838291103082367" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember" xlink:label="us-gaap_PensionPlansDefinedBenefitMember_637838291103082367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RetirementPlanTypeDomain_637838291103082367" xlink:to="us-gaap_PensionPlansDefinedBenefitMember_637838291103082367" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems_637838291103082367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_637838291103082367" xlink:to="us-gaap_DefinedBenefitPlanDisclosureLineItems_637838291103082367" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" xlink:label="us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_637838291103082367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems_637838291103082367" xlink:to="us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_637838291103082367" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" xlink:label="us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_637838291103082367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems_637838291103082367" xlink:to="us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_637838291103082367" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" xlink:label="us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_637838291103082367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems_637838291103082367" xlink:to="us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_637838291103082367" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" xlink:label="us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_637838291103082367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems_637838291103082367" xlink:to="us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_637838291103082367" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" xlink:label="us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_637838291103092370" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems_637838291103082367" xlink:to="us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_637838291103092370" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" xlink:label="us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_637838291103092370" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems_637838291103082367" xlink:to="us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_637838291103092370" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" xlink:label="us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear_637838291103092370" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems_637838291103082367" xlink:to="us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear_637838291103092370" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gaintherapeutics.com/role/DisclosurePensionObligationsAdditionalInformationDetails" xlink:type="extended" xlink:title="41010 - Disclosure - Pension obligations - Additional Information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_637838291103092370" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract_6" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_637838291103092370" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gaintherapeutics.com/role/DisclosureLoansDetails" xlink:type="extended" xlink:title="41101 - Disclosure - Loans (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable_637838291103092370" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentTable_637838291103092370" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_637838291103092370" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_637838291103092370" xlink:to="us-gaap_DebtInstrumentAxis_637838291103092370" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_637838291103092370" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_637838291103092370" xlink:to="us-gaap_DebtInstrumentNameDomain_637838291103092370" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_March2020ChfLoanMember" xlink:label="ganx_March2020ChfLoanMember_637838291103102367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_637838291103092370" xlink:to="ganx_March2020ChfLoanMember_637838291103102367" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_August2020ChfLoanMember" xlink:label="ganx_August2020ChfLoanMember_637838291103102367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_637838291103092370" xlink:to="ganx_August2020ChfLoanMember_637838291103102367" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems_637838291103102367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_637838291103092370" xlink:to="us-gaap_DebtInstrumentLineItems_637838291103102367" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount_637838291103102367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637838291103102367" xlink:to="us-gaap_DebtInstrumentFaceAmount_637838291103102367" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm_637838291103102367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637838291103102367" xlink:to="us-gaap_DebtInstrumentTerm_637838291103102367" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_637838291103102367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637838291103102367" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_637838291103102367" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_ExpensesOrChargesDueForEarlyExtinguishmentOfDebt" xlink:label="ganx_ExpensesOrChargesDueForEarlyExtinguishmentOfDebt_637838291103102367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637838291103102367" xlink:to="ganx_ExpensesOrChargesDueForEarlyExtinguishmentOfDebt_637838291103102367" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="us-gaap_DebtInstrumentPeriodicPayment_637838291103102367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637838291103102367" xlink:to="us-gaap_DebtInstrumentPeriodicPayment_637838291103102367" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt_637838291103102367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637838291103102367" xlink:to="us-gaap_InterestExpenseDebt_637838291103102367" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="us-gaap_DeferredFinanceCostsNet_637838291103102367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637838291103102367" xlink:to="us-gaap_DeferredFinanceCostsNet_637838291103102367" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gaintherapeutics.com/role/DisclosureLoansFutureLoanPaymentsDetails" xlink:type="extended" xlink:title="41102 - Disclosure - Loans - Future loan payments (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt_637838291103102367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract_1" xlink:to="us-gaap_LongTermDebt_637838291103102367" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_637838291103112364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract_1" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_637838291103112364" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_637838291103112364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract_1" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_637838291103112364" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_637838291103112364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract_1" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_637838291103112364" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_637838291103112364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract_1" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_637838291103112364" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_637838291103112364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract_1" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_637838291103112364" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_637838291103112364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract_1" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_637838291103112364" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gaintherapeutics.com/role/DisclosureFairValueMeasurementDetails" xlink:type="extended" xlink:title="41201 - Disclosure - Fair value measurement (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_637838291103112364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract_1" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_637838291103112364" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_637838291103112364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_637838291103112364" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_637838291103112364" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637838291103112364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_637838291103112364" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637838291103112364" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member_637838291103112364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637838291103112364" xlink:to="us-gaap_FairValueInputsLevel1Member_637838291103112364" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis_637838291103112364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_637838291103112364" xlink:to="us-gaap_FairValueByAssetClassAxis_637838291103112364" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_637838291103112364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis_637838291103112364" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_637838291103112364" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsMember" xlink:label="us-gaap_CashAndCashEquivalentsMember_637838291103112364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_637838291103112364" xlink:to="us-gaap_CashAndCashEquivalentsMember_637838291103112364" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember_637838291103122366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsMember_637838291103112364" xlink:to="us-gaap_MoneyMarketFundsMember_637838291103122366" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_637838291103122366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_637838291103112364" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_637838291103122366" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure_637838291103122366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_637838291103122366" xlink:to="us-gaap_AssetsFairValueDisclosure_637838291103122366" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gaintherapeutics.com/role/DisclosureCommonAndPreferredStockDetails" xlink:type="extended" xlink:title="41301 - Disclosure - Common and Preferred Stock (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable_637838291103122366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable_637838291103122366" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_637838291103122366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_637838291103122366" xlink:to="us-gaap_StatementClassOfStockAxis_637838291103122366" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_637838291103122366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_637838291103122366" xlink:to="us-gaap_ClassOfStockDomain_637838291103122366" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredClassAMember" xlink:label="us-gaap_PreferredClassAMember_637838291103122366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637838291103122366" xlink:to="us-gaap_PreferredClassAMember_637838291103122366" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredClassBMember" xlink:label="us-gaap_PreferredClassBMember_637838291103122366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637838291103122366" xlink:to="us-gaap_PreferredClassBMember_637838291103122366" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems_637838291103122366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_637838291103122366" xlink:to="us-gaap_ClassOfStockLineItems_637838291103122366" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_637838291103122366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_637838291103122366" xlink:to="us-gaap_CommonStockSharesAuthorized_637838291103122366" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_637838291103122366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_637838291103122366" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_637838291103122366" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized_637838291103122366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_637838291103122366" xlink:to="us-gaap_PreferredStockSharesAuthorized_637838291103122366" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_637838291103132364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_637838291103122366" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_637838291103132364" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_637838291103132364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_637838291103122366" xlink:to="us-gaap_CommonStockSharesIssued_637838291103132364" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_637838291103132364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_637838291103122366" xlink:to="us-gaap_CommonStockSharesOutstanding_637838291103132364" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_637838291103132364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_637838291103122366" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_637838291103132364" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding_637838291103132364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_637838291103122366" xlink:to="us-gaap_PreferredStockSharesOutstanding_637838291103132364" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued_637838291103132364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_637838291103122366" xlink:to="us-gaap_PreferredStockSharesIssued_637838291103132364" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_637838291103132364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_637838291103122366" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_637838291103132364" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_PreferredStockToCommonStockConversionRatio" xlink:label="ganx_PreferredStockToCommonStockConversionRatio_637838291103132364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_637838291103122366" xlink:to="ganx_PreferredStockToCommonStockConversionRatio_637838291103132364" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gaintherapeutics.com/role/DisclosureWarrantsDetails" xlink:type="extended" xlink:title="41401 - Disclosure - Warrants (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable_637838291103192398" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightTable_637838291103192398" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_637838291103192398" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable_637838291103192398" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_637838291103192398" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_637838291103192398" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_637838291103192398" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_637838291103192398" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_WarrantsToDesigneesOfPlacementAgentIssuedJuly2020Member" xlink:label="ganx_WarrantsToDesigneesOfPlacementAgentIssuedJuly2020Member_637838291103192398" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_637838291103192398" xlink:to="ganx_WarrantsToDesigneesOfPlacementAgentIssuedJuly2020Member_637838291103192398" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_WarrantsToDesigneesOfInvestmentBankIssuedMay2021Member" xlink:label="ganx_WarrantsToDesigneesOfInvestmentBankIssuedMay2021Member_637838291103192398" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_637838291103192398" xlink:to="ganx_WarrantsToDesigneesOfInvestmentBankIssuedMay2021Member_637838291103192398" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_637838291103192398" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable_637838291103192398" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_637838291103192398" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_637838291103192398" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_637838291103192398" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_637838291103192398" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_637838291103192398" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_637838291103192398" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_637838291103192398" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding_637838291103192398" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_637838291103192398" xlink:to="us-gaap_WarrantsAndRightsOutstanding_637838291103192398" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_637838291103192398" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_637838291103192398" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_637838291103192398" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_637838291103192398" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_637838291103192398" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_637838291103192398" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_637838291103192398" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_637838291103192398" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_637838291103192398" order="6" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_WarrantsAndRightsExercisedOrExchangedNumber" xlink:label="ganx_WarrantsAndRightsExercisedOrExchangedNumber_637838291103192398" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_637838291103192398" xlink:to="ganx_WarrantsAndRightsExercisedOrExchangedNumber_637838291103192398" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_IssuanceOfCommonStockThroughCashlessExerciseOfWarrants" xlink:label="ganx_IssuanceOfCommonStockThroughCashlessExerciseOfWarrants_637838291103202378" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_637838291103192398" xlink:to="ganx_IssuanceOfCommonStockThroughCashlessExerciseOfWarrants_637838291103202378" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_WarrantsAndRightsServicePeriod" xlink:label="ganx_WarrantsAndRightsServicePeriod_637838291103202378" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_637838291103192398" xlink:to="ganx_WarrantsAndRightsServicePeriod_637838291103202378" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gaintherapeutics.com/role/DisclosureWarrantsAssumptionsUnderBlackScholesPricingModelDetails" xlink:type="extended" xlink:title="41402 - Disclosure - Warrants - Assumptions under black-scholes pricing model (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable_637838291103202378" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightTable_637838291103202378" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis_637838291103202378" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable_637838291103202378" xlink:to="us-gaap_MeasurementInputTypeAxis_637838291103202378" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_637838291103202378" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis_637838291103202378" xlink:to="us-gaap_MeasurementInputTypeDomain_637838291103202378" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_637838291103202378" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_637838291103202378" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_637838291103202378" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember_637838291103202378" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_637838291103202378" xlink:to="us-gaap_MeasurementInputExpectedTermMember_637838291103202378" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_637838291103202378" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_637838291103202378" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_637838291103202378" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationTechniqueAxis" xlink:label="us-gaap_ValuationTechniqueAxis_637838291103202378" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable_637838291103202378" xlink:to="us-gaap_ValuationTechniqueAxis_637838291103202378" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="us-gaap_ValuationTechniqueDomain_637838291103202378" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationTechniqueAxis_637838291103202378" xlink:to="us-gaap_ValuationTechniqueDomain_637838291103202378" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationTechniqueOptionPricingModelMember" xlink:label="us-gaap_ValuationTechniqueOptionPricingModelMember_637838291103202378" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationTechniqueDomain_637838291103202378" xlink:to="us-gaap_ValuationTechniqueOptionPricingModelMember_637838291103202378" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_637838291103212371" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable_637838291103202378" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_637838291103212371" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_WarrantsGrantDateFairValue" xlink:label="ganx_WarrantsGrantDateFairValue_637838291103212371" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_637838291103212371" xlink:to="ganx_WarrantsGrantDateFairValue_637838291103212371" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_637838291103212371" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_637838291103212371" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_637838291103212371" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gaintherapeutics.com/role/DisclosureEquityIncentivePlanDetails" xlink:type="extended" xlink:title="41501 - Disclosure - Equity Incentive Plan (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationRelatedCostsAbstract" xlink:label="us-gaap_CompensationRelatedCostsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637838291103212371" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationRelatedCostsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637838291103212371" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_637838291103212371" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637838291103212371" xlink:to="us-gaap_PlanNameAxis_637838291103212371" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_637838291103212371" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_637838291103212371" xlink:to="us-gaap_PlanNameDomain_637838291103212371" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_OmnibusIncentivePlanTwoThousandTwentyMember" xlink:label="ganx_OmnibusIncentivePlanTwoThousandTwentyMember_637838291103212371" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_637838291103212371" xlink:to="ganx_OmnibusIncentivePlanTwoThousandTwentyMember_637838291103212371" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_TwentyTwentyoneInducementEquityIncentivePlanMember" xlink:label="ganx_TwentyTwentyoneInducementEquityIncentivePlanMember_637838291103212371" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_637838291103212371" xlink:to="ganx_TwentyTwentyoneInducementEquityIncentivePlanMember_637838291103212371" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_637838291103212371" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637838291103212371" xlink:to="srt_RangeAxis_637838291103212371" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637838291103212371" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_637838291103212371" xlink:to="srt_RangeMember_637838291103212371" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_637838291103212371" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637838291103212371" xlink:to="srt_MaximumMember_637838291103212371" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637838291103222367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637838291103212371" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637838291103222367" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_637838291103222367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637838291103222367" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_637838291103222367" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_NumberOfOptionsSubjectToTermThreshold" xlink:label="ganx_NumberOfOptionsSubjectToTermThreshold_637838291103222367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637838291103222367" xlink:to="ganx_NumberOfOptionsSubjectToTermThreshold_637838291103222367" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_637838291103222367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637838291103222367" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_637838291103222367" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_637838291103222367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637838291103222367" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_637838291103222367" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_637838291103222367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637838291103222367" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_637838291103222367" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_637838291103222367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637838291103222367" xlink:to="us-gaap_CommonStockSharesOutstanding_637838291103222367" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_637838291103222367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637838291103222367" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_637838291103222367" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gaintherapeutics.com/role/DisclosureEquityIncentivePlanStockOptionActivityDetails" xlink:type="extended" xlink:title="41502 - Disclosure - Equity Incentive Plan - Stock Option Activity (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationRelatedCostsAbstract" xlink:label="us-gaap_CompensationRelatedCostsAbstract_637560637746912872" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637838291103222367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationRelatedCostsAbstract_637560637746912872" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637838291103222367" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_637838291103222367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637838291103222367" xlink:to="us-gaap_PlanNameAxis_637838291103222367" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_637838291103232369" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_637838291103222367" xlink:to="us-gaap_PlanNameDomain_637838291103232369" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_OmnibusIncentivePlanTwoThousandTwentyMember" xlink:label="ganx_OmnibusIncentivePlanTwoThousandTwentyMember_637838291103232369" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_637838291103232369" xlink:to="ganx_OmnibusIncentivePlanTwoThousandTwentyMember_637838291103232369" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637838291103232369" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637838291103222367" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637838291103232369" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637838291103232369" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637838291103232369" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637838291103232369" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_637838291103232369" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637838291103232369" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_637838291103232369" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAfterStockSplitsNumber" xlink:label="ganx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAfterStockSplitsNumber_637838291103232369" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637838291103232369" xlink:to="ganx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAfterStockSplitsNumber_637838291103232369" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_637838291103232369" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637838291103232369" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_637838291103232369" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_637838291103232369" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637838291103232369" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_637838291103232369" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_637838291103232369" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637838291103232369" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_637838291103232369" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6378382911032323691" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637838291103232369" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6378382911032323691" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_637838291103232369" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637838291103232369" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_637838291103232369" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionNonvestedWeightedAverageExercisePriceAfterStockSplit" xlink:label="ganx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionNonvestedWeightedAverageExercisePriceAfterStockSplit_637838291103232369" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_637838291103232369" xlink:to="ganx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionNonvestedWeightedAverageExercisePriceAfterStockSplit_637838291103232369" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_637838291103232369" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_637838291103232369" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_637838291103232369" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedDuringPeriodWeightedAverageGrantDateFairValue" xlink:label="ganx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedDuringPeriodWeightedAverageGrantDateFairValue_637838291103242364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_637838291103232369" xlink:to="ganx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedDuringPeriodWeightedAverageGrantDateFairValue_637838291103242364" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_637838291103242364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_637838291103232369" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_637838291103242364" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_637838291103242364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_637838291103232369" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_637838291103242364" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637838291103242364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637838291103232369" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637838291103242364" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_637838291103242364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637838291103242364" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_637838291103242364" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAfterStockSplitsWeightedAverageExercisePrice" xlink:label="ganx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAfterStockSplitsWeightedAverageExercisePrice_637838291103242364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637838291103242364" xlink:to="ganx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAfterStockSplitsWeightedAverageExercisePrice_637838291103242364" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_637838291103242364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637838291103242364" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_637838291103242364" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_637838291103242364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637838291103242364" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_637838291103242364" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_637838291103242364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637838291103242364" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_637838291103242364" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6378382911032423641" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637838291103242364" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6378382911032423641" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_637838291103242364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637838291103232369" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_637838291103242364" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_637838291103252364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_637838291103242364" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_637838291103252364" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAfterStockSplitWeightedAverageRemainingContractualTerm" xlink:label="ganx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAfterStockSplitWeightedAverageRemainingContractualTerm_637838291103252364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_637838291103242364" xlink:to="ganx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAfterStockSplitWeightedAverageRemainingContractualTerm_637838291103252364" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" xlink:label="ganx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_637838291103252364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_637838291103242364" xlink:to="ganx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_637838291103252364" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_637838291103252364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_637838291103242364" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_637838291103252364" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gaintherapeutics.com/role/DisclosureEquityIncentivePlanOptionsOutstandingAndExercisableDetails" xlink:type="extended" xlink:title="41503 - Disclosure - Equity Incentive Plan - Options Outstanding and Exercisable (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationRelatedCostsAbstract" xlink:label="us-gaap_CompensationRelatedCostsAbstract_637560649897285282" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637838291103252364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationRelatedCostsAbstract_637560649897285282" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637838291103252364" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_637838291103252364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637838291103252364" xlink:to="us-gaap_PlanNameAxis_637838291103252364" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_637838291103252364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_637838291103252364" xlink:to="us-gaap_PlanNameDomain_637838291103252364" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_OmnibusIncentivePlanTwoThousandTwentyMember" xlink:label="ganx_OmnibusIncentivePlanTwoThousandTwentyMember_637838291103262368" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_637838291103252364" xlink:to="ganx_OmnibusIncentivePlanTwoThousandTwentyMember_637838291103262368" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_637838291103262368" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637838291103252364" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_637838291103262368" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637838291103262368" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_637838291103262368" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637838291103262368" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_ExercisePrice3.38Member" xlink:label="ganx_ExercisePrice3.38Member_637838291103262368" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637838291103262368" xlink:to="ganx_ExercisePrice3.38Member_637838291103262368" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_ExercisePrice5.86Member" xlink:label="ganx_ExercisePrice5.86Member_637838291103262368" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637838291103262368" xlink:to="ganx_ExercisePrice5.86Member_637838291103262368" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_ExercisePrice5.99Member" xlink:label="ganx_ExercisePrice5.99Member_637838291103262368" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637838291103262368" xlink:to="ganx_ExercisePrice5.99Member_637838291103262368" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_ExercisePrice7.80Member" xlink:label="ganx_ExercisePrice7.80Member_637838291103262368" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637838291103262368" xlink:to="ganx_ExercisePrice7.80Member_637838291103262368" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_ExercisePrice10.03Member" xlink:label="ganx_ExercisePrice10.03Member_637838291103262368" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637838291103262368" xlink:to="ganx_ExercisePrice10.03Member_637838291103262368" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637838291103262368" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637838291103252364" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637838291103262368" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_637838291103262368" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637838291103262368" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_637838291103262368" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_637838291103262368" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637838291103262368" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_637838291103262368" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_637838291103262368" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637838291103262368" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_637838291103262368" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_637838291103262368" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637838291103262368" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_637838291103262368" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_637838291103272364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637838291103262368" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_637838291103272364" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_637838291103272364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637838291103262368" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_637838291103272364" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_637838291103272364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637838291103262368" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_637838291103272364" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_637838291103272364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637838291103262368" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_637838291103272364" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_637838291103272364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637838291103262368" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_637838291103272364" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_637838291103272364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637838291103262368" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_637838291103272364" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637838291103272364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637838291103262368" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637838291103272364" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice_637838291103272364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637838291103262368" xlink:to="us-gaap_SharePrice_637838291103272364" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gaintherapeutics.com/role/DisclosureEquityIncentivePlanAssumptionsDetails" xlink:type="extended" xlink:title="41504 - Disclosure - Equity Incentive Plan - Assumptions (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationRelatedCostsAbstract" xlink:label="us-gaap_CompensationRelatedCostsAbstract_637560674094352688" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637838291103282367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationRelatedCostsAbstract_637560674094352688" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637838291103282367" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_637838291103282367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637838291103282367" xlink:to="us-gaap_PlanNameAxis_637838291103282367" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_637838291103282367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_637838291103282367" xlink:to="us-gaap_PlanNameDomain_637838291103282367" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_OmnibusIncentivePlanTwoThousandTwentyMember" xlink:label="ganx_OmnibusIncentivePlanTwoThousandTwentyMember_637838291103282367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_637838291103282367" xlink:to="ganx_OmnibusIncentivePlanTwoThousandTwentyMember_637838291103282367" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637838291103282367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637838291103282367" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637838291103282367" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_637838291103282367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637838291103282367" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_637838291103282367" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_637838291103282367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637838291103282367" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_637838291103282367" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_637838291103282367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637838291103282367" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_637838291103282367" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_637838291103282367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637838291103282367" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_637838291103282367" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_637838291103282367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637838291103282367" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_637838291103282367" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gaintherapeutics.com/role/DisclosureEquityIncentivePlanStockBasedCompensationDetails" xlink:type="extended" xlink:title="41505 - Disclosure - Equity Incentive Plan - Stock-based compensation (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationRelatedCostsAbstract" xlink:label="us-gaap_CompensationRelatedCostsAbstract_637560686035096084" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637838291103282367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationRelatedCostsAbstract_637560686035096084" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637838291103282367" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_637838291103292368" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637838291103282367" xlink:to="us-gaap_PlanNameAxis_637838291103292368" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_637838291103292368" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_637838291103292368" xlink:to="us-gaap_PlanNameDomain_637838291103292368" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_OmnibusIncentivePlanTwoThousandTwentyMember" xlink:label="ganx_OmnibusIncentivePlanTwoThousandTwentyMember_637838291103292368" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_637838291103292368" xlink:to="ganx_OmnibusIncentivePlanTwoThousandTwentyMember_637838291103292368" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_637838291103292368" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637838291103282367" xlink:to="us-gaap_IncomeStatementLocationAxis_637838291103292368" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_637838291103292368" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_637838291103292368" xlink:to="us-gaap_IncomeStatementLocationDomain_637838291103292368" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_637838291103292368" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_637838291103292368" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_637838291103292368" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_637838291103292368" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_637838291103292368" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_637838291103292368" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637838291103292368" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637838291103282367" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637838291103292368" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_637838291103292368" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637838291103292368" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_637838291103292368" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gaintherapeutics.com/role/DisclosureCollaborationAgreementDetails" xlink:type="extended" xlink:title="41601 - Disclosure - Collaboration Agreement (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_CollaborationAgreementAbstract" xlink:label="ganx_CollaborationAgreementAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637838291103292368" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ganx_CollaborationAgreementAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637838291103292368" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_637838291103292368" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637838291103292368" xlink:to="us-gaap_TypeOfArrangementAxis_637838291103292368" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637838291103302369" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_637838291103292368" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637838291103302369" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_MultiTargetCollaborationAgreementMember" xlink:label="ganx_MultiTargetCollaborationAgreementMember_637838291103302369" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637838291103302369" xlink:to="ganx_MultiTargetCollaborationAgreementMember_637838291103302369" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_637838291103302369" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637838291103292368" xlink:to="srt_CounterpartyNameAxis_637838291103302369" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_637838291103302369" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_637838291103302369" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_637838291103302369" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_ZentalisPharmaceuticalsInc.Member" xlink:label="ganx_ZentalisPharmaceuticalsInc.Member_637838291103302369" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_637838291103302369" xlink:to="ganx_ZentalisPharmaceuticalsInc.Member_637838291103302369" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_637838291103302369" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637838291103292368" xlink:to="srt_RangeAxis_637838291103302369" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637838291103302369" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_637838291103302369" xlink:to="srt_RangeMember_637838291103302369" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_637838291103302369" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637838291103302369" xlink:to="srt_MaximumMember_637838291103302369" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637838291103302369" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637838291103292368" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637838291103302369" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_CollaborativeArrangementMinimumNumberOfTargets" xlink:label="ganx_CollaborativeArrangementMinimumNumberOfTargets_637838291103302369" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637838291103302369" xlink:to="ganx_CollaborativeArrangementMinimumNumberOfTargets_637838291103302369" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_CollaborativeArrangementTerminationNoticePeriodDays" xlink:label="ganx_CollaborativeArrangementTerminationNoticePeriodDays_637838291103302369" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637838291103302369" xlink:to="ganx_CollaborativeArrangementTerminationNoticePeriodDays_637838291103302369" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_CollaborativeArrangementProgramInitiationFee" xlink:label="ganx_CollaborativeArrangementProgramInitiationFee_637838291103302369" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637838291103302369" xlink:to="ganx_CollaborativeArrangementProgramInitiationFee_637838291103302369" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_CollaborativeArrangementEmployeeAndExternalResearchAndDevelopmentCosts" xlink:label="ganx_CollaborativeArrangementEmployeeAndExternalResearchAndDevelopmentCosts_637838291103302369" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637838291103302369" xlink:to="ganx_CollaborativeArrangementEmployeeAndExternalResearchAndDevelopmentCosts_637838291103302369" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_CollaborativeArrangementOptionExerciseFee" xlink:label="ganx_CollaborativeArrangementOptionExerciseFee_637838291103302369" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637838291103302369" xlink:to="ganx_CollaborativeArrangementOptionExerciseFee_637838291103302369" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_CollaborativeArrangementEventBasedMilestonePayments" xlink:label="ganx_CollaborativeArrangementEventBasedMilestonePayments_637838291103312367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637838291103302369" xlink:to="ganx_CollaborativeArrangementEventBasedMilestonePayments_637838291103312367" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="us-gaap_RevenueRemainingPerformanceObligation_637838291103312367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637838291103302369" xlink:to="us-gaap_RevenueRemainingPerformanceObligation_637838291103312367" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_637838291103312367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637838291103302369" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_637838291103312367" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability_637838291103312367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637838291103302369" xlink:to="us-gaap_ContractWithCustomerLiability_637838291103312367" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent_637838291103312367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637838291103302369" xlink:to="us-gaap_AccountsReceivableNetCurrent_637838291103312367" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gaintherapeutics.com/role/DisclosureIncomeTaxesDomesticAndForeignNetOperatingLossesDetails" xlink:type="extended" xlink:title="41701 - Disclosure - Income taxes - Domestic and foreign net operating losses (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_637838291103312367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_2" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_637838291103312367" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_637838291103312367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_637838291103312367" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_637838291103312367" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_637838291103312367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_637838291103312367" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_637838291103312367" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_637838291103312367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_637838291103312367" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_637838291103312367" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gaintherapeutics.com/role/DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseDetails" xlink:type="extended" xlink:title="41702 - Disclosure - Income taxes - Components of income tax expense (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract_637838291103322368" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_3" xlink:to="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract_637838291103322368" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_637838291103322368" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract_637838291103322368" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_637838291103322368" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit_637838291103322368" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_637838291103322368" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit_637838291103322368" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_637838291103322368" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_637838291103322368" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_637838291103322368" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_637838291103322368" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract_637838291103322368" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_637838291103322368" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_637838291103322368" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_637838291103322368" xlink:to="us-gaap_IncomeTaxExpenseBenefit_637838291103322368" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gaintherapeutics.com/role/DisclosureIncomeTaxesDomesticAndForeignNetOperatingLossesAndRelatedDeferredTaxAssetsDetails" xlink:type="extended" xlink:title="41703 - Disclosure - Income taxes - Domestic and foreign net operating losses and related deferred tax assets (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable_637838291103322368" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_4" xlink:to="us-gaap_OperatingLossCarryforwardsTable_637838291103322368" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis_637838291103322368" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable_637838291103322368" xlink:to="us-gaap_IncomeTaxAuthorityAxis_637838291103322368" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_637838291103322368" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis_637838291103322368" xlink:to="us-gaap_IncomeTaxAuthorityDomain_637838291103322368" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember_637838291103322368" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_637838291103322368" xlink:to="us-gaap_ForeignCountryMember_637838291103322368" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember_637838291103332366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_637838291103322368" xlink:to="us-gaap_DomesticCountryMember_637838291103332366" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_637838291103332366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable_637838291103322368" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_637838291103332366" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards_637838291103332366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_637838291103332366" xlink:to="us-gaap_OperatingLossCarryforwards_637838291103332366" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_637838291103332366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_637838291103332366" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_637838291103332366" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_637838291103332366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_637838291103332366" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_637838291103332366" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_637838291103332366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_637838291103332366" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_637838291103332366" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_637838291103332366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_637838291103332366" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_637838291103332366" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_637838291103332366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_637838291103332366" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_637838291103332366" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_DeferredTaxAssetsFmwWarrant" xlink:label="ganx_DeferredTaxAssetsFmwWarrant_637838291103332366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_637838291103332366" xlink:to="ganx_DeferredTaxAssetsFmwWarrant_637838291103332366" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther_637838291103332366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_637838291103332366" xlink:to="us-gaap_DeferredTaxAssetsOther_637838291103332366" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross_637838291103332366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_637838291103332366" xlink:to="us-gaap_DeferredTaxAssetsGross_637838291103332366" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_637838291103332366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_637838291103332366" xlink:to="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_637838291103332366" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_637838291103332366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_637838291103332366" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_637838291103332366" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_637838291103342366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_637838291103332366" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_637838291103342366" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_637838291103342366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_637838291103332366" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_637838291103342366" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_637838291103342366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_637838291103332366" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_637838291103342366" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gaintherapeutics.com/role/DisclosureIncomeTaxesAdditionalDisclosuresDetails" xlink:type="extended" xlink:title="41704 - Disclosure - Income taxes - Additional disclosures (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable_637838291103342366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_5" xlink:to="us-gaap_OperatingLossCarryforwardsTable_637838291103342366" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis_637838291103342366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable_637838291103342366" xlink:to="srt_StatementGeographicalAxis_637838291103342366" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_637838291103342366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis_637838291103342366" xlink:to="srt_SegmentGeographicalDomain_637838291103342366" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_ES" xlink:label="country_ES_637838291103342366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_637838291103342366" xlink:to="country_ES_637838291103342366" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_637838291103342366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable_637838291103342366" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_637838291103342366" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_637838291103342366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_637838291103342366" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_637838291103342366" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_637838291103342366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_637838291103342366" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_637838291103342366" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_ExpenseForInterestAndPenaltiesRelatedToUncertainTaxPositionRecognizedInStatementOfOperations" xlink:label="ganx_ExpenseForInterestAndPenaltiesRelatedToUncertainTaxPositionRecognizedInStatementOfOperations_637838291103352367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_637838291103342366" xlink:to="ganx_ExpenseForInterestAndPenaltiesRelatedToUncertainTaxPositionRecognizedInStatementOfOperations_637838291103352367" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gaintherapeutics.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails" xlink:type="extended" xlink:title="41705 - Disclosure - Income taxes - Effective income tax rate reconciliation (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_637838291103352367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_6" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_637838291103352367" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_637838291103352367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_637838291103352367" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_637838291103352367" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_637838291103352367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_637838291103352367" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_637838291103352367" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_EffectiveIncomeTaxRateReconciliationPermanentDifferences" xlink:label="ganx_EffectiveIncomeTaxRateReconciliationPermanentDifferences_637838291103352367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_637838291103352367" xlink:to="ganx_EffectiveIncomeTaxRateReconciliationPermanentDifferences_637838291103352367" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_EffectiveIncomeTaxRateReconciliationProvisionToReturn" xlink:label="ganx_EffectiveIncomeTaxRateReconciliationProvisionToReturn_637838291103352367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_637838291103352367" xlink:to="ganx_EffectiveIncomeTaxRateReconciliationProvisionToReturn_637838291103352367" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_637838291103352367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_637838291103352367" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_637838291103352367" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_637838291103352367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_637838291103352367" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_637838291103352367" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_637838291103352367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_637838291103352367" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_637838291103352367" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gaintherapeutics.com/role/DisclosureNetLossPerCommonShareComputationOfDilutedNetLossPerShareDetails" xlink:type="extended" xlink:title="41801 - Disclosure - Net loss per common share - Computation of diluted net loss per share (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_637838291103362371" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_637838291103362371" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_637838291103362371" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_637838291103362371" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_637838291103362371" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_637838291103362371" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_637838291103362371" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_637838291103362371" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember_637838291103362371" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_637838291103362371" xlink:to="us-gaap_SeriesAPreferredStockMember_637838291103362371" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredClassBMember" xlink:label="us-gaap_PreferredClassBMember_637838291103362371" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_637838291103362371" xlink:to="us-gaap_PreferredClassBMember_637838291103362371" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_637838291103362371" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_637838291103362371" xlink:to="us-gaap_EmployeeStockOptionMember_637838291103362371" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember_637838291103362371" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_637838291103362371" xlink:to="us-gaap_WarrantMember_637838291103362371" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis_637838291103362371" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_637838291103362371" xlink:to="srt_RestatementAxis_637838291103362371" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain_637838291103362371" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementAxis_637838291103362371" xlink:to="srt_RestatementDomain_637838291103362371" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="srt_ScenarioPreviouslyReportedMember_637838291103362371" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementDomain_637838291103362371" xlink:to="srt_ScenarioPreviouslyReportedMember_637838291103362371" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_637838291103362371" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_637838291103362371" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_637838291103362371" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_637838291103362371" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_637838291103362371" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_637838291103362371" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_637838291103362371" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_637838291103362371" xlink:to="us-gaap_EarningsPerShareBasic_637838291103362371" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gaintherapeutics.com/role/DisclosureRelatedPartiesDetails" xlink:type="extended" xlink:title="41901 - Disclosure - Related Parties (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_637838291103372370" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_637838291103372370" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_637838291103372370" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_637838291103372370" xlink:to="srt_RangeAxis_637838291103372370" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637838291103372370" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_637838291103372370" xlink:to="srt_RangeMember_637838291103372370" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_637838291103372370" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637838291103372370" xlink:to="srt_MaximumMember_637838291103372370" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis_637838291103372370" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_637838291103372370" xlink:to="us-gaap_RelatedPartyTransactionAxis_637838291103372370" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain_637838291103372370" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis_637838291103372370" xlink:to="us-gaap_RelatedPartyTransactionDomain_637838291103372370" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_LicenseAgreementWithMinoryxTherapeuticsSlMember" xlink:label="ganx_LicenseAgreementWithMinoryxTherapeuticsSlMember_637838291103372370" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain_637838291103372370" xlink:to="ganx_LicenseAgreementWithMinoryxTherapeuticsSlMember_637838291103372370" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems_637838291103372370" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_637838291103372370" xlink:to="us-gaap_RelatedPartyTransactionLineItems_637838291103372370" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_RelatedPartyTransactionPercentageOfNetRevenuesBasedOnOneCompositionOfMatterClaim" xlink:label="ganx_RelatedPartyTransactionPercentageOfNetRevenuesBasedOnOneCompositionOfMatterClaim_637838291103372370" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637838291103372370" xlink:to="ganx_RelatedPartyTransactionPercentageOfNetRevenuesBasedOnOneCompositionOfMatterClaim_637838291103372370" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_RelatedPartyTransactionPercentageOfNetRevenuesBasedOnOneMethodOfClaim" xlink:label="ganx_RelatedPartyTransactionPercentageOfNetRevenuesBasedOnOneMethodOfClaim_637838291103372370" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637838291103372370" xlink:to="ganx_RelatedPartyTransactionPercentageOfNetRevenuesBasedOnOneMethodOfClaim_637838291103372370" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_RelatedPartyTransactionPercentageOfConsiderationReceived" xlink:label="ganx_RelatedPartyTransactionPercentageOfConsiderationReceived_637838291103372370" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637838291103372370" xlink:to="ganx_RelatedPartyTransactionPercentageOfConsiderationReceived_637838291103372370" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableRelatedParties" xlink:label="us-gaap_AccountsReceivableRelatedParties_637838291103382371" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637838291103372370" xlink:to="us-gaap_AccountsReceivableRelatedParties_637838291103382371" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent" xlink:label="us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent_637838291103382371" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637838291103372370" xlink:to="us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent_637838291103382371" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromRelatedParties" xlink:label="us-gaap_RevenueFromRelatedParties_637838291103382371" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637838291103372370" xlink:to="us-gaap_RevenueFromRelatedParties_637838291103382371" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_637838291103382371" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637838291103372370" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_637838291103382371" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gaintherapeutics.com/role/DisclosureOtherInformationDetails" xlink:type="extended" xlink:title="42001 - Disclosure - Other Information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_OtherInformationAbstract" xlink:label="ganx_OtherInformationAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentsTable" xlink:label="us-gaap_OtherCommitmentsTable_637838291103382371" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ganx_OtherInformationAbstract_2" xlink:to="us-gaap_OtherCommitmentsTable_637838291103382371" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="us-gaap_OtherCommitmentsAxis_637838291103382371" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsTable_637838291103382371" xlink:to="us-gaap_OtherCommitmentsAxis_637838291103382371" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain_637838291103382371" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsAxis_637838291103382371" xlink:to="us-gaap_OtherCommitmentsDomain_637838291103382371" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ganx-20211231.xsd#ganx_CollaborationAgreementsMember" xlink:label="ganx_CollaborationAgreementsMember_637838291103382371" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsDomain_637838291103382371" xlink:to="ganx_CollaborationAgreementsMember_637838291103382371" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="us-gaap_OtherCommitmentsLineItems_637838291103382371" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsTable_637838291103382371" xlink:to="us-gaap_OtherCommitmentsLineItems_637838291103382371" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:label="us-gaap_ContractualObligationDueInNextTwelveMonths_637838291103382371" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_637838291103382371" xlink:to="us-gaap_ContractualObligationDueInNextTwelveMonths_637838291103382371" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139934221975720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Feb. 28, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-40237<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">GAIN THERAPEUTICS,&#160;INC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">85-1726310<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">4800 Montgomery Lane<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Adress Line Two</a></td>
<td class="text">Suite 220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Bethesda<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address State Or Province</a></td>
<td class="text">MD<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">20814<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">301<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">500-1556<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.0001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">GANX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 118.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,883,368<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001819411<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Ernst&#160;& Young AG<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">1460<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Lugano, Switzerland<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139934222015592">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 36,880,673<span></span>
</td>
<td class="nump">$ 7,492,910<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,371<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,548<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxesAndOtherTaxReceivableCurrent', window );">Tax credits</a></td>
<td class="nump">113,586<span></span>
</td>
<td class="nump">58,017<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">727,785<span></span>
</td>
<td class="nump">198,994<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Deferred offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,217,988<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">37,722,044<span></span>
</td>
<td class="nump">8,987,828<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>Non-current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">105,986<span></span>
</td>
<td class="nump">29,633<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ganx_CapitalizedComputerSoftwareForInternalUse', window );">Internal-use software</a></td>
<td class="nump">202,609<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease - right of use assets</a></td>
<td class="nump">901,042<span></span>
</td>
<td class="nump">523,080<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">31,279<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ganx_DepositsAndOtherAssetsNoncurrent', window );">Long-term deposits and other non-current assets</a></td>
<td class="nump">22,111<span></span>
</td>
<td class="nump">63,817<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total non-current assets</a></td>
<td class="nump">1,263,027<span></span>
</td>
<td class="nump">616,530<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">38,985,071<span></span>
</td>
<td class="nump">9,604,358<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">560,479<span></span>
</td>
<td class="nump">961,516<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability - current</a></td>
<td class="nump">219,137<span></span>
</td>
<td class="nump">122,756<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">1,402,600<span></span>
</td>
<td class="nump">768,450<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrent', window );">Tax provision</a></td>
<td class="nump">380<span></span>
</td>
<td class="nump">1,070<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeCurrent', window );">Deferred income</a></td>
<td class="nump">266,504<span></span>
</td>
<td class="nump">239,483<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Loans - short term</a></td>
<td class="nump">103,826<span></span>
</td>
<td class="nump">22,626<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">2,552,546<span></span>
</td>
<td class="nump">2,114,831<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Non-current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent', window );">Defined benefit pension plan</a></td>
<td class="nump">329,458<span></span>
</td>
<td class="nump">171,558<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability - non-current</a></td>
<td class="nump">695,053<span></span>
</td>
<td class="nump">400,324<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Loans - long term</a></td>
<td class="nump">590,468<span></span>
</td>
<td class="nump">715,656<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total non-current liabilities</a></td>
<td class="nump">1,614,979<span></span>
</td>
<td class="nump">1,287,538<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">4,167,525<span></span>
</td>
<td class="nump">3,402,369<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common Stock, $0.0001 par value: 11,883,368 and 3,543,163 issued and outstanding as of December 31, 2021 and December 31, 2020, respectively</a></td>
<td class="nump">1,189<span></span>
</td>
<td class="nump">354<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">55,832,461<span></span>
</td>
<td class="nump">13,388,771<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(90,645)<span></span>
</td>
<td class="num">(152,698)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(7,034,853)<span></span>
</td>
<td class="num">(3,457,171)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ganx_IncomeLossForPeriod', window );">Loss of the period</a></td>
<td class="num">(13,890,606)<span></span>
</td>
<td class="num">(3,577,682)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">34,817,546<span></span>
</td>
<td class="nump">6,201,989<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 38,985,071<span></span>
</td>
<td class="nump">9,604,358<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred Stock, Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">118<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred Stock, Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 297<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ganx_CapitalizedComputerSoftwareForInternalUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of capitalized internally use software as on date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ganx_CapitalizedComputerSoftwareForInternalUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ganx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ganx_DepositsAndOtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer and noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ganx_DepositsAndOtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ganx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ganx_IncomeLossForPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period income or loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ganx_IncomeLossForPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ganx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income excluding obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 25<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=28183603&amp;loc=d3e692-112598<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxesAndOtherTaxReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and other tax receivables expected to be realized or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxesAndOtherTaxReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.A)<br> -URI http://asc.fasb.org/extlink&amp;oid=122040515&amp;loc=d3e105025-122735<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability, recognized in statement of financial position, for defined benefit pension plan, classified as noncurrent. Excludes other postretirement benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1731-114919<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1703-114919<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139934220166808">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">50,000,000<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares, issued</a></td>
<td class="nump">11,883,368<span></span>
</td>
<td class="nump">3,543,163<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares, outstanding</a></td>
<td class="nump">11,883,368<span></span>
</td>
<td class="nump">3,543,163<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,185,879<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,185,879<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,965,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,965,600<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139934221977368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statement of Operations - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenues</a></td>
<td class="nump">$ 133,928<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Other income</a></td>
<td class="nump">31,066<span></span>
</td>
<td class="nump">$ 28,881<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">164,994<span></span>
</td>
<td class="nump">28,881<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="num">(7,164,229)<span></span>
</td>
<td class="num">(2,259,204)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="num">(6,826,938)<span></span>
</td>
<td class="num">(1,249,126)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="num">(13,991,167)<span></span>
</td>
<td class="num">(3,508,330)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(13,826,173)<span></span>
</td>
<td class="num">(3,479,449)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Interest income, net</a></td>
<td class="nump">12,495<span></span>
</td>
<td class="nump">3,637<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign exchange loss, net</a></td>
<td class="num">(72,920)<span></span>
</td>
<td class="num">(96,484)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income tax</a></td>
<td class="num">(13,886,598)<span></span>
</td>
<td class="num">(3,572,296)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax</a></td>
<td class="num">(4,008)<span></span>
</td>
<td class="num">(5,386)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (13,890,606)<span></span>
</td>
<td class="num">$ (3,577,682)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract', window );"><strong>Net loss per shares:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share attributable to common stockholders - Basic</a></td>
<td class="num">$ (1.37)<span></span>
</td>
<td class="num">$ (1.33)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share attributable to common stockholders - Diluted</a></td>
<td class="num">$ (1.37)<span></span>
</td>
<td class="num">$ (1.33)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares - Basic</a></td>
<td class="nump">10,165,404<span></span>
</td>
<td class="nump">2,681,408<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common shares - Diluted</a></td>
<td class="nump">10,165,404<span></span>
</td>
<td class="nump">2,681,408<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30690-110894<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123602790&amp;loc=d3e30226-110892<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=120253306&amp;loc=d3e28228-110885<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124440516&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of operating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139934222160072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statement of Comprehensive Loss - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Consolidated Statement of Comprehensive Loss</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (13,890,606)<span></span>
</td>
<td class="num">$ (3,577,682)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive gain/(loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax', window );">Defined benefit pension plan</a></td>
<td class="num">(101,780)<span></span>
</td>
<td class="num">(36,218)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation</a></td>
<td class="nump">163,833<span></span>
</td>
<td class="num">(35,317)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive gain/(loss):</a></td>
<td class="nump">62,053<span></span>
</td>
<td class="num">(71,535)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (13,828,553)<span></span>
</td>
<td class="num">$ (3,649,217)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i-k)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139934217836984">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statement of Changes in Stockholders' Equity (Deficit) - USD ($)<br></strong></div></th>
<th class="th">
<div>Preferred Stock </div>
<div>Series A Preferred Stock.</div>
</th>
<th class="th">
<div>Preferred Stock </div>
<div>Series B Preferred Stock</div>
</th>
<th class="th">
<div>Common Stock </div>
<div>Common Stock</div>
</th>
<th class="th"><div>APIC</div></th>
<th class="th"><div>AOCI</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2019</a></td>
<td class="nump">$ 87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 198<span></span>
</td>
<td class="nump">$ 3,088,193<span></span>
</td>
<td class="num">$ (81,163)<span></span>
</td>
<td class="num">$ (3,457,171)<span></span>
</td>
<td class="num">$ (449,856)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2019</a></td>
<td class="nump">875,006<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,981,765<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ganx_IssuanceOfSeriesPreferredStockNetOfIssuanceCost', window );">Issuance of Series A Preferred Stock, net of issuance cost</a></td>
<td class="nump">$ 31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,091,314<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,091,345<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ganx_IssuanceOfSeriesPreferredStockInShares', window );">Issuance of Series A Preferred Stock (in shares)</a></td>
<td class="nump">310,873<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ganx_IssuanceOfSeriesBPreferredStockNetOfIssuanceCost', window );">Issuance of Series B Preferred Stock, net of issuance cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 297<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,713,716<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,714,013<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ganx_IssuanceOfSeriesBPreferredStockInShares', window );">Issuance of Series B Preferred Stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,965,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 156<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">177<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of stock, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,561,398<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81,640<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81,640<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Issuance of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">413,887<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">413,887<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax', window );">Defined benefit pension plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(36,218)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(36,218)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(35,317)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(35,317)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,577,682)<span></span>
</td>
<td class="num">(3,577,682)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2020</a></td>
<td class="nump">$ 118<span></span>
</td>
<td class="nump">$ 297<span></span>
</td>
<td class="nump">$ 354<span></span>
</td>
<td class="nump">13,388,771<span></span>
</td>
<td class="num">(152,698)<span></span>
</td>
<td class="num">(7,034,853)<span></span>
</td>
<td class="nump">6,201,989<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2020</a></td>
<td class="nump">1,185,879<span></span>
</td>
<td class="nump">2,965,600<span></span>
</td>
<td class="nump">3,543,163<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ganx_ConversionOfSeriesPreferredStockIntoCommonStock', window );">Conversion of Series A Preferred Stock into Common Stock</a></td>
<td class="num">$ (118)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 118<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ganx_ConversionOfSeriesPreferredStockIntoCommonStockInShares', window );">Conversion of Series A Preferred Stock into Common Stock (in shares)</a></td>
<td class="num">(1,185,879)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,185,879<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ganx_ConversionOfSeriesBPreferredStockIntoCommonStock', window );">Conversion of Series B Preferred Stock into Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (297)<span></span>
</td>
<td class="nump">$ 297<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ganx_ConversionOfSeriesBPreferredStockIntoCommonStockInShares', window );">Conversion of Series B Preferred Stock into Common Stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,965,600)<span></span>
</td>
<td class="nump">2,965,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ganx_IssuanceOfCommonStockInIpoNetOfIssuanceCosts', window );">Issuance of Common Stock in IPO, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 419<span></span>
</td>
<td class="nump">40,558,103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,558,522<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ganx_IssuanceOfCommonStockInIpoInShares', window );">Issuance of Common Stock in IPO (In shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,181,818<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ganx_IssuanceOfCommonStockThroughCashlessExerciseOfWarrants', window );">Issuance of Common Stock due to warrants cashless exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,283<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of Common Share due to stock option exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">12,216<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,217<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of Common Share due to stock option exercise (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">839,371<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">839,371<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Issuance of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,034,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,034,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax', window );">Defined benefit pension plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(101,780)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(101,780)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">163,833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">163,833<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13,890,606)<span></span>
</td>
<td class="num">(13,890,606)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,189<span></span>
</td>
<td class="nump">$ 55,832,461<span></span>
</td>
<td class="num">$ (90,645)<span></span>
</td>
<td class="num">$ (20,925,459)<span></span>
</td>
<td class="nump">$ 34,817,546<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,883,368<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ganx_ConversionOfSeriesBPreferredStockIntoCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity from conversion of Series B Preferred Stock into Common Stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ganx_ConversionOfSeriesBPreferredStockIntoCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ganx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ganx_ConversionOfSeriesBPreferredStockIntoCommonStockInShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in number of shares resulting from the conversion of Series B Preferred Stock into Common Stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ganx_ConversionOfSeriesBPreferredStockIntoCommonStockInShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ganx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ganx_ConversionOfSeriesPreferredStockIntoCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity from conversion of Series A Preferred Stock into Common Stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ganx_ConversionOfSeriesPreferredStockIntoCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ganx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ganx_ConversionOfSeriesPreferredStockIntoCommonStockInShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in number of shares resulting from the conversion of Series B Preferred Stock into Common Stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ganx_ConversionOfSeriesPreferredStockIntoCommonStockInShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ganx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ganx_IssuanceOfCommonStockInIpoInShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase in shares issued resulting from the company's initial public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ganx_IssuanceOfCommonStockInIpoInShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ganx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ganx_IssuanceOfCommonStockInIpoNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity from the issuance of common stock in initial public offering, net of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ganx_IssuanceOfCommonStockInIpoNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ganx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ganx_IssuanceOfCommonStockThroughCashlessExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock through cashless exercise of warrants</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ganx_IssuanceOfCommonStockThroughCashlessExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ganx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ganx_IssuanceOfSeriesBPreferredStockInShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase in number of shares resulting from issuance of Series B Preferred Stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ganx_IssuanceOfSeriesBPreferredStockInShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ganx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ganx_IssuanceOfSeriesBPreferredStockNetOfIssuanceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from the issuance of Series B Preferred Stock, net of issuance cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ganx_IssuanceOfSeriesBPreferredStockNetOfIssuanceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ganx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ganx_IssuanceOfSeriesPreferredStockInShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase in number of shares resulting from issuance of Series A Preferred Stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ganx_IssuanceOfSeriesPreferredStockInShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ganx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ganx_IssuanceOfSeriesPreferredStockNetOfIssuanceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from the issuance of Series A Preferred Stock, net of issuance cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ganx_IssuanceOfSeriesPreferredStockNetOfIssuanceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ganx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123466302&amp;loc=d3e4724-112606<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i-k)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139934216539752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statement of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (13,890,606)<span></span>
</td>
<td class="num">$ (3,577,682)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">15,484<span></span>
</td>
<td class="nump">9,592<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation expense</a></td>
<td class="nump">839,371<span></span>
</td>
<td class="nump">81,640<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Issuance of warrants</a></td>
<td class="nump">1,034,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ganx_CapitalizedComputerSoftwareAdjustment', window );">Internal-use software</a></td>
<td class="num">(34,135)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Account receivables</a></td>
<td class="nump">8,264<span></span>
</td>
<td class="num">(196)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(534,502)<span></span>
</td>
<td class="num">(117,704)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ganx_IncreaseDecreaseInValueAddedTaxCredits', window );">VAT credits</a></td>
<td class="num">(71,618)<span></span>
</td>
<td class="num">(21,454)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Long term deposit and other non current assets</a></td>
<td class="nump">33,979<span></span>
</td>
<td class="num">(63,095)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(521,394)<span></span>
</td>
<td class="nump">395,543<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities', window );">Other current liabilities</a></td>
<td class="nump">665,460<span></span>
</td>
<td class="nump">173,725<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionExpenseReversalOfExpenseNoncash', window );">Defined benefit pension plan</a></td>
<td class="nump">55,326<span></span>
</td>
<td class="nump">8,709<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredLiabilities', window );">Deferred income</a></td>
<td class="nump">34,701<span></span>
</td>
<td class="num">(129,315)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ganx_IncreaseDecreaseInOperatingAssetsAndLiabilities', window );">Total changes in operating assets and liabilities</a></td>
<td class="num">(329,784)<span></span>
</td>
<td class="nump">246,213<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(12,365,670)<span></span>
</td>
<td class="num">(3,240,237)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(94,212)<span></span>
</td>
<td class="num">(20,826)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(94,212)<span></span>
</td>
<td class="num">(20,826)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flow from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from long-term debts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">738,282<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ganx_ProceedsFromIssuanceOfSeriesA.PreferredStockNetOfIssuanceCosts', window );">Proceeds from issuance of Series A Preferred Stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,091,345<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ganx_ProceedsFromIssuanceOfSeriesBPreferredStockNetOfIssuanceCosts', window );">Proceeds from issuance of Series B Preferred Stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,127,902<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from issuance of common shares upon completion of initial public offering, net of underwriter discounts</a></td>
<td class="nump">42,629,998<span></span>
</td>
<td class="nump">177<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of deferred offering costs</a></td>
<td class="num">(853,488)<span></span>
</td>
<td class="num">(470,745)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfShortTermDebt', window );">Payments of current portion of long-term debt</a></td>
<td class="num">(21,951)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from stock option exercise</a></td>
<td class="nump">12,216<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">41,766,775<span></span>
</td>
<td class="nump">10,486,961<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents', window );">Effect of exchange rate changes</a></td>
<td class="nump">100,778<span></span>
</td>
<td class="num">(35,317)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase in cash, cash equivalents and restricted cash</a></td>
<td class="nump">29,407,671<span></span>
</td>
<td class="nump">7,190,581<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at beginning of period</a></td>
<td class="nump">7,504,281<span></span>
</td>
<td class="nump">313,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at end of period</a></td>
<td class="nump">$ 36,911,952<span></span>
</td>
<td class="nump">$ 7,504,281<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ganx_CapitalizedComputerSoftwareAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of adjustment for capitalized computer software.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ganx_CapitalizedComputerSoftwareAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ganx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ganx_IncreaseDecreaseInOperatingAssetsAndLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) in Operating Assets and Liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ganx_IncreaseDecreaseInOperatingAssetsAndLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ganx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ganx_IncreaseDecreaseInValueAddedTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in value-added tax credits</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ganx_IncreaseDecreaseInValueAddedTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ganx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ganx_ProceedsFromIssuanceOfSeriesA.PreferredStockNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of Series A Preferred Stock, net of issuance costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ganx_ProceedsFromIssuanceOfSeriesA.PreferredStockNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ganx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ganx_ProceedsFromIssuanceOfSeriesBPreferredStockNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of Series B Preferred Stock, net of issuance costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ganx_ProceedsFromIssuanceOfSeriesBPreferredStockNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ganx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change during the period in carrying value for all deferred liabilities due within one year or operating cycle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionExpenseReversalOfExpenseNoncash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense (reversal of expense) for pension benefits. Excludes other postretirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionExpenseReversalOfExpenseNoncash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139934219881048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of the Business and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Nature of the Business and Basis of Presentation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Nature of the Business and Basis of Presentation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">1.&#160;&#160;&#160;&#160;Nature of the business and basis of presentation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Operations and business</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Gain Therapeutics,&#160;Inc. (and together with its subsidiary, the &#8220;Company&#8221;), was incorporated under the laws of the state of Delaware (U.S.) on June&#160;26, 2020. On July&#160;20, 2020, the Company consummated a corporate reorganization, pursuant to which all of the issued and outstanding common and preferred stock of GT Gain Therapeutics SA, a Swiss company formed in 2017, were exchanged for common stock or preferred stock, as applicable, of Gain Therapeutics,&#160;Inc., reflecting a 10:1 stock split. The corporate reorganization was accounted for as a recapitalization for accounting purposes, with GT Gain Therapeutics SA resulting in the predecessor entity of the Company. As a result of the corporate reorganization, GT Gain Therapeutics SA became a wholly-owned subsidiary of Gain Therapeutics,&#160;Inc. For periods and at dates prior to the corporate reorganization, the consolidated financial statements presented were prepared based on the historical financial statements of GT Gain Therapeutics SA, adjusted to give retroactive effect to the share exchange transactions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On March 17, 2021, the Company&#8217;s registration statement on Form S-1 related to its Initial Public Offering (&#8220;IPO&#8221;) was declared effective by the Securities and Exchange Commission (&#8220;SEC&#8221;). The IPO closed on March 17, 2021 at the Nasdaq. In conjunction with the IPO the Company completed a reverse stock split of the Company&#8217;s outstanding equity instruments. The reverse stock split was approved by the stockholders on March 4, 2021 and became effective on March 17, 2021. Upon closing of the IPO, the Series A and the Series B Preferred Stock, as resulting form the reverse stock split, were converted to common stock at a ratio of 1-for-1. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company is a biotechnology company developing novel therapies to treat diseases caused by protein misfolding, with an initial focus on rare genetic diseases and neurological disorders. We use our licensed platform, SEE-Tx&#174;, to discover novel allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites, potentially restoring protein folding and treating disease. These small molecule binding sites, away from the protein&#8217;s active areas, are called allosteric sites. Targeting the allosteric binding site instead of the active binding site provides superior regulation of misfolded enzymes implicated by disease, is non-competitive with the natural substrate, provides superior drug-like properties and ultimately enhances both safety and efficacy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Risks and uncertainties</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, risks associated with completion and success of preclinical studies and clinical testing, dependence on key personnel, protection of proprietary technology, compliance with applicable governmental regulations, development by competitors of new technological innovations, protection of proprietary technology and the ability to secure additional capital to fund operations. Drug candidates currently under development will require significant additional research and development efforts, including preclinical and clinical testing and prior to regulatory approval and commercialization. These efforts require significant amounts of additional capital, adequate personnel, and infrastructure and extensive compliance-reporting capabilities. Even if the Company&#8217;s drug development efforts are successful, it is uncertain when, if ever, the Company will realize revenue from product sales.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Going concern</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has incurred recurring losses and negative cash flows from operations since its inception and has primarily funded these losses through proceeds from capital contributions. The Company anticipates incurring additional losses until such time, if ever, that it can generate significant sales of its product candidates currently in development. Substantial additional capital will be needed by the Company to fund its operations and to develop its product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In March 2021, the Company closed its initial public offering, or IPO, in which the Company issued and sold 4,181,818 shares of its common stock, which included shares sold pursuant to an option granted to the underwriters to purchase additional shares, at a public offering price of $11.00 per share for net proceeds of $40.5 million after deducting underwriting discounts, commissions and other offering expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s operations have consisted primarily of organizing the Company, securing financing, developing licensed technology, performing research and conducting preclinical studies. The Company faces risks associated with early-stage biotechnology companies whose product candidates are in development. Product candidates currently under development will require significant additional research and development efforts, including extensive preclinical and clinical testing, establishing manufacturing capacity and regulatory approval prior to commercialization. These efforts require significant amounts of additional capital for the Company to complete its research and development, achieve its research and development objectives, defend its intellectual property rights, and recruit and retain skilled personnel, and key members of management. Even if the Company&#8217;s product development efforts are successful, it is uncertain when, if ever, the Company will realize revenue from product sales. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company plans to seek additional funding through public or private equity offerings, debt financings, other collaborations,strategic alliances and licensing arrangements. The Company may not be able to obtain financing on acceptable terms, or at all,and the Company may not be able to enter into strategic alliances or other arrangements on favorable terms, or at all. The terms of any financing may adversely affect the holdings or the rights of the Company&#8217;s stockholders. If the Company is unable to obtain funding, the Company could be required to delay, reduce or eliminate research and development programs, product portfolio expansion or future commercialization efforts, which could adversely affect its business prospects. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In accordance with Accounting Standards Update, or &#8220;ASU&#8221;, No. 2014-15, Disclosure of Uncertainties about an Entity&#8217;s Ability to Continue as a Going Concern, the Company has evaluated whether there are certain conditions and events, considered in the aggregate, that raise substantial doubt about the Company&#8217;s ability to continue as a going concern within one year after the date that the financial statements are issued. As of the issuance date of these financial statements, the Company expects that its cash and cash equivalents will be sufficient to fund its forecasted operating expenses and capital expenditure requirements for at least the next twelve months from the issuance date of these financialstatements. Accordingly, the consolidated financial statements have been prepared assuming that the Company will continue as a going concern.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Basis of presentation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The consolidated financial statements reflect the accounts of the Gain Therapeutics, Inc., GT Gain Therapeutics SA and its wholly owned branch, Gain Therapeutics Sucursal en Espa&#241;a. All intercompany transactions and balances have been eliminated in the preparation of the consolidated financial statements. The consolidated financial statements as of December 31, 2021, represented by the Consolidated Balance Sheet, the Consolidated Statement of Operations, the Consolidated Statements of Changes in Shareholders&#8217; Equity, the Consolidated Statement of Comprehensive Loss, the Consolidated Statements of Cash Flows and the accompanying Notes, have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;US GAAP&#8221;). Any reference in these notes to applicable guidance is meant to refer to the authoritative United States generally accepted accounting principles as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Update (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The &#160;financial statements as of December 31, 2021 reflect, for all periods presented, the retroactive application of the reverse stock split that occurred on March 17, 2021. All amounts in the consolidated financial statements are expressed in United States Dollars (USD/$) and disclosed within these explanatory notes in United States Dollars (USD/$) or Swiss Franc (CHF), which are the functional currencies of the Company and its operating subsidiary, GT Gain Therapeutics SA, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The consolidated financial statements have been prepared on the same basis as the audited annual consolidated financial statements as of and for the year ended December 31, 2020, and, in the opinion of management, reflect all adjustments, consisting of normal recurring adjustments, necessary for the fair presentation of the Company&#8217;s financial position as of December 31, 2021, and the results of its operations for the years ended December 31, 2021 and 2020, its statements of stockholders&#8217; equity and its statements of cash flows for the years then ended. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Reverse Stock Split </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">On March 3, 2021, the Board approved a 1-for-<span style="-sec-ix-hidden:Hidden_PPLEqeAgy0iiPmdWllrCSA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">0.880784</span></span> reverse stock split of the Company&#8217;s outstanding equity instruments. The reverse stock split was approved by the stockholders on March 4, 2021 and became effective in conjunction with the IPO on March 17, 2021. Stockholders were no entitled to fractional shares as a result of the reverse stock split. All share and per share data shown in the accompanying consolidated financial statements and </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">related notes have been retroactively revised to reflect the reverse stock split. Shares of common stock underlying outstanding stock options and other equity instruments were proportionately reduced and the respective exercise prices, if applicable, were proportionately increased in accordance with the terms of the agreements governing such securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Initial Public Offering </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On March 17, 2021, the Company&#8217;s registration statement on Form S-1 relating to its IPO was declared effective by the Securities and Exchange Commission (&#8220;SEC&#8221;). The IPO closed on March 17, 2021 and the Company issued and sold 3,636,364 common shares at a public offering price of $11.00 per share for net proceeds of $34,978 thousand after deducting underwriting discounts and commissions of $2,950 thousand and other offering expenses of $2,071 thousand. On March 22, 2021, the Company issued and sold 545,454 additional common shares, pursuant to the full exercise of the underwriters&#8217; option to purchase additional shares, for net proceeds of $5,580 thousand after deducting underwriting discounts and commissions of $420 thousand. Thus, the aggregate net proceeds to the Company from the IPO, after deducting underwriting discounts commissions, were $42,630 thousand. After deducting other IPO offering expenses amounting to $2,071 thousand, the net cash proceeds resulting from the IPO were $40,558 thousand, which are reflected in the statement of stockholders&#8217; equity as Issuance of Common Stock in IPO, net of issuance costs. Upon the closing of the IPO, series A convertible preferred stock (the &#8220;Series A Preferred Stock&#8221;) and series B convertible preferred stock (the &#8220;Series B Preferred Stock&#8221;, and together with the Series A Preferred Stock, are collectively referred to as the &#8220;Preferred Stock&#8221;) were converted into shares of common stock at ratio of 1-for-1.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Segment information</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Operating segments are defined as components of an enterprise for which separate discrete information is available for evaluation by the chief operating decision-maker in deciding how to allocate resources and assess performance. The Company&#8217;s chief operating decision-maker, the Chief Executive Officer, oversees the Company&#8217;s operations and manages the business as a single operating segment, which is research and development in the pharmaceutical sector with a focus on developing novel therapeutics to treat diseases caused by protein misfolding, such as rare genetic diseases and neurological disorders. Geographically, the research and development activities are mainly performed in Switzerland and Spain. The Company does not consider these geographies to be separate segments.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139934219831080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">2. &#160;&#160;&#160;&#160;Summary of significant accounting policies</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Foreign currency translation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company is incorporated in the United States of America and has operations in Switzerland and Spain. The Company&#8217;s functional currency is USD. The functional currencies of the Company&#8217;s foreign operations are the local currencies (Swiss Franc in Switzerland and Euro in Spain). Assets and liabilities reported in the consolidated balance sheets are translated into U.S. dollars (the currency in which these financial statements are presented) at the exchange rates applicable at the balance sheet dates and for the consolidated statement of operations at the average exchange rates for the periods presented. Items representing the share capital and additional paid-in capital are presented at the historical exchange rates. Adjustments resulting from the translation of the financial statements of the Company&#8217;s foreign operations into U.S. dollars are excluded from the determination of net income and are recorded in accumulated other comprehensive income/(loss), a separate component of shareholders&#8217; equity. The Company has not utilized any foreign currency hedging strategies to mitigate the effect of its foreign currency exposure. As of December 31, 2021 and 2020, accumulated currency translation adjustment recorded in the accumulated other comprehensive loss amounted to $165,156 and $1,323, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The preparation of our consolidated financial statements in conformity with US GAAP requires management to make estimates, judgments and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting periods. On an ongoing basis, we evaluate our estimates judgments and, assumptions including those related to recognition of grant funds, accrued expenses, defined benefit pension liability, warrants and stock-based compensation. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. Changes in estimates are recorded in the period in which they become known. To the extent that material differences arise between the estimates and actual results, the Company&#8217;s future results of operations will be affected. The COVID-19 pandemic did not have a significant impact on the Company&#8217;s estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Cash and cash equivalents</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company reports cash on hand and held at banks, and all highly liquid investments in money market, certificates of deposit, time deposit, and other short-term liquid securities with original maturities of less than 90 day, as cash and cash equivalents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Concentrations of credit risk</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has no significant off-balance sheet risk, such as foreign exchange contracts, option contracts, or other foreign hedging arrangements. Financial instruments that may expose the Company to concentrations of credit risk consist primarily of cash, cash equivalents which are deposited in accredited financial institutions in excess of federally insured limits. The Company deposits its cash and cash equivalents in financial institutions that it believes have high credit quality and has not experienced any losses on such accounts and does not believe it is exposed to any unusual credit risk beyond the normal credit risk associated with commercial banking relationships.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Deferred Issuance Costs</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company capitalizes certain legal, professional accounting and other third-party fees that are directly associated with in-process equity financings as deferred issuance costs until such financings are consummated. After consummation of the equity financing, these costs are recorded as a reduction of the proceeds generated as a result of the offering. Should the planned equity financing be abandoned, the deferred issuance costs will be expensed immediately as a charge to operating expenses in the consolidated statements of operations. There were nil and $1,217,988 deferred issuance costs as of December 31, 2021 and 2020, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Property and equipment</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Property and equipment are stated at cost, including any accessory and direct costs that are necessary to make the assets fit for use, and adjusted by the corresponding accumulated depreciation. The depreciation rates recorded in the consolidated financial statements of operations have been calculated by taking into consideration the use, purpose and financial-technical duration of the assets, on the basis of their estimated useful economic lives. The Company believes the above criteria to be represented by the following depreciation rates:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:61.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:33.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:61.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">-&#8195; Equipment &amp; Furniture</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:33.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 12.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:top;width:61.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">-&#8195; Electronic office equipment:</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:33.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:top;width:61.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">-&#8195; Leasehold Improvements</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:33.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">based on the terms of the lease</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:61.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">-&#8195; Laboratory equipment:</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:33.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 15</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Ordinary maintenance costs are entirely attributed to the consolidated statements of operations in the&#160;year in which they are incurred. Extraordinary maintenance costs, the purpose of which is to extend the useful economic life of the asset, to technologically upgrade it and/or to increase its productivity or safety for the purposes of the economic productivity of the Company, are attributed to the asset to which they refer and depreciated on the basis of its estimated useful economic lives. Amortization of leasehold improvements is computed using the straight-line method based upon the terms of the applicable lease or estimated useful life of the improvements, whichever is lower.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Capitalized Software Development Costs</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company capitalizes the costs of software obtained for internal use in accordance with ASC 350-40, Internal-Use Software. Capitalized software development costs consist of costs incurred during the development stage and include purchased software licenses, implementation costs, consulting costs, and payroll-related costs for projects that qualify for capitalization. All other costs, primarily related to maintenance and minor software fixes, are expensed as incurred. As of December 31, 2021 and 2020, internal-use software amount to $202,609 and nil, and refer to the </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">external and internal labor costs incurred in the development of the Company ERP, amounting respectively to $168,474 and $34,135. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company amortizes the capitalized software development costs on a straight-line basis over the estimated useful life of the software, which is generally six years, beginning when the asset is substantially ready for use. The amortization of capitalized software development costs is reflected in general and administrative expenses. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Impairment of long-lived assets</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">In accordance with ASC Topic 360-10-20, &#8220;Property, Plant and Equipment,&#8221; the Company performs an impairment test whenever events or circumstances indicate that the carrying value of long-lived assets with finite lives may be impaired. Impairment is measured by comparing the carrying value of the long-lived assets to the estimated undiscounted pre-tax cash flows expected to result from the use of such assets and their ultimate disposition. In circumstances where impairment is determined to exist, the Company will write down the asset to its fair value based on the present value of estimated cash flows. </span><span style="font-weight:normal;">No</span><span style="font-weight:normal;"> impairments have been identified by management as of and for any periods presented.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Patents</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">Patent-related costs, refer to legal fees incurred in connection with filing and prosecuting patent applications and are expensed as incurred due to uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Leases</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Effective January&#160;1, 2018, the Company adopted ASC 842, using the additional transition method option provided by ASU 2018-11. Under this transition method, we applied the new accounting guidance as of the date of adoption. Upon adoption, a cumulative effect adjustment was not required.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Subsequent to the adoption, the Company determines if an arrangement contains a lease at inception based on whether or not the Company has the right to control the asset during the contract period and other facts and circumstances. The Company is the lessee in a lease contract when it obtains the right to control the asset. Operating lease right of use (&#8220;ROU&#8221;) assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease, both of which are recognized based on the present value of the future minimum lease payments over the lease term at the commencement date. Leases with a term of 12 months or less at inception are expensed on a straight-line basis over the lease term in the statement of operations. The Company determines the lease term by assuming the exercise of renewal options that are reasonably certain. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, the Company subleases portions of its office premises in Lugano. The Company recognizes sublease income on a straight-line basis over the sublease terms, reported within other income. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Accounts Payable</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Accounts payable are reported at their nominal amounts due to their short-term maturities. Trade accounts payable are recorded net of trade discounts; cash discounts are recorded at the time of payment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Payables for Social Securities</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Social Security charges are reported in compliance with rules and laws applicable in the countries where our employees work. Charges are accrued in accordance with the policies stipulated and in connection with salaries due for the period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Accrued expenses</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">As part of the process of preparing our consolidated financial statements, we are required to estimate our accrued expenses as of each balance sheet date. This process involves reviewing open contracts and purchase orders, communicating with our personnel to identify services that have been performed on our behalf and estimating the level </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of the actual cost. We make estimates of our accrued expenses as of each balance sheet date based on facts and circumstances known to us at that time at the date of the preparation of the consolidated financial statements. There may be instances in which payments made to our vendors exceed the level of services provided, and result in prepayment reported under other current assets, which are subsequently expenses in the consolidated statement of operations when the related activity has been performed rather than when the payment is made. To date, there have been no material differences between our estimates of accrued expenses reported at each balance sheet date and the amounts actually incurred.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Pension obligations</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We operate defined benefit pension plan and defined contribution pension plans in accordance with local regulations and practices in the countries in which the Company operates. These plans are funded by regular contribution made by the employer and the employees. For defined benefit pension plan, the liability recognized in the consolidated balance sheets is the present value of the defined benefit obligation at the balance sheet date less the fair value of plan assets. The overfunded or underfunded status of the defined benefit plan is calculated as the difference between plan assets and the projected benefit obligations. Estimates are used in determining the assumptions incorporated in the calculation of the pension obligations, which is supported by input from independent actuaries. Actuarial gains and losses arising from experience adjustments and changes in actuarial assumptions are recognized in &#8220;Accumulated other comprehensive income (loss)&#8221; in the consolidated statements of equity and are charged or credited to income over the employees&#8217; expected average remaining working lives. The measurement date used for our employee benefit plan is December 31.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For defined contribution pension plans, the Company pays contributions to publicly or privately administered pension insurance plans on a mandatory, contractual or volutanry basis. The Company has no further payment obligations once the contributions have been paid. The contributions are recognized as employee benefit expense when they are due. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Equity-based Compensation and Warrants</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company applies the fair value method of measuring equity-based compensation and warrants, which requires an entity to measure the cost of services received in exchange for an award of equity instruments based on the grant-date fair value of the award. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company issues equity-based compensation with only service-based vesting conditions and record the expense for these awards using the straight-line method. The Company has not issued any stock-based awards with performance- or market-based vesting conditions.The Company recognizes the related costs in the consolidated statement of operations and as additional paid-in capital in the consolidated statement of shareholders&#8217; equity, in accordance with the vesting period during which the award recipients are required to provide services in exchange for the award. The Company accounts for forfeitures as they occur.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Before being a public company, given the absence of an active market for the Company&#8217;s common stock, the Company and the Board of Directors estimated the fair value of the Company&#8217;s common stock at the grant date determining the estimated fair value of the Company&#8217;s equity instruments based on a number of factors, including prices paid for the Company&#8217;s convertible preferred stock sold to outside investors in arm&#8217;s-length transactions; the Company&#8217;s stage of development; the fact that the grants of stock-based awards involved illiquid securities in a private company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The fair value of each stock option award is estimated on the date of grant using the Black-Scholes option pricing model. Given the absence of an active public market for the Company&#8217;s common stock prior to March 19, 2021, which was the first day of trading, the Company determined the volatility and the expected term for awards granted based on an analysis of reported data for a peer group of similar biopharmaceuticals companies that issued options with substantially similar terms. After the IPO, we continued to do so, and we expect not to change our methodology until such time as we will have reliable historical data regarding the volatility of our traded stock price and expected term of exercise patterns. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. The Company has not paid, and does not anticipate paying, cash dividends on our common stock; therefore, the expected dividend yield is assumed to be zero.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Black-Scholes option pricing model is also used for warrants issued, using consistent inputs and methodology to quantify such inputs, as described above in relation &#160;to equity-based compensation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The assumptions used in calculating the fair value of share-based awards and warrants represent management&#8217;s best estimates and involve inherent uncertainties and the application of management&#8217;s judgment. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Revenue Recognition</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company derives revenues from collaboration and licensing agreements. The Company recognize revenue related to these agreements in accordance with&#160;ASC&#160;606, <i style="font-style:italic;">Revenues from contracts with customers</i> and ASC 808, <i style="font-style:italic;">Collaborative arrangements</i>. The terms of these arrangements typically include payment from third parties customers of one or more of the following: non-refundable initiation fee, reimbursement of development costs, development and regulatory milestone payments and royalties on net sales of the licensed product. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In determining the appropriate amount of revenue to be recognized as we fulfill our obligations, the Company applies the five steps model of ASC606: (i)&#160;identify the contract(s) with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when (or as) we satisfy a performance obligation. The Company only apply the five-step model to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods and services it transfers to the customer. If a contract is determined to be within the scope of ASC 606 at inception, the Company assesses the goods or services promised within such contract, determines which of those goods and services are performance obligations, and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Costs and revenues associated with collaborative arrangements are reported in the consolidated statements of operations on a gross basis when the counterpart is identified as being a customer, when the performance obligations incurred and rendered to fulfil the agreements are deemed to be in the ordinary course of the Company&#8217;s business, or when there is an expectation that the collaborative arrangement will result in a future constant flow of revenues in the form of sale of products, royalties or licenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Research grants</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the terms of the research and development grants awarded (such as those awarded by the The Michael J. Fox Foundation for Parkinson&#8217;s Research (MJFF) and The Silverstein Foundation for Parkinson&#8217;s Disease and from Innosuisse &#8211; Swiss Innovation Agency), we are entitled to receive reimbursement of our allowable direct expenses and payroll costs. Contributions from research and development activities under the grants are recorded based on management&#8217;s best estimate of the periods in which the related expenditures are incurred and activities performed and are classified in the statement of operations as a reduction to research and development expenses, measuring according to the time periods during which the research and development activities are carried out and related costs sustained.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Research and development expenses</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company expenses all costs incurred in performing research and development activities. Research and development expenses include salaries and other related costs, materials and supplies, preclinical expenses, manufacturing expenses, contract services and other third-party expenses. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">General and administrative expenses</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">General and administrative expenses consist primarily of salaries, benefits and other related costs, for personnel and consultants in the Company&#8217;s executive and finance functions. General and administrative expenses also include professional fees for legal, finance, accounting, intellectual property, auditing, tax and consulting services, travel expenses and facility-related expenses, which include allocated expenses for rent and maintenance of facilities and other operating costs not otherwise included in research and development expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Income taxes</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for income taxes under the liability method. Under this method deferred income tax liabilities and assets are determined based on the difference between the financial statement carrying amounts of assets and liabilities and the related tax basis using enacted tax rates in effect in the&#160;years in which the associated deferred taxes are expected to reverse. A valuation allowance is recorded if it is &#8220;more likely than not&#8221; that a portion or all of a deferred tax asset will not be realized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of each reporting date, the Company considers existing evidence, both positive and negative, that could impact its view with regards to future realization of deferred tax assets. In consideration of the start-up status of the Company, a full valuation allowance has been established to offset the deferred tax assets, as the related realization is currently uncertain. In the future, should management conclude that it is more likely than not that the deferred tax assets are partially or fully realizable, the valuation allowance will be reduced to the extent of such expected realization, and the corresponding amount will be recognized as income tax benefit in the Company&#8217;s consolidated statement of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company recognizes tax liabilities from an uncertain tax position if it is more likely than not that the tax position will not be sustained upon examination by the taxing authorities, based on the technical merits of the tax position. There are no uncertain tax positions that have been recognized in the accompanying consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Fair value measurements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Company applies the following fair value hierarchy, which prioritizes the inputs used to measure fair value into three levels based on their observability in the market and degree of judgment involved:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:21.3pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:14.15pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 1&#160;&#8211; Quoted prices in active markets for identical assets or liabilities.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:21.3pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:14.15pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 2&#160;&#8211; Observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:21.3pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:14.15pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 3&#160;&#8211; Inputs that are generally unobservable and typically reflect management&#8217;s estimates of assumptions that market participants would use in pricing the asset or liability.</span></td></tr></table><div style="margin-top:10pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In determining fair value, we utilize valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and consider counterparty credit risk in their assessment of fair value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Comprehensive income/(loss)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">Comprehensive income/(loss) is composed of net income(loss) and certain changes in stockholder&#8217;s equity that are excluded from the net income(loss), primarily foreign currency translation adjustments and defined benefit obligation adjustments.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Net loss per share</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Basic net loss per share is computed by dividing the reported net loss by the weighted average number of shares of common stock outstanding during the period. The Company gives consideration to all potentially dilutive impacts, except where the effect of including such securities would be antidilutive. As of December 31, 2021, common stock equivalents consisted of stock options and warrants, while as of &#160;December 31, 2020, common stock equivalents consisted of the Series&#160;A preferred stock, Series B preferred stock, stock options and warrants. Because the Company has reported net losses since inception, these potential impacts would be anti-dilutive, and therefore common stock equivalents have been excluded from the computation, resulting in basic and diluted net loss per share being the same for all periods presented.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Recently issued accounting pronouncements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that we adopt as of the specified effective date. We do not believe that the adoption of any recently issued standards have or may have a material impact on our consolidated financial statements or disclosures.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139934219923160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research Grants<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ganx_ResearchGrantsAbstract', window );"><strong>Research Grants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ganx_ResearchGrantsDisclosureTextBlock', window );">Research Grants</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">3.&#160;&#160;&#160;&#160;Research Grants </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In December 2018 and in February 2019, our wholly owned subsidiary, GT Gain Therapeutics SA, obtained a research grants for a total amount of USD 186,956 from The Michael J. Fox Foundation for Parkinson's Research (MJFF) and The Silverstein Foundation for Parkinson's disease with GBA to advance its proprietary non-competitive molecular chaperones for Parkinson's disease and research project "therapeutic target of GCase enzyme in Parkinson's disease with novel pharmacological chaperones". Under the terms of the research and development grants awarded, we are entitled to receive reimbursement of our allowable direct expenses. As of December 31, 2021 and 2020, we recorded as reductions to research and development expenses of nil, since the grant term terminated in 2020, &#160;and USD 98,318, respectively. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In July 2019, our wholly owned subsidiary, GT Gain Therapeutics SA, announced that, in a consortium with the Institute for Research in Biomedicine, Bellinzone (Switzerland) and Neuro-Sys SAS in Gardanne (France), it obtained a research grant of approximately USD 1,500,000 from Eurostars-2 joint programme, with co-funding from the European Union Horizon 2020 research and Innosuisse &#8211; Swiss Innovation Agency. The contribution attributed to our subsidiary was CHF 386,218, of which CHF 286,787 was already received as of December 31, 2019. The funding will support the development of the drugs portfolio for the treatment of Gaucher Disease, GM1 Gangliosidosis, Mucopolysaccharidosis type 1 and Krabbe. Under the terms of the research and development grants awarded, we are entitled to receive reimbursement of our allowable direct expenses. As of December 31, 2021 and 2020, we recorded as reductions to research and development expenses USD 136,177 and USD 151,230, respectively and receivables of USD 81,862 and USD 51,665, respectively. The unrecognized portions of the grants are reported as deferred income on the consolidated balance sheet.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ganx_ResearchGrantsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Information pertaining to research grants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ganx_ResearchGrantsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ganx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ganx_ResearchGrantsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of information pertaining to research grants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ganx_ResearchGrantsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ganx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139934224884920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash, cash equivalents and restricted cash<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Cash, cash equivalents and restricted cash</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsDisclosureTextBlock', window );">Cash, cash equivalents and restricted cash</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">4.&#160;&#160;&#160;&#160; Cash, cash equivalents and restricted cash</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company considers all short-term, highly liquid investments, with an original maturity of three&#160;months or less, to be cash equivalents. The Company&#8217;s cash and cash equivalents include short-term highly liquid investments which are readily convertible into cash. These investments relate to money market securities with maturities of three&#160;months or less when acquired. The Company&#8217;s institutional money market accounts permit daily redemption and the fair values of these investments are based upon the quoted prices in active markets provided by the holding financial institutions, which are considered Level 1 inputs in the fair value hierarchy (see note 12). Given their short-term maturities and the underlying being represented by cash equivalents, their face value amount approximate the related fair market value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has not experienced any losses in these accounts and does not believe it is exposed to any significant credit risk on cash and cash equivalents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Cash, cash equivalents and restricted cash are broken down as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:67.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:67.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:top;width:67.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,262,977</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 907,255</p></td></tr><tr><td style="vertical-align:top;width:67.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Money Market</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 33,617,696</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 6,585,655</p></td></tr><tr><td style="vertical-align:top;width:67.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 36,880,673</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 7,492,910</p></td></tr><tr><td style="vertical-align:top;width:67.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 31,279</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 11,371</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Restricted cash refers to an amount required under our Lugano new office lease agreement and deposited into a restricted bank account as a guarantee for expenses to be incurred in case of damage to the premises noted at the termination of the lease. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Details of the cash and cash equivalents balances as of December 31, 2021 and 2020, broken down by currency in which the funds are denominated, are reported in the following table:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:69.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:top;width:69.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash in CHF</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 157,310</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 128,074</p></td></tr><tr><td style="vertical-align:top;width:69.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash in EUR</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 338,766</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 145,726</p></td></tr><tr><td style="vertical-align:top;width:69.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash in USD</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 36,322,777</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 7,149,386</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for cash and cash equivalent footnotes,  which may include the types of deposits and money market instruments, applicable carrying amounts, restricted amounts and compensating balance arrangements. Cash and equivalents include: (1) currency on hand (2) demand deposits with banks or financial institutions (3) other kinds of accounts that have the general characteristics of demand deposits (4) short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments maturing within three months from the date of acquisition qualify.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139934327088984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Current Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>Other Current Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ganx_PrepaidExpensesAndOtherCurrentAssetsTextBlock', window );">Other Current Assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="font-style:italic;">5.&#160;&#160;&#160;&#160;Other Current Assets</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Other current assets consist of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:73.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:top;width:73.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Tax Credits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 113,586</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 58,017</p></td></tr><tr><td style="vertical-align:top;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:73.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepaid and deferred expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 498,252</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 198,994</p></td></tr><tr><td style="vertical-align:top;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other receivable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 81,862</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:73.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepaid D&amp;O Insurance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 147,671</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total Prepaid expenses and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 727,785</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 198,994</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Tax credit consist of a value added tax credit (&#8220;VAT&#8221;). It is an indirect tax receivables from Switzerland and Spain tax authorities on purchases of goods and services executed on those countries. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Prepaid expenses refers to pre-payments made to vendors for future services. Deferred expenses mainly refer to research agreements entered into with third parties for research projects that will be recognized as expenses throughout the research period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Prepaid D&amp;O insurance costs relate to insurance premium which will be recognized in the statement of operations on a monthly basis through the twelve months insurance period.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ganx_PrepaidExpensesAndOtherCurrentAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for Prepaid expenses and other current assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ganx_PrepaidExpensesAndOtherCurrentAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ganx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139934219881048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property and Equipment, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment, net</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">6.&#160;&#160;&#160;&#160;Property and Equipment, net</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Property and equipment, net, consists of the following<span style="font-size:11pt;">:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:69.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:69.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:top;width:69.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Computer</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 55,141</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 25,436</p></td></tr><tr><td style="vertical-align:top;width:69.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Furniture and fixtures</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 42,148</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 4,865</p></td></tr><tr><td style="vertical-align:top;width:69.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 17,327</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 8,889</p></td></tr><tr><td style="vertical-align:top;width:69.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Laboratory instruments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 19,759</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,348</p></td></tr><tr><td style="vertical-align:top;width:69.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total property and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 134,375</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 42,538</p></td></tr><tr><td style="vertical-align:top;width:69.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: accumulated depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (28,389)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (12,905)</p></td></tr><tr><td style="vertical-align:top;width:69.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 105,986</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 29,633</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Property and equipment mainly consist of computers and set-up of a conference room in our Spanish and Lugano offices. No disposals, nor impairments occurred during the periods. Depreciation has been calculated by taking into consideration the use, purpose and financial-technical duration of the assets, based on their estimated economic lives.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Depreciation expense for the year ended December 31, 2021, and 2020 was USD 15,484 and USD 9,592, respectively.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139934219811912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating lease. Right of use ("ROU") assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Operating lease. Right of use ("ROU") assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Operating lease. Right of use ("ROU") assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">7.&#160;&#160;&#160;&#160;Operating lease. Right of use (&#8220;ROU&#8221;) assets</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Our leased assets include offices in Bethesda, Lugano and Barcelona and a lab in Barcelona. Our current lease portfolio consists of leases with remaining terms ranging from <span style="-sec-ix-hidden:Hidden_ZalXIiQg2kKnz87xVmLaUQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">three</span></span> to five years. Renewal options are excluded </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">from our calculation of lease liabilities unless we are reasonably certain that we will exercise the renewal option. Our lease agreements do not contain residual value guarantees or material restrictive covenants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On June 1, 2021, the Company entered into a five year operating lease agreement to lease office space in Via Soave, n.6 in Lugano, Switzerland. The lease agreement is renewable for additional five years. The Company is required to pay for operating costs, including heating and water, which are adjusted and billed yearly based on usage. These additional charges are considered variable lease costs and are recognized in the period in which the costs are incurred. In connection with the lease, as guarantee for any damages claimed by the lessor, the Company deposited into a restricted bank account CHF 28,500 or USD 31,279 classified as restricted cash. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On August 31, 2021, the three year operating lease agreement to lease office space in Via Pietro Peri, 9D Lugano, Switzerland terminated and CHF 10,500 or USD 11,371 deposited into a restricted bank account were remitted to the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On October 1, 2021, the Company entered into a three year operating lease agreement to lease office space in Bethesda, Maryland. In connection with the lease, the Company paid a security deposit of USD 5,227, classified as deposit in non-current assets, for the performance of all obligations, covenants and conditions and agreements under the lease. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On November 1, 2021, the Company entered into a five-years new operating lease agreement in Torre D Building with Parc Cientific de Barcelona for larger office space of 1,417 square feet to accommodate the Company&#8217;s continued continuos growth and contemporaneosly terminated a lease, entered in October 2020, in Torre I Building for 830 square feet. In connection with the Torre D Building lease, the Company paid a security deposit of EUR 4,325 or USD 4,918 classified as deposit in non-current assets. The Company is required to pay for operating costs, including general services, scientific services, utilities, waste management services and taxes, which are billed monthly based on the Company's share of the total rentable square footage. These additional charges are considered variable lease costs and are recognized in the period in which the costs are incurred. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Operating leases are reflected on our balance sheet as operating lease ROU assets and the related current and non-current operating lease liabilities. ROU assets represent the right to use an underlying asset for the lease term, and lease liabilities represent the obligation to make lease payments arising from the lease agreement. Operating lease ROU assets and liabilities are recognized at the commencement date, or the date on which the lessor makes the underlying asset available for use, based upon the present value of the lease payments over the respective lease term. Lease expense is recognized on a straight-line basis over the lease term. Variable lease costs such as common area maintenance, property taxes and insurance are expensed as incurred.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The breakdown of the significant components of ROU assets and lease liabilities as of December 31, 2021 and 2020 is reported in the table below, together with the discount rate used in order to calculate the net present value of the lease liabilities as of those periods.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:69.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:top;width:69.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating Lease</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:69.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease- right of use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 901,042</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 523,080</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:69.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:69.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease liability - current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 219,137</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 122,756</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:69.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease liability - non current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 695,053</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 400,324</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:69.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average remaining lease term - years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:69.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average discount rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1.86</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 3.61</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The components of the lease costs which are included in the consolidated statements of operations and comprehensive loss were as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:69.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:top;width:69.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 191,329</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 121,800</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The future minimum lease payments for the Company&#8217;s operating leases as of December 31, 2021, were as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:68.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:27.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Fiscal Year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Operating Leases</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 237,926</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 245,685</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 227,115</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 167,526</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 58,738</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total future minimum lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 936,990</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less amount representing interest or imputed interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 22,800</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Present value of lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.99%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 914,190</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139934219923160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Payable<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrentAbstract', window );"><strong>Accounts Payable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">Accounts Payable</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">8.&#160;&#160;&#160;&#160;Accounts Payable</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Accounts payable are reported at their nominal value. Accounts payable refer to amounts due to third parties on outstanding invoices received before year-end for services already provided. As of December 31, 2021 and 2020, accounts payable amounted to USD 560,479 and USD 961,516, respectively. All accounts payable are due in less than 12&#160;months. Details of the vendor outstanding payables as of December&#160;31, 2021 and 2020, broken down by currencies in which they are denominated, are reported in the following table:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:69.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:top;width:69.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Vendors Payables in CHF</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 13,166</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 29,423</p></td></tr><tr><td style="vertical-align:top;width:69.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Vendors Payables in EUR</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 309,378</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 202,223</p></td></tr><tr><td style="vertical-align:top;width:69.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Vendors Payables in USD</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 197,045</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 673,600</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139934219922600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other current liabilities and deferred income<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCreditsAndOtherLiabilitiesAbstract', window );"><strong>Other current liabilities and deferred income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ganx_OtherCurrentLiabilitiesAndDeferredIncomeTextBlock', window );">Other current liabilities and deferred income</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">9.&#160;&#160;&#160;&#160;Other current liabilities and deferred income</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Other current liabilities and deferred income consist of the following as of December&#160;31, 2021 and 2020:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:68.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:top;width:68.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Payable for social securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 255,068</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 88,334</p></td></tr><tr><td style="vertical-align:top;width:68.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued payroll</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 465,382</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 294,469</p></td></tr><tr><td style="vertical-align:top;width:68.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 681,770</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 379,270</p></td></tr><tr><td style="vertical-align:top;width:68.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Tax provision</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 380</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,070</p></td></tr><tr><td style="vertical-align:top;width:68.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deposit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 5,307</p></td></tr><tr><td style="vertical-align:top;width:68.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">  Total Other Current Liabilities</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,402,600</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 768,450</p></td></tr><tr><td style="vertical-align:top;width:68.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 266,504</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 239,483</p></td></tr><tr><td style="vertical-align:top;width:68.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">  Total Other Current Liabilities and Deferred Income</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,669,104</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,007,933</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Payables for social securities refer to amounts due to social securities and employees withholding tax. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Accrued payroll refers to accruals for year-end bonuses, accrued vacations and extra-hours including social security charges, to be paid to employees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Accrued expenses refer to invoices to be received from vendors for services performed and not yet billed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Deferred income mainly refers to research grants received and, as of December 31, 2021, to a collaboration agreement entered into with Zentalis. Deferred income will be recognized in the consolidated statement of operations in accordance with the costs sustained.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ganx_OtherCurrentLiabilitiesAndDeferredIncomeTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other current liabilities and deferred income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ganx_OtherCurrentLiabilitiesAndDeferredIncomeTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ganx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCreditsAndOtherLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCreditsAndOtherLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139934219951112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pension obligations<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Pension obligations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Pension obligations</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">10.&#160;&#160;&#160;&#160;Pension obligations</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Net pension obligations related to the Company&#8217;s defined pension plan refer only to Swiss employees and as of December&#160;31, 2021 and 2020, can be summarized as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">End of year funed status:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Fair value of plan assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 943,025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 477,288</p></td></tr><tr><td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">(Projected benefit obligation)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,272,483)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (648,846)</p></td></tr><tr><td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Funded status</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (329,458)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (171,558)</p></td></tr><tr><td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accumululated benefit obligation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,233,053</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 652,445</p></td></tr><tr><td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Reconciliation of funded status:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Funded status beginning of year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (171,558)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (126,629)</p></td></tr><tr><td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (144,146)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (44,474)</p></td></tr><tr><td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Employer contribution</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 88,819</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 36,264</p></td></tr><tr><td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Translation differences</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,437)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (501)</p></td></tr><tr><td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Change in AOCI over the year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (101,136)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (36,218)</p></td></tr><tr><td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Funded status at end of year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (329,458)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (171,558)</p></td></tr><tr><td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Component of net periodic pension costs:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Service cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 132,809</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 36,597</p></td></tr><tr><td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Interest cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,318</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 947</p></td></tr><tr><td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Expected return on plan assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5,558)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,564)</p></td></tr><tr><td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Amortization of (gain)/losses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 16,212</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 10,494</p></td></tr><tr><td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Amortization of prior service cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (635)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 144,146</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 44,474</p></td></tr><tr><td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="7" style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Service cost is reported in research and development and general and administrative expenses. All other components of net period costs are reported in interest income, net in the consolidated statement of operations</p></td></tr><tr><td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Reconciliation of projected benefit obligation:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Projected benefit obligation at January 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 648,846</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 496,819</p></td></tr><tr><td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Services cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 132,809</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 36,597</p></td></tr><tr><td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Employee contribution</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 59,208</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 25,770</p></td></tr><tr><td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Interest Cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,318</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 947</p></td></tr><tr><td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Benefit payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 315,300</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 48,602</p></td></tr><tr><td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"> (Gain)/loss on financial assumption</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (27,799)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 4,379</p></td></tr><tr><td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"> (Gain)/loss on demographic assumption</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (43,123)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"> (Gain)/loss on experience</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 193,984</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 35,732</p></td></tr><tr><td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">    Plan Amendement</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (8,060)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,272,483</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 648,846</p></td></tr><tr><td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Reconciliation of fair value of plan assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Fair value at January 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 477,288</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 370,190</p></td></tr><tr><td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Expected return on plan assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 5,558</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,564</p></td></tr><tr><td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Gain/(loss) on plan assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,148)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (9,454)</p></td></tr><tr><td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Employer contributions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 88,819</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 36,264</p></td></tr><tr><td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Employee contributions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 59,208</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 25,770</p></td></tr><tr><td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Benefit payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 315,300</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 48,602</p></td></tr><tr><td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Others</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2,352</p></td></tr><tr><td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Fair value at December 31</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 943,025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 477,288</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change in net (gain)/loss:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">(Gain)/loss at beginning of year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 154,665</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 117,803</p></td></tr><tr><td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">(Gain)/loss on PBO during year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 122,895</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 37,902</p></td></tr><tr><td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">(Gain)/loss on assets during year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,148</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 9,454</p></td></tr><tr><td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Amortization of gain/(loss)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (16,212)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (10,494)</p></td></tr><tr><td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">(Gain)/loss at end of year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 264,496</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 154,665</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Change in accumulated other comprehensive income (AOCI):</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">AOCI at beginning of year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 154,665</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 117,803</p></td></tr><tr><td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Net gain/(loss) amortized</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (16,212)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (10,494)</p></td></tr><tr><td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">(Gain)/loss on PBO during the year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 122,895</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 37,902</p></td></tr><tr><td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">(Gain)/loss on assets during the year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 3,148</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 9,454</p></td></tr><tr><td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Prior Service Cost/(credit) occurring over the year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (8,060)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Net prior service (cost)/credit amortized</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (635)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total AOCI at end of year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 255,801</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 154,665</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The assumptions used in the determination of the benefit obligation and the plan assets for the pension plans and the pension obligation were as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:60.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:top;width:60.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Actuarial Assumptions (%pa):</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:60.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Discount rate </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">0.30%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">0.15%</p></td></tr><tr><td style="vertical-align:top;width:60.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Interest credit rate / ERoA </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">1.00%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">1.00%</p></td></tr><tr><td style="vertical-align:top;width:60.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Salary increases </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">1.00%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">1.00%</p></td></tr><tr><td style="vertical-align:top;width:60.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Pension increases </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">0.00%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">0.00%</p></td></tr><tr><td style="vertical-align:top;width:60.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Demographic Assumptions:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:60.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Lump-sum option </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">25%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">25%</p></td></tr><tr><td style="vertical-align:top;width:60.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Retirement age </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">65/64</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">65/64</p></td></tr><tr><td style="vertical-align:top;width:60.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Proportion married </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">.BVG 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">.80%</p></td></tr><tr><td style="vertical-align:top;width:60.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Allowance for child pensions </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:17.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">5% loading on risk benefits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:17.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">5% loading on risk benefits</p></td></tr><tr><td style="vertical-align:top;width:60.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Mortality base table </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">.BVG 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">.BVG 2015</p></td></tr><tr><td style="vertical-align:top;width:60.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Longevity improvement </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">CMI 2018 (1.25%)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">CMI 2016 (1.25%)</p></td></tr><tr><td style="vertical-align:top;width:60.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Turnover </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">.BVG 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">.BVG 2015</p></td></tr><tr><td style="vertical-align:top;width:60.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Disability </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">80%.BVG 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">80% BVG 2015</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:68.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected benefit payments:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Year 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 162,208</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 11,363</p></td></tr><tr><td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Year 2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 54,723</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 141,225</p></td></tr><tr><td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Year 3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 58,224</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 29,330</p></td></tr><tr><td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Year 4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 60,869</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 30,793</p></td></tr><tr><td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Year 5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 63,281</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 31,963</p></td></tr><tr><td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Next 5 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 428,371</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 169,658</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other disclosure items:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Next year's expected employer contribution</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 112,396</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 38,873</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s investment strategy for its pension plans is to optimize the long-term investment return on plan assets in relation to the liability structure to maintain an acceptable level of risk while minimizing the cost of providing pension benefits and maintaining adequate funding levels in accordance with applicable rules in each jurisdiction.&#160;The Company does not manage any assets internally. The plan assest relates to mandatory and discretionary contributions made in accordance with Swiss Law to a leading pension provider. The capital is fully insured and provides for a fixed rate of return. The fair value is based on the value of the assets held by the provider and as such has been classified within Level 3 of the fair value hierarchy. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We maintain a 401(k) saving Plan, which is available to all U.S. employees. Participants may make voluntary contributions. We make matching contributions according to the 401(k) Saving Plan&#8217;s matching formula. All matching contributions and participant contribution vest immediately. &#160;The expense related to our 401(k) Savings Pan consist of our matching contributions. Expenses related to our 401(k) Savings Plan totaled USD 3,243 and nil for the years ended December 31, 2021 and 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section S99<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=21916913&amp;loc=d3e273930-122802<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39689-114964<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139934219905480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Loans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Loans</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">11</span><span style="font-style:italic;">.&#160;&#160;&#160;&#160;Loans</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In March&#160;2020, the Company obtained a CHF 14,600 (USD 16,024) five-year loan. The loan had zero interest and original maturity on March 31, 2025. The loan was guaranteed through joint and several sureties by the Swiss government. The loan is part of the infrastructure put in place by the Federal Council and Swiss Parliament in view of the economic consequences of the coronavirus. As of December 31, 2021, the outstanding balance has been reclassified as current as the Company decided to estinguish the loan. No expenses or charges were due for the early extinguishment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In August&#160;2020, the Company obtained a CHF 638,000 (USD 700,221 at the historical forex exchange rate) nine-year loan. The loan has zero interest. The loan is due in quarterly installments of CHF 20,000, with payments commencing on December&#160;31, 2021 and ending on September&#160;30, 2029. The loan is part of the infrastructure put in place by the Federal Council and Swiss Parliament in view of the economic consequences of the coronavirus. Loans granted do <span style="-sec-ix-hidden:Hidden_4WczMy8Ec0ae6MFBpO8JBg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">not</span></span> bear interest and no issuance costs have been borne. As such they have been accounted for at face value, which is deemed to approximate the related fair value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The future loan payments are reported in the table below:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2026</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Thereafter</b></p></td></tr><tr><td style="vertical-align:top;width:11.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Loan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 694,294</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 103,826</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 87,806</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 87,806</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 87,806</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 87,806</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 239,244</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139934219843752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair value measurement<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair value measurement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair value measurement</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">12.&#160;&#160;&#160;&#160;Fair value measurement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:28.8pt;margin:0pt 0pt 12pt 0pt;">Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The Company&#8217;s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:28.8pt;margin:0pt 0pt 12pt 0pt;">The carrying amounts of the Company&#8217;s cash and cash equivalents, including money market funds, restricted cash and financial liabilities are considered to be representative of their respective fair values because of the short-term nature and the contractual terms of those instruments. The fair values of money market funds are based upon the quoted prices in active markets provided by the holding financial institution, which are considered Level 1 inputs in the fair value hierarchy according to ASC820.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:28.8pt;margin:0pt 0pt 12pt 0pt;">There have been no changes to the valuation methods utilized by the Company, nor were there transfers between levels of the fair value hierarchy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100.48%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:56.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:56.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="6" style="vertical-align:bottom;white-space:nowrap;width:41.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair value measurement at reporting date using</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Quoted prices in active market for identical assets</b></p></td><td style="vertical-align:bottom;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant other observable inputs</b></p></td><td style="vertical-align:bottom;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant unobservable inputs</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:13.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(level 1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:11.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(level 2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:11.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(level 3)</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">December 31, 2021:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Cash and cash equivalents:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 33,617,696</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:56.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 33,617,696</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:56.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total financial assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 33,617,696</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:56.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">December 31, 2020:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Cash and cash equivalents:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,585,655</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:56.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,585,655</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:56.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total financial assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,585,655</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:28.8pt;margin:0pt 0pt 12pt 0pt;">The carrying amounts of prepaid expenses and other current assets, accounts payable and accrued expenses approximate their &#160;fair value due to their short-term maturities.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139934219845992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common and Preferred Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Common and Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Common and Preferred Stock</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">13.&#160;&#160;&#160;&#160;Common and Preferred Stock</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2021 and 2020, the authorized capital stock of the Company included 50,000,000 shares of common stock, $0.0001 par value and 10,000,000 shares of preferred stock, $0.0001 par value. As of December 31, 2021 and 2020, 11,883,368 and 3,543,163 (4,022,736 <span style="-sec-ix-hidden:Hidden_ARvqt8O7vki9CqZo9ksCdw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">before</span></span> the reverse stock split) shares of common stock, $0.0001 par value, were <span style="-sec-ix-hidden:Hidden_smJgQqCN6kCASsqGpDK0oA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">issued</span></span> and <span style="-sec-ix-hidden:Hidden_eCHc0lXrwkaLahqSp1jTsw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">outstanding</span></span>. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">No preferred stocks were outstanding as of December 31, 2021. There were 1,185,879 &#160;(1,346,390 before the reverse stock split) <span style="-sec-ix-hidden:Hidden_xoy4pURJ0U6SC06b57siOQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">shares</span></span> of Series&#160;A <span style="-sec-ix-hidden:Hidden_kdwNLQKYWkiveM0sOQGupw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Preferred</span></span> Stock, par value $0.0001 and 2,965,600 (3,366,999 before the reverse stock split) <span style="-sec-ix-hidden:Hidden_VxK6clrWrk2DfpjK2-sdow;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">shares</span></span> of Series&#160;B <span style="-sec-ix-hidden:Hidden_iLyIO00eQUWJB3oyw2X5yQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Preferred</span></span> Stock, par value $0.0001, issued and outstanding as of December&#160;31, 2020. The reverse stock split did not result in any change of the original par value of the Company common and preferred stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Upon closing of the IPO, the Preferred Stock, as resulting from the reverse stock split, were converted to common stock at a ratio of 1-for-1.The holders of the Company&#8217;s Preferred Stock had certain voting, dividend, and redemption rights, as well as liquidation preferences and conversion privileges. All rights, preferences, and privileges associated with the preferred stock were terminated at the time of the Company&#8217;s IPO in conjunction with the conversion of all outstanding shares of Preferred Stock into shares of common stock.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139934219816952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract', window );"><strong>Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ganx_WarrantsAndRightsNoteDisclosureTextBlock', window );">Warrants</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">14.&#160;&#160;&#160;&#160;Warrants</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:35.45pt;margin:0pt;">In July, 2020, in connection with the issuance of the Series B Preferred Stock through a private placement, the Company issued equity-classified warrants to designees of the placement agent to purchase an aggregate of 269,360 shares of our common stock at an exercise price of $4.46 per share, valued in the aggregate at USD 413,887 and included in the issuance costs of the Series B Preferred Stock. The warrants vested immediately upon issuance, </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">provide for a cashless exercise right and are exercisable for a period of five years from July&#160;20, 2020. &#160;On March&#160;3, 2021, the Board approved a 1-for-<span style="-sec-ix-hidden:Hidden_R7-eb03Se0uFXfouVE5ALg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">0.880784</span></span> reverse stock split of the Company&#8217;s outstanding equity instruments. The reverse stock split was approved by the stockholders on March&#160;4, 2021 and became effective on March&#160;17, 2021. Shares of common stock underlying outstanding warrants were proportionately reduced from 269,360 to 237,249 and the respective exercise prices, were proportionately increased from $4.46 to $5.07 in accordance with the terms of the agreements governing such securities. As of December 31, 2021, 11,862 warrants were exercised resulting in 3,283 shares having been issued following the cashless mechanism as per the terms of the agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On May 6, 2021, the Company entered into nine months investing banking services and financial advisory agreement and issued equity-classified warrants to designees of the investment bank to purchase an aggregate of 200,000 shares of the Company common stock at an exercise price of $13.75 per share, valued in the aggregate at USD 1,034 thousand. The warrants vested immediately upon issuance, do not provide cashless exercise right and are exercisable for a period of four years from May 6, 2021. The fair value of the warrants is recognized on a straight-line basis over the nine months service period as general and administrative expense. As of December 30, 2021, no warrants were exercised or exchanged.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The fair value of the warrants issued in 2020 and 2021 is estimated using the Black-Scholes option pricing model with the following assumptions:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:70.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:70.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Grant date fair value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 5.17</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1.54</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:70.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 70</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 75</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;">%</span></p></td></tr><tr><td style="vertical-align:top;width:70.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected term (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 4.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 5.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:70.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 0.81</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 0.28</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:70.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected dividend yield -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ganx_WarrantsAndRightsNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entire disclosure of warrant and rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ganx_WarrantsAndRightsNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ganx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsNoteDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139934219946248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsAbstract', window );"><strong>Equity Incentive Plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsGeneralTextBlock', window );">Equity Incentive Plan</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">15.&#160;&#160;&#160;&#160;Equity Incentive Plan</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On September 24, 2020, the Board of Directors adopted the 2020 Omnibus Incentive Plan (the &#8220;2020 Omnibus Plan&#8221;). The 2020 Omnibus Plan provides for the granting of equity-based awards to our named executive officers, other employees, consultants and non-employee directors at a price to be determined by the Board of Directors. The 2020 Omnibus Plan is intended to encourage ownership of stock by employees and consultants of the Company and to provide additional incentives for them to promote the success of the Company&#8217;s business. The maximum number of shares to be issued under the 2020 Omnibus Plan is 1,310,000. The 2020 Omnibus Plan expires after ten years, unless terminated prior to that date by the Board of Directors. The Board of Directors is responsible for determining the individuals to be granted options, the number of options each individual will receive, the option price per share, and the exercise period of each option. No option will have a term in excess of 10 years. The exercise price for a stock option awarded under the 2020 Omnibus Plan shall not be less than the fair market value of the Company&#8217;s common stock on the date of the grant. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On December 23, 2021, the Board of Directors, has determined that it is advisable and in the best interests of the Company to adopt an Inducement Equity Incentive Plan (the &#8220;2021 Inducement Equity Incentive Plan&#8221;) intended to induce new employees to join the Company for the benefit of individuals who satisfy the standards for inducement grants under Rule 5635(c)(4) of the NASDAQ Listing Rules and the related guidance issued thereunder with respect to the Company and its affiliates. The maximum number of shares reserved for issuance pursuant to awards to be granted under the 2021 Inducement Equity Incentive Plan is to 1,000,000.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Stock Option Grants</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The following tables summarize stock option activity for the year ended December 31, 2021 :</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:29.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:29.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:29.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;width:29.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted&#160;Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted&#160;Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Remaining Contractual </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td></tr><tr><td style="vertical-align:bottom;width:29.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Grant Date Fair Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise&#160;Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Terms (Years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="vertical-align:top;width:29.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Outstanding as of December&#160;31,&#160;2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 488,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 2.97</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 9.70</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:29.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Options outstanding after stock splits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 429,822</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2.42</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 3.38</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 9.01</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:29.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Options granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 535,780</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">4.27</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 6.53</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 5.66</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:29.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Options exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,625)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2.42</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 3.38</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:29.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Options cancelled/forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,761)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2.42</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 3.38</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:29.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Options outstanding as of December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 960,216</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">3.46</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 5.13</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 6.25</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 163,237</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:27.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:19.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td colspan="8" style="vertical-align:bottom;width:68.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Options&#160;Outstanding</b></p></td><td style="vertical-align:bottom;width:0.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:17.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Options&#160;Exercisable</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:27.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:27.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted-&#160;Average&#160;Years</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Grant Date</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:27.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Remaining&#160;on&#160;Contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise</b></p></td></tr><tr><td style="vertical-align:bottom;width:27.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Life</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercisable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Price</b></p></td></tr><tr><td style="vertical-align:bottom;width:27.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$3.38</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 512,516</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 8.91</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 3.38</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 2.42</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 174,621</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 3.38</p></td></tr><tr><td style="vertical-align:bottom;width:27.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$5.86</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 210,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 9.98</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 5.86</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 4.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:27.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$5.99</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 45,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 9.94</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 5.99</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 4.34</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:27.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$7.80</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 104,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 9.61</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">$780</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 5.63</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 2,664</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">$780</p></td></tr><tr><td style="vertical-align:bottom;width:27.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$10.03</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 88,200</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 9.36</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 10.03</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 5.15</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On March&#160;3, 2021, the Board approved a 1-for-<span style="-sec-ix-hidden:Hidden_VOTL1rq_TUe6F_krbeB0zg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">0.880784</span></span> reverse stock split of the Company&#8217;s outstanding equity instruments. The reverse stock split was approved by the stockholders on March&#160;4, 2021 and became effective on March&#160;17, 2021. Shares of common stock underlying outstanding stock options were proportionately reduced from 588,000 to 517,902 and the respective exercise prices, were proportionately increased from $2.97 to $3.38 in accordance with the terms of the agreements governing such securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The reverse stock split did not impact the fair value of the stock option previously recorded and no modification accounting is required because all the three following conditions were met: &#160;(i)&#160;the fair value of the modified award is the same as the fair value of the original award immediately before the original award is modified; (ii)&#160;the vesting conditions of the modified award are the same as the vesting conditions of the original award immediately before the original award is modified and (iii)&#160;the classification of the modified award as an equity instrument is the same as the classification of the original award immediately before modification.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The aggregate intrinsic value of stock options is calculated as the difference between the weighted average exercise price of the underlying stock options and the market price of the Company&#8217;s common stock on December 31, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2021, the total unrecognized compensation cost related to non-vested stock options granted was USD 2,403 thousand and is expected to be recognized over 4 years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company uses the Black-Scholes option pricing model to estimate the fair value of stock options on the date of grant. The Black-Scholes option pricing model takes into account variables such as volatility, dividend yield rate, and risk-free interest rate. The computation of expected volatility and expected term of exercise is based on a representative group of companies with similar characteristics, including stage of product development and life science industry focus, since we do not have a reliable history. The risk-free interest rate is based on US treasury bonds whose term is consistent with the expected term of exercise of the stock options. The expected dividend yield is assumed to be zero as we have never paid dividends and have no current plans to pay any dividends on our common stock. The Company&#8217;s policy is to account for forfeitures when they occur.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The assumptions that the Company used to determine the grant-date fair value of stock options granted were as follows, presented on a weighted-average basis:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:70.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:70.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Grant date fair value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 4.27</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 2.13</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:70.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 80</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 80</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:top;width:70.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected term (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 5.66</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 7.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:70.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 0.98</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 0.67</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:70.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected dividend yield </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Each of these inputs is subjective and generally requires significant judgment to determine. The weighted average grant-date fair value of the Company&#8217;s stock options granted as of December 31, 2021 and 2020 was $4.27 and $2.13, respectively. Total stock-based compensation expense is recognized for stock options granted to employees and non-employees and has been reported in the Company&#8217;s condensed consolidated statements of operations and comprehensive loss as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Total stock-based compensation expense is recognized for stock options granted to employees and non-employees and has been reported in the Company&#8217;s consolidated statements of operations as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;width:24.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td></tr><tr><td style="vertical-align:top;width:73.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 344,304</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 57,049</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:73.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 495,067</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 24,591</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:73.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 839,371</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 81,640</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsGeneralTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for compensation costs, including compensated absences accruals, compensated absences liability, deferred compensation arrangements and income statement compensation items.  Deferred compensation arrangements may include a description of an arrangement with an individual employee, which is generally an employment contract between the entity and a selected officer or key employee containing a promise by the employer to pay certain amounts at designated future dates, usually including a period after retirement, upon compliance with stipulated requirements. This type of arrangement is distinguished from broader based employee benefit plans as it is usually tailored to the employee. Disclosure also typically includes the amount of related compensation expense recognized during the reporting period, the number of shares (units) issued during the period under such arrangements, and the carrying amount as of the balance sheet date of the related liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -URI http://asc.fasb.org/topic&amp;trid=2127225<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6409950&amp;loc=d3e20396-108366<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsGeneralTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139934219858024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreement<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ganx_CollaborationAgreementAbstract', window );"><strong>Collaboration Agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaboration Agreement</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">16.&#160;&#160;&#160;&#160;Collaboration Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On April 20, 2021, the Company entered into a multi-target collaboration agreement with Zentalis Pharmaceuticals, Inc. (&#8220;Zentalis&#8221;) to discover new product candidates for the treatment of cancer. Under the terms of the agreement, the Company will use its in-licensed SEE-Tx&#174; computational platform technology to identify binding sites on target proteins and determine the potential suitability of these sites as drug targets, as well as their prospective therapeutic use in oncology. Pursuant the terms of the agreement, Zentalis agreed to pay the Company, on a program-by-program basis, a non-creditable, non-refundable, program initiation fee and reimbursement of expenses incurred by the Company in accordance with the agreed-upon research budget for each target in a multi-target agreement with a maximum of five mutually agreed to targets at the option of Zentalis. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">With respect to any development program, and subject the delivery of the data package, the Company granted to Zentalis an option to obtain an exclusive, transferable worldwide license, with the right to sublicense, under relevant intellectual property rights and know-how of the Company arising from the collaboration to develop, manufacture and commercialize any products resulting from the development program. Zentalis may exercise the option, at its reasonable discretion, and shall use commercially reasonable efforts to develop and obtain market approval for products developed from the applicable programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Unless terminated earlier, the agreement expires at the expiration of the last valid claim of the licensed patents, subject to certain surviving rights and obligations. Zentalis and the Company can each terminate the agreement in the event of the bankruptcy or insolvency of the other party, or a material breach by the other party and failure to cure such breach within a certain period of time. Zentalis shall have the right, at its sole discretion, exercisable at any time to terminate the agreement on a program-by-program basis, upon ninety (90) days&#8217; prior written notice to the Company or, at any time, if a safety concerns arises with respect to any development program or product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In May 2021, the first target development program was identified, and the estimated development cost were approved and collected in July 2021. The transaction price of this first target development program includes (i) $50&#160;thousand of fixed consideration as program initiation fee, (ii) up to $272 thousand as reimbursement for employee and external research and development cost, (iii) $250 thousand subject to the exercise of a research program option, (iv) up to $41.5&#160;million of variable consideration in the form of event-based milestone payments, if goals will be met in the future, and (v) other royalty-based payments based on future net sales.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company analyzed the Zentalis Collaboration Agreement and concluded that it represents a contract with a customer within the scope of ASC 606 and ASC 808. Based on that evaluation, (i) the program initiation fee was recognized as revenue in full as of June 30, 2021 at a point in time, at program inception as there is no unsatisfied performance obligation; (ii) the performance obligation to provide development services, is satisfied over a period of time as services are performed and Zentalis receives the benefit for the services. The Company will recognize revenue associated with the performance obligation as the research and development services are provided using an input method, according to the costs incurred.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">As of December 31, 2021, the Company recognized $167 thousand of revenues and reported current portion of deferred revenues for $155 thousand.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ganx_CollaborationAgreementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Information pertaining to Collaboration Agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ganx_CollaborationAgreementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ganx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139934219831080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income taxes</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">17.&#160;&#160;&#160;&#160;Income taxes</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company is subject to taxation in the U.S., Switzerland and in Spain. Taxes are recorded on an accrual basis and represent the allowances for taxes paid or to be paid for the&#160;year, calculated according to the current enacted rates and applicable laws. The Company has accumulated net tax losses since inception in Switzerland and in the U.S. The Company report a provision for income taxes due to the Spanish tax authorities pertaining to our branch Gain Therapeutics Sucursal en Espa&#241;a. Spanish corporate income taxes have been computed based on an effective tax rate of 25%, which represents the statutory tax rate, as no discrete items were noted in the computation of income taxes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">For financial reporting purposes, loss before income taxes provision includes the following components:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:65.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:65.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:top;width:65.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Domestic</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (7,601,640)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (623,667)</p></td></tr><tr><td style="vertical-align:top;width:65.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Foreign</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (6,284,958)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,948,629)</p></td></tr><tr><td style="vertical-align:top;width:65.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  Total </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (13,886,598)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,572,296)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Following is the breakdown of the components of income tax expense provision for the&#160;years ended December&#160;31, 2021 and 2020:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:73.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:middle;width:73.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:middle;width:73.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;border-bottom:1.5pt solid #ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;width:2.33%;border-bottom:1.5pt solid #ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:top;width:73.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Current:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:73.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Federal</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:73.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">State</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:73.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Foreign</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 4,008</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 5,386</p></td></tr><tr><td style="vertical-align:top;width:73.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">        Total</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 4,008</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 5,386</p></td></tr><tr><td style="vertical-align:top;width:73.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:73.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">   Federal</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:73.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">State</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:73.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Foreign</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:73.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">       Total</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:73.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total income tax expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 4,008</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 5,386</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">The breakdown of domestic and foreign NOLs and related DTAs are reported in the following table:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:65.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:65.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:65.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:65.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;width:2.13%;border-bottom:1.5pt solid #ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:top;width:65.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">NOLs (foreign) </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (12,021,483)</p></td><td style="vertical-align:bottom;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (6,076,187)</p></td></tr><tr><td style="vertical-align:top;width:65.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">NOLs (domestic)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (6,218,309)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (532,209)</p></td></tr><tr><td style="vertical-align:top;width:65.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">   Total NOLs</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (18,239,792)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (6,608,396)</p></td></tr><tr><td style="vertical-align:top;width:65.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:65.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:65.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Deferred tax assets related to:</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:65.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  Net operating loss (foreign)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2,243,668</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,111,942</p></td></tr><tr><td style="vertical-align:top;width:65.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  Net operating loss (domestic)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,677,610</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 146,451</p></td></tr><tr><td style="vertical-align:top;width:65.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  Stock based compensation</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 253,439</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 22,465</p></td></tr><tr><td style="vertical-align:top;width:65.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  Warrant expense</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 284,531</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:65.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  Other temporary differences</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 4,010</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:65.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">            Total deferred tax assets</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 4,463,258</p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,280,858</p></td></tr><tr><td style="vertical-align:top;width:65.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Deferred tax liabilities</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:65.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  Depreciation and other</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,137)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,682)</p></td></tr><tr><td style="vertical-align:top;width:65.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">            Total deferred tax liabilities</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,137)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,682)</p></td></tr><tr><td style="vertical-align:top;width:65.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:65.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  Valuation allowance</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 4,462,121</p></td><td style="vertical-align:bottom;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,278,176</p></td></tr><tr><td style="vertical-align:top;width:65.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">According to Swiss tax law, the NOLs can be carried forward for seven&#160;years and will begin to expire commencing from 2025 for the NOLs generated in 2017.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">According to the U.S. Tax Cuts and Jobs Act (&#8220;TCJA&#8221;) that was signed into law on December 22, 2017, federal net operating losses (&#8220;NOLs&#8221;) incurred after December 31, 2017 can be carried forward indefinitely and are limited to 80% of taxable income in any tax period. The NOLs and tax credit carryforwards are subject to review and possible adjustment by the Internal Revenue Service and state tax authorities. NOLs and tax credit carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant stockholders over a three-year period in excess of 50 percent, as defined under Sections 382 and 383 of the Internal Revenue Code, as well as similar state provisions. This could limit the amount of tax attributes that can be utilized annually to offset future taxable income or tax liabilities. The amount of the annual limitation is determined based on the value of the Company immediately prior to the ownership change. Subsequent ownership changes may further affect the limitation in future years. The Company has not done an analysis to determine whether or not ownership changes have occurred since inception.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Deferred tax assets require an assessment of both positive and negative evidence when determining whether it is more likely than not that they can be recovered. Such assessment is made on a jurisdiction-by-jurisdiction basis. The Company&#8217;s assessment includes an evaluation of cumulative losses, future sources of taxable income, exclusive of reversing temporary differences, and risks and uncertainties related to our business. As of December&#160;31, 2021 and 2020, the Company has determined that there is not sufficient evidence that the Company will be able to realize the benefits of the domestic and foreign deferred tax assets. Accordingly, due to uncertainty regarding the realization of our deferred tax assets, the Company continues to maintain a full valuation allowance on the Company&#8217;s domestic and foreign deferred tax assets as of December&#160;31, 2021 and 2020 and until sufficient positive evidence will exist to support the reversal of the valuation allowance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A reconciliation of income tax expense (benefit) computed at the statuory federal income tax rate to the Compan&#8217;s effective tax rate as reflected in the consolidated financial statements is as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:71.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;width:1.44%;border-bottom:1.5pt solid #ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Federal income tax at US statutory rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">21.00%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">21.00%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">State income taxes, net of federal benefit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">6.52%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">6.52%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Permanent differences</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(0.10)%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">0.00%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Provision to return</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">0.13%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">0.00%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Foreign tax</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(0.03)%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(0.15)%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(27.52)%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(27.37)%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Effective income tax rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">0.00%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">0.00%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2021 and 2020, the Company had no accrued interest or penalties related to uncertain tax positions and no amounts have been recognized in the Company&#8217;s statement of operations.There are no changes expected to occur in the next 12&#160;months with respect to the status of the Company&#8217;s uncertain tax positions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company files income tax returns in Switzerland, Spain and in the United States. Tax years from 2018 and after remain subject to examination by the taxing jurisdictions. The NOL and tax carryforwards remain subject to review until utilized. The Company is currently not under examination by any tax authorities.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139934219928984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net loss per common share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net loss per common share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net loss per common share</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">18.&#160;&#160;&#160;&#160;Net loss per common share</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Basic net loss per common share is computed by dividing the net loss available to common stockholders by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per common share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock and potentially dilutive securities outstanding during the period determined using the treasury-stock and if-converted methods. For purposes of the diluted net loss per share calculation, preferred stock, warrants and stock options are considered to be potentially dilutive securities, but are excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive and therefore basic and diluted net loss per share are the same for all periods presented.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table sets forth the outstanding potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to do so would have resulted in anti-dilutive impacts:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series A Preferred Stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,185,879</p></td></tr><tr><td style="vertical-align:bottom;width:74.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series B Preferred Stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 2,695,600</p></td></tr><tr><td style="vertical-align:bottom;width:74.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Options to purchase common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 960,216</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 429,822</p></td></tr><tr><td style="vertical-align:bottom;width:74.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrants to purchase common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 425,387</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 237,249</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The net loss per share for the comparative period ending December 31, 2020 of $1.17 has been recomputed to take into account the reverse stock split, resulting in $1.33 net loss per share.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139934219985176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Parties<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Parties</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Parties</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">19.&#160;&#160;&#160;&#160;Related Parties</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Dr.&#160;Khalid Islam, the Chairman of our Board of Directors, shareholders and founder of the Company, is currently the Chairman of the board of directors of Minoryx, and therefore Minoryx is considered a related party. In December&#160;2017, the Company entered into an exclusive worldwide, royalty-bearing, assignable, transferable license agreement with Minoryx Therapeutics SL to use and exploit Minoryx&#8217;s IP and into an exclusive worldwide, royalty-bearing, assignable, transferable sublicense agreement with Universitat de Barcelona and Institucio Catalana Recerca Estudis Avancats in order to be able to develop its business, directly or indirectly, through sub-licensing to third parties </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">or any other way of operation. According to the Minoryx License Agreement, &#160;the Company shall pay to Minoryx as royalties:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">an amount equal to </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">8%</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> of (i)&#160;net revenues with regard to products that would infringe (a)&#160;at least one composition of matter claim or (b)&#160;Minoryx molecules and (ii)&#160;sublicensing revenues;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">an amount equal to </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3%</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> of net revenues with regard to products that would infringe at least (a)&#160;one method of claim or (b)&#160;Minoryx know-how.</span></td></tr></table><div style="margin-top:12pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In addition to royalties, the Company shall pay Minoryx certain milestones payments of 1.25% of any consideration received in the event of a sale of the Company or substantially all of the assets, including by merger, change of control, or reorganization.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">As of December 31, 2021 and 2020, there were no receivables and payables, revenues or expenses with Minoryx.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139934219835160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ganx_OtherInformationAbstract', window );"><strong>Other Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ganx_OtherInformationDisclosureTextBlock', window );">Other Information</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">20.&#160;&#160;&#160;&#160;Other Information</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Own Shares</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company does not hold, either directly or indirectly, its own shares and in these periods &#160;has not purchased or alienated its own shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Commitments</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31,2021, the Company had research commitments with contractual maturity date in 2022 for $ 453,305.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ganx_OtherInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ganx_OtherInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ganx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ganx_OtherInformationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of information pertaining to other information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ganx_OtherInformationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ganx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139934219880200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant events after the balance sheet date<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Significant events after the balance sheet date</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Significant events after the balance sheet date</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">21.&#160;&#160;&#160;&#160;Significant events after the balance sheet date</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:14.2pt;margin:0pt 0pt 12pt 0pt;">None.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139934218834312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of presentation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Basis of presentation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The consolidated financial statements reflect the accounts of the Gain Therapeutics, Inc., GT Gain Therapeutics SA and its wholly owned branch, Gain Therapeutics Sucursal en Espa&#241;a. All intercompany transactions and balances have been eliminated in the preparation of the consolidated financial statements. The consolidated financial statements as of December 31, 2021, represented by the Consolidated Balance Sheet, the Consolidated Statement of Operations, the Consolidated Statements of Changes in Shareholders&#8217; Equity, the Consolidated Statement of Comprehensive Loss, the Consolidated Statements of Cash Flows and the accompanying Notes, have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;US GAAP&#8221;). Any reference in these notes to applicable guidance is meant to refer to the authoritative United States generally accepted accounting principles as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Update (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The &#160;financial statements as of December 31, 2021 reflect, for all periods presented, the retroactive application of the reverse stock split that occurred on March 17, 2021. All amounts in the consolidated financial statements are expressed in United States Dollars (USD/$) and disclosed within these explanatory notes in United States Dollars (USD/$) or Swiss Franc (CHF), which are the functional currencies of the Company and its operating subsidiary, GT Gain Therapeutics SA, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The consolidated financial statements have been prepared on the same basis as the audited annual consolidated financial statements as of and for the year ended December 31, 2020, and, in the opinion of management, reflect all adjustments, consisting of normal recurring adjustments, necessary for the fair presentation of the Company&#8217;s financial position as of December 31, 2021, and the results of its operations for the years ended December 31, 2021 and 2020, its statements of stockholders&#8217; equity and its statements of cash flows for the years then ended. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ganx_ReverseStockSplitPolicyPolicyTextBlock', window );">Reverse Stock Split</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Reverse Stock Split </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">On March 3, 2021, the Board approved a 1-for-<span style="-sec-ix-hidden:Hidden_PPLEqeAgy0iiPmdWllrCSA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">0.880784</span></span> reverse stock split of the Company&#8217;s outstanding equity instruments. The reverse stock split was approved by the stockholders on March 4, 2021 and became effective in conjunction with the IPO on March 17, 2021. Stockholders were no entitled to fractional shares as a result of the reverse stock split. All share and per share data shown in the accompanying consolidated financial statements and </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">related notes have been retroactively revised to reflect the reverse stock split. Shares of common stock underlying outstanding stock options and other equity instruments were proportionately reduced and the respective exercise prices, if applicable, were proportionately increased in accordance with the terms of the agreements governing such securities.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ganx_InitialPublicOfferingPolicyTextBlock', window );">Initial Public Offering</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Initial Public Offering </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On March 17, 2021, the Company&#8217;s registration statement on Form S-1 relating to its IPO was declared effective by the Securities and Exchange Commission (&#8220;SEC&#8221;). The IPO closed on March 17, 2021 and the Company issued and sold 3,636,364 common shares at a public offering price of $11.00 per share for net proceeds of $34,978 thousand after deducting underwriting discounts and commissions of $2,950 thousand and other offering expenses of $2,071 thousand. On March 22, 2021, the Company issued and sold 545,454 additional common shares, pursuant to the full exercise of the underwriters&#8217; option to purchase additional shares, for net proceeds of $5,580 thousand after deducting underwriting discounts and commissions of $420 thousand. Thus, the aggregate net proceeds to the Company from the IPO, after deducting underwriting discounts commissions, were $42,630 thousand. After deducting other IPO offering expenses amounting to $2,071 thousand, the net cash proceeds resulting from the IPO were $40,558 thousand, which are reflected in the statement of stockholders&#8217; equity as Issuance of Common Stock in IPO, net of issuance costs. Upon the closing of the IPO, series A convertible preferred stock (the &#8220;Series A Preferred Stock&#8221;) and series B convertible preferred stock (the &#8220;Series B Preferred Stock&#8221;, and together with the Series A Preferred Stock, are collectively referred to as the &#8220;Preferred Stock&#8221;) were converted into shares of common stock at ratio of 1-for-1.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment information</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Segment information</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Operating segments are defined as components of an enterprise for which separate discrete information is available for evaluation by the chief operating decision-maker in deciding how to allocate resources and assess performance. The Company&#8217;s chief operating decision-maker, the Chief Executive Officer, oversees the Company&#8217;s operations and manages the business as a single operating segment, which is research and development in the pharmaceutical sector with a focus on developing novel therapeutics to treat diseases caused by protein misfolding, such as rare genetic diseases and neurological disorders. Geographically, the research and development activities are mainly performed in Switzerland and Spain. The Company does not consider these geographies to be separate segments.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign currency translation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Foreign currency translation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company is incorporated in the United States of America and has operations in Switzerland and Spain. The Company&#8217;s functional currency is USD. The functional currencies of the Company&#8217;s foreign operations are the local currencies (Swiss Franc in Switzerland and Euro in Spain). Assets and liabilities reported in the consolidated balance sheets are translated into U.S. dollars (the currency in which these financial statements are presented) at the exchange rates applicable at the balance sheet dates and for the consolidated statement of operations at the average exchange rates for the periods presented. Items representing the share capital and additional paid-in capital are presented at the historical exchange rates. Adjustments resulting from the translation of the financial statements of the Company&#8217;s foreign operations into U.S. dollars are excluded from the determination of net income and are recorded in accumulated other comprehensive income/(loss), a separate component of shareholders&#8217; equity. The Company has not utilized any foreign currency hedging strategies to mitigate the effect of its foreign currency exposure. As of December 31, 2021 and 2020, accumulated currency translation adjustment recorded in the accumulated other comprehensive loss amounted to $165,156 and $1,323, respectively.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The preparation of our consolidated financial statements in conformity with US GAAP requires management to make estimates, judgments and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting periods. On an ongoing basis, we evaluate our estimates judgments and, assumptions including those related to recognition of grant funds, accrued expenses, defined benefit pension liability, warrants and stock-based compensation. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. Changes in estimates are recorded in the period in which they become known. To the extent that material differences arise between the estimates and actual results, the Company&#8217;s future results of operations will be affected. The COVID-19 pandemic did not have a significant impact on the Company&#8217;s estimates.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Cash and cash equivalents</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company reports cash on hand and held at banks, and all highly liquid investments in money market, certificates of deposit, time deposit, and other short-term liquid securities with original maturities of less than 90 day, as cash and cash equivalents.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Credit Risk</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Concentrations of credit risk</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has no significant off-balance sheet risk, such as foreign exchange contracts, option contracts, or other foreign hedging arrangements. Financial instruments that may expose the Company to concentrations of credit risk consist primarily of cash, cash equivalents which are deposited in accredited financial institutions in excess of federally insured limits. The Company deposits its cash and cash equivalents in financial institutions that it believes have high credit quality and has not experienced any losses on such accounts and does not believe it is exposed to any unusual credit risk beyond the normal credit risk associated with commercial banking relationships.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredChargesPolicyTextBlock', window );">Deferred Issuance Costs</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Deferred Issuance Costs</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company capitalizes certain legal, professional accounting and other third-party fees that are directly associated with in-process equity financings as deferred issuance costs until such financings are consummated. After consummation of the equity financing, these costs are recorded as a reduction of the proceeds generated as a result of the offering. Should the planned equity financing be abandoned, the deferred issuance costs will be expensed immediately as a charge to operating expenses in the consolidated statements of operations. There were nil and $1,217,988 deferred issuance costs as of December 31, 2021 and 2020, respectively.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and equipment</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Property and equipment</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Property and equipment are stated at cost, including any accessory and direct costs that are necessary to make the assets fit for use, and adjusted by the corresponding accumulated depreciation. The depreciation rates recorded in the consolidated financial statements of operations have been calculated by taking into consideration the use, purpose and financial-technical duration of the assets, on the basis of their estimated useful economic lives. The Company believes the above criteria to be represented by the following depreciation rates:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:61.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:33.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:61.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">-&#8195; Equipment &amp; Furniture</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:33.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 12.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:top;width:61.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">-&#8195; Electronic office equipment:</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:33.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:top;width:61.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">-&#8195; Leasehold Improvements</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:33.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">based on the terms of the lease</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:61.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">-&#8195; Laboratory equipment:</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:33.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 15</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Ordinary maintenance costs are entirely attributed to the consolidated statements of operations in the&#160;year in which they are incurred. Extraordinary maintenance costs, the purpose of which is to extend the useful economic life of the asset, to technologically upgrade it and/or to increase its productivity or safety for the purposes of the economic productivity of the Company, are attributed to the asset to which they refer and depreciated on the basis of its estimated useful economic lives. Amortization of leasehold improvements is computed using the straight-line method based upon the terms of the applicable lease or estimated useful life of the improvements, whichever is lower.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock', window );">Capitalized Software Development Costs</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Capitalized Software Development Costs</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company capitalizes the costs of software obtained for internal use in accordance with ASC 350-40, Internal-Use Software. Capitalized software development costs consist of costs incurred during the development stage and include purchased software licenses, implementation costs, consulting costs, and payroll-related costs for projects that qualify for capitalization. All other costs, primarily related to maintenance and minor software fixes, are expensed as incurred. As of December 31, 2021 and 2020, internal-use software amount to $202,609 and nil, and refer to the </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">external and internal labor costs incurred in the development of the Company ERP, amounting respectively to $168,474 and $34,135. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company amortizes the capitalized software development costs on a straight-line basis over the estimated useful life of the software, which is generally six years, beginning when the asset is substantially ready for use. The amortization of capitalized software development costs is reflected in general and administrative expenses. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of long-lived assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Impairment of long-lived assets</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">In accordance with ASC Topic 360-10-20, &#8220;Property, Plant and Equipment,&#8221; the Company performs an impairment test whenever events or circumstances indicate that the carrying value of long-lived assets with finite lives may be impaired. Impairment is measured by comparing the carrying value of the long-lived assets to the estimated undiscounted pre-tax cash flows expected to result from the use of such assets and their ultimate disposition. In circumstances where impairment is determined to exist, the Company will write down the asset to its fair value based on the present value of estimated cash flows. </span><span style="font-weight:normal;">No</span><span style="font-weight:normal;"> impairments have been identified by management as of and for any periods presented.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">Patents</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Patents</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">Patent-related costs, refer to legal fees incurred in connection with filing and prosecuting patent applications and are expensed as incurred due to uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Leases</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Effective January&#160;1, 2018, the Company adopted ASC 842, using the additional transition method option provided by ASU 2018-11. Under this transition method, we applied the new accounting guidance as of the date of adoption. Upon adoption, a cumulative effect adjustment was not required.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Subsequent to the adoption, the Company determines if an arrangement contains a lease at inception based on whether or not the Company has the right to control the asset during the contract period and other facts and circumstances. The Company is the lessee in a lease contract when it obtains the right to control the asset. Operating lease right of use (&#8220;ROU&#8221;) assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease, both of which are recognized based on the present value of the future minimum lease payments over the lease term at the commencement date. Leases with a term of 12 months or less at inception are expensed on a straight-line basis over the lease term in the statement of operations. The Company determines the lease term by assuming the exercise of renewal options that are reasonably certain. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, the Company subleases portions of its office premises in Lugano. The Company recognizes sublease income on a straight-line basis over the sublease terms, reported within other income. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ganx_AccountsPayablePolicyTextBlock', window );">Accounts Payable</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Accounts Payable</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Accounts payable are reported at their nominal amounts due to their short-term maturities. Trade accounts payable are recorded net of trade discounts; cash discounts are recorded at the time of payment.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ganx_PayablesForSocialSecuritiesPolicyTextBlock', window );">Payables for Social Securities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Payables for Social Securities</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Social Security charges are reported in compliance with rules and laws applicable in the countries where our employees work. Charges are accrued in accordance with the policies stipulated and in connection with salaries due for the period.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ganx_AccruedExpensesPolicyPolicyTextBlock', window );">Accrued expenses</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Accrued expenses</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">As part of the process of preparing our consolidated financial statements, we are required to estimate our accrued expenses as of each balance sheet date. This process involves reviewing open contracts and purchase orders, communicating with our personnel to identify services that have been performed on our behalf and estimating the level </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of the actual cost. We make estimates of our accrued expenses as of each balance sheet date based on facts and circumstances known to us at that time at the date of the preparation of the consolidated financial statements. There may be instances in which payments made to our vendors exceed the level of services provided, and result in prepayment reported under other current assets, which are subsequently expenses in the consolidated statement of operations when the related activity has been performed rather than when the payment is made. To date, there have been no material differences between our estimates of accrued expenses reported at each balance sheet date and the amounts actually incurred.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementPlansPolicy', window );">Pension obligations</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Pension obligations</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We operate defined benefit pension plan and defined contribution pension plans in accordance with local regulations and practices in the countries in which the Company operates. These plans are funded by regular contribution made by the employer and the employees. For defined benefit pension plan, the liability recognized in the consolidated balance sheets is the present value of the defined benefit obligation at the balance sheet date less the fair value of plan assets. The overfunded or underfunded status of the defined benefit plan is calculated as the difference between plan assets and the projected benefit obligations. Estimates are used in determining the assumptions incorporated in the calculation of the pension obligations, which is supported by input from independent actuaries. Actuarial gains and losses arising from experience adjustments and changes in actuarial assumptions are recognized in &#8220;Accumulated other comprehensive income (loss)&#8221; in the consolidated statements of equity and are charged or credited to income over the employees&#8217; expected average remaining working lives. The measurement date used for our employee benefit plan is December 31.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For defined contribution pension plans, the Company pays contributions to publicly or privately administered pension insurance plans on a mandatory, contractual or volutanry basis. The Company has no further payment obligations once the contributions have been paid. The contributions are recognized as employee benefit expense when they are due. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Equity-based Compensation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Equity-based Compensation and Warrants</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company applies the fair value method of measuring equity-based compensation and warrants, which requires an entity to measure the cost of services received in exchange for an award of equity instruments based on the grant-date fair value of the award. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company issues equity-based compensation with only service-based vesting conditions and record the expense for these awards using the straight-line method. The Company has not issued any stock-based awards with performance- or market-based vesting conditions.The Company recognizes the related costs in the consolidated statement of operations and as additional paid-in capital in the consolidated statement of shareholders&#8217; equity, in accordance with the vesting period during which the award recipients are required to provide services in exchange for the award. The Company accounts for forfeitures as they occur.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Before being a public company, given the absence of an active market for the Company&#8217;s common stock, the Company and the Board of Directors estimated the fair value of the Company&#8217;s common stock at the grant date determining the estimated fair value of the Company&#8217;s equity instruments based on a number of factors, including prices paid for the Company&#8217;s convertible preferred stock sold to outside investors in arm&#8217;s-length transactions; the Company&#8217;s stage of development; the fact that the grants of stock-based awards involved illiquid securities in a private company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The fair value of each stock option award is estimated on the date of grant using the Black-Scholes option pricing model. Given the absence of an active public market for the Company&#8217;s common stock prior to March 19, 2021, which was the first day of trading, the Company determined the volatility and the expected term for awards granted based on an analysis of reported data for a peer group of similar biopharmaceuticals companies that issued options with substantially similar terms. After the IPO, we continued to do so, and we expect not to change our methodology until such time as we will have reliable historical data regarding the volatility of our traded stock price and expected term of exercise patterns. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. The Company has not paid, and does not anticipate paying, cash dividends on our common stock; therefore, the expected dividend yield is assumed to be zero.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Black-Scholes option pricing model is also used for warrants issued, using consistent inputs and methodology to quantify such inputs, as described above in relation &#160;to equity-based compensation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The assumptions used in calculating the fair value of share-based awards and warrants represent management&#8217;s best estimates and involve inherent uncertainties and the application of management&#8217;s judgment. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Revenue Recognition</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company derives revenues from collaboration and licensing agreements. The Company recognize revenue related to these agreements in accordance with&#160;ASC&#160;606, <i style="font-style:italic;">Revenues from contracts with customers</i> and ASC 808, <i style="font-style:italic;">Collaborative arrangements</i>. The terms of these arrangements typically include payment from third parties customers of one or more of the following: non-refundable initiation fee, reimbursement of development costs, development and regulatory milestone payments and royalties on net sales of the licensed product. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In determining the appropriate amount of revenue to be recognized as we fulfill our obligations, the Company applies the five steps model of ASC606: (i)&#160;identify the contract(s) with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when (or as) we satisfy a performance obligation. The Company only apply the five-step model to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods and services it transfers to the customer. If a contract is determined to be within the scope of ASC 606 at inception, the Company assesses the goods or services promised within such contract, determines which of those goods and services are performance obligations, and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Costs and revenues associated with collaborative arrangements are reported in the consolidated statements of operations on a gross basis when the counterpart is identified as being a customer, when the performance obligations incurred and rendered to fulfil the agreements are deemed to be in the ordinary course of the Company&#8217;s business, or when there is an expectation that the collaborative arrangement will result in a future constant flow of revenues in the form of sale of products, royalties or licenses.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ganx_ResearchGrantsPolicyPolicyTextBlock', window );">Research grants</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Research grants</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the terms of the research and development grants awarded (such as those awarded by the The Michael J. Fox Foundation for Parkinson&#8217;s Research (MJFF) and The Silverstein Foundation for Parkinson&#8217;s Disease and from Innosuisse &#8211; Swiss Innovation Agency), we are entitled to receive reimbursement of our allowable direct expenses and payroll costs. Contributions from research and development activities under the grants are recorded based on management&#8217;s best estimate of the periods in which the related expenditures are incurred and activities performed and are classified in the statement of operations as a reduction to research and development expenses, measuring according to the time periods during which the research and development activities are carried out and related costs sustained.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and development expenses</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Research and development expenses</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company expenses all costs incurred in performing research and development activities. Research and development expenses include salaries and other related costs, materials and supplies, preclinical expenses, manufacturing expenses, contract services and other third-party expenses. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock', window );">General and administrative expenses</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">General and administrative expenses</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">General and administrative expenses consist primarily of salaries, benefits and other related costs, for personnel and consultants in the Company&#8217;s executive and finance functions. General and administrative expenses also include professional fees for legal, finance, accounting, intellectual property, auditing, tax and consulting services, travel expenses and facility-related expenses, which include allocated expenses for rent and maintenance of facilities and other operating costs not otherwise included in research and development expenses.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income taxes</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Income taxes</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for income taxes under the liability method. Under this method deferred income tax liabilities and assets are determined based on the difference between the financial statement carrying amounts of assets and liabilities and the related tax basis using enacted tax rates in effect in the&#160;years in which the associated deferred taxes are expected to reverse. A valuation allowance is recorded if it is &#8220;more likely than not&#8221; that a portion or all of a deferred tax asset will not be realized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of each reporting date, the Company considers existing evidence, both positive and negative, that could impact its view with regards to future realization of deferred tax assets. In consideration of the start-up status of the Company, a full valuation allowance has been established to offset the deferred tax assets, as the related realization is currently uncertain. In the future, should management conclude that it is more likely than not that the deferred tax assets are partially or fully realizable, the valuation allowance will be reduced to the extent of such expected realization, and the corresponding amount will be recognized as income tax benefit in the Company&#8217;s consolidated statement of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company recognizes tax liabilities from an uncertain tax position if it is more likely than not that the tax position will not be sustained upon examination by the taxing authorities, based on the technical merits of the tax position. There are no uncertain tax positions that have been recognized in the accompanying consolidated financial statements.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair value measurements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Fair value measurements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Company applies the following fair value hierarchy, which prioritizes the inputs used to measure fair value into three levels based on their observability in the market and degree of judgment involved:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:21.3pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:14.15pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 1&#160;&#8211; Quoted prices in active markets for identical assets or liabilities.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:21.3pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:14.15pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 2&#160;&#8211; Observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:21.3pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:14.15pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 3&#160;&#8211; Inputs that are generally unobservable and typically reflect management&#8217;s estimates of assumptions that market participants would use in pricing the asset or liability.</span></td></tr></table><div style="margin-top:10pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In determining fair value, we utilize valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and consider counterparty credit risk in their assessment of fair value.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive income/(loss)</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Comprehensive income/(loss)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">Comprehensive income/(loss) is composed of net income(loss) and certain changes in stockholder&#8217;s equity that are excluded from the net income(loss), primarily foreign currency translation adjustments and defined benefit obligation adjustments.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net loss per share</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Net loss per share</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Basic net loss per share is computed by dividing the reported net loss by the weighted average number of shares of common stock outstanding during the period. The Company gives consideration to all potentially dilutive impacts, except where the effect of including such securities would be antidilutive. As of December 31, 2021, common stock equivalents consisted of stock options and warrants, while as of &#160;December 31, 2020, common stock equivalents consisted of the Series&#160;A preferred stock, Series B preferred stock, stock options and warrants. Because the Company has reported net losses since inception, these potential impacts would be anti-dilutive, and therefore common stock equivalents have been excluded from the computation, resulting in basic and diluted net loss per share being the same for all periods presented.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently issued accounting pronouncements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Recently issued accounting pronouncements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that we adopt as of the specified effective date. We do not believe that the adoption of any recently issued standards have or may have a material impact on our consolidated financial statements or disclosures.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ganx_AccountsPayablePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ganx_AccountsPayablePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ganx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ganx_AccruedExpensesPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ganx_AccruedExpensesPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ganx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ganx_InitialPublicOfferingPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for initial public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ganx_InitialPublicOfferingPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ganx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ganx_PayablesForSocialSecuritiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for payables for social securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ganx_PayablesForSocialSecuritiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ganx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ganx_ResearchGrantsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy research grants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ganx_ResearchGrantsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ganx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ganx_ReverseStockSplitPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reverse stock split.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ganx_ReverseStockSplitPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ganx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123345438&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredChargesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for deferral and amortization of significant deferred charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredChargesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI http://asc.fasb.org/topic&amp;trid=2175825<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155638-234783<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155628-234783<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155628-234783<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementPlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for pension and other postretirement benefit plans. This accounting policy may address (1) the types of plans sponsored by the entity, and the benefits provided by each plan (2) groups that participate in (or are covered by) each plan (3) how plan assets, liabilities and expenses are measured, including the use of any actuaries and (4) significant assumptions used by the entity to value plan assets and liabilities and how such assumptions are derived.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66047640&amp;loc=d3e39622-114963<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 80<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=65877416&amp;loc=d3e29149-114947<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6412939&amp;loc=d3e15145-114933<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementPlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its research and development and computer software activities including the accounting treatment for costs incurred for (1) research and development activities, (2) development of computer software for internal use, (3) computer software to be sold, leased or otherwise marketed as a separate product or as part of a product or process and (4) in-process research and development acquired in a purchase business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 50<br> -Section 25<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=16397303&amp;loc=d3e19347-109286<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 40<br> -Section 30<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118172244&amp;loc=d3e17916-109280<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.15)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139934224950264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ganx_DepreciationRatesOnPropertyPlantAndEquipmentTableTextBlock', window );">Schedule of depreciation rates</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:61.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:33.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:61.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">-&#8195; Equipment &amp; Furniture</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:33.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 12.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:top;width:61.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">-&#8195; Electronic office equipment:</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:33.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:top;width:61.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">-&#8195; Leasehold Improvements</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:33.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">based on the terms of the lease</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:61.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">-&#8195; Laboratory equipment:</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:33.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 15</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ganx_DepreciationRatesOnPropertyPlantAndEquipmentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for depreciation rates on property plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ganx_DepreciationRatesOnPropertyPlantAndEquipmentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ganx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139934220785928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash, cash equivalents and restricted cash (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Cash, cash equivalents and restricted cash</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock', window );">Schedule of cash, cash equivalents and restricted cash</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:67.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:67.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:top;width:67.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,262,977</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 907,255</p></td></tr><tr><td style="vertical-align:top;width:67.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Money Market</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 33,617,696</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 6,585,655</p></td></tr><tr><td style="vertical-align:top;width:67.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 36,880,673</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 7,492,910</p></td></tr><tr><td style="vertical-align:top;width:67.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 31,279</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 11,371</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ganx_ScheduleOfCashAndCashEquivalentsBalancesTableTextBlock', window );">Schedule of cash and cash equivalents balances broken down by currency</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:69.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:top;width:69.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash in CHF</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 157,310</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 128,074</p></td></tr><tr><td style="vertical-align:top;width:69.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash in EUR</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 338,766</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 145,726</p></td></tr><tr><td style="vertical-align:top;width:69.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash in USD</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 36,322,777</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 7,149,386</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ganx_ScheduleOfCashAndCashEquivalentsBalancesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cash and cash equivalents balances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ganx_ScheduleOfCashAndCashEquivalentsBalancesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ganx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139934219814792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Current Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>Other Current Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ganx_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock', window );">Schedule of Other Current Assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:73.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:top;width:73.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Tax Credits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 113,586</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 58,017</p></td></tr><tr><td style="vertical-align:top;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:73.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepaid and deferred expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 498,252</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 198,994</p></td></tr><tr><td style="vertical-align:top;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other receivable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 81,862</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:73.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepaid D&amp;O Insurance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 147,671</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total Prepaid expenses and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 727,785</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 198,994</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ganx_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for Prepaid expenses and other current assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ganx_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ganx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139934219864632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property and Equipment, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and equipment</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:69.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:69.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:top;width:69.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Computer</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 55,141</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 25,436</p></td></tr><tr><td style="vertical-align:top;width:69.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Furniture and fixtures</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 42,148</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 4,865</p></td></tr><tr><td style="vertical-align:top;width:69.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 17,327</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 8,889</p></td></tr><tr><td style="vertical-align:top;width:69.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Laboratory instruments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 19,759</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,348</p></td></tr><tr><td style="vertical-align:top;width:69.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total property and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 134,375</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 42,538</p></td></tr><tr><td style="vertical-align:top;width:69.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: accumulated depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (28,389)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (12,905)</p></td></tr><tr><td style="vertical-align:top;width:69.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 105,986</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 29,633</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139934221863640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating lease. Right of use ("ROU") assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Operating lease. Right of use ("ROU") assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLeaseIncomeTableTextBlock', window );">Schedule of components of lease accounting</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:69.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:top;width:69.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating Lease</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:69.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease- right of use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 901,042</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 523,080</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:69.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:69.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease liability - current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 219,137</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 122,756</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:69.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease liability - non current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 695,053</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 400,324</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:69.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average remaining lease term - years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:69.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average discount rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1.86</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 3.61</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of components of lease expense</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:69.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:top;width:69.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 191,329</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 121,800</p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of future minimum lease payments</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:68.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:27.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Fiscal Year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Operating Leases</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 237,926</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 245,685</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 227,115</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 167,526</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 58,738</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total future minimum lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 936,990</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less amount representing interest or imputed interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 22,800</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Present value of lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.99%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 914,190</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLeaseIncomeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of components of income from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919372-209981<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6A<br> -URI http://asc.fasb.org/extlink&amp;oid=124502072&amp;loc=SL77927221-108306<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLeaseIncomeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139934219942376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Payable (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrentAbstract', window );"><strong>Accounts Payable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of vendor outstanding payables</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:69.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:top;width:69.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Vendors Payables in CHF</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 13,166</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 29,423</p></td></tr><tr><td style="vertical-align:top;width:69.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Vendors Payables in EUR</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 309,378</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 202,223</p></td></tr><tr><td style="vertical-align:top;width:69.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Vendors Payables in USD</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 197,045</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 673,600</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139934220252328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other current liabilities and deferred income (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCreditsAndOtherLiabilitiesAbstract', window );"><strong>Other current liabilities and deferred income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ganx_OtherCurrentLiabilitiesAndDeferredIncomeTableTextBlock', window );">Schedule of Other current liabilities and deferred income</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:68.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:top;width:68.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Payable for social securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 255,068</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 88,334</p></td></tr><tr><td style="vertical-align:top;width:68.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued payroll</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 465,382</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 294,469</p></td></tr><tr><td style="vertical-align:top;width:68.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 681,770</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 379,270</p></td></tr><tr><td style="vertical-align:top;width:68.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Tax provision</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 380</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,070</p></td></tr><tr><td style="vertical-align:top;width:68.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deposit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 5,307</p></td></tr><tr><td style="vertical-align:top;width:68.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">  Total Other Current Liabilities</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,402,600</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 768,450</p></td></tr><tr><td style="vertical-align:top;width:68.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 266,504</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 239,483</p></td></tr><tr><td style="vertical-align:top;width:68.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">  Total Other Current Liabilities and Deferred Income</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,669,104</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,007,933</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ganx_OtherCurrentLiabilitiesAndDeferredIncomeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for other current liabilities and deferred income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ganx_OtherCurrentLiabilitiesAndDeferredIncomeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ganx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCreditsAndOtherLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCreditsAndOtherLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139934302310248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pension obligations (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Pension obligations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock', window );">Schedule of Pension obligations</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Net pension obligations related to the Company&#8217;s defined pension plan refer only to Swiss employees and as of December&#160;31, 2021 and 2020, can be summarized as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">End of year funed status:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Fair value of plan assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 943,025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 477,288</p></td></tr><tr><td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">(Projected benefit obligation)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,272,483)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (648,846)</p></td></tr><tr><td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Funded status</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (329,458)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (171,558)</p></td></tr><tr><td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accumululated benefit obligation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,233,053</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 652,445</p></td></tr><tr><td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Reconciliation of funded status:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Funded status beginning of year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (171,558)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (126,629)</p></td></tr><tr><td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (144,146)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (44,474)</p></td></tr><tr><td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Employer contribution</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 88,819</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 36,264</p></td></tr><tr><td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Translation differences</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,437)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (501)</p></td></tr><tr><td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Change in AOCI over the year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (101,136)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (36,218)</p></td></tr><tr><td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Funded status at end of year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (329,458)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (171,558)</p></td></tr><tr><td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Component of net periodic pension costs:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Service cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 132,809</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 36,597</p></td></tr><tr><td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Interest cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,318</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 947</p></td></tr><tr><td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Expected return on plan assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5,558)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,564)</p></td></tr><tr><td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Amortization of (gain)/losses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 16,212</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 10,494</p></td></tr><tr><td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Amortization of prior service cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (635)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 144,146</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 44,474</p></td></tr><tr><td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="7" style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Service cost is reported in research and development and general and administrative expenses. All other components of net period costs are reported in interest income, net in the consolidated statement of operations</p></td></tr><tr><td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Reconciliation of projected benefit obligation:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Projected benefit obligation at January 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 648,846</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 496,819</p></td></tr><tr><td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Services cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 132,809</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 36,597</p></td></tr><tr><td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Employee contribution</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 59,208</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 25,770</p></td></tr><tr><td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Interest Cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,318</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 947</p></td></tr><tr><td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Benefit payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 315,300</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 48,602</p></td></tr><tr><td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"> (Gain)/loss on financial assumption</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (27,799)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 4,379</p></td></tr><tr><td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"> (Gain)/loss on demographic assumption</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (43,123)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"> (Gain)/loss on experience</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 193,984</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 35,732</p></td></tr><tr><td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">    Plan Amendement</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (8,060)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,272,483</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 648,846</p></td></tr><tr><td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Reconciliation of fair value of plan assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Fair value at January 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 477,288</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 370,190</p></td></tr><tr><td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Expected return on plan assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 5,558</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,564</p></td></tr><tr><td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Gain/(loss) on plan assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,148)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (9,454)</p></td></tr><tr><td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Employer contributions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 88,819</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 36,264</p></td></tr><tr><td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Employee contributions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 59,208</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 25,770</p></td></tr><tr><td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Benefit payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 315,300</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 48,602</p></td></tr><tr><td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Others</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2,352</p></td></tr><tr><td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Fair value at December 31</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 943,025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 477,288</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change in net (gain)/loss:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">(Gain)/loss at beginning of year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 154,665</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 117,803</p></td></tr><tr><td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">(Gain)/loss on PBO during year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 122,895</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 37,902</p></td></tr><tr><td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">(Gain)/loss on assets during year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,148</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 9,454</p></td></tr><tr><td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Amortization of gain/(loss)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (16,212)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (10,494)</p></td></tr><tr><td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">(Gain)/loss at end of year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 264,496</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 154,665</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Change in accumulated other comprehensive income (AOCI):</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">AOCI at beginning of year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 154,665</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 117,803</p></td></tr><tr><td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Net gain/(loss) amortized</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (16,212)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (10,494)</p></td></tr><tr><td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">(Gain)/loss on PBO during the year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 122,895</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 37,902</p></td></tr><tr><td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">(Gain)/loss on assets during the year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 3,148</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 9,454</p></td></tr><tr><td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Prior Service Cost/(credit) occurring over the year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (8,060)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Net prior service (cost)/credit amortized</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (635)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total AOCI at end of year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 255,801</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 154,665</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock', window );">Schedule of assumptions used</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The assumptions used in the determination of the benefit obligation and the plan assets for the pension plans and the pension obligation were as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:60.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:top;width:60.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Actuarial Assumptions (%pa):</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:60.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Discount rate </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">0.30%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">0.15%</p></td></tr><tr><td style="vertical-align:top;width:60.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Interest credit rate / ERoA </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">1.00%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">1.00%</p></td></tr><tr><td style="vertical-align:top;width:60.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Salary increases </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">1.00%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">1.00%</p></td></tr><tr><td style="vertical-align:top;width:60.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Pension increases </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">0.00%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">0.00%</p></td></tr><tr><td style="vertical-align:top;width:60.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Demographic Assumptions:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:60.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Lump-sum option </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">25%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">25%</p></td></tr><tr><td style="vertical-align:top;width:60.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Retirement age </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">65/64</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">65/64</p></td></tr><tr><td style="vertical-align:top;width:60.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Proportion married </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">.BVG 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">.80%</p></td></tr><tr><td style="vertical-align:top;width:60.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Allowance for child pensions </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:17.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">5% loading on risk benefits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:17.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">5% loading on risk benefits</p></td></tr><tr><td style="vertical-align:top;width:60.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Mortality base table </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">.BVG 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">.BVG 2015</p></td></tr><tr><td style="vertical-align:top;width:60.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Longevity improvement </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">CMI 2018 (1.25%)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">CMI 2016 (1.25%)</p></td></tr><tr><td style="vertical-align:top;width:60.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Turnover </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">.BVG 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">.BVG 2015</p></td></tr><tr><td style="vertical-align:top;width:60.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Disability </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">80%.BVG 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">80% BVG 2015</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock', window );">Schedule of expected benefit payments</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:68.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected benefit payments:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Year 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 162,208</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 11,363</p></td></tr><tr><td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Year 2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 54,723</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 141,225</p></td></tr><tr><td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Year 3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 58,224</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 29,330</p></td></tr><tr><td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Year 4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 60,869</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 30,793</p></td></tr><tr><td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Year 5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 63,281</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 31,963</p></td></tr><tr><td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Next 5 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 428,371</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 169,658</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other disclosure items:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Next year's expected employer contribution</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 112,396</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 38,873</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assumption used to determine benefit obligation and net periodic benefit cost of defined benefit plan. Includes, but is not limited to, discount rate, rate of compensation increase, expected long-term rate of return on plan assets and interest crediting rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAssumptionsUsedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of one or more of the entity's defined benefit pension plans or one or more other defined benefit postretirement plans, separately for pension plans and other postretirement benefit plans including the entity's schedule of fair value of plan assets for defined benefit or other postretirement plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2439-114920<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2410-114920<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2417-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of benefits expected to be paid by pension plans and/or other employee benefit plans in each of the next five fiscal years and in the aggregate for the five fiscal years thereafter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139934219984344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loans (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Loans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of future loan payments</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2026</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Thereafter</b></p></td></tr><tr><td style="vertical-align:top;width:11.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Loan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 694,294</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 103,826</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 87,806</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 87,806</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 87,806</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 87,806</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 239,244</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139934219918664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair value measurement (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair value measurement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Schedule of assets measured at fair value</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100.48%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:56.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:56.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="6" style="vertical-align:bottom;white-space:nowrap;width:41.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair value measurement at reporting date using</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Quoted prices in active market for identical assets</b></p></td><td style="vertical-align:bottom;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant other observable inputs</b></p></td><td style="vertical-align:bottom;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant unobservable inputs</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:13.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(level 1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:11.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(level 2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:11.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(level 3)</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">December 31, 2021:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Cash and cash equivalents:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 33,617,696</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:56.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 33,617,696</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:56.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total financial assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 33,617,696</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:56.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">December 31, 2020:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Cash and cash equivalents:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,585,655</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:56.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,585,655</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:56.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total financial assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,585,655</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets measured at fair value measured on a recurring or nonrecurring basis. Includes, but is not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139934219936936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract', window );"><strong>Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of fair value of the warrants is estimated using the Black-Scholes option pricing model</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:70.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:70.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Grant date fair value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 5.17</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1.54</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:70.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 70</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 75</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;">%</span></p></td></tr><tr><td style="vertical-align:top;width:70.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected term (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 4.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 5.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:70.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 0.81</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 0.28</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:70.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected dividend yield -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsNoteDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139934217819816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plan (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsAbstract', window );"><strong>Equity Incentive Plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of the Company's stock option activity</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:29.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:29.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:29.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;width:29.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted&#160;Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted&#160;Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Remaining Contractual </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td></tr><tr><td style="vertical-align:bottom;width:29.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Grant Date Fair Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise&#160;Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Terms (Years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="vertical-align:top;width:29.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Outstanding as of December&#160;31,&#160;2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 488,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 2.97</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 9.70</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:29.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Options outstanding after stock splits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 429,822</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2.42</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 3.38</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 9.01</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:29.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Options granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 535,780</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">4.27</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 6.53</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 5.66</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:29.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Options exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,625)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2.42</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 3.38</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:29.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Options cancelled/forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,761)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2.42</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 3.38</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:29.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Options outstanding as of December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 960,216</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">3.46</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 5.13</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 6.25</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 163,237</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:27.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:19.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td colspan="8" style="vertical-align:bottom;width:68.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Options&#160;Outstanding</b></p></td><td style="vertical-align:bottom;width:0.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:17.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Options&#160;Exercisable</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:27.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:27.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted-&#160;Average&#160;Years</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Grant Date</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:27.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Remaining&#160;on&#160;Contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise</b></p></td></tr><tr><td style="vertical-align:bottom;width:27.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Life</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercisable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Price</b></p></td></tr><tr><td style="vertical-align:bottom;width:27.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$3.38</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 512,516</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 8.91</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 3.38</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 2.42</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 174,621</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 3.38</p></td></tr><tr><td style="vertical-align:bottom;width:27.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$5.86</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 210,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 9.98</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 5.86</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 4.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:27.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$5.99</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 45,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 9.94</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 5.99</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 4.34</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:27.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$7.80</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 104,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 9.61</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">$780</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 5.63</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 2,664</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">$780</p></td></tr><tr><td style="vertical-align:bottom;width:27.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$10.03</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 88,200</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 9.36</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 10.03</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 5.15</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of grant-date fair value of stock options granted to employees and directors</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:70.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:70.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Grant date fair value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 4.27</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 2.13</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:70.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 80</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 80</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:top;width:70.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected term (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 5.66</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 7.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:70.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 0.98</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 0.67</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:70.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected dividend yield </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Schedule of stock-based compensation expense is recognized for stock options granted to employees and non-employees</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;width:24.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td></tr><tr><td style="vertical-align:top;width:73.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 344,304</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 57,049</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:73.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 495,067</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 24,591</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:73.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 839,371</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 81,640</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139934224722120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of components of loss before income taxes provision</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:65.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:65.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:top;width:65.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Domestic</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (7,601,640)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (623,667)</p></td></tr><tr><td style="vertical-align:top;width:65.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Foreign</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (6,284,958)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,948,629)</p></td></tr><tr><td style="vertical-align:top;width:65.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  Total </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (13,886,598)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,572,296)</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of components of income tax expense</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:73.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:middle;width:73.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:middle;width:73.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;border-bottom:1.5pt solid #ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;width:2.33%;border-bottom:1.5pt solid #ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:top;width:73.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Current:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:73.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Federal</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:73.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">State</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:73.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Foreign</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 4,008</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 5,386</p></td></tr><tr><td style="vertical-align:top;width:73.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">        Total</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 4,008</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 5,386</p></td></tr><tr><td style="vertical-align:top;width:73.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:73.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">   Federal</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:73.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">State</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:73.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Foreign</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:73.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">       Total</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:73.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total income tax expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 4,008</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 5,386</p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of net operating losses and related deferred tax assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:65.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:65.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:65.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:65.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;width:2.13%;border-bottom:1.5pt solid #ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:top;width:65.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">NOLs (foreign) </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (12,021,483)</p></td><td style="vertical-align:bottom;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (6,076,187)</p></td></tr><tr><td style="vertical-align:top;width:65.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">NOLs (domestic)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (6,218,309)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (532,209)</p></td></tr><tr><td style="vertical-align:top;width:65.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">   Total NOLs</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (18,239,792)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (6,608,396)</p></td></tr><tr><td style="vertical-align:top;width:65.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:65.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:65.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Deferred tax assets related to:</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:65.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  Net operating loss (foreign)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2,243,668</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,111,942</p></td></tr><tr><td style="vertical-align:top;width:65.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  Net operating loss (domestic)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,677,610</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 146,451</p></td></tr><tr><td style="vertical-align:top;width:65.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  Stock based compensation</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 253,439</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 22,465</p></td></tr><tr><td style="vertical-align:top;width:65.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  Warrant expense</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 284,531</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:65.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  Other temporary differences</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 4,010</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:65.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">            Total deferred tax assets</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 4,463,258</p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,280,858</p></td></tr><tr><td style="vertical-align:top;width:65.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Deferred tax liabilities</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:65.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  Depreciation and other</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,137)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,682)</p></td></tr><tr><td style="vertical-align:top;width:65.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">            Total deferred tax liabilities</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,137)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,682)</p></td></tr><tr><td style="vertical-align:top;width:65.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:65.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  Valuation allowance</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 4,462,121</p></td><td style="vertical-align:bottom;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,278,176</p></td></tr><tr><td style="vertical-align:top;width:65.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of effective income tax rate reconciliation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:71.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;width:1.44%;border-bottom:1.5pt solid #ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Federal income tax at US statutory rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">21.00%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">21.00%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">State income taxes, net of federal benefit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">6.52%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">6.52%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Permanent differences</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(0.10)%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">0.00%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Provision to return</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">0.13%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">0.00%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Foreign tax</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(0.03)%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(0.15)%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(27.52)%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(27.37)%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Effective income tax rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">0.00%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">0.00%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139934219835160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net loss per common share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net loss per common share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of potentially dilutive common stock excluded from the computation of diluted net loss per share attributable to common stockholders</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series A Preferred Stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,185,879</p></td></tr><tr><td style="vertical-align:bottom;width:74.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series B Preferred Stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 2,695,600</p></td></tr><tr><td style="vertical-align:bottom;width:74.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Options to purchase common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 960,216</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 429,822</p></td></tr><tr><td style="vertical-align:bottom;width:74.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrants to purchase common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 425,387</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 237,249</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139934214020104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of the Business and Basis of Presentation (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 22, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 22, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th"><div>Mar. 18, 2021</div></th>
<th class="th">
<div>Mar. 17, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th"><div>Mar. 03, 2021</div></th>
<th class="th"><div>Jul. 20, 2020</div></th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Stock split ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1.1353521<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ganx_PreferredStockToCommonStockConversionRatio', window );">Preferred stock to common stock conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,181,818<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Public offering price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds</a></td>
<td class="nump">$ 40,558<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ganx_UnderwritingDiscountsAndCommissions', window );">Underwriting Discounts and Commissions</a></td>
<td class="nump">2,071<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ganx_GrossProceedsFromIssuanceOfCommonStock', window );">Proceeds before deduction of offering expenses</a></td>
<td class="nump">$ 42,630<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO | Preferred stock Series A and Series B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Stock split ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Underwriters' option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">545,454<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,580<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ganx_UnderwritingDiscountsAndCommissions', window );">Underwriting Discounts and Commissions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 420<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ganx_IpoExcludingUnderwritersOptionsMember', window );">IPO excluding underwriters' options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,636,364<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Public offering price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,978<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ganx_UnderwritingDiscountsAndCommissions', window );">Underwriting Discounts and Commissions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,950<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ganx_OtherOfferingExpenses', window );">Other Offering Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,071<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ganx_GrossProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity, before deduction of offering expenses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ganx_GrossProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ganx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ganx_OtherOfferingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of other offering expense incurred during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ganx_OtherOfferingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ganx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ganx_PreferredStockToCommonStockConversionRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The conversion ratio for conversion of preferred stock to common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ganx_PreferredStockToCommonStockConversionRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ganx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ganx_UnderwritingDiscountsAndCommissions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of underwriting discount and commission incurred during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ganx_UnderwritingDiscountsAndCommissions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ganx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=ganx_PreferredStockSeriesAndSeriesBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=ganx_PreferredStockSeriesAndSeriesBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ganx_IpoExcludingUnderwritersOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ganx_IpoExcludingUnderwritersOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139934224771816">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax', window );">Accumulated currency translation adjustments</a></td>
<td class="nump">$ 165,156<span></span>
</td>
<td class="nump">$ 1,323<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Deferred issuance costs</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,217,988<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated adjustment, net of tax, that results from the process of translating subsidiary financial statements and foreign equity investments into the reporting currency from the functional currency of the reporting entity, net of reclassification of realized foreign currency translation gains or losses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5A<br> -URI http://asc.fasb.org/extlink&amp;oid=123594809&amp;loc=SL116692626-108610<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139934218501288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional disclosures (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedComputerSoftwareNet', window );">Internal-use software</a></td>
<td class="nump">$ 202,609<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedComputerSoftwareAdditions', window );">External and internal labor costs incurred in the development stage of the Company ERP</a></td>
<td class="nump">168,474<span></span>
</td>
<td class="nump">34,135<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairments of long-lived assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ganx_UncertainTaxPositionsRecognized', window );">Uncertain tax positions recognized</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember', window );">Capitalized Software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-Lived Intangible Asset, Useful Life</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ganx_EquipmentAndFurnitureMember', window );">Equipment and Furniture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ganx_PropertyPlantAndEquipmentDepreciationRates', window );">Depreciation rates (as a percent)</a></td>
<td class="nump">12.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Electronic office equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ganx_PropertyPlantAndEquipmentDepreciationRates', window );">Depreciation rates (as a percent)</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ganx_LaboratoryInstrumentsMember', window );">Laboratory instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ganx_PropertyPlantAndEquipmentDepreciationRates', window );">Depreciation rates (as a percent)</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ganx_PropertyPlantAndEquipmentDepreciationRates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of depreciation on property plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ganx_PropertyPlantAndEquipmentDepreciationRates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ganx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ganx_UncertainTaxPositionsRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value of uncertain tax positions that the entity has recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ganx_UncertainTaxPositionsRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ganx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedComputerSoftwareAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additions made to capitalized computer software costs during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedComputerSoftwareAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedComputerSoftwareNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of capitalized computer software costs net of accumulated amortization as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedComputerSoftwareNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ganx_EquipmentAndFurnitureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=ganx_EquipmentAndFurnitureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ganx_LaboratoryInstrumentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=ganx_LaboratoryInstrumentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139934220026296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research Grants (Details)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>CHF (SFr)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 31, 2019 </div>
<div>CHF (SFr)</div>
</th>
<th class="th">
<div>Feb. 28, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ganx_GtGainTherapeuticsSaMember', window );">GT Gain Therapeutics SA | The Michael J. Fox Foundation for Parkinson's Research (MJFF)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrantsReceivable', window );">Research grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 186,956<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ganx_ReductionOfResearchAndDevelopmentExpensesThroughExpensesReimbursed', window );">Reduction of research and development expenses through expenses reimbursed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 98,318<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ganx_GtGainTherapeuticsSaMember', window );">GT Gain Therapeutics SA | Eurostars-2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrantsReceivable', window );">Research grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81,862<span></span>
</td>
<td class="nump">51,665<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 386,218<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ganx_ReductionOfResearchAndDevelopmentExpensesThroughExpensesReimbursed', window );">Reduction of research and development expenses through expenses reimbursed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 136,177<span></span>
</td>
<td class="nump">$ 151,230<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ganx_ProceedsFromGrants', window );">Proceeds from grants | SFr</a></td>
<td class="nump">SFr 286,787<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ganx_ConsortiumWithGtGainTherapeuticsSaInstituteForResearchInBiomedicineAndNeuroSysSasMember', window );">Consortium with GT Gain Therapeutics SA, Institute for Research in Biomedicine and Neuro-Sys SAS | Eurostars-2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrantsReceivable', window );">Research grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ganx_ProceedsFromGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from grants</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ganx_ProceedsFromGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ganx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ganx_ReductionOfResearchAndDevelopmentExpensesThroughExpensesReimbursed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The reduction of research and development expenses through expenses reimbursed</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ganx_ReductionOfResearchAndDevelopmentExpensesThroughExpensesReimbursed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ganx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrantsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrantsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ganx_GtGainTherapeuticsSaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ganx_GtGainTherapeuticsSaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ganx_MichaelJ.FoxFoundationForParkinsonSResearchMjffMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ganx_MichaelJ.FoxFoundationForParkinsonSResearchMjffMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ganx_Eurostars2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ganx_Eurostars2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ganx_ConsortiumWithGtGainTherapeuticsSaInstituteForResearchInBiomedicineAndNeuroSysSasMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ganx_ConsortiumWithGtGainTherapeuticsSaInstituteForResearchInBiomedicineAndNeuroSysSasMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139934220185256">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash, cash equivalents and restricted cash (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash, cash equivalents and restricted cash</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Total cash and cash equivalents</a></td>
<td class="nump">$ 36,880,673<span></span>
</td>
<td class="nump">$ 7,492,910<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">31,279<span></span>
</td>
<td class="nump">11,371<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashMember', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash, cash equivalents and restricted cash</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Total cash and cash equivalents</a></td>
<td class="nump">3,262,977<span></span>
</td>
<td class="nump">907,255<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash, cash equivalents and restricted cash</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Total cash and cash equivalents</a></td>
<td class="nump">$ 33,617,696<span></span>
</td>
<td class="nump">$ 6,585,655<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139934218670280">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash, cash equivalents and restricted cash - Schedule of Cash and cash equivalents balances (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents balances</a></td>
<td class="nump">$ 36,911,952<span></span>
</td>
<td class="nump">$ 7,504,281<span></span>
</td>
<td class="nump">$ 313,700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CurrencyAxis=currency_CHF', window );">CHF</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents balances</a></td>
<td class="nump">157,310<span></span>
</td>
<td class="nump">128,074<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CurrencyAxis=currency_EUR', window );">EUR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents balances</a></td>
<td class="nump">338,766<span></span>
</td>
<td class="nump">145,726<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CurrencyAxis=currency_USD', window );">USD</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents balances</a></td>
<td class="nump">$ 36,322,777<span></span>
</td>
<td class="nump">$ 7,149,386<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_CHF">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_CHF</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_EUR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_EUR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_USD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_USD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139934214027480">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other current assets (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>Other Current Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxesAndOtherTaxReceivableCurrent', window );">Tax credits</a></td>
<td class="nump">$ 113,586<span></span>
</td>
<td class="nump">$ 58,017<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Prepaid and deferred expenses</a></td>
<td class="nump">498,252<span></span>
</td>
<td class="nump">198,994<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other receivable</a></td>
<td class="nump">81,862<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Prepaid D&amp;O Insurance</a></td>
<td class="nump">147,671<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Total Prepaid expenses and other current assets</a></td>
<td class="nump">$ 727,785<span></span>
</td>
<td class="nump">$ 198,994<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxesAndOtherTaxReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and other tax receivables expected to be realized or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxesAndOtherTaxReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6787-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123349782&amp;loc=d3e5879-108316<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6787-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139934214001560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, net (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 134,375<span></span>
</td>
<td class="nump">$ 42,538<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="num">(28,389)<span></span>
</td>
<td class="num">(12,905)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">105,986<span></span>
</td>
<td class="nump">29,633<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisposals', window );">Disposals</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation expense</a></td>
<td class="nump">15,484<span></span>
</td>
<td class="nump">9,592<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment of Long-Lived Assets Held-for-use</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">55,141<span></span>
</td>
<td class="nump">25,436<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">42,148<span></span>
</td>
<td class="nump">4,865<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">17,327<span></span>
</td>
<td class="nump">8,889<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ganx_LaboratoryInstrumentsMember', window );">Laboratory instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 19,759<span></span>
</td>
<td class="nump">$ 3,348<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisposals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of divestiture of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisposals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ganx_LaboratoryInstrumentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=ganx_LaboratoryInstrumentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139934214288248">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Operating lease. Right of use (ROU) assets - Additional information (Details)<br></strong></div></th>
<th class="th">
<div>Nov. 01, 2021 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Nov. 01, 2021 </div>
<div>EUR (&#8364;) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Oct. 01, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2021 </div>
<div>CHF (SFr)</div>
</th>
<th class="th">
<div>Jun. 01, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 01, 2021 </div>
<div>CHF (SFr)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,279<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,371<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ganx_OfficeSpaceViaSoaveN6LuganoSwitzerlandMember', window );">Office space, Via Soave n6 (Lugano, Switzerland)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating lease renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,279<span></span>
</td>
<td class="nump">SFr 28,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ganx_OfficeSpaceViaPietroPeri9DLuganoSwitzerlandMember', window );">Office Space Via Pietro Peri 9 D (Lugano Switzerland)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,371<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 10,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ganx_LesseeOperatingLeaseTermOfCancelledContract', window );">Lessee, Operating Lease, term of cancelled contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ganx_OfficeSpaceInBethesdaMarylandMember', window );">Office space in Bethesda, Maryland</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInSecurityDeposits', window );">Increase (Decrease) in Security Deposits | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,227<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ganx_OfficeSpaceTorreDBuildingBarcelonaMember', window );">Office space, Torre D building (Barcelona)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating lease term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInSecurityDeposits', window );">Increase (Decrease) in Security Deposits</a></td>
<td class="nump">$ 4,918<span></span>
</td>
<td class="nump">&#8364; 4,325<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ganx_OfficeSpace', window );">Office space | ft&#178;</a></td>
<td class="nump">1,417<span></span>
</td>
<td class="nump">1,417<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ganx_OfficeSpaceTorreIBuildingBarcelonaMember', window );">Office space, Torre I building (Barcelona)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ganx_OfficeSpace', window );">Office space | ft&#178;</a></td>
<td class="nump">830<span></span>
</td>
<td class="nump">830<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Operating lease remaining term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Operating lease remaining term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ganx_LesseeOperatingLeaseTermOfCancelledContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's cancelled operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ganx_LesseeOperatingLeaseTermOfCancelledContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ganx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ganx_OfficeSpace">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Office space, measured as an area</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ganx_OfficeSpace</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ganx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInSecurityDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in security deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInSecurityDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ganx_OfficeSpaceViaSoaveN6LuganoSwitzerlandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=ganx_OfficeSpaceViaSoaveN6LuganoSwitzerlandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ganx_OfficeSpaceViaPietroPeri9DLuganoSwitzerlandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=ganx_OfficeSpaceViaPietroPeri9DLuganoSwitzerlandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ganx_OfficeSpaceInBethesdaMarylandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=ganx_OfficeSpaceInBethesdaMarylandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ganx_OfficeSpaceTorreDBuildingBarcelonaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=ganx_OfficeSpaceTorreDBuildingBarcelonaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ganx_OfficeSpaceTorreIBuildingBarcelonaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=ganx_OfficeSpaceTorreIBuildingBarcelonaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139934217478488">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Operating lease. Right of use (ROU) assets - Summary of components of lease accounting (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Operating lease. Right of use ("ROU") assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease- right of use assets</a></td>
<td class="nump">$ 901,042<span></span>
</td>
<td class="nump">$ 523,080<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability - current</a></td>
<td class="nump">219,137<span></span>
</td>
<td class="nump">122,756<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability - non current</a></td>
<td class="nump">$ 695,053<span></span>
</td>
<td class="nump">$ 400,324<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate</a></td>
<td class="nump">1.86%<span></span>
</td>
<td class="nump">3.61%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139934220712520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating lease. Right of use (ROU) assets - Summary of components of lease expense (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Operating lease. Right of use ("ROU") assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating lease costs</a></td>
<td class="nump">$ 191,329<span></span>
</td>
<td class="nump">$ 121,800<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139934221980872">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Operating lease. Right of use (ROU) assets - Future minimum lease payments (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Operating lease. Right of use ("ROU") assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent', window );">2022</a></td>
<td class="nump">$ 237,926<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">2023</a></td>
<td class="nump">245,685<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears', window );">2024</a></td>
<td class="nump">227,115<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears', window );">2025</a></td>
<td class="nump">167,526<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears', window );">2026</a></td>
<td class="nump">58,738<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Total future minimum lease payments</a></td>
<td class="nump">936,990<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ganx_AdjustmentToReconcileOperatingLeaseLiabilitiesAmountsRepresentingInterestOrImputedInterest', window );">Less amount representing interest or imputed interest</a></td>
<td class="nump">22,800<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">$ 914,190<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ganx_AdjustmentToReconcileOperatingLeaseLiabilitiesAmountsRepresentingInterestOrImputedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustment to reconcile operating lease liabilities, amounts representing interest or imputed interest not recognized in balance sheet.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ganx_AdjustmentToReconcileOperatingLeaseLiabilitiesAmountsRepresentingInterestOrImputedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ganx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123403562&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123403562&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123403562&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123403562&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123403562&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123403562&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139934218670520">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accounts Payable (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ganx_AccountsPayableCurrentLineItems', window );"><strong>Accounts Payable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts Payable</a></td>
<td class="nump">$ 560,479<span></span>
</td>
<td class="nump">$ 961,516<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CurrencyAxis=currency_CHF', window );">CHF</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ganx_AccountsPayableCurrentLineItems', window );"><strong>Accounts Payable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts Payable</a></td>
<td class="nump">13,166<span></span>
</td>
<td class="nump">29,423<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CurrencyAxis=currency_EUR', window );">EUR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ganx_AccountsPayableCurrentLineItems', window );"><strong>Accounts Payable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts Payable</a></td>
<td class="nump">309,378<span></span>
</td>
<td class="nump">202,223<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CurrencyAxis=currency_USD', window );">USD</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ganx_AccountsPayableCurrentLineItems', window );"><strong>Accounts Payable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts Payable</a></td>
<td class="nump">$ 197,045<span></span>
</td>
<td class="nump">$ 673,600<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ganx_AccountsPayableCurrentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ganx_AccountsPayableCurrentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ganx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_CHF">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_CHF</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_EUR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_EUR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_USD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_USD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139934218864968">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other current liabilities and deferred income (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCreditsAndOtherLiabilitiesAbstract', window );"><strong>Other current liabilities and deferred income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ganx_PayableForSocialSecuritiesCurrent', window );">Payable for social securities</a></td>
<td class="nump">$ 255,068<span></span>
</td>
<td class="nump">$ 88,334<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ganx_AccruedPayrollCurrent', window );">Accrued payroll</a></td>
<td class="nump">465,382<span></span>
</td>
<td class="nump">294,469<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">681,770<span></span>
</td>
<td class="nump">379,270<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrent', window );">Tax provision</a></td>
<td class="nump">380<span></span>
</td>
<td class="nump">1,070<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ganx_DepositsCurrent', window );">Deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,307<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other Current Liabilities</a></td>
<td class="nump">1,402,600<span></span>
</td>
<td class="nump">768,450<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeCurrent', window );">Deferred income</a></td>
<td class="nump">266,504<span></span>
</td>
<td class="nump">239,483<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent', window );">Total Other Current Liabilities and Deferred Income</a></td>
<td class="nump">$ 1,669,104<span></span>
</td>
<td class="nump">$ 1,007,933<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ganx_AccruedPayrollCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for current portion of payroll.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ganx_AccruedPayrollCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ganx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ganx_DepositsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ganx_DepositsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ganx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ganx_PayableForSocialSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for current portion of payable for social securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ganx_PayableForSocialSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ganx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCreditsAndOtherLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCreditsAndOtherLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of unearned revenue or income, not otherwise specified in the taxonomy, which is expected to be taken into income during the current period and current obligations not separately disclosed in the balance sheet (other liabilities, current).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income excluding obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 25<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=28183603&amp;loc=d3e692-112598<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139934214189512">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Pension obligations - End of year funded status (Details) - Pension Plan - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">$ 943,025<span></span>
</td>
<td class="nump">$ 477,288<span></span>
</td>
<td class="nump">$ 370,190<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">(Projected benefit obligation)</a></td>
<td class="num">(1,272,483)<span></span>
</td>
<td class="num">(648,846)<span></span>
</td>
<td class="num">(496,819)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFundedStatusOfPlan', window );">Funded status</a></td>
<td class="num">(329,458)<span></span>
</td>
<td class="num">(171,558)<span></span>
</td>
<td class="num">$ (126,629)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">SWITZERLAND</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation', window );">Accumululated benefit obligation</a></td>
<td class="nump">$ 1,233,053<span></span>
</td>
<td class="nump">$ 652,445<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of actuarial present value of benefits attributed to employee service rendered, excluding assumptions about future compensation level.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(02)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanFairValueOfPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanFundedStatusOfPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of funded (unfunded) status of defined benefit plan, measured as difference between fair value of plan assets and benefit obligation. Includes, but is not limited to, overfunded (underfunded) status.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1703-114919<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanFundedStatusOfPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=country_CH">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=country_CH</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139934218493256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pension obligations - Reconciliation of funded status (Details) - Pension Plan - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Reconciliation of funded status</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFundedStatusOfPlan', window );">Funded status beginning of the year</a></td>
<td class="num">$ (171,558)<span></span>
</td>
<td class="num">$ (126,629)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ganx_IncreaseDecreaseThroughTotalExpensesToReconcileFundedStatusOfDefinedBenefitPlan', window );">Expense</a></td>
<td class="num">(144,146)<span></span>
</td>
<td class="num">(44,474)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanContributionsByEmployer', window );">Employer contributions</a></td>
<td class="nump">88,819<span></span>
</td>
<td class="nump">36,264<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss', window );">Translation difference</a></td>
<td class="num">(1,437)<span></span>
</td>
<td class="num">(501)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ganx_IncreaseDecreaseInAccumulatedOtherComprehensiveIncomeToReconcileFundedStatusOfDefinedBenefitPlan', window );">Change in AOCI over the year</a></td>
<td class="num">(101,136)<span></span>
</td>
<td class="num">(36,218)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFundedStatusOfPlan', window );">Funded status at end of year</a></td>
<td class="num">$ (329,458)<span></span>
</td>
<td class="num">$ (171,558)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ganx_IncreaseDecreaseInAccumulatedOtherComprehensiveIncomeToReconcileFundedStatusOfDefinedBenefitPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in accumulated other comprehensive income to reconcile funded status of defined benefit plan</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ganx_IncreaseDecreaseInAccumulatedOtherComprehensiveIncomeToReconcileFundedStatusOfDefinedBenefitPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ganx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ganx_IncreaseDecreaseThroughTotalExpensesToReconcileFundedStatusOfDefinedBenefitPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) through total expenses to reconcile funded status of defined benefit plan</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ganx_IncreaseDecreaseThroughTotalExpensesToReconcileFundedStatusOfDefinedBenefitPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ganx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanContributionsByEmployer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contribution received by defined benefit plan from employer which increases plan assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanContributionsByEmployer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanFundedStatusOfPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of funded (unfunded) status of defined benefit plan, measured as difference between fair value of plan assets and benefit obligation. Includes, but is not limited to, overfunded (underfunded) status.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1703-114919<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanFundedStatusOfPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of foreign currency translation gain (loss) which increases (decreases) plan assets of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139934218495784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pension obligations - Component of net periodic pension costs (Details) - Pension Plan - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Services cost</a></td>
<td class="nump">$ 132,809<span></span>
</td>
<td class="nump">$ 36,597<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">1,318<span></span>
</td>
<td class="nump">947<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets', window );">Expected return on plan asset</a></td>
<td class="num">(5,558)<span></span>
</td>
<td class="num">(3,564)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses', window );">Amortization of (gain)/losses</a></td>
<td class="nump">16,212<span></span>
</td>
<td class="nump">10,494<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit', window );">Amortization of prior year service cost</a></td>
<td class="num">(635)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Total</a></td>
<td class="nump">$ 144,146<span></span>
</td>
<td class="nump">$ 44,474<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in net periodic benefit (cost) credit of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of prior service cost (credit) recognized in net periodic benefit cost (credit) of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(5)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(5)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanInterestCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost recognized for passage of time related to defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanInterestCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of net periodic benefit cost (credit) for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanServiceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanServiceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139934218003720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pension obligations - Reconciliation of projected benefit obligation (Details) - Pension Plan - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Projected benefit obligation at January 1</a></td>
<td class="nump">$ 648,846<span></span>
</td>
<td class="nump">$ 496,819<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Services cost</a></td>
<td class="nump">132,809<span></span>
</td>
<td class="nump">36,597<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant', window );">Employee contribution</a></td>
<td class="nump">59,208<span></span>
</td>
<td class="nump">25,770<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">1,318<span></span>
</td>
<td class="nump">947<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid', window );">Benefit payments</a></td>
<td class="nump">315,300<span></span>
</td>
<td class="nump">48,602<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ganx_DefinedBenefitPlanBenefitObligationGainsLossesOnFinancialAssumptions', window );">(Gain)/loss on financial assumption</a></td>
<td class="num">(27,799)<span></span>
</td>
<td class="nump">4,379<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ganx_DefinedBenefitPlanBenefitObligationGainsLossesOnDemographicAssumptions', window );">(Gain)/loss on demographic assumption</a></td>
<td class="num">(43,123)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ganx_DefinedBenefitPlanBenefitObligationGainsLossesOnExperience', window );">(Gain)/loss on experience</a></td>
<td class="nump">193,984<span></span>
</td>
<td class="nump">35,732<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAmendments', window );">Plan Amendment</a></td>
<td class="num">(8,060)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Projected benefit obligation at December 31</a></td>
<td class="nump">$ 1,272,483<span></span>
</td>
<td class="nump">$ 648,846<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ganx_DefinedBenefitPlanBenefitObligationGainsLossesOnDemographicAssumptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gains (losses) on demographic assumptions by defined benefit plan which decreases (increases) benefit obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ganx_DefinedBenefitPlanBenefitObligationGainsLossesOnDemographicAssumptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ganx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ganx_DefinedBenefitPlanBenefitObligationGainsLossesOnExperience">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gains (losses) on experience by defined benefit plan which decreases (increases) benefit obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ganx_DefinedBenefitPlanBenefitObligationGainsLossesOnExperience</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ganx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ganx_DefinedBenefitPlanBenefitObligationGainsLossesOnFinancialAssumptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gains (losses) on financial assumptions by defined benefit plan which decreases (increases) benefit obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ganx_DefinedBenefitPlanBenefitObligationGainsLossesOnFinancialAssumptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ganx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of payment to participant of defined benefit plan which decreases benefit obligation. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(6)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39716-114964<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contributions received by defined benefit plan from participant which increase benefit obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanInterestCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost recognized for passage of time related to defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanInterestCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPlanAmendments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in benefit obligation of defined benefit plan from change in terms of existing plan or initiation of new plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(7)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPlanAmendments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanServiceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanServiceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139934218691432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pension obligations - Reconciliation of fair value of plan assets (Details) - Pension Plan - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value at January 1</a></td>
<td class="nump">$ 477,288<span></span>
</td>
<td class="nump">$ 370,190<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets', window );">Expected return on plan assets</a></td>
<td class="nump">5,558<span></span>
</td>
<td class="nump">3,564<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets', window );">Gain/(loss) on plan assets</a></td>
<td class="num">(3,148)<span></span>
</td>
<td class="num">(9,454)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanContributionsByEmployer', window );">Employer contributions</a></td>
<td class="nump">88,819<span></span>
</td>
<td class="nump">36,264<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant', window );">Employee contributions</a></td>
<td class="nump">59,208<span></span>
</td>
<td class="nump">25,770<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid', window );">Benefit payments</a></td>
<td class="nump">315,300<span></span>
</td>
<td class="nump">48,602<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ganx_DefinedBenefitPlanPlanAssetsOtherIncreasesDecreases', window );">Others</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,352<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value at December 31</a></td>
<td class="nump">$ 943,025<span></span>
</td>
<td class="nump">$ 477,288<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ganx_DefinedBenefitPlanPlanAssetsOtherIncreasesDecreases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other changes to the plan assets in a defined benefit plan which increases (decreases) plan assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ganx_DefinedBenefitPlanPlanAssetsOtherIncreasesDecreases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ganx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in plan assets of defined benefit plan from actual return (loss) determined by change in fair value of plan assets adjusted for contributions, benefit payments, and other expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanContributionsByEmployer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contribution received by defined benefit plan from employer which increases plan assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanContributionsByEmployer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(02)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanFairValueOfPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of payment to participant under defined benefit plan which decreases plan assets. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(5)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39716-114964<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contributions received by defined benefit plan from participant which increases plan assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139934220614520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pension obligations - Change in net (gain) loss (Details) - Pension Plan - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax', window );">(Gain)/loss at beginning of year</a></td>
<td class="nump">$ 154,665<span></span>
</td>
<td class="nump">$ 117,803<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligationPeriodIncreaseDecrease', window );">(Gain)/loss on PBO during year</a></td>
<td class="nump">122,895<span></span>
</td>
<td class="nump">37,902<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssetsPeriodIncreaseDecrease', window );">(Gain)/loss on assets during year</a></td>
<td class="nump">3,148<span></span>
</td>
<td class="nump">9,454<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses', window );">Amortization of (gain)/losses</a></td>
<td class="num">(16,212)<span></span>
</td>
<td class="num">(10,494)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax', window );">(Gain)/loss at end of year</a></td>
<td class="nump">$ 264,496<span></span>
</td>
<td class="nump">$ 154,665<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated other comprehensive income (loss) for gain (loss) of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (j)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in net periodic benefit (cost) credit of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanBenefitObligationPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in benefit obligation of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanBenefitObligationPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssetsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in plan assets of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanFairValueOfPlanAssetsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139934218692136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pension obligations - Change in accumulated other comprehensive income (AOCI) (Details) - Pension Plan - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax', window );">AOCI at beginning of year</a></td>
<td class="nump">$ 154,665<span></span>
</td>
<td class="nump">$ 117,803<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses', window );">Net gain/(loss) amortized</a></td>
<td class="num">(16,212)<span></span>
</td>
<td class="num">(10,494)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligationPeriodIncreaseDecrease', window );">(Gain)/loss on PBO during year</a></td>
<td class="nump">122,895<span></span>
</td>
<td class="nump">37,902<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssetsPeriodIncreaseDecrease', window );">(Gain)/loss on assets during the year</a></td>
<td class="nump">3,148<span></span>
</td>
<td class="nump">9,454<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax', window );">Prior Service Cost/(credit) occurring over the year</a></td>
<td class="num">(8,060)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit', window );">Net prior service (cost)/credit amortized</a></td>
<td class="num">(635)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax', window );">Total AOCI at end of year</a></td>
<td class="nump">$ 255,801<span></span>
</td>
<td class="nump">$ 154,665<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated other comprehensive (income) loss for defined benefit plan, that has not been recognized in net periodic benefit cost (credit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (j)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i-k)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in net periodic benefit (cost) credit of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of prior service cost (credit) recognized in net periodic benefit cost (credit) of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(5)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(5)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, after reclassification adjustment, of (increase) decrease in accumulated other comprehensive income from prior service cost (credit) of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (j)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanBenefitObligationPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in benefit obligation of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanBenefitObligationPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssetsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in plan assets of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanFairValueOfPlanAssetsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139934214188264">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Pension obligations - Assumptions (Details) - Pension Plan<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedInCalculationsAbstract', window );"><strong>Financial and Demographic Assumptions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate', window );">Discount rate</a></td>
<td class="nump">0.30%<span></span>
</td>
<td class="nump">0.15%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate', window );">Interest credit rate / ERoA</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease', window );">Salary increases</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ganx_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfPensionIncreases', window );">Pension increases</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ganx_DefinedBenefitPlanDemographicAssumptionLumpSumOption', window );">Lump-sum option</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ganx_DefinedBenefitPlanDemographicAssumptionProportionMarried', window );">Proportion married</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.80%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ganx_DefinedBenefitPlanDemographicAssumptionAllowanceForChildPensions', window );">Allowance for child pensions</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ganx_DefinedBenefitPlanMortalityImprovementPercentage', window );">Longevity improvement</a></td>
<td class="nump">1.25%<span></span>
</td>
<td class="nump">1.25%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ganx_DefinedBenefitPlanDisabilityPercentage', window );">Disability</a></td>
<td class="nump">80.00%<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ganx_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfPensionIncreases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average rate increase of pension, used to determine benefit obligation of defined benefit plan. Plan includes, but is not limited to, pension-related defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ganx_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfPensionIncreases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ganx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ganx_DefinedBenefitPlanDemographicAssumptionAllowanceForChildPensions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Demographic assumption of allowance for child pensions  under the defined benefit pension plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ganx_DefinedBenefitPlanDemographicAssumptionAllowanceForChildPensions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ganx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ganx_DefinedBenefitPlanDemographicAssumptionLumpSumOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Demographic assumption of lumpsum option under the defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ganx_DefinedBenefitPlanDemographicAssumptionLumpSumOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ganx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ganx_DefinedBenefitPlanDemographicAssumptionProportionMarried">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Demographic assumption of proportion of married persons under the defined benefit pension plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ganx_DefinedBenefitPlanDemographicAssumptionProportionMarried</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ganx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ganx_DefinedBenefitPlanDisabilityPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disability percentage in a defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ganx_DefinedBenefitPlanDisabilityPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ganx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ganx_DefinedBenefitPlanMortalityImprovementPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Mortality improvement percentage in a defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ganx_DefinedBenefitPlanMortalityImprovementPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ganx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average rate for present value of future retirement benefits cash flows, used to determine benefit obligation of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average rate increase of compensation, used to determine benefit obligation of defined benefit plan. Plan includes, but is not limited to, pay-related defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average interest crediting rate used to determine benefit obligation of defined benefit plan. Plan includes, but is not limited to, cash balance and other defined benefit plans with promised interest crediting rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssumptionsUsedInCalculationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssumptionsUsedInCalculationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139934218689544">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Pension obligations - Expected benefit payments (Details) - Pension Plan - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths', window );">Year 1</a></td>
<td class="nump">$ 162,208<span></span>
</td>
<td class="nump">$ 11,363<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo', window );">Year 2</a></td>
<td class="nump">54,723<span></span>
</td>
<td class="nump">141,225<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree', window );">Year 3</a></td>
<td class="nump">58,224<span></span>
</td>
<td class="nump">29,330<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour', window );">Year 4</a></td>
<td class="nump">60,869<span></span>
</td>
<td class="nump">30,793<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive', window );">Year 5</a></td>
<td class="nump">63,281<span></span>
</td>
<td class="nump">31,963<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter', window );">Next 5 years</a></td>
<td class="nump">428,371<span></span>
</td>
<td class="nump">169,658<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear', window );">Next year's expected employer contribution</a></td>
<td class="nump">$ 112,396<span></span>
</td>
<td class="nump">$ 38,873<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of benefit for defined benefit plan expected to be paid in five fiscal years after fifth fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of benefit for defined benefit plan expected to be paid in next fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of benefit for defined benefit plan expected to be paid in fifth fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of benefit for defined benefit plan expected to be paid in fourth fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of benefit for defined benefit plan expected to be paid in third fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of benefit for defined benefit plan expected to be paid in second fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contribution expected to be received by defined benefit plan from employer in next fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139934220285800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pension obligations - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Pension obligations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Expenses related to savings plan</a></td>
<td class="nump">$ 3,243<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139934222140040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loans (Details)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Aug. 31, 2020 </div>
<div>CHF (SFr)</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2020 </div>
<div>CHF (SFr)</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>CHF (SFr)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ganx_ExpensesOrChargesDueForEarlyExtinguishmentOfDebt', window );">Expenses or charges due for early extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Deferred issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,217,988<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ganx_March2020ChfLoanMember', window );">March 2020 CHF loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Loan amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 14,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Term of loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ganx_August2020ChfLoanMember', window );">August 2020 CHF loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Loan amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,221<span></span>
</td>
<td class="nump">SFr 638,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Term of loan</a></td>
<td class="text">9 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPayment', window );">Loan is due in quarterly installments | SFr</a></td>
<td class="nump">SFr 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ganx_ExpensesOrChargesDueForEarlyExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expenses or charges due for early extinguishment of debt</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ganx_ExpensesOrChargesDueForEarlyExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ganx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the required periodic payments including both interest and principal payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ganx_March2020ChfLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ganx_March2020ChfLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ganx_August2020ChfLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ganx_August2020ChfLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139934221937896">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Loans - Future loan payments (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Loans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="nump">$ 694,294<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2022</a></td>
<td class="nump">103,826<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2023</a></td>
<td class="nump">87,806<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2024</a></td>
<td class="nump">87,806<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2025</a></td>
<td class="nump">87,806<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive', window );">2026</a></td>
<td class="nump">87,806<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive', window );">Thereafter</a></td>
<td class="nump">$ 239,244<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139934220188360">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair value measurement (Details) - Level 1 - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, Fair Value Disclosure</a></td>
<td class="nump">$ 33,617,696<span></span>
</td>
<td class="nump">$ 6,585,655<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Cash and Cash Equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, Fair Value Disclosure</a></td>
<td class="nump">33,617,696<span></span>
</td>
<td class="nump">6,585,655<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Money Market</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, Fair Value Disclosure</a></td>
<td class="nump">$ 33,617,696<span></span>
</td>
<td class="nump">$ 6,585,655<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139934214300184">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Common and Preferred Stock (Details)<br></strong></div></th>
<th class="th"><div>Mar. 18, 2021</div></th>
<th class="th"><div>Mar. 17, 2021</div></th>
<th class="th"><div>Mar. 03, 2021</div></th>
<th class="th"><div>Jul. 20, 2020</div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 16, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Common and Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Authorized capital, Common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Authorized capital, Preferred stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,883,368<span></span>
</td>
<td class="nump">4,022,736<span></span>
</td>
<td class="nump">3,543,163<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,883,368<span></span>
</td>
<td class="nump">4,022,736<span></span>
</td>
<td class="nump">3,543,163<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse stock split ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1.1353521<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ganx_PreferredStockToCommonStockConversionRatio', window );">Preferred stock to common stock conversion ratio</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredClassAMember', window );">Series A Preferred Stock.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Common and Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,346,390<span></span>
</td>
<td class="nump">1,185,879<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,346,390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredClassBMember', window );">Series B Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Common and Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,366,999<span></span>
</td>
<td class="nump">2,965,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,366,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ganx_PreferredStockToCommonStockConversionRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The conversion ratio for conversion of preferred stock to common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ganx_PreferredStockToCommonStockConversionRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ganx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_PreferredClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_PreferredClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139934214126632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>May 06, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 17, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th"><div>Mar. 03, 2021</div></th>
<th class="th"><div>Jul. 20, 2020</div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 16, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse stock split ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1.1353521<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ganx_WarrantsToDesigneesOfPlacementAgentIssuedJuly2020Member', window );">Warrants to designees of the placement agent, issued July 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">269,360<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.46<span></span>
</td>
<td class="nump">$ 4.46<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrants value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 413,887<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Class of Warrant or Right, Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">237,249<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">269,360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ganx_WarrantsAndRightsExercisedOrExchangedNumber', window );">Warrants exercised or exchanged</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,862<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ganx_IssuanceOfCommonStockThroughCashlessExerciseOfWarrants', window );">Issuance of Common Stock due to warrants cashless exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,283<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ganx_WarrantsToDesigneesOfInvestmentBankIssuedMay2021Member', window );">Warrants to designees of investment bank, issued May 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase common stock</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price | $ / shares</a></td>
<td class="nump">$ 13.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrants value | $</a></td>
<td class="nump">$ 1,034,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants term</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ganx_WarrantsAndRightsExercisedOrExchangedNumber', window );">Warrants exercised or exchanged</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ganx_WarrantsAndRightsServicePeriod', window );">Warrants, Service period</a></td>
<td class="text">9 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ganx_IssuanceOfCommonStockThroughCashlessExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock through cashless exercise of warrants</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ganx_IssuanceOfCommonStockThroughCashlessExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ganx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ganx_WarrantsAndRightsExercisedOrExchangedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights exercised or exchanged.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ganx_WarrantsAndRightsExercisedOrExchangedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ganx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ganx_WarrantsAndRightsServicePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Service period for fair value of the warrants to be recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ganx_WarrantsAndRightsServicePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ganx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ganx_WarrantsToDesigneesOfPlacementAgentIssuedJuly2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ganx_WarrantsToDesigneesOfPlacementAgentIssuedJuly2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ganx_WarrantsToDesigneesOfInvestmentBankIssuedMay2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ganx_WarrantsToDesigneesOfInvestmentBankIssuedMay2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139934217624872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants - Assumptions under black-scholes pricing model (Details) - Valuation Technique, Option Pricing Model [Member]<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ganx_WarrantsGrantDateFairValue', window );">Grant date fair value | $ / shares</a></td>
<td class="nump">$ 5.17<span></span>
</td>
<td class="nump">$ 1.54<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants</a></td>
<td class="nump">0.70<span></span>
</td>
<td class="nump">0.75<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Expected term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants</a></td>
<td class="nump">4.00<span></span>
</td>
<td class="nump">5.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants | $</a></td>
<td class="nump">0.0081<span></span>
</td>
<td class="nump">0.0028<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ganx_WarrantsGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The grant date fair value of warrants granted during period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ganx_WarrantsGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ganx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueOptionPricingModelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueOptionPricingModelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139934214128744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plan (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 17, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 16, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th"><div>Mar. 03, 2021</div></th>
<th class="th">
<div>Sep. 24, 2020 </div>
<div>shares</div>
</th>
<th class="th"><div>Jul. 20, 2020</div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>Options </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 23, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Equity Incentive Plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse stock split ratio</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.1353521<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,022,736<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,883,368<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,543,163<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ganx_OmnibusIncentivePlanTwoThousandTwentyMember', window );">2020 Omnibus Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Equity Incentive Plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ganx_NumberOfOptionsSubjectToTermThreshold', window );">Number of options subject to term threshold | Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Award Expiry term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse stock split ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.1353521<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock outstanding (in shares)</a></td>
<td class="nump">517,902<span></span>
</td>
<td class="nump">588,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise prices upper limit | $ / shares</a></td>
<td class="nump">$ 3.38<span></span>
</td>
<td class="nump">$ 2.97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ganx_OmnibusIncentivePlanTwoThousandTwentyMember', window );">2020 Omnibus Plan | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Equity Incentive Plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Maximum number of shares available to be issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,310,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Award Expiry term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ganx_TwentyTwentyoneInducementEquityIncentivePlanMember', window );">2021 Inducement Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Equity Incentive Plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Maximum number of shares reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ganx_NumberOfOptionsSubjectToTermThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of options subject to the term threshold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ganx_NumberOfOptionsSubjectToTermThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ganx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ganx_OmnibusIncentivePlanTwoThousandTwentyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ganx_OmnibusIncentivePlanTwoThousandTwentyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ganx_TwentyTwentyoneInducementEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ganx_TwentyTwentyoneInducementEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139934217610712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plan - Stock Option Activity (Details) - 2020 Omnibus Plan - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 17, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding as at beginning of period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">488,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ganx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAfterStockSplitsNumber', window );">Options outstanding after stock splits (in shares)</a></td>
<td class="nump">429,822<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">535,780<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,625)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Options cancelled/forfeited (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,761)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding as at end of period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">960,216<span></span>
</td>
<td class="nump">488,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract', window );"><strong>Weighted Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ganx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionNonvestedWeightedAverageExercisePriceAfterStockSplit', window );">Weighted Average Grant Date Fair Value, options outstanding after stock split</a></td>
<td class="nump">$ 2.42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.27<span></span>
</td>
<td class="nump">$ 2.13<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ganx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedDuringPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, options cancelled/forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, options outstanding as of December 31</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding as at beginning of period (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ganx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAfterStockSplitsWeightedAverageExercisePrice', window );">Options outstanding after stock splits (in dollars per share)</a></td>
<td class="nump">3.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Options granted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Options exercised (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Options cancelled/forfeited (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding as at end of period (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.13<span></span>
</td>
<td class="nump">$ 2.97<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Additional disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Years Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 3 months<span></span>
</td>
<td class="text">9 years 8 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ganx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAfterStockSplitWeightedAverageRemainingContractualTerm', window );">Weighted Average Remaining Contractual Years Outstanding Options outstanding after stock splits</a></td>
<td class="text">9 years 3 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ganx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm', window );">Weighted Average Remaining Contractual Years Options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 7 months 28 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 163,237<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ganx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionNonvestedWeightedAverageExercisePriceAfterStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options outstanding after stock split.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ganx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionNonvestedWeightedAverageExercisePriceAfterStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ganx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ganx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedDuringPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options exercised during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ganx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedDuringPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ganx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ganx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards granted, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ganx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ganx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ganx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAfterStockSplitWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding after stock splits, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ganx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAfterStockSplitWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ganx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ganx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAfterStockSplitsNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding after stock split, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ganx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAfterStockSplitsNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ganx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ganx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAfterStockSplitsWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance after stock split under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ganx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAfterStockSplitsWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ganx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ganx_OmnibusIncentivePlanTwoThousandTwentyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ganx_OmnibusIncentivePlanTwoThousandTwentyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139934218307016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plan - Options Outstanding and Exercisable (Details) - 2020 Omnibus Plan - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 17, 2021</div></th>
<th class="th"><div>Mar. 16, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Equity Incentive Plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price</a></td>
<td class="nump">$ 3.38<span></span>
</td>
<td class="nump">$ 2.97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">960,216<span></span>
</td>
<td class="nump">488,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted- Average Years Remaining on Contractual Life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 3 months<span></span>
</td>
<td class="text">9 years 8 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.13<span></span>
</td>
<td class="nump">$ 2.97<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Total unrecognized compensation cost related to non-vested stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,403<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation recognition period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ganx_OmnibusIncentivePlanTwoThousandTwentyMember', window );">$3.38</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Equity Incentive Plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">512,516<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted- Average Years Remaining on Contractual Life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years 10 months 28 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">174,621<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ganx_OmnibusIncentivePlanTwoThousandTwentyMember', window );">$5.86</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Equity Incentive Plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">210,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted- Average Years Remaining on Contractual Life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years 11 months 23 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ganx_OmnibusIncentivePlanTwoThousandTwentyMember', window );">$5.99</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Equity Incentive Plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted- Average Years Remaining on Contractual Life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years 11 months 8 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ganx_OmnibusIncentivePlanTwoThousandTwentyMember', window );">$7.80</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Equity Incentive Plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">104,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted- Average Years Remaining on Contractual Life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years 7 months 9 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 780<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,664<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 780<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ganx_OmnibusIncentivePlanTwoThousandTwentyMember', window );">$10.03</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Equity Incentive Plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">88,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted- Average Years Remaining on Contractual Life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years 4 months 9 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ganx_OmnibusIncentivePlanTwoThousandTwentyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ganx_OmnibusIncentivePlanTwoThousandTwentyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ganx_ExercisePrice3.38Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ganx_ExercisePrice3.38Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ganx_ExercisePrice5.86Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ganx_ExercisePrice5.86Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ganx_ExercisePrice5.99Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ganx_ExercisePrice5.99Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ganx_ExercisePrice7.80Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ganx_ExercisePrice7.80Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ganx_ExercisePrice10.03Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ganx_ExercisePrice10.03Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139934214034424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plan - Assumptions (Details) - 2020 Omnibus Plan - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Equity Incentive Plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Grant date fair value</a></td>
<td class="nump">$ 4.27<span></span>
</td>
<td class="nump">$ 2.13<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">80.00%<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">5 years 7 months 28 days<span></span>
</td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.98%<span></span>
</td>
<td class="nump">0.67%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ganx_OmnibusIncentivePlanTwoThousandTwentyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ganx_OmnibusIncentivePlanTwoThousandTwentyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139934220495960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plan - Stock-based compensation (Details) - 2020 Omnibus Plan - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Equity Incentive Plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">$ 839,371<span></span>
</td>
<td class="nump">$ 81,640<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ganx_OmnibusIncentivePlanTwoThousandTwentyMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Equity Incentive Plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">344,304<span></span>
</td>
<td class="nump">57,049<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ganx_OmnibusIncentivePlanTwoThousandTwentyMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Equity Incentive Plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">$ 495,067<span></span>
</td>
<td class="nump">$ 24,591<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ganx_OmnibusIncentivePlanTwoThousandTwentyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ganx_OmnibusIncentivePlanTwoThousandTwentyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139934218508792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreement (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Apr. 20, 2021 </div>
<div>item</div>
</th>
<th class="th">
<div>May 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration Agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 133,928<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Recorded receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,548<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ganx_MultiTargetCollaborationAgreementMember', window );">Multi-target collaboration agreement | Zentalis Pharmaceuticals, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration Agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ganx_CollaborativeArrangementMinimumNumberOfTargets', window );">Number of targets | item</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ganx_CollaborativeArrangementTerminationNoticePeriodDays', window );">Agreement termination notice period days</a></td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ganx_CollaborativeArrangementProgramInitiationFee', window );">First target development program initiation fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ganx_CollaborativeArrangementOptionExerciseFee', window );">Option exercise fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Unsatisfied performance obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">167,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 155,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ganx_MultiTargetCollaborationAgreementMember', window );">Multi-target collaboration agreement | Zentalis Pharmaceuticals, Inc. | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration Agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ganx_CollaborativeArrangementEmployeeAndExternalResearchAndDevelopmentCosts', window );">Employee and external research and development cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">272,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ganx_CollaborativeArrangementEventBasedMilestonePayments', window );">Event-based milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ganx_CollaborativeArrangementEmployeeAndExternalResearchAndDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of first target development program reimbursement for employee and external research and development costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ganx_CollaborativeArrangementEmployeeAndExternalResearchAndDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ganx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ganx_CollaborativeArrangementEventBasedMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of first target development program event-based milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ganx_CollaborativeArrangementEventBasedMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ganx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ganx_CollaborativeArrangementMinimumNumberOfTargets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum number of targets mutually agreed per agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ganx_CollaborativeArrangementMinimumNumberOfTargets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ganx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ganx_CollaborativeArrangementOptionExerciseFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of first target development program option exercise fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ganx_CollaborativeArrangementOptionExerciseFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ganx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ganx_CollaborativeArrangementProgramInitiationFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of first target development program initiation fees receivable per terms of agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ganx_CollaborativeArrangementProgramInitiationFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ganx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ganx_CollaborativeArrangementTerminationNoticePeriodDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Notice period days for agreement termination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ganx_CollaborativeArrangementTerminationNoticePeriodDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ganx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ganx_MultiTargetCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ganx_MultiTargetCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ganx_ZentalisPharmaceuticalsInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ganx_ZentalisPharmaceuticalsInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139934221862424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes - Domestic and foreign net operating losses (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract', window );"><strong>Components of income (loss) before income taxes provision</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">Domestic</a></td>
<td class="num">$ (7,601,640)<span></span>
</td>
<td class="num">$ (623,667)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="num">(6,284,958)<span></span>
</td>
<td class="num">(2,948,629)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income tax</a></td>
<td class="num">$ (13,886,598)<span></span>
</td>
<td class="num">$ (3,572,296)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139934218915160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes - Components of income tax expense (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Foreign</a></td>
<td class="nump">$ 4,008<span></span>
</td>
<td class="nump">$ 5,386<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total</a></td>
<td class="nump">4,008<span></span>
</td>
<td class="nump">5,386<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total income tax expense</a></td>
<td class="nump">$ 4,008<span></span>
</td>
<td class="nump">$ 5,386<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139934218289960">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income taxes - Domestic and foreign net operating losses and related deferred tax assets (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Income taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Total NOLs</a></td>
<td class="num">$ (18,239,792)<span></span>
</td>
<td class="num">$ (6,608,396)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract', window );"><strong>Deferred tax assets related to:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign', window );">Net operating loss (foreign)</a></td>
<td class="nump">2,243,668<span></span>
</td>
<td class="nump">1,111,942<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic', window );">Net operating loss (domestic)</a></td>
<td class="nump">1,677,610<span></span>
</td>
<td class="nump">146,451<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock based compensation</a></td>
<td class="nump">253,439<span></span>
</td>
<td class="nump">22,465<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ganx_DeferredTaxAssetsFmwWarrant', window );">Warrant expense</a></td>
<td class="nump">284,531<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other temporary differences</a></td>
<td class="nump">4,010<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">4,463,258<span></span>
</td>
<td class="nump">1,280,858<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Depreciation and other</a></td>
<td class="num">(1,137)<span></span>
</td>
<td class="num">(2,682)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">(1,137)<span></span>
</td>
<td class="num">(2,682)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="nump">4,462,121<span></span>
</td>
<td class="nump">1,278,176<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Income taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Total NOLs</a></td>
<td class="num">(12,021,483)<span></span>
</td>
<td class="num">(6,076,187)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Income taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Total NOLs</a></td>
<td class="num">$ (6,218,309)<span></span>
</td>
<td class="num">$ (532,209)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ganx_DeferredTaxAssetsFmwWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from fmw warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ganx_DeferredTaxAssetsFmwWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ganx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible foreign operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139934218666760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes - Additional disclosures (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Income taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Accrued interest or penalties</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ganx_ExpenseForInterestAndPenaltiesRelatedToUncertainTaxPositionRecognizedInStatementOfOperations', window );">Expense for interest and penalties related to uncertain tax position, recognized in statement of operations</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_ES', window );">Spain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Income taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ganx_ExpenseForInterestAndPenaltiesRelatedToUncertainTaxPositionRecognizedInStatementOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expense for interest and penalties related to uncertain tax position, recognized in statement of operations</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ganx_ExpenseForInterestAndPenaltiesRelatedToUncertainTaxPositionRecognizedInStatementOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ganx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_ES">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_ES</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139934218868664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes - Effective income tax rate reconciliation (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Income tax rate reconciliation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal income tax at US statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State income taxes, net of federal benefit</a></td>
<td class="nump">6.52%<span></span>
</td>
<td class="nump">6.52%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ganx_EffectiveIncomeTaxRateReconciliationPermanentDifferences', window );">Permanent differences</a></td>
<td class="num">(0.10%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ganx_EffectiveIncomeTaxRateReconciliationProvisionToReturn', window );">Provision to return</a></td>
<td class="nump">0.13%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Foreign tax</a></td>
<td class="num">(0.03%)<span></span>
</td>
<td class="num">(0.15%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(27.52%)<span></span>
</td>
<td class="num">(27.37%)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ganx_EffectiveIncomeTaxRateReconciliationPermanentDifferences">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations attributable to permanent differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ganx_EffectiveIncomeTaxRateReconciliationPermanentDifferences</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ganx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ganx_EffectiveIncomeTaxRateReconciliationProvisionToReturn">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations attributable to provision to return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ganx_EffectiveIncomeTaxRateReconciliationProvisionToReturn</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ganx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139934218171464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net loss per common share - Computation of diluted net loss per share (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Net loss per common share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share</a></td>
<td class="num">$ (1.37)<span></span>
</td>
<td class="num">$ (1.33)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember', window );">Previously reported</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Net loss per common share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1.17)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Net loss per common share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of diluted net loss per share attributable to common stockholders (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,185,879<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_PreferredClassBMember', window );">Series B Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Net loss per common share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of diluted net loss per share attributable to common stockholders (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,695,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Options to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Net loss per common share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of diluted net loss per share attributable to common stockholders (in shares)</a></td>
<td class="nump">960,216<span></span>
</td>
<td class="nump">429,822<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Net loss per common share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of diluted net loss per share attributable to common stockholders (in shares)</a></td>
<td class="nump">425,387<span></span>
</td>
<td class="nump">237,249<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_PreferredClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_PreferredClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139934214055368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Parties (Details) - License agreement Minoryx Therapeutics SL - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Parties</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ganx_RelatedPartyTransactionPercentageOfConsiderationReceived', window );">Percentage of consideration received</a></td>
<td class="nump">1.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableRelatedParties', window );">Receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent', window );">Payables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromRelatedParties', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Parties</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ganx_RelatedPartyTransactionPercentageOfNetRevenuesBasedOnOneCompositionOfMatterClaim', window );">Percentage of net revenue based on one composition matter</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ganx_RelatedPartyTransactionPercentageOfNetRevenuesBasedOnOneMethodOfClaim', window );">Percentage of net revenue based on one method of claim</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ganx_RelatedPartyTransactionPercentageOfConsiderationReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of consideration received in the event of a sale of the Company or substantially all of the assets, including by merger, change of control, or reorganization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ganx_RelatedPartyTransactionPercentageOfConsiderationReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ganx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ganx_RelatedPartyTransactionPercentageOfNetRevenuesBasedOnOneCompositionOfMatterClaim">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of revenues that would infringe at least one composition of matter claim.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ganx_RelatedPartyTransactionPercentageOfNetRevenuesBasedOnOneCompositionOfMatterClaim</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ganx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ganx_RelatedPartyTransactionPercentageOfNetRevenuesBasedOnOneMethodOfClaim">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of revenues that would infringe at least one method of matter claim.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ganx_RelatedPartyTransactionPercentageOfNetRevenuesBasedOnOneMethodOfClaim</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ganx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount for accounts payable to related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an unclassified balance sheet, amount of receivables arising from transactions with related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07.1(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401555&amp;loc=SL114874292-224272<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=ganx_LicenseAgreementWithMinoryxTherapeuticsSlMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=ganx_LicenseAgreementWithMinoryxTherapeuticsSlMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139934219953272">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Information (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAxis=ganx_CollaborationAgreementsMember', window );">Research agreements</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Commitment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInNextTwelveMonths', window );">Commitment with contractual maturity date in 2022</a></td>
<td class="nump">$ 453,305<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationDueInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationDueInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=ganx_CollaborationAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=ganx_CollaborationAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>ganx-20211231x10k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2021"
  xmlns:currency="http://xbrl.sec.gov/currency/2021"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:ganx="http://www.gaintherapeutics.com/20211231"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="ganx-20211231.xsd" xlink:type="simple"/>
    <context id="As_Of_12_31_2021_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_ValuationTechniqueAxis_us-gaap_ValuationTechniqueOptionPricingModelMember_imxnCtN6ykq3qhuSJY2jEg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_us-gaap_ValuationTechniqueAxis_us-gaap_ValuationTechniqueOptionPricingModelMember_jbd4-HDMH0K2ZzXOCoSCFA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_us-gaap_ValuationTechniqueAxis_us-gaap_ValuationTechniqueOptionPricingModelMember_9QqzfSmMzkiY1DCoSmnXjg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_ValuationTechniqueAxis_us-gaap_ValuationTechniqueOptionPricingModelMember_pn73ofcvSUeZsLeHLTUKsg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_us-gaap_ValuationTechniqueAxis_us-gaap_ValuationTechniqueOptionPricingModelMember_LWxcsazXDk2P_fSZ_3WyGA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_us-gaap_ValuationTechniqueAxis_us-gaap_ValuationTechniqueOptionPricingModelMember_1wOkdymSaEyzTP505R_Yzw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_uZL4jiBANU-5t9wJ3fQwpA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_3_17_2021_To_3_17_2021_us-gaap_StatementClassOfStockAxis_ganx_PreferredStockSeriesAndSeriesBMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_r8J2spGPVEeD9l3nZ-VHoQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ganx:PreferredStockSeriesAndSeriesBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-17</startDate>
            <endDate>2021-03-17</endDate>
        </period>
    </context>
    <context id="Duration_3_3_2021_To_3_3_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_lfgvFolLLU68lyHCSIQe6A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ganx:OmnibusIncentivePlanTwoThousandTwentyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-03</startDate>
            <endDate>2021-03-03</endDate>
        </period>
    </context>
    <context id="Duration_3_3_2021_To_3_3_2021_pvtif4URAkie9GX28TaLHA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
        </entity>
        <period>
            <startDate>2021-03-03</startDate>
            <endDate>2021-03-03</endDate>
        </period>
    </context>
    <context id="Duration_7_20_2020_To_7_20_2020_CH_oHqEadU-bNi2WtP4JnA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
        </entity>
        <period>
            <startDate>2020-07-20</startDate>
            <endDate>2020-07-20</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_n0BVNh7nXEOEg7ig4OTueQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_BSZ8PS8MmUKSjqHr7IV3kw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_aTBx7lbU9EmXTzCop7s5VQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_wUcCiJ_aL0uNAaoLQz_kIQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_AmnlCLXS4EW0T11vxuv4dA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_gy5vyeo0XECt7V84YflbPw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_triyROczKkOUjFoGUVGRSg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_5pVNHNLDU0aNGDOeH5tWLQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_gMslWnX56U6NnNQwJeyNJQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_SekcF5i21U2sPnRupyd-qQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredClassBMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_HKF8S1_Sj0ytyt6XZS1DhQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_pyBaEfYw3k-Bre7rOUHY8A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_9f9qYFGKFEi5lUCxbnfGyA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_UWKqqxKGa0GJPrjjqykVHA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_7i8WecRBqEmSQhLalEWwQQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_jyeDTSFma0emcErckg2zrw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_17_2021_us-gaap_SubsidiarySaleOfStockAxis_ganx_IpoExcludingUnderwritersOptionsMember_TfY1dJMilk2kFQZuPi8-sw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ganx:IpoExcludingUnderwritersOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-17</instant>
        </period>
    </context>
    <context id="Duration_3_16_2021_To_3_16_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_8OFhhtn3CkCh-eZfG1m3iA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ganx:OmnibusIncentivePlanTwoThousandTwentyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-16</startDate>
            <endDate>2021-03-16</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ganx_ExercisePrice7.80Member_azVHc_tr_02k1bZtu5dcVA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ganx:OmnibusIncentivePlanTwoThousandTwentyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ganx:ExercisePrice7.80Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ganx_ExercisePrice5.99Member_IRU-JBn3zUmz8JgkEa1wmQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ganx:OmnibusIncentivePlanTwoThousandTwentyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ganx:ExercisePrice5.99Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ganx_ExercisePrice5.86Member_ldKP04Tc_EiQ1aX3hzo_jQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ganx:OmnibusIncentivePlanTwoThousandTwentyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ganx:ExercisePrice5.86Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ganx_ExercisePrice3.38Member_q48VnEGwiUKrGR7I5_LISQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ganx:OmnibusIncentivePlanTwoThousandTwentyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ganx:ExercisePrice3.38Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ganx_ExercisePrice10.03Member__Arw4xIJUEO-yWegbRND-A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ganx:OmnibusIncentivePlanTwoThousandTwentyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ganx:ExercisePrice10.03Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_liEc-LEvuUmppacbgwHfFg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ganx:OmnibusIncentivePlanTwoThousandTwentyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ganx_ExercisePrice5.99Member__H3l5fnJok-E9OkINM3A4Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ganx:OmnibusIncentivePlanTwoThousandTwentyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ganx:ExercisePrice5.99Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ganx_ExercisePrice5.86Member_gBKLZo1l-0W49gJ_33Ix3Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ganx:OmnibusIncentivePlanTwoThousandTwentyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ganx:ExercisePrice5.86Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ganx_ExercisePrice10.03Member_t43zzwTn0EOG01iusAqyuA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ganx:OmnibusIncentivePlanTwoThousandTwentyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ganx:ExercisePrice10.03Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ganx_ExercisePrice7.80Member_IAhcMx9gQUiYIcwUzGxvUw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ganx:OmnibusIncentivePlanTwoThousandTwentyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ganx:ExercisePrice7.80Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ganx_ExercisePrice3.38Member_vX53-sp5zEGR0K2gPjCseA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ganx:OmnibusIncentivePlanTwoThousandTwentyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ganx:ExercisePrice3.38Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_23_2021_us-gaap_PlanNameAxis_ganx_TwentyTwentyoneInducementEquityIncentivePlanMember_dc6nUQZMq0iDFdVD-aASTQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ganx:TwentyTwentyoneInducementEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-23</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_0JEx-N7nxEOplYgSWCGOgw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_9_24_2020_To_9_24_2020_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_RTjAu4qAPEqUn3L27gh5Ow">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ganx:OmnibusIncentivePlanTwoThousandTwentyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-24</startDate>
            <endDate>2020-09-24</endDate>
        </period>
    </context>
    <context id="Duration_9_24_2020_To_9_24_2020_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_7U57Cx256U2tLHUf4s6Y8A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ganx:OmnibusIncentivePlanTwoThousandTwentyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-24</startDate>
            <endDate>2020-09-24</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_ganx_ZentalisPharmaceuticalsInc.Member_us-gaap_TypeOfArrangementAxis_ganx_MultiTargetCollaborationAgreementMember_vo15OpWqgkuGY59e7z-yzg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ganx:ZentalisPharmaceuticalsInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ganx:MultiTargetCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_8_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ganx_OfficeSpaceViaPietroPeri9DLuganoSwitzerlandMember_DFphXJwj90K3f5xEo5ZU9Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ganx:OfficeSpaceViaPietroPeri9DLuganoSwitzerlandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_RelatedPartyTransactionAxis_ganx_LicenseAgreementWithMinoryxTherapeuticsSlMember_mBz6FxcSTU-e2iDkMK0uyg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ganx:LicenseAgreementWithMinoryxTherapeuticsSlMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_RelatedPartyTransactionAxis_ganx_LicenseAgreementWithMinoryxTherapeuticsSlMember_cr-ykWSWVE6F-fAwmXseZg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ganx:LicenseAgreementWithMinoryxTherapeuticsSlMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_bbRnKwgINUGLy8vnaZzYFA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_-nBpIitRCkCtsIXc9x1o_w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_DEcpOGG1JU2_mxWcWch9wA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ganx_LaboratoryInstrumentsMember_QYgSSMkkV06NDZOYiqbepA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ganx:LaboratoryInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_eLOEQvd7zk-xTusLDMYb_Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_K3apo3t_cUqHmQGcaov5QQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_6bdG0fwN7EC_-yHkMAKyHQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ganx_LaboratoryInstrumentsMember_5du392y7_Ea3X3SOCPm2GA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ganx:LaboratoryInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="Duration_3_1_2021_To_3_31_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_N45LChwtn0m3vTVdPokCZw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="As_Of_3_16_2021_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredClassBMember_HBe32B_mIkuJvMwKt7oZ-g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-16</instant>
        </period>
    </context>
    <context id="As_Of_3_16_2021_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredClassAMember_LA-5cb6F00S56dV8R_wEsQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-16</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_UOpY8hOKmEaY4smAqVjcoQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_bnIOh52EIUC-yTsdpcG0NQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_SZL-8g69ikyvM5ITtvQ_vA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_HPxGCJIoKkWKHRC95IDwMg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredClassBMember_G4x0CiU2mUOuiMOxwNFS6Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredClassAMember_QpkPvPPAwEiZSl5LOyqQvA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_lVp5EHBSO0a3sKcZW9whJg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_5l4ULFPqR0yL1UAG81fHvA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember_eYHQNzPoa0Kj3sShxdX8jQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_dHaFDA1AQUSlfDaHicQ8uw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember_cfBf_8Ckq0Gp_Dh77YRizw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_MuNTVlrNBkqVSW1-Y7sqjA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_BvTE8F6mxk6Kxv6RzTF0bw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_AYWDjeIOSU-RxGjTZOS7Tw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_10_1_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ganx_OfficeSpaceInBethesdaMarylandMember_UeSQeDvOw0SJcAM-RLo4Lg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ganx:OfficeSpaceInBethesdaMarylandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-01</instant>
        </period>
    </context>
    <context id="As_Of_6_1_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ganx_OfficeSpaceViaSoaveN6LuganoSwitzerlandMember_PifC1TMuyUCNw5rbo-bIqg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ganx:OfficeSpaceViaSoaveN6LuganoSwitzerlandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-01</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_srt_RangeAxis_srt_MinimumMember_eU0rUPNa5UKucFJIXpiTPg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_srt_RangeAxis_srt_MaximumMember_Tv-_F37-xki1Z4qnJJZcNg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_11_1_2021_To_11_1_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ganx_OfficeSpaceTorreDBuildingBarcelonaMember_b34IOdjLSEeVrGT01vF1Rg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ganx:OfficeSpaceTorreDBuildingBarcelonaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-01</startDate>
            <endDate>2021-11-01</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2021_To_10_1_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ganx_OfficeSpaceInBethesdaMarylandMember_9U2vOl3u9U-cCfj_ThszJA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ganx:OfficeSpaceInBethesdaMarylandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_dei_LegalEntityAxis_ganx_GtGainTherapeuticsSaMember_srt_CounterpartyNameAxis_ganx_Eurostars2Member_YNqIuW1F40W5tgg_Hji_3Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ganx:Eurostars2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ganx:GtGainTherapeuticsSaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_dei_LegalEntityAxis_ganx_GtGainTherapeuticsSaMember_srt_CounterpartyNameAxis_ganx_Eurostars2Member_FaVauHMhk0mEw4Cnb7EatA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ganx:Eurostars2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ganx:GtGainTherapeuticsSaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_7_31_2019_dei_LegalEntityAxis_ganx_GtGainTherapeuticsSaMember_srt_CounterpartyNameAxis_ganx_Eurostars2Member_bQ8j0nCuy0GId24-qC-Rwg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ganx:Eurostars2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ganx:GtGainTherapeuticsSaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-31</instant>
        </period>
    </context>
    <context id="As_Of_7_31_2019_dei_LegalEntityAxis_ganx_ConsortiumWithGtGainTherapeuticsSaInstituteForResearchInBiomedicineAndNeuroSysSasMember_srt_CounterpartyNameAxis_ganx_Eurostars2Member_rZtMNPgqTUK8vf9PccniAQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ganx:Eurostars2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ganx:ConsortiumWithGtGainTherapeuticsSaInstituteForResearchInBiomedicineAndNeuroSysSasMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-31</instant>
        </period>
    </context>
    <context id="As_Of_2_28_2019_dei_LegalEntityAxis_ganx_GtGainTherapeuticsSaMember_srt_CounterpartyNameAxis_ganx_MichaelJ.FoxFoundationForParkinsonSResearchMjffMember_pOgW2epL9EG_XiGfjitJLQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ganx:MichaelJ.FoxFoundationForParkinsonSResearchMjffMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ganx:GtGainTherapeuticsSaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-02-28</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_ComputerSoftwareIntangibleAssetMember_IyvNJLfe-0C5bmjgl1g7MQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_RVGfoikIBESMbmCXz6RCfw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ganx:OmnibusIncentivePlanTwoThousandTwentyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_StatementGeographicalAxis_country_ES_No2V5hdzvE6TY_AfyyLEBQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:ES</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_BhPyaAaDOkudfThK5f94MA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_RetirementPlanSponsorLocationAxis_country_CH_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_JNWw1VrK5kqfZgK60b8Pdw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:CH</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_RetirementPlanSponsorLocationAxis_country_CH_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_XR8N6cpyV0WdwjyDiJrSbA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:CH</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="Duration_3_1_2020_To_3_31_2020_us-gaap_DebtInstrumentAxis_ganx_March2020ChfLoanMember_S8zeqoa7qEuI5LdFwXbKLw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ganx:March2020ChfLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="Duration_8_1_2020_To_8_31_2020_us-gaap_DebtInstrumentAxis_ganx_August2020ChfLoanMember_QkIhdbW_8Uis0Buu2_viHA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ganx:August2020ChfLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="As_Of_8_31_2020_us-gaap_DebtInstrumentAxis_ganx_August2020ChfLoanMember_os9qx323O06rGZDMfoiU8Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ganx:August2020ChfLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2020_us-gaap_DebtInstrumentAxis_ganx_March2020ChfLoanMember_FV-iSHC9DECOjK6nXfZqag">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ganx:March2020ChfLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_srt_CounterpartyNameAxis_ganx_ZentalisPharmaceuticalsInc.Member_us-gaap_TypeOfArrangementAxis_ganx_MultiTargetCollaborationAgreementMember_VaQZuPvZpUe8IpzXfakMYA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ganx:ZentalisPharmaceuticalsInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ganx:MultiTargetCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_OtherCommitmentsAxis_ganx_CollaborationAgreementsMember_Yr71bAiK8EiGzhgz_kIr8Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">ganx:CollaborationAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_3_16_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_-yJfbN_d1U6z9SG-fWFZ5A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ganx:OmnibusIncentivePlanTwoThousandTwentyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-16</instant>
        </period>
    </context>
    <context id="As_Of_3_16_2021_fYMXRlaU00CBob3C4xDimg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
        </entity>
        <period>
            <instant>2021-03-16</instant>
        </period>
    </context>
    <context id="As_Of_9_24_2020_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_yL43kRndvEW68muLtDGB3g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ganx:OmnibusIncentivePlanTwoThousandTwentyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-24</instant>
        </period>
    </context>
    <context id="As_Of_5_6_2021_us-gaap_ClassOfWarrantOrRightAxis_ganx_WarrantsToDesigneesOfInvestmentBankIssuedMay2021Member_vInDzK2VLEaPLuCJ2B3g4g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ganx:WarrantsToDesigneesOfInvestmentBankIssuedMay2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-06</instant>
        </period>
    </context>
    <context id="As_Of_3_17_2021_us-gaap_ClassOfWarrantOrRightAxis_ganx_WarrantsToDesigneesOfPlacementAgentIssuedJuly2020Member_g-_VaNc3WkybZ1HHEFo_GQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ganx:WarrantsToDesigneesOfPlacementAgentIssuedJuly2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-17</instant>
        </period>
    </context>
    <context id="As_Of_3_16_2021_us-gaap_ClassOfWarrantOrRightAxis_ganx_WarrantsToDesigneesOfPlacementAgentIssuedJuly2020Member_YF5W3invl02ldRF6Cq2TAQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ganx:WarrantsToDesigneesOfPlacementAgentIssuedJuly2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-16</instant>
        </period>
    </context>
    <context id="As_Of_7_31_2020_us-gaap_ClassOfWarrantOrRightAxis_ganx_WarrantsToDesigneesOfPlacementAgentIssuedJuly2020Member__xz3VXdq4UepWPvW5n-chA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ganx:WarrantsToDesigneesOfPlacementAgentIssuedJuly2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_jVvLJZrhl0W1Aw8CczgC5A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_gnHItaHOm0WTAQXAM2HTwQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CashMember_fDDfSQp6UU-oqPAB4e119Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_YVDinHFXT0-dz2LLkYn02Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CashMember_hSR99mDOLk29CBNFU890Kw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_jwo2h2HgjU-Oaoug1oOjXg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_FairValueByAssetClassAxis_us-gaap_CashAndCashEquivalentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_aPJD3-UwWk2aYpTKhM55uA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_uuaa7xnlyki6ykqgX7Pttw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_yQGxUTb4_kyBt2-oIiFKuQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_FairValueByAssetClassAxis_us-gaap_CashAndCashEquivalentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_zzuqJkU6kk6sqgnOWt5eyA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_c2-Hsc31bki-8GK8iPACMA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_eFtEzOEVSUW8fCSfS0makQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_nWZin8CUEka_hYHuxWQ98g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_BLTwMarrSki4A2b_zuzjjQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_SeriesAPreferredStockMember_gYxd91evBkC5xqONi1hr9g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_PreferredClassBMember_ulJHYyt9xkm7k2JpVT1HlQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PreferredClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_o5CVJWPFxkyUPRNzDIKUWw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_8kdx5frm8UGeszq3O_KyBg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ganx:OmnibusIncentivePlanTwoThousandTwentyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_idnllJAzZk6p-wCg6SCFow">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ganx:OmnibusIncentivePlanTwoThousandTwentyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_W_1SbimhkkmXrYE8c7oscg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ganx:OmnibusIncentivePlanTwoThousandTwentyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_I180bvlxRk2MS8zltC_nhQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ganx:OmnibusIncentivePlanTwoThousandTwentyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_oZ2efAweo0yRRNPJFNieTA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ganx:OmnibusIncentivePlanTwoThousandTwentyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_t7HEGl5NAk-CsgC95XNoeg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_RelatedPartyTransactionAxis_ganx_LicenseAgreementWithMinoryxTherapeuticsSlMember_uoLGxPyxJ0uSfZ7e2uoHkg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ganx:LicenseAgreementWithMinoryxTherapeuticsSlMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_RelatedPartyTransactionAxis_ganx_LicenseAgreementWithMinoryxTherapeuticsSlMember_VIe1l_ajWEuJhOrR7dlifQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ganx:LicenseAgreementWithMinoryxTherapeuticsSlMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_srt_CurrencyAxis_currency_USD_JNFtn3l03kGKX0UlySPmQQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_srt_CurrencyAxis_currency_EUR_FPdG1lChOEK7NjX3VPs_Hw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_srt_CurrencyAxis_currency_CHF_rDufzY5Ouk6hLwlR1vAueQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CHF</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_srt_CurrencyAxis_currency_USD_MG28bHY0C0G-LS6iFm77lQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_srt_CurrencyAxis_currency_EUR_jtopedrPUk-JApA2wqKkRg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_srt_CurrencyAxis_currency_CHF_x9IJv5F-j0en4mIAdI3ZtA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CHF</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_ValuationTechniqueAxis_us-gaap_ValuationTechniqueOptionPricingModelMember_QzEVNtuW9US0oSPFOgMt6A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_ValuationTechniqueAxis_us-gaap_ValuationTechniqueOptionPricingModelMember_2H_dl4e8hE-KkfFPdigrJA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_5_6_2021_To_5_6_2021_us-gaap_ClassOfWarrantOrRightAxis_ganx_WarrantsToDesigneesOfInvestmentBankIssuedMay2021Member_94Oz4J1U90W8gKhVhzq1zg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ganx:WarrantsToDesigneesOfInvestmentBankIssuedMay2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-06</startDate>
            <endDate>2021-05-06</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_ganx_WarrantsToDesigneesOfInvestmentBankIssuedMay2021Member_Xr6HpqPQo0W86a4ZrsARSQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ganx:WarrantsToDesigneesOfInvestmentBankIssuedMay2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_3_22_2021_To_3_22_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_T4IMo7Q7FkixFavhC2S9FA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-22</startDate>
            <endDate>2021-03-22</endDate>
        </period>
    </context>
    <context id="Duration_3_17_2021_To_3_17_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_VPlkneswlU6lplZPmfwMQg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ganx:OmnibusIncentivePlanTwoThousandTwentyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-17</startDate>
            <endDate>2021-03-17</endDate>
        </period>
    </context>
    <context id="As_Of_3_17_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_NETjxmYYrkyazfL5gwskGw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ganx:OmnibusIncentivePlanTwoThousandTwentyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-17</instant>
        </period>
    </context>
    <context id="Duration_12_1_2017_To_12_31_2017_srt_RangeAxis_srt_MaximumMember_us-gaap_RelatedPartyTransactionAxis_ganx_LicenseAgreementWithMinoryxTherapeuticsSlMember_wfhEAoIeSEyyfIL5XTMUAQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ganx:LicenseAgreementWithMinoryxTherapeuticsSlMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="Duration_12_1_2017_To_12_31_2017_us-gaap_RelatedPartyTransactionAxis_ganx_LicenseAgreementWithMinoryxTherapeuticsSlMember_cbGjmh51ckuCzbppGr1veQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ganx:LicenseAgreementWithMinoryxTherapeuticsSlMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_ganx_GtGainTherapeuticsSaMember_srt_CounterpartyNameAxis_ganx_MichaelJ.FoxFoundationForParkinsonSResearchMjffMember__G2vs2A3Nk-gHqckeDfJ_w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ganx:MichaelJ.FoxFoundationForParkinsonSResearchMjffMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ganx:GtGainTherapeuticsSaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_ganx_GtGainTherapeuticsSaMember_srt_CounterpartyNameAxis_ganx_Eurostars2Member_QdIjpEm0HEmiFVdv-rxIew">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ganx:Eurostars2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ganx:GtGainTherapeuticsSaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_dei_LegalEntityAxis_ganx_GtGainTherapeuticsSaMember_srt_CounterpartyNameAxis_ganx_MichaelJ.FoxFoundationForParkinsonSResearchMjffMember__vvtnvxiGkihO0mrEzCOXQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ganx:MichaelJ.FoxFoundationForParkinsonSResearchMjffMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ganx:GtGainTherapeuticsSaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_dei_LegalEntityAxis_ganx_GtGainTherapeuticsSaMember_srt_CounterpartyNameAxis_ganx_Eurostars2Member_3HTuGjlZh0OM3ztzJoNVeA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ganx:Eurostars2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ganx:GtGainTherapeuticsSaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_vxw_50xpsk-K6Rt4Xg-w-w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ganx_LaboratoryInstrumentsMember_UGsEilKkZ0-amCM5X6BAdw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ganx:LaboratoryInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ganx_EquipmentAndFurnitureMember_eYeOQu_NukuBM3xRUGpAow">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ganx:EquipmentAndFurnitureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2019_To_12_31_2019_dei_LegalEntityAxis_ganx_GtGainTherapeuticsSaMember_srt_CounterpartyNameAxis_ganx_Eurostars2Member_kHOQVkb_30--8vvOt4dYkQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ganx:Eurostars2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ganx:GtGainTherapeuticsSaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_3_18_2021_To_3_18_2021_iMaj3AAJbEqmShHP_jyriA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
        </entity>
        <period>
            <startDate>2021-03-18</startDate>
            <endDate>2021-03-18</endDate>
        </period>
    </context>
    <context id="Duration_3_17_2021_To_3_17_2021_u6CMktnXaUyF6ar7hHmEcw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
        </entity>
        <period>
            <startDate>2021-03-17</startDate>
            <endDate>2021-03-17</endDate>
        </period>
    </context>
    <context id="Duration_3_17_2021_To_3_17_2021_us-gaap_SubsidiarySaleOfStockAxis_ganx_IpoExcludingUnderwritersOptionsMember_zUbax__QHU2jXdFcxwazTA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ganx:IpoExcludingUnderwritersOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-17</startDate>
            <endDate>2021-03-17</endDate>
        </period>
    </context>
    <context id="As_Of_11_1_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ganx_OfficeSpaceTorreIBuildingBarcelonaMember_iI-D9SSrGEKpT_zGFsqoww">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ganx:OfficeSpaceTorreIBuildingBarcelonaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-01</instant>
        </period>
    </context>
    <context id="As_Of_11_1_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ganx_OfficeSpaceTorreDBuildingBarcelonaMember_irdsQ60cnEm7ZZpQvK104Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ganx:OfficeSpaceTorreDBuildingBarcelonaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-01</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_9J9hcs3P0U-I30H9M7barQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ganx:OmnibusIncentivePlanTwoThousandTwentyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_8_31_2021_To_8_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ganx_OfficeSpaceViaPietroPeri9DLuganoSwitzerlandMember_KKvzTiG970Ce6TsWGr7BeA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ganx:OfficeSpaceViaPietroPeri9DLuganoSwitzerlandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-31</startDate>
            <endDate>2021-08-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_xAFkHxT11EGU0yxL99Adfg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_1HYzj4oHZUevOEIRtTmDzw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredClassBMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember__qh10NtWoEa7l7GjkQhs9A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_ganx_WarrantsToDesigneesOfPlacementAgentIssuedJuly2020Member_YAr_SbLTRk2XAPVCkBuVtg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ganx:WarrantsToDesigneesOfPlacementAgentIssuedJuly2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ubdNM3dDp0mLTH7OlcI_NA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_3_17_2021_To_3_22_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_SaCdeyGh10qyXh2PUIfaFw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-17</startDate>
            <endDate>2021-03-22</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_JDEb6LtAmEuXGmEieWNlsw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_NLtbBeqGQESB9Jjk98teAA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_kMW3hEdOQk-Go8nyyVufvA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_i6PZAoMNcEySLcgBUKmmjw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_HLv731xR10GVgI0Jt-JL5w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_i98h5sWV5U-TOn1S0EBWxQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredClassBMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_W4zZ56C1Q0yKk0LZMBsvMA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_RRjkaPqvD06cYjwCnpc1bQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_4_20_2021_To_4_20_2021_srt_CounterpartyNameAxis_ganx_ZentalisPharmaceuticalsInc.Member_us-gaap_TypeOfArrangementAxis_ganx_MultiTargetCollaborationAgreementMember_79uwIK2uDU2loW-PUu8mAg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ganx:ZentalisPharmaceuticalsInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ganx:MultiTargetCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-20</startDate>
            <endDate>2021-04-20</endDate>
        </period>
    </context>
    <context id="As_Of_5_31_2021_srt_CounterpartyNameAxis_ganx_ZentalisPharmaceuticalsInc.Member_us-gaap_TypeOfArrangementAxis_ganx_MultiTargetCollaborationAgreementMember_UAOVQT0JhEyX-WpaUYbKmA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ganx:ZentalisPharmaceuticalsInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ganx:MultiTargetCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-31</instant>
        </period>
    </context>
    <context id="Duration_5_1_2021_To_5_31_2021_srt_CounterpartyNameAxis_ganx_ZentalisPharmaceuticalsInc.Member_us-gaap_TypeOfArrangementAxis_ganx_MultiTargetCollaborationAgreementMember_nrRCfgERCkCz3HkVyPGAgA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ganx:ZentalisPharmaceuticalsInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ganx:MultiTargetCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="As_Of_4_20_2021_srt_CounterpartyNameAxis_ganx_ZentalisPharmaceuticalsInc.Member_us-gaap_TypeOfArrangementAxis_ganx_MultiTargetCollaborationAgreementMember_MduiqnTW20mQ__WJtWGk9Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ganx:ZentalisPharmaceuticalsInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ganx:MultiTargetCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-20</instant>
        </period>
    </context>
    <context id="Duration_5_1_2021_To_5_31_2021_srt_CounterpartyNameAxis_ganx_ZentalisPharmaceuticalsInc.Member_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_ganx_MultiTargetCollaborationAgreementMember_VJHihOl1_0O-yMpbRCHaPA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ganx:ZentalisPharmaceuticalsInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ganx:MultiTargetCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2021_Coki50uufUmBg7YC34rJmQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_2_28_2022_K5iAOzWiVE2Y5lP5jccqMA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
        </entity>
        <period>
            <instant>2022-02-28</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <unit id="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_Standard_item_jlWcaGVl5kGYwaQ1kPo68Q">
        <measure>ganx:item</measure>
    </unit>
    <unit id="Unit_Standard_pure_YPFUW3Xga0mVMPZT28RXUw">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_Standard_Options_mZpQ0toHqki8W4R9nXDMkA">
        <measure>ganx:Options</measure>
    </unit>
    <unit id="Unit_Standard_sqft_u3pgKg_7-0iwjFi0GwLPFg">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="Unit_Standard_CHF_tZXBcOteZE6rGAnlVuK3Ng">
        <measure>iso4217:CHF</measure>
    </unit>
    <unit id="Unit_Divide_USD_shares_ZUfWDOiJrESFdyfJo2gfWg">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Unit_Standard_EUR_Q6wJYXg2bk-dYmARpDyDyQ">
        <measure>iso4217:EUR</measure>
    </unit>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      decimals="2"
      id="Hidden_ZqfVXUdYkUaQWl9swYAeKg"
      unitRef="Unit_Divide_USD_shares_ZUfWDOiJrESFdyfJo2gfWg">-1.37</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2020_To_12_31_2020_JDEb6LtAmEuXGmEieWNlsw"
      decimals="2"
      id="Hidden_59XMxIKltEOAN65oF3AfFw"
      unitRef="Unit_Divide_USD_shares_ZUfWDOiJrESFdyfJo2gfWg">-1.33</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      decimals="0"
      id="Hidden_lKxvqb-Ic0Ojx_i9R3MPew"
      unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw">10165404</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2020_To_12_31_2020_JDEb6LtAmEuXGmEieWNlsw"
      decimals="0"
      id="Hidden_B3odu59CiE2QRJMA1CJZhw"
      unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw">2681408</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <dei:EntityCentralIndexKey
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      id="Tc_aTfCrWp3KE2Foa2HC3TAfA_1_1">0001819411</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      id="Tc_XU5tUSnECUGTvgWNgHTRxQ_2_1">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      id="Tc_Mi4Ly1nO7EKGDb2U9zXxKA_3_1">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      id="Tc_uGb-2dEHKUmfaUO8RRyXeg_4_1">FY</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      id="Tc_a7VGj4AT-kaOOkHF95BRhQ_5_1">false</dei:AmendmentFlag>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_UOpY8hOKmEaY4smAqVjcoQ"
      decimals="INF"
      id="Hidden_nBFWja__nUKaF0_2r1-5ew"
      unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_SZL-8g69ikyvM5ITtvQ_vA"
      decimals="INF"
      id="Hidden_WaxhVkpREkyl-jjvJbdCHQ"
      unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw">2965600</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_UOpY8hOKmEaY4smAqVjcoQ"
      decimals="INF"
      id="Hidden_qM3TS5mT-UC-jzM-fri5OQ"
      unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_bnIOh52EIUC-yTsdpcG0NQ"
      decimals="INF"
      id="Hidden_nUKSBhSCh0moQENn0OnE_w"
      unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_HPxGCJIoKkWKHRC95IDwMg"
      decimals="INF"
      id="Hidden_OklE6u_bskKwCDxGHn2ymg"
      unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw">1185879</us-gaap:PreferredStockSharesIssued>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm
      contextRef="As_Of_12_31_2021_srt_RangeAxis_srt_MinimumMember_eU0rUPNa5UKucFJIXpiTPg"
      id="Hidden_ZalXIiQg2kKnz87xVmLaUQ">P3Y</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:InterestExpenseDebt
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      decimals="0"
      id="Hidden_4WczMy8Ec0ae6MFBpO8JBg"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">0</us-gaap:InterestExpenseDebt>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="Duration_1_1_2020_To_12_31_2020_JDEb6LtAmEuXGmEieWNlsw"
      decimals="0"
      id="Hidden_4TswneAzZ0yP-xAbG1nbdw"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      decimals="0"
      id="Hidden_os3GPhf0qUifLjdDnxEjsg"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="Duration_3_3_2021_To_3_3_2021_pvtif4URAkie9GX28TaLHA"
      decimals="7"
      id="Hidden_PPLEqeAgy0iiPmdWllrCSA"
      unitRef="Unit_Standard_pure_YPFUW3Xga0mVMPZT28RXUw">1.1353521</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg"
      decimals="INF"
      id="Hidden_smJgQqCN6kCASsqGpDK0oA"
      unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw">3543163</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A"
      decimals="INF"
      id="Hidden_eCHc0lXrwkaLahqSp1jTsw"
      unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw">11883368</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_3_16_2021_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredClassAMember_LA-5cb6F00S56dV8R_wEsQ"
      decimals="INF"
      id="Hidden_xoy4pURJ0U6SC06b57siOQ"
      unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw">1346390</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_3_16_2021_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredClassBMember_HBe32B_mIkuJvMwKt7oZ-g"
      decimals="INF"
      id="Hidden_VxK6clrWrk2DfpjK2-sdow"
      unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw">3366999</us-gaap:PreferredStockSharesIssued>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="Duration_3_3_2021_To_3_3_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_lfgvFolLLU68lyHCSIQe6A"
      decimals="INF"
      id="Hidden_VOTL1rq_TUe6F_krbeB0zg"
      unitRef="Unit_Standard_pure_YPFUW3Xga0mVMPZT28RXUw">1.1353521</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:AccountsPayableRelatedPartiesCurrentAndNoncurrent
      contextRef="As_Of_12_31_2020_us-gaap_RelatedPartyTransactionAxis_ganx_LicenseAgreementWithMinoryxTherapeuticsSlMember_VIe1l_ajWEuJhOrR7dlifQ"
      decimals="-3"
      id="Hidden_oVxgLsgpXUKvH9ftuFwVIg"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">0</us-gaap:AccountsPayableRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:AccountsPayableRelatedPartiesCurrentAndNoncurrent
      contextRef="As_Of_12_31_2021_us-gaap_RelatedPartyTransactionAxis_ganx_LicenseAgreementWithMinoryxTherapeuticsSlMember_uoLGxPyxJ0uSfZ7e2uoHkg"
      decimals="-3"
      id="Hidden_UBkW5eX88UutloWkqiLS3Q"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">0</us-gaap:AccountsPayableRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:RevenueFromRelatedParties
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_RelatedPartyTransactionAxis_ganx_LicenseAgreementWithMinoryxTherapeuticsSlMember_cr-ykWSWVE6F-fAwmXseZg"
      decimals="-3"
      id="Hidden_hWewlVC51Ui9nanprIOh2A"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">0</us-gaap:RevenueFromRelatedParties>
    <us-gaap:RevenueFromRelatedParties
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_RelatedPartyTransactionAxis_ganx_LicenseAgreementWithMinoryxTherapeuticsSlMember_mBz6FxcSTU-e2iDkMK0uyg"
      decimals="-3"
      id="Hidden_v0zh4D61U0W62I-2KUdtrQ"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">0</us-gaap:RevenueFromRelatedParties>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_RelatedPartyTransactionAxis_ganx_LicenseAgreementWithMinoryxTherapeuticsSlMember_cr-ykWSWVE6F-fAwmXseZg"
      decimals="-3"
      id="Hidden_jR1LzriL-0SBUDw1tY_yqg"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">0</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_RelatedPartyTransactionAxis_ganx_LicenseAgreementWithMinoryxTherapeuticsSlMember_mBz6FxcSTU-e2iDkMK0uyg"
      decimals="-3"
      id="Hidden_OjxvEsGIu0inzt8v3me_aA"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">0</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_HPxGCJIoKkWKHRC95IDwMg"
      decimals="INF"
      id="Hidden_kdwNLQKYWkiveM0sOQGupw"
      unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw">1185879</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_SZL-8g69ikyvM5ITtvQ_vA"
      decimals="INF"
      id="Hidden_iLyIO00eQUWJB3oyw2X5yQ"
      unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw">2965600</us-gaap:PreferredStockSharesIssued>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="Duration_3_3_2021_To_3_3_2021_pvtif4URAkie9GX28TaLHA"
      decimals="INF"
      id="Hidden_R7-eb03Se0uFXfouVE5ALg"
      unitRef="Unit_Standard_pure_YPFUW3Xga0mVMPZT28RXUw">1.1353521</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg"
      decimals="INF"
      id="Hidden_ofEil3W8JECpBaDUijTFww"
      unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw">3543163</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A"
      decimals="INF"
      id="Hidden_vhbG_gva8kyxLeHJvfawEw"
      unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw">11883368</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_3_16_2021_fYMXRlaU00CBob3C4xDimg"
      decimals="0"
      id="Hidden_ARvqt8O7vki9CqZo9ksCdw"
      unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw">4022736</us-gaap:CommonStockSharesOutstanding>
    <dei:DocumentType
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      id="Narr_DS9AOj3MPkWPhlTOPO1xJw">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      id="Narr_tUOD0R0-5Eu32QDRzIS1MA">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      id="Narr_ht9GJhwcakOTDDuRZZ7TEg">2021-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      id="Narr_j-YZ3RUcDEWGciQPb6tswQ">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      id="Narr_fpQtaqzrZE6TFOliZvCbUg">001-40237</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      id="Narr_qs5QnIjEjEemaN9kbDHDsA">GAIN THERAPEUTICS,&#160;INC</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      id="Tc_nfhm164OAkurMzulh5oDcA_1_0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      id="Tc_Mm64ygh78EWjy5TZ3GwxNg_1_2">85-1726310</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      id="Narr_tv2bkqCiHEKxIbf-GTuoNA">4800 Montgomery Lane</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      id="Narr_MkZ3vTakzE2ETEOV3AjwxQ">Suite 220</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      id="Narr_ZrE0jOxHfU-99yveYXOQrw">Bethesda</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      id="Narr_skl_f6xIeEGuU2dGq9_5nQ">MD</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      id="Tc_I12JE9-OXkuHfLBxc6Mu1Q_4_2">20814</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      id="Narr__i1hKH7L1Ee_7nbZnn_3mw">301</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      id="Narr_51rUBkf1JE6oedUjiCo7cg">500-1556</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      id="Tc_MyorGBJrekOdlWXUV3UlBw_2_0">Common Stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      id="Tc_IJOiNQPZbkOAu6QGMcK1yg_2_2">GANX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      id="Tc_8d2TkrFDHkiihJMJKo6FLg_2_4">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      id="Narr_xolfJyXbyEy0dDwO8TYQUQ">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      id="Narr_xE8rbxefWkOqWcNl5xw42w">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      id="Narr_Gn9bpUph_U67wolNr4cFaw">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      id="Narr_Q2s2fLKBc02QR-Sw0C1Omw">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      id="Tc_hfb7Xn8ObUC88k5V0jPxcw_1_4">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      id="Tc_jFNwv4d4KUGHoC0YRqTBRQ_1_7">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      id="Tc_LFqtDZ6GuEOH3BL1EOUFHg_3_7">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      id="Narr_6Ij0391E902TvOHRd33yMw">false</dei:EntityExTransitionPeriod>
    <dei:IcfrAuditorAttestationFlag
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      id="Narr_Qkz8P4JfmUG8g2qvE_FCAw">false</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      id="Narr_Lg7PfX0TQEm2QMLLcoTMaw">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="As_Of_6_30_2021_Coki50uufUmBg7YC34rJmQ"
      decimals="-5"
      id="Narr_k423MrtfYkiPWtOs3ileNA"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">118700000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="As_Of_2_28_2022_K5iAOzWiVE2Y5lP5jccqMA"
      decimals="INF"
      id="Narr_PSMZBzKflkSRoFkDoaU2gQ"
      unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw">11883368</dei:EntityCommonStockSharesOutstanding>
    <dei:AuditorFirmId
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      id="Narr_khR2Q8QbbkC3ha7aKb570g">1460</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      id="Narr_-HlgC2-uiUuI7TnwBFrvcg">Ernst&#160;&amp; Young AG</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      id="Narr_LYpPmSkq-0q-QzTcVGYWXA">Lugano, Switzerland</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A"
      decimals="0"
      id="Tc_0ZpdnUtAHU6Yx8YoYYLu9Q_5_4"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">36880673</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg"
      decimals="0"
      id="Tc_U55MsEOjq0e5vvJ-2jQVsw_5_7"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">7492910</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashCurrent
      contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg"
      decimals="0"
      id="Tc_PGMmYhXwZkWnEVxI0P2MFA_6_7"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">11371</us-gaap:RestrictedCashCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg"
      decimals="0"
      id="Tc_p_acjEZKmUKCDB5yHcyr_w_7_7"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">8548</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:DeferredIncomeTaxesAndOtherTaxReceivableCurrent
      contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A"
      decimals="0"
      id="Tc_LxVpuMOvYU6pFQhJ7_GUSQ_8_4"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">113586</us-gaap:DeferredIncomeTaxesAndOtherTaxReceivableCurrent>
    <us-gaap:DeferredIncomeTaxesAndOtherTaxReceivableCurrent
      contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg"
      decimals="0"
      id="Tc_G1kHuNsc8k2vN3sJO-1FGA_8_7"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">58017</us-gaap:DeferredIncomeTaxesAndOtherTaxReceivableCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A"
      decimals="0"
      id="Tc_q_0k0mgIYEq6rutJOHZhXQ_9_4"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">727785</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg"
      decimals="0"
      id="Tc_fJmI8cve_E-yboCjAD6usw_9_7"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">198994</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:DeferredOfferingCosts
      contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg"
      decimals="0"
      id="Tc_fcEyWW6EG0-LV8-z-ARTuw_10_7"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">1217988</us-gaap:DeferredOfferingCosts>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A"
      decimals="0"
      id="Tc_wfVXxW9qs0eFXwpemM7Haw_11_4"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">37722044</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg"
      decimals="0"
      id="Tc_w6P0YdonUEmmXYZJBEALeA_11_7"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">8987828</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A"
      decimals="0"
      id="Tc_rCkpqKtp_ku9n_SOSArrRg_14_4"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">105986</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg"
      decimals="0"
      id="Tc_o-moV5VtFUGQre6_77x7cQ_14_7"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">29633</us-gaap:PropertyPlantAndEquipmentNet>
    <ganx:CapitalizedComputerSoftwareForInternalUse
      contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A"
      decimals="0"
      id="Tc_1PFb6HXj-0arqqxzuAP5kA_15_4"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">202609</ganx:CapitalizedComputerSoftwareForInternalUse>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A"
      decimals="0"
      id="Tc_RLOlgQU6Nk6AgICXYvxEZQ_16_4"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">901042</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg"
      decimals="0"
      id="Tc_V9MroYBTk0mMgn_xSKXL5A_16_7"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">523080</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A"
      decimals="0"
      id="Tc_zWRrk1MftEmVB-QHdAUn2g_17_4"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">31279</us-gaap:RestrictedCashNoncurrent>
    <ganx:DepositsAndOtherAssetsNoncurrent
      contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A"
      decimals="0"
      id="Tc_uS_B0T_9B0mCa9bE5BjQgw_18_4"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">22111</ganx:DepositsAndOtherAssetsNoncurrent>
    <ganx:DepositsAndOtherAssetsNoncurrent
      contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg"
      decimals="0"
      id="Tc_5ltKBhhR9ES585maTS-n0g_18_7"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">63817</ganx:DepositsAndOtherAssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A"
      decimals="0"
      id="Tc_T6Qey3V5ckau--oSrR5OOA_19_4"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">1263027</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg"
      decimals="0"
      id="Tc_70s2R3WkzEez5gMgrf7ADw_19_7"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">616530</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A"
      decimals="0"
      id="Tc_CYnQV2wdM0O3d3WS6SHa9A_20_4"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">38985071</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg"
      decimals="0"
      id="Tc_xpA2jkDuNUquUShvxOMYMQ_20_7"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">9604358</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A"
      decimals="0"
      id="Tc_0QIBAkzZ70ql3NDwYqAeSQ_24_4"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">560479</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg"
      decimals="0"
      id="Tc_yyWQ57P3202jixz0O1dm8w_24_7"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">961516</us-gaap:AccountsPayableCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A"
      decimals="0"
      id="Tc__fWP1Gvtvkq8NGS9NPqtfQ_25_4"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">219137</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg"
      decimals="0"
      id="Tc_vtqlyE_EC0GjjnjgzoaEuw_25_7"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">122756</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A"
      decimals="0"
      id="Tc_It1ChEhPA0ynLNfhodbZ0A_26_4"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">1402600</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg"
      decimals="0"
      id="Tc_UFTWOZZM9EuT8RsHOLH9rQ_26_7"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">768450</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:DeferredIncomeCurrent
      contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A"
      decimals="0"
      id="Tc_x2fQ4-LuU0CF7TmW8Qc1MQ_27_4"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">266504</us-gaap:DeferredIncomeCurrent>
    <us-gaap:DeferredIncomeCurrent
      contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg"
      decimals="0"
      id="Tc_zvYjFBxKPEKhrQyLFwcA6Q_27_7"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">239483</us-gaap:DeferredIncomeCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A"
      decimals="0"
      id="Tc_COnvdCLqy0-OpNn4_5U2Ww_28_4"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">103826</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg"
      decimals="0"
      id="Tc_ILhkMc0fxk6kWp5BwBPh1w_28_7"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">22626</us-gaap:LongTermDebtCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A"
      decimals="0"
      id="Tc_JshuwXNNUUO9lfzV2X_ZgA_29_4"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">2552546</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg"
      decimals="0"
      id="Tc_-2IWhhfyjke6df4TjktvoQ_29_7"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">2114831</us-gaap:LiabilitiesCurrent>
    <us-gaap:DefinedBenefitPensionPlanLiabilitiesNoncurrent
      contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A"
      decimals="0"
      id="Tc_3YggIy9t8kG7OtQ8oMT-3A_32_4"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">329458</us-gaap:DefinedBenefitPensionPlanLiabilitiesNoncurrent>
    <us-gaap:DefinedBenefitPensionPlanLiabilitiesNoncurrent
      contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg"
      decimals="0"
      id="Tc_OTKTGM8VnEiwmJZhrRsyEg_32_7"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">171558</us-gaap:DefinedBenefitPensionPlanLiabilitiesNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A"
      decimals="0"
      id="Tc_fGCK_6_P8EmvQLsrhC4ejQ_33_4"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">695053</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg"
      decimals="0"
      id="Tc_-wrOMh92lkOoJMWmtMQKeQ_33_7"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">400324</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A"
      decimals="0"
      id="Tc_KE-8BLhgckGoSe4JyIS5KA_34_4"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">590468</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg"
      decimals="0"
      id="Tc_cXdXxhI4R0GgNyWMjZWqDg_34_7"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">715656</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A"
      decimals="0"
      id="Tc_8rOcDf0hTUWGICtFD75Dkw_35_4"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">1614979</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg"
      decimals="0"
      id="Tc_Ldoua_3lgkCoB1_TGVC7qA_35_7"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">1287538</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A"
      decimals="0"
      id="Tc_gS4zdO3a4UqT4Kj4xF68DA_36_4"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">4167525</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg"
      decimals="0"
      id="Tc_rsebeWqio0yq7MJNxS8juw_36_7"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">3402369</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_HPxGCJIoKkWKHRC95IDwMg"
      decimals="INF"
      id="Narr_ybnnqK1brEWVclFm4AOy9g"
      unitRef="Unit_Divide_USD_shares_ZUfWDOiJrESFdyfJo2gfWg">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_bnIOh52EIUC-yTsdpcG0NQ"
      decimals="INF"
      id="Narr_ZjLHbPOzgU2TuvA99_1kQg"
      unitRef="Unit_Divide_USD_shares_ZUfWDOiJrESFdyfJo2gfWg">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_bnIOh52EIUC-yTsdpcG0NQ"
      decimals="INF"
      id="Narr_lPtU-9NgF0y2MgXhwrDTZA"
      unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_HPxGCJIoKkWKHRC95IDwMg"
      decimals="INF"
      id="Narr_AVK1YEvuTkKLiqCNUunqDg"
      unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw">1185879</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_HPxGCJIoKkWKHRC95IDwMg"
      decimals="0"
      id="Tc_9X_gmCrPgEK6Rxdfs8pIMA_39_7"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">118</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_SZL-8g69ikyvM5ITtvQ_vA"
      decimals="INF"
      id="Narr_XkRDHsX_mUakxnW3NKq3Cg"
      unitRef="Unit_Divide_USD_shares_ZUfWDOiJrESFdyfJo2gfWg">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_UOpY8hOKmEaY4smAqVjcoQ"
      decimals="INF"
      id="Narr_CEdZ62UQo0Cg1t_Ngs6N7Q"
      unitRef="Unit_Divide_USD_shares_ZUfWDOiJrESFdyfJo2gfWg">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_SZL-8g69ikyvM5ITtvQ_vA"
      decimals="INF"
      id="Narr_scHeo2x8Ik-T7BDkCZteKg"
      unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw">2965600</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_SZL-8g69ikyvM5ITtvQ_vA"
      decimals="0"
      id="Tc_bjMtcUAgHUaW4dY6kvw-fQ_40_7"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">297</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg"
      decimals="INF"
      id="Narr_JeZL91AMv0CzjDVNiYKF8Q"
      unitRef="Unit_Divide_USD_shares_ZUfWDOiJrESFdyfJo2gfWg">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A"
      decimals="INF"
      id="Narr_c6wPD9h4bEWNdXHRkA3uEg"
      unitRef="Unit_Divide_USD_shares_ZUfWDOiJrESFdyfJo2gfWg">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A"
      decimals="INF"
      id="Narr_IQE_sWkoYESdq3bPtIYXcQ"
      unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw">50000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A"
      decimals="INF"
      id="Narr_Mza9zWRfgUWJtNDk5kvkdw"
      unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw">11883368</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg"
      decimals="INF"
      id="Narr_mMnf3ouxb0C8z99wYEKMgA"
      unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw">3543163</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A"
      decimals="0"
      id="Tc_p5uyzQ903UerwwYPn0Xayg_41_4"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">1189</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg"
      decimals="0"
      id="Tc_YI8qmcq7WE2Hf7H03Xs-Pg_41_7"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">354</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A"
      decimals="0"
      id="Tc_ReNv9ZSYAUOFUlUNxSDnow_42_4"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">55832461</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg"
      decimals="0"
      id="Tc_rXV4AwiBgkKqxELVuElzPQ_42_7"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">13388771</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A"
      decimals="0"
      id="Tc_djOg5uyrv02FHVDdKGNDtQ_43_4"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">-90645</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg"
      decimals="0"
      id="Tc_GlYC18d-t0-LllLY4grH9w_43_7"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">-152698</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A"
      decimals="0"
      id="Tc_kQeOII8YW0SXQxdxgeIU9w_44_4"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">-7034853</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg"
      decimals="0"
      id="Tc_A40umysvzkOh6SQQw1K_Eg_44_7"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">-3457171</us-gaap:RetainedEarningsAccumulatedDeficit>
    <ganx:IncomeLossForPeriod
      contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A"
      decimals="0"
      id="Tc_JUFzgIhjkki2Xk-49aSw6A_45_4"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">-13890606</ganx:IncomeLossForPeriod>
    <ganx:IncomeLossForPeriod
      contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg"
      decimals="0"
      id="Tc_0zmXFVF7kUqeleu733dB8w_45_7"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">-3577682</ganx:IncomeLossForPeriod>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A"
      decimals="0"
      id="Tc_VimogO93a0m4nEO2Q_b9PQ_46_4"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">34817546</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg"
      decimals="0"
      id="Tc_LGUMcFDECUmDaz7gLNAXlQ_46_7"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">6201989</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A"
      decimals="0"
      id="Tc_OzS67-4zKUOXaKrjB_i8cw_47_4"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">38985071</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg"
      decimals="0"
      id="Tc_h4eqZpcuqkWtY1TdQ1yjAQ_47_7"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">9604358</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      decimals="0"
      id="Tc_nLaHioOwc0i4m8ZMCJCUIA_4_3"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">133928</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:SubleaseIncome
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      decimals="0"
      id="Tc_vCYIFLEXPUm6Jpjq3KWt5w_5_3"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">31066</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome
      contextRef="Duration_1_1_2020_To_12_31_2020_JDEb6LtAmEuXGmEieWNlsw"
      decimals="0"
      id="Tc_sK232JOYYUq8Lhv9fnLEsQ_5_6"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">28881</us-gaap:SubleaseIncome>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      decimals="0"
      id="Tc_pPTRKNjV5UCrVxK259lbEw_6_3"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">164994</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2020_To_12_31_2020_JDEb6LtAmEuXGmEieWNlsw"
      decimals="0"
      id="Tc_ujo0zWSkl0GsguBhaHx8NQ_6_6"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">28881</us-gaap:Revenues>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      decimals="0"
      id="Tc_eMaklUKgFUebs-r_ezvPCg_9_3"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">7164229</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_JDEb6LtAmEuXGmEieWNlsw"
      decimals="0"
      id="Tc_9biAt7P_tEGAXqy7286FtQ_9_6"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">2259204</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      decimals="0"
      id="Tc_IfjGHYKySUKlndYvq1QmaA_10_3"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">6826938</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_JDEb6LtAmEuXGmEieWNlsw"
      decimals="0"
      id="Tc_JheuQjeci06Yy_3Yo1Y00w_10_6"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">1249126</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      decimals="0"
      id="Tc_ACW0usyWF06ioYprD0j-nw_11_3"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">13991167</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2020_To_12_31_2020_JDEb6LtAmEuXGmEieWNlsw"
      decimals="0"
      id="Tc__nxkCRWMDECbkmVW8avqNQ_11_6"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">3508330</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      decimals="0"
      id="Tc_x7J573cYFEaMIxFjlGwA7A_13_3"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">-13826173</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_JDEb6LtAmEuXGmEieWNlsw"
      decimals="0"
      id="Tc_JXPjXFNN5Uy_hFtIA9cmQA_13_6"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">-3479449</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      decimals="0"
      id="Tc_hM6Qi3VriUm85aUtqjSqcw_16_3"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">12495</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="Duration_1_1_2020_To_12_31_2020_JDEb6LtAmEuXGmEieWNlsw"
      decimals="0"
      id="Tc_AuHVkT4h6kW58r0jCly6yQ_16_6"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">3637</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      decimals="0"
      id="Tc_suWnCTV-9UCs2FktaN_vFg_17_3"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">-72920</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="Duration_1_1_2020_To_12_31_2020_JDEb6LtAmEuXGmEieWNlsw"
      decimals="0"
      id="Tc_dLx2bInU2EyOVFqBUpkNzQ_17_6"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">-96484</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      decimals="0"
      id="Tc_1j5jkTzRj0GTGhiKqg0eGw_18_3"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">-13886598</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2020_To_12_31_2020_JDEb6LtAmEuXGmEieWNlsw"
      decimals="0"
      id="Tc_MMrMUjjJMEaPLb4L80AomQ_18_6"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">-3572296</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      decimals="0"
      id="Tc_VXca31RAd0agltwyf_CTMg_20_3"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">4008</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2020_To_12_31_2020_JDEb6LtAmEuXGmEieWNlsw"
      decimals="0"
      id="Tc_qe4lCIQlRkuZ4EzbYrzbeg_20_6"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">5386</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      decimals="0"
      id="Tc_cn8Hnd4fYUK2L3QQ_sQF3g_22_3"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">-13890606</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_JDEb6LtAmEuXGmEieWNlsw"
      decimals="0"
      id="Tc_w-YrAdolu0uwtO22EWIL6A_22_6"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">-3577682</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      decimals="2"
      id="Tc_FZ649mFMQkuQBIVJqfLTPw_25_3"
      unitRef="Unit_Divide_USD_shares_ZUfWDOiJrESFdyfJo2gfWg">-1.37</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2020_To_12_31_2020_JDEb6LtAmEuXGmEieWNlsw"
      decimals="2"
      id="Tc_Q2B29faHWE6EjPrt3FNtsA_25_6"
      unitRef="Unit_Divide_USD_shares_ZUfWDOiJrESFdyfJo2gfWg">-1.33</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      decimals="0"
      id="Tc_LCuuCg5tBECzelefnHAD6g_26_3"
      unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw">10165404</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2020_To_12_31_2020_JDEb6LtAmEuXGmEieWNlsw"
      decimals="0"
      id="Tc_VDqfrSVnU0Gdq2D4Xg4eQA_26_6"
      unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw">2681408</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      decimals="0"
      id="Tc_LS8pRaSAGUOX6YNvHZM_og_3_3"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">-13890606</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_JDEb6LtAmEuXGmEieWNlsw"
      decimals="0"
      id="Tc_8kxYRZoafUWU0q8LswpxDg_3_6"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">-3577682</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      decimals="0"
      id="Tc_NliVZsXmhEKT60yuGflgbw_4_3"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">101780</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="Duration_1_1_2020_To_12_31_2020_JDEb6LtAmEuXGmEieWNlsw"
      decimals="0"
      id="Tc_lymsqJ7oDkSfhfbm2JR7HQ_4_6"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">36218</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      decimals="0"
      id="Tc_DCnndCR-qUS4ICgWcYF13A_5_3"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">163833</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Duration_1_1_2020_To_12_31_2020_JDEb6LtAmEuXGmEieWNlsw"
      decimals="0"
      id="Tc_aH7jZOZxi0SIARMADVkFzA_5_6"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">-35317</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      decimals="0"
      id="Tc_t2fe6X_hyk6tvXubjkl8mg_6_3"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">62053</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="Duration_1_1_2020_To_12_31_2020_JDEb6LtAmEuXGmEieWNlsw"
      decimals="0"
      id="Tc_rjdxBC_SGkeYd-DccU-EGw_6_6"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">-71535</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      decimals="0"
      id="Tc_gd5Q1xGqL0KWotaKW-OsZg_7_3"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">-13828553</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Duration_1_1_2020_To_12_31_2020_JDEb6LtAmEuXGmEieWNlsw"
      decimals="0"
      id="Tc_fzAXjGgKak-rA7uwY21CPA_7_6"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">-3649217</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_pyBaEfYw3k-Bre7rOUHY8A"
      decimals="INF"
      id="Tc_8FqsKSrFi0yNgOv97y_RlQ_3_2"
      unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw">1185879</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_pyBaEfYw3k-Bre7rOUHY8A"
      decimals="0"
      id="Tc_yQ5Ch4Ui_0eMpTawXRGQfw_3_4"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">118</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredClassBMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_HKF8S1_Sj0ytyt6XZS1DhQ"
      decimals="INF"
      id="Tc_R3wXhbucDUqSMxNpDIqZhA_3_6"
      unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw">2965600</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredClassBMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_HKF8S1_Sj0ytyt6XZS1DhQ"
      decimals="0"
      id="Tc_tncERw5o0k-RFvEZv3yz-A_3_8"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">297</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_9f9qYFGKFEi5lUCxbnfGyA"
      decimals="INF"
      id="Tc_k2Yt4somwUOcgKLqpW9f5w_3_10"
      unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw">3543163</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_9f9qYFGKFEi5lUCxbnfGyA"
      decimals="0"
      id="Tc_HhomVpvA-EGdyCZIlgWmiA_3_12"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">354</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_AmnlCLXS4EW0T11vxuv4dA"
      decimals="0"
      id="Tc_hx7YlZEXh0-PnJbTnivt5g_3_14"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">13388771</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_gy5vyeo0XECt7V84YflbPw"
      decimals="0"
      id="Tc_X5KVTOnhUEmqz0RFM41wQQ_3_16"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">-152698</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_wUcCiJ_aL0uNAaoLQz_kIQ"
      decimals="0"
      id="Tc_9q94PFE9j028yrfS1fIE1Q_3_18"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">-7034853</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg"
      decimals="0"
      id="Tc_c3jw-7El-Uy--vNd9_F6zQ_3_20"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">6201989</us-gaap:StockholdersEquity>
    <ganx:ConversionOfSeriesPreferredStockIntoCommonStockInShares
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_i98h5sWV5U-TOn1S0EBWxQ"
      decimals="INF"
      id="Tc_dliGMymBsUSfqCR74FH_xA_4_2"
      unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw">-1185879</ganx:ConversionOfSeriesPreferredStockIntoCommonStockInShares>
    <ganx:ConversionOfSeriesPreferredStockIntoCommonStock
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_i98h5sWV5U-TOn1S0EBWxQ"
      decimals="0"
      id="Tc_ldos-bzJhUOZVPu8_7WYCw_4_4"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">-118</ganx:ConversionOfSeriesPreferredStockIntoCommonStock>
    <ganx:ConversionOfSeriesPreferredStockIntoCommonStockInShares
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_RRjkaPqvD06cYjwCnpc1bQ"
      decimals="INF"
      id="Tc_iALT9dyS20GOT4ic7FDByA_4_10"
      unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw">1185879</ganx:ConversionOfSeriesPreferredStockIntoCommonStockInShares>
    <ganx:ConversionOfSeriesPreferredStockIntoCommonStock
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_RRjkaPqvD06cYjwCnpc1bQ"
      decimals="0"
      id="Tc_BxgLCSAT9ku7GbDlx07Bmw_4_12"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">118</ganx:ConversionOfSeriesPreferredStockIntoCommonStock>
    <ganx:ConversionOfSeriesBPreferredStockIntoCommonStockInShares
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredClassBMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_W4zZ56C1Q0yKk0LZMBsvMA"
      decimals="INF"
      id="Tc_V_vfmBHxXk2mGb_IE1msbw_5_6"
      unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw">-2965600</ganx:ConversionOfSeriesBPreferredStockIntoCommonStockInShares>
    <ganx:ConversionOfSeriesBPreferredStockIntoCommonStock
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredClassBMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_W4zZ56C1Q0yKk0LZMBsvMA"
      decimals="0"
      id="Tc_ptZb2UeL30i15UP3dQ__Dw_5_8"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">-297</ganx:ConversionOfSeriesBPreferredStockIntoCommonStock>
    <ganx:ConversionOfSeriesBPreferredStockIntoCommonStockInShares
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_RRjkaPqvD06cYjwCnpc1bQ"
      decimals="INF"
      id="Tc_1J5hfA1C90aTP0D3EpKmXQ_5_10"
      unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw">2965600</ganx:ConversionOfSeriesBPreferredStockIntoCommonStockInShares>
    <ganx:ConversionOfSeriesBPreferredStockIntoCommonStock
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_RRjkaPqvD06cYjwCnpc1bQ"
      decimals="0"
      id="Tc_LBSaquukyEmoT0RAjrFRcg_5_12"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">297</ganx:ConversionOfSeriesBPreferredStockIntoCommonStock>
    <ganx:IssuanceOfCommonStockInIpoInShares
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_RRjkaPqvD06cYjwCnpc1bQ"
      decimals="INF"
      id="Tc_wlLHr7LW-USpnbKVEn4yBA_6_10"
      unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw">4181818</ganx:IssuanceOfCommonStockInIpoInShares>
    <ganx:IssuanceOfCommonStockInIpoNetOfIssuanceCosts
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_RRjkaPqvD06cYjwCnpc1bQ"
      decimals="0"
      id="Tc_qqV8o-yePkmzdui079tvjw_6_12"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">419</ganx:IssuanceOfCommonStockInIpoNetOfIssuanceCosts>
    <ganx:IssuanceOfCommonStockInIpoNetOfIssuanceCosts
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ubdNM3dDp0mLTH7OlcI_NA"
      decimals="0"
      id="Tc_FTE1u3vM6kGZstVXF6vSdw_6_14"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">40558103</ganx:IssuanceOfCommonStockInIpoNetOfIssuanceCosts>
    <ganx:IssuanceOfCommonStockInIpoNetOfIssuanceCosts
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      decimals="0"
      id="Tc_-ORAx0npTEGnEcIEDHrQkA_6_20"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">40558522</ganx:IssuanceOfCommonStockInIpoNetOfIssuanceCosts>
    <ganx:IssuanceOfCommonStockThroughCashlessExerciseOfWarrants
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_RRjkaPqvD06cYjwCnpc1bQ"
      decimals="INF"
      id="Tc_njFxm1vGwkyGEdGmgq5G6A_7_10"
      unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw">3283</ganx:IssuanceOfCommonStockThroughCashlessExerciseOfWarrants>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_RRjkaPqvD06cYjwCnpc1bQ"
      decimals="INF"
      id="Tc_rREIJxiCEUGec_MJTKHurA_8_10"
      unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw">3625</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_RRjkaPqvD06cYjwCnpc1bQ"
      decimals="0"
      id="Tc_jACajxFjLUuFrrvNgcsDyw_8_12"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">1</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ubdNM3dDp0mLTH7OlcI_NA"
      decimals="0"
      id="Tc_3ig-oISOjkKZ7XIG857hEg_8_14"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">12216</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      decimals="0"
      id="Tc_m8h17-RQt0W5aTooWiQANw_8_20"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">12217</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ubdNM3dDp0mLTH7OlcI_NA"
      decimals="0"
      id="Tc_G6MKpJv2eUKjDllXwWaE0A_9_14"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">839371</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      decimals="0"
      id="Tc_KU331pXmQkSsewFPRWTiJQ_9_20"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">839371</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ubdNM3dDp0mLTH7OlcI_NA"
      decimals="0"
      id="Tc_DxQ7mGq2bEqiVaGfLUzRxA_10_14"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">1034000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      decimals="0"
      id="Tc_ZU-52nFA9kG6AkofmqqbDw_10_20"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">1034000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_lVp5EHBSO0a3sKcZW9whJg"
      decimals="0"
      id="Tc_FKD6ljmAbkSNVXDwxGfzVA_11_16"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">101780</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      decimals="0"
      id="Tc_B_H6d2zjN0GEMYPk7aE0mA_11_20"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">101780</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_lVp5EHBSO0a3sKcZW9whJg"
      decimals="0"
      id="Tc_hRMihA0VckObE8wnpYc-ug_12_16"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">163833</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      decimals="0"
      id="Tc_jM0kBl_KAE69vRqnSyX8-Q_12_20"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">163833</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_BvTE8F6mxk6Kxv6RzTF0bw"
      decimals="0"
      id="Tc_52gJALzJVkKz7Dk-dYra1A_13_18"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">-13890606</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      decimals="0"
      id="Tc_ERY_v9OSf0-FLxuEQoYLaw_13_20"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">-13890606</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_SekcF5i21U2sPnRupyd-qQ"
      decimals="INF"
      id="Tc_dH4f6pJLX0uROKNuJ2La9w_14_10"
      unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw">11883368</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_SekcF5i21U2sPnRupyd-qQ"
      decimals="0"
      id="Tc_9lugp4Hmd0WrKQv8uGB8Cg_14_12"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">1189</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_BSZ8PS8MmUKSjqHr7IV3kw"
      decimals="0"
      id="Tc_dtFuy8a5q0SoMBADWatZRw_14_14"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">55832461</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_aTBx7lbU9EmXTzCop7s5VQ"
      decimals="0"
      id="Tc_HXzFkkCuV0iSQhPFpqZxDg_14_16"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">-90645</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_n0BVNh7nXEOEg7ig4OTueQ"
      decimals="0"
      id="Tc_dV39iBjfSUC9oWiZbaRW_g_14_18"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">-20925459</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A"
      decimals="0"
      id="Tc_YBSsQ5_0a0eDSTFOauX25w_14_20"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">34817546</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_UWKqqxKGa0GJPrjjqykVHA"
      decimals="INF"
      id="Tc_JjUqUktaUEGO_u9qqI4PPQ_3_2"
      unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw">875006</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_UWKqqxKGa0GJPrjjqykVHA"
      decimals="0"
      id="Tc_NfM_SVF6pEKqiH9spRFg8Q_3_4"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">87</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_7i8WecRBqEmSQhLalEWwQQ"
      decimals="INF"
      id="Tc_8z9diGjF6UmVFIv4rcNmfg_3_10"
      unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw">1981765</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_7i8WecRBqEmSQhLalEWwQQ"
      decimals="0"
      id="Tc_bEtwYsncI0-cB3f4A01ioQ_3_12"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">198</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_5pVNHNLDU0aNGDOeH5tWLQ"
      decimals="0"
      id="Tc_hMrDCKv94E6-rcv4Xun1Tg_3_14"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">3088193</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_gMslWnX56U6NnNQwJeyNJQ"
      decimals="0"
      id="Tc_ejUMfeNbRE6-qNczPdZ2-Q_3_16"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">-81163</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_triyROczKkOUjFoGUVGRSg"
      decimals="0"
      id="Tc_pvjDd_fHnUCm8Oixq8skvw_3_18"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">-3457171</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_jVvLJZrhl0W1Aw8CczgC5A"
      decimals="0"
      id="Tc_sCx4C0CY7kCchGhlV_Hjqg_3_20"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">-449856</us-gaap:StockholdersEquity>
    <ganx:IssuanceOfSeriesPreferredStockInShares
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_xAFkHxT11EGU0yxL99Adfg"
      decimals="INF"
      id="Tc_Ve08TRNp80ejF3xD9G9rIA_4_2"
      unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw">310873</ganx:IssuanceOfSeriesPreferredStockInShares>
    <ganx:IssuanceOfSeriesPreferredStockNetOfIssuanceCost
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_xAFkHxT11EGU0yxL99Adfg"
      decimals="0"
      id="Tc_nmIQ86Y7b0Su3PdAJO19_w_4_4"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">31</ganx:IssuanceOfSeriesPreferredStockNetOfIssuanceCost>
    <ganx:IssuanceOfSeriesPreferredStockNetOfIssuanceCost
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_1HYzj4oHZUevOEIRtTmDzw"
      decimals="0"
      id="Tc_Rb_NN4C1YkmFD_tr-zXAJA_4_14"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">1091314</ganx:IssuanceOfSeriesPreferredStockNetOfIssuanceCost>
    <ganx:IssuanceOfSeriesPreferredStockNetOfIssuanceCost
      contextRef="Duration_1_1_2020_To_12_31_2020_JDEb6LtAmEuXGmEieWNlsw"
      decimals="0"
      id="Tc_Jw28ZVlqAkC99iGdkMj7Uw_4_20"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">1091345</ganx:IssuanceOfSeriesPreferredStockNetOfIssuanceCost>
    <ganx:IssuanceOfSeriesBPreferredStockInShares
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredClassBMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember__qh10NtWoEa7l7GjkQhs9A"
      decimals="INF"
      id="Tc_CHb29esOe0KzGskcDAeKhA_5_6"
      unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw">2965600</ganx:IssuanceOfSeriesBPreferredStockInShares>
    <ganx:IssuanceOfSeriesBPreferredStockNetOfIssuanceCost
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredClassBMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember__qh10NtWoEa7l7GjkQhs9A"
      decimals="0"
      id="Tc_YJqvZIlvC0mfkqm3l2_8Kg_5_8"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">297</ganx:IssuanceOfSeriesBPreferredStockNetOfIssuanceCost>
    <ganx:IssuanceOfSeriesBPreferredStockNetOfIssuanceCost
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_1HYzj4oHZUevOEIRtTmDzw"
      decimals="0"
      id="Tc_EoKtrVpIZEiULSfTM2Medg_5_14"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">8713716</ganx:IssuanceOfSeriesBPreferredStockNetOfIssuanceCost>
    <ganx:IssuanceOfSeriesBPreferredStockNetOfIssuanceCost
      contextRef="Duration_1_1_2020_To_12_31_2020_JDEb6LtAmEuXGmEieWNlsw"
      decimals="0"
      id="Tc_IFy2ttos1kSuX_lab-e5uA_5_20"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">8714013</ganx:IssuanceOfSeriesBPreferredStockNetOfIssuanceCost>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_uZL4jiBANU-5t9wJ3fQwpA"
      decimals="INF"
      id="Tc_SQl7kc4IF0CVqu3ZVpIu_Q_6_10"
      unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw">1561398</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_uZL4jiBANU-5t9wJ3fQwpA"
      decimals="0"
      id="Tc_PHzTYT0d0EGjV9DgmhF6BQ_6_12"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">156</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_1HYzj4oHZUevOEIRtTmDzw"
      decimals="0"
      id="Tc_P-07XOdeLkuI7HTbpj0Wtg_6_14"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">21</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2020_To_12_31_2020_JDEb6LtAmEuXGmEieWNlsw"
      decimals="0"
      id="Tc_DRwJd0nax0Ky008RU6QY_A_6_20"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">177</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_1HYzj4oHZUevOEIRtTmDzw"
      decimals="0"
      id="Tc_QdnMn1cwxEWJcWcNpfmMhA_7_14"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">413887</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="Duration_1_1_2020_To_12_31_2020_JDEb6LtAmEuXGmEieWNlsw"
      decimals="0"
      id="Tc_Mfx41tphj0K2-EDYvCxIaA_7_20"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">413887</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_1HYzj4oHZUevOEIRtTmDzw"
      decimals="0"
      id="Tc_4Xmr6I44PE-jzZCYqXb6Iw_8_14"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">81640</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2020_To_12_31_2020_JDEb6LtAmEuXGmEieWNlsw"
      decimals="0"
      id="Tc_A1mxN9WHsUqhO8uiLISoCA_8_20"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">81640</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_5l4ULFPqR0yL1UAG81fHvA"
      decimals="0"
      id="Tc_vQEMp08ApkGnfQG7k3YFqA_9_16"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">36218</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="Duration_1_1_2020_To_12_31_2020_JDEb6LtAmEuXGmEieWNlsw"
      decimals="0"
      id="Tc_PHgzQa9sDEONLXmApe6n0w_9_20"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">36218</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_5l4ULFPqR0yL1UAG81fHvA"
      decimals="0"
      id="Tc_WdNAIJ-o50yB_eZSYRD2SQ_10_16"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">-35317</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Duration_1_1_2020_To_12_31_2020_JDEb6LtAmEuXGmEieWNlsw"
      decimals="0"
      id="Tc_S6JVRAiX3ESTNW6wHEBhNA_10_20"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">-35317</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_AYWDjeIOSU-RxGjTZOS7Tw"
      decimals="0"
      id="Tc__wvsLmzen0SfLec4KPheaw_11_18"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">-3577682</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_JDEb6LtAmEuXGmEieWNlsw"
      decimals="0"
      id="Tc_xEwcbzHOTEO6tpjHPfDEQw_11_20"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">-3577682</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_pyBaEfYw3k-Bre7rOUHY8A"
      decimals="INF"
      id="Tc_S8omJMXcR0qmfMUAzfTFQQ_12_2"
      unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw">1185879</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_pyBaEfYw3k-Bre7rOUHY8A"
      decimals="0"
      id="Tc_D4y4fGnH40-wYeNCjHcpkg_12_4"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">118</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredClassBMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_HKF8S1_Sj0ytyt6XZS1DhQ"
      decimals="INF"
      id="Tc_NmlTlKxDUEyfnlKHOuTQ0A_12_6"
      unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw">2965600</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredClassBMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_HKF8S1_Sj0ytyt6XZS1DhQ"
      decimals="0"
      id="Tc_k3hoDoWD4Ei9PDnNRcx9_w_12_8"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">297</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_9f9qYFGKFEi5lUCxbnfGyA"
      decimals="INF"
      id="Tc_gpIv6BLvu067Et8Dds675Q_12_10"
      unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw">3543163</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_9f9qYFGKFEi5lUCxbnfGyA"
      decimals="0"
      id="Tc_roxIYG14yU63XbjIuDbldA_12_12"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">354</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_AmnlCLXS4EW0T11vxuv4dA"
      decimals="0"
      id="Tc_ntmZJBNe9UaksgjX0DXlfQ_12_14"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">13388771</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_gy5vyeo0XECt7V84YflbPw"
      decimals="0"
      id="Tc_OGKZSmvWS0K7UjdRt6tnhA_12_16"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">-152698</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_wUcCiJ_aL0uNAaoLQz_kIQ"
      decimals="0"
      id="Tc_WZJolZ0JIUest4H32rjwsw_12_18"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">-7034853</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg"
      decimals="0"
      id="Tc_VT-ovVQ3m0aLMIXAPVrI5w_12_20"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">6201989</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      decimals="0"
      id="Tc_6SwF3o6Tl0-4jGfJmQX5AA_5_3"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">-13890606</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_JDEb6LtAmEuXGmEieWNlsw"
      decimals="0"
      id="Tc_pq_0OEfdrEOT4GPW0gVRbg_5_6"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">-3577682</us-gaap:ProfitLoss>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      decimals="0"
      id="Tc_BqkiCG7KnEGsmlqsosp2xA_8_3"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">15484</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2020_To_12_31_2020_JDEb6LtAmEuXGmEieWNlsw"
      decimals="0"
      id="Tc_D068D4Ed2E2_g5IUHLmLow_8_6"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">9592</us-gaap:Depreciation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      decimals="0"
      id="Tc_jxec6FMEmUie_42mUzoAmw_9_3"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">839371</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2020_To_12_31_2020_JDEb6LtAmEuXGmEieWNlsw"
      decimals="0"
      id="Tc_GEkXTZiRX0WvfqxQzHpUkQ_9_6"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">81640</us-gaap:ShareBasedCompensation>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      decimals="0"
      id="Tc_bp0A9KfHlkGgqaosL98Qow_10_3"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">1034000</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <ganx:CapitalizedComputerSoftwareAdjustment
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      decimals="0"
      id="Tc_ZIWY7Bvr9k2mSO4r_BV9fQ_11_3"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">34135</ganx:CapitalizedComputerSoftwareAdjustment>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      decimals="0"
      id="Tc_ou20pOwoWEmyBTDSzm3Wpw_13_3"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">-8264</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="Duration_1_1_2020_To_12_31_2020_JDEb6LtAmEuXGmEieWNlsw"
      decimals="0"
      id="Tc_AGZZdb1T8EyW-6MmUJH-Mw_13_6"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">196</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      decimals="0"
      id="Tc_zdVoCCfD5ESvtEb6fTsIFw_14_3"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">534502</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2020_To_12_31_2020_JDEb6LtAmEuXGmEieWNlsw"
      decimals="0"
      id="Tc_OvawNs37cEeq1D_OlNt28Q_14_6"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">117704</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <ganx:IncreaseDecreaseInValueAddedTaxCredits
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      decimals="0"
      id="Tc_Tv6F12Q7s0uFyL2dkGjBAw_15_3"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">71618</ganx:IncreaseDecreaseInValueAddedTaxCredits>
    <ganx:IncreaseDecreaseInValueAddedTaxCredits
      contextRef="Duration_1_1_2020_To_12_31_2020_JDEb6LtAmEuXGmEieWNlsw"
      decimals="0"
      id="Tc_ehV78JuIQES9-wcXVfAMYw_15_6"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">21454</ganx:IncreaseDecreaseInValueAddedTaxCredits>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      decimals="0"
      id="Tc_oucjFT9IcESBgMapgHWIqg_16_3"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">-33979</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="Duration_1_1_2020_To_12_31_2020_JDEb6LtAmEuXGmEieWNlsw"
      decimals="0"
      id="Tc_lJQtHY_TsE6qnBQDo40kEw_16_6"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">63095</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      decimals="0"
      id="Tc_ir4Igy41cEiQfj2rDqt_kA_17_3"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">-521394</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="Duration_1_1_2020_To_12_31_2020_JDEb6LtAmEuXGmEieWNlsw"
      decimals="0"
      id="Tc_FqCjzmxv4Ue5kNTZtVQGTQ_17_6"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">395543</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      decimals="0"
      id="Tc_BaFy9Iq23kCRx5m3-oWxbA_18_3"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">665460</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities
      contextRef="Duration_1_1_2020_To_12_31_2020_JDEb6LtAmEuXGmEieWNlsw"
      decimals="0"
      id="Tc_1kTyr7jcNUOn7qtjdd5Fcw_18_6"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">173725</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:PensionExpenseReversalOfExpenseNoncash
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      decimals="0"
      id="Tc_-dBDpSMxeEGmEJeCbqoEOw_19_3"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">55326</us-gaap:PensionExpenseReversalOfExpenseNoncash>
    <us-gaap:PensionExpenseReversalOfExpenseNoncash
      contextRef="Duration_1_1_2020_To_12_31_2020_JDEb6LtAmEuXGmEieWNlsw"
      decimals="0"
      id="Tc_KUhGpYaGRkCJSx-AJ3xvug_19_6"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">8709</us-gaap:PensionExpenseReversalOfExpenseNoncash>
    <us-gaap:IncreaseDecreaseInDeferredLiabilities
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      decimals="0"
      id="Tc_5Wr73B-az0KIv_Z6Z8FlIg_20_3"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">34701</us-gaap:IncreaseDecreaseInDeferredLiabilities>
    <us-gaap:IncreaseDecreaseInDeferredLiabilities
      contextRef="Duration_1_1_2020_To_12_31_2020_JDEb6LtAmEuXGmEieWNlsw"
      decimals="0"
      id="Tc_ESDcbdob6E2MAusM40n78A_20_6"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">-129315</us-gaap:IncreaseDecreaseInDeferredLiabilities>
    <ganx:IncreaseDecreaseInOperatingAssetsAndLiabilities
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      decimals="0"
      id="Tc_ddGvM8Wa7k6i8SzFQptZvw_21_3"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">329784</ganx:IncreaseDecreaseInOperatingAssetsAndLiabilities>
    <ganx:IncreaseDecreaseInOperatingAssetsAndLiabilities
      contextRef="Duration_1_1_2020_To_12_31_2020_JDEb6LtAmEuXGmEieWNlsw"
      decimals="0"
      id="Tc_XJS0CbIgbkSv5wtSYdrKvw_21_6"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">-246213</ganx:IncreaseDecreaseInOperatingAssetsAndLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      decimals="0"
      id="Tc_YCsE-3bse0GrAi9yDqqG1g_22_3"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">-12365670</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2020_To_12_31_2020_JDEb6LtAmEuXGmEieWNlsw"
      decimals="0"
      id="Tc_3V6pFJp31Eyl1UXpINaHfA_22_6"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">-3240237</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      decimals="0"
      id="Tc_6eWn5A1BsU6ou95CeR2Oug_25_3"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">94212</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2020_To_12_31_2020_JDEb6LtAmEuXGmEieWNlsw"
      decimals="0"
      id="Tc_x7vZ9rHdgkKnlmPa20CHfg_25_6"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">20826</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      decimals="0"
      id="Tc_LjAvwNU0pkOXZdHX5S5KUQ_26_3"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">-94212</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2020_To_12_31_2020_JDEb6LtAmEuXGmEieWNlsw"
      decimals="0"
      id="Tc_XE2-4-QfnEG0YnNM7VWyPg_26_6"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">-20826</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="Duration_1_1_2020_To_12_31_2020_JDEb6LtAmEuXGmEieWNlsw"
      decimals="0"
      id="Tc_KgbMTZUw9EmAtUX5UWwwsg_29_6"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">738282</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <ganx:ProceedsFromIssuanceOfSeriesA.PreferredStockNetOfIssuanceCosts
      contextRef="Duration_1_1_2020_To_12_31_2020_JDEb6LtAmEuXGmEieWNlsw"
      decimals="0"
      id="Tc_ufhMMeaqI0yEfa3d5nr2Gg_30_6"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">1091345</ganx:ProceedsFromIssuanceOfSeriesA.PreferredStockNetOfIssuanceCosts>
    <ganx:ProceedsFromIssuanceOfSeriesBPreferredStockNetOfIssuanceCosts
      contextRef="Duration_1_1_2020_To_12_31_2020_JDEb6LtAmEuXGmEieWNlsw"
      decimals="0"
      id="Tc_rMN5hExyuEiwYiChlxMxJg_31_6"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">9127902</ganx:ProceedsFromIssuanceOfSeriesBPreferredStockNetOfIssuanceCosts>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      decimals="0"
      id="Tc__wp1QORiWEamaXjLWjOV5Q_32_3"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">42629998</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="Duration_1_1_2020_To_12_31_2020_JDEb6LtAmEuXGmEieWNlsw"
      decimals="0"
      id="Tc__54r2Nba2ESgr7d3QvBeVA_32_6"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">177</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      decimals="0"
      id="Tc_kHRXKWFt-0e2P96-aa97lQ_33_3"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">853488</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="Duration_1_1_2020_To_12_31_2020_JDEb6LtAmEuXGmEieWNlsw"
      decimals="0"
      id="Tc_X7OCNIpp5kWOyjKaMG3s3g_33_6"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">470745</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:RepaymentsOfShortTermDebt
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      decimals="0"
      id="Tc__eNK2_WMy0CKRTySf8z4OQ_34_3"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">21951</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      decimals="0"
      id="Tc_fwKSG4-qMUqtbkglIaQ_VQ_35_3"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">12216</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      decimals="0"
      id="Tc_eHgCVNNHRk2ir3pCuDXNyw_36_3"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">41766775</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2020_To_12_31_2020_JDEb6LtAmEuXGmEieWNlsw"
      decimals="0"
      id="Tc_eTPYDNC19UqL_6LQ6spZ_g_36_6"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">10486961</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      decimals="0"
      id="Tc_6Jim5DHKVEOOAPzS3m_EfA_37_3"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">100778</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents
      contextRef="Duration_1_1_2020_To_12_31_2020_JDEb6LtAmEuXGmEieWNlsw"
      decimals="0"
      id="Tc_jJDAQSj8jkWnVSGjuEjkCg_37_6"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">-35317</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      decimals="0"
      id="Tc_Ci-rY-ToDkibkoxzGTXAfQ_38_3"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">29407671</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2020_To_12_31_2020_JDEb6LtAmEuXGmEieWNlsw"
      decimals="0"
      id="Tc_KnhCSfaP20qMEc-RzU_BxQ_38_6"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">7190581</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg"
      decimals="0"
      id="Tc_E4PpsUh_Yky-w3uL5fBy3A_39_3"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">7504281</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2019_jVvLJZrhl0W1Aw8CczgC5A"
      decimals="0"
      id="Tc_Ae_fwZaLDEKAE7yjCldiAA_39_6"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">313700</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A"
      decimals="0"
      id="Tc_yFmbLLTFL0me04tVf6_pdg_40_3"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">36911952</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg"
      decimals="0"
      id="Tc_QLarmY90w06HreMli-23og_40_6"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">7504281</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      id="Tb_2jGxi3CD40y15DwXRYi54Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;1.&#160;&#160;&#160;&#160;Nature of the business and basis of presentation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Operations and business&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Gain Therapeutics,&#160;Inc. (and together with its subsidiary, the &#x201c;Company&#x201d;), was incorporated under the laws of the state of Delaware (U.S.) on June&#160;26, 2020. On July&#160;20, 2020, the Company consummated a corporate reorganization, pursuant to which all of the issued and outstanding common and preferred stock of GT Gain Therapeutics SA, a Swiss company formed in 2017, were exchanged for common stock or preferred stock, as applicable, of Gain Therapeutics,&#160;Inc., reflecting a 10:1 stock split. The corporate reorganization was accounted for as a recapitalization for accounting purposes, with GT Gain Therapeutics SA resulting in the predecessor entity of the Company. As a result of the corporate reorganization, GT Gain Therapeutics SA became a wholly-owned subsidiary of Gain Therapeutics,&#160;Inc. For periods and at dates prior to the corporate reorganization, the consolidated financial statements presented were prepared based on the historical financial statements of GT Gain Therapeutics SA, adjusted to give retroactive effect to the share exchange transactions.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On March 17, 2021, the Company&#x2019;s registration statement on Form S-1 related to its Initial Public Offering (&#x201c;IPO&#x201d;) was declared effective by the Securities and Exchange Commission (&#x201c;SEC&#x201d;). The IPO closed on March 17, 2021 at the Nasdaq. In conjunction with the IPO the Company completed a reverse stock split of the Company&#x2019;s outstanding equity instruments. The reverse stock split was approved by the stockholders on March 4, 2021 and became effective on March 17, 2021. Upon closing of the IPO, the Series A and the Series B Preferred Stock, as resulting form the reverse stock split, were converted to common stock at a ratio of 1-for-1. &#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company is a biotechnology company developing novel therapies to treat diseases caused by protein misfolding, with an initial focus on rare genetic diseases and neurological disorders. We use our licensed platform, SEE-Tx&#xae;, to discover novel allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites, potentially restoring protein folding and treating disease. These small molecule binding sites, away from the protein&#x2019;s active areas, are called allosteric sites. Targeting the allosteric binding site instead of the active binding site provides superior regulation of misfolded enzymes implicated by disease, is non-competitive with the natural substrate, provides superior drug-like properties and ultimately enhances both safety and efficacy.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;Risks and uncertainties&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, risks associated with completion and success of preclinical studies and clinical testing, dependence on key personnel, protection of proprietary technology, compliance with applicable governmental regulations, development by competitors of new technological innovations, protection of proprietary technology and the ability to secure additional capital to fund operations. Drug candidates currently under development will require significant additional research and development efforts, including preclinical and clinical testing and prior to regulatory approval and commercialization. These efforts require significant amounts of additional capital, adequate personnel, and infrastructure and extensive compliance-reporting capabilities. Even if the Company&#x2019;s drug development efforts are successful, it is uncertain when, if ever, the Company will realize revenue from product sales.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;Going concern&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has incurred recurring losses and negative cash flows from operations since its inception and has primarily funded these losses through proceeds from capital contributions. The Company anticipates incurring additional losses until such time, if ever, that it can generate significant sales of its product candidates currently in development. Substantial additional capital will be needed by the Company to fund its operations and to develop its product candidates.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In March 2021, the Company closed its initial public offering, or IPO, in which the Company issued and sold 4,181,818 shares of its common stock, which included shares sold pursuant to an option granted to the underwriters to purchase additional shares, at a public offering price of $11.00 per share for net proceeds of $40.5 million after deducting underwriting discounts, commissions and other offering expenses.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s operations have consisted primarily of organizing the Company, securing financing, developing licensed technology, performing research and conducting preclinical studies. The Company faces risks associated with early-stage biotechnology companies whose product candidates are in development. Product candidates currently under development will require significant additional research and development efforts, including extensive preclinical and clinical testing, establishing manufacturing capacity and regulatory approval prior to commercialization. These efforts require significant amounts of additional capital for the Company to complete its research and development, achieve its research and development objectives, defend its intellectual property rights, and recruit and retain skilled personnel, and key members of management. Even if the Company&#x2019;s product development efforts are successful, it is uncertain when, if ever, the Company will realize revenue from product sales. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company plans to seek additional funding through public or private equity offerings, debt financings, other collaborations,strategic alliances and licensing arrangements. The Company may not be able to obtain financing on acceptable terms, or at all,and the Company may not be able to enter into strategic alliances or other arrangements on favorable terms, or at all. The terms of any financing may adversely affect the holdings or the rights of the Company&#x2019;s stockholders. If the Company is unable to obtain funding, the Company could be required to delay, reduce or eliminate research and development programs, product portfolio expansion or future commercialization efforts, which could adversely affect its business prospects. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In accordance with Accounting Standards Update, or &#x201c;ASU&#x201d;, No. 2014-15, Disclosure of Uncertainties about an Entity&#x2019;s Ability to Continue as a Going Concern, the Company has evaluated whether there are certain conditions and events, considered in the aggregate, that raise substantial doubt about the Company&#x2019;s ability to continue as a going concern within one year after the date that the financial statements are issued. As of the issuance date of these financial statements, the Company expects that its cash and cash equivalents will be sufficient to fund its forecasted operating expenses and capital expenditure requirements for at least the next twelve months from the issuance date of these financialstatements. Accordingly, the consolidated financial statements have been prepared assuming that the Company will continue as a going concern.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Basis of presentation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The consolidated financial statements reflect the accounts of the Gain Therapeutics, Inc., GT Gain Therapeutics SA and its wholly owned branch, Gain Therapeutics Sucursal en Espa&#xf1;a. All intercompany transactions and balances have been eliminated in the preparation of the consolidated financial statements. The consolidated financial statements as of December 31, 2021, represented by the Consolidated Balance Sheet, the Consolidated Statement of Operations, the Consolidated Statements of Changes in Shareholders&#x2019; Equity, the Consolidated Statement of Comprehensive Loss, the Consolidated Statements of Cash Flows and the accompanying Notes, have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;US GAAP&#x201d;). Any reference in these notes to applicable guidance is meant to refer to the authoritative United States generally accepted accounting principles as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;) and Accounting Standards Update (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;). &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The &#160;financial statements as of December 31, 2021 reflect, for all periods presented, the retroactive application of the reverse stock split that occurred on March 17, 2021. All amounts in the consolidated financial statements are expressed in United States Dollars (USD/$) and disclosed within these explanatory notes in United States Dollars (USD/$) or Swiss Franc (CHF), which are the functional currencies of the Company and its operating subsidiary, GT Gain Therapeutics SA, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The consolidated financial statements have been prepared on the same basis as the audited annual consolidated financial statements as of and for the year ended December 31, 2020, and, in the opinion of management, reflect all adjustments, consisting of normal recurring adjustments, necessary for the fair presentation of the Company&#x2019;s financial position as of December 31, 2021, and the results of its operations for the years ended December 31, 2021 and 2020, its statements of stockholders&#x2019; equity and its statements of cash flows for the years then ended. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;Reverse Stock Split &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;On March 3, 2021, the Board approved a 1-for-&lt;span style="-sec-ix-hidden:Hidden_PPLEqeAgy0iiPmdWllrCSA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;0.880784&lt;/span&gt;&lt;/span&gt; reverse stock split of the Company&#x2019;s outstanding equity instruments. The reverse stock split was approved by the stockholders on March 4, 2021 and became effective in conjunction with the IPO on March 17, 2021. Stockholders were no entitled to fractional shares as a result of the reverse stock split. All share and per share data shown in the accompanying consolidated financial statements and &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;related notes have been retroactively revised to reflect the reverse stock split. Shares of common stock underlying outstanding stock options and other equity instruments were proportionately reduced and the respective exercise prices, if applicable, were proportionately increased in accordance with the terms of the agreements governing such securities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;Initial Public Offering &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On March 17, 2021, the Company&#x2019;s registration statement on Form S-1 relating to its IPO was declared effective by the Securities and Exchange Commission (&#x201c;SEC&#x201d;). The IPO closed on March 17, 2021 and the Company issued and sold 3,636,364 common shares at a public offering price of $11.00 per share for net proceeds of $34,978 thousand after deducting underwriting discounts and commissions of $2,950 thousand and other offering expenses of $2,071 thousand. On March 22, 2021, the Company issued and sold 545,454 additional common shares, pursuant to the full exercise of the underwriters&#x2019; option to purchase additional shares, for net proceeds of $5,580 thousand after deducting underwriting discounts and commissions of $420 thousand. Thus, the aggregate net proceeds to the Company from the IPO, after deducting underwriting discounts commissions, were $42,630 thousand. After deducting other IPO offering expenses amounting to $2,071 thousand, the net cash proceeds resulting from the IPO were $40,558 thousand, which are reflected in the statement of stockholders&#x2019; equity as Issuance of Common Stock in IPO, net of issuance costs. Upon the closing of the IPO, series A convertible preferred stock (the &#x201c;Series A Preferred Stock&#x201d;) and series B convertible preferred stock (the &#x201c;Series B Preferred Stock&#x201d;, and together with the Series A Preferred Stock, are collectively referred to as the &#x201c;Preferred Stock&#x201d;) were converted into shares of common stock at ratio of 1-for-1.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Segment information&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;Operating segments are defined as components of an enterprise for which separate discrete information is available for evaluation by the chief operating decision-maker in deciding how to allocate resources and assess performance. The Company&#x2019;s chief operating decision-maker, the Chief Executive Officer, oversees the Company&#x2019;s operations and manages the business as a single operating segment, which is research and development in the pharmaceutical sector with a focus on developing novel therapeutics to treat diseases caused by protein misfolding, such as rare genetic diseases and neurological disorders. Geographically, the research and development activities are mainly performed in Switzerland and Spain. The Company does not consider these geographies to be separate segments.&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="Duration_7_20_2020_To_7_20_2020_CH_oHqEadU-bNi2WtP4JnA"
      decimals="INF"
      id="Narr_axeh2Ldxnk2XsyTvIStvyg"
      unitRef="Unit_Standard_pure_YPFUW3Xga0mVMPZT28RXUw">10</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="Duration_3_17_2021_To_3_17_2021_us-gaap_StatementClassOfStockAxis_ganx_PreferredStockSeriesAndSeriesBMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_r8J2spGPVEeD9l3nZ-VHoQ"
      decimals="INF"
      id="Narr_UxkYgociAU2UY1wpoIhsZw"
      unitRef="Unit_Standard_pure_YPFUW3Xga0mVMPZT28RXUw">1</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_3_1_2021_To_3_31_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_N45LChwtn0m3vTVdPokCZw"
      decimals="INF"
      id="Narr_3GGSDe8bl0K-b9w1saIURw"
      unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw">4181818</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharePrice
      contextRef="As_Of_3_31_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_jyeDTSFma0emcErckg2zrw"
      decimals="2"
      id="Narr_LROCJnS1ZE--nA-3NU65lA"
      unitRef="Unit_Divide_USD_shares_ZUfWDOiJrESFdyfJo2gfWg">11.00</us-gaap:SharePrice>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_3_1_2021_To_3_31_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_N45LChwtn0m3vTVdPokCZw"
      decimals="-5"
      id="Narr_934PgupmUEW6fPQRKMWuVQ"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">40500000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      id="Tb_lkYCjsbcQkCo4OdRE9mP4g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Basis of presentation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The consolidated financial statements reflect the accounts of the Gain Therapeutics, Inc., GT Gain Therapeutics SA and its wholly owned branch, Gain Therapeutics Sucursal en Espa&#xf1;a. All intercompany transactions and balances have been eliminated in the preparation of the consolidated financial statements. The consolidated financial statements as of December 31, 2021, represented by the Consolidated Balance Sheet, the Consolidated Statement of Operations, the Consolidated Statements of Changes in Shareholders&#x2019; Equity, the Consolidated Statement of Comprehensive Loss, the Consolidated Statements of Cash Flows and the accompanying Notes, have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;US GAAP&#x201d;). Any reference in these notes to applicable guidance is meant to refer to the authoritative United States generally accepted accounting principles as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;) and Accounting Standards Update (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;). &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The &#160;financial statements as of December 31, 2021 reflect, for all periods presented, the retroactive application of the reverse stock split that occurred on March 17, 2021. All amounts in the consolidated financial statements are expressed in United States Dollars (USD/$) and disclosed within these explanatory notes in United States Dollars (USD/$) or Swiss Franc (CHF), which are the functional currencies of the Company and its operating subsidiary, GT Gain Therapeutics SA, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The consolidated financial statements have been prepared on the same basis as the audited annual consolidated financial statements as of and for the year ended December 31, 2020, and, in the opinion of management, reflect all adjustments, consisting of normal recurring adjustments, necessary for the fair presentation of the Company&#x2019;s financial position as of December 31, 2021, and the results of its operations for the years ended December 31, 2021 and 2020, its statements of stockholders&#x2019; equity and its statements of cash flows for the years then ended. &lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <ganx:ReverseStockSplitPolicyPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      id="Tb_NDdjNs5pY0W_JC9kG458Zw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;Reverse Stock Split &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;On March 3, 2021, the Board approved a 1-for-&lt;span style="-sec-ix-hidden:Hidden_PPLEqeAgy0iiPmdWllrCSA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;0.880784&lt;/span&gt;&lt;/span&gt; reverse stock split of the Company&#x2019;s outstanding equity instruments. The reverse stock split was approved by the stockholders on March 4, 2021 and became effective in conjunction with the IPO on March 17, 2021. Stockholders were no entitled to fractional shares as a result of the reverse stock split. All share and per share data shown in the accompanying consolidated financial statements and &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;related notes have been retroactively revised to reflect the reverse stock split. Shares of common stock underlying outstanding stock options and other equity instruments were proportionately reduced and the respective exercise prices, if applicable, were proportionately increased in accordance with the terms of the agreements governing such securities.&lt;/p&gt;</ganx:ReverseStockSplitPolicyPolicyTextBlock>
    <ganx:InitialPublicOfferingPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      id="Tb_4NGgRDPRQki34GLBDg0WHQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;Initial Public Offering &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On March 17, 2021, the Company&#x2019;s registration statement on Form S-1 relating to its IPO was declared effective by the Securities and Exchange Commission (&#x201c;SEC&#x201d;). The IPO closed on March 17, 2021 and the Company issued and sold 3,636,364 common shares at a public offering price of $11.00 per share for net proceeds of $34,978 thousand after deducting underwriting discounts and commissions of $2,950 thousand and other offering expenses of $2,071 thousand. On March 22, 2021, the Company issued and sold 545,454 additional common shares, pursuant to the full exercise of the underwriters&#x2019; option to purchase additional shares, for net proceeds of $5,580 thousand after deducting underwriting discounts and commissions of $420 thousand. Thus, the aggregate net proceeds to the Company from the IPO, after deducting underwriting discounts commissions, were $42,630 thousand. After deducting other IPO offering expenses amounting to $2,071 thousand, the net cash proceeds resulting from the IPO were $40,558 thousand, which are reflected in the statement of stockholders&#x2019; equity as Issuance of Common Stock in IPO, net of issuance costs. Upon the closing of the IPO, series A convertible preferred stock (the &#x201c;Series A Preferred Stock&#x201d;) and series B convertible preferred stock (the &#x201c;Series B Preferred Stock&#x201d;, and together with the Series A Preferred Stock, are collectively referred to as the &#x201c;Preferred Stock&#x201d;) were converted into shares of common stock at ratio of 1-for-1.&lt;/p&gt;</ganx:InitialPublicOfferingPolicyTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_3_17_2021_To_3_17_2021_us-gaap_SubsidiarySaleOfStockAxis_ganx_IpoExcludingUnderwritersOptionsMember_zUbax__QHU2jXdFcxwazTA"
      decimals="INF"
      id="Narr_Q_jtdXi8T0GSoLkz_4xgaQ"
      unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw">3636364</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharePrice
      contextRef="As_Of_3_17_2021_us-gaap_SubsidiarySaleOfStockAxis_ganx_IpoExcludingUnderwritersOptionsMember_TfY1dJMilk2kFQZuPi8-sw"
      decimals="2"
      id="Narr_21M-wBf8F0OZ2PN7x9fZ_Q"
      unitRef="Unit_Divide_USD_shares_ZUfWDOiJrESFdyfJo2gfWg">11.00</us-gaap:SharePrice>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_3_17_2021_To_3_17_2021_us-gaap_SubsidiarySaleOfStockAxis_ganx_IpoExcludingUnderwritersOptionsMember_zUbax__QHU2jXdFcxwazTA"
      decimals="-3"
      id="Narr_lbnzInjiDkq2SCBHzbYsMg"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">34978000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <ganx:UnderwritingDiscountsAndCommissions
      contextRef="Duration_3_17_2021_To_3_17_2021_us-gaap_SubsidiarySaleOfStockAxis_ganx_IpoExcludingUnderwritersOptionsMember_zUbax__QHU2jXdFcxwazTA"
      decimals="-3"
      id="Narr_wzHHfo5y5UmVQAwpw1zapA"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">2950000</ganx:UnderwritingDiscountsAndCommissions>
    <ganx:OtherOfferingExpenses
      contextRef="Duration_3_17_2021_To_3_17_2021_us-gaap_SubsidiarySaleOfStockAxis_ganx_IpoExcludingUnderwritersOptionsMember_zUbax__QHU2jXdFcxwazTA"
      decimals="-3"
      id="Narr_8O_UzCg0C0OgkbtwQ2RVag"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">2071000</ganx:OtherOfferingExpenses>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_3_22_2021_To_3_22_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_T4IMo7Q7FkixFavhC2S9FA"
      decimals="INF"
      id="Narr_9YseH0c01UevRyg-TXOH7A"
      unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw">545454</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_3_22_2021_To_3_22_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_T4IMo7Q7FkixFavhC2S9FA"
      decimals="-3"
      id="Narr_kVjM69SlFUiz91HRBmBtpQ"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">5580000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <ganx:UnderwritingDiscountsAndCommissions
      contextRef="Duration_3_22_2021_To_3_22_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_T4IMo7Q7FkixFavhC2S9FA"
      decimals="-3"
      id="Narr_iOhVUaKauU2ps_WHCYlJmQ"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">420000</ganx:UnderwritingDiscountsAndCommissions>
    <ganx:GrossProceedsFromIssuanceOfCommonStock
      contextRef="Duration_3_17_2021_To_3_22_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_SaCdeyGh10qyXh2PUIfaFw"
      decimals="-3"
      id="Narr_0MGIXdV4OEeqqz4NsW-pgw"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">42630000</ganx:GrossProceedsFromIssuanceOfCommonStock>
    <ganx:UnderwritingDiscountsAndCommissions
      contextRef="Duration_3_17_2021_To_3_22_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_SaCdeyGh10qyXh2PUIfaFw"
      decimals="-3"
      id="Narr_jW-_jHb7RE2VKY7L9P-wbA"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">2071000</ganx:UnderwritingDiscountsAndCommissions>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_3_17_2021_To_3_22_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_SaCdeyGh10qyXh2PUIfaFw"
      decimals="-3"
      id="Narr_IqNNLEht3kq3MlsRxjWsag"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">40558000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <ganx:PreferredStockToCommonStockConversionRatio
      contextRef="Duration_3_18_2021_To_3_18_2021_iMaj3AAJbEqmShHP_jyriA"
      decimals="INF"
      id="Narr_0jkP8FuVV0eyZ5Z1xvPz8w"
      unitRef="Unit_Standard_pure_YPFUW3Xga0mVMPZT28RXUw">1</ganx:PreferredStockToCommonStockConversionRatio>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      id="Tb_14rFpqpGj0yujN958-wx-A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Segment information&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;Operating segments are defined as components of an enterprise for which separate discrete information is available for evaluation by the chief operating decision-maker in deciding how to allocate resources and assess performance. The Company&#x2019;s chief operating decision-maker, the Chief Executive Officer, oversees the Company&#x2019;s operations and manages the business as a single operating segment, which is research and development in the pharmaceutical sector with a focus on developing novel therapeutics to treat diseases caused by protein misfolding, such as rare genetic diseases and neurological disorders. Geographically, the research and development activities are mainly performed in Switzerland and Spain. The Company does not consider these geographies to be separate segments.&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      id="Tb_Ztqo9jWWIUua8VOE7WvLOQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;2. &#160;&#160;&#160;&#160;Summary of significant accounting policies&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;Foreign currency translation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company is incorporated in the United States of America and has operations in Switzerland and Spain. The Company&#x2019;s functional currency is USD. The functional currencies of the Company&#x2019;s foreign operations are the local currencies (Swiss Franc in Switzerland and Euro in Spain). Assets and liabilities reported in the consolidated balance sheets are translated into U.S. dollars (the currency in which these financial statements are presented) at the exchange rates applicable at the balance sheet dates and for the consolidated statement of operations at the average exchange rates for the periods presented. Items representing the share capital and additional paid-in capital are presented at the historical exchange rates. Adjustments resulting from the translation of the financial statements of the Company&#x2019;s foreign operations into U.S. dollars are excluded from the determination of net income and are recorded in accumulated other comprehensive income/(loss), a separate component of shareholders&#x2019; equity. The Company has not utilized any foreign currency hedging strategies to mitigate the effect of its foreign currency exposure. As of December 31, 2021 and 2020, accumulated currency translation adjustment recorded in the accumulated other comprehensive loss amounted to $165,156 and $1,323, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The preparation of our consolidated financial statements in conformity with US GAAP requires management to make estimates, judgments and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting periods. On an ongoing basis, we evaluate our estimates judgments and, assumptions including those related to recognition of grant funds, accrued expenses, defined benefit pension liability, warrants and stock-based compensation. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. Changes in estimates are recorded in the period in which they become known. To the extent that material differences arise between the estimates and actual results, the Company&#x2019;s future results of operations will be affected. The COVID-19 pandemic did not have a significant impact on the Company&#x2019;s estimates.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company reports cash on hand and held at banks, and all highly liquid investments in money market, certificates of deposit, time deposit, and other short-term liquid securities with original maturities of less than 90 day, as cash and cash equivalents.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;Concentrations of credit risk&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has no significant off-balance sheet risk, such as foreign exchange contracts, option contracts, or other foreign hedging arrangements. Financial instruments that may expose the Company to concentrations of credit risk consist primarily of cash, cash equivalents which are deposited in accredited financial institutions in excess of federally insured limits. The Company deposits its cash and cash equivalents in financial institutions that it believes have high credit quality and has not experienced any losses on such accounts and does not believe it is exposed to any unusual credit risk beyond the normal credit risk associated with commercial banking relationships.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;Deferred Issuance Costs&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company capitalizes certain legal, professional accounting and other third-party fees that are directly associated with in-process equity financings as deferred issuance costs until such financings are consummated. After consummation of the equity financing, these costs are recorded as a reduction of the proceeds generated as a result of the offering. Should the planned equity financing be abandoned, the deferred issuance costs will be expensed immediately as a charge to operating expenses in the consolidated statements of operations. There were nil and $1,217,988 deferred issuance costs as of December 31, 2021 and 2020, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;Property and equipment&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Property and equipment are stated at cost, including any accessory and direct costs that are necessary to make the assets fit for use, and adjusted by the corresponding accumulated depreciation. The depreciation rates recorded in the consolidated financial statements of operations have been calculated by taking into consideration the use, purpose and financial-technical duration of the assets, on the basis of their estimated useful economic lives. The Company believes the above criteria to be represented by the following depreciation rates:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:61.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:33.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:61.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;-&#x2003; Equipment &amp;amp; Furniture&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:33.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 12.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:61.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;-&#x2003; Electronic office equipment:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:33.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 20&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:61.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;-&#x2003; Leasehold Improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:33.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;based on the terms of the lease&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:61.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;-&#x2003; Laboratory equipment:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:33.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 15&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Ordinary maintenance costs are entirely attributed to the consolidated statements of operations in the&#160;year in which they are incurred. Extraordinary maintenance costs, the purpose of which is to extend the useful economic life of the asset, to technologically upgrade it and/or to increase its productivity or safety for the purposes of the economic productivity of the Company, are attributed to the asset to which they refer and depreciated on the basis of its estimated useful economic lives. Amortization of leasehold improvements is computed using the straight-line method based upon the terms of the applicable lease or estimated useful life of the improvements, whichever is lower.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;Capitalized Software Development Costs&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The Company capitalizes the costs of software obtained for internal use in accordance with ASC 350-40, Internal-Use Software. Capitalized software development costs consist of costs incurred during the development stage and include purchased software licenses, implementation costs, consulting costs, and payroll-related costs for projects that qualify for capitalization. All other costs, primarily related to maintenance and minor software fixes, are expensed as incurred. As of December 31, 2021 and 2020, internal-use software amount to $202,609 and nil, and refer to the &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;external and internal labor costs incurred in the development of the Company ERP, amounting respectively to $168,474 and $34,135. &#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company amortizes the capitalized software development costs on a straight-line basis over the estimated useful life of the software, which is generally six years, beginning when the asset is substantially ready for use. The amortization of capitalized software development costs is reflected in general and administrative expenses. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;Impairment of long-lived assets&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-weight:normal;"&gt;In accordance with ASC Topic 360-10-20, &#x201c;Property, Plant and Equipment,&#x201d; the Company performs an impairment test whenever events or circumstances indicate that the carrying value of long-lived assets with finite lives may be impaired. Impairment is measured by comparing the carrying value of the long-lived assets to the estimated undiscounted pre-tax cash flows expected to result from the use of such assets and their ultimate disposition. In circumstances where impairment is determined to exist, the Company will write down the asset to its fair value based on the present value of estimated cash flows. &lt;/span&gt;&lt;span style="font-weight:normal;"&gt;No&lt;/span&gt;&lt;span style="font-weight:normal;"&gt; impairments have been identified by management as of and for any periods presented.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;Patents&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-weight:normal;"&gt;Patent-related costs, refer to legal fees incurred in connection with filing and prosecuting patent applications and are expensed as incurred due to uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Effective January&#160;1, 2018, the Company adopted ASC 842, using the additional transition method option provided by ASU 2018-11. Under this transition method, we applied the new accounting guidance as of the date of adoption. Upon adoption, a cumulative effect adjustment was not required.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Subsequent to the adoption, the Company determines if an arrangement contains a lease at inception based on whether or not the Company has the right to control the asset during the contract period and other facts and circumstances. The Company is the lessee in a lease contract when it obtains the right to control the asset. Operating lease right of use (&#x201c;ROU&#x201d;) assets represent the Company&#x2019;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#x2019;s obligation to make lease payments arising from the lease, both of which are recognized based on the present value of the future minimum lease payments over the lease term at the commencement date. Leases with a term of 12 months or less at inception are expensed on a straight-line basis over the lease term in the statement of operations. The Company determines the lease term by assuming the exercise of renewal options that are reasonably certain. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In addition, the Company subleases portions of its office premises in Lugano. The Company recognizes sublease income on a straight-line basis over the sublease terms, reported within other income. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Accounts Payable&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Accounts payable are reported at their nominal amounts due to their short-term maturities. Trade accounts payable are recorded net of trade discounts; cash discounts are recorded at the time of payment.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Payables for Social Securities&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Social Security charges are reported in compliance with rules and laws applicable in the countries where our employees work. Charges are accrued in accordance with the policies stipulated and in connection with salaries due for the period.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;Accrued expenses&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;As part of the process of preparing our consolidated financial statements, we are required to estimate our accrued expenses as of each balance sheet date. This process involves reviewing open contracts and purchase orders, communicating with our personnel to identify services that have been performed on our behalf and estimating the level &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of the actual cost. We make estimates of our accrued expenses as of each balance sheet date based on facts and circumstances known to us at that time at the date of the preparation of the consolidated financial statements. There may be instances in which payments made to our vendors exceed the level of services provided, and result in prepayment reported under other current assets, which are subsequently expenses in the consolidated statement of operations when the related activity has been performed rather than when the payment is made. To date, there have been no material differences between our estimates of accrued expenses reported at each balance sheet date and the amounts actually incurred.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;Pension obligations&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;We operate defined benefit pension plan and defined contribution pension plans in accordance with local regulations and practices in the countries in which the Company operates. These plans are funded by regular contribution made by the employer and the employees. For defined benefit pension plan, the liability recognized in the consolidated balance sheets is the present value of the defined benefit obligation at the balance sheet date less the fair value of plan assets. The overfunded or underfunded status of the defined benefit plan is calculated as the difference between plan assets and the projected benefit obligations. Estimates are used in determining the assumptions incorporated in the calculation of the pension obligations, which is supported by input from independent actuaries. Actuarial gains and losses arising from experience adjustments and changes in actuarial assumptions are recognized in &#x201c;Accumulated other comprehensive income (loss)&#x201d; in the consolidated statements of equity and are charged or credited to income over the employees&#x2019; expected average remaining working lives. The measurement date used for our employee benefit plan is December 31.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;For defined contribution pension plans, the Company pays contributions to publicly or privately administered pension insurance plans on a mandatory, contractual or volutanry basis. The Company has no further payment obligations once the contributions have been paid. The contributions are recognized as employee benefit expense when they are due. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Equity-based Compensation and Warrants&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company applies the fair value method of measuring equity-based compensation and warrants, which requires an entity to measure the cost of services received in exchange for an award of equity instruments based on the grant-date fair value of the award. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company issues equity-based compensation with only service-based vesting conditions and record the expense for these awards using the straight-line method. The Company has not issued any stock-based awards with performance- or market-based vesting conditions.The Company recognizes the related costs in the consolidated statement of operations and as additional paid-in capital in the consolidated statement of shareholders&#x2019; equity, in accordance with the vesting period during which the award recipients are required to provide services in exchange for the award. The Company accounts for forfeitures as they occur.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Before being a public company, given the absence of an active market for the Company&#x2019;s common stock, the Company and the Board of Directors estimated the fair value of the Company&#x2019;s common stock at the grant date determining the estimated fair value of the Company&#x2019;s equity instruments based on a number of factors, including prices paid for the Company&#x2019;s convertible preferred stock sold to outside investors in arm&#x2019;s-length transactions; the Company&#x2019;s stage of development; the fact that the grants of stock-based awards involved illiquid securities in a private company.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The fair value of each stock option award is estimated on the date of grant using the Black-Scholes option pricing model. Given the absence of an active public market for the Company&#x2019;s common stock prior to March 19, 2021, which was the first day of trading, the Company determined the volatility and the expected term for awards granted based on an analysis of reported data for a peer group of similar biopharmaceuticals companies that issued options with substantially similar terms. After the IPO, we continued to do so, and we expect not to change our methodology until such time as we will have reliable historical data regarding the volatility of our traded stock price and expected term of exercise patterns. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. The Company has not paid, and does not anticipate paying, cash dividends on our common stock; therefore, the expected dividend yield is assumed to be zero.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Black-Scholes option pricing model is also used for warrants issued, using consistent inputs and methodology to quantify such inputs, as described above in relation &#160;to equity-based compensation.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The assumptions used in calculating the fair value of share-based awards and warrants represent management&#x2019;s best estimates and involve inherent uncertainties and the application of management&#x2019;s judgment. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;Revenue Recognition&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company derives revenues from collaboration and licensing agreements. The Company recognize revenue related to these agreements in accordance with&#160;ASC&#160;606, &lt;i style="font-style:italic;"&gt;Revenues from contracts with customers&lt;/i&gt; and ASC 808, &lt;i style="font-style:italic;"&gt;Collaborative arrangements&lt;/i&gt;. The terms of these arrangements typically include payment from third parties customers of one or more of the following: non-refundable initiation fee, reimbursement of development costs, development and regulatory milestone payments and royalties on net sales of the licensed product. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In determining the appropriate amount of revenue to be recognized as we fulfill our obligations, the Company applies the five steps model of ASC606: (i)&#160;identify the contract(s) with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when (or as) we satisfy a performance obligation. The Company only apply the five-step model to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods and services it transfers to the customer. If a contract is determined to be within the scope of ASC 606 at inception, the Company assesses the goods or services promised within such contract, determines which of those goods and services are performance obligations, and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. &#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Costs and revenues associated with collaborative arrangements are reported in the consolidated statements of operations on a gross basis when the counterpart is identified as being a customer, when the performance obligations incurred and rendered to fulfil the agreements are deemed to be in the ordinary course of the Company&#x2019;s business, or when there is an expectation that the collaborative arrangement will result in a future constant flow of revenues in the form of sale of products, royalties or licenses.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;Research grants&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Under the terms of the research and development grants awarded (such as those awarded by the The Michael J. Fox Foundation for Parkinson&#x2019;s Research (MJFF) and The Silverstein Foundation for Parkinson&#x2019;s Disease and from Innosuisse &#x2013; Swiss Innovation Agency), we are entitled to receive reimbursement of our allowable direct expenses and payroll costs. Contributions from research and development activities under the grants are recorded based on management&#x2019;s best estimate of the periods in which the related expenditures are incurred and activities performed and are classified in the statement of operations as a reduction to research and development expenses, measuring according to the time periods during which the research and development activities are carried out and related costs sustained.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;Research and development expenses&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company expenses all costs incurred in performing research and development activities. Research and development expenses include salaries and other related costs, materials and supplies, preclinical expenses, manufacturing expenses, contract services and other third-party expenses. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;General and administrative expenses&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;General and administrative expenses consist primarily of salaries, benefits and other related costs, for personnel and consultants in the Company&#x2019;s executive and finance functions. General and administrative expenses also include professional fees for legal, finance, accounting, intellectual property, auditing, tax and consulting services, travel expenses and facility-related expenses, which include allocated expenses for rent and maintenance of facilities and other operating costs not otherwise included in research and development expenses.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;Income taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company accounts for income taxes under the liability method. Under this method deferred income tax liabilities and assets are determined based on the difference between the financial statement carrying amounts of assets and liabilities and the related tax basis using enacted tax rates in effect in the&#160;years in which the associated deferred taxes are expected to reverse. A valuation allowance is recorded if it is &#x201c;more likely than not&#x201d; that a portion or all of a deferred tax asset will not be realized.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of each reporting date, the Company considers existing evidence, both positive and negative, that could impact its view with regards to future realization of deferred tax assets. In consideration of the start-up status of the Company, a full valuation allowance has been established to offset the deferred tax assets, as the related realization is currently uncertain. In the future, should management conclude that it is more likely than not that the deferred tax assets are partially or fully realizable, the valuation allowance will be reduced to the extent of such expected realization, and the corresponding amount will be recognized as income tax benefit in the Company&#x2019;s consolidated statement of operations.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company recognizes tax liabilities from an uncertain tax position if it is more likely than not that the tax position will not be sustained upon examination by the taxing authorities, based on the technical merits of the tax position. There are no uncertain tax positions that have been recognized in the accompanying consolidated financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;Fair value measurements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Company applies the following fair value hierarchy, which prioritizes the inputs used to measure fair value into three levels based on their observability in the market and degree of judgment involved:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:21.3pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:14.15pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Level 1&#160;&#x2013; Quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:21.3pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:14.15pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Level 2&#160;&#x2013; Observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:21.3pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:14.15pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Level 3&#160;&#x2013; Inputs that are generally unobservable and typically reflect management&#x2019;s estimates of assumptions that market participants would use in pricing the asset or liability.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:10pt;"/&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In determining fair value, we utilize valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and consider counterparty credit risk in their assessment of fair value.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;Comprehensive income/(loss)&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-weight:normal;"&gt;Comprehensive income/(loss) is composed of net income(loss) and certain changes in stockholder&#x2019;s equity that are excluded from the net income(loss), primarily foreign currency translation adjustments and defined benefit obligation adjustments.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;Net loss per share&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Basic net loss per share is computed by dividing the reported net loss by the weighted average number of shares of common stock outstanding during the period. The Company gives consideration to all potentially dilutive impacts, except where the effect of including such securities would be antidilutive. As of December 31, 2021, common stock equivalents consisted of stock options and warrants, while as of &#160;December 31, 2020, common stock equivalents consisted of the Series&#160;A preferred stock, Series B preferred stock, stock options and warrants. Because the Company has reported net losses since inception, these potential impacts would be anti-dilutive, and therefore common stock equivalents have been excluded from the computation, resulting in basic and diluted net loss per share being the same for all periods presented.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;Recently issued accounting pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that we adopt as of the specified effective date. We do not believe that the adoption of any recently issued standards have or may have a material impact on our consolidated financial statements or disclosures.&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      id="Tb_xO4bdTHsW0i-mkcE23rZLA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;Foreign currency translation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company is incorporated in the United States of America and has operations in Switzerland and Spain. The Company&#x2019;s functional currency is USD. The functional currencies of the Company&#x2019;s foreign operations are the local currencies (Swiss Franc in Switzerland and Euro in Spain). Assets and liabilities reported in the consolidated balance sheets are translated into U.S. dollars (the currency in which these financial statements are presented) at the exchange rates applicable at the balance sheet dates and for the consolidated statement of operations at the average exchange rates for the periods presented. Items representing the share capital and additional paid-in capital are presented at the historical exchange rates. Adjustments resulting from the translation of the financial statements of the Company&#x2019;s foreign operations into U.S. dollars are excluded from the determination of net income and are recorded in accumulated other comprehensive income/(loss), a separate component of shareholders&#x2019; equity. The Company has not utilized any foreign currency hedging strategies to mitigate the effect of its foreign currency exposure. As of December 31, 2021 and 2020, accumulated currency translation adjustment recorded in the accumulated other comprehensive loss amounted to $165,156 and $1,323, respectively.&lt;/p&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax
      contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A"
      decimals="0"
      id="Narr_0ZWOwuRKhEmH36WNXQnkHw"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">165156</us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax
      contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg"
      decimals="0"
      id="Narr_5afVZmbuNUm7XHv3XLGcCA"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">1323</us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax>
    <us-gaap:UseOfEstimates
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      id="Tb_7F0-OpU300qL4yNXbzGSdA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The preparation of our consolidated financial statements in conformity with US GAAP requires management to make estimates, judgments and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting periods. On an ongoing basis, we evaluate our estimates judgments and, assumptions including those related to recognition of grant funds, accrued expenses, defined benefit pension liability, warrants and stock-based compensation. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. Changes in estimates are recorded in the period in which they become known. To the extent that material differences arise between the estimates and actual results, the Company&#x2019;s future results of operations will be affected. The COVID-19 pandemic did not have a significant impact on the Company&#x2019;s estimates.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      id="Tb_EdfHnc4E1Uyb_ngvBx-Hfw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company reports cash on hand and held at banks, and all highly liquid investments in money market, certificates of deposit, time deposit, and other short-term liquid securities with original maturities of less than 90 day, as cash and cash equivalents.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      id="Tb_acrftdZ-I0enGoLVcjHaFQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;Concentrations of credit risk&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has no significant off-balance sheet risk, such as foreign exchange contracts, option contracts, or other foreign hedging arrangements. Financial instruments that may expose the Company to concentrations of credit risk consist primarily of cash, cash equivalents which are deposited in accredited financial institutions in excess of federally insured limits. The Company deposits its cash and cash equivalents in financial institutions that it believes have high credit quality and has not experienced any losses on such accounts and does not believe it is exposed to any unusual credit risk beyond the normal credit risk associated with commercial banking relationships.&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:DeferredChargesPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      id="Tb_1uIwOBFW7UWFCRPJU9SsrA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;Deferred Issuance Costs&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company capitalizes certain legal, professional accounting and other third-party fees that are directly associated with in-process equity financings as deferred issuance costs until such financings are consummated. After consummation of the equity financing, these costs are recorded as a reduction of the proceeds generated as a result of the offering. Should the planned equity financing be abandoned, the deferred issuance costs will be expensed immediately as a charge to operating expenses in the consolidated statements of operations. There were nil and $1,217,988 deferred issuance costs as of December 31, 2021 and 2020, respectively.&lt;/p&gt;</us-gaap:DeferredChargesPolicyTextBlock>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A"
      decimals="0"
      id="Narr_JVIf-g3GJE-xf95rNN3fcQ"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">0</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg"
      decimals="0"
      id="Narr_2dkiYhv7WEG2NM8OWpwyTA"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">1217988</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      id="Tb_9e4T_glEWkWMZLrZsp0hOA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;Property and equipment&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Property and equipment are stated at cost, including any accessory and direct costs that are necessary to make the assets fit for use, and adjusted by the corresponding accumulated depreciation. The depreciation rates recorded in the consolidated financial statements of operations have been calculated by taking into consideration the use, purpose and financial-technical duration of the assets, on the basis of their estimated useful economic lives. The Company believes the above criteria to be represented by the following depreciation rates:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:61.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:33.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:61.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;-&#x2003; Equipment &amp;amp; Furniture&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:33.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 12.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:61.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;-&#x2003; Electronic office equipment:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:33.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 20&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:61.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;-&#x2003; Leasehold Improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:33.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;based on the terms of the lease&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:61.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;-&#x2003; Laboratory equipment:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:33.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 15&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Ordinary maintenance costs are entirely attributed to the consolidated statements of operations in the&#160;year in which they are incurred. Extraordinary maintenance costs, the purpose of which is to extend the useful economic life of the asset, to technologically upgrade it and/or to increase its productivity or safety for the purposes of the economic productivity of the Company, are attributed to the asset to which they refer and depreciated on the basis of its estimated useful economic lives. Amortization of leasehold improvements is computed using the straight-line method based upon the terms of the applicable lease or estimated useful life of the improvements, whichever is lower.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <ganx:DepreciationRatesOnPropertyPlantAndEquipmentTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      id="Tb_1X9VTprqS0G7id067aqOmA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:61.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:33.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:61.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;-&#x2003; Equipment &amp;amp; Furniture&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:33.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 12.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:61.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;-&#x2003; Electronic office equipment:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:33.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 20&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:61.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;-&#x2003; Leasehold Improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:33.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;based on the terms of the lease&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:61.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;-&#x2003; Laboratory equipment:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:33.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 15&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ganx:DepreciationRatesOnPropertyPlantAndEquipmentTableTextBlock>
    <ganx:PropertyPlantAndEquipmentDepreciationRates
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ganx_EquipmentAndFurnitureMember_eYeOQu_NukuBM3xRUGpAow"
      decimals="3"
      id="Tc_y2mjfDjNLEGppZ2T2isqTQ_1_2"
      unitRef="Unit_Standard_pure_YPFUW3Xga0mVMPZT28RXUw">0.125</ganx:PropertyPlantAndEquipmentDepreciationRates>
    <ganx:PropertyPlantAndEquipmentDepreciationRates
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_vxw_50xpsk-K6Rt4Xg-w-w"
      decimals="2"
      id="Tc_A_aeLC_UwUiYARvXi72sYQ_2_2"
      unitRef="Unit_Standard_pure_YPFUW3Xga0mVMPZT28RXUw">0.20</ganx:PropertyPlantAndEquipmentDepreciationRates>
    <ganx:PropertyPlantAndEquipmentDepreciationRates
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ganx_LaboratoryInstrumentsMember_UGsEilKkZ0-amCM5X6BAdw"
      decimals="2"
      id="Tc_RRYppYCRL0uaxJ1tnjpA9g_4_2"
      unitRef="Unit_Standard_pure_YPFUW3Xga0mVMPZT28RXUw">0.15</ganx:PropertyPlantAndEquipmentDepreciationRates>
    <us-gaap:ResearchDevelopmentAndComputerSoftwarePolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      id="Tb_y3B0SED6sU2shy5BcgVpRg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;Capitalized Software Development Costs&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The Company capitalizes the costs of software obtained for internal use in accordance with ASC 350-40, Internal-Use Software. Capitalized software development costs consist of costs incurred during the development stage and include purchased software licenses, implementation costs, consulting costs, and payroll-related costs for projects that qualify for capitalization. All other costs, primarily related to maintenance and minor software fixes, are expensed as incurred. As of December 31, 2021 and 2020, internal-use software amount to $202,609 and nil, and refer to the &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;external and internal labor costs incurred in the development of the Company ERP, amounting respectively to $168,474 and $34,135. &#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company amortizes the capitalized software development costs on a straight-line basis over the estimated useful life of the software, which is generally six years, beginning when the asset is substantially ready for use. The amortization of capitalized software development costs is reflected in general and administrative expenses. &lt;/p&gt;</us-gaap:ResearchDevelopmentAndComputerSoftwarePolicyTextBlock>
    <us-gaap:CapitalizedComputerSoftwareNet
      contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A"
      decimals="0"
      id="Narr_qg3VxC1i40-dqXCqc2aVYA"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">202609</us-gaap:CapitalizedComputerSoftwareNet>
    <us-gaap:CapitalizedComputerSoftwareNet
      contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg"
      decimals="0"
      id="Narr_Ib8BTfftjka67PRL3F5dLQ"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">0</us-gaap:CapitalizedComputerSoftwareNet>
    <us-gaap:CapitalizedComputerSoftwareAdditions
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      decimals="0"
      id="Narr_3NmZX6p4G0apoU9cBKAOfQ"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">168474</us-gaap:CapitalizedComputerSoftwareAdditions>
    <us-gaap:CapitalizedComputerSoftwareAdditions
      contextRef="Duration_1_1_2020_To_12_31_2020_JDEb6LtAmEuXGmEieWNlsw"
      decimals="0"
      id="Narr_N8Oa_w0Xm0WtHm2WQ5gHTg"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">34135</us-gaap:CapitalizedComputerSoftwareAdditions>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_ComputerSoftwareIntangibleAssetMember_IyvNJLfe-0C5bmjgl1g7MQ"
      id="Narr_ofCd-LZU2kyke-sqLvt45g">P6Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      id="Tb_pncA-bYEDUmuL9LH5iRRJw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;Impairment of long-lived assets&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-weight:normal;"&gt;In accordance with ASC Topic 360-10-20, &#x201c;Property, Plant and Equipment,&#x201d; the Company performs an impairment test whenever events or circumstances indicate that the carrying value of long-lived assets with finite lives may be impaired. Impairment is measured by comparing the carrying value of the long-lived assets to the estimated undiscounted pre-tax cash flows expected to result from the use of such assets and their ultimate disposition. In circumstances where impairment is determined to exist, the Company will write down the asset to its fair value based on the present value of estimated cash flows. &lt;/span&gt;&lt;span style="font-weight:normal;"&gt;No&lt;/span&gt;&lt;span style="font-weight:normal;"&gt; impairments have been identified by management as of and for any periods presented.&lt;/span&gt;&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:AssetImpairmentCharges
      contextRef="Duration_1_1_2020_To_12_31_2020_JDEb6LtAmEuXGmEieWNlsw"
      decimals="0"
      id="Narr_PElOgxtOEkaXPMRIlZkOTg"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      decimals="0"
      id="Narr_JdecyAtmDEmZMwIyX614Lw"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:IntangibleAssetsFiniteLivedPolicy
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      id="Tb_jLYdija_C0qeP1tzXlghPg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;Patents&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-weight:normal;"&gt;Patent-related costs, refer to legal fees incurred in connection with filing and prosecuting patent applications and are expensed as incurred due to uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses.&lt;/span&gt;&lt;/p&gt;</us-gaap:IntangibleAssetsFiniteLivedPolicy>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      id="Tb_gmVkyXb4REm3YcGVR3TT1A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Effective January&#160;1, 2018, the Company adopted ASC 842, using the additional transition method option provided by ASU 2018-11. Under this transition method, we applied the new accounting guidance as of the date of adoption. Upon adoption, a cumulative effect adjustment was not required.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Subsequent to the adoption, the Company determines if an arrangement contains a lease at inception based on whether or not the Company has the right to control the asset during the contract period and other facts and circumstances. The Company is the lessee in a lease contract when it obtains the right to control the asset. Operating lease right of use (&#x201c;ROU&#x201d;) assets represent the Company&#x2019;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#x2019;s obligation to make lease payments arising from the lease, both of which are recognized based on the present value of the future minimum lease payments over the lease term at the commencement date. Leases with a term of 12 months or less at inception are expensed on a straight-line basis over the lease term in the statement of operations. The Company determines the lease term by assuming the exercise of renewal options that are reasonably certain. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In addition, the Company subleases portions of its office premises in Lugano. The Company recognizes sublease income on a straight-line basis over the sublease terms, reported within other income. &lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <ganx:AccountsPayablePolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      id="Tb_gF9xDbSxQkqbt30yF3DiJQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Accounts Payable&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Accounts payable are reported at their nominal amounts due to their short-term maturities. Trade accounts payable are recorded net of trade discounts; cash discounts are recorded at the time of payment.&lt;/p&gt;</ganx:AccountsPayablePolicyTextBlock>
    <ganx:PayablesForSocialSecuritiesPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      id="Tb_3ect8K-3IEu3ixrtxeyp8w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Payables for Social Securities&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Social Security charges are reported in compliance with rules and laws applicable in the countries where our employees work. Charges are accrued in accordance with the policies stipulated and in connection with salaries due for the period.&lt;/p&gt;</ganx:PayablesForSocialSecuritiesPolicyTextBlock>
    <ganx:AccruedExpensesPolicyPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      id="Tb_Au_9HCw5oEyjU-x1fDJILA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;Accrued expenses&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;As part of the process of preparing our consolidated financial statements, we are required to estimate our accrued expenses as of each balance sheet date. This process involves reviewing open contracts and purchase orders, communicating with our personnel to identify services that have been performed on our behalf and estimating the level &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of the actual cost. We make estimates of our accrued expenses as of each balance sheet date based on facts and circumstances known to us at that time at the date of the preparation of the consolidated financial statements. There may be instances in which payments made to our vendors exceed the level of services provided, and result in prepayment reported under other current assets, which are subsequently expenses in the consolidated statement of operations when the related activity has been performed rather than when the payment is made. To date, there have been no material differences between our estimates of accrued expenses reported at each balance sheet date and the amounts actually incurred.&lt;/p&gt;</ganx:AccruedExpensesPolicyPolicyTextBlock>
    <us-gaap:PensionAndOtherPostretirementPlansPolicy
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      id="Tb__f3pX9Xl5UOH7cWY02gTbA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;Pension obligations&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;We operate defined benefit pension plan and defined contribution pension plans in accordance with local regulations and practices in the countries in which the Company operates. These plans are funded by regular contribution made by the employer and the employees. For defined benefit pension plan, the liability recognized in the consolidated balance sheets is the present value of the defined benefit obligation at the balance sheet date less the fair value of plan assets. The overfunded or underfunded status of the defined benefit plan is calculated as the difference between plan assets and the projected benefit obligations. Estimates are used in determining the assumptions incorporated in the calculation of the pension obligations, which is supported by input from independent actuaries. Actuarial gains and losses arising from experience adjustments and changes in actuarial assumptions are recognized in &#x201c;Accumulated other comprehensive income (loss)&#x201d; in the consolidated statements of equity and are charged or credited to income over the employees&#x2019; expected average remaining working lives. The measurement date used for our employee benefit plan is December 31.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;For defined contribution pension plans, the Company pays contributions to publicly or privately administered pension insurance plans on a mandatory, contractual or volutanry basis. The Company has no further payment obligations once the contributions have been paid. The contributions are recognized as employee benefit expense when they are due. &lt;/p&gt;</us-gaap:PensionAndOtherPostretirementPlansPolicy>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      id="Tb_xVoYgGjVaEOyhReCE-2dLw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Equity-based Compensation and Warrants&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company applies the fair value method of measuring equity-based compensation and warrants, which requires an entity to measure the cost of services received in exchange for an award of equity instruments based on the grant-date fair value of the award. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company issues equity-based compensation with only service-based vesting conditions and record the expense for these awards using the straight-line method. The Company has not issued any stock-based awards with performance- or market-based vesting conditions.The Company recognizes the related costs in the consolidated statement of operations and as additional paid-in capital in the consolidated statement of shareholders&#x2019; equity, in accordance with the vesting period during which the award recipients are required to provide services in exchange for the award. The Company accounts for forfeitures as they occur.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Before being a public company, given the absence of an active market for the Company&#x2019;s common stock, the Company and the Board of Directors estimated the fair value of the Company&#x2019;s common stock at the grant date determining the estimated fair value of the Company&#x2019;s equity instruments based on a number of factors, including prices paid for the Company&#x2019;s convertible preferred stock sold to outside investors in arm&#x2019;s-length transactions; the Company&#x2019;s stage of development; the fact that the grants of stock-based awards involved illiquid securities in a private company.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The fair value of each stock option award is estimated on the date of grant using the Black-Scholes option pricing model. Given the absence of an active public market for the Company&#x2019;s common stock prior to March 19, 2021, which was the first day of trading, the Company determined the volatility and the expected term for awards granted based on an analysis of reported data for a peer group of similar biopharmaceuticals companies that issued options with substantially similar terms. After the IPO, we continued to do so, and we expect not to change our methodology until such time as we will have reliable historical data regarding the volatility of our traded stock price and expected term of exercise patterns. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. The Company has not paid, and does not anticipate paying, cash dividends on our common stock; therefore, the expected dividend yield is assumed to be zero.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Black-Scholes option pricing model is also used for warrants issued, using consistent inputs and methodology to quantify such inputs, as described above in relation &#160;to equity-based compensation.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The assumptions used in calculating the fair value of share-based awards and warrants represent management&#x2019;s best estimates and involve inherent uncertainties and the application of management&#x2019;s judgment. &lt;/p&gt;</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_0JEx-N7nxEOplYgSWCGOgw"
      decimals="INF"
      id="Narr_qmM9_ZMSi0yEP93FxXaqFQ"
      unitRef="Unit_Standard_pure_YPFUW3Xga0mVMPZT28RXUw">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      id="Tb_-ik0vbZwak-2fy-tYrvQMA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;Revenue Recognition&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company derives revenues from collaboration and licensing agreements. The Company recognize revenue related to these agreements in accordance with&#160;ASC&#160;606, &lt;i style="font-style:italic;"&gt;Revenues from contracts with customers&lt;/i&gt; and ASC 808, &lt;i style="font-style:italic;"&gt;Collaborative arrangements&lt;/i&gt;. The terms of these arrangements typically include payment from third parties customers of one or more of the following: non-refundable initiation fee, reimbursement of development costs, development and regulatory milestone payments and royalties on net sales of the licensed product. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In determining the appropriate amount of revenue to be recognized as we fulfill our obligations, the Company applies the five steps model of ASC606: (i)&#160;identify the contract(s) with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when (or as) we satisfy a performance obligation. The Company only apply the five-step model to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods and services it transfers to the customer. If a contract is determined to be within the scope of ASC 606 at inception, the Company assesses the goods or services promised within such contract, determines which of those goods and services are performance obligations, and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. &#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Costs and revenues associated with collaborative arrangements are reported in the consolidated statements of operations on a gross basis when the counterpart is identified as being a customer, when the performance obligations incurred and rendered to fulfil the agreements are deemed to be in the ordinary course of the Company&#x2019;s business, or when there is an expectation that the collaborative arrangement will result in a future constant flow of revenues in the form of sale of products, royalties or licenses.&lt;/p&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <ganx:ResearchGrantsPolicyPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      id="Tb_G0sFCQA0i0KDK8vMZN4uYA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;Research grants&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Under the terms of the research and development grants awarded (such as those awarded by the The Michael J. Fox Foundation for Parkinson&#x2019;s Research (MJFF) and The Silverstein Foundation for Parkinson&#x2019;s Disease and from Innosuisse &#x2013; Swiss Innovation Agency), we are entitled to receive reimbursement of our allowable direct expenses and payroll costs. Contributions from research and development activities under the grants are recorded based on management&#x2019;s best estimate of the periods in which the related expenditures are incurred and activities performed and are classified in the statement of operations as a reduction to research and development expenses, measuring according to the time periods during which the research and development activities are carried out and related costs sustained.&lt;/p&gt;</ganx:ResearchGrantsPolicyPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      id="Tb_wUgzge6CDEi8YlgV4DCXTQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;Research and development expenses&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company expenses all costs incurred in performing research and development activities. Research and development expenses include salaries and other related costs, materials and supplies, preclinical expenses, manufacturing expenses, contract services and other third-party expenses. &lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      id="Tb_UUuzElvrvESFLh2kBf3b8A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;General and administrative expenses&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;General and administrative expenses consist primarily of salaries, benefits and other related costs, for personnel and consultants in the Company&#x2019;s executive and finance functions. General and administrative expenses also include professional fees for legal, finance, accounting, intellectual property, auditing, tax and consulting services, travel expenses and facility-related expenses, which include allocated expenses for rent and maintenance of facilities and other operating costs not otherwise included in research and development expenses.&lt;/p&gt;</us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      id="Tb_VFWPov0mYE-aVUog9uVA-Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;Income taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company accounts for income taxes under the liability method. Under this method deferred income tax liabilities and assets are determined based on the difference between the financial statement carrying amounts of assets and liabilities and the related tax basis using enacted tax rates in effect in the&#160;years in which the associated deferred taxes are expected to reverse. A valuation allowance is recorded if it is &#x201c;more likely than not&#x201d; that a portion or all of a deferred tax asset will not be realized.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of each reporting date, the Company considers existing evidence, both positive and negative, that could impact its view with regards to future realization of deferred tax assets. In consideration of the start-up status of the Company, a full valuation allowance has been established to offset the deferred tax assets, as the related realization is currently uncertain. In the future, should management conclude that it is more likely than not that the deferred tax assets are partially or fully realizable, the valuation allowance will be reduced to the extent of such expected realization, and the corresponding amount will be recognized as income tax benefit in the Company&#x2019;s consolidated statement of operations.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company recognizes tax liabilities from an uncertain tax position if it is more likely than not that the tax position will not be sustained upon examination by the taxing authorities, based on the technical merits of the tax position. There are no uncertain tax positions that have been recognized in the accompanying consolidated financial statements.&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <ganx:UncertainTaxPositionsRecognized
      contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A"
      decimals="0"
      id="Narr_BytsCEf0Xkm3GMWsqZM9sQ"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">0</ganx:UncertainTaxPositionsRecognized>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      id="Tb_DW_lwz8FdEi18gKvjqC4OQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;Fair value measurements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Company applies the following fair value hierarchy, which prioritizes the inputs used to measure fair value into three levels based on their observability in the market and degree of judgment involved:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:21.3pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:14.15pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Level 1&#160;&#x2013; Quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:21.3pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:14.15pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Level 2&#160;&#x2013; Observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:21.3pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:14.15pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Level 3&#160;&#x2013; Inputs that are generally unobservable and typically reflect management&#x2019;s estimates of assumptions that market participants would use in pricing the asset or liability.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:10pt;"/&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In determining fair value, we utilize valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and consider counterparty credit risk in their assessment of fair value.&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      id="Tb_drMhfaBOf0Wm-1R_MUfKTg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;Comprehensive income/(loss)&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-weight:normal;"&gt;Comprehensive income/(loss) is composed of net income(loss) and certain changes in stockholder&#x2019;s equity that are excluded from the net income(loss), primarily foreign currency translation adjustments and defined benefit obligation adjustments.&lt;/span&gt;&lt;/p&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      id="Tb_uQ3blQu5M0SWTR8jBD9BIw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;Net loss per share&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Basic net loss per share is computed by dividing the reported net loss by the weighted average number of shares of common stock outstanding during the period. The Company gives consideration to all potentially dilutive impacts, except where the effect of including such securities would be antidilutive. As of December 31, 2021, common stock equivalents consisted of stock options and warrants, while as of &#160;December 31, 2020, common stock equivalents consisted of the Series&#160;A preferred stock, Series B preferred stock, stock options and warrants. Because the Company has reported net losses since inception, these potential impacts would be anti-dilutive, and therefore common stock equivalents have been excluded from the computation, resulting in basic and diluted net loss per share being the same for all periods presented.&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      id="Tb_wx9nhncQRkCsFCZkhY1Hqg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;Recently issued accounting pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that we adopt as of the specified effective date. We do not believe that the adoption of any recently issued standards have or may have a material impact on our consolidated financial statements or disclosures.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <ganx:ResearchGrantsDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      id="Tb_1e-aTl6cHUaqdARUMtayag">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;3.&#160;&#160;&#160;&#160;Research Grants &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In December 2018 and in February 2019, our wholly owned subsidiary, GT Gain Therapeutics SA, obtained a research grants for a total amount of USD 186,956 from The Michael J. Fox Foundation for Parkinson's Research (MJFF) and The Silverstein Foundation for Parkinson's disease with GBA to advance its proprietary non-competitive molecular chaperones for Parkinson's disease and research project "therapeutic target of GCase enzyme in Parkinson's disease with novel pharmacological chaperones". Under the terms of the research and development grants awarded, we are entitled to receive reimbursement of our allowable direct expenses. As of December 31, 2021 and 2020, we recorded as reductions to research and development expenses of nil, since the grant term terminated in 2020, &#160;and USD 98,318, respectively. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;In July 2019, our wholly owned subsidiary, GT Gain Therapeutics SA, announced that, in a consortium with the Institute for Research in Biomedicine, Bellinzone (Switzerland) and Neuro-Sys SAS in Gardanne (France), it obtained a research grant of approximately USD 1,500,000 from Eurostars-2 joint programme, with co-funding from the European Union Horizon 2020 research and Innosuisse &#x2013; Swiss Innovation Agency. The contribution attributed to our subsidiary was CHF 386,218, of which CHF 286,787 was already received as of December 31, 2019. The funding will support the development of the drugs portfolio for the treatment of Gaucher Disease, GM1 Gangliosidosis, Mucopolysaccharidosis type 1 and Krabbe. Under the terms of the research and development grants awarded, we are entitled to receive reimbursement of our allowable direct expenses. As of December 31, 2021 and 2020, we recorded as reductions to research and development expenses USD 136,177 and USD 151,230, respectively and receivables of USD 81,862 and USD 51,665, respectively. The unrecognized portions of the grants are reported as deferred income on the consolidated balance sheet.&lt;/p&gt;</ganx:ResearchGrantsDisclosureTextBlock>
    <us-gaap:GrantsReceivable
      contextRef="As_Of_2_28_2019_dei_LegalEntityAxis_ganx_GtGainTherapeuticsSaMember_srt_CounterpartyNameAxis_ganx_MichaelJ.FoxFoundationForParkinsonSResearchMjffMember_pOgW2epL9EG_XiGfjitJLQ"
      decimals="0"
      id="Narr_5I7SQVuzbkOMpNPZ0T-jzA"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">186956</us-gaap:GrantsReceivable>
    <ganx:ReductionOfResearchAndDevelopmentExpensesThroughExpensesReimbursed
      contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_ganx_GtGainTherapeuticsSaMember_srt_CounterpartyNameAxis_ganx_MichaelJ.FoxFoundationForParkinsonSResearchMjffMember__G2vs2A3Nk-gHqckeDfJ_w"
      decimals="0"
      id="Narr_2Ikunp3SekGTPAlO6rzZDA"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">0</ganx:ReductionOfResearchAndDevelopmentExpensesThroughExpensesReimbursed>
    <ganx:ReductionOfResearchAndDevelopmentExpensesThroughExpensesReimbursed
      contextRef="Duration_1_1_2020_To_12_31_2020_dei_LegalEntityAxis_ganx_GtGainTherapeuticsSaMember_srt_CounterpartyNameAxis_ganx_MichaelJ.FoxFoundationForParkinsonSResearchMjffMember__vvtnvxiGkihO0mrEzCOXQ"
      decimals="0"
      id="Narr_uFpIc9VnLEySIQw9r5R5ig"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">98318</ganx:ReductionOfResearchAndDevelopmentExpensesThroughExpensesReimbursed>
    <us-gaap:GrantsReceivable
      contextRef="As_Of_7_31_2019_dei_LegalEntityAxis_ganx_ConsortiumWithGtGainTherapeuticsSaInstituteForResearchInBiomedicineAndNeuroSysSasMember_srt_CounterpartyNameAxis_ganx_Eurostars2Member_rZtMNPgqTUK8vf9PccniAQ"
      decimals="0"
      id="Narr_wFfZ1KChdEiw1l-A0Rv2pg"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">1500000</us-gaap:GrantsReceivable>
    <us-gaap:GrantsReceivable
      contextRef="As_Of_7_31_2019_dei_LegalEntityAxis_ganx_GtGainTherapeuticsSaMember_srt_CounterpartyNameAxis_ganx_Eurostars2Member_bQ8j0nCuy0GId24-qC-Rwg"
      decimals="0"
      id="Narr_SBKmZZTrhkC4XTLqHzN_Pg"
      unitRef="Unit_Standard_CHF_tZXBcOteZE6rGAnlVuK3Ng">386218</us-gaap:GrantsReceivable>
    <ganx:ProceedsFromGrants
      contextRef="Duration_7_1_2019_To_12_31_2019_dei_LegalEntityAxis_ganx_GtGainTherapeuticsSaMember_srt_CounterpartyNameAxis_ganx_Eurostars2Member_kHOQVkb_30--8vvOt4dYkQ"
      decimals="0"
      id="Narr_OyoObZgg_UuLFRLTkRCpaw"
      unitRef="Unit_Standard_CHF_tZXBcOteZE6rGAnlVuK3Ng">286787</ganx:ProceedsFromGrants>
    <ganx:ReductionOfResearchAndDevelopmentExpensesThroughExpensesReimbursed
      contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_ganx_GtGainTherapeuticsSaMember_srt_CounterpartyNameAxis_ganx_Eurostars2Member_QdIjpEm0HEmiFVdv-rxIew"
      decimals="0"
      id="Narr_QwTlZ31IE0mWQCcJFjiHNA"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">136177</ganx:ReductionOfResearchAndDevelopmentExpensesThroughExpensesReimbursed>
    <ganx:ReductionOfResearchAndDevelopmentExpensesThroughExpensesReimbursed
      contextRef="Duration_1_1_2020_To_12_31_2020_dei_LegalEntityAxis_ganx_GtGainTherapeuticsSaMember_srt_CounterpartyNameAxis_ganx_Eurostars2Member_3HTuGjlZh0OM3ztzJoNVeA"
      decimals="0"
      id="Narr_ZEU05VbKG0eOIBGeqrPOHQ"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">151230</ganx:ReductionOfResearchAndDevelopmentExpensesThroughExpensesReimbursed>
    <us-gaap:GrantsReceivable
      contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_ganx_GtGainTherapeuticsSaMember_srt_CounterpartyNameAxis_ganx_Eurostars2Member_YNqIuW1F40W5tgg_Hji_3Q"
      decimals="0"
      id="Narr_FNOvdvtG9kO34Uc3vTdhjQ"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">81862</us-gaap:GrantsReceivable>
    <us-gaap:GrantsReceivable
      contextRef="As_Of_12_31_2020_dei_LegalEntityAxis_ganx_GtGainTherapeuticsSaMember_srt_CounterpartyNameAxis_ganx_Eurostars2Member_FaVauHMhk0mEw4Cnb7EatA"
      decimals="0"
      id="Narr_958npUTQPEijr6lKvDye5Q"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">51665</us-gaap:GrantsReceivable>
    <us-gaap:CashAndCashEquivalentsDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      id="Tb_6LvLYCBvske3ieJAyI159g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;4.&#160;&#160;&#160;&#160; Cash, cash equivalents and restricted cash&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company considers all short-term, highly liquid investments, with an original maturity of three&#160;months or less, to be cash equivalents. The Company&#x2019;s cash and cash equivalents include short-term highly liquid investments which are readily convertible into cash. These investments relate to money market securities with maturities of three&#160;months or less when acquired. The Company&#x2019;s institutional money market accounts permit daily redemption and the fair values of these investments are based upon the quoted prices in active markets provided by the holding financial institutions, which are considered Level 1 inputs in the fair value hierarchy (see note 12). Given their short-term maturities and the underlying being represented by cash equivalents, their face value amount approximate the related fair market value.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has not experienced any losses in these accounts and does not believe it is exposed to any significant credit risk on cash and cash equivalents.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Cash, cash equivalents and restricted cash are broken down as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:67.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:67.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Cash&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 3,262,977&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 907,255&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:67.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Money Market&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 33,617,696&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 6,585,655&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:67.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total cash and cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 36,880,673&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 7,492,910&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:67.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Restricted cash&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 31,279&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 11,371&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Restricted cash refers to an amount required under our Lugano new office lease agreement and deposited into a restricted bank account as a guarantee for expenses to be incurred in case of damage to the premises noted at the termination of the lease. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Details of the cash and cash equivalents balances as of December 31, 2021 and 2020, broken down by currency in which the funds are denominated, are reported in the following table:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:69.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:69.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cash in CHF&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 157,310&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 128,074&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:69.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cash in EUR&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 338,766&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 145,726&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:69.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cash in USD&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 36,322,777&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 7,149,386&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsDisclosureTextBlock>
    <us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      id="Tb_qKbGTWsC6kyzHlH1bvGYXQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:67.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:67.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Cash&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 3,262,977&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 907,255&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:67.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Money Market&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 33,617,696&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 6,585,655&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:67.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total cash and cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 36,880,673&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 7,492,910&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:67.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Restricted cash&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 31,279&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 11,371&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2021_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CashMember_fDDfSQp6UU-oqPAB4e119Q"
      decimals="0"
      id="Tc_F0905GiNWE2uHxaX09DGpA_3_3"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">3262977</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2020_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CashMember_hSR99mDOLk29CBNFU890Kw"
      decimals="0"
      id="Tc_zTLCxCH3dUKghD2gmnvsBw_3_6"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">907255</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2021_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_gnHItaHOm0WTAQXAM2HTwQ"
      decimals="0"
      id="Tc_OrtDDce51UOM6uIG2UxxBQ_4_3"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">33617696</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2020_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_YVDinHFXT0-dz2LLkYn02Q"
      decimals="0"
      id="Tc__Pd6I53eH0KogE7ji_w_xA_4_6"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">6585655</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A"
      decimals="0"
      id="Tc_xlI_6gq9YkaWb-_RFeoPZA_5_3"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">36880673</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg"
      decimals="0"
      id="Tc_TDEI3Pg_6kG6R29d3x7img_5_6"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">7492910</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCash
      contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A"
      decimals="0"
      id="Tc_lfelnBciz0CrB5XAdNdydg_6_3"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">31279</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg"
      decimals="0"
      id="Tc_WhS1rUTbO0q-zaDPacSUsA_6_6"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">11371</us-gaap:RestrictedCash>
    <ganx:ScheduleOfCashAndCashEquivalentsBalancesTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      id="Tb__K6pXaL6Nk2ZAY7mxyGfcg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:69.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:69.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cash in CHF&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 157,310&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 128,074&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:69.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cash in EUR&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 338,766&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 145,726&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:69.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cash in USD&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 36,322,777&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 7,149,386&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ganx:ScheduleOfCashAndCashEquivalentsBalancesTableTextBlock>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2021_srt_CurrencyAxis_currency_CHF_rDufzY5Ouk6hLwlR1vAueQ"
      decimals="0"
      id="Tc_4YGpMDZ6CkKXnw1p21U6rA_3_2"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">157310</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2020_srt_CurrencyAxis_currency_CHF_x9IJv5F-j0en4mIAdI3ZtA"
      decimals="0"
      id="Tc_WKg3c9EMSki7g6-sTG6dCg_3_4"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">128074</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2021_srt_CurrencyAxis_currency_EUR_FPdG1lChOEK7NjX3VPs_Hw"
      decimals="0"
      id="Tc_VvOuE2AhzEeCbwkmlwImGA_4_2"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">338766</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2020_srt_CurrencyAxis_currency_EUR_jtopedrPUk-JApA2wqKkRg"
      decimals="0"
      id="Tc_EDKFyyKQTkmtrL3d6H8fTQ_4_4"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">145726</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2021_srt_CurrencyAxis_currency_USD_JNFtn3l03kGKX0UlySPmQQ"
      decimals="0"
      id="Tc_wZudlV1H-kqF-ye_38pWgA_5_2"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">36322777</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2020_srt_CurrencyAxis_currency_USD_MG28bHY0C0G-LS6iFm77lQ"
      decimals="0"
      id="Tc_EoK_F6oKeUmlUXrBvkpvVw_5_4"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">7149386</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <ganx:PrepaidExpensesAndOtherCurrentAssetsTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      id="Tb_i_XnfVOSWUaYel-X7TiqmA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"&gt;&lt;span style="font-style:italic;"&gt;5.&#160;&#160;&#160;&#160;Other Current Assets&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;Other current assets consist of the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:73.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Tax Credits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 113,586&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 58,017&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Prepaid and deferred expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 498,252&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 198,994&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other receivable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 81,862&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Prepaid D&amp;amp;O Insurance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 147,671&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total Prepaid expenses and other current assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 727,785&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 198,994&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Tax credit consist of a value added tax credit (&#x201c;VAT&#x201d;). It is an indirect tax receivables from Switzerland and Spain tax authorities on purchases of goods and services executed on those countries. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Prepaid expenses refers to pre-payments made to vendors for future services. Deferred expenses mainly refer to research agreements entered into with third parties for research projects that will be recognized as expenses throughout the research period.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Prepaid D&amp;amp;O insurance costs relate to insurance premium which will be recognized in the statement of operations on a monthly basis through the twelve months insurance period.&lt;/p&gt;</ganx:PrepaidExpensesAndOtherCurrentAssetsTextBlock>
    <ganx:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      id="Tb_ncTP1f4c4U6BA8X85MtN7w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:73.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Tax Credits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 113,586&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 58,017&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Prepaid and deferred expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 498,252&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 198,994&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other receivable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 81,862&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Prepaid D&amp;amp;O Insurance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 147,671&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total Prepaid expenses and other current assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 727,785&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 198,994&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ganx:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock>
    <us-gaap:DeferredIncomeTaxesAndOtherTaxReceivableCurrent
      contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A"
      decimals="0"
      id="Tc_IGbFUJlmkUaTSNpvFt7JiA_3_3"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">113586</us-gaap:DeferredIncomeTaxesAndOtherTaxReceivableCurrent>
    <us-gaap:DeferredIncomeTaxesAndOtherTaxReceivableCurrent
      contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg"
      decimals="0"
      id="Tc_xD5c11DBQ0-_PaHMswiLSQ_3_6"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">58017</us-gaap:DeferredIncomeTaxesAndOtherTaxReceivableCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A"
      decimals="0"
      id="Tc_JHReo3_lJESt_iMuPLuYBw_5_3"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">498252</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg"
      decimals="0"
      id="Tc_7e4higlzR0yUA-_CWJyXEg_5_6"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">198994</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A"
      decimals="0"
      id="Tc_oI-5iybrCkWq_K2wyFwwug_6_3"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">81862</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:PrepaidInsurance
      contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A"
      decimals="0"
      id="Tc_M5rdGESkA0awceJbPmIfsw_7_3"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">147671</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A"
      decimals="0"
      id="Tc_zm7LmC1TskmuCYhbACqPVQ_8_3"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">727785</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg"
      decimals="0"
      id="Tc_BLXs1tcmg0uatBl5kleX-w_8_6"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">198994</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      id="Tb_mZsstONLU0i55Pho_obTcQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;6.&#160;&#160;&#160;&#160;Property and Equipment, net&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Property and equipment, net, consists of the following&lt;span style="font-size:11pt;"&gt;:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:69.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:69.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Computer&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 55,141&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 25,436&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:69.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Furniture and fixtures&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 42,148&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 4,865&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:69.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 17,327&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 8,889&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:69.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Laboratory instruments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 19,759&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 3,348&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:69.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total property and equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 134,375&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 42,538&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:69.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Less: accumulated depreciation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (28,389)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (12,905)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:69.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Property and equipment, net&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 105,986&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 29,633&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Property and equipment mainly consist of computers and set-up of a conference room in our Spanish and Lugano offices. No disposals, nor impairments occurred during the periods. Depreciation has been calculated by taking into consideration the use, purpose and financial-technical duration of the assets, based on their estimated economic lives.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Depreciation expense for the year ended December 31, 2021, and 2020 was USD 15,484 and USD 9,592, respectively.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      id="Tb_SFdxhCBKLk6z6iHuAHnChg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:69.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:69.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Computer&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 55,141&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 25,436&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:69.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Furniture and fixtures&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 42,148&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 4,865&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:69.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 17,327&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 8,889&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:69.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Laboratory instruments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 19,759&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 3,348&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:69.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total property and equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 134,375&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 42,538&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:69.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Less: accumulated depreciation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (28,389)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (12,905)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:69.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Property and equipment, net&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 105,986&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 29,633&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_DEcpOGG1JU2_mxWcWch9wA"
      decimals="0"
      id="Tc_bj3ZnH3GykuYwnqPUXzs1A_3_3"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">55141</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_6bdG0fwN7EC_-yHkMAKyHQ"
      decimals="0"
      id="Tc_--r2l2xNBkenIhcYc_3_Iw_3_6"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">25436</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_-nBpIitRCkCtsIXc9x1o_w"
      decimals="0"
      id="Tc_qllOGe5oG0KFY7cQKzbYGQ_4_3"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">42148</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_K3apo3t_cUqHmQGcaov5QQ"
      decimals="0"
      id="Tc_Mv45sLdNXEqXEYJkyE3rDw_4_6"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">4865</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_bbRnKwgINUGLy8vnaZzYFA"
      decimals="0"
      id="Tc_KntTfNNtKE-v1nfBDyHRBQ_5_3"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">17327</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_eLOEQvd7zk-xTusLDMYb_Q"
      decimals="0"
      id="Tc_ELgOyOXPHEGBB4qyh2C73w_5_6"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">8889</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ganx_LaboratoryInstrumentsMember_QYgSSMkkV06NDZOYiqbepA"
      decimals="0"
      id="Tc__hcu3_ojHUel4OwUpaHlAQ_6_3"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">19759</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ganx_LaboratoryInstrumentsMember_5du392y7_Ea3X3SOCPm2GA"
      decimals="0"
      id="Tc_yqtQUu5YL06fP15WB7M0NQ_6_6"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">3348</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A"
      decimals="0"
      id="Tc_bEpFbj0Sqk2vT3O0frFoNg_7_3"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">134375</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg"
      decimals="0"
      id="Tc_SqbwdlcF3UinLTAmlQx6YQ_7_6"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">42538</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A"
      decimals="0"
      id="Tc_p5U8Gxsk5kGn6jHTJ8q8Ww_8_3"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">28389</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg"
      decimals="0"
      id="Tc_2t7-it3RQEqtVkLNIq8WwQ_8_6"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">12905</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A"
      decimals="0"
      id="Tc_qytVinA5a0un60TseU-CBg_9_3"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">105986</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg"
      decimals="0"
      id="Tc_moe2kl1w7kOw9wy-OJadLw_9_6"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">29633</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentDisposals
      contextRef="Duration_1_1_2020_To_12_31_2020_JDEb6LtAmEuXGmEieWNlsw"
      decimals="0"
      id="Narr_GMKwXE_nREuir94cRA2NZg"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">0</us-gaap:PropertyPlantAndEquipmentDisposals>
    <us-gaap:PropertyPlantAndEquipmentDisposals
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      decimals="0"
      id="Narr__wq9a95Ya0yOtuy_XpCCXA"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">0</us-gaap:PropertyPlantAndEquipmentDisposals>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      decimals="0"
      id="Narr_BbbhvEV5s0eM1tlixu2GcQ"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">15484</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="Duration_1_1_2020_To_12_31_2020_JDEb6LtAmEuXGmEieWNlsw"
      decimals="0"
      id="Narr_QZQ4wFy_X0yy1lNS12oB2g"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">9592</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      id="Tb_so6A4nWfL02HCwH3RyQa6w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;7.&#160;&#160;&#160;&#160;Operating lease. Right of use (&#x201c;ROU&#x201d;) assets&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;Our leased assets include offices in Bethesda, Lugano and Barcelona and a lab in Barcelona. Our current lease portfolio consists of leases with remaining terms ranging from &lt;span style="-sec-ix-hidden:Hidden_ZalXIiQg2kKnz87xVmLaUQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;three&lt;/span&gt;&lt;/span&gt; to five years. Renewal options are excluded &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;from our calculation of lease liabilities unless we are reasonably certain that we will exercise the renewal option. Our lease agreements do not contain residual value guarantees or material restrictive covenants.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On June 1, 2021, the Company entered into a five year operating lease agreement to lease office space in Via Soave, n.6 in Lugano, Switzerland. The lease agreement is renewable for additional five years. The Company is required to pay for operating costs, including heating and water, which are adjusted and billed yearly based on usage. These additional charges are considered variable lease costs and are recognized in the period in which the costs are incurred. In connection with the lease, as guarantee for any damages claimed by the lessor, the Company deposited into a restricted bank account CHF 28,500 or USD 31,279 classified as restricted cash. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On August 31, 2021, the three year operating lease agreement to lease office space in Via Pietro Peri, 9D Lugano, Switzerland terminated and CHF 10,500 or USD 11,371 deposited into a restricted bank account were remitted to the Company.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On October 1, 2021, the Company entered into a three year operating lease agreement to lease office space in Bethesda, Maryland. In connection with the lease, the Company paid a security deposit of USD 5,227, classified as deposit in non-current assets, for the performance of all obligations, covenants and conditions and agreements under the lease. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On November 1, 2021, the Company entered into a five-years new operating lease agreement in Torre D Building with Parc Cientific de Barcelona for larger office space of 1,417 square feet to accommodate the Company&#x2019;s continued continuos growth and contemporaneosly terminated a lease, entered in October 2020, in Torre I Building for 830 square feet. In connection with the Torre D Building lease, the Company paid a security deposit of EUR 4,325 or USD 4,918 classified as deposit in non-current assets. The Company is required to pay for operating costs, including general services, scientific services, utilities, waste management services and taxes, which are billed monthly based on the Company's share of the total rentable square footage. These additional charges are considered variable lease costs and are recognized in the period in which the costs are incurred. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Operating leases are reflected on our balance sheet as operating lease ROU assets and the related current and non-current operating lease liabilities. ROU assets represent the right to use an underlying asset for the lease term, and lease liabilities represent the obligation to make lease payments arising from the lease agreement. Operating lease ROU assets and liabilities are recognized at the commencement date, or the date on which the lessor makes the underlying asset available for use, based upon the present value of the lease payments over the respective lease term. Lease expense is recognized on a straight-line basis over the lease term. Variable lease costs such as common area maintenance, property taxes and insurance are expensed as incurred.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The breakdown of the significant components of ROU assets and lease liabilities as of December 31, 2021 and 2020 is reported in the table below, together with the discount rate used in order to calculate the net present value of the lease liabilities as of those periods.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:69.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:69.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating Lease&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:69.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating lease- right of use assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 901,042&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 523,080&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:69.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:69.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating lease liability - current&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 219,137&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 122,756&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:69.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating lease liability - non current&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 695,053&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 400,324&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:69.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted average remaining lease term - years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:69.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted average discount rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 1.86&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 3.61&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The components of the lease costs which are included in the consolidated statements of operations and comprehensive loss were as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:69.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:69.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating lease costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 191,329&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 121,800&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;The future minimum lease payments for the Company&#x2019;s operating leases as of December 31, 2021, were as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.99%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Fiscal Year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Operating Leases&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 237,926&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 245,685&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 227,115&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 167,526&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 58,738&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total future minimum lease payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 936,990&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less amount representing interest or imputed interest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 22,800&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Present value of lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.99%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 914,190&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm
      contextRef="As_Of_12_31_2021_srt_RangeAxis_srt_MaximumMember_Tv-_F37-xki1Z4qnJJZcNg"
      id="Narr_yIQu0ZocnUqFO_ZK4eoB-Q">P5Y</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="As_Of_6_1_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ganx_OfficeSpaceViaSoaveN6LuganoSwitzerlandMember_PifC1TMuyUCNw5rbo-bIqg"
      id="Narr_fE-Nja0KCUWqPhFUr02FAA">P5Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="As_Of_6_1_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ganx_OfficeSpaceViaSoaveN6LuganoSwitzerlandMember_PifC1TMuyUCNw5rbo-bIqg"
      id="Narr__8xl1VjBCUm_HRSAsRjnAg">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:RestrictedCash
      contextRef="As_Of_6_1_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ganx_OfficeSpaceViaSoaveN6LuganoSwitzerlandMember_PifC1TMuyUCNw5rbo-bIqg"
      decimals="0"
      id="Narr_Ck7Ih-dWOEetK5-rTq9Hyg"
      unitRef="Unit_Standard_CHF_tZXBcOteZE6rGAnlVuK3Ng">28500</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="As_Of_6_1_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ganx_OfficeSpaceViaSoaveN6LuganoSwitzerlandMember_PifC1TMuyUCNw5rbo-bIqg"
      decimals="0"
      id="Narr_OpSFyVbR80q0b6SYWEG9Nw"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">31279</us-gaap:RestrictedCash>
    <ganx:LesseeOperatingLeaseTermOfCancelledContract
      contextRef="Duration_8_31_2021_To_8_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ganx_OfficeSpaceViaPietroPeri9DLuganoSwitzerlandMember_KKvzTiG970Ce6TsWGr7BeA"
      id="Narr_1BiVECrBX0axW_QNefK85g">P3Y</ganx:LesseeOperatingLeaseTermOfCancelledContract>
    <us-gaap:RestrictedCash
      contextRef="As_Of_8_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ganx_OfficeSpaceViaPietroPeri9DLuganoSwitzerlandMember_DFphXJwj90K3f5xEo5ZU9Q"
      decimals="0"
      id="Narr_X3aLH-8Q9kK2cSIJV-McUQ"
      unitRef="Unit_Standard_CHF_tZXBcOteZE6rGAnlVuK3Ng">10500</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="As_Of_8_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ganx_OfficeSpaceViaPietroPeri9DLuganoSwitzerlandMember_DFphXJwj90K3f5xEo5ZU9Q"
      decimals="0"
      id="Narr_OUbprBISfE6PICLND56ZMA"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">11371</us-gaap:RestrictedCash>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="As_Of_10_1_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ganx_OfficeSpaceInBethesdaMarylandMember_UeSQeDvOw0SJcAM-RLo4Lg"
      id="Narr_lgK2cRZwlkGhU5xWXOE_jg">P3Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:IncreaseDecreaseInSecurityDeposits
      contextRef="Duration_10_1_2021_To_10_1_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ganx_OfficeSpaceInBethesdaMarylandMember_9U2vOl3u9U-cCfj_ThszJA"
      decimals="0"
      id="Narr_F8CZ2Q47T0S46iEEvN3nDg"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">5227</us-gaap:IncreaseDecreaseInSecurityDeposits>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="As_Of_11_1_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ganx_OfficeSpaceTorreDBuildingBarcelonaMember_irdsQ60cnEm7ZZpQvK104Q"
      id="Narr_71q7uSgs_ESEDurvkQVc_Q">P5Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <ganx:OfficeSpace
      contextRef="As_Of_11_1_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ganx_OfficeSpaceTorreDBuildingBarcelonaMember_irdsQ60cnEm7ZZpQvK104Q"
      decimals="0"
      id="Narr_Va_baf6gHE2vOfyZTZJUoQ"
      unitRef="Unit_Standard_sqft_u3pgKg_7-0iwjFi0GwLPFg">1417</ganx:OfficeSpace>
    <ganx:OfficeSpace
      contextRef="As_Of_11_1_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ganx_OfficeSpaceTorreIBuildingBarcelonaMember_iI-D9SSrGEKpT_zGFsqoww"
      decimals="0"
      id="Narr_ZA6zUiibQk2Q6qtkJQ41nw"
      unitRef="Unit_Standard_sqft_u3pgKg_7-0iwjFi0GwLPFg">830</ganx:OfficeSpace>
    <us-gaap:IncreaseDecreaseInSecurityDeposits
      contextRef="Duration_11_1_2021_To_11_1_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ganx_OfficeSpaceTorreDBuildingBarcelonaMember_b34IOdjLSEeVrGT01vF1Rg"
      decimals="0"
      id="Narr_eIyuX1zRQEyVzfBlvwwblQ"
      unitRef="Unit_Standard_EUR_Q6wJYXg2bk-dYmARpDyDyQ">4325</us-gaap:IncreaseDecreaseInSecurityDeposits>
    <us-gaap:IncreaseDecreaseInSecurityDeposits
      contextRef="Duration_11_1_2021_To_11_1_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ganx_OfficeSpaceTorreDBuildingBarcelonaMember_b34IOdjLSEeVrGT01vF1Rg"
      decimals="0"
      id="Narr_kAM2IACHrEyPnBavKjG7gg"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">4918</us-gaap:IncreaseDecreaseInSecurityDeposits>
    <us-gaap:OperatingLeaseLeaseIncomeTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      id="Tb_wottwxrP3EmMgz-nEVBEJg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:69.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:69.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating Lease&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:69.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating lease- right of use assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 901,042&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 523,080&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:69.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:69.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating lease liability - current&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 219,137&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 122,756&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:69.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating lease liability - non current&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 695,053&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 400,324&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:69.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted average remaining lease term - years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:69.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted average discount rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 1.86&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 3.61&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:OperatingLeaseLeaseIncomeTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A"
      decimals="0"
      id="Tc_eeMa8kwcxUy79nNOy0CXbA_4_3"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">901042</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg"
      decimals="0"
      id="Tc_f9YkC3lD9kag_VwjeB97rw_4_6"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">523080</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A"
      decimals="0"
      id="Tc_DWYudpPjJkWe6x4w9MxoLQ_6_3"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">219137</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg"
      decimals="0"
      id="Tc_feZ7Fq3IHkWuTisWh40Jdw_6_6"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">122756</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A"
      decimals="0"
      id="Tc_djbiVFT9W0GxbrLx4feS4w_7_3"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">695053</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg"
      decimals="0"
      id="Tc_SHkwERY0A0SW8HlqF-htog_7_6"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">400324</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A"
      id="Tc_Q09evtjwxUKGLwfJd7sOKw_8_3">P4Y</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg"
      id="Tc_86ZmHtrSAkyDZvVd-s_Wuw_8_6">P5Y</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A"
      decimals="4"
      id="Tc__gpY5vxm5kSSZQ45uBMTgg_9_3"
      unitRef="Unit_Standard_pure_YPFUW3Xga0mVMPZT28RXUw">0.0186</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg"
      decimals="4"
      id="Tc_LENh6kth6UKEBj2Eic_YCg_9_6"
      unitRef="Unit_Standard_pure_YPFUW3Xga0mVMPZT28RXUw">0.0361</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      id="Tb_um6JfueeGE2rOElK0vhe7w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:69.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:69.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating lease costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 191,329&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 121,800&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      decimals="0"
      id="Tc_Vn8t0l5klUKUB5wx8zOpOw_3_2"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">191329</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_JDEb6LtAmEuXGmEieWNlsw"
      decimals="0"
      id="Tc_8siX9EmKGU6N2Jss0QNNwQ_3_4"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">121800</us-gaap:OperatingLeaseExpense>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      id="Tb_0liG3joA0kawcNrSDsvGDQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.99%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Fiscal Year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Operating Leases&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 237,926&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 245,685&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 227,115&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 167,526&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 58,738&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total future minimum lease payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 936,990&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less amount representing interest or imputed interest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 22,800&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Present value of lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.99%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 914,190&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent
      contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A"
      decimals="0"
      id="Tc_wpKxb19O90GlLN1CJw3IfQ_2_2"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">237926</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears
      contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A"
      decimals="0"
      id="Tc_TsmY8iide0Kr_OwyTVd3fw_3_2"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">245685</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears
      contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A"
      decimals="0"
      id="Tc_ciOI_D75s0ymeY6Ul8JkpQ_4_2"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">227115</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears
      contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A"
      decimals="0"
      id="Tc_US42PjNLR0qbcMGJV9QoXQ_5_2"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">167526</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears
      contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A"
      decimals="0"
      id="Tc_KStTtO8OXUSUEwVJiHqfCA_6_2"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">58738</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDue
      contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A"
      decimals="0"
      id="Tc_DtDiRSzxIkSbJCyo5mpLBA_8_2"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">936990</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
    <ganx:AdjustmentToReconcileOperatingLeaseLiabilitiesAmountsRepresentingInterestOrImputedInterest
      contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A"
      decimals="0"
      id="Tc_bGXzbcshzEi3kCO1uhJ8pA_9_2"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">22800</ganx:AdjustmentToReconcileOperatingLeaseLiabilitiesAmountsRepresentingInterestOrImputedInterest>
    <us-gaap:OperatingLeaseLiability
      contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A"
      decimals="0"
      id="Tc_-AbFyk8hZEWUdnVnBMQN6Q_10_2"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">914190</us-gaap:OperatingLeaseLiability>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      id="Tb_iIYti8xjLEuOdu3NkwcYuQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;8.&#160;&#160;&#160;&#160;Accounts Payable&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Accounts payable are reported at their nominal value. Accounts payable refer to amounts due to third parties on outstanding invoices received before year-end for services already provided. As of December 31, 2021 and 2020, accounts payable amounted to USD 560,479 and USD 961,516, respectively. All accounts payable are due in less than 12&#160;months. Details of the vendor outstanding payables as of December&#160;31, 2021 and 2020, broken down by currencies in which they are denominated, are reported in the following table:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:69.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:69.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Vendors Payables in CHF&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 13,166&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 29,423&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:69.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Vendors Payables in EUR&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 309,378&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 202,223&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:69.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Vendors Payables in USD&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 197,045&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 673,600&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A"
      decimals="0"
      id="Narr_9HQlerwGfkKFH-yDbLj0wg"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">560479</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg"
      decimals="0"
      id="Narr_veyM_szFp0Kgple76P93wg"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">961516</us-gaap:AccountsPayableCurrent>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      id="Tb_Z1LO0i-DsUCQbB5Wu16hcg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:69.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:69.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Vendors Payables in CHF&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 13,166&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 29,423&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:69.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Vendors Payables in EUR&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 309,378&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 202,223&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:69.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Vendors Payables in USD&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 197,045&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 673,600&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2021_srt_CurrencyAxis_currency_CHF_rDufzY5Ouk6hLwlR1vAueQ"
      decimals="0"
      id="Tc_b99HSFjJWkyLSuwUYWvb9w_3_2"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">13166</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2020_srt_CurrencyAxis_currency_CHF_x9IJv5F-j0en4mIAdI3ZtA"
      decimals="0"
      id="Tc_XvD3ptXY4EK3AIsVdMn_Hw_3_4"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">29423</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2021_srt_CurrencyAxis_currency_EUR_FPdG1lChOEK7NjX3VPs_Hw"
      decimals="0"
      id="Tc_Z5aIJ26C20qlrJ4twHGRCQ_4_2"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">309378</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2020_srt_CurrencyAxis_currency_EUR_jtopedrPUk-JApA2wqKkRg"
      decimals="0"
      id="Tc_FkINQAN_yUSAlaOYpjruhw_4_4"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">202223</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2021_srt_CurrencyAxis_currency_USD_JNFtn3l03kGKX0UlySPmQQ"
      decimals="0"
      id="Tc_G1bafZFjWE663P6BfAIg1Q_5_2"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">197045</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2020_srt_CurrencyAxis_currency_USD_MG28bHY0C0G-LS6iFm77lQ"
      decimals="0"
      id="Tc_D2h8S7ZMFE6poP7jWnJpJw_5_4"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">673600</us-gaap:AccountsPayableCurrent>
    <ganx:OtherCurrentLiabilitiesAndDeferredIncomeTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      id="Tb_GdVxgpmlqkOIwJ1D0HoiBQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;9.&#160;&#160;&#160;&#160;Other current liabilities and deferred income&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Other current liabilities and deferred income consist of the following as of December&#160;31, 2021 and 2020:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:68.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Payable for social securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 255,068&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 88,334&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued payroll&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 465,382&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 294,469&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 681,770&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 379,270&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Tax provision&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 380&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 1,070&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Deposit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 5,307&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;  Total Other Current Liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 1,402,600&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 768,450&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Deferred income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 266,504&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 239,483&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;  Total Other Current Liabilities and Deferred Income&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 1,669,104&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 1,007,933&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Payables for social securities refer to amounts due to social securities and employees withholding tax. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Accrued payroll refers to accruals for year-end bonuses, accrued vacations and extra-hours including social security charges, to be paid to employees.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Accrued expenses refer to invoices to be received from vendors for services performed and not yet billed.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Deferred income mainly refers to research grants received and, as of December 31, 2021, to a collaboration agreement entered into with Zentalis. Deferred income will be recognized in the consolidated statement of operations in accordance with the costs sustained.&lt;/p&gt;</ganx:OtherCurrentLiabilitiesAndDeferredIncomeTextBlock>
    <ganx:OtherCurrentLiabilitiesAndDeferredIncomeTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      id="Tb_zxdPKAoiRE64wSeK_4xkDQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:68.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Payable for social securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 255,068&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 88,334&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued payroll&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 465,382&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 294,469&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 681,770&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 379,270&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Tax provision&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 380&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 1,070&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Deposit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 5,307&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;  Total Other Current Liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 1,402,600&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 768,450&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Deferred income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 266,504&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 239,483&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;  Total Other Current Liabilities and Deferred Income&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 1,669,104&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 1,007,933&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ganx:OtherCurrentLiabilitiesAndDeferredIncomeTableTextBlock>
    <ganx:PayableForSocialSecuritiesCurrent
      contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A"
      decimals="0"
      id="Tc_UlgCY1u_HE2LdqVC0LlgHg_3_3"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">255068</ganx:PayableForSocialSecuritiesCurrent>
    <ganx:PayableForSocialSecuritiesCurrent
      contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg"
      decimals="0"
      id="Tc_71QMOSOmAkeXWT7bPfGv7Q_3_6"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">88334</ganx:PayableForSocialSecuritiesCurrent>
    <ganx:AccruedPayrollCurrent
      contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A"
      decimals="0"
      id="Tc_23CUyiuC70ezm_Ql4i9JgA_4_3"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">465382</ganx:AccruedPayrollCurrent>
    <ganx:AccruedPayrollCurrent
      contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg"
      decimals="0"
      id="Tc_d7hTBiQPi02wgfKfRhWfMA_4_6"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">294469</ganx:AccruedPayrollCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A"
      decimals="0"
      id="Tc_CBxpdbO_UkuTqiAdySzF-w_5_3"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">681770</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg"
      decimals="0"
      id="Tc_--QVmTV5f0-LeyossGcetQ_5_6"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">379270</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A"
      decimals="0"
      id="Tc_4ZNbKdMr00aLbFElUDDWkQ_6_3"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">380</us-gaap:TaxesPayableCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg"
      decimals="0"
      id="Tc_moemJHcFv0mkfyx2k6bEsQ_6_6"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">1070</us-gaap:TaxesPayableCurrent>
    <ganx:DepositsCurrent
      contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg"
      decimals="0"
      id="Tc_IARNZ_JJhEehmTFry7-HYg_7_6"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">5307</ganx:DepositsCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A"
      decimals="0"
      id="Tc_8PCoD2ykEEWI0B2pOclPGA_8_3"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">1402600</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg"
      decimals="0"
      id="Tc_vqWCFcmTgEegUaH5kKWlkQ_8_6"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">768450</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:DeferredIncomeCurrent
      contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A"
      decimals="0"
      id="Tc_TasHfvyq30qlXp01rwYHXA_9_3"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">266504</us-gaap:DeferredIncomeCurrent>
    <us-gaap:DeferredIncomeCurrent
      contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg"
      decimals="0"
      id="Tc_Rt9e3katTkalqsTzmd-u3w_9_6"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">239483</us-gaap:DeferredIncomeCurrent>
    <us-gaap:DeferredCreditsAndOtherLiabilitiesCurrent
      contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A"
      decimals="0"
      id="Tc_FioXV412bEiq5k7QvY74mA_10_3"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">1669104</us-gaap:DeferredCreditsAndOtherLiabilitiesCurrent>
    <us-gaap:DeferredCreditsAndOtherLiabilitiesCurrent
      contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg"
      decimals="0"
      id="Tc_gr90dxSVMkKJTfXo7vjisw_10_6"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">1007933</us-gaap:DeferredCreditsAndOtherLiabilitiesCurrent>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      id="Tb_cUf1gTgbbUWJ1_DNWqkIAg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;10.&#160;&#160;&#160;&#160;Pension obligations&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Net pension obligations related to the Company&#x2019;s defined pension plan refer only to Swiss employees and as of December&#160;31, 2021 and 2020, can be summarized as follows:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;End of year funed status:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Fair value of plan assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 943,025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 477,288&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;(Projected benefit obligation)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,272,483)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (648,846)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Funded status&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (329,458)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (171,558)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accumululated benefit obligation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,233,053&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 652,445&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Reconciliation of funded status:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Funded status beginning of year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (171,558)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (126,629)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (144,146)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (44,474)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Employer contribution&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 88,819&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 36,264&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Translation differences&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,437)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (501)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Change in AOCI over the year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (101,136)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (36,218)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Funded status at end of year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (329,458)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (171,558)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Component of net periodic pension costs:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Service cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 132,809&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 36,597&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Interest cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,318&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 947&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Expected return on plan assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (5,558)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,564)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Amortization of (gain)/losses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 16,212&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 10,494&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Amortization of prior service cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (635)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 144,146&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 44,474&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="7" style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Service cost is reported in research and development and general and administrative expenses. All other components of net period costs are reported in interest income, net in the consolidated statement of operations&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Reconciliation of projected benefit obligation:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Projected benefit obligation at January 1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 648,846&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 496,819&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Services cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 132,809&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 36,597&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Employee contribution&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 59,208&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 25,770&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Interest Cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,318&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 947&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Benefit payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 315,300&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 48,602&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt; (Gain)/loss on financial assumption&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (27,799)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 4,379&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt; (Gain)/loss on demographic assumption&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (43,123)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt; (Gain)/loss on experience&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 193,984&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 35,732&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Plan Amendement&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (8,060)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,272,483&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 648,846&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Reconciliation of fair value of plan assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Fair value at January 1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 477,288&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 370,190&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Expected return on plan assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 5,558&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 3,564&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Gain/(loss) on plan assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,148)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (9,454)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Employer contributions&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 88,819&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 36,264&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Employee contributions&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 59,208&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 25,770&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Benefit payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 315,300&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 48,602&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Others&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 2,352&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Fair value at December 31&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 943,025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 477,288&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Change in net (gain)/loss:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;(Gain)/loss at beginning of year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 154,665&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 117,803&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;(Gain)/loss on PBO during year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 122,895&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 37,902&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;(Gain)/loss on assets during year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 3,148&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 9,454&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Amortization of gain/(loss)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (16,212)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (10,494)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;(Gain)/loss at end of year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 264,496&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 154,665&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Change in accumulated other comprehensive income (AOCI):&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;AOCI at beginning of year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 154,665&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 117,803&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Net gain/(loss) amortized&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (16,212)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (10,494)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;(Gain)/loss on PBO during the year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 122,895&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 37,902&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;(Gain)/loss on assets during the year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 3,148&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 9,454&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Prior Service Cost/(credit) occurring over the year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (8,060)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Net prior service (cost)/credit amortized&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (635)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Total AOCI at end of year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 255,801&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 154,665&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The assumptions used in the determination of the benefit obligation and the plan assets for the pension plans and the pension obligation were as follows:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:60.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:60.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Actuarial Assumptions (%pa):&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:60.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Discount rate &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;0.30%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;0.15%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:60.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Interest credit rate / ERoA &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;1.00%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;1.00%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:60.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Salary increases &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;1.00%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;1.00%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:60.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Pension increases &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;0.00%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;0.00%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:60.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Demographic Assumptions:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:60.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Lump-sum option &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;25%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;25%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:60.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Retirement age &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;65/64&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;65/64&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:60.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Proportion married &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;.BVG 2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;.80%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:60.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Allowance for child pensions &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:17.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;5% loading on risk benefits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:17.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;5% loading on risk benefits&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:60.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Mortality base table &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;.BVG 2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;.BVG 2015&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:60.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Longevity improvement &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;CMI 2018 (1.25%)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;CMI 2016 (1.25%)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:60.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Turnover &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;.BVG 2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;.BVG 2015&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:60.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Disability &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;80%.BVG 2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;80% BVG 2015&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected benefit payments:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Year 1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 162,208&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 11,363&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Year 2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 54,723&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 141,225&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Year 3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 58,224&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 29,330&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Year 4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 60,869&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 30,793&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Year 5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 63,281&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 31,963&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Next 5 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 428,371&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 169,658&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other disclosure items:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Next year's expected employer contribution&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 112,396&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 38,873&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s investment strategy for its pension plans is to optimize the long-term investment return on plan assets in relation to the liability structure to maintain an acceptable level of risk while minimizing the cost of providing pension benefits and maintaining adequate funding levels in accordance with applicable rules in each jurisdiction.&#160;The Company does not manage any assets internally. The plan assest relates to mandatory and discretionary contributions made in accordance with Swiss Law to a leading pension provider. The capital is fully insured and provides for a fixed rate of return. The fair value is based on the value of the assets held by the provider and as such has been classified within Level 3 of the fair value hierarchy. &#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;We maintain a 401(k) saving Plan, which is available to all U.S. employees. Participants may make voluntary contributions. We make matching contributions according to the 401(k) Saving Plan&#x2019;s matching formula. All matching contributions and participant contribution vest immediately. &#160;The expense related to our 401(k) Savings Pan consist of our matching contributions. Expenses related to our 401(k) Savings Plan totaled USD 3,243 and nil for the years ended December 31, 2021 and 2020.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:ScheduleOfDefinedBenefitPlansDisclosuresTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      id="Tb_SYsvhMeC_0C9in7Y10fbkw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Net pension obligations related to the Company&#x2019;s defined pension plan refer only to Swiss employees and as of December&#160;31, 2021 and 2020, can be summarized as follows:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;End of year funed status:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Fair value of plan assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 943,025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 477,288&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;(Projected benefit obligation)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,272,483)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (648,846)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Funded status&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (329,458)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (171,558)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accumululated benefit obligation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,233,053&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 652,445&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Reconciliation of funded status:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Funded status beginning of year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (171,558)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (126,629)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (144,146)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (44,474)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Employer contribution&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 88,819&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 36,264&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Translation differences&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,437)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (501)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Change in AOCI over the year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (101,136)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (36,218)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Funded status at end of year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (329,458)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (171,558)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Component of net periodic pension costs:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Service cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 132,809&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 36,597&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Interest cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,318&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 947&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Expected return on plan assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (5,558)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,564)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Amortization of (gain)/losses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 16,212&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 10,494&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Amortization of prior service cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (635)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 144,146&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 44,474&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="7" style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Service cost is reported in research and development and general and administrative expenses. All other components of net period costs are reported in interest income, net in the consolidated statement of operations&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Reconciliation of projected benefit obligation:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Projected benefit obligation at January 1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 648,846&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 496,819&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Services cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 132,809&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 36,597&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Employee contribution&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 59,208&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 25,770&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Interest Cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,318&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 947&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Benefit payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 315,300&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 48,602&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt; (Gain)/loss on financial assumption&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (27,799)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 4,379&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt; (Gain)/loss on demographic assumption&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (43,123)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt; (Gain)/loss on experience&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 193,984&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 35,732&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Plan Amendement&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (8,060)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,272,483&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 648,846&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Reconciliation of fair value of plan assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Fair value at January 1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 477,288&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 370,190&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Expected return on plan assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 5,558&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 3,564&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Gain/(loss) on plan assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,148)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (9,454)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Employer contributions&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 88,819&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 36,264&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Employee contributions&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 59,208&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 25,770&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Benefit payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 315,300&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 48,602&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Others&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 2,352&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Fair value at December 31&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 943,025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 477,288&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Change in net (gain)/loss:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;(Gain)/loss at beginning of year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 154,665&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 117,803&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;(Gain)/loss on PBO during year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 122,895&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 37,902&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;(Gain)/loss on assets during year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 3,148&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 9,454&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Amortization of gain/(loss)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (16,212)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (10,494)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;(Gain)/loss at end of year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 264,496&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 154,665&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Change in accumulated other comprehensive income (AOCI):&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;AOCI at beginning of year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 154,665&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 117,803&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Net gain/(loss) amortized&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (16,212)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (10,494)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;(Gain)/loss on PBO during the year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 122,895&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 37,902&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;(Gain)/loss on assets during the year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 3,148&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 9,454&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Prior Service Cost/(credit) occurring over the year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (8,060)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Net prior service (cost)/credit amortized&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (635)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Total AOCI at end of year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 255,801&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 154,665&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDefinedBenefitPlansDisclosuresTextBlock>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="As_Of_12_31_2021_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_i6PZAoMNcEySLcgBUKmmjw"
      decimals="0"
      id="Tc_Q27ZdDWE0kq53DyMQHFXgg_4_3"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">943025</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="As_Of_12_31_2020_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_HLv731xR10GVgI0Jt-JL5w"
      decimals="0"
      id="Tc_edSNlr6Yn0ScXmoEopVshg_4_6"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">477288</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="As_Of_12_31_2021_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_i6PZAoMNcEySLcgBUKmmjw"
      decimals="0"
      id="Tc_JLi6GcGp4kyOwi6K3vREmg_5_3"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">1272483</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="As_Of_12_31_2020_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_HLv731xR10GVgI0Jt-JL5w"
      decimals="0"
      id="Tc_oPHfv3JRIUyZKWMwcg0EPQ_5_6"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">648846</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanFundedStatusOfPlan
      contextRef="As_Of_12_31_2021_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_i6PZAoMNcEySLcgBUKmmjw"
      decimals="0"
      id="Tc_FzjJ3rggdk23d421YxMTiA_6_3"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">-329458</us-gaap:DefinedBenefitPlanFundedStatusOfPlan>
    <us-gaap:DefinedBenefitPlanFundedStatusOfPlan
      contextRef="As_Of_12_31_2020_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_HLv731xR10GVgI0Jt-JL5w"
      decimals="0"
      id="Tc_avwiyMdFGU2PuFpZsApe7w_6_6"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">-171558</us-gaap:DefinedBenefitPlanFundedStatusOfPlan>
    <us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation
      contextRef="As_Of_12_31_2021_us-gaap_RetirementPlanSponsorLocationAxis_country_CH_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_JNWw1VrK5kqfZgK60b8Pdw"
      decimals="0"
      id="Tc_xFRQcVo8BEKX1D8PRWk8-Q_8_3"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">1233053</us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation>
    <us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation
      contextRef="As_Of_12_31_2020_us-gaap_RetirementPlanSponsorLocationAxis_country_CH_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_XR8N6cpyV0WdwjyDiJrSbA"
      decimals="0"
      id="Tc_nbRwcoA0cUG3xRVArH4HYg_8_6"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">652445</us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation>
    <us-gaap:DefinedBenefitPlanFundedStatusOfPlan
      contextRef="As_Of_12_31_2020_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_HLv731xR10GVgI0Jt-JL5w"
      decimals="0"
      id="Tc_WbzBZubPZU6n-3kSaBhWtw_11_3"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">-171558</us-gaap:DefinedBenefitPlanFundedStatusOfPlan>
    <us-gaap:DefinedBenefitPlanFundedStatusOfPlan
      contextRef="As_Of_12_31_2019_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_t7HEGl5NAk-CsgC95XNoeg"
      decimals="0"
      id="Tc_kdmpSoAEE0OaTkqAC2dUlg_11_6"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">-126629</us-gaap:DefinedBenefitPlanFundedStatusOfPlan>
    <ganx:IncreaseDecreaseThroughTotalExpensesToReconcileFundedStatusOfDefinedBenefitPlan
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_kMW3hEdOQk-Go8nyyVufvA"
      decimals="0"
      id="Tc_l89hIsdCX0CDZKL2WthIJQ_12_3"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">144146</ganx:IncreaseDecreaseThroughTotalExpensesToReconcileFundedStatusOfDefinedBenefitPlan>
    <ganx:IncreaseDecreaseThroughTotalExpensesToReconcileFundedStatusOfDefinedBenefitPlan
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_NLtbBeqGQESB9Jjk98teAA"
      decimals="0"
      id="Tc_-cGqCHkoD06oTiuvmkXj6A_12_6"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">44474</ganx:IncreaseDecreaseThroughTotalExpensesToReconcileFundedStatusOfDefinedBenefitPlan>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_kMW3hEdOQk-Go8nyyVufvA"
      decimals="0"
      id="Tc_H98mdQEYTkunfdoAdqNCWQ_13_3"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">88819</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_NLtbBeqGQESB9Jjk98teAA"
      decimals="0"
      id="Tc_8BIlCqxFckqJtxWvCByaBw_13_6"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">36264</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_kMW3hEdOQk-Go8nyyVufvA"
      decimals="0"
      id="Tc_biu970vIU0uoAXh9PLDVwQ_14_3"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">1437</us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss>
    <us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_NLtbBeqGQESB9Jjk98teAA"
      decimals="0"
      id="Tc_jKZm6CerR0mjAtmbHHgh8w_14_6"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">501</us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss>
    <ganx:IncreaseDecreaseInAccumulatedOtherComprehensiveIncomeToReconcileFundedStatusOfDefinedBenefitPlan
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_kMW3hEdOQk-Go8nyyVufvA"
      decimals="0"
      id="Tc_OxZ6MgT3SESpuxghwuwt5g_15_3"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">101136</ganx:IncreaseDecreaseInAccumulatedOtherComprehensiveIncomeToReconcileFundedStatusOfDefinedBenefitPlan>
    <ganx:IncreaseDecreaseInAccumulatedOtherComprehensiveIncomeToReconcileFundedStatusOfDefinedBenefitPlan
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_NLtbBeqGQESB9Jjk98teAA"
      decimals="0"
      id="Tc_wxP239XwikSdrfxVZu-Qwg_15_6"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">36218</ganx:IncreaseDecreaseInAccumulatedOtherComprehensiveIncomeToReconcileFundedStatusOfDefinedBenefitPlan>
    <us-gaap:DefinedBenefitPlanFundedStatusOfPlan
      contextRef="As_Of_12_31_2021_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_i6PZAoMNcEySLcgBUKmmjw"
      decimals="0"
      id="Tc_F8Et3vUy_k-EJGHgeOB6ig_16_3"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">-329458</us-gaap:DefinedBenefitPlanFundedStatusOfPlan>
    <us-gaap:DefinedBenefitPlanFundedStatusOfPlan
      contextRef="As_Of_12_31_2020_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_HLv731xR10GVgI0Jt-JL5w"
      decimals="0"
      id="Tc_MuhG19vO60igGDbaEO2s8Q_16_6"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">-171558</us-gaap:DefinedBenefitPlanFundedStatusOfPlan>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_kMW3hEdOQk-Go8nyyVufvA"
      decimals="0"
      id="Tc_Q2KToW-kk0yaGVREX2TvyA_19_3"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">132809</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_NLtbBeqGQESB9Jjk98teAA"
      decimals="0"
      id="Tc_P-tuIj0hlEC5S6W40OtcRw_19_6"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">36597</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_kMW3hEdOQk-Go8nyyVufvA"
      decimals="0"
      id="Tc_pqS1fb4QekS8tx10IyXYHw_20_3"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">1318</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_NLtbBeqGQESB9Jjk98teAA"
      decimals="0"
      id="Tc_ml2wl2GYGk-3m0twJtdx_A_20_6"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">947</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_kMW3hEdOQk-Go8nyyVufvA"
      decimals="0"
      id="Tc_ZlkW842UJUuzu0Fb5CgJGg_21_3"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">5558</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_NLtbBeqGQESB9Jjk98teAA"
      decimals="0"
      id="Tc_4k3uYO1FcEuZmekLPyNXsw_21_6"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">3564</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_kMW3hEdOQk-Go8nyyVufvA"
      decimals="0"
      id="Tc_QsbaJNvfJ0qrPmcas9cUgw_22_3"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">-16212</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_NLtbBeqGQESB9Jjk98teAA"
      decimals="0"
      id="Tc_RB815e35JU6kdWLnezqVTw_22_6"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">-10494</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_kMW3hEdOQk-Go8nyyVufvA"
      decimals="0"
      id="Tc_o24YiHME8UyhuUJIkYTmCw_23_3"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">-635</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_kMW3hEdOQk-Go8nyyVufvA"
      decimals="0"
      id="Tc_XSpZ4ldgH06u26D9kK600A_24_3"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">144146</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_NLtbBeqGQESB9Jjk98teAA"
      decimals="0"
      id="Tc_sGPfURTQ1k6tflgF1flEsA_24_6"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">44474</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="As_Of_12_31_2020_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_HLv731xR10GVgI0Jt-JL5w"
      decimals="0"
      id="Tc_k6OGlJcHHUSG8bnlATdMUg_29_3"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">648846</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="As_Of_12_31_2019_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_t7HEGl5NAk-CsgC95XNoeg"
      decimals="0"
      id="Tc_endUBZjkYECjJub7BTRUmQ_29_6"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">496819</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_kMW3hEdOQk-Go8nyyVufvA"
      decimals="0"
      id="Tc_eVoyLG9a90mBgJILROJaAA_30_3"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">132809</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_NLtbBeqGQESB9Jjk98teAA"
      decimals="0"
      id="Tc_YK9NZsYGgUmzxGAde_llCg_30_6"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">36597</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_kMW3hEdOQk-Go8nyyVufvA"
      decimals="0"
      id="Tc_kRqyBjnIDEGIf2UNLPMN3g_31_3"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">59208</us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant>
    <us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_NLtbBeqGQESB9Jjk98teAA"
      decimals="0"
      id="Tc_lDWCwa8o_Ea_PCJ29ZASNg_31_6"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">25770</us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_kMW3hEdOQk-Go8nyyVufvA"
      decimals="0"
      id="Tc_eBHfeObnbEKz1nzpXmAGIg_32_3"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">1318</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_NLtbBeqGQESB9Jjk98teAA"
      decimals="0"
      id="Tc_8PkUNfLX_UC_EQiYtO1ZRg_32_6"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">947</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_kMW3hEdOQk-Go8nyyVufvA"
      decimals="0"
      id="Tc__vpIz_tfN0a-BsGLyyRIsw_33_3"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">315300</us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid>
    <us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_NLtbBeqGQESB9Jjk98teAA"
      decimals="0"
      id="Tc_aa-kej0dh0KuT3JSj6MnRA_33_6"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">48602</us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid>
    <ganx:DefinedBenefitPlanBenefitObligationGainsLossesOnFinancialAssumptions
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_kMW3hEdOQk-Go8nyyVufvA"
      decimals="0"
      id="Tc_119fa-jbB06gA5BBKTKqsA_34_3"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">27799</ganx:DefinedBenefitPlanBenefitObligationGainsLossesOnFinancialAssumptions>
    <ganx:DefinedBenefitPlanBenefitObligationGainsLossesOnFinancialAssumptions
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_NLtbBeqGQESB9Jjk98teAA"
      decimals="0"
      id="Tc_RQbOIsCRNkmipdbhohHfyw_34_6"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">-4379</ganx:DefinedBenefitPlanBenefitObligationGainsLossesOnFinancialAssumptions>
    <ganx:DefinedBenefitPlanBenefitObligationGainsLossesOnDemographicAssumptions
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_kMW3hEdOQk-Go8nyyVufvA"
      decimals="0"
      id="Tc_TVuyNCX2mkiPrO123XsOfg_35_3"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">43123</ganx:DefinedBenefitPlanBenefitObligationGainsLossesOnDemographicAssumptions>
    <ganx:DefinedBenefitPlanBenefitObligationGainsLossesOnExperience
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_kMW3hEdOQk-Go8nyyVufvA"
      decimals="0"
      id="Tc_RrArjlZMFUSn30wwMp3TYQ_36_3"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">-193984</ganx:DefinedBenefitPlanBenefitObligationGainsLossesOnExperience>
    <ganx:DefinedBenefitPlanBenefitObligationGainsLossesOnExperience
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_NLtbBeqGQESB9Jjk98teAA"
      decimals="0"
      id="Tc_nncm7njGoUivy9uPwz9RKQ_36_6"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">-35732</ganx:DefinedBenefitPlanBenefitObligationGainsLossesOnExperience>
    <us-gaap:DefinedBenefitPlanPlanAmendments
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_kMW3hEdOQk-Go8nyyVufvA"
      decimals="0"
      id="Tc_XQej1CiMnUaBj4gk5dM9XA_37_3"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">-8060</us-gaap:DefinedBenefitPlanPlanAmendments>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="As_Of_12_31_2021_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_i6PZAoMNcEySLcgBUKmmjw"
      decimals="0"
      id="Tc_FMucpMDwCUuKgd_htq0b2Q_38_3"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">1272483</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="As_Of_12_31_2020_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_HLv731xR10GVgI0Jt-JL5w"
      decimals="0"
      id="Tc_DSxj91DiwkGDPYDS6Uh9Eg_38_6"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">648846</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="As_Of_12_31_2020_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_HLv731xR10GVgI0Jt-JL5w"
      decimals="0"
      id="Tc_lKTtwSEZ0kaSeAOv8tVyIQ_4_3"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">477288</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="As_Of_12_31_2019_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_t7HEGl5NAk-CsgC95XNoeg"
      decimals="0"
      id="Tc_jy-rfbr7cU-bjuFQ6UoLPw_4_6"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">370190</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_kMW3hEdOQk-Go8nyyVufvA"
      decimals="0"
      id="Tc_xsHG3l4tGk2vIJ-9yj8DRA_5_3"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">5558</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_NLtbBeqGQESB9Jjk98teAA"
      decimals="0"
      id="Tc_DaR2VpVeUU2fwssheLDq-Q_5_6"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">3564</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_kMW3hEdOQk-Go8nyyVufvA"
      decimals="0"
      id="Tc_LnDXr4gVakac_H3nbbZ_xw_6_3"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">-3148</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_NLtbBeqGQESB9Jjk98teAA"
      decimals="0"
      id="Tc_thRv21BGg02dhQoe8Q_tog_6_6"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">-9454</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_kMW3hEdOQk-Go8nyyVufvA"
      decimals="0"
      id="Tc_tiCBSbzAok-KvGf-BUIfdA_7_3"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">88819</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_NLtbBeqGQESB9Jjk98teAA"
      decimals="0"
      id="Tc_p8S1t2FIzkGJHGtJGyZR3A_7_6"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">36264</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_kMW3hEdOQk-Go8nyyVufvA"
      decimals="0"
      id="Tc_9mrzLOPri0WQCcobXqq_Ew_8_3"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">59208</us-gaap:DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant>
    <us-gaap:DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_NLtbBeqGQESB9Jjk98teAA"
      decimals="0"
      id="Tc_u_PHpAtmEUaSnYgIjPaD5w_8_6"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">25770</us-gaap:DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant>
    <us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_kMW3hEdOQk-Go8nyyVufvA"
      decimals="0"
      id="Tc_3aoNo-mOLES2NyINiZADYA_9_3"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">315300</us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid>
    <us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_NLtbBeqGQESB9Jjk98teAA"
      decimals="0"
      id="Tc_f7d8DBBhDUuQEbdU-e0r1w_9_6"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">48602</us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid>
    <ganx:DefinedBenefitPlanPlanAssetsOtherIncreasesDecreases
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_NLtbBeqGQESB9Jjk98teAA"
      decimals="0"
      id="Tc_N_wF6a5oiUe0GOymxvkhkg_10_6"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">2352</ganx:DefinedBenefitPlanPlanAssetsOtherIncreasesDecreases>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="As_Of_12_31_2021_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_i6PZAoMNcEySLcgBUKmmjw"
      decimals="0"
      id="Tc_5PblzWlbD0SZ5jwmFvJl-w_11_3"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">943025</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="As_Of_12_31_2020_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_HLv731xR10GVgI0Jt-JL5w"
      decimals="0"
      id="Tc_D67DQMgZZEiIwMKRWIxA_Q_11_6"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">477288</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax
      contextRef="As_Of_12_31_2020_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_HLv731xR10GVgI0Jt-JL5w"
      decimals="0"
      id="Tc_eBcy3cwKY0mXoTxmKhPCHw_4_3"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">154665</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax
      contextRef="As_Of_12_31_2019_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_t7HEGl5NAk-CsgC95XNoeg"
      decimals="0"
      id="Tc_yGDXDMKK-U-FuHdJnsizQw_4_6"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">117803</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax>
    <us-gaap:DefinedBenefitPlanBenefitObligationPeriodIncreaseDecrease
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_kMW3hEdOQk-Go8nyyVufvA"
      decimals="0"
      id="Tc_RRIAmsKskEKxBWTzHUEQmw_5_3"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">122895</us-gaap:DefinedBenefitPlanBenefitObligationPeriodIncreaseDecrease>
    <us-gaap:DefinedBenefitPlanBenefitObligationPeriodIncreaseDecrease
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_NLtbBeqGQESB9Jjk98teAA"
      decimals="0"
      id="Tc_8AykUM7MiEmXHyDYocUfCA_5_6"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">37902</us-gaap:DefinedBenefitPlanBenefitObligationPeriodIncreaseDecrease>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssetsPeriodIncreaseDecrease
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_kMW3hEdOQk-Go8nyyVufvA"
      decimals="0"
      id="Tc_MSiNe4eHk06sTMF2F8AlCQ_6_3"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">3148</us-gaap:DefinedBenefitPlanFairValueOfPlanAssetsPeriodIncreaseDecrease>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssetsPeriodIncreaseDecrease
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_NLtbBeqGQESB9Jjk98teAA"
      decimals="0"
      id="Tc_Zy8VpYcPcUu7c6sn68-8Dw_6_6"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">9454</us-gaap:DefinedBenefitPlanFairValueOfPlanAssetsPeriodIncreaseDecrease>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_kMW3hEdOQk-Go8nyyVufvA"
      decimals="0"
      id="Tc_linhj_S0UkqEdMbLx5AJNg_7_3"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">-16212</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_NLtbBeqGQESB9Jjk98teAA"
      decimals="0"
      id="Tc_ipwaBlI32keSOuMnDWorCg_7_6"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">-10494</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax
      contextRef="As_Of_12_31_2021_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_i6PZAoMNcEySLcgBUKmmjw"
      decimals="0"
      id="Tc_b4a2Kd07_kyCGFJmQDyh4A_8_3"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">264496</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax
      contextRef="As_Of_12_31_2020_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_HLv731xR10GVgI0Jt-JL5w"
      decimals="0"
      id="Tc_SSXxdcMQMEmdgbzXj6P67g_8_6"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">154665</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax
      contextRef="As_Of_12_31_2020_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_HLv731xR10GVgI0Jt-JL5w"
      decimals="0"
      id="Tc_DeTjN0Ij3kqn3sBGHREJTQ_4_3"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">154665</us-gaap:AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax
      contextRef="As_Of_12_31_2019_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_t7HEGl5NAk-CsgC95XNoeg"
      decimals="0"
      id="Tc_9Zr93sF5TkSjrv8tUprw2Q_4_6"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">117803</us-gaap:AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_kMW3hEdOQk-Go8nyyVufvA"
      decimals="0"
      id="Tc_iMmG1vCnOU2WRJWzisXQXw_5_3"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">-16212</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_NLtbBeqGQESB9Jjk98teAA"
      decimals="0"
      id="Tc_cZKgW90G90mgFJqlqSw2Mw_5_6"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">-10494</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanBenefitObligationPeriodIncreaseDecrease
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_kMW3hEdOQk-Go8nyyVufvA"
      decimals="0"
      id="Tc_rJJX5XaPKEqQASUr_pRqcg_6_3"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">122895</us-gaap:DefinedBenefitPlanBenefitObligationPeriodIncreaseDecrease>
    <us-gaap:DefinedBenefitPlanBenefitObligationPeriodIncreaseDecrease
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_NLtbBeqGQESB9Jjk98teAA"
      decimals="0"
      id="Tc_5wnK_CQQ-UOUv_W1gaca1w_6_6"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">37902</us-gaap:DefinedBenefitPlanBenefitObligationPeriodIncreaseDecrease>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssetsPeriodIncreaseDecrease
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_kMW3hEdOQk-Go8nyyVufvA"
      decimals="0"
      id="Tc_IhwFSN3XZU2p4zrfRHx88g_7_3"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">3148</us-gaap:DefinedBenefitPlanFairValueOfPlanAssetsPeriodIncreaseDecrease>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssetsPeriodIncreaseDecrease
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_NLtbBeqGQESB9Jjk98teAA"
      decimals="0"
      id="Tc_j_QeWjGgq0u1HniS6Oxouw_7_6"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">9454</us-gaap:DefinedBenefitPlanFairValueOfPlanAssetsPeriodIncreaseDecrease>
    <us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_kMW3hEdOQk-Go8nyyVufvA"
      decimals="0"
      id="Tc_KCKG5lloBkufYWJklrDf7g_8_3"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">-8060</us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_kMW3hEdOQk-Go8nyyVufvA"
      decimals="0"
      id="Tc_JdW0RTUfJUiuTZXol8-ImA_9_3"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">-635</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax
      contextRef="As_Of_12_31_2021_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_i6PZAoMNcEySLcgBUKmmjw"
      decimals="0"
      id="Tc_jmjlGNk2dECxnbsSCQPXoQ_10_3"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">255801</us-gaap:AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax
      contextRef="As_Of_12_31_2020_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_HLv731xR10GVgI0Jt-JL5w"
      decimals="0"
      id="Tc_wDLH0rLmBky8pIPBYDZQgg_10_6"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">154665</us-gaap:AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax>
    <us-gaap:ScheduleOfAssumptionsUsedTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      id="Tb_DEk84f5zB0WCftFOI40W-A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The assumptions used in the determination of the benefit obligation and the plan assets for the pension plans and the pension obligation were as follows:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:60.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:60.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Actuarial Assumptions (%pa):&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:60.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Discount rate &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;0.30%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;0.15%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:60.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Interest credit rate / ERoA &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;1.00%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;1.00%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:60.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Salary increases &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;1.00%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;1.00%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:60.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Pension increases &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;0.00%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;0.00%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:60.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Demographic Assumptions:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:60.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Lump-sum option &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;25%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;25%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:60.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Retirement age &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;65/64&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;65/64&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:60.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Proportion married &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;.BVG 2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;.80%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:60.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Allowance for child pensions &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:17.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;5% loading on risk benefits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:17.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;5% loading on risk benefits&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:60.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Mortality base table &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;.BVG 2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;.BVG 2015&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:60.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Longevity improvement &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;CMI 2018 (1.25%)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;CMI 2016 (1.25%)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:60.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Turnover &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;.BVG 2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;.BVG 2015&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:60.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Disability &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;80%.BVG 2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;80% BVG 2015&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfAssumptionsUsedTableTextBlock>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate
      contextRef="As_Of_12_31_2021_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_i6PZAoMNcEySLcgBUKmmjw"
      decimals="4"
      id="Tc_VH1CRsihlkiNeJvEBkPYgg_4_3"
      unitRef="Unit_Standard_pure_YPFUW3Xga0mVMPZT28RXUw">0.0030</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate
      contextRef="As_Of_12_31_2020_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_HLv731xR10GVgI0Jt-JL5w"
      decimals="4"
      id="Tc_Y1h4Oe9jxkeeeIuatt105g_4_6"
      unitRef="Unit_Standard_pure_YPFUW3Xga0mVMPZT28RXUw">0.0015</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate
      contextRef="As_Of_12_31_2021_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_i6PZAoMNcEySLcgBUKmmjw"
      decimals="4"
      id="Tc_wv3ZtiwWU0isps8SqY_Bbw_5_3"
      unitRef="Unit_Standard_pure_YPFUW3Xga0mVMPZT28RXUw">0.0100</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate
      contextRef="As_Of_12_31_2020_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_HLv731xR10GVgI0Jt-JL5w"
      decimals="4"
      id="Tc_ISFz4rSNT0qwsK2gHfR6pg_5_6"
      unitRef="Unit_Standard_pure_YPFUW3Xga0mVMPZT28RXUw">0.0100</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease
      contextRef="As_Of_12_31_2021_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_i6PZAoMNcEySLcgBUKmmjw"
      decimals="4"
      id="Tc_r2wJyP8frk-uRBhRy0lnhw_6_3"
      unitRef="Unit_Standard_pure_YPFUW3Xga0mVMPZT28RXUw">0.0100</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease
      contextRef="As_Of_12_31_2020_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_HLv731xR10GVgI0Jt-JL5w"
      decimals="4"
      id="Tc__b4Y0oSY9kanVjg0T1PErQ_6_6"
      unitRef="Unit_Standard_pure_YPFUW3Xga0mVMPZT28RXUw">0.0100</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease>
    <ganx:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfPensionIncreases
      contextRef="As_Of_12_31_2021_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_i6PZAoMNcEySLcgBUKmmjw"
      decimals="4"
      id="Tc_4msnr7ebPUq3H4EL-fAPDw_7_3"
      unitRef="Unit_Standard_pure_YPFUW3Xga0mVMPZT28RXUw">0.0000</ganx:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfPensionIncreases>
    <ganx:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfPensionIncreases
      contextRef="As_Of_12_31_2020_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_HLv731xR10GVgI0Jt-JL5w"
      decimals="4"
      id="Tc_nCVA5kXG-UKsyoB4qtGG7A_7_6"
      unitRef="Unit_Standard_pure_YPFUW3Xga0mVMPZT28RXUw">0.0000</ganx:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfPensionIncreases>
    <ganx:DefinedBenefitPlanDemographicAssumptionLumpSumOption
      contextRef="As_Of_12_31_2021_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_i6PZAoMNcEySLcgBUKmmjw"
      decimals="2"
      id="Tc_bBpzcjIs1E6KZz5d7Aoj6g_9_3"
      unitRef="Unit_Standard_pure_YPFUW3Xga0mVMPZT28RXUw">0.25</ganx:DefinedBenefitPlanDemographicAssumptionLumpSumOption>
    <ganx:DefinedBenefitPlanDemographicAssumptionLumpSumOption
      contextRef="As_Of_12_31_2020_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_HLv731xR10GVgI0Jt-JL5w"
      decimals="2"
      id="Tc_wHC97_YHEE65oocgyGJflg_9_6"
      unitRef="Unit_Standard_pure_YPFUW3Xga0mVMPZT28RXUw">0.25</ganx:DefinedBenefitPlanDemographicAssumptionLumpSumOption>
    <ganx:DefinedBenefitPlanDemographicAssumptionProportionMarried
      contextRef="As_Of_12_31_2020_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_HLv731xR10GVgI0Jt-JL5w"
      decimals="4"
      id="Tc_CNmBlHjYFkyWxyOo8nin9Q_11_6"
      unitRef="Unit_Standard_pure_YPFUW3Xga0mVMPZT28RXUw">0.0080</ganx:DefinedBenefitPlanDemographicAssumptionProportionMarried>
    <ganx:DefinedBenefitPlanDemographicAssumptionAllowanceForChildPensions
      contextRef="As_Of_12_31_2021_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_i6PZAoMNcEySLcgBUKmmjw"
      decimals="2"
      id="Narr_GjSdlzjjWkeI0hw2ivpIew"
      unitRef="Unit_Standard_pure_YPFUW3Xga0mVMPZT28RXUw">0.05</ganx:DefinedBenefitPlanDemographicAssumptionAllowanceForChildPensions>
    <ganx:DefinedBenefitPlanDemographicAssumptionAllowanceForChildPensions
      contextRef="As_Of_12_31_2020_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_HLv731xR10GVgI0Jt-JL5w"
      decimals="2"
      id="Narr_QClPknMHMUqNxbmI05bKNQ"
      unitRef="Unit_Standard_pure_YPFUW3Xga0mVMPZT28RXUw">0.05</ganx:DefinedBenefitPlanDemographicAssumptionAllowanceForChildPensions>
    <ganx:DefinedBenefitPlanMortalityImprovementPercentage
      contextRef="As_Of_12_31_2021_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_i6PZAoMNcEySLcgBUKmmjw"
      decimals="4"
      id="Narr_DPdsoM8yL0-jVrrGV-Rlbg"
      unitRef="Unit_Standard_pure_YPFUW3Xga0mVMPZT28RXUw">0.0125</ganx:DefinedBenefitPlanMortalityImprovementPercentage>
    <ganx:DefinedBenefitPlanMortalityImprovementPercentage
      contextRef="As_Of_12_31_2020_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_HLv731xR10GVgI0Jt-JL5w"
      decimals="4"
      id="Narr_e1_wR1H6nk2O41DkvzTmbw"
      unitRef="Unit_Standard_pure_YPFUW3Xga0mVMPZT28RXUw">0.0125</ganx:DefinedBenefitPlanMortalityImprovementPercentage>
    <ganx:DefinedBenefitPlanDisabilityPercentage
      contextRef="As_Of_12_31_2021_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_i6PZAoMNcEySLcgBUKmmjw"
      decimals="4"
      id="Narr_2V4W0DYv40WtPGFbbM3PXw"
      unitRef="Unit_Standard_pure_YPFUW3Xga0mVMPZT28RXUw">0.80</ganx:DefinedBenefitPlanDisabilityPercentage>
    <ganx:DefinedBenefitPlanDisabilityPercentage
      contextRef="As_Of_12_31_2020_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_HLv731xR10GVgI0Jt-JL5w"
      decimals="4"
      id="Narr_Ap-OhTCxmkmurgybqH-ahQ"
      unitRef="Unit_Standard_pure_YPFUW3Xga0mVMPZT28RXUw">0.80</ganx:DefinedBenefitPlanDisabilityPercentage>
    <us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      id="Tb_aEhD-AMUIUiMnH4ux2xpSw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected benefit payments:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Year 1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 162,208&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 11,363&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Year 2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 54,723&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 141,225&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Year 3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 58,224&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 29,330&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Year 4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 60,869&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 30,793&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Year 5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 63,281&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 31,963&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Next 5 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 428,371&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 169,658&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other disclosure items:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Next year's expected employer contribution&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 112,396&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 38,873&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths
      contextRef="As_Of_12_31_2021_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_i6PZAoMNcEySLcgBUKmmjw"
      decimals="0"
      id="Tc_6Rzfr0T5hkWZfeDbZ8XV_w_4_3"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">162208</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths
      contextRef="As_Of_12_31_2020_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_HLv731xR10GVgI0Jt-JL5w"
      decimals="0"
      id="Tc_G2-MYeTLOkyouRUu50OSvg_4_6"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">11363</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo
      contextRef="As_Of_12_31_2021_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_i6PZAoMNcEySLcgBUKmmjw"
      decimals="0"
      id="Tc_jjdWDL3os02qpifEIOzbmQ_5_3"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">54723</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo
      contextRef="As_Of_12_31_2020_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_HLv731xR10GVgI0Jt-JL5w"
      decimals="0"
      id="Tc_rHWxAjCXDUOXGJFnwMb0bQ_5_6"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">141225</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree
      contextRef="As_Of_12_31_2021_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_i6PZAoMNcEySLcgBUKmmjw"
      decimals="0"
      id="Tc_BzbXPWaSL0ek4I9urHoPJQ_6_3"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">58224</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree
      contextRef="As_Of_12_31_2020_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_HLv731xR10GVgI0Jt-JL5w"
      decimals="0"
      id="Tc_KNX_ldSO_kuqVNC0V8eA7A_6_6"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">29330</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour
      contextRef="As_Of_12_31_2021_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_i6PZAoMNcEySLcgBUKmmjw"
      decimals="0"
      id="Tc_V-D8VrCbJkurOJnEo6uSFg_7_3"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">60869</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour
      contextRef="As_Of_12_31_2020_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_HLv731xR10GVgI0Jt-JL5w"
      decimals="0"
      id="Tc_SILJb_4L0EO7CJGS_eue8A_7_6"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">30793</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive
      contextRef="As_Of_12_31_2021_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_i6PZAoMNcEySLcgBUKmmjw"
      decimals="0"
      id="Tc_ATfV4E3xFUWg-Atq86GTug_8_3"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">63281</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive
      contextRef="As_Of_12_31_2020_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_HLv731xR10GVgI0Jt-JL5w"
      decimals="0"
      id="Tc_Av_M45SHhkm8I3jurQ3zdQ_8_6"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">31963</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter
      contextRef="As_Of_12_31_2021_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_i6PZAoMNcEySLcgBUKmmjw"
      decimals="0"
      id="Tc_eU7YnyQkUkmYS_H5dgdWwQ_9_3"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">428371</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter
      contextRef="As_Of_12_31_2020_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_HLv731xR10GVgI0Jt-JL5w"
      decimals="0"
      id="Tc_1glGETqKYE62Ml65ZVSogA_9_6"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">169658</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter>
    <us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear
      contextRef="As_Of_12_31_2021_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_i6PZAoMNcEySLcgBUKmmjw"
      decimals="0"
      id="Tc_NqlT9I95JUybfq3xVkIy9Q_12_3"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">112396</us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear>
    <us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear
      contextRef="As_Of_12_31_2020_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_HLv731xR10GVgI0Jt-JL5w"
      decimals="0"
      id="Tc_3qDgVfalk0qcBfzAA5wklA_12_6"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">38873</us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      decimals="0"
      id="Narr_p-dfRP3-FE-52NK3UFuWSQ"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">3243</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="Duration_1_1_2020_To_12_31_2020_JDEb6LtAmEuXGmEieWNlsw"
      decimals="0"
      id="Narr_xVhpZNbJkUeqDH2odMh4NA"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">0</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      id="Tb_I5-8FQl_j0KrnPvlp4CoZw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;11&lt;/span&gt;&lt;span style="font-style:italic;"&gt;.&#160;&#160;&#160;&#160;Loans&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In March&#160;2020, the Company obtained a CHF 14,600 (USD 16,024) five-year loan. The loan had zero interest and original maturity on March 31, 2025. The loan was guaranteed through joint and several sureties by the Swiss government. The loan is part of the infrastructure put in place by the Federal Council and Swiss Parliament in view of the economic consequences of the coronavirus. As of December 31, 2021, the outstanding balance has been reclassified as current as the Company decided to estinguish the loan. No expenses or charges were due for the early extinguishment.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In August&#160;2020, the Company obtained a CHF 638,000 (USD 700,221 at the historical forex exchange rate) nine-year loan. The loan has zero interest. The loan is due in quarterly installments of CHF 20,000, with payments commencing on December&#160;31, 2021 and ending on September&#160;30, 2029. The loan is part of the infrastructure put in place by the Federal Council and Swiss Parliament in view of the economic consequences of the coronavirus. Loans granted do &lt;span style="-sec-ix-hidden:Hidden_4WczMy8Ec0ae6MFBpO8JBg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;not&lt;/span&gt;&lt;/span&gt; bear interest and no issuance costs have been borne. As such they have been accounted for at face value, which is deemed to approximate the related fair value.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The future loan payments are reported in the table below:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2026&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Thereafter&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:11.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Loan&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 694,294&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 103,826&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 87,806&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 87,806&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 87,806&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 87,806&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 239,244&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_3_31_2020_us-gaap_DebtInstrumentAxis_ganx_March2020ChfLoanMember_FV-iSHC9DECOjK6nXfZqag"
      decimals="0"
      id="Narr_L0QEw_e7YkS-0sNcRwuxBg"
      unitRef="Unit_Standard_CHF_tZXBcOteZE6rGAnlVuK3Ng">14600</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_3_31_2020_us-gaap_DebtInstrumentAxis_ganx_March2020ChfLoanMember_FV-iSHC9DECOjK6nXfZqag"
      decimals="0"
      id="Narr_qibc7i-ds0KVutTHQjDK0Q"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">16024</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentTerm
      contextRef="Duration_3_1_2020_To_3_31_2020_us-gaap_DebtInstrumentAxis_ganx_March2020ChfLoanMember_S8zeqoa7qEuI5LdFwXbKLw"
      id="Narr_RP4dPBjUGEapiiFhhi6wPg">P5Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_3_31_2020_us-gaap_DebtInstrumentAxis_ganx_March2020ChfLoanMember_FV-iSHC9DECOjK6nXfZqag"
      decimals="2"
      id="Narr_Ie3qXWMAZkKPhn_BzntvKg"
      unitRef="Unit_Standard_pure_YPFUW3Xga0mVMPZT28RXUw">0</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <ganx:ExpensesOrChargesDueForEarlyExtinguishmentOfDebt
      contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A"
      decimals="0"
      id="Narr_sloEmN99uUu3lDnnJxcRRw"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">0</ganx:ExpensesOrChargesDueForEarlyExtinguishmentOfDebt>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_8_31_2020_us-gaap_DebtInstrumentAxis_ganx_August2020ChfLoanMember_os9qx323O06rGZDMfoiU8Q"
      decimals="0"
      id="Narr_rCXr9TBqL0CHhixjld6YFg"
      unitRef="Unit_Standard_CHF_tZXBcOteZE6rGAnlVuK3Ng">638000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_8_31_2020_us-gaap_DebtInstrumentAxis_ganx_August2020ChfLoanMember_os9qx323O06rGZDMfoiU8Q"
      decimals="0"
      id="Narr_1ufqka3vGE-YdRQV14uqBw"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">700221</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentTerm
      contextRef="Duration_8_1_2020_To_8_31_2020_us-gaap_DebtInstrumentAxis_ganx_August2020ChfLoanMember_QkIhdbW_8Uis0Buu2_viHA"
      id="Narr_RyXcSF3JFEOFX3_JxOnt7A">P9Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_8_31_2020_us-gaap_DebtInstrumentAxis_ganx_August2020ChfLoanMember_os9qx323O06rGZDMfoiU8Q"
      decimals="2"
      id="Narr_NZ3Q5qeXB0u4o_dVf3iV9A"
      unitRef="Unit_Standard_pure_YPFUW3Xga0mVMPZT28RXUw">0</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentPeriodicPayment
      contextRef="Duration_8_1_2020_To_8_31_2020_us-gaap_DebtInstrumentAxis_ganx_August2020ChfLoanMember_QkIhdbW_8Uis0Buu2_viHA"
      decimals="0"
      id="Narr_-0bBPDdrPEqeiqoi3t4T8w"
      unitRef="Unit_Standard_CHF_tZXBcOteZE6rGAnlVuK3Ng">20000</us-gaap:DebtInstrumentPeriodicPayment>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A"
      decimals="0"
      id="Narr_nMrgpYQz6kqZ7Q5yABCIkw"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">0</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      id="Tb_Y5s9rlkYZUCiYLMSu720-A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2026&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Thereafter&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:11.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Loan&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 694,294&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 103,826&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 87,806&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 87,806&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 87,806&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 87,806&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 239,244&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebt
      contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A"
      decimals="0"
      id="Tc_3pHTFK67OkmTIERZ-wNa6Q_2_2"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">694294</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A"
      decimals="0"
      id="Tc_1usnZGfwt0-47d3-0_yW0A_2_4"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">103826</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A"
      decimals="0"
      id="Tc_OjyMRjDSxkmAb7B-p5chow_2_6"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">87806</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A"
      decimals="0"
      id="Tc_FFTaVVquUk22JqFk1YUInA_2_8"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">87806</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
      contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A"
      decimals="0"
      id="Tc_6ndpm3UxxEe0GiTSUwaEwg_2_10"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">87806</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
      contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A"
      decimals="0"
      id="Tc_fc8Ut2Iqx0OElMSHjp4Y1A_2_12"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">87806</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive
      contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A"
      decimals="0"
      id="Tc_PFfBKCfr1EeLWwvL1iyjHw_2_14"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">239244</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      id="Tb_-ldaStEofUe_xsvJQkpiEg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;12.&#160;&#160;&#160;&#160;Fair value measurement&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:28.8pt;margin:0pt 0pt 12pt 0pt;"&gt;Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The Company&#x2019;s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:28.8pt;margin:0pt 0pt 12pt 0pt;"&gt;The carrying amounts of the Company&#x2019;s cash and cash equivalents, including money market funds, restricted cash and financial liabilities are considered to be representative of their respective fair values because of the short-term nature and the contractual terms of those instruments. The fair values of money market funds are based upon the quoted prices in active markets provided by the holding financial institution, which are considered Level 1 inputs in the fair value hierarchy according to ASC820.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:28.8pt;margin:0pt 0pt 12pt 0pt;"&gt;There have been no changes to the valuation methods utilized by the Company, nor were there transfers between levels of the fair value hierarchy.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100.48%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:56.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:56.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;white-space:nowrap;width:41.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair value measurement at reporting date using&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:13.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Quoted prices in active market for identical assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:11.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant other observable inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:11.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant unobservable inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:13.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(level 1)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:11.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(level 2)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:11.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(level 3)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;December 31, 2021:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Cash and cash equivalents:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 33,617,696&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Total cash and cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 33,617,696&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Total financial assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 33,617,696&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;December 31, 2020:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Cash and cash equivalents:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,585,655&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Total cash and cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,585,655&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Total financial assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,585,655&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:28.8pt;margin:0pt 0pt 12pt 0pt;"&gt;The carrying amounts of prepaid expenses and other current assets, accounts payable and accrued expenses approximate their &#160;fair value due to their short-term maturities.&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      id="Tb_UnpUOBBGJEWDXscNHyvWxg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100.48%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:56.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:56.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;white-space:nowrap;width:41.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair value measurement at reporting date using&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:13.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Quoted prices in active market for identical assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:11.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant other observable inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:11.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant unobservable inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:13.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(level 1)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:11.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(level 2)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:11.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(level 3)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;December 31, 2021:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Cash and cash equivalents:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 33,617,696&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Total cash and cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 33,617,696&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Total financial assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 33,617,696&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;December 31, 2020:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Cash and cash equivalents:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,585,655&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Total cash and cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,585,655&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Total financial assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,585,655&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2021_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_jwo2h2HgjU-Oaoug1oOjXg"
      decimals="0"
      id="Tc_PuPRf844M0uP5PYx6mUSDw_7_3"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">33617696</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2021_us-gaap_FairValueByAssetClassAxis_us-gaap_CashAndCashEquivalentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_aPJD3-UwWk2aYpTKhM55uA"
      decimals="0"
      id="Tc_4-Q5IpFcqkSwh3bKfLhznA_8_3"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">33617696</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_uuaa7xnlyki6ykqgX7Pttw"
      decimals="0"
      id="Tc_nT_-PMp2PUqQdX-p5G6aVA_10_3"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">33617696</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2020_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_yQGxUTb4_kyBt2-oIiFKuQ"
      decimals="0"
      id="Tc_C1Rmh5e9w0yxC4syO0W5ug_15_3"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">6585655</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2020_us-gaap_FairValueByAssetClassAxis_us-gaap_CashAndCashEquivalentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_zzuqJkU6kk6sqgnOWt5eyA"
      decimals="0"
      id="Tc_cfN5ADn6MkGf4_Ow0L2QWg_16_3"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">6585655</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_c2-Hsc31bki-8GK8iPACMA"
      decimals="0"
      id="Tc_khtTbQ5eHEGzciGho2OeJw_18_3"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">6585655</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      id="Tb_iaYH-axrxEqBfgXM3XHw_w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;13.&#160;&#160;&#160;&#160;Common and Preferred Stock&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December 31, 2021 and 2020, the authorized capital stock of the Company included 50,000,000 shares of common stock, $0.0001 par value and 10,000,000 shares of preferred stock, $0.0001 par value. As of December 31, 2021 and 2020, 11,883,368 and 3,543,163 (4,022,736 &lt;span style="-sec-ix-hidden:Hidden_ARvqt8O7vki9CqZo9ksCdw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;before&lt;/span&gt;&lt;/span&gt; the reverse stock split) shares of common stock, $0.0001 par value, were &lt;span style="-sec-ix-hidden:Hidden_smJgQqCN6kCASsqGpDK0oA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;issued&lt;/span&gt;&lt;/span&gt; and &lt;span style="-sec-ix-hidden:Hidden_eCHc0lXrwkaLahqSp1jTsw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;outstanding&lt;/span&gt;&lt;/span&gt;. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;No preferred stocks were outstanding as of December 31, 2021. There were 1,185,879 &#160;(1,346,390 before the reverse stock split) &lt;span style="-sec-ix-hidden:Hidden_xoy4pURJ0U6SC06b57siOQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;shares&lt;/span&gt;&lt;/span&gt; of Series&#160;A &lt;span style="-sec-ix-hidden:Hidden_kdwNLQKYWkiveM0sOQGupw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Preferred&lt;/span&gt;&lt;/span&gt; Stock, par value $0.0001 and 2,965,600 (3,366,999 before the reverse stock split) &lt;span style="-sec-ix-hidden:Hidden_VxK6clrWrk2DfpjK2-sdow;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;shares&lt;/span&gt;&lt;/span&gt; of Series&#160;B &lt;span style="-sec-ix-hidden:Hidden_iLyIO00eQUWJB3oyw2X5yQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Preferred&lt;/span&gt;&lt;/span&gt; Stock, par value $0.0001, issued and outstanding as of December&#160;31, 2020. The reverse stock split did not result in any change of the original par value of the Company common and preferred stock.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Upon closing of the IPO, the Preferred Stock, as resulting from the reverse stock split, were converted to common stock at a ratio of 1-for-1.The holders of the Company&#x2019;s Preferred Stock had certain voting, dividend, and redemption rights, as well as liquidation preferences and conversion privileges. All rights, preferences, and privileges associated with the preferred stock were terminated at the time of the Company&#x2019;s IPO in conjunction with the conversion of all outstanding shares of Preferred Stock into shares of common stock.&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg"
      decimals="INF"
      id="Narr__Ap69RDEwE2ctZYPGGsF3Q"
      unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw">50000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A"
      decimals="INF"
      id="Narr_D1I7IiTgtUiWnpxAdmQD4Q"
      unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw">50000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg"
      decimals="INF"
      id="Narr_XeAyo2mKCEOqTIpqjG_hlA"
      unitRef="Unit_Divide_USD_shares_ZUfWDOiJrESFdyfJo2gfWg">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A"
      decimals="INF"
      id="Narr_90PjsW7RZkejuXpPKc5L4Q"
      unitRef="Unit_Divide_USD_shares_ZUfWDOiJrESFdyfJo2gfWg">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg"
      decimals="INF"
      id="Narr_qnPUIHi9b0GALYVtRZ8ipA"
      unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A"
      decimals="INF"
      id="Narr_fnbeLl7qrU6WAyjeHXY9ug"
      unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg"
      decimals="4"
      id="Narr_7LojEldETUadtKRbSwGvqg"
      unitRef="Unit_Divide_USD_shares_ZUfWDOiJrESFdyfJo2gfWg">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A"
      decimals="4"
      id="Narr_FbtDjrnUUkWjgRFJn2eSyA"
      unitRef="Unit_Divide_USD_shares_ZUfWDOiJrESFdyfJo2gfWg">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A"
      decimals="INF"
      id="Narr_rNqLbYh7WkiwpOzHjsOS4w"
      unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw">11883368</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg"
      decimals="INF"
      id="Narr_J4iGouVOiE2fLxLeu8KY2Q"
      unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw">3543163</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_3_16_2021_fYMXRlaU00CBob3C4xDimg"
      decimals="0"
      id="Narr_bzbjkEhUc06iL_cqGGOJXA"
      unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw">4022736</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg"
      decimals="INF"
      id="Narr_6aqH3f4AsUGtlADISb4edA"
      unitRef="Unit_Divide_USD_shares_ZUfWDOiJrESFdyfJo2gfWg">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A"
      decimals="INF"
      id="Narr_cRd2EY0AgkueKPKZGNykLA"
      unitRef="Unit_Divide_USD_shares_ZUfWDOiJrESFdyfJo2gfWg">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A"
      decimals="INF"
      id="Narr_e-9V1uvqPUStUPnKVjLhFQ"
      unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredClassAMember_QpkPvPPAwEiZSl5LOyqQvA"
      decimals="INF"
      id="Narr_Po7C2nxNFUu5j-K-8FlPwg"
      unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw">1185879</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_3_16_2021_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredClassAMember_LA-5cb6F00S56dV8R_wEsQ"
      decimals="INF"
      id="Narr_7c25fXz-X0OEfED1pHUO-Q"
      unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw">1346390</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredClassAMember_QpkPvPPAwEiZSl5LOyqQvA"
      decimals="INF"
      id="Narr_6GeduYpAFE-hTC2h49Xpzw"
      unitRef="Unit_Divide_USD_shares_ZUfWDOiJrESFdyfJo2gfWg">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredClassBMember_G4x0CiU2mUOuiMOxwNFS6Q"
      decimals="INF"
      id="Narr_MMV68o1LeU6NIhc0aezLNA"
      unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw">2965600</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_3_16_2021_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredClassBMember_HBe32B_mIkuJvMwKt7oZ-g"
      decimals="INF"
      id="Narr_7XLFKAT_e0mYRvTxnJ2Xrw"
      unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw">3366999</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredClassBMember_G4x0CiU2mUOuiMOxwNFS6Q"
      decimals="INF"
      id="Narr_b6U59OrBeU2RooQ2K_x4uw"
      unitRef="Unit_Divide_USD_shares_ZUfWDOiJrESFdyfJo2gfWg">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <ganx:PreferredStockToCommonStockConversionRatio
      contextRef="Duration_3_17_2021_To_3_17_2021_u6CMktnXaUyF6ar7hHmEcw"
      decimals="INF"
      id="Narr_nS5p6-Uvik695CDBMNPyJQ"
      unitRef="Unit_Standard_pure_YPFUW3Xga0mVMPZT28RXUw">1</ganx:PreferredStockToCommonStockConversionRatio>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="Duration_3_17_2021_To_3_17_2021_u6CMktnXaUyF6ar7hHmEcw"
      decimals="INF"
      id="Narr_6ZfMIgh0MkiebE-L6gzkYA"
      unitRef="Unit_Standard_pure_YPFUW3Xga0mVMPZT28RXUw">1</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <ganx:WarrantsAndRightsNoteDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      id="Tb_5qSLNxljFEWk1_HAGOMZ-g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;14.&#160;&#160;&#160;&#160;Warrants&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:35.45pt;margin:0pt;"&gt;In July, 2020, in connection with the issuance of the Series B Preferred Stock through a private placement, the Company issued equity-classified warrants to designees of the placement agent to purchase an aggregate of 269,360 shares of our common stock at an exercise price of $4.46 per share, valued in the aggregate at USD 413,887 and included in the issuance costs of the Series B Preferred Stock. The warrants vested immediately upon issuance, &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;provide for a cashless exercise right and are exercisable for a period of five years from July&#160;20, 2020. &#160;On March&#160;3, 2021, the Board approved a 1-for-&lt;span style="-sec-ix-hidden:Hidden_R7-eb03Se0uFXfouVE5ALg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;0.880784&lt;/span&gt;&lt;/span&gt; reverse stock split of the Company&#x2019;s outstanding equity instruments. The reverse stock split was approved by the stockholders on March&#160;4, 2021 and became effective on March&#160;17, 2021. Shares of common stock underlying outstanding warrants were proportionately reduced from 269,360 to 237,249 and the respective exercise prices, were proportionately increased from $4.46 to $5.07 in accordance with the terms of the agreements governing such securities. As of December 31, 2021, 11,862 warrants were exercised resulting in 3,283 shares having been issued following the cashless mechanism as per the terms of the agreement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On May 6, 2021, the Company entered into nine months investing banking services and financial advisory agreement and issued equity-classified warrants to designees of the investment bank to purchase an aggregate of 200,000 shares of the Company common stock at an exercise price of $13.75 per share, valued in the aggregate at USD 1,034 thousand. The warrants vested immediately upon issuance, do not provide cashless exercise right and are exercisable for a period of four years from May 6, 2021. The fair value of the warrants is recognized on a straight-line basis over the nine months service period as general and administrative expense. As of December 30, 2021, no warrants were exercised or exchanged.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The fair value of the warrants issued in 2020 and 2021 is estimated using the Black-Scholes option pricing model with the following assumptions:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:70.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:70.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:70.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:70.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Grant date fair value&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 5.17&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 1.54&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:70.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 70&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 75&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:70.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected term (years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 4.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 5.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:70.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 0.81&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 0.28&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:70.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected dividend yield -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</ganx:WarrantsAndRightsNoteDisclosureTextBlock>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_7_31_2020_us-gaap_ClassOfWarrantOrRightAxis_ganx_WarrantsToDesigneesOfPlacementAgentIssuedJuly2020Member__xz3VXdq4UepWPvW5n-chA"
      decimals="INF"
      id="Narr_KV_A3lZH2kyW4uWKxvBXbQ"
      unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw">269360</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_7_31_2020_us-gaap_ClassOfWarrantOrRightAxis_ganx_WarrantsToDesigneesOfPlacementAgentIssuedJuly2020Member__xz3VXdq4UepWPvW5n-chA"
      decimals="2"
      id="Narr_5k662-voo0qGOiCauR_uow"
      unitRef="Unit_Divide_USD_shares_ZUfWDOiJrESFdyfJo2gfWg">4.46</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="As_Of_7_31_2020_us-gaap_ClassOfWarrantOrRightAxis_ganx_WarrantsToDesigneesOfPlacementAgentIssuedJuly2020Member__xz3VXdq4UepWPvW5n-chA"
      decimals="INF"
      id="Narr_rajswGZl106-SM9Oz_7JiA"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">413887</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="As_Of_7_31_2020_us-gaap_ClassOfWarrantOrRightAxis_ganx_WarrantsToDesigneesOfPlacementAgentIssuedJuly2020Member__xz3VXdq4UepWPvW5n-chA"
      id="Narr_yW890Pexw0W4cyqATHmXjw">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_3_16_2021_us-gaap_ClassOfWarrantOrRightAxis_ganx_WarrantsToDesigneesOfPlacementAgentIssuedJuly2020Member_YF5W3invl02ldRF6Cq2TAQ"
      decimals="INF"
      id="Narr_bZ7RQFMY-0u4S9YvJk2Dyw"
      unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw">269360</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_3_17_2021_us-gaap_ClassOfWarrantOrRightAxis_ganx_WarrantsToDesigneesOfPlacementAgentIssuedJuly2020Member_g-_VaNc3WkybZ1HHEFo_GQ"
      decimals="INF"
      id="Narr_yEGyJ9vc40y3e5ORLEvHeg"
      unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw">237249</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_3_16_2021_us-gaap_ClassOfWarrantOrRightAxis_ganx_WarrantsToDesigneesOfPlacementAgentIssuedJuly2020Member_YF5W3invl02ldRF6Cq2TAQ"
      decimals="2"
      id="Narr_ZJVdgvkj0kyS1QjRrwHCfA"
      unitRef="Unit_Divide_USD_shares_ZUfWDOiJrESFdyfJo2gfWg">4.46</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_3_17_2021_us-gaap_ClassOfWarrantOrRightAxis_ganx_WarrantsToDesigneesOfPlacementAgentIssuedJuly2020Member_g-_VaNc3WkybZ1HHEFo_GQ"
      decimals="2"
      id="Narr_IdHF2ua9BUqrC5ElhfCWag"
      unitRef="Unit_Divide_USD_shares_ZUfWDOiJrESFdyfJo2gfWg">5.07</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <ganx:WarrantsAndRightsExercisedOrExchangedNumber
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_ganx_WarrantsToDesigneesOfPlacementAgentIssuedJuly2020Member_YAr_SbLTRk2XAPVCkBuVtg"
      decimals="INF"
      id="Narr_rVEar5eMzk6sYXeX7eNg9g"
      unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw">11862</ganx:WarrantsAndRightsExercisedOrExchangedNumber>
    <ganx:IssuanceOfCommonStockThroughCashlessExerciseOfWarrants
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_ganx_WarrantsToDesigneesOfPlacementAgentIssuedJuly2020Member_YAr_SbLTRk2XAPVCkBuVtg"
      decimals="INF"
      id="Narr_3ASeayB2w0Cv0RBZ8e_abA"
      unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw">3283</ganx:IssuanceOfCommonStockThroughCashlessExerciseOfWarrants>
    <ganx:WarrantsAndRightsServicePeriod
      contextRef="Duration_5_6_2021_To_5_6_2021_us-gaap_ClassOfWarrantOrRightAxis_ganx_WarrantsToDesigneesOfInvestmentBankIssuedMay2021Member_94Oz4J1U90W8gKhVhzq1zg"
      id="Narr_O0jJ587PWEqliR6RRwsGzg">P9M</ganx:WarrantsAndRightsServicePeriod>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_5_6_2021_us-gaap_ClassOfWarrantOrRightAxis_ganx_WarrantsToDesigneesOfInvestmentBankIssuedMay2021Member_vInDzK2VLEaPLuCJ2B3g4g"
      decimals="INF"
      id="Narr_zWVL-4osjUKS0cLepA7HNA"
      unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw">200000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_5_6_2021_us-gaap_ClassOfWarrantOrRightAxis_ganx_WarrantsToDesigneesOfInvestmentBankIssuedMay2021Member_vInDzK2VLEaPLuCJ2B3g4g"
      decimals="2"
      id="Narr_WhhmTtwHPEOjzFRqs1ytRQ"
      unitRef="Unit_Divide_USD_shares_ZUfWDOiJrESFdyfJo2gfWg">13.75</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="As_Of_5_6_2021_us-gaap_ClassOfWarrantOrRightAxis_ganx_WarrantsToDesigneesOfInvestmentBankIssuedMay2021Member_vInDzK2VLEaPLuCJ2B3g4g"
      decimals="-3"
      id="Narr_9PHCDMdeC06iu85z500YJQ"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">1034000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="As_Of_5_6_2021_us-gaap_ClassOfWarrantOrRightAxis_ganx_WarrantsToDesigneesOfInvestmentBankIssuedMay2021Member_vInDzK2VLEaPLuCJ2B3g4g"
      id="Narr_uyvHWc3Ia0-VKFusnOPMqA">P4Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <ganx:WarrantsAndRightsServicePeriod
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_ganx_WarrantsToDesigneesOfInvestmentBankIssuedMay2021Member_Xr6HpqPQo0W86a4ZrsARSQ"
      id="Narr_x7Fx48L1HkyLNtOlYjVzXA">P9M</ganx:WarrantsAndRightsServicePeriod>
    <ganx:WarrantsAndRightsExercisedOrExchangedNumber
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_ganx_WarrantsToDesigneesOfInvestmentBankIssuedMay2021Member_Xr6HpqPQo0W86a4ZrsARSQ"
      decimals="INF"
      id="Narr_sWqevyQCOEulWGNOLfdWJg"
      unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw">0</ganx:WarrantsAndRightsExercisedOrExchangedNumber>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      id="Tb_gyaHAdmg60-3sCUi8gt6Hg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:70.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:70.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:70.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:70.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Grant date fair value&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 5.17&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 1.54&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:70.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 70&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 75&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:70.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected term (years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 4.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 5.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:70.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 0.81&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 0.28&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:70.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected dividend yield -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <ganx:WarrantsGrantDateFairValue
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_ValuationTechniqueAxis_us-gaap_ValuationTechniqueOptionPricingModelMember_QzEVNtuW9US0oSPFOgMt6A"
      decimals="2"
      id="Tc_srXvw9lLm0afsDE0GynMGg_3_2"
      unitRef="Unit_Divide_USD_shares_ZUfWDOiJrESFdyfJo2gfWg">5.17</ganx:WarrantsGrantDateFairValue>
    <ganx:WarrantsGrantDateFairValue
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_ValuationTechniqueAxis_us-gaap_ValuationTechniqueOptionPricingModelMember_2H_dl4e8hE-KkfFPdigrJA"
      decimals="2"
      id="Tc_nkmaasfY0Uq9jaMhweby6A_3_4"
      unitRef="Unit_Divide_USD_shares_ZUfWDOiJrESFdyfJo2gfWg">1.54</ganx:WarrantsGrantDateFairValue>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="As_Of_12_31_2021_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_us-gaap_ValuationTechniqueAxis_us-gaap_ValuationTechniqueOptionPricingModelMember_jbd4-HDMH0K2ZzXOCoSCFA"
      decimals="2"
      id="Tc_FbSeZm-E6EifPEUiv8Y9MA_4_2"
      unitRef="Unit_Standard_pure_YPFUW3Xga0mVMPZT28RXUw">0.70</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="As_Of_12_31_2020_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_us-gaap_ValuationTechniqueAxis_us-gaap_ValuationTechniqueOptionPricingModelMember_LWxcsazXDk2P_fSZ_3WyGA"
      decimals="2"
      id="Tc_L9nzN32sz0CxNacAC2jndA_4_4"
      unitRef="Unit_Standard_pure_YPFUW3Xga0mVMPZT28RXUw">0.75</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="As_Of_12_31_2021_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_us-gaap_ValuationTechniqueAxis_us-gaap_ValuationTechniqueOptionPricingModelMember_9QqzfSmMzkiY1DCoSmnXjg"
      decimals="2"
      id="Tc_1zWHueB0xUyyxpzwsUfjZA_5_2"
      unitRef="Unit_Standard_pure_YPFUW3Xga0mVMPZT28RXUw">4.00</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="As_Of_12_31_2020_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_us-gaap_ValuationTechniqueAxis_us-gaap_ValuationTechniqueOptionPricingModelMember_1wOkdymSaEyzTP505R_Yzw"
      decimals="2"
      id="Tc_ujJKJvqRjUOb2sxKJNqcIg_5_4"
      unitRef="Unit_Standard_pure_YPFUW3Xga0mVMPZT28RXUw">5.00</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="As_Of_12_31_2021_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_ValuationTechniqueAxis_us-gaap_ValuationTechniqueOptionPricingModelMember_imxnCtN6ykq3qhuSJY2jEg"
      decimals="4"
      id="Tc_Rd8FM-EvJUmIIP4J5WeiTg_6_2"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">0.0081</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="As_Of_12_31_2020_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_ValuationTechniqueAxis_us-gaap_ValuationTechniqueOptionPricingModelMember_pn73ofcvSUeZsLeHLTUKsg"
      decimals="4"
      id="Tc_LlJCz9jAtUyUh-5nMS8VOg_6_4"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">0.0028</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:CompensationRelatedCostsGeneralTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      id="Tb_IL4-MsoXiEm_eUc1pxjSwg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;15.&#160;&#160;&#160;&#160;Equity Incentive Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On September 24, 2020, the Board of Directors adopted the 2020 Omnibus Incentive Plan (the &#x201c;2020 Omnibus Plan&#x201d;). The 2020 Omnibus Plan provides for the granting of equity-based awards to our named executive officers, other employees, consultants and non-employee directors at a price to be determined by the Board of Directors. The 2020 Omnibus Plan is intended to encourage ownership of stock by employees and consultants of the Company and to provide additional incentives for them to promote the success of the Company&#x2019;s business. The maximum number of shares to be issued under the 2020 Omnibus Plan is 1,310,000. The 2020 Omnibus Plan expires after ten years, unless terminated prior to that date by the Board of Directors. The Board of Directors is responsible for determining the individuals to be granted options, the number of options each individual will receive, the option price per share, and the exercise period of each option. No option will have a term in excess of 10 years. The exercise price for a stock option awarded under the 2020 Omnibus Plan shall not be less than the fair market value of the Company&#x2019;s common stock on the date of the grant. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On December 23, 2021, the Board of Directors, has determined that it is advisable and in the best interests of the Company to adopt an Inducement Equity Incentive Plan (the &#x201c;2021 Inducement Equity Incentive Plan&#x201d;) intended to induce new employees to join the Company for the benefit of individuals who satisfy the standards for inducement grants under Rule 5635(c)(4) of the NASDAQ Listing Rules and the related guidance issued thereunder with respect to the Company and its affiliates. The maximum number of shares reserved for issuance pursuant to awards to be granted under the 2021 Inducement Equity Incentive Plan is to 1,000,000.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;Stock Option Grants&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;The following tables summarize stock option activity for the year ended December 31, 2021 :&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:29.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:29.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:29.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Aggregate&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:29.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&#160;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&#160;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Remaining Contractual &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Intrinsic&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:29.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Grant Date Fair Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&#160;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Terms (Years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:29.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Outstanding as of December&#160;31,&#160;2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 488,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 2.97&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 9.70&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:29.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Options outstanding after stock splits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 429,822&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;2.42&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 3.38&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 9.01&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:29.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Options granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 535,780&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;4.27&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 6.53&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 5.66&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:29.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Options exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3,625)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;2.42&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 3.38&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:29.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Options cancelled/forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,761)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;2.42&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 3.38&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:29.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Options outstanding as of December&#160;31,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 960,216&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;3.46&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 5.13&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 6.25&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 163,237&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:27.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.99%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="8" style="vertical-align:bottom;width:68.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Options&#160;Outstanding&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:11.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:17.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Options&#160;Exercisable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted-&#160;Average&#160;Years&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Grant Date&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:27.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Remaining&#160;on&#160;Contractual&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:27.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Outstanding&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Life&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercisable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:27.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$3.38&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 512,516&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 8.91&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 3.38&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 2.42&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 174,621&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 3.38&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:27.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$5.86&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 210,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 9.98&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 5.86&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 4.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:27.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$5.99&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 45,500&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 9.94&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 5.99&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 4.34&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:27.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$7.80&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 104,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 9.61&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;$780&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 5.63&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 2,664&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;$780&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:27.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$10.03&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 88,200&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 9.36&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 10.03&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 5.15&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On March&#160;3, 2021, the Board approved a 1-for-&lt;span style="-sec-ix-hidden:Hidden_VOTL1rq_TUe6F_krbeB0zg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;0.880784&lt;/span&gt;&lt;/span&gt; reverse stock split of the Company&#x2019;s outstanding equity instruments. The reverse stock split was approved by the stockholders on March&#160;4, 2021 and became effective on March&#160;17, 2021. Shares of common stock underlying outstanding stock options were proportionately reduced from 588,000 to 517,902 and the respective exercise prices, were proportionately increased from $2.97 to $3.38 in accordance with the terms of the agreements governing such securities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The reverse stock split did not impact the fair value of the stock option previously recorded and no modification accounting is required because all the three following conditions were met: &#160;(i)&#160;the fair value of the modified award is the same as the fair value of the original award immediately before the original award is modified; (ii)&#160;the vesting conditions of the modified award are the same as the vesting conditions of the original award immediately before the original award is modified and (iii)&#160;the classification of the modified award as an equity instrument is the same as the classification of the original award immediately before modification.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The aggregate intrinsic value of stock options is calculated as the difference between the weighted average exercise price of the underlying stock options and the market price of the Company&#x2019;s common stock on December 31, 2021.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December 31, 2021, the total unrecognized compensation cost related to non-vested stock options granted was USD 2,403 thousand and is expected to be recognized over 4 years.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company uses the Black-Scholes option pricing model to estimate the fair value of stock options on the date of grant. The Black-Scholes option pricing model takes into account variables such as volatility, dividend yield rate, and risk-free interest rate. The computation of expected volatility and expected term of exercise is based on a representative group of companies with similar characteristics, including stage of product development and life science industry focus, since we do not have a reliable history. The risk-free interest rate is based on US treasury bonds whose term is consistent with the expected term of exercise of the stock options. The expected dividend yield is assumed to be zero as we have never paid dividends and have no current plans to pay any dividends on our common stock. The Company&#x2019;s policy is to account for forfeitures when they occur.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The assumptions that the Company used to determine the grant-date fair value of stock options granted were as follows, presented on a weighted-average basis:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:70.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:70.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:70.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:70.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Grant date fair value&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 4.27&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 2.13&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:70.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 80&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 80&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:70.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected term (years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 5.66&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 7.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:70.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 0.98&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 0.67&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:70.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected dividend yield &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Each of these inputs is subjective and generally requires significant judgment to determine. The weighted average grant-date fair value of the Company&#x2019;s stock options granted as of December 31, 2021 and 2020 was $4.27 and $2.13, respectively. Total stock-based compensation expense is recognized for stock options granted to employees and non-employees and has been reported in the Company&#x2019;s condensed consolidated statements of operations and comprehensive loss as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Total stock-based compensation expense is recognized for stock options granted to employees and non-employees and has been reported in the Company&#x2019;s consolidated statements of operations as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;width:24.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 344,304&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 57,049&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 495,067&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 24,591&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total stock-based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 839,371&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 81,640&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:CompensationRelatedCostsGeneralTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_9_24_2020_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_yL43kRndvEW68muLtDGB3g"
      decimals="INF"
      id="Narr_wIHOdtLBsE-kNMu5RTPRMg"
      unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw">1310000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="Duration_9_24_2020_To_9_24_2020_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_7U57Cx256U2tLHUf4s6Y8A"
      id="Narr_kxeAFdVr30uDY3an9XkiSg">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <ganx:NumberOfOptionsSubjectToTermThreshold
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_9J9hcs3P0U-I30H9M7barQ"
      decimals="INF"
      id="Narr_9mWOso2_DkWBX5Mo4ZdTdA"
      unitRef="Unit_Standard_Options_mZpQ0toHqki8W4R9nXDMkA">0</ganx:NumberOfOptionsSubjectToTermThreshold>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="Duration_9_24_2020_To_9_24_2020_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_RTjAu4qAPEqUn3L27gh5Ow"
      id="Narr__xmQbn4ANECGlRzB3H9guQ">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="As_Of_12_23_2021_us-gaap_PlanNameAxis_ganx_TwentyTwentyoneInducementEquityIncentivePlanMember_dc6nUQZMq0iDFdVD-aASTQ"
      decimals="INF"
      id="Narr_Ep6BwY3J90mMufh-swOe7w"
      unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw">1000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      id="Tb_Iy0WKfWebk2iQQvlN0lB1g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:29.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:29.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:29.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Aggregate&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:29.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&#160;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&#160;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Remaining Contractual &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Intrinsic&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:29.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Grant Date Fair Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&#160;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Terms (Years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:29.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Outstanding as of December&#160;31,&#160;2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 488,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 2.97&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 9.70&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:29.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Options outstanding after stock splits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 429,822&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;2.42&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 3.38&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 9.01&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:29.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Options granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 535,780&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;4.27&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 6.53&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 5.66&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:29.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Options exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3,625)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;2.42&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 3.38&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:29.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Options cancelled/forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,761)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;2.42&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 3.38&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:29.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Options outstanding as of December&#160;31,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 960,216&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;3.46&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 5.13&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 6.25&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 163,237&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:27.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.99%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="8" style="vertical-align:bottom;width:68.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Options&#160;Outstanding&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:11.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:17.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Options&#160;Exercisable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted-&#160;Average&#160;Years&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Grant Date&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:27.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Remaining&#160;on&#160;Contractual&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:27.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Outstanding&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Life&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercisable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:27.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$3.38&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 512,516&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 8.91&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 3.38&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 2.42&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 174,621&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 3.38&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:27.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$5.86&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 210,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 9.98&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 5.86&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 4.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:27.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$5.99&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 45,500&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 9.94&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 5.99&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 4.34&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:27.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$7.80&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 104,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 9.61&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;$780&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 5.63&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 2,664&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;$780&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:27.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$10.03&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 88,200&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 9.36&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 10.03&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 5.15&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2020_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_liEc-LEvuUmppacbgwHfFg"
      decimals="INF"
      id="Tc_YcQkDiGH50icp5iZHu7HyA_5_2"
      unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw">488000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2020_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_liEc-LEvuUmppacbgwHfFg"
      decimals="2"
      id="Tc_UIY1MBh-t0OwCgmoymMRaQ_5_6"
      unitRef="Unit_Divide_USD_shares_ZUfWDOiJrESFdyfJo2gfWg">2.97</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_oZ2efAweo0yRRNPJFNieTA"
      id="Tc_oZ53J1M4V0iAkODIfhldgQ_5_8">P9Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <ganx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAfterStockSplitsNumber
      contextRef="As_Of_3_17_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_NETjxmYYrkyazfL5gwskGw"
      decimals="INF"
      id="Tc_WVZE4q0EKUSJnHNNUUnqeA_6_2"
      unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw">429822</ganx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAfterStockSplitsNumber>
    <ganx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionNonvestedWeightedAverageExercisePriceAfterStockSplit
      contextRef="As_Of_3_17_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_NETjxmYYrkyazfL5gwskGw"
      decimals="2"
      id="Tc_9XIukwRAqUuzFPIqHq_pnQ_6_4"
      unitRef="Unit_Divide_USD_shares_ZUfWDOiJrESFdyfJo2gfWg">2.42</ganx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionNonvestedWeightedAverageExercisePriceAfterStockSplit>
    <ganx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAfterStockSplitsWeightedAverageExercisePrice
      contextRef="As_Of_3_17_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_NETjxmYYrkyazfL5gwskGw"
      decimals="2"
      id="Tc_TtMgllWvBEyXRsgvdCH6GQ_6_6"
      unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw">3.38</ganx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAfterStockSplitsWeightedAverageExercisePrice>
    <ganx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAfterStockSplitWeightedAverageRemainingContractualTerm
      contextRef="Duration_3_17_2021_To_3_17_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_VPlkneswlU6lplZPmfwMQg"
      id="Tc_BMpOTU1R3EGDBfbALnZqqw_6_8">P9Y3D</ganx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAfterStockSplitWeightedAverageRemainingContractualTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_9J9hcs3P0U-I30H9M7barQ"
      decimals="INF"
      id="Tc_lO3K_dHVZkO7zoi-GGwu3Q_7_2"
      unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw">535780</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_9J9hcs3P0U-I30H9M7barQ"
      decimals="2"
      id="Tc_qBDumGguuUu00qpRSyK-0g_7_4"
      unitRef="Unit_Divide_USD_shares_ZUfWDOiJrESFdyfJo2gfWg">4.27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_9J9hcs3P0U-I30H9M7barQ"
      decimals="2"
      id="Tc_r1ZdiodvPkOWtYALkcaHOA_7_6"
      unitRef="Unit_Divide_USD_shares_ZUfWDOiJrESFdyfJo2gfWg">6.53</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <ganx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_9J9hcs3P0U-I30H9M7barQ"
      id="Tc_1cjAoHvfrk-I5-kELQgnzw_7_8">P5Y7M28D</ganx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_9J9hcs3P0U-I30H9M7barQ"
      decimals="INF"
      id="Tc_zj-P_WRtJE2xfROEiK_Scw_8_2"
      unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw">3625</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <ganx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedDuringPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_9J9hcs3P0U-I30H9M7barQ"
      decimals="2"
      id="Tc_RRsoCViPL06-pGuGd5DDVQ_8_4"
      unitRef="Unit_Divide_USD_shares_ZUfWDOiJrESFdyfJo2gfWg">2.42</ganx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedDuringPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_9J9hcs3P0U-I30H9M7barQ"
      decimals="2"
      id="Tc_n3NrAPqzQkOL2zG2r8PjoA_8_6"
      unitRef="Unit_Divide_USD_shares_ZUfWDOiJrESFdyfJo2gfWg">3.38</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_9J9hcs3P0U-I30H9M7barQ"
      decimals="INF"
      id="Tc_EhIl1DFdtE6lmDwKr0X0Aw_9_2"
      unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw">1761</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_9J9hcs3P0U-I30H9M7barQ"
      decimals="2"
      id="Tc_PimsX3S-q0Kc4gdr1Qm73A_9_4"
      unitRef="Unit_Divide_USD_shares_ZUfWDOiJrESFdyfJo2gfWg">2.42</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_9J9hcs3P0U-I30H9M7barQ"
      decimals="2"
      id="Tc_fop0zfHHYEuFxIXGhqGcMA_9_6"
      unitRef="Unit_Divide_USD_shares_ZUfWDOiJrESFdyfJo2gfWg">3.38</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_RVGfoikIBESMbmCXz6RCfw"
      decimals="INF"
      id="Tc_NXTmjEHySUCcevpBI2tM1Q_10_2"
      unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw">960216</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_RVGfoikIBESMbmCXz6RCfw"
      decimals="2"
      id="Tc_hFoR8lFpX0qxPRaV0WBr8A_10_4"
      unitRef="Unit_Divide_USD_shares_ZUfWDOiJrESFdyfJo2gfWg">3.46</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_RVGfoikIBESMbmCXz6RCfw"
      decimals="2"
      id="Tc_jR5L1BxMTEqEKEduUxAEtw_10_6"
      unitRef="Unit_Divide_USD_shares_ZUfWDOiJrESFdyfJo2gfWg">5.13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_9J9hcs3P0U-I30H9M7barQ"
      id="Tc_ketCbWfDs0if_J7kbreGVQ_10_8">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_RVGfoikIBESMbmCXz6RCfw"
      decimals="2"
      id="Tc_RjydcVSzUkmbt7r1R3zbSw_10_10"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">163237</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ganx_ExercisePrice3.38Member_q48VnEGwiUKrGR7I5_LISQ"
      decimals="2"
      id="Tc_TNr-z7QybUCQH76gKgSkDQ_6_0"
      unitRef="Unit_Divide_USD_shares_ZUfWDOiJrESFdyfJo2gfWg">3.38</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ganx_ExercisePrice3.38Member_vX53-sp5zEGR0K2gPjCseA"
      decimals="INF"
      id="Tc_8_o27WsU40CbqHwl0ibtHA_6_2"
      unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw">512516</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ganx_ExercisePrice3.38Member_q48VnEGwiUKrGR7I5_LISQ"
      id="Tc_bTZx_bpxdkqe4mTPxW2TmQ_6_4">P8Y10M28D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ganx_ExercisePrice3.38Member_vX53-sp5zEGR0K2gPjCseA"
      decimals="2"
      id="Tc_HRkkaVsyjEOGA5Aey7rl9g_6_7"
      unitRef="Unit_Divide_USD_shares_ZUfWDOiJrESFdyfJo2gfWg">3.38</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ganx_ExercisePrice3.38Member_vX53-sp5zEGR0K2gPjCseA"
      decimals="2"
      id="Tc_Pr6W5kSCKUm260aoiXKOIA_6_10"
      unitRef="Unit_Divide_USD_shares_ZUfWDOiJrESFdyfJo2gfWg">2.42</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ganx_ExercisePrice3.38Member_vX53-sp5zEGR0K2gPjCseA"
      decimals="INF"
      id="Tc_BVjGO8rmJU-Q_t-8fBs3FA_6_12"
      unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw">174621</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ganx_ExercisePrice3.38Member_vX53-sp5zEGR0K2gPjCseA"
      decimals="INF"
      id="Tc_T9CVgF9toUOrrajOtCgq5g_6_15"
      unitRef="Unit_Divide_USD_shares_ZUfWDOiJrESFdyfJo2gfWg">3.38</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ganx_ExercisePrice5.86Member_ldKP04Tc_EiQ1aX3hzo_jQ"
      decimals="2"
      id="Tc_g5h2bb3dLECGUrRIPfvCdA_7_0"
      unitRef="Unit_Divide_USD_shares_ZUfWDOiJrESFdyfJo2gfWg">5.86</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ganx_ExercisePrice5.86Member_gBKLZo1l-0W49gJ_33Ix3Q"
      decimals="INF"
      id="Tc_WRm1kNe0U0eChIjmTzQf_g_7_2"
      unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw">210000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ganx_ExercisePrice5.86Member_ldKP04Tc_EiQ1aX3hzo_jQ"
      id="Tc_Tcvd2hz2C0SBCSfjiMiC6Q_7_4">P9Y11M23D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ganx_ExercisePrice5.86Member_gBKLZo1l-0W49gJ_33Ix3Q"
      decimals="2"
      id="Tc_f2EyR5nvMU6ifNCLMwORMw_7_7"
      unitRef="Unit_Divide_USD_shares_ZUfWDOiJrESFdyfJo2gfWg">5.86</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ganx_ExercisePrice5.86Member_gBKLZo1l-0W49gJ_33Ix3Q"
      decimals="2"
      id="Tc_chaO6l44BEWgB-xIXVFKeQ_7_10"
      unitRef="Unit_Divide_USD_shares_ZUfWDOiJrESFdyfJo2gfWg">4.00</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ganx_ExercisePrice5.99Member_IRU-JBn3zUmz8JgkEa1wmQ"
      decimals="2"
      id="Tc_v4_4ZdPfWU6cZA4brpgSog_8_0"
      unitRef="Unit_Divide_USD_shares_ZUfWDOiJrESFdyfJo2gfWg">5.99</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ganx_ExercisePrice5.99Member__H3l5fnJok-E9OkINM3A4Q"
      decimals="INF"
      id="Tc_D11WfjLmDEaq9LoQ0fBplw_8_2"
      unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw">45500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ganx_ExercisePrice5.99Member_IRU-JBn3zUmz8JgkEa1wmQ"
      id="Tc_Tm5xfNZuVUGV02N7MjPB3g_8_4">P9Y11M8D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ganx_ExercisePrice5.99Member__H3l5fnJok-E9OkINM3A4Q"
      decimals="2"
      id="Tc_fyFBkT7dVE6uIat-oNyj8g_8_7"
      unitRef="Unit_Divide_USD_shares_ZUfWDOiJrESFdyfJo2gfWg">5.99</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ganx_ExercisePrice5.99Member__H3l5fnJok-E9OkINM3A4Q"
      decimals="2"
      id="Tc_H3z0uy1DVUig8cKFc2YlGQ_8_10"
      unitRef="Unit_Divide_USD_shares_ZUfWDOiJrESFdyfJo2gfWg">4.34</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ganx_ExercisePrice7.80Member_azVHc_tr_02k1bZtu5dcVA"
      decimals="2"
      id="Tc_oV4uTsHUC0G_ctTMnxrqVQ_9_0"
      unitRef="Unit_Divide_USD_shares_ZUfWDOiJrESFdyfJo2gfWg">7.80</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ganx_ExercisePrice7.80Member_IAhcMx9gQUiYIcwUzGxvUw"
      decimals="INF"
      id="Tc_gR_L-IzIxUKhCuEwG1nOZw_9_2"
      unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw">104000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ganx_ExercisePrice7.80Member_azVHc_tr_02k1bZtu5dcVA"
      id="Tc_w-fGu0WwHkCEOCO4F16UHg_9_4">P9Y7M9D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ganx_ExercisePrice7.80Member_IAhcMx9gQUiYIcwUzGxvUw"
      decimals="2"
      id="Tc_s8wjgtmos0WIBOlDuuXbxw_9_7"
      unitRef="Unit_Divide_USD_shares_ZUfWDOiJrESFdyfJo2gfWg">780</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ganx_ExercisePrice7.80Member_IAhcMx9gQUiYIcwUzGxvUw"
      decimals="2"
      id="Tc_TwMFcBkEcEeU1G7zDrC2HQ_9_10"
      unitRef="Unit_Divide_USD_shares_ZUfWDOiJrESFdyfJo2gfWg">5.63</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ganx_ExercisePrice7.80Member_IAhcMx9gQUiYIcwUzGxvUw"
      decimals="INF"
      id="Tc_KqUKQhALpkie0qeQsbatnA_9_12"
      unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw">2664</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ganx_ExercisePrice7.80Member_IAhcMx9gQUiYIcwUzGxvUw"
      decimals="INF"
      id="Tc_8Vj-0oe64UqL1_XnrY7CWQ_9_15"
      unitRef="Unit_Divide_USD_shares_ZUfWDOiJrESFdyfJo2gfWg">780</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ganx_ExercisePrice10.03Member__Arw4xIJUEO-yWegbRND-A"
      decimals="2"
      id="Tc_VwCzY2KnrEOvhS6S87UNkA_10_0"
      unitRef="Unit_Divide_USD_shares_ZUfWDOiJrESFdyfJo2gfWg">10.03</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ganx_ExercisePrice10.03Member_t43zzwTn0EOG01iusAqyuA"
      decimals="INF"
      id="Tc_gRpYCRvXak2ob7v57Kkj_Q_10_2"
      unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw">88200</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ganx_ExercisePrice10.03Member__Arw4xIJUEO-yWegbRND-A"
      id="Tc_Z4zKnt4i6kKbdmWKnoxFgQ_10_4">P9Y4M9D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ganx_ExercisePrice10.03Member_t43zzwTn0EOG01iusAqyuA"
      decimals="2"
      id="Tc_hmlOc-v6hkScYntOm7l2DA_10_7"
      unitRef="Unit_Divide_USD_shares_ZUfWDOiJrESFdyfJo2gfWg">10.03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ganx_ExercisePrice10.03Member_t43zzwTn0EOG01iusAqyuA"
      decimals="2"
      id="Tc_oQakhTae602vBtWEdWdU9g_10_10"
      unitRef="Unit_Divide_USD_shares_ZUfWDOiJrESFdyfJo2gfWg">5.15</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_3_16_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_-yJfbN_d1U6z9SG-fWFZ5A"
      decimals="INF"
      id="Narr__i5V4SNPeEeBpgX21aOJZQ"
      unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw">588000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_3_17_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_NETjxmYYrkyazfL5gwskGw"
      decimals="INF"
      id="Narr_-VzToYB0eEaaUnIR9U50uw"
      unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw">517902</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="Duration_3_16_2021_To_3_16_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_8OFhhtn3CkCh-eZfG1m3iA"
      decimals="2"
      id="Narr_xH8J4V3YWEGTdgOYcfdJkA"
      unitRef="Unit_Divide_USD_shares_ZUfWDOiJrESFdyfJo2gfWg">2.97</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="Duration_3_17_2021_To_3_17_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_VPlkneswlU6lplZPmfwMQg"
      decimals="2"
      id="Narr_pjIfQsd-CEm0pCXk0L6GwA"
      unitRef="Unit_Divide_USD_shares_ZUfWDOiJrESFdyfJo2gfWg">3.38</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_RVGfoikIBESMbmCXz6RCfw"
      decimals="-3"
      id="Narr_bfWEUsch40y9srJBmZGA-w"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">2403000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_9J9hcs3P0U-I30H9M7barQ"
      id="Narr_IdRRFMqMnkaq-r6sqf-yUw">P4Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_9J9hcs3P0U-I30H9M7barQ"
      decimals="2"
      id="Narr_YAE_pIa09UWgD_r6kOnr5Q"
      unitRef="Unit_Standard_pure_YPFUW3Xga0mVMPZT28RXUw">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      id="Tb_c5r-Nc2qcky6_StOXdIJRw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:70.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:70.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:70.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:70.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Grant date fair value&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 4.27&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 2.13&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:70.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 80&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 80&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:70.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected term (years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 5.66&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 7.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:70.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 0.98&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 0.67&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:70.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected dividend yield &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_9J9hcs3P0U-I30H9M7barQ"
      decimals="2"
      id="Tc_SgNa9vUWj0qkxVZIy0qWuQ_3_2"
      unitRef="Unit_Divide_USD_shares_ZUfWDOiJrESFdyfJo2gfWg">4.27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_oZ2efAweo0yRRNPJFNieTA"
      decimals="2"
      id="Tc_qFEkOw4jSU2SOc0prvNg1g_3_4"
      unitRef="Unit_Divide_USD_shares_ZUfWDOiJrESFdyfJo2gfWg">2.13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_9J9hcs3P0U-I30H9M7barQ"
      decimals="2"
      id="Tc_c-iq8USlQkqzJ2H247VCxg_4_2"
      unitRef="Unit_Standard_pure_YPFUW3Xga0mVMPZT28RXUw">0.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_oZ2efAweo0yRRNPJFNieTA"
      decimals="4"
      id="Tc_JQP-DBg7lkegb2uoCHFeWg_4_4"
      unitRef="Unit_Standard_pure_YPFUW3Xga0mVMPZT28RXUw">0.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_9J9hcs3P0U-I30H9M7barQ"
      id="Tc_8fETv3pQhUWuozLlYqbKkg_5_2">P5Y7M28D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_oZ2efAweo0yRRNPJFNieTA"
      id="Tc_gPDcO99pcUKQruAC2A7ASg_5_4">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_9J9hcs3P0U-I30H9M7barQ"
      decimals="4"
      id="Tc_VHcH4ImNHEmMqq1S7VJj3g_6_2"
      unitRef="Unit_Standard_pure_YPFUW3Xga0mVMPZT28RXUw">0.0098</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_oZ2efAweo0yRRNPJFNieTA"
      decimals="4"
      id="Tc_UirheTLX-EKyAN0fu4SzYA_6_4"
      unitRef="Unit_Standard_pure_YPFUW3Xga0mVMPZT28RXUw">0.0067</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_9J9hcs3P0U-I30H9M7barQ"
      decimals="2"
      id="Narr_ea43AOs_L0iARzBFqaZ-wA"
      unitRef="Unit_Divide_USD_shares_ZUfWDOiJrESFdyfJo2gfWg">4.27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_oZ2efAweo0yRRNPJFNieTA"
      decimals="2"
      id="Narr_yqebQB9RoES6EA5I4CtuoA"
      unitRef="Unit_Divide_USD_shares_ZUfWDOiJrESFdyfJo2gfWg">2.13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      id="Tb_PsEFNagtVE2s7QaF0bRXFg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;width:24.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 344,304&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 57,049&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 495,067&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 24,591&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total stock-based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 839,371&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 81,640&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_8kdx5frm8UGeszq3O_KyBg"
      decimals="INF"
      id="Tc_qpdsHsNioUGf9fz6exgMiA_3_2"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">344304</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_W_1SbimhkkmXrYE8c7oscg"
      decimals="INF"
      id="Tc_5c_jCXNkPU6AKakDwBoNqg_3_4"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">57049</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_idnllJAzZk6p-wCg6SCFow"
      decimals="INF"
      id="Tc_BGmwQyPLD068EaGsmt0hzQ_4_2"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">495067</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_I180bvlxRk2MS8zltC_nhQ"
      decimals="INF"
      id="Tc_C4WDaa8KT0in2QDqlAbDJw_4_4"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">24591</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_9J9hcs3P0U-I30H9M7barQ"
      decimals="INF"
      id="Tc_tvGeWI8N3Um6hV_TuHSMjw_5_2"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">839371</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_oZ2efAweo0yRRNPJFNieTA"
      decimals="INF"
      id="Tc_nnR4faCyikmWoM7uxiVdvw_5_4"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">81640</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      id="Tb_NkbJOo_RrUS-bUfg0QObMQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;16.&#160;&#160;&#160;&#160;Collaboration Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On April 20, 2021, the Company entered into a multi-target collaboration agreement with Zentalis Pharmaceuticals, Inc. (&#x201c;Zentalis&#x201d;) to discover new product candidates for the treatment of cancer. Under the terms of the agreement, the Company will use its in-licensed SEE-Tx&#xae; computational platform technology to identify binding sites on target proteins and determine the potential suitability of these sites as drug targets, as well as their prospective therapeutic use in oncology. Pursuant the terms of the agreement, Zentalis agreed to pay the Company, on a program-by-program basis, a non-creditable, non-refundable, program initiation fee and reimbursement of expenses incurred by the Company in accordance with the agreed-upon research budget for each target in a multi-target agreement with a maximum of five mutually agreed to targets at the option of Zentalis. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;With respect to any development program, and subject the delivery of the data package, the Company granted to Zentalis an option to obtain an exclusive, transferable worldwide license, with the right to sublicense, under relevant intellectual property rights and know-how of the Company arising from the collaboration to develop, manufacture and commercialize any products resulting from the development program. Zentalis may exercise the option, at its reasonable discretion, and shall use commercially reasonable efforts to develop and obtain market approval for products developed from the applicable programs.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Unless terminated earlier, the agreement expires at the expiration of the last valid claim of the licensed patents, subject to certain surviving rights and obligations. Zentalis and the Company can each terminate the agreement in the event of the bankruptcy or insolvency of the other party, or a material breach by the other party and failure to cure such breach within a certain period of time. Zentalis shall have the right, at its sole discretion, exercisable at any time to terminate the agreement on a program-by-program basis, upon ninety (90) days&#x2019; prior written notice to the Company or, at any time, if a safety concerns arises with respect to any development program or product.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In May 2021, the first target development program was identified, and the estimated development cost were approved and collected in July 2021. The transaction price of this first target development program includes (i) $50&#160;thousand of fixed consideration as program initiation fee, (ii) up to $272 thousand as reimbursement for employee and external research and development cost, (iii) $250 thousand subject to the exercise of a research program option, (iv) up to $41.5&#160;million of variable consideration in the form of event-based milestone payments, if goals will be met in the future, and (v) other royalty-based payments based on future net sales.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company analyzed the Zentalis Collaboration Agreement and concluded that it represents a contract with a customer within the scope of ASC 606 and ASC 808. Based on that evaluation, (i) the program initiation fee was recognized as revenue in full as of June 30, 2021 at a point in time, at program inception as there is no unsatisfied performance obligation; (ii) the performance obligation to provide development services, is satisfied over a period of time as services are performed and Zentalis receives the benefit for the services. The Company will recognize revenue associated with the performance obligation as the research and development services are provided using an input method, according to the costs incurred.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;As of December 31, 2021, the Company recognized $167 thousand of revenues and reported current portion of deferred revenues for $155 thousand.&lt;/p&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <ganx:CollaborativeArrangementMinimumNumberOfTargets
      contextRef="As_Of_4_20_2021_srt_CounterpartyNameAxis_ganx_ZentalisPharmaceuticalsInc.Member_us-gaap_TypeOfArrangementAxis_ganx_MultiTargetCollaborationAgreementMember_MduiqnTW20mQ__WJtWGk9Q"
      decimals="INF"
      id="Narr_y2tVMDkbhUSVieBkoEQGDA"
      unitRef="Unit_Standard_item_jlWcaGVl5kGYwaQ1kPo68Q">5</ganx:CollaborativeArrangementMinimumNumberOfTargets>
    <ganx:CollaborativeArrangementTerminationNoticePeriodDays
      contextRef="Duration_4_20_2021_To_4_20_2021_srt_CounterpartyNameAxis_ganx_ZentalisPharmaceuticalsInc.Member_us-gaap_TypeOfArrangementAxis_ganx_MultiTargetCollaborationAgreementMember_79uwIK2uDU2loW-PUu8mAg"
      id="Narr_Of1GX6YPSE6WQfAoZqfbCw">P90D</ganx:CollaborativeArrangementTerminationNoticePeriodDays>
    <ganx:CollaborativeArrangementProgramInitiationFee
      contextRef="As_Of_5_31_2021_srt_CounterpartyNameAxis_ganx_ZentalisPharmaceuticalsInc.Member_us-gaap_TypeOfArrangementAxis_ganx_MultiTargetCollaborationAgreementMember_UAOVQT0JhEyX-WpaUYbKmA"
      decimals="-3"
      id="Narr_fwjB0yYi9UWXcPslZkpXVQ"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">50000</ganx:CollaborativeArrangementProgramInitiationFee>
    <ganx:CollaborativeArrangementEmployeeAndExternalResearchAndDevelopmentCosts
      contextRef="Duration_5_1_2021_To_5_31_2021_srt_CounterpartyNameAxis_ganx_ZentalisPharmaceuticalsInc.Member_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_ganx_MultiTargetCollaborationAgreementMember_VJHihOl1_0O-yMpbRCHaPA"
      decimals="-3"
      id="Narr__5VKm9j8M0O4Gx_3qmLyqg"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">272000</ganx:CollaborativeArrangementEmployeeAndExternalResearchAndDevelopmentCosts>
    <ganx:CollaborativeArrangementOptionExerciseFee
      contextRef="Duration_5_1_2021_To_5_31_2021_srt_CounterpartyNameAxis_ganx_ZentalisPharmaceuticalsInc.Member_us-gaap_TypeOfArrangementAxis_ganx_MultiTargetCollaborationAgreementMember_nrRCfgERCkCz3HkVyPGAgA"
      decimals="-3"
      id="Narr_84H8rhzPLUSH8dM3uCwnFg"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">250000</ganx:CollaborativeArrangementOptionExerciseFee>
    <ganx:CollaborativeArrangementEventBasedMilestonePayments
      contextRef="Duration_5_1_2021_To_5_31_2021_srt_CounterpartyNameAxis_ganx_ZentalisPharmaceuticalsInc.Member_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_ganx_MultiTargetCollaborationAgreementMember_VJHihOl1_0O-yMpbRCHaPA"
      decimals="-5"
      id="Narr_MnDyBKJOfUSj2KIVmN0IqA"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">41500000</ganx:CollaborativeArrangementEventBasedMilestonePayments>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="As_Of_12_31_2021_srt_CounterpartyNameAxis_ganx_ZentalisPharmaceuticalsInc.Member_us-gaap_TypeOfArrangementAxis_ganx_MultiTargetCollaborationAgreementMember_VaQZuPvZpUe8IpzXfakMYA"
      decimals="0"
      id="Narr__n4eTwyg-kmID8nh5x50Sw"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">0</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_ganx_ZentalisPharmaceuticalsInc.Member_us-gaap_TypeOfArrangementAxis_ganx_MultiTargetCollaborationAgreementMember_vo15OpWqgkuGY59e7z-yzg"
      decimals="-3"
      id="Narr_dTG6QnZZnUGo-g_K-9ZPQw"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">167000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerLiability
      contextRef="As_Of_12_31_2021_srt_CounterpartyNameAxis_ganx_ZentalisPharmaceuticalsInc.Member_us-gaap_TypeOfArrangementAxis_ganx_MultiTargetCollaborationAgreementMember_VaQZuPvZpUe8IpzXfakMYA"
      decimals="-3"
      id="Narr_DtfD3VyQzku_j9nZ62uTTg"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">155000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      id="Tb_oFE0HtXL60euR2qH_3Jn0A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;17.&#160;&#160;&#160;&#160;Income taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company is subject to taxation in the U.S., Switzerland and in Spain. Taxes are recorded on an accrual basis and represent the allowances for taxes paid or to be paid for the&#160;year, calculated according to the current enacted rates and applicable laws. The Company has accumulated net tax losses since inception in Switzerland and in the U.S. The Company report a provision for income taxes due to the Spanish tax authorities pertaining to our branch Gain Therapeutics Sucursal en Espa&#xf1;a. Spanish corporate income taxes have been computed based on an effective tax rate of 25%, which represents the statutory tax rate, as no discrete items were noted in the computation of income taxes.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;For financial reporting purposes, loss before income taxes provision includes the following components:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:65.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:65.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Domestic&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (7,601,640)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (623,667)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:65.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Foreign&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (6,284,958)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,948,629)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:65.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;  Total &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (13,886,598)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,572,296)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Following is the breakdown of the components of income tax expense provision for the&#160;years ended December&#160;31, 2021 and 2020:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:73.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:73.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:73.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;border-bottom:1.5pt solid #ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.33%;border-bottom:1.5pt solid #ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Current:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Federal&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;State&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Foreign&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 4,008&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 5,386&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;        Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 4,008&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 5,386&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Deferred:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;   Federal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;State&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Foreign&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;       Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total income tax expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 4,008&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 5,386&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;The breakdown of domestic and foreign NOLs and related DTAs are reported in the following table:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:65.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:65.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:65.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:65.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.13%;border-bottom:1.5pt solid #ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:65.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;NOLs (foreign) &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (12,021,483)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (6,076,187)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:65.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;NOLs (domestic)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (6,218,309)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (532,209)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:65.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;   Total NOLs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (18,239,792)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (6,608,396)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:65.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:65.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:65.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;Deferred tax assets related to:&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:65.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;  Net operating loss (foreign)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 2,243,668&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,111,942&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:65.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;  Net operating loss (domestic)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,677,610&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 146,451&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:65.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;  Stock based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 253,439&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 22,465&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:65.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;  Warrant expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 284,531&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:65.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;  Other temporary differences&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 4,010&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:65.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;            Total deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 4,463,258&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,280,858&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:65.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;Deferred tax liabilities&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:65.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;  Depreciation and other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,137)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,682)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:65.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;            Total deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,137)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,682)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:65.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:65.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;  Valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 4,462,121&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,278,176&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:65.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Net deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;According to Swiss tax law, the NOLs can be carried forward for seven&#160;years and will begin to expire commencing from 2025 for the NOLs generated in 2017.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;According to the U.S. Tax Cuts and Jobs Act (&#x201c;TCJA&#x201d;) that was signed into law on December 22, 2017, federal net operating losses (&#x201c;NOLs&#x201d;) incurred after December 31, 2017 can be carried forward indefinitely and are limited to 80% of taxable income in any tax period. The NOLs and tax credit carryforwards are subject to review and possible adjustment by the Internal Revenue Service and state tax authorities. NOLs and tax credit carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant stockholders over a three-year period in excess of 50 percent, as defined under Sections 382 and 383 of the Internal Revenue Code, as well as similar state provisions. This could limit the amount of tax attributes that can be utilized annually to offset future taxable income or tax liabilities. The amount of the annual limitation is determined based on the value of the Company immediately prior to the ownership change. Subsequent ownership changes may further affect the limitation in future years. The Company has not done an analysis to determine whether or not ownership changes have occurred since inception.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Deferred tax assets require an assessment of both positive and negative evidence when determining whether it is more likely than not that they can be recovered. Such assessment is made on a jurisdiction-by-jurisdiction basis. The Company&#x2019;s assessment includes an evaluation of cumulative losses, future sources of taxable income, exclusive of reversing temporary differences, and risks and uncertainties related to our business. As of December&#160;31, 2021 and 2020, the Company has determined that there is not sufficient evidence that the Company will be able to realize the benefits of the domestic and foreign deferred tax assets. Accordingly, due to uncertainty regarding the realization of our deferred tax assets, the Company continues to maintain a full valuation allowance on the Company&#x2019;s domestic and foreign deferred tax assets as of December&#160;31, 2021 and 2020 and until sufficient positive evidence will exist to support the reversal of the valuation allowance.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;A reconciliation of income tax expense (benefit) computed at the statuory federal income tax rate to the Compan&#x2019;s effective tax rate as reflected in the consolidated financial statements is as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:71.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:71.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:71.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:71.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.44%;border-bottom:1.5pt solid #ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:71.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Federal income tax at US statutory rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;21.00%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;21.00%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:71.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;State income taxes, net of federal benefit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;6.52%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;6.52%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:71.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Permanent differences&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;(0.10)%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;0.00%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:71.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Provision to return&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;0.13%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;0.00%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:71.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Foreign tax&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;(0.03)%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;(0.15)%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:71.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;(27.52)%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;(27.37)%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:71.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Effective income tax rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;0.00%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;0.00%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December 31, 2021 and 2020, the Company had no accrued interest or penalties related to uncertain tax positions and no amounts have been recognized in the Company&#x2019;s statement of operations.There are no changes expected to occur in the next 12&#160;months with respect to the status of the Company&#x2019;s uncertain tax positions.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company files income tax returns in Switzerland, Spain and in the United States. Tax years from 2018 and after remain subject to examination by the taxing jurisdictions. The NOL and tax carryforwards remain subject to review until utilized. The Company is currently not under examination by any tax authorities.&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_StatementGeographicalAxis_country_ES_No2V5hdzvE6TY_AfyyLEBQ"
      decimals="INF"
      id="Narr_uTvY43SVUEijduFQcfOdNA"
      unitRef="Unit_Standard_pure_YPFUW3Xga0mVMPZT28RXUw">0.25</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      id="Tb_gVCm6AbL20ikfyQ74mxfmg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:65.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:65.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Domestic&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (7,601,640)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (623,667)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:65.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Foreign&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (6,284,958)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,948,629)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:65.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;  Total &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (13,886,598)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,572,296)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      decimals="0"
      id="Tc_QEAoJq9h2kCCrZhdbv7rqA_4_3"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">-7601640</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="Duration_1_1_2020_To_12_31_2020_JDEb6LtAmEuXGmEieWNlsw"
      decimals="0"
      id="Tc_BWlW_Hkaz0S-NEYngtBrKQ_4_6"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">-623667</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      decimals="0"
      id="Tc_ASrafMdIakG4ijkoN8blLw_5_3"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">-6284958</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="Duration_1_1_2020_To_12_31_2020_JDEb6LtAmEuXGmEieWNlsw"
      decimals="0"
      id="Tc_T1lUE0E-dk6s5nSLXMGLvQ_5_6"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">-2948629</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      decimals="0"
      id="Tc_KrKHCwRSCEuN8gGIHB-KVg_6_3"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">-13886598</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2020_To_12_31_2020_JDEb6LtAmEuXGmEieWNlsw"
      decimals="0"
      id="Tc_dkUxnlfn30OorHLo0uNciQ_6_6"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">-3572296</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      id="Tb_drHJ5l7DHUKz8vJU1tWGyg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:73.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:73.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:73.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;border-bottom:1.5pt solid #ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.33%;border-bottom:1.5pt solid #ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Current:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Federal&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;State&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Foreign&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 4,008&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 5,386&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;        Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 4,008&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 5,386&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Deferred:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;   Federal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;State&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Foreign&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;       Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total income tax expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 4,008&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 5,386&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      decimals="0"
      id="Tc_-4pdYSKWGEuRxESwz2jMrQ_7_3"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">4008</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="Duration_1_1_2020_To_12_31_2020_JDEb6LtAmEuXGmEieWNlsw"
      decimals="0"
      id="Tc_hxbuuXG4RkC5syHlbaHfJg_7_6"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">5386</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      decimals="0"
      id="Tc_rg15yn9EYkqHWcLmoP9opw_8_3"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">4008</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2020_To_12_31_2020_JDEb6LtAmEuXGmEieWNlsw"
      decimals="0"
      id="Tc_rpZj4DayXkSk2ZAmOQ2gMw_8_6"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">5386</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      decimals="0"
      id="Tc_ZDhV6JbNHE-FSoMBBXJe9A_14_3"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">4008</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2020_To_12_31_2020_JDEb6LtAmEuXGmEieWNlsw"
      decimals="0"
      id="Tc_vExJYCR48Em8W_nJdYNsTA_14_6"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">5386</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      id="Tb_MWuFn9dl1ESUxjcaVQ4LEg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:65.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:65.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:65.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:65.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.13%;border-bottom:1.5pt solid #ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:65.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;NOLs (foreign) &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (12,021,483)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (6,076,187)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:65.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;NOLs (domestic)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (6,218,309)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (532,209)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:65.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;   Total NOLs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (18,239,792)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (6,608,396)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:65.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:65.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:65.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;Deferred tax assets related to:&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:65.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;  Net operating loss (foreign)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 2,243,668&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,111,942&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:65.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;  Net operating loss (domestic)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,677,610&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 146,451&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:65.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;  Stock based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 253,439&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 22,465&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:65.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;  Warrant expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 284,531&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:65.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;  Other temporary differences&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 4,010&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:65.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;            Total deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 4,463,258&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,280,858&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:65.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;Deferred tax liabilities&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:65.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;  Depreciation and other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,137)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,682)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:65.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;            Total deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,137)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,682)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:65.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:65.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;  Valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 4,462,121&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,278,176&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:65.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Net deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember_eYHQNzPoa0Kj3sShxdX8jQ"
      decimals="0"
      id="Tc_vSk-afSa6k6YCFfb-vrSZw_4_3"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">12021483</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2020_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember_cfBf_8Ckq0Gp_Dh77YRizw"
      decimals="0"
      id="Tc_73PpJ8hLyUKwcB_BdPlcNw_4_6"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">6076187</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_dHaFDA1AQUSlfDaHicQ8uw"
      decimals="0"
      id="Tc_W_NgyEO3QE-TYDSd-sDqSA_5_3"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">6218309</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2020_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_MuNTVlrNBkqVSW1-Y7sqjA"
      decimals="0"
      id="Tc_IrsGpdi4FEmq7XhDrONusg_5_6"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">532209</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A"
      decimals="0"
      id="Tc_VcmfUU_OZ0OLncy5fhexXA_6_3"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">18239792</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg"
      decimals="0"
      id="Tc_NOHgLD-iIUSA0zUdiup7jA_6_6"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">6608396</us-gaap:OperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign
      contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A"
      decimals="0"
      id="Tc_e32TC2DG2Ue3r3vUfjxRGQ_10_3"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">2243668</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign
      contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg"
      decimals="0"
      id="Tc_10xpFZdSVEafqnyzjjbKNA_10_6"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">1111942</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic
      contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A"
      decimals="0"
      id="Tc_ypOjss2_Jk-er09ZS9uBew_11_3"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">1677610</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic
      contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg"
      decimals="0"
      id="Tc__TYk3ZF0hkKSxHFpHcvgSw_11_6"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">146451</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A"
      decimals="0"
      id="Tc_4WxjMjPl9ECUCTcJfTOznQ_12_3"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">253439</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg"
      decimals="0"
      id="Tc_1UZQWx9j2ke2Lhv4jILShg_12_6"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">22465</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <ganx:DeferredTaxAssetsFmwWarrant
      contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A"
      decimals="0"
      id="Tc_bOL-kz1s2E-8vh5pFURCEg_13_3"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">284531</ganx:DeferredTaxAssetsFmwWarrant>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A"
      decimals="0"
      id="Tc_EN6lGmxrqkGPdxnifQt3Eg_14_3"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">4010</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A"
      decimals="0"
      id="Tc_umAkbou2IECt31Yl0M8NyQ_15_3"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">4463258</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg"
      decimals="0"
      id="Tc_XM86NcnVXEeqONrER0PoCQ_15_6"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">1280858</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A"
      decimals="0"
      id="Tc_BAccOHUKEEWHWzeNP60tQg_17_3"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">1137</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg"
      decimals="0"
      id="Tc_5pv9E4RDFUOZrVrRyypsMA_17_6"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">2682</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A"
      decimals="0"
      id="Tc_DeNgQORlxEiW5iZvcTAbZw_18_3"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">1137</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg"
      decimals="0"
      id="Tc_285BUrx1Bk2JUKT3ub5sdQ_18_6"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">2682</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A"
      decimals="0"
      id="Tc_Fj8e-_YqO0W4dC0nPPpZkg_20_3"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">4462121</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg"
      decimals="0"
      id="Tc_OHNFMHvsuESZpyk2PxPX7w_20_6"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">1278176</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      id="Tb_H970w4VlGkC8hi-kuU7gBg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:71.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:71.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:71.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:71.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.44%;border-bottom:1.5pt solid #ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:71.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Federal income tax at US statutory rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;21.00%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;21.00%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:71.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;State income taxes, net of federal benefit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;6.52%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;6.52%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:71.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Permanent differences&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;(0.10)%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;0.00%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:71.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Provision to return&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;0.13%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;0.00%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:71.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Foreign tax&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;(0.03)%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;(0.15)%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:71.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;(27.52)%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;(27.37)%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:71.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Effective income tax rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;0.00%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;0.00%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      decimals="4"
      id="Tc_F1Ry8MUkUkqE3ItNfpzcgA_4_3"
      unitRef="Unit_Standard_pure_YPFUW3Xga0mVMPZT28RXUw">0.2100</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2020_To_12_31_2020_JDEb6LtAmEuXGmEieWNlsw"
      decimals="4"
      id="Tc_nAfsyQFgrEOZ0e2MaJJxig_4_6"
      unitRef="Unit_Standard_pure_YPFUW3Xga0mVMPZT28RXUw">0.2100</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      decimals="4"
      id="Tc_XTZp2duPI0WFvIn37oZbmw_5_3"
      unitRef="Unit_Standard_pure_YPFUW3Xga0mVMPZT28RXUw">0.0652</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="Duration_1_1_2020_To_12_31_2020_JDEb6LtAmEuXGmEieWNlsw"
      decimals="4"
      id="Tc_zTPWPjamCkKX4DU3XejMYg_5_6"
      unitRef="Unit_Standard_pure_YPFUW3Xga0mVMPZT28RXUw">0.0652</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <ganx:EffectiveIncomeTaxRateReconciliationPermanentDifferences
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      decimals="4"
      id="Tc_lw-d5khB10Oxq4eUGR0Lnw_6_3"
      unitRef="Unit_Standard_pure_YPFUW3Xga0mVMPZT28RXUw">-0.0010</ganx:EffectiveIncomeTaxRateReconciliationPermanentDifferences>
    <ganx:EffectiveIncomeTaxRateReconciliationPermanentDifferences
      contextRef="Duration_1_1_2020_To_12_31_2020_JDEb6LtAmEuXGmEieWNlsw"
      decimals="4"
      id="Tc_S5vBRuBlr0SULEd7l-PPew_6_6"
      unitRef="Unit_Standard_pure_YPFUW3Xga0mVMPZT28RXUw">0.0000</ganx:EffectiveIncomeTaxRateReconciliationPermanentDifferences>
    <ganx:EffectiveIncomeTaxRateReconciliationProvisionToReturn
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      decimals="4"
      id="Tc_9XoRK8OI6UCaZ6ig_9RZeQ_7_3"
      unitRef="Unit_Standard_pure_YPFUW3Xga0mVMPZT28RXUw">0.0013</ganx:EffectiveIncomeTaxRateReconciliationProvisionToReturn>
    <ganx:EffectiveIncomeTaxRateReconciliationProvisionToReturn
      contextRef="Duration_1_1_2020_To_12_31_2020_JDEb6LtAmEuXGmEieWNlsw"
      decimals="4"
      id="Tc_uFGRnRPnjEG35bk1qNyl4Q_7_6"
      unitRef="Unit_Standard_pure_YPFUW3Xga0mVMPZT28RXUw">0.0000</ganx:EffectiveIncomeTaxRateReconciliationProvisionToReturn>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      decimals="4"
      id="Tc_w0Ai9oibmUOy3UChiffjGQ_8_3"
      unitRef="Unit_Standard_pure_YPFUW3Xga0mVMPZT28RXUw">-0.0003</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="Duration_1_1_2020_To_12_31_2020_JDEb6LtAmEuXGmEieWNlsw"
      decimals="4"
      id="Tc_39Gp-9oWd0qczz135EQdcQ_8_6"
      unitRef="Unit_Standard_pure_YPFUW3Xga0mVMPZT28RXUw">-0.0015</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      decimals="4"
      id="Tc_lMjlkLYK6UqDTRdDyCwjcA_9_3"
      unitRef="Unit_Standard_pure_YPFUW3Xga0mVMPZT28RXUw">-0.2752</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_1_1_2020_To_12_31_2020_JDEb6LtAmEuXGmEieWNlsw"
      decimals="4"
      id="Tc_ezjt3V6G4UWLr93ZWsjDew_9_6"
      unitRef="Unit_Standard_pure_YPFUW3Xga0mVMPZT28RXUw">-0.2737</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      decimals="4"
      id="Tc_UO01vQR0YkiS2ATYjFznIg_10_3"
      unitRef="Unit_Standard_pure_YPFUW3Xga0mVMPZT28RXUw">0.0000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="Duration_1_1_2020_To_12_31_2020_JDEb6LtAmEuXGmEieWNlsw"
      decimals="4"
      id="Tc_ArVXID8A5EGfCPHmEfO7DQ_10_6"
      unitRef="Unit_Standard_pure_YPFUW3Xga0mVMPZT28RXUw">0.0000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg"
      decimals="0"
      id="Narr_QW3XK8KIi0GV7dg_XmnQbA"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A"
      decimals="0"
      id="Narr_Jo3oaeIBv0eJwCB7ytyn-g"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <ganx:ExpenseForInterestAndPenaltiesRelatedToUncertainTaxPositionRecognizedInStatementOfOperations
      contextRef="Duration_1_1_2020_To_12_31_2020_JDEb6LtAmEuXGmEieWNlsw"
      decimals="0"
      id="Narr_oHyKKKuzc0GXHuS4MOUnkA"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">0</ganx:ExpenseForInterestAndPenaltiesRelatedToUncertainTaxPositionRecognizedInStatementOfOperations>
    <ganx:ExpenseForInterestAndPenaltiesRelatedToUncertainTaxPositionRecognizedInStatementOfOperations
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      decimals="0"
      id="Narr_tFipniISB0m65tqpHO53Fw"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">0</ganx:ExpenseForInterestAndPenaltiesRelatedToUncertainTaxPositionRecognizedInStatementOfOperations>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      id="Tb_2jLidE0Kg06shwlAy7pgRQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;18.&#160;&#160;&#160;&#160;Net loss per common share&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Basic net loss per common share is computed by dividing the net loss available to common stockholders by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per common share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock and potentially dilutive securities outstanding during the period determined using the treasury-stock and if-converted methods. For purposes of the diluted net loss per share calculation, preferred stock, warrants and stock options are considered to be potentially dilutive securities, but are excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive and therefore basic and diluted net loss per share are the same for all periods presented.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table sets forth the outstanding potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to do so would have resulted in anti-dilutive impacts:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:74.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Series A Preferred Stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 1,185,879&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Series B Preferred Stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 2,695,600&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Options to purchase common stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 960,216&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 429,822&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Warrants to purchase common stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 425,387&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 237,249&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The net loss per share for the comparative period ending December 31, 2020 of $1.17 has been recomputed to take into account the reverse stock split, resulting in $1.33 net loss per share.&lt;/p&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      id="Tb_Wh77tnIY20SL3BVV5sH3MA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:74.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Series A Preferred Stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 1,185,879&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Series B Preferred Stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 2,695,600&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Options to purchase common stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 960,216&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 429,822&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Warrants to purchase common stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 425,387&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 237,249&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_SeriesAPreferredStockMember_gYxd91evBkC5xqONi1hr9g"
      decimals="INF"
      id="Tc_gbIT6hAmAUGelU7hd74UJg_3_4"
      unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw">1185879</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_PreferredClassBMember_ulJHYyt9xkm7k2JpVT1HlQ"
      decimals="INF"
      id="Tc_QuEs6viYOk2RQF3tKA5LRw_4_4"
      unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw">2695600</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_nWZin8CUEka_hYHuxWQ98g"
      decimals="INF"
      id="Tc_R9Sgam6QPEORc8I_JOG_1w_5_2"
      unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw">960216</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_o5CVJWPFxkyUPRNzDIKUWw"
      decimals="INF"
      id="Tc_pp8yXbCr0UGUIidnnzL64g_5_4"
      unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw">429822</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_eFtEzOEVSUW8fCSfS0makQ"
      decimals="INF"
      id="Tc_WnwkJyCC1E2uGF0zW_WRPA_6_2"
      unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw">425387</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_BLTwMarrSki4A2b_zuzjjQ"
      decimals="INF"
      id="Tc_LzwB71SvuUymNPPSvsuyzg_6_4"
      unitRef="Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw">237249</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_BhPyaAaDOkudfThK5f94MA"
      decimals="2"
      id="Narr_NLgvbe9UyUubD_mP5ymM_A"
      unitRef="Unit_Divide_USD_shares_ZUfWDOiJrESFdyfJo2gfWg">-1.17</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2020_To_12_31_2020_JDEb6LtAmEuXGmEieWNlsw"
      decimals="2"
      id="Narr_lnv6wpAYYEy5KsUOe9Wrqg"
      unitRef="Unit_Divide_USD_shares_ZUfWDOiJrESFdyfJo2gfWg">-1.33</us-gaap:EarningsPerShareBasic>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      id="Tb_R7PwWZNc2Eag0vSJfhgAUg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;19.&#160;&#160;&#160;&#160;Related Parties&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;Dr.&#160;Khalid Islam, the Chairman of our Board of Directors, shareholders and founder of the Company, is currently the Chairman of the board of directors of Minoryx, and therefore Minoryx is considered a related party. In December&#160;2017, the Company entered into an exclusive worldwide, royalty-bearing, assignable, transferable license agreement with Minoryx Therapeutics SL to use and exploit Minoryx&#x2019;s IP and into an exclusive worldwide, royalty-bearing, assignable, transferable sublicense agreement with Universitat de Barcelona and Institucio Catalana Recerca Estudis Avancats in order to be able to develop its business, directly or indirectly, through sub-licensing to third parties &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;or any other way of operation. According to the Minoryx License Agreement, &#160;the Company shall pay to Minoryx as royalties:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;an amount equal to &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;8%&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; of (i)&#160;net revenues with regard to products that would infringe (a)&#160;at least one composition of matter claim or (b)&#160;Minoryx molecules and (ii)&#160;sublicensing revenues;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;an amount equal to &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;3%&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; of net revenues with regard to products that would infringe at least (a)&#160;one method of claim or (b)&#160;Minoryx know-how.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"/&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;In addition to royalties, the Company shall pay Minoryx certain milestones payments of 1.25% of any consideration received in the event of a sale of the Company or substantially all of the assets, including by merger, change of control, or reorganization.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;As of December 31, 2021 and 2020, there were no receivables and payables, revenues or expenses with Minoryx.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <ganx:RelatedPartyTransactionPercentageOfNetRevenuesBasedOnOneCompositionOfMatterClaim
      contextRef="Duration_12_1_2017_To_12_31_2017_srt_RangeAxis_srt_MaximumMember_us-gaap_RelatedPartyTransactionAxis_ganx_LicenseAgreementWithMinoryxTherapeuticsSlMember_wfhEAoIeSEyyfIL5XTMUAQ"
      decimals="INF"
      id="Narr_3GCgSf9STk2NH1R3xdrs2Q"
      unitRef="Unit_Standard_pure_YPFUW3Xga0mVMPZT28RXUw">0.08</ganx:RelatedPartyTransactionPercentageOfNetRevenuesBasedOnOneCompositionOfMatterClaim>
    <ganx:RelatedPartyTransactionPercentageOfNetRevenuesBasedOnOneMethodOfClaim
      contextRef="Duration_12_1_2017_To_12_31_2017_srt_RangeAxis_srt_MaximumMember_us-gaap_RelatedPartyTransactionAxis_ganx_LicenseAgreementWithMinoryxTherapeuticsSlMember_wfhEAoIeSEyyfIL5XTMUAQ"
      decimals="INF"
      id="Narr_9RrLxq3GUEWdtKGvUYuU5g"
      unitRef="Unit_Standard_pure_YPFUW3Xga0mVMPZT28RXUw">0.03</ganx:RelatedPartyTransactionPercentageOfNetRevenuesBasedOnOneMethodOfClaim>
    <ganx:RelatedPartyTransactionPercentageOfConsiderationReceived
      contextRef="Duration_12_1_2017_To_12_31_2017_us-gaap_RelatedPartyTransactionAxis_ganx_LicenseAgreementWithMinoryxTherapeuticsSlMember_cbGjmh51ckuCzbppGr1veQ"
      decimals="4"
      id="Narr_T_vq8OXMSECzjDX3-oXlEA"
      unitRef="Unit_Standard_pure_YPFUW3Xga0mVMPZT28RXUw">0.0125</ganx:RelatedPartyTransactionPercentageOfConsiderationReceived>
    <us-gaap:AccountsReceivableRelatedParties
      contextRef="As_Of_12_31_2020_us-gaap_RelatedPartyTransactionAxis_ganx_LicenseAgreementWithMinoryxTherapeuticsSlMember_VIe1l_ajWEuJhOrR7dlifQ"
      decimals="INF"
      id="Narr_2a-czAJVJEeqLR6yOMwBYA"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">0</us-gaap:AccountsReceivableRelatedParties>
    <us-gaap:AccountsReceivableRelatedParties
      contextRef="As_Of_12_31_2021_us-gaap_RelatedPartyTransactionAxis_ganx_LicenseAgreementWithMinoryxTherapeuticsSlMember_uoLGxPyxJ0uSfZ7e2uoHkg"
      decimals="INF"
      id="Narr_Jh1rPwTkvEGpIGxvGSEPxg"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">0</us-gaap:AccountsReceivableRelatedParties>
    <ganx:OtherInformationDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      id="Tb_mIk3_1imsESQghW-XYmV6Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;20.&#160;&#160;&#160;&#160;Other Information&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Own Shares&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company does not hold, either directly or indirectly, its own shares and in these periods &#160;has not purchased or alienated its own shares.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Commitments&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December 31,2021, the Company had research commitments with contractual maturity date in 2022 for $ 453,305.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</ganx:OtherInformationDisclosureTextBlock>
    <us-gaap:ContractualObligationDueInNextTwelveMonths
      contextRef="As_Of_12_31_2021_us-gaap_OtherCommitmentsAxis_ganx_CollaborationAgreementsMember_Yr71bAiK8EiGzhgz_kIr8Q"
      decimals="0"
      id="Narr_yxiEHRpycUKGhbZeCkoyvw"
      unitRef="Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA">453305</us-gaap:ContractualObligationDueInNextTwelveMonths>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA"
      id="Tb__3krA90G70GT5FRy3WR0NQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;21.&#160;&#160;&#160;&#160;Significant events after the balance sheet date&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:14.2pt;margin:0pt 0pt 12pt 0pt;"&gt;None.&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>121
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
M6'!VULS2 Y9>*?IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T1G*=D 4. #?$
MT4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB!]4>"(<7<K_WUE[O)I#-ZG7TZSFN4
M?VFK :?MNYO/D_QSZ.2?IY/734+.<+PL"?'[(UMAAR=N.Q-R.AQG0GS/]O:1
MI24RS^_Y"NM./&<?5I:P7<_/Y)Z,<B.[W?98??9/1VXCUZG LR+7E$8D19_(
M+;KD$3BU20TR$S\(G8:8:E < J0),9:AAOBTQJP1X!-]M[X(R-^-B/>K;YH]
M5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5 9<8WS2J-2S%UGB5P/&M
MG#P=$Q+-E L&08:7)"82J3E^34@3_BNEVOZ<TT#PE"\D^DJ1CVFS(Z=T)LWH
M,QK!1J\;=8=HTCQZ_@7YG#4*')$;'0)G&[-&(81IN_ >KR2.FJW"$2M"/F(9
M-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$.$9)>-T(^8LZ+
MD!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]072N0/)J<_Z3(T
M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
M.7\N?<^E[[GT/:'2MS<C?6?!TXM;WD9N6\3[KC':US0N*&-7<LW(QU2ODRG8
M.9_ [/UH/I[Q[?K9)(2OFEDM(Q:02X&S022X_(O*\"K$">AD6R4)RU3393>*
M$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.W<DOJMI2^M28X
M2O2QS'!.'LL,.V<\DAVV=Z =-?OV77;D(Z4P4Y=#N!I"O@-MNIW<.CB>F)&Y
M"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>(\J(A[J&&F,_#
M0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R4E5@,5O& RN0
MHGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K>9;'!51W/55OR
ML+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4XOT4SMA*7&+SC
MYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5YYN<KGHB=OJ7
M=\%@\OUPR4</Y3OG7_1=0ZY^]MWC^FZ3.TA,G'G%$0%T10(CE1P&%A<RY%#N
MDI &$P'-E,E$\ *"9*8<@)CZ"[WR#+DI%<ZM/CE_12R#ADY>TB42%(JP# 4A
M%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+A=OB5,V[&KXF
M8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.'<YMZN,)%K/]8UA[Y,M\Y<-LZW@->
MYA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> ,?-2K6J5D*Q$_
M2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H:,]6+K#F-"F]!
MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M>H&,T^(O66_N;7<:),A2+9,R& B22&S^LZ>R(_8"?'H@@)8!]%6 ZQ\(\,H
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M3F#G&BB)MDH#BTY8JG52VPO-I75*"2'SZ+EF@F4ACB4C_Y-W!*!GBB.A>N2
M"H9I.@?K&@HB$A;:ZE$22%P3]F@C"%U"9T!4"4Z=>+J6N< <Q"V <21_DAU5
M1-55<5?5E:EDG-)&3B=Q4C^4"=OB)5 C7!*7J!-8UB33A^6[=KD@"1'^U=.1
MSRG^5S3R&H47()0APWRX!Z]O3@')H;2:X?;8$4K3)(1[U L:UXO/;PJ+R=YY
MT7K4@EL6QG.XKF$J,IX$#@*=%.IQO;!UV[93CY7M$[T079U@F0//-2(X#8$;
MI83&I>10_U1MJ1IOGE)7#*@0"9[7'3X[EO,L(+AT% T:%XU/JFAMZZ8WJC/(
M4K@7IJ?>QRRC\[+ 8T>IH*&L'/6%QO7E;1WW7E9ZE"1):,(=M!Y#0B"H@3Z&
MCFI"Q='5W)'\1T?RIW'RA[2";];H3K;P9-!VN"790C?NC8='#&C.)PP_A,/3
M!:0D"2D!'96 QON &!=.%->+W6T,1)[@9-X)>^PXQHP&.A@ZB@V-B\WK^:BA
MP@D?#X_:Y)@+)\*N'018A%B;C6K#XFKC5B_OG!'FT0]!>.X(I,^09FG" EG!
M1J5A<:798WX/IRL<G(@43O,<IVO(0(J8"-2V;)08%K\,NC6J_+Y1]5IV^L>^
MA3(OL1NAR970.W="JFG@V/;^E^@'?(HQ)E#4=.BQJ'?R R)DF65LR4365]-L
MF7"V)(*A2NL=$$!?8N^,-O!@3U>A;9=R+4O9W(&(O]ZG]7;S;_$2=5)O97\M
M6K]X8^]J#B&9DR"N%4L"QXZ-LL3BLO1QO:[LO2UDB+W\.*E:Z&FV%62,%ZDK
M.T!;</K%O-SU6!+&LBP-W5VQ4:/8N[=7NV97]S>CP_6,:K:=W%AZ?@364]J?
MXJX*G>18<"?#/78DH2(/G<11K5B\]YDB7X.DE)67BYG;S9RDF/',86.?)>-)
M2H)1'L6/Q<7O$T319CD$&(2OJ]3:"]65LA,"'1 6>%X$^$Q9DD)Y2@-81]UC
M<=W;,YQ^ES\&S*Z$06Q)ZM8M'DM!L;VQ"R >U8X=<U\VX>2>.XY>0>Y>7/N[
M3N9KNR)=)Q^5D,>5\!9R F!_1#?=:_7=$VR$L?DH69S\GU+ 1XWA\39F!G:)
MOED%\%Z\>UH5$HK:*$4\+D5#U"[G43N-K6[R.H'_KV$;*9?'*?=?A"UQ4I/F
M\TNCU>2]F'TI^7O1/510_=7R'D;ATQ2<=/OW?/L/1FW[5V5WRAC5](\;6< R
MK0'\?J^4>?U@W[X=WK9>_ -02P,$%     @ "W-Y5#9CBG,H P  2@T  !@
M  !X;"]W;W)K<VAE971S+W-H965T,RYX;6RUEU%OFS 0Q[^*A?;02EW $ BI
MDDA-JFE[F!0UVO;LPB58-9C93K/MT\\&2I)"",FT/ 3;W)U_?WSXS&3'Q8M,
M !3ZE;),3JU$J?S>MF640$KD@.>0Z3MK+E*B=%=L;)D+(''AE#+;=9S 3@G-
MK-FD&%N*V81O%:,9+ 62VS0EXO<<&-]-+6R]#3S13:+,@#V;Y&0#*U#?\J70
M/;N.$M,4,DEYA@2LI]8#OE_@P#@4%M\I[.1!&QDISYR_F,Z7>&HYA@@81,J$
M(/KR"@M@S$32'#^KH%8]IW$\;+]%_U2(UV*>B80%9S]HK)*I%5HHAC79,O7$
M=Y^A$N2;>!%GLOA'N]+6'UDHVDK%T\I9$Z0T*Z_D5_4@#ASP\(2#6SFX?1V\
MRL$KA)9DA:Q'HLAL(O@."6.MHYE&\6P*;ZV&9F895TKHNU3[J=F"9Y(S&A,%
M,9H31K((T,J$D^AF201D*@%%(\)NT4?T =E()GI43FRE9S<Q[*B::5[.Y)Z8
MZ1&B ?+P'7(=%[>X+_J[.\?NMM9<"W=KX6X1;W@BWE*G"PBA5>MG'+W<H9P(
M]$K8%M -S5#,&2-"HAQ$J?BV37$Y15A,85Z8UYDS<!Q'RWL]5';6[$B!5ROP
M+E-0K@PB6Y5P0?] W(9<Q@P.6+!3_MY!]S \PA[6V,.KL/4>(Q7)8IIMVKB'
M#9P3''[-X7=R+'B:ZGWD'U;?[[?Z9\V.\(,:/[@ O]?2!XU'Z+<O?0_#(^91
MS3RZF/D.42FW[<"C9@KB,/2\('P'W#3T_*&' Z^=-ZQYPRMXSR1JV!>Z:=@)
M/:ZAQYW0*Q!4I\(#VK]H*R.@8\_$SKY:./]_UZSF./OBG+<[5G%0\_!56]#I
M3*P"MF\_%6W31"^\'X[&)W#WE0I?6*KZ[9A5U$[FIDDW\[XVX>[B5&7A_'T6
M#KK2<%]"\(4UY*HT'/9,P[-VQRKV!0AW5Z KTM _OZ1-$W<<^,&IO1OO"P[N
MKCC7IF&SFC28FR;MS/;!0==\97PE8D,SB1BLM:<S&&GQHCRXEQW%\^+L^\R5
M/DD7S41_[( P!OK^FG/UUC''Z?KS:?874$L#!!0    (  MS>51QXL;L<00
M #,0   8    >&PO=V]R:W-H965T<R]S:&5E=#0N>&ULI5C;;N,V$/T5PNC#
M+K ;B:2N@6-@D_02H-L-DF[WF;9H2X@DNB1MIW_?H21+CD010?MBW68.SPPY
M-R]/0KZHG'.-7JNR5C>+7.O]M>>I3<XKIJ[$GM?P92MDQ30\RIVG]I*SK%&J
M2H_X?N15K*@7JV7S[E&NEN*@RZ+FCQ*I0U4Q^<\M+\7I9H$7YQ=/Q2[7YH6W
M6N[9CC]S_7W_*.')ZU&RHN*U*D2-)-_>++[@ZSM"C$(C\5?!3^KB'AE3UD*\
MF(>'[&;A&T:\Y!MM(!A<COR.EZ5! AY_=Z"+?DVC>'E_1O^E,1Z,63/%[T3Y
MH\AT?K-(%BCC6W8H]9,X_<8[@T*#MQ&E:G[1J96-P@7:')065:<,#*JB;J_L
MM7/$A0*.9A1(IT#&"L&, NT4:&-HRZPQZYYIMEI*<4+22 .:N6E\TVB#-45M
MMO%92_A:@)Y>W8E:B;+(F.89>M9P@3W22&S1MSV7S+A:H<_H^_,]^O#3QZ6G
M84VCZ6TZ_-L6G\S@8X*^BEKG"OU<9SQ["^ !V9XQ.3.^)4[$>[ZY0A1_0L0G
MV$+H[OWJOH,.[1U(&SPZ@_?$C[P^<'7MP IZK*#!"F8WHRS96K1NAR!ID6U.
M;W'B!L=$ZG&%*4U)LO2.EO7#?OW0N?XWG7.)BGHC*FY;M=6.+E:EV(^B?M'6
M_^&$&TF2!-NI13VUR$GM3Z%9Z71)-"&'HR!-@Q&[J9B#7=RSBYV'H(N5>H?X
M*R18Y3X.28^:.&U^XHHSN<D1JS-(34?(N7L3G3;KDXE9GV.PGY!T9+]%D) P
M)7Y@=T':DTV=9'_E-?B@;+BR##)5H;3QR=%ZDM(IBR@A44J3$5V+("9!BDED
MIXO](?'Y[SA18K)SUASG6VC0-,4XBD>$;:(T]!-*_1G&%ZD:.QG_+I1"6RFJ
M,VO(S5:VV,86W(MC.F9K$:5!G 9!.L.6#&R).R8ND@GZT'GWHRLN\)!S,75Z
MXJ'67'*E._A/J.;6J.A@WB0%.#WAV M3,1K1>,8#0S;'[G0.?09T$36<K$W.
MZAU')6S@/-? $L(D)?Z8K$4NC8)D)G[QD/RQ._LWQVO-H37DYVW3[-5*=5H(
MS %+HC =QZ]-E(8QY*6Y !XJ G:7A <WQVFB_QSX_H2?12RDR1RYH2#@V$GN
M#^C S79;J<63"FG<E_J1/ZZE-E%P7PS)<H;A4%QPXHS/,T,$N02IG$EWT<)#
M(<#N2C %1DQK6:P/FJU+V#"!8.,JZ'"@N]V\Y*+,N#1-YBU3Q<;JL';!](W#
MKN@D]=K%J-U39*@4Q%TI_K-!]T5YT..FM^MQ_7>9-",V9])02HB[E/QHQAMH
M^=D1*@FDIK,!S3EP[0695@SLXR@,_'&G99$D48(#?Z9+)4-I(>3_L7<YGKR;
M_U32SM^[&+\J+G?-5*J U*'6[5S3O^TGWR_-O#=Z?PL3<3N_#C#M./V5R5T!
MDUC)MP#I7\605F4[H;8/6NR;(6\M-(R,S6T.4SV71@"^;X70YP>S0/\_P>I?
M4$L#!!0    (  MS>51D%GC!U0(  "L(   8    >&PO=V]R:W-H965T<R]S
M:&5E=#4N>&ULK59M;]HP$/XK5K0/K;0V+R8O5(!48-,FM5M5U.VS20R)ZMB9
M;:#]]SL[(>,E1)NT+\1V[IY[[C%WE]%.R%>54ZK16\FX&CNYUM6=ZZHTIR51
MMZ*B'-ZLA"R)AJU<NZJ2E&36J61NX'F16Y*".Y.1/7N2DY'8:%9P^B21VI0E
MD>]3RL1N[/C._N"Y6.?:'+B34476=$'U2_4D8>>V*%E14JX*P9&DJ[%S[]_-
MAL;>&OPHZ$X=K)')9"G$J]E\S<:.9PA11E-M$ @\MG1&&3- 0.-7@^FT(8WC
MX7J/_MGF#KDLB:(SP7X6F<['3N*@C*[(ANEGL?M"FWQ"@Y<*INPOVM6V8>B@
M=*.T*!MG8% 6O'Z2MT:' P<_NN 0- [!J</@@@-N'+!-M&9FTYH3328C*79(
M&FM ,PNKC?6&; IN;G&A);PMP$]/9H(KP8J,:)JAA88'7)%&8H5FHH3_16XN
M;$O1@U *W:"7Q1Q=?;@>N1IB&P0W;>),ZSC!A3A^@!X%U[E"GWA&LV, %TBW
MS(,]\VG0BSBGZ2W"_D<4>('?06CV]^Y>#QW<"HDM'OX/0O:$&[3A!C;<X$*X
M;U#@[ RJUJWVC*VGJ>+MY,;'R="+O&CD;@\EZK#$81Q'2= :'K$+6W9AKQC?
M=4XE2H\27T-+<:\,Y^N['@&B-D34*\"<KN D0TO*8:51U726BA'>)4J-%AV)
MXOEQXIU(TF&'H\!/N@6)6[9Q+UMH.=!0.%2TE)2G[TA+PA4CII5UL8W/6/@1
M3C ^(7MN!O>'_;B;;-*237K)_MOMU823,R91X(6G?,^M;F(_Q&$WWV'+=]C+
M][C +E7%L+,J@B0\8]EAB:/!,#C3U3WHNR65:SN.%"BWX;IN9.UI._'N;:,_
M.9_")*P'UQ^8>HP^$KDNN$*,K@#2NXVA\&0]FNJ-%I7M[DNA85;890[3G$IC
M .]70NC]Q@1HOP\FOP%02P,$%     @ "W-Y5"8<]M9:!@  1!X  !@   !X
M;"]W;W)K<VAE971S+W-H965T-BYX;6RM66UOVS80_BN$,6 I,,<BJ=?",=#8
M3IP/6X-FW3XK,AT+E417I./VWX^29;V0%*6D0X%&MI\[/G='\;F3YB>:?V-[
M0CCXD289NYGL.3]\G,U8M"=IR*[I@63BEQW-TY"+C_G+C!UR$FY+HS29(<MR
M9VD89Y/%O/SN,5_,Z9$G<48><\".:1KF/V])0D\W$SBY?/$E?MGSXHO98GX(
M7\@3X5\/C[GX-*N];..49"RF&<C)[F;R"7[<8%08E(A_8G)BK6M0A/),Z;?B
MP\/V9F(5C$A"(EZX",6?5[(D25)X$CR^5TXG]9J%8?OZXOVN#%X$\QPRLJ3)
MO_&6[V\F_@1LR2X\)OP+/6U(%9!3^(MHPLK_P>F,]00X.C).T\I8,$CC[/PW
M_%$EHF5@PQX#5!D@V<#J,<"5 98,D--C8%<&MF0 <8^!4QDX8PW<RL"5*?7%
MX%4&WM@5_,K +ZM[+D=9RU7(P\4\IR>0%VCAK;@H-T1I+4H89\7>?>*Y^#46
M=GRQI!FC2;P-.=F")R[^B(W) =V!Y3[,7@@#<2:^I]&W/4VV)&>_@_7W8\Q_
M@JL5V<51S#^ *?CZM )7OWV8S[B@5#B>1=7RM^?E4<_RCV*GDCPOUQ9K/)$\
M%DM^ M+WUQK/R_=XOI4]:QROS(Z7-$UIE9/VM<;3VNSIT^/#4F-U-V#U>?F@
ML;H?L(JB8WI,RC)7A=,XV9B=_$UYF'3-9F*_U9L.U9L.E7[L'C^W81)F$0$A
M%URB:X#A'P!9,-#MG[,GK_14',2O"]^;SU[;]5(A,/"[F+6*P9;OPP!W<7<J
M;NI#Z$JP>PT,VXX'/=@%;C1 VPY\QZUQG0SB.H-X5 :OQ-W)]F%.V(=1V3Q[
M=3O9=(3,21E582*CT',=/6N[9FT;63\P=BQIB^.E[U;_ V2D/'_B"SBB3+=7
M;VVUI%+VU[8:AQ5 #&VI2CTXNR=>IX[7^>5XVR741>DHU#"T? _KF;DU,_>M
MS)2C<70EEJY2"11(-^G:U>P\B#TH;;V-%F=;L"=@KP[8^^6 !TJQ]!1J*' =
MU[+TU/R:FC^:&NM//--)E:\>?8Z4T;6OTI9/*14"/4\?55!'%?PO40TD?16H
MU!P7XM8!WZ$'K:;QL8P$SR4O^MZM8)**88"%93M-?A371*OGEKH[H6M;4CH'
M85W*K5X-CL[I*<SS,-/NBG7EIKV^#;$O"^=F&-<EVN@[- M\T6%D(J_/)!-7
M'!RJ8><@5$O;\2"%R!2["/HRX4%<EW CI]"LIV(.$E-.)CIN<1QDT4_ 17)9
M4FX(+6%5(:?8P5#)\""N2[A14FB6TK_$O910IBO_/53E3"SJ>:Z/9'HCD%V"
MC?1!L_;I>SQD:6<$1SW&Y-HO-2!%958:$'8DM5]#55,A+K:]W+W=:9!3Z"!7
M;B_O=4#/PK;O8#GE*M(MNC4_Z,EX(^G0K.G#/6%/]E7)%=EW?"^0*Z "90&L
MJJ "115PNXWNQMBH.#3+N!A77\406IPEIIXJSC@% \/9;;54IS=7MMU*@X*]
MYTTC^="L^>^-8ZA;A*J23[7%7&F0,K ;6R/\T*S\VMC49FM,C9;54IT::>YZ
M%=4&=6?4ID% Y@;AO7$,M9%([0ZF^OM(@S1VG*CI)-#X3J+#75!_>/S\A@ZT
M6JB=>QM*FVV--(V&Y3@^M.3CL0_IH!Y%0JV'#N:F9"!F</5@;$21VGO8T"_^
M]1!KF@]D;CYZB6V/!(C-=6GU0!2R?4(8$RTJR:-8VZ.ND-IR8.3WG+RH:3C0
M^-G]0K)(UH5DV>,#>JA:: ,_=6Z7QW:DF<<14D;%'EC?C=^T+FC\V#XZU*$Y
M!FD&>1?U/&! C>@CL^B_9XI!FAD;!UA]=C6(ZY)N5!R-'\9-<PQ2)VYQ8MB6
M?%!N1@"[5!NA1F:A?NLD@W0";$'/5R@/ [N4&_U%9OU]ZRR#-".VBWVL',V#
MN.ZCS$9HL5EH3;,,UHBE&%$#RY4?6FY&0;L4&[W$9KWLF6:@[D['JB**SDJ6
M1 U*R!Q&MBL/(1KD5 35>CA9I4J#0U: '-L)Y%2I4#&K0,^Q^S+5J"P>]VS?
M,(7HLZ;*J\B:V%VNK*^SUMNNXOWJGV'^$F<,)&0G3*UK3YRT^?F5Y?D#IX?R
M!=@SY9RFY>6>A%N2%P#Q^XY2?OE0O%.K7QPO_@-02P,$%     @ "W-Y5*VI
MU&R^!@  11H  !@   !X;"]W;W)K<VAE971S+W-H965T-RYX;6RE6=MNVS@0
M_17"V(==H*YYT35( B1.BRVPW09-VWVF)3K65A)5DHZ3O]^A)$N.1"D)]L76
M93@\<^&<(75^D.JGW@EAT&.1E_IBL3.F.ENM=+(3!=?O925*>+.5JN &;M7]
M2E=*\+0>5.0KBG&P*GA6+B[/ZV>WZO)<[DV>E>)6(;TO"JZ>KD4N#Q<+LC@^
M^)K=[XQ]L+H\K_B]N!/F>W6KX&[5:4FS0I0ZDR528GNQN")G:Q;8 ;7$CTP<
M],DULJ9LI/QI;SZE%PML$8E<),:JX/#W(-8BSZTFP/&K5;KHYK0#3Z^/VC_6
MQH,Q&Z[%6N;_9*G972RB!4K%EN]S\U4>_A2M0;[5E\A<U[_HT,KB!4KVVLBB
M'0P(BJQL_OECZXB3 228&$#; 70XP)L8P-H!K#:T05:;=<,-OSQ7\H"4E09M
M]J+V33T:K,E*&\8[H^!M!N/,Y5J66N99RHU(T9V!/XB107*+UESOT$<(LT9+
M]/WN!OW^VQ_G*P-SVI&KI-5_W>BG$_H)19]E:78:?2A3D3Y7L *P'6)Z1'Q-
M9S7>B.0]8N0=HI@2!Z#UZX?C&3BL<R"K];$)?5\JH;C)ROLF(S.3"7TVH]?K
M]'JU7F]"[]^PA'.IM<OES<BP'FG7Z</EDK HQ@$.SE</I[YP2#(_#(.(=H+/
MT/D=.G_6ZJOT7\A-FRH:&0GK.9%EDN4"E2UL^]1>)S:+]AJ2*RN1?*.O@@Y-
M,.NK&P$E+,FX+0PN?S6C@Q,O$-^+O(&OQE*Q'T_X*>R0A;/([HQ,?M9U)D6)
M+*#XZAHE$H_V6KC0AB,<$8M92 9P'6(D\+ ;;]3AC6;Q?M)ZS\M$V )PX$IQ
M"+ +8S3V*&8>QA/3Q]WT\?STI1&JY/D2,@9IN36 P>FC>#3_DGF$^>[I">ZK
M(9[-Z_6.E_="#Y)5:P%YSLL4Y1G?9/F+B4M.RB^9M?@J2>0>"B[DK\@>^"87
M3G^W6IY%FP;##'9(+4D<3#B%]ACI+,9;)2J>I<><;3PAS4XH8"BE+%\T+G(B
MIV-,/O-\3(?@'8*$A"'V)O#W%9JP6?P_KKZA1(DTFT#(QA.')"#1$*!#CA+/
MG\+75WHR7^K_DI!DD/@%]!^5U)DY<7 )M>(53O9&T!B+PWAHP5AL&3 <3RV;
MG@V(_YHLUJCB3S:'G1A]1R)0PN)1%H\%6>S['IM V;,$F:>)+\]2]F0I.^&.
MZ2 (?"_ 0[0.<@E92*=\VC,'F:>.&[&%)RG:B!*N#*K:WKG*N9/DR)@0?)_1
M84?@$(M"'$^@[7F#S!,'H!7@5TOSP'/N!!B3!O-"/.0UA]B2T)B1*8_VY$+F
MV>6;-#Q'R>M+O-,*%_70.!RU$PY!Z@60\&XS:,]1%+_8&;[85KF@MWH'GF6!
M'X3#K':),NIARL()^#WC43)/L1;ZMMY7;)4LP( 'H=_0%-*>M^@+O+57$&Q=
M-S.5LEXR3W6(Q:]]5MGFU>DE!P_%'B5#OG+)41S1";JE/5W1>;H:Q=?E(2=R
M!T$YD;N(; 9Y3V34>UUHF\A"_8)>\@V1[?F&SO/-K9*)$&F;03GPY[+ESXV3
M(-=TS"DAB^C4-HCVG$+G.>4YDNRD?;X3"NQ%5PC:I[8VUKN!=_6^" 0ZX43J
M"=0.;L$Q@>YI G9/+G2>7%Z$??U_8(\I)B8TC/&4MWN6H?,L,PT;2*< <M0[
MV#!HM*]LVP3[K5S4NRT+NX3\@_)?[3=YEL 3, Y2LS-K7Z9"'50&>8323#?]
MC'.5C?G)HP&-XWC8,#HDH9^=\$'/8G2>Q6[Y4[/O!M#I,41'<R:#<DT=O!5!
M(QZ-4#L$@:;#J:1C/7&Q>>(Z17[LPBJICA%ZOHQ=-C '*U$2^V0"6<]);'X7
M]CRO=+UIEU6[41<JR=P[=3;>;Q%*R40=93UQL7GBZA@ 6.LA2VT3^.2LIDY0
M8U[R2!@$8>@/(NV0)-B+@CB8<NC)H=@\AWV ?$SJ=24>FX8+08LBCLV7$_>8
ME0C&83C,3X?<DOF,3"PLUK,7>_G$#;I7)6S+ +1K(_"NB8-M&!YX7B>O;2"@
MQAB5)?;,U+YWFC/>:]'8PV$P.LAQ2(8DQGXT%86>)MD\3:Y?;0'B!C8:]UE9
MV@2S_1*4$YDZ#7-0J8\]&HWL<NSC" NGSHA8S[ELGG/?9I:P>^E9@X+1(2D+
M8@)U9=@X.22'IC<FK4X.Y NA[NOO%!K5I-*<='=/NV\A5_47@,'S:W*V;KYH
M]&J:#RR?N8)P:92++:C$[T/PMFJ^630W1E;UL?]&&B.+^G(G.)"<%8#W6RG-
M\<9.T'TYNOP/4$L#!!0    (  MS>52;2/@<I1$  '$T   8    >&PO=V]R
M:W-H965T<R]S:&5E=#@N>&ULQ5MM;^,V$OXK0GHHMH#BV$ZRFW9?@"2;W?9P
MUPWJS?4S+=$V&TET12G9]-??,S.D1#ER-@5:]$MB2^3,<-Y?Z#?WMKYU&ZV;
MY$M95.[MP:9IMC\<';ELHTOE)G:K*[Q9V;I4#;[6ZR.WK;7*>5-9',VGTY='
MI3+5P;LW_.RZ?O?&MDUA*GU=)ZXM2U4_7.C"WK\]F!V$![^8]::A!T?OWFS5
M6B]T<[.]KO'MJ(.2FU)7SM@JJ?7J[<'Y[(>+$UK/"_YG]+V+/B=TDJ6UM_3E
MI_SMP90(TH7.&H*@\.].7^JB($ @XW</\Z!#21OCSP'Z!SX[SK)43E_:XE>3
M-YNW!V<'2:Y7JBV:7^S]C]J?YY3@9;9P_#>YE[4GWQ\D6>L:6_K-H* TE?Q7
M7SP?H@UGTST;YG[#G.D61$SE>]6H=V]J>Y_4M!K0Z ,?E7>#.%.14!9-C;<&
M^YIW/ZNFK75B5TFST<E%Z_#>N415>7*AG''TYKK63E>-(C:^.6J E?8>91[#
MA6"8[\$PFR?_M56S<<E5E>M\". (Y'8TSP/-%_,G(;[7V20YGJ7)?#J?/0'O
MN./!,<,[_EMX,$!YTJ$\890G?R/;G\8PFR1#),L8R3(@V49(DD];7?,GORCL
M^ CC3CYO\'*KV\9D+DU^JB"#%[2JL6L-^#44M]DDIG$P\*4SN8&-IXSYVV_.
MYO/IZTM;;E7UP-]FK[]+DWOE$E-EMMY:H-5YTD)!:MY2J'L7"'>@CD_Q7N.Q
MPHE>W$P6D^\24/SOMM+)_"6KPG22?*(GQ0.^R1/![Q$G&0Y&OH=0J:3#"]\"
MIZ8J\P>?/4VV;>U:534X6G*_,=DF4441J#'.M;0?)X>/ VU5;JHUH)4E.1D\
M!DM7NJZQ"-:;W=+&CY\?\S!9G*<@8W$/B+2=220OBXU8.I_.7H%%&L?57[*-
MJM9XCM<!DX==[Z(#3$AONRU,II:%3AG]N/Q2\JKL'G$ E<RF/\P\6(?MS82V
M[&432T]EF6VKQE-&#[ J4UO3J"*LXS>RCO" N5OK-$A@?=G#&8!Q\*NT 2^)
M[SAFKC-H(\!!84WS$"3BQ3M)S@4_;0SO]@MY'^(EZ"\U -UO;%$\'-K[BEC;
MJ?03_$P^D#AT;6PN!J2:) =N!^(-7D&=GJ9)WE;.%B9G+5V92E694848 8)A
MXX+)XC5K![YN%8F?@E-.1D%@-@:2K*$#Q3B0)Y4R_PV!1Y-I)VO$3-#9U%;B
M9Z)7*VA,.(O;J$A!DZ96E5,<;QU;XW]5#?,A329?/3!'\@.S5Z\=H*]!K#B>
MGD0Z",7=9'$XPY)">8+(P?Q4F8;.<]TNH>;))Y!4DZJ\\)[FI^M/P<NPFD)Q
M"F:1$$_'6#XP+0N=M36 :1'853@(:"QAET11 +JXN@Q Q3* )<D*ZYD^/"F)
MGN#_K%RN?I^ 8A+L;VTEN0BK?N-A#%U4N2VT.*A:W^G:Z=@D=U2^8V'LB?3O
M+1F'J<#3EH4MY(Z!NQ=?4=L[TI\'[V[Q'KH/5^SZ@YV$<U%<$!/IF?GH^)/D
M9HN'Q!TBR5.-PZ:>ZS5Q_)RA10\N*.9Y9[;HG%GO"L@[\OJ1LWA?"2[CE=>5
M@:N$1,!3TC*B9W8(8(<S84W@OB$'LC2VT=FFLH5=/W2..0?&PFZ)B@K<*H@,
M6 U13:: ?!BV;IR&#<*;J]8)0\':1L/&H$PKL!3;O=]3%20D6KRRR/.(AS79
MTEI7&I;8 R,>5;JMB1ZV9[RQ-4EGDORJ$V""^.L$AH!4&5BW,!5B5)HLKJX.
M/W_Y]IO9JY/7*9&)G1F(K_T1$-4L[!Q>(G&&W)3M""4X0KH08'+RN2L^$)R9
M;L@3NI+B8FD10MJ"&+$!$Y9&9$K2(: (IX!3T4D1F"%+<DL4!SQG/%M$%8B-
M],4?GJ5#@ :(& 6M\O"1$R!PUK;T<8+A=J;AW198JV@MJ0B D8'MG![(5(U4
MAB 3H.A]C) -"]5/4&H/?["$# H<HTR(PT%-/JXMQ,-A7\]D7?WQ4&*A*3E@
M-Z(U_O@I*61EJT-20A#&B#K745%V1TX=H8F\)Y8_QIO7[?JP,+=,$YYUGHXL
MBC(AR$17\'F(K,G2 K13*PWW06M@X* I0V3]Q;A;OP\KZP9A@R'M& ](^<T'
MAWK/#F^26*%5C? *M[76WLKHO8_V0R,$;Q&0*)U$NEBT8D;+M@%S&BA^:<3>
MTX 520+B'4=(XI9WJL;G9Z[-*(_PV6^&Q)G-RC4 [+G3/81>-(PMURB#8009
M>[M;_4"!WMFJTD4J.I<%Z<8FTA\B%3(,L=J[@"Y)2]9DE14Y:^#L=<6EP>]P
M1%R*.R)-L#737Z'J[5 PP::";8?-SZ&K\\%J:0H*'!"-HZB()WEN:#/ ^IR.
M7JY:2GV[2F&2O(>.80'T7Y(=[*U!+C1+\OGX"/>FH ,B1-7D']:5(17#BP@7
MI3<<38BR>#/TT=:-B[1@(, QP?F$W&=?GK,6#)"H%W9!*75-*9)/Q8+C\1C'
M*2XII64Q/&84)5'80TE>I"?L2:M5K2@T9UR<L9U]::C+<:<C%3E$5@?47%JH
MK<C&D).ZNM,('>-I %G[&,?8[7FU7[4@!*$?YMI9)G)=C?034"FN#HLF+S%B
MC<3=JM7B;<' '*> QRB(L(]6ZB "6@T\PT;JO);C>DVZQ1$ [K6/;VO%WBU3
M;I.L"HOJCW'T>@;>D^50^D<?MITY$W1(N%2U@<J1=NH0@#R&9E/;=KTA@C.M
M<P\ZJ#0H;FH#;R+:'!,.,9O,;%FKY0"L4KVT/0(J;<@10V?A5?6 DPB)X#8T
MAB,[I_VQ%C'S2(<,9_;"T5%C@I@BT4Z2!?E]Q8%US%)9;DN$"9RX3^["R8(=
M$U8[K/HI3Q \>VCB;%;RO4=)?4B(14R2WVPE2[<^2T^I:.54D!6/RNMF$$:Z
M^AIU4([$<W8V2\]F9U)K=+R*<[O4PQ&_0.6:+&4 <34/*5C1G#4J%9\E$G;V
M5/>H!"CIQ3-L0B7@!CY0@*:22.X<BC0PXR;%OV:SR71*5N^+(ZI_D=+UVD>+
M3J:34Z0!1<%:O&K831*?"59'C$^%N'9V'$!\42*2LMQVZ4C07[:4 0YUN"\1
M>BEOU)W4F8:KO-YX0)DO2$,2Y*&D$A(X!Y=J4F)BEQ-WV6<<\("1$E%Z/_#I
M0!V..A* AR:X4I29C,?U.(,8R]HIFJ.*=WK,L$@TNR9U_93]_?W!K(\#7PMK
M:8+_R!R,V]#&4E4M&-6(A"A>9,;G<&,AKXN'?WW<8VW?<32AIF6SW<</F%6V
M,?C^Y*K$<H()%G%JM-)5<#7(9*F3U?+Q.--%L4$=>9=Z/F0UZF+_F8.>NS5<
M".P$:,KM2ETNM:18X"WT2_3CJ=@;5.R?"K^QT: $K)PD<OHVEA+Y?#%M'Q&]
M%Z,NHKFCV.2[!\&I,)N736_U>"!N)[-%H9;6^Y142A#DH%0W&:DGB)OB&#AL
MUC6U5J*.1""W1/U&F?R2DE!DPR#<+IDQ'=J$!S@4]F6%KDO'@82<<5&D(8E]
M B2US&K2%+!EA%C DH/%=!+:E;K#*<>PRBGX*5L#N:N.8*) Y=RF@/-0OFM&
MG3DI>!DC]S)82_=U=N)N# +O:B=60HEV628BWNU\MP7U;8)!^RA?J ?J 4.-
M-%&CJ92JI#&YQ_Z@=(B<I=06K'Z4I:*8-9;BCY)A'6"M6DYO'WF8WN])R!;*
M'C&*C+H;/P"5V^*I9![42Z[SOHPZ[WO+"^J!J1HQ]F:;<T4,2GS[[GQQX]MW
M:?*SG5!__>1P=IHF[Q%@D;3X2<G-H%J%@K?D,Y(K[CAW4CGO:Z5+2[AAE-S]
MEB3X4I+@H0PH3]5POZT$L(T,3>B/EK:$=P84'4V?CI')2_ ';Z$%,AW@@FV]
MKBEOUC[-K)6A7DF4%N:VA>W*(<:4*RKYLL$QUH-<GM@,G+;2R0/4PN<K!)"8
M+,CIVVBCF>,LYW3<H(^F*"S"W,]V)&$?@S#D(B4YT(206#NI&#A&T@=2;_"8
M,8<,V+74QS!:4L N[84::NPA8?C<*,JA/$2):?P0,B$5\08D9UN)*R@TP$A/
M!B$\:>YU@3A6RM"S:TQ][<C]B2>LTS69<?'PW*D )W5+C0#5#020+[6EN'O5
M/(XJ3XA\TD\A!P/"S\\BQ4^5?'LLZ](%^KYW%+5O'J.\N&0<D\@X9@D7G6W2
ML1TM,C9'0H/1NJWZ]IOYR>RU DN+@M.$.G1TXUF%GXD6$@IZ5G8>,8_&4&!N
MU\E[EFPFS^2;<C+ES#C[Z";<Y*+[F4]7R$70+H3R9$'7 -+'[Q?]4&45#7F?
M6LFD7/(PA)MR"ZIE?!SR_B.YXESA:_A(Y[#59[;_0<7\=;QDRA^X"]!UIS(O
M-]+2GRTW?D=4WCR.#_'L$2D-ZGFJN*48)XV2M**7\$UE.HJ8FO.2FL"J&P3=
M+)*/Y^?7_3#HO*+&-A(F;@\*&%AV151RU1DU^EHCI,&X2NVK4MX;*E'5-AN+
MVD_Z(4-B1H@>/YTBW\2.3LXT&B,O;<XY?1-/N<X7W92+>?]$=(WVW'1[O$U\
MZ/1[%,"%Q;]N_X?SQ<5PM/9GS".XFU3<,<P\C& [HTG]T*B?8GJ1Q&8\-A]C
MQVDSW[H:&7.15PD%D>?U,^R<1Z9$G1.U&TKY/676*#Y>W"S>'_U+Q)!+DN(K
MWT[%  66+^6=J-M7H8%'<N7@ _G0Y,7ECQ^^"\D8$<:!W,\IJ:[C^C<S>C=#
M[1QS'SSC>Q][A\LX]59*N.+AN8YQQ-#]F-O1(%(NLRCG[2?GXZNJ:J6[]RRO
M2Z<)M2LG.9K[B+O:-N4:,0VRIN9'F.ET=6)WK8*548;I993$26.:NO=TK:R(
M.J*#M17?=J!F?:!KI4P]C,=[BH;^G%OKC'1*]\66X&!ERMJUUZ)V4<P6MX<O
M,A@6!O$5H($_CXN8$#Q\H1FT:+@A;@,/L.-3)21,DE^\P?*D.%FPP797#H[C
M&P?B;KI!M_+3WV0Z.3N;OCH[Z>X7B WUZA:Y#!Y>WADGM5.<XHPXCHG$2SE+
M/(3F)E+!02R>V?O+/-MFI[?W>)8?[GQ8G@[82D9X4L/EL3"]D<%%4/W%/3"4
MXH[;#/'UH%%X""0T+QT/J$U<]$HA4FLO.QEDB3. %%QWO6*R]]+&7WQ+A/-=
M?TWD^M,_=OUCIQ^QV]4^3E\>OTR/7YYTZB'Z\E?TEH]/TN]?G0&];1W?0GI6
M>[D;A(4.,X&:I]^?3B-(^YO.?OGTU:Q;'ET FL]'1/N(*:<GI^G)Z<F@K1AS
M9W@S3P)54?0:[M4Q[N4';^.[_E_I[(^R\S0]/9O^)=P\F4\CYGS>M#X3[@KY
M(7)_QJX3'@I)GIT\DXR(!&_JH *Z%Q-RO@-*)$SJ_5C*DNMX&]N1=^I+X$;<
M=W>.Z/Y.=(1 S30]/3V+8/29B/>Q?6;NXK+BJ9@"TP_%MA0@I$,2)@"*^4=D
M4J@+ZS+KJ%#C:TN<Q8U<77+AVI*_9&0HH]^][?FBZ6^\=O><=JXU#3)L%^X^
M_4FHCRY+=>VMQ[=R!Y>N'M^QXD8=]\]#H/,+J'B1M,KCWG>0G;M7TF4=#X'<
MJ=J]A;70:Q:LJ>1W!M%M9(HE\E8RYUPCO>'N!D\6;!62!E5)CQ?NTHEK%%UR
M4K%K-HN:!Q$1%LH<[Y0IN#RC3;Y'1^]\E*#!Q"K*<Q%/#)G48:ENN:7,3SB0
M;^P],ZTH;.8;J18.Q\<71=-B%^9BI'?CL[JG$7HGRFNNOB""<43[1$TN>FDY
M&]%N_*+@<-8K2:LL[>^'4SN(E+_0<7(O,NA&K4\,:4*K!/(O5<:Y/SE9J)?U
M^JCZ2V][+M;YBN'/WJWCK(/N#/[IJW0?-76VMQMZ'KIN>T_(*:'/&X"(?OQ2
M/ 2YBL-"D=7\@5POQ,W%%HN&<X_<:L=3BM#;]57=.I B[0-J8085#I8P&?L-
MPE'T,Y!2UVO^L0M9"5RV_"*D>]K]GN9<?D;2+Y<?XR!LK^GN7Z%7V#J=O#H]
MD$%%^-+8+?^H9&F;QI;\<:,5SD +\'YE(1S_A1!TOS)Z]W]02P,$%     @
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M(AS9<?CF%,(=2%^2),\U]+0)R@,&LM(N>YCS>UL"\K9JN!2V[>V--A%H\L4
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MR*\O4&H_$:=5$)L)*$B%C28GOFEB$2(GS\VD<]I5!(AA"[G)TK:A'YRSIJ>
MFG9R)"&9#T=#>*DRFEM)1ANY]4WQ;%*FBE7P8+46D,?\_(R:;OH3>P)C&NK-
MZ5FDI&S-,/MP;'_F:5Y\U;-M7Y.S9'DMI[>:_L5S3J+9"B=+N0738W1IR6($
MLB*-BBG#0Q@8SM,E'5.*8<.KI[K27IZ_G'F: RT^$RT]_WR3 <$[FC@0B5-
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MBDYS=&Q \UM+A.H_>('A[\SYGU!+ P04    "  +<WE4)7J"T[@#   0"0
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MLO05OD&7YR#P#7XXSZ]HAQWM,- ._V/Y7F<9]>$<T=Z8[XVB->:&GPA'8%;
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M+=;F!9>YT%KDYNL*0H])G #/%T+H_0_<H'[CZ?*_4$L#!!0    (  MS>53
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M@E%[_KJ!-W5X(MT;3P^N\+.D%RY:-J#UW!C?#7B#_LU\^2]02P,$%     @
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M\\\#_$5E2GXEOS1597+^NE$2;2\MP/.5,55[00*ZWVB\_ ]02P,$%     @
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M NM4L[.=YP "4B X^?P.>BZ;L#Z8S=MS(JZJM55_5&SXHX_>A395R?@O>0#
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M1M?Y8=J[IP:,3W#[K=9X"KS ^GA5?P!02P,$%     @ "W-Y5)?[($25)P
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MN#O#:!??\AM@=%D#DO+SW9NG/_ U%-KD98V/(TX[%(-9@/*SM@:1P^CVX&P
MH[N]-B9YASPT>7S[]W=/4N"N&LZ%&\,CK+J*^")LFXY>D>06.-T*_[2,N69^
M O=KNJ71A0;Y-\K.D9>9G:)+* ^G,L8!0J\9V";;*M2G-*$'TT]!Q\^JJL/]
MG\AU\32(/SC%064-R _0,(ZP[3S%)U-[U_5.5X)"6[B'-4V9.@&(R)@5_P']
MBY9*:3?:$+!@2(4*80E/(Y#QN^C9"I8V!I4)NZ]5IIM8'L=7(GS9!.?<U4:S
MWCHF6RR#A6E!!:6G@EM%V1B"Q8S 94[S,(!PN(GX.9%43W@H$AX.B^(!.0J
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ML>$#REJ6Z/AH[L[-4RW2%U?GP4R.1MS>0"B#LJOLX^?/Y^[QF;_:Q6+@:H^
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MV]4-T#<Z,W.+,X%7F\4IHK9(00P:H* "#$:P!K!?UAWC3@Z ("<I7I>:P-
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M*O+# D_.)X\I<4]TVP,6(?.3(%]ZC,7>VRFHY%1?FC 2W+A!W7;.]@0X(,K
MY"M52*H$/-.A=PY3>6PNCK/S>05#:NDH8N',(VL25."4(IXD9H?$9,__!W Z
M&^BT^K27>*Q2H]ZIR.?"%YL''G/GBI E<#407'P+[(Z$&;JJ,Q3N#H"^5(=:
MI))$FL-?08[5<)Y64@K((8E! W@,60.B!0>/X)@;O9NFKH6GKL4D-;RQOE+G
MC;Y%+_,@77W73-'UBKT(IHLAKH4)":5:9V6*+JJ5HB@ VI,^1\5SK7:CF^(,
M1#1<WDJ%0KP -3AO4?[V8*BK,W+Q PJ*WUW0IEJ3\ZZP>XY][ FN7?+=AP/8
M?TR9KB3C."KAO@K,U?YJJ>@!/'TD[<F'V'!DPT_@(A.<8M3Z!U'\VJ=L\ /#
MRG57,FYA!@KJD_T]D'P&5"I >$@@9.S\5IR+O@2_ RX6FF/ M ]@;PVP-\!V
M[_=TVM60]R4VV[WJ0/0/\"#O?*5+:]F!V$]?7%^/;G$L^<@;IJ>:A7.?2SJ_
MF$3QCPWN6W@'@I=<G(.T\CT3)2-?([H0^$A/P..G@?5!J3\YXC@F'7%N$I*#
MP,EKNBY]Q1J)9(&S]HQV!ZK>G5&B@I#1[M,; 5D1GC6G)81V>X&>(R0Z:X)$
MWXC_J:_;/FSWQ?JES[P  R67E7%K;"J0>\>ZAGE=BK+B:79=0_*1/&IV)5!^
M\DW%CNTNSAYEB*16$5W:O%OXH+UI6.#DJPZ,)5BV1M6V!$3K23,GA&C>90UG
MR"GFJS-G-ATEDJ[JLJSW',OHP_%'BG&=7[Q\\-\S^&/^XHIS0AF-_I9M=R^3
M=UT#EBEJ\O/%["KYW^!)#*XU=<5A?0SG.Q3TZR[.PR&_8K  _5;)^RWET/#=
MV8>=K7F4&5+BP./-_@I :CA[;F#M.6[7?OB 1AUB,T84P/P)60.Z]H"#-\2M
MVK;1RTXL\Y/9DD542CV+33"<'LB/4A!GR=NOH&/5HYMA/FMQT%F]FEQR9+<5
M%E5[V+12$4:FM'W$6AN2@<-UNW63%:2" 'H_K2EIU>;HD X%MT*2Y1Y% ?QN
MLI5J?0:;;,S=BUL_'A?Y63D8>PQ7VB9^"&#%F;0<$Q)D]ACA2 LW^B!AW6S1
ME_.GH]72X9X.<4]SK+/CF9PW&RX)"SG.D!,G6]5NZD+0L]L-(6C@I6=<K0=H
M/[RD<!,2^</T+]P/D+-J)B60+S"83U<8W#H%JDCNZE6[QZMX$X3;QK6W[Z@Y
M.&VU40V/B<U(RJ$=7R]1[5,<WJ " -3X.J.&4LIN[FZ3BZOSL\MS+$O@9\_0
MNVJW,TO"3;I%P@@D;\%:/.2I-&1#2!9QX# ,AP%G6+/48%FK7%I.L [@B'CQ
MX/Y+NOU,K#QC\TLENB'?X(2[[-  ES^S+D/>$,(#<.@_P(5%;).ILF)J=8 5
M08N)SM9E3A-[4R[P1(;\B*+8ND(F8+>_TE]Q[Y+_S*I>9@+N]K#[W][@&=Z@
MFYB=M)R <[Y(GYV_X(BR+AD"488]LD%" @:V?"A1%O3O2KAR>$^]+.BWGSZF
M00I0J 1* .$ZO7Q^R6KFQ64ZO[B*A7;&?,;B[VG8A6&.'I,1[G8OOM!)YF%G
M#E(&?&F!T5\YV38%C6&M*\JBW&_$D<=<%P9@LG>;52U[(M&G>; J'1\PZS'0
M$X^F7?T0PU\V)EHB()2D/-X['#*3J<!SGPL\G\[C!9TBTXV]Y+*NUF<H"PI1
MT0:YW%^:$5C,( ?ZO=Z!'+IX=GXV/S]#I'>91JROI\G'$KU#%*FV>DLJB4<1
M=DK> WH2R.$IFP'5KJ4K)9&!40W$J29VH /P"W+R,7,X=H</GXE. 8HOZ)TL
M2LEIM%2R/H6 _4ZX#(8=-*"04HV/8X_'RW$PO[^DI6N/\I5-]X,/(%_.VNQK
MF%..B).[X E9N"XDV['>)!XVY^MG=1QYZU82EFQJ_0RO,8;<GDQ,'1W3AGIY
M5?55FS9._20CF'(TDZ+>5[&.0V%33/]G4$2:KJCT'DH>$/[,L^2?=;"CT,0!
M(Z9"ARY?01#=BRLC!)]Z\?PIRO/YU//I/.B/63OJ##]I9,+_QA(N]6R?G#[L
MQ0EY.XC+2NIZ!6U+ZP,"R6@H@0NC>31Y6#-D7'1^2(Z!B"=715>)TPE-;!=3
M0ML4R,ZIN31#0382:9U22R13D1.H!#S@"\K,20QQZE9\]N!\.O./K*WA2YD<
M.*S<\6S)6Y=O_H^LZM"&(1D_OXZ)(2MJ*F]#=GA]N4@#W3K("Z&P/\<]1<<6
MIS?JQKI@A+ZY^TP+G,WGL^2S! O1(.H/IL L7;(2KZG:AZY!5[N7.;7=QI9I
MN\0+*%O6?L0,#/%<T/5P[#M(4-B+0UABZ\ ;[T"LP@?E$[K]9"& '#LQ5$A1
MA3Y\\OD#VJ'CC*V)C+)*% /',0]@4Z3188IWW4;3;R3'M4$%0_S[8*R7 5<*
M]%@;8[ Q1.]$I6@O.]5##CGKYYVQD0[SLEHNVW;SDOH!5B<K\P]M;18DJ/)$
M_"Q<%')W6[[PZ8,O6Q1.[_PC@T%!MV)'_IVPB(9!8LU<7I0"7A0GIH^]Q+&)
M=>IEB:DSDIU/OC.> A1YF_FE393"1+^#PE9C,&T598Q3;L"?JGA :) OB&.N
MR%.VW;:_J-,MP^.)8H#! [A8PCXDBEDB]"Y)I?0P9C<O,)B(%?P *@KO1:@9
M<=2'E=Q@(T/Y\#VO[Q#M]&99'CB!P2)V6$?1 -_= ].IHW26)LA%.-@@ ZD$
MED_%= MJ<\F0D4(G7W''3C"XF*T6K_:OW3JKZEDOL"L7:MQ<-F/L88"Y$>1\
M2'V6BU25,M'R=--:M4]EG4]GG][88-;'[(#^C4%Y\FU3).Z+G7S!UV S=EK1
MUM"?0W:>"%41R_QC$)3V06< -3FXLN$%Q*DLA1(M/>H*2UZRMA74NT1A%R84
M"I%C5P4FJDE![?/'YM/I7P(6-NGO:G)M^S*N08#_E0E[WQPD.&/B6R#U:@O"
MU-LV35=* DB9[:/,5.>F!\!1209KT)0<!7/4!]3<L#$+Y;.XQ6QRTTAQX,[V
M' %]>"=.?+;YCS0_DY49+8PX$F>O3MW1PF> +*:S-FYZ>5A#M_*-4Z"W!,.3
M40S/V*8=8D>=E/;'F@_='NLA9**(%4%3]-/(1 =2&8B9XWQBY%C:N WIZKXN
M[TGLW6M%L0;L!^13$UCCME5HG/>?DE#I*M*XT0-!>2*P%;@5@[=7DEW$MLL!
M2X;NL:Z4V7)0,.XR_]$+ <.7:I.5;-7("2VS+]$70;8?SQ6,=5TH?, 730RO
MIEN4L4-)80&@TD90N3JH5JPM (;&P+_-QMAK[A7!"K[U!W.&%"XR2_ZM>EF6
M-I_SVV[%*P C6AFG>;&"PPP+_X<<:R"5\KL;H5!5!GL$*N]J$)7%*1M;Y*T8
M[H5CWH-]A#F F-TAJGG_KHQ3^:W#CZQZ+1T##I(.++R)4P;%G2EYB38.YU4G
MXU3Q\G!BL+F?IF:]9M8NS6R( _7K'G["($X[R"H_T&Y=,T0H!0_7)*6B40&B
M5_5P+I[-PHL33=%FZ2-/*$#'4,@1@HA4QE.NU&8?[A2W]$E8B^FDJ8^2D^HU
MX6&&.3G+L!TZ,#42&-^:&LV.Q2P'"2SQ \2\,")%OP9/F2%QQ!4HC5IW9>!
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MXZ^=U!OC#NG-,122& "&[2ID7TK31MT+;8VG0_'@T/ZM2+T^-.Q \!.'KK^
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M[G&/JQTH>P#?;Z4T)\$ZZ)?%]=]02P,$%     @ "W-Y5*;D<"]  @  .P4
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M0HPJ.!/$ "KN9.[C7Y,H37V:Y0-/GOMQG)"+HM!K;$+#GK42H@](LM2/\^A
M.4[\)!OW\;#% 68&'%D>^J,1[>UX-/8CM!_8EC1:/?%VX/RJ.<[I;[[0IYAW
M#8TRW![MAM$A"LNC(_*@+$KN#OIJ=]"?!P=]T!OZ"8W\C-*!;Y3E?I(ZKN,+
MV8O.,C^ER<&.QWZ2QW]E=9]7CWESC.DJR;*Q'PYPG8_2D3^.XS]=@6 PB&K0
MJW;<&E*HM;3=3.J]_42_Z ;9(;S['=PRO>+2$ %+3*5GH]0CNANQG6%5TXZU
MA;(X)-MEA7\ET"X ]Y=*V;WA"/K_W.PG4$L#!!0    (  MS>52SXF7#: @
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MR]=%4*$'?933)7*L)$38]TT#$8*']O<<WXTM+]I52V*%/=WR2Y^F=209%"8
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M--1.@?9317_K]<0Y:#N_R1]02P,$%     @ "W-Y5#!Z?*V- @  U04  !D
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M/Z? ,I!& -?'0NCEP!AH_AEQ^B]02P,$%     @ "W-Y5*"@8+SD!   HQ(
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MM%3\L: MCMH9D'ZKZ+%V@G/0_R\L_@)02P,$%     @ "W-Y5,-YSH:&!
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MUKI)@S !>G_!N7J=F#;@VG[Q%U!+ P04    "  +<WE4.,3?-;D"  "$"0
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M=(+ ^FY!UN6,:CK-I=@3:59C--.PJ5HUFF.5^2K/6N(L0YV>/M4@J6;5AG#
MY$;$?A<B"M(H(#>+IY=;0I4"K<@G\MCH1H*QP<JF;!6DIN_XE7#^9@::,JYN
M<U>C,Q/?774N[EL7P1D7,UB-2.A_)($7^"_/,W+SX9\H+N;5)Q?TR04V;/A_
MR3F8G7-([P(N['&AQ8W/X-!\,)1[JTJLRIR2W30(DRR(<W<W0!OWM/$U6CA$
M:U7Q,6T<Q6DT3(MZ6G2--AZB1:>T(/'],[2XI\77:-$0+3ZA^7$2G=O)I*<E
MUVCQ$"TYH45I$J;#L+2'I1=A/X2FG!273M*0E_3$2Q;&6>8-F\EZ,]E%,]]
M*4)+T50:2RR6=85\<UY8I0%[>%8D867=:%CW8T/VLH'?(/7.N/.]O\7)N^AO
MWCHB.\H;,.>VW2C.Z))QIAD,[E47]/C 9?[8/]DL]ZALFBOH.Y4;5BF$%"CT
M1@G^W+*MZFU'B]I6TJ706)=M<XLW(4BS .<+(?2A8XIS?[=._P!02P,$%
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M0-H L[X20K],[''776\F?P%02P,$%     @ "W-Y5"$OW:_; @  0 @  !D
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MA+IOHKFOFHGBR_H$GW&E[X-ZN-!7/ @#T.\SSM5F8BZ%[D_#^"]02P,$%
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M0WV 1-/PFHGB:]LS5ESI#F2'I?Y& &$,]/.<<[6;F #=5\?T-U!+ P04
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MH=C#_K4!&T-LX_0N<:Z\JQ8WD-X1WWU+/,=S1X#6/Z_N7,'QV[3[QIX_:>^
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MGO U!4(+X/J!<W49: ?M^VSY/U!+ P04    "  +<WE46+;=Q>$"  #Y!P
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M]UC6]U-M:%%61_Q<:'-A5,.UN=)!6@>SOA1"'PQ[:[1_$D;_ 5!+ P04
M"  +<WE47@>--2L"   2!0  &0   'AL+W=O<FMS:&5E=',O<VAE970V-RYX
M;6R-5,ENVS 0_15"Z"$!6E-;G"*0!7A)T1P"&#'2GFEI+!'AHI*TE?Y]N<BJ
MF\9&+M+,<-Z;A3,L>JE>= M@T"MG0L^BUICN#F-=M<")GL@.A#W92<6)L:IJ
ML.X4D-J#.,-I'$\Q)U1$9>%M:U46<F\8%;!62.\Y)^KW ICL9U$2'0U/M&F-
M,^"RZ$@#&S#/W5I9#8\L->4@-)4"*=C-HGERM\R=OW?X0:'7)S)RE6RE?''*
M0SV+8I<0,*B,8R#V=X E,.:(;!J_!LYH#.F I_*1_9NOW=:R)1J6DOVDM6EG
MT=<(U; C>V:>9/\=AGIN'%\EF?9?U ??Z4V$JKTVD@]@FP&G(OS)Z]"'$T R
M/0-(!T#Z%I"? 60#(/.%ALQ\62MB2%DHV2/EO"V;$WQO/-I60X6[Q8U1]I1:
MG"G7PX7(+:,-<9W5Z N:US5U,F'H0811<4Y7*S"$,GUM79XW*W3UZ;K QF;A
MN' U1%R$B.F9B$F*'J4PK4;WHH;Z7P)LTQ]K2(\U+-*+C"NH)BA+/J,T3I-W
M$EI^'!Y?2"<;6YIYONSC+;W FH^LN6?-S[#>O]K%U:#MZC!BH$9&(DT.5#0:
M=8R(]RXB,-YZ1K?.AS)+\ZS A]/F_.\4CQXA4WPR7AQ4X[=.HTKNA0FW-%K'
MQ9[[>7YC7]B%#_OYER:\%H]$-=2.'H.=I8PGMW:_5-C H!C9^2'>2F-7PHNM
M?;1 .0=[OI/2'!478'P&RS]02P,$%     @ "W-Y5 HWA5[. P  L0X  !D
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M >C? &0AV -?3X'/!^&;"7#+'H1_'8?_<8QG$IK#K1[X_3A\0\(9L&$Q^F_
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MHG,]&M),O>K><+Q]OQ 621?<MG<&LY&M :Q:*W0^?N<!JW8'Q_O=A]^DCWK
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M@'R^IE0<;M1YK?ZGQ/Q?4$L#!!0    (  MS>51-8P[ ^P(   X)   9
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MKH:V&>L?%A F0,_/.5>;CEF@^@4:_@502P,$%     @ "W-Y5/)BM8_W P
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MG1JA@6)8DR*1#VS_!6J'/,T7L4245[2O;#W70%$A)$MKL%*0TJSZ)X=Z(DX
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M$E]W]54139]I)HI7ME0ON-*%WPYSW9M!F "]O^1<;2?F -?M1^]02P,$%
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MOZS=";=BABWG2AZ)LK.1S=XX]1T:]>*YW2@/1N%;CCBS1($%VTC%W+)=;14
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M2_.# &D#S/>U$/I@V 3=+R?["U!+ P04    "  +<WE4MW=</E\"  !W!@
M&0   'AL+W=O<FMS:&5E=',O<VAE970X,2YX;6R-55UOFS 4_2L6VD,K;85
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MY:B::;_9&+FK!^9G:6#\KI=;^$)BRAK _;64YKBQ,WCWS;7\#U!+ P04
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M;05(A;;:?:B$BMI]-LD$K"8V:T]*^_=K.R&%RICM"_AVSLR9<3PSV@KYJM8
M2-ZKDJMQL$;<W(2ARM904=43&^!ZIQ"RHJBG<A6JC02:6U!5ADD4#<**,AY,
M1G9M+B<C46/).,PE47554?DQA5)LQT$<[!:>V&J-9B&<C#9T!0O Y\U<ZEG8
ML>2L JZ8X$1",0YNXYM9'!F /?'"8*OVQL1(60KQ:B:_\W$0&8^@A P-!=5_
M;S"#LC1,VH^_+6G0V33 _?&._<&*UV*65,%,E']8CNMQ<!60' I:E_@DMK^@
M%=0W?)DHE?TEV^;L8!"0K%8HJA:L/:@8;_[I>QN(/4!\#)"T@.0KX/(((&T!
MJ17:>&9EW5&DDY$46R+-:<UF!C8V%JW5,&[2N$"I=YG&X>0WST0%!.D[*/*3
MW!<%V, 2UFT021%TRC+!,U8R:L-_?@=(6:E^C$+4;ABR,&M-3AN3R1&3<4(>
M!<>U(O<\A_R0(-3^=R*2G8AIXF6\@ZQ'TOB")%$2.QR:_3\\\KB3=C%-+5]Z
M,J:NT'D,7'8&+JV!RR,&'B '2<O]'%$DSPNBD&*-0GY8PZ[4^(F3N!=%9ZX(
M?A]WH*S?*>M[B19H L;V+N4%X?HQ$P4I6M%+X% P=(GS<P]Z_<2I[=NP VF#
M3MK RS,'_>IPX$ARIK\R"3P#Y5+AISF/>G%TYOKL9GY@=")%PT['T*]#BC=F
M7W$4^FIC+;E+A9]$BTB=N3@%\VNXZC1<^3\@(?7[SLT-<_GN!^L,1*D[ R>!
M<?\K\,#_Z\[_:R_3"RWKYAVFI2[$5%\EEPX_R7DR-%?;*>0T,AUZE<319P&*
MO&1'2XZSLOBY'/>CT?-]7*,FW*NL%<B5;3@4R43-L:E/W6K7U-S:4OYE?6J:
M'5NQ/VF:3NF1RA7CBI10:,JH-]3/D6R:CV:"8F/K]U*@[@;L<*T;-I#F@-XO
MA,#=Q!CH6L#)/U!+ P04    "  +<WE4[G5:@5 #  !4#0  &0   'AL+W=O
M<FMS:&5E=',O<VAE970X-2YX;6S55U%OTS 0_BM6Q -(L,1.FS:HK;1V('@
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MI+G,B-)=.?/*0E*2E."4<:_;Z81>1IAPAWVQR,:9*IUIOA!JX$:-R3&WS\G
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MJB!$T]2"ZJ:A,1W@WV0SW)NT5R_B=0KVD*M/"ST=4?6AT.B-I"E;5OUEV@C
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MG7H/X^>A#K>>KS4^_SNI'B_WUMOCK\NODQ-VKCB'^XKA^2]02P,$%     @
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MQR_/M#?M\)R?+?_BN/D%4$L! A0#%     @ "W-Y5 =!36*!    L0   !
M             ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    "  +
M<WE4\/Y9_^\    K @  $0              @ &O    9&]C4')O<',O8V]R
M92YX;6Q02P$"% ,4    "  +<WE4F5R<(Q &  "<)P  $P
M@ '- 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    (  MS>50/!.NV
M6@8  %0;   8              " @0X(  !X;"]W;W)K<VAE971S+W-H965T
M,2YX;6Q02P$"% ,4    "  +<WE49._^[ D'  !Y'0  &
M@(&>#@  >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @ "W-Y
M5#9CBG,H P  2@T  !@              ("!W14  'AL+W=O<FMS:&5E=',O
M<VAE970S+GAM;%!+ 0(4 Q0    (  MS>51QXL;L<00  #,0   8
M      " @3L9  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4
M"  +<WE49!9XP=4"   K"   &               @('B'0  >&PO=V]R:W-H
M965T<R]S:&5E=#4N>&UL4$L! A0#%     @ "W-Y5"8<]M9:!@  1!X  !@
M             ("![2   'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4
M Q0    (  MS>52MJ=1LO@8  $4:   8              " @7TG  !X;"]W
M;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4    "  +<WE4FTCX'*41  !Q
M-   &               @(%Q+@  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL
M4$L! A0#%     @ "W-Y5%JO!OWT'P  V&$  !@              ("!3$
M 'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0    (  MS>525FUS*
M'P4  .P+   9              " @79@  !X;"]W;W)K<VAE971S+W-H965T
M,3 N>&UL4$L! A0#%     @ "W-Y5)?#\KH=!0  V@P  !D
M ("!S&4  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4    "  +
M<WE4)7J"T[@#   0"0  &0              @($@:P  >&PO=V]R:W-H965T
M<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    (  MS>50M.)MSH@,  (8(   9
M          " @0]O  !X;"]W;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#
M%     @ "W-Y5%V%E*MW"   *!@  !D              ("!Z'(  'AL+W=O
M<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4    "  +<WE4?&VG'!0#   ^
M!P  &0              @(&6>P  >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM
M;%!+ 0(4 Q0    (  MS>53Y_(!WY0,  /$)   9              " @>%^
M  !X;"]W;W)K<VAE971S+W-H965T,38N>&UL4$L! A0#%     @ "W-Y5'?&
M'6(^"@  _20  !D              ("!_8(  'AL+W=O<FMS:&5E=',O<VAE
M970Q-RYX;6Q02P$"% ,4    "  +<WE4P#(%W>L#  """0  &0
M    @(%RC0  >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    (
M  MS>5253?>@YP0  #8/   9              " @921  !X;"]W;W)K<VAE
M971S+W-H965T,3DN>&UL4$L! A0#%     @ "W-Y5%)L/6%U P  6P@  !D
M             ("!LI8  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"
M% ,4    "  +<WE4_YA9+*,$   _"P  &0              @(%>F@  >&PO
M=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    (  MS>535MP#."0L
M *\A   9              " @3B?  !X;"]W;W)K<VAE971S+W-H965T,C(N
M>&UL4$L! A0#%     @ "W-Y5%BC\XW>!P  [!(  !D              ("!
M>*H  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4    "  +<WE4
MCM-<=.L*   F(0  &0              @(&-L@  >&PO=V]R:W-H965T<R]S
M:&5E=#(T+GAM;%!+ 0(4 Q0    (  MS>51Y" 3;"00  *T*   9
M      " @:^]  !X;"]W;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#%
M  @ "W-Y5(<$='".!   3@H  !D              ("![\$  'AL+W=O<FMS
M:&5E=',O<VAE970R-BYX;6Q02P$"% ,4    "  +<WE4U,O?5&\"  !I!0
M&0              @(&TQ@  >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+
M 0(4 Q0    (  MS>53@W6?DYP$  ,@$   9              " @5K)  !X
M;"]W;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#%     @ "W-Y5)?[($25
M)P  JX0  !D              ("!>,L  'AL+W=O<FMS:&5E=',O<VAE970R
M.2YX;6Q02P$"% ,4    "  +<WE4N"G%;&4"  !]!0  &0
M@(%$\P  >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    (  MS
M>50>5[7FS (  ),'   9              " @>#U  !X;"]W;W)K<VAE971S
M+W-H965T,S$N>&UL4$L! A0#%     @ "W-Y5,4O%V6& @  508  !D
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M=#,V+GAM;%!+ 0(4 Q0    (  MS>52SXF7#: @  "8A   9
M  " @<0' 0!X;"]W;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%     @
M"W-Y5&+6TP0J @  404  !D              ("!8Q ! 'AL+W=O<FMS:&5E
M=',O<VAE970S."YX;6Q02P$"% ,4    "  +<WE4P]9H%M("   %"@  &0
M            @('$$@$ >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4
M Q0    (  MS>50P>GRMC0(  -4%   9              " @<T5 0!X;"]W
M;W)K<VAE971S+W-H965T-# N>&UL4$L! A0#%     @ "W-Y5.!Q/30>!0
MF!   !D              ("!D1@! 'AL+W=O<FMS:&5E=',O<VAE970T,2YX
M;6Q02P$"% ,4    "  +<WE4H*!@O.0$  "C$@  &0              @('F
M'0$ >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4 Q0    (  MS>52:
MSSQ?F@(  ",&   9              " @0$C 0!X;"]W;W)K<VAE971S+W-H
M965T-#,N>&UL4$L! A0#%     @ "W-Y5,-YSH:&!   QA(  !D
M     ("!TB4! 'AL+W=O<FMS:&5E=',O<VAE970T-"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    (  MS>50XQ-\UN0(  (0)   9              "
M@>DW 0!X;"]W;W)K<VAE971S+W-H965T-#DN>&UL4$L! A0#%     @ "W-Y
M5(10NYIX @  L08  !D              ("!V3H! 'AL+W=O<FMS:&5E=',O
M<VAE970U,"YX;6Q02P$"% ,4    "  +<WE4_.D(\K$#  #B#0  &0
M        @(&(/0$ >&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+ 0(4 Q0
M   (  MS>53"J?<5T 0  ',6   9              " @7!! 0!X;"]W;W)K
M<VAE971S+W-H965T-3(N>&UL4$L! A0#%     @ "W-Y5,0H3=FJ @  T <
M !D              ("!=T8! 'AL+W=O<FMS:&5E=',O<VAE970U,RYX;6Q0
M2P$"% ,4    "  +<WE4&VW)#S\"  !.!0  &0              @(%820$
M>&PO=V]R:W-H965T<R]S:&5E=#4T+GAM;%!+ 0(4 Q0    (  MS>522S6?%
MI (  &<'   9              " @<Y+ 0!X;"]W;W)K<VAE971S+W-H965T
M-34N>&UL4$L! A0#%     @ "W-Y5)"Q:R%D @  ^@<  !D
M ("!J4X! 'AL+W=O<FMS:&5E=',O<VAE970U-BYX;6Q02P$"% ,4    "  +
M<WE4BP-ZHN8"  #J"   &0              @(%$40$ >&PO=V]R:W-H965T
M<R]S:&5E=#4W+GAM;%!+ 0(4 Q0    (  MS>50A+]VOVP(  $ (   9
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M970V,BYX;6Q02P$"% ,4    "  +<WE46+;=Q>$"  #Y!P  &0
M    @($690$ >&PO=V]R:W-H965T<R]S:&5E=#8S+GAM;%!+ 0(4 Q0    (
M  MS>50:*\QS5@,  $$)   9              " @2YH 0!X;"]W;W)K<VAE
M971S+W-H965T-C0N>&UL4$L! A0#%     @ "W-Y5&(AQJ'< @  @PH  !D
M             ("!NVL! 'AL+W=O<FMS:&5E=',O<VAE970V-2YX;6Q02P$"
M% ,4    "  +<WE4QPU/HLL"   P"   &0              @('.;@$ >&PO
M=V]R:W-H965T<R]S:&5E=#8V+GAM;%!+ 0(4 Q0    (  MS>51>!XTU*P(
M !(%   9              " @=!Q 0!X;"]W;W)K<VAE971S+W-H965T-C<N
M>&UL4$L! A0#%     @ "W-Y5 HWA5[. P  L0X  !D              ("!
M,G0! 'AL+W=O<FMS:&5E=',O<VAE970V."YX;6Q02P$"% ,4    "  +<WE4
M4 5.^S("   W!@  &0              @($W> $ >&PO=V]R:W-H965T<R]S
M:&5E=#8Y+GAM;%!+ 0(4 Q0    (  MS>52=N.O0C0(   ((   9
M      " @:!Z 0!X;"]W;W)K<VAE971S+W-H965T-S N>&UL4$L! A0#%
M  @ "W-Y5,K,9H 5!   '1,  !D              ("!9'T! 'AL+W=O<FMS
M:&5E=',O<VAE970W,2YX;6Q02P$"% ,4    "  +<WE4UT_7+#<$  "@$
M&0              @(&P@0$ >&PO=V]R:W-H965T<R]S:&5E=#<R+GAM;%!+
M 0(4 Q0    (  MS>51-8P[ ^P(   X)   9              " @1Z& 0!X
M;"]W;W)K<VAE971S+W-H965T-S,N>&UL4$L! A0#%     @ "W-Y5/)BM8_W
M P  10\  !D              ("!4(D! 'AL+W=O<FMS:&5E=',O<VAE970W
M-"YX;6Q02P$"% ,4    "  +<WE4BRV&8'X$  "M$P  &0
M@(%^C0$ >&PO=V]R:W-H965T<R]S:&5E=#<U+GAM;%!+ 0(4 Q0    (  MS
M>53EJ^WEJ04  ,0=   9              " @3.2 0!X;"]W;W)K<VAE971S
M+W-H965T-S8N>&UL4$L! A0#%     @ "W-Y5$P(>FK" @  "P@  !D
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M=#@Q+GAM;%!+ 0(4 Q0    (  MS>50E/@M&Q@,  '\-   9
M  " @2&G 0!X;"]W;W)K<VAE971S+W-H965T.#(N>&UL4$L! A0#%     @
M"W-Y5+]7"22S @  UP<  !D              ("!'JL! 'AL+W=O<FMS:&5E
M=',O<VAE970X,RYX;6Q02P$"% ,4    "  +<WE4$T0;#NL"   ."@  &0
M            @($(K@$ >&PO=V]R:W-H965T<R]S:&5E=#@T+GAM;%!+ 0(4
M Q0    (  MS>53N=5J!4 ,  %0-   9              " @2JQ 0!X;"]W
M;W)K<VAE971S+W-H965T.#4N>&UL4$L! A0#%     @ "W-Y5$*.)07_ @
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M96QS+RYR96QS4$L! A0#%     @ "W-Y5/9"<HI*!@  &#D   \
M     ( !AKX! 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    (  MS>51 RG71
MC@(  $PS   :              "  ?W$ 0!X;"]?<F5L<R]W;W)K8F]O:RYX
M;6PN<F5L<U!+ 0(4 Q0    (  MS>50AV_FQ,0(  ,TQ   3
M  "  </' 0!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@    !? %\ $!H  "7*
$ 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>122
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>123
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>124
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>182</ContextCount>
  <ElementCount>409</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>71</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>9</UnitCount>
  <MyReports>
    <Report instance="ganx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gaintherapeutics.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ganx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00100 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gaintherapeutics.com/role/StatementConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ganx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00105 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gaintherapeutics.com/role/StatementConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ganx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00200 - Statement - Consolidated Statement of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfOperations</Role>
      <ShortName>Consolidated Statement of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="ganx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00300 - Statement - Consolidated Statement of Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfComprehensiveLoss</Role>
      <ShortName>Consolidated Statement of Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="ganx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00400 - Statement - Consolidated Statement of Changes in Stockholders' Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfChangesInStockholdersEquityDeficit</Role>
      <ShortName>Consolidated Statement of Changes in Stockholders' Equity (Deficit)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="ganx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00500 - Statement - Consolidated Statement of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfCashFlows</Role>
      <ShortName>Consolidated Statement of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="ganx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>10101 - Disclosure - Nature of the Business and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gaintherapeutics.com/role/DisclosureNatureOfBusinessAndBasisOfPresentation</Role>
      <ShortName>Nature of the Business and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="ganx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>10201 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gaintherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="ganx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>10301 - Disclosure - Research Grants</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gaintherapeutics.com/role/DisclosureResearchGrants</Role>
      <ShortName>Research Grants</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="ganx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>10401 - Disclosure - Cash, cash equivalents and restricted cash</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gaintherapeutics.com/role/DisclosureCashCashEquivalentsAndRestrictedCash</Role>
      <ShortName>Cash, cash equivalents and restricted cash</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="ganx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>10501 - Disclosure - Other Current Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gaintherapeutics.com/role/DisclosureOtherCurrentAssets</Role>
      <ShortName>Other Current Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="ganx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>10601 - Disclosure - Property and Equipment, net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gaintherapeutics.com/role/DisclosurePropertyAndEquipmentNet</Role>
      <ShortName>Property and Equipment, net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="ganx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>10701 - Disclosure - Operating lease. Right of use ("ROU") assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gaintherapeutics.com/role/DisclosureOperatingLeaseRightOfUserouAssets</Role>
      <ShortName>Operating lease. Right of use ("ROU") assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="ganx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>10801 - Disclosure - Accounts Payable</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gaintherapeutics.com/role/DisclosureAccountsPayable</Role>
      <ShortName>Accounts Payable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="ganx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>10901 - Disclosure - Other current liabilities and deferred income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gaintherapeutics.com/role/DisclosureOtherCurrentLiabilitiesAndDeferredIncome</Role>
      <ShortName>Other current liabilities and deferred income</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="ganx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>11001 - Disclosure - Pension obligations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gaintherapeutics.com/role/DisclosurePensionObligations</Role>
      <ShortName>Pension obligations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="ganx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>11101 - Disclosure - Loans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gaintherapeutics.com/role/DisclosureLoans</Role>
      <ShortName>Loans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="ganx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>11201 - Disclosure - Fair value measurement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gaintherapeutics.com/role/DisclosureFairValueMeasurement</Role>
      <ShortName>Fair value measurement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="ganx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>11301 - Disclosure - Common and Preferred Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gaintherapeutics.com/role/DisclosureCommonAndPreferredStock</Role>
      <ShortName>Common and Preferred Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="ganx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>11401 - Disclosure - Warrants</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gaintherapeutics.com/role/DisclosureWarrants</Role>
      <ShortName>Warrants</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="ganx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>11501 - Disclosure - Equity Incentive Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gaintherapeutics.com/role/DisclosureEquityIncentivePlan</Role>
      <ShortName>Equity Incentive Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="ganx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>11601 - Disclosure - Collaboration Agreement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gaintherapeutics.com/role/DisclosureCollaborationAgreement</Role>
      <ShortName>Collaboration Agreement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="ganx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>11701 - Disclosure - Income taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gaintherapeutics.com/role/DisclosureIncomeTaxes</Role>
      <ShortName>Income taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="ganx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>11801 - Disclosure - Net loss per common share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gaintherapeutics.com/role/DisclosureNetLossPerCommonShare</Role>
      <ShortName>Net loss per common share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="ganx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>11901 - Disclosure - Related Parties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gaintherapeutics.com/role/DisclosureRelatedParties</Role>
      <ShortName>Related Parties</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="ganx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>12001 - Disclosure - Other Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gaintherapeutics.com/role/DisclosureOtherInformation</Role>
      <ShortName>Other Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="ganx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>12101 - Disclosure - Significant events after the balance sheet date</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gaintherapeutics.com/role/DisclosureSignificantEventsAfterBalanceSheetDate</Role>
      <ShortName>Significant events after the balance sheet date</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="ganx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>20202 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gaintherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.gaintherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="ganx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>30203 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gaintherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gaintherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="ganx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>30403 - Disclosure - Cash, cash equivalents and restricted cash (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gaintherapeutics.com/role/DisclosureCashCashEquivalentsAndRestrictedCashTables</Role>
      <ShortName>Cash, cash equivalents and restricted cash (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gaintherapeutics.com/role/DisclosureCashCashEquivalentsAndRestrictedCash</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="ganx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>30503 - Disclosure - Other Current Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gaintherapeutics.com/role/DisclosureOtherCurrentAssetsTables</Role>
      <ShortName>Other Current Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gaintherapeutics.com/role/DisclosureOtherCurrentAssets</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="ganx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>30603 - Disclosure - Property and Equipment, net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gaintherapeutics.com/role/DisclosurePropertyAndEquipmentNetTables</Role>
      <ShortName>Property and Equipment, net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gaintherapeutics.com/role/DisclosurePropertyAndEquipmentNet</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="ganx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>30703 - Disclosure - Operating lease. Right of use ("ROU") assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gaintherapeutics.com/role/DisclosureOperatingLeaseRightOfUserouAssetsTables</Role>
      <ShortName>Operating lease. Right of use ("ROU") assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gaintherapeutics.com/role/DisclosureOperatingLeaseRightOfUserouAssets</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="ganx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>30803 - Disclosure - Accounts Payable (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gaintherapeutics.com/role/DisclosureAccountsPayableTables</Role>
      <ShortName>Accounts Payable (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gaintherapeutics.com/role/DisclosureAccountsPayable</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="ganx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>30903 - Disclosure - Other current liabilities and deferred income (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gaintherapeutics.com/role/DisclosureOtherCurrentLiabilitiesAndDeferredIncomeTables</Role>
      <ShortName>Other current liabilities and deferred income (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gaintherapeutics.com/role/DisclosureOtherCurrentLiabilitiesAndDeferredIncome</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="ganx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>31003 - Disclosure - Pension obligations (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gaintherapeutics.com/role/DisclosurePensionObligationsTables</Role>
      <ShortName>Pension obligations (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gaintherapeutics.com/role/DisclosurePensionObligations</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="ganx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>31103 - Disclosure - Loans (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gaintherapeutics.com/role/DisclosureLoansTables</Role>
      <ShortName>Loans (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gaintherapeutics.com/role/DisclosureLoans</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="ganx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>31203 - Disclosure - Fair value measurement (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gaintherapeutics.com/role/DisclosureFairValueMeasurementTables</Role>
      <ShortName>Fair value measurement (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gaintherapeutics.com/role/DisclosureFairValueMeasurement</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="ganx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>31403 - Disclosure - Warrants (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gaintherapeutics.com/role/DisclosureWarrantsTables</Role>
      <ShortName>Warrants (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gaintherapeutics.com/role/DisclosureWarrants</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="ganx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>31503 - Disclosure - Equity Incentive Plan (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gaintherapeutics.com/role/DisclosureEquityIncentivePlanTables</Role>
      <ShortName>Equity Incentive Plan (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gaintherapeutics.com/role/DisclosureEquityIncentivePlan</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="ganx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>31703 - Disclosure - Income taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gaintherapeutics.com/role/DisclosureIncomeTaxesTables</Role>
      <ShortName>Income taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gaintherapeutics.com/role/DisclosureIncomeTaxes</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="ganx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>31803 - Disclosure - Net loss per common share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gaintherapeutics.com/role/DisclosureNetLossPerCommonShareTables</Role>
      <ShortName>Net loss per common share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gaintherapeutics.com/role/DisclosureNetLossPerCommonShare</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="ganx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>40101 - Disclosure - Nature of the Business and Basis of Presentation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gaintherapeutics.com/role/DisclosureNatureOfBusinessAndBasisOfPresentationDetails</Role>
      <ShortName>Nature of the Business and Basis of Presentation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.gaintherapeutics.com/role/DisclosureNatureOfBusinessAndBasisOfPresentation</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="ganx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>40201 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gaintherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.gaintherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="ganx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>40202 - Disclosure - Summary of Significant Accounting Policies - Additional disclosures (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gaintherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalDisclosuresDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional disclosures (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="ganx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>40301 - Disclosure - Research Grants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gaintherapeutics.com/role/DisclosureResearchGrantsDetails</Role>
      <ShortName>Research Grants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.gaintherapeutics.com/role/DisclosureResearchGrants</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="ganx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>40401 - Disclosure - Cash, cash equivalents and restricted cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gaintherapeutics.com/role/DisclosureCashCashEquivalentsAndRestrictedCashDetails</Role>
      <ShortName>Cash, cash equivalents and restricted cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.gaintherapeutics.com/role/DisclosureCashCashEquivalentsAndRestrictedCashTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="ganx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>40402 - Disclosure - Cash, cash equivalents and restricted cash - Schedule of Cash and cash equivalents balances (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gaintherapeutics.com/role/DisclosureCashCashEquivalentsAndRestrictedCashScheduleOfCashAndCashEquivalentsBalancesDetails</Role>
      <ShortName>Cash, cash equivalents and restricted cash - Schedule of Cash and cash equivalents balances (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="ganx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>40501 - Disclosure - Other current assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gaintherapeutics.com/role/DisclosureOtherCurrentAssetsDetails</Role>
      <ShortName>Other current assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="ganx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>40601 - Disclosure - Property and Equipment, net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gaintherapeutics.com/role/DisclosurePropertyAndEquipmentNetDetails</Role>
      <ShortName>Property and Equipment, net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.gaintherapeutics.com/role/DisclosurePropertyAndEquipmentNetTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="ganx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>40701 - Disclosure - Operating lease. Right of use (ROU) assets - Additional information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gaintherapeutics.com/role/DisclosureOperatingLeaseRightOfUseRouAssetsAdditionalInformationDetails</Role>
      <ShortName>Operating lease. Right of use (ROU) assets - Additional information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.gaintherapeutics.com/role/DisclosureOperatingLeaseRightOfUserouAssetsTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="ganx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>40702 - Disclosure - Operating lease. Right of use (ROU) assets - Summary of components of lease accounting (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gaintherapeutics.com/role/DisclosureOperatingLeaseRightOfUseRouAssetsSummaryOfComponentsOfLeaseAccountingDetails</Role>
      <ShortName>Operating lease. Right of use (ROU) assets - Summary of components of lease accounting (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.gaintherapeutics.com/role/DisclosureOperatingLeaseRightOfUserouAssetsTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="ganx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>40703 - Disclosure - Operating lease. Right of use (ROU) assets - Summary of components of lease expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gaintherapeutics.com/role/DisclosureOperatingLeaseRightOfUseRouAssetsSummaryOfComponentsOfLeaseExpenseDetails</Role>
      <ShortName>Operating lease. Right of use (ROU) assets - Summary of components of lease expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.gaintherapeutics.com/role/DisclosureOperatingLeaseRightOfUserouAssetsTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="ganx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>40704 - Disclosure - Operating lease. Right of use (ROU) assets - Future minimum lease payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gaintherapeutics.com/role/DisclosureOperatingLeaseRightOfUseRouAssetsFutureMinimumLeasePaymentsDetails</Role>
      <ShortName>Operating lease. Right of use (ROU) assets - Future minimum lease payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.gaintherapeutics.com/role/DisclosureOperatingLeaseRightOfUserouAssetsTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="ganx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>40801 - Disclosure - Accounts Payable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gaintherapeutics.com/role/DisclosureAccountsPayableDetails</Role>
      <ShortName>Accounts Payable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.gaintherapeutics.com/role/DisclosureAccountsPayableTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="ganx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>40901 - Disclosure - Other current liabilities and deferred income (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gaintherapeutics.com/role/DisclosureOtherCurrentLiabilitiesAndDeferredIncomeDetails</Role>
      <ShortName>Other current liabilities and deferred income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.gaintherapeutics.com/role/DisclosureOtherCurrentLiabilitiesAndDeferredIncomeTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="ganx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>41001 - Disclosure - Pension obligations - End of year funded status (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gaintherapeutics.com/role/DisclosurePensionObligationsEndOfYearFundedStatusDetails</Role>
      <ShortName>Pension obligations - End of year funded status (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="ganx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>41002 - Disclosure - Pension obligations - Reconciliation of funded status (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gaintherapeutics.com/role/DisclosurePensionObligationsReconciliationOfFundedStatusDetails</Role>
      <ShortName>Pension obligations - Reconciliation of funded status (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="ganx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>41003 - Disclosure - Pension obligations - Component of net periodic pension costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gaintherapeutics.com/role/DisclosurePensionObligationsComponentOfNetPeriodicPensionCostsDetails</Role>
      <ShortName>Pension obligations - Component of net periodic pension costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="ganx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>41004 - Disclosure - Pension obligations - Reconciliation of projected benefit obligation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gaintherapeutics.com/role/DisclosurePensionObligationsReconciliationOfProjectedBenefitObligationDetails</Role>
      <ShortName>Pension obligations - Reconciliation of projected benefit obligation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="ganx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>41005 - Disclosure - Pension obligations - Reconciliation of fair value of plan assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gaintherapeutics.com/role/DisclosurePensionObligationsReconciliationOfFairValueOfPlanAssetsDetails</Role>
      <ShortName>Pension obligations - Reconciliation of fair value of plan assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="ganx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>41006 - Disclosure - Pension obligations - Change in net (gain) loss (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gaintherapeutics.com/role/DisclosurePensionObligationsChangeInNetGainLossDetails</Role>
      <ShortName>Pension obligations - Change in net (gain) loss (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="ganx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>41007 - Disclosure - Pension obligations - Change in accumulated other comprehensive income (AOCI) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gaintherapeutics.com/role/DisclosurePensionObligationsChangeInAccumulatedOtherComprehensiveIncomeAociDetails</Role>
      <ShortName>Pension obligations - Change in accumulated other comprehensive income (AOCI) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="ganx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>41008 - Disclosure - Pension obligations - Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gaintherapeutics.com/role/DisclosurePensionObligationsAssumptionsDetails</Role>
      <ShortName>Pension obligations - Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="ganx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>41009 - Disclosure - Pension obligations - Expected benefit payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gaintherapeutics.com/role/DisclosurePensionObligationsExpectedBenefitPaymentsDetails</Role>
      <ShortName>Pension obligations - Expected benefit payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="ganx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>41010 - Disclosure - Pension obligations - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gaintherapeutics.com/role/DisclosurePensionObligationsAdditionalInformationDetails</Role>
      <ShortName>Pension obligations - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="ganx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>41101 - Disclosure - Loans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gaintherapeutics.com/role/DisclosureLoansDetails</Role>
      <ShortName>Loans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.gaintherapeutics.com/role/DisclosureLoansTables</ParentRole>
      <Position>68</Position>
    </Report>
    <Report instance="ganx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>41102 - Disclosure - Loans - Future loan payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gaintherapeutics.com/role/DisclosureLoansFutureLoanPaymentsDetails</Role>
      <ShortName>Loans - Future loan payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="ganx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>41201 - Disclosure - Fair value measurement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gaintherapeutics.com/role/DisclosureFairValueMeasurementDetails</Role>
      <ShortName>Fair value measurement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.gaintherapeutics.com/role/DisclosureFairValueMeasurementTables</ParentRole>
      <Position>70</Position>
    </Report>
    <Report instance="ganx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>41301 - Disclosure - Common and Preferred Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gaintherapeutics.com/role/DisclosureCommonAndPreferredStockDetails</Role>
      <ShortName>Common and Preferred Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.gaintherapeutics.com/role/DisclosureCommonAndPreferredStock</ParentRole>
      <Position>71</Position>
    </Report>
    <Report instance="ganx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>41401 - Disclosure - Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gaintherapeutics.com/role/DisclosureWarrantsDetails</Role>
      <ShortName>Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.gaintherapeutics.com/role/DisclosureWarrantsTables</ParentRole>
      <Position>72</Position>
    </Report>
    <Report instance="ganx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>41402 - Disclosure - Warrants - Assumptions under black-scholes pricing model (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gaintherapeutics.com/role/DisclosureWarrantsAssumptionsUnderBlackScholesPricingModelDetails</Role>
      <ShortName>Warrants - Assumptions under black-scholes pricing model (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="ganx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>41501 - Disclosure - Equity Incentive Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gaintherapeutics.com/role/DisclosureEquityIncentivePlanDetails</Role>
      <ShortName>Equity Incentive Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.gaintherapeutics.com/role/DisclosureEquityIncentivePlanTables</ParentRole>
      <Position>74</Position>
    </Report>
    <Report instance="ganx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>41502 - Disclosure - Equity Incentive Plan - Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gaintherapeutics.com/role/DisclosureEquityIncentivePlanStockOptionActivityDetails</Role>
      <ShortName>Equity Incentive Plan - Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="ganx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>41503 - Disclosure - Equity Incentive Plan - Options Outstanding and Exercisable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gaintherapeutics.com/role/DisclosureEquityIncentivePlanOptionsOutstandingAndExercisableDetails</Role>
      <ShortName>Equity Incentive Plan - Options Outstanding and Exercisable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="ganx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>41504 - Disclosure - Equity Incentive Plan - Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gaintherapeutics.com/role/DisclosureEquityIncentivePlanAssumptionsDetails</Role>
      <ShortName>Equity Incentive Plan - Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="ganx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>41505 - Disclosure - Equity Incentive Plan - Stock-based compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gaintherapeutics.com/role/DisclosureEquityIncentivePlanStockBasedCompensationDetails</Role>
      <ShortName>Equity Incentive Plan - Stock-based compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="ganx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>41601 - Disclosure - Collaboration Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gaintherapeutics.com/role/DisclosureCollaborationAgreementDetails</Role>
      <ShortName>Collaboration Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.gaintherapeutics.com/role/DisclosureCollaborationAgreement</ParentRole>
      <Position>79</Position>
    </Report>
    <Report instance="ganx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>41701 - Disclosure - Income taxes - Domestic and foreign net operating losses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gaintherapeutics.com/role/DisclosureIncomeTaxesDomesticAndForeignNetOperatingLossesDetails</Role>
      <ShortName>Income taxes - Domestic and foreign net operating losses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="ganx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>41702 - Disclosure - Income taxes - Components of income tax expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gaintherapeutics.com/role/DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseDetails</Role>
      <ShortName>Income taxes - Components of income tax expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="ganx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>41703 - Disclosure - Income taxes - Domestic and foreign net operating losses and related deferred tax assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gaintherapeutics.com/role/DisclosureIncomeTaxesDomesticAndForeignNetOperatingLossesAndRelatedDeferredTaxAssetsDetails</Role>
      <ShortName>Income taxes - Domestic and foreign net operating losses and related deferred tax assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="ganx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>41704 - Disclosure - Income taxes - Additional disclosures (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gaintherapeutics.com/role/DisclosureIncomeTaxesAdditionalDisclosuresDetails</Role>
      <ShortName>Income taxes - Additional disclosures (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>83</Position>
    </Report>
    <Report instance="ganx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>41705 - Disclosure - Income taxes - Effective income tax rate reconciliation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gaintherapeutics.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails</Role>
      <ShortName>Income taxes - Effective income tax rate reconciliation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>84</Position>
    </Report>
    <Report instance="ganx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>41801 - Disclosure - Net loss per common share - Computation of diluted net loss per share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gaintherapeutics.com/role/DisclosureNetLossPerCommonShareComputationOfDilutedNetLossPerShareDetails</Role>
      <ShortName>Net loss per common share - Computation of diluted net loss per share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>85</Position>
    </Report>
    <Report instance="ganx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>41901 - Disclosure - Related Parties (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gaintherapeutics.com/role/DisclosureRelatedPartiesDetails</Role>
      <ShortName>Related Parties (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.gaintherapeutics.com/role/DisclosureRelatedParties</ParentRole>
      <Position>86</Position>
    </Report>
    <Report instance="ganx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>42001 - Disclosure - Other Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gaintherapeutics.com/role/DisclosureOtherInformationDetails</Role>
      <ShortName>Other Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.gaintherapeutics.com/role/DisclosureOtherInformation</ParentRole>
      <Position>87</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="ganx-20211231x10k.htm">ganx-20211231x10k.htm</File>
    <File>ganx-20211231.xsd</File>
    <File>ganx-20211231_cal.xml</File>
    <File>ganx-20211231_def.xml</File>
    <File>ganx-20211231_lab.xml</File>
    <File>ganx-20211231_pre.xml</File>
    <File>ganx-20211231xex10d8.htm</File>
    <File>ganx-20211231xex23d1.htm</File>
    <File>ganx-20211231xex31d1.htm</File>
    <File>ganx-20211231xex31d2.htm</File>
    <File>ganx-20211231xex32d1.htm</File>
    <File>ganx-20211231xex4d1.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>ganx-20211231x10k001.jpg</File>
    <File>ganx-20211231x10k002.jpg</File>
    <File>ganx-20211231x10k003.jpg</File>
    <File>ganx-20211231x10k004.jpg</File>
    <File>ganx-20211231x10k005.jpg</File>
    <File>ganx-20211231x10k006.jpg</File>
    <File>ganx-20211231x10k007.jpg</File>
    <File>ganx-20211231x10k008.jpg</File>
    <File>ganx-20211231x10k009.jpg</File>
    <File>ganx-20211231x10k010.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="709">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="38">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>127
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "ganx-20211231x10k.htm": {
   "axisCustom": 0,
   "axisStandard": 28,
   "contextCount": 182,
   "dts": {
    "calculationLink": {
     "local": [
      "ganx-20211231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "ganx-20211231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "ganx-20211231x10k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "ganx-20211231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ganx-20211231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "ganx-20211231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/currency/2021/currency-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 628,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 31,
    "http://xbrl.sec.gov/dei/2021q4": 5,
    "total": 36
   },
   "keyCustom": 84,
   "keyStandard": 325,
   "memberCustom": 28,
   "memberStandard": 39,
   "nsprefix": "ganx",
   "nsuri": "http://www.gaintherapeutics.com/20211231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00090 - Document - Document and Entity Information",
     "role": "http://www.gaintherapeutics.com/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ganx:ResearchGrantsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10301 - Disclosure - Research Grants",
     "role": "http://www.gaintherapeutics.com/role/DisclosureResearchGrants",
     "shortName": "Research Grants",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ganx:ResearchGrantsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10401 - Disclosure - Cash, cash equivalents and restricted cash",
     "role": "http://www.gaintherapeutics.com/role/DisclosureCashCashEquivalentsAndRestrictedCash",
     "shortName": "Cash, cash equivalents and restricted cash",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ganx:PrepaidExpensesAndOtherCurrentAssetsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10501 - Disclosure - Other Current Assets",
     "role": "http://www.gaintherapeutics.com/role/DisclosureOtherCurrentAssets",
     "shortName": "Other Current Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ganx:PrepaidExpensesAndOtherCurrentAssetsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10601 - Disclosure - Property and Equipment, net",
     "role": "http://www.gaintherapeutics.com/role/DisclosurePropertyAndEquipmentNet",
     "shortName": "Property and Equipment, net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10701 - Disclosure - Operating lease. Right of use (\"ROU\") assets",
     "role": "http://www.gaintherapeutics.com/role/DisclosureOperatingLeaseRightOfUserouAssets",
     "shortName": "Operating lease. Right of use (\"ROU\") assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10801 - Disclosure - Accounts Payable",
     "role": "http://www.gaintherapeutics.com/role/DisclosureAccountsPayable",
     "shortName": "Accounts Payable",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ganx:OtherCurrentLiabilitiesAndDeferredIncomeTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10901 - Disclosure - Other current liabilities and deferred income",
     "role": "http://www.gaintherapeutics.com/role/DisclosureOtherCurrentLiabilitiesAndDeferredIncome",
     "shortName": "Other current liabilities and deferred income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ganx:OtherCurrentLiabilitiesAndDeferredIncomeTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11001 - Disclosure - Pension obligations",
     "role": "http://www.gaintherapeutics.com/role/DisclosurePensionObligations",
     "shortName": "Pension obligations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11101 - Disclosure - Loans",
     "role": "http://www.gaintherapeutics.com/role/DisclosureLoans",
     "shortName": "Loans",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11201 - Disclosure - Fair value measurement",
     "role": "http://www.gaintherapeutics.com/role/DisclosureFairValueMeasurement",
     "shortName": "Fair value measurement",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00100 - Statement - Consolidated Balance Sheets",
     "role": "http://www.gaintherapeutics.com/role/StatementConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2020_mjsAQai9I0CY9_lj5t9aSg",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:RestrictedCashCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11301 - Disclosure - Common and Preferred Stock",
     "role": "http://www.gaintherapeutics.com/role/DisclosureCommonAndPreferredStock",
     "shortName": "Common and Preferred Stock",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ganx:WarrantsAndRightsNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11401 - Disclosure - Warrants",
     "role": "http://www.gaintherapeutics.com/role/DisclosureWarrants",
     "shortName": "Warrants",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ganx:WarrantsAndRightsNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CompensationRelatedCostsGeneralTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11501 - Disclosure - Equity Incentive Plan",
     "role": "http://www.gaintherapeutics.com/role/DisclosureEquityIncentivePlan",
     "shortName": "Equity Incentive Plan",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CompensationRelatedCostsGeneralTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11601 - Disclosure - Collaboration Agreement",
     "role": "http://www.gaintherapeutics.com/role/DisclosureCollaborationAgreement",
     "shortName": "Collaboration Agreement",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11701 - Disclosure - Income taxes",
     "role": "http://www.gaintherapeutics.com/role/DisclosureIncomeTaxes",
     "shortName": "Income taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11801 - Disclosure - Net loss per common share",
     "role": "http://www.gaintherapeutics.com/role/DisclosureNetLossPerCommonShare",
     "shortName": "Net loss per common share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11901 - Disclosure - Related Parties",
     "role": "http://www.gaintherapeutics.com/role/DisclosureRelatedParties",
     "shortName": "Related Parties",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ganx:OtherInformationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "12001 - Disclosure - Other Information",
     "role": "http://www.gaintherapeutics.com/role/DisclosureOtherInformation",
     "shortName": "Other Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ganx:OtherInformationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "12101 - Disclosure - Significant events after the balance sheet date",
     "role": "http://www.gaintherapeutics.com/role/DisclosureSignificantEventsAfterBalanceSheetDate",
     "shortName": "Significant events after the balance sheet date",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "20202 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.gaintherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "Unit_Divide_USD_shares_ZUfWDOiJrESFdyfJo2gfWg",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00105 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "role": "http://www.gaintherapeutics.com/role/StatementConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_bnIOh52EIUC-yTsdpcG0NQ",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Divide_USD_shares_ZUfWDOiJrESFdyfJo2gfWg",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ganx:DepreciationRatesOnPropertyPlantAndEquipmentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30203 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "role": "http://www.gaintherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ganx:DepreciationRatesOnPropertyPlantAndEquipmentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30403 - Disclosure - Cash, cash equivalents and restricted cash (Tables)",
     "role": "http://www.gaintherapeutics.com/role/DisclosureCashCashEquivalentsAndRestrictedCashTables",
     "shortName": "Cash, cash equivalents and restricted cash (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ganx:PrepaidExpensesAndOtherCurrentAssetsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ganx:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30503 - Disclosure - Other Current Assets (Tables)",
     "role": "http://www.gaintherapeutics.com/role/DisclosureOtherCurrentAssetsTables",
     "shortName": "Other Current Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ganx:PrepaidExpensesAndOtherCurrentAssetsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ganx:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30603 - Disclosure - Property and Equipment, net (Tables)",
     "role": "http://www.gaintherapeutics.com/role/DisclosurePropertyAndEquipmentNetTables",
     "shortName": "Property and Equipment, net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseLeaseIncomeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30703 - Disclosure - Operating lease. Right of use (\"ROU\") assets (Tables)",
     "role": "http://www.gaintherapeutics.com/role/DisclosureOperatingLeaseRightOfUserouAssetsTables",
     "shortName": "Operating lease. Right of use (\"ROU\") assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseLeaseIncomeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30803 - Disclosure - Accounts Payable (Tables)",
     "role": "http://www.gaintherapeutics.com/role/DisclosureAccountsPayableTables",
     "shortName": "Accounts Payable (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "ganx:OtherCurrentLiabilitiesAndDeferredIncomeTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ganx:OtherCurrentLiabilitiesAndDeferredIncomeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30903 - Disclosure - Other current liabilities and deferred income (Tables)",
     "role": "http://www.gaintherapeutics.com/role/DisclosureOtherCurrentLiabilitiesAndDeferredIncomeTables",
     "shortName": "Other current liabilities and deferred income (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ganx:OtherCurrentLiabilitiesAndDeferredIncomeTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ganx:OtherCurrentLiabilitiesAndDeferredIncomeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDefinedBenefitPlansDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "31003 - Disclosure - Pension obligations (Tables)",
     "role": "http://www.gaintherapeutics.com/role/DisclosurePensionObligationsTables",
     "shortName": "Pension obligations (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDefinedBenefitPlansDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "31103 - Disclosure - Loans (Tables)",
     "role": "http://www.gaintherapeutics.com/role/DisclosureLoansTables",
     "shortName": "Loans (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "31203 - Disclosure - Fair value measurement (Tables)",
     "role": "http://www.gaintherapeutics.com/role/DisclosureFairValueMeasurementTables",
     "shortName": "Fair value measurement (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00200 - Statement - Consolidated Statement of Operations",
     "role": "http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfOperations",
     "shortName": "Consolidated Statement of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:SubleaseIncome",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "31403 - Disclosure - Warrants (Tables)",
     "role": "http://www.gaintherapeutics.com/role/DisclosureWarrantsTables",
     "shortName": "Warrants (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "31503 - Disclosure - Equity Incentive Plan (Tables)",
     "role": "http://www.gaintherapeutics.com/role/DisclosureEquityIncentivePlanTables",
     "shortName": "Equity Incentive Plan (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "31703 - Disclosure - Income taxes (Tables)",
     "role": "http://www.gaintherapeutics.com/role/DisclosureIncomeTaxesTables",
     "shortName": "Income taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "31803 - Disclosure - Net loss per common share (Tables)",
     "role": "http://www.gaintherapeutics.com/role/DisclosureNetLossPerCommonShareTables",
     "shortName": "Net loss per common share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "Duration_3_17_2021_To_3_17_2021_u6CMktnXaUyF6ar7hHmEcw",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquityNoteStockSplitConversionRatio1",
      "reportCount": 1,
      "unitRef": "Unit_Standard_pure_YPFUW3Xga0mVMPZT28RXUw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40101 - Disclosure - Nature of the Business and Basis of Presentation (Details)",
     "role": "http://www.gaintherapeutics.com/role/DisclosureNatureOfBusinessAndBasisOfPresentationDetails",
     "shortName": "Nature of the Business and Basis of Presentation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "Duration_3_1_2021_To_3_31_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_N45LChwtn0m3vTVdPokCZw",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40201 - Disclosure - Summary of Significant Accounting Policies (Details)",
     "role": "http://www.gaintherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails",
     "shortName": "Summary of Significant Accounting Policies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:ResearchDevelopmentAndComputerSoftwarePolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CapitalizedComputerSoftwareNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40202 - Disclosure - Summary of Significant Accounting Policies - Additional disclosures (Details)",
     "role": "http://www.gaintherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalDisclosuresDetails",
     "shortName": "Summary of Significant Accounting Policies - Additional disclosures (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:ResearchDevelopmentAndComputerSoftwarePolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CapitalizedComputerSoftwareNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ganx:ResearchGrantsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "As_Of_2_28_2019_dei_LegalEntityAxis_ganx_GtGainTherapeuticsSaMember_srt_CounterpartyNameAxis_ganx_MichaelJ.FoxFoundationForParkinsonSResearchMjffMember_pOgW2epL9EG_XiGfjitJLQ",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:GrantsReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40301 - Disclosure - Research Grants (Details)",
     "role": "http://www.gaintherapeutics.com/role/DisclosureResearchGrantsDetails",
     "shortName": "Research Grants (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ganx:ResearchGrantsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "As_Of_2_28_2019_dei_LegalEntityAxis_ganx_GtGainTherapeuticsSaMember_srt_CounterpartyNameAxis_ganx_MichaelJ.FoxFoundationForParkinsonSResearchMjffMember_pOgW2epL9EG_XiGfjitJLQ",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:GrantsReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40401 - Disclosure - Cash, cash equivalents and restricted cash (Details)",
     "role": "http://www.gaintherapeutics.com/role/DisclosureCashCashEquivalentsAndRestrictedCashDetails",
     "shortName": "Cash, cash equivalents and restricted cash (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CashMember_fDDfSQp6UU-oqPAB4e119Q",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40402 - Disclosure - Cash, cash equivalents and restricted cash - Schedule of Cash and cash equivalents balances (Details)",
     "role": "http://www.gaintherapeutics.com/role/DisclosureCashCashEquivalentsAndRestrictedCashScheduleOfCashAndCashEquivalentsBalancesDetails",
     "shortName": "Cash, cash equivalents and restricted cash - Schedule of Cash and cash equivalents balances (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ganx:ScheduleOfCashAndCashEquivalentsBalancesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_srt_CurrencyAxis_currency_CHF_rDufzY5Ouk6hLwlR1vAueQ",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00300 - Statement - Consolidated Statement of Comprehensive Loss",
     "role": "http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfComprehensiveLoss",
     "shortName": "Consolidated Statement of Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredIncomeTaxesAndOtherTaxReceivableCurrent",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40501 - Disclosure - Other current assets (Details)",
     "role": "http://www.gaintherapeutics.com/role/DisclosureOtherCurrentAssetsDetails",
     "shortName": "Other current assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ganx:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
       "ganx:PrepaidExpensesAndOtherCurrentAssetsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:OtherPrepaidExpenseCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40601 - Disclosure - Property and Equipment, net (Details)",
     "role": "http://www.gaintherapeutics.com/role/DisclosurePropertyAndEquipmentNetDetails",
     "shortName": "Property and Equipment, net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:RestrictedCash",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40701 - Disclosure - Operating lease. Right of use (ROU) assets - Additional information (Details)",
     "role": "http://www.gaintherapeutics.com/role/DisclosureOperatingLeaseRightOfUseRouAssetsAdditionalInformationDetails",
     "shortName": "Operating lease. Right of use (ROU) assets - Additional information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "As_Of_6_1_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ganx_OfficeSpaceViaSoaveN6LuganoSwitzerlandMember_PifC1TMuyUCNw5rbo-bIqg",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:RestrictedCash",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40702 - Disclosure - Operating lease. Right of use (ROU) assets - Summary of components of lease accounting (Details)",
     "role": "http://www.gaintherapeutics.com/role/DisclosureOperatingLeaseRightOfUseRouAssetsSummaryOfComponentsOfLeaseAccountingDetails",
     "shortName": "Operating lease. Right of use (ROU) assets - Summary of components of lease accounting (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:OperatingLeaseLeaseIncomeTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40703 - Disclosure - Operating lease. Right of use (ROU) assets - Summary of components of lease expense (Details)",
     "role": "http://www.gaintherapeutics.com/role/DisclosureOperatingLeaseRightOfUseRouAssetsSummaryOfComponentsOfLeaseExpenseDetails",
     "shortName": "Operating lease. Right of use (ROU) assets - Summary of components of lease expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40704 - Disclosure - Operating lease. Right of use (ROU) assets - Future minimum lease payments (Details)",
     "role": "http://www.gaintherapeutics.com/role/DisclosureOperatingLeaseRightOfUseRouAssetsFutureMinimumLeasePaymentsDetails",
     "shortName": "Operating lease. Right of use (ROU) assets - Future minimum lease payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccountsPayableCurrent",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40801 - Disclosure - Accounts Payable (Details)",
     "role": "http://www.gaintherapeutics.com/role/DisclosureAccountsPayableDetails",
     "shortName": "Accounts Payable (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_srt_CurrencyAxis_currency_CHF_rDufzY5Ouk6hLwlR1vAueQ",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:AccountsPayableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ganx:OtherCurrentLiabilitiesAndDeferredIncomeTableTextBlock",
       "ganx:OtherCurrentLiabilitiesAndDeferredIncomeTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ganx:PayableForSocialSecuritiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40901 - Disclosure - Other current liabilities and deferred income (Details)",
     "role": "http://www.gaintherapeutics.com/role/DisclosureOtherCurrentLiabilitiesAndDeferredIncomeDetails",
     "shortName": "Other current liabilities and deferred income (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ganx:OtherCurrentLiabilitiesAndDeferredIncomeTableTextBlock",
       "ganx:OtherCurrentLiabilitiesAndDeferredIncomeTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ganx:PayableForSocialSecuritiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDefinedBenefitPlansDisclosuresTextBlock",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_i6PZAoMNcEySLcgBUKmmjw",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedBenefitPlanFairValueOfPlanAssets",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41001 - Disclosure - Pension obligations - End of year funded status (Details)",
     "role": "http://www.gaintherapeutics.com/role/DisclosurePensionObligationsEndOfYearFundedStatusDetails",
     "shortName": "Pension obligations - End of year funded status (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDefinedBenefitPlansDisclosuresTextBlock",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_us-gaap_RetirementPlanSponsorLocationAxis_country_CH_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_JNWw1VrK5kqfZgK60b8Pdw",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDefinedBenefitPlansDisclosuresTextBlock",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2020_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_HLv731xR10GVgI0Jt-JL5w",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedBenefitPlanFundedStatusOfPlan",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41002 - Disclosure - Pension obligations - Reconciliation of funded status (Details)",
     "role": "http://www.gaintherapeutics.com/role/DisclosurePensionObligationsReconciliationOfFundedStatusDetails",
     "shortName": "Pension obligations - Reconciliation of funded status (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDefinedBenefitPlansDisclosuresTextBlock",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_kMW3hEdOQk-Go8nyyVufvA",
      "decimals": "0",
      "lang": null,
      "name": "ganx:IncreaseDecreaseThroughTotalExpensesToReconcileFundedStatusOfDefinedBenefitPlan",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_UWKqqxKGa0GJPrjjqykVHA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00400 - Statement - Consolidated Statement of Changes in Stockholders' Equity (Deficit)",
     "role": "http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfChangesInStockholdersEquityDeficit",
     "shortName": "Consolidated Statement of Changes in Stockholders' Equity (Deficit)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_UWKqqxKGa0GJPrjjqykVHA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDefinedBenefitPlansDisclosuresTextBlock",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_kMW3hEdOQk-Go8nyyVufvA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedBenefitPlanServiceCost",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41003 - Disclosure - Pension obligations - Component of net periodic pension costs (Details)",
     "role": "http://www.gaintherapeutics.com/role/DisclosurePensionObligationsComponentOfNetPeriodicPensionCostsDetails",
     "shortName": "Pension obligations - Component of net periodic pension costs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDefinedBenefitPlansDisclosuresTextBlock",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_kMW3hEdOQk-Go8nyyVufvA",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDefinedBenefitPlansDisclosuresTextBlock",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2020_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_HLv731xR10GVgI0Jt-JL5w",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedBenefitPlanBenefitObligation",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41004 - Disclosure - Pension obligations - Reconciliation of projected benefit obligation (Details)",
     "role": "http://www.gaintherapeutics.com/role/DisclosurePensionObligationsReconciliationOfProjectedBenefitObligationDetails",
     "shortName": "Pension obligations - Reconciliation of projected benefit obligation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDefinedBenefitPlansDisclosuresTextBlock",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_kMW3hEdOQk-Go8nyyVufvA",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDefinedBenefitPlansDisclosuresTextBlock",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2020_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_HLv731xR10GVgI0Jt-JL5w",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedBenefitPlanFairValueOfPlanAssets",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41005 - Disclosure - Pension obligations - Reconciliation of fair value of plan assets (Details)",
     "role": "http://www.gaintherapeutics.com/role/DisclosurePensionObligationsReconciliationOfFairValueOfPlanAssetsDetails",
     "shortName": "Pension obligations - Reconciliation of fair value of plan assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_kMW3hEdOQk-Go8nyyVufvA",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2020_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_HLv731xR10GVgI0Jt-JL5w",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41006 - Disclosure - Pension obligations - Change in net (gain) loss (Details)",
     "role": "http://www.gaintherapeutics.com/role/DisclosurePensionObligationsChangeInNetGainLossDetails",
     "shortName": "Pension obligations - Change in net (gain) loss (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2019_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_t7HEGl5NAk-CsgC95XNoeg",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2020_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_HLv731xR10GVgI0Jt-JL5w",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41007 - Disclosure - Pension obligations - Change in accumulated other comprehensive income (AOCI) (Details)",
     "role": "http://www.gaintherapeutics.com/role/DisclosurePensionObligationsChangeInAccumulatedOtherComprehensiveIncomeAociDetails",
     "shortName": "Pension obligations - Change in accumulated other comprehensive income (AOCI) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2019_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_t7HEGl5NAk-CsgC95XNoeg",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAssumptionsUsedTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_i6PZAoMNcEySLcgBUKmmjw",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_YPFUW3Xga0mVMPZT28RXUw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41008 - Disclosure - Pension obligations - Assumptions (Details)",
     "role": "http://www.gaintherapeutics.com/role/DisclosurePensionObligationsAssumptionsDetails",
     "shortName": "Pension obligations - Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAssumptionsUsedTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_i6PZAoMNcEySLcgBUKmmjw",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_YPFUW3Xga0mVMPZT28RXUw",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_i6PZAoMNcEySLcgBUKmmjw",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41009 - Disclosure - Pension obligations - Expected benefit payments (Details)",
     "role": "http://www.gaintherapeutics.com/role/DisclosurePensionObligationsExpectedBenefitPaymentsDetails",
     "shortName": "Pension obligations - Expected benefit payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_i6PZAoMNcEySLcgBUKmmjw",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41010 - Disclosure - Pension obligations - Additional Information (Details)",
     "role": "http://www.gaintherapeutics.com/role/DisclosurePensionObligationsAdditionalInformationDetails",
     "shortName": "Pension obligations - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ganx:ExpensesOrChargesDueForEarlyExtinguishmentOfDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41101 - Disclosure - Loans (Details)",
     "role": "http://www.gaintherapeutics.com/role/DisclosureLoansDetails",
     "shortName": "Loans (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ganx:ExpensesOrChargesDueForEarlyExtinguishmentOfDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LongTermDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41102 - Disclosure - Loans - Future loan payments (Details)",
     "role": "http://www.gaintherapeutics.com/role/DisclosureLoansFutureLoanPaymentsDetails",
     "shortName": "Loans - Future loan payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LongTermDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00500 - Statement - Consolidated Statement of Cash Flows",
     "role": "http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfCashFlows",
     "shortName": "Consolidated Statement of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_uuaa7xnlyki6ykqgX7Pttw",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41201 - Disclosure - Fair value measurement (Details)",
     "role": "http://www.gaintherapeutics.com/role/DisclosureFairValueMeasurementDetails",
     "shortName": "Fair value measurement (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_uuaa7xnlyki6ykqgX7Pttw",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41301 - Disclosure - Common and Preferred Stock (Details)",
     "role": "http://www.gaintherapeutics.com/role/DisclosureCommonAndPreferredStockDetails",
     "shortName": "Common and Preferred Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "As_Of_3_16_2021_fYMXRlaU00CBob3C4xDimg",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "Duration_3_17_2021_To_3_17_2021_u6CMktnXaUyF6ar7hHmEcw",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquityNoteStockSplitConversionRatio1",
      "reportCount": 1,
      "unitRef": "Unit_Standard_pure_YPFUW3Xga0mVMPZT28RXUw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41401 - Disclosure - Warrants (Details)",
     "role": "http://www.gaintherapeutics.com/role/DisclosureWarrantsDetails",
     "shortName": "Warrants (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ganx:WarrantsAndRightsNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "As_Of_7_31_2020_us-gaap_ClassOfWarrantOrRightAxis_ganx_WarrantsToDesigneesOfPlacementAgentIssuedJuly2020Member__xz3VXdq4UepWPvW5n-chA",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_us-gaap_ValuationTechniqueAxis_us-gaap_ValuationTechniqueOptionPricingModelMember_QzEVNtuW9US0oSPFOgMt6A",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "ganx:WarrantsGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Divide_USD_shares_ZUfWDOiJrESFdyfJo2gfWg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41402 - Disclosure - Warrants - Assumptions under black-scholes pricing model (Details)",
     "role": "http://www.gaintherapeutics.com/role/DisclosureWarrantsAssumptionsUnderBlackScholesPricingModelDetails",
     "shortName": "Warrants - Assumptions under black-scholes pricing model (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_us-gaap_ValuationTechniqueAxis_us-gaap_ValuationTechniqueOptionPricingModelMember_QzEVNtuW9US0oSPFOgMt6A",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "ganx:WarrantsGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Divide_USD_shares_ZUfWDOiJrESFdyfJo2gfWg",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "Duration_3_17_2021_To_3_17_2021_u6CMktnXaUyF6ar7hHmEcw",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquityNoteStockSplitConversionRatio1",
      "reportCount": 1,
      "unitRef": "Unit_Standard_pure_YPFUW3Xga0mVMPZT28RXUw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41501 - Disclosure - Equity Incentive Plan (Details)",
     "role": "http://www.gaintherapeutics.com/role/DisclosureEquityIncentivePlanDetails",
     "shortName": "Equity Incentive Plan (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CompensationRelatedCostsGeneralTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_9J9hcs3P0U-I30H9M7barQ",
      "decimals": "INF",
      "lang": null,
      "name": "ganx:NumberOfOptionsSubjectToTermThreshold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_Options_mZpQ0toHqki8W4R9nXDMkA",
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2020_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_liEc-LEvuUmppacbgwHfFg",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41502 - Disclosure - Equity Incentive Plan - Stock Option Activity (Details)",
     "role": "http://www.gaintherapeutics.com/role/DisclosureEquityIncentivePlanStockOptionActivityDetails",
     "shortName": "Equity Incentive Plan - Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "As_Of_3_17_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_NETjxmYYrkyazfL5gwskGw",
      "decimals": "INF",
      "lang": null,
      "name": "ganx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAfterStockSplitsNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_8AYwJZkZdkuToq-rPLadkw",
      "xsiNil": "false"
     }
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "Duration_3_17_2021_To_3_17_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_VPlkneswlU6lplZPmfwMQg",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit",
      "reportCount": 1,
      "unitRef": "Unit_Divide_USD_shares_ZUfWDOiJrESFdyfJo2gfWg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41503 - Disclosure - Equity Incentive Plan - Options Outstanding and Exercisable (Details)",
     "role": "http://www.gaintherapeutics.com/role/DisclosureEquityIncentivePlanOptionsOutstandingAndExercisableDetails",
     "shortName": "Equity Incentive Plan - Options Outstanding and Exercisable (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_RVGfoikIBESMbmCXz6RCfw",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA",
      "xsiNil": "false"
     }
    },
    "R77": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_9J9hcs3P0U-I30H9M7barQ",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unitRef": "Unit_Divide_USD_shares_ZUfWDOiJrESFdyfJo2gfWg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41504 - Disclosure - Equity Incentive Plan - Assumptions (Details)",
     "role": "http://www.gaintherapeutics.com/role/DisclosureEquityIncentivePlanAssumptionsDetails",
     "shortName": "Equity Incentive Plan - Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_9J9hcs3P0U-I30H9M7barQ",
      "decimals": "2",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_YPFUW3Xga0mVMPZT28RXUw",
      "xsiNil": "false"
     }
    },
    "R78": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_9J9hcs3P0U-I30H9M7barQ",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41505 - Disclosure - Equity Incentive Plan - Stock-based compensation (Details)",
     "role": "http://www.gaintherapeutics.com/role/DisclosureEquityIncentivePlanStockBasedCompensationDetails",
     "shortName": "Equity Incentive Plan - Stock-based compensation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_ganx_OmnibusIncentivePlanTwoThousandTwentyMember_9J9hcs3P0U-I30H9M7barQ",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA",
      "xsiNil": "false"
     }
    },
    "R79": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41601 - Disclosure - Collaboration Agreement (Details)",
     "role": "http://www.gaintherapeutics.com/role/DisclosureCollaborationAgreementDetails",
     "shortName": "Collaboration Agreement (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "As_Of_4_20_2021_srt_CounterpartyNameAxis_ganx_ZentalisPharmaceuticalsInc.Member_us-gaap_TypeOfArrangementAxis_ganx_MultiTargetCollaborationAgreementMember_MduiqnTW20mQ__WJtWGk9Q",
      "decimals": "INF",
      "lang": null,
      "name": "ganx:CollaborativeArrangementMinimumNumberOfTargets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_item_jlWcaGVl5kGYwaQ1kPo68Q",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10101 - Disclosure - Nature of the Business and Basis of Presentation",
     "role": "http://www.gaintherapeutics.com/role/DisclosureNatureOfBusinessAndBasisOfPresentation",
     "shortName": "Nature of the Business and Basis of Presentation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R80": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41701 - Disclosure - Income taxes - Domestic and foreign net operating losses (Details)",
     "role": "http://www.gaintherapeutics.com/role/DisclosureIncomeTaxesDomesticAndForeignNetOperatingLossesDetails",
     "shortName": "Income taxes - Domestic and foreign net operating losses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA",
      "xsiNil": "false"
     }
    },
    "R81": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CurrentForeignTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41702 - Disclosure - Income taxes - Components of income tax expense (Details)",
     "role": "http://www.gaintherapeutics.com/role/DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseDetails",
     "shortName": "Income taxes - Components of income tax expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CurrentForeignTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA",
      "xsiNil": "false"
     }
    },
    "R82": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41703 - Disclosure - Income taxes - Domestic and foreign net operating losses and related deferred tax assets (Details)",
     "role": "http://www.gaintherapeutics.com/role/DisclosureIncomeTaxesDomesticAndForeignNetOperatingLossesAndRelatedDeferredTaxAssetsDetails",
     "shortName": "Income taxes - Domestic and foreign net operating losses and related deferred tax assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA",
      "xsiNil": "false"
     }
    },
    "R83": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "reportCount": 1,
      "unitRef": "Unit_Standard_pure_YPFUW3Xga0mVMPZT28RXUw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41704 - Disclosure - Income taxes - Additional disclosures (Details)",
     "role": "http://www.gaintherapeutics.com/role/DisclosureIncomeTaxesAdditionalDisclosuresDetails",
     "shortName": "Income taxes - Additional disclosures (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_Azjy--iLiEKwHr5Pudik5A",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA",
      "xsiNil": "false"
     }
    },
    "R84": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_YPFUW3Xga0mVMPZT28RXUw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41705 - Disclosure - Income taxes - Effective income tax rate reconciliation (Details)",
     "role": "http://www.gaintherapeutics.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails",
     "shortName": "Income taxes - Effective income tax rate reconciliation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_YPFUW3Xga0mVMPZT28RXUw",
      "xsiNil": "false"
     }
    },
    "R85": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:EarningsPerShareBasic",
      "reportCount": 1,
      "unitRef": "Unit_Divide_USD_shares_ZUfWDOiJrESFdyfJo2gfWg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41801 - Disclosure - Net loss per common share - Computation of diluted net loss per share (Details)",
     "role": "http://www.gaintherapeutics.com/role/DisclosureNetLossPerCommonShareComputationOfDilutedNetLossPerShareDetails",
     "shortName": "Net loss per common share - Computation of diluted net loss per share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_BhPyaAaDOkudfThK5f94MA",
      "decimals": "2",
      "lang": null,
      "name": "us-gaap:EarningsPerShareBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Divide_USD_shares_ZUfWDOiJrESFdyfJo2gfWg",
      "xsiNil": "false"
     }
    },
    "R86": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "Duration_12_1_2017_To_12_31_2017_us-gaap_RelatedPartyTransactionAxis_ganx_LicenseAgreementWithMinoryxTherapeuticsSlMember_cbGjmh51ckuCzbppGr1veQ",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "ganx:RelatedPartyTransactionPercentageOfConsiderationReceived",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_YPFUW3Xga0mVMPZT28RXUw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41901 - Disclosure - Related Parties (Details)",
     "role": "http://www.gaintherapeutics.com/role/DisclosureRelatedPartiesDetails",
     "shortName": "Related Parties (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "Duration_12_1_2017_To_12_31_2017_us-gaap_RelatedPartyTransactionAxis_ganx_LicenseAgreementWithMinoryxTherapeuticsSlMember_cbGjmh51ckuCzbppGr1veQ",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "ganx:RelatedPartyTransactionPercentageOfConsiderationReceived",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_YPFUW3Xga0mVMPZT28RXUw",
      "xsiNil": "false"
     }
    },
    "R87": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ganx:OtherInformationDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_us-gaap_OtherCommitmentsAxis_ganx_CollaborationAgreementsMember_Yr71bAiK8EiGzhgz_kIr8Q",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ContractualObligationDueInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "42001 - Disclosure - Other Information (Details)",
     "role": "http://www.gaintherapeutics.com/role/DisclosureOtherInformationDetails",
     "shortName": "Other Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ganx:OtherInformationDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_us-gaap_OtherCommitmentsAxis_ganx_CollaborationAgreementsMember_Yr71bAiK8EiGzhgz_kIr8Q",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ContractualObligationDueInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_P77gzpjV3EuJg4kXNUKrCA",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10201 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://www.gaintherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_GWFAfa0w7U2FpMsxAkBPsA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 71,
   "tag": {
    "country_CH": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SWITZERLAND"
       }
      }
     },
     "localname": "CH",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosurePensionObligationsEndOfYearFundedStatusDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_ES": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Spain"
       }
      }
     },
     "localname": "ES",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureIncomeTaxesAdditionalDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_AllCurrenciesDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Currencies [Domain]"
       }
      }
     },
     "localname": "AllCurrenciesDomain",
     "nsuri": "http://xbrl.sec.gov/currency/2021",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureAccountsPayableDetails",
      "http://www.gaintherapeutics.com/role/DisclosureCashCashEquivalentsAndRestrictedCashScheduleOfCashAndCashEquivalentsBalancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_CHF": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CHF"
       }
      }
     },
     "localname": "CHF",
     "nsuri": "http://xbrl.sec.gov/currency/2021",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureAccountsPayableDetails",
      "http://www.gaintherapeutics.com/role/DisclosureCashCashEquivalentsAndRestrictedCashScheduleOfCashAndCashEquivalentsBalancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_EUR": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "EUR"
       }
      }
     },
     "localname": "EUR",
     "nsuri": "http://xbrl.sec.gov/currency/2021",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureAccountsPayableDetails",
      "http://www.gaintherapeutics.com/role/DisclosureCashCashEquivalentsAndRestrictedCashScheduleOfCashAndCashEquivalentsBalancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_USD": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "USD"
       }
      }
     },
     "localname": "USD",
     "nsuri": "http://xbrl.sec.gov/currency/2021",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureAccountsPayableDetails",
      "http://www.gaintherapeutics.com/role/DisclosureCashCashEquivalentsAndRestrictedCashScheduleOfCashAndCashEquivalentsBalancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r660",
      "r661",
      "r662"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r660",
      "r661",
      "r662"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r660",
      "r661",
      "r662"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Document and Entity Information [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r660",
      "r661",
      "r662"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r663"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Adress Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address State Or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r658"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureResearchGrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r658"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r667"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r658"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r665"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r658"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r658"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r658"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r658"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r666"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r660",
      "r661",
      "r662"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureResearchGrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r657"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r659"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "ganx_AccountsPayableCurrentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accounts Payable Current [Line Items]",
        "verboseLabel": "Accounts Payable"
       }
      }
     },
     "localname": "AccountsPayableCurrentLineItems",
     "nsuri": "http://www.gaintherapeutics.com/20211231",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureAccountsPayableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ganx_AccountsPayableCurrentTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule that describes accounts payable current",
        "label": "Accounts Payable Current [Table]"
       }
      }
     },
     "localname": "AccountsPayableCurrentTable",
     "nsuri": "http://www.gaintherapeutics.com/20211231",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureAccountsPayableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ganx_AccountsPayablePolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for accounts payable.",
        "label": "Accounts Payable Policy [Text Block]",
        "terseLabel": "Accounts Payable"
       }
      }
     },
     "localname": "AccountsPayablePolicyTextBlock",
     "nsuri": "http://www.gaintherapeutics.com/20211231",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ganx_AccruedExpensesPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for accrued expenses.",
        "label": "Accrued Expenses Policy [Policy Text Block]",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "AccruedExpensesPolicyPolicyTextBlock",
     "nsuri": "http://www.gaintherapeutics.com/20211231",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ganx_AccruedPayrollCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.gaintherapeutics.com/role/DisclosureOtherCurrentLiabilitiesAndDeferredIncomeDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for current portion of payroll.",
        "label": "Accrued Payroll Current",
        "verboseLabel": "Accrued payroll"
       }
      }
     },
     "localname": "AccruedPayrollCurrent",
     "nsuri": "http://www.gaintherapeutics.com/20211231",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureOtherCurrentLiabilitiesAndDeferredIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ganx_AdjustmentToReconcileOperatingLeaseLiabilitiesAmountsRepresentingInterestOrImputedInterest": {
     "auth_ref": [],
     "calculation": {
      "http://www.gaintherapeutics.com/role/DisclosureOperatingLeaseRightOfUseRouAssetsFutureMinimumLeasePaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustment to reconcile operating lease liabilities, amounts representing interest or imputed interest not recognized in balance sheet.",
        "label": "Adjustment to reconcile operating lease liabilities, amounts representing interest or imputed interest",
        "terseLabel": "Less amount representing interest or imputed interest"
       }
      }
     },
     "localname": "AdjustmentToReconcileOperatingLeaseLiabilitiesAmountsRepresentingInterestOrImputedInterest",
     "nsuri": "http://www.gaintherapeutics.com/20211231",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureOperatingLeaseRightOfUseRouAssetsFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ganx_August2020ChfLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "August 2020 CHF loan",
        "label": "August 2020 CHF loan"
       }
      }
     },
     "localname": "August2020ChfLoanMember",
     "nsuri": "http://www.gaintherapeutics.com/20211231",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureLoansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ganx_CapitalizedComputerSoftwareAdjustment": {
     "auth_ref": [],
     "calculation": {
      "http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of adjustment for capitalized computer software.",
        "label": "Capitalized Computer Software, Adjustment",
        "negatedLabel": "Internal-use software"
       }
      }
     },
     "localname": "CapitalizedComputerSoftwareAdjustment",
     "nsuri": "http://www.gaintherapeutics.com/20211231",
     "presentation": [
      "http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ganx_CapitalizedComputerSoftwareForInternalUse": {
     "auth_ref": [],
     "calculation": {
      "http://www.gaintherapeutics.com/role/StatementConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount of capitalized internally use software as on date.",
        "label": "Capitalized Computer Software For Internal Use",
        "terseLabel": "Internal-use software"
       }
      }
     },
     "localname": "CapitalizedComputerSoftwareForInternalUse",
     "nsuri": "http://www.gaintherapeutics.com/20211231",
     "presentation": [
      "http://www.gaintherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ganx_CollaborationAgreementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information pertaining to Collaboration Agreement.",
        "label": "Collaboration Agreement"
       }
      }
     },
     "localname": "CollaborationAgreementAbstract",
     "nsuri": "http://www.gaintherapeutics.com/20211231",
     "xbrltype": "stringItemType"
    },
    "ganx_CollaborationAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Collaboration agreements.",
        "label": "Collaboration Agreements",
        "terseLabel": "Research agreements"
       }
      }
     },
     "localname": "CollaborationAgreementsMember",
     "nsuri": "http://www.gaintherapeutics.com/20211231",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureOtherInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ganx_CollaborativeArrangementEmployeeAndExternalResearchAndDevelopmentCosts": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of first target development program reimbursement for employee and external research and development costs.",
        "label": "Collaborative Arrangement, Employee and External Research and Development Costs",
        "terseLabel": "Employee and external research and development cost"
       }
      }
     },
     "localname": "CollaborativeArrangementEmployeeAndExternalResearchAndDevelopmentCosts",
     "nsuri": "http://www.gaintherapeutics.com/20211231",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureCollaborationAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ganx_CollaborativeArrangementEventBasedMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of first target development program event-based milestone payments.",
        "label": "Collaborative Arrangement, Event Based Milestone Payments",
        "terseLabel": "Event-based milestone payments"
       }
      }
     },
     "localname": "CollaborativeArrangementEventBasedMilestonePayments",
     "nsuri": "http://www.gaintherapeutics.com/20211231",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureCollaborationAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ganx_CollaborativeArrangementMinimumNumberOfTargets": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum number of targets mutually agreed per agreement.",
        "label": "Collaborative Arrangement, Minimum Number of targets",
        "terseLabel": "Number of targets"
       }
      }
     },
     "localname": "CollaborativeArrangementMinimumNumberOfTargets",
     "nsuri": "http://www.gaintherapeutics.com/20211231",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureCollaborationAgreementDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ganx_CollaborativeArrangementOptionExerciseFee": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of first target development program option exercise fee.",
        "label": "Collaborative Arrangement, Option Exercise Fee",
        "terseLabel": "Option exercise fees"
       }
      }
     },
     "localname": "CollaborativeArrangementOptionExerciseFee",
     "nsuri": "http://www.gaintherapeutics.com/20211231",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureCollaborationAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ganx_CollaborativeArrangementProgramInitiationFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of first target development program initiation fees receivable per terms of agreement.",
        "label": "Collaborative Arrangement, Program Initiation Fee",
        "terseLabel": "First target development program initiation fees"
       }
      }
     },
     "localname": "CollaborativeArrangementProgramInitiationFee",
     "nsuri": "http://www.gaintherapeutics.com/20211231",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureCollaborationAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ganx_CollaborativeArrangementTerminationNoticePeriodDays": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Notice period days for agreement termination.",
        "label": "Collaborative Arrangement, Termination , Notice Period Days",
        "terseLabel": "Agreement termination notice period days"
       }
      }
     },
     "localname": "CollaborativeArrangementTerminationNoticePeriodDays",
     "nsuri": "http://www.gaintherapeutics.com/20211231",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureCollaborationAgreementDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ganx_ConsortiumWithGtGainTherapeuticsSaInstituteForResearchInBiomedicineAndNeuroSysSasMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to a consortium with GT Gain Therapeutics SA, Institute for Research in Biomedicine and Neuro-Sys SAS",
        "label": "Consortium with GT Gain Therapeutics SA, Institute for Research in Biomedicine and Neuro-Sys SAS [Member]",
        "terseLabel": "Consortium with GT Gain Therapeutics SA, Institute for Research in Biomedicine and Neuro-Sys SAS"
       }
      }
     },
     "localname": "ConsortiumWithGtGainTherapeuticsSaInstituteForResearchInBiomedicineAndNeuroSysSasMember",
     "nsuri": "http://www.gaintherapeutics.com/20211231",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureResearchGrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ganx_ConversionOfSeriesBPreferredStockIntoCommonStock": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) in equity from conversion of Series B Preferred Stock into Common Stock",
        "label": "Conversion of Series B Preferred Stock into Common Stock"
       }
      }
     },
     "localname": "ConversionOfSeriesBPreferredStockIntoCommonStock",
     "nsuri": "http://www.gaintherapeutics.com/20211231",
     "presentation": [
      "http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ganx_ConversionOfSeriesBPreferredStockIntoCommonStockInShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) in number of shares resulting from the conversion of Series B Preferred Stock into Common Stock.",
        "label": "Conversion of Series B Preferred Stock into Common Stock (in shares)"
       }
      }
     },
     "localname": "ConversionOfSeriesBPreferredStockIntoCommonStockInShares",
     "nsuri": "http://www.gaintherapeutics.com/20211231",
     "presentation": [
      "http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "ganx_ConversionOfSeriesPreferredStockIntoCommonStock": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) in equity from conversion of Series A Preferred Stock into Common Stock",
        "label": "Conversion of Series A Preferred Stock into Common Stock"
       }
      }
     },
     "localname": "ConversionOfSeriesPreferredStockIntoCommonStock",
     "nsuri": "http://www.gaintherapeutics.com/20211231",
     "presentation": [
      "http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ganx_ConversionOfSeriesPreferredStockIntoCommonStockInShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) in number of shares resulting from the conversion of Series B Preferred Stock into Common Stock.",
        "label": "Conversion of Series A Preferred Stock into Common Stock (in shares)"
       }
      }
     },
     "localname": "ConversionOfSeriesPreferredStockIntoCommonStockInShares",
     "nsuri": "http://www.gaintherapeutics.com/20211231",
     "presentation": [
      "http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "ganx_DeferredTaxAssetsFmwWarrant": {
     "auth_ref": [],
     "calculation": {
      "http://www.gaintherapeutics.com/role/DisclosureIncomeTaxesDomesticAndForeignNetOperatingLossesAndRelatedDeferredTaxAssetsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from fmw warrants.",
        "label": "Deferred Tax Assets, Fmw Warrant",
        "terseLabel": "Warrant expense"
       }
      }
     },
     "localname": "DeferredTaxAssetsFmwWarrant",
     "nsuri": "http://www.gaintherapeutics.com/20211231",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureIncomeTaxesDomesticAndForeignNetOperatingLossesAndRelatedDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ganx_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfPensionIncreases": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average rate increase of pension, used to determine benefit obligation of defined benefit plan. Plan includes, but is not limited to, pension-related defined benefit plan.",
        "label": "Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Rate of Pension Increases",
        "terseLabel": "Pension increases"
       }
      }
     },
     "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfPensionIncreases",
     "nsuri": "http://www.gaintherapeutics.com/20211231",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosurePensionObligationsAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ganx_DefinedBenefitPlanBenefitObligationGainsLossesOnDemographicAssumptions": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gains (losses) on demographic assumptions by defined benefit plan which decreases (increases) benefit obligation.",
        "label": "Defined Benefit Plan, Benefit Obligation, Gains (Losses) on demographic assumptions",
        "negatedLabel": "(Gain)/loss on demographic assumption"
       }
      }
     },
     "localname": "DefinedBenefitPlanBenefitObligationGainsLossesOnDemographicAssumptions",
     "nsuri": "http://www.gaintherapeutics.com/20211231",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosurePensionObligationsReconciliationOfProjectedBenefitObligationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ganx_DefinedBenefitPlanBenefitObligationGainsLossesOnExperience": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gains (losses) on experience by defined benefit plan which decreases (increases) benefit obligation.",
        "label": "Defined Benefit Plan, Benefit Obligation, Gains (Losses) on experience",
        "negatedLabel": "(Gain)/loss on experience"
       }
      }
     },
     "localname": "DefinedBenefitPlanBenefitObligationGainsLossesOnExperience",
     "nsuri": "http://www.gaintherapeutics.com/20211231",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosurePensionObligationsReconciliationOfProjectedBenefitObligationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ganx_DefinedBenefitPlanBenefitObligationGainsLossesOnFinancialAssumptions": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gains (losses) on financial assumptions by defined benefit plan which decreases (increases) benefit obligation.",
        "label": "Defined Benefit Plan, Benefit Obligation, Gains (Losses) on financial assumptions",
        "negatedLabel": "(Gain)/loss on financial assumption"
       }
      }
     },
     "localname": "DefinedBenefitPlanBenefitObligationGainsLossesOnFinancialAssumptions",
     "nsuri": "http://www.gaintherapeutics.com/20211231",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosurePensionObligationsReconciliationOfProjectedBenefitObligationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ganx_DefinedBenefitPlanDemographicAssumptionAllowanceForChildPensions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Demographic assumption of allowance for child pensions  under the defined benefit pension plan.",
        "label": "Defined Benefit Plan, Demographic Assumption, Allowance for Child Pensions",
        "terseLabel": "Allowance for child pensions"
       }
      }
     },
     "localname": "DefinedBenefitPlanDemographicAssumptionAllowanceForChildPensions",
     "nsuri": "http://www.gaintherapeutics.com/20211231",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosurePensionObligationsAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ganx_DefinedBenefitPlanDemographicAssumptionLumpSumOption": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Demographic assumption of lumpsum option under the defined benefit plan.",
        "label": "Defined Benefit Plan, Demographic Assumption Lump Sum Option",
        "terseLabel": "Lump-sum option"
       }
      }
     },
     "localname": "DefinedBenefitPlanDemographicAssumptionLumpSumOption",
     "nsuri": "http://www.gaintherapeutics.com/20211231",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosurePensionObligationsAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ganx_DefinedBenefitPlanDemographicAssumptionProportionMarried": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Demographic assumption of proportion of married persons under the defined benefit pension plan.",
        "label": "Defined Benefit Plan, Demographic Assumption, Proportion Married",
        "terseLabel": "Proportion married"
       }
      }
     },
     "localname": "DefinedBenefitPlanDemographicAssumptionProportionMarried",
     "nsuri": "http://www.gaintherapeutics.com/20211231",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosurePensionObligationsAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ganx_DefinedBenefitPlanDisabilityPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disability percentage in a defined benefit plan.",
        "label": "Defined Benefit Plan, Disability Percentage",
        "terseLabel": "Disability"
       }
      }
     },
     "localname": "DefinedBenefitPlanDisabilityPercentage",
     "nsuri": "http://www.gaintherapeutics.com/20211231",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosurePensionObligationsAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ganx_DefinedBenefitPlanMortalityImprovementPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Mortality improvement percentage in a defined benefit plan.",
        "label": "Defined Benefit Plan, Mortality Improvement Percentage",
        "verboseLabel": "Longevity improvement"
       }
      }
     },
     "localname": "DefinedBenefitPlanMortalityImprovementPercentage",
     "nsuri": "http://www.gaintherapeutics.com/20211231",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosurePensionObligationsAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ganx_DefinedBenefitPlanPlanAssetsOtherIncreasesDecreases": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other changes to the plan assets in a defined benefit plan which increases (decreases) plan assets.",
        "label": "Defined Benefit Plan, Plan Assets, other increases (decreases)",
        "terseLabel": "Others"
       }
      }
     },
     "localname": "DefinedBenefitPlanPlanAssetsOtherIncreasesDecreases",
     "nsuri": "http://www.gaintherapeutics.com/20211231",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosurePensionObligationsReconciliationOfFairValueOfPlanAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ganx_DepositsAndOtherAssetsNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.gaintherapeutics.com/role/StatementConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer and noncurrent assets classified as other.",
        "label": "Deposits And Other Assets, Noncurrent",
        "terseLabel": "Long-term deposits and other non-current assets"
       }
      }
     },
     "localname": "DepositsAndOtherAssetsNoncurrent",
     "nsuri": "http://www.gaintherapeutics.com/20211231",
     "presentation": [
      "http://www.gaintherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ganx_DepositsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.gaintherapeutics.com/role/DisclosureOtherCurrentLiabilitiesAndDeferredIncomeDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of current deposits.",
        "label": "Deposits, Current",
        "terseLabel": "Deposit"
       }
      }
     },
     "localname": "DepositsCurrent",
     "nsuri": "http://www.gaintherapeutics.com/20211231",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureOtherCurrentLiabilitiesAndDeferredIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ganx_DepreciationRatesOnPropertyPlantAndEquipmentTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for depreciation rates on property plant and equipment.",
        "label": "Depreciation Rates On Property Plant And Equipment [Table Text Block]",
        "terseLabel": "Schedule of depreciation rates"
       }
      }
     },
     "localname": "DepreciationRatesOnPropertyPlantAndEquipmentTableTextBlock",
     "nsuri": "http://www.gaintherapeutics.com/20211231",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ganx_EffectiveIncomeTaxRateReconciliationPermanentDifferences": {
     "auth_ref": [],
     "calculation": {
      "http://www.gaintherapeutics.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations attributable to permanent differences.",
        "label": "Effective Income Tax Rate Reconciliation, Permanent Differences",
        "terseLabel": "Permanent differences"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationPermanentDifferences",
     "nsuri": "http://www.gaintherapeutics.com/20211231",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ganx_EffectiveIncomeTaxRateReconciliationProvisionToReturn": {
     "auth_ref": [],
     "calculation": {
      "http://www.gaintherapeutics.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations attributable to provision to return.",
        "label": "Effective Income Tax Rate Reconciliation, Provision to Return",
        "terseLabel": "Provision to return"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationProvisionToReturn",
     "nsuri": "http://www.gaintherapeutics.com/20211231",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ganx_EquipmentAndFurnitureMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Equipment &amp; Furniture.",
        "label": "Equipment and Furniture"
       }
      }
     },
     "localname": "EquipmentAndFurnitureMember",
     "nsuri": "http://www.gaintherapeutics.com/20211231",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ganx_Eurostars2Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Eurostars-2",
        "label": "Eurostars 2 [Member]",
        "terseLabel": "Eurostars-2"
       }
      }
     },
     "localname": "Eurostars2Member",
     "nsuri": "http://www.gaintherapeutics.com/20211231",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureResearchGrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ganx_ExercisePrice10.03Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to exercise price 10.03.",
        "label": "$10.03"
       }
      }
     },
     "localname": "ExercisePrice10.03Member",
     "nsuri": "http://www.gaintherapeutics.com/20211231",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureEquityIncentivePlanOptionsOutstandingAndExercisableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ganx_ExercisePrice3.38Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to exercise price 3.38.",
        "label": "$3.38"
       }
      }
     },
     "localname": "ExercisePrice3.38Member",
     "nsuri": "http://www.gaintherapeutics.com/20211231",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureEquityIncentivePlanOptionsOutstandingAndExercisableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ganx_ExercisePrice5.86Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to exercise price 5.86.",
        "label": "$5.86"
       }
      }
     },
     "localname": "ExercisePrice5.86Member",
     "nsuri": "http://www.gaintherapeutics.com/20211231",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureEquityIncentivePlanOptionsOutstandingAndExercisableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ganx_ExercisePrice5.99Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to exercise price 5.99.",
        "label": "$5.99"
       }
      }
     },
     "localname": "ExercisePrice5.99Member",
     "nsuri": "http://www.gaintherapeutics.com/20211231",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureEquityIncentivePlanOptionsOutstandingAndExercisableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ganx_ExercisePrice7.80Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price 7.80",
        "label": "$7.80"
       }
      }
     },
     "localname": "ExercisePrice7.80Member",
     "nsuri": "http://www.gaintherapeutics.com/20211231",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureEquityIncentivePlanOptionsOutstandingAndExercisableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ganx_ExpenseForInterestAndPenaltiesRelatedToUncertainTaxPositionRecognizedInStatementOfOperations": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expense for interest and penalties related to uncertain tax position, recognized in statement of operations",
        "label": "Expense for interest and penalties related to uncertain tax position, recognized in statement of operations"
       }
      }
     },
     "localname": "ExpenseForInterestAndPenaltiesRelatedToUncertainTaxPositionRecognizedInStatementOfOperations",
     "nsuri": "http://www.gaintherapeutics.com/20211231",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureIncomeTaxesAdditionalDisclosuresDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ganx_ExpensesOrChargesDueForEarlyExtinguishmentOfDebt": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expenses or charges due for early extinguishment of debt",
        "label": "Expenses or charges due for early extinguishment of debt"
       }
      }
     },
     "localname": "ExpensesOrChargesDueForEarlyExtinguishmentOfDebt",
     "nsuri": "http://www.gaintherapeutics.com/20211231",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureLoansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ganx_GrossProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity, before deduction of offering expenses",
        "label": "Gross proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds before deduction of offering expenses"
       }
      }
     },
     "localname": "GrossProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://www.gaintherapeutics.com/20211231",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureNatureOfBusinessAndBasisOfPresentationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ganx_GtGainTherapeuticsSaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to GT Gain Therapeutics SA",
        "label": "GT Gain Therapeutics SA [Member]",
        "terseLabel": "GT Gain Therapeutics SA"
       }
      }
     },
     "localname": "GtGainTherapeuticsSaMember",
     "nsuri": "http://www.gaintherapeutics.com/20211231",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureResearchGrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ganx_IncomeLossForPeriod": {
     "auth_ref": [],
     "calculation": {
      "http://www.gaintherapeutics.com/role/StatementConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current period income or loss.",
        "label": "Income Loss For The Period",
        "terseLabel": "Loss of the period"
       }
      }
     },
     "localname": "IncomeLossForPeriod",
     "nsuri": "http://www.gaintherapeutics.com/20211231",
     "presentation": [
      "http://www.gaintherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ganx_IncreaseDecreaseInAccumulatedOtherComprehensiveIncomeToReconcileFundedStatusOfDefinedBenefitPlan": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (decrease) in accumulated other comprehensive income to reconcile funded status of defined benefit plan",
        "label": "Increase (decrease) in accumulated other comprehensive income to reconcile funded status of defined benefit plan",
        "negatedLabel": "Change in AOCI over the year"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccumulatedOtherComprehensiveIncomeToReconcileFundedStatusOfDefinedBenefitPlan",
     "nsuri": "http://www.gaintherapeutics.com/20211231",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosurePensionObligationsReconciliationOfFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ganx_IncreaseDecreaseInOperatingAssetsAndLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) in Operating Assets and Liabilities.",
        "label": "Increase (Decrease) in Operating Assets and Liabilities",
        "negatedTotalLabel": "Total changes in operating assets and liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingAssetsAndLiabilities",
     "nsuri": "http://www.gaintherapeutics.com/20211231",
     "presentation": [
      "http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ganx_IncreaseDecreaseInValueAddedTaxCredits": {
     "auth_ref": [],
     "calculation": {
      "http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfCashFlows": {
       "order": 6.0,
       "parentTag": "ganx_IncreaseDecreaseInOperatingAssetsAndLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in value-added tax credits",
        "label": "Increase (Decrease) in value-added tax credits",
        "negatedLabel": "VAT credits"
       }
      }
     },
     "localname": "IncreaseDecreaseInValueAddedTaxCredits",
     "nsuri": "http://www.gaintherapeutics.com/20211231",
     "presentation": [
      "http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ganx_IncreaseDecreaseThroughTotalExpensesToReconcileFundedStatusOfDefinedBenefitPlan": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (decrease) through total expenses to reconcile funded status of defined benefit plan",
        "label": "Increase (decrease) through total expenses to reconcile funded status of defined benefit plan",
        "negatedLabel": "Expense"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughTotalExpensesToReconcileFundedStatusOfDefinedBenefitPlan",
     "nsuri": "http://www.gaintherapeutics.com/20211231",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosurePensionObligationsReconciliationOfFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ganx_InitialPublicOfferingPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for initial public offering.",
        "label": "Initial Public Offering [Policy Text Block]",
        "terseLabel": "Initial Public Offering"
       }
      }
     },
     "localname": "InitialPublicOfferingPolicyTextBlock",
     "nsuri": "http://www.gaintherapeutics.com/20211231",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ganx_IpoExcludingUnderwritersOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First sale of stock by a private company to the public excluding underwriters' options",
        "label": "IPO excluding underwriters' options [Member]",
        "terseLabel": "IPO excluding underwriters' options"
       }
      }
     },
     "localname": "IpoExcludingUnderwritersOptionsMember",
     "nsuri": "http://www.gaintherapeutics.com/20211231",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureNatureOfBusinessAndBasisOfPresentationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ganx_IssuanceOfCommonStockInIpoInShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase in shares issued resulting from the company's initial public offering.",
        "label": "Issuance of Common Stock in IPO (In shares)"
       }
      }
     },
     "localname": "IssuanceOfCommonStockInIpoInShares",
     "nsuri": "http://www.gaintherapeutics.com/20211231",
     "presentation": [
      "http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "ganx_IssuanceOfCommonStockInIpoNetOfIssuanceCosts": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) in equity from the issuance of common stock in initial public offering, net of issuance costs.",
        "label": "Issuance of Common Stock in IPO, net of issuance costs"
       }
      }
     },
     "localname": "IssuanceOfCommonStockInIpoNetOfIssuanceCosts",
     "nsuri": "http://www.gaintherapeutics.com/20211231",
     "presentation": [
      "http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ganx_IssuanceOfCommonStockThroughCashlessExerciseOfWarrants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of common stock through cashless exercise of warrants",
        "label": "Issuance of common stock through cashless exercise of warrants",
        "terseLabel": "Issuance of Common Stock due to warrants cashless exercise"
       }
      }
     },
     "localname": "IssuanceOfCommonStockThroughCashlessExerciseOfWarrants",
     "nsuri": "http://www.gaintherapeutics.com/20211231",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureWarrantsDetails",
      "http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "ganx_IssuanceOfSeriesBPreferredStockInShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase in number of shares resulting from issuance of Series B Preferred Stock.",
        "label": "Issuance of Series B Preferred Stock (in shares)"
       }
      }
     },
     "localname": "IssuanceOfSeriesBPreferredStockInShares",
     "nsuri": "http://www.gaintherapeutics.com/20211231",
     "presentation": [
      "http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "ganx_IssuanceOfSeriesBPreferredStockNetOfIssuanceCost": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) in equity resulting from the issuance of Series B Preferred Stock, net of issuance cost.",
        "label": "Issuance of Series B Preferred Stock, net of issuance cost"
       }
      }
     },
     "localname": "IssuanceOfSeriesBPreferredStockNetOfIssuanceCost",
     "nsuri": "http://www.gaintherapeutics.com/20211231",
     "presentation": [
      "http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ganx_IssuanceOfSeriesPreferredStockInShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase in number of shares resulting from issuance of Series A Preferred Stock.",
        "label": "Issuance of Series A Preferred Stock (in shares)"
       }
      }
     },
     "localname": "IssuanceOfSeriesPreferredStockInShares",
     "nsuri": "http://www.gaintherapeutics.com/20211231",
     "presentation": [
      "http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "ganx_IssuanceOfSeriesPreferredStockNetOfIssuanceCost": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) in equity resulting from the issuance of Series A Preferred Stock, net of issuance cost.",
        "label": "Issuance of Series A Preferred Stock, net of issuance cost"
       }
      }
     },
     "localname": "IssuanceOfSeriesPreferredStockNetOfIssuanceCost",
     "nsuri": "http://www.gaintherapeutics.com/20211231",
     "presentation": [
      "http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ganx_LaboratoryInstrumentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Laboratory instruments.",
        "label": "Laboratory instruments"
       }
      }
     },
     "localname": "LaboratoryInstrumentsMember",
     "nsuri": "http://www.gaintherapeutics.com/20211231",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosurePropertyAndEquipmentNetDetails",
      "http://www.gaintherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ganx_LesseeOperatingLeaseTermOfCancelledContract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's cancelled operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, term of cancelled contract"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfCancelledContract",
     "nsuri": "http://www.gaintherapeutics.com/20211231",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureOperatingLeaseRightOfUseRouAssetsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ganx_LicenseAgreementWithMinoryxTherapeuticsSlMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to license agreement with Minoryx Therapeutics SL.",
        "label": "License agreement Minoryx Therapeutics SL"
       }
      }
     },
     "localname": "LicenseAgreementWithMinoryxTherapeuticsSlMember",
     "nsuri": "http://www.gaintherapeutics.com/20211231",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureRelatedPartiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ganx_March2020ChfLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "March 2020 CHF loan",
        "label": "March 2020 CHF loan"
       }
      }
     },
     "localname": "March2020ChfLoanMember",
     "nsuri": "http://www.gaintherapeutics.com/20211231",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureLoansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ganx_MichaelJ.FoxFoundationForParkinsonSResearchMjffMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to The Michael J. Fox Foundation for Parkinson's Research (MJFF)",
        "label": "The Michael J. Fox Foundation for Parkinson's Research (MJFF) [Member]",
        "terseLabel": "The Michael J. Fox Foundation for Parkinson's Research (MJFF)"
       }
      }
     },
     "localname": "MichaelJ.FoxFoundationForParkinsonSResearchMjffMember",
     "nsuri": "http://www.gaintherapeutics.com/20211231",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureResearchGrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ganx_MultiTargetCollaborationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information relating to Multi-target collaboration agreement.",
        "label": "Multi-target collaboration agreement"
       }
      }
     },
     "localname": "MultiTargetCollaborationAgreementMember",
     "nsuri": "http://www.gaintherapeutics.com/20211231",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureCollaborationAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ganx_NumberOfOptionsSubjectToTermThreshold": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of options subject to the term threshold.",
        "label": "Number Of Options Subject To Term Threshold",
        "terseLabel": "Number of options subject to term threshold"
       }
      }
     },
     "localname": "NumberOfOptionsSubjectToTermThreshold",
     "nsuri": "http://www.gaintherapeutics.com/20211231",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureEquityIncentivePlanDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ganx_OfficeSpace": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Office space, measured as an area",
        "label": "Office space"
       }
      }
     },
     "localname": "OfficeSpace",
     "nsuri": "http://www.gaintherapeutics.com/20211231",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureOperatingLeaseRightOfUseRouAssetsAdditionalInformationDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "ganx_OfficeSpaceInBethesdaMarylandMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Office space in Bethesda, Maryland",
        "label": "Office space in Bethesda, Maryland [Member]",
        "terseLabel": "Office space in Bethesda, Maryland"
       }
      }
     },
     "localname": "OfficeSpaceInBethesdaMarylandMember",
     "nsuri": "http://www.gaintherapeutics.com/20211231",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureOperatingLeaseRightOfUseRouAssetsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ganx_OfficeSpaceTorreDBuildingBarcelonaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Office space, Torre D building (Barcelona)",
        "label": "Office space, Torre D building (Barcelona) [Member]",
        "terseLabel": "Office space, Torre D building (Barcelona)"
       }
      }
     },
     "localname": "OfficeSpaceTorreDBuildingBarcelonaMember",
     "nsuri": "http://www.gaintherapeutics.com/20211231",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureOperatingLeaseRightOfUseRouAssetsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ganx_OfficeSpaceTorreIBuildingBarcelonaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Office space, Torre I building (Barcelona)",
        "label": "Office space, Torre I building (Barcelona) [Member]",
        "terseLabel": "Office space, Torre I building (Barcelona)"
       }
      }
     },
     "localname": "OfficeSpaceTorreIBuildingBarcelonaMember",
     "nsuri": "http://www.gaintherapeutics.com/20211231",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureOperatingLeaseRightOfUseRouAssetsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ganx_OfficeSpaceViaPietroPeri9DLuganoSwitzerlandMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Office space, Via Pietro Peri, 9D (Lugano, Switzerland)",
        "label": "Office Space Via Pietro Peri 9 D Lugano Switzerland [Member]",
        "terseLabel": "Office Space Via Pietro Peri 9 D (Lugano Switzerland)"
       }
      }
     },
     "localname": "OfficeSpaceViaPietroPeri9DLuganoSwitzerlandMember",
     "nsuri": "http://www.gaintherapeutics.com/20211231",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureOperatingLeaseRightOfUseRouAssetsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ganx_OfficeSpaceViaSoaveN6LuganoSwitzerlandMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Office space, Via Soave n6 (Lugano, Switzerland)",
        "label": "Office space, Via Soave n6 (Lugano, Switzerland) [Member]",
        "terseLabel": "Office space, Via Soave n6 (Lugano, Switzerland)"
       }
      }
     },
     "localname": "OfficeSpaceViaSoaveN6LuganoSwitzerlandMember",
     "nsuri": "http://www.gaintherapeutics.com/20211231",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureOperatingLeaseRightOfUseRouAssetsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ganx_OmnibusIncentivePlanTwoThousandTwentyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Omnibus Incentive Plan 2020.",
        "label": "2020 Omnibus Plan"
       }
      }
     },
     "localname": "OmnibusIncentivePlanTwoThousandTwentyMember",
     "nsuri": "http://www.gaintherapeutics.com/20211231",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureEquityIncentivePlanAssumptionsDetails",
      "http://www.gaintherapeutics.com/role/DisclosureEquityIncentivePlanDetails",
      "http://www.gaintherapeutics.com/role/DisclosureEquityIncentivePlanOptionsOutstandingAndExercisableDetails",
      "http://www.gaintherapeutics.com/role/DisclosureEquityIncentivePlanStockBasedCompensationDetails",
      "http://www.gaintherapeutics.com/role/DisclosureEquityIncentivePlanStockOptionActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ganx_OtherCurrentLiabilitiesAndDeferredIncomeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for other current liabilities and deferred income.",
        "label": "Other Current Liabilities and Deferred Income [Table Text Block]",
        "verboseLabel": "Schedule of Other current liabilities and deferred income"
       }
      }
     },
     "localname": "OtherCurrentLiabilitiesAndDeferredIncomeTableTextBlock",
     "nsuri": "http://www.gaintherapeutics.com/20211231",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureOtherCurrentLiabilitiesAndDeferredIncomeTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ganx_OtherCurrentLiabilitiesAndDeferredIncomeTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for other current liabilities and deferred income.",
        "label": "Other Current Liabilities and Deferred Income [Text Block]",
        "verboseLabel": "Other current liabilities and deferred income"
       }
      }
     },
     "localname": "OtherCurrentLiabilitiesAndDeferredIncomeTextBlock",
     "nsuri": "http://www.gaintherapeutics.com/20211231",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureOtherCurrentLiabilitiesAndDeferredIncome"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ganx_OtherInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Other Information"
       }
      }
     },
     "localname": "OtherInformationAbstract",
     "nsuri": "http://www.gaintherapeutics.com/20211231",
     "xbrltype": "stringItemType"
    },
    "ganx_OtherInformationDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of information pertaining to other information.",
        "label": "Other Information Disclosure [Text Block]",
        "terseLabel": "Other Information"
       }
      }
     },
     "localname": "OtherInformationDisclosureTextBlock",
     "nsuri": "http://www.gaintherapeutics.com/20211231",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureOtherInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ganx_OtherOfferingExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of other offering expense incurred during the reporting period.",
        "label": "Other Offering Expenses"
       }
      }
     },
     "localname": "OtherOfferingExpenses",
     "nsuri": "http://www.gaintherapeutics.com/20211231",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureNatureOfBusinessAndBasisOfPresentationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ganx_PayableForSocialSecuritiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.gaintherapeutics.com/role/DisclosureOtherCurrentLiabilitiesAndDeferredIncomeDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for current portion of payable for social securities.",
        "label": "Payable for Social Securities, Current",
        "verboseLabel": "Payable for social securities"
       }
      }
     },
     "localname": "PayableForSocialSecuritiesCurrent",
     "nsuri": "http://www.gaintherapeutics.com/20211231",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureOtherCurrentLiabilitiesAndDeferredIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ganx_PayablesForSocialSecuritiesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for payables for social securities.",
        "label": "Payables for Social Securities Policy [Text Block]",
        "terseLabel": "Payables for Social Securities"
       }
      }
     },
     "localname": "PayablesForSocialSecuritiesPolicyTextBlock",
     "nsuri": "http://www.gaintherapeutics.com/20211231",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ganx_PreferredStockSeriesAndSeriesBMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Preferred stock Series A and Series B",
        "label": "Preferred stock Series A and Series B [Member]",
        "terseLabel": "Preferred stock Series A and Series B"
       }
      }
     },
     "localname": "PreferredStockSeriesAndSeriesBMember",
     "nsuri": "http://www.gaintherapeutics.com/20211231",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureNatureOfBusinessAndBasisOfPresentationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ganx_PreferredStockToCommonStockConversionRatio": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The conversion ratio for conversion of preferred stock to common stock.",
        "label": "Preferred stock to common stock conversion ratio"
       }
      }
     },
     "localname": "PreferredStockToCommonStockConversionRatio",
     "nsuri": "http://www.gaintherapeutics.com/20211231",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureCommonAndPreferredStockDetails",
      "http://www.gaintherapeutics.com/role/DisclosureNatureOfBusinessAndBasisOfPresentationDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "ganx_PrepaidExpensesAndOtherCurrentAssetsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for Prepaid expenses and other current assets.",
        "label": "Prepaid Expenses and Other Current Assets [Text Block]",
        "verboseLabel": "Other Current Assets"
       }
      }
     },
     "localname": "PrepaidExpensesAndOtherCurrentAssetsTextBlock",
     "nsuri": "http://www.gaintherapeutics.com/20211231",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureOtherCurrentAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ganx_ProceedsFromGrants": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from grants",
        "label": "Proceeds from grants"
       }
      }
     },
     "localname": "ProceedsFromGrants",
     "nsuri": "http://www.gaintherapeutics.com/20211231",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureResearchGrantsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ganx_ProceedsFromIssuanceOfSeriesA.PreferredStockNetOfIssuanceCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from issuance of Series A Preferred Stock, net of issuance costs",
        "label": "Proceeds from issuance of Series A. Preferred Stock, net of issuance costs",
        "terseLabel": "Proceeds from issuance of Series A Preferred Stock, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSeriesA.PreferredStockNetOfIssuanceCosts",
     "nsuri": "http://www.gaintherapeutics.com/20211231",
     "presentation": [
      "http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ganx_ProceedsFromIssuanceOfSeriesBPreferredStockNetOfIssuanceCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from issuance of Series B Preferred Stock, net of issuance costs",
        "label": "Proceeds from issuance of Series B Preferred Stock, net of issuance costs",
        "terseLabel": "Proceeds from issuance of Series B Preferred Stock, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSeriesBPreferredStockNetOfIssuanceCosts",
     "nsuri": "http://www.gaintherapeutics.com/20211231",
     "presentation": [
      "http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ganx_PropertyPlantAndEquipmentDepreciationRates": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of depreciation on property plant and equipment.",
        "label": "Property Plant and Equipment, Depreciation Rates",
        "terseLabel": "Depreciation rates (as a percent)"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDepreciationRates",
     "nsuri": "http://www.gaintherapeutics.com/20211231",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalDisclosuresDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ganx_ReductionOfResearchAndDevelopmentExpensesThroughExpensesReimbursed": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The reduction of research and development expenses through expenses reimbursed",
        "label": "Reduction of research and development expenses through expenses reimbursed"
       }
      }
     },
     "localname": "ReductionOfResearchAndDevelopmentExpensesThroughExpensesReimbursed",
     "nsuri": "http://www.gaintherapeutics.com/20211231",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureResearchGrantsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ganx_RelatedPartyTransactionPercentageOfConsiderationReceived": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of consideration received in the event of a sale of the Company or substantially all of the assets, including by merger, change of control, or reorganization.",
        "label": "Related Party Transaction, Percentage of Consideration Received",
        "verboseLabel": "Percentage of consideration received"
       }
      }
     },
     "localname": "RelatedPartyTransactionPercentageOfConsiderationReceived",
     "nsuri": "http://www.gaintherapeutics.com/20211231",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureRelatedPartiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ganx_RelatedPartyTransactionPercentageOfNetRevenuesBasedOnOneCompositionOfMatterClaim": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of revenues that would infringe at least one composition of matter claim.",
        "label": "Related Party Transaction, Percentage of Net Revenues, Based on One Composition of Matter Claim",
        "verboseLabel": "Percentage of net revenue based on one composition matter"
       }
      }
     },
     "localname": "RelatedPartyTransactionPercentageOfNetRevenuesBasedOnOneCompositionOfMatterClaim",
     "nsuri": "http://www.gaintherapeutics.com/20211231",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureRelatedPartiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ganx_RelatedPartyTransactionPercentageOfNetRevenuesBasedOnOneMethodOfClaim": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of revenues that would infringe at least one method of matter claim.",
        "label": "Related Party Transaction, Percentage of Net Revenues, Based on One Method of Claim",
        "verboseLabel": "Percentage of net revenue based on one method of claim"
       }
      }
     },
     "localname": "RelatedPartyTransactionPercentageOfNetRevenuesBasedOnOneMethodOfClaim",
     "nsuri": "http://www.gaintherapeutics.com/20211231",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureRelatedPartiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ganx_ResearchGrantsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information pertaining to research grants.",
        "label": "Research Grants"
       }
      }
     },
     "localname": "ResearchGrantsAbstract",
     "nsuri": "http://www.gaintherapeutics.com/20211231",
     "xbrltype": "stringItemType"
    },
    "ganx_ResearchGrantsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of information pertaining to research grants.",
        "label": "Research Grants Disclosure [Text Block]",
        "terseLabel": "Research Grants"
       }
      }
     },
     "localname": "ResearchGrantsDisclosureTextBlock",
     "nsuri": "http://www.gaintherapeutics.com/20211231",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureResearchGrants"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ganx_ResearchGrantsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy research grants.",
        "label": "Research Grants Policy [Policy Text Block]",
        "terseLabel": "Research grants"
       }
      }
     },
     "localname": "ResearchGrantsPolicyPolicyTextBlock",
     "nsuri": "http://www.gaintherapeutics.com/20211231",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ganx_ReverseStockSplitPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for reverse stock split.",
        "label": "Reverse Stock Split Policy [Policy Text Block]",
        "terseLabel": "Reverse Stock Split"
       }
      }
     },
     "localname": "ReverseStockSplitPolicyPolicyTextBlock",
     "nsuri": "http://www.gaintherapeutics.com/20211231",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ganx_ScheduleOfCashAndCashEquivalentsBalancesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cash and cash equivalents balances.",
        "label": "Schedule of Cash And cash Equivalents Balances [Table Text Block]",
        "terseLabel": "Schedule of cash and cash equivalents balances broken down by currency"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsBalancesTableTextBlock",
     "nsuri": "http://www.gaintherapeutics.com/20211231",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureCashCashEquivalentsAndRestrictedCashTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ganx_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for Prepaid expenses and other current assets.",
        "label": "Schedule of Prepaid Expenses and Other Current Assets [Table Text Block]",
        "verboseLabel": "Schedule of Other Current Assets"
       }
      }
     },
     "localname": "ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
     "nsuri": "http://www.gaintherapeutics.com/20211231",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureOtherCurrentAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ganx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionNonvestedWeightedAverageExercisePriceAfterStockSplit": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average grant-date fair value of non-vested options outstanding after stock split.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price, after stock split",
        "terseLabel": "Weighted Average Grant Date Fair Value, options outstanding after stock split"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionNonvestedWeightedAverageExercisePriceAfterStockSplit",
     "nsuri": "http://www.gaintherapeutics.com/20211231",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureEquityIncentivePlanStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ganx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedDuringPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options exercised during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, exercised during the period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted Average Grant Date Fair Value, options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedDuringPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://www.gaintherapeutics.com/20211231",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureEquityIncentivePlanStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ganx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards granted, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Granted, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Contractual Years Options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm",
     "nsuri": "http://www.gaintherapeutics.com/20211231",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureEquityIncentivePlanStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ganx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAfterStockSplitWeightedAverageRemainingContractualTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding after stock splits, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, After Stock Split Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Contractual Years Outstanding Options outstanding after stock splits"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAfterStockSplitWeightedAverageRemainingContractualTerm",
     "nsuri": "http://www.gaintherapeutics.com/20211231",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureEquityIncentivePlanStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ganx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAfterStockSplitsNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding after stock split, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, After Stock Splits Number",
        "terseLabel": "Options outstanding after stock splits (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAfterStockSplitsNumber",
     "nsuri": "http://www.gaintherapeutics.com/20211231",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureEquityIncentivePlanStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ganx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAfterStockSplitsWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance after stock split under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, After Stock Splits Weighted Average Exercise Price",
        "terseLabel": "Options outstanding after stock splits (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAfterStockSplitsWeightedAverageExercisePrice",
     "nsuri": "http://www.gaintherapeutics.com/20211231",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureEquityIncentivePlanStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ganx_TwentyTwentyoneInducementEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to the 2021 Inducement Equity Incentive Plan",
        "label": "Twenty-twentyone Inducement Equity Incentive Plan [Member]",
        "terseLabel": "2021 Inducement Equity Incentive Plan"
       }
      }
     },
     "localname": "TwentyTwentyoneInducementEquityIncentivePlanMember",
     "nsuri": "http://www.gaintherapeutics.com/20211231",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureEquityIncentivePlanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ganx_UncertainTaxPositionsRecognized": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value of uncertain tax positions that the entity has recognized.",
        "label": "Uncertain tax positions recognized"
       }
      }
     },
     "localname": "UncertainTaxPositionsRecognized",
     "nsuri": "http://www.gaintherapeutics.com/20211231",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalDisclosuresDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ganx_UnderwritingDiscountsAndCommissions": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of underwriting discount and commission incurred during the reporting period.",
        "label": "Underwriting Discounts and Commissions"
       }
      }
     },
     "localname": "UnderwritingDiscountsAndCommissions",
     "nsuri": "http://www.gaintherapeutics.com/20211231",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureNatureOfBusinessAndBasisOfPresentationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ganx_WarrantsAndRightsExercisedOrExchangedNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights exercised or exchanged.",
        "label": "Warrants and Rights, Exercised or Exchanged, Number",
        "terseLabel": "Warrants exercised or exchanged"
       }
      }
     },
     "localname": "WarrantsAndRightsExercisedOrExchangedNumber",
     "nsuri": "http://www.gaintherapeutics.com/20211231",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ganx_WarrantsAndRightsNoteDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entire disclosure of warrant and rights.",
        "label": "Warrants and Rights Note Disclosure [Text Block]",
        "terseLabel": "Warrants"
       }
      }
     },
     "localname": "WarrantsAndRightsNoteDisclosureTextBlock",
     "nsuri": "http://www.gaintherapeutics.com/20211231",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureWarrants"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ganx_WarrantsAndRightsServicePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Service period for fair value of the warrants to be recognized.",
        "label": "Warrants and Rights, Service Period",
        "terseLabel": "Warrants, Service period"
       }
      }
     },
     "localname": "WarrantsAndRightsServicePeriod",
     "nsuri": "http://www.gaintherapeutics.com/20211231",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureWarrantsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ganx_WarrantsGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The grant date fair value of warrants granted during period.",
        "label": "Warrants, grant date fair value",
        "terseLabel": "Grant date fair value"
       }
      }
     },
     "localname": "WarrantsGrantDateFairValue",
     "nsuri": "http://www.gaintherapeutics.com/20211231",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureWarrantsAssumptionsUnderBlackScholesPricingModelDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ganx_WarrantsToDesigneesOfInvestmentBankIssuedMay2021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants to designees of investment bank, issued May 2021",
        "label": "Warrants to designees of investment bank, issued May 2021"
       }
      }
     },
     "localname": "WarrantsToDesigneesOfInvestmentBankIssuedMay2021Member",
     "nsuri": "http://www.gaintherapeutics.com/20211231",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ganx_WarrantsToDesigneesOfPlacementAgentIssuedJuly2020Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants to designees of the placement agent, issued July 2020",
        "label": "Warrants to designees of the placement agent, issued July 2020"
       }
      }
     },
     "localname": "WarrantsToDesigneesOfPlacementAgentIssuedJuly2020Member",
     "nsuri": "http://www.gaintherapeutics.com/20211231",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ganx_ZentalisPharmaceuticalsInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information relating to Zentalis Pharmaceuticals, Inc.",
        "label": "Zentalis Pharmaceuticals, Inc."
       }
      }
     },
     "localname": "ZentalisPharmaceuticalsInc.Member",
     "nsuri": "http://www.gaintherapeutics.com/20211231",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureCollaborationAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r64",
      "r66",
      "r120",
      "r121",
      "r241",
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureCollaborationAgreementDetails",
      "http://www.gaintherapeutics.com/role/DisclosureResearchGrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CurrencyAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Currency [Axis]"
       }
      }
     },
     "localname": "CurrencyAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureAccountsPayableDetails",
      "http://www.gaintherapeutics.com/role/DisclosureCashCashEquivalentsAndRestrictedCashScheduleOfCashAndCashEquivalentsBalancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r240",
      "r277",
      "r416",
      "r421",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r625",
      "r627",
      "r653",
      "r654"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureCollaborationAgreementDetails",
      "http://www.gaintherapeutics.com/role/DisclosureEquityIncentivePlanDetails",
      "http://www.gaintherapeutics.com/role/DisclosureOperatingLeaseRightOfUseRouAssetsAdditionalInformationDetails",
      "http://www.gaintherapeutics.com/role/DisclosureRelatedPartiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r240",
      "r277",
      "r416",
      "r421",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r625",
      "r627",
      "r653",
      "r654"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureOperatingLeaseRightOfUseRouAssetsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r240",
      "r277",
      "r352",
      "r416",
      "r421",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r625",
      "r627",
      "r653",
      "r654"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureCollaborationAgreementDetails",
      "http://www.gaintherapeutics.com/role/DisclosureEquityIncentivePlanDetails",
      "http://www.gaintherapeutics.com/role/DisclosureOperatingLeaseRightOfUseRouAssetsAdditionalInformationDetails",
      "http://www.gaintherapeutics.com/role/DisclosureRelatedPartiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r240",
      "r277",
      "r352",
      "r416",
      "r421",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r625",
      "r627",
      "r653",
      "r654"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureCollaborationAgreementDetails",
      "http://www.gaintherapeutics.com/role/DisclosureEquityIncentivePlanDetails",
      "http://www.gaintherapeutics.com/role/DisclosureOperatingLeaseRightOfUseRouAssetsAdditionalInformationDetails",
      "http://www.gaintherapeutics.com/role/DisclosureRelatedPartiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r65",
      "r66",
      "r120",
      "r121",
      "r241",
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureCollaborationAgreementDetails",
      "http://www.gaintherapeutics.com/role/DisclosureResearchGrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RestatementAxis": {
     "auth_ref": [
      "r1",
      "r124",
      "r125",
      "r126",
      "r127",
      "r128",
      "r129",
      "r130",
      "r131",
      "r132",
      "r134",
      "r135",
      "r136",
      "r137",
      "r138",
      "r139",
      "r152",
      "r198",
      "r199",
      "r455",
      "r484",
      "r514",
      "r515",
      "r516",
      "r517",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r668",
      "r669"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period [Axis]"
       }
      }
     },
     "localname": "RestatementAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureNetLossPerCommonShareComputationOfDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RestatementDomain": {
     "auth_ref": [
      "r1",
      "r124",
      "r125",
      "r126",
      "r127",
      "r128",
      "r129",
      "r130",
      "r131",
      "r132",
      "r134",
      "r135",
      "r136",
      "r137",
      "r138",
      "r139",
      "r152",
      "r198",
      "r199",
      "r455",
      "r484",
      "r514",
      "r515",
      "r516",
      "r517",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r668",
      "r669"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period [Domain]"
       }
      }
     },
     "localname": "RestatementDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureNetLossPerCommonShareComputationOfDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioPreviouslyReportedMember": {
     "auth_ref": [
      "r1",
      "r124",
      "r126",
      "r127",
      "r128",
      "r129",
      "r130",
      "r131",
      "r132",
      "r134",
      "r135",
      "r137",
      "r138",
      "r152",
      "r198",
      "r199",
      "r455",
      "r484",
      "r514",
      "r515",
      "r516",
      "r517",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r668",
      "r669"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Previously Reported [Member]",
        "verboseLabel": "Previously reported"
       }
      }
     },
     "localname": "ScenarioPreviouslyReportedMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureNetLossPerCommonShareComputationOfDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r190",
      "r191",
      "r314",
      "r317",
      "r626",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureIncomeTaxesAdditionalDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r190",
      "r191",
      "r314",
      "r317",
      "r626",
      "r639",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureIncomeTaxesAdditionalDisclosuresDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.",
        "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]",
        "verboseLabel": "Accounts Payable"
       }
      }
     },
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureAccountsPayable"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r52",
      "r571"
     ],
     "calculation": {
      "http://www.gaintherapeutics.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable",
        "verboseLabel": "Accounts Payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureAccountsPayableDetails",
      "http://www.gaintherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable"
       }
      }
     },
     "localname": "AccountsPayableCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r119",
      "r564",
      "r598",
      "r619"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount for accounts payable to related parties.",
        "label": "Accounts Payable, Related Parties",
        "verboseLabel": "Payables"
       }
      }
     },
     "localname": "AccountsPayableRelatedPartiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureRelatedPartiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r5",
      "r37",
      "r193",
      "r194"
     ],
     "calculation": {
      "http://www.gaintherapeutics.com/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable",
        "verboseLabel": "Recorded receivables"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureCollaborationAgreementDetails",
      "http://www.gaintherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableRelatedParties": {
     "auth_ref": [
      "r36",
      "r119",
      "r564",
      "r566",
      "r617"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an unclassified balance sheet, amount of receivables arising from transactions with related parties.",
        "label": "Accounts Receivable, Related Parties",
        "verboseLabel": "Receivables"
       }
      }
     },
     "localname": "AccountsReceivableRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureRelatedPartiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://www.gaintherapeutics.com/role/DisclosureOtherCurrentLiabilitiesAndDeferredIncomeDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "verboseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureOtherCurrentLiabilitiesAndDeferredIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r49",
      "r214"
     ],
     "calculation": {
      "http://www.gaintherapeutics.com/role/DisclosurePropertyAndEquipmentNetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less: accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosurePropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax": {
     "auth_ref": [
      "r68",
      "r73",
      "r373"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax, of accumulated other comprehensive (income) loss for defined benefit plan, that has not been recognized in net periodic benefit cost (credit).",
        "label": "Accumulated Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax",
        "periodEndLabel": "Total AOCI at end of year",
        "periodStartLabel": "AOCI at beginning of year"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosurePensionObligationsChangeInAccumulatedOtherComprehensiveIncomeAociDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r67",
      "r71",
      "r72",
      "r73",
      "r525"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated adjustment, net of tax, that results from the process of translating subsidiary financial statements and foreign equity investments into the reporting currency from the functional currency of the reporting entity, net of reclassification of realized foreign currency translation gains or losses.",
        "label": "Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax",
        "terseLabel": "Accumulated currency translation adjustments"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r40",
      "r71",
      "r72",
      "r73",
      "r614",
      "r633",
      "r637"
     ],
     "calculation": {
      "http://www.gaintherapeutics.com/role/StatementConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r70",
      "r73",
      "r81",
      "r82",
      "r83",
      "r124",
      "r125",
      "r126",
      "r508",
      "r628",
      "r629",
      "r669"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r38",
      "r455",
      "r571"
     ],
     "calculation": {
      "http://www.gaintherapeutics.com/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r124",
      "r125",
      "r126",
      "r452",
      "r453",
      "r454",
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "APIC"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r423",
      "r425",
      "r458",
      "r459"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "auth_ref": [
      "r236",
      "r291",
      "r298"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.",
        "label": "Adjustments to Additional Paid in Capital, Warrant Issued",
        "terseLabel": "Issuance of warrants"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r425",
      "r448",
      "r457"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Total stock-based compensation"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureEquityIncentivePlanStockBasedCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r149"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "verboseLabel": "Antidilutive securities excluded from computation of diluted net loss per share attributable to common stockholders (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureNetLossPerCommonShareComputationOfDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r149"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureNetLossPerCommonShareComputationOfDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Net loss per common share"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureNetLossPerCommonShareComputationOfDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r149"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureNetLossPerCommonShareComputationOfDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureCollaborationAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetImpairmentCharges": {
     "auth_ref": [
      "r102",
      "r211"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.",
        "label": "Asset Impairment Charges",
        "terseLabel": "Impairments of long-lived assets"
       }
      }
     },
     "localname": "AssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalDisclosuresDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r114",
      "r172",
      "r181",
      "r187",
      "r196",
      "r223",
      "r224",
      "r225",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r234",
      "r235",
      "r503",
      "r509",
      "r526",
      "r569",
      "r571",
      "r593",
      "r611"
     ],
     "calculation": {
      "http://www.gaintherapeutics.com/role/StatementConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r8",
      "r10",
      "r63",
      "r114",
      "r196",
      "r223",
      "r224",
      "r225",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r234",
      "r235",
      "r503",
      "r509",
      "r526",
      "r569",
      "r571"
     ],
     "calculation": {
      "http://www.gaintherapeutics.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r518"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureFairValueMeasurementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsNoncurrent": {
     "auth_ref": [
      "r18",
      "r19",
      "r20",
      "r21",
      "r22",
      "r23",
      "r24",
      "r25",
      "r114",
      "r196",
      "r223",
      "r224",
      "r225",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r234",
      "r235",
      "r503",
      "r509",
      "r526",
      "r569"
     ],
     "calculation": {
      "http://www.gaintherapeutics.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.",
        "label": "Assets, Noncurrent",
        "totalLabel": "Total non-current assets"
       }
      }
     },
     "localname": "AssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Noncurrent [Abstract]",
        "terseLabel": "Non-current assets:"
       }
      }
     },
     "localname": "AssetsNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalizedComputerSoftwareAdditions": {
     "auth_ref": [
      "r203"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions made to capitalized computer software costs during the period.",
        "label": "Capitalized Computer Software, Additions",
        "terseLabel": "External and internal labor costs incurred in the development stage of the Company ERP"
       }
      }
     },
     "localname": "CapitalizedComputerSoftwareAdditions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalDisclosuresDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalizedComputerSoftwareNet": {
     "auth_ref": [
      "r655"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying amount of capitalized computer software costs net of accumulated amortization as of the balance sheet date.",
        "label": "Capitalized Computer Software, Net",
        "terseLabel": "Internal-use software"
       }
      }
     },
     "localname": "CapitalizedComputerSoftwareNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalDisclosuresDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r4",
      "r46",
      "r104"
     ],
     "calculation": {
      "http://www.gaintherapeutics.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "verboseLabel": "Total cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureCashCashEquivalentsAndRestrictedCashDetails",
      "http://www.gaintherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash and Cash Equivalents [Axis]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureCashCashEquivalentsAndRestrictedCashDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsDisclosureTextBlock": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for cash and cash equivalent footnotes,  which may include the types of deposits and money market instruments, applicable carrying amounts, restricted amounts and compensating balance arrangements. Cash and equivalents include: (1) currency on hand (2) demand deposits with banks or financial institutions (3) other kinds of accounts that have the general characteristics of demand deposits (4) short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments maturing within three months from the date of acquisition qualify.",
        "label": "Cash and Cash Equivalents Disclosure [Text Block]",
        "terseLabel": "Cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureCashCashEquivalentsAndRestrictedCash"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Cash and Cash Equivalents [Line Items]",
        "verboseLabel": "Cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureCashCashEquivalentsAndRestrictedCashDetails",
      "http://www.gaintherapeutics.com/role/DisclosureCashCashEquivalentsAndRestrictedCashScheduleOfCashAndCashEquivalentsBalancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Member]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureFairValueMeasurementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r17",
      "r105"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r99",
      "r104",
      "r106"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period",
        "verboseLabel": "Cash and cash equivalents balances"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureCashCashEquivalentsAndRestrictedCashScheduleOfCashAndCashEquivalentsBalancesDetails",
      "http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r99",
      "r531"
     ],
     "calculation": {
      "http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashMember": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits.",
        "label": "Cash"
       }
      }
     },
     "localname": "CashMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureCashCashEquivalentsAndRestrictedCashDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r111",
      "r114",
      "r142",
      "r143",
      "r144",
      "r146",
      "r148",
      "r157",
      "r158",
      "r159",
      "r196",
      "r223",
      "r228",
      "r229",
      "r230",
      "r234",
      "r235",
      "r275",
      "r276",
      "r280",
      "r284",
      "r526",
      "r664"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureCommonAndPreferredStockDetails",
      "http://www.gaintherapeutics.com/role/DisclosureNatureOfBusinessAndBasisOfPresentationDetails",
      "http://www.gaintherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalDisclosuresDetails",
      "http://www.gaintherapeutics.com/role/StatementConsolidatedBalanceSheets",
      "http://www.gaintherapeutics.com/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "verboseLabel": "Common and Preferred Stock"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureCommonAndPreferredStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r300",
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
        "label": "Class of Warrant or Right [Domain]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Warrants exercise price"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Warrant or Right [Line Items]",
        "terseLabel": "Warrants"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureWarrantsAssumptionsUnderBlackScholesPricingModelDetails",
      "http://www.gaintherapeutics.com/role/DisclosureWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Warrants to purchase common stock"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Outstanding"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "auth_ref": [
      "r300",
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Class of Warrant or Right [Table]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureWarrantsAssumptionsUnderBlackScholesPricingModelDetails",
      "http://www.gaintherapeutics.com/role/DisclosureWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r497",
      "r498",
      "r500"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaboration Agreement [Text Block]",
        "terseLabel": "Collaboration Agreement"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureCollaborationAgreement"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaboration Agreement"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureCollaborationAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r60"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Maximum number of shares available to be issued"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureEquityIncentivePlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r124",
      "r125",
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalDisclosuresDetails",
      "http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r35"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)",
        "verboseLabel": "Common stock par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureCommonAndPreferredStockDetails",
      "http://www.gaintherapeutics.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r35"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized",
        "verboseLabel": "Authorized capital, Common stock (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureCommonAndPreferredStockDetails",
      "http://www.gaintherapeutics.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r35"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares, issued",
        "verboseLabel": "Common stock issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureCommonAndPreferredStockDetails",
      "http://www.gaintherapeutics.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r35",
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares, outstanding",
        "verboseLabel": "Common stock outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureCommonAndPreferredStockDetails",
      "http://www.gaintherapeutics.com/role/DisclosureEquityIncentivePlanDetails",
      "http://www.gaintherapeutics.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r35",
      "r571"
     ],
     "calculation": {
      "http://www.gaintherapeutics.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common Stock, $0.0001 par value: 11,883,368 and 3,543,163 issued and outstanding as of December 31, 2021 and December 31, 2020, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension obligations"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CompensationRelatedCostsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Incentive Plan"
       }
      }
     },
     "localname": "CompensationRelatedCostsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CompensationRelatedCostsGeneralTextBlock": {
     "auth_ref": [
      "r324",
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for compensation costs, including compensated absences accruals, compensated absences liability, deferred compensation arrangements and income statement compensation items.  Deferred compensation arrangements may include a description of an arrangement with an individual employee, which is generally an employment contract between the entity and a selected officer or key employee containing a promise by the employer to pay certain amounts at designated future dates, usually including a period after retirement, upon compliance with stipulated requirements. This type of arrangement is distinguished from broader based employee benefit plans as it is usually tailored to the employee. Disclosure also typically includes the amount of related compensation expense recognized during the reporting period, the number of shares (units) issued during the period under such arrangements, and the carrying amount as of the balance sheet date of the related liability.",
        "label": "Compensation Related Costs, General [Text Block]",
        "terseLabel": "Equity Incentive Plan"
       }
      }
     },
     "localname": "CompensationRelatedCostsGeneralTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureEquityIncentivePlan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CompensationRelatedCostsPolicyTextBlock": {
     "auth_ref": [
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.",
        "label": "Compensation Related Costs, Policy [Policy Text Block]",
        "terseLabel": "Equity-based Compensation"
       }
      }
     },
     "localname": "CompensationRelatedCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Assets [Abstract]",
        "terseLabel": "Deferred tax assets related to:"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxAssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureIncomeTaxesDomesticAndForeignNetOperatingLossesAndRelatedDeferredTaxAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Assets and Liabilities [Abstract]",
        "terseLabel": "Components of deferred tax assets and liabilities"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureIncomeTaxesDomesticAndForeignNetOperatingLossesAndRelatedDeferredTaxAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Liabilities [Abstract]",
        "terseLabel": "Deferred tax liabilities"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureIncomeTaxesDomesticAndForeignNetOperatingLossesAndRelatedDeferredTaxAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Components of income tax expense (benefit)"
       }
      }
     },
     "localname": "ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r76",
      "r78",
      "r79",
      "r87",
      "r601",
      "r621"
     ],
     "calculation": {
      "http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Comprehensive income/(loss)"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosurePropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ComputerSoftwareIntangibleAssetMember": {
     "auth_ref": [
      "r203",
      "r205",
      "r496"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collection of computer programs and related data that provide instructions to a computer, for example, but not limited to, application program, control module or operating system, that perform one or more particular functions or tasks.",
        "label": "Computer Software, Intangible Asset [Member]",
        "terseLabel": "Capitalized Software"
       }
      }
     },
     "localname": "ComputerSoftwareIntangibleAssetMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r162",
      "r608"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentrations of Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r302",
      "r303",
      "r315"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureCollaborationAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractualObligationDueInNextTwelveMonths": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contractual obligation to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Contractual Obligation, to be Paid, Year One",
        "verboseLabel": "Commitment with contractual maturity date in 2022"
       }
      }
     },
     "localname": "ContractualObligationDueInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureOtherInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "auth_ref": [
      "r115",
      "r481"
     ],
     "calculation": {
      "http://www.gaintherapeutics.com/role/DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Foreign Tax Expense (Benefit)",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "CurrentForeignTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r115",
      "r481",
      "r487",
      "r488"
     ],
     "calculation": {
      "http://www.gaintherapeutics.com/role/DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense (Benefit)",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Current:"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loans"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r110",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r254",
      "r261",
      "r262",
      "r264",
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "verboseLabel": "Loans"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureLoans"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r26",
      "r27",
      "r28",
      "r113",
      "r122",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r244",
      "r250",
      "r251",
      "r252",
      "r253",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r267",
      "r268",
      "r269",
      "r270",
      "r542",
      "r594",
      "r596",
      "r610"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureLoansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r237",
      "r267",
      "r268",
      "r540",
      "r542",
      "r543"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "verboseLabel": "Loan amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureLoansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r57",
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "verboseLabel": "Interest rate (as a percent)"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureLoansDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureLoansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r58",
      "r113",
      "r122",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r244",
      "r250",
      "r251",
      "r252",
      "r253",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r267",
      "r268",
      "r269",
      "r270",
      "r542"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureLoansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentPeriodicPayment": {
     "auth_ref": [
      "r58",
      "r606"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the required periodic payments including both interest and principal payments.",
        "label": "Debt Instrument, Periodic Payment",
        "verboseLabel": "Loan is due in quarterly installments"
       }
      }
     },
     "localname": "DebtInstrumentPeriodicPayment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureLoansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r58",
      "r113",
      "r122",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r244",
      "r250",
      "r251",
      "r252",
      "r253",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r263",
      "r267",
      "r268",
      "r269",
      "r270",
      "r292",
      "r295",
      "r296",
      "r297",
      "r539",
      "r540",
      "r542",
      "r543",
      "r607"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureLoansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Term",
        "verboseLabel": "Term of loan"
       }
      }
     },
     "localname": "DebtInstrumentTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureLoansDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DeferredChargesPolicyTextBlock": {
     "auth_ref": [
      "r51"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for deferral and amortization of significant deferred charges.",
        "label": "Deferred Charges, Policy [Policy Text Block]",
        "terseLabel": "Deferred Issuance Costs"
       }
      }
     },
     "localname": "DeferredChargesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredCreditsAndOtherLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other current liabilities and deferred income"
       }
      }
     },
     "localname": "DeferredCreditsAndOtherLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.gaintherapeutics.com/role/DisclosureOtherCurrentLiabilitiesAndDeferredIncomeDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of unearned revenue or income, not otherwise specified in the taxonomy, which is expected to be taken into income during the current period and current obligations not separately disclosed in the balance sheet (other liabilities, current).",
        "label": "Deferred Credits and Other Liabilities, Current",
        "totalLabel": "Total Other Current Liabilities and Deferred Income"
       }
      }
     },
     "localname": "DeferredCreditsAndOtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureOtherCurrentLiabilitiesAndDeferredIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFinanceCostsNet": {
     "auth_ref": [
      "r51",
      "r250",
      "r541"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Net",
        "verboseLabel": "Deferred issuance costs"
       }
      }
     },
     "localname": "DeferredFinanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureLoansDetails",
      "http://www.gaintherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeCurrent": {
     "auth_ref": [
      "r221"
     ],
     "calculation": {
      "http://www.gaintherapeutics.com/role/DisclosureOtherCurrentLiabilitiesAndDeferredIncomeDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.gaintherapeutics.com/role/StatementConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income excluding obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Deferred Income, Current",
        "verboseLabel": "Deferred income"
       }
      }
     },
     "localname": "DeferredIncomeCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureOtherCurrentLiabilitiesAndDeferredIncomeDetails",
      "http://www.gaintherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Deferred:"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r31",
      "r32",
      "r471",
      "r595",
      "r609"
     ],
     "calculation": {
      "http://www.gaintherapeutics.com/role/DisclosureIncomeTaxesDomesticAndForeignNetOperatingLossesAndRelatedDeferredTaxAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Liabilities, Gross",
        "negatedTotalLabel": "Total deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureIncomeTaxesDomesticAndForeignNetOperatingLossesAndRelatedDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxesAndOtherTaxReceivableCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.gaintherapeutics.com/role/StatementConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and other tax receivables expected to be realized or consumed within one year or operating cycle, if longer.",
        "label": "Deferred Income Taxes and Other Tax Receivable, Current",
        "terseLabel": "Tax credits"
       }
      }
     },
     "localname": "DeferredIncomeTaxesAndOtherTaxReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureOtherCurrentAssetsDetails",
      "http://www.gaintherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredOfferingCosts": {
     "auth_ref": [
      "r62",
      "r202"
     ],
     "calculation": {
      "http://www.gaintherapeutics.com/role/StatementConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.",
        "label": "Deferred Offering Costs",
        "terseLabel": "Deferred offering costs"
       }
      }
     },
     "localname": "DeferredOfferingCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r472"
     ],
     "calculation": {
      "http://www.gaintherapeutics.com/role/DisclosureIncomeTaxesDomesticAndForeignNetOperatingLossesAndRelatedDeferredTaxAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureIncomeTaxesDomesticAndForeignNetOperatingLossesAndRelatedDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r474"
     ],
     "calculation": {
      "http://www.gaintherapeutics.com/role/DisclosureIncomeTaxesDomesticAndForeignNetOperatingLossesAndRelatedDeferredTaxAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Net deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureIncomeTaxesDomesticAndForeignNetOperatingLossesAndRelatedDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic": {
     "auth_ref": [
      "r479",
      "r480"
     ],
     "calculation": {
      "http://www.gaintherapeutics.com/role/DisclosureIncomeTaxesDomesticAndForeignNetOperatingLossesAndRelatedDeferredTaxAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Domestic",
        "terseLabel": "Net operating loss (domestic)"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsDomestic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureIncomeTaxesDomesticAndForeignNetOperatingLossesAndRelatedDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign": {
     "auth_ref": [
      "r479",
      "r480"
     ],
     "calculation": {
      "http://www.gaintherapeutics.com/role/DisclosureIncomeTaxesDomesticAndForeignNetOperatingLossesAndRelatedDeferredTaxAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible foreign operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Foreign",
        "terseLabel": "Net operating loss (foreign)"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsForeign",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureIncomeTaxesDomesticAndForeignNetOperatingLossesAndRelatedDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r479",
      "r480"
     ],
     "calculation": {
      "http://www.gaintherapeutics.com/role/DisclosureIncomeTaxesDomesticAndForeignNetOperatingLossesAndRelatedDeferredTaxAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other temporary differences"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureIncomeTaxesDomesticAndForeignNetOperatingLossesAndRelatedDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r479",
      "r480"
     ],
     "calculation": {
      "http://www.gaintherapeutics.com/role/DisclosureIncomeTaxesDomesticAndForeignNetOperatingLossesAndRelatedDeferredTaxAssetsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost",
        "terseLabel": "Stock based compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureIncomeTaxesDomesticAndForeignNetOperatingLossesAndRelatedDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r473"
     ],
     "calculation": {
      "http://www.gaintherapeutics.com/role/DisclosureIncomeTaxesDomesticAndForeignNetOperatingLossesAndRelatedDeferredTaxAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "terseLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureIncomeTaxesDomesticAndForeignNetOperatingLossesAndRelatedDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "auth_ref": [
      "r479",
      "r480"
     ],
     "calculation": {
      "http://www.gaintherapeutics.com/role/DisclosureIncomeTaxesDomesticAndForeignNetOperatingLossesAndRelatedDeferredTaxAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "negatedLabel": "Depreciation and other"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureIncomeTaxesDomesticAndForeignNetOperatingLossesAndRelatedDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent": {
     "auth_ref": [
      "r30",
      "r328",
      "r329",
      "r351"
     ],
     "calculation": {
      "http://www.gaintherapeutics.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit pension plan, classified as noncurrent. Excludes other postretirement benefit plan.",
        "label": "Liability, Defined Benefit Pension Plan, Noncurrent",
        "terseLabel": "Defined benefit pension plan"
       }
      }
     },
     "localname": "DefinedBenefitPensionPlanLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation": {
     "auth_ref": [
      "r361"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of actuarial present value of benefits attributed to employee service rendered, excluding assumptions about future compensation level.",
        "label": "Defined Benefit Plan, Accumulated Benefit Obligation",
        "terseLabel": "Accumululated benefit obligation"
       }
      }
     },
     "localname": "DefinedBenefitPlanAccumulatedBenefitObligation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosurePensionObligationsEndOfYearFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax": {
     "auth_ref": [
      "r73",
      "r373"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax, of accumulated other comprehensive income (loss) for gain (loss) of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit.",
        "label": "Accumulated Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), after Tax",
        "periodEndLabel": "(Gain)/loss at end of year",
        "periodStartLabel": "(Gain)/loss at beginning of year"
       }
      }
     },
     "localname": "DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosurePensionObligationsChangeInNetGainLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets": {
     "auth_ref": [
      "r343",
      "r402"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in plan assets of defined benefit plan from actual return (loss) determined by change in fair value of plan assets adjusted for contributions, benefit payments, and other expenses.",
        "label": "Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss)",
        "terseLabel": "Gain/(loss) on plan assets"
       }
      }
     },
     "localname": "DefinedBenefitPlanActualReturnOnPlanAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosurePensionObligationsReconciliationOfFairValueOfPlanAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses": {
     "auth_ref": [
      "r330",
      "r368",
      "r396",
      "r402",
      "r403"
     ],
     "calculation": {
      "http://www.gaintherapeutics.com/role/DisclosurePensionObligationsComponentOfNetPeriodicPensionCostsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit of defined benefit plan.",
        "label": "Defined Benefit Plan, Amortization of Gain (Loss)",
        "negatedLabel": "Amortization of (gain)/losses",
        "terseLabel": "Amortization of (gain)/losses",
        "verboseLabel": "Net gain/(loss) amortized"
       }
      }
     },
     "localname": "DefinedBenefitPlanAmortizationOfGainsLosses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosurePensionObligationsChangeInAccumulatedOtherComprehensiveIncomeAociDetails",
      "http://www.gaintherapeutics.com/role/DisclosurePensionObligationsChangeInNetGainLossDetails",
      "http://www.gaintherapeutics.com/role/DisclosurePensionObligationsComponentOfNetPeriodicPensionCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit": {
     "auth_ref": [
      "r330",
      "r369",
      "r397",
      "r402",
      "r403"
     ],
     "calculation": {
      "http://www.gaintherapeutics.com/role/DisclosurePensionObligationsComponentOfNetPeriodicPensionCostsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of prior service cost (credit) recognized in net periodic benefit cost (credit) of defined benefit plan.",
        "label": "Defined Benefit Plan, Amortization of Prior Service Cost (Credit)",
        "terseLabel": "Amortization of prior year service cost",
        "verboseLabel": "Net prior service (cost)/credit amortized"
       }
      }
     },
     "localname": "DefinedBenefitPlanAmortizationOfPriorServiceCostCredit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosurePensionObligationsChangeInAccumulatedOtherComprehensiveIncomeAociDetails",
      "http://www.gaintherapeutics.com/role/DisclosurePensionObligationsComponentOfNetPeriodicPensionCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax": {
     "auth_ref": [
      "r69",
      "r71",
      "r372"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, after reclassification adjustment, of (increase) decrease in accumulated other comprehensive income from prior service cost (credit) of defined benefit plan.",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), after Reclassification Adjustment, before Tax",
        "terseLabel": "Prior Service Cost/(credit) occurring over the year"
       }
      }
     },
     "localname": "DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosurePensionObligationsChangeInAccumulatedOtherComprehensiveIncomeAociDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate": {
     "auth_ref": [
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average rate for present value of future retirement benefits cash flows, used to determine benefit obligation of defined benefit plan.",
        "label": "Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate",
        "terseLabel": "Discount rate"
       }
      }
     },
     "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosurePensionObligationsAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease": {
     "auth_ref": [
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average rate increase of compensation, used to determine benefit obligation of defined benefit plan. Plan includes, but is not limited to, pay-related defined benefit plan.",
        "label": "Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Rate of Compensation Increase",
        "terseLabel": "Salary increases"
       }
      }
     },
     "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosurePensionObligationsAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate": {
     "auth_ref": [
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average interest crediting rate used to determine benefit obligation of defined benefit plan. Plan includes, but is not limited to, cash balance and other defined benefit plans with promised interest crediting rate.",
        "label": "Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Weighted-Average Interest Crediting Rate",
        "terseLabel": "Interest credit rate / ERoA"
       }
      }
     },
     "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosurePensionObligationsAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedBenefitPlanAssumptionsUsedInCalculationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan, Assumptions Used in Calculations [Abstract]",
        "terseLabel": "Financial and Demographic Assumptions"
       }
      }
     },
     "localname": "DefinedBenefitPlanAssumptionsUsedInCalculationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosurePensionObligationsAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanBenefitObligation": {
     "auth_ref": [
      "r331"
     ],
     "calculation": {
      "http://www.gaintherapeutics.com/role/DisclosurePensionObligationsEndOfYearFundedStatusDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DefinedBenefitPlanFundedStatusOfPlan",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.",
        "label": "Defined Benefit Plan, Benefit Obligation",
        "negatedLabel": "(Projected benefit obligation)",
        "periodEndLabel": "Projected benefit obligation at December 31",
        "periodStartLabel": "Projected benefit obligation at January 1"
       }
      }
     },
     "localname": "DefinedBenefitPlanBenefitObligation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosurePensionObligationsEndOfYearFundedStatusDetails",
      "http://www.gaintherapeutics.com/role/DisclosurePensionObligationsReconciliationOfProjectedBenefitObligationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid": {
     "auth_ref": [
      "r338",
      "r408"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of payment to participant of defined benefit plan which decreases benefit obligation. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services.",
        "label": "Defined Benefit Plan, Benefit Obligation, Benefits Paid",
        "verboseLabel": "Benefit payments"
       }
      }
     },
     "localname": "DefinedBenefitPlanBenefitObligationBenefitsPaid",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosurePensionObligationsReconciliationOfProjectedBenefitObligationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant": {
     "auth_ref": [
      "r335"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contributions received by defined benefit plan from participant which increase benefit obligation.",
        "label": "Defined Benefit Plan, Benefit Obligation, Contributions by Plan Participant",
        "terseLabel": "Employee contribution"
       }
      }
     },
     "localname": "DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosurePensionObligationsReconciliationOfProjectedBenefitObligationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanBenefitObligationPeriodIncreaseDecrease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in benefit obligation of defined benefit plan.",
        "label": "Defined Benefit Plan, Benefit Obligation, Period Increase (Decrease)",
        "terseLabel": "(Gain)/loss on PBO during year"
       }
      }
     },
     "localname": "DefinedBenefitPlanBenefitObligationPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosurePensionObligationsChangeInAccumulatedOtherComprehensiveIncomeAociDetails",
      "http://www.gaintherapeutics.com/role/DisclosurePensionObligationsChangeInNetGainLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanContributionsByEmployer": {
     "auth_ref": [
      "r345",
      "r353",
      "r355",
      "r400",
      "r402",
      "r403"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contribution received by defined benefit plan from employer which increases plan assets.",
        "label": "Defined Benefit Plan, Plan Assets, Contributions by Employer",
        "terseLabel": "Employer contributions"
       }
      }
     },
     "localname": "DefinedBenefitPlanContributionsByEmployer",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosurePensionObligationsReconciliationOfFairValueOfPlanAssetsDetails",
      "http://www.gaintherapeutics.com/role/DisclosurePensionObligationsReconciliationOfFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Defined Benefit Plan Disclosure [Line Items]",
        "terseLabel": "Reconciliation of funded status"
       }
      }
     },
     "localname": "DefinedBenefitPlanDisclosureLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosurePensionObligationsAssumptionsDetails",
      "http://www.gaintherapeutics.com/role/DisclosurePensionObligationsChangeInAccumulatedOtherComprehensiveIncomeAociDetails",
      "http://www.gaintherapeutics.com/role/DisclosurePensionObligationsChangeInNetGainLossDetails",
      "http://www.gaintherapeutics.com/role/DisclosurePensionObligationsComponentOfNetPeriodicPensionCostsDetails",
      "http://www.gaintherapeutics.com/role/DisclosurePensionObligationsEndOfYearFundedStatusDetails",
      "http://www.gaintherapeutics.com/role/DisclosurePensionObligationsExpectedBenefitPaymentsDetails",
      "http://www.gaintherapeutics.com/role/DisclosurePensionObligationsReconciliationOfFairValueOfPlanAssetsDetails",
      "http://www.gaintherapeutics.com/role/DisclosurePensionObligationsReconciliationOfFundedStatusDetails",
      "http://www.gaintherapeutics.com/role/DisclosurePensionObligationsReconciliationOfProjectedBenefitObligationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter": {
     "auth_ref": [
      "r362"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of benefit for defined benefit plan expected to be paid in five fiscal years after fifth fiscal year following current fiscal year.",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment, after Year Five for Next Five Years",
        "terseLabel": "Next 5 years"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosurePensionObligationsExpectedBenefitPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths": {
     "auth_ref": [
      "r362"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of benefit for defined benefit plan expected to be paid in next fiscal year following current fiscal year.",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year One",
        "terseLabel": "Year 1"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosurePensionObligationsExpectedBenefitPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive": {
     "auth_ref": [
      "r362"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of benefit for defined benefit plan expected to be paid in fifth fiscal year following current fiscal year.",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Five",
        "terseLabel": "Year 5"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosurePensionObligationsExpectedBenefitPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour": {
     "auth_ref": [
      "r362"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of benefit for defined benefit plan expected to be paid in fourth fiscal year following current fiscal year.",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Four",
        "terseLabel": "Year 4"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosurePensionObligationsExpectedBenefitPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree": {
     "auth_ref": [
      "r362"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of benefit for defined benefit plan expected to be paid in third fiscal year following current fiscal year.",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Three",
        "terseLabel": "Year 3"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosurePensionObligationsExpectedBenefitPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo": {
     "auth_ref": [
      "r362"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of benefit for defined benefit plan expected to be paid in second fiscal year following current fiscal year.",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Two",
        "terseLabel": "Year 2"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosurePensionObligationsExpectedBenefitPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear": {
     "auth_ref": [
      "r363",
      "r403"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contribution expected to be received by defined benefit plan from employer in next fiscal year following current fiscal year.",
        "label": "Defined Benefit Plan, Expected Future Employer Contributions, Next Fiscal Year",
        "terseLabel": "Next year's expected employer contribution"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosurePensionObligationsExpectedBenefitPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets": {
     "auth_ref": [
      "r330",
      "r367",
      "r395",
      "r402",
      "r403"
     ],
     "calculation": {
      "http://www.gaintherapeutics.com/role/DisclosurePensionObligationsComponentOfNetPeriodicPensionCostsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan.",
        "label": "Defined Benefit Plan, Expected Return (Loss) on Plan Assets",
        "negatedLabel": "Expected return on plan asset",
        "terseLabel": "Expected return on plan assets"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedReturnOnPlanAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosurePensionObligationsComponentOfNetPeriodicPensionCostsDetails",
      "http://www.gaintherapeutics.com/role/DisclosurePensionObligationsReconciliationOfFairValueOfPlanAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanFairValueOfPlanAssets": {
     "auth_ref": [
      "r342",
      "r353",
      "r355",
      "r356",
      "r402"
     ],
     "calculation": {
      "http://www.gaintherapeutics.com/role/DisclosurePensionObligationsEndOfYearFundedStatusDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DefinedBenefitPlanFundedStatusOfPlan",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee.",
        "label": "Defined Benefit Plan, Plan Assets, Amount",
        "periodEndLabel": "Fair value at December 31",
        "periodStartLabel": "Fair value at January 1",
        "terseLabel": "Fair value of plan assets"
       }
      }
     },
     "localname": "DefinedBenefitPlanFairValueOfPlanAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosurePensionObligationsEndOfYearFundedStatusDetails",
      "http://www.gaintherapeutics.com/role/DisclosurePensionObligationsReconciliationOfFairValueOfPlanAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanFairValueOfPlanAssetsPeriodIncreaseDecrease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in plan assets of defined benefit plan.",
        "label": "Defined Benefit Plan, Plan Assets, Period Increase (Decrease)",
        "terseLabel": "(Gain)/loss on assets during year",
        "verboseLabel": "(Gain)/loss on assets during the year"
       }
      }
     },
     "localname": "DefinedBenefitPlanFairValueOfPlanAssetsPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosurePensionObligationsChangeInAccumulatedOtherComprehensiveIncomeAociDetails",
      "http://www.gaintherapeutics.com/role/DisclosurePensionObligationsChangeInNetGainLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanFundedStatusOfPlan": {
     "auth_ref": [
      "r328",
      "r351",
      "r402"
     ],
     "calculation": {
      "http://www.gaintherapeutics.com/role/DisclosurePensionObligationsEndOfYearFundedStatusDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of funded (unfunded) status of defined benefit plan, measured as difference between fair value of plan assets and benefit obligation. Includes, but is not limited to, overfunded (underfunded) status.",
        "label": "Defined Benefit Plan, Funded (Unfunded) Status of Plan",
        "periodEndLabel": "Funded status at end of year",
        "periodStartLabel": "Funded status beginning of the year",
        "totalLabel": "Funded status"
       }
      }
     },
     "localname": "DefinedBenefitPlanFundedStatusOfPlan",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosurePensionObligationsEndOfYearFundedStatusDetails",
      "http://www.gaintherapeutics.com/role/DisclosurePensionObligationsReconciliationOfFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanInterestCost": {
     "auth_ref": [
      "r330",
      "r334",
      "r366",
      "r394",
      "r402",
      "r403"
     ],
     "calculation": {
      "http://www.gaintherapeutics.com/role/DisclosurePensionObligationsComponentOfNetPeriodicPensionCostsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost recognized for passage of time related to defined benefit plan.",
        "label": "Defined Benefit Plan, Interest Cost",
        "terseLabel": "Interest cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanInterestCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosurePensionObligationsComponentOfNetPeriodicPensionCostsDetails",
      "http://www.gaintherapeutics.com/role/DisclosurePensionObligationsReconciliationOfProjectedBenefitObligationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost": {
     "auth_ref": [
      "r364",
      "r392",
      "r402",
      "r403"
     ],
     "calculation": {
      "http://www.gaintherapeutics.com/role/DisclosurePensionObligationsComponentOfNetPeriodicPensionCostsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of net periodic benefit cost (credit) for defined benefit plan.",
        "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit)",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "DefinedBenefitPlanNetPeriodicBenefitCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosurePensionObligationsComponentOfNetPeriodicPensionCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanPlanAmendments": {
     "auth_ref": [
      "r339"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in benefit obligation of defined benefit plan from change in terms of existing plan or initiation of new plan.",
        "label": "Defined Benefit Plan, Benefit Obligation, Increase (Decrease) for Plan Amendment",
        "terseLabel": "Plan Amendment"
       }
      }
     },
     "localname": "DefinedBenefitPlanPlanAmendments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosurePensionObligationsReconciliationOfProjectedBenefitObligationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid": {
     "auth_ref": [
      "r347",
      "r408"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of payment to participant under defined benefit plan which decreases plan assets. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services.",
        "label": "Defined Benefit Plan, Plan Assets, Benefits Paid",
        "terseLabel": "Benefit payments"
       }
      }
     },
     "localname": "DefinedBenefitPlanPlanAssetsBenefitsPaid",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosurePensionObligationsReconciliationOfFairValueOfPlanAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant": {
     "auth_ref": [
      "r346"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contributions received by defined benefit plan from participant which increases plan assets.",
        "label": "Defined Benefit Plan, Plan Assets, Contributions by Plan Participant",
        "terseLabel": "Employee contributions"
       }
      }
     },
     "localname": "DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosurePensionObligationsReconciliationOfFairValueOfPlanAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss": {
     "auth_ref": [
      "r344"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) plan assets of defined benefit plan.",
        "label": "Defined Benefit Plan, Plan Assets, Foreign Currency Translation Gain (Loss)",
        "negatedLabel": "Translation difference"
       }
      }
     },
     "localname": "DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosurePensionObligationsReconciliationOfFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanServiceCost": {
     "auth_ref": [
      "r332",
      "r365",
      "r393",
      "r402",
      "r403"
     ],
     "calculation": {
      "http://www.gaintherapeutics.com/role/DisclosurePensionObligationsComponentOfNetPeriodicPensionCostsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.",
        "label": "Defined Benefit Plan, Service Cost",
        "terseLabel": "Services cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanServiceCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosurePensionObligationsComponentOfNetPeriodicPensionCostsDetails",
      "http://www.gaintherapeutics.com/role/DisclosurePensionObligationsReconciliationOfProjectedBenefitObligationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan.",
        "label": "Defined Contribution Plan, Employer Discretionary Contribution Amount",
        "terseLabel": "Expenses related to savings plan"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosurePensionObligationsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r102",
      "r212"
     ],
     "calculation": {
      "http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "verboseLabel": "Depreciation"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r102",
      "r170"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "verboseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosurePropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureResearchGrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r314",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureResearchGrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureIncomeTaxesDomesticAndForeignNetOperatingLossesAndRelatedDeferredTaxAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DomesticPlanMember": {
     "auth_ref": [
      "r410",
      "r414",
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location of employer sponsoring plan, designed to provide retirement benefits, determined as principal place of business. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Domestic Plan [Member]",
        "terseLabel": "Domestic Plan"
       }
      }
     },
     "localname": "DomesticPlanMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosurePensionObligationsEndOfYearFundedStatusDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss per common share"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r88",
      "r129",
      "r130",
      "r132",
      "r133",
      "r134",
      "r140",
      "r142",
      "r146",
      "r147",
      "r148",
      "r152",
      "r153",
      "r516",
      "r517",
      "r602",
      "r622"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per share attributable to common stockholders - Basic",
        "verboseLabel": "Net loss per share"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureNetLossPerCommonShareComputationOfDilutedNetLossPerShareDetails",
      "http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic and Diluted [Abstract]",
        "terseLabel": "Net loss per shares:"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r88",
      "r129",
      "r130",
      "r132",
      "r133",
      "r134",
      "r142",
      "r146",
      "r147",
      "r148",
      "r152",
      "r153",
      "r516",
      "r517",
      "r602",
      "r622"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per share attributable to common stockholders - Diluted"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r149",
      "r150"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net loss per share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r149",
      "r150",
      "r151",
      "r154"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "verboseLabel": "Net loss per common share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureNetLossPerCommonShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents": {
     "auth_ref": [
      "r531"
     ],
     "calculation": {
      "http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.",
        "label": "Effect of Exchange Rate on Cash and Cash Equivalents",
        "terseLabel": "Effect of exchange rate changes"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashAndCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r465"
     ],
     "calculation": {
      "http://www.gaintherapeutics.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "terseLabel": "Effective tax rate",
        "totalLabel": "Effective income tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureIncomeTaxesAdditionalDisclosuresDetails",
      "http://www.gaintherapeutics.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Percent [Abstract]",
        "terseLabel": "Income tax rate reconciliation"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r117",
      "r465",
      "r490"
     ],
     "calculation": {
      "http://www.gaintherapeutics.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Federal income tax at US statutory rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r465",
      "r490"
     ],
     "calculation": {
      "http://www.gaintherapeutics.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": {
     "auth_ref": [
      "r465",
      "r490"
     ],
     "calculation": {
      "http://www.gaintherapeutics.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent",
        "terseLabel": "Foreign tax"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r465",
      "r490"
     ],
     "calculation": {
      "http://www.gaintherapeutics.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "terseLabel": "State income taxes, net of federal benefit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Unrecognized compensation recognition period"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureEquityIncentivePlanOptionsOutstandingAndExercisableDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r449"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Total unrecognized compensation cost related to non-vested stock options"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureEquityIncentivePlanOptionsOutstandingAndExercisableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Options to purchase common stock"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureNetLossPerCommonShareComputationOfDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common and Preferred Stock"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r81",
      "r82",
      "r83",
      "r124",
      "r125",
      "r126",
      "r128",
      "r135",
      "r138",
      "r156",
      "r197",
      "r291",
      "r298",
      "r452",
      "r453",
      "r454",
      "r483",
      "r484",
      "r515",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r628",
      "r629",
      "r630",
      "r669"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "auth_ref": [
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "terseLabel": "Schedule of fair value of the warrants is estimated using the Black-Scholes option pricing model"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureWarrantsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "auth_ref": [
      "r518",
      "r519"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets measured at fair value measured on a recurring or nonrecurring basis. Includes, but is not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2.",
        "label": "Fair Value, Assets Measured on Recurring and Nonrecurring Basis [Table Text Block]",
        "terseLabel": "Schedule of assets measured at fair value"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureFairValueMeasurementTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "auth_ref": [
      "r522"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of asset.",
        "label": "Asset Class [Domain]"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureFairValueMeasurementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureFairValueMeasurementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "auth_ref": [
      "r522",
      "r524"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of assets using significant unobservable inputs (level 3). Such reconciliation, separately presenting changes during the period, at a minimum, may include, but is not limited to: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income, and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset.",
        "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table]"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureFairValueMeasurementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "auth_ref": [
      "r518",
      "r524"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of asset.",
        "label": "Asset Class [Axis]"
       }
      }
     },
     "localname": "FairValueByAssetClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureFairValueMeasurementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r252",
      "r267",
      "r268",
      "r353",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r402",
      "r519",
      "r574",
      "r575",
      "r576"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureFairValueMeasurementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value measurement"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r523"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "verboseLabel": "Fair value measurement"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureFairValueMeasurement"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r252",
      "r353",
      "r355",
      "r360",
      "r402",
      "r519",
      "r574"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureFairValueMeasurementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair value measurements"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r252",
      "r267",
      "r268",
      "r353",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r402",
      "r574",
      "r575",
      "r576"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureFairValueMeasurementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalDisclosuresDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r203",
      "r204",
      "r206",
      "r207",
      "r589",
      "r590"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalDisclosuresDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r203",
      "r205"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile.",
        "label": "Foreign"
       }
      }
     },
     "localname": "ForeignCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureIncomeTaxesDomesticAndForeignNetOperatingLossesAndRelatedDeferredTaxAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "auth_ref": [
      "r527",
      "r528",
      "r529",
      "r530"
     ],
     "calculation": {
      "http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign Currency Transaction Gain (Loss), before Tax",
        "terseLabel": "Foreign exchange loss, net"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r538"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Foreign currency translation"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosurePropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r91"
     ],
     "calculation": {
      "http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "negatedLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureEquityIncentivePlanStockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GrantsReceivable": {
     "auth_ref": [
      "r62"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants.",
        "label": "Grants Receivable",
        "terseLabel": "Research grants"
       }
      }
     },
     "localname": "GrantsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureResearchGrantsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IPOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First sale of stock by a private company to the public.",
        "label": "IPO"
       }
      }
     },
     "localname": "IPOMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureNatureOfBusinessAndBasisOfPresentationDetails",
      "http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": {
     "auth_ref": [
      "r102",
      "r211",
      "r216"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).",
        "label": "Impairment of Long-Lived Assets Held-for-use"
       }
      }
     },
     "localname": "ImpairmentOfLongLivedAssetsHeldForUse",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosurePropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r210",
      "r218"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment of long-lived assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "auth_ref": [
      "r116",
      "r489"
     ],
     "calculation": {
      "http://www.gaintherapeutics.com/role/DisclosureIncomeTaxesDomesticAndForeignNetOperatingLossesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "terseLabel": "Domestic"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureIncomeTaxesDomesticAndForeignNetOperatingLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r85",
      "r172",
      "r180",
      "r183",
      "r186",
      "r188",
      "r591",
      "r599",
      "r604",
      "r623"
     ],
     "calculation": {
      "http://www.gaintherapeutics.com/role/DisclosureIncomeTaxesDomesticAndForeignNetOperatingLossesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before income tax"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureIncomeTaxesDomesticAndForeignNetOperatingLossesDetails",
      "http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "auth_ref": [
      "r116",
      "r489"
     ],
     "calculation": {
      "http://www.gaintherapeutics.com/role/DisclosureIncomeTaxesDomesticAndForeignNetOperatingLossesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureIncomeTaxesDomesticAndForeignNetOperatingLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest [Abstract]",
        "terseLabel": "Components of income (loss) before income taxes provision"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureIncomeTaxesDomesticAndForeignNetOperatingLossesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Statement of Operations"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r217",
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureEquityIncentivePlanStockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureEquityIncentivePlanStockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureIncomeTaxesDomesticAndForeignNetOperatingLossesAndRelatedDeferredTaxAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureIncomeTaxesDomesticAndForeignNetOperatingLossesAndRelatedDeferredTaxAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r117",
      "r466",
      "r469",
      "r476",
      "r485",
      "r491",
      "r493",
      "r494",
      "r495"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureIncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r118",
      "r137",
      "r138",
      "r171",
      "r464",
      "r486",
      "r492",
      "r624"
     ],
     "calculation": {
      "http://www.gaintherapeutics.com/role/DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "Income tax",
        "totalLabel": "Total income tax expense"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseDetails",
      "http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r80",
      "r462",
      "r463",
      "r469",
      "r470",
      "r475",
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r101"
     ],
     "calculation": {
      "http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfCashFlows": {
       "order": 7.0,
       "parentTag": "ganx_IncreaseDecreaseInOperatingAssetsAndLiabilities",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r101"
     ],
     "calculation": {
      "http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfCashFlows": {
       "order": 1.0,
       "parentTag": "ganx_IncreaseDecreaseInOperatingAssetsAndLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Account receivables"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredLiabilities": {
     "auth_ref": [
      "r101"
     ],
     "calculation": {
      "http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfCashFlows": {
       "order": 5.0,
       "parentTag": "ganx_IncreaseDecreaseInOperatingAssetsAndLiabilities",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change during the period in carrying value for all deferred liabilities due within one year or operating cycle.",
        "label": "Increase (Decrease) in Deferred Liabilities",
        "terseLabel": "Deferred income"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherCurrentLiabilities": {
     "auth_ref": [
      "r101"
     ],
     "calculation": {
      "http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfCashFlows": {
       "order": 8.0,
       "parentTag": "ganx_IncreaseDecreaseInOperatingAssetsAndLiabilities",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in current liabilities classified as other.",
        "label": "Increase (Decrease) in Other Current Liabilities",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherCurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "auth_ref": [
      "r101"
     ],
     "calculation": {
      "http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfCashFlows": {
       "order": 3.0,
       "parentTag": "ganx_IncreaseDecreaseInOperatingAssetsAndLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "negatedLabel": "Long term deposit and other non current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r101"
     ],
     "calculation": {
      "http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfCashFlows": {
       "order": 2.0,
       "parentTag": "ganx_IncreaseDecreaseInOperatingAssetsAndLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInSecurityDeposits": {
     "auth_ref": [
      "r101"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in security deposits.",
        "label": "Increase (Decrease) in Security Deposits"
       }
      }
     },
     "localname": "IncreaseDecreaseInSecurityDeposits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureOperatingLeaseRightOfUseRouAssetsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsFiniteLivedPolicy": {
     "auth_ref": [
      "r108",
      "r205",
      "r585",
      "r586",
      "r587",
      "r589"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.",
        "label": "Intangible Assets, Finite-Lived, Policy [Policy Text Block]",
        "terseLabel": "Patents"
       }
      }
     },
     "localname": "IntangibleAssetsFiniteLivedPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InterestExpenseDebt": {
     "auth_ref": [
      "r92",
      "r258",
      "r266",
      "r269",
      "r270"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.",
        "label": "Interest Expense, Debt",
        "verboseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpenseDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureLoansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeExpenseNet": {
     "auth_ref": [
      "r603"
     ],
     "calculation": {
      "http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of operating interest income (expense).",
        "label": "Interest Income (Expense), Net",
        "terseLabel": "Interest income, net"
       }
      }
     },
     "localname": "InterestIncomeExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": {
     "auth_ref": [
      "r102"
     ],
     "calculation": {
      "http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.",
        "label": "Issuance of Stock and Warrants for Services or Claims",
        "terseLabel": "Issuance of warrants"
       }
      }
     },
     "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r556"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "verboseLabel": "Schedule of components of lease expense"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureOperatingLeaseRightOfUserouAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosurePropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease. Right of use (\"ROU\") assets"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureOperatingLeaseRightOfUseRouAssetsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureOperatingLeaseRightOfUseRouAssetsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r549"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of future minimum lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureOperatingLeaseRightOfUserouAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": {
     "auth_ref": [
      "r550"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Remaining Lease Term",
        "verboseLabel": "Operating lease remaining term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRemainingLeaseTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureOperatingLeaseRightOfUseRouAssetsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r551"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "verboseLabel": "Operating lease renewal term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureOperatingLeaseRightOfUseRouAssetsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r551"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Operating lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureOperatingLeaseRightOfUseRouAssetsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "verboseLabel": "Operating lease. Right of use (\"ROU\") assets"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureOperatingLeaseRightOfUserouAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r54",
      "r114",
      "r182",
      "r196",
      "r223",
      "r224",
      "r225",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r234",
      "r235",
      "r504",
      "r509",
      "r510",
      "r526",
      "r569",
      "r570"
     ],
     "calculation": {
      "http://www.gaintherapeutics.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities [Abstract]",
        "terseLabel": "Liabilities:"
       }
      }
     },
     "localname": "LiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r43",
      "r114",
      "r196",
      "r526",
      "r571",
      "r597",
      "r616"
     ],
     "calculation": {
      "http://www.gaintherapeutics.com/role/StatementConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Equity:"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r56",
      "r114",
      "r196",
      "r223",
      "r224",
      "r225",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r234",
      "r235",
      "r504",
      "r509",
      "r510",
      "r526",
      "r569",
      "r570",
      "r571"
     ],
     "calculation": {
      "http://www.gaintherapeutics.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "auth_ref": [
      "r14",
      "r15",
      "r16",
      "r28",
      "r29",
      "r114",
      "r196",
      "r223",
      "r224",
      "r225",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r234",
      "r235",
      "r504",
      "r509",
      "r510",
      "r526",
      "r569",
      "r570"
     ],
     "calculation": {
      "http://www.gaintherapeutics.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.",
        "label": "Liabilities, Noncurrent",
        "totalLabel": "Total non-current liabilities"
       }
      }
     },
     "localname": "LiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Noncurrent [Abstract]",
        "terseLabel": "Non-current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r28",
      "r251",
      "r265",
      "r267",
      "r268",
      "r596",
      "r612"
     ],
     "calculation": {
      "http://www.gaintherapeutics.com/role/DisclosureLoansFutureLoanPaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureLoansFutureLoanPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtCurrent": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://www.gaintherapeutics.com/role/StatementConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Current Maturities",
        "terseLabel": "Loans - short term"
       }
      }
     },
     "localname": "LongTermDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive": {
     "auth_ref": [
      "r122",
      "r222",
      "r256"
     ],
     "calculation": {
      "http://www.gaintherapeutics.com/role/DisclosureLoansFutureLoanPaymentsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureLoansFutureLoanPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "auth_ref": [
      "r122",
      "r222",
      "r256"
     ],
     "calculation": {
      "http://www.gaintherapeutics.com/role/DisclosureLoansFutureLoanPaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year One",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureLoansFutureLoanPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": {
     "auth_ref": [
      "r122",
      "r222",
      "r256"
     ],
     "calculation": {
      "http://www.gaintherapeutics.com/role/DisclosureLoansFutureLoanPaymentsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Five",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureLoansFutureLoanPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": {
     "auth_ref": [
      "r122",
      "r222",
      "r256"
     ],
     "calculation": {
      "http://www.gaintherapeutics.com/role/DisclosureLoansFutureLoanPaymentsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureLoansFutureLoanPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "auth_ref": [
      "r122",
      "r222",
      "r256"
     ],
     "calculation": {
      "http://www.gaintherapeutics.com/role/DisclosureLoansFutureLoanPaymentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureLoansFutureLoanPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "auth_ref": [
      "r122",
      "r222",
      "r256"
     ],
     "calculation": {
      "http://www.gaintherapeutics.com/role/DisclosureLoansFutureLoanPaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureLoansFutureLoanPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://www.gaintherapeutics.com/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Excluding Current Maturities",
        "terseLabel": "Loans - long term"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "auth_ref": [
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date.",
        "label": "Expected term"
       }
      }
     },
     "localname": "MeasurementInputExpectedTermMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureWarrantsAssumptionsUnderBlackScholesPricingModelDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "auth_ref": [
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.",
        "label": "Volatility"
       }
      }
     },
     "localname": "MeasurementInputPriceVolatilityMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureWarrantsAssumptionsUnderBlackScholesPricingModelDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "auth_ref": [
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.",
        "label": "Risk-free interest rate"
       }
      }
     },
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureWarrantsAssumptionsUnderBlackScholesPricingModelDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureWarrantsAssumptionsUnderBlackScholesPricingModelDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureWarrantsAssumptionsUnderBlackScholesPricingModelDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureCashCashEquivalentsAndRestrictedCashDetails",
      "http://www.gaintherapeutics.com/role/DisclosureFairValueMeasurementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r99"
     ],
     "calculation": {
      "http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flow from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r99"
     ],
     "calculation": {
      "http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r99",
      "r100",
      "r103"
     ],
     "calculation": {
      "http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r2",
      "r74",
      "r77",
      "r83",
      "r86",
      "r103",
      "r114",
      "r127",
      "r129",
      "r130",
      "r132",
      "r133",
      "r137",
      "r138",
      "r145",
      "r172",
      "r180",
      "r183",
      "r186",
      "r188",
      "r196",
      "r223",
      "r224",
      "r225",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r234",
      "r235",
      "r517",
      "r526",
      "r600",
      "r620"
     ],
     "calculation": {
      "http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfChangesInStockholdersEquityDeficit",
      "http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfComprehensiveLoss",
      "http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently issued accounting pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income (expense):"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OfficeEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine.",
        "label": "Electronic office equipment"
       }
      }
     },
     "localname": "OfficeEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "negatedTotalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r172",
      "r180",
      "r183",
      "r186",
      "r188"
     ],
     "calculation": {
      "http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r548"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease, Expense",
        "terseLabel": "Operating lease costs"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureOperatingLeaseRightOfUseRouAssetsSummaryOfComponentsOfLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLeaseIncomeTableTextBlock": {
     "auth_ref": [
      "r155",
      "r560"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of components of income from operating lease.",
        "label": "Operating Lease, Lease Income [Table Text Block]",
        "verboseLabel": "Schedule of components of lease accounting"
       }
      }
     },
     "localname": "OperatingLeaseLeaseIncomeTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureOperatingLeaseRightOfUserouAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r547"
     ],
     "calculation": {
      "http://www.gaintherapeutics.com/role/DisclosureOperatingLeaseRightOfUseRouAssetsFutureMinimumLeasePaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "totalLabel": "Present value of lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureOperatingLeaseRightOfUseRouAssetsFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r547"
     ],
     "calculation": {
      "http://www.gaintherapeutics.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liability - current",
        "verboseLabel": "Operating lease liability - current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureOperatingLeaseRightOfUseRouAssetsSummaryOfComponentsOfLeaseAccountingDetails",
      "http://www.gaintherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r547"
     ],
     "calculation": {
      "http://www.gaintherapeutics.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liability - non-current",
        "verboseLabel": "Operating lease liability - non current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureOperatingLeaseRightOfUseRouAssetsSummaryOfComponentsOfLeaseAccountingDetails",
      "http://www.gaintherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r546"
     ],
     "calculation": {
      "http://www.gaintherapeutics.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease - right of use assets",
        "verboseLabel": "Operating lease- right of use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureOperatingLeaseRightOfUseRouAssetsSummaryOfComponentsOfLeaseAccountingDetails",
      "http://www.gaintherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r555",
      "r558"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "verboseLabel": "Weighted average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureOperatingLeaseRightOfUseRouAssetsSummaryOfComponentsOfLeaseAccountingDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r554",
      "r558"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "verboseLabel": "Weighted average remaining lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureOperatingLeaseRightOfUseRouAssetsSummaryOfComponentsOfLeaseAccountingDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDue": {
     "auth_ref": [
      "r544",
      "r545"
     ],
     "calculation": {
      "http://www.gaintherapeutics.com/role/DisclosureOperatingLeaseRightOfUseRouAssetsFutureMinimumLeasePaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.",
        "label": "Operating Leases, Future Minimum Payments Due",
        "totalLabel": "Total future minimum lease payments"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureOperatingLeaseRightOfUseRouAssetsFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent": {
     "auth_ref": [
      "r544",
      "r545"
     ],
     "calculation": {
      "http://www.gaintherapeutics.com/role/DisclosureOperatingLeaseRightOfUseRouAssetsFutureMinimumLeasePaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments Due, Next Twelve Months",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureOperatingLeaseRightOfUseRouAssetsFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears": {
     "auth_ref": [
      "r544",
      "r545"
     ],
     "calculation": {
      "http://www.gaintherapeutics.com/role/DisclosureOperatingLeaseRightOfUseRouAssetsFutureMinimumLeasePaymentsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due in Five Years",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInFiveYears",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureOperatingLeaseRightOfUseRouAssetsFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears": {
     "auth_ref": [
      "r544",
      "r545"
     ],
     "calculation": {
      "http://www.gaintherapeutics.com/role/DisclosureOperatingLeaseRightOfUseRouAssetsFutureMinimumLeasePaymentsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due in Four Years",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInFourYears",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureOperatingLeaseRightOfUseRouAssetsFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears": {
     "auth_ref": [
      "r544",
      "r545"
     ],
     "calculation": {
      "http://www.gaintherapeutics.com/role/DisclosureOperatingLeaseRightOfUseRouAssetsFutureMinimumLeasePaymentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due in Three Years",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInThreeYears",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureOperatingLeaseRightOfUseRouAssetsFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears": {
     "auth_ref": [
      "r544",
      "r545"
     ],
     "calculation": {
      "http://www.gaintherapeutics.com/role/DisclosureOperatingLeaseRightOfUseRouAssetsFutureMinimumLeasePaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due in Two Years",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInTwoYears",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureOperatingLeaseRightOfUseRouAssetsFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r477"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "negatedLabel": "Total NOLs"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureIncomeTaxesDomesticAndForeignNetOperatingLossesAndRelatedDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Loss Carryforwards [Line Items]",
        "terseLabel": "Income taxes"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureIncomeTaxesAdditionalDisclosuresDetails",
      "http://www.gaintherapeutics.com/role/DisclosureIncomeTaxesDomesticAndForeignNetOperatingLossesAndRelatedDeferredTaxAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "auth_ref": [
      "r478"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.",
        "label": "Operating Loss Carryforwards [Table]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureIncomeTaxesAdditionalDisclosuresDetails",
      "http://www.gaintherapeutics.com/role/DisclosureIncomeTaxesDomesticAndForeignNetOperatingLossesAndRelatedDeferredTaxAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nature of the Business and Basis of Presentation"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r3",
      "r513"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Nature of the Business and Basis of Presentation"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureNatureOfBusinessAndBasisOfPresentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherCommitmentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of other commitment.",
        "label": "Other Commitments [Axis]"
       }
      }
     },
     "localname": "OtherCommitmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureOtherInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherCommitmentsDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other future obligation.",
        "label": "Other Commitments [Domain]"
       }
      }
     },
     "localname": "OtherCommitmentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureOtherInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherCommitmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Other Commitments [Line Items]",
        "verboseLabel": "Commitment"
       }
      }
     },
     "localname": "OtherCommitmentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureOtherInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherCommitmentsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about obligations resulting from other commitments.",
        "label": "Other Commitments [Table]"
       }
      }
     },
     "localname": "OtherCommitmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureOtherInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "terseLabel": "Foreign currency translation"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfChangesInStockholdersEquityDeficit",
      "http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Other comprehensive gain/(loss):"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r75",
      "r78",
      "r501",
      "r502",
      "r507"
     ],
     "calculation": {
      "http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "totalLabel": "Other comprehensive gain/(loss):"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax": {
     "auth_ref": [
      "r68",
      "r71"
     ],
     "calculation": {
      "http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax",
        "negatedLabel": "Defined benefit pension plan"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfChangesInStockholdersEquityDeficit",
      "http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r12",
      "r13",
      "r55",
      "r571"
     ],
     "calculation": {
      "http://www.gaintherapeutics.com/role/DisclosureOtherCurrentLiabilitiesAndDeferredIncomeDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.gaintherapeutics.com/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Other current liabilities",
        "totalLabel": "Other Current Liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureOtherCurrentLiabilitiesAndDeferredIncomeDetails",
      "http://www.gaintherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "auth_ref": [
      "r6",
      "r9",
      "r201"
     ],
     "calculation": {
      "http://www.gaintherapeutics.com/role/DisclosureOtherCurrentAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Other Prepaid Expense, Current",
        "verboseLabel": "Prepaid and deferred expenses"
       }
      }
     },
     "localname": "OtherPrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherReceivablesNetCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.gaintherapeutics.com/role/DisclosureOtherCurrentAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.",
        "label": "Other Receivables, Net, Current",
        "terseLabel": "Other receivable"
       }
      }
     },
     "localname": "OtherReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OverAllotmentOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.",
        "label": "Underwriters' option"
       }
      }
     },
     "localname": "OverAllotmentOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureNatureOfBusinessAndBasisOfPresentationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r97"
     ],
     "calculation": {
      "http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "negatedLabel": "Payments of deferred offering costs"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchase of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "auth_ref": [
      "r352",
      "r354",
      "r360",
      "r379",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r402",
      "r404",
      "r407",
      "r409",
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for retirement benefits.",
        "label": "Retirement Benefits [Text Block]",
        "terseLabel": "Pension obligations"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosurePensionObligations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PensionAndOtherPostretirementPlansPolicy": {
     "auth_ref": [
      "r386",
      "r405",
      "r406",
      "r409",
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for pension and other postretirement benefit plans. This accounting policy may address (1) the types of plans sponsored by the entity, and the benefits provided by each plan (2) groups that participate in (or are covered by) each plan (3) how plan assets, liabilities and expenses are measured, including the use of any actuaries and (4) significant assumptions used by the entity to value plan assets and liabilities and how such assumptions are derived.",
        "label": "Pension and Other Postretirement Plans, Policy [Policy Text Block]",
        "terseLabel": "Pension obligations"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementPlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PensionExpenseReversalOfExpenseNoncash": {
     "auth_ref": [
      "r102"
     ],
     "calculation": {
      "http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfCashFlows": {
       "order": 4.0,
       "parentTag": "ganx_IncreaseDecreaseInOperatingAssetsAndLiabilities",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense (reversal of expense) for pension benefits. Excludes other postretirement benefits.",
        "label": "Pension Expense (Reversal of Expense), Noncash",
        "terseLabel": "Defined benefit pension plan"
       }
      }
     },
     "localname": "PensionExpenseReversalOfExpenseNoncash",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionPlansDefinedBenefitMember": {
     "auth_ref": [
      "r326",
      "r328",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r375",
      "r377",
      "r378",
      "r380",
      "r383",
      "r387",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r409",
      "r410",
      "r417",
      "r418",
      "r419",
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan designed to provide participant with pension benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes other postretirement benefits.",
        "label": "Pension Plan"
       }
      }
     },
     "localname": "PensionPlansDefinedBenefitMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosurePensionObligationsAssumptionsDetails",
      "http://www.gaintherapeutics.com/role/DisclosurePensionObligationsChangeInAccumulatedOtherComprehensiveIncomeAociDetails",
      "http://www.gaintherapeutics.com/role/DisclosurePensionObligationsChangeInNetGainLossDetails",
      "http://www.gaintherapeutics.com/role/DisclosurePensionObligationsComponentOfNetPeriodicPensionCostsDetails",
      "http://www.gaintherapeutics.com/role/DisclosurePensionObligationsEndOfYearFundedStatusDetails",
      "http://www.gaintherapeutics.com/role/DisclosurePensionObligationsExpectedBenefitPaymentsDetails",
      "http://www.gaintherapeutics.com/role/DisclosurePensionObligationsReconciliationOfFairValueOfPlanAssetsDetails",
      "http://www.gaintherapeutics.com/role/DisclosurePensionObligationsReconciliationOfFundedStatusDetails",
      "http://www.gaintherapeutics.com/role/DisclosurePensionObligationsReconciliationOfProjectedBenefitObligationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r426",
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureEquityIncentivePlanAssumptionsDetails",
      "http://www.gaintherapeutics.com/role/DisclosureEquityIncentivePlanDetails",
      "http://www.gaintherapeutics.com/role/DisclosureEquityIncentivePlanOptionsOutstandingAndExercisableDetails",
      "http://www.gaintherapeutics.com/role/DisclosureEquityIncentivePlanStockBasedCompensationDetails",
      "http://www.gaintherapeutics.com/role/DisclosureEquityIncentivePlanStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureEquityIncentivePlanAssumptionsDetails",
      "http://www.gaintherapeutics.com/role/DisclosureEquityIncentivePlanDetails",
      "http://www.gaintherapeutics.com/role/DisclosureEquityIncentivePlanOptionsOutstandingAndExercisableDetails",
      "http://www.gaintherapeutics.com/role/DisclosureEquityIncentivePlanStockBasedCompensationDetails",
      "http://www.gaintherapeutics.com/role/DisclosureEquityIncentivePlanStockOptionActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredClassAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outstanding nonredeemable preferred class A stock or outstanding convertible preferred class A stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Series A Preferred Stock."
       }
      }
     },
     "localname": "PreferredClassAMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureCommonAndPreferredStockDetails",
      "http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredClassBMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outstanding nonredeemable preferred class B stock or outstanding preferred class B stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Series B Preferred Stock"
       }
      }
     },
     "localname": "PreferredClassBMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureCommonAndPreferredStockDetails",
      "http://www.gaintherapeutics.com/role/DisclosureNetLossPerCommonShareComputationOfDilutedNetLossPerShareDetails",
      "http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.",
        "label": "Preferred Stock"
       }
      }
     },
     "localname": "PreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r34",
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureCommonAndPreferredStockDetails",
      "http://www.gaintherapeutics.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r34"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized",
        "verboseLabel": "Authorized capital, Preferred stock (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureCommonAndPreferredStockDetails",
      "http://www.gaintherapeutics.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r34",
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureCommonAndPreferredStockDetails",
      "http://www.gaintherapeutics.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r34"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureCommonAndPreferredStockDetails",
      "http://www.gaintherapeutics.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r34",
      "r571"
     ],
     "calculation": {
      "http://www.gaintherapeutics.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred Stock, Value"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r8",
      "r44",
      "r45"
     ],
     "calculation": {
      "http://www.gaintherapeutics.com/role/DisclosureOtherCurrentAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.gaintherapeutics.com/role/StatementConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets",
        "totalLabel": "Total Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureOtherCurrentAssetsDetails",
      "http://www.gaintherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Current Assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PrepaidInsurance": {
     "auth_ref": [
      "r7",
      "r9",
      "r200",
      "r201"
     ],
     "calculation": {
      "http://www.gaintherapeutics.com/role/DisclosureOtherCurrentAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Insurance",
        "verboseLabel": "Prepaid D&amp;O Insurance"
       }
      }
     },
     "localname": "PrepaidInsurance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "auth_ref": [
      "r94"
     ],
     "calculation": {
      "http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.",
        "label": "Proceeds from Issuance Initial Public Offering",
        "terseLabel": "Proceeds from issuance of common shares upon completion of initial public offering, net of underwriter discounts"
       }
      }
     },
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r94"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureNatureOfBusinessAndBasisOfPresentationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.",
        "label": "Proceeds from Issuance of Long-term Debt",
        "terseLabel": "Proceeds from long-term debts"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r94",
      "r451"
     ],
     "calculation": {
      "http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from stock option exercise"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r2",
      "r74",
      "r77",
      "r83",
      "r98",
      "r114",
      "r127",
      "r137",
      "r138",
      "r172",
      "r180",
      "r183",
      "r186",
      "r188",
      "r196",
      "r223",
      "r224",
      "r225",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r234",
      "r235",
      "r501",
      "r505",
      "r506",
      "r511",
      "r512",
      "r517",
      "r526",
      "r604"
     ],
     "calculation": {
      "http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r49",
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureOperatingLeaseRightOfUseRouAssetsAdditionalInformationDetails",
      "http://www.gaintherapeutics.com/role/DisclosurePropertyAndEquipmentNetDetails",
      "http://www.gaintherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalDisclosuresDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r219",
      "r641",
      "r642",
      "r643"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "verboseLabel": "Property and Equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosurePropertyAndEquipmentNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisposals": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of divestiture of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Disposals",
        "verboseLabel": "Disposals"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisposals",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosurePropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r48",
      "r213"
     ],
     "calculation": {
      "http://www.gaintherapeutics.com/role/DisclosurePropertyAndEquipmentNetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "verboseLabel": "Total property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosurePropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "verboseLabel": "Property and Equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosurePropertyAndEquipmentNetDetails",
      "http://www.gaintherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalDisclosuresDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r21",
      "r22",
      "r215",
      "r571",
      "r605",
      "r618"
     ],
     "calculation": {
      "http://www.gaintherapeutics.com/role/DisclosurePropertyAndEquipmentNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.gaintherapeutics.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosurePropertyAndEquipmentNetDetails",
      "http://www.gaintherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and Equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r47",
      "r215",
      "r641",
      "r642"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r21",
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "verboseLabel": "Schedule of Property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosurePropertyAndEquipmentNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r21",
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureOperatingLeaseRightOfUseRouAssetsAdditionalInformationDetails",
      "http://www.gaintherapeutics.com/role/DisclosurePropertyAndEquipmentNetDetails",
      "http://www.gaintherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r380",
      "r563",
      "r564",
      "r566"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureRelatedPartiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party.",
        "label": "Related Party Transaction [Domain]"
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureRelatedPartiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty": {
     "auth_ref": [
      "r563"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.",
        "label": "Related Party Transaction, Expenses from Transactions with Related Party",
        "verboseLabel": "Expenses"
       }
      }
     },
     "localname": "RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureRelatedPartiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "verboseLabel": "Related Parties"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureRelatedPartiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Parties"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r561",
      "r562",
      "r564",
      "r567",
      "r568"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "verboseLabel": "Related Parties"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureRelatedParties"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfShortTermDebt": {
     "auth_ref": [
      "r96"
     ],
     "calculation": {
      "http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.",
        "label": "Repayments of Short-term Debt",
        "negatedLabel": "Payments of current portion of long-term debt"
       }
      }
     },
     "localname": "RepaymentsOfShortTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r461",
      "r584",
      "r656"
     ],
     "calculation": {
      "http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "negatedLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureEquityIncentivePlanStockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r461"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock": {
     "auth_ref": [
      "r50",
      "r208",
      "r209",
      "r656"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for its research and development and computer software activities including the accounting treatment for costs incurred for (1) research and development activities, (2) development of computer software for internal use, (3) computer software to be sold, leased or otherwise marketed as a separate product or as part of a product or process and (4) in-process research and development acquired in a purchase business combination.",
        "label": "Research, Development, and Computer Software, Policy [Policy Text Block]",
        "terseLabel": "Capitalized Software Development Costs"
       }
      }
     },
     "localname": "ResearchDevelopmentAndComputerSoftwarePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCash": {
     "auth_ref": [
      "r106",
      "r592",
      "r613"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted cash",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCash",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureCashCashEquivalentsAndRestrictedCashDetails",
      "http://www.gaintherapeutics.com/role/DisclosureOperatingLeaseRightOfUseRouAssetsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureCashCashEquivalentsAndRestrictedCashDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashCurrent": {
     "auth_ref": [
      "r4",
      "r17",
      "r106"
     ],
     "calculation": {
      "http://www.gaintherapeutics.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Current",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "auth_ref": [
      "r11",
      "r25",
      "r106",
      "r640"
     ],
     "calculation": {
      "http://www.gaintherapeutics.com/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Noncurrent",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r39",
      "r298",
      "r455",
      "r571",
      "r615",
      "r632",
      "r637"
     ],
     "calculation": {
      "http://www.gaintherapeutics.com/role/StatementConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r124",
      "r125",
      "r126",
      "r128",
      "r135",
      "r138",
      "r197",
      "r452",
      "r453",
      "r454",
      "r483",
      "r484",
      "r515",
      "r628",
      "r630"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetirementPlanSponsorLocationAxis": {
     "auth_ref": [
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r375",
      "r376",
      "r377",
      "r378",
      "r380",
      "r383",
      "r388",
      "r389",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r410",
      "r414",
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Retirement Plan Sponsor Location [Axis]"
       }
      }
     },
     "localname": "RetirementPlanSponsorLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosurePensionObligationsEndOfYearFundedStatusDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetirementPlanSponsorLocationDomain": {
     "auth_ref": [
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r375",
      "r376",
      "r377",
      "r378",
      "r380",
      "r383",
      "r388",
      "r389",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r410",
      "r414",
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Retirement Plan Sponsor Location [Domain]"
       }
      }
     },
     "localname": "RetirementPlanSponsorLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosurePensionObligationsEndOfYearFundedStatusDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetirementPlanTypeAxis": {
     "auth_ref": [
      "r326",
      "r327",
      "r328",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r375",
      "r377",
      "r378",
      "r380",
      "r383",
      "r387",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r417",
      "r418",
      "r419",
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of retirement benefit plan. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.",
        "label": "Retirement Plan Type [Axis]"
       }
      }
     },
     "localname": "RetirementPlanTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosurePensionObligationsAssumptionsDetails",
      "http://www.gaintherapeutics.com/role/DisclosurePensionObligationsChangeInAccumulatedOtherComprehensiveIncomeAociDetails",
      "http://www.gaintherapeutics.com/role/DisclosurePensionObligationsChangeInNetGainLossDetails",
      "http://www.gaintherapeutics.com/role/DisclosurePensionObligationsComponentOfNetPeriodicPensionCostsDetails",
      "http://www.gaintherapeutics.com/role/DisclosurePensionObligationsEndOfYearFundedStatusDetails",
      "http://www.gaintherapeutics.com/role/DisclosurePensionObligationsExpectedBenefitPaymentsDetails",
      "http://www.gaintherapeutics.com/role/DisclosurePensionObligationsReconciliationOfFairValueOfPlanAssetsDetails",
      "http://www.gaintherapeutics.com/role/DisclosurePensionObligationsReconciliationOfFundedStatusDetails",
      "http://www.gaintherapeutics.com/role/DisclosurePensionObligationsReconciliationOfProjectedBenefitObligationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetirementPlanTypeDomain": {
     "auth_ref": [
      "r326",
      "r327",
      "r328",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r375",
      "r377",
      "r378",
      "r380",
      "r383",
      "r387",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r417",
      "r418",
      "r419",
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of plan designed to provide participants with retirement benefits. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.",
        "label": "Retirement Plan Type [Domain]"
       }
      }
     },
     "localname": "RetirementPlanTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosurePensionObligationsAssumptionsDetails",
      "http://www.gaintherapeutics.com/role/DisclosurePensionObligationsChangeInAccumulatedOtherComprehensiveIncomeAociDetails",
      "http://www.gaintherapeutics.com/role/DisclosurePensionObligationsChangeInNetGainLossDetails",
      "http://www.gaintherapeutics.com/role/DisclosurePensionObligationsComponentOfNetPeriodicPensionCostsDetails",
      "http://www.gaintherapeutics.com/role/DisclosurePensionObligationsEndOfYearFundedStatusDetails",
      "http://www.gaintherapeutics.com/role/DisclosurePensionObligationsExpectedBenefitPaymentsDetails",
      "http://www.gaintherapeutics.com/role/DisclosurePensionObligationsReconciliationOfFairValueOfPlanAssetsDetails",
      "http://www.gaintherapeutics.com/role/DisclosurePensionObligationsReconciliationOfFundedStatusDetails",
      "http://www.gaintherapeutics.com/role/DisclosurePensionObligationsReconciliationOfProjectedBenefitObligationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r168",
      "r169",
      "r179",
      "r184",
      "r185",
      "r189",
      "r190",
      "r192",
      "r313",
      "r314",
      "r588"
     ],
     "calculation": {
      "http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Collaboration revenues",
        "verboseLabel": "Revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureCollaborationAgreementDetails",
      "http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r109",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromRelatedParties": {
     "auth_ref": [
      "r90",
      "r226",
      "r228",
      "r229",
      "r233",
      "r234",
      "r235",
      "r638"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.",
        "label": "Revenue from Related Parties",
        "verboseLabel": "Revenues"
       }
      }
     },
     "localname": "RevenueFromRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureRelatedPartiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "auth_ref": [
      "r304"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.",
        "label": "Revenue, Remaining Performance Obligation, Amount",
        "terseLabel": "Unsatisfied performance obligation"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureCollaborationAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r84",
      "r114",
      "r168",
      "r169",
      "r179",
      "r184",
      "r185",
      "r189",
      "r190",
      "r192",
      "r196",
      "r223",
      "r224",
      "r225",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r234",
      "r235",
      "r526",
      "r604"
     ],
     "calculation": {
      "http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "totalLabel": "Total revenues"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenues:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureNatureOfBusinessAndBasisOfPresentationDetails",
      "http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.",
        "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]",
        "verboseLabel": "Schedule of vendor outstanding payables"
       }
      }
     },
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureAccountsPayableTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r149"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureNetLossPerCommonShareComputationOfDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r149"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "verboseLabel": "Schedule of potentially dilutive common stock excluded from the computation of diluted net loss per share attributable to common stockholders"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureNetLossPerCommonShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAssumptionsUsedTableTextBlock": {
     "auth_ref": [
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assumption used to determine benefit obligation and net periodic benefit cost of defined benefit plan. Includes, but is not limited to, discount rate, rate of compensation increase, expected long-term rate of return on plan assets and interest crediting rate.",
        "label": "Defined Benefit Plan, Assumptions [Table Text Block]",
        "terseLabel": "Schedule of assumptions used"
       }
      }
     },
     "localname": "ScheduleOfAssumptionsUsedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosurePensionObligationsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of cash and cash equivalent balances. This table excludes restricted cash balances.",
        "label": "Schedule of Cash and Cash Equivalents [Table]"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureCashCashEquivalentsAndRestrictedCashDetails",
      "http://www.gaintherapeutics.com/role/DisclosureCashCashEquivalentsAndRestrictedCashScheduleOfCashAndCashEquivalentsBalancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureCollaborationAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "auth_ref": [
      "r447"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.",
        "label": "Share-based Payment Arrangement, Cost by Plan [Table Text Block]",
        "terseLabel": "Schedule of stock-based compensation expense is recognized for stock options granted to employees and non-employees"
       }
      }
     },
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureEquityIncentivePlanTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Schedule of components of income tax expense"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r474"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of net operating losses and related deferred tax assets"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": {
     "auth_ref": [
      "r386",
      "r387",
      "r390",
      "r391",
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans.  Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Defined Benefit Plans Disclosures [Table]"
       }
      }
     },
     "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosurePensionObligationsAssumptionsDetails",
      "http://www.gaintherapeutics.com/role/DisclosurePensionObligationsChangeInAccumulatedOtherComprehensiveIncomeAociDetails",
      "http://www.gaintherapeutics.com/role/DisclosurePensionObligationsChangeInNetGainLossDetails",
      "http://www.gaintherapeutics.com/role/DisclosurePensionObligationsComponentOfNetPeriodicPensionCostsDetails",
      "http://www.gaintherapeutics.com/role/DisclosurePensionObligationsEndOfYearFundedStatusDetails",
      "http://www.gaintherapeutics.com/role/DisclosurePensionObligationsExpectedBenefitPaymentsDetails",
      "http://www.gaintherapeutics.com/role/DisclosurePensionObligationsReconciliationOfFairValueOfPlanAssetsDetails",
      "http://www.gaintherapeutics.com/role/DisclosurePensionObligationsReconciliationOfFundedStatusDetails",
      "http://www.gaintherapeutics.com/role/DisclosurePensionObligationsReconciliationOfProjectedBenefitObligationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock": {
     "auth_ref": [
      "r386",
      "r387",
      "r390",
      "r391",
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of one or more of the entity's defined benefit pension plans or one or more other defined benefit postretirement plans, separately for pension plans and other postretirement benefit plans including the entity's schedule of fair value of plan assets for defined benefit or other postretirement plans.",
        "label": "Schedule of Defined Benefit Plans Disclosures [Table Text Block]",
        "terseLabel": "Schedule of Pension obligations"
       }
      }
     },
     "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosurePensionObligationsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r465"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of effective income tax rate reconciliation"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock": {
     "auth_ref": [
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of benefits expected to be paid by pension plans and/or other employee benefit plans in each of the next five fiscal years and in the aggregate for the five fiscal years thereafter.",
        "label": "Schedule of Expected Benefit Payments [Table Text Block]",
        "terseLabel": "Schedule of expected benefit payments"
       }
      }
     },
     "localname": "ScheduleOfExpectedBenefitPaymentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosurePensionObligationsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "auth_ref": [
      "r115"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.",
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "terseLabel": "Schedule of components of loss before income taxes provision"
       }
      }
     },
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "auth_ref": [
      "r222"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.",
        "label": "Schedule of Maturities of Long-term Debt [Table Text Block]",
        "terseLabel": "Schedule of future loan payments"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureLoansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r49",
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosurePropertyAndEquipmentNetDetails",
      "http://www.gaintherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalDisclosuresDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r565",
      "r566"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureRelatedPartiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": {
     "auth_ref": [
      "r17",
      "r106",
      "r592",
      "r613"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.",
        "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]",
        "verboseLabel": "Schedule of cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureCashCashEquivalentsAndRestrictedCashTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r426",
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureEquityIncentivePlanAssumptionsDetails",
      "http://www.gaintherapeutics.com/role/DisclosureEquityIncentivePlanDetails",
      "http://www.gaintherapeutics.com/role/DisclosureEquityIncentivePlanOptionsOutstandingAndExercisableDetails",
      "http://www.gaintherapeutics.com/role/DisclosureEquityIncentivePlanStockBasedCompensationDetails",
      "http://www.gaintherapeutics.com/role/DisclosureEquityIncentivePlanStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r430",
      "r436",
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of the Company's stock option activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureEquityIncentivePlanTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of grant-date fair value of stock options granted to employees and directors"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureEquityIncentivePlanTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r59",
      "r111",
      "r157",
      "r158",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r280",
      "r284",
      "r289",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureCommonAndPreferredStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r190"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment information"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock": {
     "auth_ref": [
      "r460"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.",
        "label": "Selling, General and Administrative Expenses, Policy [Policy Text Block]",
        "terseLabel": "General and administrative expenses"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SeriesAPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outstanding nonredeemable series A preferred stock or outstanding series A preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Series A Preferred Stock"
       }
      }
     },
     "localname": "SeriesAPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureNetLossPerCommonShareComputationOfDilutedNetLossPerShareDetails",
      "http://www.gaintherapeutics.com/role/StatementConsolidatedBalanceSheets",
      "http://www.gaintherapeutics.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeriesBPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outstanding nonredeemable series B preferred stock or outstanding series B preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Series B Preferred Stock."
       }
      }
     },
     "localname": "SeriesBPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/StatementConsolidatedBalanceSheets",
      "http://www.gaintherapeutics.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r101"
     ],
     "calculation": {
      "http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "verboseLabel": "Stock based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Dividend yield",
        "verboseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureEquityIncentivePlanAssumptionsDetails",
      "http://www.gaintherapeutics.com/role/DisclosureEquityIncentivePlanOptionsOutstandingAndExercisableDetails",
      "http://www.gaintherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalDisclosuresDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r443"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureEquityIncentivePlanAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureEquityIncentivePlanAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Equity Incentive Plan"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureEquityIncentivePlanAssumptionsDetails",
      "http://www.gaintherapeutics.com/role/DisclosureEquityIncentivePlanDetails",
      "http://www.gaintherapeutics.com/role/DisclosureEquityIncentivePlanOptionsOutstandingAndExercisableDetails",
      "http://www.gaintherapeutics.com/role/DisclosureEquityIncentivePlanStockBasedCompensationDetails",
      "http://www.gaintherapeutics.com/role/DisclosureEquityIncentivePlanStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "terseLabel": "Maximum number of shares reserved for issuance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureEquityIncentivePlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Additional disclosures"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureEquityIncentivePlanStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Number exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureEquityIncentivePlanOptionsOutstandingAndExercisableDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureEquityIncentivePlanOptionsOutstandingAndExercisableDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "auth_ref": [
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period",
        "negatedLabel": "Options cancelled/forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureEquityIncentivePlanStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price of options that were either forfeited or expired.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Options cancelled/forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureEquityIncentivePlanStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Options granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureEquityIncentivePlanStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted Average Grant Date Fair Value, options granted",
        "verboseLabel": "Grant date fair value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureEquityIncentivePlanAssumptionsDetails",
      "http://www.gaintherapeutics.com/role/DisclosureEquityIncentivePlanStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r450"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureEquityIncentivePlanStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r432",
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Options outstanding as at end of period (in shares)",
        "periodStartLabel": "Outstanding as at beginning of period (in shares)",
        "terseLabel": "Number outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureEquityIncentivePlanOptionsOutstandingAndExercisableDetails",
      "http://www.gaintherapeutics.com/role/DisclosureEquityIncentivePlanStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureEquityIncentivePlanStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Options outstanding as at end of period (in dollars per share)",
        "periodStartLabel": "Outstanding as at beginning of period (in dollars per share)",
        "terseLabel": "Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureEquityIncentivePlanOptionsOutstandingAndExercisableDetails",
      "http://www.gaintherapeutics.com/role/DisclosureEquityIncentivePlanStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureEquityIncentivePlanStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Options exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureEquityIncentivePlanStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Options granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureEquityIncentivePlanStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": {
     "auth_ref": [
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by range of option prices pertaining to options granted.",
        "label": "Exercise Price Range [Axis]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureEquityIncentivePlanOptionsOutstandingAndExercisableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": {
     "auth_ref": [
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.",
        "label": "Exercise Price Range [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureEquityIncentivePlanOptionsOutstandingAndExercisableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": {
     "auth_ref": [
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.",
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit",
        "terseLabel": "Exercise prices upper limit",
        "verboseLabel": "Exercise price"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureEquityIncentivePlanDetails",
      "http://www.gaintherapeutics.com/role/DisclosureEquityIncentivePlanOptionsOutstandingAndExercisableDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "terseLabel": "Share price",
        "verboseLabel": "Public offering price"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureEquityIncentivePlanOptionsOutstandingAndExercisableDetails",
      "http://www.gaintherapeutics.com/role/DisclosureNatureOfBusinessAndBasisOfPresentationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "terseLabel": "Award Expiry term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureEquityIncentivePlanDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r442",
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureEquityIncentivePlanAssumptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average grant-date fair value of non-vested options forfeited.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted Average Grant Date Fair Value, options cancelled/forfeited"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureEquityIncentivePlanStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average grant-date fair value of non-vested options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted Average Grant Date Fair Value, options outstanding as of December 31",
        "terseLabel": "Weighted Average Grant Date Fair Value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureEquityIncentivePlanOptionsOutstandingAndExercisableDetails",
      "http://www.gaintherapeutics.com/role/DisclosureEquityIncentivePlanStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted Average Grant Date Fair Value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureEquityIncentivePlanStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted- Average Years Remaining on Contractual Life",
        "verboseLabel": "Weighted Average Remaining Contractual Years Outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureEquityIncentivePlanOptionsOutstandingAndExercisableDetails",
      "http://www.gaintherapeutics.com/role/DisclosureEquityIncentivePlanStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balance (in shares)",
        "periodStartLabel": "Balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r107",
      "r123"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r33",
      "r34",
      "r35",
      "r111",
      "r114",
      "r142",
      "r143",
      "r144",
      "r146",
      "r148",
      "r157",
      "r158",
      "r159",
      "r196",
      "r223",
      "r228",
      "r229",
      "r230",
      "r234",
      "r235",
      "r275",
      "r276",
      "r280",
      "r284",
      "r291",
      "r526",
      "r664"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureCommonAndPreferredStockDetails",
      "http://www.gaintherapeutics.com/role/DisclosureNatureOfBusinessAndBasisOfPresentationDetails",
      "http://www.gaintherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalDisclosuresDetails",
      "http://www.gaintherapeutics.com/role/StatementConsolidatedBalanceSheets",
      "http://www.gaintherapeutics.com/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r61",
      "r81",
      "r82",
      "r83",
      "r124",
      "r125",
      "r126",
      "r128",
      "r135",
      "r138",
      "r156",
      "r197",
      "r291",
      "r298",
      "r452",
      "r453",
      "r454",
      "r483",
      "r484",
      "r515",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r628",
      "r629",
      "r630",
      "r669"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/StatementConsolidatedBalanceSheets",
      "http://www.gaintherapeutics.com/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Statement of Cash Flows"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Balance Sheets"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Statement of Comprehensive Loss"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Statement of Changes in Stockholders' Equity (Deficit)"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r124",
      "r125",
      "r126",
      "r156",
      "r588"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/StatementConsolidatedBalanceSheets",
      "http://www.gaintherapeutics.com/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r34",
      "r35",
      "r291",
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of stock, net of issuance costs (in shares)",
        "verboseLabel": "Shares issued"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureEquityIncentivePlanOptionsOutstandingAndExercisableDetails",
      "http://www.gaintherapeutics.com/role/DisclosureNatureOfBusinessAndBasisOfPresentationDetails",
      "http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r34",
      "r35",
      "r291",
      "r298",
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Options exercised (in shares)",
        "verboseLabel": "Issuance of Common Share due to stock option exercise (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureEquityIncentivePlanStockOptionActivityDetails",
      "http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r34",
      "r35",
      "r291",
      "r298"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of stock, net of issuance costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r61",
      "r291",
      "r298"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Issuance of Common Share due to stock option exercise"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r35",
      "r41",
      "r42",
      "r114",
      "r195",
      "r196",
      "r526",
      "r571"
     ],
     "calculation": {
      "http://www.gaintherapeutics.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/StatementConsolidatedBalanceSheets",
      "http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r112",
      "r276",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r290",
      "r298",
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "verboseLabel": "Common and Preferred Stock"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureCommonAndPreferredStock"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "auth_ref": [
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.",
        "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "terseLabel": "Stock split ratio",
        "verboseLabel": "Reverse stock split ratio"
       }
      }
     },
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureCommonAndPreferredStockDetails",
      "http://www.gaintherapeutics.com/role/DisclosureEquityIncentivePlanDetails",
      "http://www.gaintherapeutics.com/role/DisclosureNatureOfBusinessAndBasisOfPresentationDetails",
      "http://www.gaintherapeutics.com/role/DisclosureWarrantsDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_SubleaseIncome": {
     "auth_ref": [
      "r553",
      "r558"
     ],
     "calculation": {
      "http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of sublease income excluding finance and operating lease expense.",
        "label": "Sublease Income",
        "terseLabel": "Other income"
       }
      }
     },
     "localname": "SubleaseIncome",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant events after the balance sheet date"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r572",
      "r573"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Significant events after the balance sheet date"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureSignificantEventsAfterBalanceSheetDate"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Different names of stock transactions and the different attributes of each transaction.",
        "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]"
       }
      }
     },
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureNatureOfBusinessAndBasisOfPresentationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureNatureOfBusinessAndBasisOfPresentationDetails",
      "http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Subsidiary, Sale of Stock [Line Items]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureNatureOfBusinessAndBasisOfPresentationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxesPayableCurrent": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://www.gaintherapeutics.com/role/DisclosureOtherCurrentLiabilitiesAndDeferredIncomeDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Taxes Payable, Current",
        "terseLabel": "Tax provision"
       }
      }
     },
     "localname": "TaxesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureOtherCurrentLiabilitiesAndDeferredIncomeDetails",
      "http://www.gaintherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureCollaborationAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "auth_ref": [
      "r467"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued",
        "terseLabel": "Accrued interest or penalties"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureIncomeTaxesAdditionalDisclosuresDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r160",
      "r161",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationTechniqueAxis": {
     "auth_ref": [
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by valuation approach and technique.",
        "label": "Valuation Approach and Technique [Axis]"
       }
      }
     },
     "localname": "ValuationTechniqueAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureWarrantsAssumptionsUnderBlackScholesPricingModelDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ValuationTechniqueDomain": {
     "auth_ref": [
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation approach and technique.",
        "label": "Valuation Approach and Technique [Domain]"
       }
      }
     },
     "localname": "ValuationTechniqueDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureWarrantsAssumptionsUnderBlackScholesPricingModelDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ValuationTechniqueOptionPricingModelMember": {
     "auth_ref": [
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation technique calculating price of option.",
        "label": "Valuation Technique, Option Pricing Model [Member]"
       }
      }
     },
     "localname": "ValuationTechniqueOptionPricingModelMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureWarrantsAssumptionsUnderBlackScholesPricingModelDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrants to purchase common stock"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureNetLossPerCommonShareComputationOfDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsAndRightsNoteDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants"
       }
      }
     },
     "localname": "WarrantsAndRightsNoteDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_WarrantsAndRightsOutstanding": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.",
        "label": "Warrants and Rights Outstanding",
        "terseLabel": "Warrants value"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureWarrantsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": {
     "auth_ref": [
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.",
        "label": "Warrants and Rights Outstanding, Measurement Input",
        "terseLabel": "Warrants"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureWarrantsAssumptionsUnderBlackScholesPricingModelDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "auth_ref": [
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Warrants and Rights Outstanding, Term",
        "terseLabel": "Warrants term"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DisclosureWarrantsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r141",
      "r148"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "verboseLabel": "Weighted average common shares - Diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfOperations"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r140",
      "r148"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "verboseLabel": "Weighted average common shares - Basic"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gaintherapeutics.com/role/StatementConsolidatedStatementOfOperations"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 9
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6812-107765"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=SL124452830-107794"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(24))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(25))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=124502072&loc=SL77927221-108306"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(26))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(10))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(11))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(12))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=123349782&loc=d3e5879-108316"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.A)",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=122040515&loc=d3e105025-122735"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "40",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=118172244&loc=d3e17916-109280"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "50",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=16397303&loc=d3e19347-109286"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2420-110228"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=28183603&loc=d3e692-112598"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466302&loc=d3e4724-112606"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(23))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 4.C)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(24))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130561-203045"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130564-203045"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "710",
   "URI": "http://asc.fasb.org/extlink&oid=6409950&loc=d3e20396-108366"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "710",
   "URI": "http://asc.fasb.org/topic&trid=2127225"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "712",
   "URI": "http://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "712",
   "URI": "http://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123453770&loc=d3e1703-114919"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123453770&loc=d3e1731-114919"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123453770&loc=SL108413299-114919"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(10)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(8)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(9)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(6)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(7)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(8)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(a)(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(6)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(7)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(j)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(l)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(o)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(p)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2439-114920"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2919-114920"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4587-114921"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=6412939&loc=d3e15145-114933"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=66047640&loc=d3e39622-114963"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=6414203&loc=d3e39716-114964"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=29639808&loc=d3e29008-114946"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=d3e29149-114947"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450691-114947"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "http://asc.fasb.org/topic&trid=2235017"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f(1))",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)-(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(a)",
   "Topic": "720",
   "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.15)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569643-111683"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594809&loc=SL116692626-108610"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=120253306&loc=d3e28228-110885"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123602790&loc=d3e30226-110892"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "http://asc.fasb.org/topic&trid=2175825"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(Note 3)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=123403562&loc=d3e38371-112697"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=123406913&loc=d3e41502-112717"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918666-209980"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=124258985&loc=SL77919372-209981"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(a)",
   "Topic": "920",
   "URI": "http://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(b)",
   "Topic": "920",
   "URI": "http://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(a)",
   "Topic": "920",
   "URI": "http://asc.fasb.org/extlink&oid=120155617&loc=SL120155638-234783"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.10)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "(c)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.17)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07.1(c))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r657": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r658": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r659": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r660": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r661": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r662": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r663": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r664": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r665": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r666": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r667": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848"
  },
  "r669": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(i-k)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)(1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6787-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1(e))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>128
<FILENAME>0001558370-22-004363-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001558370-22-004363-xbrl.zip
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M3K[?6/WC@W]^9N'O*65( *5R121U]Q?\\4"]4L*+VC94)GM54YLX$HW5.3F
MMRFA#Q4S5!Q?/X#%%ZI36Y&:*KBQ$- CG^LU3=^6E*5K=UE/CF]*I.M*Q1.#
MG)Z<G!RHMUF=F5LO%%Z49(9T@1W8T'#8W <)6:8GC\-(-*FI7Y:* 2-JL-_T
M34UKRF@E&K2 -R7Y%CT^[=*LO4M/6"@C$KJTV)&8P60VZ;U(;.A;XH'7!_@:
M53A$G7-%%B1<=QGJ$B,*X^"HKI\?'8(91324[,&G$R0#21%,'W)RA--'4EVZ
M$M2UL8.<,C>@J-UXHKPD5H\HO%!:_?%F#^8!QU$S 0E#'JGJJF?IT]6*A7.>
M/(*':/@?L*1[:%,'?WR]O6IO1%6W"R9=G\M8T#M T"/".PV]\UA&/#A=,WG!
M V!-#$KN.0Q:J!M+5LVTHAZ=LY II:#;'L(TZ^02X8]4J -2'2W60;F.%NRD
MDG\YV!2W65(,L_8L_(OZ#;!)F.]48^+ G' G)"9.E_AN[/=@S&O6S)<\3<';
M#:;0@I&:W<_!SKG//+37,^)C#[U;4IH":4%G0@^&#(5>)@9^%R4YB2A'RQKQ
MZH17]G VGZW20<N 6SV]&;\C,W[Y"SYW<J$CD'V!/.<!-,<2IZ-'^IE+2SRK
M;&98CSO 6I+MH/ 1WM[P$KF\]/F3+:P9N1G.MUW@!)F.$CK"V.[RS)#@7*U*
MHE,I89*ZH!%A?L71:28T0?<&H)MNNC=*E*.70I%#E##GAT3<CR-J[:C=" YS
M4?0,_N&G/V*V0MO_0J,&Z%JHS?B]J^*7RG/ 2W4RB3\YX.2/,';J?-JA"!>?
M*9'TEBV6,"9^A5\\UEWL,HZ [!KJ&<2!(KHAS]C8C;UT>XEF<_CY\$VE.Z=E
M.C[*VW=4L3@40VLZ/]S.OOZ8=O*)H\MW ET!S>&LDBJ,UM-WZ/[,R /SH3Y4
M0B^']2&%Q]Y5"&S48D"W83?;Q4G;,._G1:AQPTL*<9@J982^T_B/SBH/9P\^
M6^@5R:?0F\W_AQ)Q&8>>]K'BID&B([<1>%C_5N<'+=_A>0'P%,K ,>$92G'F
MJAA'JG)&Z+>#'M<O/%3^-,SJ-U0P[C$WH3OGLG&RV$94FU$<VQE%5B":!OH/
MJZ1,^*'I72QU-)$N)O*9DS"9Z/%GB\O00FT&>GIXM FTDI?/]#[\.4[PO7#4
M\^\]65.,*%,)=# [7W)!V2*$_ID[>QS<JR9\>THQX_YS==37Y3@1%H3ODK+4
M9#_7I:D>SG-W414XVD1/F\C&3CF;9X\_K7'@;/+Y.G*WV4"E[V_80%X&#N\L
M>^E07<X(_0L.!_#NEOH8'TO]>6 UAGAV7T"; 56\A-Z#"!((79M\:8&F-H:7
MMK*T3_,Y=2/VF#^[A3:^I2X/75C.*?W:S:F+E#:;>=MB,UE9Q0$'C 6:HU3>
M:!(6)I&DCJ7_QPAB&+'H^2J$WA@H51+8;2C-0?[#$[41GF:K%7ZJ.*.2YA3$
MC;#UW_V^(1B465+@([[M5GB9J6U?_*W]OKCS0TGTV"'[[[\M2;B@\BJ\B[C[
M^Y+['A420_31,TS2S&61Y<9<NQPS_F^Z[-CIPF"\=HK%_;>C"\2!6A4YVH7%
MW/V%X+)[-C^+)0NI1"_MC$@&7OY-H3T:INQNS.:(\+2Z1-3B$7+0PDD+4<.[
M*@;?% L:I^A.V6MQ$!#Q/)O?@9?,H,<0F(9=E8H)CO(-]#V7-48)NC&;D3^J
M(I^(1X +!3AY"4Y:Q(CY[C$_]3Q53>+GG-L9@E%BFW54P@8=K&/BY$4[7E[V
M:#9=S.86E";"7?XJ2'-@N)[(#.YQM>NG8APM9P2J"U"8S(3_H2?T2'P,I:FP
MBXP$<\&1PG<-\'5A-8/ZI@HJ,O_DN)AJ17/Y210F+4&_'_'>,=YX0,&+?:K3
MYS#QO,R0K*V:NO5+%-%F/Y41OX/]P/20U";+[D.R"N]#4J?1X'::@I1/MX70
M2]_L(Z.PML2C:H))E\2C@MO \K)'8^EB+(E#)F_(,WGPFS:9&JC,\+ZOPIO*
M<1)!(U;;Y8F4P^VS>:],(1LA;;DAE=F@/C>D7!1VZS%MZ 7-X4;PWRA.NV<T
MA/I&.6EOXV@7V68JE6136U-9I44[#[KL L=H.3L>2 @3?R=^#.[B#?A@QCWF
M+:6UV4ME<]!Z:(%2G4<L5ED/%#SN'.\F.U$%]Z\P?^!7$("I _;IB,V\;8;P
MSC+_4)6 .P_J\ *J^*-**1AAWPWLX,3%0:SR,G3">?&PG=ZY/^4NZVP2'>6V
MF<O/7<V%Y.4[7">ZEXX1IEGMI[/SJQ]'8]K.F& .B(.5^FEM*#4\;4;PWLX(
M"I)'8+<\M;!>%?W#EDSESOQM@)]8GEQ(2LE<R3&=N7=:NBD)W3;EO!(IT"GG
M(Q@=P,B\[&M*\&^5NU6/C8G4#%7-1O!E[F<'N;@1NTZ;!#P(>'@:>C<BR715
M:3--\7XSM1G!FOT\+4_%X#.).F]G1+$+BO\@PK3[NOG:C%/-%ETJ8$2E#RH%
M)^]KZ%%QYA/W]SMW"=3R1C"7A8MK[E&_!;VN8MI0KH1.,Y3+?BD&2H7S@*5-
MI"[.6>GRG  +'*VBBU7H1$185H+JL+K#N%0#\ 9*,[8U]V0DZ8^9, >EC<!M
M"9R:JF:JGYSB.0&5TFJ+I8&Y#=Y*UZV'=Y+,I;H0)RUEA'U+V'5[RED<X3V-
M>%\N'E%84^$R:=C,W$)2FT%4#C\U&412H%,H41^)R,L<S6-+\V@/,=DQM8%>
MV=!J GV,,NUXR%<W6&.8F(;2M*W9F;\-\LJ>E''@GSRHF[;=0D$C_MU6Q[Y/
M'KB^J?%T(:@IMF$F-B-;<S-629R3R1L!['GZM$OBNBV;&=2:^ZTVSI>.^><[
M.*1$(]S,O5'[=@$/[Y9$!:I6<91D 5PP/XZHEQ,JDJ9C2UN*,YM$36H:R-&[
MQ"N]\8<!,8D2DTL/DG(QE<#3):O]Y8Q%TXXFT^G(@MILO2$B:C[%5$]DAK?F
MYK)$C)/(&8'J?"V=1:YP YD1K*.:V\;T-7-78T[O2YX7[7=0U CF=!<G1$>$
M=W5&L-\YP!:$MSH).F+;]2"?^01?"U;M1_=&0'9S@*O/B:P6\+8ZHC?BVN>>
M]/8+TELP:[P9/1'B:"DC.KWO0[>\"+T%IVXWH(]P]3]T*-)S@K8'"W,&,X3=
M#P_NW<Z^[J7'!T=,.Y\-;#D4V(*7Q6G $9/=W1#?]VKX%A2WO1-^A+A/3G5[
MUK09-LL;W4=P+#.>:U.=6R!HRG$>&[U?9K--2G,+)-:YS"-&O3.8+5.76Y#J
ME+,\HF6?$]N4Y-J"AR$W>6S]7ODL%BDK+9C89IN. /5-.+'+-&F!R3[%9 2J
M4V*)(7FD!9*6+U^,./3,_K#*Z6C!IDNFQ@A4UYP+<[)%"S3M618C(-US*]J2
M*LR@6&53C+!8[+#G&]F?'M7VW3RBHGAW_@58>F6'W8[+#&%-I*"XK4X?]:8?
M2E8I%<DMB3 &@GP'+V,? =Y5"L5VJ116*15'6UZ?_$/Z:\R-VAGL][@=T1/T
MA-<$^3% 7CDJU 5R7<8(^(ZR-^KA[L!I!OM-%>PNERV/8&^1TE$/;2.=&<B:
M WYUZ1TC9-OG>=3C9B8V@_>NY@.VIJ_>CQCN+OFCH1=:LIEQK?GD8)=$D!'H
M_ADA];#6$YE!?%\%L7I7] C4SM-$VJ='"VXSM"=-DZ9ERLB(^U:Y(PT3:1.=
M$4O;C\"/B'5,**D'J?C*C,NTBDMR@=Z(Q%99)O7 &"C-.-4L^YMNSQN!ZYS,
M4 _6QELS0#5+]?S2M1&2;3(<ZM%I)C0#97W7SHA:K]WT>K2J!&:4VCX'/X*S
MY19[/4PF4C-@->NPYHL11O1V^%&N;',!+YO@(8:#9W-%G.\ ]/U&5Q?9)OO
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MEAYI_S,[9!;<@^ENA;;1'W#6'S#]R_\!4$L#!!0    (  MS>51_M(]( Q0
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MC<Z.CDX')P?'AXFJ6ZFLG*84UEFFX54_'9T.SP:#@\'H;#@Z2E<]Q9,QRZ)
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M+L34*:LE$Q@&+LH?)'R^B((0=,&^O[E>Q%\XX%<'X;^IVE^L(,D^+A1:5$F
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MSL410;ME:,#XSAQDK1""&CKOC4-VE;T?GH#%M5K=]^7=O!5AK#<4E3J*KP[
M69JKU?N]RUKQ@\-QJ_4\^EH0T5HC9[:MC*"M'+>_AZYCNKP;OZ8XM>)BVF'S
MHA"8^8G[:5DU-&OWR38P9+KW"\38._2TKXA-2]P\<T$=X(#:H!ILJ*8 :^>
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MEGVD>DHO,11'S/JZ']L5_O>( OS7_P=02P,$%     @ "W-Y5/@,<TE+00
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M9R;1JDB(-#I(6E;,I*ITH^@?'6%C#2)Z#?E1$)W&_2B)'7P4/-K(MXB+JT9
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M=PD^Q\,^&GE!XKB]6Q2N,=TDO* @1"@3*7NV*Q=.BRDS1+3:Q71;H+6\$AU
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MF+#2NVL_"$G$(\GE0T-9'(+UK\[04#(%;FA<,=&B&_<%.==^:/DKERZ:\R!
M87"VN[5^PR3.["S?.!BU ,B%W6 #8<0R<)0/Y+(X(^6FPK@5(!N,&CJNB;:8
M;0B(LZ#Y*$3D$2_#KQ9!!<JKW@O2J0MA[U)3L0NIQG6XA0#JN&.)9!ZV!A/Q
M%"=TY'%"W]A+:8W>X@#Z9H)T5)<LM[HVC!L(P4+Z;.4F+.W)KO]@(*F/04+H
M!=H29+OQO7 Z20@]<":U09^Q57X&?1;!G?^22]WL4?/B1N@.%1,IZE8"?717
MCL\JSL:$7^JHD<VO>E4A!/JTCF6&/W"(RH\T7P*TC+P;=RES3NE5A1 ,5 ]1
M/?[ (<HIO-YL+9?PC?3:(BMI<*2L,(1@H7JHR3@"AQ./#CPKIKR9LW0GJSA?
MQ>Y0Y-[:<?\'G4Z<*\H:3WQ#68TV:0ZF+;)#Y%RX+ZZ#?(=M %1QE=WV"R'B
MJ>:.N7OA]!!$:%/&J:2>K-=[',1+3Y(TZ<]2JB&]*A#"IFILEBOY&CX2YP$%
MB(IC_9EG1C0+KOE83@*1-C>+VQM-H QEPEJM"%KQ ;=8/J 7Y$?*G WJ*@WF
M] #9;U?XA0+O<@;^^(Y]/(D_<JKIG[_>T(Z]2Y^"L1,8184EX 2TZ(B;C2(A
M&^VMGGJ2COL6FC3+/P]LR%1H1BK//+V=A-&&G]F<EYEY'BVY7UQ5>DA[I SZ
M0V"L@O".'O@(, G=:/.+&ZY%O3,?O!O2L]\5)NE,?.V?N7B#'->FRQ1=MNY0
M1/#CCI96Q"ITUM605J]*0#OCNH/]?D#"S.I&_RJN;/0KRE#DAXAL+;IM87Y!
MP4(A+P8G>D%WM9#S,A0 #V@;416ANYHYI3_V+!4(%*XKAG4'7G2J5"W%QH"C
M+N;/6Y?VC;S_?GN%7Z]HOPY7)SJ2[RWRNTN'OO^8CNG;WY9+^>Q8LZ$A%[-:
MRKB?&&LRW$D\*IU<@] BP0=%$&JIS)#+3C/1EWF!8#R2S,BED[#>D>D&@HM3
MEZ6LN4:],(TVPT%\=G] -G)?% ?@<C$(/LTZ.)8YZ=Q*]H"<R$XIC*=.NG>\
MH,1ZF%N5TFN/R6L6Z9\/R-T\1Z3\+$!KK4+P9YJ V!KC/5Q@/%RB_"Q]LT54
M"H)?TA@3$2/#&SS9LS#L_\Q\^V)Y*+[2394F)"ZSEK/?S,R@WY7-H*R1_YC9
M]+\S=.B'Y\(E^Y[BW\=B(3T$\S#FV"WXO!#U[A$JZPX44R"B2!%GJJH Q\)J
M!%<^D$#.'H2M9WZDEBD5?ZL,A&S6))#0U6H]SJ+<C&4(>L!(4X>W9@I B&MM
M0W&+ Q42(+?81[M;B_R.PJO(=]1#3E88P@FB;:!DO$( 3<Q+U3F^LM9PQWA-
MAL1ARLJE<K3'><G*$)Y;A.Q<?Z5Z24RS+H1A6P-Y3>[ Q6[E9RBM70V,<WT-
MC(ILC.,$636GG%D>2Z%D&'#S73F;C<%)\V264L5RW["*O%BI[G-"VW0T;?=H
MJN>R35YXDKEJ<S^/^+A99J;]L!X[:3^6>OH7ESJ7=_K-KW//2VAQZ9 4.635
M12'X7P5ZP^2L)GQ F9__XTHF8_[3D$<V'<7("9=3/* P+[\\R(3)?QIR?V8L
M3$[Q@,+\\G@A$R;_:<B-E+$P.<40]JS32?/;.&D66"H94_)?9$HJ-*!!FR,^
MF3;@>OA#4GI;(GM1X@Z%9N>='\J>M;1=?G39M_P?,Q^%(SRO3%DYIZR<4U;.
MX9UG8+-RMIP@2R\KI+0T!#=:S;R04IX@P+-/*LH2C+JO[)/:?::J &''4Q,D
M%5L0<+I!=,O WC*ZWFP)?D'RC)]:-2!8Y&LBI>1K2K;:(,O'T21;G5)AC205
M5M=X\P=$3+%.*H%>S)2(5W$&;KS.;3O:1)[%,D9D<GG1SQ[B<O>=^89=C_R3
M?R_E3X)T>\V#7C:5.M&>#,!ICY16>6(U=170BW2]D0\SJ9H\HY\;;'%@><9S
M=Z;B>--OZ7 '#DN=646"IE[5\2;FTN,/'**'5&*+Y0WV5SP?7)SS^Q_(<ZXP
M^1+(#,6:=<>;+DN3P>&](0O*G,7>%N/GY@=WM:844]H><!23>WAG[-I?8K))
MU-3$6?*WLK-DW^W,8_V^G?&>6?07E<+L+P^++W^=6;S__%-G[H&&T3A5;A!E
M!''Y7J# )BZ'6.5'4=;H+T4$2^TFB?;*_ ;'[:$AZ'W"AP/]@V7@8"0([42E
M7P%$<964(2?)H=/)W%*I;**-5)J%WP?/=U&&/A5G@=+!!&J]J@6:_WWP+!8*
M@>8IA;!S.CX_M,0^I3DA3Z[GR?7<@B,F?F#O<6O9Z)^N]8BM%W3WPTU$?\./
M7]WP3T0H18[<,V-6?X0>YQI<=H_3O8M"@N\1<3]=U 9+JQ'0%GMMQ+18[1BV
M:_\,T8-EX%BW%MEI R6O!MIPK@>-G+F.P7C"A*"+L\CU''J>/J.\(X_VI(5(
M15W0EFX]6"HX[ .;ZP;8R.N"ME\;8"/G$,).3[R#+9G^M.PW-Q""!#09RD?4
M*';QHPT*B+DJF#\14]GTKR=$-DJ JRM#V'+41KR:/7 ^"1'AC-3%\IQJ)+%L
MF<=7IR*$34I+8!99&P60#\A'7RW/>%AF:D'8T+0V'C-\@<,/?AX(R9:F!CKF
M>2#Z]M3Z-HD9BO^]]A^1'3$2+]"6/?XBV\?H5(3@=Z\!F@YKG:?=5$S-+,^%
MY['7EH3KEGEU"+YT YS,&>P<K<S)I>+H!N-9*%-IYQ@8/C)A;MLL$7EP;^W8
M4<,LY.#'<LA!VMXL:;#[^ &)'A48BR_+"^]55A>?LK^(C[NZ@IX2ODP)7Z:$
M+VT*<TKXTJ(PIX0O]1=4F9%6KTK_%EH35O9[-N42-UK;K)@KR2%55GC(B<84
MRRI>AM^-W\?+_^+9<^-G%H)+WUDL_X4LPE('(^<QM,+(+&ODZ7M!%I6XGQD^
M=$2_I7VQV. =[6VVY-W- M[?:(* #]<L+Q@FR#E#/OT0,M=9<)" 9D9(K38&
M,OR%+N$S"Z/J<<L?+KQA';+Q)X]LTZ@W_*FB$9AYDV$EMQ ,ATHRE7%N6C6!
MQ+EIJZPV@I 2K%!:4$!G=4:F,B&$J""$(#<#)<S=JA*PT\%.GBW7)-W(QW]D
M]O'Q%_1,5MS%9WZ (&.YDO =?(9:""J=UXB*D&E983A1TBVO)K!"I<NT&:P;
M (.BU;JG1@72LI#LLV,=RZF=<I&HK@9A.JM2NERX>B5'$. JSPR'B4%FZ#"L
M.UQ,FA%SXMPU6C/G:.TA9>ZN+)?P-T 62_9G?%57&W]);0C1:K5U09M+<.$9
M9<J3CP=CBS:R@IH0PM9:1%7 X0@0S=K(8G74'ZR"JA#BV-H<J0(61P!J)FE2
M_1&K;@1"2%R+0*N9A6CE?D!T?V"[GIN\+=S$V%UZ(DEL[,YWR>S>D\E[/";O
M\9@C^C%N3^:(R1PQF2,F<\1DCCAF<\2(CS<]&"(Z/=Y(@J**%QR>U@1'J_43
M#BWO\G5+IQFJB#C=:Z(\C64>1$%4K7<Q2E-%-Z(8P?&77[UPGR-^;CG;76ZV
M'M[)W<OZ]8_,NB'E<P08'PRG5Y@@=^6GP=U/A*YI'C^A?J92O9$G4F_:Z)&9
M0,R8[WV9N,[::!;,7L+>IR%HS?:E+_1G&V]0R^M&^WU"N)38SD+2OFP@6MD8
M3]CGV7+O4,B2&V''M9-RYS@(C6UM'_5L;?N.F9F-O=2W3?J>;9/R-NM]LKE-
M-K?)YC;9W":;VV1S@[,YGVQNW[+-[1&1%]=&;'>DC7JNSI%9V7*\C>!H?4UU
MCBIF: 1@OM(H[66ZS(T 0F;98WE_Z&(3$7^1.=MK ZIJXLCL8"I61P!V]CF>
MQ9*9: )FHT'Z6"M:.#(CEX+3T2%]SPC.+"[G!#FN_HRMU]@H#59-F1Z!*F2L
M4<FW1LNUK#J$9%PMPBUC$Z*IL1C0=T_P;WQ9*@4DFIH<OZL;WK=-29@]QS1D
M:DR6Q\GR.%D>)\OC9'F<+(]PMD63Y?%;MCR.]WI:]U;(<5Y/&Y<MN7M+Y-AL
MR26M*\2<\< CBQ[);7=K23.IM=#ND9DLC?D?@:Z,S>_0O;5R='Z'DEHF7P3W
MENO4']SY5H[,)%G!;>>!EAH49>SD"__*]2W?=BUO'@31AM,BS&3:3KNC-$BV
MR#\X^"_0!J^(M5V[=LL*(&L9PI,%_:B 3 +@E(!Y3(F+?/&#$TU:ZQ7L3T."
MG>5Z!$M[[#U#OL/, (97*C+5^C6$O>]\]2[R-P;/DC#_D*E3Z?O:.2-H[[,7
MUCUW,5$"9A:G8/(H31ZER:,T>90FC]+D48*S[YD\2M^R1VE*9UF]!1YO.LMC
M"I/NWO<T]C!I.XPLKP'4\@:.S+DD9W0$,!]'\H_N?4O'D?RC)7>R?H-'YGS2
M9WQ4:E'+[2BK/DH7E#F; S@9#J3P!")IBI$@S3&BZ5;2:.:8?$@:[$*T0I^O
M+7^%KMF=C#2-D*G-^0?-W"F\IYGK\\0I?V'D_G5&ZTP6YLG"/%F8)POS9&&>
M+,R MJV3A?E;MC!K9-%+=DQ)Y,A\&2+R9+T:V*UJ]W!DENH&DAC!\;<4;A1?
M?2XF;JP?ABMK[\CLW-I\CT GA+Z9AGIAU.:1F<:->!^!?DRY8WK*'3.<O45C
MT9MCVS6UQ?S-U!9C'>B884;(S,Y20HLP4F9_F2_.K_\Z66HF2\UDJ9DL-9.E
M9K+4P-DM39::;\=2H[%MBEU8.2'$BCWWXSKW. A);EP$=RA<+.76F\Y[';5%
MIW/I3">VH[+DC#O;Y[=ASQL@5\:([37?ECVO>YO.$=KS(C_D-SY7OOLGHEPH
M/!WB_+=G:(D),O(PM=OKD<58MBR=<6CA4>>I[CY(LZT\U?V;G3.)*TQ-RC_J
MF90S/4QFXLE,/)F))S/Q9":>S,1PMC^3F?C;,1,+MFZ'[<F7@&WVSRW/CKQD
M=_0<A,2R#7:_>JV-VJQ;F^LQ'(7RG.SY\%<ELQ23%CLI/EBAOO&F=OL0%H.&
M@\=(A_0E<UQ:]0MR5^L0.?,7>I)C\4!)2EE^A*05NM(VO7YASEO#:*&>Q(Y+
M.QE/BR6SA-&]'O\F-;MVH9.JWF"ZOH;11)6<!K@F;$QY<G#8WXPMZ%)WW<#T
MG!DK47<"&D![A$EU;^B_C]%FP?_04P^==F!ZQ]K"7T<"4 "^)WC+3.C8O[4(
M<5$Q#43#MF"ZJ#H%6B %*&#//0]_M7P;76%ROG8])YEX-"=^TS9A^IHZ!5\A
MC0&4X);JH>71/J\W6X)?8G,B(C;]AVZ<]4"O:@-FQI"V0*[B?HB1[0;6L\MH
M,H527!-F)OG61JF09X@.X31M8$J\M>.ITDV=PY_TG,-I;_L7:[=)?Y.K>'(5
M3Z[BR54\N8HG5S$<4^GD*OZ67<7I9N4J"BF#A0W2'67GZ2OR7M MY6UMGI):
MLU68+IC&6:HUN1^!.T7)T;^019Z^XG:48]\83&=(-SJQ9_HH5($2H.\ZTVT.
MIENC0W6(V3X&A;C"D7[N<\W68'HYNE.'F.NCT ;WI<79(6X-IBND0VW@7(]=
M&Q@75U1&EL=X"I[6B""+9;MK1ST4S</TGG2C+PHQC$Z!TA<B<@\%L WU@<&:
MNJ/5,DQ_3$MJHR6!X8W[-]@RO=5U^OZT:+CGK8S&''^!GL-K/PA)Q$:TRN@N
M+#G04,Y2HC"KBPK",:DK1)\?7&4F8$RH6;KNK(W::"XO#L1H+M<J.1I9-KIP
M(]]29M;TZ_?GZR6;5X1F;V5)");N*DW9^X%E3'3NKI]'JR@(M00M+0K#T*@I
M:2D7 /=M69:JW0B2TD,Z#I0,R">7\3L$LMQ<63:*4T5H09<M#F]D&:"8903X
MX'I"9*.W^>,%85C1ZPXNS@)P0-([,BS<_#%D>>&DL6-U&H!A]ZX)H)JUSG<,
M[(#K!RA8D/.U158HN(A8\.BE1;S=Y2N[-!"YP9H1ROR^S\5)KV8;,$S3E8C5
MY [X:(SS9KEV8OW2&H"E.C#,R37'7(D;<(BELT*B?(*1IRP)PWBKC8Z0!W"8
M7* E(@0Y5Z[/0NQ9AB>6DU1N3167AF$A-1@Y$CZ&MW/NLP+>(HO]S7@Q,WM^
M*)L]6:.S%];J;'-H=C1VT+U,XAR)B62<A?^ [(@0=@G0"MS@BX^? T1>V-'L
MVM]&(4M[Y]NNY_(0;97]M-4>!AG(>P[.=ON/_W"IKA%[O;M!+\A3V&)U*\.Q
MSW:@$MD)0E<@$*9PT8P1E*E6&H -VP!B%3;3>2&^>OR"@IGK<<#9.U6&6BMK
M0+ ]U])<(8PB#D&!=K;C$]6Y9P6!WD1<+#_ W"LQM_4W]Q9E  K21MQG>=.;
MF5OO#MXD+AXB0MUH71H05.O<"M9SWV'_7/X1N73#SB9$Y1ROK@)JDN]HO&35
M0RT-"!#?8A_M;BWR.PJO(M]1@RLK# %6'5W-0B/C!0(H[:AHE?NS]5Z&<YMV
M)+#V9_JQNVECYO>R.!AU)#JF* _!4=N#WB@D,+QQ[QQO-OPYJ'N26" ?0VS_
M;F;?^UBV[\7MSBS?F>U;GO&F1V/C.]S$Y'2?[?A2KY=H0%!CD-'*79UL"N&4
M)'0I3GN*\G L;1K Y&[4RGF"L-1GJ5*>NT0%@9R8*M4LMR46\ $!B/T\%9_W
MU#D#Q&5!;(.E^I1+$2!F !X.9P8XG$$*KJR#PQDD'+(,5)TD)&6'.P\HB1?G
M6Q L)J/=I<?;+\[1X]HB*)A'X9IN-?\LI7[4J@%M/"D157("+MPA0^V]118D
M#D[C)X5[1#@#U8C):T*(NJR#G)PC< CF3TZ:PZVJ$H1@2VW<JI@!!UEIBK@.
M@DA_:DQ+0XBOK#\MIES 1V<1A4%H^8[KKW0ARE6!$$59'Z<<*^# RH]]PR5,
MMS*$0,N:L^'(%[+JH5=9"T(D9J.E;$P#4&,Y4U6 D":X$59@%S5.XQI[E/.
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M,2GLI=<3.3QT4+\,"1K=$,- %^E-O5OR()))*>B/UE/M!/N4)J""B0"^B-O
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MT7_I15%)[@6XGCG EJ3.*W$%XXGKN4QC# 423F("S168B2SQZ_))I:;=A1<
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M&A=&]'HBQ3@#]>L.\C=T0YV]Z$O?V\-A%:1\T%RRP3??F=PJ7LDJ"-9)'VG
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M[SZ6B] \8WBDL2CD*'XX5R.?9C_,P-=%]1SW=#IAA[U..IBZ\0.\V9[P#5D
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MWT7Q'3_DVX@>?:%!)&9Y298<P@<7\K64JX=[E%L%OR1TM0]N_97JH+AF5^2
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M9_%/@RATM+"KK>], $S+!'4HUMAQ1E"FI\<PLR+.BPW,SY(;>9?SLY?.83$
M$I##8HX1$>^F!^(U])T3XK690(EXJHYS0[Q6/8;T\!N$B(?  )@0#X$YT!VH
MNFTI0-_>"RDD=E2[_7#5[0P*T.M*/L8AJUL4+UX+">]V-&;#1+CF@C[0K5B)
MY+\]T7C;:#Z-SK/P>5TCG+I^6T_T$:"M0-] R!EE(9'S$G\@P,W6^?F);%'8
M(. JQ[D)TAKE+6,!:'RWNHC"-'9<U7U?K8XSQ(!ZY=OBO]IK9K&O$'[PN <^
M_,E.R<E.!;T)+' <[0AC_(&&]*L3=![HR[UF&-TU:K</[7F7F<5UG>0C#.:<
M"<)!?#CE3T=OH;/EN+X)W5A,8\2_-^$C=?>QGQXNZ2Y*_).W[3MU1![=^LI7
MKK^U]D(<XQV$-[[X)EF0=QF3][ 1E_$A&:,!5Z4;QF,HCQD$U%.DH@;=D3JU
MJ2'RY>D.?;&O4)NH8ERJ26:D >?Y;4+<C 6)JIB_@##X]C[\]_!S>/D4_H7]
M\_@M$4>Y%O OH:_.=A>PAM_>?_KW/W[^],/EMVR@R,]]L1^C&.JAK)C@P#,*
M*3E0)V:]_1=*MDRG32+*R:0;GS6E(?&<0_)AVO7Q*<VO3"I2^;T47X>KF#,,
MLQW6LC*.'#AJ%*G;M\(>^'6B#K/;L!7WQCSBP%.8Q&$#F[5-IT%5L_F00@4A
M_DK]]8:AVY)EZ\ZZ9@7MDR*G,2"#-!3[&J;R%$-'&HB35F-5^D_6Y&"2\222
M*:KUY\G-DUO#D=8HEJ)1+%8U&N323]QH'Z8/3DKO*?LVU,^V="<S9UQI,(PV
MKM30F"NN-*DR'JYD7 FP71#)&"6RC&&@$V3Q,GLP.?"D*O*A*RVK%6UG!0Y'
M*JH10#:<39@?RSM8+%_5%S6;9D=J;!W%N.Y&B=6"\E4MD^L]/-$@BR[<.P=>
M[_YRW_:"8E<BLXI;7:.H [J-PFPB75N1@2 @61#!D4B6).-)&%-X^>TU)4]?
M:?#"6O"E.@Q8,;J56"Q_CQ\S;L*GK]&_4R=6;7B9T'D;R'%J&@/P*(C,'S]J
M=!D=0A: (;"!P%@3SALU> QH(A;7/\P"/QA;.@R"E"F]&0PY,8\9BN1DW@2.
MG&HS(9( \WE@R7!F8E'^ASF@R34S]R!@4B;T5K#DQ#A&4))3>0M(<JK,=$ "
MO&>!(\,9B87W'V<!(_[+,#E)F=";@9%CXYC!2$;E3<#(B3(3P@B<89H%C QF
M)!;>?\(/(_WL]68 HP=*S!\:IETL'0< X%'- 0!@H-<]5T+]K51?[+#L))L!
MSR@NO;_ODQ2H/D4/%,+!#XX.9][ZSK,?^*E/D^46MEN3O-H@:W(3,NBD27H7
MW_#WW+WL#T=F')\;4AR9R,SY@<SQ6&$_WSF!YJ9!78@&A3CC3+CC0^ D*.1;
M$$=(6!SRAG:^%(E$,;SD#5(6?PNCE!-?A_X_^=_)LQ/ $6>2;"A-)S[I_1_^
M^[!0;@6QS>$POK2AN0FMY;^9U0Y:Z4&Y-=)Q25--=3Z;-YU-_GHJ\6#G>W+2
M&)+3X?2\%U%*7IR 3</Y1:8C6!PR%W7Y:;Z$9=/P5I@\8E#WVIQ&<Z11IZMH
MD<ZIVZ+/QS1$-W7,1W=#O3T;L=.-DQ*/UT!ZI@D\#"X&Z9U@2ES!=>+,9T3-
M,]I$$B>2>I\7]CH%Y*VB6IEFE_D%YHG"+<%YBZ1(F6& GHIOG/%!-3(?2!4)
M'UGY(9N1^$Y Y+<!3Q:XP=X3$Q:'I"#+!_*TH?Q0J6SCQ)3L$]:&Y>MP[CN(
M>)T$N//*HZ#\[(&3)!&\)LQ:?_73#?'X2VYDRPL-)@PMF R"&]R195GGU@D/
MQ'EE^,&HIQLJ9<  &L-]&VK@N%57C1O[,H$5S0>$2$GQ.HH?P>4"6<B )4;U
MYXRU.V&&26VE<Z!L[8$=*O45,'72"R>.#S"C$+FVDT"Z#5A46<(A'H,U?KO_
M.?#77%R.GR"$Q^_V9XD/E R0R0\!E 1@9/W*'W.4#$B2ZS(QXHUOU/N2MH('
M*9@L,@2T GK3*G_R50^;)L9[ZC%V3/&@ ?=4#3%C7:-RY43PM!5V3&L6&C^.
M@=33YV@CF$Q2)9*L55@:5T/YK5E<U962E!;!FR^$-;5'BEO:JI;7=I6-$:_N
MMLO<UU]OR_L_EL)R.FVIN!DZ9&Z0U7-KR I.FR"-JR:%\DS@Z'/L.8!*7./3
M*VR@EWM\4%Y+CMN>Y#+Q:#VT<AF]<:&@>8-W))TLCLB7=$4AZ[M@_V>*+4/O
MCJ6+L?8(W:4_4F0Q-D5Y!-?NC'A$[ZZ#N=\+3D2RXG,.SFRZ0;]U6W<Z<XA3
MAT+_;%VXQ(9;)S?93>A&6YL%5[+=O[O5I5C+/Z<A^R&]9]HGEV)W8,^^D;J]
M8U,:R*'#R"1E^.A$ #&$F.G1>Q^:93N2'Y$,">=(2BS[;-$.%#D/-/5C"BDA
M2/?$^"U??=7]'V5CY+'0K&39Z>M;(O;N%H%-W;@@R[V6 &'R&Y#&Y:R7?"=7
MVS9Y\]DY;%719I<5;6?EM$<B#^NV@KA-Q[VG8<(FW&+(J8Q"M0^@=NB&W)%U
M%2\[=%L?Q(ZM+;KQ%IY@P+T;#1 _[J(PB>);8,B$TTX@ZOLA]VAMU=487=,)
ML4_KRSX4:DL>)&."+?$XLD&''$35<\X^KYN9U':;J]^/E*^<>K[]W(5)0)/4
M=T' QFREMB%RSU8K5UE)/6F%V&\;A#5>&Y4DA9/:>3Q\*O5Z1UI"W0_KZ.4C
M/V(:'T2@R5]XC/'HDG_XV\5?CO2L?( T>DZ%AV@I_HHP.FJ$,U[B^^O-T_^Y
M>KA=?KFTNTMVM)A9+"S>MKP?K]L7J?L9F>!H9ZR](T(G-I._QX[8R?)U:?5Z
M_&L"[6/!)';(KDW[3G;6<+4/X79*DCKIWF:%\U/]KQT__A7.6=ZMX-=EDE#E
MHYSZO6>' XUF:$:"VJZSPH)F#89$@X7 !,%A043U@%&@8$=C/_*N0J\;'(QC
M"J":G69.R25U>1I*?O@THNJ/J1.G^)3_-R?<._&!C*.ZP0 PNM)PU!R<WN&4
M48&__/$N/T&O;;6ZGK,#?:7ZS8!_TFU68*^6?EB@SWXK& T;\3\*Y4.ZAFNZ
MW6)^>!N\NX^COU,7+@P_2\6+>RGO,8UPP^O>I#KJ\6YZ4RA'/[MS #X[>>23
M$S$*ZH^>=5UG-Q"H#="2^I_TF]50T"#^L&.!8$3>_1**B?![(IA";E2WA&IU
M!C"\4:[+LW^  1IZH#J\K8X+$4=7_IFN_9 _Y2KO=(YF YVCT1-KCPKTEZZ[
MW^X#2)[,IP$M1&8W$.@8I7E(:*(PJ\%!2Y%AAXD2R]&G#^8+!J,:1A*71CA-
M(@>\6'D3NC'4XF/I.?_W:1-'^_6&W^.0+WPFI1*@57 \-<N1_49B@111QC1H
M?C%T8/K8+Y:.I:YI:&;RD'>>E.@]RV"X3(0G&_GMYVI%X,K>#Z0]6?6P++IW
M8V7 =8#_GZ8=>]D)I845KT=;S4 OHC"-_><]+]UR?KC:[H+HH#XLUJ$_TE'"
MV!3-*:>B\ZRRS38=1MR$K+ FSP>2,<>2<(YEFXP0E,@L&*""B&)'[CJ*J;\.
MQ<UB]_ 4.V$2\-SA9\</;Z-$_]!"1Z*S Q,3HS4C3!>*LX(=(\5&Q"(I!<G$
M("4Y" A"WH$H V\H]=E*F]2"96MX_FI%@=.0Q5B/T[:;\FR?US:XB+:[F&[@
M5M4+%64,!IXDC\ 3*81-:G+E-'IHAG.;5X^F_Y"S0:CK75H=C'B9$;<L)]1^
M9():GR!VG7O_I_DQS,_1?0L7&]:/OUNZO+NX(=$+,[AJO\QJBOY(XQ??I1?1
MR8-]NGV0CDZ=5&[.GTL=9I4>U\D];/8K.1!@@66^/:36DE;"P-+J4V2G6F:O
MLG4*W*-.LXO<.J6;0[?<8U:Q6ROXL,&;L4 5O8/JG6N(+GQA01\.&C[0=!^'
M=Z5YN+:E&DG,+K3;#=(<Z.K^LPI[#36&!8&,(1$<Y0(5D25GY,H6GO6J$>V3
M6R(6EF F*"Y^8(%'6_KCVE=8;N$=B'_R-9*[%:Q/)N"V5!\\FRC,#CM;S=%R
MYDW5?5;(V:[%P*?=2OQ@;03E\OYX1CE6_]V:$7__,>#4L:#E6U)?XX&(*0WP
MA:8$=/[X+N )@R,X40_Q0'$?^U%<6AX05;4-C:DD-O/AH]E(74:2>DHS'E1:
M%!IW?.',*PMNY)T08)S[B;WA=B1K'=MEQ^T"Z^HDD<:IF^UCP>"1K )P+"R1
M&>$=6.']1Y?31PK/3.I[?M?)=^5?.RUG*KO/#H*;#=$,NO5]9P6S+2H,"ZP0
M*AFW_*,)\+3[A;:1S,)/,:/"@9.+.$=G)OE))8<!F.OOG*9W@'K3G1UR&)JN
M8XF,9J*SPAI3W<8NKU%SDIFOP)9DP9+G36U">=*95DXZXP8P^8?DWO$]<[L>
M49D_.-69I2,4E4G,&WAJ-1D?9C*V!/CBF2:-:Y[,$#OG *<KAWWAM%65TL+;
M77CMATX(C[$ODV2_W7',/++2D'21@L;@IBL]P-J?*/9#P(/JV&,E1C[S"@O!
M"7DG5K_YYO$J8PC;AQE'R&GJCI"2KQO?W9#LO"JCY,OSG8Q8UK"X1#_Y([((
M;*T/[S^+[^*VY;NP<FP7A2G?_9QOU:BL8W%TN*3;:!T[.Q81 X\/2LIO:81H
M-I_Q&%%/]JV-$BU:CC%.> 7+_W@CQ4CV[C-6*+Z/68P6(YGS:+RHMY#%$0/.
M;<4^W*0<PH@5:F]I9#@UD_%H4)!Z:R- C69CH#[-V?S' /H!S=H'W NSSP+/
M![3:$8:K#6&_7 :+9X\O46FOG)UT0PK;7177*&J1]YG52K!"]/$AH;@;?)G?
M#5Y%L3SJGTF$99MI8#,U*VFYF&NZ=X(>=X$:",P.#-J,T5; M;[WK "B58D1
M:]BH,$+(5+TFA 4I1K/7SZ43SHCOPQ0:#W1PI@/!V>%+5V/IUM9Z0V=D.BLU
M97T_K*=B)C-:[7$8K(!D=!!&V7W&8-/]Z$M]WYD"R02'72JP,?XIEUX0,=_#
M+84.O,Y2EBXF6;:HN5>I0P9IM/<U3,.Z<RN-^2TXZZO4?Z59%C;CM;=XK7$H
MN55*VGDAM*;UYGR1N:B>QC+_$@7K"\WCFU,#7(6=:XTU+=1:,Q*GBROGTJB
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M!V XGI9;5@J %X2'MU5)^VV]]N-C\3((HJ\.PZSK*+[8^($G,V[-=9C.--\
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MD*29F"K4HV?)+I=+@E(P65.:0O82&KQ = &?:X+/I% 1MDFG%MQZV%3((Y5
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M?*-_]L"<NM:!$$Y.*P7%J.P0(-\3$(;T8\^0[4>?5[TSJ>56]!&2GC+)G\I
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M>HS,:KY*#Y$](]FT?6"6!P>!;OL(.3H-G?L1PNPFSZ1?X7GA!?1]L(P?3(7
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MC(2W&<*U(2@6/,B"Z5%P$I#Z%& OR%GX[A^)H!]ID+[+<_)8?[2;))HX.FI
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MOX.0!B%R=E(2+8"#@.(=55=6&!!ES6'!F@'D0A-W-R;9"CA<=06"%+2$.6+
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M$_;HHC@,'E'HGEVU1HA (]L!D[:,T/[<53-6;OT+%"]0-+7O[?!3&!VL:EN
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MJ4,1/KX2PKEK2+7@N. @M8 ($JO]9<+Z($02MQ/F,8CIAT((8OK%;Y?_W Q
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M!XL/:[950HD9:A4?!D#^_0I.)CYL/+)N'1]&'C$Z@Q&7PN2_7'Q81I&9\6&
MQ,7AO:KX,+6BU&W&'-I-#@ K0ZORGE@(^%YR:XHS5UO!?O$4>-Y-$)(?52.4
MVQD\U/:#(H5PE><G+-\Z//#79G;MK1]S("^/Q%ZG 8>]BF; &_7:/L=V&/<6
M8Z*0(>>S.+/<42=(Q,Y@W'NG.]"O=L1Z>&UNK$P'5M(+[OALDD9C_!(&D?+]
M.;NGW910N0Z(,MC,Z!JB M+W\*Z2$/,_Y4+JR2GX)=:IV7D1!U(-[5!<B4/H
MSK^N03%G*4A]-"<&=#@P[2@:+(L9<DDH,<DHL0ZF6TW[GI1W8[^[2:!2E;=C
M=]?HG88YHRMZQZ1CKNZ+D6.>%(+\511RE!YTK_WJ/-!J[FD3<YWQ[R&@CP>C
MZ:^(9")"T_-W%-IS5,UQU1"%,/Q S%E=6ME(]?,:UMFY'[L1BU6E0*\->T,/
MEJ0VPX Y/_3#5JW=29EDC$P7J-9\T2CW0:Q4C:/83;RFB0=),-NPBJWM*D7S
MB^QTTCB2LN2^8<E]VTTI]3X4A<+IU: \NDO(FU(OFW0$4-#WJ4MZ0+L9*;7(
MP9&1F3=+!Q.^=O/';N(-/O$Z3;2N]V;9-L>Q'NH*-EO>H9D8DV=#Q5X*#@3F
MY!M97&877IL9IS ,;_7.(G.FCEI$:YMJO/FUY1&A$K-(YU!V4ZII2H&3#BQK
MXU#K%_,BDX@=5\D:IFX$NTFG;!WK62C;N5=L8FK.-ZW336H0NQDWV(SK+I=>
MS8M@)UW7T$T-Q[9.8]I-R:$.<^K%I,@N:=8,':L)Q9S885C3KI-$S(XV[L#5
M\^G437FQ3N?6E-ZLUS[-6<>&MN?+L]7<G6$''R-;SSPADDL(?W\9^)2IB>V1
MW/\'O'DR[$C*8CX:\>QI#6KU7F=5<E!DR6=EV3T#;\47Y-ZP]GS!0>UFUG!&
M_"XB@67.[VF*43-L)0IFR/DD-X+=Y%$]>13POU=C_%C/0P6E=(M9Z/J1Z_1Y
MD879WV[*]&M#$.#V,,<C34G@:Q9A8LRDEA22RU(V(_RA:$;XK&.KT+.%_V,5
M^M[EAT]SAW\[.ST[.3@].CC=Y8>72KT*0%VVDG&-QNN502/(&=XJ/SP ^?<K
MN"I0&IDQ EFWS@\/0-Z-_&>+C$.1F?GACS%QIS#$Q>']QHFM*[5CR ]/OVUZ
M4>GBL_JF$D=+]] 3.#0-K>R'XNGH4LH+L:#* .["TT-/\  \$*"40EF*N_VN
MI*6A''X]/&6OFHRB)D%"2C ;RZP,>P:4Z='7TV-!F:Z+[F0JSQY%_ALOM;?U
M 82S,V$@Y$5W0)!GCR+W1&] ./EZNB<(A'71'1#DV<,TPZN7Z?[>U[U#0:$6
MRNZDVH(_S*!G0,<)@.^E04 7B--N9Q9NT66TEC,?VI/G$+#?#Q9[/A>+<+7G
MZ$0# D)TIJ7?05\U*WL-%-P%OVL/NMZZ&0. V5NTI3+Z(N/6S1U-#-Y=P#(I
M\^>)_BB4T:PX'7G<ZXUYL$F;Q%*%$,M*KT>52C];/@UZ9Z6BV^L EPDUK-.P
MK1+L?3<S=# XFR\G1LV7Z^6;%WPB](S"=TQX/7]7RRIE9?02Q+97_)V$H#\$
M\7^B^ DYP=PG-L3B:Z^,V3)(W]L[5_2Q-YLII[N9(L+.-+W331!F7Y%R^T-/
MF=I![.:.1CYGD^C,J$G46H#KMR&B*%GFB_D;<C#[K]QW=XK\Z1,^X*G>F(GV
MN[U310]K<[_BGEG3@ZRLMY@=Y9>Y4O_L _I!?V+&A A5WF*@MN=/CK:^W-A:
MU7'C@79WYN3Q(,=&SRY?31?Z"[I9]N[^-]&[^X4^=G?TT_O;)]_VSKX='AT<
MGY[J4@WCO*-_BB?ER3CNZ)=D7*-V>F70".YMM[JC#T#^_0JN"I1&9HQ UJWO
MZ .0=R/_V2+C4&3F'7U XN+P?N,"0E=JQW!''^"=! !8&5J5]\1"<X-2.[@"
MN8\.R44%#3<*>#.D'\2J]_RJ8'3/EQE&-Y-X%MQ_!?CDXWJ8L*'-\N6>=S-F
M:.::N]JTB4SD,9.$O+,\O?UUN.4S8CB>[NXM-/'PR8U^OPD1NO4QD2B*AUHJ
MZOK=\FDQ.&O-O:5@?GS#;G;TS5I%5Q$:CQJ:W(K4%U]AJJR'\4C4PTB[^T*7
M=<LI=+AS-Z:NJ-/CO<.CO;/CO5-MBG/G;NS9W5B2\<[=J,;=> ;@2BL8=^-9
M8\H/*+)N[6X$(.]&_LNY&YN$-FIW(R!Q<7BORMVH5I2*IAPF(UBB9\QSJH+N
M2%>$^VQMRZD!3KI#*U]9W@!.M<T@A:N:N77 @4-66,+B[E^/*Y+Q$^8YYM?B
MW)]>H7?D!6^$#'((]B-4J^\E:HY%WD*:ORO=L.3^"_)1:'N8B//ITO5=<A(A
M2YF(Y(7J&BG[]I0SU?RXC*!#1Q@!P,W8(XS* #3+U77NT=;1M)YIV;1D8%6L
M,CP\]H./*A [\$=1&$[#$[-#6,8O P_#)@A3)L]#1%DL9P8_WMO?-(.7FK56
M[?9O[68<_^O)9-BNA6IHME$7AO>.BBH:K]T/ =X*U/_\@O^*\/B))TC,6*VJ
M(S!Z1@(/]=;I7CD"V'3Y@GN8S H4<2PHM67!0&!@F5;!),X>P'BHLLFNYPSW
ML"792HE)AWN826=Z,20NRIH=B +:^S6;WR=>[+[8X1S%]2J3;3(7K I.H"J$
MLF%/[\**7LTJ41@7YCO^M#G7\5=XK4Q()!7F7/S)<%.RBH$3[N :7XHSP]G*
MA03_A-Z2T%G@/?@*J)NDU-K*I>J"@8B4I,H"[D9LOQK\_Q#V>6[TB ^Y2]NA
M)T';([Z]KVS=W5@)E-2ZL7]#5[<C7;^6?F(\5USZ#8S8M.IC/CLXAD0M2I@,
MMG:F;OP*1K;-+*X1!^BY=6]_N,MDR91"Z7=X<A#:J(K1 <O)IT!G-#E\5'8!
M!AG:[1^]<Q76U8YFHW2)S'O7)],P39P^F:4'QTV MF@!'/YZA\'&WDX!NX;Q
M_/0$+')1T/6IA!\"O*]%Z57T*_M3"EV<9G804\2S7J\P]XVSQS"8A_;REB07
MIB3?H$U'DW3]';*Z,JO7"(F^(96GP\;,O?[ 0\ #KP]4HS=/9, FU_(.AOVQ
ML==-6]\ 39.\Y&]X2"J\2N4=S#IQJM=GM'I7=>\DR(F$(]V['HKBP$=9F).<
M7F,W4^;9/H0;A##0)<NS7A^PTO6R]!/6U7ZR?B$5[U1G0;BT?0=-7CUW3H'!
M#)H7J+O-\.O.*",?@<K8<8/%DC_(^ZL;+RX3/ >7*+S^<+R$O$1Z'D4(___T
MQ?[@(U"FI1T>U;%-T<-+T!+4U?'DSK5?:1XRINF84V>'N38,,O)%HG/'(=[J
MZ DYR'VG3V:B^#()B<1807.<*CMDM>"/JL=\0&2[26^"80V-HBO\1X3+85;?
M!"%RYSYFQ.0-$6[[\[N :'.Y8/^3:K!_VI\5DP[);UF?ENU/K5G:J^6CV KR
M?BV/=CR:W#<KAJ[);DA[PZGQF][KSD3F^2KO^@F61@8'/,TN$!%7 3[WKD\!
MG*=2PS JMY*F.[I'\2+ OY"WZ-*9+<*=04<"3BLV(*2JTZ PK5</F*XGRELP
M-U=SZC">MP@4J_JAIV12<+F\ W?*I&RSH [;68,[:/<);1Z3>W4HCPC9UQ]8
M")@9KF^'G_1,0<\@^"2*SR&X:BY5== 7[7$W-_J<&YVDH,IU3MYG9D^>@<^&
MY+)[X!/N3V:KK[-;[[)GPH.&,^&Z+RN86>[J1PNE_6WI45"7BX<G^@ODHYD;
MUTTJ@5RO'5HMS[P#_=>#&R179]!4SP C=Z29*4XA]%HW" YU?8"H!JIJ&68R
M2K-==85)?"BR:L'#FUHD,*$FQ1"3\<3@="O-MK5HDN&'JJ,O?_<^,)BNLJ&K
M6T,[M @/AH,LHJHY9K"-1E3=C47/J18]R\8Q['()RCXAXKO&OV4O3N0"P55)
MC%(L[=8^5.;6)@7"=%36-!L6-7;8=&!;:NO0%5Y30LRE'8:?6'@D7R0W 5Y#
M+7#ZJ('S5?72AD!%:L9+-8S>U>@\B1=4P36^ [!9&)SLVXB2L]XT$VLD#@32
M_E>+@\."A!1%(,"AT@ 09-L*FBPHK'_]A5=T!,+GR*\J?F$:#1!]OIL3D7UM
MV3)C#C%CCD<M?'$B%9U2=4J?O6+>->2#$:@)#AEJ]@=M*>_!J $,,])0&1%"
M^+*500D/'*U7DK,4'#Z:D],V&)M7T?Q8,4R<^]/\EHN+9'SJ@BT9C"Y5W##2
MT,IG3A>80066*CC( DT 6F9Y+BLL8$]I?N2P?$,C YT<S!2Q8]LQUW 5HT5+
M.]0)\,/(5;3"'&)3S[[+/'&E=ZG\:>:8B^J?D2+ICD1QJ:"K[0)N7PSK-56:
M-+(9^8,JW+A9_OB5OE51^Z 5I[B1H&E%=*\IR,"HM GQP@LOEJ2PD0AI07*O
MB<7 X..7$.\#1/%!"V\7/M@DJTH(!BK4D,'+SD:L,=BN!C<Q;+4)JYX/CR$)
ML8H_'SV\;)/\HG\D+DTEVJRB1%H9"^;:0TT%0PRUU%?B. L,$HV3+E0IL^Z;
MP5@2IKZKHBH#YP74REA9$?YE>TDJ7L\+?I!LCJ+;J&K-L6!)P5K8EANPSNE]
M@:K UP<D;$PJU]IF, EP0M6Y'U0 _?ETZJ9TK'^6#HO_UA 6O^[$FJY[V=(8
M]R-PL2G*8MP!J(P&SLL$H[ )A!?;*/1$W3.6!$V;^0LBSX&\+<BKE8SG()EE
MP4F\C0#7,)"G=:S"1_--$ID/\S++@A&^O-@V1"Y%(1B11\CY.@_>?W;2 -Q4
MZMD'*G0J[NR+WZZ?-V2[_@&6(*6$L19D SE@I#:*&.31:_*NE)L2@WP]FR&'
MY,E>;86>L)ZLNVS,@(YX R-"$%_V511U9(*1T5;?_1 YP=QW_Z0'YSQN8L6A
M1X1)I(=QDM$O2^[G.&&R/C1N0*U#BP9C3S578+F!&)$J66S.31 6\D*N*,TN
M\+\$WWT'A3'>&Q ^!!$U*SRMN'7KKS:%DQE3T?7>7UD*1_JS=';'IAZ>*;+=
M>E"L;?6K"N&-[[A>^C2GK/'MJ,'XMNJSF%(3,QU98:G?+37''8/?IM6BI(%B
M1:V#4V0-DNRRCY-GA)&;/!$5=1[?($RZ[1%-GN"1?)8*2V%2JF5P>.P37J)@
M[L[!K04RW8D01R(>AU=8ISL@F-7D#KIJ63>.0XT U8^(/.F)A77EXM)8:DX%
M?YW:VE+@J><9K$"2+H@+@W<WPG^\!$\H3L)-%U#[AG984\$P(R^8B+ GN[]:
M*I'/RM@E'&B]+#<UO:7([9V%1EZ&$>'6Y8(\4GKKMP__5-S+#N&]<U/5S9X1
M@'T ?^(.HG*,RM!W,O[XU <4$T<%WIE?!LLE/AB2F]DD&#A)VY_,KEPOB=%T
M79 6D3.=GU9?*<;MT03-%N:TY="^K8BTG#U/E?5/WJ>:IB.@V9U75=*R8S&D
M7]NACV&U8E^339E97(M>>G86:)IX:#([QQ.$B@-/G6?D)"$-X[[^<+P$RSU]
M_:V G4TZ>.&O:CLI3]OC@\.3?<WZK0$!1>TT "LX=LA<#^EZ&+LCS1>?]0UP
M$DOWV",X' Z K2J@AV;PZ-#]8"\1-^-U4S5P.!M:Y**@:V 9$SEZ%EX4$IH?
M\UWE<QPXOW.3(W-JC 0B#0*J62TE288EXM6P+ST[BBZXPJTM:ZI8Q8EE^J?T
M'.*7;U[PB1"%X82.A2M49GE3!2M',-,5I$6X6;(JKD!+94P58C.13-?*8/>P
MGE"4AS\RKMYME  GK$$WZZ(,@??@@"P:F+?Q*F7 ($)4.$QQMMGSPA;HLX-\
M&Y_G\$;AW0V2R/M\0F]!&*-IK7H6J0)5W$*JN36!BN3_CL+70.^%K(Y:\J[A
MII^JYL' ;,Q&(3XW>XT@TO5V8D>.G2_)+=Y^L)VV#0[8O6),.:0Y3.Q%1Z\1
M?:CKL+QI]K,C9M[XVK+;CCAQIBC:MK,0-*C7.KO_]FB'A+ERONBSJB\Z:\[*
MVAN-5[G AL\7?!R/;(?&+#1XEYNK:?8RLP9X\5GZ1<B9+-%6>=J<X&FSIU>7
MB,JWWG?<E?+AG&ABYW<2,,:RX^2_@1.A.G%LG.RY%$,4'?-07O@5C/B:65PC
M#@X-O?J<A&1P;W^XRV3)E$+I=WARX(RK+(EF.F#Y_QAJ@1.MPJD!1FY]JK^V
M?.!L@'4'A3!(X4:$<.N  X*LL(3%S:%7T41G7/^Z<QV2H>-\'B)JH_W5C1?W
MKA^$GQ\OA>/+LU>K<MLT,1:A<D2R%JLR!HQ"G3=9EINJ@1.]!L7.9X8B@R_+
MO"%M\F5H#09MCRATB 3GF*$/*'Y"[\A/4$2?2)OX$Y^&Y&?Y?2:S>SN.47CI
MV>ZR3JVH[@,<^%H!9$/U#,(D:%9;Q:"\1_$BF$YFRI%8:G@'/RG.]&SG'1!S
MEW@5<:?91:PGY"#WO9+>L%-;VXHL<69 6U55.5(=FM X2FDG6Y.R1X'E(VVH
M5F;AJ7YG5$<\=:);46H%J-!YM#^KC+A,0B*2<W_Z$/A.^J$!2\+MF ZN;HQ0
ME/P &MJR#0!Q&PMI*&9Y4]$C1["BK 'P4%++RRR';$284SR9$RM+L8J<34*T
M57,1IYXMBO()-.)RB-@,^EKSK3\+PJ5\DEU,2R4Z@S9H%5KL/SZ#<6;9)(T1
M9\$M^YLN'P,=$$GRX,;$U,I_BJJN+)@)W<C?ZJ05)PA>,'QG27-\B75%P<A9
M7GC-@F<2:*#<N>[#^L+@9<^47[/H.13VZRF\##S,_" UMZQ\71';+\BM %Y$
M'#YOF*KDZ>PA?3*(J=KD'V26!X^&+LJ:3V4OAFXM:"!YQ\C>);&]R:OGSM-]
M<X)N_0>\47[Y@;QW=(_++%CP$&\ /%[X,J]BIB/I/7OH^%'Q__%S*LSLC/+?
M_R]02P,$%     @ "W-Y5"@0$G44WP, 5J$C !4   !G86YX+3(P,C$Q,C,Q
M>#$P:RYH=&WLO7MSJLK6-_K_6W6^ V?N]WGV6E733"Y>LRZG4/&N&)68Y!\*
MH=$6!.6BXJ<_W8"W1!,3-<%,UZZ=J=A ]^C?N'6/,?KO_V\^THDIL&QH&O_\
ME[HA_TL 0S85:/3_^:_0*<32__W__OT_!/K/_T,0?_^_L1@!'[*M&J&8LCL"
MAD/(%I <H! SZ QNB8XY'DL&40>6!76=R%I0Z8/PELQ-\B9-QND;)IFF2"(6
M^W?SL5G)1D\QC=NP-75#/6^2"U^%&S&_Z,0OFJ1I(GE+I6^I!-&L/V\?/*@&
M>Y9D><N!WJ(GD^M^)'??U ;6%,J J)@]HIR_)1))NJ?2Z4Q,HM1X+$Y+()96
M5!7] :E,(IY49+FW\23TS]\#!U$74=BP;UT[UI>D\3\_!HXSOOWU2Y7LWHUI
M]7^%/^"!4#&2BC'4C_ 6'1K:JOUL-KN9]RS=OX<F2>87_KF'*+9L+INNX5C>
MZ@Z_M0WDF[XY_17^Z+]E>0-NH#C;[<.G)WX%/RZ;PKD30X_:ZLWRT=! /0&8
M9+\<2S)LU;1&DH/(C!Y$)6)D>F-(MN6\I "ZN&/TLFM9"(K[QA/^NC4@.-]'
M+HK9Z.:RN074O>1-_D*_+ANZCK6W8>87^G63HO"5*8.&[4B&O)HR!<#=PT,_
M^".;Q%=CL\TX3:5>>WC0(KQAJ^&,\9M1F4SFUQR#<M7A%QC;:HI_73;M2\8V
M>?L2-)P!L*0Q<!THVS>R.?([3='K69SO[ CJ+_7KH5YKRP,PDF+/R8+0MGN<
M;T&-CM')+73#G>A.!NB&/_[]>P DY=^_1\"1"-DT'"3-_OGA@+GS*Z 2OCD&
M)BZ<_O,C_#WF>&/4TU___NU 1P?__OUK^6_PK)ZI>/_^K< I83N>#O[Y,9*L
M/C1BCCF^9<BQ\Q=ZZR_T\U8;!=IC7?)N#=, N &<W^*G 2OX"!4%&/Y'U*!@
M23(>,^$:T&EA# OH@YB'4Z@ 46CG17L@6< 6GP2UF^=AQ>+:!<53*R;=5[O]
M'X0-^\8_/V(_@A'/@V?D7<NGI$BA_^%9%#NF2-$B$WXK=@NL*I&SE$ 7QG5[
MSFK9ILW^(!0@PY&DHVFF?Q"&-$*#"27:+2=9!M(C=A-8;=RC/-1=)+M_$%#Y
MYT?)'Y/X-%'O'P3E41.DNZZ>L6>/+*CV?_Q+W3"IOW]M#_AS"4!N$8 4*WFN
MEZPY[(AS'XHC#H)N0[=G1Q,@D7FHS\M5W>%XMI%,F 6&50LSGP#,.PG01DRD
M2):R''Z:?9Q5GK0G17,[YB1F-6N2HLU./>WD\U%W >P/T#!9I&VE/FBXHQZP
M>#4<O$\(FW<=S/+8S-BBAEZ=3R>]6%DF^>%<A)D64V\"3 V22B;B9/P+*/)^
M')R4(EG&5-Q$)@<Y^JY5J;-4KO(T0!2AD>$2)]/["(+> 2PHGV2N@\$@E73+
M&4C6>3DD!2U)+QL*F%>!%W2W(XM21\U9W3%3Y>B"*=&E'--A51:_[<>_))+X
M:2H3IZAEC\,>GK?#.=],< K0EB7]$4@69RAY9$"N^OP@)!RA;7 YH=B9]KN-
M?JG3FM^)-.YS+$;1R"#YU [G0YMZW>,"NF*O^EN'\9I'&7R*JQ;S/5K(+![F
M559D<'_Q*[ZPLTC*05/9[JY;[,5HA2M5A9$J"7RZU?(>0%^,X^X6'C^ULRSJ
MJ>+W5I?Z:\RF[HO#.-N):1+/:Z5")I%M#>[$!.Z@BK@9[.GC"04.:XN\NCF6
M4&S@ASD ]SBG2[;-JVW'E#5V#NUU"]0E8&>;R%9%WA82);A%'6#Q(@K\^#$]
MX*LC3GJ,VR-V<C^4S;M-.55N%)Y+JNTGO2Z9C&RA.Y1$T1"J4H$4:8N*);"L
M)C]!2#^C&7DBFK6?:K%T/YF!FC>M)\H=9WHG3MD/T*QLV^XS1=^5YH-[;=SB
M-$^/#8?32D_)E>X0UV:2B23Y!42+'-!V$&U29SKMQ*@3$W*QX:(>4RV8X.^^
M!&/O)Q>[DUP]H\P/$C171D/R.K8REHMDXZ1\*53;V4$[-R!'YAW7,$C>X,1+
MX<O=-"LUY\5<I6Q6M6ZUU,IE$N7\K-X_#<1X3>>2KMBSM>HLEY\72P;MC; '
M0J43Z53F/0;6"\38EB.V)*,/_)'B;W5HP)$["L<%!-(2F@TI(51=N5 I/XQA
MI]E_/I :L&T ^#' *M#HUX!D@Q;RFZ&Q_-8!UFC;K9+TAS*\Z]-:U5BD4_/[
M44T2$-\TF7U*]RT08+>JF4KU%^/A/<.YE7Y<>V@(52O'GMVA**.GH[ESN/D8
M&#;(@YZS-=AX5U[4O30GDQ)(U@O9,9^N9/M' /ZC8SV!JU >C25H84;AU9J)
MIA=.D=^ YM^Q2T!'UI4EV&![]!U[9@!V\41ZS=B<[14IHZ<<P^Y?.=/O'KUI
M,\7F0"4G E1K0R5OS+FA?<S<CUT+B(_-@M!E'OH2.;JO-Y\Z=+KU(.SS$QGT
MO^7P5Y_'4P>J<:'%:A!DB@]TNB/52EN#3ST?O"^F!J:N ,OF)BYRM!JF P+A
M-=:ADS.-</VZA5],;=&AV:QQ$\#V/1+"YDCIZKJ5:[-X&8%B$DQB[1A\IO ?
M#6WV3H*9,IE[S(CZ,.%DI/9;8CMGCD:F\;K,MD>5_MTDUTAJ.;9M3XKC?)4T
MT6B91)RADI^Q;O)"U+.+H1>+P1KDJK.2E6BZ"M02;YF.+\:Z3Z>#7$DF]0=K
MIDDU:3!ICZDA8GM?2:49)KEW&>#D(T:.9O*]UM!*$?LMV%#WU=A80NXE"R39
M3B25^W1+G''VB<S&N>G%QT*K0@K)=HY,]A(I&V*SD6+B22;S>8;0\=3*+BV@
M+&#HK#@J:VYE6I]5G93Y%#N1!70_KR9EW>I:&IU7Q\,J';,5$X$+ 2N9R>RU
M@#Y)DJ[HHDM& PW/)Q;>C!#YD0%[KETV9$1/I"EPB\[,[ Q,UT9]Z,S092^D
MGZ[VIP53K]6$9%KW2KEV^0XDWV+/HR3R/=^I4=9$[ @@61 UJP>RY*)_ HE\
MJ'[>:XNW@([W4)N2Y7@=O(T2O&]-V!J4L:'%]BW@8[4+G0$R7$W+FW<V-GS:
M>DC<^S*@=%$:=E%O!KS52BDZ5+=8.<8\IRTK^UN2=E/RI)X.-OJ$O(!PV8XU
ME(9I!%M]VR:?>3_OU^S^^$&H3DL9U7$+L_OR9YA\>YW"DQ/5-6O%>=.;5TBW
MK3ZE .V:):U_3J(*6:V;  _IM. ZNMG5)K#69HYQMD]E1Y^-QK(5\[1NNWO/
M)0LQE9V-'FSP] :-6V *#!<4+'.T3=\M6@ZZ8*;?YQ*4 #.&9(PMY/33; 2L
M\K/1<I1=) MSN=T18H"&>:U>)5WO)+2<DHM!/)^D!+*;I,LQNBHHCG7%Y0M:
M[NQ$Z#3;F,8;EVW<A<U;MB@^;%&UA05K,;*=%?(SRGD4O<E7>-011^_I*,X/
MYU/.+I9=$AH+)SUE1D"4CI$7WWO13E-FC=I=];&K(;NO3MK\7=$=S]Y<M(L2
MT3Y_!P+6O#)/DN!.Z%:RC.G-Z(>$=_P.Q*>MF)S:0F^E8J!',FU NH4'U73O
MN01;.X6%'LDU$U/EH,YTTQ4N-\Y*>0$..X79[!NOF4P'O:+8GTIIS9O70*DR
M5:49][5K)NIC_:&E2P))YK)FC\G%YWDXZK^Z)'KP<-G6=.*D^=14@YG<Y,G,
M:'8.KP/'29I.,<F7H_VU'5GFRQ" ?&G[W[]QW-^M[0?GH7$0?AS@+8Y[^^>'
M#4=C'4?J^=<&?@PEUKBQ9>3?S=Q6<(C;]C."UVV^P_]JFZ[E?_,C)V]#VOG#
MVNMIU8%D(Y&#16S9&+M.!_5K2[X^;]""ME9 =L!R'P&) K!TLL);[B7=]653
M!\@# T[<[2>^_)D?XZ]-"\IH'NJF I:&!!S-C9S32'K:A)D,W';ED1YR2*B$
M(P1^!,WR&U3P=Q4"B_ I!78&V.;*U>T FN<W+Q]G@SX>=/!502^;(QDH0R?H
M&J% ]*L?Z+U"USY:_OAW7XO]Q/S[U\[7OJ,WNV=AW9?#IV%O7WX]H]2O7=,R
M]B-95I/D1Z<Z?GC-,B)H^Y?E]^5]O[;0?%YPX[&#>Q.9E1#I.^]LN![VE'BL
ME*^7R"K]M'C@<V8[5V"_#ZYWTO$*Z:^ -':@9.0EX5WML^$Y<S=9J.U1?:'!
M1RJ/T#PR'H;?2$Z_).(5S!\&,WDAQL?82#&F*D_; GBRD<U;ZPA5^QN!^K<V
M/LCH@?NSC(]:=R[;TN(AK]%-46T_B4S7*UZ-CRND3P_I3S$^J!FO*=ZH+7'>
MHM-,D(F6^+B8?1\\_Y;&Q\G ?.BVT]LKS1N+1\^PO+HW6#5%#<>F@;[:;]W_
M5(L/899M"+&$DYE5&/5N-HZL)-Y+H35L7@SQ>*2^2MN/O/D#N$38LQR<Z10@
MD\3)U:OGK'Y;S9JR;KH%XN4O1X"8$:G4QFK_\LO;(/;W\9YM;03;3882;J$\
M![7;LZ$")<MK2SK8Q1#E)A_>8Z4KM#TN-N\YD,_HC/$4NR^9=Q<(9$RFYSM
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M[.:'H,RWA5AK7AQVGOAVJG,%QZ58WJ3XT=C4C9RPLI$%R&>Q%:DN6=Y&/IP
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MG#WU.QV!N6VX;1Y;>"RV$N(SR1G6YNE*V!IP>*L%^X,-TRN\;G?,/+!AWP
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MS9(6X7G?._Q0,+QS_&<*P/B,:J8G!L)]&5"Z* V[G%L9\%8KI>A0C:SU<BE
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MHE+88#G(M@F:GM9=WX/?L^%3[A6'HT&"DC4WM^B-QT6+FD9O\^&*HE,X7 J
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MZJ9UNQ3FSW_%X@;9%4C^XT\O?@X4J:\/T%L+?*O^O_^ADN1?_L0BP\,P#=\
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MGM]&K)F(?YMXZEY$2B0H2\AJ*E7ADB90A"',F2FY_RX2)$@R1B42R4_/BKC
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MW\Y/,D.B*F?ZV6+KI&EI<]8WZ+ QJ<])O8N"O[>\^_Q^A]F8%)F4,K*4$),
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ME*'ZMG7O"\K (_7%'1(>NCE&\K#G<R!B7A?9&R:2BM(8VV<(I*HOZ10LF$?
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M5P#MG1FMBP>V+;&'.\PJ]Q8P^!>-W%?K.:_=MEB68HY->?FQ.B 6"Q33MNE
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M#T):2.: %VGN4:UV6,]U%VO6=0=8NJ,6B*KS,.Q9J4T$]68'3N3485-V-]K
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M4(+KB_!2,";C&5HO+BJO,$;L.JU)-P@ VP0P&(KX:O+WJEZE'!/A3=Z1FM6
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MHPQ6\:!;A#6 <"1Z9_4=-(F@36:(FC&D0L10\+A[?2ED1-J\7*R0VGNM*P(
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M,IR%V]V4C]LED]%O@T8) >$>(J8?1MD9]*I\S,>;N+!:_3AHB(!><\&][,E
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M56D? 3#+*SJ.#>63-CV3T0_>Z"_IT#Q<D*7=O=/<O4X=@P+W6K\<:]IODA:
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M"3K@H$(O=[@@0/L"5%#SS&![U1]&O7;!)XFJ]'JT$[#P(4,PMGB9;Z\NI6R
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MF1J'+$7NS82YCJ-F4K9C1):(R&:$)O-Z@C?3 T.ZP^-KMCHC?X3&"I<(3U>
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MGA@]N*=;V]LI$VQ:9Q29JJNT?.J[LVHFIC;W_]'A_KVHY;\$/O,24\H:LP^
M-E\EB=/7EOLDVLA_^49CI5 [P")UGWXZ'X=F>*(Y! ,3:1\*DZ2SM;S> "Y;
M2 9-H1%V==H K-NT/>"?/W,R>C687?;&X"$-;-U(W8GD,*9GY0(0D@V)<IV0
M0XNDO*];'TMZ7HESIZ>SKA;).Z,WF02(85L@#8ABJ(%0<FN!XG(+HT&VJ#>$
M'2JPD(28 S/M4LB2P?M\!JMR"UR6.K6I+OGI1<_A/:$&P$2^637O*NU%YZ^=
M>)N#]3RB* >&AYC1J8+OZ5?G;GNO<DS^5\PWVBR=AIGE44<,@*X2RFBJM<Z*
M!3P3.QD=:4:VTBKC?ZY1W<IB+04/&XM:J(#%4Q*8%\D3+HW@RP=58A4Q\T$9
MWLGH-;X Z.P>JXP'Y)F?#IT[(ZVN32PLA>X $]!KN="+E=7HZJ"Z9%3WTN">
M/M!C>S$2B(97VK?(_VVA0?S[WO[>K# 4H98_@_25G69"YQE99BZX"EIHUIU(
M[[9=WKO+]$&TTKG420\,F9Y5-6H(!]"^3N5A72>=J,[*8@Z4(UJ$CYV3B11N
M10Z"8]6><EWP;([#(G=+F4'3AF)<2 FW&R#6^;D22H.6:E74^<AM^P?\#ZW/
M5PF(P?R((= :#.\D[V]%#4SA=>1]H5(TZ$))J-OW^*SSW[$9@6C62NG"$&%C
MDQP? 4[4C;E'WJ1KVCEA<%J*DZ'34N1FM(RV;QD<:DK,9B3?7M=B&[5:KN,"
M%Y&_XB*"8-=WCM$Y6R_7&$3 1\#<\FS3 2XJHD&B *T8TP*P-GFR^:@J=R$D
M&*L'MA.A/SU]U5/D5JUOUYZ6+(2_>V7,?.!$&6.Y%:*%3L"$J5J+(/U3+(TQ
M!C>:CIFD3:)A8I*'"&@$:^F444?<3!$?G96KHE*L[F70UX976W6>P/![*F36
ML'Z;F,F90DS]0M1"9[]=K(& _&O:5N2I#&=<YE8LD".Q *[_7>3CN%2N:W (
MQT*)- 5L=D5@K;%ZCLGH!TOX<K9CN^$V*5*?F/ 07S89M8]?]_+SLSK*ZO&'
M4!W^1'4PK  KH$455/+\MR<Q69T@3( 4"30M_0>[5HX[#4.GSJ/EU,ELO!MH
M:KI4J.K@7_2>#AG"<5ZP:0['S$X'0>GW^DF@#$%+N&12LA4GE96W<W*L#[-)
M=Y:SWY;YA8[;5RS2^C?#>!D3.%DX,+GA/PE&GF%_D@*>&VT2GVOB-#1EY2&W
M#(G?];R55S8-^YY?5KA %"P],UQT-"&VUC.I"9"-]:(:#;=G-F$!%+719M@N
M!KV!/3@N*?7Q+A8!6M>:(NQ?QYQ#:_P&NH&)L1D+<%1U)45'#E3O7VI6WZ,K
M-'3E+=FH P8P4>)*K),8G+11>M_++)+>(\W:'3J99BO9'3KEVIY I73&(WL<
MR9-4QB\N+B;^ GW^1-9 _(QCQ"IOSL5[%$3LXJQAL5/9I>5.6]+5)^P$AGR!
M)CX@IZE+[4X?BF U<)M:Y\FS!P_&3,UT:KSG)]J 7FO[\D]6>NGV+Q_]ZC@[
M/+#.="_5[8BM6O-')OHW#QEK?CR<4BMLUDQYH4"G0*210I]L9)?,X/+A@U0M
M&@[H<;@3$+UM+:2V+;PEG%69'7EGO-B.2Q'8-2"X1 7&7"Q&,4,)LFQIB7J%
MHMW<','M6R+0W'I3Y\W6TUH(M@#2797]U+,;(V(A& ?M%4F1LJ67]2K!_,'K
MG81U9P6+O@T8#"H0T73S8JDKE:3 /D]P-\3 ^L'>:RQN+V)E77R^JVI9VG+O
M>-Y,WS)=F<1ZTV<PS[P=E$U"KQJKJBX/B?WE/U]A_4;/_^.;BA&[@\/O[3<#
M>$$Z (9.!6A@I?9^X@%<YMRS2:![ NI[7N(/A%Z-WMA3O&#RW+"R:V9<1%;W
MY1&[3%Y22AWX_ FDD,8L?)M5,Q<))1-A<2PJRIIEBHDJM]:\ZA9*>)54/UT]
MPQ!P$SM8^]SJFZ&LU7#M$+]JIH3VZD3E,H2=1<*OAG*L!#\GJ!+N*FVRU8Q.
MH<I+,O&5L),,[IF;P]M)WUN)WR'Q R*_+?,)V9M)_[#GNR.H!9J(!5D43,9E
M:Y<>"#46I1@;&!+WOFI%5&O.$CM$70T@.V;'5X1+5<35?C/?K0/[TMI:SL!#
MT%9XFR!E@5\BEU8$.=41HW-Q*V+O*6)#,O9YA(PM,0IR4PZ(&0+7ZKQ&05(Q
M&5LQ,4,4"&C+6VTPT*)LEXBZAD3KA.&GZ**O"!EU[Q89=8N,^F!DU$W5?;J"
MH5S"%+V?^I5G:MP.BD%41F&L!^=I"4[NY9E;4J([<2OTO7^%^[@5MA4W:)6>
MRXER\X0<F3\1*)4+Y1N+'FF6[BHU9U-R9452)(-^:A.:DR:6;$=? N!.CQ,'
M[H*!FRQ9;G@Y\2S>!&?K5<89XZ$4)#Y7'(><FK)M'7$[LKOFO[>C+U9A%GTJ
MS5>Y3;_MC/DN)YN[MF 4K5(G9I0O@[*DK7A-! ]_A4ZD#N,)1K[%(:.4#/J+
M(12)W$I3\WZ,8N4XLW0$9JS0LU;*>7*;19K,Q%I/ BM=N=),]_-!*NB0I)*U
MDZT.#GRO^.JR15=2YFC-)>0/26SCQOCUK\#+K^0(<-23)((3-:4IZ2T!2_,,
M&1WL=E!/-(_H7K!6U_5:^8]# &@R^L.:+C%E:$:HC6AWY-Y"+UG6:'12B9Q[
M1]4D4;N5'HI,8VGP6N714U*=U61X$/5$FT,RRHO7K^O PL^8L1XTL[#9X%#Y
M,Y3JC&=%%RSA-C+L ^M+#1+A"6S&BKOUZ2F4>I'9:="J',Z6C^W)$=\PG*;0
M;L?<T-(/9@=V:8/[MX%HW:>X/2?PYZELGRL3N.RL=K4))SUNQNBX;:9GZ];@
M%R'"CDUE\!IMMDYB"8TAK9)%/2F,QD1VH]Q#2 CT=DK2=.G0Y!1VC?XW>#T(
MF5;@0E0N760YC,@<*R#*H)B+OBG:0;'IYQ-=AR9U/3T!NCF'7*PCZ]SKW2]Z
MQUC[;4(6U]W:PG":"DCU;0^@$S(OQCEI]-+Q\]56>H ZQ$%"R65=L&,ZBDQE
M]G!)NLN3S$Z%11;%(I"[:' QA<,$G%UR#238O'^BU8@6M@P$>;<J5F[.;K[9
MJM?Q-7!-.2V6;AA[QRER(>M"X!M>#'-<K*9GY16KG?'*Z4MLMX<3S5Z\PV1W
MT&+E-:MR8EM&R%"Z@9/141 N]+!(B=@"[5&\+IR6FU=$V:V<D3I T8(DAW5+
M$ZZS4J:F'*1)OFYK@69-J:D11]=E&3M>+Y7W.J"^1#%@=U;.3ZC/OA"5Y7M#
M)9EH>AGLPR,W86XL-/+(>](8'2Y:1.8U<0F*(W5QG)AMP-P9 @@R3]K7GSDJ
M3TTH7H=1 :9T;HDD17Q*Q$YF+&^Q^@TGQ,O=(RO;T $LVFN!_'XA.EIA9FE"
M1KZ@GD$F\LIR%LL*DTP/H8*_.+ +(X9-+5]$OCD"GL-<!RK^U3K(')*0XUVP
M98I"<>"YC^KR5#GD:.8LCJO3-2R59/>NO7,)&%4# .S;H;;:9/2,L$DB"!>E
M=\M@:^H]LP<&F1:BV]++2&R1'!1;<K#6<+ U?Z_7BV,0)9\H8W*MTS;VQR$J
MIT F @!*9A23[][S<=N>WSAF*:/H1-,;8ZX4&);I;+M%-Y^$UL$D-=2U)@>7
M3D+:_"6181^E-SIRY&"AM\<..K8;H[T\U:U8HH[@LK@-S)[:I*J5I<+IL&CC
M>RL==^XYQ^I>8HK)973FAJ\^RB]H+&9\7DS *[ZF>,LE+:<&VDN_;3N1#.:2
M4G@SE^TF!F T/#!C;R3D.% S@M8Z0==.1K]Z4]F$S &9=P[(^EF=&!;.E1\1
MHYV"DO=F\KFSR+-Z[C"NI#0DSC_LBLXR):@>5L I0[H"]%7I^6DP*#'!"\E'
M0]UU8,2M2+V>7 BSP/O)'VGU*&N]F!2R_25:9!!+RPY\:78TU%L/7#Z&;IJ%
MB.&V7389_1X@EJ>-0X;8\A;*%?3I?$U"AQ QF:]$-T_;BHE7V@^CWU'D]6-9
M!H;75\]^__$H[I8FA$7(W8V795Z=><\B-1"3]DJQ[5D3?1=2PP8_S;=7M*K\
ML&C$/&2[(#5*N;.*Z(=JC_ WO8AJ%]GJ73J<P=%<\1(-7!JMN0XKBEHP)S6Q
MP WE/+@\7/B1<E,R#&$;/4H?"6T1,2G> <Q<!,#I3A!H"<W-CC<FXU0:UHYE
M6',@32F38?CA9GFX!M8<F\B9+*4TP<09IK<%/#[U>JUSEI<=QLW0OH<:&=+U
MCZ6)#%A:+$LCTA.*\T7!QO-*QFIX":,NT"Y6\S+M03>MVNEZ$8*/*5A0G^0*
M*36(9 ".)+;N]=E?:7MR2MT"%TGHF-SSG^HFF0]'R'H;J),Z(G8":W-HLD<J
MU*9=X@(A(VI6[1!B\H@*F#9'2!3-_NQ+T72<?)7-=N[?YA1O<XHWK]G.AS2'
MP"%-6Y9T>3W-Z#>$F'\(M7Z\5EY6;KN/7FN/E@UO\-]^>/EZ[)U^AS#K#A_/
MJF";]8I;H"Q)!)Y0 >-IX6&Y;8C&8:;L3M?5#(HS)OT0XEO7_O?EG" MU6S,
M3/$WF,<WP.7/M_AH:*>M4<+DO7O1KK*M&!?*,&(6YQH'#$;$1B?\\3*C/</;
M.SQ#W/F;<W4&(Y]2<**HV.P^@4$@ZON\M'"<(E"VZZ 9!MC^M180RA$JY]K%
M)2'01 YQ-0 3KXJ,O+^C[TDL>/B*FGMFFH\#TB4$2I VULI%+=::%9X88/>:
M:'6G<^W.*&C'*>UW[6CA"\AQR.QUT4XP</0Q5+[;O_EKK8)\L'B<:8E5J#ZW
MGM'][T\+^$,(S<O8$1-Y2W/3G*<;)$]6HZSK%WW#Q+(/ "@"NPT!G3M EQ%/
MA5!^[A3UL.*TGXW-OR?,9J@ FYYF_DQ!#8;53:22\2CFX1HL5XQ/)8Q5IF)B
M4-XG-%!69PYTB%AZ-40(N66VW/%5JZY!-%WJ-(PW3.V2##6?(\#O:4>AWF0]
MSW^:1O+#*WK1I23_>V.D]X@)OZ0(S>,BW$J6_&EU5*_Y:=H0=T %YJ>9D-^B
MWEA);2P!\)1W1#-L2V4JAUL13=V_WJZCQ;>= PV=:;L)W-GCO*)^3.B"><_J
M""-1RH^+Q%WZMP1@9-%?:%Y6S#L:)!3S1 6:%X4M2@87:>>R=$ \Y];30 /,
M'5FXJVJS3&58%/HOVT7AX3WN15GM.K9)M7#_9IB($50:@C>WD58H41MVF.,^
M '(EOT-W+ P9:GN6&$:IA@H1  V#^FT2.A>%:DK>RP&W@^(=#2<AO-ET9;K0
M[,=V7):T69)SET3D8\@UCIK*-.V /2Q(>N_GOPME2&5W"2%*8@+JJKJ +#56
M=-RG-&# PS^49A]NC/*@B%2Q$7NHBPQA_K'U9N0*&/K"IP1+\4YW5\-+6BHK
M8M6J1UZM*#@$E[O(J'V25MQHS\L^_BFP-:O :;^PY&NA)TWGYZ58Z_/(3DZ;
M.X3-_7J*&:CLX7F[LT!;$17DY6"U?@+6T8S& E(,YY"HKV,2(PPF4*0@S-R>
MER+*A;4=A$?!.RXM&0UA"SXP[=488E_*?>!,U^%TI;/+_ -:CET9_(<J:W!$
M\([(I'C_U)&+<GI6U%6W\"KYPAPJ-71150<-@L4"CI-!9!UYX&VSK)T9P.)I
M];N<>QX]M?EEO\^M^:9*EZ][=E:#!"/6I1&B7L*4.Q^_DS9N&UI_41J]K>,U
MA&;R?!P6X[3LDC"LBGN0:??.-'+!<&LFT_FMZ8]3BRPHZ] [B2TN8^HT$, D
MB-J*O<5Z!L\E#%,W-:W_JP;@&(%_9O$\%]4?M*#_7 3FIB7W8^8AG<"1$J$<
M/'YT+[=XM/6Y1RB3:;) QQB3DB0M$&7P%-D*?: D)_!!4 L-UNR0$<(*:4[*
M"\^O'>[OC_?W][,B_2IME0>U<L*DGGUYH9PGU_GNBFX1G<^T?E^!<T4<%VUP
M.9T)QT=,%[YU*S,HP#1,[2\+AM+@[&.G26^USK0(",_ZT**)[V"Z+9%)@3F(
MF,$U7R'Z,X-?#Q:3C.B\W! _*#:XR "*_VCKP;%O5Z5.:+;.*VT2XVJ(+,[<
M0*PWBW<C6"Y93!.V$"R'*(EF.27P\(0]B1UIC/@R&#@RMZ%X)X9=.:LL 1/I
M4+9L5UIY(3702PO\B<80FD"F]X02#R69@F3'(F<'V\5.RRHT0F,Z(TOT[Q2]
M$Y;26ZH4;[.<<GA7SH@FAZ7TIGM4!D1^[FW*HC4J)FV,Y[=8&74BQ(:)[4#;
MX>HF#S=X2\>L^W(.J>F*15XUC=ZH@1Q&_QSO,I:8HO:=7:ZUN+"7-@IW8<J&
MTD_RRA&XL-L\8F/6G+5ZZ^=E;@II.UK=O70AN.0>D7'.HY@HA:F")3%>\!0\
MDF N"=(QE?!43I2LMQ+^R"B!1QZ;;T?9R/R_677"'M*K[24,O?G2NH(H(CK>
M]*!29'IS\X;???G;L6M%,JCDS53C/ ?O,X:@X_SOZ?@T$,ZZQL0NTH5A6"=K
MBVM98LBXNA40]([1!ZHQ772;<?=>4QX05-?:%T!%CD=?96KOP6UJ[S:U=_-2
M>Y>;QA;0EC/'#+Y1CVR!E],&IW())G4A?@58"*E_74>7*U[4 R0>U()UI@S:
MIIBY'<S4295B",8>TF#FI,RNY>T[)]!QC5/@0?A$BAREG&>6LB, Y["!D_",
M%H ,Y0%2MLO4;@$W3.*$STI'<IE"3)'R"7 C\URQ#.O:-\J3CI?=D>E]#".B
M-!,"U#]=5F47J#0N=6-NJE/Z@S@L,YHUSQ(&0MBYOZDY_LIC-C<6?1X#*I6%
MOUE4I=Z#CCWU."V&[P46I2U QL"H6#0'K2&\H=V'2;'*L*"($<*YF@V?FTB8
MW&>5F%[*-51#98+299(2JGV3T6OJ_4=4\+UIY1K,C>PGN.2<WN@-+89-_HE7
M;F?^%GVLH^FTG%O_@*,0" HT@NM6 VX\!MEHE("HHJ$=5H].0K*"H9,2T\ZA
M_"U;RE,]3X0KA*,$[I7*59<&XP+2CB"]X6V*G(DW)R1]%*9+WR?U2(>WTL(1
M53<8(KF&).7^&6E)XF74]2*65P@SK5<Z=(.\0)?,("3_O=!1G#K"WM>UZE7-
M)&@A(F;9%A:<#3J4N^Q9X)@_RA)NB10HJ^@L$KCDLV3]:#.?:P11)1*QT.*2
M@@=4MP/$AU*JHLX( V& 3S?F&ZG4H2PU:^4T],B$3-=GKL&5SL)#7NZ7MM]-
MBB-ZIW=,3L0U4Q/'L@H7-T?BG\>=&!L,-RT#R([ 55KK,QR&E,TGB%(@7#'[
M*;5%PN!3FRX UY%P7-# 4)5W3H58A:([F5&E:-6AI'^?]Z6>+9N*]<H>44A?
M%.\4IPQJCMF :V9L554]>#HF5Z]SQ.L@XX@XD+P*FA12?9FBRH\<=XBV(#!A
MA9$SPXP,IA67,E7>#B]C:0#WK>AL+I%781P"_4U[*L?Q7UZVHNE]901NPC4T
MZRL&C_$9W4^\E.M*:U;E3%O)=N14")>*K/[)B3$8M$W7[>'@57)(*4&MG4:-
MQR0%D3?G/![5FV#!#A:EI7GL' &=!:(2*;C&R=7P$>&-_4.?I'^T-=[_9^]=
MF]RVDFS1O\*8<V?"CH,J2[+;;5MS3T19DFWU6):.)(_C?IH 2; *+1+@X%$E
M]J^_.U<^=FX 9)7\&)<Z\.',::M($-C(G3L?*]>:"-"2F.)D4=AU-@<!SGK0
M7YD*=@A4X6N3_CZ'UV-?1,6BT1EJ+"G)=O:.@6 >W#$EU*-GDAM%C.3;\\NJ
M;DOM!U-_T!"AZO6FCV3NU(Q."RN7,O.[K&=ZZ%6CX0I4VAN=I*O2P0N4W2PL
MDSF*^V/U"3KK>%M@RB@D1ST(SST*MW!Q@'&P1V,8%PJ^33!@.A/4>_/14;:Q
M)T2X@7<%,V[LJ<NP<DR] LK-F(8BN78\GY)+RVV%V(1RUW4:+B>7*!LRGH;I
M%\+)LRS74F3=43".WK2UUD[>[@=?UOKLXP?MN.D%EDJ: NDK*<L+#P:I,2@?
M!ED_T4*L#%21'N>(R;AC9LC%+7Q4.K)IN^L^Y0:3MN<Y(&@J#!5?-K4!!09F
MOO3X,P;CZ%TGL2 @QJ6'.4AN *S/D;&TP:M+@0MT*JR;_"8="150>9,P"VD)
MAG.Y(WLN8Z;V]SF%PIF^ZTU)^"/J#3+ ;A/>M7\(OF\8J>_6*=?5L/N91*=2
MNX.=WI2MXT[W2B+J.X7"8VN(-QY?S@?=L.F<VB0+P)32E:VV$L,'=K6\,"UM
M2?294'MMF >]+4SW>,#$+7C5AX_\Q.>F5A&-B9KA%*>/Y#=1!5G3,%GG:$^:
M_HB "F_&7 $\=[^-[ .6Y02K42(+8WI@BH?EN (4\1L;23RUG/?'2RBH+89C
M*3&2SRM&E9H4EZ$%UQ3\J)>M:DCY$/((4ZR)LTW:XBM;,00N44=G)!@8(TM?
M:Q8P .'&$Y6'/[ZXM5C7C%0 '(E/G3C;0,LH]8\XPNO#8WUDG<XE5F!-'8TT
MW/-NQ[W6<[7]#L4R"6T_SM&\+^?^W=R_^Y/[=[\[#P_X(,V%O![*RMW+C@AN
M*AG2$245QL<6H!5HJ==%_LH#?MHA").$HO)6"1.$JX!KJ2K&EP1,EI)/DS,D
M&$Y/RT/PM6;]KBCV^"X?*9 \$>J_+!8R*$C46,&#?K-4;<5H *VPXXK,!F5%
M]?6@K!DQ]A"T:HQ,3HE4I2CC2J]27<;L$_#P*D;#TO894TBWBT_>591TAOB2
MHO%'#Q[7F\T9T++T-?S;P\>?X@:!2<KM=X-Y],1CY!ARW!&'*E>X&ZVA4>7]
M&E7Y\\7%5A!V3NE+$,J2)$ "B(ISAE%,GBVYQP0"#.(R"0 $B,6C[6&)"BYV
MTE?<Z+_-."$BQ;0-2B9$RD]1NO"/;/,;%8*,PI#ANE?ELNQBW*HO%(1(Z4WB
M'2NMD.7N&\P2:LZ/2DZP(.9PHWM>#ZZCY6VW;7PI:%N:_&92D(PT/+2#QG*7
M,L7![R<A\5!BMCM%R:G42]C!?^^KE64-]+>R$>B?\A_A/WQ '!$ 7!YI!/$0
M%FT7MJE-QNF/T0TF@Z6" "\]2B&LOT' 1P2"<?XO&4?,M*TO<#=9>1O40_@%
M^1L8D5/F2?)4:DS\A*(R_C^*V'@8V:N;Q-F*0;2V\8DVYNH&HTXG6*_N3V[A
MTWF9KO"<5VD!(<7>WX5E=_'=,*&/@\Z\KFYH(3+!W6589317,C&P0OCJ\83)
M$18T5Y ],H)R?UY;4L20_I3WM%(8*]%CY'&C%7AYI05BPT3N:Z.3-+Y3:JD@
MFG Z9VL^L"]9:)9_S/C'=BD@1OVY0K#%M9E?%][I-.+@HS^<EE457/&J\'.:
MK2<Y.G%EX+X' [2JOY: SJ<UA&F>V$YYWAWZ0PHU$&>]KE?]CC7QZBK=*/V>
MIIYEF+YO%OHZTE=&O?1R"[(&X4\ZR%1>N&:/NW2'W/"F5?(+RY>G*"A:327@
M904_9)IV'9TYU(:CC*+)&"$ZD:3#I].6B8=V\5A1_H/%*DL[6XC7-L06V_ V
M@Y/L9!@I'&"[4DCG:,24SY:W.DK!>GHNR,R4XV<_=?KAQ[6+: 1"]V:C_L@%
M%Y(O#$'D09@1KZE_LR6.90[RPOV'M[-K59_&XE+7BTOHK.DZM#.B,*2GD-X
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M IIP 6'"S2D1FFKIR"UR2PACQ@-OQP*!ET-+/_(XL7E37N<8_O%3PE1(YA!
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M: 33&M;"\H/XCO*F(8!Z=&OR96YS#CIEMV$PR ,D0_7=5=FLS\A+'Z0O/9B
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M\0]1+AFN)-VP"(>&W)9N?"%W_C\B1'+BUD^2"/Y_=;]H&2)"TC6401UBI(J
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M:J'!TE_W;5OF,SG);+1WKY'J8;TUI.QJFY>[]C?R8MP'*/S%:E5#\8:@PZ(
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M L87. #GA?:C!)Z;C78VVM..,E^]@]VLP_$*SN5(#6L]]]D3SD;U(495%9>
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M83,,<K,!UZND:IP0>V)_WF,)T/>Z#$^?G.)2X#2X,C,0M7?=<<A;\JF!E(R
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M[7/"'8&JULMZM.9,1%F2;<W8EJY*'M^Y7Q0@"5;! H%J@*@2^]>?W&L_<B<
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MM/(#C-Y$VZ?XID'8YU6S^#C1W#HB+YOLBIIO-0NC]X67JP_:K>3G6PCFX&+
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M[^-DF-: 0+C%I53V/=#4PI0^&(XQL^D@N2/&Y/'+C(,9]I5%]6W;OHNOF[@
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M%<D[=3L(SVTT09+.RX89/"776Q95";_ !N/$?.-!*@]2>5-C:S\/EE;%L<.
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M=Y1#YNGO:<M;5U0\0S<^(+A?N<3WHSPB[1S5.221R "$$D^<2 1JLA')PIA
MHYV(1_ <YZPG)0<U'/E'SBB]*5P@'[S8Z:G^8E]6&P0_ST6ZZ-NNSWD8UM E
M4E3C.!?TW!2%DRL_8RO&K.$U%SVN.O"W=2?=-6V;2R^.X8DHX1SBXX4L+RA_
MCJUDSN'@E(.,?=JZ/SX7]LE4_EFII7DFG5R7!UFLYR77O8)%*3L*V)%1X9LT
MN7!,= BJC)["*2IKOJ0JQ!G]&:-O\\5YOZ'\_)9_F00_YMKDB\42T9'2.F1C
M;<'_Q?>CNT;G4IZ'5&YXD7">B(Q6+&<;BE27- "R9NLO.RU])S3U!R)'&0T
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M$7=J8<"E+#J:^B.T6@]-8_1+9!:-0#<<3]'2QU0![)=;2) ^@#_%0Z!0B$&
MI#+/*,VW(Z2$[Q()RY<%F38*'Z"VR3,8OOQ0[3-G^412=N+7PJ9GQJ8\E>#.
M=OPFC-UEPS@8C?C49G4(3JOR[P24XS"L-=YB2,.U:&P;'$7;Q+\1Q."JX*G@
M8O90[) LX$"P4J_M;;KR% E. L?>EI5?L$+:^IA^H]U%@2"8/;92:J3@0"*]
M)4#R%=/B]6U^QEL3W@-IH(8AMX7 =&?<3B:E::[6K&:]L$"'&]_![CN>YOPC
M\)HH"ZTO-MUUNY=82@_0/ZGHJ,\L/TEQ+$%P."17Z/Q [K8B4K#^+ [XHYCK
M\77,Y+"Q>;[61&M[_?:->3UITH83-7<G.J9"0.*7&=^1]BMKF@IN8'<>?4L4
M7"Z8-'%.=V_0@=!2W!,V9:MRPFF]89=T++C%>-D$(AL%T2@:2'5!6-V3T&SO
MU"C=A5N40PST6-:KJF<>>S$?B3>O6\[E)3VLIIUJ-;<SX_.)?(!Z2HS;MN?;
M2)#YULN!KS?;HPD%;#-3I"I^/'M%<[G+E=0A\%$W:$3@U]RQ[-6]Z#][^-5Y
MPU^C-2^;J_HL;*!+J(S%XDH&K$MVC44!^8;1SW3NAQ: @]L*HU^.I&!#Z4>J
MV#2"BZ8>B'@/^"#" ?9^RG<%&'\9=%_2>#3"]UBZ+OP[Y;VORQQ1Q)+*/-2;
M"OQ=438G034?F1%(H!8R/N4LKX7ZC[ - A+E<.]EL$)7!,,(_T^*L&:FL$,P
M4]&T$'1JP=G<7JX+97CYFP2Y+9=(+U\&CV9>[9_>@/NUY@*X0#,8&D^I7>0)
M-L78+?N*9$W /B?R[1?G*%()QN<OG&"?>O)\&_:VFWS&-_@G>P39>^I[\X>(
M+3;\%&+>HCWC3CJ<A)3PX2/PA:02.C47;<Q_@QH8L$)/Y?A/UH1 4A/-HS(V
M P3/%QKYX/]T:+G=DY;;G$:20!$$M= '66N)K105;1>24>U+?,;E5(BRH$XF
MAFW"U\Z3>$/B @#;_/@KCEPH.P77/DZJFKM&+;F+J"U;NCWYJ'/R=T<ZJ-/9
MM[2-I.O)Z]=01\;7N&_%X&<8Y+#++VS#'3^H)'/4Q$!C*C#VKLT^L4H<+N<>
M7DZ%5EFQ1PR10HO$!G' 4>34$@.D9'!3*0/\:[C,&X6_[:QS-ZWZTP3X $KK
MLK O#=.]U)>:!^?U\>/9@[\^_%_Z$?JX1O[4/SJJ3%UI2$YAZ*:2)B%Z4LD%
M7D'G ,EI)7Q9XX$[XG!7;KHK9C 8+KD +)EBA 0KN@)[P3K$'((HI>8]$3G8
M0'=)6OPKM74U'0>IW*#)35QYC2L(V#&J><1JYB4^3TW1NBC(RG3_ V@JONU;
M,H72<VOQAW.W#=J.8IY#WSBW.%QP'[KX296<)P[/'B;&=I2]Z3O :<Z+N@B.
M<S#B6MK*=X56KA,[_I$Q/DE$)4D4BZ@D[9>YI!\M-);C'#&990*E%=@R@<E4
M Q6^G:]&$)\( @;A1M/*PNKB# K[,PN^8U2_9!SIO%SXR)!L6GNA;=^(8LK-
M,%"ANT)Q9-S7Y#VHN83NF3<\ @5:G#=\P?):K *%^GW$/RNOD';:ZXX-O#W,
MRBOO5):18ME!-*IXZBZ66U^$74+Z.7R$ $Q;@_%O)-8UB=5D&=SE1H8A%I^"
MK-'@6CJD?LTXB0AKJ#"W-8[F4"ZH/DY9314;);Z*92%$5IN6<!TD,)ONUK\O
ME!0Q-6>P>!MSZS+Y2*.-%J*4WZZB(C-X\YB^F/T:;AF\^OCN]J:(56+VST23
M\MY!K MAQP^:IVJVQ1ZPD]Q&9+*@Q0 YO^(.ZB*FYSOO75'/786FDHT=3?:Y
M\E9V-Q[UWR*0F_R\<'+E)?^DZ$LVL@0P!I^"\ <).'1>G.?5ZKG#>L-9Y&]2
MFTRK-1<>Z[N:49V<LO#4S+/LP]&']2][ @I=<>K8,4OM.G$!8>BYT_ZQF(B'
MX,7PN0>+7[NXO"V[88<.[9[MYG<RM_6%2US]$&R03SR]_.[%#YINXN,:2H/
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M;#"0$_B0BLM!TU]3IVE!:\" E!W!NB'^ZW>7@'(<&)'<KKR7>Y$N)G<S1,"
M]_/C7R[+J]D"G\LKZR-_PJ80X*7S>9EK?!U;8$BQ!4@A\E(ASRN%[#J1 @2G
ME)T/0XJ4G,).88_,YW(BKZK2POE\0([:J- 4EMF. B>W0#GX:I*_C1 J\9*$
MH%3-K5OH8<2<P?;&91=1$/B\M$A]M\?HPV [%5O>:B20)%Y5Y'6(("F33JN0
MB[ZCDC=31Y>**_D<KXK,0O,ME5&&$DL)?%[A%5%D]IGOB!+,/O-;N%,H\)*P
MJ/INF7'F:K:]["Y(^+OCD_U-RK8*<O\0U2R?SZI_,KO-;NFV#/)?@WQ91#J
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MP(6KGLY+U]@E%8L-FH[D5V)U![(,Q8U,'=?]A?)K,3%>XK*:*R3)@),!YXO
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M.PN\9<'MR6"()#@GKF<6M)&238/@/8AFA<8F5@>6@98KQWUA2$2JWS.]&%)
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M[X6:F=Z8Q3M!NAP=Y?+JK59&U$I: H3GWLV--C:*V7[@%Z>UUOC>.'71 I9
MUO#*'3K-N_-1.=!..Q7GXKI5'Z*A2R!K.+:-,\4_ORK?%LO5ZHU1\N]5M-8E
MX)(/[J]K?K-VT:AFG6+A/N<<GU^BM2XC1/LEY[E^63'Z",$-Z^$A=WM9*(+.
MM3 T.+QV:V=/P[/^Z8'N#+MNMM*>( ZTY&+EX&)4S<MWW<9IXU&J54?CLG"/
M9EURL7?CQU&EM7_=%Y3JZ;4Q/LH<%!Z[37G)Q39*A6?9&%W?-([0_DZOVG*]
MWADWY257T'TJZI.L(!3Z1\))/W]G"1/A *UUR15D+CO#MI*]J0C5X')B^VAR
M_VD,0Q? Q?1<02[(!X_]JG:A'][>/LFNA8<N@,M=VSD-AHYJEY\ZI<=V\58^
M/KQ&)[#DMGJW1].*\>Q7RT'S\3'W-,VH*N(:\I+;NBEWK[/B4'AJ'.W7G/:E
MEC?.[O'0!5YP7\C=W%EGW=-^Z5QOW/3.C,YD5&QFE]"!ZTYS='YX=]_LWS:&
MVC1?K6?LZRX,79BU,G#*0G/DZ^7IT_6M=')1ZZD':.@\N&"EV^I/.V>7E_F@
M4<]GSVZ&M8EL!+6%DU*>2I*M5*M]Z>'&.[F[-#7;0PM= E87UT.MTNT[>2%S
M<7)8+*J%?7F"ABX!J^*]7+SOWLE"7[GK739O1_EIMH$6N@2L!@_%^O6D7:TV
MZKVQ?-1Z,AJE 9IU"5B-$!PI9M^[%.I71D69M&[\4X18V668_?SL'V?,:EN0
MGBJU<K[ACT43#5V"V?V)-WP4'EU5N-UO%]3'T=@]&>&A"Q#8[7?V6VHAYY:/
M'N43,S<8VGVM"T-#"$QW:GNX,/I"D2@R;XARS M[THMAC@EU+S$Y[@QF.>/0
MNA%^SHR18O2+Z/1C=$BOJM+1[UH+:2*!;_P-6O5G&3O6'!V8,(2\,0ZS9_I&
M!DV@@RH.9Q5N<R^_P4N@-B;\XH7[8/? [F$#]_!RI#*[B*^Z"'$OQVXB%3?!
M2%-*[H&1IG1<A+"G%MA-K.\FWIE>]JKJ\-N[5M_EFN&P%V95_S\\:*TY51\D
MU%]\*JLK<;6^\6:1P@[7_;\?TH^/;ES:4^1/W_KO%!Y;"/5F%[^6BQ?W"I^;
M1?DE%Y\Z8O]F%J<N<WKO!&5G1_"U1[ V+K#!^I2_2RP@!'!+6,*VP09A%-L-
M&\)[N<:":V'C=4->VF$1MVE8)_RG>KOKEP"_TW8W5!_F%8KW]2( ,0FGKE+.
MFQ4$!O\,_G_?[K@K\/\!EOZE-TYZ7_FTH]*OK913WUW\?B>7_A7%I[ZHGM:'
MW:5?00@^V'"!P=R6PMQK?K#-P=RVJ8M1OIM"6,^J?J&[(CVNET9L>C=ID U3
M(23_W%4MCY/W<C,9J6%2^J&KX7:97&";).L9"KPTZ[1@2+-1/VA>YO/=Y^'C
MC5P.3KK9_MU%X]0M%7_,Y$H7O6:UDTR.+CX_3C,9\\PLGXZ/W=QET#;[.?10
MV]#-@69Y__LA_( L_('F_^^'.?%_V<&@[?CTYS").O R74T;_@*"4K3;\)]R
M3$V*?DES7:C@=0/=BG]P'KHF \\<YO\\#-MVPR\>-Y3[B7KOW-^?!85:,P>!
MY++"JZK *WDYS+ .#V-WE%R&V&M$[#2JKU^-V$)S\.@5:YI9J BE^T+3>LSY
M!:W>_6K$;N1RYUZY^O@D&+G1Z"0C/=9NO'$3I]7E^6Q!X@NB\ )>IUIYGY.F
MK@S/=TU<" KDJ>^NF6S45_:%-'-+[V?CBOPB2<1U920&?=\ ^C:NTF\[0XZ9
M#?!D:D->PH OC\X'][V[\4/_UB[?3"K"I71^",42$ ,615[.B^OEOFDR;]#Z
MF%!-43>0S-*RC%W1&';8L/&-U)UU<_.TZSQK9O";OCX&MDQ53Y]D$'*]JXCI
M71C^:@%AV-3TQ_+#Z:!Q6CK8STV/]:G;A,I'2$!0^5Q6W1'M_%J;<+IK0,%1
MIF"P/7XK!VH*=?WM\FL<T!X9%5MW!@8B)897M-M5*#*-/L24=C69/9O<#(/S
MZNB^H0P/:[V3?/.H4:\U5?!PB*+,YU3ET]P;NP[>WP*'F<7D-^6BW\?A([%_
M'%QXNMJ71A>R=U+-B(='183#2%3*J;P@YG?7EG+I&D/-A%KW0\/V:%L.!U?9
MUV<"&'=%N6,6%J:J;I^%9;O$*DI4RH2FA-28Y"RM)L-/3:$O#+J5^_*3X@;^
M2?7XH7=7:^):AGDIS^?5W/>(%&%XS$Q.J1"M/H;'G9-!1=5'1K.<F;:<TF/Q
M0 F\,<)C<$T55+Y0R.Z([2D4/3FG@_X@G2R]+;5#L0@1IIHN%XTVEP>^<4_4
MKM_PMP!C*AEL$QAOEY@0LL$JY8(E8(++! .]/+V]5<I'0N;L1LT\9XI7UP%N
M<@&2 2^)>;Z@KMDOM6D!]]KQH=TC,Z6D?C??507[W*0;1G8_S<KRFAXV[MS<
M36X+3YY@'-Z-A\;@/'^LX3X]D'V3Y_.2Q O9EW0QAM#?%J%7FE,80G]>A,]K
M"*U<"O=MQVZ4!X.[^X>3_7+QS"@"0N.8GH*:YU5I:^-ZTI(O]QW4ON^PQ^^@
MVGY- -"F=\G =4<V^36Q+NO9Y1;:&BX<.Z-_3M6I36^-F1IV03/9[:B-:(,,
M6!FPICTT826PIEI'7 A>=(9H;5,<M AEKH8#Q/MXSC;\K90[F0\^W2+S3E=I
MV"[C=XCZEY9F^T6[70ZQ_\)89CIS2_WATZD_;/:#@MVL5^M%U[W"W>4A3T/(
M\066I_$M$9&E7_QVC."[$-')#)R;W(U_V#BJN8;2S.<G>;T&B)C_\:]4X!7Y
MI7)PVZ:4S\DK%>AC8:.U!I[!>4[''VONSI2NV)!A\#MN.PWJT>;B$5.E1VVK
M'-75[,FODC8T?;2O9Z-=<@;# %&G.J5*AXX;4JN&MZP"H'AYV%*.[QXS@N8^
M/4V>@^)EKE]LBKBV)UHHKP@%%EK D'X7C2=OB#O>)C-*%0EPF@_I"Y:A(<DD
MP^$-<TZ' T%EO4&+6ZHG,#TNW??##"J_:5")B, 9T( KV%VU@U@_#DI:PO^O
MSJI6M]90+OI*L5LIW=V/)N4'I,@IP/\+@L@+68E95+XA)C*+RF]:5-Z+B3>%
M<]>YW[_N"X/SKMV<U$_OSG)%P$2H7R')O*"NN11WFFPJGU2=>].2-O,A[X*^
MM-L!#]LN\LS66KYP;'UEZ/7S[97;%\\[?GEPLY^I';>+#5OJ-L4\SJ40>2G/
MC!T,>9D-8V-BP)EC=S.^X0X0+1@ZGNDG*UG9"X&16ZF(,&O&=]&AF#7C=]P:
M!Y0"S!:L>9&_!_7FOG#=+.P+@Y)6:)5S^X^U[K@IXCJ>DL2+XDO]%!@B[BHB
M,F/&!XT9'T7$G.6?[O=Z5X5R/:?F!MIU/6,+74#$_(]_%9E7=ZH8Y]]A@8C/
MDU VO3]FR-@%72A-T1XL _V32TJ\2*"OE9HQE6]R>E\+,AFG[E[EJM5B4\1E
M.D5>0C1:D%ZBT8P , + 2E"D3%Q[!P'("YYT)=_VG\O&<ZY[WG4[^>+!& @
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M;J"LH7@OD;%O"1=LU?]]2QT)=-'$M,+5GBH#O?J4SNLI^=$1<4[ 20%GO_W
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MD"B^$N:XQ-DLQ!Q7PAPQ/'YT<3U]QH3;;^C6<F%+ !JZN-[U1X(A3E(*[<,
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M*SG7A/R!.)+][.>?$-GC2'9T3NHD:9L_56WYSKHB8Y:XP:I;#&,[?:;]*'!
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M"&TM0[0\SI+Y'>".A'L896C1')YU^XSM9^B<TB&:_E0@@L:/&2I)X&=L/HV
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M^I!HPH^-;?0Q%GZ<C*1(, 4(*]<WS>"E8N)Y!@E'L?<0GDPL? ?V;?' (A/
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M/E?PX%V"( 'KJ>OP+1U-*SZ[?+!LU+E)O H?[4B[<)?:C#L_'%7U%4E6,&U
MI630T4P6SV64NFPUIEUQ%^P3>!HTMG;[85Y8EJ.)07W8TA9E\ DDXN%(/!$0
MWT/;=^&U_.A^GY^UEG%QVG]:CNUZ;YD<EC?18;4TR0&68#@J1(]6,JBT[+-]
M+3U3;DP+)@%C-QUU+5GDN<:J%^7Y=36VKP_'+Z6.E#E6Q(.O^S:*>(^$G9WY
M?[5"1W6X@PIR:*_P>MT$*0W!Z&+6GECSM R9X5&8GE([+-7%A0RH663NX="S
M+<W<&@P,#$&SH7%5J0<GQ]&5O,A7@6H5L=<E'WP*(:(9MM>#=3&J!7A ,-Y8
M.')J< PFBB!YT\B71,#!W'NP>46T')QG ABL&L&\P)62$,)TX%GPMCBKYU^\
ML&_U7#@S"T.O>5H1P:$VTQ2VTQCJ%:./F/AP-""5A8TW['C8QK*&_K)"\#W<
MR99N#ZWM "*)K@9V?G.DN10&I4=6FP_3S!G]X8:#KN(TI:* ;P \!^65/MT,
ME@O7M,,3-B):._ >X>,8+@<(_+&L HJ91%TFD-2N$V0DM^W>1#&0A(9<_ FC
M&4]9)5&>G=8])UTLWQG&,W:K#;K5!OUDA][N9+3J31NQ5=[L%W*F&,E+HZQ@
MF2VD(?"^SKSH2O4^QV6B?*;#EY*#A-)>/$T>Y RZ,GIXY3+ZL.N:<B?1LW>5
M'-\9V*-=?SL2CI^Y[L;GJ:62?^;E[;,N[N>):22505<>/7/"O[SLDMQHNK!S
M?+?4WQE"NM\:18^?*2CK97<K5?:]A&DT]LIL:&Y',PA8'SVSVXFHXWV.*SP4
MYYOUJ'R?6@\SH]CQ,[L58RSEZ]GM8A"M%%KR?:3=Z,W0E6R<)ZJFSOL=W^&E
M/%.9=5:E^I+*+((2 &X I#' ,>8YZQS8L DZ>'!-%1R/\AF-P'-.4_PJN-8Y
ME(FJ@2M5P>83)4!A%5> 70!'$&ZE@(\7&K\!'"R,<<G."P#WDQ1(<PG!V6:0
MQD_$"<&0[)C-[CT#[[Q8-IZ3\<!J=STA/K?.'FIUP=)?:/H6#EB=^F\LK&S!
MI-AHZ.AD@L.(8V)CV=I"K1N^Q7\H^R877*U#\?P\!Z;'>\$ SHCV)DO4*=#H
M5_)<)!U"#Y+D)8[%X-([4G@G^IS/"GK=Q&+ $8=O=Q?PD\O+F D#4$"0LH/^
M*;C(;J<<T05I6M8FL4*DMQ^/M-DFN^/*T^TWL%5RIS#LOMIH.>>%)GHU!>!#
M!#1G3MFYK&)GWUC4%A2/%C _YFBI$'^J"IH>,-A&9JX^B"?J&@#1BL8"(*P
M"I& $Q%I(\GX9 SCQB7N)S=SWYRCH7#@HV//=TLCB;V$M%HT)\1N2^AM1GY
M3U8A^(I86 NE>623['%+R9.0@E]CQV,T28V6[$%CLIPA2XH%?SFD+TZ,J24]
M<15>UDIZM3]Y+HO%[U!=Z9L<R>[!L\,@V-=,_L3GZA.F^G3*^9WV, DW0,[\
MJ8[;&W?U(98738/W?L.0<=EMS'_K1_1UL;:\9<ST5*(N6]F7[4O0/D^O.@/D
M\4.E R^$ T VG?PZRI:. QP_T&?0PP 5RW8B4&@=:!^XJ2Q1:#-TC0WY8+BK
MW %@,7V#^0KNIPM@?/A.UNB(FJVT%!T$$YO_&IW(#(&'>=5=2Y@XUFD_)<A
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M%H 5]6%B[!O)K*^6N(X8JT)A/%1UA2I+W#5B25)]?D4%[S-EVI6K;$[._1'
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M'$=$H\F$]^EQIC),AI6AF[CS#$"9XH>SL)?;7.:4QSHDV1@ZP-8H" 34XCH
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MNH%.UBT2?KH/K=WP0&WO&:P3=1%=@SP!YP(5W'X!8MICE6P1QF2GV',*SH3
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M^_C7'WU.R(DAS<::'70 )!WEO?U?D#:$/46(UL\LCX8QH\ 7NS)8QR(R$1/
M9K!/RH+V*;3E**P/4+RQ9 _A5%F; =%#CB!),3?_"7P;@;[ #4F=FJY_Z!I/
MF ..K1U!]SB6*S0R@\X&];A7*<Y#HVH@(Z'KH?3N$35AQQ-9;IJ-2<2"XB5"
M>IXQ=R2A+%=@9U41K5%G@L03N+I84J>".Z@M=4E6[T*E\TQ$>>X=O 0O(/A+
M-0#<"472!,&#'?I;:NE.%<,$-MBSO O66NXXL8MP&]I<)+:=)I+LT"(U/Y#S
M@=4 0@IX);Q)<MC)(JI["K3DN/C0THGD1B2.$<- V&B%Z4M!=" :H;&BKY"(
M7XH3V<8(:B:E'H6%Y^AAQQ+)2 3<5^#(GH6SHUBK/1A_I=G T4I'N85EDW3$
M8,1[NV53)!F=.K5WL5E'SE_ P-I[>_P1-[4)M^+B(VQ4H!-2P5&5N0)\2IH8
MP<P->2:2=N('*TP=ZS@?1G(WEH*Z^-<==R*GF74KT8*R>&H308=-;FK@-%"P
MN-"&8V>8OW1J3.&Q,/71--G>70<2=[ JN _M%>A\C'@9&^9.!K __X90OU>+
M(_0*/[-J$Z3*&OH.<X^*,29%U:DT.YS3B4.4Z3@@/</^UJ2PX>C0AADBLP_3
M,\T?@N-:DTP6MO7RRS_$@PTG7=@_$'8;G;YB$L\&H9+QFSL,?CBX8H?I/[A\
MN3'MP#0.JYC1_/#WM&*9OR_LN'I2VQ4:*_5QUAGD2HV9KR"L4B^^IR*J WI7
M%MC;:TQEW+3I[-Z]I$F,\ SL9A&)V3Y(V8SK)BK0)<_3%0<DQB,@1@*]LZRE
M1T^UCL+O"\UTM+@;BNMBZX]_7V3CN+XJ.-GE^X??D[?P^RW\_HF0,K%W1=GC
MI]]QUFET/9K@ZWH;/@Q44W<]O<RW0M415NI#0>APZ!0<\L3F]>H.Z"Q!QR#-
M.P(-@EP7)CV%S8FAC$'%QJT(T=G+FF%3,!%(K3KEC;@N]=H;%6 1$2?"014@
MOPJ.37N_B>'U8GG*/MQ*5T<E'H.RX\:92:8DMD_0OW#@@Z;NU PJLAO;\90>
M8N?:\;.?;6F&4XV_"KNB#? "MEPT]&6.NL8'2.W-H9W1EQ!T#O;M<LJ"WXR?
MMDC2"],]9ST:FU;M.X2:Z7Q#;>)X@@6\ME"SOR+&4&B&(@S;)&$TW'D2HUTS
M?RS!DL3.E1E2TMW4E&-/&WN6%^J1N@F=6P/\741(9#HY\D>"3X21VOJ&I7;&
MS)(JL5DUH00&<#,$^@E7-O*IUYZ:<^>^D;W%=?A)9,Y>V%O3?U'(VJ\HTK #
MS4GC.K1F2S$DG+X*C.R,$EM1&H;,78(CB]5EL7:M?R.K0>/0>8U4)9JYC6B+
M[,]4EJ&.1EF.;<-TO(U'D#=AWU?$IXMS 0!#']$A^&4T;ZD97*'O116/%+T'
M"A],4761CRG J,20CZ_(%5X)B&&#08>.1IR30R! L7E/B)5US/5&S+:0U*!.
MP38&4\P7R?9Y ;U1#Z :=(JN3'K\HG<@RD/D_'?H3^4O0MQ.]JX3V4.$^Z?Y
M%RN:8V3Q#[HE\!Z/2]P7+G1]T/B1^'[V ,>,)J:PZV@CUCI<NZ&7(O+5*?1+
MP)7,#'[S(("2_F3//I83./[X)SA68 70ZJ'GF&BBXHDW^.4.#F' #NR=]>=@
M_>GRLS)1(AEH-2G)T1YC1G(<AC2LA%TA( #E"2MQ]'9^)G?C:U46H3_VJ,]T
MG:H KN/=(BLY!6YGV.ITG^]"E2EL.ZMZ/<*+&<NL/@Y'5R;Z2J:$%4*4Y2NE
M/"!-R)$P*6V240'&KB<#$$K]G.H[K-6Q882]]9+$(X<9'U#9 R8(H8<3)$&[
M?K.QL/)C[+ATA@"/] P.+X("X0\0+-X=MV 7/8$=T72Y>.[E[1/42SQQ(4;D
M#AB[BZMX8AY^2CW- CC!!1.Q GA'5X:EER.H_UC^TP/4DZ-+#L^39^!1K=$K
M22Z>"!H.-B!CWS1I3:B3L4F@F@Q<TX&^]T##X)1/$M)AO!+V9'J>%$ ,)0-/
M$G*MR"X3:4ZHQ-5%"$"<['K+Z+2<#@5H?(9Y,KHR!O,)$788B)>-S<#T"\%J
M["]B7>.=JND3ZTNDCYN)*[+*;%AB\!)C-"?/N>5(6U@(;(F(Q"2G1S)4V+IG
MN.%@@G]!<17#U2]AD^A\;56)-XNY5H97^(?\0VI3>ZK'[,?OH?Z32=+PT[6I
M_@R-XZ!S@\%&3;)+72V1!M&P28O8XT\*BT8/ ?8US>H$&5U#IX2(CMU[2.3<
MH?] 7R5:*J*^I@@):::N.<SCK->?M?MB\2\\ 'A.1T'FKX'.<43>KSXDC\X/
M#'8!H%&@9%<T33=M!1TV.(<O$ODGU-FBC_B'#7E49B9KD_U?3@F8]TBGJ2/'
M2C6N( "5'*L.$@[V>DH)7/A\HG+?8<^8FY2%!W=RL6FF.W"J[>P3VP%O-;$3
MJGK-F>#F8I*8AB^CEYEG'J AT]>HA1S:[J#\M1T'"$3G81APZ@1Z(^Z/0M M
M3BX#6\ZP)UF(V(I8D]?=2 Z;UE%:Q%N6&(\?B5Y<06(S@\B;'F(B_L+=(+ZV
M#TE&DSR--6AMZD%F_K8W>YG)B5R^H*0>U5D_EL\-NY>"([B(O#Q%!=<F0;V*
MJ,OXC.%],&*47RAD]VL$>1=Z=2T<CX)3->WB[1Q G+&Z%JJCV\1"A48<\D15
M-!S6]3":J-F0/4$S\YSO'8/$5?*=%V)'!@<ZF[L07Y0XVI%5 &@K$00TQ"\9
M'_Z9OYS[6-GH]>R7@KHQ-H5.L3H7%MEI=)P**.0.ON[;%'*77@>(NS9F>\.0
MG=XY;HL9H@5C!@FS9.<SK();VSBUU;A4@#3&$34W1_ HI6J'40 W5.E02!>;
MJ:U-:%W%6X:.PS*.E]#0I\B*(+F%&))PBI&29J(:9B\(>]#12'<;[*: U(25
M PXLVI"BB#-DQ)UW/L#;C)'#8!A#/:!/>4$R .=T<#[= (L"6KE!!^O:SL[]
M,%J#>1:]K7U(8AD#P'*W07>@NHCHA+0(M[J3ODDB@:17!..O&CU/W:+GM^CY
M)T;/X^^*GB=.O^/L4?DE$/JXC*HK[DXI ?WBH*EO^.5C@1/[/7V6MOL9[CMH
MT&1F(.NO[_P^F5&N> ;M,7;=JDY6,N"!#Z5%)!)+,':?X4-89)YFQ['G)@]Z
M"SL"JB=)^."H!-_%H6<5W)#VZA99'K[<:UO#X(BSD^18H"-QPK['9;2>',7#
M%JH'YKK'1^LL 5D_AIWH0MJ#ZP10@W&" @WB8J^%1OSJCB=!F=* !BUUQ+%'
M55G@SD)058\.9;>Q , >,M! <":"V0-KX1L01<3$CDPXTG%4C?3CN)XLCXP+
M^D"<V; Y#DB VS"2AGY, MB/=Q"G_4T8Y"81O%0-U.09%KYALE:(WDFG51S2
M0=0"($ 4D0LGTYK$)XT=O&2-G%2.XQ4U2:,!7S"*=:>QD!7&V:N#4F*W]RPX
MOM5 8G! %603FB@KYIS0D#Z=XM8#I"+Y<"AA5H/,Z-P[>BA6)@ 1T&U7<Y Q
M*Y3#\'S#@, 'R^-!?D=S(]HEB= 0!(< @G3]Z %#(V$H"*_C&#Q4K]BT<PR,
M$!VY9(N#%@/3+*97R9ZX<2'<<MARND(XK.:9=-CA?,18$$>":B1'8G@>[ TO
M>P08*\D\86V\I4+I>ICK5/W5@:#&SE ,IDM)!%_!-!E7-)TG =\]7J'C>.](
MMV)Y)P(<),%!WK-;\1[9Z%PAI1]A_QF!6T=C5PFH)9;#6-YW,GP6(+MKZR9Z
M(B\:1V-Z;-6Q3D3F8K8=^@SL%Y'=6V:N,.6'BV6T5!N8ZZ=:VH2NF<?YS"=V
M]0BF[!B] ?0$3#LL)_$\/,Z7.)R<Q/":6TY_/J"5'XS4[4NJ*!642&KVL'E>
MYV*-[Z!>%KU5O,YDKUK3))@ OH8Y(H/]<!( MOCT(3*9E EC>6025V*(X6A@
M1  H?H.S@*9O $JYHZ@JN& (&\T@GSS9!DRMI 51^$R"D@\<SB'"ZQ"-X: &
MTYM6Q!+!O+.:*TCX&Y/YGKEG<#V5XC;'HWF\.(?54R[M>82BX4,.ZFXP/I2_
M_%F!I"=P&7EFB\=-ID3<,1!(!\G(4DV=XKJ_,758V,QE'@N\4!R.?Z],^6_V
MQS\?8*8SUXWW*W 98.*"07"JN-=MZV]H+!W8>L1C4#,W"&$2RT#_26P2Y#(A
M<A<EO_['DKP__]14<"$EDKQT9'B0:!+_H/VU9 [QW 2<"EM#7+'1QNXB<>S<
MP8X5.N+_^:]T(IG^YW!H_HN.>?\#X [.>3RJ&($L0DP<%IAMV3IIT\7*DWTU
MN=1<Q!DA$P+8(ELTD\%1)=R^)C#=_\!N_0?O^(WZ;M1W0'V"G_H:5+RICK!D
MT2TTN/6/D.:!2R!\\!3_/9#N1BL^ RD;7JIH_M>&'1A$-F2G(8'NS@9@A$0X
MA+!%HH\I7A-2?3T743GN5+;Z:U&)M88T:E^9X[4SX(W_KIK_HG[^JQQ0L-M5
MU]8\A(JM:R>QGC9N#4I_\<,U>NIX\!N"5#&B"-HXY.143CF4[B7T_1DR#XY6
M1.A2$T_^->C)!WGQKB:(\Z!L*.E^\3I'B F\MF5G!7=(7KV03%O:*U,_DJ$X
M! B]9 ZN].TI$UX^)PLR%$V%[3AS=GD31/<4'0T7C%-]5#%H;C'SBKC3^AK[
M,.?%AR,.^O/FH634YE,QVYCR@R47:8]JO>E#]SNT"O3-E'JT_D.0\#ZK?>!'
M]0H\,Q7LTT0_Z]@TFN)*&'(!_1U3*_5W>( &<=4^0?PY!&-Q))Z\HX%NIZ73
MX=/#GMP&J/U'K$\]K!-J<=(ZRT/(PW. ENZE7]H5L" :((C,IFS@&OQ3#&*W
MHF.U9<=K?&?0;:>>L_ETMA* ]19\W;?)T:FCK8<]AX044E1Z;8Z6K&@B0M".
MQLE8Q*9:)D:D8$>I4S#@W$==L&39/."5+A@1?BH^QGV0,0 D!(Y4'+!Q&]'1
MEB$^_\D,5S;Z(R;HM(&HU4J'TX:HN9*BDDP>$JE!^C6 9J\LV@L%'TXD0@=M
MLAQD)!P+\* &.0XET)_9,^]")-+DP<]D$#>^68%00.<5YEQ6ARTYV$4.8,P1
M,I[*>B,2K>KP-?Q;7P.3[ !RJDG+, ^!G,+TYU#V^)?38[P+9>6)"(>_-ZHV
M%\UCBD"/-A4<GO05,@%.#-LKMD'^I>;86CLQ&(*0<GKFKO?Y6/82$J8Q'5*'
M 9NMX.:)B/"Q6(47>HG990)2K()C<DC,$;0@(+> #L:_9,)2^I:P=$M8^L2$
MI3,I2&<U@:](04*[F'&R-YN&KNDV;9SY2C'4=I?6YMJDU5[DS&+N:3%_C)37
MW\$X:,L3D@7 0#[=UKXKW_RO3<DIXN, 2DS .D7_A@];$_O'3\IFR"2I9E/,
M=+*NH\ZDL5^D,%CX_K$N.:AP6]KJU]/F& I125V-[/1P)@&B@0RH;R3&K2KR
MQE/ S/H%$U@^''OW+3\;!#T!,9+JGOPMNHTP:+Z* S_V2@ 6'@--#]%!" 5$
M;SW8/K'2,.^,[IBU(C(G=M7$I-P3UU*FW:M9XEZ\%&M]<F_#Z!USM1W^WRDT
M(0L4NC;VJVBNP@R-Q%GSP*(\-J"-.7R9#F/ZW"+K&M)\MF#G@OL:J=XBX+"7
MNJ$26..0G8&V$@ 9S5 G$Z:=I$$:N7GEM,B.@#M:NN5T#056ZG7RE\GL$$9"
M:@13&4FR,JI"IG\!8Q!@@#R@Y%')@DEXY] 1*4R>:5BCG,<O5D?T[]Y(ZS#O
M[XKZSJV?+.J&4SW98510>YY.Z3-7C=E D%?5=*$T&BJEZ;-BW5=;IQ-,(+E$
MTBWZ\^&!1ZBKC>/KH#H$YI3$*\E.JV^_C!>-VJK>?.*[W/-+YH]_(ZE$.!U/
M'">68%7]7:6FT?1/%YKB1TBTS!1G\)6R&6Q,2AN25&EA,(45LI$LH%! :\$
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M\;Q^&)>Z S.76.Q?RFHY,MZ4'H>70F?PI(+R=^?U7/=.7!WX-JWW'1679%!
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M]4%UT]MWVHM!U4KVY&(F"!6HR!?W^^:N92VX>N/I41MLQK7]S(,*=**KSEF
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MNM@8/3W$9#W+(9$_16(*'YKFH91"W"!K\A9I#OJ*-(@1#1F=MYC*I%"@8".
MFQX<T0FB$0,,WSDE7\>&A1VY!)#H24@H(>9:J51TI".'8*'____G0T%U+'%
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MU1@TJP5[(^7D$+8\Z;-0U+IET=W4>4JR0B._IMW\E#L77#&O%A;"LLJ,":I
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MA<JBF'?&DPI%,,!R%;W0SU;J< !GF$_+]B>5S<*@"5"@%VP["RK%K(::G@S
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MQ[5@V1?N<N3/>=6[3/PV9'VU7V</*(ZM0*S:6WR=66(FZ6YB+9E!Y$RU1$D
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MC*%(?<[-Y^*G]*VS!\: 6\2 *U&P?QP#N&6J/1\4-I9A!:ZVE5>5E#3OGL>
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M*2P0@8^1#0@U@L'_&4$)$5DB$1&1X/\LW?^K.=$-"[. ,8O []B&;,G ?/1
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M,E1_+4/P/4=N6[I38Q6_3V/UXZ![=Z'J18Q5L[, RW4]5>5LM9.M5$LCJ5-
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MSF[&2RAZE+(<'2:'TYF&5I[NM.),EO@DA66X=395KDT$#5<FKD0YV6E4+(Y
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MY?X192&C)&0W&>P,%2Z2:7N6'=LV;^/X8MYHKHL8CH9XT;_^T(_D58*/85)
MF!3P/<G5_ R]ON8X,(B^!+^UK"G5CM5C2XHHY*JL-^X/\GTJE)9AGL 7D]%7
MN!>RGI7U7E\"(4Y9/;<<&0J6CV(*5ZJ/M0T:CHE\"=%'A@GS [ZI&?==\@.
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MZ* WFTE#O!U1_@./MOOWFE(F!,MMP))X)%Z4A"%<0G()P?($EL0C'0T!$T#
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M@#Q'M%6X6MK>"#S7"*(P8B%#8#D :.['CN^_BPB> ^](ZF]O;D\Y/GS75F^
MFU> =?BE8Z/@0-V&/Z2!Z++S"$7XNGE@;IQUL?UD@YZ)9^D6Q"%;0QQGK"'9
M@(ZV$QSP%]."/,:[?BAH(3?'/&_IT>6-D;<4?HJL'BAGWZK>(I%<B\7&F_FT
M37%V84PKW0I?-%+LE_C &^WL2)>5?))KEH>S5'?#-%*C ^46H]XA?;G97-77
M #2!L83(<UX8[_S-KA/:;"$([/\]!:^\HEL] $^^!<J>K#9W8IC:$\/#48?C
M37%"X^N$:122LWZ6Q1Q45T"?B<%!T'N7X>(\I#&P0IJR!^(AB.QA Y+ D9MG
MI20*B8EH4C6<Q_(4GDN48T/!.-^7V(&2TP3:EX&F!J]$ES*ZX7^$UA%[D,E+
MC4:FO"AKB@#M-L9<C+ U#R%#1U 6BWGLT H.WV@]L;T(5"P\UIM4!5'!FN)$
M5Y'?8:NYR")BIU#B !6A$)*W,\3?3Y6#0ZZA>YQ;0FOA'UTFXGE4WO(B08%_
M@B)$W^I$\#6&C/R$IJ<P0EZTU"'O<CUQ#U!N(#, 8OQ:!JH4@8@+'EP*,&13
MP49(7Y)13C= / _^T=L)XH>VM1.^.U)Y>K+[C"<2@LJLM]"7/I"^W-@3.JT
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M36E3[\B:>M)P/YE!13XR+[;Y"N%R&[A 33_V8A>?$#"W <R+[:1"H-R.6D+
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M.SR>(ZLJFL@=D5&!J89!J'J55TV.PUHK",D8_8^KWMN6>TRH^,]5P4)<&KY
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M@GH;!-=N"U^^GW/OW<)A7K6##CZL@RR@%AQP!]\C\<P5FVLE.?8,/$)\%%
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MVIG;VB1%=Z_[1;&JU^PL=TVD]/K0*SLSL<_KG?O1XX O70[O.G>/\3P,W5C
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MQ&U53%48N[5[AH("C1])U0C;H,YTK Z1HC\*9CN6;I@QAQ"\-%K(M91UIUS
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MZ,3@X+. <$,(Z4.J/L/3XS>22#PGK.?U)M;^BB"*T.F(C9]W-P"SN4U-3"<
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M61&S_1J-U\;#%/K6/TGBNKMA^K!+ <V(*@9>[ Y?P7H?EG/XL=%3"QSMR^\
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MN*AS"6:%83"5A3'M/_S_'NU!0=\@J/3#,(;/B$'I;9TPD%)9/SX.PWCSC'>
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M^@&[=!8 JA;ATR%14F9"V09K,"/M%VCUNI]*$[H" 9 1E:]I_*TA)>^ #3/
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M06L0SA *OY(=\ YP7204 @O:"^95"VUPB'VD77$9<275T+,@RUD)3&3JO$@
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M:JC511J%AR"PL.9ZHO,8)H<G9"ZTBUZRK!A";)Y>&Y_"R'D(>5[Y%@%V4^\
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M\),2J,(DASQ'WFK%?PJT#S:QQK12E5[KDJ7? 1<IW]_HJIJ/]<)#,WZPR:R
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M5N^X0B@6D,6'-^J*D7 Y7\^-CE*U$QL6.AOP7340(<[-H?!7#E5Z<B$8'O2
M7_Q%=.H?O>VD]#O6*C:'.3J<*LQ%JUIX*))ZX H]F0;XZ&+8AIJ34[A4]7XC
MJLAXQTL9<4,)E%._*'I,VAN$&.AMBK>9I[GL1$7<53J#/ ($@?%-IFGO@);6
MOVBJ,YJ:9GD*%:1SKC;2Y]_^-B==__5N?]M] F.E%0[]\N222\<]O-[U(D]3
M'\(0=9DG,-6T^8L4Q0UBI*_B0"KW,B<9ZC/ZTUD?VQ@JX[)P;[="+!><CX=#
M%1G"4_RPMJ<SUX4N9@N]M#HY.?!'$5WP2$ACTF3UV \G$K[B<+'*S@$J-2X-
MQW2C)7"D6KIKG@->)!'XMHD5?4#CB"^TB1*<\P?K8!/G4<*A1&_59LECOCJ-
M7(G"6BW%;O@/(F?<5.,]>F,B?WI:,LNH+%OS*(:--V/Q]B59.\OZ\HAC8=CC
MVG*Y*\>8-1%,VP(]ON;E?8XC?]/;?H<7N=!F]-WN?+/U[321DHE-85,V!U)K
M50'Y@_G?IAZ^'-GMA@U=W7F&ZM"N<LJN%&@4^FC)G<I8 %4KQV^SLY/KP2/O
M12LY[$"W$Q$:QG9]O"T4/Q(]0[WJ,'[Q(>._!1B3#W5"@3=+RW?5RC\S;*K/
MUO(/UB:*1RSVXGG_W U;/^F*^91/8VBQMF>4VJN!5,/HE:@X;C>;"RLT[NN0
MRH&_]8:PN>B]J."PEG_L<)V? U>A0W''F!3.M'9/;'YW"5D\!MKW@W56;QXY
MW&KZ2$*_\<=B=T1KY0PL$5<T71!KE8"1C)5V%I#/X61IL$&1U%!, ];^M6:I
MR(WM%+O$9\PFSU"J5LO*9% ]]H)997NS%)<RR,$T9$G?3^![*Q30-[E5<)4N
M2"8[<BZH &!RN*M<% ]ADQ^!CT#8?/@D$[T?&WJ!RSY+DH]TT4[:OWKV?A%C
M,$$)O,5 \M1CJNS,"IO^QEI5]+ HX3@0)&]>["#T+ZF,^37MP!\X=YRVWK?1
M#[&0^=>7;H4T=EXN6:-5:0M26XOIF[=)S6V9F&X"D4?D+%KJR_4N5?8PT<)\
M+6M08CUS?O;.<-_U5AG6#4.B%?HOT(AF9FQ^=N>-@0+1,E/H6__:AA3R*;[D
M#7:&Q]8H7'.GSU($>[OV+8]V?W%V!F+I2V%[]!)$\0^ZJ&^=B=MN:?GR^<RZ
M3HE2A%.\ZJWK>V%$RIU3<@8+C(T;$DSTR1;QW"-;[8!L9CB]6)[C]%M_I$?&
MT2PWFH:MLT>"Z@2C^F0"E^0SKT-"&/VY#O3"1^>#KS^1THPUT/E#$MO;LU?
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M:FP*8?4JQB!.OQ.U26B/R-9E59Q(<T?'/#3P2G*LZAOD ('[N>IQ6TQ!,LB
M^1NJS!F=1]\W>-=1/4[QNA0U\$YV\/5!QS'0I=C*%0[+.;VW3)+MGGKZK4%H
M6T5'WYIU;,3U%@)^]$;I45/^'> *]$UY/JWN:X4<Q8!5$P6)ED4G^B .O1W^
M=("%8@B1"GP'"*"5@G_K53QW+M='8S6HICA<Y%Q6A:UN\EEJ<"\ 8* D8:,P
M5MG6 N.^>L01#>SY\QY#'&MQL608?F(Y)ESX_C&#G3?8N F'8S"?WCDU*P7Q
M!(+6UQ(WH\1^OE%\$?!U8WZL=9A/TM._O[O1J1O3CU@HBH%\D;VR6"60&9M?
M,>N??Y: &!R6N6L7DDQ:^6&'1YGO#/W53Z6;N/"\J)1H[Y^F5TRYH=Z&SF_Y
M?:FA]NWHM!9^T/D[V7&T4@^;+2;UQ>,3Y9>0UV(!=4]640MRUT[(QE3? 8P/
M'Q6M(<!.*)9NY6X2N]_@J\B7SF)ZE\!0K_#D4_!9</#3$D+I#^C:#%8KWO69
MTCV*JPBIMUMXCBQ9Y>Q# VQ"0\0/_=V>SQ3;^._(^4C*,8CLA=#T1)[P:.*<
MCY;0NQ%C-$78$:2'U*S9[KH-."&;/HQ4O'0'/+^UR=![QZ:1D="[="K";7^S
M,H1VFU090YH^1^&D+M3O=[\W$DRM %<7MJ8!;[QX7-J4NW.;\9*CC+0O."P/
M?Y6&C3],#6^ CY[WEE@J'F,O#%FL[MV'-J?]3!JB&.>X'E+OS-]@O,,R+C&F
M"&3*;1+'\LMT!\B)'V:_ML?\M_;>,JJNI5L47#A! ]E8<$EP$BRX!)?@[@F0
MX"Y! AL))! D>(*[2W#WX.[N[L%A WN_3<XYWSG?ZWN[[WNWQ^@>H_O'\IJS
M:DV?56M58;9#B7X-]:1;]+$.B=.9#'R]T_\EPJZKEH5N'::O^>9S![.ZAZL>
MF5W;4:#3SJ/LQF(I_&VLN3F*4GB@N0A=*!A1A@'6EJ6]B3.Z[$QW65$Y%.U3
MDSE6 D7B7R8?SEU6!Y7IW6U"_4^SDL_$VOH4@]XF22$^>_#PW&1N9[*"=X"V
MI9A6Q.8JP'$MQH_KR_&N5<$IJ=*8KEY?.'>ZV!$U@M-2:K%>J[+0SZA=#O^F
M5:GHK:6<G6#@0%KN_M.WGTWA^_QU!CA4=7-DG\JZA=<H<Z_!3'.YQ3;I]561
MBV\7R+Y4!@ LBG2&WVC]A)@8U</4'7$)4G+F96WLK9\15VQS1%)>6Z<L0L+6
MCHO\$$A2,3HG3)]DH]^:6.C[GA4R)XD9<%SL,MBL@=G;#ZEN&YQYBZ-#SO;4
M31?,N(I+[4[M7PZ)H8F+@KAY*TD;V9XQ(LS7)Z&BG>Z=%>A^H)$G^$;GT/#-
MGG8[@Q@:8XGJ;KWFNG+<G4OE,QNHKOK&&.SJAJ&DKXQJ,-EN3R9EH",C@*LV
MO9HYEJ$"\M/.V$*1-FH7KJ3[525AS,%C%HDCJ61FTWM(K#(&0I>Q(4BP++ A
M2QJ(N-;\R+Y/V9LIB3F7)4"\?I;Z6AN%+A%A3]\[6;%YE:124:$,EV9J >$Z
M!8H,%F4"/]Q5RAV<)?^"EXC9HW4%@@%]S\$-GA",^=%]_-X)/'4V ,!I'_5Y
MAE I2IYGGN[#69RADBO:*N6:;/72 R/K/0R@_ &NL]P] SV@8+R1!G<W9X"G
MYF# -FJ3\X 7T>\[Z3#@KUM%._NOJC%TY71+'\C&J\F*8LI8F*?BFEWAK56,
MGC\0Y,Q5Q)\\N)PM3T2)J]NZ*]D4VMM!.#!"D:3M8.H.T1@^U$1#QAMMRKE2
M.N:G))IF2\B3R2MJ:7Z^S08"$Q^DJ%Q-<H96LG)04NSP?Y_,&8=VENEV/08E
M, %(^<E.B?'K36,.+)'I+T$VS#:S:%2^!X9[^1:3LU5)W#'#)EA]@;/VWJE3
MX;OQDLDIJ\Q?/-]%7RL2\F'YQ%HCOG<(CF[=UJ+.+$OLPU(N0^B<OVT?AHRG
M%G"A(2HM?&W20J;TB,A>B XQ#0I\3SXC-,A8>I=D]X2I10[U(4(UW26!3$]]
MA)Y>W?H0<_KG*P&W-SN:K#\Y<P/1B9D2JSP*O#S5_>AJGEF^QWHV>-?NH4Y8
M1DQ3(QU4GO*]IY7;LHO<C+F2' 84228\;*58EB-A9]-ST#5%(/K =$B<*%72
MB5:$2PD1C!"4D&?>4*=4C!F[ DOY02=F(4,,+Z+98, +*:?A=0Q5KAS7+\*@
MLECBS!H&VJ#.">*-TO$[YHRGG]=D5$Q"Q=)#  &,GF/<SRP- MF5&VO+7N,A
M7ENV+>JVYF\^2!P_WH:0SK;S9QT,3_O7E1QSN]EVB)R,@'4;"RU/K>H2JR_#
M-F5Q 1.,1A^(!MX&#*B&:(YH2MG$QHO&_DJM"?"^5.\1#/;H15NH]5D/0_0"
M#ZTIRU+)N_D-/ Y/^:2?/![1?45[\! +!I2>PP"1& ]UH[IPM@H[^COOP&@M
M,R:>GV[0HTI=3U^6L)'/&?/N>"$,A=V;$:@'.]2=PIL"&"/CF@*>5B)/3XCB
MS;_T^SBA"6$[YY$YYA3[4ZR^O@I5#U=[.@\%)@,3+/)W52OL]3I.TAP'^)"0
MEK@53[6"K>2)(A=[P3243$\T("=7NPM[I >.1'TRUSLG5<^%H\>+14R\/RE8
MFS6&%FXD3\X0!SI>ZG\5^80<,5EQ:%M8D;MF)SQK*IK-F_XA%K*6"G>)>X$X
MWW@U>?,RW'3I*726;ND:4=7:<ZS.GM361^X>ZF2^J=-B\>)0$#,S_[;_9B?F
M2 $OTCX_)<0ORN.:@SI8J"O#W9\FK\HV\G'UT^?MQDDM)0L[\0F*/WB<".VQ
MY*>2FR;(LT*JHSY/?,4IG/N$6)<U-CG;0D!%0P;D\-U:)6?.#N_DH-0S?T0.
MT% )0QOP59&[(8DNH5H+S.$3<\>^'L<R7NKV:E;1GC^0,>G_QB<U9!<?;_OF
MAJ7@1^$G%!D2&'"N1C^W^:+]9"L$HJ&UQIOK]"[X05CRBBUPZMM;3$0YF5L=
M*Q)4NE.5Q2NDC=N6YH(&U<7M'G'2SJR0L%F'5&^H$ :];.=%*Q88FR&">H1W
MC[,$P:DBO6YA$!M)UF-Q(6W_LQL72*3L:Y1/TR-ME.D"*>I+#9V<MI (:KRO
M#M&M^/)T$PL5C?AV3[IUU6E5)GYQ6T_F<S\=K5"=R5(6HVR6LY5<SY+CX:H,
M4J.5P9639D4DPWKE]:9R3Z5O-S?!N.NLM9/>DL58PJJL)J=/+NZK7+*4SIPF
M_J)!?[L/[]Z7FI1&(,P]P@%$=&>F<J_=-4KF1\FJ+X,#%UA&#P5RUXGR D0C
ML>CSK%U6TZJ2WS8$2\RPI*X(+GWSPO%4CXW5BEB4!/D6?BQ(X7BM(;<F\CD?
M!LS2]H4Q'!R,J/2Y!Z<(X(HI62;45UI5R0HHV)#A9^A25AY=FS[Z$+07@)0R
M6(3-9#7=,5!8VEW(2?]ME2-TGKPKI]%L%[7#%NWB0Z3@J]0(JE:I0\ZE/56%
M/+V^3-T9::2,G_LG?*_%HPZT0!/QC;?=D7$SB)W$!,OX4J2.,MM;5BE*BC%/
MR@FJ=!9>NU'9-\EZ%<] G(*YKMC8N&YV)*:KJU\R2\C0B,^%0"L-F7--:YR<
M*&@C[ 4+V=IG2A?+ZW7US&K3%15_7K['=+)_%S9#I0J<K/60G&\6[3Q.G"0R
M5&7H#T$[(GTM-83&M><:)GO RK(N.[@J&TOUI;D*O4<D#$5Y?+,^%J*62\@C
MY]I33[*VH]>6(U)O@SR1]'W)2N6KPM:"-?1:FIKR9NDPY72R]I-]2X:IJ%+W
MQRVS2FFS/'UYTZ^OW,A069QH+K#/#F09F4^?8EP.68XFLE0^EG0W,4_8W% 2
M5X[20HHXB8B![D"3*Y$*WWZ6FO5Z7$FBT<YSC'>6BX58)*B*E%1[23:&T7RI
M=U(XKS:/[E=V9G(]5AVERL+)U]8)IF"$ 6\E6N-?Y]SD<UAD3K;12+CKTUGJ
M- +%X4J>-DP,R9J(JRK?AD,B#B7?_EPALI0LH^%#.VJ^4L?HG%S69[+U69''
MBDR>$=J.M'/@_/'C=:=>0A[&G/1IWQ#R.>;Y>8GD+XK,NN((H=YN(^>MD-?/
MR-D-N5U6&?HI%"JL2W-_OC[KV57**U&X$IMK>&8/WMEH_EI,9HJ?/1V[E?K7
M[Z-?PMM*FA>XI?_ZE90NI]:%5H(NWT=)UPNDS"FB76Y5(#1B<O"P^CO>)7GS
M8Z[ZRIIJ::.Z-9'#Y+5?11AM=5*CS^)W7KYP(NM%NRVW._(2,D<R7ETD_1:B
MUEE&O5O(J3RG*V]#]<#U")4W3*4F/,/E]E3MY\HP>6L99X2J,Q<0$KRK$<V1
MG!KBKX$3\[;>L856N!0_!?* P#48&$J0TWD3R5U7+[JK=>? VWV9ZWSP@.N.
M'Y/3_3W3SWJGS9BA96;=8"";JX!J+A[E*Z1;'@8(3F1):F#D ^0 &88+/1>"
MZNJ@7A"Z9XZVR%:BN(6(YMZU<;;?(J;V1^7.TE0H 7&>U3.#R=01ZX8=U.N4
MC4#JB;FQ'5%B;\YF'FR<(%O'TZ^G$;<, MY/Z[ ?=^MH2WUK[>(>N+*22][=
M55"\.HK7G.^J\D+[43R,A?7WQ$_R-\1':1@_,S^_EZ;YU;V8GC=GB:_76Q4?
M2QN7_@H5WPA*=Z/9*.Y@13"N0-9=G/G:CU,4?QTAWBJ]%J46J=+4*Q8&*(AL
M.UX/XUZ;L \*AXY[5YQ/I8I_J7E7)=3'MG'; 5@YQ&/X99H$%^!DO77DQ)['
M/?OZKM"]=$U@BJ(^ .#*EN)0X%,SSQ_;K2+,X%S4RYE\F=);SB:H\@#%FC6G
MWF2DZMKBNOH,U8?G0>=[,H;U^,U*;&^]RQ>ZS*9FUG&I;]5F1!H6[U D)CV*
M:T3'G\S9P0#AX0UXP-W@4;TM5.#1)1_8RXV1X>OKZ\. F!V4+IFCEXLYI!85
M*;LK>ZA49*,B"8#@V[_^2G7YOXK@2N"AF_G1-=&9$>0&? =,#7[_(X!CM.#4
MI$H/&55&')%A- ?RBM@.6=A6ZBN^K]0&^'<QD1'0IA%@R]LAZ<M6.!]Z,2*<
MA;>7A$Q"#LHL%JEF++QK).OH\12Z'+WWO&-RBK=YWC\^&)^$.-0&+C^@C>4\
MV2);WRKZL/NY-%626)G=P"[0F]H*2O02.ZMMR"+EZK(691Q<OP#&&&B'N\-I
M:T'Z7'T9K..L8*]?N^)-7NP&$K/8 8,)V*$_WTE^QBY)Y*5MDK2??=99]'B?
MSJ.R<!+_TH7"%)Q#>U)<-]791-P$M!9/1WIRI>&N.ZB.B3%80K'\9.BBY%RK
M:Z8!L27:E ^G*1Z;]&53U!%%3\MB-F8Q&F3K3X281\!5%=DD!HK=X2KV*6L:
M;!_44G7]WDT6/L19,E>[#7U0SB?&L4!FF)2YJW6(I-=;AD-G%<  \O2(WW'&
MQC^22]:LB:=_96/PO<]I?%*SX-BH71/XXK[>'%76DO)L58]@J^ZHP\!.7=JO
M_VD*TOO/4=241Q0I 1H)V'@[4(;CJKB5&G)#C>0;2M8*F]BA&T._!A[#8Q08
M\/G\D;L7%9T#F=6EB=%+G5<'S.7='4EA\NP]]//#3./6XB8!O&J2O!KXVJST
M,1B9$5NX'YEC#^2JGWP:<#!'(T<S;((!6\$UU9:S-C%)N7Z+9WU/;0TN(HM\
MJX4"S.:EL1O;.\@70D;\ 'OV^I*2ZQV#\92Z<.%"M2A625K04!).!_0Y+QI%
MI47PXCQ[7:,/9TA#F$.B,TGV] #VQRH>A2>5"]_MQW0_S3Y 2B,Y.U*6\)XH
MD"]C=@VT(*;#IGW#0QF78LN<)K/E?#YOFQ][,:(C;9N@D[;T;*">+LI__(*<
MR:][>GG\??Z;IGC\WDYZ]@T/,@>53YF9-GW96>?UWTW<+K&+G[\D((0ZA5D"
M9[8#&MWK!@^^^R)A(!Q*\M-Y!FD23[%T 1KVLJ]339,!@@D+W??3:4M4=S=A
MX!F*&/P4)JX @3(K 9G"HI^6/.P;">/C1=28U9MS._7!FMR8E4ZU+OS14NR&
MNV#^,,WP'@3U3VA14\'$-^I8X\6Z$HH>XUB66KEDH]P2K,I\>VK<HF>A>)CJ
MK*K-ND%YA)]3HN)3Y,-TGL50HZ18=*):UFL,$$+7%,8G-V>EPD0S4=5VF5:L
M"F)MV>)RFT7,8H(NGA:2&MA8#V3/I5G5.WQ!L_5RT#0YOFA^V&;4+?)81YCF
M*B@0)X.:,L"93QP" P*QI6<%O[QUY08UQN_U85H2VTH*7^_HQ(=$&2Z0^K\E
MJ&4"%>(=& JL3>: '^]QG$R5P8 E#8U;Z3SYR^(LD5],T7GT_=446<9A_/X*
M>$Y)TWF4V@UVC0[T=^<JI#>!,"!V" 9XJ6WZ!&D^$7H'F(C<64;8K-(A.:82
M# DWQ2@O]'OTPH#+">K:N+P8&,!OF8G8/^JW2+7M/1^,<4A?(QS#-),92I9B
MCA^X\9D<-]LR-+_/Y>G2BU=8A +UFL/*!:5*O1DADZ4;D=.6+&(_;U.QU-90
M!:,2*<ZZ!V4*RA5P9_SR0]<*-'/+,O+9L7BA&IBQ@\2(33DID]^._.P=%$YE
M8,">>BTU#A8"-28B7_?FUWD1YLT7X(4=E8K4<P *:CN.2L2(8VM[>HJ)&R\M
M$L:H?'K"  D#JVG<KI.C[;SRC*,ENS/?$BLMP$"E=QC*1;N.=UGX&=%5"GK.
M["/WJ_GE8N[.%%[F[JAC[;J6;+&EKLM$(:L)8F8$H&]6TFB9G>A,MSGXQ?&A
M3']#2  ?:N.GY:/;X"G*\[.E;JUO R4S"L0L_4]IOTH#4P6W3))&V(/J?KK+
MI;2U+<4L'][LVR&^8>1Y]_[9I8+*& Q8VUS;93J]GTP*!EQ=UT""C[$--P-
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MC7[701$&?*1M2SECW3&ZPDA9T;F1<$WA<$>[.08O&2=2B2Q]@=X0G W=4E.
M8$":G2P,:%&'4\3H2DP0'H6++<+MA$\!%.0IP::VZ?#@B,[H<CKK1!;*VWR4
M9O0*W(:WH@0A/"NY13'ZE0%]&(X!'J[. B\S@0/(MO5S!FB0[J[@!>6H::\R
M8$!3@!<K#$"7#A#9UAMM_D4 ;HO[!P@,"* 80:,^5?X()Y#(S;Y:0R0X#'[4
M&@7_\K]2@P8T,L, !*U;1O *VJ^<.TP/+2ABR97*P</&[Z=FD>!FRKL+QD59
MZ!GX<KHDL_F/,KI*]V5484 ;[GT[*_YHYRS5A:'90/JCNRNX#)8JXE$>W?]0
M& R1ACX$PUM3F0D#?C?GV2T5])XH5G)PHFC B2*43E1V*FQ=)T =)%LE^.+]
MB:<Z4\LY849$UQ84S'2A1++-+Q2;98=='/,62XSL8Q@*TI/P2J>4F5AB>#!'
M"KXY8YY,D^W%T!+T.%_#",.VMA>S)BO4W I7>J-U=E/]47\>;"9-%4S3,8[5
MZ=2.%>+2M6( OO"*NX7 )=&[@U='%^4MX7" +3KZ<ZN,F7K;-^>?704;^&RU
M3]RY]GT7&UEV8M&*8IKO;D#@=]K@H?LS HI.@UZWW O!\1<"HT<ELM#^'S @
MA1E\<\&<]:O9GVMOZL9F,<G:9OSV\P@6'_P5@PMFI.-?C88J67&C9PQPL7*:
MZ_5,;0IVYE0WVK(/>*+_ZO3C-Z^BO%RQ *\0#X.WL=_ FT;8,!6DL-B5^^.
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M<F!]8UMLL.XF?]M?;PM$UV1E=2#AQ\8& [_)\$,0[N]IDBYO,JZG7FI3<,&
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M[UHR8/[UL]3_ES9*V,S_ %!+ P04    "  +<WE4GA%7-KZB  "=K@  &
M &=A;G@M,C R,3$R,S%X,3!K,# R+FIP9[2Z97 D2\\NV&9F9F88,^-XS,S,
MS,SC,8V9F9F9V1XS,S.S/6;F[7/>]WXW8F-_[-V(S8Z,J*Q22GJ42J54U5\K
M7SL 9"DQ23$ ""@   +\ ;[6 2( :$A(*$@(:"@H*!@8:%AX= 1X.#AX'%0T
M)'0"7")" EQ\?&)R1BIB4GHR?'QJ3AIZ)F8V-C8B*FY^+A8^1E8VEG^8@,#
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MA!D255@1RM 1C93%'QK]>UQ>72\,&:O2-8:1TRPL)CG;+L7-/]#^1?;_#EC
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M@D\WEOM[KFE *:;3'X]-A^=SQ5'2]>4!&M> *]4'+=W .,)4 8HUHI?@C2_
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M.9<;>2@9"7MLN/0Z?F=\\3T!Y#QC^CZ'.SQOT@"W)ZCOCN878(]NO/I^O4N
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MJDFA2ZR9'0 "OU]G+Z@V@U;#^=!VMU\AJ?Y%X-N'M;L+Y+  Y!#UR=X.3>9
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M:GP(@V+I&P&'1L$DE'(;\ >X0V9.K +$STK[ Z.6C]*#+>FD0H@920TJ#X*
M[1B(=4LW]U/VP3_8+SL7]@K\=(BS/W6A!DA<G0F>5I*-C_ARSB+-BZ&$]1(X
MNHI'C[1Z?6$ZU@<,@W?DFUR,\'?EV'3FHU]=VM(;W&D]Z&02)*\GNRKG84S
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M]WET+-\9ZQE&/VOI)$7ID<ALL.%R<2%![[(7J#/\F%QDR))V.;<C6S+JA%$
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M9]8]O][V(;'=&DI,8FY7,XU"#*'O.)K9_\Q*VM97KJ-5PBCM23*'(9U#-8'
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MA/V>7<3#@;KE6ER<B5)T^9A7, ZD']>;*&?S\N.DR?(RJ4J\I'&G?NHC[0X
M>EB.SJMOZ]U"#&YYVVELQ\YA "PKM\4Y^B$/7;&O@S2*3/\RWT]0*MZ/6YJ!
M52V.K4.[0B(WNE>2I;*WL[_1#W#&<Y=>5V2QG)QP:D^;BWDM%6]X%S!,1M@T
M.S<#18>84'9ZN[K9;Y."*D*^FX<:]*)S@"R/496[IJNY.M82ABM-?D6YLNX
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M,>W^3JJW['Y:_7?H#=P<!S>2T%S=',"CQ<D#Q895P*"8.0C.YVXO*3/U]2$
MGG!]_5LH5A]5<%G4Q_\=N?X?L[RF+)S?WV;MY.X^!GBUJ@SJ4 Q5W]Q1#RB)
MHH/E"[2_'<@*;8&?#MX]#_;@[.P-7/828.2O^U8.;4@/H3Q&6X2*M!AR+TM*
M JE9*S5$@[[W+DBJSM(X>47J/=NOPUT-YB&A'#G+-GEK05^_<U7&.?"![A"%
M\H::EX#*\G<(@-EJQJJ;Q$2_MT>_N3DN>I 46-'GV1D3Y21EIH<!*AP.VWD)
M$-7K_!M3V4K91YY[I!54TW[XDJR_7?'AU3^#I (^1HBOT)?1LJNX<DQPKV=+
M712K[%J8B#=;K4RXL[+SD)<2^OB$[-21..NX;[8011V<K]QIKV^NKR<ZKXJ.
M++6ABDWE9C73#H.6EQ.CTH5Q1<[DD6.E7YRO/<\O0)9ER#^O(D.CE'']R.1V
M"H*W3RS&G(*+SV@"C?)%<XB>;<1>%OX%2"?/?/G'HPK*$<Q4$"UEYES#W_K>
MZQ?R8/3WGY=%'!&W+4!><>@!FF:Z'OGF0J%_,92=DZ%Y!D:Y2F/G<\/0+38V
M3T;,9[/'Z6\.FGV0-"GCLM>)]G"'D1UWQ\[FCMR:\.K$@FWB4; 04MM=3XQ/
M(IH@>UO3OW\T?F9RHZ042@C:7LZS97^XYWI/;+?MB+%"]KU84&7;W-C8Y^@V
M;=6BA@*ZR\51O%>\AQ+9!/67,E&J82K;A3+ZDR];^LG8%[N)+04<(-S31/ S
MWX\E?+8+\\1V;%VEBIP_4S+\H-=65/HJYS#/+(U>O1FK$=L7XI _74+=/;T$
M*)=*"N)Q<F*6_T<GJ3#"^T#.<EU5'.0SMT5C0NR"\9,C_VDA?*<^JVRB%"AE
M3(^'CJ1%@+C<_I';\'G]N_]B'4F^T=N(I%I*^Z43)R6KX'$Y#7^>@=AE-B@F
M"=MN)+KTLS0/Z7\\8SU0V4@,;_0PL$@XM:OGDA2#D23;K4D;![1&C=;Y'%]Q
M-L=BQ&S4I]+\!?1]%HO062D?+S1603.7L%>$KB]1$2(3798:$:%BPD>M;,CY
MMUE9GOZ@'B_+F!,39*LO&YHI!08P[F\+8>0@CSAF=+5:8Q/S.YG*!T]^*0RN
M/W%X)X.U&"DFT/87P,MZEI+K8%<]1$#VJ6ZAODR0KACLQA=*H38%,.G,L"=\
M?X@34N,-2/MC7LUFXRM/:YME)JCTDD,ER+C! DWV7!3)QY0K"L@>_0L8UNRV
M2NHTCE:C3TE&D*4_\W+!I$-PF;;32-[40#.FWN37^;L ]XP^XJ\E8XABO#TV
M3:I.F<#H<R<T%2_Z9+1:$Y^!"TM4OO27IX8WW (JT\/=\RJO%X7ELK"H(8]5
M$^CN"8TZG6:'IO7DK'KV#ME"+W:3/8V76>DRZ>./^#8A=3[6&W(OG?>WTL,,
M\TLE5.TPL@A&'<\T,W3\H6HD1<B3LL]7AXQ]-7*!()K8!5/7[=_W8OI_ 7R4
MKD>U*52NXXL)P<2)9@88'[*E]P*HYXZZ&[)VG](3&3>[.[?M$WNNZ"A*$\[^
MM*@ MY>(K5]DWR5O\I#TV#V$&UW0N-&P$&>#K#>0;.")S,S:L\U-?B5;4# X
MG[:RD?9:Q6E<R,C!?/_9)2)I_H@R]&HUHC&]QP\/M7C;7/O9UKW+,:G*]K'S
MCF3FAHIMS#+@G[>+(ULC@ET-B!=GM?SG/!0^RAEZIF\&%.HASN*"*<BZLPM+
MQ^D+*EP8YXWI@TG)++_"!43YL8WP>YO$UGY*[YR?#)I[+/7TWL8Z#.C+//EI
M3/Z]&')W.<:9Z[A!EFUZRG5D-5AM1 C%P0*0HH[5][9Y_+AJ$NK9<@S;$E?%
MQG/7<F,+1!8*#\I0@5(!KQ#),@X4FOV6JA:<'&<9Q28;"*^;G^?[R<;9(16)
MY'#B FV2EP))KI+L6Q-20J$6L(@O9'H7%V9%E9[3Y77W2W.?%MWX=\SHNH4V
M@O:B9K V2E&R*OSB-?[8WV/V^)&;IQ= IH>F;952,9D0#YUJJ]XE6A[L^+04
M@3?T5,3D/]P.A]J#2?\"P%_TQAA&.'0G$):D>0^Z[+"-NIJ\QOZQ6\/D>>S<
M>XAIOXE,B&R$:P=#T1^H 'O+HZP:<VZVCI@&K4#%ELWE2-BBM%'-H]K07T %
MDCWCX ^YH-#1L$G)T*)_2QH(91JON,.C?A\OC?NC IE8!](^F!Y1>U^1C/YZ
MEGI_I6AE]>#!\33GV%WE2XNUBJ/'HG^]II>],<>3PA+[A458QM#MO +) %I@
M$2UJ*,@_ 'Q_U&D'WUQ^66T>D6^<1LN65>XAG.J'+[J<EE1W$FQNZ]D1-*]&
MR*=&N"I#,V/9M UN-1"OJ18[*+,G)W+G(&FK><[&TT,_C;=863"4W8&K([SS
MO;ZV3CBAB7-UMH/9S1W.8SZC9V%)<+Z+UOS 5]2C\E3]I3*'-4>?:E67JV<#
M%#*KN6&HV6.5C/FDY$^?M-9K_>()W7BYH)6V.A\01RR0M.XZ4"[6L#OH0P"'
MX!I'FJDHKA0T_73JH(,.^-AY@(#?Q,;QV&9?71WP (4RBZT^/>_ *@GS(.^V
M6!=(HLH1KFBY5^C@3?LE13]V8G@66)< ;Y.B!^+^2A/ N'^K'_*K3GUPV -$
ML^*4[V"-D==!#I;+4E\8"C+.(==,MY)8R6W#OZ9L=F"*!$N5GN.7VL./TRN+
M0B41CV)?/T=^@00_MQ3W_S.CKO7"5+P1D$Y7UI(?GNEDN6]EFNJGXT.V:T'A
MLNAKCEZMSIAHSYE.>3Y]'O:0K*7RXD/;8Y+8S3WE2ZQ))\DW@G8KDB\2?O&0
MO60*27]XW:JL:#'&C[N7YLFQK/^%?3O,=^P97*'N.&?)/*+79]CM&IUW<)V6
MH$B'"=AM"%_,VDC!0<UI9UB:3U&&NG/VG'&^Z YAA62#Q.D:2KLV13.4"")E
M4SJS.)Z4&*0MYB:^NB29I' 3WLB==W<(IE%^9O))TIBD))=%B@7AK/JU4>#B
MSXQTGIW+FQDQ3X=8Y96G7%-+C7CH^N<?SHCGU7Q!4QL_T:P=E.?X27>1#Y<S
M"-.F!9P8RN?>SE8]1EPY/GIG(Z_]U4AR:EQY7./_ X4JA'C^9<K[+XP$D)E3
M">.F^^\*^?^)\N"?:>[:NSF">JX$^)_9AEBZ8,\-L BZGA 'X*<#<UM8>;8=
M9-_>;683IY'*=368JGRYR968CZ#)X+$(M4=T)?Q9RYBXK8L"9F'13[]3/^*&
MJO#8E^G@C'\.](P0=?5;X*\+PGX1TL0I4IBB:1R705-JU^)ZX:"I[/KTS-KM
MC/=+VHCE-62M+*KP:W))=42,>GL^"KDHP=I#3Q7WNN" [B%9>A[MDI/F=AT*
M*;'],)D^BTO_G,LR>?GPNB&C#P3P%\\/*K4)D)(;=Q2?E17A5>U27#[,&-U%
M2&BU9/RAK,L-YFEML9>U84E7E7[+5(+L3M-2+5=V>F7D+&6'2_0T#-OAF.:)
M3KV2#V@Q/!"1S:6XY05*)!O!RY_ZJ-/_9Z:8X+31 6'RTIW(LK&$@%F]/XQ4
MD*"AL8\J\@"(6"S-T>[+7V\X2.!,6)C4W;8X3P^C%)KF;;RE@3$92Y 1(U4=
M<L>H8:,J&-,*QKLOU$_#]6?Q^.2R1,/>/+5?:-0_,EOGM$ (*Y_]WM'&!X^(
M+9@G#%>P[]64V%P3WH"2??6#85"L_P>:6 R"E[KFKRF"%>>>$=V9?I^X ::9
M/X, M@.]R4*"!Z7!R'*60JY,DIK#KK<ZS">32AWGO?.1?)3*TB:=/PN4&/Y\
M ,=')&\*"WVC"Y@*^3H=U;BLZ>F\X%6 !QBA#_0NI5;--H@O.Q3C4&\4P)&^
M4"U&LMUVD*]+\+DI6Y(9_[F8AR9PON_P-_)E6%C.C!2RQ#*$=LAYN<VO:\G:
MFJ;CJ6?3C1?F8XL'\=#P"4M9\PQ%S2X630!\7$](ZLQ;16P?"0%P_QK1DVL?
M7\.SN8,<K)K*28PW(*N6R ;&/H#:LR(.TPU!+;&S2$W4W9/1$9P$]BP,H2(4
M1OZ2$Z4QU,[IOE6G-[(U'6'U\HL4'91(?._BLZQQL;'HJ.PBI>KJ%>^-DYI0
MX2RFI>KYQE<GY*_5/6(_(7U\VHD)(_%8T5QSP'.+2<X1\SJF4^C>I0FL/?!C
MJKNDXJ1Z<E_UL69#V5E7<]51V4UH,L%=W1-7+>P)1,)K=5B5NS#ZB\U*\5>X
MM^@2MNJQ(IGYMZ24(CC/M57+6II%0R%A4_#(=$&H>0?LUXN^OF2^O$#L. )Y
M3TALY],4ZK1:-5]_+[L%BOS+.&K=K8YJ> K&RYV_@-,I!:_%D%+6>,KM/SZ^
MT_/^PX8U+QR._4'2@6 F9EXC$Y&D ?CX!D?K)6E"(]K\9Q!1C!N%8JZVW_ID
MR>^PYIT(=^O7Y$</@<B"0_/.E^RB;.7VFP?EVV<#\667G"NHLLXXUEA5 4;.
M EGJ1M5^Q*-C8:H#C^UGH*388-@81WV*>%N!SN5SB.S4RR&_TI;?:Y+&A+V7
MA3[OLEQ^EG\.DGCX"M]<;0 I3U5RWS.Q]-XT#*BW=+686"2DR_MV>+V#:P1Z
MX@P!M2A[V,;3I76)IUM;:,0'V40F_BP$5F0W:)B9%^V8F?=>3.,#PC+,@=GE
MQT-_S*L>!SM&U+<0?"=GTFB9;5&_E%Y;-&"DJKIA2 U5^O6FSOWQS;T_U(9,
M[TS;M<P' 919[E+350N@_,-HE2<,%#^]&7[YNXI0)R@CZSUH/ ;8CC$ZLVU6
MI#0T#QGO7O)\URK04%\)V88B][&_JS&[N?XHDEYTB#NXXH;9D"Z"11;D2I(
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MDOBB,-F/[/OM#TJ[""7U3)@ZKU!;]D77Q2 A@XK=2$JO3MW/=Q:(".D536V
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MV,D+;:@IBYRO)&=9M[!ER@!. R;YF,--^G;L>8E/PKL_1?$F0TZO._>T>RX
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MLMJRI]^#ZEI(,\>O,$@DF63GR!5-2ETHU_:H4O\SD^5BXXM1 %<CG8NN?.D
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M_R]N8_3E6K.<S%]/KIS]^"]02P,$%     @ "W-Y5($SN7M(L@  ,+8  !@
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MU@V.QSPOM(O5Y]?)*;[Y/07[TP-YFGF%:ELH["$?1Q*GR:?\SV)[WY*=?@5
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MT7^<UU.U676>>>GC.^DRZ$M=0!JS"K*"_A7R B?G 'ZPPL2.T_.1L5"2:+-
ME(.'% )"(_/SI@G&-!R_#[9GH#"6Z10])5+[$E'37J\Y%060^.,5A]""3<=N
MQ/,Y%<D*$8J<?!YS?EY^-G1>?EZVT6\Q+ !)LV7MYJV<!$4XE@U%5&$$Z^@
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M?6%D 8OL:XZL7];JVDWI6H,36^@538AKKX!X^5[.Q"I''?>"&%%G:,E\3?^
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M00$RX6P]U4 _'4ITNG!3\8D9"A_GQ/KG;)H>W,8P#W&4%I_S% @7C]U8R0,
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M\=)LL_(MT9)E062'>Y-E[80'0I,XMX/(RG2FC. ,%!Z:CO=K*@]R81RB'V&
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MY!D  &^?4*20NRV4A1%/%;MT"N'F_"CR\Z"!:U.3D,K*4XH0*_'-4[=YMK6
M).S99CW0B!VEJV2^/.^E\A0;M/*H2"$^Q7F$H<G03X1;_EL[]K[XI!4.4FQH
M[Y70 *O\E4BGF[M?P>2^C!R:B_#%I7@)6@[3F;-M,*.X4NTK%MN*#M\,>ZZ*
MO)2A&+UQ>,KF2'A"_N@;_(""U.$9Y'?;^,[^04QSLR7)J/?SO-73(R_PYK;/
M2HK>OGP?2+N%G*726;!%'"HD#1@@)HX<RQCKR>+0\]G8LN49$I#G,ROPIO(*
M#YZ)?/N.F/H @DC@4AMFDENDD\\1ES_5!6#V*QI3C,QCZAW%EYA>Y 1YJ3(L
MO3 L9RBL/Q]BL)?)@W7]$P\L9<. [PWQ:X*I$H51\_-^_4 7[#X@Q._W&"@#
M"'Y3P1%U'"Y%4 D!7!4H0DA:(E>%J#'^3'LO[CF5"N!3DK"BA@ ;6&9JO7VC
M@^U?C[)5H5$29*1XIG " UCAN9T);"4=H]6,W&M"VI/Y>;"*DYOJ>BEL]#IS
MXE$V/:QGJ ZICGO)^\ PBD0TW&^>SDL*UV6\-/[^!9:XKMHE$_7,Y2=Z(U!-
M"L*PK&@5'),$TBK_O(<'_\+D1%!#6(+](@0U^%@D_E@[[.4-,H5$+.$(SN\;
M5J#_^.NCGQM&OR,KQ);Y7)F&0-&RP*\:_OCE :1(-=/H.!+V$R'JB:L=/P[R
MWU=W#4?U2AV!"?*P3OZ)G1/<V&Q:B_BR99@I3*V)RU4-0BG8X3<M<QD; :I^
M9FYVR[ 4Y4NH/@4<V..Y'--D(TY @U:_LO:N'UR&"6CZ'<-^G#E3].^A);YD
M8_(F. 3&P2H B'LB,LH,W<PMNLP,MQ[B)^<05_6#XGK8'0:0Y6@^HO/%?N_!
M/V*FE1-2:VZ;6WG'6DH]3D!6S!9E#'?Z[E"8P,F2D^T54-H E^!NQ)8I;^_Q
MH)KUYR;3268K^N@3L3PK+] <VPQL.X@3/^,\)P]S78^\B_F+Y+.Z* 9-"KR0
MI^,KX)@XZ0,6A/!>L\.?-$-79.06YRO^"X%HK=0II #D*CKT?'%O-*O4"$ 1
M9YJY0\N8'V8OYD?2+7L>V%QO7#GWW/"R=R;&5H44R"X#^A)S%;^%L3JJOR#'
MOJ_7 ^]OZ20]W!-M"C;6*'FF[]41Y7W,S81^4/[*\4/TM3(5J@.(>Z8._N87
M@@V:%T?(3SQ&QF_P[V>;)M&>%[ H<.+"6A[WD:.\/*Y>ZA]+=#VJJHG.9O\L
MZN?K3C+-H4Y$X%SI[,[8VOW.V3TJM_&%C.TR5ME>LJQ$3YLP0V1C 4L)*U,Y
M8<"IG548;S_6IS\_4:TR+-MK4+6#%LD%O]_GQT9 E.M4 >SZ*Z!F4HJU>\I#
M%F#/TLZ_R[^YYVUY\\#7-LR>O*)6/$3>][_X>JNP.*+FW7=PAX3@3G!W=V=P
M=PON[@0//K@/&MQ]< ($=W=W"P0G^$F^_?_VWN=<G(O53]WVT^_J^E6]7:MA
MN"5U-6&"7.8_Q2V4>E7IZ#[^M$O90KYP-]()O'LM/U*':'KYJ'[6U-K4K_FU
M%]=5AA_J4+#.5#0FZ&5II=A@S[:KM9&S$> T1(3)H/K+HFV6B>FP18KA,[ZI
M1!@R8>Y;3L68[9,KI?U275@"9H27"CK&@;;O;3ZZZ8U<%ROCAU7HR%F\R%6Y
MKSTU2"*T@[YN6KA*:8N[-E_J'W_,-F*&B24ZL_/?3?HNB8D5_46P3!<*I LF
MK.$HNEC*9#(^>]#VDX:>9[H_45!7=TKN5S7[1PU4F-8@I/L'KCGU,OR)K56@
M1Y5!9+7N(0INNO EK P-#?Z;1FUANQ0A)#//HT^H7VS0W,CSCI?,5ULF.'LW
M&G 0'N/>S;\&EUF]R9GL3,WL"L5WNQ>=MB;7&KVA17NHG,<87R_Z*+M-=U>3
ME!2<R:\$7L2,K?>QGJ8-S.(+V']^7NSZ3WXLF?N7#@'2L(5PO)3._@SI;Z-I
M5#[@"1/K?*J23:3$WG4,HC?J=O DP4;6)B<*/9;L6,=1<&C\8 9^HLT#AU#.
MFEY$KL0/=>9%*517;\'0"[KR(L.5U;"61G&CC5T+&<T^3%F:F^JTA5^8ZTI+
M]!24H.TCBEJ\";J%*ACL9[DT9+P@)#*2G'*HS-=8GNP':$I<87L+JHW1,@/2
MI1;?,'=3^UWM63.;W502&<:(R4'70(,;O27^B5A(^JKB3VS:\="\+-((TECZ
MT_M<O4Q*%/+X<;H0/RO 'NQN$/O1; W!SJ8^=GMPKEI=NA&*_^)1O).J/'H$
M/Q]89^9"<V>%^5<"%F!9)&^Q:6^1B2J6"AT')V9\\\@&AO?81@E2BBA9<L%:
M'!W7-GS*!CH,HK7SQ$U/3^3$.1[-0A[EOE CI4D>QKL]4^&.<"V;U1^L7Q]>
M(MS'")&P<E0N52YV=QE.EFZ0[DT,UPS>CO:R!1SLS1W$^9#%*^,D&N$EINK\
MS2%MO-M6P;_!#4^&O?-@,=L?5JN" QV;[!2#W+[/9J6^Q[3YR/Q"(39/]JR1
M:GS<H=2;Y^O)F[6S:O^?U B567.R1%"3S%0,6=,;/9!-=4L,S5V?,ZO/G>N3
M'@7J';JWF+.,,#O[^U3+81"!?UB-C4VCJU;?$?)FPU#@6BLD%=F+>#7%MBJY
M8ABXA6IAUR;IDQ\:&G"0JT$#\?!I4(';VR8?UA]J0J=BQC!]ZG^]W5_%3V9Z
M^* 5P0/U0>8 :>5IKS*87':C34;5C)KA.%K)7'-S&+($Q[/Y;1(;Y D[QS/<
MM<Z!#D_KYI$H,<H@//>S[-N[FIQ]V4'#A<!-$UKV@N:YS^$PO(P<T8#Q!>%%
M\=>\2363K[]."6%(8X$6Q/TB=I&=O_+I8HM-AZA\>H7O'&J9$@NT<EDM*&5N
M,+).E/PB9W1"N[] A;B*/:D@<+DP'2R4#$;_B=P5HZ8PD0_'7SMU6=?8@4#'
M.?Q8-'L]2C)'\&1ER[Y9XIUP_RQI14LLCY[/\[F@M3-\94_&OC/N RV%X,-0
M,<#M?LFU:'*&._]2AE)J4=-T^X.7"8D+&#A[?3TP7N[3]-VAU60K, Z!;\CV
MN*^'!(A=B,J;&(R/=U>*$BD7_DE:C!?!^S"(C4"@_ BQUCOMG+47+B5E;?WN
M3-,B2PW-.D2@F\TE_7%RIP.!#-7]PJ[D4[]JMEP8UG;S3O"?>>ZE^P>V"!ED
ME!2H2+C(V[M\5#S3CI:H0HC^=_HQ.I.=R'V7$.^7LE@GRT>39!5]3[8(&QX$
MM!>=*=Z[<_TS?R<*AV@Q<HR#YDG//-_DR=@64TD!;Z<,E[O;?&2P3B93$7 \
MPKRJS)R/RL]MLU9=<V&:G=5":'Y?O>P_V(#\%Z]%L?X%ZD Y&\ _7_3?^M<2
M8Z)BH@)08:F*(FYY9BH[=2CFBZMAPX9H8/)CTLVK0#N0A"1;3WJ"XCBB/;
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M0]&6HCG779E9=BS-PDC *FZA>/L)KUB7P8V\T;M@<EYD]4MKY. S$7N(QF.
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MDZHZG9L 6!P9>7ATD=-CWHA/?@PBO?(YMK[+CJ*?)V]%CVAQ4<M(A6TGYZG
MG2DX*9#@S"[K"CT/*_VS#.XGSF%-LJ@X_)X],L\BW?VE  SO \QE(S&J]J\S
MBAV80UO9SGWK 9HG.$;(C4N<.GE&'Z<$P\S1; ]$]TC]RJ=\KWHYAFHP(,?:
M2VZ9W!,X@]&<%/5"T/%]9\:2UMH?UX\7&XJ[5Q:2#^(%37S]?#4G&L$@K18Z
ME%H,;]VW47-]'V()HG#/+SF%-$D^Q_2:5YY!;TXO"@7&]%)1#Y7,Q.TL%.55
MYX'B3?-W7KIWL@X3 ZT2'U<.OU8GC'64SKO2=EX2A^?C*7OYJN[?_-!E]3I'
M1I>A*0F ("BM$7[PC@"VM;4VA[_A@-=W-49@ _P#D=OL/-#.J[RX?_^@@]>L
M!RV1!1 O^Y=-$+_VM*]3>I++XQ 3ON;U5;N#-2-GW+W/#S,^?K#TP8!) @KW
M@24XR\H<+O([8R::,ZGC>;<(S:W.U%581=SG>4BO?M,\EY3\#1VS]LQI\/$F
M..$<Q%?M)DCT_7R^EANQ8C?(G#)\ EXN#)04._BXFO7KWP\V-/KX# )H:GV/
MM?A2H.Y#@X>>ZI766%[NWP%#< :V<G0#4!,3.Y5;=9TVO E=8W+3@E7U#=G;
MYJAQ;15+)%CS^Q VPL@2IMC> P^T:X<1BEPTCS_);[Z!>P7IAV_O@!.MR@G4
M?9&=3]VN7NO4 &K6AM:^KZV"_FB*.QT,?[C&3FH=2N&N<;0#TVL5O(3O%LR?
MWE+:./FO76RB=[64.HJX2TUF>G;IO"(H:1^OEA<A3";4M=^/P'&<O)@SGS4]
M#1KE)'X(Y\#_E9)(G(<07U6U PFW/%?_DKI4*V=$!4D&P,2JK59]_C;++E/J
MC/93?\3A2FLJT1X)9.>-KB-I2QLL[T(&/GIHD&$T(4/H=FP]B9[E-BV%+;5J
MI+-1&=F-V9^+U/<K9T89I*"L033+,VP[,]0.>R/\$\T'%A+#&5U7(@S,Q;^'
M1L=BJ4$\JJ_>"N.^<6CK2'M03@$2G(>LAWNWG2K;/V'(74!.F+]<WA=2I?UN
MJFX*9^KR<N =ZJ*3_]Z8I8]P3Y*SSVELI:*?3/:\OX>_L5BCUW=OIY//CB\(
M06EKS_9=@D%KB6)>-6EI;PT]=^94A_^8C$+$?TZV3]N[L27<5I&N? 7M?:'&
M6_.=W8 P ]]<H<B/]$$&)C15(G2CC;>J4(GMCR9H/6O]]E1NC[-+QJCU2JI*
M^TH1R[L5UL?BXRX4-QL^K\D0R2/O;@=]/FX7A4?Q;]D-:VBD=\"2?N"2\6O*
M$IW;CJ+<X>&]KM'*K"Z.9/RX2966XOH3<:<5^,PR<J2N,L7<H2<XMS]0CUOY
M'2!"^HBJ55>V4X>GMQCL7[XEXX;6SYIEO?3KM,]KJO73E&.0U9DF]>5@P:"V
M+IG "!-IQB@1OE<J)6J0#/;\>=:;WSM@+R0=\QTP9?SBK*Y9E"2++FR,>,HA
M:IIDG<W5**V0U APE0O;(T,-SG6+2WD'_)&"<*>=@'9@Z^U%T]&^$8JN@<R#
MQ'HG/);_1XM'_[2H?/8)?_P=\)/'"WN54YJ.2<WA#&9R&ZH)X,J?(,;[4,ZE
M^$FE?;X4/+'; BR@H_"I?MYD96_=#ETG.'YS^AV0XG;VI/%L8[3+VW(9^S0X
M,T I5Q+(U:PT:DXH>A0:@L'54J-78*TN>S7&,/"!2G72('B+"+QZM)@0U!,Z
M+"1%-Y_R #/"&6/CX%C8J2\;4GZ#-;DFP6,6G!P_6F;[5'CJF[Y*8FIEA4*+
MED)&@AV0M]C2J>N O[@D6S^;&4.3@0FW;OXRB6W'W2>^>'%># E5L!Y.X*@Z
M.Z@R]T3;_.XH);E.(-WOR=JH'_H)VWU,6!GA48-U&2D1<1*%/6U2]#;?V\O8
M\LMK@K1 5N1E0/:B9V')*;=70I_?IU5XM;.#<21[OUJY8T6AS+W1[():VA5"
MIH**SIBCNF4$*@01)=OBM]SFYGB:G+8VO+6AHS,-7*6DJY78B;E4@S2_Y)X7
MFZ03834&P24X Z*/SHI"LE^;9TB^YP<.=YN] PRTFBJG7DC]O- ;B8/;<_6U
MPB+CM#=:B-ER4X^QIZ@L_3AMZ1,4T0JBZ0C"F*A8?$6QM,E=]GPHVL"T[G5C
MA"D;5(.SLG=02B+\E>\ I)JBB;"Z)OSS0[ZWU*])EIC]LTH3.1-T-<(L^!O2
M,FN<X2L;YP?K,B]P06\>7:5V[0%5^/9'\!;X;++(K4^A:^L:K9 VYTJD%\:C
M .K 80CIJQ?I\'P@2O<^U/]@T=#588>+A[W[RCD.3IS*0"BF=]46@G?)C9Q8
M\8K-B0=3_XI!FY'L4*D2PVPL?B<+_87=]#T]&K?0(1<['$9\!HO"LWJL3P@K
M1 C>4$:5HWI4-/:3Y""GP#HVA1W1-BC[=D(EZZ>7]L> ^XN%?4O[BQ8J4;8*
M9XYYAV&N[U0WC"WJ0F-5T\.:3#??D!)@6(<H<E9*>BLW)QB_8.+&^Y8[@'C"
M7?.#UP[4 NEK+$$;M$*C>S]G&6MV_3Q)K>/<M;_5C1Y11?&-(+00J5M>%G)U
M-:D:B 93VE )*S/+AR,(N05'+T)\OG>W!E^@)DI@MJ%W\U$F*?D+F-8[< GL
M$,H:'J[CB-VD&9Q;4O#B'9DP3"W&69*,$D>(?,.+U%#&2,=*(L[5-:CD-?$6
M\3;#OZV)%=F[=WK ?5HD/JS^6K&8UPY<3M'6<,I(0[E^95?R#W.49O.A/?NF
M? 9L'@51$,<05Z!T_[G.>VMKN2Y_UL -O#H0>75S.I!U,JT>K$0+U=7O= 4R
M]?RD-ZO#/Y4Y6$QZ,*YK")*;8XCM^5":O]&4E\^9_B1GN]A\-<89A1G&&%WA
MY7XA+?: K?A"A]*8U[P.:E;Y$NAU\WLOSN>N0NO4<OT)U_(*/145WLR/D"Q^
M_%'8K.6R--#I1%\GZ_B')FJ?8)"O91D&TIK#JJ-5;^Q,)#)*V@AE M_^$3&]
MKB /5O/UX));>&IB3@^,@#2K-%NTT'27TD#8%7K*!.NSN8E$BQM)]NU0M35E
M%*,\I3T^'G05NACVMZ]4_T]?7QT55[-OV5C00 CN!'>"NVM#".X2W&G</03W
MQH(U[A;<"<'=M;'@[DZ0(=^]][V966_FCSJKJE9UG7.J?ZMJ[UIU]K;;NA??
ML<LS4E*71<L#7.W&S-;;PT*AO; FMM;8AC /*)]74"*SH%25C+U8MK/GK[25
ML626!61[9+ !1<A, '^+CU_#V4EK:(!6G$)UV#"A>):V\^;HB04LH%!<X3H3
M4H.B8FWBA4[__;07  .DV?[MW==#-9=Z>4XM(U%2_=W8YW97KE&-]&\5E)71
MLC-?$R63-D*XP1IJ4ENUQ# *$;(@RO>2^Q2D4444N3/,D),^+<ROM5&PWAK>
M>UKC21_&NB\%B$^%[BJUQ_+-3OKV9F93!B,XJ+ZKD0 ++HR-,@-B*PR%(UWV
M\'QXX9^/6NT^9PKY$WI.5J4[7&[0<=2![--I>863LAK+_ ,TI,<7CS/B<( D
MHJ DLGAB'L=[FT8&Y\&=G.FKF]IFB'@\72(L]WM9RD:ATIFL\UN\/X4M]$,J
MFN ?:9)U=8GU4N\@_WRQ$/#7%0,VG1.BAO%!90F[ 5$U4!M"-5_QR)6K6+)<
MXAJ+4AWT]>@S8'RN^13C$3A=+VXT"\]ONGN"EX&?3SHB^NN&\^C8D8_J:"RT
MFW#X+JA[KJ6L,PXU3M]$F^=8+X[=@6\S_A5@./FA0.9THQTY&]];'GJV0"7_
M!"^8*X7F**UFF*8=TF/SUW*1L'N7+=FTVDS;4Y%'V2[CD_9H9&J"G\<8FXZI
M6@-93 ED==31NQ>=$T0)=C]A&92G/+A&3Y/=>VAU&L4J><W>.]Y\GW'#,2Y!
MO.3"A;MSH),<Z#ZG_>;?6#72=<+H<(:O!T^=CY@MPHTT+L1QJA8::$\9^/ZM
M68[;>,90I1-OW_+/X2CON>2?ZX/7;W5(Y 9TJ4>X+Z3!P+A?XRM\<(T5SHU0
MUNCC<G+Z$GW]SZ92<;K+F]9H8*=.Y^DT%&;: %:C[WIBI;TD_<G%4TBF C\4
M:7=/(;[[9F<(PU1T7'WP IS!29' N#?"MY_<\F.[#9B,:5)TW9HTXOI&'1QR
M$@,[#98=G ]5]X6)SXGYY[(\2ZW]K4,6/TN,:7T5P^^;P)BO (@ S^SFDLH6
M/[&N''_0L,+4*G;_S3I\/.IF4@";'-?Y-*U0]/?(&QI=;H0A,[8FP685*>NW
MM#DHJN6)/0C& 2RKK([H)$H3F.?>DS8XP0FTGUL;-S.5$O^CR?1+S/Q7YVZ%
MM?3(.26O4J_8A\_2OM&.&JN\9^-ACUQ.:>V][> ZID;NV_<!HOW4BN?>)FG0
M,]M;'E*LZ:V62Y[O9Q5TW37^R)0S42I8$RM_0PH)E*96F_E;?ZK<5ME7EQAC
MK"U%_:PA?$.(8>$ 47G*E;=OD(4&*.ED4?V*6HH^:99+^%LX.C*WX3G(<PH"
M">7*!Z\!6WY<A@%#ZB%B^.07;V%V' S>W'D7>C!PM\O'.YPT:4219/.H9H![
MSD?=^ MZ)BWGG:'\5(>HG(H4' P-O%3HL@^J]F!&;_@(NBG.5=A2 . !1C%S
M-U8N_CC*V#6JA@"&,7Z<_)UUVM0F:)? 9*,*$W]3HA!Y92.L*)VH;T0VKI6D
M+,H,0")\-JY#<SY6)10%UMY;58/(MYE[;'](50<JP>Y2,L\3]!,4%?70U,LS
M>A]^$+J>+5U&J+<K136QCMNE_,JWKT+;$V9PM<02[S)^DV"+E":LY;#RAVP\
M0X7*RZ-?+5WU#[8.O8 I!5!N )MNV4G8P*D4B>P81MO_+-4CYD17OIAS\$/H
M[J6AY8 F"A7?LK0F.>NFQOI=.F9#>"5GLV0%$EB1Q87N6[42,I5C/^V=][SB
M^K&<@GWW7,H\,K[W-^IX3X-\DV5#%5@%.#4[&\GZF:@W""V*W)PFX\F* XHY
MC$&Q7I.@NHC2"!Q1=3@ 3  "HVNV\3_'!_/J<634YCB/<6>6K7D<EWH/=A.N
MX!)$\8HK!?3/#7%U%)Y3// 4DI_(VYLN:B8_[,=U;P]"D?LE]*/)<?^MI(3^
M17.Z_NY1GC0O-YT=+/[AN]Z5$KISOTB2I8[8!N^)\LGIU;[A^"DF<RH2V5%F
M_W596I"AI)!!R5WRV,,+H!LO&>H2S (1I$%'OAEO5]&%D=&\"UP_)I2.T!T7
M=OW=#VH=>( $758)GM/V,#(;/"!7'!6IAQ/X>W1B914XN+NEX&IB("RS2[!G
ML,LV453M8VE3R#7:AOGTQ&OG,<=A,':>&M1]5-LDM5E>63=2P4UHN>"Q$W0D
M:>7#C0W5+]H]OC.N?$6UVD4&Y=8+C0L?853'+RMM])JF6<!\MK/P/1>86D;^
M4,2H)T92WJTTJ1@JB_@8V.)!D> OLX;SW'U8PW1->U"A]*YW"MSM)%,2=(VR
MNNSL. 9>)I1I5_S;?F3[T,+4=8_L651D5-P8'CZV*D/_KI;2\P.?3T/1U'*"
MQ7;8RBK6V,KRLNB4O8126] #!3/CB_!-E%'\30\AK9M-XCE06<[RGO$<D&7.
MA(T\6*$5W[F_^&$^?QZGHOGGN=)7F1YNQZ]XL[%4+P#6H;HH2#\I1=3[Q(=:
M&! K5<IP,(@F[FTO150SW$P O_HQ+G17>9YI^^NJ;'#K:;)QL"@^I3VYD_-4
MPR/-.^ZR8C94S!30R8+R^(&"JU%0L1D?O"FA4Y:XI9%ZXA(?*XF'7;TOYPJT
M$/2; ,H_T)&EK.2!VK6VR/T3RA/O7SCVDR%^!+A_+718GUMVB'7C-YZS3*.8
M4\73-NNJJ^#W^*M$_OL)@7CU&H%!CAN$=XSWUT8[33/.&96X%:'"9W^J6O92
MZ9R0SYXF&<_B-9'  R,#+BIP4=,P*_%QUT%R,*($5X>^3+/J)<S5J*N2?K\K
MK"+(9R_#3!__G<P\UW9RC701N['I($R[J"#/IN:1?>%DY=N=C$]Q'!AU.@G=
M&,I[JT\/9#9)PL4[>9%6%S-"9"/^]YNT^\^<$)M7JH3LKWB>7]T>I%P3<;)X
MV\UPHOJ$D4/"ICHGDRUJX7]_D_X"('D!$-H*0#>T"6E$Q0-;B3>%0\J515&A
M:0,D*#^&XK]B>#GL2P$T=(E< 4@#<$\-K\T]&L)<5%\ OF3G)<79&I+&V"2Q
M3U?6]&8Q- O"MWY>JE6DEL=4WAZ/@Z+WFG/-GES(']RTI[2V*1W?EZBL7DTU
M9P(O*//Q4! -_.KN\JW"4:015;6QI,\MS]?*H_J'W_-#O@N>7Q5/J^BJOEVP
M7^;&%8,$S656_6B&NL5/FD1I9MZE=VG"J<?H\U-,ZG6@!/;8/>/LM7LIZRA7
M,;#OA%7C>\S',D4]$0%#9:;!<RRRVVNM/,Z:^Y;E!;2T;C;XQ04X-5A9.M+H
M:L>VW+Q4JJ7MQUL:N+&.W&Y59@14-[ %=4F+4GIKW9B>D@*:8.669^.B&',?
MO^O0WXQT"L76<+X#NC:@7&H^*O^ZE>>@"##10.J/<D4!"00!YWU(:A7'8?SN
MTPJ4)-H._'%CO?_WSW7QSBYERI$3T4YXF,=@*;3EV('9EBLC+BX7A6\%N1'5
M<?_!,L7;R;P4GF8.\=E,(UXPVAH0^LE3T'9=S*G9"-M]C02G'1&#OS>\2[8F
MP48[TP%4KOOF2SV%7.698XJ!6*<@UI@_RH40\$J?<;QF^BK%.Q%$V11-*L)1
M\SN9=B+0(+#*(V;\2WW3Y-6HM+RGUKTS=U^$0GF;[3(B_&^LTU,#.R.3PCL?
M<2ZQ8J _)IOQ2F(PV2H*$CGF\I]+33(.2*UF"[\(\MVF9D># H-Y!&[*DU[#
MS2'>XJRG*PHOL0OOYFJY%81O#JO7?W&?4E_+'M/XM_FG33X-@./UJ$B7#DE(
MJ[NSNXF[NRUS6'A03W[-CVN^+</+<>M0[4G74=0^'L+@@H9,TE0*)K=;=\U#
MI+!CP&/^>UW YF$:&;WR3<Q41XA=;UNU59I_A.VC5&.O\PB(%/F$*IXJ#"R8
M@V*Q#4?2ZEHRUZ\^5[=>I'WGK>0K=^ *.>TA3(1=_@!/W(>\%O &V_&JI(T&
M*AQ8MOK%,D%Z2OX%0.96(TME,N84PT=6+#R[G[9=?WV2M;TP4*KE<[#,@2'J
MK;:DJFCCT9"\@A"D4Y^H]\UW& 1@)]L4GK$2*+3(;,UXYAJT(E2[L):>,IS@
M)?@P7RG$V-X8R)RCE9!-EJD&C@D;^K:KN0I>V'X$FFW(9X*@FY\,F8XG0B+'
M%\R9?VT6P<U5ES/YN!;I2MFCOFTV-[Z0H2W2[Q?Y1&Q187T7W*:*%Y:3!02:
M5L=\:"&7GK>](K^^W8WHC>R%L#Y/A?1Y(\UM#K!SRELNNEV-':%GR07EUU5[
M/'_4-[6[P!]^8ZE'#C@!.*X1/#&,<#^S1VP0;">,KFJ.7XR()8+X4#"&HTP@
M]<JN(L3(:.$%H\_QCM$UT@7&L8A/E0*DUU2$13%?F:0[!<+.3)-G6/G^+(O0
M+DUG3"#Z\*O,T896NGINMN@;D(!EV+0RI+;#\6;0$N[G5B@"_H/C ,I2RK/U
MD4*XX\>:E4.IT-+(YN\/,*O?\0Y'_:CNC/55;@1NZO!P2]#G#8?0)$F+'(F]
M@_0E27G/GL;B68K>'@IBBB0?4-BMMW-O<NUDO7/UO_MD5[&FT&9B_-WE6^5T
MF^MJT<\B:\?VX:_N$UMF\[J?,5\ YM NZN@.S30HO5S5;<"OQU$WC'-$C9DK
MCP\\3MV.H(*BY&5;]A> >]%G_L#5IH'-']5-_0^V-3\TV:4/.KU-N6%(D_:>
MWYQ)%1842937;T43Y\?;3B(0]8E2[19Z]C&L))=/:>C4$DF<KT6XOL53:T@^
M=<:?-&HVA97WO8 ?I*R"O_".R%+]X?_V(&2^J^-#4QI1$[Q.HG)=8R/2_8XD
M:ERE#'%\3'T22VR%Y8U72%*I3"%4C,_\N[\5>?*.R#I*NR@Q1':0:_*1==YH
MVH#DS?1PVI 5T; I $AD0NM(YN$X7_QW2XB'Z" : WW_-F659@K$),@J')2_
M'R];P;6@!CEU@+-2 O;Y&0,%YPO=LC6)BN\NIM9ZW!Y<T$,6\2-3'P+[I1Z]
MIXL^JY/DAO%PA?_TMP,< $T>2Z][1W3\TIEGCG#Q*=CYA ((N$:M4I@K;>Q=
M8-Z5#(R;D3!FS]$VU$_:@UC)L98D4(%44F++I1Q1I +J:K',N1Q1H1M2W^8:
MYL%:,MBF,'PL!#D?%F5_.]^*D>DD>J1WZVB#Y85PC9P% _.C[6:UFE*,!FF)
M FU_>_V925ZE.W,]$C_8@2)1-V%0(C-W)Z/(#IK!$Q_S7O=BE'LP6>7JV@E#
M397(M?SZ?P0SY<>F>I#Q6H^ @8^>.?=8[?49ET#\=(2*AAPD]EWW6^?^^7H7
M'>DRNS)=P;GX@1]YB1HN4#)$^*H&,9(63=Y77AR$T!-/G>9W36VEI=7 T:R<
M&&7AC*L<Y1Q_J&GK([]NR>*3#EL-=&4'75202 S\CF\Z[CN"R[A@&R7G]_N/
MUM(KQM3X$LYE,7%%5"%.!W_1!XAA=R!8"-:#=%.9?R>LWWFF:I]B =7;4:IV
M_!'.$1DDH!O]TP:;+@N/1@P6\D=I+/2X\?CFEC:B!/2ZP$@;U2*/;<7AHX3?
M7(V6Z7[P*Q.ZR;&\2&D#<UJ)UP@21_> B-%AQNAA G-DRJR]7G'3TGZD*\+<
MDJ<]E6^\5("8<;YIQCM1TA7&IO1>_L_A-PK"VJ!"<B3)84RC1,#[T;4U@M(.
MU.?.R:.8!*-*ZJ>>!,%QJB@XN?Y*Q$^&Z$FJ/7XDX!U=K5R!@A@KJD;4%3FP
MVC/?8R_ ]HM'7[=B*OR$WG>JA&'@!.,;T)W>2>=UKPO2T%YE$4/G.U\ICX+N
MM0.PMEB15:V,?2%/O+.K!TH_)A_K-%CT=$+3\06 #$TO=EFAE.R881&L9\B5
MW>PR";7-*,U200"X'%98V962,%ESASQ)*S1F=!B2G>QR>;7=[$K,^8BYE;&&
ME',RK<BXLF2GR',>*04%X,A0H9E"DA8R03TV9(O&^O,4')2!DX!KX;H9W84W
MUBKF-TBA]M_G<J/H2&='%Y9? -8V3I_:^HI0?(-=ZIWU&D35VZ>97+$7O2T0
MNEX TUK=QC_,[]S7M<<^)Q"2/5A0LEYPS:A$)-'+F./RR780>ZA08-RH-+\
M0)HB<PU'+OH<\OC5/QH:A:O[8!X?9A\D)#(@1TQ_76APR+DCZ IAY(%2Y+C5
MUU_>:EG/PVZH"JK"U+6]MV,2PE"^NRYQ%?+JEW/$+K]8;EQI#':7]3U?\,Y
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MW0VO5*BX[NMWA/\SVZ'T<8AO3&P0COBZLE;Q_'O#G.U5N,&J2WSRLHP5P0M
M6@@;=^R5<7G/XVQD'<FO81L,/]69M'K7RTC9)TL.Z%%B1L6( 2;2._*;?HF?
MSUR)O+%.9C1RMP/9!E?DED-<:X[TB'<=GL_Z5>=JZU&76/$&"NP(>F!F5=Q1
ME&MC/[+>_YZ'\SM>US>^6Y1@T!G%UU3I"5<K'A@\$-MIK>!?O'YKC&R7M[P!
MPQ2=E80?]7;U6XSON5[3K :G&0/KZG[!"Z!J8O7;)CV=(BC?_RQRW^'@YK9&
M1S"$ "=75B['&%%B^6K?(!(ME@GI0GRB%2W1&/E+CZ/6#UU]JX>DVJ&O+K8Y
MR524(%\9D/?<R?F>/\/V<%Y8-*F>Q*S5K><U?YFWL$VW.8+:#^/L'WNR6ZH'
M(A^]>)XNK'QF7P VS_=<>P26(MB&JH*S5_9_MB9W6?-> &MO EK( O>!@9\N
M4R9? *=!,FE%M?YK-'$GH;_AY!4TWH)%DOC_6UX-;@S$RG)%1F#ME;0]<I%Y
MK\OA@ VTU0PBK$;1_NP<!+$)/A>)[0^'N(<3,G_KMK=OXD [;PZ[%Q,Q8%RI
MNAI^JX&)GF-FY_Z.#UE0[C=93I7(>6C7'SOQ<RYFFD6> /ADL6^.#?SL,0#A
M_HCBO:&@6L%&28B\QU8=6 TE/%7MHXB(V$!E< >I1\3*D=ET^:I+DY1/;?!%
MC;"9S\U.S:.R$4VT%U,E96.$,KZG"CDJK!>]_Y<B19UK9MK>-/6B;[D_.N8I
M[,284>IB=$%/;6_O?HE$J_I&4QU7;]\2DC2&<F%'W&CI>#ST4GWUJ#U!O.[U
MVDG:9!3PA^\M79%ZSX#U7LJR35:L?T# 7^[LCZXW:K2"H>XBM:8&#1ZUK+UJ
M)Y7:@WF1HP4:H:X,>0-8?YC(L3J C]P+4Z%OT[$]]O/S6-W\=>.<8&(\M5WO
MEL-8'CYRS$*9 ?'9=DAHE6\+M$N[RH #'[.&H31AV.0A+?)7,IYF@[.B+2X7
MZW9JP7UB\/,>B4W5M(:^\,&.0/$-HYT10U09:0;9<,19#K']O&["+7=[J\W%
M897*SOX? >91@6%E;S/FVD$J&X8D9BRCT(GY[]9DZ*=UAUMIL]';D/-6^_<,
MNQ"!)RFO@-9O+X!7/-^A>*<2^3WVG.S/U@L@V/O*9BRENWI$HG"_H<6L.&2.
MO6P&[ 2\Y1(:K>-)KEG2DZ8*4:/;\V*'(!5@]3]MWA,J,Y"^ '+*=>U6PGZU
MG7T.\L0>OJ$.WM;0 -,P./33=F#P'0ADZ=A5!;J@>B09#.CQ]U&RCQR-#"&1
MDSHNH&<"2,IR+O'FKPI6.^J^]J'<L7:7((6[-'T%_ :,/NHZCSD_,EYU]C$8
MK=MA&LNF*(91R(*#$:K;WV!#//M_SE?8FGI-F0>@_$L3190X\J[#QA[OB];J
M:QCFZWS/X5'A0Z-R62U?O!<GQAF_+=,'<6;A[,W+HPT[&VZO6RFM PT*=#LP
M'/ND.'3/9I-;\H>99^O*(:K#-BQ]+L^;IN^Z#WB/M4X+%RR3'2W/E@[8H1*7
M5.@5#"/],[> 5]S5.5X/L-A[QD^0;&EJ4Q31 MLG$VRX0-5(L2\OLE3'?%LT
MQ4ITEOV[^)-O+RL7,YC7$AU@>8C4KJ&\!(=1\T0YA]#:NT(^RAA473[0V^;Z
M*%@JY3EQ&4 4J0P^R>%TI=U&6[T'M=+Y0!/Y%2?,]HWPNQF$Z[[O7%K)O/,^
MXMY.BBD9OK^[DX170]K)%" ($8PX[3P)W>]/$S-[6\W"-FF:3S$]G)X/99J3
M:?]('46E;\1N8;QO^&2397!_./5#D"=?'_BV=ZS RDW%"A S2,&GT&;6#R=X
MNR]*HG"3E>?A#YQ1KNKH)_G3&N_H,/)5>NM8=8+TM^:'HB]6>/-?+*=8$!JJ
M0$/<N@T:G^*0X/(^W#Q*VY2UG*6O0:M2!60<05HZ T>ZF''",F1?)"!)63EW
M/$<0RHA+I>9:[T@S5F*E-V.*1#'^20#7M/&;E!N];CFMZ'5\1;8?B-.K;:!I
MQ5G$L-Z"B634Q34;@G#]Q6NA7N]OX'P&0NE.6KA#]4)N'BFTR?)@]"UF@J$L
MY7Z<60G,HP2-9<L@J2E-8"UF,@:C[PU<;':%7.@Q&]F&R.W@"P#E2YW4T^8+
MP"=M-\')W9BZ  <_C6/Y63I1#E)TP47.'S?E&7GXH-Q$>@5H+\X?Z&7Y]V?>
MW>=OJIA+(KIZ8AOUT$(H*:A.^M>F&ADC+2X?U4MDGY3*;8X ^?#);FS:97;#
M0[LNX.;AYFN:6E?4(,YMF'NL $9SS8L-=Z$0F]34].'XE!2H[,,$/"L:-/@1
M5T-NU(5$[Y4P#S-A7B8L8,RU'-OW.ED^)+HI+T;&$QO+A[+;?5"\E497A+_4
M?&2U-T,/LJ..4ZDI]J0BKOWIU#\ODN3\S&BIVQ-_;TJ@LH1ETCB:A+A6 7 =
MNEG5GO&;&8;K(W*6#^OL-_# &3MX)I]^$\FDP5]?_S0\4!IV2S1(==GU3A:.
MEH3Q^Q\F*7A3MO#/ZYAN;$$'6+Q/#"[UL-P9#,7$%O,+2HC.ZT]JUE"=@<E\
MYYY/JM+M.*%%U?B4"W,5#JOOXHK"*G._M#+7M&+<)(4A7H@4N'/^GT+**/S*
MH@6]@'_IC22J;,3%E0+W^++1%-_9_%RT3)XKKED;PT@.S8TY6NV^KK0X^CKO
M^W04LO/PN8I6)."*M#O"+8OV)KG(L^3GB*E3=98D?#!9CD@T3?G62/@"V@0"
M@?ZN.4N_XZ9P4@)NL"NQ..IMM)V2,1O\"*%JQHFMB>7-N,Y,X8A>UQ]V+?HE
M!>X&"J6H\JT&#B9<Z<:F#U#9BBTZ*A.PFA?D.;'!77,:1JB]T,CG2-@KQ.A
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M><^U9V[AW80[VV[G^GW[BK&!(3?Z!=5JB&)EMSF22#M_M]*_P$I[L=O(ECP
M$Y^ZF8^/EB:QV0L/P\K?:XY:L>T%H./+)GSY9'7])@QCA1/J^(H 1;M>23<B
MPJ9]Z(_#VY)2J'2%Q\>:7LICH.B>+[O0X7";&,:-7WF+^NWBX[?.5"/CWB\_
M5HZ/^.<GK]?7WODPF)_[KD\Q5=JS&'SP_!CX<\8+(KNU24D\*ZTQ,875$$IV
M(^#2'AY3@OY>"IF2CA7WL[ A!N7^O68;](Y(S%L>R]?B[75OFX?VE@J/!21@
MD_AVU ,OE(O>UD<&H(A>,0-_'&]/<:!8I%?O*V8[<C/)T;M5+?K)=->>A"X!
M)<I%J1]>'ILMWS&[*Y<.@&%(G_+EX'7RKXQ\/+ ..7S2\[^>],^4XV#DKK=Z
MUVJUW)-<$Y::GCDB2@EP\IKQ/XO?%W!'G6&@O 2B]"#<;@8=S^4UGQVWCUQ^
M E5.C\8IU!,C:+_YV!W3YLO >B=E*SU:J_<VOLXDB6]<Q8EO/&<36B^7HM'Y
MT[E\04>GUUFH/P7[IT.B+81CFF!?+33<;M$5^)[6P^4:;:SHR8)@4V2<BVJ5
MM"ZY"SJCX$RX1"\93W7?$!\"'[^L%B19B\OC%KF#! K0A&D!Y'@\ G*\J7Y6
MO@"V$+P5<:QJ*VGBEN3;$TRS>%8 "<U.'V$.TSS.I<$7G>%.NF/F2I*VL'$<
MEZ:.O\:LK3@%"$1526=P3^VK/Y955T,R[TJ'U[T_8M?=J@";:F6GWHZAV$(]
M]ALC_)M]^P3OLN2A8.HA3D2_>W3IT5*B.&E%>/4_C'_TI9?'K3XF?^Q%!D1A
MSKSSQ$EZ 2 E0VQ[:X%\4F@P0T$A2NT!XW E%;KR=.4=D]NXPCZC'"=\]S$<
ML2 &BZ/CDQ.*\7\KT<S)PA>?F,>L0K7-?>,I<-VN ,XJ2IZ%B+&^/[MU_).X
MQM)=?6T5![EF2 VC,7RSXZ-,!,U;CU$.B.S0;W8F/OP(3SV>XDA"P7Z/]Y2Q
M"W>H=]M#@O[*2T/L^$U_0$X.!.S&.D73EQ BX@/OC+,*[A15ID',Y:$]R KY
MCL&XCK]@DTD#B*/("GWW8:IM*EX %KJZJ]8\1'-;01S5O)\J-8U? "XNFX?Z
M[U>EN +:&HT<465VI$W(3_$'?E6QGH^'VM6Y8RWNGS1\,4\2C3907*TF=H>R
M33CPSWO^7F-\?M>.+2X6I2T)0R*\-WXH2N!P-^EJ*J\KNSITHX&/!>BAP1AI
M#]_$/U)P5O: &/F%E\0S,>U /0<7U+Z*,D__=#S4)RWZ/;AUCE-84C@*B[3-
MSJ_8NCU ?MROY,M;X>%#7^#I0#0L"SJA,'ZV#9^-Q-V?)A"$RU""3[.=UK.:
MJ^+@\'L!6,MV(TR0XK\ (%XS,KUNRFN*]@XUXO&X;S3(8U,(?COQ/VC4][]%
M?'+%4:A#I0G91_G(P]HA@[^R%+59A)//)SR!.;H130/O!(IDIWF*B :S9:#S
M;S;J^!A03.VX2K62FLCLV#(L]G'LSY.TS#A[@(8V=K3SP9NVJ30?7P!TQA^U
M'.=QWGMH])(L*SAH3YN\'T[HX\@P)?92AT:W1-63A;F4I*JS8M?2V]H9BI(
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M3-SBF62;:O%9<=<2.2U\I:,.?V1<0Y\?1-9UO2WL5 @&TNV<[&L'>6>B(LR
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MN/=F8B'0X:B^QCX(JZU:+Q5U/6QU*P0<X+[XVY5^>POQD]N$O=6Q)>'[8G4
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MNBN==::6)1JC(0J:*LYL_DP5&41.H\X_QW$EO.=*P]*_=U^#:2FO\U? SEA
MB2V^+\XSJ;ZC3>0UQ?LW58?S_*J_H._*03JE Q_$7-(<H ?K*I%^00ESJQ1G
MV$-_?)FZKXHW&J<KZ3!P4DIY,B,(EUI GV2M-N]\R8M"^.9O/!M?  *Y^P8:
M<;I_N#VHKO7E'P6CJ0[?^@KX0ZDA7'<ZFD#&0"78X3FHKTQFN8>LET7[[>35
M+!)]G(Z,RCU3P6B$EEQ=4K3E:9IM4I:[8];FQ0TC_&JAQ*2F)32@Q(H_U8DJ
MKM]G2&D&-$DVKR>B#%NIS/)T=P<("C@!ZR# 6\2HL^M!JNL*X]_J@2&9]W$Q
M:T2.Z&$O@&_I74=R8[1:ACCZO]8FK=XM:^DP=_S8%,E0'S3R51>_W4?K<+O)
MQ&VR)/+5W[@F#:&FL U2JG5_<M;2P9AN!Q6OZZY:-I44MU>0E6H/,2Q\NW=K
M1G,#T^VE/VJ,O0 BV%\E^)]]A!G6QWK:BT".,<EC=&^/6>B6%PZ+%/$T38^R
M""QN%&WSLD[>,([<> N.EHM5YR&=]YFN6J_1QF\PUD]7'+O,J>W*E8[2&/E*
MJ#J(U_?^Z6PQO(&(,>K)\G;W9B^__<%9A^#O.R97?*##$(,_44S?7^%)O8RL
MR4VJKWGU^3'O*)K%A==.:7"B=MYLWI5OY@6P02/TW0TGQ>*#ITJ\Z/RXTJ2F
ME/5&%,N2"L_/>4VD+.&3T:H70(S+$TM7\)-HJFK'RF0/X<KZQ3!"Z&_]-N*'
MS-U63/)C/+V_MJZ$:6#^C%$V9^8XFI,3,B(#O!B#_EU4!!TOUT RTT -MZ-&
MP7DD,;E3I191&)V:U L (^BZ;W:JOS&I.-3D"V(P7<W>/E.R5OL\Q?*^05OC
M./ULAI_*"0G(X_&*ZNID4JZ@V"-$9S:OHW&&%[DI%;[,X]G"B@U=LW$I:U6,
M3H6FB$XWC#VMC#G!(0LXPR*8:9^F*US2G E;X\?=Y5C3VZ/@NV)C>KGPUQ!(
M=;G2:[V/1T3?S1;:.^B=0#OIT-X70*+![#43;QEQ:WHZ#B%QDIL8 <XV3#.(
MO0%#8:VB?(G<^R@,,]_FYX]-H*MOQ[Y>]^&QC:6P0F%8$=C8E&I0+?U-O-RA
MW'79K(JJ1:+_OQNL_E^AY%!8/;C*[NTLNU%+*/_O6NROOI:MP35%EBIG'>W!
M5-R$/^SLLP^M\4<&EOBV/YTF-]X9 9*F[JFZF&@)IKUS=?/JV+*PR?G7<P_?
M'+P K@;@-HS/@%40(G.6W3EA&,VE7/@-UPN W8:^QX^K$_3>RO0\Z>L FLJ'
M%T!EZ,'3S[*;I?$4SY@Z*Z*Z-XL,JE"VF?GB"JK(425B2Y$;/3F^P*S5CJ!<
MN.S D0[L5N/6LG/)H]! :T7@(G>3G%)_W-HR4)/_[$(V!5L\A#!)E#@;3%9.
MY@5)(-'\ELH/#!7BM2"*:Y V? $86B6%"+MU"*E,LR[TCMS_Z;DL? %86;LA
MOP L+3I]I)XA!].>6:G\Y!=C1%BW L7E)R#=&=?W&K"#3WEG[W_G1URKC5E,
M_Z>C@E K$]\_-1B^WX-=SHU^2QCH@A4E--KZ:F\1K&;^CM-N77(.A#O<M)^[
M89S:<A[8^D&6+X/HAIB-8,@FU\(1?M(3*Q8ZQI'E;EMZ5RE_(L!IQ_[!6?%U
MD/MJ(JF8+.G347XV-C8.BDB.]BT/7P77-0F-M^<'@<:)W>5A+]0KT'%<=WF;
M/3EZPX^K"F/%-,64[PR>6IYL/;5-#MZ:2BICR )X)'MA])'7FLH_GU$C;K'$
MIGB=!KC1PN9FKUB<6+#@XO-J#=;6@QI:86AHD7B3 ;- KR%[#(NVB!X+6]T7
M &%Y!?&SOU7%64!>1],[_J8*N@\!]7KF12VDN2/-R[ZA.9,^2H:EBC:N^\L*
MRS^^M$FQ(L&G5RB\MV&9B8Y4-;:<RS9?Y)OI+1@5<F8%K^B<<%'+JH(+ETHX
M0UW#:)'(?79T8XIU817!&=:%$"QKV49P_ !=?.\U7:;<;>$B,T79PE!EQU3U
MY!6HMH?G/=F6TT=M18Q[M)$)Q>LI#W?YUFF7F^#3XQ79<=U7HR.O0;\*PNAP
MO<(O>QJ;!)3<[?G&HI;A]Q4F"P;PC:DN/)57//J11ISXQ,"KM2&2YR_AY,WT
MYMZ4K\"B>+K+0\B#5,R?\TKVAV70*ZTF9,[IRQ7([_+&5_J:ADP*@KUQTPH4
M710TU!Y? &\,C*=)C&(>R#0N6=,&JPQ_=]5^F%*H/)SY@$,C*21)YJ8O/&>K
M,_!A.MMV*2E_/M"(R:@S;M?MF- )JA(^_0((U)F6?$[T+EE]"*L"HOW1Q6PS
MS#U(U6;H[T<GN78U^ %7TG%G6).Z2NR( =<I2-[JHVN."QTN[#8_CEG!9OI.
MX%WF4&8Y1_/:E78\!E2ZK3,NH3TTPC45.:[Z+QGFFG,.K3*IL,G,)B__!(!7
M.=2SBT(]0T J?'BCBH,QZ0;>3[9K8X(KC11$]:O!(G>KR2$WG/D?^8?P_O+#
M#!]68'-[=5/F9Q+-.(2WZCOJTIC9*$@ A*_,%MF(I5;"48W)%O,"JK:2/Y'B
M!ZJ16DI;,]M>)?R:7N-OGZ7P2:IQ?:C9SUN!N8@3MK7#;*XK#%3C3MG'=^H#
M$;#-)\V_7Y\I<&RV[>O,\!Y5R%SS^>J V).?Q6PQ!@.AGAVZSXF34RICHAJ3
M]76#<?UY;*<.:%MR;4F)8:P"G^?9>7/CNE+X9K,.*W+TID&3;E1[X6.^9B\
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MGG(G?@%1SWNY =(^O<UP %-N.#*!BC2 0$5%5U?2&DO!D=?Q0WO=8+?$DP)
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M%BN?[E7%QWV?^&,E:0*UMW^E+X!51/N[>O243!RRZOA90ZK,SRAH1V0D+(H
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M(<K."A%1_*KN8$T/?I*9\>3GRB,RGC84=5*Z*\26A@8#DG'3UL@,'.X/*@)
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MZ\DC=3DWHK8\-+O1?PX1TDW (B+S#7R@.O4?\7N"S\XK4M9($Z(1%++<XWL
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ME&<6]!;V=!GGI<DW&[\^ -X#I(IF)%BF?[1DJ0O-XIUX%K.*=_$B?..65FM
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MA5\FBGM9D18P(A[<6<)/@O:__.ULOO6MVQZ9SVP+QA*@"!@_:Z^X;A.1^)Q
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MU^%#[SR\2IKS4]NKO"BXV3]*"&''.QL+Y-K&8[]T6!%JCIU!=77]P.H#4F#
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M1A&5!!TP_F.3]:S^U2I:& M%])ADML1XYP#'%RRA=_(GI28%A?9Y1FV+4_<
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M@[/])F$Q&[[.2: G)LV'/(>-?+?A-3[2R;@[]WHC\TYX-PFK(B<)-$U6Q%Q
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MX5\S:4#^>S,DB.(I50?AV,Q6Q''<H-= [2_CQ;*+@!0#O\X:X^*R?TU<!1F
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M:[1BG[/\M&^;*G!N9UC\D+G^U:4W3@W^-I_U0+Y,UKSR%LOWLH87%I12"RS
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MZ'^[A@1V$CU@"-\,T$]<0T%QISDD<'H6A8"#H#A:36>CK^=P+5DN%T2QO]2
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M6"[Q(_ 7A4A@_2428-_+(U3\W/A^)?_MLWCMBFU:VS"$KP8"@2<Q1 N'9UW
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M(#"("J"5-9+R;?JV,V32<%&#^U:6N+E"_:![3]JI"3#V^"4D OT4%:0!+^3
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MPHR/]?7264+9:0UCOH #YK]:7MQ[5U:L%V7#YOV$O$."MBO 1 OLM8.8':F
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ME&04HG5T6+S/;0C^4WY'U47H_B,FUD2*[$7L05KBF6T/8)M?9*EBJ6H^;J-
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MS<MR^_9^AIYKRR,"<K *97I^2EPVFB]>UKG.GF^UY"S#_%((_HM),#95)MS
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MAZ,&GF'#P6/#/?4 %# _$>'^L@%_W>">P2,@(B&CH**APPZH?0$\@X.'?X8
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M$A>V@S:+/R*-3 H\+R,8X$>.VM!OK5A,E!N2"1+[=ACBF$RXOX=_W:H[^B7
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M;=S3+,(J]^I',S6GB\*Q>EA4B9+1_'@+/JO.D'X2L3'J)O%UBZRZB5*6K2=
M?.I8=/R0GHT&Z!4@M1_)Z% M]Z;(UV^)X4ON/5[Y#9G?WCQ/ R\S=>+"?;<\
MP^^"KO(F$C@MUQ21:E35?#JW?;.VQ3O.6X(3'QNIX;,;PX.NH*A>FSC+D& :
M_ D],!'4=*%\]] AA]+_Z5YCTIT.Y;=1O8*FDC:+F39+.6Y?M6008S0.9@(M
M64>\RHH[O7Q[+;M>ZW#0BJ3G*T[,#35U):?H=20?1XMG!&?&#<Z\U_7LBR2W
M1RH',C,Y&9RX1NV\TI3GTJV6[H:J&=JGRXE9CH4_W@<G478\]#C<J<MX4U@B
MI!JL\C0MHS?8)(MO=VU(4"WVV6NEYYYU]%KM"YH2\WY#ROBDU_TL0667OD@8
MZ@SG^K>D^*_LA[!$D6S.K><3H!R.+\N298FGFT4S6W.06)4O7;IWX_FI6MAA
MJ6>"*Y^/U2OR3(RPC?;L[;WD['=K\T_?</3&7C0LO:<*7E9U(_O)#GA1R)6G
M\_2'U>IZ9&I=EC!)?;?U6&;*^6V/G.^K?"!>9 M!+K *)TTNC?'PCGN[^HFA
MB(;9KE$I&# IW$]7> T1/ETXX-3'%'DF;VODY>M=C7Y"3]Z("Q<,BJG5XBZ1
M/:::^F1KUM@<H>Q"@R".0LOJ>2PBVEKL]020'*#:VF5%D.BZES$/_W1]3I.\
MWH\A#:)VE'YX4\?]!#RS)+89?MD154=2=!QD%Z(R&4G>%I@G:[,>^"JJRW D
MY7.4C&&SY,!0 T-+M+^R]*X84:(A]B=-V=K&:<V;>%32UL)EHF#:>3J22E=R
ME ,K!;M^3+L\0\4<RPL#!3M.<9*!8./OPY])7K<[HO;/IC\!6+^#-_06]87?
MQ;!B9T:H:2U#NB+(9)1(:+$'!O&,W#EYM->(T^:KO/*:H^=0ZQ@1LE4#([]H
M.=/[*0 :=6=7N0_;NA[Y$:IH"Y)VY'=YYI'-C :]KG4^[%:]%>';#7-KE5KC
M_2S3IU4,0Q-!X;1 X#0$,JVP1B)386OWB>WX]W%>VX.S;8K6VVTT=G4CJ5F,
M?N3&DNMTO/K:&9-IT1D'VD'A'VD/OA_=)[E2L=XB'R@ =LJ2N,!_:BL10N-P
MDKA*?S&]0/?R?6_"Y(!^="LWSA$[:P(J[9EE*9^ _,W?F"Y7(^)K:3PL6[5-
M<=:';T;/=)<17/Q3JSX$,5!"^HNXX9+:.%N3=[N5Q!*';6>1I@VA'G=55>K*
MZ;E%PI?P*X4&MP_*R#U<NGFEKAJ)XR-FS'YIZ_D6R5*=#XTJTI4WY?["<.L#
MZU,Y^H(O9EE(I"G%&Z^?P1JWYTZ<82B4PO)X.V1<EZ20QK\'H$2+\PB$)Y/M
M\_'+Q/ALAW?@=CUKGUMY]P1\2HL:YH@EZZUA;&@*&87G4!OU<5!WQ@J[$$T1
MF2TT:A2K^TFRF!5Z<\%(A[-#ZIT)WTQI-/?!65%(OZ6]P85C\&/=E^)(PNDX
MO4=9IB? .V(TI<-3KZKGI6Y2;@BZNXJD&2VATW8CP@M=C(XMH\!()3BS36L;
MI<4HP:[S==,@!>X( IN&5U_M!':_VC6G(UDCR]Q^=GA5]MEJO!MCT$YX;O %
M_39*# [EI9G#[9;F^W2<"*&!\GB5=ED$)HQU(CQ;/'F\E6=K)@X/#6L;)8IK
MF"^WRQ8D,YP%G2R; ]=JWF+@]*\0KEUGH@D61-J5*:=]RON1I(OJ^].%D-87
MRG_1J!4=[5Z^TE@D3 #C2$=-P8]+^6RO\I,EES2'M9$E <? ^G=S\F*(N,K_
MO>&EE5AK)'/;I_@SQXT^4 6@#,?)S0^BY90CTUX7.I^\M&S*G>A&B&.N( %]
M8S8C<FWKRB6/)(E40FK%"R]VKW@W:2L<_NY"L']7_MI"1QG#H^]F\48:^5PT
M(;]^-BI5KTM&G(JD[TUZT(,28@03_V&3O77%Y==%JV(S[ZC,RB5 !+6?_X:\
M5LV]7I*>XI.29,QU8$ !(Q;AQTL0^V898#.A[0D.XWZ4&K7^FI"I191HVJB*
MTZ/VS UIRU[\'EM9<J.,7%]T]-'6K[9%TSW/N,9&3)YC3+S_@ '^8\3N$[#.
M.;' A*HBNR4_GV@Q;,_U*2IZ_,3_/. ]I]7(;KCS(ID4.E&>$VVOU%9DM71C
M7?DU*:O6"ZX5/YZ]XFN^2BO\$@?;GBSF AJ$%S*4T3TO)+7^>RR.8$+;[&TR
M:\N??<=J^#/!*'&#GR@K0JH/+Q4#?N#>]*,?GT6QJTY>VF/RLCC[>5)LXIU,
M)\T7WY ?EZOX^YYY<_'P[XLG:BI'F)EC1S_??"<\[3#U)1U'VL9[[Z/2MS"^
M+.^&$B0U:?O\N1I&G(BG:^&KN<N]5S41'CTJ2T5FTFN9*'HG%-T=(A;P[R-V
M=?ONB>=U#$K/!^V<R_?.ND;")NIJHOS/"_FW[F<3=NH+M!3-$6YD7K6D#/C#
M#;I=;DXU9F*B,9%!E'/["[N-YO@;D_?+3&+LF ^:4\B[\SW-(Q38>HD-*K@G
M=(;O8KY,4DG&NN$M!3VN?Y&2S@,^36CQ&K!-LBTQ<\IQ45-_"__*[OW;(;VP
M5P9SBJ?UGTS'^!+WB#&9="$/FJ:&QEB, '0M8DT4P2KXS"+N([?W,VXI\GX'
M8=%:49DEK&M2/NVO@<GLRF-OW;R%@X^#PT=U;R.T)_$M/KCUS9B3/G,$<23/
M\,U&T-+MO*"QJ?B./.2#E96)NE?:Z"V1WVDN,AT?'$)$3*UX5OV%Q +*C!,M
M@BD.^NP<9MH>IL<].=^BK$#*H-\RB(H2@:Q!ZXP+5R]IFO%RGS&SKO;59+]I
M['>R7$1M,=H7:A>I 1P'',HKMSF*5?CKP</5>F^K>W%?<$>O77:0=V1TC"/-
MX,43A#M_+Y@RBC[249"C2_XE!N)D&*0?]_&:<-A08%U5BNM8\OBFO,"SV?MB
MZ:U\M/O50,>)&/&T*E6R4!A-.@$6;@09H3-E9*#B?YN!S\$].K99/-"T8LNJ
M?N'9#UH+R/$_6>,8$$K6UOV5I#?U4GU?GG$:Z%BIXC8FKSAPBK/\<D7=,97>
MP1X$XE--A#7S8?+")V?/@.[T4N6GI:69@X./;1&#5P#^BKIYY_Y%/JE#Y\!-
M:?,3$)H\LI-3V%)!VK4A2\M%]*:T>!VIJ]G-R.A4R]\_XDH')I/LO+F<>&8>
M\^J^VSG@$J@T+8P\-*31^2N3O><XQS/K-TYU+1.*03W@M+B^'N=I<2H/FGW)
M(4RDF' TA=(MTE"^$@%L>7-D*N8/@A:<!VCJT]WB^%?  F73V8R(83]M7RM6
M/LL=]Q9R^?AI$LIO(*2K;2+V?+U-5IX<M*P&&7%14T).;@_@<8Y1X$"!3I$%
M\>:;-9@],.7F03J05]?#^NNSRH2>@.<'F@3Q>:T)-?CU.W <..#"<W/S <"[
MMQ."*O"'!YVGN9RO$JZZB]XVMZ=OO#(.P,X(C/$V/RL[^">H68/N,G(/(\](
M8KHZRTZ[]< )33-'4G>EN39-YVJTP^ASZ7>:+I* 1UY[H$M#/F\47F--0SJ1
M69)B2"3=J9B>HWU'3%^9WIX!8]MIL;O'>G5]R.R,\47<IY3L8%<_CH=*]?=.
MZ0W[!H&P4UC?$E]COC[>T%6S5%GX&$*](1WY/2B8P,J/LUAZB./B0^VG%AX7
MML\V5U(_:A,GR@N:^4I76^(8/W3UJ46>=>Q&PIWH'^'"[7R#HLSD3_X^:@DS
MMUAO"A=KX @SC;,YI*+T/D#BK)U>VKLAX- ZJJV/T/61-'=5 ;EGQHU-!2P[
MZ./AP@W1AY8OS$G$R:P3V%LAG1_Y0T^_?,'R)J!(,-DCQYKFWE\]XL7_'47<
MS402!36YBUSQ#!!5R I'XQB\'O$D@UV\H+NIE+=2THW4X1U5U>01Y-MJBR1?
MTF2ZJ'*-O4B4I_I?Z<M_8\A,Y?N"F;-FT\[SON/U&M;6W-8NUQXT"]L)L:?@
M%G$*N5W-+E&ZVLCAOI7[8WGS>L>+A.UUU&9:IQH_$9F=5LX(8,-YF;['D]FN
M0%O\X[B> NF(!VTC^[:23!['!6G1@M.2>9[1ON'S6L**HV0H?WX(T287T2L-
M CC]1=_QG&F?#47Z6L\\7+AMDR[/A-GDNI_&UBZTKZ\C;[ J%YN6B(1G-M.&
MAMPO\=K+;@VNCV_4TE<(30/6?Z\.O/3XJ(PCQ+\DNB_DC[S0#"N@F"EO 1?D
MX&/GP5*;1,V:!&HPE\>;X6T:VLBTYM"1 P6-UHD6:<2O@8I:R99Q*S/?S5'.
M.F(AVX2!(:S#7/-.^B.X<)V+M[Q03.MWT^ON.0&OF%[%OZY/( S*[JEV88KS
MZ->@JRV86AA3K9O5F62P.:II_)!,V$@5D_@F$BL)"/)5GU(6(_(EKDWN[Q:T
MJ>V@MCB*U5<\376&"&KD_?N!1\(O*+;"3Z>;^/VA/O0W@>TA\_ OGTZB@.+K
MAT;:Q]?19>4'^ :, 4LEG7EP:*V=-9Q,LC0)"X;VBQ :?N'*$6<^WA?Z^CIZ
M0X2#%CLR8?R=K]5VYP*L>171M17<,'M^K R8, S'V,O)*7^F<E@* (NG;OB1
MT$?6,+2HI!-[+5F-W1AQU(-83UHCG6_*#M8A!IGN#QVY</$>3O$Q]T;6#4?_
M7 _Z>S-V;U:;YK;#4O3*7^QFKEJK^GY:V+I(T>.#W&H[HR_5A:FJF#RTQ1%@
MMK#^_KEH#5S,QHBJZE39$=)W.^8HYK*=0;*BC)^2;V074 [$R*Q8)/K3*<8O
MTU@OU*=G/K2'">,PLX7S(Z0"KH_KG668\MVS][DALK85)CZ+L5FI66*:ENA[
M*(<G8SJ[HG3:NO.05S,L+-E:Z_7UT?Q?P6BA8LC;8F1#E2X8!921$3K1JU"1
MC2? 'OPZ[G]\,X"ZT<.D+F$M3)ZSB)'()BNE<LRNS,G^L*FF'6M54U<M1?T\
MXQ/^GOX[_R$_9!7^\OQJBNY$A7S65.)UEC=-OV4C'G>64Z,=L2BO,S%^@O!U
MYMVM#E7GV-#0!2 I<3;$O.'AA"I^55!*1U0$;%U/WA_&&YBO,17?98S]2,4A
M39$9144.'%.RY'ZD7I2O22:,C/MN:FF6Z+IR+G"L. YWJ\ES^@TJ6_<="GD"
M[@7VX&O_%PLL\&%GH9"8-H0GH.)GQN,+Z_HC/>E(T);/*?VCK]X3L!>HWVX%
M,&1'_(^-*?*VX@F@[8:=I%SV"<C!;Q;<%(5)BD'V.=!A''BO-_-YV[]-3$[]
M$Q#CWKY$,93[G[2,:)?8HRTM0],\&:D^UU1[J^A FR+MO=E3JYO/'MY^X?22
M"R3I_/<?_+@+_PNGI!Y"]_4,N^SNZ!;,'RY@X>V63[2MWVL2G*;\[P<RA<H8
MYVL?A*RYZ6/+8<?]3H57Q9@-V$TXHLT\B968V;;+2+IFR\][S*;A1(P\1O*C
M_F&=J^=RR!>HB;Z!+0.>K#I:[G:,^/A&R:I[\D*_5HRBM5<H2;:VN202O\Z;
MM\:-8[2NI#!ZS XQ?@)H3OQ!A^<P O^6^.A!$VL3_@G ._$'__6M8R$E."62
M1249/O8 ?LJ&HL/PL] @8?YTO-D3@K>5!-23E@C9<,VNDTX9>N/(1O6NHYTJ
M&W0F'7"==/GE;K*G,:$V)C]: M]61>QP2\NJO"#2A?_B8YW]3U#[O]E%FK3^
M3%F+]RS8^CNU)0U*2@[^(?DVO0.]_8>VCUZ[MDP_YFH705B643Y>.X3=B.I1
M\EPX\UB'8L0N?=Z:3T"<<3EXCO8)F/BLN[#2C!_Q!=Y.9/HB\7S-[]DPGAO'
MEK\?\GFY]8;^%G%H%XO*^:^;3@<;W*KZXA]9R.?<<(NZ3T!_B^$QUK:*FNL3
M<'9"\!!XI_854-9J^O;9F8S\=,&*.!?_!DZ"<"EU[;+89(,B*&Q@KG3@"@/<
MY2=HQ1@K%]\5U]>9XX)1*A0XP'W_#YFSRX.%8ZAMJ&!'$%S[N29R31'X;'(V
M;=;Y^#HD8[,Y[?TL>HDAJG6,'3]&W%$H OD3<,A497R>D><$Q@J%*.GP/7IA
M[5C Y_W'2;361GEPG__-)_\Q>6.'20K$7\-Q\G'T^=IR77RDVZ$8V1%>FK&G
M9O?U3?V4E+;-S&X<)Y$;XEU5?87 OGK.&4]D&P'QK6QOUIM.M \2%S;P=D7"
M)BM^O+K'%'D.8-3VK13+C),Q6 FF-XDP:<1H5"<J8]2==]-(<'/!-?&11:.2
MH0B013EE_/V1?D(Z#/G"53UPL3/B^PT;?A22$M?-=G<G!(_7K]_&TNH/='Z;
M)AV'_Z]J[6\6[=/V-F6^^$C >-ZDS ,4TB) 5U2X?UX6I/%%FYJG=L,R!$?8
M>*8>G^5F0/DHQ&05[Y#+5)P.QV/!OJW%N8+CUO=&Z3;F=S55-(Z5MK&R*(UJ
M9<Q54*1I]=FHTG7F\P?E*=.6Z<N47&?UZK1M>Z=$)-[W(/Q2^8SGAP2>&2FT
M=4QVSM?G!HBLVN_8&E!NM]C1GCM$DM?.P:B\W4;4RZ&YC?8@'O<X<0\W)TZY
M/HW7;SH<@NGA3RMD_B,<O*O85(STELV&2"2/O9NML&$)KGE'':)2C(I,C[=+
M0/'"6]_%AJ4%2CUM&J+.L#<51Z2H9%UR^_ $O'H#OK\*O2.^0 /VYS;X(F/?
M5(2[4&8:P0FL:19!4,_,PWA."%<6K9IZM[?034>K1AB-2#PC'SUXUFI_@WYD
M0&)@Q7&-9?>(R0"_?_!/MB[A"JU)<*VWMH\Y4AKF3$U]V(6!:+*I11Y*>S.G
MZ;/ [3'29Y*N<\D(4^Y,#VA"7\X_OZW'^9F15 A/?QBQR8/?5'\;N$O[D7"K
M/0J-(?5[V'F?NTUJ"<X4H43R%3&P4[M,K]76%G+=6_JV+F\6\7LJDBS-0F\E
M/Y4?#9E8/]X@Y-UI6A %&NX[TT0?_%G^HZV7G,\<(V25[)VB0_DKE,NY-MHA
M\9A.T$9Z:*0.<%CV!&PNL-T@GU=0WSYND)F(37'+<D?)[0QN)RM3^0\=PVD2
M51C\:X]H 5TG/ %?I/R? $,<\!Z3&#FO+XU[3VK&2RO:^^]1$C:;%;B_>C[4
MS]EE1S8+J'_U;XR6A<C2-1XPP$]"X#?'\%9O;][4-)\A9?&TU,?FQK;TE# *
M!S =RMT6K-=#OF8\?P+F+L&C;;,P2&.LEHF5FI0Y",MYE;2&!KC@]B;RN;Z-
MU8XG\1.@$>'Z%]F)8-?DFS "$7T"8M$E8:W4&#+B''6C.-G8'KIZ3F71?O4;
M]#WS>>)_A)DM%_WC1"[-BM6_) L-1%*K:FMFZ=:DL8V_(Z%TFT>Z7?=ZDGG,
M]:@W0*=^)*/,4N$U$S2+N@WE3;,__B+%"!$XFO03!*/L9<SK,-0-+-+<%0>P
ML?U$5 ,TZ9$C,QRM4M-)I[&""22CO8PZA+[K.O0$*--Z>YH'WFOL1-'\S)J7
MI:X>F)U(Q$P-K#&O *499#XW *&Q9F59\7J>:MI(;2V-D966%P?9H!5#.#K$
MQXAV"KVI)6/6T[]^OE$;1A:-%W$=N<&:;&@/6CU7J!F[@76AB3&QEQ#5EL;*
M6\NR9>TQ6@+LGKQ7X1'5D -^ZK8WT][BI5;K!,HS;*RSG'*H^1\7%/5,YV97
M"9Z K03K)^"J%WSY8:YOMPP C<0_'-TE3U>=O6_/7T2W)OMXOP#(8O<*O0[P
M/,4T51:C<'/WE4[I]M2K;A:.,<?AXABDS1SDR='V)8;-@JX,;!88P)=P.C#\
M5SNIM<;DU74_L=WP/S;\&21DXF7"CR<%(G#W-63[6&;EW?&[P3=+]&9;C$1-
MW8ODT$9NB.2G0)RUQU=N1ZH!8XT_P_7@1/[L=H8R<6MM"P=+)_Y'?-H6_<^>
MQ,#L7P]YEE_ ,BWXZ5S[S0\]Q#OL;>R8\HWG'',%5NL09"[TGVK-4P8D*9]Q
MV)MMWFBWC<,#,IJ$1/RB'=%]S6E2UZN*E<D')^ O@;N_2&3LW1^*446LXT_S
MQH*/>=2(%;8?>[I^137IH[I*/Y?R;EW#,+<X&5="MOE#W&%O8MU1>*/":N(;
MZ)YRSFZA(880//"PIG@/:83-"U*S[S3<.;A_]>XU#BR_2T$#<TF:!1 ?6-O-
M CUZ=D.B/((!O'^$&Z;^DGFP.>B.'$;E?I.OWA,K(4]-*TL")M:>&GF%RY;G
M6H<OYZ41@@MD)A1343I( R/BNQ=<H-]R^JV+K!RM-.6&==:G&04$X.$G:RW^
ME/N,Y?NX-K21>+@OA_L!N*5Q),,P[L5'E2Y^YR,-?4&S[[2<?5F?&028QLJL
M->@A=.1$3T!6H/P3T%'S!!!7F6VP$"@WXE\+MD8-;[VD"5G7#R-[#Y>)*?@W
M!)1()76TM$0%7GJB 1?\K"=8$?F-,\Y1,%[ &0%GWU0:S/*982$%0'. S,./
M>-K8TZB?!C\!87B]*[ET<<<BLSM$DT@-F\9&FG -!FU^<SYBB X9>+ L3;+.
MN!H$P9+47,^\%WQ'1[S[Z*CX2%@#-[?X-_IA0/$@]P0,T(C!<C"\_1*OPOX_
M1RX*065)7+AI""]L&N+75^^A,7=S"S-GBMUV=XRB9+ 3[#T!:3YE8HA*L\Y>
M(F#9ABFVB?19>[P9K:(^ITXR0?7[CND6Z\Q]@G-M@Q59LA[WI1(;)O_8V*$B
M7#C>F'4?-HFVYI:JX#CKRL^,K#)44DC(MDP?&_FAK]S?JV.1YQX7Y+"4]H#W
M\&9R0B7-!# X&> LLI,GJ4V<BG>G-_SPVO;O-?E.'Z!O60B@K:$7/./<9S:@
MEO<9*WBC[L^TYCH\V3D90!_)9*ZXX::5WVF;F 2[T(\3^P!X0X?D>%P^=7?>
MXA5BO0;BN'S-)JJ1:Y@M:$NM,V7<=QI"H4;#?!BL[J4/JR_V+[26WL8)F$=]
MQ0PM0O+C$.9;#V=S5J!7S>A)I_3(KP]Q4_4YY\+#D.*]'+,ZMDXX/:XU-UY/
M>SVZGD87,,FPI9]&2(G@Z_+#LDS;8 F%RI55G!*/VH_;XF]*9+3%D#>'/KS'
MT5+J>@B=T4S>_8J1ZB-0Q(DG/I>6^=)IH16_(0;G8(50L#%0J66ZS&XM/"%Y
ME/%KC32BOYD*D:</)N#29%HUDJ?]\\4SOF B,<>U9SD4'%N/5C,:4VT_'[];
M?*JZ5GPEG&I^;&1S>!3Q0PQEU?Z1Z?.M DP +;Y[ GS!CZ17"WQ+(+D-* YX
MD'<*M)KQ!$B+ 'PP^0.)*P-#&RI@;?!VZ:JB6I0-II%>S\$(9 2,=O161(WI
M_"6*AXINPW,F2XJK;2RH'Y-*-83G":"NBWT"#)1@QSVK%J6Q%HP.7-L_J2F*
M(QD318F3%EMW&RAV%W'GAAM?WJ_3G-*5=[$AK=8%?4?G'XQJE<XJ5G8WE CJ
MW]YW'=Q&Q6//<):]Z7@"O-K+/&:@,6?/(?G>+K@D7$\ ^345U]5N<L$3@-+>
MPW;/$ ]> \$N6W7?*[H+FBUR$PD9'5I4_!$Q.8H;L$)5QS]NK.8)ISH7:14/
M>7/:'GQ\$O/YJ'QVE.[;2ZUG)V,*/7.5VG)3\[I#NZQG3!SDN?":J'U69SS!
M,B,&S.D1#"7,_T(<,YM; OJH6+J/WCBDFB<#HS-7(@9#ZSB*XZ;3)F8_9>HY
M^FMV\PFW9E]]B^19%C^>7.TBP+ QYSW?N<<.!5X*7G2CK3X!0:&PT<^(@3C/
M8H5<">DR17F4DWW1LXI3P'[M:\K@AWT;>*>$K&G.//6KEV6DJN[[-$%0PX?0
M*9I U=D/A_=.3=EC<?WPVSP%?UGSP'.A:]07-+'$4%6HWY;-Y2BZ^@DX]'EI
M9K@_][#EV9;/$8AFTL G=_X]5&6KY-W2U]R/QO?R/<>A_FAS8137NP<):DZB
M[/"@J&"TXT)9T<X2]"Y>ST]Q/N7H=\?D2R/6=@CU3)0!/%^*%I#+>[=V(V%4
M,6^:>:TE8E*W4&7'Z)T#E]_8)=D^_?1OF_*-FO1SE&.Z_F\X _ @_C6W<C[=
M*;979R+C\D2Y7HVEIO5-:D-OJP0XS=I#X>E775@+,)?[P]>F/]GPR!SG\0ZE
MK*DB?ZWF2Z*@81"CO4(^WN2&H_\SV;T X^H>A)^9=.&,^> F.RT-LQPE,G-_
MHA0*M[U[9)H44D(>? (HP%N%BK!<J(0I4P-C@XRS&ZA<$*R+'V*=\^S@ IJ5
MT%'PN8CA$S OTG[)74%>8?R8"L-0S_8GH-(+O&<I1J&H^?W @/HL;36*9X3M
M;89,R-1[=O_K!OWO]7TDA:*-%>\JN*?:M_+<IZ!-VC#/DH=JEB@7.'H4NE*^
MN@D4M7"=/5=Z\-:H^F&ZS7HL:I@YHE4]#J6:7^YW3*>I2\@10!7I[0E;5:=/
M/MDKIRB=/O9HURM9&CH%APG+.VVB/V+UO+2<O.-57I:Z=JA^W&4*;'C0]#%P
M6S^Y8UJH>/2W>0(NK>>R-;/>OU=22,]C%!"7#<95LQ-6%J2-RV[>M?H!Z)*F
M>LXDOU1^%V&Q&VX6(AG'2Z0A\46ZJF <3FUG^A-V.F,Y-8)W:2E8KM' IQ36
M%#X<0IN(@8P^]KUJBW%T72\Z!["5C(Q:6K8IRV(^5_(^5<J;NF_#@;^59?B7
MPHK![$PAV4GD\79N=LZ$G:\'",JG)O/+K;M !^7M*X:'^BR4?^MU+GGY<E ]
MUC5SJ_B8+C_A-OF4G;/DQ96W'VKBKND:(TCRK>U VTR)YVTW:*['0*IFWHKA
M@N5I> 7KA_JP2J7S!N7X1;H&'V)]MA[BL9172U].(B:A\F^;5#%^\--ZMSJB
ML1%M;4;,GYEB7;?R_IY7\+)YD48;0=C21;39E=:>-&:S\A6NW:WPEY9N6>_R
M-/N;'N"<7TGVAF<0HAK[ZE:[3)8$23J$5T/UBWBL!YZF2E5:#1G^[,Z<YH7S
MWHS^[PW-GA",YRA"(;)$9%@&3%P;ZNUAIK>*I#_T.S]]J(D\<(7*T&D,V>?:
M-PCLBY&GV<$PZ0S< $IP!Q\Q/0&44?#0-KHG8%RC]8\5I>R_K"B=82UH0L6)
MD1^]82"<609X[_]!D51/%Z%RBJ'@PWO0KJ&U9B\(LWTK]]8-VIX#=;FN!>Q%
MA6>$Q;'"+C'I)69HIJ +WS"98VRK=XU4^$&JVJNFM["V+9'7#D5_6>'^$RH'
M"@(?1IU _6JK]+0BIH*.\#UNBZ^HA"1375.RW%=E*Z.'IOK8:;$37Q>\5[U)
MJMK*4+&2N6(CLH"^/CUJR]G@MSOB0>]&B&6)D[+'3BF\U]35&PL#;]F=:CX&
MDSP!;VLE7U]\G?P401@15YC]:W\SSUVS7RMQL^<>0<5VWL:<'T-:Z-MDZ[1S
M!>8M#.IH;&'.&<3#:D1>WV51;6OB5[B-<KQ^#!MTJ ;Z.^/FJKW//_=7(4#C
M)X1* K$ZPMMXL,H8AE[L^E9IWF6L6$,$:B/F-D)#(6F;7L.$!/2@)CN=>\\V
M\U,LR-<G *:(VOF@$3R7_597E7&.N2DBOS%2"^GIW8H&W.NAH/4GH-QP>@ZD
MC_P9O FEN-]^5'"ZFG8)MKZUADHH/P%-JT/53(:P!D8<\S@+58-;@I$>O[_T
MYI$6%Y>BQ4.'UAH[W#;YXD%SQS[-P(#%J2&C3(J-0X-XO>=Y8+-B]TAQD:4F
MGV$W52V/ZSDF$L(@>;9A%!%%^*E9/\%'CJ.R2Q(^J6@AK:,O 12O"W'!V <<
M2],3![RJ6B1[Q^M>8GF10VN9\$5C<KUG=$F3MW2ZF+PXK_M)W_!_V6JQ&)*+
MT2N./='*']*-P;2^/LH_8'R>Y\0\WHTA;HKM3RC,AZ:+(2;BD?E\<N%^3JF6
MZ]>2I+!>U!F_<49AN>(Z'R3>ANOQ#H843M/)+N6M?"$\*-P/=55)RQ258SZ?
MT,-\]4[$HPOLB3K[7E,$B8=VBS ((1E]'(0G$G4:ASL#0V4U8&BH!V/<4BS>
MMIYSORC^O1;ZXR%8G[GUBCN\FIC[\] G0 QOQ%L7)G/0#.\A,#H\L:_/%M*^
MI3$).ARB> 0T><[LH&\9P8?G4S"6D4=?F=[G?^!;H^2948:WD2'J9/BB?2O#
MNOUJ;W6R%0?6(+^H%SS:*SXB:*9!WL!HJ$\Y3![D@.4N%;B@XAH95YV@2VR#
M$)QU\P+_6XHBJPB&\A\-$4Q)=(E:V<E\<33A>%HO"U8G\TH/,7$4I]@J3E@H
M444N ^1#1]TJ"2%,4GYHW6>:D  8@,=L63M60M1A%0OSN3SGCAC8A.6 D0(L
M5@I[V#4EH2[[/#NS[6<W6(_.AKL&\3)_* 64<AN;$Y:5E0.4@F#HI6.FF5VA
ML+JU"('<U Z7MF6BZV1L30O[:P[R[_!Y!O_"_?G_K'MF>MR[H=*KS\!SVV/0
M,)[%ZTRL>"A,K \J94!;C:%2+5VMH,T32 ),.QW.4FQ9#S, ?^Y4!B(&W0\"
M, "_ C\!1M<PM)GT$TW_4W.Z;+I0$(+*:4:!#O,RH.&E'*!N<UZV6^:]PNR(
M\S'"GM,;2,*1)K2C[@FXYSF<8!J%B#P!K[Q@(U+)T@Z-\KR4NRI\ C#)=RAN
ME=$&9[SY\JTU$[^YC7O$ZR!CDUZNL+N?]%I5+>15OD>R%TS>/!&E[#?^-$=@
M0'R&JU0$-&N7P]'"0?0'G]7R"HI0R/P8KRGD7A8%L<XB+D2\ER$:,[CR;'SD
MZ\4J7.VW\@:5+2"/G93;!$@U$&T=\XPKP?U=@[HDOC@RATH0&%Z-CR,2,V0G
MD6D&@6?TP2WMLTTZ.RTTT.+#QVUH[>3DOSRC&1E)_E59C"C6W4DBP#F9A>1]
MM)K-T+Z5_]?[P&A,RPE) .]/R[OZ:?\HIL:1#?]S4._ZU]L$IT_ _P+5/6XB
MV[=R;J6A#2NP24+7Q8O99+MC@&+#<I"O_?[9;*_'?/N&=PP3"43QBR;7!L4=
M"03FF[$4S%$6?1XG42I8H;5W&E[CVCV^G$G#VJ!AYCM3_@..[?J>@#L29ZS[
M2QB;?Z-S0S79PK<)AD0U(3]ZPEA1%HO;!BB836*R%XQD$)JN+(FWEL%I>XL,
ME0.'@E=3G@!)XGN36N^Q-8H[1BA,ZOG:/>):[T?/'!D] 0$Q63^?@.6YL0L!
M+'R8KH2 KG[>)^\>9I[90<#=,+QH+RKW;1H=+P-C@@>L0#>Z=QJ2?P>V?D(1
M#-E?_G*CSESO%BS9DK;;-,E,_QUZ&;=(P^4C2SH;A0O,;\KD:&U*OE7"4Y<"
MX#.?I4GB E'_;C5'/\>G^[*<[>]Q;AS>]]^+E >:/VN9O^A\K*8_"97&BL_@
M<RJ8CC=,S+@78<H[G8-$+$@_>DC )A1MIXT%EH+!;(^^.N"]R]QKG/EQ$<79
M""S5J^P6U=U1ZPT"2/R1&[25Y%XSVS+C'.T/'($5;6;$17N8X;EB[>K]I=V^
M07@^>.#U%+2!'AK --[ES7QY"H*_8M&0^F%<NB*+8^FYL+]7+%%4HUV?WD\;
MJ;[X*-<O5_?P/LL-L90DX"Y>!MO1$R-Y""8>5KO:+SGV#6_Q,S;US1T"\R4V
M#A^E-6I%F<(1H[JZ""T+W0*)VWQO*+PH@ET37RSKSO?B;8\W-2B')DG1K/BX
M1B?T6HBRG2X)[H;3QAM,*;]JE8I*W@<<MJ0X!7:_2*_K V?UP=_]R*DG!^D!
M]#]6-8"54A >>( %=%@(E:J'&QCXNUT__B%8'>+HP))A"70U 4[S5/"HK8#X
MP))!G^!N+G?R?WQ7[^X?,8]IZA\AT0_MFN+7&%2ZY EX0*Z'AB1LSOS[M>A_
MP+L*^3_A83<.A-?I RR;1R,B&"J8SR(5L<"#!C/@W^BP:L\Q:'W9<M*]>JY9
M:_CP;!%V_%S%6Q&FV1P(MU<2>/WMK@L6N;NN?%MBWX->=7UCT(9,;CQ& ='N
M1;EN7QOH-.T)"+8M.W(Y)/IH246%_RX.H5!Q#[6"X:Q4>?",J6=[4XIZ7_0\
M\ E@GJV"CL"N)TS]!+0A.LWTO79RJ.M_]:E3)264M7_B"3BMAL!:K@0=K(C!
MUII29Z+A&SCLDSQ"7MW/A3O1=VV=(J%2;;H//.V0T\_06[Q]\+-8DSG(N\(L
MZ02;#D+HHSJ&2@FKKE8++X]F!K6&2%O+ RSX+[USC\X\>SR["V.0$-;VPRQ8
MT\R1Q%6%+SZ-N2^IN/EV/R>O-_=OH"KV]S]X^?_A\O\:7/[5_C]?P$F^K8?!
M(F[[U9TEK!0FFPQACI7E@N>^@NZ!<NN-54B8"HP1;1= 8^04C46BX*<?+3*O
M0#I,O:+>.VU4X$'1.?#A1'N>)]UWV.27*-ZO9=RC5 C=!L,<?M"'E;T4-&$O
MV1P24 8Z# #O4;=BT'>-*<*?@E3'H (,=H!4*1RRDM\+W_P6]GGM7:B(\1^U
MX570CW7W J:?*J/:+W@VS,N<-K>F$[[__#Y8)#5<<8T.NKL*A16 P?7D@I#*
MOMW+2N=.%#@*]C*TDD)P?SRX+>.>L%Q.]5M-=*MR]QO'ZZJY8M'6F$<5'\0/
MMR50<5B<^M+G/+44]WGW:+W_1@E71)/^&1KXER?XL'2G*TS.1*;Z?;AMS'DB
M[75*UE]IZX4RM_?&?A'AG:J-DMJ%OA3X&*J<"*H>,2%K;7$$XIFK\;QC-@8&
MQFQJYQ7RM98,)7QX<E_JO^' '?9KPC)19@W/*[V>*L^P>E6'(+9!E=2YNRW2
ME#'JQ\]&8G (/DW94YV_U55MJYNDB]-()FLV6\5?8E544A2XA 'C:8;UZJ6B
MR\DHZ*S\.@*X\]H A0@;;]KA#Y8NW$JKUH>O1X-8E?*J<\BB'#17GPL;YFLI
M^GAE+G?;/".(DU8.5IY.MSZR*O,@RQOFU#&@5>FFIN 4$'NMN40^#7?6 T9O
ML6&6I?4E;35UP<AEV"*7]CQN(]@S8#TE"+-U86I'/OC&R%(51$LECE IL/6@
M.7&J: 7+Y_I$NGF.*D*R3(=QM4NX3G"73P5X0F2NG?\)Z&O4U5?LJ70O,9@9
M\Z^-)\\=QQ7_P5@M4B!\4V&>G>^@JF'Z'LUA.['_RX$H_TQ-"JI=!02G5-P:
M!4E6+Q,]/MKCBKH,"^<V*/()Z$(L@SH\ 5&>+C-YK5<_%O4[24]!6*011+KM
ME-/S\!']!],/A#[OOYGT78[H]M2)\K;,&78T34F*!+EF<_RP?_W[U^%4\OX3
ML"XZU[Z7?KB:"M[4/\)K^9!=&AW6*^F8LQ/E)G[F6K)1IJL9TWF?+>G%.1#6
MZ9C)8.!Q71HE+7W&&O_1]@3" T9L,).@.>K3"H:O<!2K*"E&+Q&RWL,@4)(6
M?AO"2!U"A$RY=H^=W.6NX_2-2R?UBEW-2G9(7L.[]PE J8@$[ZE,M[^"==X#
M7PHLW%LAE9GR<F^\DB66@[>%U/-HOY=3MQ[F6B?>IY.G\8W@"FKIJ.6-(!;]
M:4B;C\Q[OKE-O6]#G/TJT^OW"M37&A*QM"_,IG1&7IO7$6]P*Z01P)= I>&8
MQ-J/)GC#8_<@T;-Z26,-2@9'>>&-I-7^MB:;QAZ..#BH9C B) T<L[?R!,Z7
M"7I%J28GS<# 84Q+ &_2@R\/+.-0KUN?@+<W!I!-F-<G%IEH"R[3]4TNK<.S
MU0ORS,8+J Y-G."@S882[K^"F2.4)5&C::JT;94GJJ7+@S:1B)?#-.9U<ZM@
MJMNBOJ1Z^U1IK0P"P?67I1Y"=EDE=@2W'3_^Q<?W!T^ _.D6EQ7GK\_-YLD'
M%GHTR%H2A6.?XG3)SO:UVSA;YW@J@C4T$A=8=G*\2K3?3@[: MA\ SV5HBV7
MY=#=MY,GV).[BG4)M&9N6"^H(B(90>+]DQ6(:%EJ - !7PO8<]R>&,C$@M8-
MK?LMX$O!FP;@,PTV/&^QZBFC'Z<&%58VM&XFO-W-]O"1%%8W]PSPFQ2WZ@8P
M!99E]0"]H]A4YWX"0M-99FQ\ITRR],>>7\=X,O1MO])R^2V.=]W<)-6<&DP$
M3[M1#)/)'_>'6,J@([9Y@^?CQ=OANS$J%O#;=FBWZ'WI%&<:WTM&UFW>:/T^
M?OGQK3JBGPB2@M<8A'[AYA%GV>LB!F+=FNTG[*8W*RQ;XIXC.9-SREH3N[\O
MV,0[7)\$$.[6O;Z!T*[ J$46NNY?YN1*CK^T0 K'+39*[D7A"<V \PFIU4)K
MI%L=.>HL?5T\%>V;)'Y:<FAF1%'1 3E=V^PER=8I;W51_@I)J.H/5C2\CMT*
MGM^N=8FSO#_M+!'LWS0NDEKA2;U7A%^:GLYY@^WV)H0XE8)3&O%/J7 ! \_^
MC0I":T&;J_J 6G?\251JLWAC9JT CL C@P=)2X8B>GQK?L;>WM]CB1E=4+:W
MYG:H!^)JIJEL\!?%][Z?-VPT%4.@_=V"0=<_RO>V%1J,#P0J2HC4OY8 XH24
M-X5E-BR_;7+J:@/X*2-M9#:5BG/&X6!44C5G?@LZEK5X)NIXNA.U<833VV10
MQ19X)4O]PQ)=RM^-=XNI7_3J8/4?D7+E123-3[+H9.?-]\)5\^=1YCV^U-/'
M)@G"B&69:HLA'/>/UG0^ACT:I[+"*ZBS+QFFFZL8_8!!$>M%RVJI>*F)@8B]
MM1(FC  L):L1+.SJ.9ZC-T/H/Q41#\X71P-D<E62S&@HHZU5Y>9:I M6R[IO
ML72,X B11#</#:H06WCKSA87>V(EB(-D)NR+D<60C564D/\\GOLM(B7+ASI>
M2P86-YYJGZG$$6>7A]F?KP=.I?KB5?P;53.^[;K>Z.Z:^X9?G61&@C-"9J+A
MHF%\B9#1U;@S?5P*8:R0),]A(I&?LD$<CB:6#$OJ)NLOTC\:^Z3IPLVQ].9T
MA'@0ITA3B@@#2TE2+49JBJI.WN(W2R*"=)0)-F:6[@F&)RG&_3BR@$GQRGX3
M>:51?>ML5-2%N!TQOZ7IFQ>Q#5<+VHV7>$.W7(9G%"'"3):Y8VLBMI:4G"_W
MM]>.76UW5UI51H?F%&OEK87<U_Q%?SL4JE/X%>W!#T!L*MSC>T6?3]=H":.6
M2; L(&K3G@^5$Y+;^Y1T@]?5W7>AP24G#UO@*)\T&7LX^LQ,K/"-6X^-7U=,
M48(L:/L5++'D%GXDL;I"LKMMF+ J"U;?S+C'KV@_B87R7 /0X8#U$_!$3KJS
MTOFVA&#DT> Q,G])V$]J9"F,7-,7CIB QVC")NB%Y;UD0OPMO/['^@#^S_#D
MJ.KP(CXE3'W))^'"BNO]4Y2G=+484<*<H6#F2-J(+9AO<Q:96,PP<9;18WA)
M90V&M0UU%HA3B?ZJ@;;X6MD'^13.[ T>BPLBXX0QD7Z>PQD$#==Q/44'7.S<
MJ2]FL6I(7_S]XU>?-4++%*M&KN3T8\C.6',V;)RZ=:*_$?C7)FTU!?65/[#G
MWE_HBU1$\SQX\1N#L*XF3:*4OICLPI/7[JEI5!80,KV=36.8T@B'!<"C^/*V
MNSL\7]>=1#M LC':Y_P3#=I[::0&MEM);Q,8T4W,NV.[G9MV5E/+0HL^IZXC
M3ON8.ML_Q)L,"K<K9UVK.YV!5"_(;K\OJ>=H@^O<'8](W.V$<J;#$YZFYZ*:
M"5!YO?#Q*3E@8#XJRTO78MF(EEWU+HV <^WC]'F/J*A,^HJA9I(S&BE2)TZ7
M%.WVQD ='HIWW=K1KP5K3876Y*QGS_,^5A;X\?10=9M%PE V1=(Y+?0SV,(]
M!1ID8WZA>%:<:$ ]6XO?J*N(;#5%HIV\8I0G*HO$69#>$G$C%[(RNC ^9+,6
M3<,=HHW&0+)T97+@?BA&#GI>M*&U$RVQIF\:;.3P];=O[32,$OQ;5[PMAO6F
MY];=;733M26_*%M/V_+RI&)/</1Q%_HI;0A%O*!XDQ/_^"M_O)V,%\+T98?$
M6TWIT=_C1 18U-_YO\W*L^-0;% IQ2JLD,_V$[##<+<5(3$X0]R8%[>MUWQM
MY-Z!F',^)2*(N1XM8EWTQXIR^EG_(FC]^73[CY&]EO-VIVO*=\$/<-&_#H]T
MB8,W]N]=9@Y+.'6[SJLK5'!Q_.\TT=H$9C_6!77;Y*6$LQYEND=60W^_YPQ*
M:_CD&1FXX$=4L'3KS_.H<B_9'HU0T_#E,4\FE,2$'1'Y-H1V>76V&ES?8E8B
M85RJH[6Z,>$[7G>(&F4[DQUF(]K.)2/]4#NQY'Z6-^?;:8R8>YU)JZ) FP?V
M/*0B-3G&8MAZF&$0I;0*F'J75M-,@S=,P%DM;2^.W4,8+J4&1V*CA-IY%PPX
M^Z($JM6>;G26R@O/Q2Z]*X,)0H^Y87[0.^?K\N@&3*Q^P?S*>RIY)O;ZFY?=
MS+XFX2^DX\9J*@#,%E+2RJOR?NWI>.D).Q=&&DO\6>2D["N;'/[,Y^!^3$^S
M"9,J?07]"N7<]&$N6N4BQ/K"AU_P%LC1LD=Z.VE%MY_?CKL<R5W9=8:7U94M
M)-*I4N%XF#2ME7/TYUD41/$4*=0X+.XK<AV@FG&&FY&K"OL:':2>8M$$=N(^
MQ%"0I%G)"Z$PFU7"_R3@P\$E-_]JMB2U\@*Q4\1)C/1Q>2Z:AVGQ>]G:]-%F
M2]!\ D=2;YN.% [#%5HQUT%7*^CM@]BX\TGMR8/BKYP+[['6=HM1GPL]@=O0
MXGXS<S>Z!"L-&U[K7S0$",+B7+71TBB[%F1W^[VZX]Z6Q=9\R=0^T2/&TP@[
MZMH4PV%OY7[@,76,3@2.*@!N+D.W7?*W%2VBU\\>J[R%M^O>#)B\%N<TJ9.#
MUC:6'CA8P,A,G@"Y?@T+U6"?/3]%>$<Y[]A&0LK^K*)#@;ZL!_LBLZN13.Q@
MZY3MAI2CTN8B+EQ&GE4;U;@WCX>/Y[?=1\Y1]F\6!E(?&7[\)K/7JEM92<AP
MX8NN14JW6)_.?/#)7F@*8KPV)TD=R*GJ2KBO+(]8W="/K.#4V[]185*L&QL*
MXTOG(H2/[X9_O9M9H@IY-W$TLZ"K>Z5,G9W!0/:0EH/@-.7)^>BPF P<.+<+
M/5#_/*(*@K[Q\+\_7N#*\)YIVEP[VZZ%%IF8F]DP/$B.)1JX=%B<,:PD@5;#
MHAWT@__#_Z[A9" XGG]&'PJJWE@.MS7BY.2=+*1%3*)00@*C;3NS(1XH%%K4
M-QUGV+%,$]S$+0VYUJF''B^>?2)UI6L5_>L3%@.[=C@#Y$PN<V'Z;W9_'^\-
MR>-']A@6')_M//@FS*S<-IUY*[/&6F(FOWY75WS#>A?W,6880%3!<XB6W4UU
M+F:'B#6!,2SK[>P^\NC+Q@_4OZSKD:9%<NU_H"^H!=3.*,*$)5U*K!?(4Q G
M9!)R9(\R!2)KFZHACRD>H#S=4\?;S-MD69XLU[J)7SS%J**;-2JOP\$K#@V/
MKU^='3TL6A$HS>\/DNHX:ZZ8++&CZ#F0)AFV22_#B[1:5D(DILU;IFU2%&M_
MQ(WV'RE>?]=%4S<Q5Q';BMHR<D0A.F" GRA.+]T1H3[K<7N)%SSZT^ZJK',=
MM'"9OS>GJ;GP*F'YJFE17P%MD/GU8M G*8<,J^UCB+G/8[.;L3EB7*[*H!W!
M KG8Y$ L*LEQ$1J[^^!@)[6?P!@6?<3[LJR[U44A-QKV5/9H_O"O0W'X#ST?
M*5&W-JGC;O3/S,,RO11$F>9UA/K4&T.>A;US>XEA>]S\!OYV=KK]A:W)Z<HW
M>Y;?*1K3V!_QH=8HFU$YEG LT0UO1/-SXON;(K2LYM@M[]TC)E%8:>A<@9K,
M^KAYPZN"[0ZBAVYNN((UJ;E\&Y43/?FDY&.M8^H VR]([TT,;]R15WGF_T\?
M5_X-]>*&/QI+EL0P8S<QUBA<)$YBKL;2R%"'$1'99NPDD345LF8;6;*$T)BR
M9$8H6\:>92R9J7%GLE5<1K:R?>>>[X_?\[W_P7O>\YSG?9[WO,\[4P1+_ITZ
M^NJ#WA[J+O74S^02[R5NWAOW$T)#^LRZ7B/J\:P (YIS"UXF_[&3X^0\7#2;
M:^V!J8@?1P4T:+636C ;,!Q)ZHEL")G1SIF 0>"1NMW(ZDR'*Z1U_OT%#6B7
MV./VX2- *L=;=]3:H6$W"P=]1_B$\O?,&/^:,K>R(F_UN24]D:&3Y&:TN5@6
ME^+@M;*8:M,.S7CU\U?6?<532*]@W83VXIVO58"[7%PO TYE1IW7\L JBVG6
M=]JI8(?W<HPG5]/CI%?:!?0K_&JO$%/S"EEKHQD<^["0W8ZE2\Q::6SQ$I!L
M&:L-MX@5K6DIQX>*R@!(%4^<J3 !_3Q?4[%;7NE"TYQVV E42FMLHQRK'NYO
M>_M1L-;5V%@-]/9Y+78GLV:9)#%QNN(SO4_W]"9/+IAO"8/]G^ONE[2TJ^@7
M+DB1X4S!EVD[ITT)>K9\CVG[!C,>XVN;>VV76A^'_;!<B>[CIAQZ_Q+CT+OP
MDM2F_BITF^U$[^,6K;.EE-N)N*G) 1#E?Q+KH>_/LCW?PTH8C.-EFNNHVYID
MG@0ENU4^+H12]E<R2&F,UR2E<AKC,@6O=W'_*THC^I<:74(,I,:Q[-$4]'M?
M_JTC0!3;>C')3Z[Y2^_"L%A#>MD?@\<&BU"_;YTSW.GU-?OJG&I6-T3H\Y*%
M*E^%*5IX%] 4U&1K^@9#MEXZQ67<00U],9*@^@LUN>B_297K@8(&P4$W\_^.
M'Y0L.5 #G;3.[+M):PW#P&@P]\QK$FBXS^T^I;3WSG&-Y:@82<QK3$$?6\-N
M+[P ^_M.44SCZNH']D>*JITB1<Z&(9X=Z7\, R+>>0^9#FHFH&:#W,B9_6W9
M- -RN&>N"I?[DY.,SR8"P-SK4QR]P83C=S!1Y_?-Y @N1KW"L'"V6/+\M8.>
ML^=E =Y[,QZL#LFA,E\=)S,A22CE>^0KJ>Z7?,<!@<ILU)UE/J?XB(G%;JIS
M*29E1)IR78&<P2];\ 4.%AUD]YR<CM?=&A6-R)"[%2,]08LL"'#'R3-.,*Y'
M+'#_+2>\91VK?_(ABQT6JTS].E6X.^ODC/(=5?CE<TJCCG@X,T+^_H+HN#MG
M_W9R-4"XJ/K7!"HDR#"#V?A"677XX]Q6=,W TAE[XD4E7XS$;^,"*A'D*[S<
MQ%\TY/YNG-,#"&G>AZ>I%[AG#WG$-/;^Z3+.V-@XKJC(<JS RC9:)M/OIL4'
M6^J;N;+?&*FFOGD'89EG?!-$J^?P:LY;/%K+KKY8;,NG6FN2/)^Q+6,_0].?
M#!32:L@;T-'*&86U@7FW*;J8Z&LL&#@.YWM/I2CHMKJCQS"I'JJSEHAFR0FO
MMQ ,2B%GD#G-)?G19]%X#^?D;D*B3O$QF5HK+ACQYLWD5F>\]C?:@\%P=4%P
M@@N9J=NVQB53:F,TQNOS(*>WIU?G" B,>;T2OGWU>L(1$.J=3A6#;1>+<?!7
MN.G+PK!B4]5RG>ES-M\6]A^+\) IGC<\CX 05*Q\<S,S)NX0K($:JD(Z5K1%
ME&N4%@!7^4?C"N,-_F^BQ_[.Z4X(G%NT"Y*#8P8(=_^!;_5JO^QMM4[8Q^V@
MF?2)YN4RH:$YX6_2Z4MT+;U=E9:--%X+U\LB"%B62<'+D%W5'CL]_T+C>AW*
MK1L)P4F&KN\,+S@<B',5N3,/5%'8PL%N22=E3W.[?B%$(+H6M$'DAUL]CYA'
MA@7;YR4B^&H4GR$!S]D('R3UN251;UGQ4O$--;L)TW.)O^_W3:3."2T7YGTF
M8PJ]VJE#_ D6=Q9RQJ:;Q;D2+D"8S6YSL]#YY#3#4\75)NI+60.$:6GY@JI&
M_;Q<6[V0IWFYH>(DEN[?D?KE2 !QUR<@SG]Z)KARK($GBX+HXHXMLX?MFH<A
M0I0[J6<^-%HJA_-/48)CVPNGGL?KN*_C[P<%^Z1:D:QLANM=8Z\*'"(Q&^(F
M#R\8PS^.5CHUE)AI%J#;/XB6[D<<>I-JRH0(-T]@21A>%OT*.>6:5K$+YMDN
MW&3W9ZQW,_;?<P:Z+\;T:K<BMG#^"GZ[;%)HAW;GJ9B0G$SK"5093G?Y1R7*
M71#W'7 4V"<\R,J\//$\7MMK'9.XB!LN-&[8,Y_3<XO?"R'#C>M-3F==@)<I
M/'V5%U10(3KPQ&9!\J\C8$ZC](;0])0XX.!9(C^A/-71[-HM%O.FMBAH&"$3
MET6)T;!) 4;>KA_F1%:957UV-%-.4[@4W+A?2[Z?:2U0I9K0;J!5VF%!4F0A
ME"JX>=W'6[?^>;@EK<6_K/UF1#[/7X@>/9J_%J"0])UK!UXXR\'4X$7I\>OE
M'B^< Q\-9STK)D"%;>(8P(&OU 4%YB\\),>JV9W_FJ3Z3D@GL54-)']38/F:
M8(A*OG_W)^TDC1T#L(T)&#W]M$1D?3.T]S0.FL(._/2G1Z#YB8!Q4]$N;H=I
M=I< =XKR\>1W$-/.8Y7_EJ$S<1C;?!>JQII<*6^U'/ $GVQ%\_'-=1"Q=J80
M#VH=:\\B/T#ZH%H^7&*-^2>'X3M-(?D2"?L&H$XV#MH_S7R(1/"8R98<_+B7
M G23UGV2-&FSQ,U4[$A34!*PG_2@[V(9C.AW?9;^R:FJN5)=B/]9S0/ <_ZP
M<G+3EC>\MNR;TUS>097'B8&'V8G(A=N3,>=EPP@@FR91%XMM[+9+ VY&UO+R
M(\.M?L"^4 W$P\%T"TWEBORLM=W3W'ASD27X:\.!'S]L2.MWDXA*Y.P3*E_D
MZ0=6P'ZI353XYJISKBWW.?P31QK2SP_<RWU9%(Z(+PN'."TAJ5I*>%21FE=D
M>)#/C9SZA<AM J<@/8;86*"B#JK*V4A$ N?:96^Q_-*$RRP"C8A2:0HX2U]9
M$1&G=\T^Z\"C%_V\4X">HBZ&7(N%55B4 X;";)+JZO]V&.50595.3+#$/[$0
MZ%\T/ZXM*"MTF%#WWV4I[&CV/U!+ P04    "  +<WE4=7L',-7E  "J_P
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M^@%RR#KAH/YQ ?]^04'#P,+!(R B(:- !C1A M!0,##0L#!P<+"PD+M^D/L
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MN3X:M85G5SQ5[]\!CK-Q>Y0JBC#QK,U++VFV:<'FA[(J4$X:/11P.=-7VYC
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MNYR#":B)E?; L,_--O<,&%J2KMU<]I.P&;4\'0OLS)FG6QEN&35TXQ,BEUS
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MAOS-!$' ),H?,O9C_3%:9ED(4E/$6" 4!8$SX)(%<)'L%:$CQR'7>IX3_8F
M</SL\K2Z?;S:[O&@X]20W<DT94,N/E?+S3.[T54?/'W8>ZPCT.-L(?U#^3L!
M^UMA6AB"$RWO#YU;U1;2=7,L5VB$AIV@N"WN9,W/;S24NDETL++(5<5(S;PF
MS^,CA_J'Y@.:%&_$>QY$LUX #R]!7OO5Y_D5VSV'=P?^_UQD'BQB1/?A\E^
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MD^E2?-<*TJK5$UQS-<^D(()6VGC>E?QKTI?;?@+)34H8LLL'+3D^NN"33X\
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MFJ_7P?>A\UH/@6J/@'<**FJKOL&*V ];&=#$+7=ZEQ4,T$:!.PC6J/0(R)D
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MG&*(1)M?GE_6A@31K]1MQ:@WX0['1;YFF3 '_- ]F[/#'2Y]0:08].Y+_?(
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M)Q7=7/?X=YW<1%^)-[A.MJG;X+ M7V%0?UHN:%9#].+=]+S.;W'F_:_0RT<
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MPT::MZ)G;S)?;A;LP[U1;X2IO[<[#!;]4IU2E.9H]5=.XITMVFIS1,8F8]@
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M'\C<M(KF<D]HUYF])8418=*'<-7@:G3+LU?H#0<#4:+8\%7#E9V-+?/RYT<
M[=6OO6--\,M<-$3@GEU?1O OO? (J*W#+P U2T_[&A?<DWB*]J_OSH/N(PV)
MX _]"MH5FIIWA?,];6(@_&R:E5LE;A]"%BBGD+[HJ<JNR&_$+(NR.F#_/7+;
M5S/7D7'V"( M/0(6HLQPQB)!T.NXA\G[HL.6?\3SC/Y/X$7D-8Q>5.D<4V2H
M#NX!]*2]^-\N &K,/A4F=YJ$?EO+5\43XSX')[I",*$35\X;7(SH6=91OF/#
MC.QY8/Z.*Z%J\5/ZEFH'SH4"[<\:@"^HT<T.Z=.NO_+ER4<5V8+EZBJQ0_:
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M:8\*20>-(H%)%V;!NB8FNOAH./C_J_/_\X[\_^[8OM> _&CF0,ZX?3;]L'0
MDZPI*2?;L,;UH , \)-YPYT?M)0JTR$L$9R0([=:.;F-.?;D%G6L>\R 73&*
M9P3!#NM46+H2=&"!Z50.2=<952#=9PT&E83PN'9J92&SM;QQL!;I4M25DRPU
MD8CY+-5=SI6H+F"QC'Y*B+]T3X"W>Y %PV.UH:U9L\;LK?_:DY>K.:O/VSFW
M\[EW>%I?G5Q>Q3D4+ECQ<&KKD2O85SV+R9 2;HPJM>2[-ULKJ+9P<;]L8IC,
M<B!/Q&!D#I<!\&9NN%Q^QV:;O!=^:"@T6K0P1&T8<[X8RZM,7SZ;^WAGT-$A
MA@<]D?+NFHK*-2%C?;O=F<P6UH9UU DR:::R$!"26K-[$Q#'@//B;J'_)YUQ
MM-7T82N]N^%==ZTG14(VQ="U U?,(!XB"?6ZK5=%QZHK2LW%"H$YZ?!P3VU*
M\9S!L/73^!=)VC_(\2ZN=\4HW5:?L:C5GN9]=G+*6^[ -,0,FP"^K'-63S(C
M"8_EL\9<+^7?53K%]K\$X7A+@QDJI[G3\",X$:S<+&A[\"N?K+!$B[SG6R4/
M!^M8G>*)336K?,C<U8JVQ#7(&3*M33+X>-;.9^TT:GQ@964(MO;FS^7)_=%4
M4MDH)<NVGO@^.ZH 'V'-LR^8NR@#Q=UD?D<@OLC"S4VN< %D]M"PD=;^<-O#
MT;VG>$ >S6OO7A2:N9=L%GC!R@;"6+:<<4K)QY7+TDLIDH[V_T%KYASX=!#7
MIYZXS&'*3DMQXN@X#2.WFOT-\^4+]53L@8;]#'+=!7=>N=,757]U_.!NS!$/
MVC@/012N'^5"V#8D/_D&/C[9 ^N-,23,#XP\L$&::HS)E9HVL=#ZA+6$W6FR
M'@%?-&]OW6I;QHXVJQ/[KHE4Z1)&*TK"3E^L_S6JL.(,+HPB@^KO&2O ELN)
M\M9*O ->8V\%^/]U^;.O 9(GPGIR @958%69/N0WV<UYK[6Y73OL'\[X">EI
MC2>*!^TL[13/<QER<.;%;X; P#@AS#>,L[A.XUK\NV.DL2M2DS7"9#T5[,$N
M,C:'E_VV'\HGJ8,L;&8E,I()!8D=):1XW]>^%AOV+ NA/[$+K9;[:F"K)]@B
M@G%<*4O1?U8JWCO6A6RTU8?:*CBM@*T*!:VAB%!,N#SC[#2J_FL>//JPEO+Y
MG) ^=(=3J0;P <J14W.R5+AOB&$?:V5>RX3RE9Q3.I[,=BL4B$- [;\>S6&8
MJ4V4SGO2FO:C-<VK3%MO66J?K.M5AXY.D)3X%6UZZM1\XE<AX6RC'N,"*TV>
M1%4_5:8\C8_8@/,Q*C4Q,BY-K-QUHV?FUY5SEJ3#N2U3P)8UC]=KK@DC(G[)
MHY,B]% ME9-%@?V]:!U=N3=BR)-?7!Q&)C@].E 1A7#$*%P(8D"0,NQ=5\W$
MQ/GA<,(Z=YYSH3U"93%^M70IM.U\FNR3C%";>[TU:,U7[71&D]AW&I^0[B.U
M^,G?KW,AU/U3CP1DKP4R&ZG9A27IK7<R@FXX_;=:W]QYU40HH<94H4,H>]K'
M)F%G.GFNIK5W0"E:NK-LU)V\%M\&JS:,GCQWK$= URU][")]MQI-EP,'NGQ3
M'>Z20P+#C3**Y$HWV9J=\'!D&M)8FJ\PX51SX+LY04-Y/W?L:([TH RO]335
M&0K'/6'."2\#0*%17>K 1.W8F8=89%@Q1_U]7Z3 3&3HJAP&-JHY*<'$L8!Z
M]!)*:%A0O41S7?TRL$=WRALO:\^M3HL71Q%Y5\(#TZFQQZF*S+L;%=4/M9Z8
M'Q\A&+1^*+721TA)&B!?%[WGSW1@J^M3M&%CS.2R1^&:]MV$]T<AC^&K^O*V
MEMJ*<AW3IE/U>8<[R<'GHHYES?:ND2([ZV4ESN!TQ+&R2Z8:IK6_5II/%1-I
M5"GQB-!H13N;TU%1&?@+XCJ2A=S\=XT3ATE3+!O.L82N%+X\\%Q]QU(5#7L#
M) @LTEZ0^+&XLC0G,TI;C?.0<2R*4;_M".!828]OH6QC"!$A,=S;FK!ZNMR[
M[LP>/=X89(B%T"LEWKX:&2_@COTN5+T]\?E(8IQAGP/^0:7TJV9@3?!)^6ID
M1G2)^84>HS->-LW/*Y[ [R]R/CD6H_%_!-)MG)DCCG ID5MYN@5S'0I?[+"5
M]@6N3[.FC'ZR>,OL7]:W_.'\B6"JTTQU*8P1FT&U:;)8=6]B69!Q-;I?7<[!
MR1\_]3F!QK?T>TBC3#-+OH63SLKL?'.=KFLRU[[YLC7*%V-TIUY?E9_%2FC>
M_%43,"K18!<K]Z32+:N4^+H8/^E7Z-:V9,P$ )$B,?*Y4YZ&M39\]ZM;R#)+
MT9=$8"29BOVRTC%">#R=J:.'D,OEGN==&=Z^7)&!!:$FX9OE61V,P5J/)%K!
MK]81(JJ.;U,K5CTI)Z."&TE\I(#(BY5[G L*3G1UF$/'"$-F#/G"C;X$7IHG
MZ4G%AC4'CP"+H,W#X>)*/7TA*6W@2.^\!PE#>C8#DC+J"]#IVS-^(1&N!QJF
MN&Y[*>?U5VOHLCH2Q:UAB"8$(TK$QUI;IX<; MW)9-IB\S]FLLME9B0";$]O
M6CV..U'Z*?IT)UJA;FLM8G49GQ;U)*U0?J(_)/#UF^(8'Y'[.?+S%4:[RWK
MF#((##K0)2SROPI^.N<%LASQQ]2WWP"-#!4 [\U;61HF/DZSCB=L'1UWSW]Y
MW<<4*XT6D4IG7CR$BECY@Y_.+?88TGT"M1.;$:U<KPU0KXN5KJ^W($4ST42O
M2)#D6W0Z?PZXWJ:0@Z)*6/1TLDYI8;@YN%=)V/?OG3\"2@ !UWJ(D;.06"K
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M)4%NAD_LF:[.G4#'QP]/PP<PE T!VO=:<O]DM_C7V8$ W.G4EGI,&G$%R!:
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MZ 1R4D%N*-"S ),KZWC92%:2Z.9X)S]1:4@.6BB\9T1'1^;N_\=GEGZ4NTX
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M8S5^&>QWWTI,IO<PBZ5EQH4^G XNQWO\,I#"'J* Z*%.L2#8N0+"JNVRJ:0
MYUFR/8/L$%AA9F5I?4G<F"ENQ<G@3_D,-PC%7G+/D29-WA]Q">1CW@D$;R:O
M'OC5IMZQ>FUU5A1B> RS0U:?,C)*+N+'CW2\,Y* ;X(M^H(;[FWV<TAH##UI
MD3CJ.SAMUM&\I!)QG#NI\DP1^5\8,]E?>Y]6_GOOT_QZ&;V*80O",@$MGB\'
MN)J_>/-SAQU0TSH%M^T=DNZ/[)T@8AJO?4BX_H+%ID;K6D4Y8I?Q8-+,/[_R
M[U$6_.GNS@R)1.6B(+=UE!'U#SE>V^I_GS?0/794R^FTL/K)LM02^BJI1#9
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MT,ST_ 3%\G2?V(=]6[40_&H"\I+EY!R)+A:UO (8!#Y);%']]2_*&Q?P:ZZ
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MH9^CB]H2/&@_O(F4NJ-Y(S1CJ^(\<@]A'.),LR#[EH0DG_"^DN"6A)^U>-+
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M9JC7WMR?]XA5$VT<2A_,AD\%</SO?\QLM]\LII7^J;MZLC9Z136?^/H^M\A
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M8PEGY3KE_1R'' ?Z)D_^V5FQ5OPK(DI9^P/+X(@UPKU0W^95XG*\DBV7*?&
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M%,=DF>P@"LZ"9,Q>RC%H2V6 ]I#>I[CC/)@H,-45M@=[CY%F;E\F__Y_]P=
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M,%*+.WOJSIP?8W.3I!GV+5 $[4$*F*_UZ' 4?.3!H]>%"^6AQC0?1_M3FA<
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M9T3(2?C@=0=I*9>U6)>!TS%OP950&^KPU+VUYUXZ]D>6K<ZWGIUH'<73^'>
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M%S096]4RG[<=7EDCF,S2%F$<*'?\O5UN2'/M.2*B7!TC+_,V$:G_SL%>L--
MECXX8('#9=Z]LO3:N%?->_=A6.!T[Z>^Z/@;:,(__S6F 2]A>ETUU?H_=S4H
MZ7D::.4I%J@V/R\%[]RSW9N+!>T)XR;X'963QZ#?QG-_C+]M9>VRW;^)"C(S
M;]4^X?-1/=OYF2G+@L4H.UP%IE;# OY8X(# 6'OAJ3CD55P^OQV_0Y_\ES^5
M6X*W2$O;28'.Q=([9,8(;7U6%>IF'BSP1C7VA-M]Q_2H8%'7K\Z_.5*.JW"]
MBF[VSI/:?=U@#4;ZV<M)JPQ247ZRWHORQOY,:.LCV[(<.IXT89IW-&HG+VU
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MY_\\S^]Y?K_Q.N-USKGF.-=U?3[OY7.NP?S)G #V&>E?T@=8=@$ "_@#,$>
M"P#'GCWL>W9SL+.S<W)R<'$+\7#OW<LM)B#()W3P $3RX $)B4/2\C*'CIR2
MDI XKG;BU&G%,V?.0&3.:JLK:<DKGU':N0@+)R<G]UYN41X>4:7#$H>5_M<O
MYA> GP,8W*7&RG($V,7/PLK/POP&0,#[W,WRZP7\?K'L8F7;O8>=@Y-K+]B@
M8A^PBX65=1<;Z^[=;&S@61AX'F#CWRUP6%%WCZ#9;?8CWD)*X?%O.:3.EWX5
M-N]>E5;^X\$C3J[](J)B!XX>DSE^XN09%54U];,:%R[JZ1L87C*Z=OV&A:75
M36O'.W>=G%U<W7Q\_1[Z!P0&/7X2\33RV?.HA,272<DIKU+3LK)S<O/RW[W_
M\*FLO.)S955U36/3M^86=&M;>T]O7__ X,^AX<DIW/3,+'YN?H&XMKZQ2=HB
M;U-V^L4"L++\]?I/^\4/]FL7&QLK&_M.OUAV^>\TX&?;?5AQCX"N&?MM;\$C
M2N$<0N?CWY9^Y912-E\5_N-!-]=^Z3.31XD[7?O5L_]9QQ[]7_7L7QW[=[^&
M 6Y6%G#R6/D!*+!%.9X5QO6?;<U$IP8MA<F"'[=&Q)%E$3I78;6?O@:1%FUN
M_ B@ZM41^1Y5'#S9;%;LS+%/TX.=EQ,_QP/<@G[K*-C?=VA ZZQ<[,SGUY08
M1=A[Z9O9]ARC*%^Z>Z;.V54:S]W=*[E>[OY^W.;/#CZ7G06N"\9PXV-P*K'O
M0M1["FDR1=9S!^YYNUD.R'E*)UC\\4!G95:&5043$/FU0;%O.?^C85%NQ>FA
M9QPU_!RTS-K^%*_.;X\?7=D-!(D'U)ZSN^?RXX--[#E4RO0TG>;LZ1T[/O3#
M,A'=L/\I<?GHP++4&VF75+%GPXO]EUI8&+""1&2CY&$'\3<73!YI[@U4&)@-
M-"?7F>>+5YYK]SX\GW3(3":\PK(L3=G#T]Y4*/9:BL3(XSZD[<-,WNHZO\FD
MGNR^SE(OTJ6CIPMB$FP?6'HJO] N<#3MDU,Q%O6ZYRE5]3G5W^"4\\G&NF$'
M+G(QQKP^K47V87GU@+Q\AG#UOE9BS>[STL-&$_A##PR"%AH@+BGC!U?O)J>\
MRW'U8;U4I4]-29&^1><!_(3,](#_\V:;_^S8X+%^C\)3?M%V!S0?67 >&%Q6
MZIST/PV\>)<9-/T:O._BJ+9N0>MPZ<H!F<^U=] I_FRAEJ\TGUY^4Z@=QU?A
M?I5%3^FF.8?]3=%3+KFIB'/LT@-JD74W<\BOK_BVY?APZ-]-WA^3=&_YOBCW
M^Z]?)5^R5.L)@9_YO5EE'"-J1T;XDE<(R8'</87[FKPDMX^^V+@A7&FKT"Q^
MI[K+0P"G5]-7F#QO_?#30Y']3>P"+>SFVMISNW[D?WO#ZR%KUE!K7*]=/K1?
ML\"]BJL]!NOK04B;G^V3F_P<6!DY'-%X>'<ZJSIK=0E;;6\%S/(+X^@SW4(W
M:Y.ZSSVNG]PLINWV\SP_K;-^W#QH@! 9HI"/=0\]U9]H4!.E+I?-:+N9E:"=
M&AX^G/]^3K.+O6 ^[4=#=JZU0U)"O^<+)3W?78;:SS#6?Y C36"AL'VV?)6Z
MNT:-(L,^7&'7:>A?[\S/6Q"1/-"[Y+1*'QZ[\/9=Y9O"V0R#1.^C0KOV']$L
M%2OR<#^7!C.][IUM_P/V+L!SS^=7Y_#*3R2=3)T.>S\^!SDGEFW_Z="V_X.F
M_)*>-,],EN=I6B> -[A'099/W1Z,+Q+>CPZ[:N1X*SSAR4HMLN-.*'AT0U<B
M RYQ( Z^RR:ZZ(IBMNVKE,8V+<=[K]R_PPB!VC5=[ W=5@U\U'.KGE'RWQY-
MW+PH+?!(5+7[-?[U0/]_&2G"U]TLCBT-1W?XW%=?>U* 6NMT<\T2/$],]N/E
M2HAD@_&YK0<+K\[WS_3*ATAT*#:X'*J/O'SG:G5C]:OUVK/;X8OG)%-?=U^.
MU:KJ5U/V .[&7:+T/O\B3<K<G56%V1O0LVC?U[,WG:-H>65Y?*&YQ_Q[=TXZ
MAW?XT[D S)XR/RC$/>URVFLUZZ,H)$_EL%S6TX=)+\4NNAWE4I=[TR0V<0#8
ML):-Z0D]/,]N^ AGTU_>8?S>F+%\YRX@Z\BFSLVQPE'<HG;3\2;_8RG@1GCK
MH:U,=C,](>"_W'2+K0G-(@\9JF7=\+)AS1-'4H=G3;==S%AO[PGB7C,YD_Z3
M-R]J?5D*G5;4FVT[[_V]\K-IL"//6YW;-^ZG0_S%IB7BV%6JLP*2C;&[\I]Y
MO34<U3W58[#_ONK^B= ;5UXG3_B66R+)\!;KEOJ<<8P'/?9HNYY$:[1L.(=7
MG33;G>6#@X\"/I <]OD%%BUY3O?>=C\KX*7JDM1>)JOTWF%E.F+;!IF!_)3\
M)4A/V+[EIM.GB%F7X3\>?U^+L_2_KUUF(7OZ_P?-Z] HC:?QRO/#OD6[FY=\
ME+=E+&T49*=;G>_AXWOJE>JV6H@NE*-8TN?,89OZD0@KKW*,5O6-I5:U./:0
M\'/B#GP/X8UBSJ4W+'VK]OJ37D #L&N#9$9%GP7[8X7"305NZS&KFWK.;C.D
M"US+ND\/O> 099O>$$:=$R9,)<-T9D7%+%R/^.E[OQ!]M,<@S_T';>\$S/ER
M65^15QKLI.8SN2D^CX='4W,0FCF6Z-;(0VS+&*--KN.LKU:U!KURL;K^@=HX
MZP7!D9S>%W;Q-K'?_%1Z!V4G;ND55R IW&/PN?,U'X#C65'_VA1WD"5*\;^;
MXC\W%F.+JJKR'L_\<L.,*?4._4\)^S*&I%Y;ILZE\=:^"\C@L9]P+4-\YIQ-
MP%IEF$0C:Z2@\NR7#VP^MK<JF))%/.,\,V =97WL;43\J2-6=9D!Q\[YQ\?-
MAFF;/U("1_TLC_*7^_,B)MK)[X,*'W=\YN:/J#MFJHBS/\L=G.%]=8C,%:S7
M!Q#E\TQPJ:G=C@8W_7>)WQ=3;U'-4&R1K<@*4R]R;AJHD6EZ$[H/XZ<\;(N1
M^SXADJ!O?K/F%HP]US>-CQ8][$P/TF,"F5RY.*]M_@H"E1T#[AVHSV0"K?5Y
M3&"PT($"9/+\IW3]U]9>US59/^A+OS%]GV36<: %&)XZQX*9L2Z_FF[#\MW%
M?F]95TG:K&9!*NGB *E-4;3R>;KWC2_X#'S7=9*D6%R3?EF/^9KSIXB[EQSO
M.F +\$\W6DR-L-JR:9^[_5[17+T_&']0=HU+-Q_4YKM'[#U:3WG@UI=>_U.H
MB"%I/3+2CARNB;Y\)&ZO>^Q"B9>$1[70K5L3FYT^EK=6/>HTSL^WK 0*&.?5
MUL03:P)%):^H2TRL0I]8FNC)!_JSBC0R)$VYYQ;S<YNNL,7,#)U?@P'SO=L#
M_4+F'I4/07XQ![*BCO]K*]$BSKY].VK[U>.=_>) XDV3M884[O!7-<Y/N1XH
M#@K/^;4$K"^7R2/W)\&]#FY<"^QPEQL*NRS"GGPP\NT$?CCL3-T^#_'&SWDM
M4XRIT?+TNWTL@I6=/B@MO$Y%UP#D2<- B*;GX-;#+;53/6<0GLWQEQYNLVB]
M0?G+]%3^N@'6I%5%Z-V!,B:@FUY"Y["\85L2WNGA5^+A- ?'-?Z'&#Z>%=/%
MHG?,Y0<@)Y2:?08HWT'B5*&*F?&C=54](:ZN[ZW=!I4;MQ2XB45?[L32LC_S
M'?=M8ZF4='O+ZW]+^\*1F*@U;&1-;.N W!-*SI89UN4]W!O?424]:U[GO!+C
MC7 K^F"'=6U0J^Y7(!Q3Y0OQF*"J,"99^.]X/;EOP/8BL(!DFEH0A2^:-DM;
M)?"@IWB<.A=-XQB+RR*J%H.E:!4<__WTSEG>LPA_5B^W^1"Y*;W* 8^)?L\5
MY]2LN,9QO=U9'H4W<AT9HV'O=*()5ZY;+RCWNF3Z9I7^-1^[]G;<#G16J4ZV
M>O+N:IUIQ:#VUR7W[T72W9/$]N&V G>YD)3V>!O5K#OK&M/E5MM7'5%_\ 0E
M/FH]7VINP/9PJT2U9Z;65%SO;B!.UCCZ7:Z7DE#OKDN'IK>=[-]P3 1=9<_M
MWDGRF]9>S\_$_D%:P)BBGDX%7WMNQC>&ASQK;3$(>M>@OMJ;/E%37TKE&(/*
MS(B-Q"]B))PSCK.,JS*!>'%[)O QA E06 J&=U+-BQ[4O)-J+43)?.<"FMI
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M@\C+6O6DC7'A\X\$((,(Z48C\;6<Q[RW!R9*I"#B;Q4TF(!CY8K^I?4JKZV
MV;10]<;#3TV77!5/?-EE;[F@V&R<K=8EC[#/*O,]>(WJ?K&B+Z1$%F,RHN8L
M@2N9M+Z1:/'0D4OV&3D))XO=XVKA;W%55QES-O;)T!=QG^&Z08;(YWHF<(X.
M78,3BVZ?]P%EPL9N'WL.)O#B!A.@1RA -WPL$^"-I$'4W,%\ABE#Q<"(W%3H
MNG_] D]L8F&EP*C )-GYCV]^\XD6']<K'N&[-RPQV-7Z30*%?9X))((!>X]\
M#;>GM"0@_TK/RJE[";*I#Y4/W?IR*T,)]L%>TM56/EA/Z'&NW*W3?\6<RFQ0
M<N[47(G7/9S(#_YZ/0&#>V%HD=0$J;.::V]:)XCCH.<T'X!I,V2$I4S4'(:7
M]LQ4N9(]?S!*:.Q"+$O))K)#YWIW'55\?U^?0QU_)']')^2T;F9+#82=KO-@
M D=4P1[?VF8"&ZR6Y9!MD7(L93,:' -A@Y8<R*[%;Y#MR/^!$2J6FG)^3@B1
MS1JQO]DJI:#:<E3-.PYJ[1V=^(FU,J<D SYYCUQEZ%&WZ/7Y^'C'3&RZML_B
M,IB3$4U34(5E!Q?$TITEGNE8*EUQGF #L[=K]AD)D0)OKCE_P)0NVE_MH#X4
M<IFH]^1$GDU]36=F:VG2[H<"ES1+!V5RC9G WNAOH68UU(MPQVNEZ6WB6Q26
M>5 F2X_X[T5>G(U:4XAD: ]N$H3RTC^T<5H\SQDYP%<;QPN#%0RZG_CZ=2A6
M,Q:^Z;&A0O3XR@0NI<PRE&EW_$O*<YB !?:"@\B5!7GIW:@8)B"I.:@O\BY5
M! +B#_J'!#R8"4#.@%"#W1:(7:03:,_M+*6O0,'11*0I8WZUD=]D;#$NYO)6
M[[2)#M],"8-.ZW8Q@<5NV9QBKR^0M4-S\,VYI![+5.CS9)#*#'<+F9W[UQ:(
M;KYWK_MF\JE3:S-84[7T4-/M66U8L+<]PA8:IW(0VN0D9^3^0W\@L /PD.8^
M^));(7F(+0, G,+.Z$ <&?M&E'(-QQ1DW4G>C-(: QK4:$%6O'$X9K@X?/=8
MJ[?F?DL^47UST4<<;#'$GP,_?E'I@P9VS)!?(7([YL]:P$P(]Z6*O]FLWS>7
MFOM+@W'@F8"9##5_V[)UL!%:CA7&_*QK(G6%$KU(<"/*+'Q3 %X#3PJ)#W6@
MWDA]N;?"AV15MM:N;;-97*CZ/=GR\-;("OH-@IP2WVU ]06@/:J@4'X5!X^F
MM^M6WIFT>O6*">25:GV!"3*!(N-$:@RQDJ$5R 0<&$R "=C7L!WF_(1]& +.
MS+<JW@_89<;+59EU_,]KR[7PWDO47.C05O,AA88'F6)6\+R\@+"@?"9@_2JD
MY)BPJZCU"29P\24DS6G#ZUX7>Y\."T@E'*KQ92O;6LZ],L(]EF<GM+&K3UQM
MPGBFU]@=$^T.WK].'G).H 5A:%)I]E#\TA9Z]<"J5B6*3BL)(:^#D;J2 MZ9
M\V=XV."C=?H $VC0\[_-!)X^#WZ>O 7NS2N!$;$U)F^Z9<,@9\M0BYA B$6C
MH!R!"<!E/Y"]D&2KM&,^8$0='-&.?3#*!/Q0A' [RR:0\QN_=:M#B<0Q;]JQ
M//A>-MAU#?,N#3-[L]N_*[]L/HUEC41EC4C1HZ+O(><U+(7=IQ1%HGKU/E?7
MU,3>&8(B!3X^F8X0_\HNPQ:FJSX]Z/!.ST\5J65QK:B^XS"_45N5U$-U@CTL
MWS0T0_Y1([Z95*E\](M2XYFWD%=?'F1=22]%E[@!&S7ZG;UQY>57V1,"^"P4
MW4O;?-X;8;1S(J_;/']NM5)'+RWFXS!L!?Q$\Q<5[2^HQ7K(^\T["AQ-EL\;
M%=C]\"P@,R8JBIDR"4H9DGO^X%:T_-=72Q!EWB>4-!^;QI;SW8>5N'6NAS1U
M4;K8XV--+4TC*$7U<8B#8U%-@8)8N7FN=B6M;P)WH^(Q]J.6[UR@:PJNJ,U%
M$4:8++3%+,=^UZ#YF>MZO?DLUV^Q?!QX^AB<$%(Z&"2E\+E=86?^89"^,\X$
M8E?CA@*Y8F4R[D/R5-<IEGF6KT(\UU"3HF7K;WJ@Y0^N%7NC%ZW-R%T9:/!2
MV?07M[%4-7B;#*U<*0CBE@).Z#VH-'S8)C":<7,[%&7-646]('@ [N*Q_98)
M)/\!)? %16]!G-&I,J2'C&/@H:>F*W39FF^1%(6?#!IR*'T[D6&]G8$T2J=+
M+;NO&=#SRZ;!2XG23>ME**;#/C-H>FXEW8#V:8T)U&^^8P+>) O).\BAD89
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MZ1@BO-"KYD<;Q'K!/6GUZ'<E%W<O=V^5Y;JCI3!I2</4U.B#!>&]4B\4[6X
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M2UL.E336&K8H.-IWA+.SR&_V8DF5E*>8&,'6H>4:&&3&K!E_>H<,K'W_7_8
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M:YT4WMC<K[=9#>?WS4Q[?%^Z8JRX<DFZ?^%XYJZ8_X<_#&<._7]02P,$%
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M*XO8D_7&TJ=SJ4G1.,K-?B1I&2/MJB=-*"^D"*&97W,??_*!K6?1,B[(%#Y
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M [;CH/NKE[F\G_)<\ZTJMGV5'E+PY%I5(4<U<8<[J&XZ-]>68BB5O].ERUL
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MFEQ]X 3&:^FU6E7YOE2,;]OEU8/P_;0V%X1__,AJF[_6=N"EM7U1F2?@34A
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ML\E+SA2!8K^7692'.K>)J5R_=*(E66,R!IK))L)DR(IOP%%9I<M*>=%&VM,
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MV7-#/K/!]]R0/3=DSPW9<T/VW) ]-^1C<$,.7;.HYX;LN2%[;D@5USAMX0*
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MLQ-M^\JOOM.0]ET=/ OJ15F1.\]"(^+<>>T&<KEOTBCL5<F_9!@DJ-3(R[2
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M- E$EE1PI: 1;1BP1D'<JNQVE<R!UK%UG'?>=6PM/BZ/:NI$EWC[\>OT1BX
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M$.HSA+8X0VAMJW7O):;SBMC1\<(@'AT:S/Q2'/'YMVDTC@IVILM2_F4!7-1
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MS6EE4R5:KE]GRZP+83]A2Y+@%U?U ?N7V<Y<5@4<1S;9EA79H0Q//B,9G<M
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M,[^G^J,?.:)E#V8_51O>66W1#9*<93JP^BH_KU,A1W1?AWO&M6!C ?4AY<8
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MSE>[=EGUGR?)X+@JG8ZCFLO1!2(^)IE(;&%T?3+OY"B,MMS#ZJB//^U*W\Z
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M_<)EP28I:%Y"965BNNRB2'KCKT^S+<3_MS*$H4W)ACWVFAL7J5F^9#>%6F2
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M68G53N"S%C[%##;B<R5%#8.CH][P8,6POJWO7E#S;[&YU^)._@)02P,$%
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MSMZA6$3S&>$*19)@!:,+JE(T$5F&.3HC4E+&T%M)XRE!Z,CV/-NU>UW+&@X
MU:A<(WB .H[?=7S7]Y%[&'A'\$(79VCO>C+:-]#'YZ/)WQ?C8M>+Z[?O3D>H
M93G.7YV1XQQ/CHN) ]OUT$1BGE-%!<?,<<;O6ZB5*I4%CK-8+.Q%QQ9RZDPN
MG53-V('#A,B)':NX-1SH$7@G.!X.9D1A%*58YD2];EU/3JP>0"BJ&!D.G.JS
M@ U%O!P.8GJ#<K5DY'5KAN64<DN)+.BXF>K#2@>FMV!NK06-51IXKOMK/\-Q
M3/G48B110=?N]=9#DD[3U9@H6 LD85C1&Z)QU[!&C& 9A$*E_>T-[EJ95>L2
MP965X!EER^#5A,Y(CMZ3!;H4,\Q?M8L1^,R)I,FKOH'.Z;\$4 -[BMPJ"S,Z
M!>2:UG[!?P!SR/S;AP?%5[UGN+'G@ACN0L%BF!S?IC2D"G5\VQLX(8@M>RPB
M[Z5)PU:[W- <:&!4+8.4QC'A /#R1<]W._V!HP$?DZJ:Z"+P(R(?+KL1D8HF
M-,):RT@D:#0^1YC':'1RCB[F,I]C8%*)1Y;K(W+@]="U?66/;'1%(L.%U^FZ
M[>82C'/T)A:9#F)/(^#/$5C)\<@]U!:A4H*NL PQ)[EU?LO($KV)E)[Q7=?_
MP70WP>?^F>?@,\M-RDXYB@3GI>A,1M.">\/Y'#-T23(A068<G0@Y0YYK_:D%
M^#NF'$U2(G%&YHI&>1N=\LA&>WKIRX]SH?HC,8.TN"P>]E$BI,&[A(B-"(_!
MB(Y)1&8AD:CCM4$EOH? PA+*JL1J]$>BN81(#BQKYQ[?0I+BD%X!^XSFN?%]
M;B!CR*X(*") 7HV,@H&2BC8:2QJA4QM=TB@%Z;7UEJ.4D@10PU8Z4Z#S!.(*
MD%6:4,E(VQ!PA=D-5D+",&8XE"0G:Q0GE$.U0$%LGT)!<)0:(L,EBHH(1D!V
MV=J=T#HLO'SA'?[6+Z*"W@27SE>'+F&^R.+;,(]5\%VR3--,W Q1,#.N@L[A
MO:3&-,\87@:4,\J)%3(1?:BCU#7*!CZ-HR@U#.8M=-_$2?&H$04<_ VS?CW,
ME4-WL-L:[GG[*\&:#_#.RGN3.6-@;V"$3#O2RKDD^3BGDNB2-M=&LLY#>W@?
M@<-ZW;UX?V58:U=<N6%I7=Y1YZ"O_:,Q2OWQ]O>MQM8\XS*&#Y;EWV%9E"<:
MWI@+I \%^0 B$RU"<65VF$JPNTP'2;"PMI[&T"'!,J /HB1,9&!R>=NL2E;1
M$Q#&IGHW(1>@YJPP4)%!QM$3^59DM7^^H-9$,HY!<X%..6[_#$M(97[79&[_
M)^?[(63H-M7XT>N6=B3=3N.0D0I+*&1,I!4)QG"6DZ#Z4J=#!X"T\$[=WFH_
M T?:;)XU@9NM\SJ"F$Y8;RRK74ML7L&5BE<\Z5HDPJST?&CE2Q1=P% 31;E3
M)99:*U[#+ !;PL2B$D_U;"V@7 R@9L(?K 6P_]GV?C6/PURPN2)]?<:PR]]W
MT+B3.\BHL3C)*-]5?(_00J&4F#5!;@4EQ<8[(OSNHMM-6 4@3'ZAZ^S(W%%2
M6_$C6&Q#@L-76E(9+$J]>MDM F72&+UPS=^/Y5>[1M%&55W4FJ5G11E%Z3#U
MQ%K::G2?5?0D_'SB:&%'&]O9P/],@IZ!/!AIA)9J@/Y7A/A[E?;$[-%-WDS'
M1!60%NEVZ$)2:%,RZ%-V] J-$AT^*[?1RGUHA'E69L/9>X R_[=)L'$%Y1WG
MZL_::EY5^:RF9E66.[\X/6NCV27CCL+N*AD=<U)8G8 T1?RU0YET50:%./HP
ME6+.8WV4*610A:7:U9S-B;)PTA6(^0FD?*X"6?U*4#E2OQ&T?=<HPU-B%4=C
M.%%$!OA&T+@T@U[/]@]6X;,8<\WUI.(.D[D4-?P/4$L#!!0    (  MS>50'
M1TK-MQT  %FO   7    9V%N>"TR,#(Q,3(S,7AE>#1D,2YH=&WM77MSVS:V
M_RJXV=O;9$9^)NVZ=C8SKN.FF4G33.S<[OT3(B$)#46P &E%^^GO>0 @2%&R
MZ]BMTVIGNDDH$L^#<W[GB>?_M;-S7LYDF:E<_'CYTQN1FZR9J[(6F56RAJ<+
M7<_$I:DJ68J?E+6Z*,3W5N=3)<1WNP<'N_N[1]_L[+QX#DV=^6],>2R>[AU^
MLW>X?W@H]K\]/OCN>/] O/M)//YP>?:$WG[Y\]GE_[T[YU[???C^S>LS\6AG
M;^^7IV=[>R\O7_(/SW;ANTLK2Z=K;4I9[.V=OWTD'LWJNCK>VULL%KN+I[O&
M3O<NW^_-ZGGQ;*\PQJG=O,X?O7B.3^#_E<Q?/)^K6HIL)JU3];\>?;C\8><(
MWJAU7:@7S_?"G_SNV.3+%\]S?25<O2S4OQ[-I9WJ<J<VU?'3_:H^@2_WX.?>
M.Y]V%CJO9\<'^_M?G50RSW4YW2G4I#[^9O?HJ'UD]706GQF>VK%5A:SUE<*V
MDU:S0DE[/#;U[*3?P="75?AN8LIZ9R+GNE@>?WVIY\J)MVHAWINY++\>\1/X
MTRFK)U^?T-M._T=!TS"]6GVJ=V2AI] XCO6$YW_LIS[N=,*?'<)/],^%HMF-
M39'#N^?__O'U]Z\O82,/GN^-8=6J/VB,^';HYTH[/=:%KI?',YWGJH07_N<?
M1X?[3T^>[^&+]S2N# Z2LK=?O)?G%V?O7[^[?/WS6_'S#^+RQW/Q_OS5ZXO+
M]Z=O+W$"!_\\N1 7YV<?WK^^?'U^\7QL7_ +Y^_/7\*I>G_Q =X4ES_C2]3,
MP:%O"=]MOQ2G9Y?XP\%W3Y_=\3X]O&WYM7&UGBPWC*RW-8]>7,Z4F)BB, LX
MOT([(46N7&9UA2=0F(FHX8W,S.?P+U>;[.-(5-***UDT2OSW_N[^/C"R2EGA
M@ ,I\1A?Q[D>[I^<\5<7^!4].CAY@BV^DKH4T+&5E6IJG;F1>%UFN_UO@3$O
MXV>+F<YF.#Y\QY3%4CB5-1:6.(S1?R&LFFH'U GLNFJL:R3,OC;B0F4T(Z 3
M_\$%-Z!AM<\_ ?\L@?.?9C7^C-0R$A)6 T1&#BVE0TM?#N/;O?M]?2#D=>LS
M_DJ5L,/%_3''0.WT2,,VE?7QX0-:N6N&>G"T<:B#)S70.)[3IIX9"[_G2-W:
M.3B.W^R/X#CB?WP:'=)R>@HWGMT1OLWG[.!@='3T=/3TVZ/0T (.%/>2"UD"
M$FIJ5\-?D&M(ZN<'-;:-M$MQ>#02B(]&].+!T)@JJR8 N:"M&["4TB1?\OCP
M\>H(7JI,S<?PW=,#&L'!KOA0%LK!CXT58R-MCJ_EV@(O,-8!IP,^,=<E-@T'
MW"ZT@U58*,"&  9Y327\K>T>&\IDI6M9\- %L+(&4*:%_=49@<2)L?-[X >?
M1TY?.N6W,BH53ZZ90SOPJ@-Q4,"NPO+K$C= TN\@"V#3\2LO(9*3()&H87/A
M3\"9Z@KE1&4-+I0I<;./Q6/])!4M'I@X\5X!Y6%?9^V^(W6 %#.V,I8Z3^4'
M_1VDC87I@^@"FE&3"0QW!%VLZ>/42QX\0[&_\;*0"[>N-7H7&O0MO@3TO,"3
MXCDQ=!$')][(14>HO7QU]B8*,]%=<5[EY1 P2)<4N=)O#6S[1-,V"%T[ 4.$
MXP92>KQD?N!FIBE@)@I67=)KF2E_A2-$S:)2-J*63V%E045P]!$^"'//3*53
M7C"35_"C4J68Z (7##K]- -BA]Z!,PZM+? 6;7*=P1!@0>"]!I;:TJNI<!_%
MOF55%;#+XT)U2837&99N*_]7Y']*&EL0<+NA_@Y6",2(4@BA-6F-K;A*L+O(
M#8R^-#5"8R1]/"%CPO=5 <*0"/Z:8RQ(=BN0>?@Q]B 35F4#J\JZK%&GK-$C
MB#5?\D'_XR7HETTV>M/)I)^.$;7H#%[^7U,C^;PG.GF^IZ\ANEWQ(QQI98FD
M>E@H)2Z4-4@H=<&@U)1*7)D:*=8*)8%7,Z";J8* &, P@Y"L)) %(KNF/DK/
MV*G1F>^YWS:U.V7!5H!H ?HJFBCI"0O0J;#0R]P M.PBOP 6@)QQ&IVN8JLL
M!V?MW >.$QTF$D%9,V_87(6#PY'X<PA'J#NF9"!;*K\_*G^IKS2TDS.$>*-_
M:W3.[.>^"1\V5R$=Y'$$BYGR@! 9+!" R@II6P(<4$Y O\$'DP:_+P#( D4*
M>25U03@$]14%!VL$\&S\*Z(_Z!AU0^2B#;2P1.(';%5;F=7 SXG!6DTT2*<,
MB;*22S**4\_I<OG&;OR-GE?&\7SP'=2K:*VPD513ZVE^H*%5>"1@"8IV@T;0
ML'.F:,(9!FE'7S<5#4Y.H/TX#CA?DZ:@ XY\1,Y-4]8(ZJ$]RQLRQE%K^FL&
MCS0ML)]FW3WCO0'BV<:>D]'Y5U " AS5-,=1OYD-U$+*Y7B88O!E8%@@Q5FM
M=0IFTFXZ,E)8&MB2L5\;X)T(204(5BG&TNDOGZ7 !*M"+H]+D!\G!6CG.S,&
MEC? 2K>8(39UPR&R9X3_?V9#QV.9?9Q:(+I\)S.%L<?_V*?_G20>CNX/?C[(
M9#KS\[/;@4]J,V>'C'^4.%O\D]37TO?B5'*J=L:@8'W<H;-R+(N%7+H3=K(<
M'>T>/OOJ9 S"5UGO>-GO>6?^0CZ?OX6P^TF[3!6%+)5I;B393E?M6BF3JF>R
MCIRJ8VH#68?L=LD<%9DH'-0=9%7.(9-BU+3*\1 H05N)M)HT%J68R(!M.V3S
MW @R=8>"I'$W%< I#@/NK.85DA")QJ@AC8"QYO0+RQ00C5?0,IF)" _0P*V*
MLRY-[PNGRX^X!"B24SM 8AWP\B0='*^'QX*564"?HU2$T!)6%B0I"/EK1$:R
M>/4,Y&TP022"AR! 9Z7Z$@T7&J4RK3W2JJ+%!T#B>)VY2P6(?-F:F;UJB"91
M#V@G3=U8]<6+F\\?ZMV<X#<@UX&Z;G)V?X9=[5O>"G1ZY0&CO94NE[^)5X49
M _+[2=J/JDZL7&XY'YLBV/Y>G;[]]ZXW_FUW\]Y8-$5[P$D4IU.$K6S815^E
ME?8FNXYLI YMR-B&#6T0.C0#I/%N!O Q5T4UT](_#6-AS^O6>-DW7KZ+/'-K
MOWQ(AJBW9KT7D:")=U'22;B!?Q Y:?"TG$'#J%=&D;?6;PCB%XV58^"Y,[)R
M07=S [T':;HZML>M@8J!1ZW9F]!Y[4GT6$;M%7!0(1=!:'-CRCLI6.M,/,'K
MUR8@B*XNB:N%,7+D=T&#0X!DDDU57IO?8 +C)1Q8(W11>T04W:PC#KJ#(5:I
MP6+=HO'T&#*E"^C-:_S#DU4P%50(<BO7.M.5Q ]&PE0<:T?DP? '!J+1-D(4
MV#I\O $\(X4?GA=Z#D3KS2"V:Q8A2XR9)#;(45S/]KOCAW V;\%&:MI%UA7_
M]6C_D4 UP^M^\=^NDIG_-WQAX;\\=,,ZWB%KI?15&,Q>G:<OTID 5<#/B&8"
M"NW)8J9KM8,]J./2+*RLO!I+;N1>FW<I-H(:GCQ!!7O-RF^R1EP0W/J:%OC@
MJ&=3Z*["@YY/RHOQE.3*P2<R=0CS85Z=X1Y2Q1X1TY:FMC2UGJ;*AD1T1]]O
M"6OD?4-K!#-HK".4CJJJT>2.44(AKH<5]IQ=FB17>A(R(69BY59)^.KQ&+@X
MVA;DV%PIMFT;C/YIQSDH?\D*@!KU$Y07N>HW-U:%68C!"</#,D4O3[:G:7N:
M;G&:X  0QHE.FM99$=!@XK,$*D4[7O(D8*'P/?H8U);/;RGS;K #$!/ ]=HS
M] U$6LDETM&6UK:T=DM:ZYKQK:H:"PJTBU9Y;X'/B O27Q(R1#UY"(ILZ7%+
MC[>D1XZ.H$@&'ZP0'#<K'J:< \H9L0:R)2)N27H8*F_I<TN?MZ3/0)5>\J)3
M:8C"8F3;E0\'0A*^,@5\*SG\2)?M/V\0W[/35,'&*"<3J>V6B+=$_#FJ#]'J
M$.5&!2BQQ>NR3KT+K8_<>\9MM$'T/.B<ATCI4XWK_D@Q7ISY0(C"&39JD]TY
MV)?#V 9[2VS5L2,.,8CA"SWH0N*!5#7^D\S:2WXD<UQ"BK#@9G+_HH?C25Y%
MLG9#JT72"Z/N>*&C1(-W<LV&\::*L;R]$6-DP1@##/(MK-^>\-N<\*' U.C-
M6D5$<J[2\[3A=)\@%6]I<DN3MX-.G=#_5HE<C=-JA='N9FI[( $9*U5!.K&<
M*V&K26CG?13OZ!:@.'Q6U6*__>_:G3K<1O5^Z5&]=YQ8]POB$TQ,]5G?&T(Y
M*#267@8]1E6*0TR\#(J)#ZG/2L\K4-<%!^_#EQ8V$OB"D!FH1+Q" K.?0*%O
MX1Z%>ODX#.K2F;EB[ G Z5<3,><U$1IBCEN)#B>MKI3/AF#-35OXN\,,"JR7
MX6K'.EN"V:YO-V0N8!J"FNMF+LR51]YS#COT\'320^.KD22G>>Z+(14>Y*82
MO;\-%)V:(Z)4F!C#&=!U&VH+GVP:_3A);L%4RIC)XC>R6_(DUZBL^NRR-/YD
MJ$(*@8D&#Z(N9?PJS2!IA[@:+7R*-5A@:$U1^Q?8XL-4,9'DZ;Q^>9B:*2(:
M*8T7"BE18HF3<G"#5K;D3ZY6\V7$"IZ"CK=S*3\J(OQS(D3:VS2XK)/&OZEL
M +TY^-7WE!=+S\Y\IN^[3C)Z3/A_(Q?;B,4[$@P#$8*C^"#9DE )@%+N8&]<
MFB% _)O"$X'3TI<80LCUZ3QS^ C\>68,!31@$[ILL+@1E4P )$BK%PQNF*[M
M)6LXMJO!$!0P[#H%"_HCD%=&H\;NL(Q$'2AX#**H0+$%S*3)."?MJBDP*=8/
M S\%Y@J+6Q!KDN/&H0SPI1/\#*PI:/CI/$,+:T>-;0.(T'-,.4C2<GUU&"X7
M4:JV6@1I<DWI3*$S31'P$XR/QB%F%$+ITT@6(/SLR+/39$U0C$0NB2<YKD-2
M5 -?RN%T+4<<S,C&%K9[@C16=LK/4H'>\E,JV0/R9JXD'U0I: \LCW7$*7R?
MEK1J*(];#!#&$M !$U)G85@,PZ=.XS]]PGY'KG?3HS%OQ+?G*3-(<I(YNAR2
MY3A;"7L'+72D1O!-M'*](PDIU7N\3 =\'PF*#X3UW%Z$M"%$&"#TH?1AS&>^
MU- V"/VNBVC([HHW8<77T#%[B%?#S;OAU)P1M1I5G1Y762'SD<5*WG8:8MS+
MIBXX-4A01!APS(@<A])\ M^7$4V'27FK:^.\3U$"4P4%A=EQ@" P$T"MQ*];
M!01-R"UK8X$'_*,P2X6U=THUT< 0"GB?TU34)\Q&\LATW5)C(TT) U/V"@N&
M7+?>C&CGP!(YV#[7$\!0!)-7%*O +HTP8T)*02"QC;[+C#O,=]3CS2USCZ&$
M6P:VPL"^!P!08M["F9F/-4=1NBW#NCOC!#*;A&&$:I8P_+0,50B/!8KV%; J
M$+AX8G.EYK$6@L_["_ @G# OGWTFH)A8,P?P-I53*@V*L,!_. Z[G;6[';YB
M3":J9@R #& E(8"HF:2*#D,'"QQDJ20@O[:N471,>;3FYS!6T)\2:X8-O(0R
M9ZA6V,  @2V3]:2>=5A;U][!76%/Z#&0Y9K.Q$(B2R16SA'%!)DPUWBLD$<!
M1&5 6#*02W[D\&32]#!O6 '+?-76L8$N-^Y.6&:JU.I'NYBA5]%,V>?)&P"L
ML=#LTT-'G7,FT^P+-(N2%P)?)(6BW0+ =,:&).:0MA-]E&O6@@J. (6!*@%M
MC\3!-U_%A"CBK\FFQQ)LWH;B;1[I MR$R!C.XN0\?QYQK0RRO)"P<+)@8]FJ
M,8UQ;J1I%G>8!!0$F9__\'0'!!PL8Z+M7:]1]).@4D'+L>8I8>57)(T]%!C0
M\QZ@-/I+.0N>;IT%7[JSX-:XYJT19VU$/*>K;F'-'<&:#X2S(S: /T:M 3\6
M>6LS$@!-Q/J%Q(!3D;^QWF ,MZ$:6FU^[TK-MN&,X-AK6PUCX,M+7Y$+ZXZD
MN 3_I"3DZ+89=H;XW-ZU1>XV%I)K$WQ]TBV]Q1$ZC7W8TN)//N,7/@?X(L$T
M/RF%F[I58>[1C!X"G+T1,J1BS_W2=XY%.$O>A($'&2T(-5E.:I@(WPDPIJA3
M6?N\)=L>E&'L%/2!;":UA559_V:7,7B[?U"S0GA;WF0Q#C;"5S;8=B<74.D,
M(:(+[*G-301>$XRKK@'5Q'\V8-*/8),X ^-+'#>93B@5G>S6G/Z>F$EP$,&"
M'_ IJP5LQ'<B-9I85&D 4(2Z?XEA>\M05AC*2T\TXJT)ZA.K82F'>6<- !Y9
M;%G,7;*8#06%DY(=0:?RQPR.4Z;RAB-=NZI9JN=68<>BOZ\TJ7J<8;HNQ]%2
MP=L@IJ5KV<@H/?EE0AX8"GLK]B7)<*KK6JE-W.LUQMGC+"8^/IG+[78-0CA#
M99&/@BX#!!W4[3'!&E*V%5?2Z+J@"'LP%S)<2WKIS1#=A?9%3;C FVQ37- D
M2^^'"M9)#?^.<8!'B_R>304]PPA9%GQ?<Z HKC)/\2DD++@:&D!#70$O5I]4
MUG#N*QJ2/<3S@!*VY[M]D8/&!$^],8.>'ASZQQU;R41;A\*HU,A'J5A^DBRK
MYW.5H_D%J^;A@!@/EF63BH1)UTLV)'" ^(R7%LO>:L9B][AR(1*[#HD9&U9J
M34<A/;TO&L-P9=W20\2SJ:A&MT9N0,>V32CC;]640#,2?' <)F(S2GYV2@Y+
M-ER_I-)S\GD@GJ[D#4/4/,3AP? U([4W0:I\C:"EY2?1.@KNX)[K050&UQQ%
MO7<_6[:C^G&R'N"=U9%SH ,"@\TB;"=7N?\^;I=9@")3>++J\("VR(%W?-#J
M&#Q&1<-6*CO@" FA!%LI/J@6) SN-)9#^L4BJRW%&= $;/16>-^1\'XW<%77
MX>%1U[F!<BL:<3O5G1'"ED$?\(S5V%78/<"GO$K!+02/;2+JPB/F]\PSN5!4
M^S(IZIIMW407OL"H(]Z,'@:\: Q;<ZJFD0#[JV?^G+.)PO 01FC:1QF-#A]8
MW=8+W(EF;&N;=<I4=R48\6M=ZGDS3\J,X& ]CUV$NUA*$$J.Y!:R[6CE,!R"
MPDJ('VB'J\;\_=5KDM:8,VJJEE7RA5+H%@EU#/'7?!1,.K>[5X* 2  5K;]V
MT*CCWR5IT@TU:HN?+?QI#[N:*)P/D6/^I<SNS[9F][^MV9W.:C V_/X06F!;
MC&.WXOD.0Z8HNC7:[%JS-$D2DF2@1I'6=N7O?2'-8XW1>T4P4.ASU$MU]P('
M$@5K7,D;)0*00K@XS$N6SVM$>F\#EF%@Y# * \6FIW11M$7//+(_8 :^0":K
M51YK!,'&Q4B4+%C()VL5EF_=W2 V@(*A->^!!8F00()Z^NVWXG#OZ5?A%<8!
MK?A>,;9&=)#N528=QXBV0&OX9ALT.808M-&?/];-7I-56HM[(UC+9UT66TJ4
M0B23TE$H0-U&(_LQ=V^*(Y-I0F1Y# BARG+;,NIW?DL:*/B&KYSI[\-*Q=\D
MY<(;0#C8,%'M>XJ]#_+NV@3]1V@9Z$:(^\#X5OV^07#^/:<'<#U_7PJ1[!%L
MMR2WYL:+B?R].<G:!,M+O:Q\SG4:T1*M.50-Q,?%\)5$/@(,.D0]9R5]8,TJ
M<:7&<''.AAR%LI,8,+1O',V3MH\FGOY6#$T59Y<EDPN!M;KT\:03?ZE$3#T@
M)2KI*LG0ZCEO4B<-:3&.C4AS2=6!T@!5%ZN^>[E*E2:D"ZKH;V3_(?[K[5>\
M$^RWFA0-;H0/.EZ?%+8F*KK-A S) S3,=G-M@X;3?"6/ 9;EHK<:<6S#-C\\
M2%0\N_5.X<!2MY2-KJ[D\+'!;267,N1$<L#7TC1MJ!@HS"R#MSD+UWBYG",-
MSWD0Y<NX$V2O*BNUDYP ](XOZMJ"\3N-FTEB?E/720PO15_3"DJ*CAH9=ZB]
MI7 ELRH)?D=F IPTCS9KS*I*C7;M<+H]SHR(;B5$6<JQN0>><'K5#0;B?>##
M8TF<3VGL4,A+3FZK(^^(U"&7C)_HEG,F%X)'HUN,3CJ#Q:16SD@LVZW)?*/)
M/#*%E]#%%6-^MJ)OE?+[X@->]Q@.FK'L<A1MU#N^5V*8>TU'-&O(Q?MKDT_#
MM8KXQD1>X263))X_ENB#(G"1M]O*+8[:>H71() :56D P6L7!N$HC[1@---!
M,=P 1_9,5F+V8<1MS'[T"!3D>P\Q,T,>SP!;%&!.ND,R5P1)&>X"2XKL#4[]
M]H"O'/#S3UG!J;X_&,!VVY-\C]%Q'5\&'JEHP5JHZ)!H74M!!KO4T('GO8#&
M2CZI$]PTML6LB+-PS"YJ;P*+D@\',HK1!4U1H B'R6+_%8K+VNN+R3UX%,L[
M9I$,LIK+Q:E(/300_/]C\?C@"3&N%8;"(-YDBJ,E?$B*\+?%CM5,%I,3\?CP
M2>H6Q"P0ZT%_5D@]QYF@.1[O#)A0M@?HBYH"-!JT22[\T%O6F<;J4%Q(XF./
M28\N9IHDX0Y<_*_/?F&,3Z\9HYQBP8 :&F F'H80FHOC2/,N41<&DH=F_D@^
MU2/=OZ-CZINM8^I+=TS]KBHT*P10)6I/QR#<C588LC3Z [TA3)$K/+DNQ F%
M1<C@T[+17QO@ +G.PE70@XS]!!M\_.RN6)!)F2 A/4!Q4S3N)%H3I<YAYKDO
MXRMRD]4  -7) $KLBX7$*!0OCD710C8]UU!U"R\,R$P*7V7*I]#'^B*6^7M&
MQL4XKG-_<1JJ(J-@V(</>0W0DM:N^43EZ.!"^Y:%+DG#'%[ZX?B"<)5:)\K]
M=\IPMUF(AR'RE>!9'<8J[?62E[5EU59AYK!UBMX$4JB[-"(;OFPVT(^7/.V-
MHA=<G!:-R+2V:7$#2K$LJ/9L'DK>>F/C*MKP1\AO:U(OAD#]6EK9%;]0")_R
M-%E>P;%":W4F2R2@A:0"-3@['6LS=!;1M3/H%/49CA@D'8*FCU<I8QS0=(:;
M&LNLI6;E8&ATOO8 DP1GH/+%0+F(CJ0LVO$]G@K;DR9*A5>BQ1V'3$<C\@U=
MAP3C46\TZW(&4K-S;"\PA@XTHN4(+&&K)ZWH23^G@"VD VP-'W<>C9"F\K7^
M>CH$5$Z%I!7^K?35!'S*/!SW1%;TRD]U6O)<0/?0_H1BPDM5<ZCW7$Y]U#_K
M&GPF8ZO!%M91/NA@)FQRU8 [+%>2W/?V2!/3BS-U-YKJX!SB!>:=Z =D!"OS
MIRRGJ%KU%"LV$OF^XIULOG6O/'J.'NZQ(-]11X2W)7%\V. $P0:R\U;O;#I&
M,)^='WE:W?<?:A]EG=)$6XVQ\9RMI\(A R7$T7D:=C717)EE=E34D3=&D_MK
ME63(7]:BK9:$KE_3MJ97)+JVM $U#"J(<X";2C6%LX=+CF.ZTL8F;DG8FJ:H
M>)7;1-> M]I-;JMIAR%$LQJKTB"$S!*0RC(&ZK(^/-?.Q=(&0.!3=&,#+ 3Y
M2S"$Q35YALGIZHL6S5$<^>!^2Z9'NOM5FR(UTOF^/!^(OR3E/$,D:GMCBNO>
M H3W7.B<D]QR<M)W.DD ?9L]DQHC::E;W!CWDNB"0#[6<R(?2'LF/2+8AGW<
MDQ7-AW&T46JI)0V!&N4'84?S$I-IJ$J*SU92GRI5.F:&ZV'/&HM86NUJF? E
MK.$38@N@ SBI+LU%]_%*UBY7Q4;::WC6\DE 9P#:RDQU8"7/*Z#'$",P9-NB
MP)4@>Z)F1ZFG6&TG=$2%:GY) 2ZK;UA4MM=;LI;D24B]_!1T$@8LJ3JC@A4D
M5E/#J<K"I?8T'G\-L\I[>]!/W;H7$/KW/4B7%'(T3S*4(KF-?L]N>Q?2#<*M
MJ,!F&V73Q1K(7Z/[2 ;5)&HF74332D^&;5T9.A11M"'PA**+V@+.:1!6(O7Q
M=$S]8JR,*3V\([HJ27AMD9,JRN@_TZ3C8AX&'(B1#U%I4[M"L,H:C-*+MUSB
M[ZP%TZZ$R-->P6SF.PDF6Y#'W&- QZ@(<U8*WESLF;&+0%TT=]?,6%3=$($!
M;M%NQ4-4)/]2ENMOMY;KOZ#E^C,Y/14L%5EC+32 RH(1X4Z#.<:R:](@(X?K
M>N48N'-HP74>M"ZX\$:J'C. D3@R[3Y$7O G&Y5>]];J=&H59W]O#4MW5VB3
M."S%\7($\0K<":O.%N0 -E;UA &,"B+:F8DD_\X01$^P]K4F]B#16TL(!2HG
M&2*K QBA>">8,U8J5%D(KAAO43:5+A/-]^+\C('*P$D-HI]K?7(4.6M2VAO(
MJ6Q$4T9C?M'-<_A+"==__AG"]7,E*5X <)T@W1N;? E_S.IY\>+_ 5!+ 0(4
M Q0    (  MS>53M93<2P!D  )\G 0 1              "  0    !G86YX
M+3(P,C$Q,C,Q+GAS9%!+ 0(4 Q0    (  MS>51_M(]( Q0  ,XG 0 5
M          "  >\9  !G86YX+3(P,C$Q,C,Q7V-A;"YX;6Q02P$"% ,4
M"  +<WE4^ QS24M!  !SE@0 %0              @ $E+@  9V%N>"TR,#(Q
M,3(S,5]D968N>&UL4$L! A0#%     @ "W-Y5&T%Z4\[E   X/D) !4
M         ( !HV\  &=A;G@M,C R,3$R,S%?;&%B+GAM;%!+ 0(4 Q0    (
M  MS>53;Y\AL%6<  ,G,!P 5              "  1$$ 0!G86YX+3(P,C$Q
M,C,Q7W!R92YX;6Q02P$"% ,4    "  +<WE4*! 2=13? P!6H2, %0
M        @ %9:P$ 9V%N>"TR,#(Q,3(S,7@Q,&LN:'1M4$L! A0#%     @
M"W-Y5+B<13>&@0  DHX  !@              ( !H$H% &=A;G@M,C R,3$R
M,S%X,3!K,# Q+FIP9U!+ 0(4 Q0    (  MS>52>$5<VOJ(  )VN   8
M          "  5S,!0!G86YX+3(P,C$Q,C,Q>#$P:S P,BYJ<&=02P$"% ,4
M    "  +<WE4@3.Y>TBR   PM@  &               @ %0;P8 9V%N>"TR
M,#(Q,3(S,7@Q,&LP,#,N:G!G4$L! A0#%     @ "W-Y5-J>(QEE7P  I68
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M:S P."YJ<&=02P$"% ,4    "  +<WE4.\!M#+$_   )1@  &
M    @ %W0@D 9V%N>"TR,#(Q,3(S,7@Q,&LP,#DN:G!G4$L! A0#%     @
M"W-Y5+Q'9W!P#   ] P  !@              ( !7H() &=A;G@M,C R,3$R
M,S%X,3!K,#$P+FIP9U!+ 0(4 Q0    (  MS>52'C5=>P9@  *V#!P 8
M          "  02/"0!G86YX+3(P,C$Q,C,Q>&5X,3!D."YH=&U02P$"% ,4
M    "  +<WE4738SC>@$   B%   &               @ '[)PH 9V%N>"TR
M,#(Q,3(S,7AE>#(S9#$N:'1M4$L! A0#%     @ "W-Y5%^VT?9;"   ZB<
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$"@    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
